PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Free, RB; Hazelwood, LA; Cabrera, DM; Spalding, HN; Namkung, Y; Rankin, ML; Sibley, DR				Free, R. Benjamin; Hazelwood, Lisa A.; Cabrera, David M.; Spalding, Heather N.; Namkung, Yoon; Rankin, Michele L.; Sibley, David R.			D-1 and D-2 dopamine receptor expression is regulated by direct interaction with the chaperone protein calnexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; N-LINKED GLYCOSYLATION; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; COUPLED RECEPTORS; DRUG DISCOVERY; ASSOCIATION; TRAFFICKING; DESENSITIZATION; D1	As for all proteins, G protein-coupled receptors (GPCRs) undergo synthesis and maturation within the endoplasmic reticulum (ER). The mechanisms involved in the biogenesis and trafficking of GPCRs from the ER to the cell surface are poorly understood, but they may involve interactions with other proteins. We have now identified the ER chaperone protein calnexin as an interacting protein for both D-1 and D-2 dopamine receptors. These protein-protein interactions were confirmed using Western blot analysis and co-immunoprecipitation experiments. To determine the influence of calnexin on receptor expression, we conducted assays in HEK293T cells using a variety of calnexin-modifying conditions. Inhibition of glycosylation either through receptor mutations or treatments with glycosylation inhibitors partially blocks the interactions with calnexin with a resulting decrease in cell surface receptor expression. Confocal fluorescence microscopy reveals the accumulation of D-1-green fluorescent protein and D-2-yellow fluorescent protein receptors within internal stores following treatment with calnexin inhibitors. Overexpression of calnexin also results in a marked decrease in both D-1 and D-2 receptor expression. This is likely because of an increase in ER retention because confocal microscopy revealed intracellular clustering of dopamine receptors that were co-localized with an ER marker protein. Additionally, we show that calnexin interacts with the receptors via two distinct mechanisms, glycan-dependent and glycan-independent, which may underlie the multiple effects (ER retention and surface trafficking) of calnexin on receptor expression. Our data suggest that optimal receptor-calnexin interactions critically regulate D-1 and D-2 receptor trafficking and expression at the cell surface, a mechanism likely to be of importance for many GPCRs.	NINDS, Mol Neuropharmacol Sect, Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Sibley, DR (corresponding author), NINDS, Mol Neuropharmacol Sect, Natl Inst Hlth, 5625 Fishers Ln,Rm 4S-04,MSC 9405, Bethesda, MD 20892 USA.	sibley@helix.nih.gov	Sibley, David/AAC-3591-2019; Cabrera, David/I-1013-2014		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003028, Z01NS003028] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bai J, 2004, BIOL PSYCHIAT, V56, P427, DOI 10.1016/j.biopsych.2004.06.022; Bergson C, 2003, TRENDS PHARMACOL SCI, V24, P486, DOI 10.1016/S0165-6147(03)00232-3; Bermak J C, 2001, Mol Interv, V1, P282; Bermak JC, 2002, EUR J CELL BIOL, V81, P77, DOI 10.1078/0171-9335-00222; Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Bulenger S, 2005, TRENDS PHARMACOL SCI, V26, P131, DOI 10.1016/j.tips.2005.01.004; Danilczyk UG, 2001, J BIOL CHEM, V276, P25532, DOI 10.1074/jbc.M100270200; Duvernay MT, 2005, CELL SIGNAL, V17, P1457, DOI 10.1016/j.cellsig.2005.05.020; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Ermonval M, 2000, GLYCOBIOLOGY, V10, P77, DOI 10.1093/glycob/10.1.77; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Karpa KD, 1999, MOL PHARMACOL, V56, P1071, DOI 10.1124/mol.56.5.1071; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; LABRIOLA C, 1995, J CELL BIOL, V130, P771, DOI 10.1083/jcb.130.4.771; Laurin N, 2005, MOL PSYCHIATR, V10, P1117, DOI 10.1038/sj.mp.4001737; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lundstrom K, 2005, IDRUGS, V8, P909; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; MCDOWELL W, 1988, BIOCHIMIE, V70, P1535, DOI 10.1016/0300-9084(88)90290-8; Meissner JD, 1999, BIOCHEM J, V338, P561, DOI 10.1042/0264-6021:3380561; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Namkung Y, 2004, J BIOL CHEM, V279, P49533, DOI 10.1074/jbc.M408319200; Okiyoneda T, 2004, MOL BIOL CELL, V15, P563, DOI 10.1091/mbc.E03-06-0379; Qi YP, 1997, J NEUROSCI, V17, P1217; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; Rozell TG, 1998, ENDOCRINOLOGY, V139, P1588, DOI 10.1210/en.139.4.1588; Salahpour A, 2004, J BIOL CHEM, V279, P33390, DOI 10.1074/jbc.M403363200; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; Siffroi-Fernandez S, 2002, EUR J BIOCHEM, V269, P4930, DOI 10.1046/j.1432-1033.2002.03192.x; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Swanton E, 2003, EMBO J, V22, P2948, DOI 10.1093/emboj/cdg300; Tan CM, 2004, ANNU REV PHARMACOL, V44, P559, DOI 10.1146/annurev.pharmtox.44.101802.121558; Van Craenenbroeck K, 2005, J BIOL CHEM, V280, P19350, DOI 10.1074/jbc.M414043200; Wanamaker CP, 2005, J BIOL CHEM, V280, P33800, DOI 10.1074/jbc.M501813200; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722	48	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21285	21300		10.1074/jbc.M701555200	http://dx.doi.org/10.1074/jbc.M701555200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17395585	hybrid			2022-12-27	WOS:000248047500057
J	Pakuts, B; Debonneville, C; Liontos, LM; Loreto, MP; McGlade, CJ				Pakuts, Benjamin; Debonneville, Christophe; Liontos, Larissa M.; Loreto, Michael P.; McGlade, C. Jane			The Src-like adaptor protein 2 regulates colony-stimulating factor-1 receptor signaling and down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; C-CBL; M-CSF; FDC-P1 CELLS; KINASE-C; INDUCED-DIFFERENTIATION; NEGATIVE REGULATOR; TYROSINE KINASE; FMS; MACROPHAGES	Src-like adaptor protein 2 (SLAP-2) is a hematopoietic adaptor protein previously implicated as a negative regulator of T-cell antigen receptor (TCR)-mediated signaling. SLAP-2 contains an SH3 and an SH2 domain, followed by a unique carboxyl-terminal tail, which is important for c-Cb1 binding. Here we describe a novel role for SLAP-2 in regulation of the colony-stimulating factor 1 receptor (CSF-1R), a receptor tyrosine kinase important for growth and differentiation of myeloid cells. SLAP-2 co-immunoprecipitates with c-Cb1 and CSF-1R in primary bone marrowderived macrophages. Using murine myeloid cells expressing CSF-1R (FD-Fms cells), we show that SLAP-2 is tyrosine-phosphorylated upon stimulation with CSF-1 and associates constitutively with both c-Cbl and CSF-1R. In addition, we show that expression of a dominant negative form of SLAP-2 impairs c-Cb1 association with the CSF-1R and receptor ubiquitination. Impaired c-Cb1 recruitment also correlated with changes in the kinetics of CSF-1R down-regulation and trafficking. CSF-1-mediated differentiation of FD-Fms cells and activation of downstream signaling events was also enhanced in cells stably expressing dominant negative SLAP-2. Together, these results demonstrate that SLAP-2 plays a role in c-Cb1-dependent downregulation of CSF-1R signaling.	Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1L7, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	McGlade, CJ (corresponding author), Hosp Sick Children, 101 Coll St TMDT 11-601, Toronto, ON M5G 1L7, Canada.	jmcglade@sickkids.ca		Debonneville, Christophe/0000-0003-4759-2165; Liontos, Larissa/0000-0003-0977-2536				Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Dragone LL, 2006, J IMMUNOL, V176, P335, DOI 10.4049/jimmunol.176.1.335; Fixe P, 1997, EUR CYTOKINE NETW, V8, P125; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; Holland SJ, 2001, J EXP MED, V194, P1263, DOI 10.1084/jem.194.9.1263; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Junttila I, 2003, J LEUKOCYTE BIOL, V73, P281, DOI 10.1189/jlb.0702359; Lebigot I, 2003, BLOOD, V102, P4555, DOI 10.1182/blood-2003-06-2077; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Loreto MP, 2003, ONCOGENE, V22, P266, DOI 10.1038/sj.onc.1206114; Loreto MP, 2002, MOL CELL BIOL, V22, P4241, DOI 10.1128/MCB.22.12.4241-4255.2002; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Manes GA, 2006, FEBS J, V273, P1791, DOI 10.1111/j.1742-4658.2006.05199.x; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mochly-Rosen D, 1998, FASEB J, V12, P35; Motoyoshi K, 1998, INT J HEMATOL, V67, P109; Myers MD, 2005, J CELL BIOL, V170, P285, DOI 10.1083/jcb.200501164; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Novak U, 1998, GROWTH FACTORS, V15, P159, DOI 10.3109/08977199809002114; Pandey A, 2002, J BIOL CHEM, V277, P19131, DOI 10.1074/jbc.M110318200; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128	38	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					17953	17963		10.1074/jbc.M701182200	http://dx.doi.org/10.1074/jbc.M701182200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17353186	hybrid			2022-12-27	WOS:000247302000002
J	Nishiyama, K; Takaji, K; Uchijima, Y; Kurihara, Y; Asano, T; Yoshimura, M; Ogawa, H; Kurihara, H				Nishiyama, Koichi; Takaji, Kentaro; Uchijima, Yasunobu; Kurihara, Yukiko; Asano, Tomoichiro; Yoshimura, Michihiro; Ogawa, Hisao; Kurihara, Hiroki			Protein kinase A-regulated nucleocytoplasmic shuttling of Id1 during angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-MEDIATED DEGRADATION; LOOP-HELIX PROTEINS; ENDOTHELIAL-CELL MIGRATION; INDUCED ACTIVATION; LOCALIZATION; INHIBITOR; NUCLEAR; GROWTH; MORPHOGENESIS; SUPPRESSION	Id1, an inhibitory partner of basic-helix-loop-helix transcriptional factors, has recently been recognized as a potent contributor to angiogenesis. However, the molecular mechanism underlying its role in angiogenesis remains essentially unknown. Herein we demonstrate the subcellular localization of Id1 to be altered depending on the cellular context of vascular endothelial cells. Id1 was localized in the nuclei of human umbilical vein endothelial cells (HUVECs) cultured on uncoated plates, whereas it was translocated to the cytoplasm in HUVECs on Matrigel along with the formation of capillary- like structures. Treatment with the nuclear export inhibitor leptomycin B and mutagenesis analysis using green fluorescent protein-fused Id1 revealed CRM1/ exportin-dependent nuclear export of Id1 in HUVECs on Matrigel. This nuclear export of Id1 was inhibited by protein kinase A ( PKA) activation by dibutyryl cyclic AMP and forskolin but was promoted by PKA inactivation by H-89 and MDL-12,330A. Mutagenesis analysis of Id1 showed the phosphorylation of Ser-5 to possibly mediate the effect of PKA. These results suggest the function of Id1 as a transcriptional factor to be controlled by nucleocytoplasmic shuttling during angiogenesis and that PKA might be involved in this process. This may serve as a novel mechanism regulating angiogenesis and as a possible target for therapeutic vascular regeneration.	Univ Tokyo, Dept Physiol Chem & Metab, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Dev Med Technol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Kumamoto Univ, Dept Cardiovasc Med, Grad Sch Med Sci, Kumamoto 8608556, Japan; Kumamoto Univ, Dept Cardiovasc Surg, Grad Sch Med Sci, Kumamoto 8608556, Japan; Jikei Univ, Sch Med, Dept Internal Med, Minato Ku, Tokyo 1058461, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Biomed Chem, Hiroshima 7348551, Japan	University of Tokyo; University of Tokyo; Kumamoto University; Kumamoto University; Jikei University; Hiroshima University	Nishiyama, K (corresponding author), Univ Tokyo, Dept Physiol Chem & Metab, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	nkanako@bio.m.u-tokyo.ac.jp	Nishiyama, Koichi/H-4275-2014	Nishiyama, Koichi/0000-0003-0529-4207; Kurihara, Hiroki/0000-0002-6476-5593				Bakre MM, 2002, NAT MED, V8, P995, DOI 10.1038/nm753; Cartwright P, 2000, CELL MOL LIFE SCI, V57, P1193, DOI 10.1007/PL00000759; Cattaneo MG, 2003, BRIT J PHARMACOL, V138, P377, DOI 10.1038/sj.bjp.0705051; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; de Candia P, 2003, P NATL ACAD SCI USA, V100, P12337, DOI 10.1073/pnas.2031337100; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; Hashimoto A, 2006, ATHEROSCLEROSIS, V189, P350, DOI 10.1016/j.atherosclerosis.2006.01.022; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268; Kurooka H, 2005, J BIOL CHEM, V280, P4313, DOI 10.1074/jbc.M412614200; Lasorella A, 2006, P NATL ACAD SCI USA, V103, P4976, DOI 10.1073/pnas.0600168103; Lazrak M, 2004, J CELL SCI, V117, P1161, DOI 10.1242/jcs.00969; Li XG, 2005, NAT CELL BIOL, V7, P1202, DOI 10.1038/ncb1326; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Liu F, 2001, AM J PHYSIOL-LUNG C, V280, pL1309, DOI 10.1152/ajplung.2001.280.6.L1309; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Makita J, 2006, FEBS LETT, V580, P1812, DOI 10.1016/j.febslet.2006.02.038; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Nishiyama K, 2005, CIRCULATION, V112, P2840, DOI 10.1161/CIRCULATIONAHA.104.516898; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Oettgen P, 2001, CIRC RES, V89, P380, DOI 10.1161/hh1701.095958; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Sakurai D, 2004, J IMMUNOL, V173, P5801, DOI 10.4049/jimmunol.173.9.5801; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Seya Y, 2006, EUR J PHARMACOL, V553, P54, DOI 10.1016/j.ejphar.2006.09.048; Shcherbik N, 2004, J CELL BIOCHEM, V93, P11, DOI 10.1002/jcb.20130; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Sikder H, 2003, CANCER CELL, V4, P291, DOI 10.1016/S1535-6108(03)00245-9; Smith JM, 2004, TRENDS GENET, V20, P4, DOI 10.1016/j.tig.2003.11.007; Sun LP, 2005, J BIOL CHEM, V280, P26448, DOI 10.1074/jbc.M500373200; Tamura Y, 1998, FEBS LETT, V436, P169, DOI 10.1016/S0014-5793(98)01117-X; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Tu X, 2003, EXP CELL RES, V288, P119, DOI 10.1016/S0014-4827(03)00178-2; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Wang SL, 2001, NEURON, V29, P603, DOI 10.1016/S0896-6273(01)00237-9; Whelan MC, 2003, J BIOL CHEM, V278, P327, DOI 10.1074/jbc.M207554200; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	47	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17200	17209		10.1074/jbc.M611609200	http://dx.doi.org/10.1074/jbc.M611609200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17412691	hybrid			2022-12-27	WOS:000246946500053
J	Conrad, S; Genth, H; Hofmann, F; Just, I; Skutella, T				Conrad, Sabine; Genth, Harald; Hofmann, Fred; Just, Ingo; Skutella, Thomas			Neogenin-RGMa signaling at the growth cone is bone morphogenetic protein-independent and involves RhoA, ROCK, and PKC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPULSIVE GUIDANCE MOLECULE; SPINAL-CORD-INJURY; AXON GUIDANCE; NEURONAL DIFFERENTIATION; ACTIN CYTOSKELETON; EXPRESSION PATTERN; COLORECTAL-CANCER; MULTIPLE ROLES; LIM-KINASE; RECEPTOR	The repulsive guidance molecule RGMa has been shown to induce outgrowth inhibition of neurites by interacting with the transmembrane receptor neogenin. Here we show that RGMa-induced growth cone collapse is mediated by activation of the small GTPase RhoA, its downstream effector Rho kinase and PKC. In contrast to DRG cultures from neogenin(-/-) mice, in which no RGMa-mediated growth cone collapse and activation of RhoA occurred, treatment of wild type DRG neurites with soluble RGMa led to a marked activation of RhoA within 3 min followed by collapse, but left Rac1 and Cdc42 unaffected. Furthermore, preincubation of DRG axons with the bone morphogenetic protein ( BMP) antagonist noggin had no effect on RGMa-mediated growth cone collapse, implying that the role of RGM in axonal guidance is neogenin- and not BMP receptor dependent. Pretreatment with 1) C3-transferase, a specific inhibitor of the Rho GTPase; 2) Y-27632, a specific inhibitor of Rho kinase; and 3) Go6976, the general PKC inhibitor, strongly inhibited the collapse rate of PC12 neurites. Growth cone collapse induced by RGMa was abolished by the expression of dominant negative RhoA, but not by dominant negative Rac1. In contrast to RGMa, netrin-1 induced no growth cone retraction but instead reduced RGMa-mediated growth cone collapse. These results suggest that activation of RhoA, Rho kinase, and PKC are physiologically relevant and important elements of the RGMa-mediated neogenin signal transduction pathway involved in axonal guidance.	Univ Tubingen, Ctr Regenerat Med & Biol, Dept Expt Embryol, Sect Tissue Engn, D-72074 Tubingen, Germany; Inst Anat, Dept Expt Embryol, Sect Tissue Engn, D-72074 Tubingen, Germany; Hannover Med Sch, Inst Toxicol, D-30625 Hannover, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Hannover Medical School	Skutella, T (corresponding author), Univ Tubingen, Ctr Regenerat Med & Biol, Dept Expt Embryol, Sect Tissue Engn, Osterberg Str 3, D-72074 Tubingen, Germany.	Thomas.Skutella@uni-tuebingen.de	Genth, Harald/HHS-0118-2022					Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Aktories K, 2005, CURR TOP MICROBIOL, V291, P113; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Augsburger A, 1999, NEURON, V24, P127, DOI 10.1016/S0896-6273(00)80827-2; Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777; Babitt JL, 2005, J BIOL CHEM, V280, P29820, DOI 10.1074/jbc.M503511200; Brinks H, 2004, J NEUROSCI, V24, P3862, DOI 10.1523/JNEUROSCI.5296-03.2004; Charron F, 2005, DEVELOPMENT, V132, P2251, DOI 10.1242/dev.01830; Fitzgerald DP, 2006, DEV DYNAM, V235, P1720, DOI 10.1002/dvdy.20744; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hata K, 2006, J CELL BIOL, V173, P47, DOI 10.1083/jcb.200508143; Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Leonardo ED, 1997, COLD SPRING HARB SYM, V62, P467; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Matsunaga E, 2004, DEV GROWTH DIFFER, V46, P481; Matsunaga E, 2006, J NEUROSCI, V26, P6082, DOI 10.1523/JNEUROSCI.4556-05.2006; Mehlen P, 2005, CELL DEATH DIFFER, V12, P1003, DOI 10.1038/sj.cdd.4401708; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Mueller BK, 2005, NAT REV DRUG DISCOV, V4, P387, DOI 10.1038/nrd1719; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Oldekamp J, 2004, GENE EXPR PATTERNS, V4, P283, DOI 10.1016/j.modgep.2003.11.008; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Redowicz MJ, 1999, ARCH BIOCHEM BIOPHYS, V364, P122, DOI 10.1006/abbi.1999.1112; Ren XR, 2004, NAT NEUROSCI, V7, P1204, DOI 10.1038/nn1330; Samad TA, 2004, J NEUROSCI, V24, P2027, DOI 10.1523/JNEUROSCI.4115-03.2004; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; Schwab JM, 2005, ARCH NEUROL-CHICAGO, V62, P1561, DOI 10.1001/archneur.62.10.1561; Schwab JM, 2005, EUR J NEUROSCI, V21, P1569, DOI 10.1111/j.1460-9568.2005.03962.x; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Vielmetter J, 1997, GENOMICS, V41, P414, DOI 10.1006/geno.1997.4688; Watanabe K, 2006, DEVELOPMENT, V133, P1379, DOI 10.1242/dev.02312; Wilson NH, 2007, INT J BIOCHEM CELL B, V39, P874, DOI 10.1016/j.biocel.2006.10.023; Wilson NH, 2006, DEV BIOL, V296, P485, DOI 10.1016/j.ydbio.2006.06.018; Xie Y, 2005, NAT CELL BIOL, V7, P1124, DOI 10.1038/ncb1321	39	77	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16423	16433		10.1074/jbc.M610901200	http://dx.doi.org/10.1074/jbc.M610901200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17389603	hybrid			2022-12-27	WOS:000246794300050
J	Kim, HS; Kim, MS; Hancock, AL; Harper, JCP; Park, JY; Poy, G; Perantoni, AO; Cam, M; Malik, K; Lee, SB				Kim, Ho-Shik; Kim, Myoung Shin; Hancock, Anne L.; Harper, James C. P.; Park, Jik Young; Poy, George; Perantoni, Alan O.; Cam, Margaret; Malik, Karim; Lee, Sean Bong			Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TRANSCRIPTIONAL REGULATION; WT1 GENE; BINDING-SITES; EGF RECEPTOR; EXPRESSION; APOPTOSIS; INDUCTION; MOUSE; SLUG	The Wilms' tumor suppressor gene (WT1) encodes a zinc finger transcription factor that is vital during development of several organs including metanephric kidneys. Despite the critical regulatory role of WT1, the pathways and mechanisms by which WT1 orchestrates development remain elusive. To identify WT1 target genes, we performed a genome-wide expression profiling analysis in cells expressing inducible WT1. We identified a number of direct WT1 target genes, including the epidermal growth factor (EGF)-family ligands epiregulin and HB-EGF, the chemokine CX3CL1, and the transcription factors SLUG and JUNB. The target genes were validated using quantitative reverse transcriptase-polymerase chain reaction, small interfering RNA knockdowns, chromatin immunoprecipitation, and luciferase reporter analyses. Immunohistochemistry of fetal kidneys confirmed that a number of the WT1 target genes had overlapping expression patterns with the highly restricted spatiotemporal expression of WT1. Finally, using an in vitro embryonic kidney culture assay, we found that the addition of recombinant epiregulin, amphiregulin, CX3CL1, and interleukin-11 significantly enhanced ureteric bud branching morphogenesis. Our genome-wide screen implicates WT1 in the transcriptional regulation of the EGF-family of growth factors as well as the CX3CL1 chemokine during nephrogenesis.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Microarray Core Facil, NIH, Bethesda, MD 20892 USA; NCI, Lab Comparat Carcinogenesis, Frederick, MD 21702 USA; Univ Bristol, Canc & Leukaemia Childhood Sargent Unit, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Bristol	Lee, SB (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10,9D11, Bethesda, MD 20892 USA.	seanL@intra.niddk.nih.gov	Harper, James/AAH-1885-2019	Harper, James/0000-0002-6416-1466; Malik, Karim/0000-0002-8965-200X; Lee, Sean/0000-0001-6211-3498	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056002, Z01DK056002] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVAGNER P, 1997, J CELL BIOL, V137, P1403; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Boehme SA, 2000, J IMMUNOL, V165, P397, DOI 10.4049/jimmunol.165.1.397; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; Dallosso AR, 2004, HUM MOL GENET, V13, P405, DOI 10.1093/hmg/ddh038; Davies JA, 2004, HUM MOL GENET, V13, P235, DOI 10.1093/hmg/ddh015; Deiva K, 2004, EUR J NEUROSCI, V20, P3222, DOI 10.1111/j.1460-9568.2004.03800.x; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Gao F, 2006, P NATL ACAD SCI USA, V103, P11987, DOI 10.1073/pnas.0600994103; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Graham K, 2006, GENE EXPRESSION, V13, P1, DOI 10.3727/000000006783991953; Grieshammer U, 2005, DEVELOPMENT, V132, P3847, DOI 10.1242/dev.01944; Guo G, 2004, J AM SOC NEPHROL, V15, P2851, DOI 10.1097/01.ASN.0000143474.91362.C4; Guo JK, 2002, HUM MOL GENET, V11, P651, DOI 10.1093/hmg/11.6.651; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HASTIE ND, 1993, CURR OPIN GENET DEV, V3, P408, DOI 10.1016/0959-437X(93)90113-4; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Hossain A, 2001, J BIOL CHEM, V276, P16817, DOI 10.1074/jbc.M009056200; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Kim J, 1999, MOL CELL BIOL, V19, P2289; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lai PC, 2001, J AM SOC NEPHROL, V12, P2310, DOI 10.1681/ASN.V12112310; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lee TH, 2001, PHYSIOL GENOMICS, V7, P187, DOI 10.1152/physiolgenomics.00046.2001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; Menke AL, 2002, CANCER RES, V62, P6615; Moore AW, 1999, DEVELOPMENT, V126, P1845; Morrison DJ, 2005, CANCER RES, V65, P8174, DOI 10.1158/0008-5472.CAN-04-3657; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Natoli TA, 2002, MOL CELL BIOL, V22, P4433, DOI 10.1128/MCB.22.12.4433-4438.2002; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PERANTONI AO, 1991, DIFFERENTIATION, V48, P25, DOI 10.1111/j.1432-0436.1991.tb00239.x; Perantoni AO, 2003, METH MOLEC MED, V86, P179; PETERS KG, 1992, DEVELOPMENT, V114, P233; Rae FK, 2004, ONCOGENE, V23, P3067, DOI 10.1038/sj.onc.1207360; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; Savagner P, 1998, DEV DYNAM, V213, P182, DOI 10.1002/(SICI)1097-0177(199810)213:2<182::AID-AJA3>3.0.CO;2-C; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Scordi IA, 1999, DERMATOLOGY, V199, P296, DOI 10.1159/000018278; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; Takemura T, 2002, KIDNEY INT, V61, P1968, DOI 10.1046/j.1523-1755.2002.00358.x; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Udtha M, 2003, ONCOGENE, V22, P3821, DOI 10.1038/sj.onc.1206597; Wagner KD, 2003, J CELL SCI, V116, P1653, DOI 10.1242/jcs.00405; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Wagner N, 2004, J AM SOC NEPHROL, V15, P3044, DOI 10.1097/01.ASN.0000146687.99058.25; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029	66	49	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16278	16287		10.1074/jbc.M700215200	http://dx.doi.org/10.1074/jbc.M700215200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430890	hybrid			2022-12-27	WOS:000246794300035
J	Yuen, EY; Liu, WH; Yan, Z				Yuen, Eunice Y.; Liu, Wenhua; Yan, Zhen			The phosphorylation state of GluR1 Subunits determines the susceptibility of AMPA receptors to calpain cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; D-ASPARTATE RECEPTORS; TYROSINE PHOSPHORYLATION; MEDIATED PROTEOLYSIS; GLUTAMATE RECEPTORS; KINASE-II; CHANNELS; NEUROTOXICITY; TRAFFICKING; ACTIVATION	The alpha-Amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor(AMPAR) is an ionotropic glutamate receptor that governs most of excitatory synaptic transmission in neurons. In vitro biochemical assay has shown that calpain, a Ca2+ activated protease, can cleave AMPAR GluR1 subunits. Our physiological study found that calpain, which was activated by prolonged stimulation of the N-methyl-D-aspartate receptor ( 100 mu M, 10 min), caused a substantial suppression of AMPAR currents in cortical neurons. Since the phosphorylation sites of GluR1 by several protein kinases are located in close proximity to the calpain cleavage sites, we investigated the effect of phosphorylation on the susceptibility of GluR1 to calpain cleavage. Interestingly, we found that the calpain regulation of AMPAR currents was diminished by inhibition of Ca2+ /calmodulin-dependent protein kinase II ( CaMKII) but was augmented by inhibition of protein phosphatase 1/2A (PP1/2A). In agreement with this, in vitro assay showed that the calpain-induced proteolytic cleavage of GluR1 C-terminal fusion protein was strongly potentiated by adding the purified active CaMKII, and GluR1 phosphorylated at Ser(831) by CaMKII is much more sensitive to calpain cleavage. Taken together, our data suggest that calpain activation suppresses AMPA receptor currents via proteolytic cleavage of GluR1 subunits, and the susceptibility of AMPARs to calpain cleavage is determined by the phosphorylation state of GluR1 subunits, which is mediated by CaMKII-PP1/2A activity.	SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Yan, Z (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, 124 Sherman Hall, Buffalo, NY 14214 USA.	zhenyan@buffalo.edu		Liu, Wenhua/0000-0003-0903-8497				Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Bi RF, 2000, J BIOL CHEM, V275, P26477, DOI 10.1074/jbc.M003763200; Bi X, 1996, NEUROSCIENCE, V73, P903, DOI 10.1016/0306-4522(96)00157-1; Bi XN, 1997, J NEUROCHEM, V68, P1484; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Cai XA, 2002, J BIOL CHEM, V277, P36553, DOI 10.1074/jbc.M203752200; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Dell'Acqua ML, 2006, EUR J CELL BIOL, V85, P627, DOI 10.1016/j.ejcb.2006.01.010; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; FISCHER I, 1991, NEUROCHEM RES, V16, P891, DOI 10.1007/BF00965538; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Liao DZ, 2001, J NEUROSCI, V21, P6008, DOI 10.1523/JNEUROSCI.21-16-06008.2001; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; MAKI M, 1989, J BIOL CHEM, V264, P18866; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; Morishita W, 2001, NEURON, V32, P1133, DOI 10.1016/S0896-6273(01)00554-2; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Rong YQ, 2001, J NEUROCHEM, V79, P382, DOI 10.1046/j.1471-4159.2001.00565.x; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; VANDERKLISH P, 1995, MOL BRAIN RES, V32, P25, DOI 10.1016/0169-328X(95)00057-Y; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Yuen EY, 2007, J PHYSIOL-LONDON, V580, P241, DOI 10.1113/jphysiol.2006.122754; Yuen EY, 2005, J NEUROSCI, V25, P5488, DOI 10.1523/JNEUROSCI.1187-05.2005	31	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16434	16440		10.1074/jbc.M701283200	http://dx.doi.org/10.1074/jbc.M701283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428797	hybrid			2022-12-27	WOS:000246794300051
J	Habuchi, H; Nagai, N; Sugaya, N; Atsumi, F; Stevens, RL; Kimata, K				Habuchi, Hiroko; Nagai, Naoko; Sugaya, Noriko; Atsumi, Fukiko; Stevens, Richard L.; Kimata, Koji			Mice deficient in heparan sulfate 6-O-sulfotransferase-1 exhibit defective heparan sulfate biosynthesis, abnormal placentation, and late embryonic lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TARGETED DISRUPTION; EXPRESSION PATTERNS; AXON GUIDANCE; GENE; BINDING; LACKING; WNT; ISOFORMS; QSULF1	Heparan sulfate (HS) plays critical roles in a variety of developmental, physiological, and pathogenic processes due to its ability to interact in a structure-dependent manner with numerous growth factors that participate in cellular signaling. The divergent structures of HS glycosaminoglycans are the result of the coordinate actions of several N- and O-sulfotransferases, C5-epimerase, and 6-O-endosulfatases. We have shown that 6-O-sulfation of the glucosamine residues in HS are catalyzed by the sulfotransferases HS6ST-1, -2, and -3. To determine the biological and physiological importance of HS6ST-1, we now describe the creation of transgenic mice that lack this sulfotransferase. Most of our HS6ST-1-null mice died between embryonic day 15.5 and the perinatal stage, and those mice that survived were considerably smaller than their wild-type littermates. Some of these HS6ST-1-null mice exhibited development abnormalities, and histochemical and molecular analyses of these mice revealed an similar to 50% reduction in the number of fetal microvessels in the labyrinthine zone of the placenta relative to that in the wild-type mice. Because we observed a modest reduction in VEGF-A mRNA and protein in the tissues of HS6ST-1-null mice, an HS-dependent defect in cytokine signaling probably contributes to increased embryonic lethality and decreased growth. Biochemical studies of the HS chains isolated from various organs of our HS6ST-1-null mice revealed a marked reduction of GlcNAc(6SO(4)) and HexA-GlcNSO(3)(6SO(4)) levels and a reduced ability to bind Wnt2. Thus, despite the presence of three closely related 6-O-sulfotransferase genes in the mouse genome, HS6ST-1 is the primary one used in HS biosynthesis in most tissues.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; Aichi Med Univ, Lab Anim Res Ctr, Nagakute, Aichi 4801195, Japan; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Aichi Medical University; Aichi Medical University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan.	kimata@aichimed-u.ac.jp						Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Ashikari- Hada S, 2005, J BIOL CHEM, V280, P31508, DOI 10.1074/jbc.M414581200; Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Balasubramaniam V, 2003, AM J PHYSIOL-LUNG C, V284, pL964, DOI 10.1152/ajplung.00421.2002; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bink RJ, 2003, J BIOL CHEM, V278, P31118, DOI 10.1074/jbc.M213124200; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Chen E, 2005, DEV BIOL, V284, P364, DOI 10.1016/j.ydbio.2005.05.032; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Grobe K, 2005, DEVELOPMENT, V132, P3777, DOI 10.1242/dev.01935; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; Habuchi H, 2003, BIOCHEM J, V371, P131, DOI 10.1042/BJ20021259; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; Holmborn K, 2004, J BIOL CHEM, V279, P42355, DOI 10.1074/jbc.C400373200; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497; Ishikawa T, 2001, DEVELOPMENT, V128, P25; Izvolsky KI, 2003, DEV BIOL, V258, P185, DOI 10.1016/S0012-1606(03)00114-3; Izvolsky KI, 2003, AM J PHYSIOL-LUNG C, V285, pL838, DOI 10.1152/ajplung.00081.2003; Kamimura K, 2001, J BIOL CHEM, V276, P17014, DOI 10.1074/jbc.M011354200; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Monkley SJ, 1996, DEVELOPMENT, V122, P3343; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nagai N, 2004, J CELL SCI, V117, P3331, DOI 10.1242/jcs.01191; Nakato H, 2002, BBA-GEN SUBJECTS, V1573, P312, DOI 10.1016/S0304-4165(02)00398-7; Nogami K, 2004, J BIOL CHEM, V279, P8219, DOI 10.1074/jbc.M307304200; Ono K, 1999, GLYCOBIOLOGY, V9, P705, DOI 10.1093/glycob/9.7.705; PETERS RW, 1977, METHODS PRENATAL TOX, P153; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Powell AK, 2004, GLYCOBIOLOGY, V14, p17R, DOI 10.1093/glycob/cwh051; Pratt T, 2006, J NEUROSCI, V26, P6911, DOI 10.1523/JNEUROSCI.0505-06.2006; Regnault TRH, 2002, PLACENTA, V23, P132, DOI 10.1053/plac.2001.0757; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Sedita J, 2004, DEV DYNAM, V231, P782, DOI 10.1002/dvdy.20173; Stickens D, 2005, DEVELOPMENT, V132, P5055, DOI 10.1242/dev.02088; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; THURLBEC.WM, 1967, AM REV RESPIR DIS, V95, P752; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Wang LC, 2005, NAT IMMUNOL, V6, P902, DOI 10.1038/ni1233; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Zhang XB, 2001, CANCER RES, V61, P6050	60	93	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15578	15588		10.1074/jbc.M607434200	http://dx.doi.org/10.1074/jbc.M607434200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17405882	hybrid			2022-12-27	WOS:000246589600035
J	Hiscott, J				Hiscott, John			Triggering the innate antiviral response through IRF-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							INTERFERON REGULATORY FACTOR-3; NF-KAPPA-B; RIG-I; VIRAL-INFECTION; VIRUS-INFECTION; IKK-EPSILON; CRYSTAL-STRUCTURE; IMMUNE-RESPONSES; RNA HELICASE; TRANSCRIPTION FACTORS	Rapid induction of type I interferon (IFN) expression is a central event in the establishment of the innate immune response against viral infection and requires the activation of multiple transcriptional proteins following engagement and signaling through Toll-like receptor-dependent and -independent pathways. The transcription factor interferon regulatory factor-3 (IRF-3) contributes to a first line of defense against viral infection by inducing the production of IFN-beta that in turn amplifies the IFN response and the development of antiviral activity. In murine knock-out models, the absence of IRF-3 and the closely related IRF-7 ablates IFN production and increases viral pathogenesis, thus supporting a pivotal role for IRF-3/IRF-7 in the development of the host antiviral response.	Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada.	john.hiscott@mcgill.ca						Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Banchereau J, 2006, IMMUNITY, V25, P383, DOI 10.1016/j.immuni.2006.08.010; Barnes BJ, 2004, J BIOL CHEM, V279, P45194, DOI 10.1074/jbc.M400726200; Bibeau-Poirier A, 2006, J IMMUNOL, V177, P5059, DOI 10.4049/jimmunol.177.8.5059; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Caillaud A, 2005, J BIOL CHEM, V280, P17671, DOI 10.1074/jbc.M411389200; Civas A, 2006, J BIOL CHEM, V281, P4856, DOI 10.1074/jbc.M506812200; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Elco CP, 2005, J VIROL, V79, P3920, DOI 10.1128/JVI.79.7.3920-3929.2005; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009; Honda K, 2006, NAT REV IMMUNOL, V6, P644, DOI 10.1038/nri1900; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Komuro A, 2006, J VIROL, V80, P12332, DOI 10.1128/JVI.01325-06; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Kumar H, 2006, J EXP MED, V203, P1795, DOI 10.1084/jem.20060792; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 2006, J BIOL CHEM, V281, P2095, DOI 10.1074/jbc.M510326200; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Okumura A, 2006, P NATL ACAD SCI USA, V103, P1440, DOI 10.1073/pnas.0510518103; Paz S, 2006, CELL MOL BIOL, V52, P17, DOI 10.1170/T694; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Peters RT, 2001, BBA-REV CANCER, V1471, pM57, DOI 10.1016/S0304-419X(00)00024-X; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Qin BY, 2005, STRUCTURE, V13, P1269, DOI 10.1016/j.str.2005.06.011; Qin BY, 2003, NAT STRUCT BIOL, V10, P913, DOI 10.1038/nsb1002; Romieu-Mourez R, 2006, CANCER RES, V66, P10576, DOI 10.1158/0008-5472.CAN-06-1279; Saito T, 2007, P NATL ACAD SCI USA, V104, P582, DOI 10.1073/pnas.0606699104; Saitoh T, 2005, J IMMUNOL, V174, P1507, DOI 10.4049/jimmunol.174.3.1507; Saitoh T, 2006, NAT IMMUNOL, V7, P598, DOI 10.1038/ni1347; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Takahasi K, 2003, NAT STRUCT BIOL, V10, P922, DOI 10.1038/nsb1001; Tenoever BR, 2007, SCIENCE, V315, P1274, DOI 10.1126/science.1136567; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	64	356	366	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15325	15329		10.1074/jbc.R700002200	http://dx.doi.org/10.1074/jbc.R700002200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17395583	hybrid			2022-12-27	WOS:000246589600007
J	Holst, B; Mokrosinski, J; Lang, M; Brandt, E; Nygaard, R; Frimurer, TM; Beck-Sickinger, AG; Schwartz, TW				Holst, Birgitte; Mokrosinski, Jacek; Lang, Manja; Brandt, Erik; Nygaard, Rie; Frimurer, Thomas M.; Beck-Sickinger, Annette G.; Schwartz, Thue W.			Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LIGAND-BINDING POCKET; CONSTITUTIVE ACTIVITY; STRUCTURAL BASIS; PITUITARY-GLAND; C5A RECEPTOR; ACTIVATION; SITE; BETA(2)-ADRENOCEPTOR; SECRETAGOGUES	The carboxyamidated wFwLL peptide was used as a core ligand to probe the structural basis for agonism versus inverse agonism in the constitutively active ghrelin receptor. In the ligand, an efficacy switch could be built at the N terminus, as exemplified by AwFwLL, which functioned as a high potency agonist, whereas KwFwLL was an equally high potency inverse agonist. The wFw-containing peptides, agonists as well as inverse agonists, were affected by receptor mutations covering the whole main ligand-binding pocket with key interaction sites being an aromatic cluster in transmembrane (TM)-VI and -VII and residues on the opposing face of TM-III. Gain-of-function in respect of either increased agonist or inverse agonist potency or swap between high potency versions of these properties was obtained by substitutions at a number of positions covering a broad area of the binding pocket on TM-III, -IV, and -V. However, in particular, space-generating substitutions at position III:04 shifted the efficacy of the ligands from inverse agonism toward agonism, whereas similar substitutions at position III:08, one helical turn below, shifted the efficacy from agonism toward inverse agonism. It is suggested that the relative position of the ligand in the binding pocket between this "efficacy shift region" on TM-III and the opposing aromatic cluster on TM-VI and TM-VII leads either to agonism, i.e. in a superficial binding mode, or it leads to inverse agonism, i.e. in a more profound binding mode. This relationship between different binding modes and opposite efficacy is in accordance with the Global Toggle Switch model for 7TM receptor activation.	Univ Copenhagen, Panum Inst, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark; Univ Leipzig, Inst Biochem, Fac Biosci Pharm & Psychol, D-04103 Leipzig, Germany; 7TM Pharma AS, DK-2970 Horsholm, Denmark	University of Copenhagen; Leipzig University	Holst, B (corresponding author), Univ Copenhagen, Panum Inst, Mol Pharmacol Lab, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	b.holst@molpharm.dk	Mokrosinski, Jacek/M-1963-2019; Nygaard, Rie/B-7351-2013; Brandt, Erik/AHI-7905-2022; Mokrosinski, Jacek/J-9506-2012	Mokrosinski, Jacek/0000-0001-5008-0457; Brandt, Erik/0000-0001-7051-0784; Mokrosinski, Jacek/0000-0003-1710-1679; Holst, Birgitte/0000-0001-7432-097X; Frimruer, Thomas/0000-0002-9682-8245; Schwartz, Thue W./0000-0002-0261-6904				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Behr B, 2006, J BIOL CHEM, V281, P18120, DOI 10.1074/jbc.M601791200; Buck E, 2005, P NATL ACAD SCI USA, V102, P2719, DOI 10.1073/pnas.0500016102; Buck E, 2005, J BIOL CHEM, V280, P4009, DOI 10.1074/jbc.C400500200; Claude PA, 1996, P NATL ACAD SCI USA, V93, P5715, DOI 10.1073/pnas.93.12.5715; DEL CR, 2004, MOL PHARM, V66, P356; Elling CE, 2006, J BIOL CHEM, V281, P17337, DOI 10.1074/jbc.M512510200; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Han SJ, 2005, J BIOL CHEM, V280, P34849, DOI 10.1074/jbc.M506711200; HOFMANN KP, 1999, NOVART FDN SYMP, V224, P175; Hoist B, 2006, J CLIN INVEST, V116, P637, DOI 10.1172/JCI27999; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Holst B, 1998, MOL PHARMACOL, V53, P166, DOI 10.1124/mol.53.1.166; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; Holst B, 2005, MOL ENDOCRINOL, V19, P2400, DOI 10.1210/me.2005-0059; Holst B, 2006, MOL PHARMACOL, V70, P936, DOI 10.1124/mol.106.024422; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kobilka B, 2004, MOL PHARMACOL, V65, P1060, DOI 10.1124/mol.65.5.1060; Lang MJ, 2004, J MED CHEM, V47, P1153, DOI 10.1021/jm030982t; Lewis JW, 2000, BIOCHEMISTRY-US, V39, P599, DOI 10.1021/bi991860z; Liapakis G, 2004, MOL PHARMACOL, V65, P1181, DOI 10.1124/mol.65.5.1181; Muccioli G, 1998, J ENDOCRINOL, V157, P99, DOI 10.1677/joe.0.1570099; Muccioli G, 2001, J ENDOCRINOL INVEST, V24, pRC7, DOI 10.1007/BF03343831; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Pantel J, 2006, J CLIN INVEST, V116, P760, DOI 10.1172/JCI25303; Rueda M, 2007, P NATL ACAD SCI USA, V104, P796, DOI 10.1073/pnas.0605534104; Schwartz T.W., 2002, TXB RECEPTOR PHARM, P81; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Shen CP, 2006, EUR J PHARMACOL, V531, P41, DOI 10.1016/j.ejphar.2005.12.026; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Srinivasan S, 2004, J CLIN INVEST, V114, P1158, DOI 10.1172/JCI200421927; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Wang HJ, 2004, J CLIN ENDOCR METAB, V89, P157, DOI 10.1210/jc.2003-031395	37	70	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15799	15811		10.1074/jbc.M609796200	http://dx.doi.org/10.1074/jbc.M609796200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17371869	hybrid			2022-12-27	WOS:000246589600055
J	Mitchell, D; O'Meara, SJ; Gaffney, A; Crean, JKG; Kinsella, BT; Godson, C				Mitchell, Derick; O'Meara, Sarah J.; Gaffney, Andrew; Crean, John K. G.; Kinsella, B. Therese; Godson, Catherine			The lipoxin A(4) receptor is coupled to SHP-2 activation - Implications for regulation of receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RENAL MESANGIAL CELLS; SIGNAL-TRANSDUCTION; IN-VIVO; PHOSPHOTYROSINE PHOSPHATASE; PEROXIREDOXIN-II; PDGF RECEPTOR; BETA-SUBUNIT; PROTEIN; PHOSPHORYLATION	Mesangial cell proliferation is pivotal to the pathology of glomerular injury in inflammation. We have previously reported that lipoxins, endogenously produced eicosanoids with anti-inflammatory and pro-resolution bioactions, can inhibit mesangial cell proliferation in response to several agents. This process is associated with elaborate receptor cross-talk involving modification receptor tyrosine kinase phosphorylation (McMahon, B., Mitchell, D., Shattock, R., Martin, F., Brady, H. R., and Godson, C. (2002) FASEB J. 16, 1817-1819). Here we demonstrate that the lipoxin A(4) (LXA4) receptor is coupled to activation and recruitment of the SHP-2 (SH2 domain-containing tyrosine phosphatase-2) within a lipid raft microdomain. Using site-directed mutagenesis of the cytosolic domain of the platelet-derived growth factor receptor beta (PDGFR beta), we report that mutation of the sites for phosphatidylinositol 3-kinase (Tyr(740) and Tyr(751)) and SHP-2 (Tyr(763) and Tyr(1009)) recruitment specifically inhibit the effect of LXA4 on the PDGFR beta signaling; furthermore inhibition of SHP-2 expression with short interfering RNA constructs blocked the effect of LXA4 on PDGFR beta phosphorylation. We demonstrate that association of the PDGFR beta with lipid raft microdomains renders it susceptible to LXA(4)-mediated dephosphorylation by possible reactivation of oxidatively inactivated SHP-2. These data further elaborate on the potential mechanisms underlying the anti-inflammatory, proresolution, and anti-fibrotic bioactions of lipoxins.	Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland; Univ Coll Dublin, Sch Biomol & Biomed Sci, Ctr Diabet Res, UCD Conway Inst, Dublin 4, Ireland	University College Dublin; University College Dublin	Godson, C (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland.	catherine.godson@ucd.ie		Kinsella, B. Therese/0000-0003-3072-941X; Godson, Catherine/0000-0003-0655-1041; /0000-0002-4337-6177	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Duchene J, 2002, J BIOL CHEM, V277, P40375, DOI 10.1074/jbc.M202744200; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Fielding PE, 2004, BIOCHEMISTRY-US, V43, P2578, DOI 10.1021/bi035442c; Fiorucci S, 2004, J PHARMACOL EXP THER, V309, P1174, DOI 10.1124/jpet.103.063651; Francois H, 2004, FASEB J, V18, P926, DOI 10.1096/fj.03-0702fje; Gilbert RE, 2001, KIDNEY INT, V59, P1324, DOI 10.1046/j.1523-1755.2001.0590041324.x; Giles KM, 2001, J IMMUNOL, V167, P976, DOI 10.4049/jimmunol.167.2.976; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Incoronato M, 2004, CELL SIGNAL, V16, P847, DOI 10.1016/j.cellsig.2004.01.002; JOHNSON RJ, 1993, J AM SOC NEPHROL, V4, P119; Kallin A, 2004, J BIOL CHEM, V279, P17897, DOI 10.1074/jbc.M312996200; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; Keilhack H, 2001, J CELL BIOL, V152, P325, DOI 10.1083/jcb.152.2.325; Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Lamb ME, 2002, BIOCHEMISTRY-US, V41, P14340, DOI 10.1021/bi020231d; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Maderna P, 2005, J IMMUNOL, V174, P3727, DOI 10.4049/jimmunol.174.6.3727; Markova B, 2003, BIOCHEMISTRY-US, V42, P2691, DOI 10.1021/bi0265574; McMahon B, 2004, AM J PHYSIOL-RENAL, V286, pF189, DOI 10.1152/ajprenal.00224.2003; McMahon B, 2002, FASEB J, V16, P1817, DOI 10.1096/fj.02-0416fje; McMahon B, 2000, J BIOL CHEM, V275, P27566; Mitchell D, 2004, AM J PATHOL, V164, P937, DOI 10.1016/S0002-9440(10)63181-1; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ostendorf T, 2001, J AM SOC NEPHROL, V12, P909, DOI 10.1681/ASN.V125909; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Perretti M, 2002, J IMMUNOL, V169, P2085, DOI 10.4049/jimmunol.169.4.2085; Phalen TJ, 2006, J CELL BIOL, V175, P779, DOI 10.1083/jcb.200606005; Rodgers K, 2005, AM J PATHOL, V167, P683, DOI 10.1016/S0002-9440(10)62043-3; Sato Y, 2004, BIOMED PHARMACOTHER, V58, P381, DOI 10.1016/j.biopha.2004.05.006; Serhan CN, 2001, J CLIN INVEST, V107, P1481, DOI 10.1172/JCI13375; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035	46	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15606	15618		10.1074/jbc.M611004200	http://dx.doi.org/10.1074/jbc.M611004200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403678	hybrid			2022-12-27	WOS:000246589600038
J	Samuel, CE				Samuel, Charles E.			Innate immunity minireview series: Making biochemical sense of nucleic acid sensors that trigger antiviral innate immunity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review									Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Biomol Sci & Engn Program, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	samuel@lifesci.ucsb.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012520, R01AI020611, R37AI012520] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-12520, AI-20611] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Hiscott J, 2007, J BIOL CHEM, V282, P15325, DOI 10.1074/jbc.R700002200; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Uematsu S, 2007, J BIOL CHEM, V282, P15319, DOI 10.1074/jbc.R700009200; Yoneyama M, 2007, J BIOL CHEM, V282, P15315, DOI 10.1074/jbc.R700007200	5	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15313	15314		10.1074/jbc.R700013200	http://dx.doi.org/10.1074/jbc.R700013200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17395579	hybrid			2022-12-27	WOS:000246589600004
J	Borsig, L; Wang, LC; Cavalcante, MCM; Cardilo-Reis, L; Ferreira, PL; Mourao, PAS; Esko, JD; Pavao, MSG				Borsig, Lubor; Wang, Lianchun; Cavalcante, Moises C. M.; Cardilo-Reis, Larissa; Ferreira, Paola L.; Mourao, Paulo A. S.; Esko, Jeffrey D.; Pavao, Mauro S. G.			Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber - Effect on tumor metastasis and neutrophil recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-AGGREGATING ACTIVITIES; P-SELECTIN; LUNG COLONIZATION; CARCINOMA MUCINS; CELL-ADHESION; IN-VIVO; HEPARIN; CANCER; LIGANDS; COLON	Heparin is an excellent inhibitor of P- and L-selectin binding to the carbohydrate determinant, sialyl Lewisx. As a consequence of its anti-selectin activity, heparin attenuates metastasis and inflammation. Here we show that fucosylated chondroitin sulfate ( FucCS), a polysaccharide isolated from sea cucumber composed of a chondroitin sulfate backbone substituted at the 3-position of the beta-D-glucuronic acid residues with 2,4-disulfated alpha-L-fucopyranosyl branches, is a potent inhibitor of P- and L-selectin binding to immobilized sialyl Lewisx and LS180 carcinoma cell attachment to immobilized P- and L-selectins. Inhibition occurs in a concentration-dependent manner. Furthermore, FucCS was 4-8-fold more potent than heparin in the inhibition of the P- and L-selectin- sialyl Lewis(x) interactions. No inhibition of E-selectin was observed. FucCS also inhibited lung colonization by adenocarcinoma MC-38 cells in an experimental metastasis model in mice, as well as neutrophil recruitment in two models of inflammation ( thioglycollate-induced peritonitis and lipopolysaccharide-induced lung inflammation). Inhibition occurred at a dose that produces no significant change in plasma activated partial thromboplastin time. Removal of the sulfated fucose branches on the FucCS abolished the inhibitory effect in vitro and in vivo. Overall, the results suggest that invertebrate FucCS may be a potential alternative to heparin for blocking metastasis and inflammatory reactions without the undesirable side effects of anticoagulant heparin.	Univ Fed Rio de Janeiro, Lab Tecido Conjuntivo, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Glicobiol, BR-21941590 Rio De Janeiro, Brazil; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; University of California System; University of California San Diego	Pavao, MSG (corresponding author), Univ Fed Rio de Janeiro, Lab Tecido Conjuntivo, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio De Janeiro, Brazil.	mpavao@hucff.ufrj.br	Mourao, Paulo/AAA-5386-2020; Pavao, Mauro Sergio Goncalves/B-1979-2010	Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271; Borsig, Lubor/0000-0003-2263-9545	FOGARTY INTERNATIONAL CENTER [R03TW005775] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW05775] Funding Source: Medline; NCI NIH HHS [CA11227] Funding Source: Medline; NHLBI NIH HHS [HL57345] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Cummings RD, 1999, BRAZ J MED BIOL RES, V32, P519, DOI 10.1590/S0100-879X1999000500004; deMoraes VLG, 1996, BRIT J PHARMACOL, V117, P1792; DENNIS JW, 1987, CANCER METAST REV, V5, P185, DOI 10.1007/BF00046998; Engelberg H, 1999, CANCER-AM CANCER SOC, V85, P257, DOI 10.1002/(SICI)1097-0142(19990115)85:2<257::AID-CNCR1>3.0.CO;2-2; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; FIELDING LP, 1992, LANCET, V340, P502, DOI 10.1016/0140-6736(92)91708-G; Foster MM, 2003, CANCER RES, V63, P2775; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Hakomori S, 1996, CANCER RES, V56, P5309; Hettiarachchi RJK, 1998, CANCER, V83, P180, DOI 10.1002/(SICI)1097-0142(19980701)83:1<180::AID-CNCR24>3.0.CO;2-S; Kannagi R, 1997, GLYCOCONJUGATE J, V14, P577, DOI 10.1023/A:1018532409041; KARPATKIN S, 1988, J CLIN INVEST, V81, P1012, DOI 10.1172/JCI113411; Kato Y, 1997, CANCER RES, V57, P3040; Kim YJ, 1999, AM J PATHOL, V155, P461, DOI 10.1016/S0002-9440(10)65142-5; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Kragh M, 2005, INT J ONCOL, V27, P1159; Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X; LEBEAU B, 1994, CANCER, V74, P38, DOI 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Ludwig RJ, 2006, THROMB HAEMOSTASIS, V95, P535, DOI 10.1160/TH05-07-0515; Ludwig RJ, 2004, CANCER RES, V64, P2743, DOI 10.1158/0008-5472.CAN-03-1054; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1988, LEUKEMIA LYMPHOMA, V29, P1; Mourao PAS, 1996, J BIOL CHEM, V271, P23973, DOI 10.1074/jbc.271.39.23973; Nieswandt B, 1999, CANCER RES, V59, P1295; Nitti D, 1997, EUR J CANCER, V33, P1209, DOI 10.1016/S0959-8049(97)00052-X; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; Ornstein DL, 1999, HAEMOSTASIS, V29, P48; RUGGIERO J, 1994, CARBOHYD RES, V256, P275, DOI 10.1016/0008-6215(94)84213-2; Stevenson JL, 2005, CLIN CANCER RES, V11, P7003, DOI 10.1158/1078-0432.CCR-05-1131; TANAKA NG, 1986, INVAS METAST, V6, P209; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; TOHGO A, 1986, INVAS METAST, V6, P58; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; Wang LC, 2002, J CLIN INVEST, V110, P127, DOI 10.1172/JCI200214996; Wei M, 2005, CANCER LETT, V229, P123, DOI 10.1016/j.canlet.2005.01.034; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; ZACHARSKI LR, 1984, CANCER, V53, P2046, DOI 10.1002/1097-0142(19840515)53:10<2046::AID-CNCR2820531007>3.0.CO;2-F; Zancan P, 2004, BLOOD COAGUL FIBRIN, V15, P45, DOI 10.1097/00001721-200401000-00008; Zielinski CC, 2000, NEW ENGL J MED, V342, P1991, DOI 10.1056/NEJM200006293422612	48	155	174	2	48	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14984	14991		10.1074/jbc.M610560200	http://dx.doi.org/10.1074/jbc.M610560200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17371880	Green Accepted, hybrid			2022-12-27	WOS:000246589000037
J	Fratti, RA; Collins, KM; Hickey, CM; Wickner, W				Fratti, Rutilio A.; Collins, Kevin M.; Hickey, Christopher M.; Wickner, William			Stringent 3Q center dot 1R composition of the SNARE 0-layer can be bypassed for fusion by compensatory SNARE mutation or by lipid bilayer modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEX RING DOMAIN; IN-VITRO REACTIONS; MEMBRANE-FUSION; VACUOLE FUSION; T-SNARE; TRANSMEMBRANE SEGMENTS; COMPLEX REVEALS; ALPHA-SNAP; V-SNARES; DOCKING	SNARE proteins form bundles of four alpha-helical SNARE domains with conserved polar amino acids, 3Q and 1R, at the "0-layer" of the bundle. Previous studies have confirmed the importance of 3Q(.)1R for fusion but have not shown whether it regulates SNARE complex assembly or the downstream functions of assembled SNAREs. Yeast vacuole fusion requires regulatory lipids (ergosterol, phosphoinositides, and diacylglycerol), the Rab Ypt7p, the Rab-effector complex HOPS, and 4 SNAREs: the Q-SNAREs Vti1p, Vam3p, and Vam7p and the R-SNARE Nyv1p. We now report that alterations in the 0-layer Gln or Arg residues of Vam7p or Nyv1p, respectively, strongly inhibit fusion. Vacuoles with wild-type Nyv1p show exquisite discrimination for the wild-type Vam7p over Vam7(Q283R), yet Vam7(Q283R) is preferred by vacuoles with Nyv1(R191Q). Rotation of the position of the arginine in the 0-layer increases the K-m for Vam7p but does not affect the maximal rate of fusion. Vam7(Q283R) forms stable 2Q(.)2R complexes that do not promote fusion. However, fusion is restored by the lipophilic amphiphile chlorpromazine or by the phospholipase C inhibitor U73122, perturbants of the lipid phase of the membrane. Thus, SNARE function as regulated by the 0-layer is intimately coupled to the lipids, which must rearrange for fusion.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Med Sch, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Bill.Wickner@dartmouth.edu	Collins, Kevin/AAA-8989-2019	Collins, Kevin/0000-0001-9930-0924	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023377] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM023377] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhalla A, 2006, NAT STRUCT MOL BIOL, V13, P323, DOI 10.1038/nsmb1076; Bone N, 1998, CURR BIOL, V8, P135, DOI 10.1016/S0960-9822(98)00060-8; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chen XC, 2006, BIOPHYS J, V90, P2062, DOI 10.1529/biophysj.105.071415; Collins KM, 2005, EMBO J, V24, P1775, DOI 10.1038/sj.emboj.7600658; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; Dennison SM, 2006, BIOPHYS J, V90, P1661, DOI 10.1529/biophysj.105.069617; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; GARRETT MD, 1995, METHOD ENZYMOL, V257, P232; Graf CT, 2005, MOL BIOL CELL, V16, P2263, DOI 10.1091/mbc.E04-09-0830; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Hofmann MW, 2006, J MOL BIOL, V364, P1048, DOI 10.1016/j.jmb.2006.09.077; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Jun Y, 2004, J BIOL CHEM, V279, P53186, DOI 10.1074/jbc.M411363200; Jun Y, 2006, EMBO J, V25, P5260, DOI 10.1038/sj.emboj.7601413; Katz L, 2000, MOL BIOL CELL, V11, P3849, DOI 10.1091/mbc.11.11.3849; Langosch D, 2001, J MOL BIOL, V311, P709, DOI 10.1006/jmbi.2001.4889; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Merz AJ, 2004, P NATL ACAD SCI USA, V101, P11548, DOI 10.1073/pnas.0404583101; Murdock DR, 2005, BIOPHYS J, V89, P4090, DOI 10.1529/biophysj.105.069872; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Oghalai JS, 2000, SCIENCE, V287, P658, DOI 10.1126/science.287.5453.658; Raucher D, 2001, J CELL SCI, V114, P3759; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Siegel DP, 2006, BIOPHYS J, V90, P200, DOI 10.1529/biophysj.105.070466; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Stroupe C, 2006, EMBO J, V25, P1579, DOI 10.1038/sj.emboj.7601051; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Wang Y, 2001, J BIOL CHEM, V276, P28598, DOI 10.1074/jbc.M101644200; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X	52	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14861	14867		10.1074/jbc.M700971200	http://dx.doi.org/10.1074/jbc.M700971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17400548	hybrid			2022-12-27	WOS:000246589000022
J	Kim, MJ; Park, SH; Opella, SJ; Marsilje, TH; Michellys, PY; Seidel, HM; Tian, SS				Kim, Min-Ju; Park, Sang Ho; Opella, Stanley J.; Marsilje, Thomas H.; Michellys, Pierre-Yves; Seidel, H. Martin; Tian, Shin-Shay			NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; HIGH-RESOLUTION NMR; ERYTHROPOIETIN RECEPTOR; MEMBRANE-PROTEINS; DIPOLAR COUPLINGS; LIGAND; MEGAKARYOCYTOPOIESIS; OLIGOMERIZATION; DIMERIZATION; SENSITIVITY	Thrombopoietin (Tpo) is a glycoprotein growth factor that supports hematopoietic stem cell survival and expansion and is the principal regulator of megakaryocyte growth and differentiation. Several small, nonpeptidyl molecules have been identified as selective human Tpo receptor (hTpoR) agonists. To understand how the small molecule Tpo mimic SB394725 interacts and activates hTpoR, we performed receptor domain swap and mutagenesis studies. The results suggest that SB394725 interacts specifically with the extracellular juxtamembrane region (JMR) and the transmembrane (TM) domain of hTpoR. Solution and solid-state NMR structural studies using a peptide containing the JMR-TM sequences showed that this region of hTpoR, unexpectedly, consists of two alpha-helices separated by a few nonhelical residues. SB394725 interacts specifically with His-499 in the TM domain and a few distinct residues in the JMR-TM region and affects several specific C-terminal TM domain residues. The unique structural information provided by these studies both sheds light on the distinctive mechanism of action of SB394725 and provides valuable insight into the mechanism of ligand-induced cytokine receptor activation.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Novartis; University of California System; University of California San Diego	Tian, SS (corresponding author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	stian@gnf.org	Park, Sang Ho/AAK-3432-2020		NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066978] Funding Source: NIH RePORTER; NIBIB NIH HHS [P41 EB002031] Funding Source: Medline; NIGMS NIH HHS [R01 GM066978] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boger DL, 2001, BIOORGAN MED CHEM, V9, P557, DOI 10.1016/S0968-0896(00)00276-5; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; De Angelis AA, 2004, J AM CHEM SOC, V126, P15340, DOI 10.1021/ja045631y; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Deng BJ, 1998, BLOOD, V92, P1981, DOI 10.1182/blood.V92.6.1981.418k15_1981_1988; Ding KY, 2003, J MAGN RESON, V163, P208, DOI 10.1016/S1090-7807(03)00081-8; Doyle ML, 2003, J BIOL CHEM, V278, P9426, DOI 10.1074/jbc.M209220200; Duffy KJ, 2001, J MED CHEM, V44, P3730, DOI 10.1021/jm010283l; Erickson-Miller CL, 2005, EXP HEMATOL, V33, P85, DOI 10.1016/j.exphem.2004.09.006; ERICKSONMILLER CL, 2004, AM SOC HEM 46 ANN M, V104, pA796; EZUMI Y, 1995, FEBS LETT, V374, P48, DOI 10.1016/0014-5793(95)01072-M; FASSI A, 1996, BLOOD, V88, P1399; Forbes LV, 2002, ONCOGENE, V21, P5981, DOI 10.1038/sj.onc.1205767; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; Ishii Y, 2001, J BIOMOL NMR, V21, P141, DOI 10.1023/A:1012417721455; Kaushansky K, 2002, ONCOGENE, V21, P3359, DOI 10.1038/sj.onc.1205323; Kubatzky KF, 2005, J BIOL CHEM, V280, P14844, DOI 10.1074/jbc.M411251200; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Kuter DJ, 2002, BLOOD, V100, P3457, DOI 10.1182/blood.V100.10.3457; LEVITT MH, 1986, J CHEM PHYS, V84, P4243, DOI 10.1063/1.450046; Lu XH, 2006, J BIOL CHEM, V281, P7002, DOI 10.1074/jbc.M512638200; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Nakamura T, 2006, BLOOD, V107, P4300, DOI 10.1182/blood-2005-11-4433; Opella SJ, 1997, NAT STRUCT BIOL, V4, P845; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Park SH, 2005, J MOL BIOL, V350, P310, DOI 10.1016/j.jmb.2005.05.004; Park SH, 2003, J MOL BIOL, V333, P409, DOI 10.1016/j.jmb.2003.08.048; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; STAUBER DJ, 2003, HDB CELL SIGNALING, V1, P251	31	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14253	14261		10.1074/jbc.M611616200	http://dx.doi.org/10.1074/jbc.M611616200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369254	hybrid			2022-12-27	WOS:000246245800036
J	Bottomley, MJ; Muraglia, E; Bazzo, R; Carfi, A				Bottomley, Matthew J.; Muraglia, Ester; Bazzo, Renzo; Carfi, Andrea			Molecular insights into quorum sensing in the human pathogen Pseudomonas aeruginosa from the structure of the virulence regulator LasR bound to its autoinducer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOSERINE LACTONES; TRANSCRIPTIONAL ACTIVATOR; GENE-EXPRESSION; DNA-BINDING; PROTEIN; BACTERIA; INHIBITORS; SIGNAL; SPECIFICITY; BIOFILMS	Many Gram-negative bacteria communicate via molecules called autoinducers to coordinate the activities of their populations. Such communication is termed quorum sensing and can regulate pathogenic virulence factor production and antimicrobial resistance. The quorum sensing system of Pseudomonas aeruginosa is currently the most intensively researched, because this bacterium is an opportunistic human pathogen annually responsible for the death of thousands of cystic fibrosis sufferers and many other immunocompromised individuals. Quorum sensing inhibitors can attenuate the pathogenicity of P. aeruginosa. Here we present the crystal structure of the P. aeruginosa LasR ligand-binding domain bound to its autoinducer 3-oxo-C-12-acylhomoserine lactone. The structure is a symmetrical dimer, with each monomer exhibiting an alpha-beta-alpha fold similar to the TraR and SdiA quorum sensing proteins of Agrobacterium tumefaciens and Escherichia coli. The structure was determined up to 1.8- angstrom resolution and reveals the atomic interactions between LasR and its autoinducer. The monomer structures of LasR, TraR, and SdiA are comparable but display differences in their quaternary organization. Inspection of their binding sites shows some unexpected variations resulting in quite different conformations of their bound autoinducers. We modeled interactions between LasR and various quorum sensing inhibitors, yielding insight into their possible mechanisms of action. The structure also provides a platform for the optimization, or de novo design, of quorum sensing inhibitors.	Ist Ric Biol Mol, I-00040 Rome, Italy		Bottomley, MJ (corresponding author), Ist Ric Biol Mol, Via Pontina Km 30-600, I-00040 Rome, Italy.	matthew_bottomley@merck.com						ANWAR H, 1990, ANTIMICROB AGENTS CH, V34, P2043, DOI 10.1128/AAC.34.11.2043; Bjarnsholt T, 2005, MICROBIOL-SGM, V151, P3873, DOI 10.1099/mic.0.27955-0; Bjarnsholt T, 2007, ANAL BIOANAL CHEM, V387, P409, DOI 10.1007/s00216-006-0774-x; Bottomley MJ, 2001, NAT STRUCT BIOL, V8, P626, DOI 10.1038/89675; Cabrol SN, 2003, J BACTERIOL, V185, P7222, DOI 10.1128/JB.185.24.7222-7230.2003; Costerton JW, 2001, TRENDS MICROBIOL, V9, P50, DOI 10.1016/S0966-842X(00)01918-1; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; Fuqua C, 2006, J BACTERIOL, V188, P3169, DOI 10.1128/JB.188.9.3169-3171.2006; Fuqua C, 2002, NAT REV MOL CELL BIO, V3, P685, DOI 10.1038/nrm907; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GAMBELLO MJ, 1993, INFECT IMMUN, V61, P1180, DOI 10.1128/IAI.61.4.1180-1184.1993; Givskov M, 1996, J BACTERIOL, V178, P6618, DOI 10.1128/jb.178.22.6618-6622.1996; Hentzer M, 2003, EMBO J, V22, P3803, DOI 10.1093/emboj/cdg366; Hentzer M, 2002, MICROBIOL-SGM, V148, P87, DOI 10.1099/00221287-148-1-87; Heras B, 2005, ACTA CRYSTALLOGR D, V61, P1173, DOI 10.1107/S0907444905019451; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Juhas M, 2005, ENVIRON MICROBIOL, V7, P459, DOI 10.1111/j.1462-2920.2005.00769.x; Kiratisin P, 2002, J BACTERIOL, V184, P4912, DOI 10.1128/JB.184.17.4912-4919.2002; Latifi A, 1996, MOL MICROBIOL, V21, P1137, DOI 10.1046/j.1365-2958.1996.00063.x; Lequette Y, 2006, J BACTERIOL, V188, P3365, DOI 10.1128/JB.188.9.3365-3370.2006; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Manefield M, 1999, MICROBIOL-SGM, V145, P283, DOI 10.1099/13500872-145-2-283; Muh U, 2006, P NATL ACAD SCI USA, V103, P16948, DOI 10.1073/pnas.0608348103; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEALSON KH, 1970, J BACTERIOL, V104, P313, DOI 10.1128/JB.104.1.313-322.1970; Olsen JA, 2002, BIOORG MED CHEM LETT, V12, P325, DOI 10.1016/S0960-894X(01)00756-9; Parsek MR, 2005, TRENDS MICROBIOL, V13, P27, DOI 10.1016/j.tim.2004.11.007; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Persson T, 2005, CURR MED CHEM, V12, P3103, DOI 10.2174/092986705774933425; Persson T, 2005, ORG BIOMOL CHEM, V3, P253, DOI 10.1039/b415761c; Pesci EC, 1997, J BACTERIOL, V179, P3127, DOI 10.1128/jb.179.10.3127-3132.1997; Rasmussen TB, 2006, INT J MED MICROBIOL, V296, P149, DOI 10.1016/j.ijmm.2006.02.005; Rasmussen TB, 2005, J BACTERIOL, V187, P1799, DOI 10.1128/JB.187.5.1799-1814.2005; Rasmussen TB, 2005, MICROBIOL-SGM, V151, P1325, DOI 10.1099/mic.0.27715-0; Ruby EG, 1996, ANNU REV MICROBIOL, V50, P591, DOI 10.1146/annurev.micro.50.1.591; Schuster M, 2003, J BACTERIOL, V185, P2066, DOI 10.1128/JB.185.7.2066-2079.2003; Schuster M, 2004, P NATL ACAD SCI USA, V101, P15833, DOI 10.1073/pnas.0407229101; Smith KM, 2003, CHEM BIOL, V10, P81, DOI 10.1016/s1074-5521(03)00002-4; Smith RS, 2003, CURR OPIN MICROBIOL, V6, P56, DOI 10.1016/S1369-5274(03)00008-0; Tateda K, 2003, INFECT IMMUN, V71, P5785, DOI 10.1128/IAI.71.10.5785-5793.2003; Van Delden C, 1998, INFECT IMMUN, V66, P4499; Van Delden C, 1998, EMERG INFECT DIS, V4, P551, DOI 10.3201/eid0404.980405; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; Visick KL, 2000, J BACTERIOL, V182, P1779, DOI 10.1128/JB.182.7.1779-1787.2000; WINANS SC, 1992, MICROBIOL REV, V56, P12, DOI 10.1128/MMBR.56.1.12-31.1992; Winans SC, 2002, J BACTERIOL, V184, P873, DOI 10.1128/jb.184.4.873-883.2002; WINSON MK, 1995, P NATL ACAD SCI USA, V92, P9427, DOI 10.1073/pnas.92.20.9427; Winzer K, 2001, INT J MED MICROBIOL, V291, P131, DOI 10.1078/1438-4221-00110; Yao Y, 2006, J MOL BIOL, V355, P262, DOI 10.1016/j.jmb.2005.10.041; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0; Zhang RG, 2002, NATURE, V417, P971, DOI 10.1038/nature00833; Zhu J, 2001, P NATL ACAD SCI USA, V98, P1507, DOI 10.1073/pnas.98.4.1507	56	274	287	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13592	13600		10.1074/jbc.M700556200	http://dx.doi.org/10.1074/jbc.M700556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17363368	hybrid			2022-12-27	WOS:000246060300048
J	Tsuiji, H; Xu, L; Schwartz, K; Gumbiner, BM				Tsuiji, Hitomi; Xu, Liang; Schwartz, Kathleen; Gumbiner, Barry M.			Cadherin conformations associated with dimerization and adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; C-CADHERIN; N-CADHERIN; MORPHOGENESIS; EXPRESSION; CALCIUM; HOMOASSOCIATION; ECTODOMAIN; INTERFACE; MECHANISM	To investigate conformations of C-cadherin associated with functional activity and physiological regulation, we generated monoclonal antibodies (mAbs) that bind differentially to monomeric or dimeric forms. These mAbs recognize conformational epitopes at multiple sites along the C-cadherin ectodomain aside from the well known Trp-2-mediated dimer interface in the N-terminal EC1 domain. Group 1 mAbs, which bind monomer better than dimer and the Trp-2-mutated protein (W2A) better than wild type, recognize epitopes in EC4 or EC5. Dimerization of the W2A mutant protein via a C-terminal immunoglobulin Fc domain restored the dimeric mAb-binding properties to EC4-5 and partial homophilic binding activity but did not restore full cell adhesion activity. Group 2 and Group 3 mAbs, which bind dimer better than monomer and wild type better than W2A, recognize epitopes in EC1 and the interface between EC1 and EC2, respectively. None of the mAbs could distinguish between different physiological states of C-cadherin at the cell surface of either Xenopus embryonic cells or Colo 205 cultured cells, demonstrating that changes in dimerization do not underlie regulation of adhesion activity. On the cell surface the EC3-EC5 domains are much less accessible to mAb binding than EC1 EC2, suggesting that they are masked by the state of cadherin organization or by other molecules. Thus, the EC2-EC5 domains either reflect, or are involved in, cadherin dimerization and organization at the cell surface.	Univ Virginia, Dept Cell Biol, Sch Med, Charlottesville, VA 22903 USA	University of Virginia	Gumbiner, BM (corresponding author), Univ Virginia, Dept Cell Biol, Sch Med, 1300 Jefferson Pk Ave, Charlottesville, VA 22903 USA.	gumbiner@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052717] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Birely J, 2005, DEV BIOL, V280, P162, DOI 10.1016/j.ydbio.2005.01.012; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; BRIEHER WM, 1994, J CELL BIOL, V126, P519, DOI 10.1083/jcb.126.2.519; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; DU XP, 1993, J BIOL CHEM, V268, P23087; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Harrison OJ, 2005, J CELL SCI, V118, P711, DOI 10.1242/jcs.01665; Haussinger D, 2004, EMBO J, V23, P1699, DOI 10.1038/sj.emboj.7600192; Haussinger D, 2002, J MOL BIOL, V324, P823, DOI 10.1016/S0022-2836(02)01137-3; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kitagawa M, 2000, BIOCHEM BIOPH RES CO, V271, P358, DOI 10.1006/bbrc.2000.2636; Koch AW, 2004, CELL MOL LIFE SCI, V61, P1884, DOI 10.1007/s00018-004-4006-2; Leckband D, 2006, ANNU REV BIOMED ENG, V8, P259, DOI 10.1146/annurev.bioeng.8.061505.095753; Masai I, 2003, DEVELOPMENT, V130, P2479, DOI 10.1242/dev.00465; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; SHAPIRO L, 1995, NATURE, V374, P237; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Troyanovsky RB, 2003, MOL CELL BIOL, V23, P7965, DOI 10.1128/MCB.23.22.7965-7972.2003; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; Zhong Y, 1999, J CELL BIOL, V144, P351, DOI 10.1083/jcb.144.2.351	36	19	21	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12871	12882		10.1074/jbc.M611725200	http://dx.doi.org/10.1074/jbc.M611725200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17347145	hybrid			2022-12-27	WOS:000245942800059
J	Nebauer, R; Rosenberger, S; Daum, GRN				Nebauer, Ruth; Rosenberger, Sabine; Daum, Guenther			Phosphatidylethanolamine, a limiting factor of autophagy in yeast strains bearing a defect in the carboxypeptidase Y pathway of vacuolar targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR-MECHANISM; DEGRADATION; MACHINERY; TRANSPORT; REQUIRES; COMPLEX; MUTANTS; ATPASE; GENES	Vps4p and Vps36p of Saccharomyces cerevisiae are involved in the transport of proteins to the vacuole via the carboxypeptidase Y pathway. We found that deletion of VPS4 and VPS36 caused impaired maturation of the vacuolar proaminopeptidase I (pAPI) via autophagy or the cytosol to vacuole targeting pathway. Supplementation with ethanolamine rescued this defect, leading to an increase of the cellular amount of phosphatidylethanolamine (PtdEtn), an enhanced level of the PtdEtn-binding autophagy protein Atg8p and a balanced rate of autophagy. We also discovered that maturation of pAPI was generally affected by PtdEtn depletion in a psd1 Delta psd2 Delta mutant due to reduced recruitment of Atg8p to the preautophagosomal structure. Ethanolamine supplementation provided the necessary amounts of PtdEtn for complete maturation of pAPI. Since the expression level of Atg8p was not compromised in the psd1 Delta psd2 Delta strain, we concluded that the amount of available PtdEtn was limiting. Thus, PtdEtn appears to be a limiting factor for the balance of the carboxypeptidase Y pathway and autophagy/the cytosol to vacuole targeting pathway in the yeast.	Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	Graz University of Technology	Daum, GRN (corresponding author), Graz Univ Technol, Inst Biochem, Petersgasse 12-2, A-8010 Graz, Austria.	guenther.daum@tugraz.at						Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Birner R, 2003, MOL BIOL CELL, V14, P370, DOI 10.1091/mbc.E02-05-0263; Birner R, 2003, INT REV CYTOL, V225, P273, DOI 10.1016/S0074-7696(05)25007-6; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; Burke D., 2000, METHODS YEAST GENETI; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hanson PK, 2002, J CELL SCI, V115, P2725; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meiling-Wesse K, 2002, FEBS LETT, V530, P174, DOI 10.1016/S0014-5793(02)03456-7; MENON AK, 1992, J BIOL CHEM, V267, P15277; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Nebauer R, 2004, TOP CURR GENET, V6, P125; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Teter SA, 2001, J BIOL CHEM, V276, P2083, DOI 10.1074/jbc.C000739200; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Westphal V, 1996, J BIOL CHEM, V271, P11865, DOI 10.1074/jbc.271.20.11865; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Zahn R, 2001, J CELL SCI, V114, P1935	38	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16736	16743		10.1074/jbc.M611345200	http://dx.doi.org/10.1074/jbc.M611345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428789	hybrid			2022-12-27	WOS:000246946500005
J	Fewou, SN; Ramakrishnan, H; Bussow, H; Gieselmann, V; Eckhardt, M				Fewou, Simon Ngamli; Ramakrishnan, Hariharasubramanian; Buessow, Heinrich; Gieselmann, Volkmar; Eckhardt, Matthias			Down-regulation of polysialic acid is required for efficient myelin formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CENTRAL-NERVOUS-SYSTEM; GROUP-B-MENINGOCOCCI; PSA-NCAM; N-CAM; NEGATIVE REGULATION; ENZYMATIC-ACTIVITY; PRECURSOR CELLS; FYN KINASE; OLIGODENDROCYTES	Oligodendrocyte precursor cells modify the neural cell adhesion molecule ( NCAM) by the attachment of polysialic acid ( PSA). Upon further differentiation into mature myelinating oligodendrocytes, however, oligodendrocyte precursor cells down-regulate PSA synthesis. In order to address the question of whether this down-regulation is a necessary prerequisite for the myelination process, transgenic mice expressing the polysialyltransferase ST8SiaIV under the control of the proteolipid protein promoter were generated. In these mice, postnatal down-regulation of PSA in oligodendrocytes was abolished. Most NCAM-120, the characteristic NCAM isoform in oligodendrocytes, carried PSA in the transgenic mice at all stages of postnatal development. Polysialylated NCAM-120 partially colocalized with myelin basic protein and was present in purified myelin. The permanent expression of PSA-NCAM in oligodendrocytes led to a reduced myelin content in the forebrains of transgenic mice during the period of active myelination and in the adult animal. In situ hybridizations indicated a significant decrease in the number of mature oligodendrocytes in the forebrain. Thus, down-regulation of PSA during oligodendrocyte differentiation is a prerequisite for efficient myelination by mature oligodendrocytes. Furthermore, myelin of transgenic mice exhibited structural abnormalities like redundant myelin and axonal degeneration, indicating that the down-regulation of PSA is also necessary for myelin maintenance.	Univ Bonn, Inst Physiol Chem, D-53115 Bonn, Germany; Univ Bonn, Inst Anat, D-53115 Bonn, Germany	University of Bonn; University of Bonn	Eckhardt, M (corresponding author), Univ Bonn, Inst Physiol Chem, Nussallee 11, D-53115 Bonn, Germany.	eckhardt@institut.physiochem.uni-bonn.de	Messier, Claude/A-2322-2008; Fewou, Simon Ngamli/AAG-3934-2020	Messier, Claude/0000-0002-4791-1763; 				ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Bansal R, 1999, J NEUROSCI, V19, P7913; BARTSCH U, 1990, J NEUROCYTOL, V19, P550, DOI 10.1007/BF01257243; BHAT S, 1988, J NEUROCHEM, V50, P1830, DOI 10.1111/j.1471-4159.1988.tb02485.x; BUSSOW H, 1978, J NEUROCYTOL, V7, P207, DOI 10.1007/BF01217919; Carenini S, 1997, CELL TISSUE RES, V287, P3; Charles P, 2000, P NATL ACAD SCI USA, V97, P7585, DOI 10.1073/pnas.100076197; Charles P, 2002, BRAIN, V125, P1972, DOI 10.1093/brain/awf216; Chazal G, 2000, J NEUROSCI, V20, P1446; Close BE, 1998, J BIOL CHEM, V273, P34586, DOI 10.1074/jbc.273.51.34586; Coman L, 2005, J NEUROL SCI, V233, P67, DOI 10.1016/j.jns.2005.03.029; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Decker L, 2002, MOL CELL NEUROSCI, V19, P225, DOI 10.1006/mcne.2001.1072; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Eckhardt M, 2002, BIOCHEM J, V368, P317, DOI 10.1042/BJ20020946; Fewou SN, 2005, J NEUROCHEM, V94, P469, DOI 10.1111/j.1471-4159.2005.03221.x; FINNE J, 1987, J IMMUNOL, V138, P4402; Franceschini I, 2004, MOL CELL NEUROSCI, V27, P151, DOI 10.1016/j.mcn.2004.05.006; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Fujimoto I, 2001, J BIOL CHEM, V276, P31745, DOI 10.1074/jbc.M104525200; Fuss B, 2001, MOL CELL NEUROSCI, V18, P221, DOI 10.1006/mcne.2001.1011; Goridis C, 1992, Semin Cell Biol, V3, P189; Harlow E., 1988, ANTIBODIES LAB MANUA; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; Klein C, 2002, J NEUROSCI, V22, P698, DOI 10.1523/JNEUROSCI.22-03-00698.2002; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; LASALLE GL, 1992, J NEUROSCI, V12, P872; Liang XQ, 2004, J NEUROSCI, V24, P7140, DOI 10.1523/JNEUROSCI.5319-03.2004; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Meyer-Franke A, 1999, MOL CELL NEUROSCI, V14, P385, DOI 10.1006/mcne.1999.0788; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; OUMESMAR BN, 1995, EUR J NEUROSCI, V7, P480, DOI 10.1111/j.1460-9568.1995.tb00344.x; Rutishauser U, 1998, J CELL BIOCHEM, V70, P304, DOI 10.1002/(SICI)1097-4644(19980901)70:3<304::AID-JCB3>3.0.CO;2-R; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seidenfaden R, 2003, MOL CELL BIOL, V23, P5908, DOI 10.1128/MCB.23.16.5908-5918.2003; SEKI T, 1991, NEUROSCI RES, V12, P503, DOI 10.1016/S0168-0102(09)80003-5; Spassky N, 1998, J NEUROSCI, V18, P8331; Stoykova LI, 2001, J NEUROSCI RES, V66, P497, DOI 10.1002/jnr.10002; Takikita S, 2004, J NEUROPATH EXP NEUR, V63, P660, DOI 10.1093/jnen/63.6.660; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TROTTER J, 1989, J NEUROSCI RES, V22, P369, DOI 10.1002/jnr.490220402; Umemori H, 1999, J NEUROSCI, V19, P1393; Vutskits L, 2001, EUR J NEUROSCI, V13, P1391, DOI 10.1046/j.0953-816x.2001.01516.x; Wang C, 1996, J CELL BIOL, V135, P1565, DOI 10.1083/jcb.135.6.1565; Weinhold B, 2005, J BIOL CHEM, V280, P42971, DOI 10.1074/jbc.M511097200; Yaghootfam A, 2005, EUR J NEUROSCI, V21, P711, DOI 10.1111/j.1460-9568.2005.03891.x; Zhang H, 2004, J CELL SCI, V117, P93, DOI 10.1242/jcs.00827	56	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16700	16711		10.1074/jbc.M610797200	http://dx.doi.org/10.1074/jbc.M610797200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17420257	hybrid			2022-12-27	WOS:000246794300075
J	Long, XC; Miano, JM				Long, Xiaochun; Miano, Joseph M.			Remote control of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MAMMALIAN TRANSCRIPTION FACTOR; SMOOTH-MUSCLE; REGULATORY ELEMENTS; TRANSGENIC MICE; COORDINATE REGULATOR; MYOCARDIN; SEQUENCE; DELETION; ENHANCER; IDENTIFICATION	The elucidation of a growing number of species' genomes heralds an unprecedented opportunity to ascertain functional attributes of non-coding sequences. In particular, cis regulatory modules (CRMs) controlling gene expression constitute a rich treasure trove of data to be defined and experimentally validated. Such information will provide insight into cell lineage determination and differentiation and the genetic basis of heritable diseases as well as the development of novel tools for restricting the inactivation of genes to specific cell types or conditions. Historically, the study of CRMs and their individual transcription factor binding sites has been limited to proximal regions around gene loci. Two important by-products of the genomics revolution, artificial chromosome vectors and comparative genomics, have fueled efforts to define an increasing number of CRMs acting remotely to control gene expression. Such regulation from a distance has challenged our perspectives of gene expression control and perhaps the very definition of a gene. This review summarizes current approaches to characterize remote control of gene expression in transgenic mice and inherent limitations for accurately interpreting the essential nature of CRM activity.	Univ Rochester, Sch Med, Cardiovasc Res Inst, Rochester, NY 14642 USA	University of Rochester	Miano, JM (corresponding author), Univ Rochester, Sch Med, Cardiovasc Res Inst, 601 Elmwood Ave, Rochester, NY 14642 USA.	j.m.miano@rochester.edu	Miano, Joseph/L-5634-2018	Miano, Joseph/0000-0001-7522-3207; Long, Xiaochun/0000-0001-9714-0023	NHLBI NIH HHS [HL-70077, HL-62572] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062572] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banerjee P, 2002, MAMM GENOME, V13, P554, DOI 10.1007/s00335-002-2169-4; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Blanchette M, 2006, GENOME RES, V16, P656, DOI 10.1101/gr.4866006; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Copeland NG, 2001, NAT REV GENET, V2, P769, DOI 10.1038/35093556; Creemers EE, 2006, DEVELOPMENT, V133, P4245, DOI 10.1242/dev.02610; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Elnitski L, 2006, GENOME RES, V16, P1455, DOI 10.1101/gr.4140006; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; Gottgens B, 2004, MOL CELL BIOL, V24, P1870, DOI 10.1128/MCB.24.5.1870-1883.2004; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; Hatton RD, 2006, IMMUNITY, V25, P717, DOI 10.1016/j.immuni.2006.09.007; Heaney JD, 2006, MAMM GENOME, V17, P791, DOI 10.1007/s00335-006-0023-9; Khandekar M, 2004, MOL CELL BIOL, V24, P10263, DOI 10.1128/MCB.24.23.10263-10276.2004; Khromov AS, 2006, P NATL ACAD SCI USA, V103, P2440, DOI 10.1073/pnas.0508566103; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Lilly B, 2001, DEV BIOL, V240, P531, DOI 10.1006/dbio.2001.0507; Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Mericskay M, 2000, DEV BIOL, V226, P192, DOI 10.1006/dbio.2000.9865; Miano JM, 2002, AM J PHYSIOL-HEART C, V282, pH1793, DOI 10.1152/ajpheart.00875.2001; Milyavsky M, 2007, CANCER CELL, V11, P133, DOI 10.1016/j.ccr.2006.11.022; Mohrs M, 2001, NAT IMMUNOL, V2, P842, DOI 10.1038/ni0901-842; Mortlock DP, 2003, GENOME RES, V13, P2069, DOI 10.1101/gr.1306003; Murisier F, 2007, DEV BIOL, V303, P838, DOI 10.1016/j.ydbio.2006.11.038; Navas PA, 2006, EXP BIOL MED, V231, P328; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Pennacchio LA, 2007, GENOME RES, V17, P201, DOI 10.1101/gr.5972507; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; Raguz S, 1998, DEV BIOL, V201, P26, DOI 10.1006/dbio.1998.8964; Sagai T, 2005, DEVELOPMENT, V132, P797, DOI 10.1242/dev.01613; SCHEDL A, 1992, NUCLEIC ACIDS RES, V20, P3073, DOI 10.1093/nar/20.12.3073; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; Sun H, 2006, HUM MOL GENET, V15, P2911, DOI 10.1093/hmg/ddl232; Sun Q, 2006, GENOME RES, V16, P197, DOI 10.1101/gr.4108706; Sun T, 2000, DEVELOPMENT, V127, P4519; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wunderle VM, 1998, P NATL ACAD SCI USA, V95, P10649, DOI 10.1073/pnas.95.18.10649; Xu R, 2003, AM J PHYSIOL-HEART C, V284, pH1398, DOI 10.1152/ajpheart.00737.2002; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yang Z, 2006, METHODS, V39, P183, DOI 10.1016/j.ymeth.2006.04.011	47	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15941	15945		10.1074/jbc.R700010200	http://dx.doi.org/10.1074/jbc.R700010200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403687	hybrid			2022-12-27	WOS:000246794300002
J	Rempe, DA; Lelli, KM; Vangeison, G; Johnson, RS; Federoff, HJ				Rempe, David A.; Lelli, Katherine M.; Vangeison, Grace; Johnson, Randall S.; Federoff, Howard J.			In cultured astrocytes, p53 and MDM2 do not alter hypoxia-inducible factor-1 alpha function regardless of the presence of DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; FACTOR 1-ALPHA; UP-REGULATION; CELL-DEATH; HIF-1-ALPHA; INDUCTION; APOPTOSIS; MEDIATOR; BINDING; PROTEIN	A principal molecular mechanism by which cells respond to hypoxia is by activation of the transcription factor hypoxia-inducible factor 1 alpha(HIF-1 alpha). Several studies describe a binding of p53 to HIF-1 alpha in a protein complex, leading to attenuated function, half-life, and abundance of HIF-1 alpha. However, these reports almost exclusively utilized transformed cell lines, and many employed transfection of p53 or HIF-1 alpha plasmid constructs and/or p53 and HIF-1 alpha reporter constructs as surrogates for endogenous protein activity and target expression, respectively. Thus, it remains an open and important question as to whether p53 inhibits HIF-1 alpha-mediated transactivation of endogenous HIF-1 alpha targets in nontransformed cells. After determining in primary astrocyte cultures the HIF-1 alpha targets that were most dependent on HIF-1 alpha function, we examined the effect of the loss of p53 function either alone or in combination with MDM2 on expression of these targets. Although p53 null astrocyte cultures resulted in markedly increased HIF-1 alpha-dependent target expression compared with controls, this altered expression was determined to be the result of increased cell density of p53 null cultures and the accompanying acidosis, not loss of p53 protein. Although activation of p53 by DNA damage induced p53 target expression in astrocytes, it did not alter hypoxia-induced HIF-1 alpha target expression. Finally, a combined loss of MDM2 and p53 did not alter HIF-1 alpha target expression compared with loss of p53 alone. These data strongly suggest that p53 and MDM2 do not influence the hypoxia induced transactivation of HIF-1 alpha targets, regardless of p53 activation, in primary astrocytes.	Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Interdept Grad Program Neurosci, Rochester, NY 14642 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of Rochester; University of Rochester; University of California System; University of California San Diego	Rempe, DA (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Dept Neurol, Box 645,301 Elmwood Ave, Rochester, NY 14642 USA.	david_rempe@urmc.rochester.edu	Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639	NIGMS NIH HHS [T32 GM007088] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007088] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bonini P, 2004, J NEUROSCI RES, V75, P83, DOI 10.1002/jnr.10822; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Brunelle JK, 2004, J BIOL CHEM, V279, P4305, DOI 10.1074/jbc.M312241200; Calvert JW, 2006, J APPL PHYSIOL, V101, P853, DOI 10.1152/japplphysiol.00268.2006; Chavez JC, 2006, J NEUROSCI, V26, P9471, DOI 10.1523/JNEUROSCI.2838-06.2006; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chung YH, 2002, NEUROL RES, V24, P324, DOI 10.1179/016164102101199828; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Huang Y, 2004, FASEB J, V18, P1138, DOI 10.1096/fj.04-1510fje; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Kietzmann T, 2001, EUR ARCH PSY CLIN N, V251, P170, DOI 10.1007/s004060170037; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LUNA RMD, 1995, NATURE, V378, P203; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757; Nieminen AL, 2005, J CELL PHYSIOL, V204, P364, DOI 10.1002/jcp.20406; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Paltoglou SM, 2005, ONCOGENE, V24, P3830, DOI 10.1038/sj.onc.1208531; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139; Rapisarda A, 2002, CANCER RES, V62, P4316; Ravi R, 2000, GENE DEV, V14, P34; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Ryan HE, 2000, CANCER RES, V60, P4010; Schmid T, 2004, J CELL MOL MED, V8, P423, DOI 10.1111/j.1582-4934.2004.tb00467.x; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Vengellur A, 2003, GENE EXPRESSION, V11, P181, DOI 10.3727/000000003108749062; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 1998, CANCER RES, V58, P5678; Wick A, 2002, J NEUROSCI, V22, P6401; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhuo L, 2001, GENESIS, V31, P85, DOI 10.1002/gene.10008	53	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16187	16201		10.1074/jbc.M702203200	http://dx.doi.org/10.1074/jbc.M702203200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17420250	hybrid			2022-12-27	WOS:000246794300027
J	Wang, DS; Buckinx, R; Lecorronc, H; Mangin, JM; Rigo, JM; Legendre, P				Wang, Dian-Shi; Buckinx, Roeland; Lecorronc, Herve; Mangin, Jean-Marie; Rigo, Jean-Michel; Legendre, Pascal			Mechanisms for picrotoxinin and picrotin blocks of alpha(2) homomeric glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITORY GLYCINE RECEPTOR; GABA(A) RECEPTOR; CHLORIDE CHANNEL; CONFORMATIONAL-CHANGE; CRAYFISH MUSCLE; SUBUNIT; BINDING; ACETYLCHOLINE; ANTAGONIST; MEMBRANE	Contrary to its effect on the gamma-aminobutyric acid type A and C receptors, picrotoxin antagonism of the alpha(1) homomeric glycine receptors (GlyRs) has been shown to be non-use-dependent and nonselective between the picrotoxin components picrotoxinin and picrotin. Picrotoxin antagonism of the embryonic alpha(2) homomeric GlyR is known to be use-dependent and reflects a channel-blocking mechanism, but the selectivity of picrotoxin antagonism of the embryonic alpha(2) homomeric GlyRs between picrotoxinin and picrotin is unknown. Hence, we used the patch clamp recording technique in the outside-out configuration to investigate, at the single channel level, the mechanism of picrotin- and picrotoxinin-induced inhibition of currents, which were evoked by the activation of alpha(2) homomeric GlyRs stably transfected into Chinese hamster ovary cells. Although both picrotoxinin and picrotin inhibited glycine-evoked outside-out currents, picrotin had a 30 times higher IC50 than picrotoxinin. Picrotin-evoked inhibition displayed voltage dependence, whereas picrotoxinin did not. Picrotoxinin and picrotin decreased the mean open time of the channel in a concentration-dependent manner, indicating that these picrotoxin components can bind to the receptor in its open state. When picrotin and glycine were co-applied, a large rebound current was observed at the end of the application. This rebound current was considerably smaller when picrotoxinin and glycine were co-applied. Both picrotin and picrotoxinin were unable to bind to the unbound conformation of the receptor, but both could be trapped at their binding site when the channel closed during glycine dissociation. Our data indicate that picrotoxinin and picrotin are not equivalent in blocking alpha(2) homomeric GlyR.	Univ Paris 06, NPA, UKMR 7102, CNRS, F-75252 Paris 05, France; Childrens Natl Med Ctr, Ctr Neurosci Res, Washington, DC 20010 USA; Univ Hasselt, Biomed Res Ctr, B-3590 Diepenbeek, Belgium; Fourth Mil Med Univ, Dept Anat, Xian 710032, Peoples R China	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Children's National Health System; Hasselt University; Air Force Military Medical University	Legendre, P (corresponding author), Univ Paris 06, NPA, UKMR 7102, CNRS, Batiment B,6 Etage,Case 1,9 Quai St, F-75252 Paris 05, France.	pascal.legendre@snv.jussieu.fr	Buckinx, Roeland/G-9482-2011; Rigo, Jean-Michel/E-3456-2010	Buckinx, Roeland/0000-0001-9976-2889; Rigo, Jean-Michel/0000-0002-0031-526X; Mangin, Jean-Marie/0000-0002-7804-0251				Adelsberger H, 1998, EUR J NEUROSCI, V10, P179, DOI 10.1046/j.1460-9568.1998.00038.x; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; Breitinger HG, 2001, J BIOL CHEM, V276, P29657, DOI 10.1074/jbc.M100446200; Burzomato V, 2004, J NEUROSCI, V24, P10924, DOI 10.1523/JNEUROSCI.3424-04.2004; Chen LG, 2006, P NATL ACAD SCI USA, V103, P5185, DOI 10.1073/pnas.0600370103; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Colquhoun D, 2004, TRENDS NEUROSCI, V27, P337, DOI 10.1016/j.tins.2004.04.010; Colquhoun David, 1995, P397; CURTIS DR, 1974, ERG PHYSIOL BIOL CH, V69, P97; Das P, 2003, NEUROPHARMACOLOGY, V44, P431, DOI 10.1016/S0028-3908(03)00032-7; Dibas MI, 2002, J BIOL CHEM, V277, P9112, DOI 10.1074/jbc.M111356200; Erkkila BE, 2004, NEUROREPORT, V15, P1969, DOI 10.1097/00001756-200408260-00027; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; Gentet LJ, 2002, J PHYSIOL-LONDON, V544, P97, DOI 10.1113/jphysiol.2001.015321; Grudzinska J, 2005, NEURON, V45, P727, DOI 10.1016/j.neuron.2005.01.028; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hawthorne R, 2005, J BIOL CHEM, V280, P35836, DOI 10.1074/jbc.M506645200; Hawthorne R, 2006, J NEUROCHEM, V98, P395, DOI 10.1111/j.1471-4159.2006.03875.x; KENAKIN TP, 1987, PHARM ANAL DRUG RECE, P163; KUHSE J, 1991, FEBS LETT, V283, P73, DOI 10.1016/0014-5793(91)80557-J; Legendre P, 1998, J NEUROSCI, V18, P2856; Legendre P, 2000, J NEUROSCI, V20, P140, DOI 10.1523/JNEUROSCI.20-01-00140.2000; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; LYNCH JW, 1995, J BIOL CHEM, V270, P13799, DOI 10.1074/jbc.270.23.13799; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; MACONOCHIE DJ, 1995, J GEN PHYSIOL, V106, P113, DOI 10.1085/jgp.106.1.113; Mangin JA, 2003, J PHYSIOL-LONDON, V553, P369, DOI 10.1113/jphysiol.2003.052142; Muroi Y, 2006, BIOCHEMISTRY-US, V45, P7013, DOI 10.1021/bi060222v; Olsen RW, 2006, P NATL ACAD SCI USA, V103, P6081, DOI 10.1073/pnas.0601121103; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Qian HH, 2005, MOL PHARMACOL, V67, P470, DOI 10.1124/mol.104.003996; Ramakrishnan L, 2005, BIOCHEMISTRY-US, V44, P8523, DOI 10.1021/bi0477283; Saul B, 1999, J NEUROSCI, V19, P869; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Steinbach JH, 2000, MOL PHARMACOL, V58, P11, DOI 10.1124/mol.58.1.11; TRILLER A, 1990, New Biologist, V2, P637; Wang DS, 2006, J BIOL CHEM, V281, P3841, DOI 10.1074/jbc.M511022200; WEBB TI, 2007, IN PRESS CURR PHARM; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	44	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16016	16035		10.1074/jbc.M701502200	http://dx.doi.org/10.1074/jbc.M701502200			20	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17405877	hybrid			2022-12-27	WOS:000246794300010
J	Andrali, SS; Qian, QW; Ozcan, S				Andrali, Sreenath S.; Qian, Qingwen; Ozcan, Sabire			Glucose mediates the translocation of NeuroD1 by O-linked glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; N-ACETYLGLUCOSAMINE; GLCNAC TRANSFERASE; NUCLEOCYTOPLASMIC PROTEINS; DYNAMIC INTERPLAY; CELL FUNCTION; NUCLEAR; PHOSPHORYLATION; ACTIVATION; EXPRESSION	O-Linked GlcNAc modification of nuclear and cytosolic proteins has been shown to regulate the function of many cellular proteins. Increased O-linked glycosylation, observed under chronic hyperglycemia conditions, has been implicated in the pathogenesis of diabetes. However, the exact role of O-GlcNAc modification in regulating glucose homeostasis remains to be established. We report here that the subcellular localization of the pancreatic beta cell-specific transcription factor NeuroD1 is regulated by O-linked glycosylation in the mouse insulinoma cell line MIN6. Under low glucose conditions, NeuroD1 is mainly in the cytosol. However, treatment of MIN6 cells with high glucose results in O-linked GlcNAc modification of NeuroD1 and its subsequent translocation into the nucleus. Consistent with these data, treatment of MIN6 cells with O-(2-acetamido-2-deoxy-D-glucopyranosylidene)-amino N-phenylcarbamate, an inhibitor of O- GlcNAcase, causes NeuroD1 localization to the nucleus and induction of insulin gene expression even on low glucose. Furthermore, we demonstrate that NeuroD1 interacts with the O- GlcNAc transferase, OGT only at high concentrations of glucose and depletion of OGT by using small interfering RNA oligos interferes with the nuclear localization of NeuroD1 on high glucose. On low glucose NeuroD1 interacts with the O-GlcNAcase and becomes deglycosylated, which is likely to be important for export of NeuroD1 into cytosol in the presence of low glucose. In summary, the presented data suggest that glucose regulates the subcellular localization of NeuroD1 in pancreatic beta cells via O-linked GlcNAc modification of NeuroD1 by OGT.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), 741 S Limestone St,BBSRC B155, Lexington, KY 40536 USA.	sozcan@uky.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065730, R01DK067581] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR20171, P20 RR020171] Funding Source: Medline; NIDDK NIH HHS [R01 DK067581-02, R21 DK065730-02, R01 DK067581, R21 DK065730] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Andrali SS, 2005, BIOCHEM BIOPH RES CO, V337, P149, DOI 10.1016/j.bbrc.2005.09.026; Buse MG, 2006, AM J PHYSIOL-ENDOC M, V290, pE1, DOI 10.1152/ajpendo.00329.2005; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Cooksey RC, 2002, ANN NY ACAD SCI, V967, P102; Dauphinee SM, 2005, J CELL BIOCHEM, V96, P579, DOI 10.1002/jcb.20508; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Gewinner C, 2004, J BIOL CHEM, V279, P3563, DOI 10.1074/jbc.M306449200; Guinez C, 2005, INT J BIOCHEM CELL B, V37, P765, DOI 10.1016/j.biocel.2004.12.001; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hui HX, 2002, EUR J ENDOCRINOL, V146, P129, DOI 10.1530/eje.0.1460129; Juang YT, 2002, J IMMUNOL, V168, P2865, DOI 10.4049/jimmunol.168.6.2865; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lefebvre T, 2003, BBA-GEN SUBJECTS, V1619, P167, DOI 10.1016/S0304-4165(02)00477-4; Lefebvre T, 2002, J CELL BIOCHEM, V85, P208, DOI 10.1002/jcb.10119; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; McClain DA, 2002, J DIABETES COMPLICAT, V16, P72, DOI 10.1016/S1056-8727(01)00188-X; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; Petersen HV, 2002, FEBS LETT, V528, P241, DOI 10.1016/S0014-5793(02)03318-5; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2004, J BIOL CHEM, V279, P9796, DOI 10.1074/jbc.M307577200; Roderigo-Milne H, 2002, BIOCHEM BIOPH RES CO, V296, P589, DOI 10.1016/S0006-291X(02)00913-0; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Rout UK, 2002, REPROD TOXICOL, V16, P253, DOI 10.1016/S0890-6238(02)00022-9; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Vanderford NL, 2007, J BIOL CHEM, V282, P1577, DOI 10.1074/jbc.M605064200; Vosseller K, 2002, CURR OPIN CHEM BIOL, V6, P851, DOI 10.1016/S1367-5931(02)00384-8; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zachara NE, 2006, BBA-MOL CELL BIOL L, V1761, P599, DOI 10.1016/j.bbalip.2006.04.007; Zachara NE, 2004, TRENDS CELL BIOL, V14, P218, DOI 10.1016/j.tcb.2004.03.005	56	99	103	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15589	15596		10.1074/jbc.M701762200	http://dx.doi.org/10.1074/jbc.M701762200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403669	Green Accepted, hybrid			2022-12-27	WOS:000246589600036
J	Bisaglia, M; Mammi, S; Bubacco, L				Bisaglia, Marco; Mammi, Stefano; Bubacco, Luigi			Kinetic and structural analysis of the early oxidation products of dopamine - Analysis of the interactions with alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN DIHYDROPTERIDINE REDUCTASE; PARKINSONS-DISEASE; QUINONE FORMATION; SUBSTANTIA-NIGRA; CELL-DEATH; NEUROMELANIN; CATECHOLAMINES; RELEVANCE; TRANSPORTER; TOXICITY	Oxidative stress appears to be directly involved in the pathogenesis of several neurodegenerative disorders, including Alzheimer and Parkinson diseases. Nigral dopaminergic neurons are particularly exposed to oxidative stress because a pathological accumulation of cytosolic dopamine gives rise to various toxic molecules, including free radicals and reactive quinones. These latter species can react with proteins preventing them from exerting their physiological functions. Among the possible targets of quinones, alpha-synuclein is of primary interest because of its direct involvement in dopamine metabolism. Contrary to the neurotoxic processes, neuromelanin synthesis seems to play a protective role by its ability to sequester a variety of potentially damaging substances. In this study, we carried out a kinetic and structural analysis of the early oxidation products of dopamine. Specifically, considering the potential high toxicity of aminochrome for both cells and mitochondria, we focused our attention on its rearrangement to 5,6- dihydroxyindole. After the spectroscopic characterization of the products derived from the oxidation of dopamine, the structural information obtained was used to analyze the reactivity of quinones toward alpha-synuclein. Our results suggest that indole-5,6-quinone, rather than dopamine-o-quinone or aminochrome, is the reactive species. We propose that the observed reactivity could represent a general reaction pathway whenever cysteinyl residues are absent in proteins or if they are sterically protected.	Univ Padua, Dept Chem Sci, I-35131 Padua, Italy; Univ Padua, Dept Biol, I-35131 Padua, Italy; CNR, Inst Biomol Chem, I-35131 Padua, Italy	University of Padua; University of Padua; Consiglio Nazionale delle Ricerche (CNR)	Mammi, S (corresponding author), Univ Padua, Dept Chem Sci, Via Marzolo,1, I-35131 Padua, Italy.	stefano.mammi@unipd.it	Bubacco, Luigi/B-5602-2012	Bubacco, Luigi/0000-0001-7927-9208				Aime S, 2000, MOVEMENT DISORD, V15, P977, DOI 10.1002/1531-8257(200009)15:5<977::AID-MDS1032>3.0.CO;2-Q; Ancian B, 1997, J MAGN RESON, V125, P348, DOI 10.1006/jmre.1997.1112; ARMAREGO WLF, 1983, BIOCHEM BIOPH RES CO, V113, P895, DOI 10.1016/0006-291X(83)91083-5; Asanuma M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BINDOLI A, 1989, TOXICOL LETT, V48, P3, DOI 10.1016/0378-4274(89)90180-X; CHEDEKEL MR, 1984, J CHEM SOC CHEM COMM, P1170, DOI 10.1039/c39840001170; Elsworth JD, 1997, EXP NEUROL, V144, P4, DOI 10.1006/exnr.1996.6379; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Fedorow H, 2005, PROG NEUROBIOL, V75, P109, DOI 10.1016/j.pneurobio.2005.02.001; GARCIACARMONA F, 1982, BIOCHIM BIOPHYS ACTA, V717, P124, DOI 10.1016/0304-4165(82)90389-0; GRAHAM DG, 1977, J BIOL CHEM, V252, P5729; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; GRAHAM DG, 1979, ARCH PATHOL LAB MED, V103, P359; Greggio E, 2005, J NEUROCHEM, V93, P246, DOI 10.1111/j.1471-4159.2005.03019.x; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hastings TG, 1996, P NATL ACAD SCI USA, V93, P1956, DOI 10.1073/pnas.93.5.1956; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; HIRSCH EC, 1993, EUR NEUROL, V33, P52, DOI 10.1159/000118538; HURD RE, 1990, J MAGN RESON, V87, P422, DOI 10.1016/0022-2364(90)90021-Z; ITO S, 1988, BIOCHEM PHARMACOL, V37, P1707, DOI 10.1016/0006-2952(88)90432-7; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; Land EJ, 2003, PIGM CELL RES, V16, P487, DOI 10.1034/j.1600-0749.2003.00082.x; LaVoie MJ, 2005, NAT MED, V11, P1214, DOI 10.1038/nm1314; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; MASON HS, 1948, J BIOL CHEM, V172, P83; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Norris EH, 2005, J BIOL CHEM, V280, P21212, DOI 10.1074/jbc.M412621200; PALUMBO A, 1987, BIOCHIM BIOPHYS ACTA, V925, P203, DOI 10.1016/0304-4165(87)90110-3; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Raper HS, 1928, PHYSIOL REV, V8, P245, DOI 10.1152/physrev.1928.8.2.245; Sidhu A, 2004, FASEB J, V18, P637, DOI 10.1096/fj.03-1112rev; SILVERSTEIN RM, 1997, SPECTROMETRIC IDENTI, P144; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; Sulzer D, 1999, NEUROTOX RES, V1, P181, DOI 10.1007/BF03033289; TSE DCS, 1976, J MED CHEM, V19, P37, DOI 10.1021/jm00223a008; WARING P, 1986, EUR J BIOCHEM, V155, P305, DOI 10.1111/j.1432-1033.1986.tb09491.x; Whitehead RE, 2001, J NEUROCHEM, V76, P1242, DOI 10.1046/j.1471-4159.2001.00125.x; Xu RD, 1996, BIOORG CHEM, V24, P110, DOI 10.1006/bioo.1996.0011; Zecca L, 2003, TRENDS NEUROSCI, V26, P578, DOI 10.1016/j.tins.2003.08.009; Zoccarato F, 2005, J BIOL CHEM, V280, P15587, DOI 10.1074/jbc.M500657200	46	213	216	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15597	15605		10.1074/jbc.M610893200	http://dx.doi.org/10.1074/jbc.M610893200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17395592	hybrid			2022-12-27	WOS:000246589600037
J	Howell, KA; Cheng, K; Murcha, MW; Jenkin, LE; Millar, AH; Whelan, J				Howell, Katharine A.; Cheng, Kim; Murcha, Monika W.; Jenkin, Linne E.; Millar, A. Harvey; Whelan, James			Oxygen initiation of respiration and mitochondrial biogenesis in rice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CYTOPLASMIC MALE-STERILITY; PROCESSING PEPTIDASE; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; PRECURSOR PROTEINS; CHEMOSTAT CULTURES; PLANT-MITOCHONDRIA; GENE-EXPRESSION; MESSENGER-RNA	Rice growth under aerobic and anaerobic conditions allowed aspects of mitochondrial biogenesis to be identified as dependent on or independent of an oxygen signal. Analysis of transcripts encoding mitochondrial components found that a subset of these genes respond to oxygen ( defined as aerobic), whereas others are relatively unaffected by oxygen availability. Mitochondria formed during growth in anaerobic conditions had reduced protein levels of tricarboxylic acid cycle components and cytochrome-containing complexes of the respiratory chain and repressed respiratory functionality. In general, the capacity of the general import pathway was found to be significantly lower in mitochondria isolated from tissue grown under anaerobic conditions, whereas the carrier import pathway capacity was not affected by changes in oxygen availability. Transcript levels of genes encoding components of the protein import apparatus were generally not affected by the absence of oxygen, and their protein abundance was severalfold higher in mitochondria isolated from anaerobically grown tissue. However, both transcript and protein abundances of the subunits of the mitochondrial processing peptidase, which in plants is integrated into the cytochrome bc(1) complex, were repressed under anaerobic conditions. Therefore, in this system, an increase in import capacity is correlated with an increase in the abundance of the cytochrome bc(1) complex, which is ultimately dependent on the presence of oxygen, providing a link between the respiratory chain and protein import apparatus.	Univ Western Australia, ARC Ctr Excellence Plant Energy Biol, Perth, WA 6009, Australia	University of Western Australia	Whelan, J (corresponding author), Univ Western Australia, ARC Ctr Excellence Plant Energy Biol, M316 MCS Bldg,35 Stirling Hwy, Perth, WA 6009, Australia.	seamus@cyllene.uwa.edu.au	Murcha, Monika W/C-3834-2011; Millar, A. Harvey/A-5452-2008; Whelan, James/F-6402-2011; Murcha, Monika W/H-5495-2014; Howell, Katharine A/A-4973-2010	Millar, A. Harvey/0000-0001-9679-1473; Whelan, James/0000-0001-5754-025X; Murcha, Monika W/0000-0002-3689-6158; Howell, Katharine A/0000-0002-5044-0034				Bellaoui M, 1997, EMBO J, V16, P5057, DOI 10.1093/emboj/16.16.5057; Binder S, 2003, PHILOS T R SOC B, V358, P181, DOI 10.1098/rstb.2002.1179; BRAUN HP, 1995, PLANTA, V195, P396, DOI 10.1007/BF00202597; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; Brumme S, 1998, J BIOL CHEM, V273, P13143, DOI 10.1074/jbc.273.21.13143; Burke PV, 1997, J BIOL CHEM, V272, P14705, DOI 10.1074/jbc.272.23.14705; Cornah JE, 2003, TRENDS PLANT SCI, V8, P224, DOI 10.1016/S1360-1385(03)00064-5; COUEE I, 1992, PLANT PHYSIOL, V98, P411, DOI 10.1104/pp.98.2.411; Dessi P, 2000, PLANT J, V24, P637, DOI 10.1046/j.1365-313x.2000.00910.x; Eads BD, 2003, J EXP BIOL, V206, P3681, DOI 10.1242/jeb.00595; FOX TC, 1991, PLANTA, V184, P510, DOI 10.1007/BF00197900; Gagliardi D, 1999, EMBO J, V18, P3757, DOI 10.1093/emboj/18.13.3757; Giege P, 2000, EMBO REP, V1, P164, DOI 10.1093/embo-reports/kvd024; Giege P, 2005, PLANT CELL, V17, P1497, DOI 10.1105/tpc.104.030254; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; Grelet J, 2005, PLANT PHYSIOL, V137, P157, DOI 10.1104/pp.104.052480; GROOT GSP, 1975, NATURE, V255, P238, DOI 10.1038/255238a0; Howell KA, 2006, PLANT MOL BIOL, V60, P201, DOI 10.1007/s11103-005-3688-7; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Millar AH, 2004, J BIOL CHEM, V279, P39471, DOI 10.1074/jbc.M406015200; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Murcha MW, 2005, J MOL BIOL, V351, P16, DOI 10.1016/j.jmb.2005.06.004; Murcha MW, 2004, J MOL BIOL, V344, P443, DOI 10.1016/j.jmb.2004.09.045; Murcha MW, 2003, PLANT PHYSIOL, V131, P1737, DOI 10.1104/pp.102.016808; Murcha MW, 1999, FEBS LETT, V464, P53, DOI 10.1016/S0014-5793(99)01674-9; Mustroph A, 2003, PHYSIOL PLANTARUM, V117, P508, DOI 10.1034/j.1399-3054.2003.00051.x; Pavlov PF, 1999, BIOCHEM J, V341, P95, DOI 10.1042/0264-6021:3410095; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Piper MDW, 2002, J BIOL CHEM, V277, P37001, DOI 10.1074/jbc.M204490200; PLATTNER H, 1970, P NATL ACAD SCI USA, V66, P1252, DOI 10.1073/pnas.66.4.1252; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; Poyton RO, 1999, RESP PHYSIOL, V115, P119, DOI 10.1016/S0034-5687(99)00028-6; Rajjou L, 2004, PLANT PHYSIOL, V134, P1598, DOI 10.1104/pp.103.036293; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Rosenfeld E, 2004, ANTON LEEUW INT J G, V85, P9, DOI 10.1023/B:ANTO.0000020268.55350.54; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SHIBASAKA M, 1988, PLANT PHYSIOL, V86, P1008, DOI 10.1104/pp.86.4.1008; SMITH MK, 1994, ARCH BIOCHEM BIOPHYS, V313, P235, DOI 10.1006/abbi.1994.1382; Tai SL, 2005, J BIOL CHEM, V280, P437, DOI 10.1074/jbc.M410573200; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tanudji M, 2001, PLANT MOL BIOL, V45, P317, DOI 10.1023/A:1006456115140; Taylor NL, 2003, FEBS LETT, V547, P125, DOI 10.1016/S0014-5793(03)00691-4; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; Tsuji H, 2000, FEBS LETT, V471, P201, DOI 10.1016/S0014-5793(00)01411-3; UEDA K, 1971, PROTOPLASMA, V73, P203, DOI 10.1007/BF01275595; van der Laan M, 2006, CURR BIOL, V16, P2271, DOI 10.1016/j.cub.2006.10.025; Vartapetian BB, 2003, ANN BOT-LONDON, V91, P155, DOI 10.1093/aob/mcf244; VARTAPETIAN BB, 1975, PLANT SCI LETT, V4, P1, DOI 10.1016/0304-4211(75)90067-X; Vijayasarathy C, 2003, EUR J BIOCHEM, V270, P871, DOI 10.1046/j.1432-1033.2003.03447.x; WALKER JE, 1994, FEBS LETT, V346, P39, DOI 10.1016/0014-5793(94)00368-8; Wang WX, 2003, PLANTA, V218, P1, DOI 10.1007/s00425-003-1105-5; Whelan J, 1996, BBA-MOL CELL RES, V1312, P48, DOI 10.1016/0167-4889(96)00014-6; WHELAN J, 1995, PLANT MOL BIOL, V27, P769, DOI 10.1007/BF00020229; WHELAN J, 1993, PLANT PHYSIOL, V103, P1481, DOI 10.1104/pp.103.4.1481; WINNING BM, 1992, PLANT J, V2, P763, DOI 10.1046/j.1365-313X.1992.t01-15-00999.x; Zhang L, 1999, CELL MOL LIFE SCI, V56, P415, DOI 10.1007/s000180050442; ZWIZINSKI C, 1983, J BIOL CHEM, V258, P3340	59	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15619	15631		10.1074/jbc.M609866200	http://dx.doi.org/10.1074/jbc.M609866200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17383966	hybrid			2022-12-27	WOS:000246589600039
J	Jin, W; Reiley, WR; Lee, AJ; Wright, A; Wu, XF; Zhang, MY; Sun, SC				Jin, Wei; Reiley, William R.; Lee, Andrew J.; Wright, Ato; Wu, Xuefeng; Zhang, Minying; Sun, Shao-Cong			Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-SUPPRESSOR CYLD; T-CELL; SIGNALING PATHWAY; NECROSIS-FACTOR; ACTIVATION; BAFF; BINDING; KINASE; UBIQUITYLATION	Deubiquitinating enzymes (DUB) form a family of cysteine proteases that digests ubiquitin chains and reverses the process of protein ubiquitination. Despite the identification of a large number of DUBs, their physiological functions remain poorly defined. Here we provide genetic evidence that CYLD, a recently identified DUB, plays a crucial role in regulating the peripheral development and activation of B cells. Disruption of the CYLD gene in mice results in B cell hyperplasia and lymphoid organ enlargement. The CYLD-deficient B cells display surface markers indicative of spontaneous activation and are hyperproliferative upon in vitro stimulation. When challenged with antigens, the CYLD-/- mice develop exacerbated lymphoid organ abnormalities and abnormal B cell responses. Although the loss of CYLD has only a minor effect on B cell development in bone marrow, this genetic deficiency disrupts the balance of peripheral B cell populations with a significant increase in marginal zone B cells. In keeping with these functional abnormalities, the CYLD-/- B cells exhibit constitutive activation of the transcription factor NF-kappa B due to spontaneous activation of I kappa B kinase beta and degradation of the NF-kappa B inhibitor I kappa B alpha. These findings demonstrate a critical role for CYLD in regulating the basal activity of NF-kappa B and maintaining the naive phenotype and proper activation of B cells.	Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, 500 Univ Dr, Hershey, PA 17033 USA.	sxs70@psu.edu	Wu, Xuefeng/F-5003-2011; Lee, Andrew/GVU-2817-2022		NCI NIH HHS [CA94922] Funding Source: Medline; NIAID NIH HHS [AI064639, R37 AI064639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064639, R37AI064639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Bishop GA, 2003, CYTOKINE GROWTH F R, V14, P297, DOI 10.1016/S1359-6101(03)00024-8; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cancro MP, 2004, IMMUNOL REV, V197, P89, DOI 10.1111/j.0105-2896.2004.0099.x; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Dorner T, 2006, CURR TOP MICROBIOL, V305, P213, DOI 10.1007/3-540-29714-6_11; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gorelik L, 2004, J IMMUNOL, V172, P762, DOI 10.4049/jimmunol.172.2.762; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Kalled SL, 2005, IMMUNOL REV, V204, P43, DOI 10.1111/j.0105-2896.2005.00219.x; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lian Fangru, 2005, Adv Dermatol, V21, P217, DOI 10.1016/j.yadr.2005.06.005; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu YC, 2005, NAT REV IMMUNOL, V5, P941, DOI 10.1038/nri1731; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Mecklenbrauker I, 2004, NATURE, V431, P456, DOI 10.1038/nature02955; Militi S, 2005, CYTOKINE, V31, P314, DOI 10.1016/j.cyto.2005.05.007; Morrison MD, 2005, J BIOL CHEM, V280, P10018, DOI 10.1074/jbc.M413634200; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Podojil JR, 2005, TRENDS IMMUNOL, V26, P180, DOI 10.1016/j.it.2005.02.005; Poe J C, 2001, Int Rev Immunol, V20, P739, DOI 10.3109/08830180109045588; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Reiley WW, 2006, NAT IMMUNOL, V7, P411, DOI 10.1038/ni1315; Rickert RC, 2005, CURR OPIN IMMUNOL, V17, P237, DOI 10.1016/j.coi.2005.03.001; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STIEF A, 1994, J IMMUNOL, V152, P3378; Su TT, 2004, IMMUNOL REV, V197, P161, DOI 10.1111/j.0105-2896.2004.0102.x; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Vos Q, 2000, IMMUNOL REV, V176, P154; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yoshida H, 2005, J BIOL CHEM, V280, P41111, DOI 10.1074/jbc.M509526200	47	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15884	15893		10.1074/jbc.M609952200	http://dx.doi.org/10.1074/jbc.M609952200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17392286	hybrid			2022-12-27	WOS:000246589600063
J	Koike, N; Kassai, Y; Kouta, Y; Miwa, H; Konishi, M; Itoh, N				Koike, Naomi; Kassai, Yoshiaki; Kouta, Yuya; Miwa, Hiroyuki; Konishi, Morichika; Itoh, Nobuyuki			Brorin, a novel secreted bone morphogenetic protein antagonist, promotes neurogenesis in mouse neural precursor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION PATTERNS; STEM-CELLS; DIFFERENTIATION; CHORDIN; CROSSVEINLESS-2; VERTEBRATES; INHIBITOR; RECEPTORS; PATHWAY; MEMBERS	We identified a gene encoding a novel secreted protein in mice and humans and named it Brorin. Mouse Brorin consists of 324 amino acids with a putative secreted signal sequence at its amino terminus and two cysteine-rich domains in its core region. Positions of 10 cysteine residues in the domains of Brorin are similar to those in the cysteine-rich domains of members of the Chordin family. However, the amino acid sequence of Brorin is not significantly similar to that of any other member of the Chordin family, indicating that Brorin is a unique member of the family. Mouse Brorin protein produced in cultured cells was efficiently secreted into the culture medium. The protein inhibited the activity of bone morphogenetic protein 2 (BMP2) and BMP6 in mouse preosteoblastic MC3T3-E1 cells. Mouse Brorin was predominantly expressed in neural tissues in embryos and also predominantly expressed in the adult brain. In the brain, the expression was detected in neurons, but not glial cells. The neural tissue-specific expression profile of Brorin is quite distinct from that of any other member of the Chordin family. Brorin protein promoted neurogenesis, but not astro-genesis, in mouse neural precursor cells. The present findings indicate that Brorin is a novel secreted BMP antagonist that potentially plays roles in neural development and functions.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan	Kyoto University	Itoh, N (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan.	itohnobu@pharm.kyoto-u.ac.jp		Miwa, Hiroyuki/0000-0001-6899-7028				Abreu JG, 2002, GENE, V287, P39, DOI 10.1016/S0378-1119(01)00827-7; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Brunet JF, 2004, GLIA, V46, P8, DOI 10.1002/glia.10348; Chandra A, 2006, BIOCHEM BIOPH RES CO, V344, P786, DOI 10.1016/j.bbrc.2006.03.195; Charytoniuk DA, 2000, NEUROSCIENCE, V100, P33, DOI 10.1016/S0306-4522(00)00246-3; Chen HL, 2003, BRAIN RES, V994, P81, DOI 10.1016/j.brainres.2003.09.020; Coffinier C, 2001, MECH DEVELOP, V100, P119, DOI 10.1016/S0925-4773(00)00507-4; Coffinier C, 2002, MECH DEVELOP, V119, pS179, DOI 10.1016/S0925-4773(03)00113-8; Ebendal T, 1998, J NEUROSCI RES, V51, P139, DOI 10.1002/(SICI)1097-4547(19980115)51:2<139::AID-JNR2>3.0.CO;2-E; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; GERFEN CR, 1989, METHODS NEUROSCIENCE, V60, P101; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ikeya M, 2006, DEVELOPMENT, V133, P4463, DOI 10.1242/dev.02647; Kimura I, 2006, J NEUROSCI RES, V83, P1415, DOI 10.1002/jnr.20849; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lein P, 2002, PROG INFLAM RES, P289; Lin JM, 2005, NAT MED, V11, P387, DOI 10.1038/nm1217; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Nakayama N, 2004, DEVELOPMENT, V131, P229, DOI 10.1242/dev.00901; Nakayama N, 2001, DEV BIOL, V232, P372, DOI 10.1006/dbio.2001.0200; Pappano WN, 1998, GENOMICS, V52, P236, DOI 10.1006/geno.1998.5474; Strelau J, 2000, J NEUROSCI, V20, P8597; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; TOMIZAWA K, 1995, MOL BRAIN RES, V28, P122, DOI 10.1016/0169-328X(94)00199-O; Ueki T, 2003, J NEUROSCI, V23, P11732; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Yamashita T, 2002, J BIOL CHEM, V277, P28265, DOI 10.1074/jbc.M202527200; Yanagisawa M, 2001, NEUROSCI RES, V41, P391, DOI 10.1016/S0168-0102(01)00297-8; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403	30	30	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15843	15850		10.1074/jbc.M701570200	http://dx.doi.org/10.1074/jbc.M701570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400546	hybrid			2022-12-27	WOS:000246589600059
J	Schroeder-Gloeckler, JM; Rahman, SM; Janssen, RC; Qiao, LP; Shao, JH; Roper, M; Fischer, SJ; Lowe, E; Orlicky, DJ; McManaman, JL; Palmer, C; Gitomer, WL; Huang, W; O'Doherty, RM; Becker, TC; Klemm, DJ; Jensen, DR; Pulawa, LK; Eckel, RH; Friedman, JE				Schroeder-Gloeckler, Jill M.; Rahman, Shaikh Mizanoor; Janssen, Rachel C.; Qiao, Liping; Shao, Jianhua; Roper, Michael; Fischer, Stephanie J.; Lowe, Erin; Orlicky, David J.; McManaman, James L.; Palmer, Carol; Gitomer, William L.; Huang, Wan; O'Doherty, Robert M.; Becker, Thomas C.; Klemm, Dwight J.; Jensen, Dalan R.; Pulawa, Leslie K.; Eckel, Robert H.; Friedman, Jacob E.			CCAAT/Enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; TRANSCRIPTIONAL INHIBITORY PROTEIN; HEPATOCELLULAR GLUCOSE-PRODUCTION; GTP GENE-TRANSCRIPTION; C/EBP-BETA; FATTY-ACID; INSULIN-RESISTANCE; X-RECEPTOR; ADIPOCYTE DIFFERENTIATION; NUCLEAR RECEPTORS	CCAAT/enhancer-binding protein beta (C/EBP beta) plays a key role in initiation of adipogenesis in adipose tissue and gluconeogenesis in liver; however, the role of C/ EBP beta in hepatic lipogenesis remains undefined. Here we show that C/EBP beta inactivation in Leprdb/ db mice attenuates obesity, fatty liver, and diabetes. In addition to impaired adipogenesis, livers from C/EB beta(-/-) x Lepr(db/db) mice had dramatically decreased triglyceride content and reduced lipogenic enzyme activity. C/EBP beta deletion in Lepr(db/db) mice down-regulated peroxisome proliferator-activated receptor gamma 2 (PPAR gamma 2) and stearoyl-CoA desaturase-1 and up-regulated PPAR alpha independent of SREBP1c. Conversely, C/EBP beta overexpression in wild-type mice increased PPAR gamma 2 and stearoyl-CoA desaturase-1 mRNA and hepatic triglyceride content. In FAO cells, overexpression of the liver inhibiting form of C/EBP beta or C/EBP beta RNA interference attenuated palmitate-induced triglyceride accumulation and reduced PPAR gamma 2 and triglyceride levels in the liver in vivo. Leptin and the anti-diabetic drug metformin acutely down-regulated C/EBP beta expression in hepatocytes, whereas fatty acids up-regulate C/EBP beta expression. These data provide novel evidence linking C/EBP beta expression to lipogenesis and energy balance with important implications for the treatment of obesity and fatty liver disease.	UCDHSC, Dept Pediat, Aurora, CO 80045 USA; UCDHSC, Dept Pathol, Aurora, CO 80045 USA; UCDHSC, Dept Obstet & Gynecol, Aurora, CO 80045 USA; UCDHSC, Dept Physiol & Biophys, Aurora, CO 80045 USA; UCDHSC, Dept Biochem & Mol Genet, Aurora, CO 80045 USA; UCDHSC, Dept Med, Div Endocrinol Diabet & Metab, Aurora, CO 80045 USA; Vet Affairs Med Ctr, Renal Sect, Denver, CO 80220 USA; Vet Affairs Med Ctr, Pulm Sect, Res Serv, Denver, CO 80220 USA; Univ Pittsburgh, Dept Med, Div Endocrinol, Pittsburgh, PA 15261 USA; Duke Univ, Med Ctr, Div Metab Endocrinol & Nutr, Durham, NC 27704 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Duke University	Friedman, JE (corresponding author), UCDHSC, Dept Pediat, Mail Stop F-8106,POB 6511, Aurora, CO 80045 USA.	jed.friedman@uchsc.edu	Rahman, Shaikh Mizanoor/GLN-7518-2022	Rahman, Shaikh Mizanoor/0000-0002-4879-2663	NICHD NIH HHS [R01 HD045965, HD-38129, U10 HD045962, P01 HD038129, HD-045962] Funding Source: Medline; NIDDK NIH HHS [DK59767, DK-26356, R01 DK059767, DK-53969, R01 DK053969, DK-072162, P30 DK048520, R01 DK072162, DK-058855, U01-DK-56047, R01 DK058855, R01 DK026356, P30-DK-48520] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD038129, R01HD045965] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD045962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048520, R01DK026356, R13DK056047, R01DK059767, R01DK058855, R01DK072162, R01DK053969] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbud RA, 2004, ENDOCRINOLOGY, V145, P867, DOI 10.1210/en.2003-0897; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; Asilmaz E, 2004, J CLIN INVEST, V113, P414, DOI 10.1172/JCI200419511; Bain JR, 2004, DIABETES, V53, P2190, DOI 10.2337/diabetes.53.9.2190; Barbour LA, 2002, AM J OBSTET GYNECOL, V186, P512, DOI 10.1067/mob.2002.121256; Beaven SW, 2006, ANNU REV MED, V57, P313, DOI 10.1146/annurev.med.57.121304.131428; Benton CR, 2006, J PHYSIOL-LONDON, V573, P199, DOI 10.1113/jphysiol.2006.106013; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boden Guenther, 2006, Curr Diab Rep, V6, P177, DOI 10.1007/s11892-006-0031-x; Bonen A, 2004, P NUTR SOC, V63, P245, DOI 10.1079/PNS2004331; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BURTON BT, 1985, INT J OBESITY, V9, P155; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; Chen JS, 2004, NEUROPSYCHOPHARMACOL, V29, P23, DOI 10.1038/sj.npp.1300289; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Chinetti-Gbaguidi G, 2005, CURR OPIN PHARMACOL, V5, P177, DOI 10.1016/j.coph.2004.11.004; Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927; Clarke D, 2006, PERS INDIV DIFFER, V40, P5, DOI 10.1016/j.paid.2005.05.008; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; CORRIGAN AP, 1983, BIOCHEM J, V214, P299, DOI 10.1042/bj2140299; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Forcheron F, 2002, DIABETES, V51, P3486, DOI 10.2337/diabetes.51.12.3486; Friedman JM, 1998, NUTR REV, V56, pS38; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Haugen BR, 2004, ENDOCRINOLOGY, V145, P3679, DOI 10.1210/en.2003-1401; Huang W, 2004, J BIOL CHEM, V279, P21695, DOI 10.1074/jbc.M401546200; Inoue Y, 2004, J BIOL CHEM, V279, P44740, DOI 10.1074/jbc.M405177200; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; Lund EG, 2006, BIOCHEM PHARMACOL, V71, P453, DOI 10.1016/j.bcp.2005.11.004; Marchesini G, 2006, Minerva Cardioangiol, V54, P229; Matsusue K, 2004, MOL ENDOCRINOL, V18, P2751, DOI 10.1210/me.2004-0213; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; McManaman JL, 2003, J LIPID RES, V44, P668, DOI 10.1194/jlr.C200021-JLR200; Millward CA, 2007, DIABETES, V56, P161, DOI 10.2337/db06-0310; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Miyazaki M, 2004, J BIOL CHEM, V279, P35017, DOI 10.1074/jbc.M405327200; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Nepokroeff C M, 1975, Methods Enzymol, V35, P37, DOI 10.1016/0076-6879(75)35136-7; Nizielski SE, 1996, AM J PHYSIOL-REG I, V270, pR1005, DOI 10.1152/ajpregu.1996.270.5.R1005; Pajvani UB, 2005, NAT MED, V11, P797, DOI 10.1038/nm1262; Perdomo G, 2004, J BIOL CHEM, V279, P27177, DOI 10.1074/jbc.M403566200; Perseghin G, 2003, INT J OBESITY, V27, pS6, DOI 10.1038/sj.ijo.0802491; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Qiao LP, 2006, ENDOCRINOLOGY, V147, P3060, DOI 10.1210/en.2005-1507; Rahimian R, 2001, MOL CELL BIOCHEM, V224, P29, DOI 10.1023/A:1011927113563; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rao MS, 2004, HEPATOLOGY, V40, P783, DOI 10.1002/hep.20453; Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Shao JH, 2005, DIABETES, V54, P976, DOI 10.2337/diabetes.54.4.976; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Smas CM, 1997, CRIT REV EUKAR GENE, V7, P281, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.10; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; Sugden MC, 2002, BIOCHEM J, V364, P361, DOI 10.1042/BJ20011699; Sztalryd C, 2006, J BIOL CHEM, V281, P34341, DOI 10.1074/jbc.M602497200; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Taubenfeld SM, 2001, NAT NEUROSCI, V4, P813, DOI 10.1038/90520; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang LQ, 2000, J BIOL CHEM, V275, P14173, DOI 10.1074/jbc.M000764200; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Yahagi N, 2002, J BIOL CHEM, V277, P19353, DOI 10.1074/jbc.M201584200; Yang JQ, 2005, J BIOL CHEM, V280, P38689, DOI 10.1074/jbc.M503486200; Yu ST, 2003, J BIOL CHEM, V278, P498, DOI 10.1074/jbc.M210062200; Zang MW, 2004, J BIOL CHEM, V279, P47898, DOI 10.1074/jbc.M408149200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhou J, 2006, J BIOL CHEM, V281, P15013, DOI 10.1074/jbc.M511116200	88	103	106	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15717	15729		10.1074/jbc.M701329200	http://dx.doi.org/10.1074/jbc.M701329200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17387171	Green Accepted, hybrid			2022-12-27	WOS:000246589600048
J	Lecine, P; Esmiol, S; Metais, JY; Nicoletti, C; Nourry, C; McDonald, C; Nunez, G; Hugot, JP; Borg, JP; Ollendorff, V				Lecine, Patrick; Esmiol, Sophie; Metais, Jean-Yves; Nicoletti, Cendrine; Nourry, Claire; McDonald, Christine; Nunez, Gabriel; Hugot, Jean-Pierre; Borg, Jean-Paul; Ollendorff, Vincent			The NOD2-RICK complex signals from the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MURAMYL DIPEPTIDE RECOGNITION; INTESTINAL EPITHELIAL-CELLS; INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; IMMUNE-RESPONSES; NOD2 VARIANTS; ACTIVATION; RECEPTOR; ERBIN	NOD2 plays an important role in the innate immunity of the intestinal tract. By sensing the muramyl dipeptide (MDP), a bacterial wall component, NOD2 triggers the NF-kappa B signaling pathway and promotes the release of proinflammatory cytokines such as interleukin-8. Mutations in Nod2 (1007FS, R702W, G908R) impinge on NOD2 functions and are associated with the pathogenesis of Crohn disease, a chronic inflammatory bowel disease. Although NOD2 is usually described as a cytosolic receptor for MDP, the protein is also localized at the plasma membrane, and the 1007FS mutation delocalizes NOD2 to the cytoplasm (Barnich, N., Aguirre, J. E., Reinecker, H. C., Xavier, R., and Podolsky, D. K. (2005) J. Cell Biol. 170, 21 - 26; McDonald, C., Chen, F. F., Ollendorff, V., Ogura, Y., Marchetto, S., Lecine, P., Borg, J. P., and Nunez, G. (2005) J. Biol. Chem. 280, 40301 - 40309). In this study, we demonstrate that membrane-bound versions of NOD2 and Crohn disease-associated mutants R702W and G908R are capable of responding to MDP and activating the NF-kappa B pathway from this location. In contrast, the 1007FS mutant remains unable to respond to MDP from the plasma membrane. We also show that NOD2 promotes the membrane recruitment of RICK, a serine-threonine kinase involved in NF-kappa B activation downstream of NOD2. Furthermore, the artificial attachment of RICK at the plasma membrane provokes a constitutive and strong activation of the NF-kappa B pathway and secretion of interleukin-8 showing that optimal RICK activity depends upon its subcellular localization. Finally, we show that endogenous RICK localizes at the plasma membrane in the THP1 cell line. Thus, our data suggest that NOD2 is responsible for the membrane recruitment of RICK to induce a regulated NF-kappa B signaling and production of proinflammatory cytokines.	Univ Paul Cezanne Fac St Jerome Serv, IMRN, INRA, UMR 1111, F-13397 Marseille 20, France; Univ Aix Marseille 2, INSERM, UMR 599, Inst J Paoli I Calmettes,Ctr Rech Cancerol Marsei, F-13009 Marseille, France; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Paris 07, Assistance Publ Hop Paris, Hop Robert Debre, INSERM U763,UFR Med Denis Diderot, F-75019 Paris, France	INRAE; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); University of Michigan System; University of Michigan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite	Ollendorff, V (corresponding author), Univ Paul Cezanne Fac St Jerome Serv, IMRN, INRA, UMR 1111, 342 Ave Escadrille Normandie Niemen, F-13397 Marseille 20, France.	vincent.ollendorff@univ-cezanne.fr	Nuñez, Gabriel/A-7160-2014; Lecine, Patrick/H-9338-2016; Hugot, Jean-Pierre/F-6594-2012; Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382; Ollendorff, Vincent/0000-0001-9751-2202; Hugot, Jean-Pierre/0000-0002-8446-6056; Lecine, Patrick/0000-0002-8091-7286; McDonald, Christine/0000-0002-6745-9487				Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Barnich N, 2005, J CELL BIOL, V170, P21, DOI 10.1083/jcb.200502153; Barnich N, 2005, J BIOL CHEM, V280, P19021, DOI 10.1074/jbc.M413776200; Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Chen CM, 2004, J BIOL CHEM, V279, P25876, DOI 10.1074/jbc.M400682200; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Dai PG, 2006, J BIOL CHEM, V281, P927, DOI 10.1074/jbc.M507360200; Damiano JS, 2004, BIOCHEM J, V381, P213, DOI 10.1042/BJ20031506; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Eckmann L, 2005, IMMUNITY, V22, P661, DOI 10.1016/j.immuni.2005.06.004; Economou M, 2004, AM J GASTROENTEROL, V99, P2393, DOI 10.1111/j.1572-0241.2004.40304.x; Gaya DR, 2006, LANCET, V367, P1271, DOI 10.1016/S0140-6736(06)68345-1; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Hoffmann E, 2005, J BIOL CHEM, V280, P9706, DOI 10.1074/jbc.M407071200; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Huang YZ, 2003, J BIOL CHEM, V278, P1108, DOI 10.1074/jbc.M205413200; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; KOLCH W, 2003, SCI STKE, pPE37; Kufer TA, 2006, INFECT IMMUN, V74, P3115, DOI 10.1128/IAI.00035-06; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; McDonald C, 2005, J BIOL CHEM, V280, P40301, DOI 10.1074/jbc.M508538200; Netea MG, 2004, EUR J IMMUNOL, V34, P2052, DOI 10.1002/eji.200425229; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Russell RK, 2004, CURR OPIN GENET DEV, V14, P264, DOI 10.1016/j.gde.2004.04.004; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; Uehara A, 2005, CELL MICROBIOL, V7, P53, DOI 10.1111/j.1462-5822.2004.00433.x; van Heel DA, 2005, LANCET, V365, P1794, DOI 10.1016/S0140-6736(05)66582-8; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092	44	93	97	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15197	15207		10.1074/jbc.M606242200	http://dx.doi.org/10.1074/jbc.M606242200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17355968	Green Published, hybrid			2022-12-27	WOS:000246589000059
J	Huang, G; Kim, JY; Dehoff, M; Mizuno, Y; Kamm, KE; Worley, PF; Muallem, S; Zeng, W				Huang, Guojin; Kim, Joo Young; Dehoff, Marlin; Mizuno, Yusuke; Kamm, Kristine E.; Worley, Paul F.; Muallem, Shmuel; Zeng, Weizhong			Ca2+ signaling in microdomains - Homer1 mediates the interaction between RyR2 and Cav1.2 to regulate excitation-contraction coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CALCIUM-RELEASE; SMOOTH-MUSCLE; RYANODINE RECEPTOR-TYPE-1; PROTEINS; SKELETAL; CHANNELS; CELLS; ACTIVATION; COMPLEXES; CA(V)1.2	Excitation-contraction (E-C) coupling and Ca2+-induced Ca2+ release in smooth and cardiac muscles is mediated by the L-type Ca2+ channel isoform Ca(v)1.2 and the ryanodine receptor isoform RyR2. Although physical coupling between Ca(v)1.1 and RyR1 in skeletal muscle is well established, it is generally assumed that Ca(v)1.2 and RyR2 do not directly communicate either passively or dynamically during E-C coupling. In the present work, we re-examined this assumption by studying E-C coupling in the detrusor muscle of wild type and Homer1(-/-) mice and by demonstrating a Homer1-mediated dynamic interaction between Ca(v)1.2 and RyR2 using the split green fluorescent protein technique. Deletion of Homer1 in mice (but not of Homer2 or Homer3) resulted in impaired urinary bladder function, which was associated with higher sensitivity of the detrusor muscle to muscarinic stimulation and membrane depolarization. This was not due to an altered expression or function of RyR2 and Ca(v)1.2. Most notably, expression of Ca(v)1.2 and RyR2 tagged with the complementary C- and N- terminal halves of green fluorescent protein and in the presence and absence of Homer1 isoforms revealed that H1a and H1b/c reciprocally modulates a dynamic interaction between Ca(v)1.2 and RyR2 to regulate the intensity of Ca2+-induced Ca2+ release and its dependence on membrane depolarization. These findings define the molecular basis of a "two-state" model of E-C coupling by Ca(v)1.2 and RyR2. In one state, Ca(v)1.2 couples to RyR2 by H1b/c, which results in reduced responsiveness to membrane depolarization and in the other state H1a uncouples Ca(v)1.2 and RyR2 to enhance responsiveness to membrane depolarization. These findings reveal an unexpected and novel mode of interaction and communication between Ca(v)1.2 and RyR2 with important implications for the regulation of smooth and possibly cardiac muscle E-C coupling.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Program Biochem Cellular & Mol Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Worley, PF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Program Biochem Cellular & Mol Biol, Baltimore, MD 21205 USA.	pworley@jhmi.edu; Shmuel.muallem@utsouthwestern.edu	Huang, Guojin/ABB-1091-2021	Huang, Guojin/0000-0001-7020-5528	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH068830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA010309, R01DA010309, P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10309, DA00266] Funding Source: Medline; NIDCR NIH HHS [DE12309] Funding Source: Medline; NIDDK NIH HHS [DK38938] Funding Source: Medline; NIMH NIH HHS [MH068830] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bers DM, 2004, J MOL CELL CARDIOL, V37, P417, DOI 10.1016/j.yjmcc.2004.05.026; Cabantous S, 2005, NAT BIOTECHNOL, V23, P102, DOI 10.1038/nbt1044; Collier ML, 2000, J GEN PHYSIOL, V115, P653, DOI 10.1085/jgp.115.5.653; Fagni Laurent, 2002, Sci STKE, V2002, pre8, DOI 10.1126/stke.2002.137.re8; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Franzini-Armstrong C, 2004, BIOL RES, V37, P507; Huang GJ, 2006, J CELL SCI, V119, P153, DOI 10.1242/jcs.02731; Hwang SY, 2003, CELL CALCIUM, V34, P177, DOI 10.1016/S0143-4160(03)00082-4; Isotani E, 2004, P NATL ACAD SCI USA, V101, P6279, DOI 10.1073/pnas.0308742101; Ji GJ, 2004, J GEN PHYSIOL, V123, P377, DOI 10.1085/jgp.200308999; Kammermeier PJ, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-1; Kiselyov K, 2005, PFLUG ARCH EUR J PHY, V451, P116, DOI 10.1007/s00424-005-1442-2; Kiselyov K, 2002, ADV EXP MED BIOL, V506, P175; Kotlikoff MI, 2003, PROG BIOPHYS MOL BIO, V83, P171, DOI 10.1016/S0079-6107(03)00056-7; Meredith AL, 2004, J BIOL CHEM, V279, P36746, DOI 10.1074/jbc.M405621200; Nakai J, 1997, P NATL ACAD SCI USA, V94, P1019, DOI 10.1073/pnas.94.3.1019; Ozawa T, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni032; Sala C, 2005, J NEUROSCI, V25, P4587, DOI 10.1523/JNEUROSCI.4822-04.2005; Sgambato-Faure V, 2006, BIOCHEM BIOPH RES CO, V343, P630, DOI 10.1016/j.bbrc.2006.03.020; Shin DM, 2003, J CELL BIOL, V162, P293, DOI 10.1083/jcb.200210109; Soloviev MM, 2000, EUR J BIOCHEM, V267, P634, DOI 10.1046/j.1432-1327.2000.01078.x; Szumlinski KK, 2006, CURR OPIN NEUROBIOL, V16, P251, DOI 10.1016/j.conb.2006.05.002; Ward CW, 2004, J BIOL CHEM, V279, P5781, DOI 10.1074/jbc.M311422200; Wegener JW, 2004, FASEB J, V18, P1159, DOI 10.1096/fj.04-1516fje; Wehrens XHT, 2005, ANNU REV PHYSIOL, V67, P69, DOI 10.1146/annurev.physiol.67.040403.114521; Westhoff JH, 2003, CELL CALCIUM, V34, P261, DOI 10.1016/S0143-4160(03)00112-X; Wray S, 2005, CELL CALCIUM, V38, P397, DOI 10.1016/j.ceca.2005.06.018; Yamamoto K, 2005, EUR J NEUROSCI, V22, P1338, DOI 10.1111/j.1460-9568.2005.04278.x; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang H, 2006, EUR J NEUROSCI, V23, P2297, DOI 10.1111/j.1460-9568.2006.04734.x; Zhang SF, 2004, CELL, V119, P137, DOI 10.1016/j.cell.2004.09.012	31	34	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14283	14290		10.1074/jbc.M611529200	http://dx.doi.org/10.1074/jbc.M611529200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355963	hybrid			2022-12-27	WOS:000246245800039
J	Penet, MF; Kober, F; Confort-Gouny, S; Le Fur, Y; Dalmasso, C; Coltel, N; Liprandi, A; Gulian, JM; Grau, GE; Cozzone, PJ; Viola, A				Penet, Marie-France; Kober, Frank; Confort-Gouny, Sylviane; Le Fur, Yann; Dalmasso, Christiane; Coltel, Nicolas; Liprandi, Agnes; Gulian, Jean-Marc; Grau, Georges E.; Cozzone, Patrick J.; Viola, Angele			Magnetic resonance spectroscopy reveals an impaired brain metabolic profile in mice resistant to cerebral malaria infected with Plasmodium berghei ANKA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULMINANT HEPATIC-FAILURE; BLOOD-STAGE MALARIA; ACUTE LIVER-FAILURE; AMINO-ACIDS; FALCIPARUM-MALARIA; IN-VIVO; PATHOGENESIS; AMMONIA; ENCEPHALOPATHY; HEMOZOIN	Malaria is a major cause of morbidity and mortality with an annual death toll exceeding one million. Severe malaria is a complex multisystem disorder, including one or more of the following complications: cerebral malaria, anemia, acidosis, jaundice, respiratory distress, renal insufficiency, coagulation anomalies, and hyperparasitemia. Using a combined in vivo/in vitro metabolic-based approach, we investigated the putative pathogenic effects of Plasmodium berghei ANKA on brain, in a mouse strain developing malaria but resistant to cerebral malaria. The purpose was to determine whether the infection could cause a brain dysfunction distinct from the classic cerebral syndrome. Mice resistant to cerebral malaria were infected with P. berghei ANKA and explored during both the symptomless and the severe stage of the disease by using in vivo brain magnetic resonance imaging and spectroscopy. The infected mice did not present the lesional and metabolic hallmarks of cerebral malaria. However, brain dysfunction caused by anemia, parasite burden, and hepatic damage was evidenced. We report an increase in cerebral blood flow, a process allowing temporary maintenance of oxygen supply to brain despite anemia. Besides, we document metabolic anomalies affecting choline-derived compounds, myo-inositol, glutamine, glycine, and alanine. The choline decrease appears related to parasite proliferation. Glutamine, myo-inositol, glycine, and alanine variations together indicate a hepatic encephalopathy, a finding in agreement with the liver damage detected in mice, which is also a feature of the human disease. These results reveal the vulnerability of brain to malaria infection at the severe stage of the disease even in the absence of cerebral malaria.	Univ Aix Marseille 2, Fac Med Timone, CNRS, UMR 6612,Ctr Resonance Magnet Biol & Med, F-13005 Marseille, France; Univ Aix Marseille 2, Fac Med Timone, Unite Rickettsies & Pathogenes Emergents, UMR 6020,Inst Federat Rech,CNRS, F-13005 Marseille, France; Hop Enfants La Timone, Serv Anat Pathol & Neuropathol, F-13005 Marseille, France; Hop Enfants La Timone, Biochim Lab, F-13005 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Viola, A (corresponding author), Univ Aix Marseille 2, Fac Med Timone, CNRS, UMR 6612,Ctr Resonance Magnet Biol & Med, 27 Blvd Jean Moulin, F-13005 Marseille, France.	viola@medecine.univ-mrs.fr	Penet, Marie-France/AGZ-6991-2022; Kober, Frank/L-8737-2013; Grau, Georges/AGR-7139-2022	Kober, Frank/0000-0002-7869-3615; Grau, Georges/0000-0002-0442-0462				Anand AC, 2005, J GASTROEN HEPATOL, V20, P1322, DOI 10.1111/j.1440-1746.2005.03884.x; Biagini GA, 2004, BLOOD, V104, P3372, DOI 10.1182/blood-2004-03-1084; Bluml S, 1998, J NEUROCHEM, V71, P1564; BORGSTROM L, 1975, ACTA PHYSIOL SCAND, V93, P505, DOI 10.1111/j.1748-1716.1975.tb05842.x; Carney CK, 2006, J BIOL INORG CHEM, V11, P917, DOI 10.1007/s00775-006-0147-0; Chang KH, 2004, INT J PARASITOL, V34, P1501, DOI 10.1016/j.ijpara.2004.10.008; Chang KH, 2004, J INFECT DIS, V189, P735, DOI 10.1086/381458; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; Cordoba J, 1996, HEPATOLOGY, V24, P919, DOI 10.1002/hep.510240427; Cordoba J, 2002, METAB BRAIN DIS, V17, P415, DOI 10.1023/A:1021926405944; De-Oliveira ACAX, 2006, EXP PARASITOL, V113, P256, DOI 10.1016/j.exppara.2006.01.013; DEKOSSODO S, 1993, J IMMUNOL, V151, P4811; Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128; Felipo V, 2002, PROG NEUROBIOL, V67, P259, DOI 10.1016/S0301-0082(02)00019-9; Freeman JJ, 1996, LIFE SCI, V58, P1921, DOI 10.1016/0024-3205(96)00181-6; Gerardin P, 2002, ARCH PEDIATRIE, V9, P1260, DOI 10.1016/S0929-693X(02)00127-6; Green MD, 1996, MOL BIOCHEM PARASIT, V83, P183, DOI 10.1016/S0166-6851(96)02769-7; Guerra CA, 2006, TRENDS PARASITOL, V22, P353, DOI 10.1016/j.pt.2006.06.006; Hansen DS, 2003, IMMUNITY, V18, P391, DOI 10.1016/S1074-7613(03)00052-9; Hare GMT, 2003, J APPL PHYSIOL, V94, P2058, DOI 10.1152/japplphysiol.00931.2002; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Icke G, 2005, PLOS MED, V2, P108, DOI 10.1371/journal.pmed.0020011; Jacobs T, 2004, EUR J IMMUNOL, V34, P972, DOI 10.1002/eji.200324477; Kennan RP, 2004, MAGN RESON MED, V51, P525, DOI 10.1002/mrm.20014; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; KLEIN J, 1990, J NEUROCHEM, V55, P1231, DOI 10.1111/j.1471-4159.1990.tb03129.x; Kober F, 2004, MAGN RESON MED, V51, P62, DOI 10.1002/mrm.10676; Kochar DK, 2003, QJM-INT J MED, V96, P505, DOI 10.1093/qjmed/hcg091; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Mackintosh CL, 2004, TRENDS PARASITOL, V20, P597, DOI 10.1016/j.pt.2004.09.006; Malaguarnera L, 2002, LANCET INFECT DIS, V2, P472, DOI 10.1016/S1473-3099(02)00344-4; MANS AM, 1994, J NEUROCHEM, V63, P1829; Martiney JA, 2000, INFECT IMMUN, V68, P2259, DOI 10.1128/IAI.68.4.2259-2267.2000; Michalak A, 1996, HEPATOLOGY, V24, P908, DOI 10.1002/hep.510240425; Mohanty N, 2004, T ROY SOC TROP MED H, V98, P753, DOI 10.1016/S0035-9203(03)00023-3; Mordmuller B, 1998, CLIN INFECT DIS, V26, P850, DOI 10.1086/513926; Penet MF, 2005, J NEUROSCI, V25, P7352, DOI 10.1523/JNEUROSCI.1002-05.2005; Pessi G, 2004, P NATL ACAD SCI USA, V101, P6206, DOI 10.1073/pnas.0307742101; Saywell W, 2006, BIOCHEM BIOPH RES CO, V340, P776, DOI 10.1016/j.bbrc.2005.12.080; Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686; Schwarzer E, 2003, BLOOD, V101, P722, DOI 10.1182/blood-2002-03-0979; Shawcross D, 2005, CELL MOL LIFE SCI, V62, P2295, DOI 10.1007/s00018-005-5089-0; Shawcross DL, 2004, AM J PHYSIOL-GASTR L, V287, pG503, DOI 10.1152/ajpgi.00104.2004; Singh RP, 2002, J IMMUNOL, V168, P4674, DOI 10.4049/jimmunol.168.9.4674; Srivastava P, 2000, ECOTOX ENVIRON SAFE, V46, P19, DOI 10.1006/eesa.1999.1867; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; SWAIN M, 1992, HEPATOLOGY, V15, P449, DOI 10.1002/hep.1840150316; SWAIN MS, 1992, HEPATOLOGY, V16, P1028, DOI 10.1002/hep.1840160428; Tofteng F, 2006, J CEREBR BLOOD F MET, V26, P21, DOI 10.1038/sj.jcbfm.9600168; Tofteng F, 2004, METAB BRAIN DIS, V19, P207, DOI 10.1023/B:MEBR.0000043970.34533.04; Turner G, 1997, BRAIN PATHOL, V7, P569, DOI 10.1111/j.1750-3639.1997.tb01075.x; Viola A, 2004, MAGN RESON MATER PHY, V17, P47, DOI 10.1007/s10334-004-0044-x; Wichmann O, 2003, INFECTION, V31, P260, DOI 10.1007/s15010-002-3143-5; Zwingmann C, 2005, NEUROCHEM INT, V47, P39, DOI 10.1016/j.neuint.2005.04.005; Zwingmann C, 2002, METAB BRAIN DIS, V17, P263, DOI 10.1023/A:1021997532352; Zwingmann C, 2001, GLIA, V34, P200, DOI 10.1002/glia.1054	57	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14505	14514		10.1074/jbc.M608035200	http://dx.doi.org/10.1074/jbc.M608035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369263	hybrid			2022-12-27	WOS:000246245800064
J	Stanne, TM; Pojidaeva, E; Andersson, FI; Clarke, AK				Stanne, Tara M.; Pojidaeva, Elena; Andersson, Fredrik I.; Clarke, Adrian K.			Distinctive types of ATP-dependent Clp proteases in cyanobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI; GENE-TRANSFER; CHLOROPLAST; ARABIDOPSIS; SUBUNIT; COMPLEX; ACCLIMATION; DEGRADATION; IDENTIFICATION	Cyanobacteria are the only prokaryotes that perform oxygenic photosynthesis and are thought to be ancestors to plant chloroplasts. Like chloroplasts, cyanobacteria possess a diverse array of proteolytic enzymes, with one of the most prominent being the ATP-dependent Ser-type Clp protease. The model Clp protease in Escherichia coli consists of a single ClpP proteolytic core flanked on one or both ends by a HSP100 chaperone partner. In comparison, cyanobacteria have multiple ClpP paralogs plus a ClpP variant (ClpR), which lacks the catalytic triad typical of Ser-type proteases. In this study, we reveal that two distinct soluble Clp proteases exist in the unicellular cyanobacterium Synechococcus elongatus. Each protease consists of a unique proteolytic core comprised of two separate Clp subunits, one with ClpP1 and ClpP2, the other with ClpP3 and ClpR. Each core also associates with a particular HSP100 chaperone partner, ClpC in the case of the ClpP3/R core, and ClpX for the ClpP1/P2 core. The two adaptor proteins, ClpS1 and ClpS2 also interact with the ClpC chaperone protein, likely increasing the range of protein substrates targeted by the Clp protease in cyanobacteria. We also reveal the possible existence of a third Clp protease in Synechococcus, one which associates with the internal membrane network. Altogether, we show that presence of several distinctive Clp proteases in cyanobacteria, a feature which contrasts from that in most other organisms.	Univ Gothenburg, Dept Plant & Environm Sci, S-40530 Gothenburg, Sweden	University of Gothenburg	Clarke, AK (corresponding author), Univ Gothenburg, Dept Plant & Environm Sci, Box 461, S-40530 Gothenburg, Sweden.	adrian.clarke@dpes.gu.se		Pojidaeva, Elena/0000-0002-5106-5707				Adam Z, 2000, BIOCHIMIE, V82, P647, DOI 10.1016/S0300-9084(00)00612-X; Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; Andersson B, 1997, PHYSIOL PLANTARUM, V100, P780, DOI 10.1034/j.1399-3054.1997.1000405.x; Andersson FI, 2006, J BIOL CHEM, V281, P5468, DOI 10.1074/jbc.M509661200; Becker G, 1999, P NATL ACAD SCI USA, V96, P6439, DOI 10.1073/pnas.96.11.6439; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; CAMPBELL D, 1995, EMBO J, V14, P5457, DOI 10.1002/j.1460-2075.1995.tb00232.x; Clarke AK, 1999, ANN BOT-LONDON, V83, P593, DOI 10.1006/anbo.1999.0878; CLARKE AK, 1992, PLANT PHYSIOL, V100, P2081, DOI 10.1104/pp.100.4.2081; Clarke AK, 1998, PLANT MOL BIOL, V37, P791, DOI 10.1023/A:1006016302074; Desimone M, 1997, BOT ACTA, V110, P234, DOI 10.1111/j.1438-8677.1997.tb00634.x; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Erbse A, 2006, NATURE, V439, P753, DOI 10.1038/nature04412; Fu GK, 1997, J BIOL CHEM, V272, P534; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Halperin T, 2001, PLANTA, V213, P614, DOI 10.1007/s004250100527; Hengge-Aronis R, 2002, CURR OPIN MICROBIOL, V5, P591, DOI 10.1016/S1369-5274(02)00372-7; Herrmann RG, 1997, EUKARYOTISM SYMBIOSI, P73, DOI [10.1007/978-3-642-60885-8_7, DOI 10.1007/978-3-642-60885-8_7]; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Kim KI, 1999, J MOL BIOL, V294, P1363, DOI 10.1006/jmbi.1999.3320; Koussevitzky S, 2007, PLANT MOL BIOL, V63, P85, DOI 10.1007/s11103-006-9074-2; Kuroda H, 2003, NATURE, V425, P86, DOI 10.1038/nature01909; Li C, 2000, J BACTERIOL, V182, P6630, DOI 10.1128/JB.182.23.6630-6637.2000; Majeran W, 2005, FEBS J, V272, P5558, DOI 10.1111/j.1742-4658.2005.04951.x; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; Martin W, 1998, PLANT PHYSIOL, V118, P9, DOI 10.1104/pp.118.1.9; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1991, BIOCHEM SOC T, V19, P719, DOI 10.1042/bst0190719; MYERS J, 1980, PLANT PHYSIOL, V66, P1144, DOI 10.1104/pp.66.6.1144; Peltier JB, 2004, J BIOL CHEM, V279, P4768, DOI 10.1074/jbc.M309212200; Peltier JB, 2001, J BIOL CHEM, V276, P16318, DOI 10.1074/jbc.M010503200; Pojidaeva E, 2004, J BACTERIOL, V186, P3991, DOI 10.1128/JB.186.12.3991-3999.2004; Porankiewicz J, 1997, J BACTERIOL, V179, P5111, DOI 10.1128/jb.179.16.5111-5117.1997; Porankiewicz J, 1998, MOL MICROBIOL, V29, P275, DOI 10.1046/j.1365-2958.1998.00928.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Rudella A, 2006, PLANT CELL, V18, P1704, DOI 10.1105/tpc.106.042861; Schelin J, 2002, MICROBIOL-SGM, V148, P2255, DOI 10.1099/00221287-148-7-2255; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Sjogren LLE, 2006, PLANT CELL, V18, P2635, DOI 10.1105/tpc.106.044594; Sokolenko A, 2002, CURR GENET, V41, P291, DOI 10.1007/s00294-002-0309-8; Sokolenko A, 1998, PLANTA, V207, P286, DOI 10.1007/s004250050485; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; YOO SJ, 1994, BIOCHEM BIOPH RES CO, V203, P798, DOI 10.1006/bbrc.1994.2253; Zeth K, 2002, NAT STRUCT BIOL, V9, P906, DOI 10.1038/nsb869; Zheng B, 2006, PLANTA, V224, P1103, DOI 10.1007/s00425-006-0292-2; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	50	69	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14394	14402		10.1074/jbc.M700275200	http://dx.doi.org/10.1074/jbc.M700275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371875	hybrid			2022-12-27	WOS:000246245800052
J	Doerner, JF; Gisselmann, G; Hatt, H; Wetzel, CH				Doerner, Julia F.; Gisselmann, Guenter; Hatt, Hanns; Wetzel, Christian H.			Transient receptor potential channel a1 is directly gated by calcium ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; TRP CHANNEL; BINDING PROTEINS; EF-HANDS; ACTIVATION; CALMODULIN; COLD; TRANSDUCTION; PEPTIDES; NEURONS	Members of the superfamily of transient receptor potential (TRP) channels are proposed to play important roles in sensory physiology. As an excitatory ion channel TRPA1 is robustly activated by pungent irritants in mustard and garlic and is suggested to mediate the inflammatory actions of environmental irritants and proalgesic agents. Here, we demonstrate that, in addition to pungent natural compounds, Ca2+ directly gates heterologously expressed TRPA1 in whole-cell and excised-patch recordings with an apparent EC50 of 905 nM. Pharmacological experiments and site-directed mutagenesis indicate that the N-terminal EF-hand calcium-binding domain of the channel is involved in Ca2+-dependent activation. Furthermore, we determine Ca2+ as prerequisite for icilin activity on TRPA1.	Ruhr Univ Bochum, Fak Biol, Lehrstuhl Zellphysiol, D-44780 Bochum, Germany	Ruhr University Bochum	Wetzel, CH (corresponding author), Ruhr Univ Bochum, Fak Biol, Lehrstuhl Zellphysiol, D-44780 Bochum, Germany.	Christian.Wetzel@rub.de	Wetzel, Christian/F-1366-2018; Wetzel, Christian H/N-9880-2017; Wetzel, Christian/C-2501-2009	Wetzel, Christian H/0000-0002-5762-0003; Wetzel, Christian/0000-0002-5762-0003				Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bautista DM, 2005, P NATL ACAD SCI USA, V102, P12248, DOI 10.1073/pnas.0505356102; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Chuang HH, 2004, NEURON, V43, P859, DOI 10.1016/j.neuron.2004.08.038; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Corey DP, 2004, NATURE, V432, P723, DOI 10.1038/nature03066; Drake SK, 1997, J GEN PHYSIOL, V110, P173, DOI 10.1085/jgp.110.2.173; Grabarek Z, 2006, J MOL BIOL, V359, P509, DOI 10.1016/j.jmb.2006.03.066; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Houtman R, 2001, J IMMUNOL, V166, P861, DOI 10.4049/jimmunol.166.2.861; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Kwan KY, 2006, NEURON, V50, P277, DOI 10.1016/j.neuron.2006.03.042; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; Lupinsky DA, 2006, J PHYSIOL-LONDON, V575, P491, DOI 10.1113/jphysiol.2006.105833; Macpherson LJ, 2005, CURR BIOL, V15, P929, DOI 10.1016/j.cub.2005.04.018; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Nagata K, 2005, J NEUROSCI, V25, P4052, DOI 10.1523/JNEUROSCI.0013-05.2005; Nilius B, 2006, EMBO J, V25, P467, DOI 10.1038/sj.emboj.7600963; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Strotmann R, 2003, J BIOL CHEM, V278, P26541, DOI 10.1074/jbc.M302590200; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; Watanabe H, 2003, CELL CALCIUM, V33, P489, DOI 10.1016/S0143-4160(03)00064-2; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; ZUFALL F, 1993, P NATL ACAD SCI USA, V90, P9335, DOI 10.1073/pnas.90.20.9335	29	236	240	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13180	13189		10.1074/jbc.M607849200	http://dx.doi.org/10.1074/jbc.M607849200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353192	hybrid			2022-12-27	WOS:000246060300006
J	Correia, JD; Miranda, Y; Leonard, N; Ulevitch, RJ				Correia, Jean da Silva; Miranda, Yvonne; Leonard, Nikki; Ulevitch, Richard J.			The subunit CSN6 of the COP9 signalosome is cleaved during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; UBIQUITIN-LIGASE; CELL-DEATH; BACTERIAL PEPTIDOGLYCAN; CASPASE ACTIVATION; CYCLIN-E; NOD1; PROTEASOME; DEGRADATION; SUBSTRATE	The COP9 signalosome is a large multiprotein complex that consists of eight subunits termed CSN1-CSN8. The diverse functions of the COP9 complex include regulation of several important intracellular pathways, including the ubiquitin/proteasome system, DNA repair, cell cycle, developmental changes, and some aspects of immune responses. Nod1 is also thought to be an important cytoplasmic receptor involved in innate immune responses. It detects specific motifs of bacterial peptidoglycan, and this results in activation of multiple signaling pathways and changes in cell function. In this report, we performed a yeast two-hybrid screening and discovered that Nod1 interacts with several components of the COP9 signalosome through its CARD domain. Moreover, we observed that activation of the Nod1 apoptotic pathway leads to specific cleavage of the subunit CSN6. This cleavage is concomitant with caspase processing and generates a short amino-terminal peptide of 3 kDa. A complete inhibition of this cleavage was achieved in the presence of the broad spectrum pharmacological inhibitor of apoptosis, Z-VAD. Furthermore, overexpression of CLARP, a specific caspase 8 inhibitor, completely blocked cleavage of CSN6. Taken together, these results suggest a critical role of caspase 8 in the processing of CSN6. Moreover, these findings suggest that CSN6 cleavage may result in modifications of functions of the COP9 complex that are involved in apoptosis.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Ulevitch, RJ (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ulevitch@scripps.edu	Ulevitch, Richard J/Q-3393-2017		NIAID NIH HHS [AI15136, U54 AI54523] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI054523, R01AI015136] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adrain C, 2004, J BIOL CHEM, V279, P36923, DOI 10.1074/jbc.M402638200; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Basu A, 2002, J BIOL CHEM, V277, P41850, DOI 10.1074/jbc.M205997200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Burger-Kentischer A, 2005, FEBS LETT, V579, P1693, DOI 10.1016/j.febslet.2005.01.080; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Communal C, 2002, P NATL ACAD SCI USA, V99, P6252, DOI 10.1073/pnas.092022999; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Correia JD, 2007, CELL DEATH DIFFER, V14, P830, DOI 10.1038/sj.cdd.4402070; Correia JD, 2006, P NATL ACAD SCI USA, V103, P1840, DOI 10.1073/pnas.0509228103; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Doronkin S, 2002, DEVELOPMENT, V129, P5053; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Fischer U, 2006, ONCOGENE, V25, P152, DOI 10.1038/sj.onc.1209015; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fulda S, 1997, CANCER RES, V57, P3823; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Giri K, 2003, FEBS LETT, V555, P380, DOI 10.1016/S0014-5793(03)01294-8; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu Y, 2002, PLANT CELL, V14, P1483, DOI 10.1105/tpc.002493; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Opitz B, 2005, CIRC RES, V96, P319, DOI 10.1161/01.RES.0000155721.83594.2c; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Schwechheimer C, 2002, PLANT CELL, V14, P2553, DOI 10.1105/tpc.003434; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Sun Y, 2002, J BIOL CHEM, V277, P45759, DOI 10.1074/jbc.M208709200; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Ting JPY, 2005, ANNU REV IMMUNOL, V23, P387, DOI 10.1146/annurev.immunol.23.021704.115616; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Travassos LH, 2005, J BIOL CHEM, V280, P36714, DOI 10.1074/jbc.M501649200; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Welter-Stahl L, 2006, CELL MICROBIOL, V8, P1047, DOI 10.1111/j.1462-5822.2006.00686.x; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Yan J, 2003, MOL CELL BIOL, V23, P6798, DOI 10.1128/MCB.23.19.6798-6808.2003; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9	54	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12557	12565		10.1074/jbc.M609587200	http://dx.doi.org/10.1074/jbc.M609587200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337451	hybrid			2022-12-27	WOS:000245942800024
J	Novoselov, SV; Kryukov, GV; Xu, XM; Carlson, BA; Hatfield, DL; Gladyshev, VN				Novoselov, Sergey V.; Kryukov, Gregory V.; Xu, Xue-Ming; Carlson, Bradley A.; Hatfield, Dolph L.; Gladyshev, Vadim N.			Selenoprotein H is a nucleolar thioredoxin-like protein with a unique expression pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE TRANSFER-RNAS; EUKARYOTIC SECIS ELEMENTS; GENE-EXPRESSION; MAMMALIAN SELENOPROTEIN; GLUTATHIONE-PEROXIDASE; UGA CODONS; INSERTION; BINDING; MUSCLE; FORM	The human selenoproteome consists of 25 known selenoproteins, but functions of many of these proteins are not known. Selenoprotein H ( SelH) is a recently discovered 14-kDa mammalian protein with no sequence homology to functionally characterized proteins. By sensitive sequence and structure analyses, we identified SelH as a thioredoxin fold-like protein in which a conserved CXXU motif ( cysteine separated by two other residues from selenocysteine) corresponds to the CXXC motif in thioredoxins. These data suggest a redox function of SelH. Indeed, a recombinant SelH shows significant glutathione peroxidase activity. In addition, SelH has a conserved RKRK motif in the N-terminal sequence. We cloned wild-type and cysteine mutant forms of SelH either upstream or downstream of green fluorescent protein ( GFP) and localized this fusion protein to the nucleus in transfected mammalian cells, whereas mutations in the RKRK motif resulted in the cytosolic protein. Interestingly, the full-length SelH-GFP fusion protein localized specifically to nucleoli, whereas the N-terminal sequence of SelH fused to GFP had a diffuse nucleoplasm location. Northern blot analyses revealed low expression levels of SelH mRNA in various mouse tissues, but it was elevated in the early stages of embryonic development. In addition, SelH mRNA was overexpressed in human prostate cancer LNCaP and mouse lung cancer LCC1 cells. Down-regulation of SelH by RNA interference made LCC1 cells more sensitive to hydrogen peroxide but not to other peroxides tested. Overall, these data establish SelH as a novel nucleolar oxidoreductase and suggest that some functions in this compartment are regulated by redox and dependent on the trace element selenium.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; NCI, Mol Biol Selenium Sect, Lab Canc Prevent, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Lincoln; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Gladyshev, Vadim N/J-6187-2013; Kryukov, Gregory V/A-9592-2008; Gladyshev, Vadim N/A-9894-2013	Kryukov, Gregory/0000-0002-6131-9483; Gladyshev, Vadim/0000-0002-0372-7016; Novoselov, Sergey/0000-0003-0104-6492	Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM061603] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBERG R, 1993, NUCLEIC ACIDS RES, V21, P5583, DOI 10.1093/nar/21.24.5583; Amsterdam A, 2004, P NATL ACAD SCI USA, V101, P12792, DOI 10.1073/pnas.0403929101; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Aumann KD, 1997, BIOMED ENVIRON SCI, V10, P136; Beilstein MA, 1996, J INORG BIOCHEM, V61, P117, DOI 10.1016/0162-0134(95)00045-3; BERRIOS M, 1997, NUCL STRUCTURE FUNCT, P6; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Boon K, 2002, P NATL ACAD SCI USA, V99, P11287, DOI 10.1073/pnas.152324199; Burk Raymond F, 2002, Nutr Clin Care, V5, P75, DOI 10.1046/j.1523-5408.2002.00006.x; BUSCH H, 1963, EXP CELL RES, P150; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Chavatte L, 2005, NAT STRUCT MOL BIOL, V12, P408, DOI 10.1038/nsmb922; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Copeland PR, 2003, GENE, V312, P17, DOI 10.1016/S0378-1119(03)00588-2; Copeland PR, 2001, BIOFACTORS, V14, P11, DOI 10.1002/biof.5520140103; DIAMOND A, 1981, CELL, V25, P497, DOI 10.1016/0092-8674(81)90068-4; Ferguson AD, 2006, J BIOL CHEM, V281, P3536, DOI 10.1074/jbc.M511386200; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Granneman S, 2005, CURR OPIN CELL BIOL, V17, P281, DOI 10.1016/j.ceb.2005.04.001; Gu QP, 1999, ARCH BIOCHEM BIOPHYS, V361, P25, DOI 10.1006/abbi.1998.0949; Gu QP, 2000, MOL CELL BIOCHEM, V204, P49, DOI 10.1023/A:1007065829068; Handwerger KE, 2006, TRENDS CELL BIOL, V16, P19, DOI 10.1016/j.tcb.2005.11.005; HATFIELD D, 1982, P NATL ACAD SCI-BIOL, V79, P6215, DOI 10.1073/pnas.79.20.6215; Hatfield D.L., 2002, SELENIUM ITS MOL BIO, V36, P235, DOI 10.1080/10715760290006394; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Holmgren A, 2005, BIOCHEM SOC T, V33, P1375, DOI 10.1042/BST0331375; Howard MT, 2005, EMBO J, V24, P1596, DOI 10.1038/sj.emboj.7600642; Hubert N, 1996, BIOCHIMIE, V78, P590, DOI 10.1016/S0300-9084(96)80005-8; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jacobson MR, 1995, J CELL BIOL, V131, P1649, DOI 10.1083/jcb.131.6.1649; Johansson L, 2005, BBA-GEN SUBJECTS, V1726, P1, DOI 10.1016/j.bbagen.2005.05.010; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kinch LN, 2003, PROTEINS, V52, P323, DOI 10.1002/prot.10425; Korotkov KV, 2002, MOL CELL BIOL, V22, P1402, DOI 10.1128/MCB.22.5.1402-1411.2002; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Low SC, 2000, EMBO J, V19, P6882, DOI 10.1093/emboj/19.24.6882; Martin GW, 1998, RNA, V4, P65; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mekhail K, 2005, J CELL BIOL, V170, P733, DOI 10.1083/jcb.200506030; Mekhail K, 2004, CELL CYCLE, V3, P1027; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Olson MOJ, 2002, INT REV CYTOL, V219, P199; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Park SI, 1997, BIOMED ENVIRON SCI, V10, P116; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Raska I, 2006, CURR OPIN CELL BIOL, V18, P325, DOI 10.1016/j.ceb.2006.04.008; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Senger M, 1998, BIOINFORMATICS, V14, P452, DOI 10.1093/bioinformatics/14.5.452; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Soding J, 2005, NUCLEIC ACIDS RES, V33, pW244, DOI 10.1093/nar/gki408; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Thisse C, 2003, GENE EXPR PATTERNS, V3, P525, DOI 10.1016/S1567-133X(03)00054-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Whanger PD, 2000, CELL MOL LIFE SCI, V57, P1846, DOI 10.1007/PL00000666; Xu XM, 2005, J BIOL CHEM, V280, P41568, DOI 10.1074/jbc.M506696200	70	90	97	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11960	11968		10.1074/jbc.M701605200	http://dx.doi.org/10.1074/jbc.M701605200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17337453	Green Submitted, hybrid			2022-12-27	WOS:000245941900039
J	Bhattacharyya, S; Mandal, D; Saha, B; Sen, GS; Das, T; Sa, G				Bhattacharyya, Sankar; Mandal, Debaprasad; Saha, Baisakhi; Sen, Gouri Sankar; Das, Tanya; Sa, Gaurisankar			Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CARCINOMA CELLS; SIGNALING PATHWAY; DIETARY SUPPLEMENTATION; CYTOKINE PRODUCTION; THYMIC INVOLUTION; COLORECTAL-CANCER; BREAST-CANCER; JANUS KINASE; EXPRESSION; LYMPHOCYTES	Patients with advanced cancer exhibit multifaceted defects in their immune capacity, which are likely to contribute to an increased susceptibility to infections and disease progression. We demonstrated earlier that curcumin inhibits tumor growth and prevents immune cell death in tumor-bearing hosts. Here we report that tumor-induced immunodepletion involves apoptosis of thymic CD4(+)/CD8(+) single/double positive cells as well as loss of circulating CD4(+)/CD8(+) T cells. Administration of curcumin to tumor-bearing animals resulted in restoration of progenitor, effecter, and circulating T cells. In fact, tumor burden decreased the expression level of the pro-proliferative protein Bcl-2 while increasing the pro-apoptotic protein Bax in T cells. Curcumin down-regulated the Bax level while augmenting Bcl-2 expression in these cells, thereby protecting the immunocytes from tumor-induced apoptosis. A search for the upstream mechanism revealed down-regulation of the common cytokine receptor gamma chain (gamma c) expression in T cells by tumor-secreted prostaglandin E-2. As a result, Jak-3 and Stat-5a phosphorylation and to a lesser extent Stat-5b phosphorylation were also decreased in T cells. These entire phenomena could be reverted back by curcumin, indicating that this phytochemical restored the cytokine-dependent Jak-3/Stat-5a signaling pathway in T cells of tumor bearers. Overexpressed Stat-5a/constitutively active Stat-5a1*6 but not Stat-5b could efficiently elevate Bcl-2 levels and protect T cells from tumor-induced death, whereas C-terminal truncated Stat-5a(713) overexpression failed to do so, indicating the importance of Stat-5a signaling in T cell survival. Thus, these results raise the possibility of inclusion of curcumin in successful therapeutic regimens against cancer.	Calcutta Improvement Trust Scheme M P1 12 7, Bose Inst, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Sa, G (corresponding author), Calcutta Improvement Trust Scheme M P1 12 7, Bose Inst, Kolkata 700054, W Bengal, India.	gauri@bic.boseinst.ernet.in	Bhattacharyya, Sankar/GZH-3091-2022; Bhattacharyya, Sankar/AAK-2204-2020	Bhattacharyya, Sankar/0000-0002-3235-4220; Mandal, Deba Prasad/0000-0002-8052-6576				Adkins B, 2000, J IMMUNOL, V164, P5635, DOI 10.4049/jimmunol.164.11.5635; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; ALEXANDER JP, 1993, CANCER RES, V53, P1380; ARISTA MC, 1994, DIS COLON RECTUM, V37, pS30, DOI 10.1007/BF02048428; Baird AM, 1998, J LEUKOCYTE BIOL, V63, P669, DOI 10.1002/jlb.63.6.669; Balasubramanyam M, 2003, J BIOSCIENCES, V28, P715, DOI 10.1007/BF02708432; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Brown DM, 1996, J IMMUNOL, V157, P1359; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014-5793(02)02292-5; Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200; FECCHIO D, 1990, INFLAMMATION, V14, P125, DOI 10.1007/BF00914035; GRATIOTDEANS J, 1994, P NATL ACAD SCI USA, V91, P10685, DOI 10.1073/pnas.91.22.10685; Hadden JW, 2003, INT IMMUNOPHARMACOL, V3, P1061, DOI 10.1016/S1567-5769(03)00060-2; Heriot AG, 2000, BRIT J CANCER, V82, P1009, DOI 10.1054/bjoc.1999.1034; Hoffmann TK, 2002, CLIN CANCER RES, V8, P2553; Iqbal M, 2003, PHARMACOL TOXICOL, V92, P33, DOI 10.1034/j.1600-0773.2003.920106.x; Kiessling R, 1999, CANCER IMMUNOL IMMUN, V48, P353, DOI 10.1007/s002620050586; Kolenko V, 1999, BLOOD, V93, P2308, DOI 10.1182/blood.V93.7.2308.407k16_2308_2318; Kolenko V, 1997, J IMMUNOL, V159, P3057; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; LAMBERT IH, 1987, J MEMBRANE BIOL, V98, P247, DOI 10.1007/BF01871187; LI X, 2002, EXP HEMATOL, V30, P265; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Lopez DM, 2002, J MAMMARY GLAND BIOL, V7, P191, DOI 10.1023/A:1020356020542; Malmberg KJ, 2002, CLIN CANCER RES, V8, P1772; Mandal D, 2005, LIFE SCI, V77, P2703, DOI 10.1016/j.lfs.2005.05.038; MARDEN VS, 2003, ANNU REV IMMUNOL, V21, P71; Mastino A, 1992, Dev Immunol, V2, P263, DOI 10.1155/1992/80863; MATSUDA M, 1995, INT J CANCER, V61, P765, DOI 10.1002/ijc.2910610605; Morales-Montor J, 1998, PARASITOL RES, V84, P616, DOI 10.1007/s004360050460; Pal S, 2001, BIOCHEM BIOPH RES CO, V288, P658, DOI 10.1006/bbrc.2001.5823; Rabinowich H, 1998, J CLIN INVEST, V101, P2579, DOI 10.1172/JCI1518; Reichert TE, 1998, J IMMUNOTHER, V21, P295, DOI 10.1097/00002371-199807000-00007; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; Saito T, 2000, CLIN CANCER RES, V6, P1351; Shanker A, 2000, TUMOR BIOL, V21, P288, DOI 10.1159/000030134; Shiku H, 2003, INT J HEMATOL, V77, P435, DOI 10.1007/BF02986610; Suzuki K, 2000, INT IMMUNOL, V12, P123, DOI 10.1093/intimm/12.2.123; Thomis DC, 1997, J EXP MED, V185, P197, DOI 10.1084/jem.185.2.197; Tuting T, 1997, J MOL MED-JMM, V75, P478, DOI 10.1007/s001090050133; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Wang H, 2004, LIFE SCI, V74, P1739, DOI 10.1016/j.lfs.2003.07.051; Wen RR, 2001, MOL CELL BIOL, V21, P678, DOI 10.1128/MCB.21.2.678-689.2001; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148	47	82	83	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15954	15964		10.1074/jbc.M608189200	http://dx.doi.org/10.1074/jbc.M608189200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392282	hybrid			2022-12-27	WOS:000246794300004
J	Yamasaki, H; Abdel-Ghany, SE; Cohu, CM; Kobayashi, Y; Shikanai, T; Pilon, M				Yamasaki, Hiroaki; Abdel-Ghany, Salah E.; Cohu, Christopher M.; Kobayashi, Yoshichika; Shikanai, Toshiharu; Pilon, Marinus			Regulation of copper homeostasis by micro-RNA in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; P-TYPE ATPASE; SUPEROXIDE-DISMUTASE; DIFFERENTIAL EXPRESSION; ASCORBATE PEROXIDASE; PLANT MICRORNAS; ELECTRON FLOW; CHLAMYDOMONAS; TRANSPORT; CHAPERONE	Major copper proteins in the cytoplasm of plant cells are plastocyanin, copper/zinc superoxide dismutase, and cytochrome c oxidase. Under copper limited conditions, expression of copper/zinc superoxide dismutase is down-regulated and the protein is replaced by iron superoxide dismutase in chloroplasts. We present evidence that a micro-RNA, miR398, mediates this regulation in Arabidopsis thaliana, by directing the degradation of copper/zinc superoxide dismutase mRNA when copper is limited. Sequence analysis indicated that the transcripts encoding cytosolic copper/zinc superoxide dismutase and COX5b- 1, a subunit of the mitochondrial cytochrome c oxidase, are also targeted by miR398. This regulation via miR398 takes place in response to changes in a low range of copper levels ( 0.2- 0.5 mu M), indicating that miR398 is involved in a response to copper limitation. On the other hand, another major copper protein, plastocyanin, which is involved in photosynthetic electron flow and is essential in higher plants, was not regulated via miR398. We propose that miR398 is a key factor in copper homeostasis in plants and regulates the stability of mRNAs of major copper proteins under copper-limited conditions.	Kyushu Univ, Grad Sch Agr, Fukuoka 8128581, Japan; Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Program Mol Plant Biol, Ft Collins, CO 80523 USA	Kyushu University; Colorado State University; Colorado State University	Shikanai, T (corresponding author), Kyushu Univ, Grad Sch Agr, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	shikanai@agr.kyushu-u.ac.jp	Shikanai, Toshiharu/AAK-9112-2020					Abdel-Ghany SE, 2005, FEBS LETT, V579, P2307, DOI 10.1016/j.febslet.2005.03.025; Abdel-Ghany SE, 2005, PLANT CELL, V17, P1233, DOI 10.1105/tpc.104.030452; Andres-Colas N, 2006, PLANT J, V45, P225, DOI 10.1111/j.1365-313X.2005.02601.x; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Bari R, 2006, PLANT PHYSIOL, V141, P988, DOI 10.1104/pp.106.079707; Baumberger N, 2005, P NATL ACAD SCI USA, V102, P11928, DOI 10.1073/pnas.0505461102; Bonnet E, 2004, P NATL ACAD SCI USA, V101, P11511, DOI 10.1073/pnas.0404025101; BOWLER C, 1994, CRIT REV PLANT SCI, V13, P199, DOI 10.1080/713608062; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briat JF, 1997, TRENDS PLANT SCI, V2, P187, DOI 10.1016/S1360-1385(97)85225-9; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Chiou TJ, 2006, PLANT CELL, V18, P412, DOI 10.1105/tpc.105.038943; Chu CC, 2005, PLANT PHYSIOL, V139, P425, DOI 10.1104/pp.105.065284; Clifton R, 2006, BBA-BIOENERGETICS, V1757, P730, DOI 10.1016/j.bbabio.2006.03.009; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Fujii H, 2005, CURR BIOL, V15, P2038, DOI 10.1016/j.cub.2005.10.016; Gasciolli V, 2005, CURR BIOL, V15, P1494, DOI 10.1016/j.cub.2005.07.024; Hart PJ, 1999, BIOCHEMISTRY-US, V38, P2167, DOI 10.1021/bi982284u; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Hunter C, 2003, CURR BIOL, V13, P1734, DOI 10.1016/j.cub.2003.09.004; Jones-Rhoades MW, 2006, ANNU REV PLANT BIOL, V57, P19, DOI 10.1146/annurev.arplant.57.032905.105218; Jones-Rhoades MW, 2004, MOL CELL, V14, P787, DOI 10.1016/j.molcel.2004.05.027; Karpinski S, 1997, PLANT CELL, V9, P627, DOI 10.1105/tpc.9.4.627; Kliebenstein DJ, 1998, PLANT PHYSIOL, V118, P637, DOI 10.1104/pp.118.2.637; Kropat J, 2005, P NATL ACAD SCI USA, V102, P18730, DOI 10.1073/pnas.0507693102; Kurihara Y, 2004, P NATL ACAD SCI USA, V101, P12753, DOI 10.1073/pnas.0403115101; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; Marschner H., 1995, MINERAL NUTR HIGHER, V2nd ed.; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; Merchant Sabeeha S., 2006, V23, P199; Mittler R, 2004, TRENDS PLANT SCI, V9, P490, DOI 10.1016/j.tplants.2004.08.009; Molina-Heredia FP, 2003, NATURE, V424, P33, DOI 10.1038/424033b; Munekage Y, 2002, CELL, V110, P361, DOI 10.1016/S0092-8674(02)00867-X; Munshi MK, 2006, PLANT PHYSIOL, V141, P737, DOI 10.1104/pp.106.080267; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURPHY A, 1995, PLANT PHYSIOL, V108, P29, DOI 10.1104/pp.108.1.29; Ono S, 2004, BIOSCI BIOTECH BIOCH, V68, P803, DOI 10.1271/bbb.68.803; Panchuk II, 2002, PLANT PHYSIOL, V129, P838, DOI 10.1104/pp.001362; Petit JM, 2001, BIOCHEM J, V359, P575, DOI 10.1042/0264-6021:3590575; Pilon M, 2006, CURR OPIN PLANT BIOL, V9, P256, DOI 10.1016/j.pbi.2006.03.007; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rashtchian Ayoub, 1995, Current Opinion in Biotechnology, V6, P30, DOI 10.1016/0958-1669(95)80006-9; Sancenon V, 2003, PLANT MOL BIOL, V51, P577, DOI 10.1023/A:1022345507112; Shikanai T, 2003, PLANT CELL, V15, P1333, DOI 10.1105/tpc.011817; Storozhenko S, 1998, PLANT PHYSIOL, V118, P1005, DOI 10.1104/pp.118.3.1005; Sunkar R, 2004, PLANT CELL, V16, P2001, DOI 10.1105/tpc.104.022830; Sunkar R, 2006, PLANT CELL, V18, P2051, DOI 10.1105/tpc.106.041673; Weigel M, 2003, J BIOL CHEM, V278, P31286, DOI 10.1074/jbc.M302876200; Welchen E, 2004, J EXP BOT, V55, P1997, DOI 10.1093/jxb/erh223; Yu B, 2005, SCIENCE, V307, P932, DOI 10.1126/science.1107130; Zhang BH, 2006, DEV BIOL, V289, P3, DOI 10.1016/j.ydbio.2005.10.036	52	305	334	2	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16369	16378		10.1074/jbc.M700138200	http://dx.doi.org/10.1074/jbc.M700138200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17405879	hybrid			2022-12-27	WOS:000246794300045
J	Beckstead, JA; Wong, K; Gupta, V; Wan, CPL; Cook, VR; Weinberg, RB; Weers, PMM; Ryan, RO				Beckstead, Jennifer A.; Wong, Kasuen; Gupta, Vinita; Wan, Chung-Ping L.; Cook, Victoria R.; Weinberg, Richard B.; Weers, Paul M. M.; Ryan, Robert O.			The C terminus of apolipoprotein A-V modulates lipid-binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; APOLIPOPHORIN-III; DOMAIN-STRUCTURE; HUMAN SERUM; MICE; HYPERTRIGLYCERIDEMIA; ASSOCIATION; LIPASE; HYDROLYSIS; DEFICIENCY	Human apolipoprotein A-V (apoA-V) is a potent modulator of plasma triacylglycerol (TG) levels. To probe different regions of this 343-amino-acid protein, four single Trp apoA-V variants were prepared. The variant with a Trp at position 325, distal to the tetraproline sequence at residues 293-296, displayed an 11-nm blue shift in wavelength of maximum fluorescence emission upon lipid association. To evaluate the structural and functional role of this C-terminal segment, a truncated apoA-V comprising amino acids 1-292 was generated. Far UV circular dichroism spectra of full-length apoA-V and apoA-V-(1-292) were similar, with similar to 50% alpha-helix content. In guanidine HCl denaturation experiments, both full-length and truncated apoA-V yielded biphasic profiles consistent with the presence of two structural domains. The denaturation profile of the lower stability component ( but not the higher stability component) was affected by truncation. Truncated apoA-V displayed an attenuated ability to solubilize L-alpha-dimyristoylphosphatidylcholine phospholipid vesicles compared with full-length apoA-V, whereas a peptide corresponding to the deleted C-terminal segment displayed markedly enhanced kinetics. The data support the concept that the C-terminal region is not required for apoA-V to adopt a folded protein structure, yet functions to modulate apoA-V lipid-binding activity; therefore, this concept may be relevant to the mechanism whereby apoA-V influences plasma TG levels.	CHORI, Ctr Prevent Obes Diabet & Cardiovasc Dis, Oakland, CA 94609 USA; Univ Calif Berkeley, Dept Nutrit Sci & Toxicol, Berkeley, CA 94720 USA; Calif State Univ Long Beach, Dept Chem & Biochem, Long Beach, CA 90840 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	Children's Hospital Oakland Research Institute; University of California System; University of California Berkeley; California State University System; California State University Long Beach; Wake Forest University; Wake Forest University	Ryan, RO (corresponding author), CHORI, Ctr Prevent Obes Diabet & Cardiovasc Dis, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	rryan@chori.org		Mauldin, Kasuen/0000-0001-9220-8033	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030897, R01HL073061, R15HL077135, R23HL030897] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL030897-23, HL 73061, R01 HL030897, R01 HL073061, HL 077135, HL 30897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ajees AA, 2006, P NATL ACAD SCI USA, V103, P2126, DOI 10.1073/pnas.0506877103; Alborn WE, 2006, CLIN CHEM, V52, P514, DOI 10.1373/clinchem.2005.061374; Beckstead JA, 2003, BIOCHEMISTRY-US, V42, P9416, DOI 10.1021/bi034509t; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; Fruchart-Najib J, 2004, BIOCHEM BIOPH RES CO, V319, P397, DOI 10.1016/j.bbrc.2004.05.003; Grosskopf I, 2005, ARTERIOSCL THROM VAS, V25, P2573, DOI 10.1161/01.ATV.0000186189.26141.12; Ishihara M, 2005, J LIPID RES, V46, P2015, DOI 10.1194/jlr.D500018-JLR200; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; Ledford AS, 2006, J BIOL CHEM, V281, P8871, DOI 10.1074/jbc.M507657200; Lookene A, 2005, J BIOL CHEM, V280, P25383, DOI 10.1074/jbc.M501589200; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Marcais C, 2005, J CLIN INVEST, V115, P2862, DOI 10.1172/JCI24471; Merkel M, 2005, J BIOL CHEM, V280, P21553, DOI 10.1074/jbc.M411412200; MONERA OD, 1994, PROTEIN SCI, V3, P1984, DOI 10.1002/pro.5560031110; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; O'Brien PJ, 2005, CLIN CHEM, V51, P351, DOI 10.1373/clinchem.2004.040824; Oliva CP, 2005, ARTERIOSCL THROM VAS, V25, P411, DOI 10.1161/01.ATV.0000153087.36428.dd; Pearson K, 2005, J BIOL CHEM, V280, P38576, DOI 10.1074/jbc.M506802200; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Schaap FG, 2004, J BIOL CHEM, V279, P27941, DOI 10.1074/jbc.M403240200; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999; Weers PMM, 2000, J LIPID RES, V41, P416; Weers PMM, 2001, EUR J BIOCHEM, V268, P3728, DOI 10.1046/j.1432-1327.2001.02282.x; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	34	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15484	15489		10.1074/jbc.M611797200	http://dx.doi.org/10.1074/jbc.M611797200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17401142	hybrid			2022-12-27	WOS:000246589600024
J	Crunkhorn, S; Dearie, F; Mantzoros, C; Gami, H; da Silva, WS; Espinoza, D; Faucette, R; Barry, K; Bianco, AC; Patti, ME				Crunkhorn, Sarah; Dearie, Farrell; Mantzoros, Christos; Gami, Hiral; da Silva, Wagner S.; Espinoza, Daniel; Faucette, Ryan; Barry, Kristen; Bianco, Antonio C.; Patti, Mary Elizabeth			Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity - Potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; INSULIN-RESISTANCE; GENE-EXPRESSION; ENERGY-EXPENDITURE; TRANSCRIPTIONAL COACTIVATORS; PGC-1-ALPHA TRANSCRIPTION; 1-ALPHA PGC-1-ALPHA; DIABETES-MELLITUS; DOWN-REGULATION; ADIPOSE-TISSUE	Peroxisome proliferator activator receptor-gamma coactivator 1 (PGC-1) is a major candidate gene for diabetes-related metabolic phenotypes, contributing to decreased expression of nuclear-encoded mitochondrial genes in muscle and adipose tissue. We have demonstrated that muscle expression of PGC-1 alpha and -beta is reduced in both genetic (Lepob/Lepob) and acquired obesity ( high fat diet). In C57BL6 mice, muscle PGC-1 alpha expression decreased by 43% (p < 0.02) after 1 week of a high fat diet and persisted more than 11 weeks. In contrast, PGC-1 alpha reductions were not sustained in obesity-resistant A/J mice. To identify mediators of obesity-linked reductions in PGC-1, we tested the effects of cellular nutrients in C2C12 myotubes. Although overnight exposure to high insulin, glucose, glucosamine, or amino acids had no effect, saturated fatty acids potently reduced PGC-1 alpha and -beta mRNA expression. Palmitate decreased PGC-1 alpha and -beta expression by 38% (p = 0.01) and 53% (p = 0.006); stearate similarly decreased expression of PGC-1 alpha and -beta by 22% (p = 0.02) and 39% (p = 0.02). These effects were mediated at a transcriptional level, as indicated by an 11-fold reduction of PGC-1 alpha promoter activity by palmitate and reversal of effects by histone deacetylase inhibition. Palmitate also ( a) reduced expression of tricarboxylic acid cycle and oxidative phosphorylation mitochondrial genes and (b) reduced oxygen consumption. These effects were reversed by overexpression of PGC-1 alpha or -beta, indicating PGC-1 dependence. Palmitate effects also required p38 MAPK, as demonstrated by 1) palmitate-induced increase in p38 MAPK phosphorylation, 2) reversal of palmitate effects on PGC-1 and mitochondrial gene expression by p38 MAPK inhibitors, and 3) reversal of palmitate effects by small interfering RNA-mediated decreases in p38 alpha MAPK. These data indicate that obesity and saturated fatty acids decrease PGC-1 and mitochondrial gene expression and function via p38 MAPK-dependent transcriptional pathways.	Joslin Diabet Ctr, Div Endocrinol, Div Res, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Thyroid Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Patti, ME (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	mary.elizabeth.patti@joslin.harvard.edu	Mantzoros, Christos/Y-2902-2019; Bianco, Antonio/AAK-6336-2020; Bianco, Antonio C/A-4965-2008; da Silva, Wagner S/A-7835-2008	Bianco, Antonio/0000-0001-7737-6813; Bianco, Antonio C/0000-0001-7737-6813; da Silva, Wagner S/0000-0002-0001-0386	NIDDK NIH HHS [DK65055, DK060837, DK062948, DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062948, P30DK036836, R01DK060837, R01DK065055] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200; Al-Khalili L, 2005, DIABETOLOGIA, V48, P1173, DOI 10.1007/s00125-005-1741-3; Berkowitz R, 1996, DIABETES, V45, P1572; Boden G, 2005, DIABETES, V54, P3458, DOI 10.2337/diabetes.54.12.3458; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Civitarese AE, 2006, CELL METAB, V4, P75, DOI 10.1016/j.cmet.2006.05.002; Coll T, 2006, DIABETES, V55, P2779, DOI 10.2337/db05-1494; Collins QF, 2006, J BIOL CHEM, V281, P24336, DOI 10.1074/jbc.M602177200; Cousin SP, 2001, ENDOCRINOLOGY, V142, P229, DOI 10.1210/en.142.1.229; CRUNKHORN S, 2008, PHYS ACTIVITY TYPE 2; Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; Esterbauer H, 2002, DIABETES, V51, P1281, DOI 10.2337/diabetes.51.4.1281; Fan M, 2004, GENE DEV, V18, P278, DOI 10.1101/gad.1152204; Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Jacob S, 1999, DIABETES, V48, P1113, DOI 10.2337/diabetes.48.5.1113; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Lelliott CJ, 2006, PLOS BIOL, V4, P2042, DOI 10.1371/journal.pbio.0040369; Lerin C, 2006, CELL METAB, V3, P429, DOI 10.1016/j.cmet.2006.04.013; Li SY, 2005, DIABETES OBES METAB, V7, P448, DOI 10.1111/j.1463-1326.2004.00387.x; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin JD, 2003, J BIOL CHEM, V278, P30843, DOI 10.1074/jbc.M303643200; Ling C, 2004, J CLIN INVEST, V114, P1518, DOI 10.1172/JCI200421889; Liu HY, 2007, J BIOL CHEM, V282, P14205, DOI 10.1074/jbc.M609701200; Luquet S, 2003, FASEB J, V17, P2299, DOI 10.1096/fj.03-0269fje; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morino K, 2005, J CLIN INVEST, V115, P3587, DOI 10.1172/JCI25151; Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512; Musi N, 2001, DIABETES, V50, P921, DOI 10.2337/diabetes.50.5.921; Oberkofler H, 2004, DIABETES, V53, P1385, DOI 10.2337/diabetes.53.5.1385; Obici S, 2002, J CLIN INVEST, V109, P1599, DOI 10.1172/JCI0215258; Patti ME, 2004, NAT MED, V10, P1049, DOI 10.1038/nm1004-1049; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; Petersen KF, 2004, NEW ENGL J MED, V350, P664, DOI 10.1056/NEJMoa031314; Pihlajamaki J, 2006, ADV MOL CELL ENDOCR, V5, P233, DOI 10.1016/S1569-2566(06)05012-5; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Rachek LI, 2007, ENDOCRINOLOGY, V148, P293, DOI 10.1210/en.2006-0998; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; Richardson DK, 2005, J BIOL CHEM, V280, P10290, DOI 10.1074/jbc.M408985200; Russell AP, 2005, FASEB J, V19, P986, DOI 10.1096/fj.04-3168fje; Santomauro ATMG, 1999, DIABETES, V48, P1836, DOI 10.2337/diabetes.48.9.1836; Schuler M, 2006, CELL METAB, V4, P407, DOI 10.1016/j.cmet.2006.10.003; Sonoda J, 2007, P NATL ACAD SCI USA, V104, P5223, DOI 10.1073/pnas.0611623104; Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V282, pE1055, DOI 10.1152/ajpendo.00554.2001; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Staiger H, 2006, DIABETOLOGIA, V49, P212, DOI 10.1007/s00125-005-0061-y; Staiger H, 2005, DIABETOLOGIA, V48, P2115, DOI 10.1007/s00125-005-1895-z; Suwa M, 2006, J APPL PHYSIOL, V101, P1685, DOI 10.1152/japplphysiol.00255.2006; Tenhunen O, 2006, CIRC RES, V99, P485, DOI 10.1161/01.RES.0000238387.85144.92; Terada S, 2004, AM J PHYSIOL-ENDOC M, V286, pE208, DOI 10.1152/ajpendo.00051.2003; Tremblay F, 2005, CURR OPIN CLIN NUTR, V8, P457, DOI 10.1097/01.mco.0000172589.55434.03; Ukropcova B, 2007, DIABETES, V56, P720, DOI 10.2337/db06-0521; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vianna CR, 2006, CELL METAB, V4, P453, DOI 10.1016/j.cmet.2006.11.003; Wang XL, 2006, DIABETES, V55, P2301, DOI 10.2337/db05-1574; Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330; Watt MJ, 2004, J MOL ENDOCRINOL, V33, P533, DOI 10.1677/jme.1.01499; Wu ZD, 2006, P NATL ACAD SCI USA, V103, P14379, DOI 10.1073/pnas.0606714103; Ye JM, 2006, DIABETES, V55, P2797, DOI 10.2337/db05-1315; Yechoor VK, 2004, P NATL ACAD SCI USA, V101, P16525, DOI 10.1073/pnas.0407574101	74	195	202	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15439	15450		10.1074/jbc.M611214200	http://dx.doi.org/10.1074/jbc.M611214200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17416903	hybrid			2022-12-27	WOS:000246589600019
J	Hook, BA; Goldstrohm, AC; Seay, DJ; Wickens, M				Hook, Brad A.; Goldstrohm, Aaron C.; Seay, Daniel J.; Wickens, Marvin			Two yeast PUF proteins negatively regulate a single mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEADENYLASE COMPLEX; BINDING PROTEINS; RECRUITMENT; HOMOLOG; FAMILY; DECAY; LOCALIZATION; SENSITIVITY; TRANSCRIPT; MICRORNAS	mRNA stability and translation are regulated by protein repressors that bind 3'-untranslated regions. PUF proteins provide a paradigm for these regulatory molecules: like other repressors, they inhibit translation, enhance mRNA decay, and promote poly( A) removal. Here we show that a single mRNA in Saccharomyces cerevisiae, encoding the HO endonuclease, is regulated by two distinct PUF proteins, Puf4p and Mpt5p. These proteins bind to adjacent sites and can co-occupy the mRNA. Both proteins are required for full repression and deadenylation in vivo; their removal dramatically stabilizes the mRNA. The two proteins act through overlapping but non-identical mechanisms: repression by Puf4p is dependent on deadenylation, whereas repression by Mpt5p can occur through additional mechanisms. Combinatorial action of the two regulatory proteins may allow responses to specific environmental cues and be common in 3'-untranslated region-mediated control.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Wickens, M (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	wickens@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050942] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50942] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956; Bernstein D, 2005, RNA, V11, P447, DOI 10.1261/rna.7255805; Bernstein DS, 2002, METHODS, V26, P123, DOI 10.1016/S1046-2023(02)00015-4; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Chen TS, 1997, MOL CELL BIOL, V17, P3429, DOI 10.1128/MCB.17.6.3429; Chou CF, 2006, MOL CELL BIOL, V26, P3695, DOI 10.1128/MCB.26.10.3695-3706.2006; Colegrove-Otero LJ, 2005, CRIT REV BIOCHEM MOL, V40, P21, DOI 10.1080/10409230590918612; Crittenden SL, 2002, NATURE, V417, P660, DOI 10.1038/nature754; Duttagupta R, 2003, MOL CELL BIOL, V23, P2623, DOI 10.1128/MCB.23.8.2623-2632.2003; Eckmann CR, 2002, DEV CELL, V3, P697, DOI 10.1016/S1534-5807(02)00322-2; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Goldstrohm AC, 2007, J BIOL CHEM, V282, P109, DOI 10.1074/jbc.M609413200; Goldstrohm AC, 2006, NAT STRUCT MOL BIOL, V13, P533, DOI 10.1038/nsmb1100; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; Hook B, 2005, RNA, V11, P227, DOI 10.1261/rna.7202705; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jackson JS, 2004, RNA, V10, P1625, DOI 10.1261/rna.7270204; Kraemer B, 1999, CURR BIOL, V9, P1009, DOI 10.1016/S0960-9822(99)80449-7; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Luitjens C, 2000, GENE DEV, V14, P2596, DOI 10.1101/gad.831700; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Moraes KCM, 2006, RNA, V12, P1084, DOI 10.1261/rna.59606; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Roush SF, 2006, ACS CHEM BIOL, V1, P132, DOI 10.1021/cb600138j; Semotok JL, 2005, CURR BIOL, V15, P284, DOI 10.1016/j.cub.2005.01.048; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801; Tadauchi T, 2001, EMBO J, V20, P552, DOI 10.1093/emboj/20.3.552; Thore S, 2003, EMBO REP, V4, P1150, DOI 10.1038/sj.embor.7400020; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Wickens M, 2002, TRENDS GENET, V18, P150, DOI 10.1016/S0168-9525(01)02616-6; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103	38	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15430	15438		10.1074/jbc.M611253200	http://dx.doi.org/10.1074/jbc.M611253200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17389596	hybrid			2022-12-27	WOS:000246589600018
J	Chou, TF; Tikh, IB; Horta, BAC; Ghosh, B; De Alencastro, RB; Wagner, CR				Chou, Tsui-Fen; Tikh, Ilya B.; Horta, Bruno A. C.; Ghosh, Brahma; De Alencastro, Ricardo B.; Wagner, Carston R.			Engineered monomeric human histidine triad nucleotide-binding protein 1 hydrolyzes fluorogenic acyl-adenylate and lysyl-tRNA synthetase-generated lysyl-adenylate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-INTERACTING PROTEIN-1; TRANSCRIPTIONAL ACTIVITY; SUBUNIT INTERFACE; FORCE-FIELD; HINT; SUBSTRATE; FHIT; MECHANISM; GROWTH; URIDYLYLTRANSFERASE	Hint1 is a homodimeric protein and member of the ubiquitous HIT superfamily. Hint1 catalyzes the hydrolysis of purine phosphoramidates and lysyl-adenylate generated by lysyl-tRNA synthetase ( LysRS). To determine the importance of homodimerization on the biological and catalytic activity of Hint1, the dimer interface of human Hint1 ( hHint1) was destabilized by replacement of Val(97) of hHint1 with Asp, Glu, or Arg. The mutants were shown to exist as monomers in solution by a combination of size exclusion chromatograph, static light scattering, and chemically induced dimerization studies. Circular dichroism studies revealed little difference between the stability of the V97D, V97E, and wild-type hHint1. Relative to wild-type and the V97E mutant, however, significant perturbation of the V97D mutant structure was observed. hHint1 was shown to prefer 3-indolepropionic acyl-adenylate ( AIPA) over tryptamine adenosine phosphoramidate monoester ( TpAd). Wild-type hHint1 was found to be 277- and 1000-fold more efficient ( k(cat)/K-m values) than the V97E and V97D mutants, respectively. Adenylation of wildtype, V97D, and V97E hHint1 by human LysRS was shown to correlate with the mutant k(cat)/K-m values using 3-indolepropionic acyl-adenylate as a substrate, but not tryptamine adenosine phosphoramidate monoester. Significant perturbations of the active site residues were not detected by molecular dynamics simulations of the hHint1s. Taken together, these results demonstrate that for hHint1; 1) the efficiency ( k(cat)/K-m) of acylated AMP hydrolysis, but not maximal catalytic turnover ( k(cat)), is dependent on homodimerization and 2) the hydrolysis of lysyl-AMP generated by LysRS is not dependent on homodimerization if the monomer structure is similar to the wild-type structure.	Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Univ Fed Rio de Janeiro, Inst Quim, Dept Quim Organ, Phys Organ Chem Grp, BR-21941909 Rio De Janeiro, Brazil	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Universidade Federal do Rio de Janeiro	Wagner, CR (corresponding author), 8-174 Weaver Densford Hall,308 Harvard St SE, Minneapolis, MN 55455 USA.	wagne003@umn.edu	Horta, Bruno AC/L-5079-2013	Horta, Bruno AC/0000-0002-3952-1474; Ghosh, Brahma/0000-0003-2288-8293				Alves CS, 2006, BIOCHEM J, V393, P523, DOI 10.1042/BJ20051066; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERG P, 1958, J BIOL CHEM, V233, P608; BERWEGER CD, 1995, CHEM PHYS LETT, V232, P429, DOI 10.1016/0009-2614(94)01391-8; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Boulanger RR, 2003, J BIOL CHEM, V278, P23497, DOI 10.1074/jbc.M301105200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; Carlson JCT, 2003, J AM CHEM SOC, V125, P1501, DOI 10.1021/ja026264y; Carlson JCT, 2006, J AM CHEM SOC, V128, P7630, DOI 10.1021/ja060631e; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Chou TF, 2005, J BIOL CHEM, V280, P15356, DOI 10.1074/jbc.M500434200; Chou TF, 2007, MOL PHARMACEUT, V4, P208, DOI 10.1021/mp060070y; Chou TF, 2007, J BIOL CHEM, V282, P4719, DOI 10.1074/jbc.M610530200; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FREY PA, 1982, METHOD ENZYMOL, V87, P20; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Hockney RW., 1970, METHOD COMPUT PHYS, V9, P136, DOI DOI 10.1021/JP805458P; Horta BAC, 2007, PROTEINS, V67, P517, DOI 10.1002/prot.21306; Huang K, 2004, BIOCHEMISTRY-US, V43, P7637, DOI 10.1021/bi049762n; Huang KS, 2005, EUR J ORG CHEM, V2005, P5198, DOI 10.1002/ejoc.200500499; Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Krakowiak A, 2004, J BIOL CHEM, V279, P18711, DOI 10.1074/jbc.M314271200; Lee YN, 2005, MOL CELL BIOL, V25, P8904, DOI 10.1128/MCB.25.20.8904-8912.2005; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Li H, 2006, ONCOGENE, V25, P713, DOI 10.1038/sj.onc.1209111; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; Sticha KRK, 1997, PROTEIN EXPRES PURIF, V10, P141, DOI 10.1006/prep.1997.0734; Su T, 2003, P NATL ACAD SCI USA, V100, P7824, DOI 10.1073/pnas.1332160100; Thompson LC, 2006, BIOCHEMISTRY-US, V45, P2267, DOI 10.1021/bi0519506; Vargo MA, 2004, BIOCHEMISTRY-US, V43, P3327, DOI 10.1021/bi030245z; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; Weiske J, 2005, J CELL SCI, V118, P3117, DOI 10.1242/jcs.02437; Weiske J, 2006, J BIOL CHEM, V281, P27356, DOI 10.1074/jbc.M513452200; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Yannay-Cohen N, 2006, MOL CELLS, V22, P127	42	31	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15137	15147		10.1074/jbc.M606972200	http://dx.doi.org/10.1074/jbc.M606972200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17337452	Green Accepted, hybrid			2022-12-27	WOS:000246589000053
J	Snellman, A; Tuomisto, A; Koski, A; Latvanlehto, A; Pihlajaniemi, T				Snellman, Anne; Tuomisto, Anne; Koski, Anu; Latvanlehto, Anne; Pihlajaniemi, Taina			The role of disulfide bonds and alpha-helical coiled-coils in the biosynthesis of type XIII collagen and other collagenous transmembrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIZATION DOMAINS; EXPRESSION; SEQUENCE; TRIMERIZATION; ASSOCIATION; SUBUNITS; CLEAVAGE; MOTIFS; CHAIN	Type XIII collagen is a type II transmembrane protein with three collagenous (COL1-3) and four noncollagenous domains (NC1-4). The human alpha 1(XIII) chain contains altogether eight cysteine residues. We introduced point mutations to six of the most N-terminal cysteine residues, and we show here that the two cysteines 117 and 119 at the end of the N-terminal noncollagenous domain (NC1) are responsible for linking the three alpha 1(XIII) chains together by means of interchain disulfide bonds. In addition, the intracellular and transmembrane domains have an impact on trimer formation, whereas the cysteines in the transmembrane domain and the COL1, the NC2, and the C-terminal NC4 domains do not affect trimer formation. We also suggest that the first three noncollagenous domains (NC1-3) harbor repeating heptad sequences typical of alpha-helical coiled-coils, whereas the conserved NC4 lacks a coiled-coil probability. Prevention of the coiled-coil conformation in the NC3 domain is shown here to result in labile type XIII collagen molecules. Furthermore, a new subgroup of collagenous transmembrane proteins, the Rattus norvegicus, Drosophila melanogaster, and Caenorhabditis elegans colmedins, is enlarged to contain also Homo sapiens collomin, and Pan troglodytes, Mus musculus, Tetraodon nigroviridis, and Dano rerio proteins. We suggest that there is a structurally varied group of collagenous transmembrane proteins whose biosynthesis is characterized by a coiled-coil motif following the transmembrane domain, and that these trimerization domains appear to be associated with each of the collagenous domains. In the case of type XIII collagen, the trimeric molecule has disulfide bonds at the junction of the NC1 and COL1 domains, and the type XIII collagen-like molecules (collagen types XXIII and XXV) and the colmedins are similar in that they all have a pair of cysteines in the same location. Moreover, furin cleavage at the NC1 domain can be expected in most of the proteins.	Univ Oulu, Collagen Res Unit, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu	Pihlajaniemi, T (corresponding author), Univ Oulu, Collagen Res Unit, Bioctr Oulu, POB 5000, FIN-90014 Oulu, Finland.	taina.pihlajaniemi@oulu.fi		Tuomisto, Anne/0000-0002-9949-1887; Heikkinen, Anne/0000-0001-9852-773X; Pihlajaniemi, Taina/0000-0002-1664-9045				Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; Chang DK, 1999, J STRUCT BIOL, V128, P270, DOI 10.1006/jsbi.1999.4182; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013; Frank S, 2002, J BIOL CHEM, V277, P19071, DOI 10.1074/jbc.M202146200; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; Franzke CW, 2004, J BIOL CHEM, V279, P24521, DOI 10.1074/jbc.M308835200; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hagg P, 2001, MATRIX BIOL, V19, P727, DOI 10.1016/S0945-053X(00)00119-0; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Hillier BJ, 2003, J CELL BIOL, V160, P597, DOI 10.1083/jcb.200210053; JUVONEN M, 1992, J BIOL CHEM, V267, P24700; Kammerer RA, 2005, P NATL ACAD SCI USA, V102, P13891, DOI 10.1073/pnas.0502390102; Kammerer RA, 1997, MATRIX BIOL, V15, P555, DOI 10.1016/S0945-053X(97)90031-7; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Latvanlehto A, 2003, J BIOL CHEM, V278, P37590, DOI 10.1074/jbc.M305974200; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malone JP, 2005, BIOCHEMISTRY-US, V44, P15269, DOI 10.1021/bi0508338; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; Peltonen S, 1997, DNA CELL BIOL, V16, P227, DOI 10.1089/dna.1997.16.227; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Snellman A, 2000, J BIOL CHEM, V275, P8936, DOI 10.1074/jbc.275.12.8936; SNELLMAN A, 2003, RECENT RES DEV BIOL, P1; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; Sund M, 2001, EMBO J, V20, P5153, DOI 10.1093/emboj/20.18.5153; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Zenga LC, 2005, FEBS LETT, V579, P5443, DOI 10.1016/j.febslet.2005.08.064	36	12	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14898	14905		10.1074/jbc.M609605200	http://dx.doi.org/10.1074/jbc.M609605200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17344215	hybrid			2022-12-27	WOS:000246589000027
J	Wang, H; Julenius, K; Hryhorenko, J; Hagen, FK				Wang, Huan; Julenius, Karin; Hryhorenko, Jennifer; Hagen, Fred K.			Systematic analysis of proteoglycan modification sites in Caenorhabditis elegans by scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; CORE-GLYCOSYLATION EFFICIENCY; ACETYL-D-GALACTOSAMINE; AMINO-ACID; HEPARAN-SULFATE; O-GLYCOSYLATION; FUNCTIONAL-CHARACTERIZATION; CHONDROITIN PROTEOGLYCANS; DROSOPHILA-MELANOGASTER; IMPORTANT DETERMINANT	Proteoglycan modification is essential for development and early cell division in Caenorhabditis elegans. The specification of proteoglycan attachment sites is defined by the Golgi enzyme polypeptide xylosyltransferase. Here we evaluate the substrate specificity of this xylosyltransferase for its downstream targets by using reporter proteins containing proteoglycan modification sites from C. elegans syndecan/SDN-1. The N terminus of the SDN-1 contains a Ser-Gly proteoglycan site at Ser(71), flanked by potential mucin and N-glycosylation sites. However, Ser(71) was exclusively used as a proteoglycan site in vivo, based on mapping studies with a Ser(71) reporter protein, glycosyltransferase RNA interference, and co-expression of worm polypeptide xylosyltransferase. To elucidate the substrate requirements of this enzyme, a library of 42 point mutants of the Ser(71) reporter was expressed in tissue culture. The nematode proteoglycan modification site in SDN-1 required serine ( not threonine), two flanking glycine residues (positions -1 and +1), and either one proximal acidic N-terminal amino acid (positions -4, -3, and -2) or a pair of distal N-terminal acidic amino acids ( positions -6 and -5). C-terminal acidic amino acids, although present in many proteoglycan modification sites, had minimal impact on xylosylation at Ser(71). Proline inhibited glycosylation when present at -1, +1, or +2. The position of glycine, proline, and acidic amino acids allows the glycosylation machinery to discriminate between mucin and proteoglycan modification sites. The key residues that define proteoglycan modification sites also function with the Drosophila polypeptide xylosyltransferase, indicating that the specificity in the glycosylation process is evolutionarily conserved. Using a neural network method, a preliminary proteoglycan predictor has been developed.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Ctr Oral Biol,Aab Inst Biomed Sci, Rochester, NY 14642 USA; Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, SE-17177 Stockholm, Sweden; Stockholm Univ, SCFAB, Stockholm Bioinformat Ctr, SE-10691 Stockholm, Sweden	University of Rochester; Karolinska Institutet; Stockholm University	Hagen, FK (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Ctr Oral Biol,Aab Inst Biomed Sci, 601 Elmwood Ave,Box 611, Rochester, NY 14642 USA.	fred_hagen@urmc.rochester.edu			NIDCR NIH HHS [DE14088-05] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014088] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Brunner A, 2006, GLYCOCONJUGATE J, V23, P543, DOI 10.1007/s10719-006-7633-z; Bulik DA, 2002, BBA-GEN SUBJECTS, V1573, P247, DOI 10.1016/S0304-4165(02)00391-4; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; Dong SC, 2003, J BIOL CHEM, V278, P1700, DOI 10.1074/jbc.M209276200; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; GERLITZ B, 1993, BIOCHEM J, V295, P131, DOI 10.1042/bj2950131; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HENIKOFF S, 1994, J MOL BIOL, V243, P574, DOI 10.1016/0022-2836(94)90032-9; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Hertz JA, 2018, INTRO THEORY NEURAL; Hudson ML, 2006, DEV BIOL, V294, P352, DOI 10.1016/j.ydbio.2006.02.036; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Hwang HY, 2003, J BIOL CHEM, V278, P11735, DOI 10.1074/jbc.C200518200; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES SJM, 1995, MOL GEN GENET, V248, P719, DOI 10.1007/BF02191712; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kinnunen T, 2005, P NATL ACAD SCI USA, V102, P1507, DOI 10.1073/pnas.0401591102; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; MANN DM, 1990, J BIOL CHEM, V265, P5317; MATTHEWS BW, 1975, BIOCHIM BIOPHYS ACTA, V405, P442, DOI 10.1016/0005-2795(75)90109-9; Mellquist JL, 1998, BIOCHEMISTRY-US, V37, P6833, DOI 10.1021/bi972217k; Minniti AN, 2004, J CELL SCI, V117, P5179, DOI 10.1242/jcs.01394; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; Olson SK, 2006, J CELL BIOL, V173, P985, DOI 10.1083/jcb.200603003; Pfeil U, 2000, GLYCOBIOLOGY, V10, P803, DOI 10.1093/glycob/10.8.803; Qian N, 1988, J MOL BIOL, V202, P865, DOI 10.1016/0022-2836(88)90564-5; Ramachandran P, 2006, J PROTEOME RES, V5, P1493, DOI 10.1021/pr050492k; Rhiner C, 2005, DEVELOPMENT, V132, P4621, DOI 10.1242/dev.02042; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Ten Hagen KG, 2003, J BIOL CHEM, V278, P35039, DOI 10.1074/jbc.M303836200; Wang H, 2005, MOL BIOL CELL, V16, P4202, DOI 10.1091/mbc.E05-05-0472; Wilson IBH, 2002, J BIOL CHEM, V277, P21207, DOI 10.1074/jbc.M201634200; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; Winzen U, 2003, J BIOL CHEM, V278, P30106, DOI 10.1074/jbc.M212676200; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	44	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14586	14597		10.1074/jbc.M609193200	http://dx.doi.org/10.1074/jbc.M609193200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369258	hybrid			2022-12-27	WOS:000246245800072
J	Periz, J; Gill, AC; Hunt, L; Brown, P; Tomley, FM				Periz, Javier; Gill, Andrew C.; Hunt, Lawrence; Brown, Philip; Tomley, Fiona M.			The microneme proteins EtMIC4 and EtMIC5 of Eimeria tenella form a novel, ultra-high molecular mass protein complex that binds target host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PRE-KALLIKREIN; COAGULATION-FACTOR-XI; TOXOPLASMA-GONDII; APICOMPLEXAN PARASITES; APPLE DOMAINS; ACTIN CYTOSKELETON; ADHESION COMPLEX; SURFACE ADHESINS; MAMMALIAN-CELLS; MYOSIN-A	Eimeria tenella, in common with other parasitic protozoa of the phylum Apicomplexa, invades host cells using an actino-myosin-powered "glideosome" complex and requires the secretion of adhesive proteins from the microneme organelles onto the parasite surface. Microneme proteins of E. tenella include EtMIC4, a transmembrane protein that has multiple thrombospondin type I domains and calcium-binding epidermal growth factor-like domains in its extracellular domain, and EtMIC5, a soluble protein composed of 11 tandemly repeated domains that belong to the plasminogen-apple-nematode superfamily. Weshow here that EtMIC4 and EtMIC5 interact to form an oligomeric, ultrahigh molecular mass protein complex. The complex was purified from lysed parasites by non-denaturing techniques, and the stoichiometry was shown to be [EtMIC4] 2:[EtMIC5] 1, with an octamer of EtMIC4 bound noncovalently to a tetramer of EtMIC5. The complex is formed within the parasite secretory pathway and is maintained after secretion onto the surface of the parasite. The purified complex binds to a number of epithelial cell lines in culture. Identification and characterization of this complex contributes to an overall understanding of the role of multimolecular protein complexes in specific interactions between pathogens and their hosts during infection.	Inst Anim Hlth, Newbury RG20 7NN, Berks, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Tomley, FM (corresponding author), Inst Anim Hlth, Newbury RG20 7NN, Berks, England.	Fiona.tomley@bbsrc.ac.uk	Gill, Andrew C/A-5219-2009; Gill, ANdrew/GRO-1248-2022; Tomley, Fiona/GWM-9070-2022	Gill, Andrew C/0000-0001-5201-9473; Tomley, Fiona/0000-0003-2188-8013	BBSRC [BBS/E/A/00001663] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/I/00000973, BBS/E/I/00000877, BBS/E/I/00001141, BBS/E/A/00001663] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bergman LW, 2003, J CELL SCI, V116, P39, DOI 10.1242/jcs.00194; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Brecht S, 2001, J BIOL CHEM, V276, P4119, DOI 10.1074/jbc.M008294200; Brossier F, 2005, P NATL ACAD SCI USA, V102, P4146, DOI 10.1073/pnas.0407918102; Brown Philip J., 2003, Journal of Structural and Functional Genomics, V4, P227, DOI 10.1023/B:JSFG.0000016118.87333.03; Brown PJ, 2000, MOL BIOCHEM PARASIT, V107, P91, DOI 10.1016/S0166-6851(00)00179-1; Brown PJ, 2001, FEBS LETT, V497, P31, DOI 10.1016/S0014-5793(01)02424-3; Bumstead J, 2000, MOL BIOCHEM PARASIT, V110, P311, DOI 10.1016/S0166-6851(00)00280-2; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 2005, MOL MICROBIOL, V55, P1617, DOI 10.1111/j.1365-2958.2005.04483.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Di Cristina M, 2000, MOL CELL BIOL, V20, P7332, DOI 10.1128/MCB.20.19.7332-7341.2000; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Glombik MM, 2000, BIOCHIMIE, V82, P315, DOI 10.1016/S0300-9084(00)00195-4; Harlow E., 1988, ANTIBODIES LAB MANUA; Harper JM, 2006, MOL BIOL CELL, V17, P4551, DOI 10.1091/mbc.E06-01-0064; Huynh MH, 2004, CELL MICROBIOL, V6, P771, DOI 10.1111/j.1462-5822.2004.00403.x; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Jewett TJ, 2004, J BIOL CHEM, V279, P9362, DOI 10.1074/jbc.M312590200; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; Keeley A, 2004, TRENDS CELL BIOL, V14, P528, DOI 10.1016/j.tcb.2004.08.002; KING CA, 1988, PARASITOL TODAY, V4, P315, DOI 10.1016/0169-4758(88)90113-5; Klein H, 1998, GLYCOCONJUGATE J, V15, P147, DOI 10.1023/A:1006964105349; Lourenco EV, 2001, GLYCOBIOLOGY, V11, P541, DOI 10.1093/glycob/11.7.541; Lovett JL, 2003, J CELL SCI, V116, P3009, DOI 10.1242/jcs.00596; Matuschewski K, 2002, EMBO J, V21, P1597, DOI 10.1093/emboj/21.7.1597; Meissner M, 2002, SCIENCE, V298, P837, DOI 10.1126/science.1074553; Meissner M, 2002, J CELL SCI, V115, P563; Ngo HM, 2003, J BIOL CHEM, V278, P5343, DOI 10.1074/jbc.M208291200; Periz J, 2005, MOL BIOCHEM PARASIT, V143, P192, DOI 10.1016/j.molbiopara.2005.06.003; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; Reiss M, 2001, J CELL BIOL, V152, P563, DOI 10.1083/jcb.152.3.563; Robibaro B, 2001, INT J PARASITOL, V31, P1343, DOI 10.1016/S0020-7519(01)00252-1; Rodriguez-Boulan E, 2005, BBA-MOL CELL RES, V1744, P455, DOI 10.1016/j.bbamcr.2005.04.007; Rosen H, 2004, BIOCHEM BIOPH RES CO, V315, P671, DOI 10.1016/j.bbrc.2004.01.106; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; Ryan R, 2000, INT J PARASITOL, V30, P1493, DOI 10.1016/S0020-7519(00)00116-8; Saouros S, 2005, J BIOL CHEM, V280, P38583, DOI 10.1074/jbc.C500365200; SHIRLEY MW, 1995, BIOTECHNOLOGY GUIDEL, P1; Tomley F, 1997, METHODS, V13, P171, DOI 10.1006/meth.1997.0509; Tomley FM, 2001, INT J PARASITOL, V31, P1303, DOI 10.1016/S0020-7519(01)00255-7; Tomley FM, 2001, TRENDS PARASITOL, V17, P81, DOI 10.1016/S1471-4922(00)01761-X; Witcombe DA, 2003, INT J PARASITOL, V33, P691, DOI 10.1016/S0020-7519(03)00086-9	48	24	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16891	16898		10.1074/jbc.M702407200	http://dx.doi.org/10.1074/jbc.M702407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17426025	Green Accepted, hybrid			2022-12-27	WOS:000246946500021
J	Litterst, C; Georgakopoulos, A; Shioi, J; Ghersi, E; Wisniewski, T; Wang, R; Ludwig, A; Robakis, NK				Litterst, Claudia; Georgakopoulos, Anastasios; Shioi, Junichi; Ghersi, Enrico; Wisniewski, Thomas; Wang, Rong; Ludwig, Andreas; Robakis, Nikolaos K.			Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CELL-CELL ADHESION; RECEPTOR TYROSINE KINASES; GAMMA-SECRETASE; EPH RECEPTORS; N-CADHERIN; CLEAVAGE; PRESENILIN-1; ENDOCYTOSIS; EPHRINS	Binding of EphB receptors to ephrinB ligands on the surface of adjacent cells initiates signaling cascades that regulate angiogenesis, axonal guidance, and neuronal plasticity. These functions require processing of EphB receptors and removal of EphB-ephrinB complexes from the cell surface, but the mechanisms involved are poorly understood. Here we show that the ectodomain of EphB2 receptor is released to extracellular space following cleavage after EphB2 residue 543. The remaining membrane-associated fragment is cleaved by the presenilin-dependent gamma-secretase activity after EphB2 residue 569 releasing an intracellular peptide that contains the cytoplasmic domain of EphB2. This cleavage is inhibited by presenilin 1 familial Alzheimer disease mutations. Processing of EphB2 receptor depends on specific treatments: ephrinB ligand-induced processing requires endocytosis, and the ectodomain cleavage is sensitive to peptide inhibitor N-benzyloxycarbonyl-Val-Leu-leucinal but insensitive to metalloproteinase inhibitor GM6001. The ligand-induced processing takes place in endosomes and involves the rapid degradation of the extracellular EphB2. EphrinB ligand stimulates ubiquitination of EphB2 receptor. Calcium influx- and N-methyl-D-aspartic acid-induced processing of EphB2 is inhibited by GM6001 and ADAM10 inhibitors but not by N-benzyloxycarbonyl-Val-Leu-leucinal. This processing requires no endocytosis and promotes rapid shedding of extracellular EphB2, indicating that it takes place at the plasma membrane. Our data identify novel cleavages and modifications of EphB2 receptor and indicate that specific conditions determine the proteolytic systems and subcellular sites involved in the processing of this receptor.	NYU, Mt Sinai Sch Med, Ctr Neurodegenerat, Dept Psychiat, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Ctr Neurodegenerat, Dept Neurosci, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Ctr Neurodegenerat, Dept Human Genet, New York, NY 10029 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Univ Hosp Rein, W Fael Tech Hochsch, Inst Mol Cardiovasc Res, D-52056 Aachen, Germany	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University; New York University; RWTH Aachen University; RWTH Aachen University Hospital	Robakis, NK (corresponding author), NYU, Mt Sinai Sch Med, Ctr Neurodegenerat, Dept Psychiat, 1 Gustave Levy Pl,Box 1229, New York, NY 10029 USA.	nikos.robakis@mssm.edu	Wisniewski, Thomas/Q-6525-2019; Robakis, Nikolaos/AAA-1838-2021; Ludwig, Andreas/I-5685-2012; Wang, Rong/A-8721-2009	Wisniewski, Thomas/0000-0002-3379-8966; Ludwig, Andreas/0000-0001-8536-4986; Georgakopoulos, Anastasios/0000-0001-8241-6306	NATIONAL CANCER INSTITUTE [R24CA088325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005138, R01AG017926, R37AG017926, R01AG008200] Funding Source: NIH RePORTER; NCI NIH HHS [CA088325, R24 CA088325] Funding Source: Medline; NIA NIH HHS [AG-17926, R01 AG008200, P50 AG005138, AG-08200, R01 AG017926, AG-05138, R37 AG017926] Funding Source: Medline; NINDS NIH HHS [R01 NS047229, NS-47229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbenante G, 2000, BIOCHEM BIOPH RES CO, V268, P133, DOI 10.1006/bbrc.2000.2098; Adams RH, 2002, SEMIN CELL DEV BIOL, V13, P55, DOI 10.1006/scdb.2001.0289; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Contractor A, 2002, SCIENCE, V296, P1864, DOI 10.1126/science.1069081; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Ellis C, 1996, ONCOGENE, V12, P1727; Fernandez-Botran R, 1999, CRIT REV CL LAB SCI, V36, P165, DOI 10.1080/10408369991239196; Georgakopoulos A, 2006, EMBO J, V25, P1242, DOI 10.1038/sj.emboj.7601031; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Ghosh A, 2002, SCIENCE, V295, P449, DOI 10.1126/science.1069391; Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Henderson JT, 2001, NEURON, V32, P1041, DOI 10.1016/S0896-6273(01)00553-0; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; Mann F, 2003, J NEUROBIOL, V57, P323, DOI 10.1002/neu.10303; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2005, GENES BRAIN BEHAV, V4, P134, DOI 10.1111/j.1601-183X.2005.00086.x; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; Martinez A, 2005, BRAIN RES REV, V49, P211, DOI 10.1016/j.brainresrev.2005.02.001; McLaughlin T, 2003, CURR OPIN NEUROBIOL, V13, P57, DOI 10.1016/S0959-4388(03)00014-X; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Pascall JC, 2004, BIOCHEM BIOPH RES CO, V317, P244, DOI 10.1016/j.bbrc.2004.03.039; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Robakis N.K., 2006, TRANSCRIPTION FACTOR, P399; Stachel SJ, 2004, J MED CHEM, V47, P6447, DOI 10.1021/jm049379g; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Uyen HD, 2002, J CELL SCI, V115, P3073; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yamaguchi Y, 2004, CURR OPIN NEUROBIOL, V14, P288, DOI 10.1016/j.conb.2004.04.003; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	51	98	105	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16155	16163		10.1074/jbc.M611449200	http://dx.doi.org/10.1074/jbc.M611449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428795	Green Published, hybrid			2022-12-27	WOS:000246794300024
J	Xu, J; Bai, XH; Lodyga, M; Han, B; Xiao, H; Keshavjee, S; Hu, J; Zhang, HB; Yang, BB; Liu, MY				Xu, Jing; Bai, Xiao-Hui; Lodyga, Monika; Han, Bing; Xiao, Helan; Keshavjee, Shaf; Hu, Jim; Zhang, Haibo; Yang, Burton B.; Liu, Mingyao			XB130, a novel adaptor protein for signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; EPITHELIAL-CELLS; TNF-ALPHA; KAPPA-B; ACTIVATION; KINASE; EXPRESSION; FAMILY; CAS; PHOSPHORYLATION	Adaptor proteins are important mediators in signal transduction. In the present study, we report the cloning and characterization of a novel adaptor protein, XB130. This gene is located on human chromosome 10q25.3 and encodes a protein of 818 amino acids. It contains several Src homology ( SH)2- and SH3-binding motifs, two pleckstrin homology domains, a coiled-coil region, and a number of potential tyrosine or serine/ threonine phosphorylation sites. Endogenous XB130 interacts with c-Src tyrosine kinase. Their co-expression in COS-7 cells resulted in activation of c-Src and elevated tyrosine phosphorylation of multiple proteins, including XB130 itself. XB130 expression in HEK293 cells enhanced serum response element- and AP-1-dependent transcriptional activation mediated by c-Src. XB130 Delta N, an N-terminal deletion mutant lacking a putative SH3-binding motif and several putative SH2-binding sites, reduced its ability to mediate Src signal transduction. Down-regulation of endogenous XB130 with siRNA reduced c-Src activity, IL-8 production, EGF-induced phosphorylation of Akt and GSK3 beta, and altered cell cycles in human lung epithelial cells. These data suggest that XB130 as an adaptor may play an important role in the regulation of signal transduction and cellular functions.	Univ Hlth Netwrk, Div Cellular & Mol Biol, Toronto Gen Res Inst, Toronto, ON M5G 1L7, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Liu, MY (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Rm TMDT 2-814,101 Coll St, Toronto, ON M5G 1L7, Canada.	mingyao.liu@utoronto.ca		Keshavjee, Shaf/0000-0003-4547-8094; Hu, Jim/0000-0001-9134-7103; Liu, Mingyao/0000-0002-9188-8417				Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cherezova L, 2002, FRONT BIOSCI-LANDMRK, V7, pD164, DOI 10.2741/cherezov; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; Dominguez-Caceres MA, 2004, ONCOGENE, V23, P7378, DOI 10.1038/sj.onc.1208002; dos Santos CC, 2004, PHYSIOL GENOMICS, V19, P331, DOI 10.1152/physiolgenomics.00153.2004; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Flynn DC, 2001, ONCOGENE, V20, P6270, DOI 10.1038/sj.onc.1204769; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gillingham AK, 2003, BBA-MOL CELL RES, V1641, P71, DOI 10.1016/S0167-4889(03)00088-0; Gregorieff A, 1998, J BIOL CHEM, V273, P13217, DOI 10.1074/jbc.273.21.13217; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Han B, 2005, J IMMUNOL, V175, P8303, DOI 10.4049/jimmunol.175.12.8303; Han B, 2004, J BIOL CHEM, V279, P54793, DOI 10.1074/jbc.M406880200; Han Bing, 2005, Proc Am Thorac Soc, V2, P181, DOI 10.1513/pats.200501-008AC; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Lappin TR, 2002, LEUKEMIA LYMPHOMA, V43, P1455, DOI 10.1080/1042819022386644; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Liu M, 2001, SEPSIS ORGAN DYSFUNC, P37; Lodyga M, 2002, AM J PHYSIOL-LUNG C, V283, pL265, DOI 10.1152/ajplung.00492.2001; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mazor M, 2004, ONCOGENE, V23, P7882, DOI 10.1038/sj.onc.1208068; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; OKADA M, 1991, J BIOL CHEM, V266, P24249; Okutani D, 2006, AM J PHYSIOL-LUNG C, V291, pL129, DOI 10.1152/ajplung.00261.2005; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Roebuck KA, 1999, J LEUKOCYTE BIOL, V65, P291, DOI 10.1002/jlb.65.3.291; Roger T, 1998, BIOCHEM J, V330, P429, DOI 10.1042/bj3300429; SCHLESSINGER I, 2003, SCI STKE, pRE12; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Tang PS, 2006, J CELL PHYSIOL, V209, P457, DOI 10.1002/jcp.20751; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Treisman R, 1990, Semin Cancer Biol, V1, P47; Tsygankov AY, 2003, FRONT BIOSCI-LANDMRK, V8, pS595, DOI 10.2741/1106; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; Xu KP, 2006, INVEST OPHTH VIS SCI, V47, P2832, DOI 10.1167/iovs.05-1361; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yeh M, 2004, J BIOL CHEM, V279, P30175, DOI 10.1074/jbc.M312198200; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	54	63	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16401	16412		10.1074/jbc.M701684200	http://dx.doi.org/10.1074/jbc.M701684200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17412687	hybrid			2022-12-27	WOS:000246794300048
J	Adams, VH; McBryant, SJ; Wade, PA; Woodcock, CL; Hansen, JC				Adams, Valerie H.; McBryant, Steven J.; Wade, Paul A.; Woodcock, Christopher L.; Hansen, Jeffrey C.			Intrinsic disorder and autonomous domain function in the multifunctional nuclear protein, MeCP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING PROTEIN; SEDIMENTATION-VELOCITY ANALYSIS; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; RETT-SYNDROME; CHROMOSOMAL-PROTEIN; DNA METHYLATION; CHROMATIN; SEQUENCE; ASSOCIATION	To probe the tertiary structure and domain organization of native methyl CpG-binding protein 2 ( MeCP2), the recombinant human e2 isoform was purified to homogeneity and characterized by analytical ultracentrifugation, CD, and protease digestion. The location of intrinsic disorder in the MeCP2 sequence was predicted using the FoldIndex algorithm. MeCP2 was found to be monomeric in low and high salt and over a nearly 1000-fold concentration range. CD indicated that the MeCP2 monomer was nearly 60% unstructured under conditions where it could preferentially recognize CpG dinucleotides and condense chromatin. Protease digestion experiments demonstrate that MeCP2 is composed of at least six structurally distinct domains, two of which correspond to the well characterized methyl DNA binding domain and transcriptional repression domain. These domains collectively are organized into a tertiary structure with coil-like hydrodynamic properties, reflecting the extensive disorder in the MeCP2 sequence. When expressed as individual fragments, the methyl DNA binding domain and transcriptional repression domain both could function as nonspecific DNA binding domains. The unusual structural features of MeCP2 provide a basis for understanding MeCP2 multifunctionality in vitro and in vivo. These studies also establish an experimental paradigm for characterizing the tertiary structures of other highly disordered proteins.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	Colorado State University; University of Massachusetts System; University of Massachusetts Amherst; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hansen, JC (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, 1870 Campus Delivery, Ft Collins, CO 80523 USA.	Jeffrey.C.Hansen@colostate.edu	Wade, Paul A/D-2374-2019	Wade, Paul A/0000-0002-6042-357X	Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [GM45916, GM70897, GM66834] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066834, R29GM045916, R01GM045916, R01GM070897] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Bienvenu T, 2000, HUM MOL GENET, V9, P1377, DOI 10.1093/hmg/9.9.1377; Brero A, 2005, J CELL BIOL, V169, P733, DOI 10.1083/jcb.200502062; Brunner E, 2000, J BIOMOL NMR, V17, P175, DOI 10.1023/A:1008394831749; Buschdorf JP, 2004, J MOL MED, V82, P135, DOI 10.1007/s00109-003-0497-9; Carro S, 2004, J BIOL CHEM, V279, P25623, DOI 10.1074/jbc.M402571200; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; Chandler SP, 1999, BIOCHEMISTRY-US, V38, P7008, DOI 10.1021/bi990224y; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Demeler B, 2004, ANAL BIOCHEM, V335, P279, DOI 10.1016/j.ab.2004.08.039; Demeler B, 2000, METHOD ENZYMOL, V321, P38; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; Hansen JC, 2006, J BIOL CHEM, V281, P1853, DOI 10.1074/jbc.R500022200; Harikrishnan KN, 2006, NAT GENET, V38, P964, DOI 10.1038/ng0906-964; Haynes C, 2006, PLOS COMPUT BIOL, V2, P890, DOI 10.1371/journal.pcbi.0020100; Heitmann B, 2003, EUR J BIOCHEM, V270, P3263, DOI 10.1046/j.1432-1033.2003.03714.x; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; Hu KP, 2006, NAT GENET, V38, P962, DOI 10.1038/ng0906-962; Huppke P, 2005, J CHILD NEUROL, V20, P732, DOI 10.1177/08830738050200090601; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kato Y, 2004, J BIOL CHEM, V279, P31833, DOI 10.1074/jbc.M404719200; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Klose RJ, 2004, J BIOL CHEM, V279, P46490, DOI 10.1074/jbc.M408284200; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Kriaucionis S, 2004, NUCLEIC ACIDS RES, V32, P1818, DOI 10.1093/nar/gkh349; Laccone F, 2001, HUM MUTAT, V17, P183, DOI 10.1002/humu.3; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Liu JG, 2006, BIOCHEMISTRY-US, V45, P6873, DOI 10.1021/bi0602718; Mann J, 2007, CELL DEATH DIFFER, V14, P275, DOI 10.1038/sj.cdd.4401979; McBryant SJ, 2006, BIOCHEMISTRY-US, V45, P15941, DOI 10.1021/bi061693k; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nikitina T, 2007, MOL CELL BIOL, V27, P864, DOI 10.1128/MCB.01593-06; Prilusky J, 2005, BIOINFORMATICS, V21, P3435, DOI 10.1093/bioinformatics/bti537; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 1999, PROTEIN SCI, V8, P370; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tompa P, 2005, FEBS LETT, V579, P3346, DOI 10.1016/j.febslet.2005.03.072; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; Wade PA, 2004, BIOESSAYS, V26, P217, DOI 10.1002/bies.20018; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Young JI, 2005, P NATL ACAD SCI USA, V102, P17551, DOI 10.1073/pnas.0507856102; Yusufzai TM, 2000, NUCLEIC ACIDS RES, V28, P4172, DOI 10.1093/nar/28.21.4172	53	101	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15057	15064		10.1074/jbc.M700855200	http://dx.doi.org/10.1074/jbc.M700855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17371874	hybrid			2022-12-27	WOS:000246589000045
J	Hatherley, D; Harlos, K; Dunlop, DC; Stuart, DI; Barclay, AN				Hatherley, Deborah; Harlos, Karl; Dunlop, D. Cameron; Stuart, David I.; Barclay, A. Neil			The structure of the macrophage signal regulatory protein alpha (SIRP alpha) inhibitory receptor reveals a binding face reminiscent of that used by T cell receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; ADHESION MOLECULE CD2; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN SUPERFAMILY; ANTIGEN RECOGNITION; MYELOID CELLS; MHC LIGAND; CLASS-I; COMPLEX; FAMILY	Signal regulatory protein ( SIRP) alpha is a membrane receptor that sends inhibitory signals to myeloid cells by engagement of CD47. The high resolution x-ray structure of the N-terminal ligand binding domain shows it to have a distinctive immunoglobulin superfamily V-like fold. Site-directed mutagenesis suggests that CD47 is bound at a surface involving the BC, FG, and DE loops, which distinguishes it from other immunoglobulin superfamily surface proteins that use the faces of the fold, but resembles antigen receptors. The SIRP interaction is confined to a single domain, and its use of an extended DE loop strengthens the similarity with T cell receptor binding and the suggestion that they are closely related in evolution. The employment of loops to form the CD47-binding surface provides a mechanism for small sequence changes to modulate binding specificity, explaining the different binding properties of SIRP family members.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford Prot Prod Facil, Oxford OX3 7BN, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; Wellcome Centre for Human Genetics	Barclay, AN (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.	neil.barclay@path.ox.ac.uk		Stuart, David/0000-0002-3426-4210	Medical Research Council [G0500365, G0400808] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0500365, G0400808] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams EJ, 2005, SCIENCE, V308, P227, DOI 10.1126/science.1106885; Bamford DH, 2005, CURR OPIN STRUC BIOL, V15, P655, DOI 10.1016/j.sbi.2005.10.012; Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859; BARCLAY AN, 1987, EMBO J, V6, P1259, DOI 10.1002/j.1460-2075.1987.tb02362.x; BARCLAY AN, 1997, LEUCOCYTE ANTIGEN FA, P1; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brooke G, 2004, J IMMUNOL, V173, P2562, DOI 10.4049/jimmunol.173.4.2562; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cao E, 2006, IMMUNITY, V25, P559, DOI 10.1016/j.immuni.2006.06.020; Choudhuri K, 2005, NATURE, V436, P578, DOI 10.1038/nature03843; Collins AV, 2002, IMMUNITY, V17, P201, DOI 10.1016/S1074-7613(02)00362-X; DAVIS SJ, 1993, PROTEIN ENG, V6, P229, DOI 10.1093/protein/6.2.229; Dietrich J, 2000, J IMMUNOL, V164, P9, DOI 10.4049/jimmunol.164.1.9; Dong XH, 2006, J BIOL CHEM, V281, P10610, DOI 10.1074/jbc.M513459200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Hatherley D, 2005, J IMMUNOL, V175, P2469, DOI 10.4049/jimmunol.175.4.2469; Hatherley D, 2004, EUR J IMMUNOL, V34, P1688, DOI 10.1002/eji.200425080; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kern PS, 1998, IMMUNITY, V9, P519, DOI 10.1016/S1074-7613(00)80635-4; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lanier LL, 2000, IMMUNOL TODAY, V21, P611, DOI 10.1016/S0167-5699(00)01745-X; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Liu Y, 2005, J BIOL CHEM, V280, P36132, DOI 10.1074/jbc.M506419200; Liu Y, 2007, J MOL BIOL, V365, P680, DOI 10.1016/j.jmb.2006.09.079; Maenaka K, 1999, STRUCTURE, V7, P391, DOI 10.1016/S0969-2126(99)80052-5; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Piccio L, 2005, BLOOD, V105, P2421, DOI 10.1182/blood-2004-07-2823; Rebres RA, 2001, J BIOL CHEM, V276, P34607, DOI 10.1074/jbc.M106107200; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Stamper CC, 2001, NATURE, V410, P608, DOI 10.1038/35069118; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tomasello E, 2000, EUR J IMMUNOL, V30, P2147, DOI 10.1002/1521-4141(2000)30:8<2147::AID-IMMU2147>3.0.CO;2-1; Tomasello E, 2005, EUR J IMMUNOL, V35, P1670, DOI 10.1002/eji.200425932; van Beek EM, 2005, J IMMUNOL, V175, P7781, DOI 10.4049/jimmunol.175.12.7781; van den Berg TK, 2005, J IMMUNOL, V175, P7788, DOI 10.4049/jimmunol.175.12.7788; van den Berg TK, 2004, TRENDS IMMUNOL, V25, P11, DOI 10.1016/j.it.2003.11.006; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; Vernon-Wilson EF, 2000, EUR J IMMUNOL, V30, P2130; Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Wang JH, 2001, P NATL ACAD SCI USA, V98, P10799, DOI 10.1073/pnas.191124098; Willcox BE, 2003, NAT IMMUNOL, V4, P913, DOI 10.1038/ni961; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wright GJ, 2000, IMMUNITY, V13, P233, DOI 10.1016/S1074-7613(00)00023-6; Zhang XW, 2001, ACTA CRYSTALLOGR D, V57, P898, DOI 10.1107/S0907444901005777	65	51	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14567	14575		10.1074/jbc.M611511200	http://dx.doi.org/10.1074/jbc.M611511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369261	hybrid			2022-12-27	WOS:000246245800070
J	Kroning, N; Willenborg, M; Tholema, N; Hanelt, I; Schmid, R; Bakker, EP				Kroening, Nadine; Willenborg, Marion; Tholema, Nancy; Haenelt, Inga; Schmid, Roland; Bakker, Evert P.			ATP binding to the KTN/RCK subunit KtrA from the K+- uptake system KtrAB of Vibrio alginolyticus - Its role in the formation of the KtrAB complex and its requirement in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PROTON-TRANSLOCATING ATPASE; ANTIMICROBIAL PEPTIDES; ENTEROCOCCUS-HIRAE; POTASSIUM CHANNEL; GROWING-CELLS; HIGH-AFFINITY; RCK DOMAIN; TRANSPORT; RESISTANCE	Subunit KtrA of the bacterial Na+-dependent K+-translocating KtrAB systems belongs to theKTN/RCKfamily of regulatory proteins and protein domains. They are located at the cytoplasmic side of the cell membrane. By binding ligands they regulate the activity of a number of K+ transporters and K+ channels. To investigate the function of KtrA from the bacterium Vibrio alginolyticus (VaKtrA), the protein was overproduced in His-tagged form (His(10)-VaKtrA) and isolated by affinity chromatography. VaKtrA contains a G-rich, ADP-moiety binding beta-alpha-beta-fold ("Rossman fold"). Photocross-linking and flow dialysis were used to determine the binding of [P-32] ATP and [P-32] NAD(+) to His(10)-VaKtrA. Binding of other nucleotides was estimated from the competition by these compounds of the binding of the P-32-labeled nucleotides to the protein. [gamma-P-32] ATP bound with high affinity to His(10)-VaKtrA (K-D of 9 mu M). All other nucleotides tested exhibited K-D (K-i) values of 30 mu M or higher. Limited proteolysis with trypsin showed that ATP was the only nucleotide that changed the conformation of VaKtrA. ATP specifically promoted complex formation of VaKtrA with the His-tagged form of its K+-translocating partner, VaKtrB-His(6), as detected both in an overlay experiment and in an experiment in which VaKtrA was added to VaKtrB-His(6) bound to Ni2+-agarose. In intact cells of Escherichia coli both a high of membrane potential and a high cytoplasmic ATP concentration were required for VaKtrAB activity. C-terminal deletions in VaKtrA showed that for in vivo activity at least 169 N-terminal amino acid residues of its total of 220 are required and that its 40 C-terminal residues are dispensable.	Univ Osnabruck, Dept Microbiol, D-49076 Osnabruck, Germany	University Osnabruck	Kroning, N (corresponding author), Univ Osnabruck, Dept Microbiol, D-49076 Osnabruck, Germany.	kroening@biologie.uni-osnabrueck.de	Hänelt, Inga/N-2982-2016	Hänelt, Inga/0000-0003-1495-3163				Albright RA, 2006, CELL, V126, P1147, DOI 10.1016/j.cell.2006.08.028; ARNOLD A, 1976, ANAL BIOCHEM, V71, P209, DOI 10.1016/0003-2697(76)90029-4; BAKKER EP, 1984, EMBO J, V3, P895, DOI 10.1002/j.1460-2075.1984.tb01902.x; BERGER EA, 1973, P NATL ACAD SCI USA, V70, P1514, DOI 10.1073/pnas.70.5.1514; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P144; CARROLL SF, 1980, J BIOL CHEM, V255, P2020; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; DINNIBIER U, 1988, ARCH MICROBIOL, V150, P348, DOI 10.1007/BF00408306; DUNN SD, 1980, J BIOL CHEM, V255, P113; Durell SR, 2000, BIOPHYS J, V78, P188, DOI 10.1016/S0006-3495(00)76584-2; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; Fersht A., 1985, ENZYME STRUCTURE MEC; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Harms C, 2001, MICROBIOL-SGM, V147, P2991, DOI 10.1099/00221287-147-11-2991; Holtmann G, 2003, J BACTERIOL, V185, P1289, DOI 10.1128/JB.185.4.1289-1298.2003; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Jung H, 2001, MICROBIAL TRANSPORT, P47; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kawano M, 1999, FEMS MICROBIOL LETT, V176, P449; KIMMICH GA, 1975, ANAL BIOCHEM, V69, P187, DOI 10.1016/0003-2697(75)90580-1; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Kuo MMC, 2005, FEMS MICROBIOL REV, V29, P961, DOI 10.1016/j.femsre.2005.03.003; Matsuda N, 2004, J BIOL CHEM, V279, P54952, DOI 10.1074/jbc.M407268200; Murata T, 1996, J BIOL CHEM, V271, P10042, DOI 10.1074/jbc.271.17.10042; Nakamura T, 1998, J BACTERIOL, V180, P3491, DOI 10.1128/JB.180.13.3491-3494.1998; Nakamura T, 1998, MICROBIOL-SGM, V144, P2281, DOI 10.1099/00221287-144-8-2281; NEIDHARDT EC, 1990, PHYSL BACTERIAL CELL, P312; Parfenova LV, 2006, J BIOL CHEM, V281, P21131, DOI 10.1074/jbc.M603109200; PARRALOPEZ C, 1994, EMBO J, V13, P3964, DOI 10.1002/j.1460-2075.1994.tb06712.x; PARRALOPEZ C, 1993, EMBO J, V12, P4053, DOI 10.1002/j.1460-2075.1993.tb06089.x; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; RHOADS DB, 1977, J BIOL CHEM, V252, P1394; RHOADS DB, 1978, J GEN PHYSIOL, V72, P283, DOI 10.1085/jgp.72.3.283; Roosild TP, 2004, TRENDS BIOCHEM SCI, V29, P39, DOI 10.1016/j.tibs.2003.11.008; Roosild TP, 2002, CELL, V109, P781, DOI 10.1016/S0092-8674(02)00768-7; SCHLEYER M, 1993, ARCH MICROBIOL, V160, P424, DOI 10.1007/BF00245302; SCHLOSSER A, 1993, MOL MICROBIOL, V9, P533, DOI 10.1111/j.1365-2958.1993.tb01714.x; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STEWART GSAB, 1986, PLASMID, V15, P172, DOI 10.1016/0147-619X(86)90035-1; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Stumpe S, 1997, ARCH MICROBIOL, V167, P126, DOI 10.1007/s002030050425; STUMPE S, 1996, HDB BIOL PHYSICS, V2, P474; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Tholema N, 2005, J BIOL CHEM, V280, P41146, DOI 10.1074/jbc.M507647200; Tholema N, 1999, FEBS LETT, V450, P217, DOI 10.1016/S0014-5793(99)00504-9; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	49	36	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14018	14027		10.1074/jbc.M609084200	http://dx.doi.org/10.1074/jbc.M609084200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17344221	hybrid			2022-12-27	WOS:000246245800011
J	Yeh, YH; Kesavulu, MM; Li, HM; Wu, SZ; Sun, YJ; Konozy, EHE; Hsiao, CD				Yeh, Yi-Hung; Kesavulu, Muppuru M.; Li, Hsou-min; Wu, Shu-Zon; Sun, Yuh-Ju; Konozy, Emadeldin H. E.; Hsiao, Chwan-Deng			Dimerization is important for the GTPase activity of chloroplast translocon components at Toc33 and psToc159	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; OUTER-MEMBRANE; PREPROTEIN RECEPTOR; BINDING; DOMAIN; INSERTION; ATTOC159; ENVELOPE; MUTANT; TOC159	Arabidopsis Toc33 (atToc33) is a GTPase and a member of the Toc (translocon at the outer-envelope membrane of chloroplasts) complex that associates with precursor proteins during protein import into chloroplasts. By inference from the crystal structure of psToc34, a homologue in pea, the arginine at residue 130 (Arg(130)) has been implicated in the formation of the atToc33 dimer and in intermolecular GTPase activation within the dimer. Here we report the crystal structure at 3.2-angstrom resolution of an atToc33 mutant, atToc33(R130A), in which Arg130 was mutated to alanine. Both in solution and in crystals, atToc33(R130A) was present in its monomeric form. In contrast, both wild-type atToc33 and another pea Toc GTPase homologue, pea Toc159 (psToc159), were able to form dimers in solution. Dimeric atToc33 and psToc159 had significantly higher GTPase activity than monomeric atToc33, psToc159, and atToc33(R130A). Molecular modeling using the structures of psToc34 and atToc33(R130A) suggests that, in an architectural dimer of atToc33, Arg130 from one monomer interacts with the beta-phosphate of GDP and several other amino acids of the other monomer. These results indicate that Arg130 is critical for dimer formation, which is itself important for GTPase activity. Activation of GTPase activity by dimer formation is likely to be a critical regulatory step in protein import into chloroplasts.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 300, Taiwan	Academia Sinica - Taiwan; National Tsing Hua University	Hsiao, CD (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	hsiao@gate.sinica.edu.tw	Hsiao, Chwan-Deng/AAZ-8869-2021; Kesavulu, Muppuru/G-4344-2013; Hsiao, Chwan-Deng/D-7327-2013; Li, Hsou-min/AAZ-8011-2021	Hsiao, Chwan-Deng/0000-0002-7012-1532; Kesavulu, Muppuru/0000-0002-3557-4739; Li, Hsou-min/0000-0002-0211-7339				Aronsson H, 2003, FEBS LETT, V544, P79, DOI 10.1016/S0014-5793(03)00478-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; Becker T, 2004, EMBO J, V23, P520, DOI 10.1038/sj.emboj.7600089; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen DD, 1997, J BIOL CHEM, V272, P6614, DOI 10.1074/jbc.272.10.6614; Constan D, 2004, PLANT J, V38, P93, DOI 10.1111/j.1365-313X.2004.02024.x; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; Hillebrand S, 2005, ANAL BIOANAL CHEM, V383, P92, DOI 10.1007/s00216-005-3375-1; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; Kessler F, 2006, TRAFFIC, V7, P248, DOI 10.1111/j.1600-0854.2005.00382.x; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kubis S, 2003, PLANT CELL, V15, P1859, DOI 10.1105/tpc.012955; Li HM, 1997, J BIOL CHEM, V272, P10968; MANNE V, 1985, BIOCHEM BIOPH RES CO, V128, P1440, DOI 10.1016/0006-291X(85)91101-5; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; Scrima A, 2006, EMBO J, V25, P2940, DOI 10.1038/sj.emboj.7601171; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; Smith MD, 2002, J CELL BIOL, V159, P833, DOI 10.1083/jcb.200208017; Soll J, 2004, NAT REV MOL CELL BIO, V5, P198, DOI 10.1038/nrm1333; Sun YJ, 2002, NAT STRUCT BIOL, V9, P95, DOI 10.1038/nsb744; Tsai LY, 1999, J BIOL CHEM, V274, P18735, DOI 10.1074/jbc.274.26.18735; Wallas TR, 2003, J BIOL CHEM, V278, P44289, DOI 10.1074/jbc.M307873200; Weibel P, 2003, J BIOL CHEM, V278, P37321, DOI 10.1074/jbc.M305946200; Young ME, 1999, PLANT PHYSIOL, V121, P237, DOI 10.1104/pp.121.1.237	33	38	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13845	13853		10.1074/jbc.M608385200	http://dx.doi.org/10.1074/jbc.M608385200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337454	hybrid			2022-12-27	WOS:000246060300074
J	Vriens, J; Owsianik, G; Janssens, A; Voets, T; Nilius, B				Vriens, Joris; Owsianik, Grzegorz; Janssens, Annelies; Voets, Thomas; Nilius, Bernd			Determinants of 4 alpha-phorbol sensitivity in transmembrane domains 3 and 4 of the cation channel TRPV4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-EVOKED ACTIVATION; MODULATION; OTRPC4; TRP12	TRPV4, a Ca2+-permeable member of the vanilloid subgroup of the transient receptor potential (TRP) channels, is activated by cell swelling and moderate heat (> 27 degrees C) as well as by diverse chemical compounds including synthetic 4 alpha-phorbol esters, the plant extract bisandrographolide A, and endogenous epoxyeicosatrienoic acids (EETs; 5,6-EET and 8,9-EET). Previous work identified a tyrosine residue located in the first half of putative transmembrane segment 3 (TM3) as a crucial determinant for the activation of TRPV4 by its most specific agonist 4 alpha-phorbol 12,13-didecanoate (4 alpha-PDD), suggesting that 4 alpha-PDD interacts with the channel through its transmembrane segments. To obtain insight in the 4 alpha-PDD-binding site and in the mechanism of ligand-dependent TRPV4 activation, we investigated the consequences of specific point mutations in TM4 on the sensitivity of the channel to different chemical and physical stimuli. Mutations of two hydrophobic residues in the central part of TM4(Leu(584) and Trp(586)) caused a severe reduction of the sensitivity of the channel to 4 alpha-PDD, bisandrographolide A, and heat, whereas responses to cell swelling, arachidonic acid, and 5,6-EET remained unaffected. In contrast, mutations of two residues in the C-terminal part of TM4 (Tyr(591) and Arg(594)) affected channel activation of TRPV4 by all stimuli, suggesting an involvement in channel gating rather than in interaction with agonists. Based on a comparison of the responses of WT and mutant TRPV4 to 4 alpha-PDD and different 4 alpha-phorbol esters, we conclude that the length of the fatty acid moiety determines the ligand binding affinity and propose a model for the interaction between 4 alpha-phorbol esters and the TM3/4 region of TRPV4.	Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium	KU Leuven	Vriens, J (corresponding author), Katholieke Univ Leuven, Dept Physiol, Campus Gasthuisberg, B-3000 Louvain, Belgium.	Joris.Vriens@med.kuleuven.be	Voets, Thomas/E-2466-2012; Voets, Thomas/AAD-4389-2019; Vriens, Joris/G-9966-2018	Voets, Thomas/0000-0001-5526-5821; Voets, Thomas/0000-0001-5526-5821; Vriens, Joris/0000-0002-2502-0409; Janssens, Annelies/0000-0002-6735-8248				Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Gavva NR, 2004, J BIOL CHEM, V279, P20283, DOI 10.1074/jbc.M312577200; Guler AD, 2002, J NEUROSCI, V22, P6408; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Nilius B, 2004, AM J PHYSIOL-CELL PH, V286, pC195, DOI 10.1152/ajpcell.00365.2003; Nilius B, 2005, PFLUG ARCH EUR J PHY, V451, P1, DOI 10.1007/s00424-005-1462-y; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Owsianik G, 2006, REV PHYSIOL BIOCH P, V156, P61, DOI 10.1007/s10254-005-0006-3; Owsianik G, 2006, ANNU REV PHYSIOL, V68, P685, DOI 10.1146/annurev.physiol.68.040204.101406; PaltaufDoburzynska J, 1997, CELL CALCIUM, V21, P43, DOI 10.1016/S0143-4160(97)90095-6; Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028; Smith PL, 2006, J BIOL CHEM, V281, P29897, DOI 10.1074/jbc.M605394200; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Strotmann R, 2003, J BIOL CHEM, V278, P26541, DOI 10.1074/jbc.M302590200; Vlachova V, 2003, J NEUROSCI, V23, P1340, DOI 10.1523/JNEUROSCI.23-04-01340.2003; Voets T, 2005, NAT CHEM BIOL, V1, P85, DOI 10.1038/nchembio0705-85; Voets T, 2007, NAT CHEM BIOL, V3, P174, DOI 10.1038/nchembio862; Vriens J, 2005, CIRC RES, V97, P908, DOI 10.1161/01.RES.0000187474.47805.30; Vriens J, 2004, PFLUG ARCH EUR J PHY, V449, P213, DOI 10.1007/s00424-004-1314-1; Vriens J, 2004, CELL CALCIUM, V36, P19, DOI 10.1016/j.ceca.2003.11.006; Vriens J, 2004, P NATL ACAD SCI USA, V101, P396, DOI 10.1073/pnas.0303329101; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2	29	97	101	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12796	12803		10.1074/jbc.M610485200	http://dx.doi.org/10.1074/jbc.M610485200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17341586	hybrid, Green Published			2022-12-27	WOS:000245942800051
J	Mazurek, N; Sun, YJ; Liu, KF; Gilcrease, MZ; Schober, W; Nangia-Makker, P; Raz, A; Bresalier, RS				Mazurek, Nachman; Sun, Yun Jie; Liu, Kai-Feng; Gilcrease, Michael Z.; Schober, Wendy; Nangia-Makker, Pratima; Raz, Avraham; Bresalier, Robert S.			Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; PROTEIN-KINASE B; TRANSCRIPTION FACTOR; SUPPRESSOR PTEN; PROSTATE-CANCER; BINDING PROTEIN; SURVIVAL; DEATH; AKT; ACTIVATION	Galectin-3 (GAL3), a beta-galactoside-binding lectin, confers chemoresistance to a wide variety of cancer cell types. It may exhibit anti- or pro-apoptotic activity depending on the nature of the stimulus. We report here that introducing phosphorylated galectin-3 (P-GAL3) into GAL3-null, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant human breast carcinoma cells promotes TRAIL-induced apoptotic cell death by stimulating the phosphorylation/inactivation of the pro-apoptotic molecule Bad resulting in the inhibition of mitochondrial depolarization and the release of cytochrome c. Exposure of the transfectant cells to TRAIL leads to the recruitment of the initiator capase-8 followed by activation of the effector caspase-9, independent of cytochrome c, and subsequently the processing of the executioner caspase-3. P-GAL3 and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) were coordinately expressed, with concomitant dephosphorylation of Akt in TRAIL-sensitive cells. In contrast, overexpression of phospho-mutant GAL3 (incapable of phosphorylation) failed to elicit similar responses. Depletion of PTEN using small interference RNAs reinstated Akt phosphorylation and conferred TRAIL resistance. In addition phosphatidylinositol 3-kinase inhibitors rendered the phospho-mutant GAL3-resistant cells sensitive to TRAIL. These findings suggest a pivotal role for P-GAL3 in promoting TRAIL sensitivity through activation of a nonclassic apoptotic pathway and identify P-GAL3 as a novel regulator of PTEN.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med & Nutr, Unit 436, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA; Wayne State Univ, Tumor Progress & Metastasis Program, Karmanos Canc Inst, Detroit, MI 48201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Barbara Ann Karmanos Cancer Institute; Wayne State University	Bresalier, RS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med & Nutr, Unit 436, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rbresali@mdanderson.org		Bresalier, Robert/0000-0002-9740-281X; Nangia-Makker, Pratima/0000-0002-1917-169X	NCI NIH HHS [CA69480, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069480, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; Agrawal S, 2006, HUM MOL GENET, V15, P777, DOI 10.1093/hmg/ddi492; Akahani S, 1997, CANCER RES, V57, P5272; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Choi JH, 2004, CANCER BIOL THER, V3, P447, DOI 10.4161/cbt.3.5.808; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davidson PJ, 2002, GLYCOBIOLOGY, V12, P329, DOI 10.1093/glycob/12.5.329; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Elad-Sfadia G, 2004, J BIOL CHEM, V279, P34922, DOI 10.1074/jbc.M312697200; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fukumori T, 2006, CANCER RES, V66, P3114, DOI 10.1158/0008-5472.CAN-05-3750; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Ho AT, 2004, EMBO J, V23, P460, DOI 10.1038/sj.emboj.7600039; Hsu DK, 2002, GLYCOCONJUGATE J, V19, P507, DOI 10.1023/B:GLYC.0000014080.95829.52; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; Kageshita T, 2002, INT J CANCER, V99, P809, DOI 10.1002/ijc.10436; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Lee YJ, 2003, EXP CELL RES, V288, P21, DOI 10.1016/S0014-4827(03)00211-8; Leffler H, 2002, GLYCOCONJUGATE J, V19, P433, DOI 10.1023/B:GLYC.0000014072.34840.04; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Mazurek N, 2000, J BIOL CHEM, V275, P36311, DOI 10.1074/jbc.M003831200; Mazurek N, 2005, CANCER RES, V65, P10767, DOI 10.1158/0008-5472.CAN-04-3333; Nakahara S, 2005, APOPTOSIS, V10, P267, DOI 10.1007/s10495-005-0801-y; Oka N, 2005, CANCER RES, V65, P7546, DOI 10.1158/0008-5472.CAN-05-1197; Paces-Fessy M, 2004, BIOCHEM J, V378, P353, DOI 10.1042/BJ20030786; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Shalom-Feuerstein R, 2005, CANCER RES, V65, P7292, DOI 10.1158/0008-5472.CAN-05-0775; Sharrard RM, 2000, BBA-GENE STRUCT EXPR, V1494, P282, DOI 10.1016/S0167-4781(00)00210-4; Shin MS, 2001, CANCER RES, V61, P4942; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Takenaka Y, 2004, MOL CELL BIOL, V24, P4395, DOI 10.1128/MCB.24.10.4395-4406.2004; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; Tang YF, 2006, CANCER RES, V66, P6139, DOI 10.1158/0008-5472.CAN-06-0772; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang WZ, 2006, NUCLEIC ACIDS RES, V34, P5166, DOI 10.1093/nar/gkl673; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	57	35	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21337	21348		10.1074/jbc.M608810200	http://dx.doi.org/10.1074/jbc.M608810200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17420249	hybrid			2022-12-27	WOS:000248047500062
J	Pozzi, A; Ibanez, MR; Gatica, AE; Yang, S; Wei, S; Mei, S; Falck, JR; Capdevila, JH				Pozzi, Ambra; Ibanez, Maria Raquel; Gatica, Arnaldo E.; Yang, Shilin; Wei, Shouzuo; Mei, Shaojun; Falck, John R.; Capdevila, Jorge H.			Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-1-NULL MICE; INTESTINAL POLYP FORMATION; GROWTH-FACTOR RECEPTOR; ANGIOGENESIS IN-VITRO; ARACHIDONIC-ACID; EPOXYEICOSATRIENOIC ACIDS; COLORECTAL-CANCER; PPAR-ALPHA; GENE-EXPRESSION; CARCINOMA-CELLS	The peroxisomal proliferator-activated nuclear receptor-alpha (PPAR alpha), the target for most hypolipidemic drugs in current clinical use, regulates the transcription of genes involved in lipid metabolism and transport, and energy homeostasis. More recently, PPAR alpha and its ligands have been implicated in inflammatory responses and the regulation of cell proliferation. PPAR alpha also regulates the expression of Cyp4a fatty acid omega-hydroxylases and Cyp2c arachidonic acid epoxygenase genes. To study the role of the PPAR alpha receptor and of its Cyp2c epoxygenase gene target in tumorigenesis, we treated mice injected with tumor cells with Wy-14,643, a PPAR alpha-selective ligand. Compared with untreated controls, Wy-14643-treated animals showed marked reductions in tumor growth and vascularization, which were accompanied by decreases in the plasma levels of pro-angiogenic epoxygenase metabolites (EETs), hepatic EET biosynthesis, and Cyp2c epoxygenase expression. All these Wy-14643-induced responses were absent in PPAR alpha(-/-) mice and are thus PPAR alpha-mediated. Primary cultures of mouse lung endothelial cells treated with Wy-14643 showed reductions in cell proliferation and in the formation of capillary-like structures. These effects were absent in cells obtained from PPRA alpha(-/-) mice and reversed by the addition of EETs. These results identify important anti- angiogenic and anti- tumorigenic roles for PPAR alpha, characterize the contribution of its Cyp2c epoxygenases gene target to these responses, and suggest potential anti-cancer roles for this nuclear receptor and its ligands.	Vanderbilt Univ, Sch Med, Dept Med, Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vet Affairs Hosp, Nashville, TN 37212 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Capdevila, JH (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Med Ctr, Med Ctr N S-3223, Nashville, TN 37232 USA.	jorge.capdevila@vanderbilt.edu	Falck, John R/B-3030-2011	Falck, John R/0000-0002-9219-7845; Ibanez, Maria Raquel/0000-0002-3371-2894	NATIONAL CANCER INSTITUTE [P30CA068485, R01CA094849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074359, P01DK038226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278, R01GM037922] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA94849, CA-68485] Funding Source: Medline; NIDDK NIH HHS [P01-DK38226, R01-DK74359] Funding Source: Medline; NIGMS NIH HHS [R01-GM37922, R01-GM31278] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARS RG, 1993, BIOCHEM PHARMACOL, V45, P2045, DOI 10.1016/0006-2952(93)90015-O; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Bouis D, 2006, PHARMACOL RES, V53, P89, DOI 10.1016/j.phrs.2005.10.006; Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673; Bruce WR, 2000, NUTR CANCER, V37, P19, DOI 10.1207/S15327914NC3701_2; Capdevila JH, 2000, J LIPID RES, V41, P163; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; Chen JK, 2002, P NATL ACAD SCI USA, V99, P6029, DOI 10.1073/pnas.092671899; Chen XW, 2005, CLIN EXP METASTAS, V22, P185, DOI 10.1007/s10585-005-7453-8; Chen XW, 2005, INT J CANCER, V116, P52, DOI 10.1002/ijc.20997; Corton JC, 1998, MOL PHARMACOL, V54, P463, DOI 10.1124/mol.54.3.463; Cowart LA, 2002, J BIOL CHEM, V277, P35105, DOI 10.1074/jbc.M201575200; DeLozier TC, 2004, J PHARMACOL EXP THER, V310, P845, DOI 10.1124/jpet.104.067819; Frank DB, 2005, CIRC RES, V97, P496, DOI 10.1161/01.RES.0000181152.65534.07; Fruchart JC, 2006, DRUGS TODAY, V42, P39, DOI 10.1358/dot.2006.42.1.963528; Gardner OS, 2003, J BIOL CHEM, V278, P46261, DOI 10.1074/jbc.M307827200; Gizard F, 2005, J CLIN INVEST, V115, P3228, DOI 10.1172/JCI22756; Goetze S, 2002, BIOCHEM BIOPH RES CO, V293, P1431, DOI 10.1016/S0006-291X(02)00385-6; Grabacka M, 2004, ARCH DERMATOL RES, V296, P54, DOI 10.1007/s00403-004-0479-y; Grabacka M, 2006, CLIN CANCER RES, V12, P3028, DOI 10.1158/1078-0432.CCR-05-2556; Jarvinen R, 2001, BRIT J CANCER, V85, P357, DOI 10.1054/bjoc.2001.1906; Jiang JG, 2005, CANCER RES, V65, P4707, DOI 10.1158/0008-5472.CAN-04-4173; Johnson EF, 2002, TOXICOLOGY, V181, P203, DOI 10.1016/S0300-483X(02)00282-2; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; Kersten S, 2002, EUR J PHARMACOL, V440, P223, DOI 10.1016/S0014-2999(02)01431-0; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lefebvre P, 2006, J CLIN INVEST, V116, P571, DOI 10.1172/JCI27989; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; Marx N, 2004, CIRC RES, V94, P1168, DOI 10.1161/01.RES.0000127122.22685.0A; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; Medhora M, 2003, AM J PHYSIOL-HEART C, V284, pH215, DOI 10.1152/ajpheart.01118.2001; Meissner M, 2004, CIRC RES, V94, P324, DOI 10.1161/01.RES.0000113781.08139.81; Michaelis UR, 2003, FASEB J, V17, P770, DOI 10.1096/fj.02-0640fje; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; Muller DN, 2004, AM J PATHOL, V164, P521, DOI 10.1016/S0002-9440(10)63142-2; Nelson David R, 2006, Methods Mol Biol, V320, P1; Niho N, 2005, P NATL ACAD SCI USA, V102, P2970, DOI 10.1073/pnas.0500153102; Niho N, 2003, CANCER RES, V63, P6090; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Otvos JD, 2006, CIRCULATION, V113, P1556, DOI 10.1161/CIRCULATIONAHA.105.565135; Pandya NM, 2006, VASC PHARMACOL, V44, P265, DOI 10.1016/j.vph.2006.01.005; Pauley CJ, 2002, CELL SIGNAL, V14, P351, DOI 10.1016/S0898-6568(01)00260-1; Peters JM, 2005, J MOL MED-JMM, V83, P774, DOI 10.1007/s00109-005-0678-9; Pighetti GM, 2001, ANTICANCER RES, V21, P825; Pozzi A, 2005, J BIOL CHEM, V280, P27138, DOI 10.1074/jbc.M501730200; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Spector AA, 2004, PROG LIPID RES, V43, P55, DOI 10.1016/S0163-7827(03)00049-3; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Tsao CC, 2001, J PHARMACOL EXP THER, V299, P39; Varet J, 2003, CELL MOL LIFE SCI, V60, P810, DOI 10.1007/s00018-003-2322-6; White IR, 2003, PROTEOMICS, V3, P505, DOI 10.1002/pmic.200390064; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yu ST, 2003, CURR MOL MED, V3, P561, DOI 10.2174/1566524033479537	60	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17685	17695		10.1074/jbc.M701429200	http://dx.doi.org/10.1074/jbc.M701429200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17405874	hybrid			2022-12-27	WOS:000247084500041
J	Rasbery, JM; Shan, H; LeClair, RJ; Norman, M; Matsuda, SPT; Bartel, B				Rasbery, Jeanne M.; Shan, Hui; LeClair, Renee J.; Norman, Michael; Matsuda, Seiichi P. T.; Bartel, Bonnie			Arabidopsis thaliana squalene epoxidase 1 is essential for root and seed development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SQUALENE EPOXIDASE; ENCODING LANOSTEROL SYNTHASE; SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; BRASSINOSTEROID BIOSYNTHESIS; MUTANTS DEFICIENT; GENE; EXPRESSION; CYCLIZATION	Squalene epoxidase converts squalene into oxidosqualene, the precursor of all known angiosperm cyclic triterpenoids, which include membrane sterols, brassinosteroid phytohormones, and non-steroidal triterpenoids. In this work, we have identified six putative Arabidopsis squalene epoxidase (SQE) enzymes and used heterologous expression in yeast to demonstrate that three of these enzymes, SQE1, SQE2, and SQE3, can epoxidize squalene. We isolated and characterized Arabidopsis sqe1 mutants and discovered severe developmental defects, including reduced root and hypocotyl elongation. Adult sqe1-3 and sqe1-4 plants have diminished stature and produce inviable seeds. The sqe1-3 mutant accumulates squalene, consistent with a block in the triterpenoid biosynthetic pathway. Therefore, SQE1 function is necessary for normal plant development, and the five SQE-like genes remaining in this mutant are not fully redundant with SQE1.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA	Rice University; Rice University	Bartel, B (corresponding author), Rice Univ, Dept Biochem & Cell Biol, 6100 Main St, Houston, TX 77005 USA.	bartel@rice.edu	Bartel, Bonnie/O-8119-2019; Bartel, Bonnie/D-3550-2011	Bartel, Bonnie/0000-0002-6367-346X; Bartel, Bonnie/0000-0002-6367-346X; LeClair, Renee/0000-0003-1895-2109	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008362] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM08362] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe I, 2007, BIOCHEM BIOPH RES CO, V352, P259, DOI 10.1016/j.bbrc.2006.11.014; AGETA H, 1990, J NAT PROD, V53, P325, DOI 10.1021/np50068a009; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARAI Y, 1989, TETRAHEDRON LETT, V30, P7209, DOI 10.1016/S0040-4039(01)93936-X; Asami T, 2005, VITAM HORM, V72, P479, DOI 10.1016/S0083-6729(05)72014-8; Ausubel F., 1999, CURRENT PROTOCOLS MO; Carland FM, 1999, PLANT CELL, V11, P2123, DOI 10.1105/tpc.11.11.2123; Carland FM, 2002, PLANT CELL, V14, P2045, DOI 10.1105/tpc.003939; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Corey EJ, 1996, BIOCHEM BIOPH RES CO, V219, P327, DOI 10.1006/bbrc.1996.0232; COREY EJ, 1994, P NATL ACAD SCI USA, V91, P2211, DOI 10.1073/pnas.91.6.2211; Cunillera N, 2000, PLANT MOL BIOL, V44, P747, DOI 10.1023/A:1026588708849; Cunillera N, 1997, J BIOL CHEM, V272, P15381, DOI 10.1074/jbc.272.24.15381; D'Auria JC, 2005, CURR OPIN PLANT BIOL, V8, P308, DOI 10.1016/j.pbi.2005.03.012; Diener AC, 2000, PLANT CELL, V12, P853, DOI 10.1105/tpc.12.6.853; Fazio GC, 2004, J AM CHEM SOC, V126, P5678, DOI 10.1021/ja0318784; Fujioka S, 1997, PLANT CELL, V9, P1951, DOI 10.1105/tpc.9.11.1951; GOLLUB EG, 1977, J BIOL CHEM, V252, P2846; Hadacek F, 2002, CRIT REV PLANT SCI, V21, P273, DOI 10.1080/0735-260291044269; Hart EA, 1999, J AM CHEM SOC, V121, P9887, DOI 10.1021/ja992589b; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; Jang JC, 2000, GENE DEV, V14, P1485; KARST F, 1977, MOL GEN GENET, V154, P269, DOI 10.1007/BF00571282; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Laden BP, 2000, ARCH BIOCHEM BIOPHYS, V374, P381, DOI 10.1006/abbi.1999.1629; LeClere S, 2001, PLANT MOL BIOL, V46, P695, DOI 10.1023/A:1011699722052; Lee HK, 2000, ARCH BIOCHEM BIOPHYS, V381, P43, DOI 10.1006/abbi.2000.1966; Martienssen RA, 1998, P NATL ACAD SCI USA, V95, P2021, DOI 10.1073/pnas.95.5.2021; NADEAU RG, 1969, METHOD ENZYMOL, V15, P346; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Noguchi T, 1999, PLANT PHYSIOL, V120, P833, DOI 10.1104/pp.120.3.833; PATTERSON GW, 1993, PHYTOCHEMISTRY, V33, P1381, DOI 10.1016/0031-9422(93)85095-9; Phillips DR, 2006, CURR OPIN PLANT BIOL, V9, P305, DOI 10.1016/j.pbi.2006.03.004; Pichersky E, 2002, CURR OPIN PLANT BIOL, V5, P237, DOI 10.1016/S1369-5266(02)00251-0; SAKAKIBARA J, 1995, J BIOL CHEM, V270, P17, DOI 10.1074/jbc.270.1.17; Schafer UA, 1999, PLANT MOL BIOL, V39, P721, DOI 10.1023/A:1006172120929; Schrick K, 2000, GENE DEV, V14, P1471; Schrick K, 2002, PLANT J, V31, P61, DOI 10.1046/j.1365-313X.2002.01333.x; Shan H, 2005, J AM CHEM SOC, V127, P18008, DOI 10.1021/ja055822g; Shiu SH, 2005, PLANT PHYSIOL, V139, P18, DOI 10.1104/pp.105.065110; Shiu SH, 2004, PLANT CELL, V16, P1220, DOI 10.1105/tpc.020834; Souter M, 2002, PLANT CELL, V14, P1017, DOI 10.1105/tpc.001248; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; Suzuki H, 2002, PLANT J, V32, P1033, DOI 10.1046/j.1365-313X.2002.01497.x; Suzuki M, 2004, PLANT J, V37, P750, DOI 10.1111/j.1365-313X.2004.02003.x; SWAIN T, 1977, ANNU REV PLANT PHYS, V28, P479, DOI 10.1146/annurev.pp.28.060177.002403; Swofford DL., 2001, PAUP PHYLOGENETIC AN; Topping JF, 1997, DEVELOPMENT, V124, P4415; Xu R, 2004, PHYTOCHEMISTRY, V65, P261, DOI 10.1016/j.phytochem.2003.11.014; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	53	69	90	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17002	17013		10.1074/jbc.M611831200	http://dx.doi.org/10.1074/jbc.M611831200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17426032	hybrid			2022-12-27	WOS:000246946500033
J	Ichimura, S; Uchida, T; Taniguchi, S; Hira, S; Tosha, T; Morishima, I; Kitagawa, T; Ishimori, K				Ichimura, Shizuo; Uchida, Takeshi; Taniguchi, Shuhei; Hira, Shusuke; Tosha, Takehiko; Morishima, Isao; Kitagawa, Teizo; Ishimori, Koichiro			Unique peroxidase reaction mechanism in prostaglandin endoperoxide H synthase-2 - Compound I in prostaglandin endoperoxide H synthase-2 can be formed without assistance by distal glutamine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE-H SYNTHASE-1; RESONANCE RAMAN-SPECTRA; HORSERADISH-PEROXIDASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; SELECTIVE-INHIBITION; HYDROGEN-PEROXIDE; HEME; CYCLOOXYGENASE-2; CO	Prostaglandin-endoperoxide H synthase-2 (PGHS-2) shows peroxidase activity to promote the cyclooxygenase reaction for prostaglandin H-2, but one of the highly conserved amino acid residues in peroxidases, distal Arg, stabilizing the developing negative charge on the peroxide through a hydrogen-bonding interaction, is replaced with a neutral amino acid residue, Gln. To characterize the peroxidase reaction in PGHS-2, we prepared three distal glutamine ( Gln-189) mutants, Arg ( Gln -> Arg), Asn ( Gln3Asn), and Val ( Gln -> Val) mutants, and examined their peroxidase activity together with their structural characterization by absorption and resonance Raman spectra. Although a previous study (Landino, L. M., Crews, B. C., Gierse, J. K., Hauser, S. D., and Marnett, L. ( 1997) J. Biol. Chem. 272, 21565-21574) suggested that the Gln residue might serve as a functionally equivalent residue to Arg, our current results clearly showed that the peroxidase activity of the Val and Asn mutants was comparable with that of the wild-type enzyme. In addition, the Fe-C and C-O stretching modes in the CO adduct were almost unperturbed by the mutation, implying that Gln-189 might not directly interact with the heme-ligated peroxide. Rather, the peroxidase activity of the Arg mutant was depressed, concomitant with the heme environmental change from a six-coordinate to a five-coordinate structure. Introduction of the bulky amino acid residue, Arg, would interfere with the ligation of a water molecule to the heme iron, suggesting that the side chain volume, and not the amide group, at position 189 is essential for the peroxidase activity of PGHS-2. Thus, we can conclude that the O-O bond cleavage in PGHS-2 is promoted without interactions with charged side chains at the peroxide binding site, which is significantly different from that in typical plant peroxidases.	Hokkaido Univ, Fac Sci, Div Chem, Hokkaido 0600810, Japan; Hokkaido Univ, Grad Sch Sci, Div Chem, Hokkaido 0600810, Japan; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan; Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Inst Mol Sci, Okazaki, Aichi 4448585, Japan	Hokkaido University; Hokkaido University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS)	Ishimori, K (corresponding author), Hokkaido Univ, Fac Sci, Div Chem, Hokkaido 0600810, Japan.	koichiro@sci.hokudai.ac.jp	Ishimori, Koichiro/S-1247-2016; Tosha, Takehiko/AAR-2404-2020; Ishimori, Koichiro/AAQ-4434-2021; Uchida, Takeshi/A-6455-2017	Ishimori, Koichiro/0000-0002-5868-0462; Tosha, Takehiko/0000-0002-8971-0759; Ishimori, Koichiro/0000-0002-5868-0462; Uchida, Takeshi/0000-0001-9270-8329				Anderton CL, 1997, BBA-PROTEIN STRUCT M, V1338, P107, DOI 10.1016/S0167-4838(96)00194-X; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BEAVEN GH, 1974, EUR J BIOCHEM, V41, P539, DOI 10.1111/j.1432-1033.1974.tb03295.x; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; Brittain T, 1997, BIOCHEM J, V326, P109, DOI 10.1042/bj3260109; Chubb AJ, 2006, BIOCHEMISTRY-US, V45, P811, DOI 10.1021/bi051973k; Crofford LJ, 2000, ARTHRITIS RHEUM-US, V43, P4, DOI 10.1002/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; Feis A, 1998, BIOCHEMISTRY-US, V37, P13575, DOI 10.1021/bi981399v; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; GLENN JK, 1985, ARCH BIOCHEM BIOPHYS, V242, P329, DOI 10.1016/0003-9861(85)90217-6; Goodwin DC, 2000, BIOCHEMISTRY-US, V39, P5422, DOI 10.1021/bi992752f; GOODWIN DC, 1995, ANAL BIOCHEM, V231, P333, DOI 10.1006/abio.1995.0059; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Hiner ANP, 2002, J INORG BIOCHEM, V91, P27, DOI 10.1016/S0162-0134(02)00390-2; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Kabeya LM, 2007, BIOORGAN MED CHEM, V15, P1516, DOI 10.1016/j.bmc.2006.10.068; Kitagawa T, 1978, Adv Biophys, V11, P153; Koshkin V, 1999, BBA-PROTEIN STRUCT M, V1430, P341, DOI 10.1016/S0167-4838(99)00016-3; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Landino LM, 1997, J BIOL CHEM, V272, P21565, DOI 10.1074/jbc.272.34.21565; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Lou BS, 2000, BIOCHEMISTRY-US, V39, P12424, DOI 10.1021/bi001257c; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; Nagano S, 2004, J BIOL CHEM, V279, P14673, DOI 10.1074/jbc.M313003200; Nielsen KL, 2001, BIOCHEMISTRY-US, V40, P11013, DOI 10.1021/bi010661o; Ohta T, 2005, J PHYS CHEM B, V109, P21110, DOI 10.1021/jp052158h; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pal B, 2004, J INORG BIOCHEM, V98, P824, DOI 10.1016/j.jinorgbio.2003.12.007; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PLE P, 1989, J BIOL CHEM, V264, P13983; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P575; Rodriguez-Lopez JN, 2001, J AM CHEM SOC, V123, P11838, DOI 10.1021/ja011853+; RodriguezLopez JN, 1996, J BIOL INORG CHEM, V1, P136, DOI 10.1007/s007750050032; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; Seibold SA, 2000, BIOCHEMISTRY-US, V39, P6616, DOI 10.1021/bi0002333; Shintaku M, 2005, J BIOL CHEM, V280, P40934, DOI 10.1074/jbc.M503472200; SINCLAIR R, 1995, BIOCHEMISTRY-US, V34, P13176, DOI 10.1021/bi00040a032; Smith T, 2000, ARCH BIOCHEM BIOPHYS, V375, P195, DOI 10.1006/abbi.1999.1659; Smith WL, 2002, PROSTAG OTH LIPID M, V68-9, P115, DOI 10.1016/S0090-6980(02)00025-4; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Smulevich G, 1998, BIOSPECTROSCOPY, V4, pS3, DOI 10.1002/(SICI)1520-6343(1998)4:5+<S3::AID-BSPY2>3.0.CO;2-R; Spiro TG, 2005, J INORG BIOCHEM, V99, P34, DOI 10.1016/j.jinorgbio.2004.09.026; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; TANIGUCHI S, 2004, STUDY PEROXIDASE REA, V2; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Tosha T, 2006, J BIOL CHEM, V281, P12610, DOI 10.1074/jbc.M600061200; TSAI AL, 1993, J BIOL CHEM, V268, P8554; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1132, DOI 10.1021/bi00535a004; UNO T, 1987, J BIOL CHEM, V262, P4549; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; Zhang Y, 1997, J PHARMACOL EXP THER, V283, P1069	63	4	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16681	16690		10.1074/jbc.M610785200	http://dx.doi.org/10.1074/jbc.M610785200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403665	hybrid			2022-12-27	WOS:000246794300073
J	Ito, I; Fukazawa, J; Yoshida, M				Ito, Ichiaki; Fukazawa, Jutarou; Yoshida, Michiteru			Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONHISTONE CHROMOSOMAL-PROTEINS; MOBILITY GROUP PROTEINS; DNA-BINDING PROTEINS; ANTIBODIES P-ANCA; NUCLEAR-LOCALIZATION; MONOCLONAL-ANTIBODY; CELLS; CHROMATIN; HMG-1; MONOCYTES	High mobility group box 1 (HMGB1) protein plays multiple roles in transcription, replication, and cellular differentiation. HMGB1 is also secreted by activated monocytes and macrophages and passively released by necrotic or damaged cells, stimulating inflammation. HMGB1 is a novel antigen of antineutrophil cytoplasmic antibodies (ANCA) observed in the sera of patients with ulcerative colitis and autoimmune hepatitis, suggesting that HMGB1 is secreted from neutrophils to the extracellular milieu. However, the actual distribution of HMGB1 in the cytoplasm of neutrophils and the mechanisms responsible for it are obscure. Here we show that HMGB1 in neutrophils is post- translationally mono-methylated at Lys42. The methylation alters the conformation of HMGB1 and weakens its DNA binding activity, causing it to become largely distributed in the cytoplasm by passive diffusion out of the nucleus. Thus, post- translational methylation ofHMGB1causes its cytoplasmic localization in neutrophils. This novel pathway explains the distribution of nuclear HMGB1 to the cytoplasm and is important for understanding how neutrophils release HMGB1 to the extracellular milieu.	Tokyo Univ Sci, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan	Tokyo University of Science	Yoshida, M (corresponding author), Tokyo Univ Sci, Dept Biol Sci & Technol, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	myoshida@rs.noda.tus.ac.jp	Fukazawa, Jutarou/AAX-7979-2021					ADACHI Y, 1990, J CHROMATOGR-BIOMED, V530, P39, DOI 10.1016/S0378-4347(00)82300-2; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Bianchi ME, 2004, BBA-GENE STRUCT EXPR, V1677, P181, DOI 10.1016/j.bbaexp.2003.10.017; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CABART P, 1995, CELL BIOCHEM FUNCT, V13, P125, DOI 10.1002/cbf.290130209; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Falciola L, 1997, J CELL BIOL, V137, P19, DOI 10.1083/jcb.137.1.19; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GAJLPECZALSKA KJ, 1975, AM J MED, V59, P674, DOI 10.1016/0002-9343(75)90228-4; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Ito I, 2004, J BIOCHEM, V136, P155, DOI 10.1093/jb/mvh107; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; MAEDA Y, 1992, EMBO J, V11, P3695, DOI 10.1002/j.1460-2075.1992.tb05454.x; MOSEVITSKY MI, 1989, EUR J BIOCHEM, V185, P303, DOI 10.1111/j.1432-1033.1989.tb15116.x; Passalacqua M, 1997, FEBS LETT, V400, P275, DOI 10.1016/S0014-5793(96)01402-0; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Rendon-Mitchell B, 2003, J IMMUNOL, V170, P3890, DOI 10.4049/jimmunol.170.7.3890; Saito K, 1999, PROTEIN ENG, V12, P235, DOI 10.1093/protein/12.3.235; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Shirakawa H, 1997, BIOCHEMISTRY-US, V36, P5992, DOI 10.1021/bi962487n; Sobajima J, 1999, GUT, V44, P867, DOI 10.1136/gut.44.6.867; Sobajima J, 1998, CLIN EXP IMMUNOL, V111, P402; Sobajima J, 1997, CLIN EXP IMMUNOL, V107, P135, DOI 10.1046/j.1365-2249.1997.d01-907.x; STERNER R, 1979, J BIOL CHEM, V254, P1577; STERNER R, 1978, J BIOL CHEM, V253, P7601; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; TSUNEOKA M, 1986, J BIOL CHEM, V261, P1829; Uesugi H, 1998, J RHEUMATOL, V25, P703; Ugrinova I, 2001, BIOCHEMISTRY-US, V40, P14655, DOI 10.1021/bi0113364; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; Wisniewski JR, 1999, J BIOL CHEM, V274, P20116; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	42	159	172	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16336	16344		10.1074/jbc.M608467200	http://dx.doi.org/10.1074/jbc.M608467200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403684	hybrid			2022-12-27	WOS:000246794300041
J	Kinugasa, Y; Hieda, M; Hori, M; Higashiyama, S				Kinugasa, Yumi; Hieda, Miki; Hori, Masatsugu; Higashiyama, Shigeki			The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR ACTIVITY; FINGER ENCODING GENE; CENTER B-CELLS; KERATINOCYTE MIGRATION; HYPERTROPHIC GROWTH; EPITHELIAL-CELLS; IN-VIVO; BCL-6; EXPRESSION	Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the EGF family, is synthesized as a type I transmembrane precursor (pro-HB-EGF). Ectodomain shedding of pro-HB-EGF yields an amino-terminal soluble ligand of EGF receptor (HB-EGF) and a carboxyl-terminal fragment (HB-EGF-CTF) consisting of the transmembrane and cytoplasmic domains. We previously showed that the HB-EGF-CTF translocates from the plasma membrane to the nucleus and plays a role as a signaling molecule. Immunoprecipitation showed that HB-EGF-CTF can associate with Bcl6, a transcriptional repressor in mammalian cells. A glutathione S-transferase pulldown assay revealed that HB-EGF-CTF interacted efficiently with zinc fingers 4-6 of Bcl6. A luciferase reporter assay showed that the nuclear translocation of HB-EGF-CTF following shedding reversed transcriptional repression of cyclin D2 by Bcl6. Additionally, the level of cyclin D2 protein increased and Bcl6 interaction with the cyclin D2 promoter decreased in parallel with the shedding of pro-HB-EGF at all endogenous levels. These findings suggest that HB-EGF-CTF is a potent regulator of gene expression via its interaction with the transcriptional repressor Bcl6.	Ehime Univ, Dept Biochem & Mol Genet, Grad Sch Med, Toon, Ehime 7910295, Japan; Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Div Internal Med, Osaka 5650871, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan	Ehime University; Osaka University; Japan Science & Technology Agency (JST)	Higashiyama, S (corresponding author), Ehime Univ, Dept Biochem & Mol Genet, Grad Sch Med, Toon, Ehime 7910295, Japan.	shigeki@m.ehime-u.ac.jp	Matsumura, Miki/AAD-1823-2021	Hieda, Miki/0000-0002-9492-7506				Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Busk PK, 2002, CARDIOVASC RES, V56, P64, DOI 10.1016/S0008-6363(02)00510-2; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chen JK, 2002, P NATL ACAD SCI USA, V99, P6029, DOI 10.1073/pnas.092671899; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Cussac D, 2002, J BIOL CHEM, V277, P19882, DOI 10.1074/jbc.M110142200; Dent AL, 2002, CRIT REV ONCOL HEMAT, V41, P1, DOI 10.1016/S1040-8428(01)00164-0; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Huynh KD, 2000, GENE DEV, V14, P1810; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li JM, 1998, AM J PHYSIOL-HEART C, V275, pH814, DOI 10.1152/ajpheart.1998.275.3.H814; MIKI T, 1994, BLOOD, V83, P26; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shirakata Y, 2005, J CELL SCI, V118, P2363, DOI 10.1242/jcs.02346; Solvason N, 1996, J EXP MED, V184, P407, DOI 10.1084/jem.184.2.407; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhong WG, 2006, EMBO J, V25, P3869, DOI 10.1038/sj.emboj.7601252	43	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14797	14806		10.1074/jbc.M611036200	http://dx.doi.org/10.1074/jbc.M611036200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17392284	hybrid			2022-12-27	WOS:000246589000015
J	Liu, C; Fei, EK; Jia, NL; Wang, HF; Tao, RS; Iwata, A; Nukina, N; Zhou, JN; Wang, GH				Liu, Chao; Fei, Erkang; Jia, Nali; Wang, Hongfeng; Tao, Ruisong; Iwata, Atsushi; Nukina, Nobuyuki; Zhou, Jiangning; Wang, Guanghui			Assembly of lysine 63-linked ubiquitin conjugates by phosphorylated alpha- synuclein implies Lewy body biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; INCLUSION FORMATION; POLYUBIQUITIN CHAINS; ALZHEIMERS-DISEASE; PROTEIN; BODIES; SYNPHILIN-1; MUTATION; MODEL; NEURODEGENERATION	alpha-Synuclein (alpha-syn) and ubiquitin (Ub) are major protein components deposited in Lewy bodies (LBs) and Lewy neurites, which are pathologic hallmarks of idiopathic Parkinson disease (PD). Almost 90% of alpha-syn in LBs is phosphorylated at serine 129 (Ser(129)). However, the role of Ser(129)-phosphorylated alpha-syn in the biogenesis of LBs remains unclear. Here, we show that compared with coexpression of wild type(WT) alpha-syn and Ub, coexpression of phospho-mimic mutant alpha-syn (S129D) and Ub in neuro2a cells results in an increase of Ub-conjugates and the formation of ubiquitinated inclusions. Furthermore, S129D alpha-syn fails to increase the Ub-conjugates and form ubiquitinated inclusions in the presence of a K63R mutant Ub. In addition, as compared with WT alpha-syn, S129D alpha-syn increased cytoplasmic and neuritic aggregates of itself in neuro2a cells treated with H2O2 and serum deprivation. These results suggest that the contribution of Ser(129)-phosphorylated alpha-syn to the Lys(63)-linked Ub-conjugates and aggregation of itself may be involved in the biogenesis of LBs in Parkinson disease and other related synucleinopathies.	Univ Sci & Technol China, Sch Life Sci, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Dept Neurobiol, Hefei 230027, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wang, GH (corresponding author), Univ Sci & Technol China, Sch Life Sci, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	wghui@ustc.edu.cn	Zhou, JiangNing/N-3374-2013; liu, chao/G-3544-2011; Wang, Guanghui/U-3979-2017; Nukina, Nobuyuki/GPP-6265-2022; Iwata, Atsushi/AAH-8924-2019; Iwata, Atsushi/A-9598-2013; FEI, Erkang/AAI-9825-2021	Wang, Guanghui/0000-0001-8551-6468; Iwata, Atsushi/0000-0001-7308-5314; Iwata, Atsushi/0000-0001-7308-5314; FEI, Erkang/0000-0002-3581-9521				Amerik AY, 1997, EMBO J, V16, P4826; Anderson JP, 2006, J BIOL CHEM, V281, P29739, DOI 10.1074/jbc.M600933200; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Chen L, 2005, NAT NEUROSCI, V8, P657, DOI 10.1038/nn1443; Chen QH, 2005, J BIOL CHEM, V280, P30009, DOI 10.1074/jbc.M501308200; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Doss-Pepe EW, 2005, J BIOL CHEM, V280, P16619, DOI 10.1074/jbc.M413591200; Eriksen JL, 2003, NEURON, V40, P453, DOI 10.1016/S0896-6273(03)00684-6; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gasser T, 2001, J NEUROL, V248, P833, DOI 10.1007/s004150170066; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Gomez-Tortosa E, 2000, ACTA NEUROPATHOL, V99, P352, DOI 10.1007/s004010051135; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Jellinger KA, 2003, MOVEMENT DISORD, V18, pS2, DOI 10.1002/mds.10557; Kirik D, 2003, P NATL ACAD SCI USA, V100, P2884, DOI 10.1073/pnas.0536383100; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Layfield R, 2003, AGEING RES REV, V2, P343, DOI 10.1016/S1568-1637(03)00025-4; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; Martin LJ, 2006, J NEUROSCI, V26, P41, DOI 10.1523/JNEUROSCI.4308-05.2006; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; Nonaka T, 2005, BIOCHEMISTRY-US, V44, P361, DOI 10.1021/bi0485528; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Olanow CW, 2004, LANCET NEUROL, V3, P496, DOI 10.1016/S1474-4422(04)00827-0; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Rideout HJ, 2002, MOL CELL NEUROSCI, V21, P223, DOI 10.1006/mcne.2002.1173; Sakamoto M, 2002, EXP NEUROL, V177, P88, DOI 10.1006/exnr.2002.7961; Sato S, 2006, EMBO J, V25, P211, DOI 10.1038/sj.emboj.7600774; Shults CW, 2006, P NATL ACAD SCI USA, V103, P1661, DOI 10.1073/pnas.0509567103; Smith WW, 2005, J NEUROSCI, V25, P5544, DOI 10.1523/JNEUROSCI.0482-05.2005; Snyder H, 2004, J MOL NEUROSCI, V24, P425, DOI 10.1385/JMN:24:3:425; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Takahashi M, 2003, NEUROSCI LETT, V336, P155, DOI 10.1016/S0304-3940(02)01258-2; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; von Coelln R, 2006, J NEUROSCI, V26, P3685, DOI 10.1523/JNEUROSCI.0414-06.2006; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; Wakabayashi K, 1999, NEUROPATH APPL NEURO, V25, P363; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yamada M, 2004, J NEUROCHEM, V91, P451, DOI 10.1111/j.1471-4159.2004.02728.x; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhang W, 2005, FASEB J, V19, P533, DOI 10.1096/fj.04-2751com	53	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14558	14566		10.1074/jbc.M700422200	http://dx.doi.org/10.1074/jbc.M700422200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360705	hybrid			2022-12-27	WOS:000246245800069
J	Liu, HY; Collins, QF; Xiong, Y; Moukdar, F; Lupo, EG; Liu, ZQ; Cao, WH				Liu, Hui-Yu; Collins, Qu Fan; Xiong, Yan; Moukdar, Fatiha; Lupo, Edgar G., Jr.; Liu, Zhenqi; Cao, Wenhong			Prolonged treatment of primary Hepatocytes with oleate induces insulin resistance through p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACIDS; HEPATIC GLUCOSE-PRODUCTION; SKELETAL-MUSCLE; RECEPTOR SUBSTRATE-1; INDUCED INHIBITION; POTENTIAL ROLE; IKK-BETA; MECHANISMS; OBESITY; GLUCONEOGENESIS	Free fatty acid (FFA) is believed to be a major environmental factor linking obesity to Type II diabetes. We have recently reported that FFA can induce gluconeogenesis in hepatocytes through p38 mitogen-activated protein kinase (p38). In this study, we have investigated the role of p38 in oleate-induced hepatic insulin resistance. Our results show that a prolonged treatment of primary hepatocytes with oleate blunted insulin suppression of hepatic gluconeogenesis, and decreased insulin-induced phosphorylation of Akt in a p38-dependent manner. Reduction of the insulin-induced Akt phosphorylation by oleate correlated with activation of p38. In the presence of p38 inhibition, prolonged exposure of hepatocytes to oleate failed to reduce insulin-stimulated phosphorylation of Akt. An siRNA against p38 alpha prevented oleate suppression of the insulin-induced phosphorylation of Akt. Furthermore, a prolonged exposure of hepatocytes to oleate decreased insulin-induced tyrosine phosphorylation of IRS1/2, while slightly increasing serine phosphorylation of IRS. The decrease of insulin-stimulated tyrosine phosphorylation of IRS1/2 in hepatocytes by oleate was reversed by the inhibition of p38. We further show that a prolonged exposure of primary hepatocytes to oleate elevated the protein level of the phosphatase and tensin homolog deleted on chromosome 10 ( PTEN) gene in a p38-dependent manner, but had no effect on the mRNA level of PTEN. Knocking down the PTEN gene prevented oleate to inhibit insulin activation of Akt and insulin suppression of gluconeogenesis. Together, results from this study demonstrate a critical role for p38 in oleate-induced hepatic insulin resistance.	Hammer Inst Hlth Sci, Endocrine Biol Program, Res Triangle Pk, NC 27709 USA; Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha 410078, Hunan, Peoples R China; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Endocrinol, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Med, Div Endocrinol, Durham, NC 27708 USA	The Hamner Institutes for Health Sciences; Central South University; University of Virginia; Duke University	Cao, WH (corresponding author), Hammer Inst Hlth Sci, Endocrine Biol Program, 6 Davis Dr,POB 12137, Res Triangle Pk, NC 27709 USA.	wcao@thehamner.org						Accili D, 2004, DIABETES, V53, P1633, DOI 10.2337/diabetes.53.7.1633; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Baldeweg SE, 2000, EUR J CLIN INVEST, V30, P45; BEVILACQUA S, 1987, METABOLISM, V36, P502, DOI 10.1016/0026-0495(87)90051-5; Bloch-Damti A, 2005, ANTIOXID REDOX SIGN, V7, P1553, DOI 10.1089/ars.2005.7.1553; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Boden G, 2005, DIABETES, V54, P3458, DOI 10.2337/diabetes.54.12.3458; Boden G, 2003, LIFE SCI, V72, P977, DOI 10.1016/S0024-3205(02)02350-0; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boden Guenther, 2006, Curr Diab Rep, V6, P177, DOI 10.1007/s11892-006-0031-x; Bolinder J, 2000, DIABETES, V49, P797, DOI 10.2337/diabetes.49.5.797; Bouzakri K, 2003, DIABETES, V52, P1319, DOI 10.2337/diabetes.52.6.1319; Brownlee M, 2000, METABOLISM, V49, P9, DOI 10.1016/S0026-0495(00)80078-5; Bysted A, 2005, EUR J CLIN NUTR, V59, P24, DOI 10.1038/sj.ejcn.1602028; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Chen S, 2006, BIOCHEM BIOPH RES CO, V346, P931, DOI 10.1016/j.bbrc.2006.05.190; Cohen P, 2006, NAT REV MOL CELL BIO, V7, P867, DOI 10.1038/nrm2043; Collins QF, 2006, J BIOL CHEM, V281, P24336, DOI 10.1074/jbc.M602177200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; De Almeida IT, 2002, CLIN NUTR, V21, P219, DOI 10.1054/clnu.2001.0529; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Fujishiro M, 2003, MOL ENDOCRINOL, V17, P487, DOI 10.1210/me.2002-0131; GAMBLE W, 1978, J LIPID RES, V19, P1068; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Gutierrez-Juarez R, 2006, J CLIN INVEST, V116, P1686, DOI 10.1172/JCI26991; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hirsch IB, 2005, J DIABETES COMPLICAT, V19, P178, DOI 10.1016/j.jdiacomp.2004.10.001; Ju HS, 2003, J PHARMACOL EXP THER, V307, P932, DOI 10.1124/jpet.103.057422; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Koistinen HA, 2003, DIABETOLOGIA, V46, P1324, DOI 10.1007/s00125-003-1196-3; Lam TKT, 2003, AM J PHYSIOL-ENDOC M, V284, pE863, DOI 10.1152/ajpendo.00033.2003; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lewis GF, 1997, DIABETES, V46, P1111, DOI 10.2337/diabetes.46.7.1111; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Liu HY, 2005, J BIOL CHEM, V280, P19461, DOI 10.1074/jbc.M500313200; Liu HY, 2002, J BIOL CHEM, V277, P26046, DOI 10.1074/jbc.M111659200; Muoio DM, 2006, ANNU REV BIOCHEM, V75, P367, DOI 10.1146/annurev.biochem.75.103004.142512; Qiao LP, 2006, J BIOL CHEM, V281, P24390, DOI 10.1074/jbc.M603038200; Rebrin K, 1996, J CLIN INVEST, V98, P741, DOI 10.1172/JCI118846; Shen YH, 2006, J BIOL CHEM, V281, P7727, DOI 10.1074/jbc.M511105200; Sindelar DK, 1997, DIABETES, V46, P187, DOI 10.2337/diabetes.46.2.187; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang XL, 2006, DIABETES, V55, P2301, DOI 10.2337/db05-1574; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wiesenthal SR, 1999, DIABETES, V48, P766, DOI 10.2337/diabetes.48.4.766; Xiong Y, 2007, J BIOL CHEM, V282, P4975, DOI 10.1074/jbc.M606742200; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhou H, 2005, BIOCHEM BIOPH RES CO, V338, P793, DOI 10.1016/j.bbrc.2005.10.007	54	59	70	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14205	14212		10.1074/jbc.M609701200	http://dx.doi.org/10.1074/jbc.M609701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17384440	hybrid			2022-12-27	WOS:000246245800031
J	Sinha-Datta, U; Datta, A; Ghorbel, S; Dodon, MD; Nicot, C				Sinha-Datta, Uma; Datta, Abhik; Ghorbel, Sofiane; Dodon, Madeleine Duc; Nicot, Christophe			Human T-cell lymphotrophic virus type I Rex and p30 interactions govern the switch between virus latency and replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-VIRUS; BINDING-PROTEIN; TAX; HTLV; RNA; ONCOPROTEIN; EXPRESSION; REGULATOR; COMPLEX; CREB	Human T-cell lymphotrophic virus type I Rex and p30 are both RNA binding regulatory proteins. Rex is a protein that interacts with a responsive element and stimulates nuclear export of incompletely spliced viral RNAs thereby increasing production of virus particles. In contrast, p30 is involved in the nuclear retention of the tax/rex mRNA leading to inhibition of virus expression and possible establishment of viral latency. How these two proteins, with apparent opposite functions, integrate in the viral replication cycle is unknown. Here, we demonstrate that Rex and p30 form ribonucleoprotein ternary complexes onto specific viral mRNA. Our results explain the selective nuclear retention of tax/rex but not other viral mRNAs by p30. Whereas p30 suppresses Rex expression, it did not affect Rex-mediated nuclear export of RNA containing the Rex response element. In contrast, Rex was able to counteract p30-mediated suppression of viral expression and restore cytoplasmic tax/rex mRNA and Tax protein expression. Together, our data demonstrate a complex regulatory mechanism of antagonizing post-transcriptional regulators evolved by human T-cell lymphotrophic virus type I to allow a vigilant control of viral gene expression.	Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, Kansas City, KS 66160 USA; Ecole Normale Super Lyon, INSERM, U758, F-69364 Lyon 07, France	University of Kansas; University of Kansas Medical Center; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Nicot, C (corresponding author), Univ Kansas, Med Ctr, Dept Microbiol Mol Genet & Immunol, 3025 Wahl Hall W,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	cnicot@kumc.edu	Duc-Dodon, Madeleine/I-6580-2016	Datta, Abhik/0000-0002-3442-5774; Ghorbel, Sofiane/0000-0001-8793-4882	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058944] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI058944, AI058944] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bellon M, 2006, INT J CANCER, V119, P2090, DOI 10.1002/ijc.22026; Datta A, 2006, BLOOD, V108, P1021, DOI 10.1182/blood-2006-01-0067; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GESSAIN A, 1985, LANCET, V2, P407; Ghorbel S, 2006, J BIOL CHEM, V281, P37150, DOI 10.1074/jbc.M603981200; Hakata Y, 1998, J VIROL, V72, P6602, DOI 10.1128/JVI.72.8.6602-6607.1998; Hamaia S, 1997, J VIROL, V71, P8514, DOI 10.1128/JVI.71.11.8514-8521.1997; HAMMES SR, 1993, VIROLOGY, V193, P41, DOI 10.1006/viro.1993.1101; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemoine FJ, 2002, ONCOGENE, V21, P7230, DOI 10.1038/sj.onc.1205898; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004; Zhang WQ, 2000, J VIROL, V74, P11270, DOI 10.1128/JVI.74.23.11270-11277.2000; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	31	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14608	14615		10.1074/jbc.M611219200	http://dx.doi.org/10.1074/jbc.M611219200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360706	hybrid			2022-12-27	WOS:000246245800074
J	Chernyavsky, AI; Arredondo, J; Kitajima, Y; Sato-Nagai, M; Grando, SA				Chernyavsky, Alex I.; Arredondo, Juan; Kitajima, Yasuo; Sato-Nagai, Miki; Grando, Sergei A.			Desmoglein versus non-desmoglein signaling in pemphigus acantholysis - Characterization of novel signaling pathways downstream of pemphigus vulgaris antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; NECROSIS-FACTOR-ALPHA; BASAL-CELL SHRINKAGE; HUMAN KERATINOCYTES; CULTURED KERATINOCYTES; CHOLINERGIC CONTROL; EPITHELIAL-CELLS; FAS-LIGAND; IGG; PHOSPHORYLATION	Although it is accepted that pemphigus antibody binding to keratinocytes (KCs) evokes an array of intracellular biochemical events resulting in cell detachment and death, the triggering events remain obscure. It has been postulated that the binding of pemphigus vulgaris IgG (PVIgG) to KCs induces "desmosomal" signaling. Because in contrast to integrins and classical cadherins, desmoglein (Dsg) molecules are not known to elicit intracellular signaling, and because PV patients also produce non-Dsg autoantibodies, we investigated the roles of both Dsg and non-desmoglein PV antigens. The time course studies of KCs treated with PVIgG demonstrated that the activity of Src peaked at 30 min, EGF receptor kinase (EGFRK) at 60 min, and p38MAPK at 240 min. The Src inhibitor PP2 decreased EGFRK and p38 activities by similar to 45 and 30%, respectively, indicating that in addition to Src, PVIgG evokes other triggering events. The shrinkage of KCs (cell volume reduction) became significant at 120 min, keratin aggregation at 240 min, and an increase of TUNEL positivity at 360 min. Pretreatment of KCs with PP2 blocked PVIgG-dependent cell shrinkage and keratin aggregation by similar to 50% and TUNEL positivity by similar to 25%. The p38 MAPK inhibitor PD169316 inhibited these effects by similar to 15, 20, and 70%, respectively. Transfection of KCs with small interfering RNAs that silenced expression of Dsg1 and/or Dsg3 proteins, blocked similar to 50% of p38 MAPK activity but did not significantly alter the PVIgG-dependent rise in Src and EGFRK activities. These results indicate that activation of p38 MAPK is a late signaling step associated with collapse of the cytoskeleton and disassembly of desmosomes caused by upstream events involving Src and EGFRK. Therefore, the early acantholytic events are triggered by non-Dsg antibodies.	Univ Calif Davis, Ctr Med, Dept Dermatol, Sacramento, CA 95816 USA; Gifu Univ, Sch Med, Gifu, Japan	University of California System; University of California Davis; Gifu University	Grando, SA (corresponding author), Univ Calif Davis, Ctr Med, Dept Dermatol, 3301 C St,Suite 1400, Sacramento, CA 95816 USA.	sagrando@ucdavis.edu						Amagai M, 2006, EXP DERMATOL, V15, P815, DOI 10.1111/j.1600-0625.2006.00499.x; Aoyama Y, 1999, EUR J IMMUNOL, V29, P2233, DOI 10.1002/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4; Aoyama Y, 1999, J INVEST DERMATOL, V112, P67, DOI 10.1046/j.1523-1747.1999.00463.x; Arredondo J, 2005, AM J PATHOL, V167, P1531, DOI 10.1016/S0002-9440(10)61239-4; BARLOW Y, 1991, J ORAL PATHOL MED, V20, P241, DOI 10.1111/j.1600-0714.1991.tb00427.x; Berkowitz P, 2005, J BIOL CHEM, V280, P23778, DOI 10.1074/jbc.M501365200; Berkowitz P, 2006, P NATL ACAD SCI USA, V103, P12855, DOI 10.1073/pnas.0602973103; Billet SE, 2006, AUTOIMMUNITY, V39, P617, DOI 10.1080/08916930600972099; Bystryn JC, 2006, J AM ACAD DERMATOL, V54, P513, DOI 10.1016/j.jaad.2005.12.003; Calkins CC, 2006, J BIOL CHEM, V281, P7623, DOI 10.1074/jbc.M512447200; Cheng H, 2002, J CELL PHYSIOL, V192, P234, DOI 10.1002/jcp.10134; Chernyavsky AI, 2005, J BIOL CHEM, V280, P39220, DOI 10.1074/jbc.M504407200; D'Alessandro M, 2002, J CELL SCI, V115, P4341, DOI 10.1242/jcs.00120; Farley N, 2006, MOL CELL BIOL, V26, P2118, DOI 10.1128/MCB.26.6.2118-2129.2006; Frusic-Zlotkin M, 2006, AUTOIMMUNITY, V39, P563, DOI 10.1080/08916930600971836; Garmyn M, 2001, J INVEST DERMATOL, V117, P1290, DOI 10.1046/j.0022-202x.2001.01553.x; Goodwin M, 2004, J MOL HISTOL, V35, P839, DOI 10.1007/s10735-004-1833-2; Grando SA, 2006, EXP DERMATOL, V15, P265, DOI 10.1111/j.0906-6705.2006.00410.x; GRANDO SA, 1993, J INVEST DERMATOL, V101, P32, DOI 10.1111/1523-1747.ep12358588; Grando SA, 2000, DERMATOLOGY, V201, P290, DOI 10.1159/000051540; Grando SA, 2006, J INVEST DERMATOL, V126, P1948, DOI 10.1038/sj.jid.5700151; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HU CH, 1978, AM J PATHOL, V90, P345; Kawasaki H, 2006, J INVEST DERMATOL, V126, P2621, DOI 10.1038/sj.jid.5700450; Kawasaki Y, 2006, AUTOIMMUNITY, V39, P587, DOI 10.1080/08916930600971943; Kippenberger S, 2000, J INVEST DERMATOL, V114, P408, DOI 10.1046/j.1523-1747.2000.00915.x; Kitajima Y, 2003, ARCH DERMATOL RES, V295, pS17, DOI 10.1007/s00403-002-0368-1; KITAJIMA Y, IN PRESS CLIN REV AL; Kurzen H, 2006, AUTOIMMUNITY, V39, P549, DOI 10.1080/08916930600971554; Lanza A, 2006, J CUTAN PATHOL, V33, P401, DOI 10.1111/j.0303-6987.2006.00523.x; LEVER WF, 1953, MEDICINE, V32, P1; Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001; MORLEY SN, 1995, J CELL SCI, V108, P3463; Nguyen VT, 2004, ARCH DERMATOL, V140, P327, DOI 10.1001/archderm.140.3.327; Nguyen VT, 2004, J BIOL CHEM, V279, P2135, DOI 10.1074/jbc.M309000200; Orlov MD, 2006, AUTOIMMUNITY, V39, P557, DOI 10.1080/08916930600971729; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Sanchez-Carpintero I, 2004, BRIT J DERMATOL, V151, P565, DOI 10.1111/j.1365-2133.2004.06147.x; Sato M, 2000, LAB INVEST, V80, P1583, DOI 10.1038/labinvest.3780168; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; STAPPENBECK TS, 1994, J BIOL CHEM, V269, P29351; Toivola DM, 1997, J CELL SCI, V110, P23; Udey MC, 1999, JAMA-J AM MED ASSOC, V282, P572, DOI 10.1001/jama.282.6.572; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; WILGRAM GF, 1961, J INVEST DERMATOL, V36, P373, DOI 10.1038/jid.1961.58; Williamson L, 2006, EMBO J, V25, P3298, DOI 10.1038/sj.emboj.7601224; Yoneda K, 2004, J BIOL CHEM, V279, P7296, DOI 10.1074/jbc.M307242200	48	107	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13804	13812		10.1074/jbc.M611365200	http://dx.doi.org/10.1074/jbc.M611365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344213	hybrid			2022-12-27	WOS:000246060300070
J	Sanchez-Tillo, E; Comalada, M; Xaus, J; Farrera, C; Valledor, AF; Caelles, C; Lloberas, J; Celada, A				Sanchez-Tillo, Ester; Comalada, Monica; Xaus, Jordi; Farrera, Consol; Valledor, Annabel F.; Caelles, Carme; Lloberas, Jorge; Celada, Antonio			JNK1 is required for the induction of Mkp1 expression in macrophages during proliferation and lipopolysaccharide-dependent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PHOSPHATASE-1; SIGNAL-REGULATED KINASE; INNATE IMMUNE-RESPONSES; N-TERMINAL KINASE; C-JUN; TRANSCRIPTION FACTORS; PATHWAY; CELLS; SPECIFICITY; RECEPTOR	Macrophages proliferate in the presence of their growth factor, macrophage colony-stimulating factor ( M-CSF), in a process that is dependent on early and short ERK activation. Lipopolysaccharide ( LPS) induces macrophage activation, stops proliferation, and delays ERK phosphorylation, thereby triggering an inflammatory response. Proliferating or activating responses are balanced by the kinetics of ERK phosphorylation, the inactivation of which correlates with Mkp1 induction. Here we show that the transcriptional induction of this phosphatase by M-CSF or LPS depends on JNK but not on the other MAPKs, ERK and p38. The lack of Mkp1 induction caused by JNK inhibition prolonged ERK-1/2 and p38 phosphorylation. The two JNK genes, jnk1 and jnk2, are constitutively expressed in macrophages. However, only the JNK1 isoform was phosphorylated and, as determined in single knock-out mice, was necessary for Mkp1 induction by M-CSF or LPS. JNK1 was also required for pro-inflammatory cytokine biosynthesis ( tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6) and LPS-induced NO production. This requirement is independent of Mkp1 expression, as shown in Mkp1 knock-out mice. Our results demonstrate a critical role for JNK1 in the regulation of Mkp1 induction and in LPS- dependent macrophage activation.	Inst Biomed Res, Macrophage Biol Grp, E-08028 Barcelona, Spain; Inst Biomed Res, Cell Signaling Grp, E-08028 Barcelona, Spain; Univ Barcelona, E-08028 Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona	Celada, A (corresponding author), Inst Biomed Res, Macrophage Biol Grp, Barcelona Sci Pk,C Josep Samitier 1-5, E-08028 Barcelona, Spain.	acelada@ub.edu	Valledor, Annabel/H-5653-2015; Lloberas, Jorge/D-4303-2014; Celada, Antonio/I-1714-2016	Valledor, Annabel/0000-0003-4232-2633; Lloberas, Jorge/0000-0001-7075-4201; Farrera, Consol/0000-0002-4214-9597; Celada, Antonio/0000-0003-3883-2171				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bailly S, 1996, EUR CYTOKINE NETW, V7, P125; Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CELADA A, 1989, EUR J IMMUNOL, V19, P205, DOI 10.1002/eji.1830190134; CELADA A, 1992, J IMMUNOL, V148, P1102; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103; Comalada M, 2003, EUR J IMMUNOL, V33, P3091, DOI 10.1002/eji.200324074; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dorfman K, 1996, ONCOGENE, V13, P925; Dreskin SC, 2001, J IMMUNOL, V166, P5646, DOI 10.4049/jimmunol.166.9.5646; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hammer M, 2006, J EXP MED, V203, P15, DOI 10.1084/jem.20051753; Herrero C, 2001, J CLIN INVEST, V107, P485, DOI 10.1172/JCI11696; Huber M, 2006, EUR J IMMUNOL, V36, P701, DOI 10.1002/eji.200535593; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Lin YW, 2006, J BIOL CHEM, V281, P915, DOI 10.1074/jbc.M508720200; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Marques L, 2004, J IMMUNOL, V173, P1103, DOI 10.4049/jimmunol.173.2.1103; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; Morse D, 2003, J BIOL CHEM, V278, P36993, DOI 10.1074/jbc.M302942200; Nishina H, 2004, J BIOCHEM, V136, P123, DOI 10.1093/jb/mvh117; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Sanchez-Tillo E, 2006, J IMMUNOL, V176, P6594, DOI 10.4049/jimmunol.176.11.6594; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Sohaskey ML, 2002, MOL BIOL CELL, V13, P454, DOI 10.1091/mbc.01-11-0553; Stawowy P, 2003, BIOCHEM BIOPH RES CO, V303, P74, DOI 10.1016/S0006-291X(03)00301-2; Teng DHF, 1997, CANCER RES, V57, P4177; Triantafilou M, 2005, J ENDOTOXIN RES, V11, P5, DOI 10.1179/096805105225006641; Valledor AF, 1999, J IMMUNOL, V163, P2452; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Ventura JJ, 2004, MOL CELL, V15, P269, DOI 10.1016/j.molcel.2004.06.007; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zhao Q, 2006, J EXP MED, V203, P131, DOI 10.1084/jem.20051794; Zhu JZ, 2005, J BIOL CHEM, V280, P8617, DOI 10.1074/jbc.M413539200	61	51	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12566	12573		10.1074/jbc.M609662200	http://dx.doi.org/10.1074/jbc.M609662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337450	hybrid			2022-12-27	WOS:000245942800025
J	Ma, C; Ying, CY; Yuan, ZM; Song, B; Li, D; Liu, YL; Lai, BQ; Li, WM; Chen, RZ; Ching, YP; Li, MT				Ma, Chi; Ying, Chunyi; Yuan, Zhongmin; Song, Bin; Li, Dan; Liu, Yulin; Lai, Bingquan; Li, Wenming; Chen, Ruzhu; Ching, Yick-Pang; Li, Mingtao			dp5/HRK is a c-jun target gene and required for apoptosis induced by potassium deprivation in cerebellar granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ENDOTHELIAL-CELLS; JNK PATHWAY; ACTIVATION; INDUCTION; SURVIVAL; PROTEIN; PHOSPHORYLATION; BIM; KINASE	In cerebellar granule neurons, a BH3-only Bcl-2 family member, death protein 5/harakiri, is up-regulated in a JNK-dependent manner during apoptosis induced by potassium deprivation. However, it is not clear whether c-Jun is directly involved in the induction of dp5. Here, we showed that the up-regulation of dp5, but not fas ligand and bim, after potassium deprivation was suppressed by the expression of a dominant negative form of c-Jun. Deletion analysis of the 5 '-flanking sequence of the dp5 gene revealed that a major responsive element responsible for the induction by potassium deprivation is an ATF binding site located at -116 to -109 relative to the transcriptional start site. Mutation of this site completely abolished promoter activation. Furthermore, a gel shift assay showed that a specific complex containing c-Jun and ATF2 recognized this site and increased in potassium-deprived cerebellar granule neurons. Chromatin immunoprecipitation demonstrated that c-Jun was able to bind to this site in vivo. Finally, we demonstrated that knockdown of Dp5 by small interfering RNA rescued neurons from potassium deprivation-induced apoptosis. Taken together, these results suggest that dp5 is a target gene of c-Jun and plays a critical role in potassium deprivation-induced apoptosis in cerebellar granule neurons.	Sun Yat Sen Univ, Zhongshan Med Coll, Dept Pharmacol, Zhongshan Sch Med, Guangzhou 510089, Peoples R China; Sun Yat Sen Univ, Zhongshan Sch Med, Proteom Ctr, Guangzhou 510089, Peoples R China; Univ Hong Kong, Dept Pathol Biochem, Pokfulam, Hong Kong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; University of Hong Kong	Li, MT (corresponding author), Sun Yat Sen Univ, Zhongshan Med Coll, Dept Pharmacol, Zhongshan Sch Med, 74 Zhongshan Rd 2, Guangzhou 510089, Peoples R China.	limt@mail.sysu.edu.cn	Ching, Yick Pang/C-4244-2009	, Chi/0000-0002-4171-0813; CHING, Yick Pang/0000-0002-6461-8358				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; [Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI 10.1038/ncb0603-490; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bozyczko-Coyne D, 2001, J NEUROCHEM, V77, P849, DOI 10.1046/j.1471-4159.2001.00294.x; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Gerhardt E, 2001, MOL CELL NEUROSCI, V17, P717, DOI 10.1006/mcne.2001.0962; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harris CA, 2001, J BIOL CHEM, V276, P37754; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Kalinec GM, 2005, P NATL ACAD SCI USA, V102, P16019, DOI 10.1073/pnas.0508053102; Kanazawa K, 1998, MOL BRAIN RES, V54, P316, DOI 10.1016/S0169-328X(97)00360-4; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Ma YH, 2003, MOL CANCER THER, V2, P73; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Shi LY, 2005, NEUROSCI LETT, V375, P7, DOI 10.1016/j.neulet.2004.10.082; Ueno Y, 1999, FEBS LETT, V457, P241, DOI 10.1016/S0014-5793(99)01049-2; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Watson A, 1998, J NEUROSCI, V18, P751; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Yin KJ, 2005, NEUROBIOL DIS, V20, P881, DOI 10.1016/j.nbd.2005.05.026; Yin KJ, 2002, J NEUROSCI, V22, P9764; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	29	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 19	2007	282	42					30901	30909		10.1074/jbc.M608694200	http://dx.doi.org/10.1074/jbc.M608694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	220DE	17428807	hybrid			2022-12-27	WOS:000250136300058
J	Dumay-Odelot, H; Marck, C; Durrieu-Gaillard, S; Lefebvre, O; Jourdain, S; Prochazkova, M; Pflieger, A; Teichmann, M				Dumay-Odelot, Helene; Marck, Christian; Durrieu-Gaillard, Stephanie; Lefebvre, Olivier; Jourdain, Sabine; Prochazkova, Martina; Pflieger, Aude; Teichmann, Martin			Identification, molecular cloning, and characterization of the sixth subunit of human transcription factor TFIIIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; 2 FUNCTIONAL COMPONENTS; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; SCHIZOSACCHAROMYCES-POMBE; YEAST GENOME; FACTOR-TAU; GENE; COMPLEX	TFIIIC in yeast and humans is required for transcription of tRNA and 5 S RNA genes by RNA polymerase III. In the yeast Saccharomyces cerevisiae, TFIIIC is composed of six subunits, five of which are conserved in humans. We report the identification, molecular cloning, and characterization of the sixth subunit of human TFIIIC, TFIIIC35, which is related to the smallest subunit of yeast TFIIIC. Human TFIIIC35 does not contain the phosphoglycerate mutase domain of its yeast counterpart, and these two proteins display only limited homology within a 34-amino acid domain. Homologs of the sixth TFIIIC subunit are also identified in other eukaryotes, and their phylogenic evolution is analyzed. Affinity-purified human TFIIIC from an epitope-tagged TFIIIC35 cell line is active in binding to and in transcription of the VA1 gene in vitro. Furthermore, TFIIIC35 specifically interacts with the human TFIIIC subunits TFIIIC63 and, to a lesser extent, TFIIIC90 in vitro. Finally, we determined a limited region in the smallest subunit of yeast TFIIIC that is sufficient for interacting with the yeast TFIIIC subunit ScTfc1 (orthologous to TFIIIC63) and found it to be adjacent to and overlap the 34-amino acid domain that is conserved from yeast to humans.	Univ Bordeaux 2, IECB, INSERM, U869, F-33607 Pessac, France; CEA, iBiTecS, F-91191 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CEA; UDICE-French Research Universities; Universite Paris Saclay	Teichmann, M (corresponding author), Univ Bordeaux 2, IECB, INSERM, U869, Rue Robert Escarpit, F-33607 Pessac, France.	M.Teichmann@iecb.u-bordeaux.fr	DUMAY-ODELOT, Hélène/M-7751-2014; LEFEBVRE, Olivier/C-3847-2014; Teichmann, Martin/M-7407-2014	LEFEBVRE, Olivier/0000-0002-3903-9450; Teichmann, Martin/0000-0002-5257-0510; DUMAY-ODELOT, Helene/0000-0002-7245-084X				Arrebola R, 1998, MOL CELL BIOL, V18, P1; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; CONESA C, 1993, J BIOL CHEM, V268, P18047; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Ducrot C, 2006, J BIOL CHEM, V281, P11685, DOI 10.1074/jbc.M600101200; Dujon B, 2005, CURR OPIN GENET DEV, V15, P614, DOI 10.1016/j.gde.2005.09.005; Dujon B, 2006, TRENDS GENET, V22, P375, DOI 10.1016/j.tig.2006.05.007; Dumay H, 1999, J BIOL CHEM, V274, P33462, DOI 10.1074/jbc.274.47.33462; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Herve M, 2000, EUR J BIOCHEM, V267, P3337, DOI 10.1046/j.1432-1327.2000.01365.x; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Huang Y, 2001, NUCLEIC ACIDS RES, V29, P2675, DOI 10.1093/nar/29.13.2675; Jourdain S, 2003, J BIOL CHEM, V278, P10450, DOI 10.1074/jbc.M213310200; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; LETOILE ND, 1994, P NATL ACAD SCI USA, V91, P1652, DOI 10.1073/pnas.91.5.1652; Manaud N, 1998, MOL CELL BIOL, V18, P3191, DOI 10.1128/MCB.18.6.3191; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; Moir RD, 2000, J BIOL CHEM, V275, P26591, DOI 10.1074/jbc.M003991200; Mylona A, 2006, MOL CELL, V24, P221, DOI 10.1016/j.molcel.2006.08.013; Oettel S, 1997, NUCLEIC ACIDS RES, V25, P2440, DOI 10.1093/nar/25.12.2440; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Rozenfeld S, 2001, MOL GENET GENOMICS, V265, P705, DOI 10.1007/s004380100467; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; TEICHMANN M, 1995, EMBO J, V14, P5974, DOI 10.1002/j.1460-2075.1995.tb00286.x; Teichmann M, 1999, P NATL ACAD SCI USA, V96, P13720, DOI 10.1073/pnas.96.24.13720; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; Wang ZX, 1998, MOL CELL, V1, P749, DOI 10.1016/S1097-2765(00)80074-X; Wang ZX, 1996, MOL CELL BIOL, V16, P6841; Weser S, 2004, J BIOL CHEM, V279, P27022, DOI 10.1074/jbc.M312790200; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726	52	27	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17179	17189		10.1074/jbc.M611542200	http://dx.doi.org/10.1074/jbc.M611542200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17409385	hybrid			2022-12-27	WOS:000246946500051
J	Predescu, SA; Predescu, DN; Knezevic, I; Klein, IK; Malik, AB				Predescu, Sanda A.; Predescu, Dan N.; Knezevic, Ivana; Klein, Irene K.; Malik, Asrar B.			Intersectin-1s regulates the mitochondrial apoptotic pathway in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			Unspecified	Article							CYTOCHROME-C RELEASE; CLATHRIN-MEDIATED ENDOCYTOSIS; PERMEABILITY TRANSITION PORE; BCL-X-L; MEMBRANE PERMEABILIZATION; OLIGOMERIZES BAK; PROTEIN; FAMILY; DYSFUNCTION; MECHANISMS	Intersectins (ITSNs) are multidomain adaptor proteins implicated in endocytosis, regulation of actin polymerization, and Ras/MAPK signaling. We have previously shown that ITSN-1s is required for caveolae fission and internalization in endothelial cells (ECs). In the present study, using small interfering RNA to knock down ITSN-1s protein expression, we demonstrate a novel role of ITSN-1s as a key antiapoptotic protein. Knockdown of ITSN-1s in ECs activated the mitochondrial pathway of apoptosis as determined by genomic DNA fragmentation, extensive mitochondrial fission, activation of the proapoptotic proteins BAK and BAX, and cytochrome c efflux from mitochondria. ITSN-1 knockdown acts as a proapoptotic signal that causes mitochondrial outer membrane permeabilization, dissipation of the mitochondrial membrane potential, and generation of reactive oxygen species. These effects were secondary to decreased activation of Erk1/2 and its direct activator MEK. Bcl-XL overexpression prevented BAX activation and the apoptotic ECs death induced by suppression of ITSN-1s. Our findings demonstrate a novel role of ITSN-1s as a negative regulator of the mitochondrial pathway-dependent apoptosis secondary to activation of the Erk1/2 survival signaling pathway.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Predescu, SA (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	sandap@uic.edu		Predescu, Sanda/0000-0002-9386-6756; Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL60678] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams A, 2000, J BIOL CHEM, V275, P27414; Armstrong JS, 2006, BIOESSAYS, V28, P253, DOI 10.1002/bies.20370; Bossy-Wetzel E, 2000, METHOD ENZYMOL, V322, P235; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Ding WX, 2000, HEPATOLOGY, V32, P547, DOI 10.1053/jhep.2000.16183; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Gogvadze V, 2004, BIOCHEM J, V378, P213, DOI 10.1042/BJ20031193; GOGVADZE V, 2003, CURRENT PROTOCOLS CE; Gogvadze V, 2006, BBA-BIOENERGETICS, V1757, P639, DOI 10.1016/j.bbabio.2006.03.016; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Han JY, 2006, NEUROSCI LETT, V398, P113, DOI 10.1016/j.neulet.2005.12.065; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Loeb CRK, 2006, J BIOL CHEM, V281, P28326, DOI 10.1074/jbc.M604544200; Ma YJ, 2003, J NEUROSCI RES, V71, P468, DOI 10.1002/jnr.10500; Marie B, 2004, NEURON, V43, P207, DOI 10.1016/j.neuron.2004.07.001; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; Mohney RP, 2003, J BIOL CHEM, V278, P47038, DOI 10.1074/jbc.M303895200; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Precht TA, 2005, CELL DEATH DIFFER, V12, P255, DOI 10.1038/sj.cdd.4401552; Predescu SA, 2003, MOL BIOL CELL, V14, P4997, DOI 10.1091/mbc.e03-01-0041; Predescu SA, 2001, MOL BIOL CELL, V12, P1019, DOI 10.1091/mbc.12.4.1019; Pucharcos C, 2000, FEBS LETT, V478, P43, DOI 10.1016/S0014-5793(00)01793-2; Pucharcos C, 2001, BBA-GENE STRUCT EXPR, V1521, P1, DOI 10.1016/S0167-4781(01)00276-7; Razani B, 2001, J BIOL CHEM, V276, P38121; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Schafer ZT, 2006, DEV CELL, V10, P549, DOI 10.1016/j.devcel.2006.04.008; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Wang JB, 2005, J BIOL CHEM, V280, P22883, DOI 10.1074/jbc.M414375200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu D, 2006, AM J PHYSIOL-LUNG C, V291, pL966, DOI 10.1152/ajplung.00045.2006; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	53	43	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17166	17178		10.1074/jbc.M608996200	http://dx.doi.org/10.1074/jbc.M608996200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17405881	hybrid			2022-12-27	WOS:000246946500050
J	Rodrigues, MA; Gomes, DA; Leite, MF; Grant, W; Zhang, L; Lam, W; Cheng, YC; Bennett, AM; Nathanson, MH				Rodrigues, Michele A.; Gomes, Dawidson A.; Leite, M. Fatima; Grant, Wayne; Zhang, Lei; Lam, Wing; Cheng, Yung-Chi; Bennett, Anton M.; Nathanson, Michael H.			Nucleoplasmic calcium is required for cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EMBRYOS; NUCLEAR CALCIUM; CYTOPLASMIC CALCIUM; CA2+ SIGNALS; CYCLE; INOSITOL; MICRODOMAINS; MITOSIS; PHOSPHORYLATION; CHECKPOINTS	Ca2+ signals regulate cell proliferation, but the spatial and temporal specificity of these signals is unknown. Here we use selective buffers of nucleoplasmic or cytoplasmic Ca2+ to determine that cell proliferation depends upon Ca2+ signals within the nucleus rather than in the cytoplasm. Nuclear Ca2+ signals stimulate cell growth rather than inhibit apoptosis and specifically permit cells to advance through early prophase. Selective buffering of nuclear but not cytoplasmic Ca2+ signals also impairs growth of tumors in vivo. These findings reveal a major physiological and potential pathophysiological role for nucleoplasmic Ca2+ signals and suggest that this information can be used to design novel therapeutic strategies to regulate conditions of abnormal cell growth.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Fed Minas Gerais, Dept Physiol & Biophys, BR-31270901 Belo Horizonte, MG, Brazil	Yale University; Yale University; Universidade Federal de Minas Gerais	Nathanson, MH (corresponding author), Yale Univ, Sch Med, Dept Med, Rm TAC S241D, New Haven, CT 06520 USA.	michael.nathanson@yale.edu	Gomes, Dawidson Assis/O-1372-2013; de Fatima Leite, Maria/AAK-2555-2021	Gomes, Dawidson Assis/0000-0001-7714-991X; Bennett, Anton/0000-0001-5187-7599	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045710, P01DK057751, R29DK045710, P30DK034989] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34989, P01 DK057751, P01 DK057751-01A1, DK57751, R01 DK045710-06A2, DK45710, R01 DK045710, P30 DK034989-169004, P30 DK034989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; CIAPA B, 1994, NATURE, V368, P875, DOI 10.1038/368875a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Echevarria W, 2003, NAT CELL BIOL, V5, P440, DOI 10.1038/ncb980; Gao WL, 2004, CANCER RES, V64, P678, DOI 10.1158/0008-5472.CAN-03-1904; Gatti L, 2005, METH MOLEC MED, V111, P127; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Grant W., 2006, CALCIUM BINDING PROT, V1, P30; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; Itano N, 2003, P NATL ACAD SCI USA, V100, P5181, DOI 10.1073/pnas.0531397100; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOPPLER P, 1993, J BIOL CHEM, V268, P26248; Lam W, 2006, MOL PHARMACOL, V69, P1607, DOI 10.1124/mol.105.021527; Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Mendes CCP, 2005, J BIOL CHEM, V280, P40892, DOI 10.1074/jbc.M506623200; Minagawa N, 2005, J BIOL CHEM, V280, P33637, DOI 10.1074/jbc.M503210200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Parry H, 2005, J CELL BIOL, V171, P47, DOI 10.1083/jcb.200503139; Pusl T, 2002, J BIOL CHEM, V277, P27517, DOI 10.1074/jbc.M203002200; RASMUSSEN CD, 1989, MOL ENDOCRINOL, V3, P588, DOI 10.1210/mend-3-3-588; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; Whitaker M, 2006, CELL CALCIUM, V40, P585, DOI 10.1016/j.ceca.2006.08.018; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576	41	99	100	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17061	17068		10.1074/jbc.M700490200	http://dx.doi.org/10.1074/jbc.M700490200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17420246	Green Accepted, hybrid			2022-12-27	WOS:000246946500039
J	Fernandes, ND; Sun, YL; Price, BD				Fernandes, Norvin D.; Sun, Yingli; Price, Brendan D.			Activation of the kinase activity of ATM by retinoic acid is required for CREB-dependent differentiation of neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA; NEUROTROPHIC FACTOR; NEURONAL DIFFERENTIATION; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; GENE-EXPRESSION; PROTEIN-KINASE; SH-SY5Y CELLS; DNA-PKCS; AUTOPHOSPHORYLATION	The ATM protein kinase is mutated in ataxia telangiectasia, a genetic disease characterized by defective DNA repair, neurodegeneration, and growth factor signaling defects. The activity of ATM kinase is activated by DNA damage, and this activation is required for cells to survive genotoxic events. In addition to this well characterized role in DNA repair, we now demonstrate a novel role for ATM in the retinoic acid ( RA)induced differentiation of SH-SY5Y neuroblastoma cells into post-mitotic, neuronal-like cells. RA rapidly activates the activity of ATM kinase, leading to the ATM-dependent phosphorylation of the CREB protein, extrusion of neuritic processes, and differentiation of SH-SY5Y cells into neuronal-like cells. When ATM protein expression was suppressed by short hairpin RNA, the ATM-dependent phosphorylation of CREB was blocked. Furthermore, ATM-negative cells failed to differentiate into neuronal-like cells when exposed to retinoic acid; instead, they underwent cell death. Expression of a constitutively active CREBVP16 construct, or exposure to forskolin to induce CREB phosphorylation, rescued ATM negative cells and restored differentiation. Furthermore, when dominant negative CREB proteins with mutations in either the CREB phosphorylation site (CREBS133A) or the DNA binding domain (KCREB) were introduced into SH-SY5Y cells, retinoic acid-induced differentiation was blocked and the cells underwent cell death. The results demonstrate that ATM is required for the retinoic acid-induced differentiation of SH-SY5Y cells through the ATM dependent-phosphorylation of serine 133 of CREB. These results therefore define a novel mechanism for activation of the activity of ATM kinase by RA, and implicate ATM in the regulation of CREB function during RA-induced differentiation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Div Genom Stabil & DNA Repair, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol,Div Genom Stabil & DNA Repair, JF 516, Boston, MA 02115 USA.	brendan_price@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [T32CA009078, R01CA093602, R01CA064585] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067751] Funding Source: NIH RePORTER; NCI NIH HHS [CA64585, CA93602, T32 CA09078] Funding Source: Medline; NIAID NIH HHS [U19AI067751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aggarwal S, 2006, MOL BIOL CELL, V17, P566, DOI 10.1091/mbc.E05-06-0519; Allio T, 2000, MUTAT RES-FUND MOL M, V453, P5, DOI 10.1016/S0027-5107(00)00030-0; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barco A, 2005, NEURON, V48, P123, DOI 10.1016/j.neuron.2005.09.005; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Biton S, 2006, J BIOL CHEM, V281, P17482, DOI 10.1074/jbc.M601895200; Canon E, 2004, MOL BIOL CELL, V15, P5583, DOI 10.1091/mbc.E04-05-0439; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; Chen P, 2003, J NEUROSCI, V23, P11453; Chen SJ, 2004, BIOCHEM BIOPH RES CO, V317, P1037, DOI 10.1016/j.bbrc.2004.03.149; Chen SJ, 2003, ONCOGENE, V22, P6332, DOI 10.1038/sj.onc.1206760; Choi SY, 2001, J NEUROCHEM, V79, P303; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471-4159.2000.0750991.x; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fernandes N, 2005, J BIOL CHEM, V280, P15158, DOI 10.1074/jbc.M412065200; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; Gao Y, 2004, NEURON, V44, P609, DOI 10.1016/j.neuron.2004.10.030; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Insel PA, 2003, CELL MOL NEUROBIOL, V23, P305, DOI 10.1023/A:1023684503883; Irwin N, 2002, P NATL ACAD SCI USA, V99, P12427, DOI 10.1073/pnas.152457399; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jiang XF, 2006, J BIOL CHEM, V281, P15741, DOI 10.1074/jbc.M513172200; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Lavin MF, 2005, MUTAT RES-FUND MOL M, V569, P123, DOI 10.1016/j.mrfmmm.2004.04.020; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee Y, 2007, NEUROSCIENCE, V145, P1365, DOI 10.1016/j.neuroscience.2006.07.026; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; MacLeod RAF, 1996, MUTAT RES-FUND MOL M, V372, P33, DOI 10.1016/S0027-5107(96)00106-6; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Miloso M, 2004, J NEUROSCI RES, V75, P241, DOI 10.1002/jnr.10848; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Ruiz-Leon Y, 2003, NEUROSCIENCE, V120, P1019, DOI 10.1016/S0306-4522(03)00391-9; Ruiz-Leon Y, 2001, J NEUROCHEM, V79, P278, DOI 10.1046/j.1471-4159.2001.00547.x; SEDGEWICK R, 1991, HDB CLIN NEUROLOGY, V61, P347; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhang YG, 2003, J BIOL CHEM, V278, P12650, DOI 10.1074/jbc.M210368200	51	38	38	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16577	16584		10.1074/jbc.M609628200	http://dx.doi.org/10.1074/jbc.M609628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426037	hybrid			2022-12-27	WOS:000246794300064
J	Kooren, J; Palstra, RJ; Klous, P; Splinter, E; von Lindern, M; Grosveld, F; de Laat, W				Kooren, Jurgen; Palstra, Robert-Jan; Klous, Petra; Splinter, Erik; von Lindern, Marieke; Grosveld, Frank; de Laat, Wouter			beta-globin active chromatin hub formation in differentiating erythroid cells and in p45 NF-E2 knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; TRANSCRIPTION FACTOR NF-E2; RNA-POLYMERASE-II; GENE-EXPRESSION; SPATIAL-ORGANIZATION; HISTONE ACETYLATION; IN-VIVO; LCR; GATA-1; RECRUITMENT	Expression of the beta-globin genes proceeds from basal to exceptionally high levels during erythroid differentiation in vivo. High expression is dependent on the locus control region (LCR) and coincides with more frequent LCR-gene contacts. These contacts are established in the context of an active chromatin hub (ACH), a spatial chromatin configuration in which the LCR, together with other regulatory sequences, loops toward the active beta-globin-like genes. Here, we used recently established I/11 cells as a model system that faithfully recapitulates the in vivo erythroid differentiation program to study the molecular events that accompany and underlie ACH formation. Upon I/11 cell induction, histone modifications changed, the ACH was formed, and the beta-globin-like genes were transcribed at rates similar to those observed in vivo. The establishment of frequent LCR-gene contacts coincided with a more efficient loading of polymerase onto the beta-globin promoter. Binding of the transcription factors GATA-1 and EKLF to the locus, although previously shown to be required, was not sufficient for ACH formation. Moreover, we used knock-out mice to show that the erythroid transcription factor p45 NF-E2, which has been implicated in beta-globin gene regulation, is dispensable for beta-globin ACH formation.	Erasmus MC, Dept Cell Biol & Genet, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Hematol, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	de Laat, W (corresponding author), Erasmus MC, Dept Cell Biol & Genet, POB 2040, NL-3000 CA Rotterdam, Netherlands.	w.delaat@erasmusmc.nl	von Lindern, Marieke/AAH-2350-2020	Palstra, Robert-Jan/0000-0003-4600-2303; de Laat, Wouter/0000-0002-6393-595X				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Bender MA, 2006, BLOOD, V108, P1395, DOI 10.1182/blood-2006-04-014431; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Bottardi S, 2006, EMBO J, V25, P3586, DOI 10.1038/sj.emboj.7601232; Brand M, 2004, NAT STRUCT MOL BIOL, V11, P73, DOI 10.1038/nsmb713; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Derjuga A, 2004, MOL CELL BIOL, V24, P3286, DOI 10.1128/MCB.24.8.3286-3294.2004; Dolznig H, 2004, METH MOLEC MED, V105, P323; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; Drissen R, 2004, GENE DEV, V18, P2485, DOI 10.1101/gad.317004; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Forsberg EC, 2000, BLOOD, V96, P334, DOI 10.1182/blood.V96.1.334.013k17_334_339; Im H, 2005, P NATL ACAD SCI USA, V102, P17065, DOI 10.1073/pnas.0506164102; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Kang SHL, 2002, NUCLEIC ACIDS RES, V30; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Kuroha T, 1998, J BIOCHEM-TOKYO, V123, P376; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Martin F, 1998, BLOOD, V91, P3459, DOI 10.1182/blood.V91.9.3459.3459_3459_3466; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; PERKINS AC, 1995, NATURE, V375, P318; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Rodriguez P, 2005, EMBO J, V24, P2354, DOI 10.1038/sj.emboj.7600702; Sawado T, 2003, GENE DEV, V17, P1009, DOI 10.1101/gad.1072303; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Schubeler D, 2000, GENE DEV, V14, P940; Schubeler D, 2001, P NATL ACAD SCI USA, V98, P11432, DOI 10.1073/pnas.201394698; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Splinter E, 2006, GENE DEV, V20, P2349, DOI 10.1101/gad.399506; Sun JY, 2004, P NATL ACAD SCI USA, V101, P1461, DOI 10.1073/pnas.0308083100; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Vieira KF, 2004, J BIOL CHEM, V279, P50350, DOI 10.1074/jbc.M408883200; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x	46	64	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16544	16552		10.1074/jbc.M701159200	http://dx.doi.org/10.1074/jbc.M701159200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428799	hybrid			2022-12-27	WOS:000246794300061
J	Naslavsky, N; Rahajeng, J; Chenavas, S; Sorgen, PL; Caplan, S				Naslavsky, Naava; Rahajeng, Juliati; Chenavas, Sylvie; Sorgen, Paul L.; Caplan, Steve			EHD1 and Eps15 interact with phosphatidylinositols via their Eps15 homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; RECYCLING COMPARTMENT; TRANSFERRIN RECEPTOR; PLASMA-MEMBRANE; BINDING PROTEIN; RAB GTPASES; ENDOCYTOSIS; ENDOSOMES; RECOGNITION; DELIVERY	The C-terminal Eps15 homology domain-containing protein, EHD1, regulates the recycling of receptors from the endocytic recycling compartment to the plasma membrane. In cells, EHD1 localizes to tubular and spherical recycling endosomes. To date, the mode by which EHD1 associates with endosomal membranes remains unknown, and it has not been determined whether this interaction is direct or via interacting proteins. Here, we provide evidence demonstrating that EHD1 has the ability to bind directly and preferentially to an array of phospholipids, preferring phosphatidylinositols with a phosphate at position 3. Previous studies have demonstrated that EH domains coordinate calcium binding and interact with proteins containing the tripeptide asparagine-proline-phenylalanine (NPF). Using two-dimensional nuclear magnetic resonance analysis, we now describe a new function for the Eps15 homology ( EH) domain of EHD1 and show that it is capable of directly binding phosphatidylinositol moieties. Moreover, we have expanded our studies to include the C-terminal EH domain of EHD4 and the second of the three N-terminal EH domains of Eps15 and demonstrated that phosphatidylinositol binding may be a more general property shared by certain other EH domains. Further studies identified a positively charged lysine residue ( Lys-483) localized within the third helix of the EH domain, on the opposite face of the NPF-binding pocket, as being critical for the interaction with the phosphatidylinositols.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Sorgen, PL (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	psorgen@unmc.edu; scaplan@unmc.edu			NIGMS NIH HHS [GM072631, GM074876] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072631, R01GM074876] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Blume JJ, 2007, EXP CELL RES, V313, P219, DOI 10.1016/j.yexcr.2006.10.006; Braun A, 2005, MOL BIOL CELL, V16, P3642, DOI 10.1091/mbc.E05-01-0076; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; Confalonieri S, 2002, FEBS LETT, V513, P24, DOI 10.1016/S0014-5793(01)03241-0; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; de Beer T, 2000, NAT STRUCT BIOL, V7, P1018, DOI 10.1038/80924; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Galperin E, 2002, TRAFFIC, V3, P575, DOI 10.1034/j.1600-0854.2002.30807.x; George M, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-3; GOLDENRING JR, 1993, J BIOL CHEM, V268, P18419; Grant B, 2001, NAT CELL BIOL, V3, P573, DOI 10.1038/35078549; Guilherme A, 2004, J BIOL CHEM, V279, P40062, DOI 10.1074/jbc.M401918200; Hayakawa A, 2004, J BIOL CHEM, V279, P5958, DOI 10.1074/jbc.M310503200; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kauppi M, 2002, J CELL SCI, V115, P899; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kleinschmidt JH, 2002, BIOPHYS J, V83, P994, DOI 10.1016/S0006-3495(02)75225-9; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; Lee DW, 2005, J BIOL CHEM, V280, P17213, DOI 10.1074/jbc.M412751200; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Lindsay AJ, 2004, J CELL SCI, V117, P4365, DOI 10.1242/jcs.01280; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miliaras NB, 2004, CELL BIOCHEM BIOPHYS, V41, P295, DOI 10.1385/CBB:41:2:295; Mintz L, 1999, GENOMICS, V59, P66, DOI 10.1006/geno.1999.5800; Naslavsky N, 2006, MOL BIOL CELL, V17, P163, DOI 10.1091/mbc.e05-05-0466; Naslavsky N, 2005, J CELL SCI, V118, P4093, DOI 10.1242/jcs.02595; Naslavsky N, 2004, MOL BIOL CELL, V15, P2410, DOI 10.1091/mbc.E03-10-0733; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Park M, 2004, SCIENCE, V305, P1972, DOI 10.1126/science.1102026; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Picciano JA, 2003, AM J PHYSIOL-CELL PH, V285, pC1009, DOI 10.1152/ajpcell.00140.2003; Pohl U, 2000, GENOMICS, V63, P255, DOI 10.1006/geno.1999.6087; POLO S, 2003, SCI STKE; Rao VR, 1999, J BIOL CHEM, V274, P37893, DOI 10.1074/jbc.274.53.37893; Rapaport D, 2006, TRAFFIC, V7, P52, DOI 10.1111/j.1600-0854.2005.00359.x; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; Rodman JS, 2000, J CELL SCI, V113, P183; Rotem-Yehudar R, 2001, J BIOL CHEM, V276, P33054, DOI 10.1074/jbc.M009913200; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Shaw JD, 2003, TRAFFIC, V4, P479, DOI 10.1034/j.1600-0854.2003.t01-1-00106.x; Simpson JC, 2004, J CELL SCI, V117, P6297, DOI 10.1242/jcs.01560; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Weigert R, 2005, METHOD ENZYMOL, V403, P243, DOI 10.1016/S0076-6879(05)03020-X; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Xu Y, 2004, MOL MEMBR BIOL, V21, P269, DOI 10.1080/09687680410001716871; Yaguchi SI, 2006, JNCI-J NATL CANCER I, V98, P545, DOI 10.1093/jnci/djj133; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	64	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16612	16622		10.1074/jbc.M609493200	http://dx.doi.org/10.1074/jbc.M609493200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17412695	hybrid			2022-12-27	WOS:000246794300067
J	Andra, J; Monreal, D; de Tejada, GM; Olak, C; Brezesinski, G; Gomez, SS; Goldmann, T; Bartels, R; Brandenburg, K; Moriyon, I				Andrae, Joerg; Monreal, Daniel; de Tejada, Guillermo Martinez; Olak, Claudia; Brezesinski, Gerald; Sanchez Gomez, Susana; Goldmann, Torsten; Bartels, Rainer; Brandenburg, Klaus; Moriyon, Ignacio			Rationale for the design of shortened derivatives of the NK-lysin-derived antimicrobial peptide NK-2 with improved activity against gram-negative pathogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; PORE-FORMING PEPTIDE; MEMBRANE SELECTIVITY; HYDROPHOBIC MOMENT; CATIONIC PEPTIDES; MODEL MEMBRANES; MOLECULAR-BASIS; ANTIBACTERIAL; SEQUENCE	The peptide NK-2 is an effective antimicrobial agent with low hemolytic and cytotoxic activities and is thus a promising candidate for clinical applications. It comprises the alpha-helical, cationic core region of porcine NK-lysin a homolog of human granulysin and of amoebapores of pathogenic amoeba. Here we visualized the impact of NK-2 on Escherichia coli by electron microscopy and used NK-2 as a template for sequence variations to improve the peptide stability and activity and to gain insight into the structure/function relationships. We synthesized 18 new peptides and tested their activities on seven Gram-negative and one Gram-positive bacterial strains, human erythrocytes, and HeLa cells. Although all peptides appeared unordered in buffer, those active against bacteria adopted an alpha-helical conformation in membrane-mimetic environments like trifluoroethanol and negatively charged phosphatidylglycerol (PG) liposomes that mimick the cytoplasmic membrane of bacteria. This conformation was not observed in the presence of liposomes consisting of zwitterionic phosphatidylcholine (PC) typical for the human cell plasma membrane. The interaction was paralleled by intercalation of these peptides into PG liposomes as determined by FRET spectroscopy. A comparative analysis between biological activity and the calculated peptide parameters revealed that the decisive factor for a broad spectrum activity is not the peptide overall hydrophobicity or amphipathicity, but the possession of a minimal positive net charge plus a highly amphipathic anchor point of only seven amino acid residues (two helical turns).	Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany; Univ Navarra, Dept Microbiol, E-31008 Pamplona, Spain; Max Planck Inst Colloids & Interfaces, D-14476 Potsdam, Germany	Forschungszentrum Borstel; University of Navarra; Max Planck Society	Andra, J (corresponding author), Leibniz Ctr Med & Biosci, Res Ctr Borstel, Pk Allee 10, D-23845 Borstel, Germany.	jandrae@fz-borstel.de	Moriyon, Ignacio/N-4764-2016; Goldmann, Torsten/E-5906-2010; Martinez-de-Tejada, Guillermo/H-3849-2017; Martinez-de-Tejada, Guillermo/AAT-8535-2020	Moriyon, Ignacio/0000-0002-4288-0195; Goldmann, Torsten/0000-0002-1621-560X; Martinez-de-Tejada, Guillermo/0000-0003-3755-451X; Martinez-de-Tejada, Guillermo/0000-0003-3755-451X; Brezesinski, Gerald/0000-0002-7880-0492; Lazaro-Anton, Leticia/0000-0001-7720-5627				ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; Andra J, 2005, BIOCHEM J, V385, P135, DOI 10.1042/BJ20041270; Andra J, 2004, ANTIMICROB AGENTS CH, V48, P1593, DOI 10.1128/AAC.48.5.1593-1599.2004; Andra J, 1999, MED MICROBIOL IMMUN, V188, P117, DOI 10.1007/s004300050113; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dathe M, 1997, FEBS LETT, V403, P208, DOI 10.1016/S0014-5793(97)00055-0; DETEJADA GM, 1995, INFECT IMMUN, V63, P3054; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Falla T. J., 2004, Mammalian host defense peptides, P69; Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; GRIFFITH OH, 1972, P NATL ACAD SCI USA, V69, P561, DOI 10.1073/pnas.69.3.561; Gutsmann T, 2005, J ENDOTOXIN RES, V11, P167, DOI 10.1179/096805105X37330; Gutsmann T, 2001, BIOPHYS J, V80, P2935, DOI 10.1016/S0006-3495(01)76259-5; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; Hong J, 1999, BIOCHEMISTRY-US, V38, P16963, DOI 10.1021/bi991850y; LEIPPE M, 1994, P NATL ACAD SCI USA, V91, P2602, DOI 10.1073/pnas.91.7.2602; Lohner K., 2001, DEV NOVEL ANTIMICROB; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; Meng FG, 2001, BIOCHIMIE, V83, P953, DOI 10.1016/S0300-9084(01)01340-2; Miteva M, 1999, FEBS LETT, V462, P155, DOI 10.1016/S0014-5793(99)01520-3; MONERA OD, 1993, J BIOL CHEM, V268, P19218; Monreal D, 2003, INFECT IMMUN, V71, P3261, DOI 10.1128/IAI.71.6.3261-3271.2003; MUNFORD RS, 1995, J LIPID RES, V36, P1653; Norrby SR, 2005, LANCET INFECT DIS, V5, P115, DOI 10.1016/S1473-3099(05)01283-1; Papo N, 2005, J BIOL CHEM, V280, P10378, DOI 10.1074/jbc.M412865200; Papo N, 2004, BIOCHEMISTRY-US, V43, P6393, DOI 10.1021/bi049944h; Pena SV, 1997, J IMMUNOL, V158, P2680; Peschel A, 2006, NAT REV MICROBIOL, V4, P529, DOI 10.1038/nrmicro1441; Powers JPS, 2006, ANTIMICROB AGENTS CH, V50, P1522, DOI 10.1128/AAC.50.4.1522-1524.2006; Schroder-Borm H, 2003, BBA-BIOMEMBRANES, V1612, P164, DOI 10.1016/S0005-2736(03)00115-9; Schromm AB, 1996, FEBS LETT, V399, P267, DOI 10.1016/S0014-5793(96)01338-5; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; Toke O, 2005, BIOPOLYMERS, V80, P717, DOI 10.1002/bip.20286; Wang Z, 2000, J IMMUNOL, V165, P1486, DOI 10.4049/jimmunol.165.3.1486; WAYNE PA, 2000, M7A5 NAT COMM CLIN L; Willumeit R, 2005, BBA-BIOMEMBRANES, V1669, P125, DOI 10.1016/j.bbamem.2005.01.011; Yang ST, 2003, FEBS LETT, V540, P229, DOI 10.1016/S0014-5793(03)00266-7; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	44	72	76	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14719	14728		10.1074/jbc.M608920200	http://dx.doi.org/10.1074/jbc.M608920200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389605	hybrid			2022-12-27	WOS:000246589000007
J	de Frutos, S; Spangler, R; Alo, D; Bosc, LVG				de Frutos, Sergio; Spangler, Rhyannon; Alo, Dominique; Bosc, Laura V. Gonzalez			NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; ACTIVATED T-CELLS; ANGIOTENSIN-CONVERTING ENZYME; SERUM RESPONSE FACTOR; NUCLEAR FACTOR; GENE-EXPRESSION; MOLECULAR REGULATION; ENDOTHELIN ETA; PROTEIN-KINASE; K+ CHANNELS	Physiological responses to chronic hypoxia include polycythemia, pulmonary arterial remodeling, and vasoconstriction. Chronic hypoxia causes pulmonary arterial hypertension leading to right ventricular hypertrophy and heart failure. During pulmonary hypertension, pulmonary arteries exhibit increased expression of smooth muscle-alpha-actin and -myosin heavy chain. NFATc3 ( nuclear factor of activated T cells isoform c3), which is a Ca2+-dependent transcription factor, has been recently linked to smooth muscle phenotypic maintenance through the regulation of the expression of alpha-actin. The aim of this study was to determine if: ( a) NFATc3 is expressed in murine pulmonary arteries, ( b) hypoxia induces NFAT activation, ( c) NFATc3 mediates the up-regulation of alpha-actin during chronic hypoxia, and ( d) NFATc3 is involved in chronic hypoxia-induced pulmonary vascular remodeling. NFATc3 transcript and protein were found in pulmonary arteries. NFAT-luciferase reporter mice were exposed to normoxia ( 630 torr) or hypoxia ( 380 torr) for 2, 7, or 21 days. Exposure to hypoxia elicited a significant increase in luciferase activity and pulmonary arterial smooth muscle nuclear NFATc3 localization, demonstrating NFAT activation. Hypoxia induced up-regulation of alpha-actin and was prevented by the calcineurin/NFAT inhibitor, cyclosporin A ( 25 mg/kg/day s.c.). In addition, NFATc3 knock-out mice did not showed increased alpha-actin levels and arterial wall thickness after hypoxia. These results strongly suggest that NFATc3 plays a role in the chronic hypoxia-induced vascular changes that underlie pulmonary hypertension.	Univ New Mexico, Sch Med, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA	University of New Mexico	Bosc, LVG (corresponding author), Univ New Mexico, Sch Med, Dept Cell Biol & Physiol, MSC 08 4750, Albuquerque, NM 87131 USA.	lgonzalezbosc@salud.unm.edu	de Frutos, Sergio/AAE-7761-2021; Alò, Dominique/AAC-9127-2019	de Frutos, Sergio/0000-0002-1225-5911; Alò, Dominique/0000-0003-0579-4156	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088151] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL088151-01A1, R01 HL088151] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott KL, 2000, MOL PHARMACOL, V58, P946, DOI 10.1124/mol.58.5.946; Abe K, 2004, CIRC RES, V94, P385, DOI 10.1161/01.RES.0000111804.34509.94; AMBERG GC, 2004, J BIOL CHEM; Blumberg FC, 2003, J APPL PHYSIOL, V94, P446, DOI 10.1152/japplphysiol.00239.2002; Bosc LVG, 2005, J BIOL CHEM, V280, P26113, DOI 10.1074/jbc.M411972200; Bosc LVG, 2004, J BIOL CHEM, V279, P10702, DOI 10.1074/jbc.M312920200; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Chassagne C, 2000, AM J RESP CELL MOL, V22, P323, DOI 10.1165/ajrcmb.22.3.3701; Cheever Kerry H, 2005, J Cardiovasc Nurs, V20, P108; Dumitrascu R, 2006, CIRCULATION, V113, P286, DOI 10.1161/CIRCULATIONAHA.105.581405; Durmowicz A G, 1999, Pediatr Rev, V20, pe91; El-Gamal Y, 2002, ANN ALLERG ASTHMA IM, V88, P370, DOI 10.1016/S1081-1206(10)62366-6; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Fagan KA, 2004, AM J PHYSIOL-LUNG C, V287, pL656, DOI 10.1152/ajplung.00090.2003; FATIGATI V, 1984, J BIOL CHEM, V259, P4383; FERRI C, 1995, J CLIN PATHOL, V48, P519, DOI 10.1136/jcp.48.6.519; Gomez MF, 2003, J BIOL CHEM, V278, P46847, DOI 10.1074/jbc.M304765200; Gomez MF, 2002, J BIOL CHEM, V277, P37756, DOI 10.1074/jbc.M203596200; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Hautmann MB, 1997, CIRC RES, V81, P600, DOI 10.1161/01.RES.81.4.600; Hill-Eubanks DC, 2003, TRENDS CARDIOVAS MED, V13, P56, DOI 10.1016/S1050-1738(02)00212-8; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hopkins N, 2002, J ANAT, V201, P335, DOI 10.1046/j.1469-7580.2002.00096.x; Ip SP, 2002, PANCREAS, V25, P296, DOI 10.1097/00006676-200210000-00013; Ivy DD, 1998, AM J PHYSIOL-LUNG C, V274, pL535, DOI 10.1152/ajplung.1998.274.4.L535; Jernigan NL, 2004, AM J PHYSIOL-LUNG C, V287, pL1220, DOI 10.1152/ajplung.00196.2004; Jones R, 1999, AM J RESP CELL MOL, V20, P582, DOI 10.1165/ajrcmb.20.4.3357; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Koulmann N, 2006, AM J RESP CRIT CARE, V174, P699, DOI 10.1164/rccm.200512-1976OC; Li KX, 1999, AM J PHYSIOL-HEART C, V277, pH363, DOI 10.1152/ajpheart.1999.277.1.H363; Lin MJ, 2004, CIRC RES, V95, P496, DOI 10.1161/01.RES.0000138952.16382.ad; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MEYRICK B, 1979, ANAT REC, V193, P71, DOI 10.1002/ar.1091930106; MORELLI S, 1993, LUPUS, V2, P367, DOI 10.1177/096120339300200606; MORRELL NW, 1995, J CLIN INVEST, V96, P1823, DOI 10.1172/JCI118228; Nagaoka T, 2006, J APPL PHYSIOL, V100, P996, DOI 10.1152/japplphysiol.01028.2005; Naik JS, 2005, J APPL PHYSIOL, V98, P1119, DOI 10.1152/japplphysiol.00819.2004; Nakayama H, 2006, FASEB J, V20, P1660, DOI 10.1096/fj.05-5560com; Nieves-Cintron M, 2007, J BIOL CHEM, V282, P3231, DOI 10.1074/jbc.M608822200; Nilsson LM, 2007, AM J PHYSIOL-CELL PH, V292, pC1167, DOI 10.1152/ajpcell.00590.2005; Nishida M, 2004, J CARDIOVASC PHARM, V44, P187, DOI 10.1097/00005344-200408000-00007; Ohkawa Y, 2003, BIOCHEM BIOPH RES CO, V301, P78, DOI 10.1016/S0006-291X(02)02965-0; Orte C, 2000, J PATHOL, V192, P379, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH715>3.0.CO;2-Q; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Owens GK, 1996, J HYPERTENS, V14, pS55; OWENS GK, 1981, P NATL ACAD SCI-BIOL, V78, P7759, DOI 10.1073/pnas.78.12.7759; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; OWENS GK, 1995, PHYSIOL REV, V75, P487; Paddenberg R, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-15; PADEH S, 1991, ARTHRITIS RHEUM, V34, P1575; RABINOVITCH M, 1979, AM J PHYSIOL, V236, pH818, DOI 10.1152/ajpheart.1979.236.6.H818; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Resta TC, 1997, AM J PHYSIOL-HEART C, V272, pH806, DOI 10.1152/ajpheart.1997.272.2.H806; Resta TC, 1999, AM J PHYSIOL-HEART C, V276, pH699, DOI 10.1152/ajpheart.1999.276.2.H699; Resta TC, 1998, RESP PHYSIOL, V114, P161, DOI 10.1016/S0034-5687(98)00086-3; Rosenberg P, 2004, P NATL ACAD SCI USA, V101, P9387, DOI 10.1073/pnas.0308179101; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Shimoda LA, 2000, PHYSIOL RES, V49, P549; Shimoda LA, 2001, AM J PHYSIOL-LUNG C, V281, pL202, DOI 10.1152/ajplung.2001.281.1.L202; Short M, 2004, AM J PHYSIOL-CELL PH, V286, pC416, DOI 10.1152/ajpcell.00169.2003; Soma S, 1999, AM J RESP CELL MOL, V20, P620, DOI 10.1165/ajrcmb.20.4.3356; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wang J, 1997, J CLIN INVEST, V100, P2347, DOI 10.1172/JCI119774; Wang J, 2006, CIRC RES, V98, P1528, DOI 10.1161/01.RES.0000227551.68124.98; WEIR EK, 1995, FASEB J, V9, P183, DOI 10.1096/fasebj.9.2.7781921; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Yaghi A, 2005, AM J PHYSIOL-LUNG C, V289, pL1061, DOI 10.1152/ajplung.00096.2005; Yang XD, 1997, CHINESE MED J-PEKING, V110, P104; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Yuan JXJ, 1998, CIRCULATION, V98, P1400, DOI 10.1161/01.CIR.98.14.1400; Yuyama H, 2005, VASC PHARMACOL, V43, P40, DOI 10.1016/j.vph.2005.03.001	75	91	93	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15081	15089		10.1074/jbc.M702679200	http://dx.doi.org/10.1074/jbc.M702679200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17403661	Green Accepted, hybrid			2022-12-27	WOS:000246589000048
J	Nagao, K; Takahashi, K; Hanada, K; Kioka, N; Matsuo, M; Ueda, K				Nagao, Kohjiro; Takahashi, Kei; Hanada, Kentaro; Kioka, Noriyuki; Matsuo, Michinori; Ueda, Kazumitsu			Enhanced ApoA-I-dependent cholesterol efflux by ABCA1 from sphingomyelin-deficient chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID EFFLUX; A-I; MEMBRANE; PHOSPHATIDYLCHOLINE; TRAFFICKING; PROTEIN; RAFTS	ATP binding cassette protein A1 (ABCA1) plays a major role in cholesterol homeostasis and high density lipoprotein ( HDL) metabolism. It is proposed that ABCA1 reorganizes the plasma membrane and generates more loosely packed domains that facilitate apoA-I-dependent cholesterol efflux. In this study, we examined the effects of the cellular sphingomyelin level on HDL formation by ABCA1 by using a Chinese hamster ovary-K1 mutant cell line, LY-A, which has a missense mutation in the ceramide transfer protein CERT. When LY- A cells were cultured in Nutridoma-BO medium and sphingomyelin content was reduced, apoA-I-dependent cholesterol efflux by ABCA1 from LY-A cells increased 1.65-fold compared with that from LY-A/CERT cells stably transfected with human CERT cDNA. Exogenously added sphingomyelin significantly reduced the apoA-I-dependent efflux of cholesterol from LY-A cells, confirming that the decrease in sphingomyelin content in the plasma membrane stimulates cholesterol efflux by ABCA1. The amount of cholesterol available to cold methyl-beta-cyclodextrin (M beta CD) extraction from LY-A cells was increased by 40% by the expression of ABCA1 and was 1.6-fold higher than that from LY-A/CERT cells. This step in ABCA1 function, making cholesterol available to cold M beta CD, was independent of apoA-I. These results suggest that the function of ABCA1 could be divided into two steps: (i) a flopping step to move phosphatidylcholine and cholesterol from the inner to outer leaflet of the plasma membrane, where cholesterol becomes available to cold M beta CD extraction, and (ii) a loading step to load phosphatidylcholine and cholesterol onto apoA-I to generate HDL.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan; Natl Inst Infect Dis, Dept Biochem & Cell Biol, Tokyo 1628640, Japan	Kyoto University; National Institute of Infectious Diseases (NIID)	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.jp		Ueda, Kazumitsu/0000-0003-2980-6078; Hanada, Kentaro/0000-0003-1383-2781; Kioka, Noriyuki/0000-0002-2708-537X				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Francone OL, 2003, BIOCHEMISTRY-US, V42, P8569, DOI 10.1021/bi034540v; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; HANADA K, 1992, J BIOL CHEM, V267, P23527; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Hojjati MR, 2006, J LIPID RES, V47, P673, DOI 10.1194/jlr.D500040-JLR200; Ito J, 2000, J LIPID RES, V41, P894; Kobayashi A, 2006, J LIPID RES, V47, P1791, DOI 10.1194/jlr.M500546-JLR200; Koseki M, 2007, J LIPID RES, V48, P299, DOI 10.1194/jlr.M600428-JLR200; Landry YD, 2006, J BIOL CHEM, V281, P36091, DOI 10.1074/jbc.M602247200; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; OHTA K, 1993, J FERMENT BIOENG, V75, P155, DOI 10.1016/0922-338X(93)90229-2; Puri V, 2003, J BIOL CHEM, V278, P20961, DOI 10.1074/jbc.M300304200; Smith JD, 2004, J LIPID RES, V45, P635, DOI 10.1194/jlr.M300336-JLR200; Takahashi K, 2006, J BIOL CHEM, V281, P10760, DOI 10.1074/jbc.M513783200; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang MM, 2004, BIOCHEMISTRY-US, V43, P2159, DOI 10.1021/bi035982+; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200	23	56	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14868	14874		10.1074/jbc.M611230200	http://dx.doi.org/10.1074/jbc.M611230200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17409096	hybrid			2022-12-27	WOS:000246589000023
J	Brucet, M; Querol-Audi, J; Serra, M; Ramirez-Espain, X; Bertlik, K; Ruiz, L; Lloberas, J; Macias, MJ; Fita, I; Celada, A				Brucet, Marina; Querol-Audi, Jordi; Serra, Maria; Ramirez-Espain, Ximena; Bertlik, Kamila; Ruiz, Lidia; Lloberas, Jorge; Macias, Maria J.; Fita, Ignacio; Celada, Antonio			Structure of the dimeric exonuclease TREX1 in complex with DNA displays a proline-rich binding site for WW domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I; 3' TERMINI; PROTEIN; RECOGNITION; EXPRESSION; MECHANISM; 3'->5'-EXONUCLEASE; IDENTIFICATION; REPLICATION; MACROPHAGE	TREX1 is the most abundant mammalian 3' -> 5' DNA exonuclease. It has been described to form part of the SET complex and is responsible for the Aicardi-Goutieres syndrome in humans. Here we show that the exonuclease activity is correlated to the binding preferences toward certain DNA sequences. In particular, we have found three motifs that are selected, GAG, ACA, and CTGC. To elucidate how the discrimination occurs, we determined the crystal structures of two murine TREX1 complexes, with a nucleotide product of the exonuclease reaction, and with a single-stranded DNA substrate. Using confocal microscopy, we observed TREX1 both in nuclear and cytoplasmic subcellular compartments. Remarkably, the presence of TREX1 in the nucleus requires the loss of a C-terminal segment, which we named leucine-rich repeat 3. Furthermore, we detected the presence of a conserved proline-rich region on the surface of TREX1. This observation points to interactions with proline-binding domains. The potential interacting motif "PPPVPRPP" does not contain aromatic residues and thus resembles other sequences that select SH3 and/or Group 2 WW domains. By means of nuclear magnetic resonance titration experiments, we show that, indeed, a polyproline peptide derived from the murine TREX1 sequence interacted with the WW2 domain of the elongation transcription factor CA150. Co-immunoprecipitation studies confirmed this interaction with the full-length TREX1 protein, thereby suggesting that TREX1 participates in more functional complexes than previously thought.	Univ Barcelona, Inst Biomed Res, Macrophage Biol Grp, E-08028 Barcelona, Spain; CSIC, Inst Biol Mol Barcelona, Biomed Res Inst, E-08028 Barcelona, Spain; ICREA, Inst Biomed Res, Prot NMR Spect, Barcelona 08028, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA	Celada, A (corresponding author), Josep Samitier 1-5, E-08028 Barcelona, Spain.	acelada@ub.edu	Serra, Maria/AAA-9222-2020; Querol-Audí, Jordi/AAJ-9259-2021; Macias, Maria J/K-3898-2014; Lloberas, Jorge/D-4303-2014; Fita, Ignasi/R-4515-2019; Celada, Antonio/I-1714-2016; Ruiz, Lidia/ABF-9720-2021	Macias, Maria J/0000-0002-6915-963X; Lloberas, Jorge/0000-0001-7075-4201; Fita, Ignasi/0000-0002-7521-2679; Querol-Audi, Jordi/0000-0003-2892-7599; Serra, Maria/0000-0002-1559-250X; Ruiz Sainz, Lidia/0000-0002-8918-9158; Celada, Antonio/0000-0003-3883-2171	ICREA Funding Source: Custom	ICREA(ICREA)		Agrawal V, 2002, PROTEIN PEPTIDE LETT, V9, P185, DOI 10.2174/0929866023408760; Ball LJ, 2005, ANGEW CHEM INT EDIT, V44, P2852, DOI 10.1002/anie.200400618; Bebenek K, 2001, J BIOL CHEM, V276, P2317, DOI 10.1074/jbc.C000690200; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Chowdhury D, 2006, MOL CELL, V23, P133, DOI 10.1016/j.molcel.2006.06.005; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; DESILVA U, 2007, J BIOL CHEM     0209; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; Horio T, 2004, FEBS LETT, V577, P111, DOI 10.1016/j.febslet.2004.09.074; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Kato Y, 2004, J BIOL CHEM, V279, P31833, DOI 10.1074/jbc.M404719200; Kay JN, 2005, DEVELOPMENT, V132, P2573, DOI 10.1242/dev.01831; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mazur DJ, 2001, J BIOL CHEM, V276, P17022, DOI 10.1074/jbc.M100623200; Morita M, 2004, MOL CELL BIOL, V24, P6719, DOI 10.1128/MCB.24.15.6719-6727.2004; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrino Fred W., 1999, Cell Biochemistry and Biophysics, V30, P331, DOI 10.1007/BF02738118; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; Perrino FW, 2005, J BIOL CHEM, V280, P15212, DOI 10.1074/jbc.M500108200; Pires JR, 2005, J MOL BIOL, V348, P399, DOI 10.1016/j.jmb.2005.02.056; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Shevelev Igor V., 2002, TheScientificWorldJOURNAL, V2, P275; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Tang WN, 2003, J BIOL CHEM, V278, P28154, DOI 10.1074/jbc.M212976200; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; Wittekind M, 1997, J MOL BIOL, V267, P933, DOI 10.1006/jmbi.1996.0886; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Yang DH, 2004, J GEN VIROL, V85, P3569, DOI 10.1099/vir.0.80592-0; Yang XC, 2006, J BIOL CHEM, V281, P30447, DOI 10.1074/jbc.M602947200; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	39	33	36	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14547	14557		10.1074/jbc.M700236200	http://dx.doi.org/10.1074/jbc.M700236200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355961	hybrid			2022-12-27	WOS:000246245800068
J	Montaudon, D; Palle, K; Rivory, LP; Robert, J; Douat-Casassus, C; Quideau, S; Bjornsti, MA; Pourquier, P				Montaudon, Daniele; Palle, Komaraiah; Rivory, Laurent P.; Robert, Jacques; Douat-Casassus, Celine; Quideau, Stephane; Bjornsti, Mary-Ann; Pourquier, Philippe			Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds - Importance of vicinal cysteines 504 and 505	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAPACHONE-INDUCED APOPTOSIS; DNA TOPOISOMERASES; BETA-LAPACHONE; EUKARYOTIC TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; CAMPTOTHECIN RESISTANCE; CRYSTAL-STRUCTURES; 3T3-L1 ADIPOCYTES; HYDROGEN-PEROXIDE; SULFHYDRYL-GROUPS	DNA topoisomerase I (Top1) is a nuclear enzyme that plays a crucial role in the removal of DNA supercoiling associated with replication and transcription. It is also the target of the anticancer agent, camptothecin (CPT). Top1 contains eight cysteines, including two vicinal residues (504 and 505), which are highly conserved across species. In this study, we show that thiol-reactive compounds such as N-ethylmaleimide and phenylarsine oxide can impair Top1 catalytic activity. We demonstrate that in contrast to CPT, which inhibits Top1-catalyzed religation, thiolation of Top1 inhibited the DNA cleavage step of the reaction. This inhibition was more pronounced when Top1 was preincubated with the thiol-reactive compound and could be reversed in the presence of dithiothreitol. We also established that phenylarsine oxide-mediated inhibition of Top1 cleavage involved the two vicinal cysteines 504 and 505, as this effect was suppressed when cysteines were mutated to alanines. Interestingly, mutation of Cys-505 also altered Top1 sensitivity to CPT, even in the context of the double Cys-504 to Cys-505 mutant, which relaxed supercoiled DNA with a comparable efficiency to that of wild-type Top1. This indicates that cysteine 505, which is located in the lower Lip domain of human Top1, is critical for optimal poisoning of the enzyme by CPT and its analogs. Altogether, our results suggest that conserved vicinal cysteines 504 and 505 of human Top1 play a critical role in enzyme catalytic activity and are the target of thiol-reactive compounds, which may be developed as efficient Top1 catalytic inhibitors.	Univ Bordeaux 2, Mol Pharmacol Grp, INSERM, E347, F-33076 Bordeaux, France; Univ Bordeaux 2, Inst Bergonie, F-33076 Bordeaux, France; St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA; Johnson & Johnson Res Pty Ltd, Preclin Dev Team, Eveleigh, NSW 1430, Australia; Inst Europeen Chim & Biol, F-33607 Pessac, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; St Jude Children's Research Hospital; Johnson & Johnson	Pourquier, P (corresponding author), Univ Bordeaux 2, Mol Pharmacol Grp, INSERM, E347, 229 Cours Argonne,146 Rue Leo Saignat, F-33076 Bordeaux, France.	pourquier@bergonie.org	Quideau, Stéphane/AAG-5686-2019; Robert, Jacques/B-2179-2008; Pourquier, Philippe/O-8030-2018; Robert, Jacques/AAS-3923-2020; Douat, Celine/H-8671-2013	Robert, Jacques/0000-0003-4380-1476; Pourquier, Philippe/0000-0001-5326-3005; Rivory, Laurent/0000-0002-1734-7882; Douat, Celine/0000-0003-2678-1047	NATIONAL CANCER INSTITUTE [R01CA058755] Funding Source: NIH RePORTER; NCI NIH HHS [CA58755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bailly C, 1997, BIOCHEMISTRY-US, V36, P3917, DOI 10.1021/bi9624898; Bailly C, 2000, CURR MED CHEM, V7, P39, DOI 10.2174/0929867003375489; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; CHAMPOUX JJ, 1990, MECH ASPECTS TYPE 1, P217; Chau YP, 1998, FREE RADICAL BIO MED, V24, P660, DOI 10.1016/S0891-5849(97)00337-7; Chrencik JE, 2004, J MOL BIOL, V339, P773, DOI 10.1016/j.jmb.2004.03.007; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; DURNFORD JM, 1978, J BIOL CHEM, V253, P1086; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; FROST SC, 1985, J BIOL CHEM, V260, P2646; Frydman B, 1997, CANCER RES, V57, P620; Gerhard R, 2003, MOL PHARMACOL, V63, P1349, DOI 10.1124/mol.63.6.1349; GOTO T, 1984, J BIOL CHEM, V259, P422; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; Haas R, 1998, FRESEN J ANAL CHEM, V361, P313, DOI 10.1007/s002160050892; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1989, CANCER RES, V49, P5077; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Koster DA, 2005, NATURE, V434, P671, DOI 10.1038/nature03395; KUTSUMI H, 1995, BLOOD, V85, P2559, DOI 10.1182/blood.V85.9.2559.bloodjournal8592559; Leppard JB, 2005, CHROMOSOMA, V114, P75, DOI 10.1007/s00412-005-0345-5; Lesher DTT, 2002, P NATL ACAD SCI USA, V99, P12102, DOI 10.1073/pnas.192282699; LI CJ, 1993, J BIOL CHEM, V268, P2263; LIAO K, 1991, J BIOL CHEM, V266, P6544; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; MCHUGH MM, 1989, BIOCHEM PHARMACOL, V38, P2323, DOI 10.1016/0006-2952(89)90472-3; Meng LH, 2003, CURR TOP MED CHEM, V3, P305; Neder K, 1998, CELL MOL BIOL, V44, P465; Niu P, 2002, BBA-PROTEIN STRUCT M, V1594, P364, DOI 10.1016/S0167-4838(01)00329-6; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Pardee AB, 2002, CURR CANCER DRUG TAR, V2, P227, DOI 10.2174/1568009023333854; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; PLOUX O, 1995, BIOCHEMISTRY-US, V34, P4159, DOI 10.1021/bi00013a003; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Portela MPM, 1996, BIOCHEM PHARMACOL, V52, P1875; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Redinbo MR, 1999, J MOL BIOL, V292, P685, DOI 10.1006/jmbi.1999.3065; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; SAMANTA AK, 1993, J BIOL CHEM, V268, P6147; Shiah SG, 1999, CANCER RES, V59, P391; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; Smyth DG, 1960, J AM CHEM SOC, V82, P4600, DOI 10.1021/ja01502a039; Sordet O, 2004, J BIOL CHEM, V279, P33968, DOI 10.1074/jbc.M404620200; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; Tirumalai RS, 1996, J BIOL CHEM, V271, P29599, DOI 10.1074/jbc.271.47.29599; van Waardenburg RCAM, 2006, MOL CELL BIOL, V26, P4958, DOI 10.1128/MCB.00160-06; Wang HM, 2001, BIOCHEMISTRY-US, V40, P3316, DOI 10.1021/bi002786j; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200	57	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14403	14412		10.1074/jbc.M611673200	http://dx.doi.org/10.1074/jbc.M611673200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355975	hybrid			2022-12-27	WOS:000246245800053
J	Pochynyuk, O; Staruschenko, A; Bugaj, V; LaGrange, L; Stockand, JD				Pochynyuk, Oleh; Staruschenko, Alexander; Bugaj, Vladislav; LaGrange, Lila; Stockand, James D.			Quantifying RhoA facilitated trafficking of the epithelial Na+ channel toward the plasma membrane with total internal reflection fluorescence- fluorescence recovery after photobleaching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; SUBUNIT STOICHIOMETRY; SECRETORY GRANULES; POTASSIUM CHANNEL; MAMMALIAN-CELLS; EXOCYTOSIS; TRANSLOCATION; TRANSPORT; PROTEINS; LOCALIZATION	The epithelial Na+ channel ( ENaC) plays a central role in control of epithelial surface hydration and vascular volume. Similar to other ion channels, ENaC activity is set, in part, by its membrane levels. The small G protein RhoA increases ENaC activity by increasing the membrane levels of this channel. We hypothesize that RhoA increases ENaC activity by promoting channel trafficking to the plasma membrane. Few experimental methods are available to directly visualize trafficking of ion channels to the plasma membrane. Here we combine electrophysiology with two complementary imaging methods, total internal reflection fluorescence microscopy and fluorescence recovery after photobleaching, to study the mechanistic basis of RhoA actions on ENaC. Patch clamp results demonstrate that RhoA increases ENaC activity in an additive manner with dominant-negative dynamin. This is consistent with a mechanism of increased ENaC trafficking to the membrane. Direct visualization of ENaC movement near the plasma membrane with total internal reflection fluorescence-fluorescence recovery after photobleaching revealed that RhoA accelerates ENaC trafficking toward the membrane. RhoA-facilitated movement of the channel was sensitive to disrupting the endomembrane system. Moreover, facilitating retrieval decreased ENaC activity but not trafficking toward the membrane. ENaC at the plasma membrane clustered and was laterally immobile suggesting that the cytoskeleton tethers or corrals membrane resident channels or membrane-directed vesicles containing ENaC. Disrupting microtubules but not microfilaments led to reorganization of ENaC clusters and slowed trafficking toward the membrane. The cytoskeleton is an established target for RhoA signaling. We conclude that RhoA, likely through effects on the cytoskeleton, promotes ENaC trafficking to the plasma membrane to increase channel membrane levels and activity.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Stockand, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stockand@uthscsa.edu		Staruschenko, Alexander/0000-0002-5190-8356; Stockand, James/0000-0002-3817-4319	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059594, R01DK070571] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK59594, R01 DK070571] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Bhalla V, 2005, MOL ENDOCRINOL, V19, P3073, DOI 10.1210/me.2005-0193; BURGHARDT TP, 1981, BIOPHYS J, V33, P455, DOI 10.1016/S0006-3495(81)84906-5; Cao H, 2000, J CELL SCI, V113, P1993; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Doussau F, 2000, J BIOL CHEM, V275, P7764, DOI 10.1074/jbc.275.11.7764; Doussau F, 2000, BIOCHIMIE, V82, P353, DOI 10.1016/S0300-9084(00)00217-0; Han WP, 1999, P NATL ACAD SCI USA, V96, P14577, DOI 10.1073/pnas.96.25.14577; Hofer D, 1998, ANN NY ACAD SCI, V859, P75, DOI 10.1111/j.1749-6632.1998.tb11112.x; Hong-Geller E, 2000, J CELL BIOL, V148, P481, DOI 10.1083/jcb.148.3.481; Johns LM, 2001, J CELL BIOL, V153, P177, DOI 10.1083/jcb.153.1.177; Jones SVP, 2003, MOL PHARMACOL, V64, P987, DOI 10.1124/mol.64.4.987; Kamynina E, 2002, AM J PHYSIOL-RENAL, V283, pF377, DOI 10.1152/ajprenal.00143.2002; Kusumi A, 2005, ANNU REV BIOPH BIOM, V34, P351, DOI 10.1146/annurev.biophys.34.040204.144637; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lorenz H, 2006, NAT METHODS, V3, P205, DOI 10.1038/nmeth857; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Pochynyuk O, 2005, J BIOL CHEM, V280, P37565, DOI 10.1074/jbc.M509071200; Pochynyuk O, 2006, J BIOL CHEM, V281, P26520, DOI 10.1074/jbc.M603716200; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Schmoranzer J, 2000, J CELL BIOL, V149, P23, DOI 10.1083/jcb.149.1.23; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2005, ENDOCRINOLOGY, V146, P5079, DOI 10.1210/en.2005-0894; Staruschenko A, 2005, J BIOL CHEM, V280, P39161, DOI 10.1074/jbc.M509608200; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staruschenko A, 2004, J BIOL CHEM, V279, P49989, DOI 10.1074/jbc.M409812200; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Storey NM, 2002, CURR BIOL, V12, P27, DOI 10.1016/S0960-9822(01)00625-X; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; THOMPSON NL, 1981, BIOPHYS J, V33, P435, DOI 10.1016/S0006-3495(81)84905-3; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; YATANI A, 1991, J BIOL CHEM, V266, P22222	42	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14576	14585		10.1074/jbc.M701348200	http://dx.doi.org/10.1074/jbc.M701348200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17376773	hybrid			2022-12-27	WOS:000246245800071
J	Tu, SJ; Bulloch, EMM; Yang, LH; Ren, C; Huang, WC; Hsu, PH; Chen, CH; Liao, CL; Yu, HM; Lo, WS; Freitas, MA; Tsai, MD				Tu, Shengjiang; Bulloch, Esther M. M.; Yang, Lanhao; Ren, Chen; Huang, Wei-Chieh; Hsu, Pang-Hung; Chen, Chein-Hung; Liao, Chung-Lin; Yu, Hui-Ming; Lo, Wan-Sheng; Freitas, Michael A.; Tsai, Ming-Daw			Identification of histone demethylases in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; LYSINE METHYLATION; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTION ELONGATION; OXIDATIVE DEMETHYLATION; ANDROGEN-RECEPTOR; ESCHERICHIA-COLI; FISSION YEAST; DNA-DAMAGE; H3	Based on the prediction that histone lysine demethylases may contain the JmjC domain, we examined the methylation patterns of five knock-out strains (ecm5 Delta, gis1 Delta, rph1 Delta, jhd1 Delta, and jhd2 Delta (yjr119c Delta)) of Saccharomyces cerevisiae. Mass spectrometry (MS) analyses of histone H3 showed increased modifications in all mutants except ecm5 Delta. High-resolution MS was used to unequivocally differentiate trimethylation from acetylation in various tryptic fragments. The relative abundance of specific fragments indicated that histones K36me3 and K4me3 accumulate in rph1 Delta and jhd2 Delta strains, respectively, whereas both histone K36me2 and K36me accumulate in gis1 Delta and jhd1 Delta strains. Analyses performed with strains overexpressing the JmjC proteins yielded changes in methylation patterns that were the reverse of those obtained in the complementary knock-out strains. In vitro enzymatic assays confirmed that the JmjC domain of Rph1 specifically demethylates K36me3 primarily and K36me2 secondarily. Overexpression of RPH1 generated a growth defect in response to UV irradiation. The demethylase activity of Rph1 is responsible for the phenotype. Collectively, in addition to Jhd1, our results identified three novel JmjC domain-containing histone demethylases and their sites of action in budding yeast S. cerevisiae. Furthermore, the methodology described here will be useful for identifying histone demethylases and their target sites in other organisms.	Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 100, Taiwan; Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan	National Taiwan University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Academia Sinica - Taiwan	Lo, WS (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 100, Taiwan.	sunnylo@ha.mc.ntu.edu.tw; Freitas.5@osu.edu; Tsai.7@osu.edu	Tu, Shengjiang/K-7868-2012; Hsu, Pang-Hung/C-5587-2018; Freitas, Michael/C-8953-2009; Tsai, Ming-Daw/G-4689-2019	Tu, Shengjiang/0000-0003-3616-3242; Hsu, Pang-Hung/0000-0001-6873-6434; Freitas, Michael/0000-0002-3103-8410; Tsai, Ming-Daw/0000-0003-1374-0414; Bulloch, Esther/0000-0002-4262-1791	NCI NIH HHS [R01 CA107106-03, R21 CA110496, CA110496, R01 CA107106-04, CA69472, R01 CA069472, R01 CA107106-01, R01 CA107106, R01 CA107106-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069472, R21CA110496, R01CA107106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed S, 2004, MOL CELL BIOL, V24, P3660, DOI 10.1128/MCB.24.9.3660-3669.2004; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Ayoub N, 2003, MOL CELL BIOL, V23, P4356, DOI 10.1128/MCB.23.12.4356-4370.2003; Balciunas D, 2000, TRENDS BIOCHEM SCI, V25, P274, DOI 10.1016/S0968-0004(00)01593-0; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Brachmann CB, 1998, YEAST, V14, P115; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Fingerman IM, 2005, J BIOL CHEM, V280, P28761, DOI 10.1074/jbc.C500097200; Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206; Gelperin DM, 2005, GENE DEV, V19, P2816, DOI 10.1101/gad.1362105; Gray SG, 2005, J BIOL CHEM, V280, P28507, DOI 10.1074/jbc.M413687200; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Jang YK, 1999, MOL CELL BIOL, V19, P7630; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jung J, 2005, J BIOL CHEM, V280, P30916, DOI 10.1074/jbc.M414482200; Kamakaka RT, 1998, GENETICS, V149, P903; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Kubicek S, 2004, CELL, V119, P903, DOI 10.1016/j.cell.2004.12.006; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Lo WS, 2004, METHOD ENZYMOL, V377, P130; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Millar CB, 2006, NAT REV MOL CELL BIO, V7, P657, DOI 10.1038/nrm1986; Morillon A, 2005, MOL CELL, V18, P723, DOI 10.1016/j.molcel.2005.05.009; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Ouspenski II, 1999, NUCLEIC ACIDS RES, V27, P3001, DOI 10.1093/nar/27.15.3001; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Ren C, 2005, J AM SOC MASS SPECTR, V16, P1641, DOI 10.1016/j.jasms.2005.06.001; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Shahbazian MD, 2005, MOL CELL, V19, P271, DOI 10.1016/j.molcel.2005.06.010; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Trewick SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wysocki R, 2005, MOL CELL BIOL, V25, P8430, DOI 10.1128/MCB.25.19.8430-8443.2005; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027	55	80	84	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14262	14271		10.1074/jbc.M609900200	http://dx.doi.org/10.1074/jbc.M609900200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369256	hybrid, Green Accepted			2022-12-27	WOS:000246245800037
J	Higashitsuji, H; Higashitsuji, H; Masuda, T; Liu, Y; Itoh, K; Fujita, J				Higashitsuji, Hisako; Higashitsuji, Hiroaki; Masuda, Tomoko; Liu, Yu; Itoh, Katsuhiko; Fujita, Jun			Enhanced deacetylation of p53 by the anti-apoptotic protein HSCO in association with histone deacetylase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HISTONE DEACETYLASE-1; HEPATOCELLULAR CARCINOMAS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; IN-VIVO; ACETYLATION; STABILITY; DEGRADATION; CELLS	HSCO ( hepatoma subtracted- cDNA library clone one, also called ETHE1) was originally identified by its frequent overexpression in hepatocellular carcinomas. HSCO inhibits function of NF-kappa B by binding to RelA and accelerating its export from the nucleus. We show here that HSCO exhibits anti-apoptotic activity in cells exposed to DNA-damaging agents by suppressing transcriptional activity of p53. Induction of pro-apoptotic genes, Noxa, Perp, PIG3, and Bax were suppressed in cells overexpressing HSCO. By increasing ubiquitylation and degradation of p53, HSCO reduces p53 protein levels. HSCO specifically associates with histone deacetylase 1 (HDAC1) independently of Mdm2 and facilitates deacetylation of p53 at Lys-373/382 by HDAC1. The metallo-beta-lactamase family consensus sequence in HSCO is important for its effect on p53 deacetylation. Co-immunoprecipitation and immunofluorescence studies suggested that HSCO, HDAC1, and p53 form a complex in the nucleus. Thus, HSCO is a cofactor that increases the deacetylase activity of HDAC1 toward p53, leading to suppression of apoptosis. Treatment of hepatocellular carcinomas that retain wildtype p53 and overexpress HSCO with anti-HSCO agents might re-establish the p53 response and revert chemoresistance.	Kyoto Univ, Grad Sch Med, Dept Clin Mol Biol, Kyoto 6068507, Japan	Kyoto University	Higashitsuji, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Clin Mol Biol, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	hhigashi@virus.kyoto-u.ac.jp						Bandyopadhyay D, 2004, CANCER RES, V64, P7706, DOI 10.1158/0008-5472.CAN-03-3897; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gotoh K, 2004, FEBS LETT, V560, P19, DOI 10.1016/S0014-5793(04)00034-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kawaguchi Y, 2006, J BIOL CHEM, V281, P1394, DOI 10.1074/jbc.M505772200; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shetty S, 2005, MOL CELL BIOL, V25, P5404, DOI 10.1128/MCB.25.13.5404-5416.2005; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thomas MB, 2005, J CLIN ONCOL, V23, P2892, DOI 10.1200/JCO.2005.03.196; Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653; Treiber G, 2001, DIGEST DIS, V19, P311, DOI 10.1159/000050698; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2005, SCIENCE, V309, P1685, DOI 10.1126/science.1118232; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	46	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13716	13725		10.1074/jbc.M609751200	http://dx.doi.org/10.1074/jbc.M609751200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353187	hybrid			2022-12-27	WOS:000246060300061
J	Reig, N; del Rio, C; Casagrande, F; Ratera, M; Gelpi, JL; Torrents, D; Henderson, PJF; Xie, H; Baldwin, SA; Zorzano, A; Fotiadis, D; Palacin, M				Reig, Nuria; del Rio, Cesar; Casagrande, Fabio; Ratera, Merce; Gelpi, Josep Lluis; Torrents, David; Henderson, Peter J. F.; Xie, Hao; Baldwin, Stephen A.; Zorzano, Antonio; Fotiadis, Dimitrios; Palacin, Manuel			Functional and structural characterization of the first prokaryotic member of the L-amino acid transporter (LAT) family - A model for APC transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSINURIC PROTEIN INTOLERANCE; MULTIPLE SEQUENCE ALIGNMENT; ESCHERICHIA-COLI; LIGHT SUBUNIT; THIOL MODIFICATION; LACTOSE PERMEASE; GENOME SEQUENCE; SYSTEM X(C)(-); IDENTIFICATION; CYSTINE	We have identified YkbA from Bacillus subtilis as a novel member of the L-amino acid transporter (LAT) family of amino acid transporters. The protein is similar to 30% identical in amino acid sequence to the light subunits of human heteromeric amino acid transporters. Purified His-tagged YkbA from Escherichia coli membranes reconstituted in proteoliposomes exhibited sodium-independent, obligatory exchange activity for L-serine and L-threonine and also for aromatic amino acids, albeit with less activity. Thus, we propose that YkbA be renamed SteT(Ser/Thr exchanger transporter). Kinetic analysis supports a sequential mechanism of exchange for SteT. Freeze-fracture analysis of purified, functionally active SteT in proteoliposomes, together with blue native polyacrylamide gel electrophoresis and transmission electron microscopy of detergent-solubilized purified SteT, suggest that the transporter exists in a monomeric form. Freeze-fracture analysis showed spherical particles with a diameter of 7.4 nm. Transmission electron microscopy revealed elliptical particles (diameters 6 x 7 nm) with a distinct central depression. To our knowledge, this is the first functional characterization of a prokaryotic member of the LAT family and the first structural data on an APC (amino acids, polyamines, and choline for organocations) transporter. SteT represents an excellent model to study the molecular architecture of the light subunits of heteromeric amino acid transporters and other APC transporters.	Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland; Univ Barcelona, Fac Biol, Inst Res Biomed, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Inst Res Biomed, E-08028 Barcelona, Spain; Inst Catalana Recerca & Estudis Avancats, Barcelona Supercomp Ctr, Life Sci Program, E-08034 Barcelona, Spain; Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England; CIBERER, E-08028 Barcelona, Spain	University of Basel; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA; Universitat Politecnica de Catalunya; Barcelona Supercomputer Center (BSC-CNS); University of Leeds; CIBER - Centro de Investigacion Biomedica en Red; CIBERER	Fotiadis, D (corresponding author), Univ Basel, Biozentrum, ME Muller Inst Microscopy, CH-4056 Basel, Switzerland.	dimitrios.fotiadis@unibas.ch; mpalacin@pcb.ub.es	Henderson, Peter JF/Q-1907-2018; Gelpí, Josep Ll./M-6401-2013; Zorzano, Antonio/R-5479-2018; Torrents, David/G-5785-2015	Gelpí, Josep Ll./0000-0002-0566-7723; Henderson, Peter/0000-0002-9187-0938; Palacin, Manuel/0000-0002-8670-293X; Ratera, Merce/0000-0001-5224-9172; Torrents, David/0000-0002-6086-9037	ICREA Funding Source: Custom	ICREA(ICREA)		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069; Bassi MT, 2001, PFLUG ARCH EUR J PHY, V442, P286, DOI 10.1007/s004240100537; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Chang AB, 2004, MOL MEMBR BIOL, V21, P171, DOI 10.1080/09687680410001720830; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; DEKKER JP, 1988, BIOCHIM BIOPHYS ACTA, V936, P307, DOI 10.1016/0005-2728(88)90006-0; DIERKS T, 1988, BIOCHIM BIOPHYS ACTA, V943, P231, DOI 10.1016/0005-2736(88)90555-X; Do CB, 2005, GENOME RES, V15, P330, DOI 10.1101/gr.2821705; ELENO N, 1994, J PHYSIOL-LONDON, V479, P291, DOI 10.1113/jphysiol.1994.sp020296; Feliubadalo L, 1999, NAT GENET, V23, P52, DOI 10.1038/12652; Fernandez E, 2002, AM J PHYSIOL-RENAL, V283, pF540, DOI 10.1152/ajprenal.00071.2002; Gasol E, 2004, J BIOL CHEM, V279, P31228, DOI 10.1074/jbc.M402428200; Habermeier A, 2003, J BIOL CHEM, V278, P19492, DOI 10.1074/jbc.M210254200; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; Hu LYA, 1999, BIOCHEM J, V339, P649, DOI 10.1042/0264-6021:3390649; Ivanova N, 2003, NATURE, V423, P87, DOI 10.1038/nature01582; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; Jimenez-Vidal M, 2004, J BIOL CHEM, V279, P11214, DOI 10.1074/jbc.M309866200; Kaleeba JAR, 2006, SCIENCE, V311, P1921, DOI 10.1126/science.1120878; Kashiwagi K, 2000, J BIOL CHEM, V275, P36007, DOI 10.1074/jbc.M006083200; KASHIWAGI K, 1992, P NATL ACAD SCI USA, V89, P4529, DOI 10.1073/pnas.89.10.4529; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lopez O, 1998, FEBS LETT, V426, P314, DOI 10.1016/S0014-5793(98)00363-9; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; Palacin M, 2005, PHYSIOLOGY, V20, P112, DOI 10.1152/physiol.00051.2004; Palacin M, 2004, PFLUG ARCH EUR J PHY, V447, P490, DOI 10.1007/s00424-003-1062-7; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Riley M, 2006, NUCLEIC ACIDS RES, V34, P1, DOI 10.1093/nar/gkj405; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; SCHAGGER H, 1988, ANAL BIOCHEM, V173, P201, DOI 10.1016/0003-2697(88)90179-0; Suda K, 2004, MOL MEMBR BIOL, V21, P435, DOI 10.1080/09687860400020291; Torras-Llort M, 2001, J MEMBRANE BIOL, V180, P213, DOI 10.1007/s002320010072; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; Turk E, 2000, J BIOL CHEM, V275, P25711, DOI 10.1074/jbc.M003127200; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Xie H, 2004, MOL MEMBR BIOL, V21, P323, DOI 10.1080/09687860400003941; Zhuang JP, 1999, J STRUCT BIOL, V125, P63, DOI 10.1006/jsbi.1998.4059	46	34	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13270	13281		10.1074/jbc.M610695200	http://dx.doi.org/10.1074/jbc.M610695200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344220	hybrid			2022-12-27	WOS:000246060300015
J	Wright, JF; Guo, YJ; Quazi, A; Luxenberg, DP; Bennett, F; Ross, JF; Qiu, YC; Whitters, MJ; Tomkinson, KN; Dunussi-Joannopoulos, K; Carreno, BM; Collins, M; Wolfman, NM				Wright, Jill F.; Guo, Yongjing; Quazi, Amira; Luxenberg, Deborah P.; Bennett, Frann; Ross, John F.; Qiu, Yongchang; Whitters, Matthew J.; Tomkinson, Kathleen N.; Dunussi-Joannopoulos, Kyri; Carreno, Beatriz M.; Collins, Mary; Wolfman, Neil M.			Identification of an interleukin 17F/17A heterodimer in activated human CD4+T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-INDUCED ARTHRITIS; COLONY-STIMULATING FACTOR; NERVE GROWTH-FACTOR; T-CELLS; INFLAMMATORY RESPONSES; CRYSTAL-STRUCTURE; CUTTING EDGE; BONE EROSION; CYTOKINE; IL-17F	IL-17F and IL-17A are members of the IL-17 pro-inflammatory cytokine family. IL-17A has been implicated in the pathogenesis of autoimmune diseases. IL-17F is a disulfide-linked dimer that contains a cysteine-knot motif. We hypothesized that IL-17F and IL-17A could form a heterodimer due to their sequence homology and overlapping pattern of expression. We evaluated the structure of recombinant IL-17F and IL-17A proteins, as well as that of natural IL-17F and IL-17A derived from activated human CD4(+) T cells, by enzyme-linked immunosorbent assay, immunoprecipitation followed by Western blotting, and mass spectrometry. We find that both IL-17F and IL-17A can form both homodimeric and heterodimeric proteins when expressed in a recombinant system, and that all forms of the recombinant proteins have in vitro functional activity. Furthermore, we find that in addition to the homodimers of IL-17F and IL-17A, activated human CD4+ T cells also produce the IL-17F/ IL-17A heterodimer. These data suggest that the IL-17F/ IL-17A heterodimer may contribute to the T cell-mediated immune responses.	Wyeth Res, Dept Inflammat, Cambridge, MA 02140 USA; Wyeth Res, Dept Biol Technol, Cambridge, MA 02140 USA	Pfizer; Pfizer	Wright, JF (corresponding author), 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	jwright@wyeth.com						Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Arican O, 2005, MEDIAT INFLAMM, P273, DOI 10.1155/MI.2005.273; Bessis N, 2001, JOINT BONE SPINE, V68, P477, DOI 10.1016/S1297-319X(01)00310-4; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Dumont FJ, 2003, EXPERT OPIN THER PAT, V13, P287, DOI 10.1517/13543776.13.3.287; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508; Kawaguchi M, 2006, J ALLERGY CLIN IMMUN, V117, P795, DOI 10.1016/j.jaci.2005.12.1346; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P444, DOI 10.1016/j.jaci.2004.03.047; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; Lubberts E, 2004, ARTHRITIS RHEUM-US, V50, P650, DOI 10.1002/art.20001; Lubberts E, 2000, J CLIN INVEST, V105, P1697, DOI 10.1172/JCI7739; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Reinhardt RL, 2006, CURR OPIN IMMUNOL, V18, P271, DOI 10.1016/j.coi.2006.03.003; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; Veldhoen M, 2006, TRENDS IMMUNOL, V27, P358, DOI 10.1016/j.it.2006.06.001; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Witowski J, 2004, CELL MOL LIFE SCI, V61, P567, DOI 10.1007/s00018-003-3228-z; YOO ZB, 1995, J IMMUNOL, V155, P5483	36	233	262	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13447	13455		10.1074/jbc.M700499200	http://dx.doi.org/10.1074/jbc.M700499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355969	hybrid			2022-12-27	WOS:000246060300034
J	Gong, XQ; Shao, Q; Langlois, SP; Bai, DL; Laird, DW				Gong, Xiang-Qun; Shao, Qing; Langlois, Stephanie; Bai, Donglin; Laird, Dale W.			Differential potency of dominant negative connexin43 mutants in oculodentodigital dysplasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; GREEN FLUORESCENT PROTEIN; FUNCTIONAL-CHARACTERIZATION; MEMBRANE CHANNELS; PLASMA-MEMBRANE; LIVING CELLS; HEARING-LOSS; HELA-CELLS; MUTATIONS; COMMUNICATION	Oculodentodigital dysplasia (ODDD) is a congenital autosomal dominant disorder with phenotypic variability, which has been associated with mutations in the GJA1 gene encoding connexin43 (Cx43). Given that Cx43 mutants are thought to be equally co-expressed with wild-type Cx43 in ODDD patients, it is imperative to examine the consequence of these mutants in model systems that reflect this molar ratio. To that end, we used differential fluorescent protein tagging of mutant and wild-type Cx43 to quantitatively monitor the ratio of mutant/wild-type within the same putative gap junction plaques and co-immunoprecipitation to determine if the mutants interact with wildtype Cx43. Together the fluorescence-based assay was combined with patch clamp analysis to assess the dominant negative potency of Cx43 mutants. Our results revealed that the ODDD-linked Cx43 mutants, G21R and G138R, as well as amino terminus green fluorescent protein-tagged Cx43, were able to co-localize with wild-type Cx43 at the gap junction plaque-like structures and to co-immunoprecipitate with wild-type Cx43. All Cx43 mutants demonstrated dominant negative action on gap junctional conductance of wild-type Cx43 but not that of Cx32. More interestingly, these Cx43 mutants demonstrated different potencies in inhibiting the function of wild-type Cx43 with the G21R mutant being two times more potent than the G138R mutant. The potency difference in the dominant negative properties of ODDD-linked Cx43 mutants may have clinical implications for the various symptoms and disease severity observed in ODDD patients.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Bai, DL (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.	donglin.bai@schulich.uwo.ca	Bai, Donglin/A-5799-2008; Laird, Dale w/E-4176-2015; Laird, Dale W/AAL-2407-2020; Bai, Donglin/ABB-9924-2021	Bai, Donglin/0000-0003-1112-6947; Laird, Dale W/0000-0002-4568-3285; Bai, Donglin/0000-0003-1112-6947				Boyadjiev SA, 1999, GENOMICS, V58, P34, DOI 10.1006/geno.1999.5814; BRUZZONE R, 1994, J CELL SCI, V107, P955; Bukauskas FF, 2000, P NATL ACAD SCI USA, V97, P2556, DOI 10.1073/pnas.050588497; Bukauskas FF, 2001, BIOPHYS J, V81, P137, DOI 10.1016/S0006-3495(01)75687-1; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chang EH, 2003, EAR HEARING, V24, P314, DOI 10.1097/01.AUD.0000079801.55588.13; Contreras JE, 2003, P NATL ACAD SCI USA, V100, P11388, DOI 10.1073/pnas.1434298100; Cottrell GT, 2005, BBA-BIOMEMBRANES, V1711, P126, DOI 10.1016/j.bbamem.2004.11.013; Duffy HS, 2002, J BIOL CHEM, V277, P36706, DOI 10.1074/jbc.M207016200; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Evans WH, 2002, MOL MEMBR BIOL, V19, P121, DOI 10.1080/09687680210139839; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; Falk MM, 2000, J CELL SCI, V113, P4109; Fiorini C, 2004, J CELL SCI, V117, P4665, DOI 10.1242/jcs.01335; Flenniken AM, 2005, DEVELOPMENT, V132, P4375, DOI 10.1242/dev.02011; Frasson Maria, 2004, Ophthalmic Genet, V25, P227, DOI 10.1080/13816810490513424; FUJIKURA Y, 1993, ANAT REC, V235, P335, DOI 10.1002/ar.1092350302; Gollob MH, 2006, NEW ENGL J MED, V354, P2677, DOI 10.1056/NEJMoa052800; Gong XQ, 2006, J BIOL CHEM, V281, P31801, DOI 10.1074/jbc.M605961200; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; Krutovskikh VA, 1998, MOL CARCINOGEN, V23, P254, DOI 10.1002/(SICI)1098-2744(199812)23:4<254::AID-MC9>3.0.CO;2-4; Kudo T, 2003, HUM MOL GENET, V12, P995, DOI 10.1093/hmg/ddg116; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lai A, 2006, J CELL SCI, V119, P532, DOI 10.1242/jcs.02770; Laird DW, 2001, MICROSC RES TECHNIQ, V52, P263, DOI 10.1002/1097-0029(20010201)52:3<263::AID-JEMT1012>3.0.CO;2-Q; LAIRD DW, 1990, J CELL SCI, V97, P109; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Liew AWC, 2005, BIOINFORMATICS TECHNOLOGIES, P63, DOI 10.1007/3-540-26888-X_4; Marziano NK, 2003, HUM MOL GENET, V12, P805, DOI 10.1093/hmg/ddg076; McLachlan E, 2005, CELL COMMUN ADHES, V12, P279, DOI 10.1080/15419060500514143; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Musa H, 2004, J PHYSIOL-LONDON, V557, P863, DOI 10.1113/jphysiol.2003.059386; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Paemeleire K, 2000, MOL BIOL CELL, V11, P1815, DOI 10.1091/mbc.11.5.1815; Pal JD, 1999, AM J PHYSIOL-CELL PH, V276, pC1443, DOI 10.1152/ajpcell.1999.276.6.C1443; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; Richard G, 2003, CLIN EXP DERMATOL, V28, P397, DOI 10.1046/j.1365-2230.2003.01312.x; Roscoe W, 2005, J BIOL CHEM, V280, P11458, DOI 10.1074/jbc.M409564200; Rouan F, 2001, J CELL SCI, V114, P2105; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Seki A, 2004, HEART RHYTHM, V1, P227, DOI 10.1016/j.hrthm.2004.03.066; Shapiro RE, 1997, AM J MED GENET, V71, P36, DOI 10.1002/(SICI)1096-8628(19970711)71:1<36::AID-AJMG7>3.0.CO;2-O; SHEPPARD D, 1994, AM J RESP CELL MOL, V11, P1; Shibayama J, 2005, CIRC RES, V96, pE83, DOI 10.1161/01.RES.0000168369.79972.d2; Sosinsky GE, 2005, BBA-BIOMEMBRANES, V1711, P99, DOI 10.1016/j.bbamem.2005.04.001; Thomas T, 2005, J CELL SCI, V118, P4451, DOI 10.1242/jcs.02569; Thomas T, 2004, J BIOL CHEM, V279, P19157, DOI 10.1074/jbc.M314117200; WHITE TW, 1995, MOL BIOL CELL, V6, P459, DOI 10.1091/mbc.6.4.459; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076	52	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19190	19202		10.1074/jbc.M609653200	http://dx.doi.org/10.1074/jbc.M609653200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17420259	hybrid			2022-12-27	WOS:000247475300060
J	Jin, Q; Ding, W; Mulder, KM				Jin, Qunyan; Ding, Wei; Mulder, Kathleen M.			Requirement for the dynein light chain km23-1 in a Smad2-dependent transforming growth factor-beta signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INTERACTING PROTEIN; TGF-BETA; CYTOPLASMIC DYNEIN; DEPENDENT DEGRADATION; ENDOCYTIC RESPONSES; AXONAL-TRANSPORT; DYNACTIN COMPLEX; MICROTUBULES; SMADS; TRANSDUCTION	We have identified km23-1 as a novel transforming growth factor-beta (TGF beta) receptor (T beta R)-interacting protein that is also a light chain of the motor protein dynein (dynein light chain). Herein, we demonstrate by sucrose gradient analyses that, in the presence of TGF beta but not in the absence, km23-1 was present in early endosomes with the T beta Rs. Further, confocal microscopy studies indicate that endogenous km23-1 was co-localized with endogenous Smad2 at early times after TGF beta treatment, prior to Smad2 translocation to the nucleus. In addition, immunoprecipitation/ blot analyses showed that TGF beta regulated the interaction between endogenous km23-1 and endogenous Smad2 in vivo. Blockade of km23-1 using a small interfering RNA approach resulted in a reduction in both total intracellular Smad2 levels and in nuclear levels of phosphorylated Smad2 after TGF beta treatment. This decrease was reversed by lactacystin, a specific inhibitor of the 26 S proteasome, suggesting that knockdown of km23-1 causes proteasomal degradation of phosphorylated (i.e. activated) Smad2. Blockade of km23-1 also resulted in a reduction in TGF beta/Smad2-dependent ARE-Lux transcriptional activity, which was rescued by a km23-1 small interfering RNA-resistant construct. In contrast, a reduction in TGF beta/Smad3-dependent SBE2-Luc transcriptional activity did not occur under similar conditions. Furthermore, overexpression of the dynactin subunit dynamitin, which is known to disrupt dynein-mediated intracellular transport, blocked TGF beta-stimulated nuclear translocation of Smad2. Collectively, our findings indicate for the first time that a dynein light chain is required for a Smad2-dependent TGF beta signaling pathway.	Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Coll Med, Dept Pharmacol, 500 Univ Dr, Hershey, PA 17033 USA.	kmm15@psu.edu			NCI NIH HHS [CA92889, CA90765, CA100239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092889, R01CA100239, R01CA090765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; Anders RA, 1998, J BIOL CHEM, V273, P23118, DOI 10.1074/jbc.273.36.23118; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Bowman AB, 1999, J CELL BIOL, V146, P165; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dhani SU, 2003, J BIOL CHEM, V278, P16262, DOI 10.1074/jbc.M209828200; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ding W, 2005, CANCER RES, V65, P6526, DOI 10.1158/0008-5472.CAN-04-4385; Ding Wei, 2004, Cancer Treat Res, V119, P315; Dohner K, 2002, MOL BIOL CELL, V13, P2795, DOI 10.1091/mbc.01-07-0348; Dore JJE, 1998, J BIOL CHEM, V273, P31770, DOI 10.1074/jbc.273.48.31770; Dorweiler IJ, 2006, J VIROL, V80, P3634, DOI 10.1128/JVI.80.7.3634-3643.2006; Ehrlich M, 2001, J CELL SCI, V114, P1777; Felici A, 2003, EMBO J, V22, P4465, DOI 10.1093/emboj/cdg428; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; GEORGATOS SD, 1994, CURR OPIN CELL BIOL, V6, P347, DOI 10.1016/0955-0674(94)90025-6; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Goldstein LSB, 2001, SCIENCE, V291, P2102, DOI 10.1126/science.1059766; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; Greber UF, 2006, CELL, V124, P741, DOI 10.1016/j.cell.2006.02.018; Grieshaber SS, 2003, J CELL SCI, V116, P3793, DOI 10.1242/jcs.00695; Grigoryev SA, 2004, J CELL SCI, V117, P6153, DOI 10.1242/cs.01537; Gunawardena S, 2004, J NEUROBIOL, V58, P258, DOI 10.1002/neu.10319; Harrell JM, 2004, J BIOL CHEM, V279, P54647, DOI 10.1074/jbc.M406863200; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Ilangovan U, 2005, J MOL BIOL, V352, P338, DOI 10.1016/j.jmb.2005.07.002; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jiang JM, 2001, GENE, V281, P103, DOI 10.1016/S0378-1119(01)00787-9; Jin Qunyan, 2008, V1, P169, DOI 10.1007/978-1-59745-292-2_11; Jin QY, 2005, CELL SIGNAL, V17, P1363, DOI 10.1016/j.cellsig.2005.02.004; Kanamoto T, 2002, EMBO J, V21, P1219, DOI 10.1093/emboj/21.5.1219; Karcher RL, 2002, TRENDS CELL BIOL, V12, P21, DOI 10.1016/S0962-8924(01)02184-5; Kelkar N, 2005, MOL CELL BIOL, V25, P2733, DOI 10.1128/MCB.25.7.2733-2743.2005; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; Klopfenstein DR, 2000, CELL, V103, P537, DOI 10.1016/S0092-8674(00)00144-6; Lassus Patrice, 2002, Sci STKE, V2002, ppl13; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu F, 2003, FRONT BIOSCI-LANDMRK, V8, pS1280, DOI 10.2741/1149; Liu GM, 2006, J BIOL CHEM, V281, P29479, DOI 10.1074/jbc.M600579200; Lo KWH, 2005, J BIOL CHEM, V280, P8172, DOI 10.1074/jbc.M411408200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Moustakas A, 2001, J CELL SCI, V114, P4359; Nguyen Q, 2005, J BIOL CHEM, V280, P30185, DOI 10.1074/jbc.M505499200; Nikulina K, 2004, CELL MOTIL CYTOSKEL, V57, P233, DOI 10.1002/cm.10172; ODA H, 1995, J BIOL CHEM, V270, P15242, DOI 10.1074/jbc.270.25.15242; Okamura SM, 2006, J BIOL CHEM, V281, P36132, DOI 10.1074/jbc.M605093200; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Pfister KK, 2005, J CELL BIOL, V171, P411, DOI 10.1083/jcb.200508078; Phung-Koskas T, 2005, J BIOL CHEM, V280, P1123, DOI 10.1074/jbc.M409918200; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Runyan CE, 2006, CELL SIGNAL, V18, P2077, DOI 10.1016/j.cellsig.2006.05.009; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Susalka SJ, 2000, BBA-MOL CELL RES, V1496, P76, DOI 10.1016/S0167-4889(00)00010-0; Tang Q, 2002, MOL BIOL CELL, V13, P4484, DOI 10.1091/mbc.e02-05-0245; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Yano H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0003.2001; Yao DY, 2002, MOL BIOL CELL, V13, P4001, DOI 10.1091/mbc.02-07-0104; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Yue JB, 2000, J BIOL CHEM, V275, P35656; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Yue JB, 1999, J CELL PHYSIOL, V178, P387; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	84	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19122	19132		10.1074/jbc.M609915200	http://dx.doi.org/10.1074/jbc.M609915200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17420258	hybrid			2022-12-27	WOS:000247475300054
J	Moran-Barrio, J; Gonzalez, JM; Lisa, MN; Costello, AL; Dal Peraro, M; Carloni, P; Bennett, B; Tierney, DL; Limansky, AS; Viale, AM; Vila, AJ				Moran-Barrio, Jorgelina; Gonzalez, Javier M.; Lisa, Maria Natalia; Costello, Alison L.; Dal Peraro, Matteo; Carloni, Paolo; Bennett, Brian; Tierney, David L.; Limansky, Adriana S.; Viale, Alejandro M.; Vila, Alejandro J.			The metallo-ss-lactamase GOB is a mono-Zn(II) enzyme with a novel active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC BETA-LACTAMASE; STENOTROPHOMONAS-MALTOPHILIA; BACTEROIDES-FRAGILIS; CRYSTAL-STRUCTURE; BACILLUS-CEREUS; CHRYSEOBACTERIUM-MENINGOSEPTICUM; ANTIBIOTIC-RESISTANCE; ANGSTROM RESOLUTION; D-CAPTOPRIL; MECHANISM	Metallo-beta-lactamases (M beta Ls) are zinc-dependent enzymes able to hydrolyze and inactivate most beta-lactam antibiotics. The large diversity of active site structures and metal content among M beta Ls from different sources has limited the design of a pan-M beta L inhibitor. Here we report the biochemical and biophysical characterization of a novel M beta L, GOB-18, from a clinical isolate of a Gram-negative opportunistic pathogen, Elizabethkingia meningoseptica. Different spectroscopic techniques, three-dimensional modeling, and mutagenesis experiments, reveal that the Zn(II) ion is bound to Asp(120), His(121), His(263), and a solvent molecule, i.e. in the canonical Zn2 site of dinuclear M beta Ls. Contrasting all other related M beta Ls, GOB-18 is fully active against a broad range of beta-lactam substrates using a single Zn(II) ion in this site. These data further enlarge the structural diversity of M beta Ls.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Mol & Cellular Biol, Dept Quim Biol, Rosario, Argentina; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Mol & Cellular Biol, Dept Microbiol, Rosario, Argentina; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Univ Penn, Ctr Mol Modeling, Philadelphia, PA 19104 USA; Sch Adv Int Studies, I-34100 Trieste, Italy; Med Coll Wisconsin, Natl Biomed EPR Ctr, Dept Biophys, Milwaukee, WI 53226 USA	National University of Rosario; National University of Rosario; University of New Mexico; University of Pennsylvania; International School for Advanced Studies (SISSA); Medical College of Wisconsin	Vila, AJ (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Mol & Cellular Biol, Dept Quim Biol, Rosario, Argentina.	vila@ibr.gov.ar	Carloni, Paolo/H-8736-2013	Moran-Barrio, Jorgelina/0000-0001-5952-9337; Lisa, Maria-Natalia/0000-0001-9630-8090; Vila, Alejandro/0000-0002-7978-3233; Gonzalez, Javier Marcelo/0000-0002-3298-2235	NCRR NIH HHS [RR16480] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016480] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; AUSUBEL KFM, 1987, CURRENT PROTOCOLS MO; AVERILL BA, 1993, METHOD ENZYMOL, V226, P33, DOI 10.1016/0076-6879(93)26004-S; Bellais S, 2000, ANTIMICROB AGENTS CH, V44, P1878, DOI 10.1128/AAC.44.7.1878-1886.2000; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; COSTA GL, 1996, IN VITRO MUTAGENESIS; Costello A, 2006, J BIOL INORG CHEM, V11, P351, DOI 10.1007/s00775-006-0083-z; Crawford PA, 2005, BIOCHEMISTRY-US, V44, P5168, DOI 10.1021/bi047463s; Cricco JA, 1999, COORDIN CHEM REV, V190, P519, DOI 10.1016/S0010-8545(99)00113-7; Cricco JA, 1999, CURR PHARM DESIGN, V5, P915; Crowder MW, 2006, ACCOUNTS CHEM RES, V39, P721, DOI 10.1021/ar0400241; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; Docquier JD, 2004, ANTIMICROB AGENTS CH, V48, P4778, DOI 10.1128/AAC.48.12.4778-4783.2004; Docquier JD, 2003, J ANTIMICROB CHEMOTH, V51, P257, DOI 10.1093/jac/dkg067; Docquier JD, 2002, ANTIMICROB AGENTS CH, V46, P1823, DOI 10.1128/AAC.46.6.1823-1830.2002; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; Frere JM, 2005, J ANTIMICROB CHEMOTH, V55, P1051, DOI 10.1093/jac/dki155; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garau G, 2005, ANTIMICROB AGENTS CH, V49, P2778, DOI 10.1128/AAC.49.7.2778-2784.2005; Garau G, 2005, J MOL BIOL, V345, P785, DOI 10.1016/j.jmb.2004.10.070; Garcia-Saez I, 2003, J BIOL CHEM, V278, P23868, DOI 10.1074/jbc.M301062200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Garrity JD, 2004, J BIOL CHEM, V279, P920, DOI 10.1074/jbc.M309852200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hall BG, 2003, J MOL EVOL, V57, P249, DOI 10.1007/s00239-003-2471-0; Hemmingsen L, 2001, J AM CHEM SOC, V123, P10329, DOI 10.1021/ja0112240; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marasinghe GPK, 2005, J BIOL CHEM, V280, P40668, DOI 10.1074/jbc.M509748200; Materon IC, 2004, J MOL BIOL, V344, P653, DOI 10.1016/j.jmb.2004.09.074; McClure CP, 2003, J INORG BIOCHEM, V94, P78, DOI 10.1016/S0162-0134(02)00611-6; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; Murphy TA, 2006, J MOL BIOL, V357, P890, DOI 10.1016/j.jmb.2006.01.003; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; QUE L, 1987, J AM CHEM SOC, V109, P5381, DOI 10.1021/ja00252a013; Riener CK, 2002, ANAL BIOANAL CHEM, V373, P266, DOI 10.1007/s00216-002-1347-2; Sharma NP, 2006, BIOCHEMISTRY-US, V45, P10729, DOI 10.1021/bi060893t; Spencer J, 2005, J AM CHEM SOC, V127, P14439, DOI 10.1021/ja0536062; Spencer J, 2001, J BIOL CHEM, V276, P33638, DOI 10.1074/jbc.M105550200; Thomas PW, 2005, BIOCHEMISTRY-US, V44, P7559, DOI 10.1021/bi050050m; Toleman MA, 2002, J ANTIMICROB CHEMOTH, V50, P673, DOI 10.1093/jac/dkf210; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Walsh TR, 2005, CLIN MICROBIOL REV, V18, P306, DOI 10.1128/CMR.18.2.306-325.2005; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Wilke MS, 2005, CURR OPIN MICROBIOL, V8, P525, DOI 10.1016/j.mib.2005.08.016; Wommer S, 2002, J BIOL CHEM, V277, P24142, DOI 10.1074/jbc.M202467200; Xu DG, 2006, J BIOL CHEM, V281, P8740, DOI 10.1074/jbc.M512517200; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524	53	65	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18286	18293		10.1074/jbc.M700467200	http://dx.doi.org/10.1074/jbc.M700467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17403673	hybrid, Green Published			2022-12-27	WOS:000247302000035
J	Moes, M; Rodius, S; Coleman, SJ; Monkley, SJ; Goormaghtigh, E; Tremuth, L; Kox, C; van der Holst, PPG; Critchley, DR; Kieffer, N				Moes, Michele; Rodius, Sophie; Coleman, Stacey J.; Monkley, Susan J.; Goormaghtigh, Erik; Tremuth, Laurent; Kox, Corinne; van der Holst, Patrick P. G.; Critchley, David R.; Kieffer, Nelly			The integrin binding site 2 (IBS2) in the talin rod domain is essential for linking integrin beta subunits to the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCULIN-BINDING-SITE; SECONDARY STRUCTURE DETERMINATION; F-ACTIN-BINDING; I/LWEQ MODULE; CYTOPLASMIC TAIL; INFRARED-SPECTRA; PROTEIN TALIN; ACTIVATION; SEQUENCE; ALPHA-IIB-BETA-3	Talin1 is a large cytoskeletal protein that links integrins to actin filaments through two distinct integrin binding sites, one present in the talin head domain (IBS1) necessary for integrin activation and a second (IBS2) that we have previously mapped to talin residues 1984-2113 (fragment J) of the talin rod domain (1 Tremuth, L., Kreis, S., Melchior, C., Hoebeke, J., Ronde, P., Plancon, S., Takeda, K., and Kieffer, N. (2004) J. Biol. Chem. 279, 22258-22266), but whose functional role is still elusive. Using a bioinformatics and cell biology approach, we have determined the minimal structure of IBS2 and show that this integrin binding site corresponds to 23 residues located in alpha helix 50 of the talin rod domain (residues 2077-2099). Alanine mutation of 2 highly conserved residues (L2094A/I2095A) within this alpha helix, which disrupted the alpha- helical structure of IBS2 as demonstrated by infrared spectroscopy and limited trypsin proteolysis, was sufficient to prevent in vivo talin fragment J targeting to alpha IIb ss 3 integrin in focal adhesions and to inhibit in vitro this association as shown by an alpha IIb ss 3 pulldown assay. Moreover, expression of a full-length mouse green fluorescent protein-talin LI/AA mutant in mouse talin1(-/-) cells was unable to rescue the inability of these cells to assemble focal adhesions ( in contrast to green fluorescent protein-talin wild type) despite the presence of IBS1. Our data provide the first direct evidence that IBS2 in the talin rod is essential to link integrins to the cytoskeleton.	Univ Luxembourg, CNRS, Lab Biol & Physiol Integree, GDRE,ITI, L-1511 Luxembourg, Luxembourg; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Univ Libre Bruxelles, Lab Struct & Funct Biol Membranes, Ctr Struct Biol & Bioinformat, B-1050 Brussels, Belgium	University of Luxembourg; University of Leicester; Universite Libre de Bruxelles	Kieffer, N (corresponding author), Univ Luxembourg, CNRS, Lab Biol & Physiol Integree, GDRE,ITI, 162A,Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	nelly.kieffer@uni.lu		Goormaghtigh, Erik/0000-0002-2071-2262; Monkley, Susan/0000-0001-9174-6278				Brett TJ, 2006, NAT STRUCT MOL BIOL, V13, P121, DOI 10.1038/nsmb1043; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Fillingham I, 2005, STRUCTURE, V13, P65, DOI 10.1016/j.str.2004.11.006; Franco SJ, 2006, CELL MOTIL CYTOSKEL, V63, P563, DOI 10.1002/cm.20145; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Gingras AR, 2006, BIOCHEMISTRY-US, V45, P1805, DOI 10.1021/bi052136l; Gingras AR, 2005, J BIOL CHEM, V280, P37217, DOI 10.1074/jbc.M508060200; GOLDMANN WH, 1994, J STRUCT BIOL, V112, P3, DOI 10.1006/jsbi.1994.1002; Goldmann WH, 2000, BIOCHEM BIOPH RES CO, V271, P553, DOI 10.1006/bbrc.2000.2653; Goormaghtigh E, 2006, BIOPHYS J, V90, P2946, DOI 10.1529/biophysj.105.072017; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Han JW, 2006, CURR BIOL, V16, P1796, DOI 10.1016/j.cub.2006.08.035; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Hemmings L, 1996, J CELL SCI, V109, P2715; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Martel V, 2000, J CELL SCI, V113, P1951; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; McCann RO, 1999, BIOCHEM BIOPH RES CO, V266, P135, DOI 10.1006/bbrc.1999.1776; McCann RO, 1997, P NATL ACAD SCI USA, V94, P5679, DOI 10.1073/pnas.94.11.5679; MCLACHLAN AD, 1994, J MOL BIOL, V235, P1278, DOI 10.1006/jmbi.1994.1081; MOLONY L, 1987, J BIOL CHEM, V262, P7790; Oberg KA, 2004, EUR J BIOCHEM, V271, P2937, DOI 10.1111/j.1432-1033.2004.04220.x; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; Patel B, 2006, J BIOL CHEM, V281, P7458, DOI 10.1074/jbc.M508058200; Plancon S, 2001, BIOCHEM J, V357, P529, DOI 10.1042/0264-6021:3570529; Ratnikov BI, 2005, J THROMB HAEMOST, V3, P1783, DOI 10.1111/j.1538-7836.2005.01362.x; Raussens V, 2004, APPL SPECTROSC, V58, P68, DOI 10.1366/000370204322729496; Senetar MA, 2005, GENE, V362, P141, DOI 10.1016/j.gene.2005.08.012; Senetar MA, 2004, BIOCHEMISTRY-US, V43, P15418, DOI 10.1021/bi0487239; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tanentzapf G, 2006, NAT CELL BIOL, V8, P601, DOI 10.1038/ncb1411; Tremuth L, 2004, J BIOL CHEM, V279, P22258, DOI 10.1074/jbc.M400947200; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200	39	50	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17280	17288		10.1074/jbc.M611846200	http://dx.doi.org/10.1074/jbc.M611846200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17430904	hybrid			2022-12-27	WOS:000246946500061
J	Pontarin, G; Ferraro, P; Hakansson, P; Thelander, L; Reichard, P; Bianchi, V				Pontarin, Giovanna; Ferraro, Paola; Hakansson, Pelle; Thelander, Lars; Reichard, Peter; Bianchi, Vera			p53R2-dependent ribonucleotide reduction provides Deoxyribonucleotides in quiescent human fibroblasts in the absence of induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE KINASE; CELL-CYCLE; SUBSTRATE CYCLES; DEOXYGUANOSINE KINASE; RECOMBINANT MOUSE; MAMMALIAN-CELLS; RENAL-FAILURE; DNTP POOLS; GENE; P53	Human fibroblasts in culture obtain deoxynucleotides by de novo ribonucleotide reduction or by salvage of deoxynucleosides. In cycling cells the de novo pathway dominates, but in quiescent cells the salvage pathway becomes important. Two forms of active mammalian ribonucleotide reductases are known. Each form contains the catalytic R1 protein, but the two differ with respect to the second protein (R2 or p53R2). R2 is cell cycle-regulated, degraded during mitosis, and absent from quiescent cells. The recently discovered p53-inducible p53R2 was proposed to be linked to DNA repair processes. The protein is not cell cycle-regulated and can provide deoxynucleotides to quiescent mouse fibroblasts. Here we investigate the in situ activities of the R1-p53R2 complex and two other enzymes of the de novo pathway, dCMP deaminase and thymidylate synthase, in confluent quiescent serum-starved human fibroblasts in experiments with [5-H-3] cytidine, [6-H-3] deoxycytidine, and [(CH3)-H-3] thymidine. These cells had increased their content of p53R2 2-fold and lacked R2. From isotope incorporation, we conclude that they have a complete de novo pathway for deoxynucleotide synthesis, including thymidylate synthesis. During quiescence, incorporation of deoxynucleotides into DNA was very low. Deoxynucleotides were instead degraded to deoxynucleosides and exported into the medium as deoxycytidine, deoxyuridine, and thymidine. The rate of export was surprisingly high, 25% of that in cycling cells. Total ribonucleotide reduction in quiescent cells amounted to only 2-3% of cycling cells. We suggest that in quiescent cells an important function of p53R2 is to provide deoxynucleotides for mitochondrial DNA replication.	Univ Padua, Dept Biol, I-35131 Padua, Italy; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	University of Padua; Umea University	Bianchi, V (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	vbianchi@bio.unipd.it		Hakansson, Pelle/0000-0003-0421-2433	Telethon [GGP05001] Funding Source: Medline	Telethon(Fondazione Telethon)		ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BIANCHI V, 1986, P NATL ACAD SCI USA, V83, P986, DOI 10.1073/pnas.83.4.986; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; DAVIS R, 1994, J BIOL CHEM, V269, P23171; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200; Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103; Gazziola C, 2001, J BIOL CHEM, V276, P6185, DOI 10.1074/jbc.M007623200; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maley F, 1990, Prog Nucleic Acid Res Mol Biol, V39, P49, DOI 10.1016/S0079-6603(08)60623-6; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; PARK I, 1988, ARCH BIOCHEM BIOPHYS, V266, P51, DOI 10.1016/0003-9861(88)90235-4; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Powell DR, 2005, PEDIATR NEPHROL, V20, P432, DOI 10.1007/s00467-004-1696-5; RODE W, 1980, J BIOL CHEM, V255, P1305; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; SPYROU G, 1987, J BIOL CHEM, V262, P16425; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thelander L, 1978, Methods Enzymol, V51, P227	35	81	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16820	16828		10.1074/jbc.M701310200	http://dx.doi.org/10.1074/jbc.M701310200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17416930	hybrid			2022-12-27	WOS:000246946500014
J	Nguyen, C; Nishi, A; Kansy, JW; Fernandez, J; Hayashi, K; Gillardon, F; Hemmings, HC; Nairn, AC; Bibb, JA				Nguyen, Chan; Nishi, Akinori; Kansy, Janice W.; Fernandez, Joseph; Hayashi, Kanehiro; Gillardon, Frank; Hemmings, Hugh C., Jr.; Nairn, Angus C.; Bibb, James A.			Regulation of protein phosphatase inhibitor-1 by cyclin-dependent kinase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SYNAPTIC VESICLE ENDOCYTOSIS; CDK5 ACTIVATOR P35; IMMUNOCYTOCHEMICAL LOCALIZATION; NEURONAL PHOSPHOPROTEIN; TYROSINE-HYDROXYLASE; HORMONAL-REGULATION; NMDA RECEPTORS; RAT-BRAIN; PHOSPHORYLATION	Inhibitor-1, the first identified endogenous inhibitor of protein phosphatase 1 ( PP-1), was previously reported to be a substrate for cyclin-dependent kinase 5 (Cdk5) at Ser(67). Further investigation has revealed the presence of an additional Cdk5 site identified by mass spectrometry and confirmed by site-directed mutagenesis as Ser(6). Basal levels of phospho-Ser(6) inhibitor-1, as detected by a phosphorylation state-specific antibody against the site, existed in specific regions of the brain and varied with age. In the striatum, basal in vivo phosphorylation and dephosphorylation of Ser6 were mediated by Cdk5, PP-2A, and PP-1, respectively. Additionally, calcineurin contributed to dephosphorylation under conditions of high Ca2+. In biochemical assays the function of Cdk5-dependent phosphorylation of inhibitor-1 at Ser(6) and Ser(67) was demonstrated to be an intramolecular impairment of the ability of inhibitor-1 to be dephosphorylated at Thr(35); this effect was recapitulated in two systems in vivo. Dephosphorylation of inhibitor-1 at Thr(35) is equivalent to inactivation of the protein, as inhibitor-1 only serves as an inhibitor of PP-1 when phosphorylated by cAMP-dependent kinase ( PKA) at Thr(35). Thus, inhibitor-1 serves as a critical junction between kinase-and phosphatase-signaling pathways, linking PP-1 to not only PKA and calcineurin but also Cdk5.	Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA; Kurume Univ, Sch Med, Dept Pharmacol, Kurume, Fukuoka 8300011, Japan; Rockefeller Univ, Prot DNA Technol Ctr, New York, NY 10021 USA; Rockefeller Univ, Lab Cellular & Mol Neurosci, New York, NY 10021 USA; Boehringer Ingelheim Pharmaceut Inc, Cent Nervous Syst Res, D-88397 Biberach, Germany; Cornell Univ, Weill Med Coll, Dept Anesthesiol & Pharmacol, New York, NY 10021 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kurume University; Rockefeller University; Rockefeller University; Boehringer Ingelheim; Cornell University; Yale University	Bibb, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	james.bibb@utsouthwestern.edu	Hayashi, Kanehiro/L-2777-2013	Nairn, Angus/0000-0002-7075-0195	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067777, F30MH072062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016672, P01DA010044] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL077101, HL077101] Funding Source: Medline; NIDA NIH HHS [R01 DA016672, DA10044, P01 DA010044, DA16672] Funding Source: Medline; NIMH NIH HHS [R01 MH067777, F30 MH072062, MH072062, MH67777] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; BARBAS H, 1993, J COMP NEUROL, V334, P1, DOI 10.1002/cne.903340102; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Bibbb JA, 2001, J BIOL CHEM, V276, P14490, DOI 10.1074/jbc.M007197200; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Campbell David G, 2002, J Biomol Tech, V13, P119; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; CZERNIK AJ, 1997, REGULATORY PROTEIN M, P219; DIBB JA, 1997, REGULATORY PROTEIN M, P275; El-Armouche A, 2004, CARDIOVASC RES, V61, P87, DOI 10.1016/j.cardiores.2003.11.005; El-Armouche A, 2003, FASEB J, V17, P437, DOI 10.1096/fj.02-0057fje; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Fletcher AI, 1999, J BIOL CHEM, V274, P4027, DOI 10.1074/jbc.274.7.4027; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; Gillardon F, 2005, J CELL BIOCHEM, V95, P817, DOI 10.1002/jcb.20463; Gillardon F, 2005, PROTEOMICS, V5, P1299, DOI 10.1002/pmic.200400992; Gupta RC, 2005, MOL CELL BIOCHEM, V269, P49, DOI 10.1007/s11010-005-2538-x; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; Gupta RC, 2003, AM J PHYSIOL-HEART C, V285, pH2373, DOI 10.1152/ajpheart.00442.2003; GUSTAFSON EL, 1991, J COMP NEUROL, V310, P170, DOI 10.1002/cne.903100204; Hayashi K, 2006, J NEUROCHEM, V99, P237, DOI 10.1111/j.1471-4159.2006.04113.x; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Kansy JW, 2004, J NEUROCHEM, V91, P374, DOI 10.1111/j.1471-4159.2004.02723.x; Kerokoski P, 2004, NEUROSCI LETT, V368, P181, DOI 10.1016/j.neulet.2004.07.007; Kesavapany S, 2001, EUR J NEUROSCI, V13, P241, DOI 10.1046/j.1460-9568.2001.01376.x; Kwon YT, 2000, CURR BIOL, V10, P363, DOI 10.1016/S0960-9822(00)00411-5; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Li BS, 2002, EMBO J, V21, P324, DOI 10.1093/emboj/21.3.324; Li BS, 2001, P NATL ACAD SCI USA, V98, P12742, DOI 10.1073/pnas.211428098; Lilja L, 2005, BIOCHEM BIOPH RES CO, V329, P673, DOI 10.1016/j.bbrc.2005.02.017; Lilja L, 2001, J BIOL CHEM, V276, P34199, DOI 10.1074/jbc.M103776200; Liu J, 2000, J BIOL CHEM, V275, P26074, DOI 10.1074/jbc.M003843200; LOWENSTEIN PR, 1995, BRAIN RES, V676, P80, DOI 10.1016/0006-8993(95)00091-4; MACDOUGALL LK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P218, DOI 10.1016/0167-4889(89)90164-X; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Morabito MA, 2004, J NEUROSCI, V24, P865, DOI 10.1523/JNEUROSCI.4582-03.2004; Moy LY, 2004, J BIOL CHEM, V279, P54487, DOI 10.1074/jbc.M406636200; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NEUMANN J, 1991, CIRC RES, V69, P1450, DOI 10.1161/01.RES.69.6.1450; Nguyen C, 2003, J CELL BIOL, V163, P697, DOI 10.1083/jcb.200310038; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; Nishi A, 1999, J NEUROCHEM, V72, P2015, DOI 10.1046/j.1471-4159.1999.0722015.x; Paglini G, 1998, J NEUROSCI, V18, P9858; Pigino G, 1997, J CELL SCI, V110, P257; Rosales JL, 2006, BIOESSAYS, V28, P1023, DOI 10.1002/bies.20473; Sahin B, 2006, J BIOL CHEM, V281, P24322, DOI 10.1074/jbc.M603282200; Saito T, 2003, J NEUROSCI, V23, P1189, DOI 10.1523/JNEUROSCI.23-04-01189.2003; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; Sharma P, 1999, P NATL ACAD SCI USA, V96, P11156, DOI 10.1073/pnas.96.20.11156; Sharma P, 2002, J BIOL CHEM, V277, P528, DOI 10.1074/jbc.M109324200; SHENOLIKAR S, 1991, ADV 2 MESSENGER PHOS, V23, P1; Shuang RQ, 1998, J BIOL CHEM, V273, P4957, DOI 10.1074/jbc.273.9.4957; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tang D, 1996, Prog Cell Cycle Res, V2, P205; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Vander Mierde D, 2007, ENDOCRINOLOGY, V148, P609, DOI 10.1210/en.2006-1012; Wei FY, 2005, NAT MED, V11, P1104, DOI 10.1038/nm1299; Wei FY, 2005, J NEUROCHEM, V93, P502, DOI 10.1111/j.1471-4159.2005.03058.x; Weiser DC, 2004, J BIOL CHEM, V279, P48904, DOI 10.1074/jbc.M404416200; Weishaupt JH, 2003, MOL CELL NEUROSCI, V24, P489, DOI 10.1016/S1044-7431(03)00221-5; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6	76	21	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16511	16520		10.1074/jbc.M701046200	http://dx.doi.org/10.1074/jbc.M701046200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17400554	Green Accepted, hybrid			2022-12-27	WOS:000246794300058
J	Murcia-Flores, L; Lorca-Pascual, JM; Garre, V; Torres-Martinez, S; Ruiz-Vazquez, RM				Murcia-Flores, Laura; Lorca-Pascual, Juan M.; Garre, Victoriano; Torres-Martinez, Santiago; Ruiz-Vazquez, Rosa M.			Non-AUG translation initiation of a fungal RING finger repressor involved in photocarotenogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOR-CIRCINELLOIDES; PHYCOMYCES-BLAKESLEEANUS; SACCHAROMYCES-CEREVISIAE; CAROTENOID BIOSYNTHESIS; PROTEIN; GENE; RNA; CAROTENOGENESIS; CODONS; CRGA	The RING finger protein CrgA acts as a negative regulator of light-induced carotene biosynthesis in the fungus Mucor circinelloides. Sequence analysis of the crgA coding region upstream of the first AUG codon revealed the existence of an additional non-canonical RING finger domain at the most N-terminal end of the protein. The newly identified RING finger domain is required for CrgA to regulate photocarotenogenesis, as deduced from site-directed mutagenesis experiments. The role of both RING finger domains in the stability of CrgA has been investigated in a yeast system. Wild type CrgA, but not the RING finger deleted forms, is highly unstable and is stabilized by inhibition of the proteasome function, which suggests that native CrgA is degraded by the proteasome and that active RING finger domains are required for proteasome-mediated CrgA degradation. To identify the translation start of CrgA, a mutational analysis of putative initiation codons in the 5' region of the crgA gene was accomplished. We demonstrated that a GUG codon located upstream of the first AUG is the sole initiator of CrgA translation. To our knowledge, this is the first report of a naturally occurring non-AUG start codon for a RING finger regulatory protein. A combination of suboptimal translation initiation and proteasome degradation may help to maintain the low cellular levels of CrgA observed in wild type cells, which is probably required for accurate regulation of photocarotenogenesis.	Univ Murcia, Fac Biol, Dept Genet & Microbiol, E-30071 Murcia, Spain	University of Murcia	Ruiz-Vazquez, RM (corresponding author), Univ Murcia, Fac Biol, Dept Genet & Microbiol, Campus Espinardo, E-30071 Murcia, Spain.	rmruiz@um.es	Garre, Victoriano/H-2533-2015; Ruiz-Vázquez, Rosa María/K-6778-2014; Torres-Martinez, Santiago/K-7660-2014; Murcia, Laura/AAD-7100-2021	Garre, Victoriano/0000-0001-7605-1726; Ruiz-Vázquez, Rosa María/0000-0002-6675-8506; Torres-Martinez, Santiago/0000-0002-7083-4516; Murcia, Laura/0000-0001-7768-0989				Abramczyk D, 2003, YEAST, V20, P1045, DOI 10.1002/yea.1020; Chang KJ, 2004, J BIOL CHEM, V279, P13778, DOI 10.1074/jbc.M311269200; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; Conlon H, 2001, MOL MICROBIOL, V40, P361, DOI 10.1046/j.1365-2958.2001.02399.x; Davies B., 1976, CAROTENOIDS CHEM BIO, P38, DOI [DOI 10.1590/S0101-20612001000200017, 10.1007/978-3-642-66632-2_11, DOI 10.1007/978-3-642-66632-2_11]; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Gietz R. D., 1998, CELLS LAB MANUAL, VI, P87; GOVIND NS, 1986, J GEN MICROBIOL, V132, P2775; GUTIERREZ S, 1991, J BACTERIOL, V173, P2354; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu G, 1999, MOL CELL BIOL, V19, P724; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Logan IR, 2004, J BIOL CHEM, V279, P11696, DOI 10.1074/jbc.M312712200; Lorca-Pascual JM, 2004, MOL MICROBIOL, V52, P1463, DOI 10.1111/j.1365-2958.2004.04070.x; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; NAMBRU C, 1997, J BIOL CHEM, V272, P32061; Navarro E, 2000, EUR J BIOCHEM, V267, P800, DOI 10.1046/j.1432-1327.2000.01058.x; Navarro E, 2001, MOL GENET GENOMICS, V266, P463, DOI 10.1007/s004380100558; Nicolas FE, 2003, EMBO J, V22, P3983, DOI 10.1093/emboj/cdg384; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PRINTEN JA, 1994, GENETICS, V138, P609; Quiles-Rosillo MD, 2005, FUNGAL GENET BIOL, V42, P141, DOI 10.1016/j.fgb.2004.10.008; Quiles-Rosillo MD, 2003, FUNGAL GENET BIOL, V38, P122, DOI 10.1016/S1087-1845(02)00519-4; Riechmann JL, 1999, MOL CELL BIOL, V19, P8505; RONCERO MIG, 1984, CARLSBERG RES COMMUN, V49, P685, DOI 10.1007/BF02907499; Rose MD., 1990, METHODS YEAST GENETI; RUIZPEREZ VL, 1995, CURR GENET, V28, P309, DOI 10.1007/BF00326428; Sambrook J., 2001, MOL CLONING LAB MANU; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Silva F, 2006, MOL MICROBIOL, V61, P1023, DOI 10.1111/j.1365-2958.2006.05291.x; SUGIHARA H, 1990, J BIOL CHEM, V265, P21714; Tang HL, 2004, J BIOL CHEM, V279, P49656, DOI 10.1074/jbc.M408081200; Touriol C, 2003, BIOL CELL, V95, P169, DOI 10.1016/S0248-4900(03)00033-9; Wu XL, 2004, MOL CELL BIOL, V24, P7748, DOI 10.1128/MCB.24.17.7748-7757.2004	39	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15394	15403		10.1074/jbc.M610366200	http://dx.doi.org/10.1074/jbc.M610366200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403679	hybrid			2022-12-27	WOS:000246589600015
J	Stefansson, S; Su, EJ; Ishigami, S; Cale, JM; Gao, YM; Gorlatova, N; Lawrence, DA				Stefansson, Steingrimur; Su, Enming J.; Ishigami, Shoji; Cale, Jacqueline M.; Gao, Yamei; Gorlatova, Natalia; Lawrence, Daniel A.			The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ARG-GLY-ASP; SOMATOMEDIN B-DOMAIN; EXTRACELLULAR-MATRIX; IN-VIVO; MICROTUBULE CYTOSKELETON; ALPHA(V)BETA(5) INTEGRIN; BINDING-SITE; TUMOR-GROWTH; MIGRATION	The serine proteinase inhibitor, plasminogen activator inhibitor type-1 (PAI- 1), binds to the adhesion protein vitronectin with high affinity at a site that is located directly adjacent to the vitronectin RGD integrin binding sequence. The binding of PAI-1 to vitronectin sterically blocks integrin access to this site and completely inhibits the binding of purified integrins to vitronectin; however, its inhibition of endothelial and smooth muscle cell adhesion to vitronectin is at most 50-75%. Because PAI-1 binds vitronectin with similar to 10-100-fold higher affinity than purified integrins, we have analyzed the mechanism whereby these cells are able to overcome this obstacle. Our studies exclude proteolytic removal of PAI-1 from vitronectin as the mechanism, and show instead that cell adhesion in the presence of PAI-1 is dependent on integrin-cytoskeleton engagement. Disrupting endothelial or smooth muscle cell actin polymerization and/or focal adhesion assembly reduces cell adhesion to vitronectin in the presence of PAI-1 to levels similar to that observed for the binding of purified integrins to vitronectin. Furthermore, endothelial cell, but not smooth muscle cell adhesion to vitronectin in the presence of PAI-1 requires both polymerized microtubules and actin, further demonstrating the importance of the cytoskeleton for integrin-mediated adhesion. Finally, we show that cell adhesion in the presence of PAI-1 leads to colocalization of PAI-1 with the integrins alpha v beta 3 and alpha v beta 5 at the cell-matrix interface.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Maryland, Inst Biotechnol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Michigan System; University of Michigan; University System of Maryland; University of Maryland Baltimore	Stefansson, S (corresponding author), Creatv MicroTech, 11609 Lake Potomac Dr, Potomac, MD 20854 USA.	stenni@creatvmicrotech.com		Lawrence, Daniel/0000-0003-3126-1935	NHLBI NIH HHS [R01 HL055747, P01 HL054710, HL055374, HL055747, HL054710, HL069624] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL069624, P01HL054710, R01HL055747, R43HL069624, R01HL055374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; Berthet V, 2000, J BIOL CHEM, V275, P33308, DOI 10.1074/jbc.M004834200; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 2004, J CELL SCI, V117, P657, DOI 10.1242/jcs.01014; Cao CZ, 2006, EMBO J, V25, P1860, DOI 10.1038/sj.emboj.7601082; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Germer M, 1998, EUR J BIOCHEM, V253, P669, DOI 10.1046/j.1432-1327.1998.2530669.x; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; Graness A, 2006, KIDNEY INT, V69, P1341, DOI 10.1038/sj.ki.5000296; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jin TQ, 2002, J BIOL CHEM, V277, P32963, DOI 10.1074/jbc.M201525200; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin W, 2002, CONNECT TISSUE RES, V43, P22; Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c; Liu SC, 2000, J CELL SCI, V113, P3563; Ludbrook SB, 2003, BIOCHEM J, V369, P311, DOI 10.1042/BJ20020809; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; Osdoit S, 2001, J BIOL CHEM, V276, P6703, DOI 10.1074/jbc.M008945200; Palmieri D, 2002, J BIOL CHEM, V277, P40950, DOI 10.1074/jbc.M202333200; Podor TJ, 2002, J BIOL CHEM, V277, P7520, DOI 10.1074/jbc.M109677200; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Sawada Y, 2002, J CELL BIOL, V156, P609, DOI 10.1083/jcb.200110068; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2004, J BIOL CHEM, V279, P29981, DOI 10.1074/jbc.M401913200; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Strachan LR, 2004, J CELL BIOL, V167, P545, DOI 10.1083/jcb.200405024; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; Wang YX, 2006, P NATL ACAD SCI USA, V103, P1774, DOI 10.1073/pnas.0510774103; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xu Z, 2004, J BIOL CHEM, V279, P17914, DOI 10.1074/jbc.M314197200; Yang TT, 1996, ANAL BIOCHEM, V241, P103, DOI 10.1006/abio.1996.0383; ZHAO Y, 1993, BIOCHEM BIOPH RES CO, V192, P575, DOI 10.1006/bbrc.1993.1454; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200	60	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15679	15689		10.1074/jbc.M702125200	http://dx.doi.org/10.1074/jbc.M702125200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403662	hybrid			2022-12-27	WOS:000246589600044
J	Xu, SC; Abbasian, M; Patel, P; Jensen-Pergakes, K; Lombardo, CR; Cathers, BE; Xie, WL; Mercurio, F; Pagano, M; Giegel, D; Cox, S				Xu, Shuichan; Abbasian, Mahan; Patel, Palka; Jensen-Pergakes, Kristen; Lombardo, Christian R.; Cathers, Brian E.; Xie, Weilin; Mercurio, Frank; Pagano, Michele; Giegel, David; Cox, Sarah			Substrate recognition and ubiquitination of SCFSkp2/Cks1 ubiquitin-protein isopeptide ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; KAPPA-B-ALPHA; MALIGNANT PHENOTYPE; CDK INHIBITOR; P27(KIP1); COMPLEX; CKS1; P27; SKP2; OVEREXPRESSION	p27, an important cell cycle regulator, blocks the G1/S transition in cells by binding and inhibiting Cdk2/cyclin A and Cdk2/cyclin E complexes (Cdk2/E). Ubiquitination and subsequent degradation play a critical role in regulating the levels of p27 during cell cycle progression. Here we provide evidence suggesting that both Cdk2/E and phosphorylation of Thr187 on p27 are essential for the recognition of p27 by the SCFSkp2/Cks1 complex, the ubiquitin-protein isopeptide ligase (E3). Cdk2/E provides a high affinity binding site, whereas the phosphorylated Thr187 provides a low affinity binding site for the Skp2/Cks1 complex. Furthermore, binding of phosphorylated p27/Cdk2/E to the E3 complex showed positive cooperativity. Consistently, p27 is also ubiquitinated in a similarly cooperative manner. In the absence of p27, Cdk2/E and Cks1 increase Skp2 phosphorylation. This phosphorylation enhances Skp2 auto-ubiquitination, whereas p27 inhibits both phosphorylation and auto- ubiquitination of Skp2.	Signal Pharmaceut LLC, Dept Biochem & Biomarker Dev, San Diego, CA 92121 USA; Signal Pharmaceut LLC, Dept Discovery Biol, San Diego, CA 92121 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Xu, SC (corresponding author), Signal Pharmaceut LLC, Dept Biochem & Biomarker Dev, 4550 Towne Ctr Ct, San Diego, CA 92121 USA.	sxu@celgene.com		Cathers, Brian/0000-0003-2793-7533; pagano, michele/0000-0003-3210-2442				Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Chen J, 1996, ONCOGENE, V13, P1395; Copeland R. A., 2000, ENZYMES PRACTICAL IN, P367; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Havlis J, 2003, ANAL CHEM, V75, P1300, DOI 10.1021/ac026136s; Honda R, 2005, EMBO J, V24, P452, DOI 10.1038/sj.emboj.7600554; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Masuda T, 2002, CANCER RES, V62, P3819; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nalepa G, 2003, CANCER TREAT REV, V29, P49, DOI 10.1016/S0305-7372(03)00083-5; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Reed SI, 2005, MOL CELL, V20, P1, DOI 10.1016/j.molcel.2005.09.011; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seeliger MA, 2003, NAT STRUCT BIOL, V10, P718, DOI 10.1038/nsb962; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stevenson-Lindert LM, 2003, J BIOL CHEM, V278, P50956, DOI 10.1074/jbc.M306546200; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Ungermannova D, 2005, J BIOL CHEM, V280, P30301, DOI 10.1074/jbc.M411103200; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu SC, 2005, METHOD ENZYMOL, V399, P729, DOI 10.1016/S0076-6879(05)99048-4; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhu XH, 2004, MOL CELL BIOL, V24, P6058, DOI 10.1128/MCB.24.13.6058-6066.2004	35	14	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15462	15470		10.1074/jbc.M610758200	http://dx.doi.org/10.1074/jbc.M610758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17409098	hybrid			2022-12-27	WOS:000246589600021
J	Banerjee, R; Schleicher, E; Meier, S; Viana, RM; Pokorny, R; Ahmad, M; Bittl, R; Batschauer, A				Banerjee, Roopa; Schleicher, Erik; Meier, Stefan; Viana, Rafael Munoz; Pokorny, Richard; Ahmad, Margaret; Bittl, Robert; Batschauer, Alfred			The signaling state of Arabidopsis cryptochrome 2 contains flavin semiquinone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-LIGHT PHOTORECEPTORS; CRYSTAL-STRUCTURE; DNA PHOTOLYASE; GREEN LIGHT; SINAPIS-ALBA; THALIANA; INDUCTION; DOMAIN	Cryptochrome ( Cry) photoreceptors share high sequence and structural similarity with DNA repair enzyme DNA-photolyase and carry the same flavin cofactor. Accordingly, DNA-photolyase was considered a model system for the light activation process of cryptochromes. In line with this view were recent spectroscopic studies on cryptochromes of the CryDASH subfamily that showed photoreduction of the flavin adenine dinucleotide ( FAD) cofactor to its fully reduced form. However, CryDASH members were recently shown to have photolyase activity for cyclobutane pyrimidine dimers in single-stranded DNA, which is absent for other members of the cryptochrome/photolyase family. Thus, CryDASH may have functions different from cryptochromes. The photocycle of other members of the cryptochrome family, such as Arabidopsis Cry1 and Cry2, which lack DNA repair activity but control photomorphogenesis and flowering time, remained elusive. Here we have shown that Arabidopsis Cry2 undergoes a photocycle in which semireduced flavin ( FADH(.)) accumulates upon blue light irradiation. Green light irradiation of Cry2 causes a change in the equilibrium of flavin oxidation states and attenuates Cry2-controlled responses such as flowering. These results demonstrate that the active form of Cry2 contains FADH(.) ( whereas catalytically active photolyase requires fully reduced flavin ( FADH(.))) and suggest that cryptochromes could represent photoreceptors using flavin redox states for signaling differently from DNA-photolyase for photorepair.	Univ Marburg, FB Biol Pflanzenphysiol, D-35032 Marburg, Germany; Free Univ Berlin, Fachbereich Phys, D-14195 Berlin, Germany; Univ Paris 06, UMR 7632, CNRS, F-75252 Paris 05, France; Penn State Univ, Dept Biol, Media, PA 19063 USA	Philipps University Marburg; Free University of Berlin; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Batschauer, A (corresponding author), Univ Marburg, FB Biol Pflanzenphysiol, Karl von Frisch Str 8, D-35032 Marburg, Germany.	batschau@staff.uni-marburg.de	Schleicher, Erik/C-9951-2010; Bittl, Robert/I-8149-2013	Bittl, Robert/0000-0003-4103-3768; Schleicher, Erik/0000-0003-2953-050X; Ahmad, Margaret/0000-0003-4524-5813				Ahmad M, 2002, PLANT PHYSIOL, V129, P774, DOI 10.1104/pp.010969; Bouly JP, 2007, J BIOL CHEM, V282, P9383, DOI 10.1074/jbc.M609842200; Bouly JP, 2003, EUR J BIOCHEM, V270, P2921, DOI 10.1046/j.1432-1033.2003.03691.x; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; Briggs W. R., 2006, PHOTOMORPHOGENESIS P, P171; Brudler R, 2003, MOL CELL, V11, P59, DOI 10.1016/S1097-2765(03)00008-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Corbesier L, 1996, PLANT J, V9, P947, DOI 10.1046/j.1365-313X.1996.9060947.x; Daiyasu H, 2004, GENES CELLS, V9, P479, DOI 10.1111/j.1356-9597.2004.00738.x; Dhingra A, 2006, PLANT PHYSIOL, V142, P1256, DOI 10.1104/pp.106.088351; EHRENBERG A, 1968, BIOL OXIDATIONS, P239; ELASSAL SED, 2003, PLANT PHYSIOL, V133, P1; Folta KM, 2004, PLANT PHYSIOL, V135, P1407, DOI 10.1104/pp.104.038893; Frechilla S, 2004, PLANT CELL PHYSIOL, V45, P1709, DOI 10.1093/pcp/pch197; Gindt YM, 1999, BIOCHEMISTRY-US, V38, P3857, DOI 10.1021/bi981191+; Giovani B, 2003, NAT STRUCT BIOL, V10, P489, DOI 10.1038/nsb933; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HANKE J, 1969, PLANTA, V86, P235, DOI 10.1007/BF00386456; Huang YH, 2006, P NATL ACAD SCI USA, V103, P17701, DOI 10.1073/pnas.0608554103; Imaizumi T, 2003, NATURE, V426, P302, DOI 10.1038/nature02090; Klar T, 2007, J MOL BIOL, V366, P954, DOI 10.1016/j.jmb.2006.11.066; Kleiner O, 1999, PLANT J, V19, P289, DOI 10.1046/j.1365-313X.1999.00535.x; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; LIN C, 1995, P NATL ACAD SCI USA, V92, P8423, DOI 10.1073/pnas.92.18.8423; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; Mancinelli Alberto L., 1994, P211; Mao J, 2005, P NATL ACAD SCI USA, V102, P12270, DOI 10.1073/pnas.0501011102; Mees A, 2004, SCIENCE, V306, P1789, DOI 10.1126/science.1101598; Mockler TC, 1999, DEVELOPMENT, V126, P2073; MOZLEY D, 1995, J EXP BOT, V46, P173, DOI 10.1093/jxb/46.2.173; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Powles, 1981, CARNEGIE I WASHINGTO, V80, P59; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Sang Y, 2005, PLANT CELL, V17, P1569, DOI 10.1105/tpc.104.029645; Saxena C, 2005, J AM CHEM SOC, V127, P7984, DOI 10.1021/ja0421607; Schamiloglu E., 2006, Proceedings of the 27th International Power Modulator Symposium and 2006 High Voltage Workshop (IEEE Cat No. 06CH37746C), DOI 10.1007/1-4020-3811-9_1; Selby CP, 2006, P NATL ACAD SCI USA, V103, P17696, DOI 10.1073/pnas.0607993103; Shalitin D, 2003, PLANT CELL, V15, P2421, DOI 10.1105/tpc.013011; Shalitin D, 2002, NATURE, V417, P763, DOI 10.1038/nature00815; Song SH, 2006, J PHOTOCH PHOTOBIO B, V85, P1, DOI 10.1016/j.jphotobiol.2006.03.007; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Talbott LD, 2006, PLANT CELL PHYSIOL, V47, P332, DOI 10.1093/pcp/pci249; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; Weber S, 2005, CHEMPHYSCHEM, V6, P292, DOI 10.1002/cphc.200400377; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; Yanovsky MJ, 2002, NATURE, V419, P308, DOI 10.1038/nature00996	50	197	205	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14916	14922		10.1074/jbc.M700616200	http://dx.doi.org/10.1074/jbc.M700616200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17355959	hybrid			2022-12-27	WOS:000246589000029
J	Cai, ML; Huang, Y; Suh, JY; Louis, JM; Ghirlando, R; Craigie, R; Clore, GM				Cai, Mengli; Huang, Ying; Suh, Jeong-Yong; Louis, John M.; Ghirlando, Rodolfo; Craigie, Robert; Clore, G. Marius			Solution NMR structure of the barrier-to-autointegration factor-emerin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MEMBRANE PROTEIN; DIPOLAR COUPLINGS; LEM-DOMAIN; 3-DIMENSIONAL STRUCTURES; STRUCTURE REFINEMENT; RETROVIRAL DNA; BAF; BINDING; MACROMOLECULES; RESTRAINTS	The barrier-to-autointegration factor BAF binds to the LEM domain (Em(LEM)) of the nuclear envelope protein emerin and plays an essential role in the nuclear architecture of metazoan cells. In addition, the BAF(2) dimer bridges and compacts double-stranded DNA nonspecifically via two symmetry-related DNA binding sites. In this article we present biophysical and structural studies on a complex of BAF(2) and EmLEM. Light scattering, analytical ultracentrifugation, and NMR indicate a stoichiometry of one molecule of EmLEM bound per BAF(2) dimer. The equilibrium dissociation constant (K-d) for the interaction of the BAF(2) dimer and Em(LEM), determined by isothermal titration calorimetry, is 0.59 +/- 0.03 mu M. Z-exchange spectroscopy between corresponding cross-peaks of the magnetically non-equivalent subunits of the BAF(2) dimer in the complex yields a dissociation rate constant of 78 +/- 2 s(-1). The solution NMR structure of the BAF(2)-Em(LEM) complex reveals that the LEM and DNA binding sites on BAF(2) are non-overlapping and that both subunits of the BAF(2) dimer contribute approximately equally to the EmLEM binding site. The relevance of the implications of the structural and biophysical data on the complex in the context of the interaction between the BAF(2) dimer and EmLEM at the nuclear envelope is discussed.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5, Bethesda, MD 20892 USA.	mariusc@intra.niddk.nih.gov	Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008; Ghirlando, Rodolfo/A-8880-2009	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Louis, John M/0000-0002-0052-1899	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK036171, Z01DK029043, ZIADK033007, Z01DK036171, Z01DK029023, Z01DK033007, ZIADK029023] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; BAX A, 1994, METHOD ENZYMOL, V239, P79; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bradley CM, 2005, NAT STRUCT MOL BIOL, V12, P935, DOI 10.1038/nsmb989; Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399; CHANCE EM, 1979, R8775 AT EN RES EST; Clore GM, 2000, P NATL ACAD SCI USA, V97, P9021, DOI 10.1073/pnas.97.16.9021; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; Clore GM, 1998, P NATL ACAD SCI USA, V95, P5891, DOI 10.1073/pnas.95.11.5891; CLORE GM, 1991, J AM CHEM SOC, V113, P4350, DOI 10.1021/ja00011a059; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Furukawa K, 1999, J CELL SCI, V112, P2485; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Grishaev A, 2004, J AM CHEM SOC, V126, P7281, DOI 10.1021/ja0319994; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Haraguchi T, 2001, J CELL SCI, V114, P4575; Iwahara J, 2006, J AM CHEM SOC, V128, P404, DOI 10.1021/ja056786o; Jacque JM, 2006, NATURE, V441, P641, DOI 10.1038/nature04682; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lee KK, 2001, J CELL SCI, V114, P4567; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; Schwieters CD, 2006, PROG NUCL MAG RES SP, V48, P47, DOI 10.1016/j.pnmrs.2005.10.001; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Shimi T, 2004, J STRUCT BIOL, V147, P31, DOI 10.1016/j.jsb.2003.11.013; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; Williams DC, 2005, J BIOL CHEM, V280, P29269, DOI 10.1074/jbc.M504642200; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; Wolff N, 2001, FEBS LETT, V501, P171, DOI 10.1016/S0014-5793(01)02649-7	55	64	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14525	14535		10.1074/jbc.M700576200	http://dx.doi.org/10.1074/jbc.M700576200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355960	hybrid			2022-12-27	WOS:000246245800066
J	Hashemy, SI; Johansson, C; Berndt, C; Lillig, CH; Holmgren, A				Hashemy, Seyed Isaac; Johansson, Catrine; Berndt, Carsten; Lillig, Christopher Horst; Holmgren, Arne			Oxidation and S-nitrosylation of cysteines in human cytosolic and mitochondrial glutaredoxins - Effects on structure and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CEREBELLAR GRANULE NEURONS; DOPAMINE-INDUCED APOPTOSIS; NMR SOLUTION STRUCTURE; RED-BLOOD-CELLS; NF-KAPPA-B; ESCHERICHIA-COLI; THIOLTRANSFERASE GLUTAREDOXIN; CATALYTIC MECHANISM; HUMAN THIOREDOXIN	Glutathione (GSH) is the major intracellular thiol present in 1-10-mM concentrations in human cells. However, the redox potential of the 2GSH/GSSG ( glutathione disulfide) couple in cells varies in association with proliferation, differentiation, or apoptosis from -260 mV to -200 or -170 mV. Hydrogen peroxide is transiently produced as second messenger in receptor-mediated growth factor signaling. To understand oxidation mechanisms by GSSG or nitric oxide-related nitrosylation we studied effects on glutaredoxins (Grx), which catalyze GSH-dependent thiol-disulfide redox reactions, particularly reversible glutathionylation of protein sulfhydryl groups. Human Grx1 and Grx2 contain Cys-Pro-Tyr-Cys and Cys-Ser-Tyr-Cys active sites and have three and two additional structural Cys residues, respectively. We analyzed the redox state and disulfide pairing of Cys residues upon GSSG oxidation and S-nitrosylation. Cytosolic/nuclear Grx1 was partly inactivated by both S-nitrosylation and oxidation. Inhibition by nitrosylation was reversible under anaerobic conditions; aerobically it was stronger and irreversible, indicating inactivation by nitration. Oxidation of Grx1 induced a complex pattern of disulfide-bonded dimers and oligomers formed between Cys-8 and either Cys-79 or Cys-83. In addition, an intramolecular disulfide between Cys-79 and Cys-83 was identified, predicted to have a profound effect on the three-dimensional structure. In contrast, mitochondrial Grx2 retains activity upon oxidation, did not form disulfide-bonded dimers or oligomers, and could not be S-nitrosylated. The dimeric iron sulfur cluster-coordinating inactive form of Grx2 dissociated upon nitrosylation, leading to activation of the protein. The striking differences between Grx1 and Grx2 reflect their diverse regulatory functions in vivo and also adaptation to different subcellular localization.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden; Univ Marburg, Dept Clin Cytobiol & Cytopathol, DE-35037 Marburg, Germany	Karolinska Institutet; Philipps University Marburg	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden.	arne.holmgren@ki.se	Lillig, Christopher Horst/AAD-7098-2019; Berndt, Carsten/X-6260-2018; Hashemy, Seyed Isaac/A-2693-2017	Lillig, Christopher Horst/0000-0003-2509-5117; Berndt, Carsten/0000-0001-8583-7966; Hashemy, Seyed Isaac/0000-0002-1323-5250				Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Aykac-Toker G, 2001, HUM EXP TOXICOL, V20, P373, DOI 10.1191/096032701680350578; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Berndt C, 2007, ANTIOXID REDOX SIGN, V9, P151, DOI 10.1089/ars.2007.9.151; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Enoksson M, 2005, BIOCHEM BIOPH RES CO, V327, P774, DOI 10.1016/j.bbrc.2004.12.067; GAN ZR, 1986, J BIOL CHEM, V261, P996; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; HOLMGREN A, 1978, J BIOL CHEM, V253, P7424; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; HOPPER S, 1989, J BIOL CHEM, V264, P20438; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Johansson C, 2007, J BIOL CHEM, V282, P3077, DOI 10.1074/jbc.M608179200; KATTI SK, 1995, PROTEIN SCI, V4, P1998, DOI 10.1002/pro.5560041005; KLINTROT IM, 1984, EUR J BIOCHEM, V144, P417, DOI 10.1111/j.1432-1033.1984.tb08481.x; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101; Lillig CH, 2003, J BIOL CHEM, V278, P22325, DOI 10.1074/jbc.M302304200; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Lundberg M, 2004, BIOCHEM BIOPH RES CO, V319, P801, DOI 10.1016/j.bbrc.2004.04.199; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Moriarty-Craige SE, 2004, ANNU REV NUTR, V24, P481, DOI 10.1146/annurev.nutr.24.012003.132208; Nakamura H, 1998, FREE RADICAL BIO MED, V24, P1176, DOI 10.1016/S0891-5849(97)00429-2; Nakamura H, 2001, P NATL ACAD SCI USA, V98, P2688, DOI 10.1073/pnas.041624998; Padilla CA, 1996, FEBS LETT, V378, P69; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; Qiao FY, 2001, INVEST OPHTH VIS SCI, V42, P743; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; Rengby O, 2004, APPL ENVIRON MICROB, V70, P5159, DOI 10.1128/AEM.70.9.5159-5167.2004; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Russell WK, 2001, ANAL CHEM, V73, P2682, DOI 10.1021/ac001332p; SAGEMARK J, 2007, IN PRESS PROTEINS; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; Sumbayev VV, 2003, ARCH BIOCHEM BIOPHYS, V415, P133, DOI 10.1016/S0003-9861(03)00199-1; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takashima Y, 1999, IMMUNOL LETT, V68, P397, DOI 10.1016/S0165-2478(99)00087-5; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Vlamis-Gardikas A, 2002, J BIOL CHEM, V277, P10861, DOI 10.1074/jbc.M111024200; Washburn MP, 1999, BIOCHEMISTRY-US, V38, P268, DOI 10.1021/bi980480v; Watson WH, 2003, J BIOL CHEM, V278, P33408, DOI 10.1074/jbc.M211107200; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; YANG YF, 1991, J BIOL CHEM, V266, P12766; YANG YF, 1991, J BIOL CHEM, V266, P12759; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504	67	80	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14428	14436		10.1074/jbc.M700927200	http://dx.doi.org/10.1074/jbc.M700927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355958	hybrid			2022-12-27	WOS:000246245800056
J	Ren, J; Sainsbury, S; Combs, SE; Capper, RG; Jordan, PW; Berrow, NS; Stammers, DK; Saunders, NJ; Owens, RJ				Ren, Jingshan; Sainsbury, Sarah; Combs, Susan E.; Capper, Richard G.; Jordan, Philip W.; Berrow, Nick S.; Stammers, David K.; Saunders, Nigel J.; Owens, Raymond J.			The structure and transcriptional analysis of a global regulator from Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NANOLITRE CRYSTALLIZATION EXPERIMENTS; THERMAL SHIFT ASSAYS; ESCHERICHIA-COLI LRP; CRYSTAL-STRUCTURE; PROTEIN LRP; BINDING; IDENTIFICATION; METABOLISM; CLUSTER; FORMS	Neisseria meningitidis, a causative agent of bacterial meningitis, has a relatively small repertoire of transcription factors, including NMB0573 (annotated AsnC), a member of the Lrp-AsnC family of regulators that are widely expressed in both Bacteria and Archaea. In the present study we show that NMB0573 binds to L-leucine and L-methionine and have solved the structure of the protein with and without bound amino acids. This has shown, for the first time that amino acid binding does not induce significant conformational changes in the structure of an AsnC/Lrp regulator although it does appear to stabilize the octameric assembly of the protein. Transcriptional profiling of wild-type and NMB0573 knock-out strains of N. meningitidis has shown that NMB0573 is associated with an adaptive response to nutrient poor conditions reflected in a reduction in major surface protein expression. On the basis of its structure and the transcriptional response, we propose that NMB0573 is a global regulator in Neisseria controlling responses to nutrient availability through indicators of general amino acid abundance: leucine and methionine.	Univ Oxford, Oxford Prot Prod Facil, Oxford OX3 7BN, England; Univ Oxford, Div Struct Biol, Henry Wellcome Bldg Genom Med, Oxford OX3 7BN, England; Univ Oxford, Sir William Dunn Sch Pathol, Bacterial Pathogenesis & Funct Genom Grp, Oxford OX1 3RE, England	University of Oxford; University of Oxford; University of Oxford	Owens, RJ (corresponding author), Univ Oxford, Oxford Prot Prod Facil, Roosevelt Dr, Oxford OX3 7BN, England.	ray@strubi.ox.ac.uk	Saunders, Nigel J/W-6745-2019; Ren, Jingshan/AAT-7729-2021	Ren, Jingshan/0000-0003-4015-1404; Saunders, Nigel/0000-0002-0160-4573; Owens, Ray/0000-0002-3705-2993; Berrow, Nick/0000-0002-6104-4117; Scott, Susan Combs/0000-0002-1797-1685	MRC [G0400717] Funding Source: UKRI; Medical Research Council [G0400717] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Berrow NS, 2006, ACTA CRYSTALLOGR D, V62, P1218, DOI 10.1107/S0907444906031337; BERROW NS, 2007, NUCLEIC ACIDS RES, V47, P1; Brinkman AB, 2003, MOL MICROBIOL, V48, P287, DOI 10.1046/j.1365-2958.2003.03442.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; Chen S, 2002, J MOL BIOL, V318, P1031, DOI 10.1016/S0022-2836(02)00187-0; Chen S, 2001, J MOL BIOL, V312, P625, DOI 10.1006/jmbi.2001.4955; Chen SL, 2005, J MOL BIOL, V345, P251, DOI 10.1016/j.jmb.2004.10.047; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; DEWIND N, 1985, NUCLEIC ACIDS RES, V13, P8797, DOI 10.1093/nar/13.24.8797; Ettema TJG, 2002, J BIOL CHEM, V277, P37464, DOI 10.1074/jbc.M206063200; Francis F, 2000, GENE, V251, P141, DOI 10.1016/S0378-1119(00)00200-6; Gunesekere IC, 2006, J BACTERIOL, V188, P4769, DOI 10.1128/JB.01807-05; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karp PD, 2005, NUCLEIC ACIDS RES, V33, P6083, DOI 10.1093/nar/gki892; KELLOGG DS, 1963, J BACTERIOL, V85, P1274, DOI 10.1128/JB.85.6.1274-1279.1963; Koike H, 2004, P NATL ACAD SCI USA, V101, P2840, DOI 10.1073/pnas.0400109101; KOLLING R, 1985, J BACTERIOL, V164, P310; Landgraf JR, 1996, J BACTERIOL, V178, P6930, DOI 10.1128/jb.178.23.6930-6936.1996; Leonard PM, 2001, EMBO J, V20, P990, DOI 10.1093/emboj/20.5.990; Lo MC, 2004, ANAL BIOCHEM, V332, P153, DOI 10.1016/j.ab.2004.04.031; Minezaki Y, 2005, DNA RES, V12, P269, DOI 10.1093/dnares/dsi016; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; PLATKO JV, 1993, J BACTERIOL, V175, P1110, DOI 10.1128/JB.175.4.1110-1117.1993; Ren JS, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-13; Saal LH, 2002, GENOME BIOL, V3; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Snyder LAS, 2005, MICROBIOL-SGM, V151, P4005, DOI 10.1099/mic.0.27925-0; Snyder LAS, 2003, MOL MICROBIOL, V47, P431, DOI 10.1046/j.1365-2958.2003.03204.x; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Thaw P, 2006, NUCLEIC ACIDS RES, V34, P1439, DOI 10.1093/nar/gkl009; Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808; Walter TS, 2003, J APPL CRYSTALLOGR, V36, P308, DOI 10.1107/S0021889803001997	37	33	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14655	14664		10.1074/jbc.M701082200	http://dx.doi.org/10.1074/jbc.M701082200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374605	hybrid			2022-12-27	WOS:000246245800079
J	West, M; Hedges, JB; Lo, KY; Johnson, AW				West, Matthew; Hedges, John B.; Lo, Kai-Yin; Johnson, Arlen W.			Novel interaction of the 60S ribosomal subunit export adapter Nmd3 at the nuclear pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; LEPTOMYCIN B; IN-VIVO; YEAST; PROTEIN; CRM1; NUCLEOPORIN; REQUIRES	Nuclear export of the large (60S) ribosomal subunit depends on the adapter protein Nmd3 to provide a nuclear export signal (NES). The leucine-rich NES is recognized by the export receptor Crm1 to mediate export via interaction with the nuclear pore complex (NPC). Here, we show that certain mutant Nmd3 proteins that are impaired for binding to the 60S subunit accumulate at the nuclear envelope. These mutant proteins also show enhanced binding to Crm1, both in vivo and in vitro. Although their interaction with the NPC is dependent on recognition of the NES by Crm1, their interaction with Crm1 is not strictly dependent on RanGTP. Using a collection of GFP-tagged nucleoporin mutants, we identified several nucleoporins, including components of the Nup82 complex that copurified with the mutant Nmd3. The Nup82 complex is on the cytoplasmic face of the NPC and has previously been shown to be important as a terminal binding site for Crm1-mediated export. Mutations in the Nup82 complex led to accumulation of wild-type Nmd3 in the nucleoplasm, suggesting that the interaction of mutant Nmd3 with the Nup82 complex reflects a defect in the bona fide export pathway for the 60S subunit. These results suggest that in the absence of the ribosome, Nmd3 is not efficiently released from Crm1 at the NPC.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Johnson, AW (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, 1 Univ Stn,A5000, Austin, TX 78712 USA.	arlen@mail.utexas.edu		Johnson, Arlen/0000-0002-4742-085X; LO, KAI-YIN/0000-0003-0440-6836	NIGMS NIH HHS [GM53655] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bernad R, 2004, MOL CELL BIOL, V24, P2373, DOI 10.1128/MCB.24.6.2373-2384.2004; Bernad R, 2006, J BIOL CHEM, V281, P19378, DOI 10.1074/jbc.M512585200; Del Priore V, 1997, J CELL SCI, V110, P2987; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fornerod Maarten, 2002, Results Probl Cell Differ, V35, P67; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Gleizes PE, 2001, J CELL BIOL, V155, P923, DOI 10.1083/jcb.200108142; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; Hedges J, 2005, EMBO J, V24, P567, DOI 10.1038/sj.emboj.7600547; Hedges J, 2006, J BIOL CHEM, V281, P36579, DOI 10.1074/jbc.M606798200; Ho JHN, 2000, J CELL BIOL, V151, P1057, DOI 10.1083/jcb.151.5.1057; Ho JHN, 2000, RNA, V6, P1625, DOI 10.1017/S1355838200001291; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; HURWITZ ME, 1995, J CELL BIOL, V130, P1275, DOI 10.1083/jcb.130.6.1275; Johnson AW, 2002, TRENDS BIOCHEM SCI, V27, P580, DOI 10.1016/S0968-0004(02)02208-9; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; LUND E, 2001, SMALL GTPASE RAN, P59; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Maurer P, 2001, MOL BIOL CELL, V12, P539, DOI 10.1091/mbc.12.3.539; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Moy TI, 1999, GENE DEV, V13, P2118, DOI 10.1101/gad.13.16.2118; Neville M, 1999, EMBO J, V18, P3746, DOI 10.1093/emboj/18.13.3746; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Petosa C, 2004, MOL CELL, V16, P761, DOI 10.1016/j.molcel.2004.11.018; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stage-Zimmermann T, 2000, MOL BIOL CELL, V11, P3777, DOI 10.1091/mbc.11.11.3777; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Thomas F, 2003, J CELL SCI, V116, P2409, DOI 10.1242/jcs.00464; Trotta CR, 2003, EMBO J, V22, P2841, DOI 10.1093/emboj/cdg249; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	45	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14028	14037		10.1074/jbc.M700256200	http://dx.doi.org/10.1074/jbc.M700256200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17347149	hybrid			2022-12-27	WOS:000246245800012
J	Witkowski, A; Joshi, AK; Smith, S				Witkowski, Andrzej; Joshi, Anil K.; Smith, Stuart			Coupling of the de Novo fatty acid biosynthesis and lipoylation pathways in mammalian mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER PROTEIN; RAT-LIVER MITOCHONDRIA; LIPOIC ACID; ESCHERICHIA-COLI; LONG-CHAIN; SACCHAROMYCES-CEREVISIAE; SYNTHASE; CLONING; IDENTIFICATION; ARABIDOPSIS	The objective of this study was to identify the products and possible role of a putative pathway for de novo fatty acid synthesis in mammalian mitochondria. Bovine heart mitochondrial matrix preparations were prepared free from contamination by proteins from other subcellular components and, using a combination of radioisotopic labeling and mass spectrometry, were shown to contain all of the enzymes required for the extension of a 2-carbon precursor by malonyl moieties to saturated acyl-ACP thioesters containing up to 14 carbon atoms. A major product was octanoyl-ACP and, in the presence of the apo-H-protein of the glycine cleavage complex, the newly synthesized octanoyl moieties were translocated to the lipoylation site on the acceptor protein. These studies demonstrate that one of the functions of the de novo fatty acid biosynthetic pathway in mammalian mitochondria is to provide the octanoyl precursor required for the essential protein lipoylation pathway.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Smith, S (corresponding author), 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	ssmith@chori.org		Witkowski, Andrzej/0000-0002-0442-4586	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM069717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRON EJ, 1966, BIOCHIM BIOPHYS ACTA, V116, P425, DOI 10.1016/0005-2760(66)90113-5; BRADY RO, 1958, P NATL ACAD SCI USA, V44, P993, DOI 10.1073/pnas.44.10.993; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; BRODY S, 1988, EUR J BIOCHEM, V173, P353, DOI 10.1111/j.1432-1033.1988.tb14005.x; CHRIST EJV, 1968, BIOCHIM BIOPHYS ACTA, V152, P50, DOI 10.1016/0005-2760(68)90007-6; Cronan JE, 2005, FEBS LETT, V579, P4892, DOI 10.1016/j.febslet.2005.07.077; DUPRE S, 1980, ARCH BIOCHEM BIOPHYS, V202, P361, DOI 10.1016/0003-9861(80)90438-5; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; Fujiwara K, 1997, J BIOL CHEM, V272, P31974, DOI 10.1074/jbc.272.51.31974; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Hagen TM, 2002, P NATL ACAD SCI USA, V99, P1870, DOI 10.1073/pnas.261708898; HARLAN WR, 1963, J BIOL CHEM, V238, P3216; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; HOWARD CF, 1968, BIOCHIM BIOPHYS ACTA, V164, P448, DOI 10.1016/0005-2760(68)90176-8; HULSMANN WC, 1962, BIOCHIM BIOPHYS ACTA, V58, P417, DOI 10.1016/0006-3002(62)90052-5; Joshi AK, 2005, BIOCHEMISTRY-US, V44, P4100, DOI 10.1021/bi047856r; Kataoka H, 1997, METHOD ENZYMOL, V279, P166; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; Morikawa T, 2001, FEBS LETT, V498, P16, DOI 10.1016/S0014-5793(01)02469-3; MORRIS TW, 1995, J BACTERIOL, V177, P1; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; Olsen JG, 2004, FEBS LETT, V577, P170, DOI 10.1016/j.febslet.2004.10.007; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; QUAGLIARIELLO E, 1968, BIOCHIM BIOPHYS ACTA, V164, P12, DOI 10.1016/0005-2760(68)90066-0; REED LJ, 1951, SCIENCE, V114, P93, DOI 10.1126/science.114.2952.93; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; RUTKOSKI A, 1978, ANAL BIOCHEM, V91, P370, DOI 10.1016/0003-2697(78)90854-0; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Schweizer E, 2004, MICROBIOL MOL BIOL R, V68, P501, DOI 10.1128/MMBR.68.3.501-517.2004; SEUBERT W, 1957, ANGEW CHEM INT EDIT, V69, P359, DOI 10.1002/ange.19570691103; SEUBERT W, 1973, MOL CELL BIOCHEM, V1, P29, DOI 10.1007/BF01659936; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Stephens JL, 2007, J BIOL CHEM, V282, P4427, DOI 10.1074/jbc.M609037200; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; Wada M, 2001, PLANT CELL PHYSIOL, V42, P650, DOI 10.1093/pcp/pce081; WAKIL SJ, 1958, J AM CHEM SOC, V80, P6465, DOI 10.1021/ja01556a086; WAKIL SJ, 1960, J BIOL CHEM, V235, P31; WHEREAT AF, 1969, J BIOL CHEM, V244, P6498; Witkowski A, 2004, BIOCHEMISTRY-US, V43, P10458, DOI 10.1021/bi048988n; Yasuno R, 1998, PLANT PHYSIOL, V118, P935, DOI 10.1104/pp.118.3.935; Yasuno R, 2004, J BIOL CHEM, V279, P8242, DOI 10.1074/jbc.M308894200; Yi XW, 2005, MOL CELL BIOL, V25, P8387, DOI 10.1128/MCB.25.18.8387-8392.2005; Zhang L, 2005, J BIOL CHEM, V280, P12422, DOI 10.1074/jbc.M413686200; Zhang L, 2003, J BIOL CHEM, V278, P40067, DOI 10.1074/jbc.M306121200; Zhao X, 2003, CHEM BIOL, V10, P1293, DOI 10.1016/j.chembiol.2003.11.016	46	59	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14178	14185		10.1074/jbc.M701486200	http://dx.doi.org/10.1074/jbc.M701486200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374604	hybrid			2022-12-27	WOS:000246245800028
J	Kasahara, T; Maeda, M; Ishiguro, M; Kasahara, M				Kasahara, Toshiko; Maeda, Mari; Ishiguro, Masaji; Kasahara, Michihiro			Identification by comprehensive chimeric analysis of a key residue responsible for high affinity glucose transport by yeast HXT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; MAJOR FACILITATOR SUPERFAMILY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBSTRATE RECOGNITION; GAL2 TRANSPORTER; FAMILY; MECHANISM; VII	Hxt2 and Hxt1 are, respectively, high affinity and low affinity facilitative glucose transporter paralogs of Saccharomyces cerevisiae. We have previously investigated which amino acid residues of Hxt2 are important for high affinity transport activity. Studies with all the possible combinations of 12 transmembrane segments (TMs) of Hxt2 and Hxt1 revealed that TMs 1, 5, 7, and 8 of Hxt2 are necessary for high affinity transport. Systematic shuffling of the 20 amino acid residues that differ between Hxt2 and Hxt1 in these TMs subsequently identified 5 residues as important for such activity: Leu(59) and Leu(61) (TM1), Leu(201) (TM5), Asn(331) (TM7), and Phe(366) (TM8). We have now studied the relative importance of these 5 residues by individually replacing them with each of the other 19 residues. Replacement of Asn(331) yielded transporters with various affinities, with those of the Ile(331), Val(331), and Cys(331) mutants being higher than that of the wild type. Replacement of the Hxt2 residues at the other four sites yielded transporters with affinities similar to that of the wild type but with various capacities. A working homology model of the chimeric transporters containing Asn(331) or its 19 replacement residues indicated that those residues at this site that yield high affinity transporters (Ile(331), Val(331), Cys(331)) face the central cavity and are within van der Waals distances of Phe(208) (TM5), Leu(357) ( TM8), and Tyr(427) (TM10). Interactions via these residues of the four TMs, which compose a half of the central pore, may thus play a pivotal role in formation of a core structure for high affinity transport.	Teikyo Univ, Sch Med, Biophys Lab, Tokyo 1920395, Japan; Teikyo Univ, Sch Med, Genome Res Ctr, Tokyo 1920395, Japan; Suntory Inst Bioorgan Res, Osaka 6188503, Japan; Niigata Univ Pharm & Appl Life Sci, Dept Appl Life Sci, Biol Chem Lab, Niigata 9568603, Japan	Teikyo University; Teikyo University; Suntory Holdings Ltd; Niigata University	Kasahara, M (corresponding author), Teikyo Univ, Sch Med, Biophys Lab, Tokyo 1920395, Japan.	kasahara@main.teikyo-u.ac.jp						Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AMBERG DC, 2005, METHODS YEAST GENETI, P200; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Ding J, 2006, J BIOL CHEM, V281, P29817, DOI 10.1074/jbc.M606152200; Hirai T, 2003, J BACTERIOL, V185, P1712, DOI 10.1128/JB.185.5.1712-1718.2003; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kasahara M, 1996, FEBS LETT, V389, P174, DOI 10.1016/0014-5793(96)00567-4; Kasahara M, 1997, J BIOL CHEM, V272, P16721, DOI 10.1074/jbc.272.27.16721; Kasahara T, 2004, J BIOL CHEM, V279, P30274, DOI 10.1074/jbc.M403762200; Kasahara T, 2003, BIOCHEM J, V372, P247, DOI 10.1042/BJ20030044; Kasahara T, 1996, BIOCHEM J, V315, P177, DOI 10.1042/bj3150177; Kasahara T, 2000, J BIOL CHEM, V275, P4422, DOI 10.1074/jbc.275.6.4422; Kasahara T, 2006, J BIOL CHEM, V281, P18532, DOI 10.1074/jbc.M602123200; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Manolescu A, 2005, J BIOL CHEM, V280, P42978, DOI 10.1074/jbc.M508678200; NISHIZAWA K, 1995, J BIOL CHEM, V270, P2423, DOI 10.1074/jbc.270.6.2423; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; Ye L, 1999, J BACTERIOL, V181, P4673, DOI 10.1128/JB.181.15.4673-4675.1999; Yin Y, 2006, SCIENCE, V312, P741, DOI 10.1126/science.1125629	22	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13146	13150		10.1074/jbc.C700041200	http://dx.doi.org/10.1074/jbc.C700041200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17369259	hybrid			2022-12-27	WOS:000246060300002
J	Kearney, A; Avramovic, A; Castro, MAA; Carmo, AM; Davis, SJ; van der Merwe, PA				Kearney, Alice; Avramovic, Adam; Castro, Monica A. A.; Carmo, Alexandre M.; Davis, Simon J.; van der Merwe, P. Anton			The contribution of conformational adjustments and long-range electrostatic forces to the CD2/CD58 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; T-CELL-ACTIVATION; ISOTHERMAL TITRATION CALORIMETRY; ADHESION MOLECULE CD2; VANT-HOFF; BINDING-SITE; SIGNIFICANT DISCREPANCIES; CD58 LFA-3; ANTIGEN RECOGNITION; MUTATIONAL ANALYSIS	CD2 is a T cell surface molecule that enhances T and natural killer cell function by binding its ligands CD58 (humans) and CD48 (rodents) on antigen-presenting or target cells. Here we show that the CD2/CD58 interaction is enthalpically driven and accompanied by unfavorable entropic changes. Taken together with structural studies, this indicates that binding is accompanied by energetically significant conformational adjustments. Despite having a highly charged binding interface, neither the affinity nor the rate constants of the CD2/CD58 interaction were affected by changes in ionic strength, indicating that long-range electrostatic forces make no net contribution to binding.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Nuffield Dept Clin Med, Weatherall Inst Mol Med, Med Res Council Human Immunol Unit, Oxford OX3 9DS, England; Univ Porto, Grp Cell Activat & Gene Express, Inst Biol Mol & Celular, P-4099002 Oporto, Portugal; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4099002 Oporto, Portugal	University of Oxford; University of Oxford; Universidade do Porto; Universidade do Porto	van der Merwe, PA (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	vandermerwe@path.ox.ac.uk	van der Merwe, P. Anton/F-8539-2011; Carmo, Alexandre/B-5191-2011	Carmo, Alexandre/0000-0002-2508-9799	Medical Research Council [G9722488, G19/31] Funding Source: Medline; Wellcome Trust [081894] Funding Source: Medline; MRC [G9722488] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anikeeva N, 2003, BIOCHEMISTRY-US, V42, P4709, DOI 10.1021/bi026864+; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; Atkins, 1998, PHYS CHEM, P830; Bachmann MF, 1999, J EXP MED, V190, P1383, DOI 10.1084/jem.190.10.1383; Bayas MV, 2007, J BIOL CHEM, V282, P5589, DOI 10.1074/jbc.M607968200; BIERER BE, 1989, IMMUNOL REV, V111, P267, DOI 10.1111/j.1600-065X.1989.tb00549.x; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; Chaires JB, 1997, BIOPHYS CHEM, V64, P15, DOI 10.1016/S0301-4622(96)02205-3; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P157; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; Davis-Harrison RL, 2005, J MOL BIOL, V346, P533, DOI 10.1016/j.jmb.2004.11.063; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; Garcia KC, 2001, P NATL ACAD SCI USA, V98, P6818, DOI 10.1073/pnas.111161198; Green JM, 2000, J IMMUNOL, V164, P3591, DOI 10.4049/jimmunol.164.7.3591; GUTFREUND H, 1995, KINETICS LIFE SCI RE, P231; Horn JR, 2001, BIOCHEMISTRY-US, V40, P1774, DOI 10.1021/bi002408e; Horn JR, 2002, BIOCHEMISTRY-US, V41, P7501, DOI 10.1021/bi025626b; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; Janin J, 1997, PROTEINS, V28, P153, DOI 10.1002/(SICI)1097-0134(199706)28:2<153::AID-PROT4>3.0.CO;2-G; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; Kim M, 2001, J MOL BIOL, V312, P711, DOI 10.1006/jmbi.2001.4980; Kitao A, 2000, P NATL ACAD SCI USA, V97, P2064, DOI 10.1073/pnas.030540397; Krogsgaard M, 2003, MOL CELL, V12, P1367, DOI 10.1016/S1097-2765(03)00474-X; Ladbury JE, 1996, CHEM BIOL, V3, P791, DOI 10.1016/S1074-5521(96)90063-0; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lee JK, 2004, J EXP MED, V200, P1455, DOI 10.1084/jem.20041251; LIU YF, 1995, PROTEIN SCI, V4, P2559, DOI 10.1002/pro.5560041212; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MURPHY KP, 1994, PROTEINS, V18, P63, DOI 10.1002/prot.340180108; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; NAGHIBI H, 1995, P NATL ACAD SCI USA, V92, P5597, DOI 10.1073/pnas.92.12.5597; Schreiber G, 1996, NAT STRUCT BIOL, V3, P427, DOI 10.1038/nsb0596-427; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; Sun ZYJ, 1999, EMBO J, V18, P2941, DOI 10.1093/emboj/18.11.2941; van der Merwe PA, 1999, J EXP MED, V190, P1371, DOI 10.1084/jem.190.10.1371; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; Wyss DF, 1997, PROTEIN SCI, V6, P534; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030	54	10	10	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13160	13166		10.1074/jbc.M700829200	http://dx.doi.org/10.1074/jbc.M700829200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344209	Green Accepted, hybrid			2022-12-27	WOS:000246060300004
J	Lee, BH; Chen, W; Stippec, S; Cobb, MH				Lee, Byung-Hoon; Chen, Wei; Stippec, Steve; Cobb, Melanie H.			Biological cross-talk between WNK1 and the transforming growth factor beta-Smad signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE GENE FAMILY; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; SOMATIC MUTATIONS; BLOOD-PRESSURE; CELLS; CANCER; HYPERTENSION; EXPRESSION; MECHANISM	WNKs (with no lysine (K)), unique serine/threonine protein kinases, have been best studied in the context of cell volume regulation and ion homeostasis. Here we describe a biological link between WNKs and transforming growth factor (TGF) beta-Smad signaling. Both WNK1 and WNK4 directly bind to and phosphorylate Smad2. Knockdown of WNK1 in HeLa cells using small interfering RNA reduces Smad2 protein expression; this decrease is at least partially due to down-regulation of Smad2 transcription. In contrast, phosphorylated Smad2 significantly accumulated in the nucleus as a consequence of depletion of WNK1, resulting in Smad-mediated transcriptional responses. In addition, TGF beta-induced target gene transcripts were increased in WNK1 small interfering RNA cells. These findings suggest WNK1 as a dual modulator of TGF beta-Smad signaling pathways.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Harvard Univ, Sch Med, Dept Cell Biol, Cambridge, MA 02138 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 6001 Forest Pk Rd, Dallas, TX 75390 USA.	Melanie.Cobb@UTSouthwestern.edu		Cobb, Melanie/0000-0003-0833-5473; Lee, Byung-Hoon/0000-0002-7101-0471	NIGMS NIH HHS [GM53032] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Anselmo AN, 2006, P NATL ACAD SCI USA, V103, P10883, DOI 10.1073/pnas.0604607103; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Funaba M, 2000, PROTEIN EXPRES PURIF, V20, P507, DOI 10.1006/prep.2000.1315; Ito M, 2001, CANCER RES, V61, P2038; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kahle KT, 2004, CURR OPIN NEPHROL HY, V13, P557, DOI 10.1097/00041552-200409000-00012; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lazrak A, 2006, P NATL ACAD SCI USA, V103, P1615, DOI 10.1073/pnas.0510609103; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Min XS, 2004, STRUCTURE, V12, P1303, DOI 10.1016/j.str.2004.04.014; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; Ventura JJ, 2004, MOL CELL, V15, P269, DOI 10.1016/j.molcel.2004.06.007; Verissimo F, 2006, ONCOGENE, V25, P4172, DOI 10.1038/sj.onc.1209449; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xie J, 2006, PEDIATR NEPHROL, V21, P1231, DOI 10.1007/s00467-006-0106-6; Xu BE, 2005, J BIOL CHEM, V280, P34218, DOI 10.1074/jbc.M505735200; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492; Yakmovych I, 2001, FASEB J, V15, P553; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100; Zeng GC, 2005, GENE, V344, P233, DOI 10.1016/j.gene.2004.10.003	54	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					17985	17996		10.1074/jbc.M702664200	http://dx.doi.org/10.1074/jbc.M702664200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17392271	hybrid			2022-12-27	WOS:000247302000005
J	Ranjith-Kumar, CT; Miller, W; Sun, JC; Xiong, J; Santos, J; Yarbrough, I; Lamb, RJ; Mills, J; Duffy, KE; Hoose, S; Cunningham, M; Holzenburg, A; Mbow, ML; Sarisky, RT; Kao, CC				Ranjith-Kumar, C. T.; Miller, William; Sun, Jingchuan; Xiong, Jin; Santos, Jon; Yarbrough, Ian; Lamb, Roberta J.; Mills, Juliane; Duffy, Karen E.; Hoose, Scott; Cunningham, Mark; Holzenburg, Andreas; Mbow, M. Lamine; Sarisky, Robert T.; Kao, C. Cheng			Effects of single nucleotide polymorphisms on toll-like receptor 3 activity and expression in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SUBCELLULAR-LOCALIZATION; FUNCTIONAL ANALYSES; RECOGNITION; TLR3; ACTIVATION; RESISTANCE; IMMUNITY	Recognition of double-stranded RNA by Toll-like receptor 3 (TLR3) will increase the production of cytokines and chemokines through transcriptional activation by the NF-kappa B protein. Over 136 single-nucleotide polymorphisms (SNPs) in TLR3 have been identified in the human population. Of these, four alter the sequence of the TLR3 protein. Molecular modeling suggests that two of the SNPs, N284I and L412F, could affect the packing of the leucine-rich repeating units in TLR3. Notably, L412F is reported to be present in 20% of the population and is higher in the asthmatic population. To examine whether the four SNPs affect TLR3 function, each were cloned and tested for their ability to activate the expression of TLR3-dependent reporter constructs. SNP N284I was nearly completely defective for activating reporter activity, and L412F was reduced in activity. These two SNPs did not obviously affect the level of TLR3 expression or their intracellular location in vesicles. However, N284I and L412F were underrepresented on the cell surface, as determined by flow cytometry analysis, and were not efficiently secreted into the culture medium when expressed as the soluble ectodomain. They were also reduced in their ability to act in a dominant negative fashion on the wild type TLR3 allele. These observations suggest that N284I and L412F affect the activities of TLR3 needed for proper signaling.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Texas A&M Univ, Microscopy & Imaging Ctr, College Stn, TX 77843 USA; Centocor Res & Dev Inc, Discovery Res, Radnor, PA 19087 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Johnson & Johnson; Johnson & Johnson USA	Kao, CC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	ckao@tamu.edu	Kumar CT, Ranjith/J-5701-2016	Miller, William/0000-0002-1518-2973				Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bell JK, 2006, P NATL ACAD SCI USA, V103, P8792, DOI 10.1073/pnas.0603245103; Bell JK, 2005, P NATL ACAD SCI USA, V102, P10976, DOI 10.1073/pnas.0505077102; Berezin C, 2004, BIOINFORMATICS, V20, P1322, DOI 10.1093/bioinformatics/bth070; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Funami K, 2004, INT IMMUNOL, V16, P1143, DOI 10.1093/intimm/dxh115; Glaubitz JC, 2004, MOL ECOL NOTES, V4, P309, DOI 10.1111/j.1471-8286.2004.00597.x; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Lancaster GI, 2005, J PHYSIOL-LONDON, V563, P945, DOI 10.1113/jphysiol.2004.081224; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Lazzaro BP, 2004, SCIENCE, V303, P1873, DOI 10.1126/science.1092447; Lee HK, 2006, IMMUNITY, V24, P153, DOI 10.1016/j.immuni.2005.12.012; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; Nishiya T, 2005, J BIOL CHEM, V280, P37107, DOI 10.1074/jbc.M504951200; Paxton WA, 1998, SEMIN IMMUNOL, V10, P187, DOI 10.1006/smim.1998.0132; Pirie FJ, 2005, TISSUE ANTIGENS, V66, P125, DOI 10.1111/j.1399-0039.2005.00454.x; Plewniak F, 2003, NUCLEIC ACIDS RES, V31, P3829, DOI 10.1093/nar/gkg518; Pupko T, 2002, BIOINFORMATICS, V18, P1116, DOI 10.1093/bioinformatics/18.8.1116; Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P7668, DOI 10.1074/jbc.M610946200; Salio M, 2005, CURR BIOL, V15, pR336, DOI 10.1016/j.cub.2005.04.025; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Sun JC, 2006, J BIOL CHEM, V281, P11144, DOI 10.1074/jbc.M510442200; Suyama M, 2006, NUCLEIC ACIDS RES, V34, pW609, DOI 10.1093/nar/gkl315; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Uematsu S, 2006, EXPERT OPIN BIOL TH, V6, P203, DOI 10.1517/14712598.6.3.203; Wallace IM, 2006, NUCLEIC ACIDS RES, V34, P1692, DOI 10.1093/nar/gkl091; Yang ZH, 2000, GENETICS, V155, P431; Yang ZH, 2000, TRENDS ECOL EVOL, V15, P496, DOI 10.1016/S0169-5347(00)01994-7	35	114	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17696	17705		10.1074/jbc.M700209200	http://dx.doi.org/10.1074/jbc.M700209200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17434873	hybrid			2022-12-27	WOS:000247084500042
J	Pan, XY; Hussain, FN; Iqbal, J; Feuerman, MH; Hussain, MM				Pan, Xiaoyue; Hussain, Farah N.; Iqbal, Jahangir; Feuerman, Miriam H.; Hussain, M. Mahmood			Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRACHLORIDE-INDUCED HEPATOTOXICITY; DIFFERENTIATED CACO-2 CELLS; CARBON-TETRACHLORIDE; APOLIPOPROTEIN-B; ISOLATED HEPATOCYTES; LIPID-PEROXIDATION; MCA-RH7777 CELLS; GENE-EXPRESSION; LIVER STEATOSIS; MTP INHIBITOR	Carbon tetrachloride (CCl4) interferes with triglyceride secretion and causes steatosis, fibrosis, and necrosis. In mice, CCl4 decreased plasma triglyceride-rich lipoproteins, increased cellular lipids, and reduced microsomal triglyceride transfer protein (MTP) without diminishing mRNA levels. Similarly, CCl4 decreased apoB-lipoprotein production and MTP activity but had no effect on mRNA levels in primary enterocytes and colon carcinoma and hepatoma cells. CCl4 did not affect MTP synthesis but induced post-translational degradation involving ubiquitinylation and proteasomes in McA-RH7777 cells. By contrast, MTP inhibitor increased cellular lipids without affecting MTP protein. MTP was covalently modified when cells were incubated with (CCl4)-C-14. This modification was prevented by the inhibition of P450 oxygenases, indicating that CCl3 center dot generated by these enzymes targets MTP for degradation. To determine whether inhibition of proteolysis could prevent CCl4 toxicity, mice were fed with CCl4 with or without lactacystin. Lactacystin increased ubiquitinylated MTP and prevented lipid accumulation in tissues. Thus, CCl4 induces post-translational degradation without affecting lipid transfer activity, whereas MTP antagonist inhibits lipid transfer activity without causing its destruction. These studies identify MTP as a major target of CCl4 and its degradation as a novel mechanism involved in the onset of steatosis, suggesting that inhibition of proteolysis may prevent some forms of steatosis.	Suny Downstate Med Ctr, Dept Anat & Cellular Biol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Biochem, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Hussain, MM (corresponding author), Suny Downstate Med Ctr, Dept Anat & Cellular Biol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.	mhussain@downstate.edu	Iqbal, Jahangir/B-3903-2014	Iqbal, Jahangir/0000-0002-9021-2271	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064272] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64272] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams J, 2003, DRUG DISCOV TODAY, V8, P307, DOI 10.1016/S1359-6446(03)02647-3; Anwar K, 2006, J LIPID RES, V47, P1261, DOI 10.1194/jlr.M500523-JLR200; Athar H, 2004, J LIPID RES, V45, P764, DOI 10.1194/jlr.D300026-JLR200; Bakillah A, 2003, FRONT BIOSCI-LANDMRK, V8, pD294; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; Basu S, 2003, TOXICOLOGY, V189, P113, DOI 10.1016/S0300-483X(03)00157-4; Boll M, 2001, Z NATURFORSCH C, V56, P649; Boll M, 2001, Z NATURFORSCH C, V56, P283; Boll M, 2001, Z NATURFORSCH C, V56, P111; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Chandler CE, 2003, J LIPID RES, V44, P1887, DOI 10.1194/jlr.M300094-JLR200; Cuchel M, 2007, NEW ENGL J MED, V356, P148, DOI 10.1056/NEJMoa061189; Dougan SK, 2005, J EXP MED, V202, P529, DOI 10.1084/jem.20050183; Dougan SK, 2007, J EXP MED, V204, P533, DOI 10.1084/jem.20062006; Fatma S, 2006, J LIPID RES, V47, P2422, DOI 10.1194/jlr.M600211-JLR200; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; Harries HM, 2001, TOXICOL IN VITRO, V15, P399, DOI 10.1016/S0887-2333(01)00043-1; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 2003, FRONT BIOSCI, V8, pS500, DOI 10.2741/1071; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; *INT AG RES CANC, 1999, RISKS HUM, V71, P401; Iqbal J, 2005, J LIPID RES, V46, P1491, DOI 10.1194/jlr.M500023-JLR200; Iqbal J, 2003, J BIOL CHEM, V278, P31610, DOI 10.1074/jbc.M301177200; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; LIN MCM, 1995, J LIPID RES, V36, P1073; Luchoomun J, 1999, J BIOL CHEM, V274, P19565, DOI 10.1074/jbc.274.28.19565; Luchoomun J, 1997, ARTERIOSCL THROM VAS, V17, P2955, DOI 10.1161/01.ATV.17.11.2955; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Mirandola S, 2006, GASTROENTEROLOGY, V130, P1661, DOI 10.1053/j.gastro.2006.02.035; Pan XY, 2002, AM J PHYSIOL-GASTR L, V283, pG57, DOI 10.1152/ajpgi.00545.2001; PENCIL SD, 1984, BIOCHEM PHARMACOL, V33, P2419, DOI 10.1016/0006-2952(84)90713-5; Plaa GL, 2000, ANNU REV PHARMACOL, V40, P43, DOI 10.1146/annurev.pharmtox.40.1.43; POLI G, 1979, EXP MOL PATHOL, V30, P116, DOI 10.1016/0014-4800(79)90086-8; Rava P, 2006, J BIOL CHEM, V281, P11019, DOI 10.1074/jbc.M512823200; Rava P, 2005, J LIPID RES, V46, P1779, DOI 10.1194/jlr.D400043-JLR200; RECKNAGE RO, 1967, PHARMACOL REV, V19, P145; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHMIDER J, 1995, J PHARMACOL EXP THER, V275, P592; Sugimoto T, 2002, J HEPATOL, V36, P157, DOI 10.1016/S0168-8278(01)00263-X; Terada T, 2005, BIOCHEM PHARMACOL, V70, P1756, DOI 10.1016/j.bcp.2005.09.027; Tietge UJF, 1999, J LIPID RES, V40, P2134; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Weber LWD, 2003, CRIT REV TOXICOL, V33, P105, DOI 10.1080/713611034; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wong FWY, 1998, TOXICOL APPL PHARM, V153, P109, DOI 10.1006/taap.1998.8547; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Zhang H, 2005, BLOOD, V105, P3286, DOI 10.1182/blood-2004-06-2101; Zhang QY, 2003, DRUG METAB DISPOS, V31, P1346, DOI 10.1124/dmd.31.11.1346	53	51	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17078	17089		10.1074/jbc.M701742200	http://dx.doi.org/10.1074/jbc.M701742200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17405876	hybrid			2022-12-27	WOS:000246946500041
J	Han, J; Goldstein, LA; Hou, W; Rabinowich, H				Han, Jie; Goldstein, Leslie A.; Hou, Wen; Rabinowich, Hannah			Functional linkage between NOXA and Bim in mitochondrial apoptotic events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; GAMMA-SECRETASE-INHIBITOR; CELL-DEATH; BH3-ONLY PROTEINS; MYELOMA CELLS; GRANZYME-B; MCL-1; SURVIVAL; PERMEABILITY; INDUCTION	NOXA is a BH3-only protein whose expression is induced by certain p53-depenent or independent apoptotic stimuli. Both NOXA and Bim are avid binders of Mcl-1, but a functional linkage between these BH3-only proteins has not yet been reported. In this study, we demonstrate that Mcl-1 binding of endogenously induced NOXA interferes with the ability of Mcl-1 to efficiently sequester endogenous Bim, as Bim is displaced from its complex with Mcl- 1. Induced NOXA significantly enhances the UV sensitivity of cells, and the ensuing mitochondrial depolarization is entirely abrogated by Bim knockdown. These results demonstrate a Mcl-1-mediated cross-talk between endogenous NOXA and Bim that occurs upstream of the Bak/Bax-dependent execution of UV-induced mitochondrial depolarization. The current findings demonstrate that the mitochondrial response to an induced expression ofNOXAis executed by endogenous Bim and suggest a plausible mechanism for the observed NOXA-Bim linkage.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rabinowich, H (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavill,Rm G17C,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	rabinow@pitt.edu			NCI NIH HHS [R01 CA109285, R01 CA111786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111786, R01CA109285] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Curry CL, 2005, ONCOGENE, V24, P6333, DOI 10.1038/sj.onc.1208783; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011; Erlacher M, 2006, J EXP MED, V203, P2939, DOI 10.1084/jem.20061552; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Gentile M, 2003, NUCLEIC ACIDS RES, V31, P4779, DOI 10.1093/nar/gkg675; Gomez-Bougie P, 2005, ONCOGENE, V24, P8076, DOI 10.1038/sj.onc.1208949; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Han J, 2005, J BIOL CHEM, V280, P16383, DOI 10.1074/jbc.M411377200; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; Johnson DE, 2000, CANCER RES, V60, P1818; Kang JH, 2005, EUR J IMMUNOL, V35, P2982, DOI 10.1002/eji.200526242; Lucken-Ardjomande S, 2005, CR BIOL, V328, P616, DOI 10.1016/j.crvi.2005.05.002; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Qin JZ, 2004, MOL CANCER THER, V3, P895; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	37	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16223	16231		10.1074/jbc.M611186200	http://dx.doi.org/10.1074/jbc.M611186200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17374615	hybrid			2022-12-27	WOS:000246794300030
J	Addison, WN; Azari, F; Sorensen, ES; Kaartinen, MT; Mckee, MD				Addison, William N.; Azari, Fereshteh; Sorensen, Esben S.; Kaartinen, Mari T.; McKee, Marc D.			Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE ANKYLOSIS GENE; MUSCLE-CELL CALCIFICATION; O-GLYCOSYLATION SITES; INORGANIC PYROPHOSPHATE; IN-VITRO; HYDROXYAPATITE FORMATION; INFANTILE HYPOPHOSPHATASIA; BETA-GLYCEROPHOSPHATE; EXTRACELLULAR-MATRIX; MC3T3-E1 CELLS	Inorganic pyrophosphate (PPi) produced by cells inhibits mineralization by binding to crystals. Its ubiquitous presence is thought to prevent "soft" tissues from mineralizing, whereas its degradation to P-i in bones and teeth by tissue-nonspecific alkaline phosphatase (Tnap, Tnsalp, Alp1, Akp2) may facilitate crystal growth. Whereas the crystal binding properties of PPi are largely understood, less is known about its effects on osteoblast activity. We have used MC3T3-E1 osteoblast cultures to investigate the effect of PPi on osteoblast function and matrix mineralization. Mineralization in the cultures was dose-dependently inhibited by PPi. This inhibition could be reversed by Tnap, but not if PPi was bound to mineral. PPi also led to increased levels of osteopontin (Opn) induced via the Erk1/2 and p38 MAPK signaling pathways. Opn regulation by PPi was also insensitive to foscarnet (an inhibitor of phosphate uptake) and levamisole (an inhibitor of Tnap enzymatic activity), suggesting that increased Opn levels did not result from changes in phosphate. Exogenous OPN inhibited mineralization, but dephosphorylation by Tnap reversed this effect, suggesting that OPN inhibits mineralization via its negatively charged phosphate residues and that like PPi, hydrolysis by Tnap reduces its mineral inhibiting potency. Using enzyme kinetic studies, we have shown that PPi inhibits Tnap-mediated P-i release from beta-glycerophosphate (a commonly used source of organic phosphate for culture mineralization studies) through a mixed type of inhibition. In summary, PPi prevents mineralization in MC3T3-E1 osteoblast cultures by at least three different mechanisms that include direct binding to growing crystals, induction of Opn expression, and inhibition of Tnap activity.	McGill Univ, Fac Dent, Montreal, PQ H3A 2B2, Canada; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; McGill Univ, Fac Med, Dept Med, Montreal, PQ H3A 2B2, Canada; McGill Univ, Fac Med, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	McGill University; Aarhus University; McGill University; McGill University	Mckee, MD (corresponding author), McGill Univ, Fac Dent, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.	marc.mckee@mcgill.ca	McKee, Marc D/E-2187-2011	McKee, Marc D/0000-0001-8349-965X; Kaartinen, Mari/0000-0003-2999-6502; Sorensen, Esben Skipper/0000-0002-7050-3354				Beck GR, 2003, J BIOL CHEM, V278, P41921, DOI 10.1074/jbc.M304470200; Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Beck GR, 2003, EXP CELL RES, V288, P288, DOI 10.1016/S0014-4827(03)00213-1; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BELLOWS CG, 1992, BONE MINER, V17, P15, DOI 10.1016/0169-6009(92)90707-K; Boileau G, 2001, BIOCHEM J, V355, P707, DOI 10.1042/bj3550707; BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169-6009(08)80225-5; Boskey AL, 2005, CELLS TISSUES ORGANS, V181, P144, DOI 10.1159/000091376; Boskey AL, 2002, CALCIFIED TISSUE INT, V71, P145, DOI 10.1007/s00223-001-1121-z; Chen C, 2004, J BIOL CHEM, V279, P29121, DOI 10.1074/jbc.M313000200; Christensen B, 2005, BIOCHEM J, V390, P285, DOI 10.1042/BJ20050341; CHUCK AJ, 1989, ANN RHEUM DIS, V48, P571, DOI 10.1136/ard.48.7.571; CHUNG CH, 1992, CALCIFIED TISSUE INT, V51, P305, DOI 10.1007/BF00334492; Coburn SP, 1998, J CLIN ENDOCR METAB, V83, P3951, DOI 10.1210/jc.83.11.3951; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Dvorak MM, 2004, CELL CALCIUM, V35, P249, DOI 10.1016/j.ceca.2003.10.014; ECAROTCHARRIER B, 1983, J CELL BIOL, V96, P639, DOI 10.1083/jcb.96.3.639; Ehara A, 2003, BIOMATERIALS, V24, P831, DOI 10.1016/S0142-9612(02)00411-8; Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015; FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0; FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671; Foster BL, 2006, CALCIFIED TISSUE INT, V78, P103, DOI 10.1007/s00223-005-0184-7; Garimella R, 2006, BONE, V38, P811, DOI 10.1016/j.bone.2005.11.027; Gericke A, 2005, CALCIFIED TISSUE INT, V77, P45, DOI 10.1007/s00223-004-1288-1; Gurley KA, 2006, J BONE MINER RES, V21, P1238, DOI 10.1359/JBMR.060515; Harmey D, 2006, J BONE MINER RES, V21, P1377, DOI 10.1359/JBMR.060619; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265; Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756-3282(00)00351-3; Hoyer JR, 2001, KIDNEY INT, V60, P77, DOI 10.1046/j.1523-1755.2001.00772.x; HUANG R, 1994, J CLIN INVEST, V94, P560, DOI 10.1172/JCI117370; Hui MZ, 1998, ANAT REC, V253, P91; HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723; James MJ, 2006, J BONE MINER RES, V21, P1034, DOI 10.1359/JBMR.060413; Johnson K, 2003, J BONE MINER RES, V18, P994, DOI 10.1359/jbmr.2003.18.6.994; Johnson KA, 2000, AM J PHYSIOL-REG I, V279, pR1365, DOI 10.1152/ajpregu.2000.279.4.R1365; Jono S, 2000, J BIOL CHEM, V275, P20197, DOI 10.1074/jbc.M909174199; Kananovich S. Zh., 2003, Journal of Applied Spectroscopy, V70, P765, DOI 10.1023/B:JAPS.0000008876.07758.08; KASUGAI S, 1991, BONE MINER, V13, P235, DOI 10.1016/0169-6009(91)90071-7; Kawazoe Y, 2004, J DENT RES, V83, P613, DOI 10.1177/154405910408300806; Kornberg A., 1962, HORIZONS BIOCH, P251; Li XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7; LUNN JE, 1993, BIOCHEM J, V290, P375, DOI 10.1042/bj2900375; MANSUROVA SE, 1989, BIOCHIM BIOPHYS ACTA, V977, P237, DOI 10.1016/S0005-2728(89)80078-7; MCKEE MD, 1995, ANN NY ACAD SCI, V760, P177, DOI 10.1111/j.1749-6632.1995.tb44629.x; McKee MD, 2000, OSTEOPOROSIS PRIMER, P46; MEYER JL, 1973, CALC TISS RES, V13, P295, DOI 10.1007/BF02015419; MORLEY JE, 1987, ENDOCR REV, V8, P256, DOI 10.1210/edrv-8-3-256; MOSS DW, 1967, BIOCHEM J, V102, P53, DOI 10.1042/bj1020053; Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205; Nanci A, 1996, MICROSC RES TECHNIQ, V33, P214; Narisawa S, 1997, DEV DYNAM, V208, P432, DOI 10.1002/(SICI)1097-0177(199703)208:3<432::AID-AJA13>3.0.CO;2-1; Nociti FH, 2002, J DENT RES, V81, P817, DOI 10.1177/154405910208101204; Nurnberg P, 2001, NAT GENET, V28, P37, DOI 10.1038/ng0501-37; Orimo H, 2006, MOL CELL BIOCHEM, V282, P101, DOI 10.1007/s11010-006-1520-6; Pampena DA, 2004, BIOCHEM J, V378, P1083, DOI 10.1042/BJ20031150; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; RUSSELL RGG, 1971, J CLIN INVEST, V50, P961, DOI 10.1172/JCI106589; Ryan LM, 2003, CURR OPIN RHEUMATOL, V15, P311, DOI 10.1097/00002281-200305000-00020; SAKAMOTO M, 1994, PATHOL INT, V44, P420, DOI 10.1111/j.1440-1827.1994.tb01705.x; Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; SORENSEN ES, 1993, J DAIRY RES, V60, P189, DOI 10.1017/S0022029900027503; TENENBAUM HC, 1992, BONE, V13, P249, DOI 10.1016/8756-3282(92)90205-B; Terkeltaub RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1; Tesch W, 2003, J BONE MINER RES, V18, P117, DOI 10.1359/jbmr.2003.18.1.117; VILLIOTTE PJ, 1991, FEMS MICROBIOL LETT, V78, P293; Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Wang W, 2005, MOL CELL BIOL, V25, P312, DOI 10.1128/MCB.25.1.312-323.2005; WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Zaka R, 2005, OSTEOARTHR CARTILAGE, V13, P745, DOI 10.1016/j.joca.2005.04.006	75	259	284	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15872	15883		10.1074/jbc.M701116200	http://dx.doi.org/10.1074/jbc.M701116200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17383965	hybrid			2022-12-27	WOS:000246589600062
J	Edlich, F; Erdmann, F; Jarczowski, F; Moutty, MC; Weiwad, M; Fischer, G				Edlich, Frank; Erdmann, Frank; Jarczowski, Franziska; Moutty, Marie-Christine; Weiwad, Matthias; Fischer, Gunter			The Bcl-2 regulator FKBP38-calmodulin-Ca2+ is inhibited by Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HEAT-SHOCK PROTEINS; HSP90-BINDING IMMUNOPHILINS; CALMODULIN; BINDING; DOMAIN; RECEPTOR; FKBP38; ACTIVATION; APOPTOSIS	FKBP38 is a negative effector of the anti-apoptotic Bcl-2 protein in neuroblastoma cells. The interaction with Bcl-2 and the enzyme activity of FKBP38 depend on prior binding of calmodulin-Ca2+ (CaM-Ca2+) at high Ca2+ concentrations. The FKBP38 protein structure contains three tetratricopeptide repeat (TPR) motifs corresponding to the Hsp90 interaction sites of other immunophilins. In this study we show that the TPR domain of FKBP38 interacts with the C-terminal domain of Hsp90, but only if the FKBP38-CaM-Ca2+ complex is preformed. Hence, FKBP38 is the first example of a TPR-containing immunophilin that interacts cofactor-dependently with Hsp90. In the ternary Hsp90-FKBP38-CaM-Ca2+ complex the active site of FKBP38 is blocked, thus preventing interactions with Bcl-2. The dual control of the active site cleft of FKBP38 by CaM-Ca2+ and Hsp90 highlights the importance of the enzyme activity of the FKBP38-CaM-Ca2+ complex in the regulation of programmed cell death.	Max Planck Res Unit Enzymol Prot Folding, D-66120 Halle, Germany	Max Planck Society	Fischer, G (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-66120 Halle, Germany.	fischer@enzyme-halle.mpg.de	Erdmann, Frank/AAF-1091-2021	Erdmann, Frank/0000-0001-5261-0984				Barker CR, 2006, NUCLEIC ACIDS RES, V34, P1148, DOI 10.1093/nar/gkj516; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Bulgakov OV, 2004, DEVELOPMENT, V131, P2149, DOI 10.1242/dev.01122; Cambiazo V, 1999, FEBS LETT, V457, P343, DOI 10.1016/S0014-5793(99)01070-4; Christner C., 2001, Mini-Reviews in Medicinal Chemistry, V1, P377, DOI 10.2174/1389557013406675; Cliff MJ, 2005, J MOL BIOL, V346, P717, DOI 10.1016/j.jmb.2004.12.017; Cliff MJ, 2006, STRUCTURE, V14, P415, DOI 10.1016/j.str.2005.12.009; Compton SA, 2006, MOL CELL BIOL, V26, P1452, DOI 10.1128/MCB.26.4.1452-1462.2006; Crackower MA, 2003, SCIENCE, V300, P1291, DOI 10.1126/science.1083022; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Edlich F, 2005, EMBO J, V24, P2688, DOI 10.1038/sj.emboj.7600739; Edlich F, 2006, J BIOL CHEM, V281, P14961, DOI 10.1074/jbc.M600452200; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; Fischer G, 2004, REV PHYSIOL BIOCH P, V148, P105, DOI 10.1007/s10254-003-0011-3; Fong S, 2003, P NATL ACAD SCI USA, V100, P14253, DOI 10.1073/pnas.2332307100; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Guo ZH, 2001, J NEUROCHEM, V79, P361, DOI 10.1046/j.1471-4159.2001.00564.x; Harrar Y, 2001, TRENDS PLANT SCI, V6, P426, DOI 10.1016/S1360-1385(01)02044-1; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Jiang BM, 2005, CELL STRESS CHAPERON, V10, P252, DOI 10.1379/CSC-124R.1; Kazlauskas A, 2002, J BIOL CHEM, V277, P11795, DOI 10.1074/jbc.M200053200; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; Okamoto T, 2006, EMBO J, V25, P5015, DOI 10.1038/sj.emboj.7601367; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; Papapetropoulos A, 2004, MOL PHARMACOL, V65, P407, DOI 10.1124/mol.65.2.407; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; RADANYI C, 1989, J BIOL CHEM, V264, P2568; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Someren JS, 1999, BIOCHEM BIOPH RES CO, V260, P619, DOI 10.1006/bbrc.1999.0800; Song Y, 2001, BIOCHEM J, V355, P357, DOI 10.1042/0264-6021:3550357; Takahashi S, 2003, J BIOL CHEM, V278, P9339, DOI 10.1074/jbc.M212651200; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Wang JD, 2006, FEBS LETT, V580, P4392, DOI 10.1016/j.febslet.2006.07.002; Weiwad M, 2005, FEBS LETT, V579, P1591, DOI 10.1016/j.febslet.2004.12.098; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	47	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15341	15348		10.1074/jbc.M611594200	http://dx.doi.org/10.1074/jbc.M611594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17379601	hybrid			2022-12-27	WOS:000246589600009
J	Morrison, BH; Bauer, JA; Lupica, JA; Tang, Z; Schmidt, H; DiDonato, JA; Lindner, DJ				Morrison, Bei H.; Bauer, Joseph A.; Lupica, Joseph A.; Tang, Zhuo; Schmidt, Heidi; DiDonato, Joseph A.; Lindner, Daniel J.			Effect of inositol hexakisphosphate kinase 2 on transforming growth factor beta-activated kinase 1 and NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL HEXAKISPHOSPHATE KINASE-2; OVARIAN-CARCINOMA CELLS; IKK-ALPHA; DNA-PK; TRAF2; DEATH; TNF; PYROPHOSPHATES; BETA; PHOSPHORYLATION	We previously showed that inositol hexakisphosphate kinase 2 (IHPK2) functions as a growth-suppressive and apoptosis-enhancing kinase during cell stress. Overexpression of IHPK2 sensitized ovarian carcinoma cell lines to the growth-suppressive and apoptotic effects of interferon beta (IFN-beta), IFN-alpha 2, and gamma-irradiation. Expression of a kinase-dead mutant abrogated 50% of the apoptosis induced by IFN-beta. Because the kinase-dead mutant retained significant response to cell stressors, we hypothesized that a portion of the death-promoting function of IHPK2 was independent of its kinase activity. We now demonstrate that IHPK2 binds to tumor necrosis factor (TNF) receptor-associated factor (TRAF) 2 and interferes with phosphorylation of transforming growth factor beta-activated kinase 1 (TAK1), thereby inhibiting NF-kappa B signaling. IHPK2 contains two sites required for TRAF2 binding, Ser-347 and Ser-359. Compared with wild type IHPK2-transfected cells, cells expressing S347A and S359A mutations displayed 3.5-fold greater TAK1 activation following TNF-alpha. This mutant demonstrated a 6-10-fold increase in NF-kappa B DNA binding following TNF-alpha compared with wild type IHPK2-expressing cells in which NF-kappa B DNA binding was inhibited. Cells transfected with wild type IHPK2 or IHPK2 mutants that lacked S347A and S359A mutations displayed enhanced terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling staining following TNF-alpha. We believe that IHPK2-TRAF2 binding leads to attenuation of TAK1- and NF-kappa B-mediated signaling and is partially responsible for the apoptotic activity of IHPK2.	Cleveland Clin, Ctr Hematol & Oncol Mol Therapeut, Taussig Canc Ctr, Cleveland, OH 44195 USA; Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland State University	Lindner, DJ (corresponding author), Cleveland Clin, Ctr Hematol & Oncol Mol Therapeut, Taussig Canc Ctr, 9500 Euclid Ave,R40, Cleveland, OH 44195 USA.	lindned@ccf.org	Hazen, Stanley L/ABD-5845-2021; Lindner, Daniel/ABB-5440-2020	Lupica, Joseph/0000-0003-1476-037X; Bauer, Joseph/0000-0003-4972-6008	NATIONAL CANCER INSTITUTE [R01CA095020] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095020-01A1, CA095020, R01 CA095020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Byrum J, 2004, NUCLEIC ACIDS RES, V32, P2776, DOI 10.1093/nar/gkh592; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Davies CC, 2005, MOL CELL BIOL, V25, P9806, DOI 10.1128/MCB.25.22.9806-9819.2005; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DiDonato JA, 2000, METHOD ENZYMOL, V322, P393; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Jackson-Bernitsas DG, 2007, ONCOGENE, V26, P1385, DOI 10.1038/sj.onc.1209945; Kinoshita S, 1998, PHARMACEUT RES, V15, P1851, DOI 10.1023/A:1011953906065; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; MA Y, 2002, J BIOL CHEM, V30, P30; Morrison BH, 2002, ONCOGENE, V21, P1882, DOI 10.1038/sj.onc.1205265; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Nagata E, 2005, J BIOL CHEM, V280, P1634, DOI 10.1074/jbc.M409416200; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Ozes ON, 1999, NATURE, V401, P82; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	31	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15349	15356		10.1074/jbc.M700156200	http://dx.doi.org/10.1074/jbc.M700156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17379600	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000246589600010
J	Yoneyama, M; Fujita, T				Yoneyama, Mitsutoshi; Fujita, Takashi			Function of RIG-I-like receptors in antiviral innate immunity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DOUBLE-STRANDED-RNA; HEPATITIS-C-VIRUS; INTERFERON REGULATORY FACTOR-3; IFN-BETA PROMOTER; INDUCIBLE GENE-I; SIGNALING PROTEIN; VIRAL-INFECTION; ADAPTER PROTEIN; HELICASE LGP2; V-PROTEINS		Kyoto Univ, Mol Genet Lab, Inst Virus Res, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Fujita, T (corresponding author), Kyoto Univ, Mol Genet Lab, Inst Virus Res, Kyoto 6068507, Japan.	tfujita@virus.kyoto-u.ac.jp	Yoneyama, Mitsutoshi/D-8244-2017	Yoneyama, Mitsutoshi/0000-0001-9512-0408				Abate DA, 2004, J VIROL, V78, P10995, DOI 10.1128/JVI.78.20.10995-11006.2004; Alff PJ, 2006, J VIROL, V80, P9676, DOI 10.1128/JVI.00508-06; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Cardenas WB, 2006, J VIROL, V80, P5168, DOI 10.1128/JVI.02199-05; Childs K, 2007, VIROLOGY, V359, P190, DOI 10.1016/j.virol.2006.09.023; Fredericksen BL, 2006, J VIROL, V80, P2913, DOI 10.1128/JVI.80.6.2913-2923.2006; GUU Z, 2007, AM J RESP CELL MOL B, V36, P263; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Jennings S, 2005, VIROLOGY, V331, P63, DOI 10.1016/j.virol.2004.10.015; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Komuro A, 2006, J VIROL, V80, P12332, DOI 10.1128/JVI.01325-06; Kumar H, 2006, J EXP MED, V203, P1795, DOI 10.1084/jem.20060792; Langland JO, 2006, J VIROL, V80, P10083, DOI 10.1128/JVI.00607-06; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Lin RT, 2006, J VIROL, V80, P6072, DOI 10.1128/JVI.02495-05; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; Marques JT, 2006, NAT BIOTECHNOL, V24, P559, DOI 10.1038/nbt1205; Melroe GT, 2007, VIROLOGY, V360, P305, DOI 10.1016/j.virol.2006.10.028; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Mibayashi M, 2007, J VIROL, V81, P514, DOI 10.1128/JVI.01265-06; Opitz B, 2007, CELL MICROBIOL, V9, P930, DOI 10.1111/j.1462-5822.2006.00841.x; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Saito T, 2007, P NATL ACAD SCI USA, V104, P582, DOI 10.1073/pnas.0606699104; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhou HX, 2007, J VIROL, V81, P568, DOI 10.1128/JVI.01512-06	42	241	261	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15315	15318		10.1074/jbc.R700007200	http://dx.doi.org/10.1074/jbc.R700007200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17395582	hybrid			2022-12-27	WOS:000246589600005
J	Namslauer, A; Lepp, H; Branden, M; Jasaitis, A; Verkhovsky, MI; Brzezinski, P				Namslauer, Andreas; Lepp, Hakan; Branden, Magnus; Jasaitis, Audrius; Verkhovsky, Michael I.; Brzezinski, Peter			Plasticity of proton pathway structure and water coordination in cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS ELECTRON-TRANSFER; SITE-DIRECTED MUTAGENESIS; HEME-COPPER OXIDASES; RHODOBACTER-SPHAEROIDES; PARACOCCUS-DENITRIFICANS; MOLECULAR-DYNAMICS; BIOLOGICAL-SYSTEMS; R-SPHAEROIDES; GLUTAMATE 286; ACTIVE-SITE	Cytochrome c oxidase (CytcO) is a redox-driven, membrane-bound proton pump. One of the proton transfer pathways of the enzyme, the D pathway, used for the transfer of both substrate and pumped protons, accommodates a network of hydrogen-bonded water molecules that span the distance between an aspartate (Asp(132)), near the protein surface, and glutamate Glu(286), which is an internal proton donor to the catalytic site. To investigate how changes in the environment around Glu(286) affect the mechanism of proton transfer through the pathway, we introduced a non-hydrogen-bonding (Ala) or an acidic residue (Asp) at position Ser(197) (S197A or S197D), located similar to 7 angstrom from Glu(286). Although Ser(197) is hydrogen- bonded to a water molecule that is part of the D pathway "proton wire," replacement of the Ser by an Ala did not affect the proton transfer rate. In contrast, the S197D mutant CytcO displayed a turnover activity of similar to 35% of that of the wild-type CytcO, and the O-2 reduction reaction was not linked to proton pumping. Instead, a fraction of the substrate protons was taken from the positive ("incorrect") side of the membrane. Furthermore, the pH dependence of the proton transfer rate was altered in the mutant CytcO. The results indicate that there is plasticity in the water coordination of the proton pathway, but alteration of the electrostatic potential within the pathway results in uncoupling of the proton translocation machinery.	Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Univ Helsinki, Inst Biotechnol, Helsinki Bioenerget Grp, FIN-00014 Helsinki, Finland	Stockholm University; University of Helsinki	Brzezinski, P (corresponding author), Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	peterb@dbb.su.se						Aagaard A, 2002, BBA-BIOENERGETICS, V1555, P133, DOI 10.1016/S0005-2728(02)00268-2; Aagaard A, 2000, BIOCHEMISTRY-US, V39, P15847, DOI 10.1021/bi0012641; Adelroth P, 1998, BIOCHEMISTRY-US, V37, P2470, DOI 10.1021/bi971813b; Adelroth P, 1997, BIOCHEMISTRY-US, V36, P13824, DOI 10.1021/bi9629079; ADELROTH P, 1995, BIOCHEMISTRY-US, V34, P2844; Adelroth P, 1998, BBA-BIOENERGETICS, V1367, P107, DOI 10.1016/S0005-2728(98)00142-X; Adelroth P, 2000, BBA-BIOENERGETICS, V1459, P533, DOI 10.1016/S0005-2728(00)00194-8; Adelroth P, 2006, BBA-BIOENERGETICS, V1757, P867, DOI 10.1016/j.bbabio.2006.08.011; Behr J, 2000, BIOCHEMISTRY-US, V39, P1356, DOI 10.1021/bi991504g; Branden G, 2005, BIOCHEMISTRY-US, V44, P10466, DOI 10.1021/bi0502745; Branden G, 2006, BBA-BIOENERGETICS, V1757, P1052, DOI 10.1016/j.bbabio.2006.05.020; Branden M, 2001, P NATL ACAD SCI USA, V98, P5013, DOI 10.1073/pnas.081088398; Brzezinski P, 2004, TRENDS BIOCHEM SCI, V29, P380, DOI 10.1016/j.tibs.2004.05.008; Brzezinski P, 1998, J BIOENERG BIOMEMBR, V30, P99, DOI 10.1023/A:1020567729941; BRZEZINSKI P, 1985, FEBS LETT, V187, P111, DOI 10.1016/0014-5793(85)81224-2; Brzezinski P, 2006, CURR OPIN STRUC BIOL, V16, P465, DOI 10.1016/j.sbi.2006.06.012; Burykin A, 2003, BIOPHYS J, V85, P3696, DOI 10.1016/S0006-3495(03)74786-9; DRACHEV LA, 1979, ANAL BIOCHEM, V96, P250, DOI 10.1016/0003-2697(79)90580-3; Dutton P L, 1978, Methods Enzymol, V54, P411; Faxen K, 2005, NATURE, V437, P286, DOI 10.1038/nature03921; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; FETTER JR, 1995, P NATL ACAD SCI USA, V92, P1604, DOI 10.1073/pnas.92.5.1604; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; Gilderson G, 2002, BIOPHYS CHEM, V98, P105, DOI 10.1016/S0301-4622(02)00088-1; Han D, 2006, BIOCHEMISTRY-US, V45, P14064, DOI 10.1021/bi061465q; Hosler JP, 1996, BIOCHEMISTRY-US, V35, P10776, DOI 10.1021/bi9606511; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Iwaki M, 2003, BIOCHEMISTRY-US, V42, P8809, DOI 10.1021/bi034522d; Jasaitis A, 1999, BIOCHEMISTRY-US, V38, P2697, DOI 10.1021/bi982275l; Junemann S, 1997, BIOCHEMISTRY-US, V36, P14456, DOI 10.1021/bi971458p; Karpefors M, 2000, BIOCHEMISTRY-US, V39, P14664, DOI 10.1021/bi0013748; Karpefors M, 2000, BIOCHEMISTRY-US, V39, P6850, DOI 10.1021/bi992719t; Karpefors M, 1998, P NATL ACAD SCI USA, V95, P13606, DOI 10.1073/pnas.95.23.13606; Karpefors M, 1999, ISRAEL J CHEM, V39, P427; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Mills DA, 2000, BBA-BIOENERGETICS, V1458, P180, DOI 10.1016/S0005-2728(00)00067-0; Mills DA, 2002, BBA-BIOENERGETICS, V1555, P96, DOI 10.1016/S0005-2728(02)00261-X; MITCHELL DM, 1995, FEBS LETT, V368, P148, DOI 10.1016/0014-5793(95)00626-K; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P13089, DOI 10.1021/bi961416l; MITCHELL R, 1992, BIOCHIM BIOPHYS ACTA, V1101, P188, DOI 10.1016/S0005-2728(05)80016-7; Morgan JE, 1996, BIOCHEMISTRY-US, V35, P12235, DOI 10.1021/bi961634e; Namslauer A, 2004, FEBS LETT, V567, P103, DOI 10.1016/j.febslet.2004.04.027; Namslauer A, 2003, P NATL ACAD SCI USA, V100, P15543, DOI 10.1073/pnas.2432106100; Namslauer A, 2003, BIOCHEMISTRY-US, V42, P1488, DOI 10.1021/bi026524o; Olkhova E, 2004, BIOPHYS J, V86, P1873, DOI 10.1016/S0006-3495(04)74254-X; Olsson MHM, 2006, P NATL ACAD SCI USA, V103, P6500, DOI 10.1073/pnas.0510860103; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; PADDOCK ML, 1994, BIOCHEMISTRY-US, V33, P734, DOI 10.1021/bi00169a015; Pawate AS, 2002, BIOCHEMISTRY-US, V41, P13417, DOI 10.1021/bi026582+; Pfitzner U, 2000, BIOCHEMISTRY-US, V39, P6756, DOI 10.1021/bi992235x; Pomes R, 1998, BBA-BIOENERGETICS, V1365, P255, DOI 10.1016/S0005-2728(98)00077-2; Popovic DM, 2004, FEBS LETT, V566, P126, DOI 10.1016/j.febslet.2004.04.016; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Puustinen A, 1999, P NATL ACAD SCI USA, V96, P35, DOI 10.1073/pnas.96.1.35; Salomonsson L, 2005, P NATL ACAD SCI USA, V102, P17624, DOI 10.1073/pnas.0505431102; Smirnova IA, 1999, BIOCHEMISTRY-US, V38, P6826, DOI 10.1021/bi982865j; Sucheta A, 1997, BIOCHEMISTRY-US, V36, P554, DOI 10.1021/bi962422k; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; Szundi I, 2003, BIOCHEMISTRY-US, V42, P5074, DOI 10.1021/bi020483e; Verkhovsky MI, 1999, NATURE, V400, P480, DOI 10.1038/22813; Verkhovsky MI, 1997, BBA-BIOENERGETICS, V1318, P6, DOI 10.1016/S0005-2728(96)00147-8; Wikstrom M, 2003, BBA-BIOENERGETICS, V1604, P61, DOI 10.1016/S0005-2728(03)00041-0; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; Wikstrom M, 2000, BBA-BIOENERGETICS, V1459, P514, DOI 10.1016/S0005-2728(00)00191-2; Xu JC, 2006, BBA-BIOENERGETICS, V1757, P852, DOI 10.1016/j.bbabio.2006.05.028; Zaslavsky D, 2000, BBA-BIOENERGETICS, V1458, P164, DOI 10.1016/S0005-2728(00)00066-9	67	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15148	15158		10.1074/jbc.M700348200	http://dx.doi.org/10.1074/jbc.M700348200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17363369	hybrid			2022-12-27	WOS:000246589000054
J	Saito, K; Williams, S; Bulankina, A; Honing, S; Mustelin, T				Saito, Kan; Williams, Scott; Bulankina, Anna; Honing, Stefan; Mustelin, Tomas			Association of protein-tyrosine phosphatase MEG2 via its Sec14p homology domain with vesicle-trafficking proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; T-CELLS; INTERACTING PROTEIN; LOCALIZATION; BINDING; TIP47; POLYPHOSPHOINOSITIDES; RECOGNITION; ACTIVATION; EXPRESSION	The protein-tyrosine phosphatase PTPMEG2 is located on the cytoplasmic face of the enclosing membrane of secretory vesicles, where it regulates vesicle size by promoting homotypic vesicle fusion by dephosphorylating N-ethylmaleimide-sensitive factor, a key regulator of vesicle fusion. Here we address the question of how PTPMEG2 is targeted to this subcellular location. Using a series of deletion mutants, we pinpointed the N-terminal Sec14p homology ( SEC14) domain of PTPMEG2, residues 1 - 261, as the region containing the secretory vesicle targeting signal. This domain, alone or appended to a heterologous protein, was localized to intracellular vesicle membranes. Yeast two-hybrid screening identified a number of secretory vesicle proteins that interacted directly with the SEC14 domain of PTPMEG2, providing a mechanism for PTPMEG2 targeting to secretory vesicles. Two such proteins, mannose 6-phosphate receptor-interacting protein TIP47 and Arfaptin2, were found to alter PTPMEG2 localization when overexpressed, and elimination of TIP47 resulted in loss of PTPMEG2 function. Weconclude that the N terminus of PTPMEG2 is necessary for the targeting of this phosphatase to the secretory vesicle compartment by association with other proteins involved in intracellular transport.	Burnham Inst Med Res, Program Inflammatory Dis Res, Infect & Inflammatory Dis Ctr, Ctr Canc, La Jolla, CA 92037 USA; Burnham Inst Med Res, Ctr Canc, Program Signal Transduct, La Jolla, CA 92037 USA; Univ Cologne, Inst Biochem 1, D-50931 Cologne, Germany	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; University of Cologne	Mustelin, T (corresponding author), Burnham Inst Med Res, Program Inflammatory Dis Res, Infect & Inflammatory Dis Ctr, Ctr Canc, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org		Mustelin, Tomas/0000-0001-5912-8840	NIAID NIH HHS [AI55741] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055741] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bulgakov OV, 2004, DEVELOPMENT, V131, P2149, DOI 10.1242/dev.01122; Burguete AS, 2005, METHOD ENZYMOL, V403, P357, DOI 10.1016/S0076-6879(05)03031-4; Cherfils J, 2001, FEBS LETT, V507, P280, DOI 10.1016/S0014-5793(01)02970-2; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; Hayess K, 1998, J CELL BIOCHEM, V69, P304, DOI 10.1002/(SICI)1097-4644(19980601)69:3<304::AID-JCB8>3.3.CO;2-U; Hickenbottom SJ, 2004, STRUCTURE, V12, P1199, DOI 10.1016/j.str.2004.04.021; Huse M, 2006, NAT IMMUNOL, V7, P247, DOI 10.1038/ni1304; Huynh H, 2004, NAT CELL BIOL, V6, P831, DOI 10.1038/ncb1164; Huynh H, 2003, J IMMUNOL, V171, P6661, DOI 10.4049/jimmunol.171.12.6661; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Kruger JM, 2002, J BIOL CHEM, V277, P2620, DOI 10.1074/jbc.M104550200; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Mustelin T, 2004, MOL IMMUNOL, V41, P687, DOI 10.1016/j.molimm.2004.04.015; Nair P, 2003, J BIOL CHEM, V278, P24753, DOI 10.1074/jbc.M300174200; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; Page LJ, 1998, BBA-MOL CELL RES, V1401, P146, DOI 10.1016/S0167-4889(97)00138-9; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Peters PJ, 2002, NAT CELL BIOL, V4, P240, DOI 10.1038/ncb761; Pettersson M, 2000, GENOMICS, V68, P351, DOI 10.1006/geno.2000.6278; Roche PA, 1999, IMMUNITY, V11, P391, DOI 10.1016/S1074-7613(00)80114-4; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Shin OH, 2001, BIOCHEM BIOPH RES CO, V285, P1267, DOI 10.1006/bbrc.2001.5330; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Wang XD, 2002, J IMMUNOL, V168, P4612, DOI 10.4049/jimmunol.168.9.4612; Wang YC, 2005, J EXP MED, V202, P1587, DOI 10.1084/jem.20051108; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Zhao RX, 2003, J BIOL CHEM, V278, P22609, DOI 10.1074/jbc.M301560200	31	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15170	15178		10.1074/jbc.M608682200	http://dx.doi.org/10.1074/jbc.M608682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387180	hybrid			2022-12-27	WOS:000246589000056
J	Sinha, KM; Stephanou, NC; Gao, F; Glickman, MS; Shuman, S				Sinha, Krishna Murari; Stephanou, Nicolas C.; Gao, Feng; Glickman, Michael S.; Shuman, Stewart			Mycobacterial UvrD1 is a Ku-dependent DNA helicase that plays a role in multiple DNA repair events, including double-strand break repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNER-SYNDROME PROTEIN; FUNCTIONAL INTERACTION; LIGASE-D; PSEUDOMONAS-AERUGINOSA; POLYMERASE COMPONENT; GENE-EXPRESSION; IDENTIFICATION; TUBERCULOSIS; HETERODIMER; COMPLEX	Mycobacterium tuberculosis and other bacterial pathogens have a Ku-dependent nonhomologous end joining pathway of DNA double-strand break repair. Here we identify mycobacterial UvrD1 as a novel interaction partner for Ku in a genome-wide yeast two-hybrid screen. UvrD1 per se is a vigorous DNA-dependent ATPase but a feeble DNA helicase. Ku stimulates UvrD1 to catalyze ATP-dependent unwinding of 3'-tailed DNAs. UvrD1, Ku, and DNA form a stable ternary complex in the absence of ATP. The Ku binding determinants are located in the distinctive C-terminal segment of UvrD1. A second mycobacterial paralog, UvrD2, is a vigorous Ku-independent DNA helicase. Ablation of UvrD1 sensitizes Mycobacterium smegmatis to killing by ultraviolet and ionizing radiation and to a single chromosomal break generated by I-SceI endonuclease. The physical and functional interactions of bacterial Ku and UvrD1 highlight the potential for cross-talk between components of nonhomologous end joining and nucleotide excision repair pathways.	Sloan Kettering Inst, Program Immunol, New York, NY 10021 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Div Infect Dis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Glickman, MS (corresponding author), Sloan Kettering Inst, Program Immunol, 1275 York Ave, New York, NY 10021 USA.	glickmam@MSKCC.ORG		Glickman, Michael S/0000-0001-7918-5164	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064693] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI064693, R01 AI064693-03, AI64693] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cadman CJ, 2006, J MOL BIOL, V362, P18, DOI 10.1016/j.jmb.2006.06.032; COLLEAUX L, 1988, P NATL ACAD SCI USA, V85, P6022, DOI 10.1073/pnas.85.16.6022; Cooper MP, 2000, GENE DEV, V14, P907; Della M, 2004, SCIENCE, V306, P683, DOI 10.1126/science.1099824; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; Ehrt S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni013; Glickman MS, 2003, J BIOL CHEM, V278, P7844, DOI 10.1074/jbc.M212458200; GOLEMIS E, 1999, CURRENT PROTOCOLS MO; Gong CL, 2005, NAT STRUCT MOL BIOL, V12, P304, DOI 10.1038/nsmb915; Gong CL, 2004, J BIOL CHEM, V279, P20594, DOI 10.1074/jbc.M401841200; Indiani C, 2006, NAT REV MOL CELL BIO, V7, P751, DOI 10.1038/nrm2022; Jacobs MA, 2003, P NATL ACAD SCI USA, V100, P14339, DOI 10.1073/pnas.2036282100; Karmakar P, 2002, NUCLEIC ACIDS RES, V30, P3583, DOI 10.1093/nar/gkf482; Korycka-Machala M, 2006, FEMS MICROBIOL LETT, V258, P83, DOI 10.1111/j.1574-6968.2006.00199.x; Lee JY, 2006, CELL, V127, P1349, DOI 10.1016/j.cell.2006.10.049; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Li BM, 2005, NUCLEIC ACIDS RES, V33, P6861, DOI 10.1093/nar/gki984; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Li BM, 2002, NUCLEIC ACIDS RES, V30, P3653, DOI 10.1093/nar/gkf488; Lieber MR, 2006, DNA REPAIR, V5, P1234, DOI 10.1016/j.dnarep.2006.05.013; Mackintosh SG, 2006, NUCLEIC ACIDS RES, V34, P4154, DOI 10.1093/nar/gkl501; Matson SW, 2006, NUCLEIC ACIDS RES, V34, P4089, DOI 10.1093/nar/gkl450; MATSON SW, 1986, J BIOL CHEM, V261, P169; MINB, 2005, P NATL ACAD SCI US, V101, P8906; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; PANG PP, 1983, J BACTERIOL, V153, P1172, DOI 10.1128/JB.153.3.1172-1179.1983; Pitcher RS, 2006, MOL CELL, V23, P743, DOI 10.1016/j.molcel.2006.07.009; Pitcher RS, 2005, J MOL BIOL, V351, P531, DOI 10.1016/j.jmb.2005.06.038; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; So S, 2004, J BIOL CHEM, V279, P55433, DOI 10.1074/jbc.M409827200; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang ST, 2006, J MOL BIOL, V358, P16, DOI 10.1016/j.jmb.2006.01.059; Weller GR, 2002, SCIENCE, V297, P1686, DOI 10.1126/science.1074584; Yakovleva L, 2006, J BIOL CHEM, V281, P25026, DOI 10.1074/jbc.M603302200; Zhu H, 2006, P NATL ACAD SCI USA, V103, P1711, DOI 10.1073/pnas.0509083103; Zhu H, 2005, J BIOL CHEM, V280, P418, DOI 10.1074/jbc.M410110200	38	51	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15114	15125		10.1074/jbc.M701167200	http://dx.doi.org/10.1074/jbc.M701167200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376770	hybrid			2022-12-27	WOS:000246589000051
J	Jeon, SH; Yoon, JY; Park, YN; Jeong, WJ; Kim, S; Jho, EH; Surh, YJ; Choi, KY				Jeon, Soung Hoo; Yoon, Ju-Yong; Park, Young-Nyun; Jeong, Woo-Jeong; Kim, Sewoon; Jho, Eek-Hoon; Surh, Young-Joon; Choi, Kang-Yell			Axin inhibits extracellular signal-regulated kinase pathway by Ras degradation via beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR CARCINOMAS; TYROSINE PHOSPHORYLATION; GENETIC ALTERATIONS; COLORECTAL-CANCER; TUMOR-DEVELOPMENT; ONCOGENIC RAS; COLON-CANCER; ACTIVATION; EXPRESSION; MUTATIONS	Interactions between the Wnt/beta-catenin and the extracellular signal-regulated kinase (ERK) pathways have been posited, but the molecular mechanisms and cooperative roles of such interaction in carcinogenesis are poorly understood. In the present study, the Raf-1, MEK, and ERK activities were concomitantly decreased in fibroblasts, which inhibit morphological transformation and proliferation by Axin induction. The inhibition of the components of the ERK pathway by Axin occurred in cells retaining wild-type beta-catenin, including primary hepatocytes, but not in cells retaining non-degradable mutant beta-catenin. Axin inhibits cellular proliferation and ERK pathway activation induced by either epidermal growth factor or Ras, indicating a role of Axin in the regulation of growth induced by ERK pathway activation. ERK pathway regulation by Axin occurs at least partly via reduction of the protein level of Ras. Both wild-type and mutant Ras proteins are subjected to regulation by Axin, which occurs in cells retaining wild-type but not mutant beta-catenin gene. The role of beta-catenin in the regulation of the Ras-ERK pathway was further confirmed by Ras reduction and subsequent inhibitions of the ERK pathway components by knock down of mutated form of beta-catenin. The Ras regulation by Axin was blocked by treatment of leupeptin, an inhibitor of the lysosomal protein degradation machinery. Overall, Axin inhibits proliferation of cells at least partly by reduction of Ras protein level via beta-catenin. This study provides evidences for the role of the Ras-ERK pathway in carcinogenesis caused by mutations of the Wnt/beta-catenin pathway components.	Yonsei Univ, Natl Res Lab Mol Complex Control, Seoul 120749, South Korea; Yonsei Univ, Dept Biotechnol, Seoul 120749, South Korea; Yonsei Univ, Dept Pathol, Ctr Chron Metab Dis, Project Med Sci BK21,Coll Med, Seoul 120749, South Korea; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea	Yonsei University; Yonsei University; Yonsei University; Yonsei University Health System; University of Seoul; Seoul National University (SNU)	Choi, KY (corresponding author), Yonsei Univ, Natl Res Lab Mol Complex Control, Seoul 120749, South Korea.	kychoi@yonsei.ac.kr		Park, Young Nyun/0000-0003-0357-7967; Jho, Eek-hoon/0000-0003-2414-6234				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BOS JL, 1989, CANCER RES, V49, P4682; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Carruba G, 1999, ANN NY ACAD SCI, V886, P212, DOI 10.1111/j.1749-6632.1999.tb09419.x; DAbaco GM, 1996, MOL CELL BIOL, V16, P884; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Harada N, 2004, CANCER RES, V64, P48, DOI 10.1158/0008-5472.CAN-03-2123; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; JEN J, 1994, CANCER RES, V54, P5523; Jura N, 2006, MOL CELL, V21, P679, DOI 10.1016/j.molcel.2006.02.011; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Lyu J, 2003, J BIOL CHEM, V278, P13487, DOI 10.1074/jbc.M300591200; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oving IM, 2002, EUR J CLIN INVEST, V32, P448, DOI 10.1046/j.1365-2362.2002.01004.x; Park KS, 2006, J CELL SCI, V119, P819, DOI 10.1242/jcs.02779; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; Tan XP, 2005, GASTROENTEROLOGY, V129, P285, DOI 10.1053/j.gastro.2005.04.013; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Woodcroft KJ, 1999, BIOCHEM BIOPH RES CO, V266, P304, DOI 10.1006/bbrc.1999.1817; Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	43	57	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14482	14492		10.1074/jbc.M611129200	http://dx.doi.org/10.1074/jbc.M611129200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374607	hybrid			2022-12-27	WOS:000246245800062
J	Masud, A; Mohapatra, A; Lakhani, SA; Ferrandino, A; Hakem, R; Flavell, RA				Masud, Ali; Mohapatra, Alexander; Lakhani, Saquib A.; Ferrandino, Anthony; Hakem, Razqallah; Flavell, Richard A.			Endoplasmic reticulum stress-induced death of mouse embryonic fibroblasts requires the intrinsic pathway of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CELL-DEATH; CASPASE ACTIVATION; ER STRESS; CROSS-TALK; EXPRESSION; MECHANISM; PROGRAM; INFLAMMATION; MICE	Members of the caspase family are essential for many apoptotic programs. We studied mouse embryonic fibroblasts (MEFs) deficient in caspases 3 and 7 and in caspase 9 to determine the role of these proteases in endoplasmic reticulum (ER) stress-induced apoptosis. Both caspase 3(-/-)/caspase 7(-/-) and caspase 9(-/-) MEFs were resistant to cytotoxicity induced via ER stress and failed to exhibit apoptotic morphology. Specifically, apoptosis induced by increased intracellular calcium was shown to depend only on caspases 3 and 9, whereas apoptosis induced by disruption of ER function depended additionally on caspase 7. Caspase 3(-/-)/caspase 7(-/-) and caspase 9(-/-) MEFs also exhibited decreased loss of mitochondrial membrane potential, which correlated with altered caspase 9 processing, increased induction of procaspase 11, and decreased processing of caspase 12 in caspase 3(-/-)/caspase 7(-/-) cells. Furthermore, disruption of ER function was sufficient to induce accumulation of cleaved caspase 3 and 7 in a heavy membrane compartment, suggesting a potential mechanism for caspase 12 processing and its role as an amplifier in the death pathway. Caspase 8(-/-) MEFs were not resistant to ER stress-induced cytotoxicity, and processing of caspase 8 was not observed upon induction of ER stress. This study thus demonstrates a requirement for caspases 3 and 9 and a key role for the intrinsic pathway in ER stress-induced apoptosis.	Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; Yale Univ, Sch Med, Dept Immunobiol, Howard Hughes Med Inst, New Haven, CT 06520 USA; Shady Grove Adventist Hosp, Rockville, MD 20850 USA; Univ Toronto, Ontario Canc Inst, Div Cellular & Mol Biol, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Howard Hughes Medical Institute; Yale University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Flavell, RA (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Immunobiol, 300 Cedar St,TAC S-569A, New Haven, CT 06519 USA.	richard.flavell@yale.edu	Lakhani, Sunil R/I-1970-2018	Lakhani, Sunil R/0000-0003-4067-2760; Lakhani, Saquib/0000-0003-3235-3460; Hakem, Razqallah/0000-0001-5948-7931				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cheung HH, 2006, EXP CELL RES, V312, P2347, DOI 10.1016/j.yexcr.2006.03.027; Dahmer MK, 2005, J NEUROSCI RES, V80, P576, DOI 10.1002/jnr.20471; Darios F, 2003, J NEUROCHEM, V84, P643, DOI 10.1046/j.1471-4159.2003.01590.x; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Endo M, 2006, J IMMUNOL, V176, P6245, DOI 10.4049/jimmunol.176.10.6245; Groenendyk J, 2005, ACTA BIOCHIM POL, V52, P381; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hansell EJ, 1995, BIOCHEM CELL BIOL, V73, P373, DOI 10.1139/o95-045; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Liu N, 2006, VIROLOGY, V348, P398, DOI 10.1016/j.virol.2006.01.002; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Saleh M, 2006, NATURE, V440, P1064, DOI 10.1038/nature04656; Salmena L, 2003, GENE DEV, V17, P883, DOI 10.1101/gad.1063703; Sanges D, 2006, APOPTOSIS, V11, P1629, DOI 10.1007/s10495-006-9006-2; Scorrano L, 2003, CELL DEATH DIFFER, V10, P1287, DOI 10.1038/sj.cdd.4401310; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200	34	81	86	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14132	14139		10.1074/jbc.M700077200	http://dx.doi.org/10.1074/jbc.M700077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371867	hybrid			2022-12-27	WOS:000246245800023
J	Ventura, C; Cantoni, S; Bianchi, F; Lionetti, V; Cavallini, C; Scarlata, I; Foroni, L; Maioli, M; Bonsi, L; Alviano, F; Fossati, V; Bagnara, GP; Pasquinelli, G; Recchia, FA; Perbellini, A				Ventura, Carlo; Cantoni, Silvia; Bianchi, Francesca; Lionetti, Vincenzo; Cavallini, Claudia; Scarlata, Ignazio; Foroni, Laura; Maioli, Margherita; Bonsi, Laura; Alviano, Francesco; Fossati, Valentina; Bagnara, Gian Paolo; Pasquinelli, Gianandrea; Recchia, Fabio A.; Perbellini, Alberto			Hyaluronan mixed esters of butyric and retinoic acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; IN-VITRO; EXPRESSION; TRANSPLANTATION; VEGF; NEOVASCULARIZATION; DIFFERENTIATION; CARDIOGENESIS; MYOCARDIUM; PROTECTION	We have developed a mixed ester of hyaluronan with butyric and retinoic acid (HBR) that acted as a novel cardiogenic/vasculogenic agent in human mesenchymal stem cells isolated from bone marrow, dental pulp, and fetal membranes of term placenta (FMhMSCs). HBR remarkably enhanced vascular endothelial growth factor (VEGF), KDR, and hepatocyte growth factor (HGF) gene expression and the secretion of the angiogenic, mitogenic, and antiapoptotic factors VEGF and HGF, priming stem cell differentiation into endothelial cells. HBR also increased the transcription of the cardiac lineage-promoting genes GATA-4 and Nkx-2.5 and the yield of cardiac marker-expressing cells. These responses were notably more pronounced in FMhMSCs. FMhMSC transplantation into infarcted rat hearts was associated with increased capillary density, normalization of left ventricular function, and significant decrease in scar tissue. Transplantation of HBR-preconditioned FMhMSCs further enhanced capillary density and the yield of human vWF-expressing cells, additionally decreasing the infarct size. Some engrafted, HBR-pretreated FMhMSCs were also positive for connexin 43 and cardiac troponin I. Thus, the beneficial effects of HBR-exposed FMhMSCs may be mediated by a large supply of angiogenic and antiapoptotic factors, and FMhMSC differentiation into vascular cells. These findings may contribute to further development in cell therapy of heart failure.	Univ Bologna, Natl Inst Biostruct & Biosyst, Lab Mol Biol & Stem Cell Engn, Inst Cardiol, I-40138 Bologna, Italy; Univ Bologna, Dept Expt Pathol, I-40138 Bologna, Italy; Univ Bologna, Dept Histol Embryol & Appl Biol, I-40138 Bologna, Italy; Scuola Super Sant Anna, CNR, Inst Clin Physiol, Sector Med, I-56124 Pisa, Italy; New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA; Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy	University of Bologna; University of Bologna; University of Bologna; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Scuola Superiore Sant'Anna; New York Medical College; University of Sassari	Ventura, C (corresponding author), Univ Bologna, Natl Inst Biostruct & Biosyst, Lab Mol Biol & Stem Cell Engn, S Orsola Malpighi Hosp, Pavill 21,Via Massarenti 9, I-40138 Bologna, Italy.	cvent@libero.it	Lionetti, Vincenzo/G-9528-2014; Bianchi, Francesca/M-2205-2016; Lionetti, Vincenzo/AAN-1994-2020; Pasquinelli, Gianandrea/I-7088-2012; Ventura, Carlo/AAV-3658-2020; Recchia, Fabio/F-2315-2010; Lionetti, Vincenzo/AAH-9503-2020; Cantoni, Silvia/H-3938-2011	Bianchi, Francesca/0000-0001-6732-0533; Lionetti, Vincenzo/0000-0002-0640-8651; Pasquinelli, Gianandrea/0000-0003-1506-1829; Cavallini, Claudia/0000-0002-8079-9697; fossati, valentina/0000-0003-1825-9371; Scarlata, Ignazio/0000-0002-5490-7834; MAIOLI, Margherita/0000-0003-0187-4968; Cantoni, Silvia/0000-0002-3866-3307; Ventura, Carlo/0000-0001-9333-0321				Bailo M, 2004, TRANSPLANTATION, V78, P1439, DOI 10.1097/01.TP.0000144606.84234.49; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Barry F, 2001, BIOCHEM BIOPH RES CO, V289, P519, DOI 10.1006/bbrc.2001.6013; Barry FP, 1999, BIOCHEM BIOPH RES CO, V265, P134, DOI 10.1006/bbrc.1999.1620; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Duda DG, 2004, TRENDS MOL MED, V10, P143, DOI 10.1016/j.molmed.2004.02.001; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004-0058; Kajstura J, 2005, CIRC RES, V96, P127, DOI 10.1161/01.RES.0000151843.79801.60; Kim BO, 2005, CIRCULATION, V112, pI96, DOI 10.1161/01.CIRCULATIONAHA.105.524678; Kim DH, 2005, CYTOKINE, V31, P119, DOI 10.1016/j.cyto.2005.04.004; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Li YW, 2003, CIRCULATION, V107, P2499, DOI 10.1161/01.CIR.0000065579.19126.B8; Makkar RR, 2005, J CARDIOVASC PHARM T, V10, P225, DOI 10.1177/107424840501000403; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Matsumoto R, 2005, ARTERIOSCL THROM VAS, V25, P1168, DOI 10.1161/01.ATV.0000165696.25680.ce; Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462; Miyahara Y, 2006, NAT MED, V12, P459, DOI 10.1038/nm1391; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nagaya N, 2005, CIRCULATION, V112, P1128, DOI 10.1161/CIRCULATIONAHA.104.500447; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; Noiseux N, 2006, MOL THER, V14, P840, DOI 10.1016/j.ymthe.2006.05.016; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Rangappa S, 2003, J THORAC CARDIOV SUR, V126, P124, DOI 10.1016/S0022-5223(03)00074-6; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Short B, 2003, ARCH MED RES, V34, P565, DOI 10.1016/j.arcmed.2003.09.007; Tang YL, 2004, REGUL PEPTIDES, V117, P3, DOI 10.1016/j.regpep.2003.09.005; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Ventura C, 2004, J BIOL CHEM, V279, P23574, DOI 10.1074/jbc.M401869200; Ventura C, 2003, CIRC RES, V92, P617, DOI 10.1161/01.RES.0000065168.31147.5B; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433	44	138	173	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14243	14252		10.1074/jbc.M609350200	http://dx.doi.org/10.1074/jbc.M609350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17363374	hybrid, Green Published			2022-12-27	WOS:000246245800035
J	Wagner, S; Klug, G				Wagner, Steffen; Klug, Gabriele			An archaeal protein with homology to the eukaryotic translation initiation factor 5A shows ribonucleolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; ESCHERICHIA-COLI; RHODOBACTER-CAPSULATUS; ANGSTROM RESOLUTION; CELL-PROLIFERATION; HYPUSINE FORMATION; EXOSOME COMPLEX; RIBOSOMAL-RNA; HALOFERAX	To identify proteins that are involved in RNA degradation and processing in Halobacterium sp. NRC-1, we purified proteins with RNA-degrading activity by classical biochemical techniques. One of these proteins showed strong homology to the eukaryotic initiation factor 5A (eIF-5A) and was accordingly named archaeal initiation factor 5A (aIF-5A). Eukaryotic IF-5A is known to be involved in mRNA turnover and to bind RNA. Hypusination of eIF-5A is required for sequence-specific binding of RNA. This unique post-translational modification is restricted to Eukarya and Archaea. The exact function of eIF-5A in RNA turnover remained obscure. Here we show for the first time that aIF-5A from Halobacterium sp. NRC-1 exhibits RNA cleavage activity, preferentially cleaving adjacent to A nucleotides. Detectable RNA binding could be shown for aIF-5A purified from Halobacterium sp. NRC-1 but not from Escherichia coli, while both proteins possess RNA cleavage activity, indicating that hypusination of aIF-5A is required for RNA binding but not for its RNA cleavage activity. Furthermore, we show that the hypusinated form of eIF-5A also shows RNase activity while the unmodified protein does not. Charged amino acids in the N-terminal domain of aIF-5A as well as in the C-terminal domain, which is highly similar to the cold shock protein A (CspA), an RNA chaperone of E. coli, are important for RNA cleavage activity. Moreover our results reveal that activity of aIF-5A depends on its oligomeric state.	Univ Giessen, Inst Mikrobiol & Mol Biol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Klug, G (corresponding author), Univ Giessen, Inst Mikrobiol & Mol Biol, Heinrich Buff Ring 26-32, D-35392 Giessen, Germany.	Gabriele.Klug@mikro.bio.uni-giessen.de	Wagner, Steffen/AAC-3086-2022; Klug, Gabriele/K-5322-2014	Wagner, Steffen/0000-0003-0873-1601; Klug, Gabriele/0000-0002-3527-5093				Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; BARTIG D, 1990, SYST APPL MICROBIOL, V13, P112, DOI 10.1016/S0723-2020(11)80156-6; BENNE R, 1978, J BIOL CHEM, V253, P3070; Caraglia M, 2001, AMINO ACIDS, V20, P91, DOI 10.1007/s007260170050; Carpousis AJ, 2002, BIOCHEM SOC T, V30, P150, DOI 10.1042/bst0300150; CHEN KY, 1984, BIOCHEM BIOPH RES CO, V124, P423, DOI 10.1016/0006-291X(84)91570-5; Chen KY, 1999, J CHIN CHEM SOC-TAIP, V46, P727, DOI 10.1002/jccs.199900100; Chen KY, 1997, BIOL SIGNAL, V6, P105; CHRISTIAN JHB, 1962, BIOCHIM BIOPHYS ACTA, V65, P506, DOI 10.1016/0006-3002(62)90453-5; CLINE SW, 1989, CAN J MICROBIOL, V35, P148, DOI 10.1139/m89-022; Evguenieva-Hackenberg E, 2000, J BACTERIOL, V182, P4719, DOI 10.1128/JB.182.17.4719-4729.2000; Evguenieva-Hackenberg E, 2002, J BIOL CHEM, V277, P46145, DOI 10.1074/jbc.M208717200; Evguenieva-Hackenberg E, 2003, EMBO REP, V4, P889, DOI 10.1038/sj.embor.embor929; Farhoud MH, 2005, MOL CELL PROTEOMICS, V4, P1653, DOI 10.1074/mcp.M500171-MCP200; FRITSCH J, 1995, MOL MICROBIOL, V15, P1017, DOI 10.1111/j.1365-2958.1995.tb02277.x; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARTMANN RK, 2005, HDB RNA BIOCH, V2, P828; HOARE DG, 1967, J BIOL CHEM, V242, P2447; Jager A, 2002, NUCLEIC ACIDS RES, V30, P5436, DOI 10.1093/nar/gkf699; Jager S, 2001, NUCLEIC ACIDS RES, V29, P4581, DOI 10.1093/nar/29.22.4581; Jansson BPM, 2000, J BACTERIOL, V182, P1158, DOI 10.1128/JB.182.4.1158-1161.2000; Jiang WN, 1997, J BIOL CHEM, V272, P196; Kamphuis MB, 2006, J MOL BIOL, V357, P115, DOI 10.1016/j.jmb.2005.12.033; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim KK, 1998, P NATL ACAD SCI USA, V95, P10419, DOI 10.1073/pnas.95.18.10419; Kristensen O, 2006, EMBO J, V25, P785, DOI 10.1038/sj.emboj.7600982; Kyrpides NC, 1996, TRENDS BIOCHEM SCI, V21, P425, DOI 10.1016/S0968-0004(96)30036-4; Lorentzen E, 2005, NAT STRUCT MOL BIOL, V12, P575, DOI 10.1038/nsmb952; Miles E W, 1977, Methods Enzymol, V47, P431; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Munoz-Gomez AJ, 2004, FEBS LETT, V567, P316, DOI 10.1016/j.febslet.2004.05.005; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Park MH, 1997, BIOL SIGNAL, V6, P115; Peat TS, 1998, STRUCT FOLD DES, V6, P1207, DOI 10.1016/S0969-2126(98)00120-8; Pellegrini O, 2005, MOL MICROBIOL, V56, P1139, DOI 10.1111/j.1365-2958.2005.04606.x; Portnoy V, 2005, EMBO REP, V6, P1188, DOI 10.1038/sj.embor.7400571; Purusharth RI, 2005, J BIOL CHEM, V280, P14572, DOI 10.1074/jbc.M413507200; Ramos CRR, 2006, J BIOL CHEM, V281, P6751, DOI 10.1074/jbc.M512495200; ROBB FT, 1995, ARCHAEA LAB MANUAL, P58; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; Schierling K, 2002, J MOL BIOL, V316, P895, DOI 10.1006/jmbi.2001.5395; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; Tang TH, 2002, NUCLEIC ACIDS RES, V30, P921, DOI 10.1093/nar/30.4.921; Valentini SR, 2002, GENETICS, V160, P393; van Hoof A, 2002, SCIENCE, V295, P2262, DOI 10.1126/science.1067272; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; Xiao SH, 2002, ANNU REV BIOCHEM, V71, P165, DOI 10.1146/annurev.biochem.71.110601.135352; Xu AG, 2004, BIOCHEM J, V384, P585, DOI 10.1042/BJ20041232; Xu AG, 2001, J BIOL CHEM, V276, P2555, DOI 10.1074/jbc.M008982200; Yao M, 2003, J BIOCHEM, V133, P75, DOI 10.1093/jb/mvg011; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7; Zhang YL, 2005, J BIOL CHEM, V280, P3143, DOI 10.1074/jbc.M411811200; Zuk D, 1998, EMBO J, V17, P2914, DOI 10.1093/emboj/17.10.2914; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	57	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13966	13976		10.1074/jbc.M701166200	http://dx.doi.org/10.1074/jbc.M701166200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369252	hybrid			2022-12-27	WOS:000246245800006
J	Zhao, YT; Kalari, SK; Usatyuk, PV; Gorshkova, I; He, DH; Watkins, T; Brindley, DN; Sun, CD; Bittman, R; Garcia, JGN; Berdyshev, EV; Natarajan, V				Zhao, Yutong; Kalari, Satish K.; Usatyuk, Peter V.; Gorshkova, Irina; He, Donghong; Watkins, Tonya; Brindley, David N.; Sun, Chaode; Bittman, Robert; Garcia, Joe G. N.; Berdyshev, Evgeni V.; Natarajan, Viswanathan			Intracellular generation of sphingosine 1-phosphate in human lung endothelial cells - Role of lipid phosphate phosphatase-1 and sphingosine kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; FUNCTIONAL-CHARACTERIZATION; LYSOPHOSPHATIDIC ACID; SPHINGOSINE-1-PHOSPHATE PHOSPHOHYDROLASE; MOLECULAR-CLONING; ACTIVATION; SURVIVAL; METABOLISM; RECEPTORS	Sphingosine 1-phosphate (S1P) regulates diverse cellular functions through extracellular ligation to S1P receptors, and it also functions as an intracellular second messenger. Human pulmonary artery endothelial cells (HPAECs) effectively utilized exogenous S1P to generate intracellular S1P. We, therefore, examined the role of lipid phosphate phosphatase (LPP)-1 and sphingosine kinase-1 (SphK1) in converting exogenous S1P to intracellular S1P. Exposure of P-32-labeled HPAECs to S1P or sphingosine (Sph) increased the intracellular accumulation of [P-32]S1P in a dose- and time-dependent manner. The S1P formed in the cells was not released into the medium. The exogenously added S1P did not stimulate the sphingomyelinase pathway; however, added [H-3]S1P was hydrolyzed to [H-3]Sph in HPAECs, and this was blocked by XY-14, an inhibitor of LPPs. HPAECs expressed LPP1-3, and overexpression of LPP-1 enhanced the hydrolysis of exogenous [H-3]S1P to [H-3]Sph and increased intracellular S1P production by 2-3-fold compared with vector control cells. Down-regulation of LPP-1 by siRNA decreased intracellular S1P production from extracellular S1P but had no effect on the phosphorylation of Sph to S1P. Knockdown of SphK1, but not SphK2, by siRNA attenuated the intracellular generation of S1P. Overexpression of wild type SphK1, but not SphK2 wild type, increased the accumulation of intracellular S1P after exposure to extracellular S1P. These studies provide the first direct evidence for a novel pathway of intracellular S1P generation. This involves the conversion of extracellular S1P to Sph by LPP-1, which facilitates Sph uptake, followed by the intracellular conversion of Sph to S1P by SphK1.	Univ Chicago, Dept Med, Ctr Integrat Sci Bldg, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21224 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	University of Chicago; Johns Hopkins University; University of Alberta; City University of New York (CUNY) System; Queens College NY (CUNY)	Natarajan, V (corresponding author), Univ Chicago, Dept Med, Ctr Integrat Sci Bldg, Sect Pulm & Crit Care Med, Rm 408B,929 E 57th St, Chicago, IL 60637 USA.	vnataraj@medicine.bsd.uchicago.edu	Kalari, Satish/C-6967-2012; Garcia, Joe GN/E-8862-2010		NHLBI NIH HHS [R01 HL079396, R01 HL79396, R01 HL079396-02, R01 HL803187] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079396] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anliker B, 2004, SEMIN CELL DEV BIOL, V15, P457, DOI 10.1016/j.semcdb.2004.05.005; Aoki S, 2005, J BIOCHEM, V138, P47, DOI 10.1093/jb/mvi100; Argraves KM, 2002, ADV EXP MED BIOL, V507, P439; Berdyshev EV, 2006, CELL SIGNAL, V18, P1779, DOI 10.1016/j.cellsig.2006.01.018; Bernatchez PN, 2003, J CELL BIOCHEM, V90, P719, DOI 10.1002/jcb.10686; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Brindley DN, 2004, J CELL BIOCHEM, V92, P900, DOI 10.1002/jcb.20126; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Chin TY, 2002, MOL PHARMACOL, V61, P486, DOI 10.1124/mol.61.3.486; Culmsee C, 2002, NEUROSCIENCE, V115, P1089, DOI 10.1016/S0306-4522(02)00539-0; De Palma C, 2006, ARTERIOSCL THROM VAS, V26, P99, DOI 10.1161/01.ATV.0000194074.59584.42; Doll F, 2005, BBA-MOL CELL BIOL L, V1738, P72, DOI 10.1016/j.bbalip.2005.12.001; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Giussani P, 2006, MOL CELL BIOL, V26, P5055, DOI 10.1128/MCB.02107-05; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Hla T, 2003, PHARMACOL RES, V47, P401, DOI 10.1016/S1043-6618(03)00046-X; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Johnson KR, 2003, J BIOL CHEM, V278, P34541, DOI 10.1074/jbc.M301741200; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kariya Y, 2005, GENES CELLS, V10, P605, DOI 10.1111/j.1365-2443.2005.00862.x; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Le Stunff H, 2002, J BIOL CHEM, V277, P8920, DOI 10.1074/jbc.M109968200; Le Stunff H, 2004, J BIOL CHEM, V279, P34290, DOI 10.1074/jbc.M404907200; Le Stunff H, 2004, J CELL BIOCHEM, V92, P882, DOI 10.1002/h=jcb.20097; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Limaye V, 2005, BLOOD, V105, P3169, DOI 10.1182/blood-2004-02-0452; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Long J, 2005, BIOCHEM J, V391, P25, DOI 10.1042/BJ20050342; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; Mechtcheriakova D, 2007, CELL SIGNAL, V19, P748, DOI 10.1016/j.cellsig.2006.09.004; Misasi R, 2001, FASEB J, V15, P467, DOI 10.1096/fj.00-0217com; Mulders ACM, 2006, ARTERIOSCL THROM VAS, V26, P2043, DOI 10.1161/01.ATV.0000237569.95046.b9; Nanjundan M, 2001, AM J PHYSIOL-LUNG C, V281, pL1484, DOI 10.1152/ajplung.2001.281.6.L1484; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Ozaki Harunobu, 2003, J Atheroscler Thromb, V10, P125; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pilquil C, 2001, PROSTAG OTH LIPID M, V64, P83, DOI 10.1016/S0090-6980(01)00101-0; Pilquil C, 2006, J BIOL CHEM, V281, P38418, DOI 10.1074/jbc.M601670200; Prestwich GD, 2005, BIOCHEM SOC T, V33, P1357, DOI 10.1042/BST0331357; Pyne S, 2005, BIOCHEM SOC T, V33, P1370, DOI 10.1042/BST0331370; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Sciorra VA, 2002, BBA-MOL CELL BIOL L, V1582, P45, DOI 10.1016/S1388-1981(02)00136-1; Sigal YJ, 2005, BIOCHEM J, V387, P281, DOI 10.1042/BJ20041771; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Smyth SS, 2003, J BIOL CHEM, V278, P43214, DOI 10.1074/jbc.M306709200; Spiegel S, 2007, J BIOL CHEM, V282, P2125, DOI 10.1074/jbc.R600028200; Sun CD, 2004, J ORG CHEM, V69, P7694, DOI 10.1021/jo0487404; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Usatyuk PV, 2005, AM J PHYSIOL-LUNG C, V289, pL999, DOI 10.1152/ajplung.00211.2005; Venkataraman K, 2006, BIOCHEM J, V397, P461, DOI 10.1042/BJ20060251; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Zhao YT, 2005, BIOCHEM J, V385, P493, DOI 10.1042/BJ20041160; Zhi L, 2006, J CELL PHYSIOL, V208, P109, DOI 10.1002/jcp.20646; ZUHERINGDORF DM, 2003, FEBS LETT, V554, P443	65	108	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14165	14177		10.1074/jbc.M701279200	http://dx.doi.org/10.1074/jbc.M701279200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17379599	hybrid, Green Accepted			2022-12-27	WOS:000246245800027
J	Cottrell, JW; Kuzmin, YI; Fedor, MJ				Cottrell, Joseph W.; Kuzmin, Yaroslav I.; Fedor, Martha J.			Functional analysis of hairpin ribozyme active site architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERTIARY STRUCTURE STABILITY; GUANOSINE REQUIREMENT; CRYSTAL-STRUCTURE; HYDROGEN-BONDS; RNA; CLEAVAGE; ENERGETICS; CATALYSIS; SECONDARY; STABILIZATION	The hairpin ribozyme is a small catalytic motif found in plant satellite RNAs where it catalyzes a reversible self-cleavage reaction during processing of replication intermediates. Crystallographic studies of hairpin ribozymes have provided high resolution views of the RNA functional groups that comprise the active site and stimulated biochemical studies that probed the contributions of nucleobase functional groups to catalytic chemistry. The dramatic loss of activity that results from perturbation of active site architecture points to the importance of positioning and orientation in catalytic rate acceleration. The current study focuses on the network of noncovalent interactions that align nucleophilic and leaving group oxygens in the orientation required for the S(N)2-type reaction mechanism and orient the active site nucleobases near the reactive phosphate to facilitate catalytic chemistry. Nucleotide modifications that alter or eliminate individual hydrogen bonding partners had different effects on the activation barrier to catalysis, the stability of ribozyme complexes in the ground state, and the internal equilibrium between cleavage and ligation of bound products. Furthermore, substitution of hydrogen bond donors and acceptors with seemingly equivalent pairs sometimes had very different functional consequences. These biochemical analyses augment high resolution structural information to provide insights into the functional significance of active site architecture.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Fedor, MJ (corresponding author), Scripps Res Inst, Dept Biol Mol, 10550 N Torrey Pines Rd,MB35, La Jolla, CA 92037 USA.	mfedor@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046422] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alam S, 2005, BIOCHEMISTRY-US, V44, P14396, DOI 10.1021/bi051550i; Canny MD, 2007, BIOCHEMISTRY-US, V46, P3826, DOI 10.1021/bi062077r; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; De la Pena M, 2003, EMBO J, V22, P5561, DOI 10.1093/emboj/cdg530; Donahue CP, 2000, J MOL BIOL, V295, P693, DOI 10.1006/jmbi.1999.3380; ENGLAND TE, 1978, BIOCHEMISTRY-US, V17, P2069, DOI 10.1021/bi00604a008; Fedor Martha J, 2004, Methods Mol Biol, V252, P19; Fedor MJ, 1999, BIOCHEMISTRY-US, V38, P11040, DOI 10.1021/bi991069q; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; Fedor MJ, 2005, NAT REV MOL CELL BIO, V6, P399, DOI 10.1038/nrm1647; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GRASBY JA, 1995, BIOCHEMISTRY-US, V34, P4068, DOI 10.1021/bi00012a025; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HEGG LA, 1995, BIOCHEMISTRY-US, V34, P15813, DOI 10.1021/bi00048a027; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Khvorova A, 2003, NAT STRUCT BIOL, V10, P708, DOI 10.1038/nsb959; Klostermeier D, 2002, BIOCHEMISTRY-US, V41, P14095, DOI 10.1021/bi025551b; Klostermeier D, 2001, BIOCHEMISTRY-US, V40, P11211, DOI 10.1021/bi010773f; Kuzmin YI, 2005, J MOL BIOL, V349, P989, DOI 10.1016/j.jmb.2005.04.005; Kuzmin YI, 2004, J MOL BIOL, V340, P233, DOI 10.1016/j.jmb.2004.04.067; Lebruska LL, 2002, CHEM BIOL, V9, P465, DOI 10.1016/S1074-5521(02)00130-8; Lubini P, 1994, CHEM BIOL, V1, P39, DOI 10.1016/1074-5521(94)90039-6; Martick M, 2006, CELL, V126, P309, DOI 10.1016/j.cell.2006.06.036; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Murchie AIH, 1998, MOL CELL, V1, P873, DOI 10.1016/S1097-2765(00)80086-6; Nesbitt SM, 1999, J MOL BIOL, V286, P1009, DOI 10.1006/jmbi.1999.2543; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Pinard R, 1999, BIOCHEMISTRY-US, V38, P16035, DOI 10.1021/bi992024s; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; Rupert PB, 2002, SCIENCE, V298, P1421, DOI 10.1126/science.1076093; Rupert PB, 2001, NATURE, V410, P780, DOI 10.1038/35071009; Ryder SP, 1999, J MOL BIOL, V291, P295, DOI 10.1006/jmbi.1999.2959; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P55; Salter J, 2006, BIOCHEMISTRY-US, V45, P686, DOI 10.1021/bi051887k; Schmidt S, 1996, NUCLEIC ACIDS RES, V24, P573, DOI 10.1093/nar/24.4.573; Shippy R, 1998, BIOCHEMISTRY-US, V37, P564, DOI 10.1021/bi9721288; Silverman SK, 1999, BIOCHEMISTRY-US, V38, P8691, DOI 10.1021/bi9906118; Walter NG, 1998, EMBO J, V17, P2378, DOI 10.1093/emboj/17.8.2378; Walter NG, 1999, NAT STRUCT BIOL, V6, P544; Wilson TJ, 2001, BIOCHEMISTRY-US, V40, P2291, DOI 10.1021/bi002644p; Yadava RS, 2001, J MOL BIOL, V309, P893, DOI 10.1006/jmbi.2001.4713; Zhao ZY, 2000, RNA, V6, P1833, DOI 10.1017/S1355838200001230	43	18	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13498	13507		10.1074/jbc.M700451200	http://dx.doi.org/10.1074/jbc.M700451200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17351263	hybrid			2022-12-27	WOS:000246060300039
J	Eoff, RL; Angel, KC; Egli, M; Guengerich, FP				Eoff, Robert L.; Angel, Karen C.; Egli, Martin; Guengerich, F. Peter			Molecular basis of selectivity of nucleoside triphosphate incorporation opposite O-6-benzylguanine by Sulfolobus solfataricus DNA polymerase Dpo4 - Steady-state and pre-steady-state kinetics and X-ray crystallography of correct and incorrect pairing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; TRANSLESION SYNTHESIS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DIFFRACTION DATA; ERROR-PRONE; O-6-METHYLGUANINE; REPLICATION; ADDUCTS; BYPASS	Previous work has shown that Sulfolobus solfataricus DNA polymerase Dpo4-catalyzed bypass of O-6-methylguanine (O-6-MeG) proceeds largely in an accurate but inefficient manner with a "wobble" base pairing between C and O-6-MeG (Eoff, R. L., Irimia, A., Egli, M., and Guengerich, F. P. ( 2007) J. Biol. Chem. 282, 1456 - 1467). We considered here the bulky lesion O-6-benzylguanine (O-6-BzG) in DNA and catalysis by Dpo4. Mass spectrometry analysis of polymerization products revealed that the enzyme bypasses and extends across from O-6-BzG, with C the major product (similar to 70%) and some T and A (similar to 15% each) incorporated opposite the lesion. Steady-state kinetic parameters indicated that Dpo4 was 7-, 5-, and 27-fold more efficient at C incorporation opposite O-6-BzG than T, A, or G, respectively. In transient state kinetic analysis, the catalytic efficiency was decreased 62-fold for C incorporation opposite O-6-BzG relative to unmodified DNA. Crystal structures reveal wobble pairing between C and O-6-BzG. Pseudo-"Watson-Crick" pairing was observed between T and O-6-BzG. Two other structures illustrate a possible mechanism for the accommodation of a +1 frameshift in the Dpo4 active site. The overall effect of O-6-BzG is to decrease the efficiency of bypass by roughly an order of magnitude in every case except correct bypass, where the effect is not as pronounced. By comparison, Dpo4 is more accurate but no more efficient than model replicative polymerases, such as bacteriophage T7(-) DNA polymerase and human immunodeficiency virus-1 reverse transcriptase in the polymerization past O-6-MeG and O-6-BzG.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Guengerich, FP (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 638 Robinson Res Bldg,23rd & Pierce Aves, Nashville, TN 37232 USA.	f.guengerich@vanderbilt.edu			NCI NIH HHS [F32 CA119776] Funding Source: Medline; NIEHS NIH HHS [P30 ES000267, P01 ES05355, R01 ES010375] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA119776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES005355, P30ES000267, R01ES010375] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUTRUP H, 1982, CANCER RES, V42, P1307; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi JY, 2006, J BIOL CHEM, V281, P38244, DOI 10.1074/jbc.M608369200; Choi JY, 2006, J BIOL CHEM, V281, P21062, DOI 10.1074/jbc.M602246200; Choi JY, 2006, J BIOL CHEM, V281, P12315, DOI 10.1074/jbc.M600112200; Choi JY, 2005, J MOL BIOL, V352, P72, DOI 10.1016/j.jmb.2005.06.079; Choi JY, 2004, J BIOL CHEM, V279, P19217, DOI 10.1074/jbc.M313759200; Christian NP, 2001, J AM SOC MASS SPECTR, V12, P744, DOI 10.1016/S1044-0305(01)00228-8; Eoff RL, 2007, J BIOL CHEM, V282, P1456, DOI 10.1074/jbc.M609661200; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2116, DOI 10.1021/bi035746z; Fiala KA, 2004, BIOCHEMISTRY-US, V43, P2106, DOI 10.1021/bi0357457; Friedberg E. C., 2006, DNA REPAIR MUTAGENES; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; Huang HF, 2000, CHEM BIOL, V7, P355, DOI 10.1016/S1074-5521(00)00113-7; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Langston LD, 2006, MOL CELL, V23, P155, DOI 10.1016/j.molcel.2006.05.034; LAWLEY PD, 1984, CHEM CARCINOGENS; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2004, MOL CELL, V13, P751, DOI 10.1016/S1097-2765(04)00101-7; Ling H, 2004, P NATL ACAD SCI USA, V101, P2265, DOI 10.1073/pnas.0308332100; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0; Margison GP, 2002, MUTAGENESIS, V17, P483, DOI 10.1093/mutage/17.6.483; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEGG AE, 1982, P NATL ACAD SCI-BIOL, V79, P5162, DOI 10.1073/pnas.79.17.5162; PEGG AE, 1985, ENVIRON HEALTH PERSP, V62, P109, DOI 10.2307/3430101; Peterson LA, 1997, CHEM RES TOXICOL, V10, P19, DOI 10.1021/tx9601014; Quinn JA, 2005, J CLIN ONCOL, V23, P7178, DOI 10.1200/JCO.2005.06.502; Singh J, 1996, J BIOL CHEM, V271, P28391, DOI 10.1074/jbc.271.45.28391; TAN HB, 1994, BIOCHEMISTRY-US, V33, P5335, DOI 10.1021/bi00183a042; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; VOIGT JM, 1995, CARCINOGENESIS, V16, P1775, DOI 10.1093/carcin/16.8.1775; Warren JJ, 2006, P NATL ACAD SCI USA, V103, P19701, DOI 10.1073/pnas.0609580103; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1027, DOI 10.1021/bi011495n; Woodside AM, 2002, BIOCHEMISTRY-US, V41, P1039, DOI 10.1021/bi011496f; Wyatt MD, 2006, CHEM RES TOXICOL, V19, P1580, DOI 10.1021/tx060164e; Yoshioka K, 2006, MOL CELL, V22, P501, DOI 10.1016/j.molcel.2006.04.023; Zang H, 2005, J BIOL CHEM, V280, P29750, DOI 10.1074/jbc.M504756200	39	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13573	13584		10.1074/jbc.M700656200	http://dx.doi.org/10.1074/jbc.M700656200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17337730	hybrid			2022-12-27	WOS:000246060300046
J	Hamik, A; Lin, ZY; Kumar, A; Balcells, M; Sinha, S; Katz, J; Feinberg, MW; Gerzsten, RE; Edelman, ER; Jain, MK				Hamik, Anne; Lin, Zhiyong; Kumar, Ajay; Balcells, Mercedes; Sinha, Sumita; Katz, Jonathan; Feinberg, Mark W.; Gerzsten, Robert E.; Edelman, Elazer R.; Jain, Mukesh K.			Kruppel-like factor 4 regulates endothelial inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; NITRIC-OXIDE SYNTHASE; FINGER TRANSCRIPTION FACTOR; CELL-ADHESION MOLECULE-1; GROWTH-FACTOR-BETA; NF-KAPPA-B; GENE-EXPRESSION; SHEAR-STRESS; MICE LACKING; PROTEIN-C	The vascular endothelium plays a critical role in vascular homeostasis. Inflammatory cytokines and non-laminar blood flow induce endothelial dysfunction and confer a pro-adhesive and pro-thrombotic phenotype. Therefore, identification of factors that mediate the effects of these stimuli on endothelial function is of considerable interest. Kruppel-like factor 4 expression has been documented in endothelial cells, but a function has not been described. In this communication we describe the expression in vitro and in vivo of Kruppel-like factor 4 in human and mouse endothelial cells. Furthermore, we demonstrate that endothelial Kruppel-like factor 4 is induced by pro-inflammatory stimuli and shear stress. Overexpression of Kruppel-like factor 4 induces expression of multiple anti-inflammatory and anti-thrombotic factors including endothelial nitric-oxide synthase and thrombomodulin, whereas knockdown of Kruppel-like factor 4 leads to enhancement of tumor necrosis factor alpha-induced vascular cell adhesion molecule-1 and tissue factor expression. The functional importance of Kruppel-like factor 4 is verified by demonstrating that Kruppel-like factor 4 expression markedly decreases inflammatory cell adhesion to the endothelial surface and prolongs clotting time under inflammatory states. Kruppel-like factor 4 differentially regulates the promoter activity of pro- and anti-inflammatory genes in a manner consistent with its anti-inflammatory function. These data implicate Kruppel-like factor 4 as a novel regulator of endothelial activation in response to pro-inflammatory stimuli.	Case Western Reserve Univ, Cardiovasc Res Inst, Cleveland, OH 44106 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med, Cambridge, MA 02138 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Harvard Univ, Ctr Immunol & Inflammatory Dis, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA; Harvard Univ, Div Cardiol, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA; Univ Penn, Sch Med, Div Gastroenterol, Dept Med, Philadelphia, PA 19104 USA	Case Western Reserve University; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Pennsylvania	Jain, MK (corresponding author), Case Western Reserve Univ, Cardiovasc Res Inst, Wolstein Res Bldg,2103 Cornell Rd, Cleveland, OH 44106 USA.	mukesh.jain2@case.edu		Balcells, Mercedes/0000-0002-2532-0516; Feinberg, Mark/0000-0001-9523-3859	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069477, R01HL076754, P01HL048743, R01HL075427, R01HL072952] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Albrecht EWJA, 2003, J PATHOL, V199, P8, DOI 10.1002/path.1250; Balcells M, 2005, J CELL PHYSIOL, V204, P329, DOI 10.1002/jcp.20281; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Berk BC, 2001, ANN NY ACAD SCI, V947, P93; BEVILACQUA MP, 1987, SEMIN THROMB HEMOST, V13, P425, DOI 10.1055/s-2007-1003519; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; BYERS SW, 1995, J CELL SCI, V108, P2053; Cadroy Y, 1997, ARTERIOSCL THROM VAS, V17, P520, DOI 10.1161/01.ATV.17.3.520; Calnek DS, 1998, EXP CELL RES, V238, P294, DOI 10.1006/excr.1997.3812; Cenni E, 2002, BIOMATERIALS, V23, P2159, DOI 10.1016/S0142-9612(01)00347-7; Chiambaretta F, 2004, MOL VIS, V10, P901; Cirino G, 2003, TRENDS PHARMACOL SCI, V24, P91, DOI 10.1016/S0165-6147(02)00049-4; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; Dwarakanath RS, 2004, J MOL CELL CARDIOL, V36, P585, DOI 10.1016/j.yjmcc.2004.02.007; Feinberg MW, 2005, J BIOL CHEM, V280, P38247, DOI 10.1074/jbc.M509378200; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Feinberg MW, 2004, TRENDS CARDIOVAS MED, V14, P241, DOI 10.1016/j.tcm.2004.06.005; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Gerszten RE, 1996, CIRC RES, V79, P1205, DOI 10.1161/01.RES.79.6.1205; Gerszten RE, 2001, J BIOL CHEM, V276, P26846, DOI 10.1074/jbc.M011235200; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; GIMBRONE MA, 1990, ANN NY ACAD SCI, V598, P77, DOI 10.1111/j.1749-6632.1990.tb42279.x; Gimbrone MA, 1997, J CLIN INVEST, V100, pS61; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; Greif DM, 2002, BIOCHEMISTRY-US, V41, P15845, DOI 10.1021/bi026732g; Grey ST, 1996, J IMMUNOL, V156, P2256; Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heeringa P, 2000, AM J PATHOL, V156, P879, DOI 10.1016/S0002-9440(10)64957-7; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Iiyama K, 1999, CIRC RES, V85, P199, DOI 10.1161/01.RES.85.2.199; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Katz JP, 2002, DEVELOPMENT, V129, P2619; Knowles JW, 2000, J CLIN INVEST, V105, P451, DOI 10.1172/JCI8376; Koedel U, 2001, J NEUROPATH EXP NEUR, V60, P1041, DOI 10.1093/jnen/60.11.1041; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Lamprecht P, 2005, AUTOIMMUN REV, V4, P28, DOI 10.1016/j.autrev.2004.06.001; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; Li Y, 2005, BLOOD, V105, P635, DOI 10.1182/blood-2004-07-2681; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Lin ZY, 2006, ARTERIOSCL THROM VAS, V26, P1185, DOI 10.1161/01.ATV.0000215638.53414.99; Lin ZY, 2005, CIRC RES, V96, pE48, DOI 10.1161/01.RES.0000159707.05637.a1; Liuzzo G, 2001, Rays, V26, P221; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; Lowe GDO, 2003, PATHOPHYSIOL HAEMO T, V33, P455, DOI 10.1159/000083845; Martinez JM, 2002, TOXICOL SCI, V69, P409, DOI 10.1093/toxsci/69.2.409; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; Michel T, 1999, BRAZ J MED BIOL RES, V32, P1361, DOI 10.1590/S0100-879X1999001100006; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NEWMAN KM, 1994, CONNECT TISSUE RES, V30, P265, DOI 10.3109/03008209409015042; NEWMAN KM, 1994, ARTERIOSCLER THROMB, V14, P1315, DOI 10.1161/01.ATV.14.8.1315; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; PERKINS AC, 1995, NATURE, V375, P318; Rose SL, 2005, J BIOMED MATER RES A, V72A, P269, DOI 10.1002/jbm.a.30222; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Sasaki M, 2003, J PHARMACOL EXP THER, V305, P78, DOI 10.1124/jpet.102.044099; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SenBanerjee S, 2004, J EXP MED, V199, P1305, DOI 10.1084/jem.20031132; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Sonveaux P, 2003, CANCER RES, V63, P1012; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stone PH, 2003, CURR OPIN CARDIOL, V18, P458, DOI 10.1097/00001573-200311000-00007; TAKADA Y, 1994, BIOCHEM BIOPH RES CO, V205, P1345, DOI 10.1006/bbrc.1994.2813; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TAZAWA R, 1993, J BIOCHEM-TOKYO, V113, P600, DOI 10.1093/oxfordjournals.jbchem.a124089; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	86	271	278	1	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13769	13779		10.1074/jbc.M700078200	http://dx.doi.org/10.1074/jbc.M700078200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339326	hybrid			2022-12-27	WOS:000246060300067
J	Kim, JA; Formoso, G; Li, YH; Potenza, MA; Marasciulo, FL; Montagnani, M; Quon, MJ				Kim, Jeong-a; Formoso, Gloria; Li, Yunhua; Potenza, Maria A.; Marasciulo, Flora L.; Montagnani, Monica; Quon, Michael J.			Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CORONARY-ARTERY-DISEASE; SPONTANEOUSLY HYPERTENSIVE-RATS; INSULIN-STIMULATED PRODUCTION; MUSCLE GLUCOSE-UPTAKE; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; MICROVASCULAR RECRUITMENT; TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1	Green tea consumption is associated with reduced cardiovascular mortality in some epidemiological studies. Epigallocatechin gallate (EGCG), a bioactive polyphenol in green tea, mimics metabolic actions of insulin to inhibit gluconeogenesis in hepatocytes. Because signaling pathways regulating metabolic and vasodilator actions of insulin are shared in common, we hypothesized that EGCG may also have vasodilator actions to stimulate production of nitric oxide (NO) from endothelial cells. Acute intra-arterial administration of EGCG to mesenteric vascular beds isolated ex vivo from WKY rats caused dose-dependent vasorelaxation. This was inhibitable by L-NAME (NO synthase inhibitor), wortmannin (phosphatidylinositol 3-kinase inhibitor), or PP2 (Src family kinase inhibitor). Treatment of bovine aortic endothelial cells (BAEC) with EGCG (50 mu m) acutely stimulated production of NO(assessed with NO-specific fluorescent dye DAF-2) that was inhibitable by L-NAME, wortmannin, or PP2. Stimulation of BAEC with EGCG also resulted in dose- and time-dependent phosphorylation of eNOS that was inhibitable by wortmannin or PP2 (but not by MEK inhibitor PD98059). Specific knockdown of Fyn (but not Src) with small interfering RNA inhibited both EGCG-stimulated phosphorylation of Akt and eNOS as well as production of NO in BAEC. Treatment of BAEC with EGCG generated intracellular H2O2 ( assessed with H2O2-specific fluorescent dye CM-H2DCF-DA), whereas treatment with N-acetylcysteine inhibited EGCG-stimulated phosphorylation of Fyn, Akt, and eNOS. We conclude that EGCG has endothelial-dependent vasodilator actions mediated by intracellular signaling pathways requiring reactive oxygen species and Fyn that lead to activation of phosphatidylinositol 3-kinase, Akt, and eNOS. This mechanism may explain, in part, beneficial vascular and metabolic health effects of green tea consumption.	NCCAM, Diabet Unit, Bethesda, MD 20892 USA; Univ Bari, Dept Pharmacol & Human Physiol, I-70124 Bari, Italy	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; Universita degli Studi di Bari Aldo Moro	Quon, MJ (corresponding author), Bldg 10,Room 6C-205, Bethesda, MD 20892 USA.	quonm@nih.gov	Montagnani, Monica/AAV-2057-2020; Quon, Michael/B-1970-2008	Montagnani, Monica/0000-0002-5697-8185; Potenza, Maria Assunta/0000-0002-9995-1468; Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000001, ZIAAT000001, Z02AT000001] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [ZIFAT000001] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Anter E, 2005, CIRC RES, V96, P1072, DOI 10.1161/01.RES.0000168807.63013.56; Anter E, 2004, J BIOL CHEM, V279, P46637, DOI 10.1074/jbc.M405547200; Ashton AW, 2004, CIRC RES, V95, P372, DOI 10.1161/01.RES.0000138300.41642.15; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Baron AD, 2000, DIABETES, V49, P768, DOI 10.2337/diabetes.49.5.768; Chou MT, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-32; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; Duffy SJ, 2001, CIRCULATION, V104, P151, DOI 10.1161/01.CIR.104.2.151; Elbling L, 2005, FASEB J, V19, P807, DOI 10.1096/fj.04-2915fje; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; Formoso G, 2006, MOL ENDOCRINOL, V20, P1153, DOI 10.1210/me.2005-0266; Fujimura Y, 2005, BIOCHEM BIOPH RES CO, V336, P674, DOI 10.1016/j.bbrc.2005.08.146; Goldstein BJ, 2005, ANTIOXID REDOX SIGN, V7, P1021, DOI 10.1089/ars.2005.7.1021; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980; Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109; Kim JA, 2006, CIRCULATION, V113, P1888, DOI 10.1161/CIRCULATIONAHA.105.563213; Kim JA, 2005, J BIOL CHEM, V280, P23173, DOI 10.1074/jbc.M501439200; Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Kuriyama S, 2006, JAMA-J AM MED ASSOC, V296, P1255, DOI 10.1001/jama.296.10.1255; Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025; Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138; Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Mather K, 2000, AM J PHYSIOL-ENDOC M, V279, pE1264, DOI 10.1152/ajpendo.2000.279.6.E1264; MAY JM, 1979, J BIOL CHEM, V254, P2214; McVeigh Gary E, 2003, Curr Diab Rep, V3, P87, DOI 10.1007/s11892-003-0059-0; Miao H, 2002, BIOCHEM BIOPH RES CO, V292, P892, DOI 10.1006/bbrc.2002.6750; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Mochizuki M, 2002, BBA-GEN SUBJECTS, V1569, P35, DOI 10.1016/S0304-4165(01)00230-6; Mochizuki Y, 2002, J CELL SCI, V115, P175; Montagnani M, 2002, MOL ENDOCRINOL, V16, P1931, DOI 10.1210/me.2002-0074; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Potenza MA, 2005, AM J PHYSIOL-HEART C, V289, pH813, DOI 10.1152/ajpheart.00092.2005; POTENZA MA, 2007, IN PRESS AM J PHYSL; Potenza MA, 2006, DIABETES, V55, P3594, DOI 10.2337/db06-0667; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Rhee S G, 2000, Sci STKE, V2000, ppe1; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Sano J, 2004, CIRC J, V68, P665, DOI 10.1253/circj.68.665; Stangl V, 2006, MOL NUTR FOOD RES, V50, P218, DOI 10.1002/mnfr.200500118; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tian WX, 2004, LIFE SCI, V74, P2389, DOI 10.1016/j.lfs.2003.09.064; Tsuda S, 2002, BIOCHEM BIOPH RES CO, V290, P1354, DOI 10.1006/bbrc.2002.6345; Vincent MA, 2003, AM J PHYSIOL-ENDOC M, V285, pE123, DOI 10.1152/ajpendo.00021.2003; Vincent MA, 2004, DIABETES, V53, P1418, DOI 10.2337/diabetes.53.6.1418; Vincent Michelle A, 2003, Curr Diab Rep, V3, P279, DOI 10.1007/s11892-003-0018-9; Vinson JA, 2000, BIOFACTORS, V13, P127, DOI 10.1002/biof.5520130121; Wallerath T, 2002, CIRCULATION, V106, P1652, DOI 10.1161/01.CIR.0000029925.18593.5C; Waltner-Law ME, 2002, J BIOL CHEM, V277, P34933, DOI 10.1074/jbc.M204672200; Werdich XQ, 2006, ANGIOGENESIS, V8, P315; Widlansky ME, 2005, FREE RADICAL BIO MED, V38, P499, DOI 10.1016/j.freeradbiomed.2004.11.013; Yang CS, 1998, CANCER EPIDEM BIOMAR, V7, P351; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539	66	173	178	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13736	13745		10.1074/jbc.M609725200	http://dx.doi.org/10.1074/jbc.M609725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17363366	hybrid			2022-12-27	WOS:000246060300063
J	Lee, JH; Kim, SY; Kil, IS; Park, JW				Lee, Jin Hyup; Kim, Sung Youl; Kil, In Sup; Park, Jeen-Woo			Regulation of ionizing radiation-induced apoptosis by mitochondrial NADP(+)-dependent isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-DEATH; PERMEABILITY TRANSITION; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; FREE-RADICALS; HYDROPEROXIDE; THIOREDOXIN; ANTIOXIDANT	Ionizing radiation induces the production of reactive oxygen species, which play an important causative role in apoptotic cell death. By supplying NADPH for antioxidant systems, we recently demonstrated that the control of mitochondrial redox balance and the cellular defense against oxidative damage are some of the primary functions of mitochondrial NADP(+)-dependent isocitrate dehydrogenase (IDPm). In this study, we demonstrate that modulation of IDPm activity in U937 cells regulates ionizing radiation-induced apoptosis. When we examined the regulatory role of IDPm against ionizing radiation-induced apoptosis in U937 cells transfected with the cDNA for mouse IDPm in sense and antisense orientations, a clear inverse relationship was observed between the amount of IDPm expressed in target cells and their susceptibility to apoptosis. Upon exposure to 2 gray gamma-irradiation, there was a distinct difference between the IDPm transfectant cells in regard to the morphological evidence of apoptosis, DNA fragmentation, cellular redox status, oxidative damage to cells, mitochondrial function, and the modulation of apoptotic marker proteins. In addition, transfection of HeLa cells with an IDPm small interfering RNA decreased the activity of IDPm, enhancing the susceptibility of radiation-induced apoptosis. Taken together, these results indicate that IDPm may play an important role in regulating the apoptosis induced by ionizing radiation, and the effect of IDPm small interfering RNA on HeLa cells offers the possibility of developing a modifier of radiation therapy.	Kyungpook Natl Univ, Coll Nat Sci, Sch Life Sci & Biotechnol, Taegu 702701, South Korea	Kyungpook National University	Park, JW (corresponding author), Kyungpook Natl Univ, Coll Nat Sci, Sch Life Sci & Biotechnol, Taegu 702701, South Korea.	parkjw@knu.ac.kr						Akerboom T P, 1981, Methods Enzymol, V77, P373; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; Buege J A, 1978, Methods Enzymol, V52, P302; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; de Grey ADNJ, 2000, ARCH BIOCHEM BIOPHYS, V373, P295, DOI 10.1006/abbi.1999.1509; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; EWING D, 1987, ARCH BIOCHEM BIOPHYS, V254, P53, DOI 10.1016/0003-9861(87)90080-4; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALLIWELL B, 1999, FREE RADICAL BIO MED, P267; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JIANG ZY, 1992, ANAL BIOCHEM, V202, P384, DOI 10.1016/0003-2697(92)90122-N; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KASTAN MB, 1991, CANCER RES, V51, P6304; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; KONO Y, 1982, J BIOL CHEM, V257, P5751; KOSHLAND DE, 1985, CURR TOP CELL REGUL, V27, P13; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANE DP, 1992, NATURE, V358, P16; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Okimoto Y, 2000, FEBS LETT, V474, P137, DOI 10.1016/S0014-5793(00)01587-8; PARK JW, 1992, FREE RADICAL BIO MED, V12, P245, DOI 10.1016/0891-5849(92)90111-S; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PIGEOLET E, 1990, MECH AGEING DEV, V51, P283, DOI 10.1016/0047-6374(90)90078-T; REPINE JE, 1981, P NATL ACAD SCI-BIOL, V78, P1001, DOI 10.1073/pnas.78.2.1001; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SPRAGG RG, 1985, J CLIN INVEST, V76, P1471, DOI 10.1172/JCI112126; Struthers L, 1998, ANAL BIOCHEM, V255, P20, DOI 10.1006/abio.1997.2354; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; WATABE S, 1995, BIOCHEM BIOPH RES CO, V213, P1010, DOI 10.1006/bbrc.1995.2229; YAMAGUCHI S, 1994, FREE RADICAL BIO MED, V17, P389, DOI 10.1016/0891-5849(94)90165-1; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9	45	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13385	13394		10.1074/jbc.M700303200	http://dx.doi.org/10.1074/jbc.M700303200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350954	hybrid			2022-12-27	WOS:000246060300027
J	Abe, Y; Jo, T; Matsuda, Y; Matsunaga, C; Katayama, T; Ueda, T				Abe, Yoshito; Jo, Takaaki; Matsuda, Yusaku; Matsunaga, Chika; Katayama, Tsutomu; Ueda, Tadashi			Structure and function of DnaA N-terminal domains - Specific sites and mechanisms in inter-DnaA interaction and in DnaB helicase loading on oriC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI CHROMOSOMAL ORIGIN; HUMAN POLY(C)-BINDING PROTEIN-2; HUMAN TELOMERIC DNA; C-RICH STRAND; ESCHERICHIA-COLI; REPLICATION-ORIGIN; INITIATOR PROTEIN; CONSERVED MOTIF; BINDING DOMAIN; SLIDING CLAMP	DnaA forms a homomultimeric complex with the origin of chromosomal replication (oriC) to unwind duplex DNA. The interaction of the DnaA N terminus with the DnaB helicase is crucial for the loading of DnaB onto the unwound region. Here, we determined the DnaA N terminus structure using NMR. This region (residues 1 -108) consists of a rigid region (domain I) and a flexible region (domain II). Domain I has an alpha-alpha-beta-beta-alpha-beta motif, similar to that of the K homology (KH) domain, and has weak affinity for oriC single-stranded DNA, consistent with KH domain function. A hydrophobic surface carrying Trp-6 most likely forms the interface for domain I dimerization. Glu-21 is located on the opposite surface of domain I from the Trp-6 site and is crucial for DnaB helicase loading. These findings suggest a model for DnaA homomultimer formation and DnaB helicase loading on oriC.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Katayama, T (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	katayama@phar.kyushu-u.ac.jp; ueda@phar.kyushu-u.ac.jp	Abe, Yoshito/AAH-6141-2021; Abe, Yoshito/D-8370-2012	Abe, Yoshito/0000-0002-0016-8490; Abe, Yoshito/0000-0002-0016-8490; Katayama, Tsutomu/0000-0001-9994-1684				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Carr KM, 2001, J BIOL CHEM, V276, P44919, DOI 10.1074/jbc.M107463200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Du ZH, 2005, J BIOL CHEM, V280, P38823, DOI 10.1074/jbc.M508183200; Du ZH, 2004, J BIOL CHEM, V279, P48126, DOI 10.1074/jbc.M405371200; Erzberger JP, 2006, NAT STRUCT MOL BIOL, V13, P676, DOI 10.1038/nsmb1115; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; Felczak MM, 2005, J BIOL CHEM, V280, P24627, DOI 10.1074/jbc.M503684200; Felczak MM, 2004, J BIOL CHEM, V279, P51156, DOI 10.1074/jbc.M409695200; Fujikawa N, 2003, NUCLEIC ACIDS RES, V31, P2077, DOI 10.1093/nar/gkg309; Grishin NV, 2001, NUCLEIC ACIDS RES, V29, P638, DOI 10.1093/nar/29.3.638; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUPP TR, 1993, J BIOL CHEM, V268, P13137; HWANG DS, 1991, J BIOL CHEM, V266, P7537; Indiani C, 2006, NAT REV MOL CELL BIO, V7, P751, DOI 10.1038/nrm2022; Ishida T, 2004, J BIOL CHEM, V279, P45546, DOI 10.1074/jbc.M402762200; Kaguni JM, 2006, ANNU REV MICROBIOL, V60, P351, DOI 10.1146/annurev.micro.60.080805.142111; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Kawakami H, 2005, J BIOL CHEM, V280, P27420, DOI 10.1074/jbc.M502764200; Kawakami H, 2006, J STRUCT BIOL, V156, P220, DOI 10.1016/j.jsb.2006.02.007; Kawakami H, 2006, MOL MICROBIOL, V62, P1310, DOI 10.1111/j.1365-2958.2006.05450.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1990, J BIOL CHEM, V265, P15134; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nishida S, 2002, J BIOL CHEM, V277, P14986, DOI 10.1074/jbc.M108303200; Obita T, 2002, BIOCHEM BIOPH RES CO, V299, P42, DOI 10.1016/S0006-291X(02)02590-1; Paziewska A, 2004, FEBS LETT, V577, P134, DOI 10.1016/j.febslet.2004.08.086; Robinson NP, 2005, FEBS J, V272, P3757, DOI 10.1111/j.1742-4658.2005.04768.x; Seitz H, 2000, MOL MICROBIOL, V37, P1270, DOI 10.1046/j.1365-2958.2000.02096.x; Simmons LA, 2003, MOL MICROBIOL, V49, P849, DOI 10.1046/j.1365-2958.2003.03603.x; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Su'etsugu M, 2005, J BIOL CHEM, V280, P6528, DOI 10.1074/jbc.M412060200; Su'etsugu M, 2004, GENES CELLS, V9, P509, DOI 10.1111/j.1356-9597.2004.00741.x; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; Weigel C, 1999, MOL MICROBIOL, V34, P53, DOI 10.1046/j.1365-2958.1999.01568.x; Worbs M, 2001, MOL CELL, V7, P1177, DOI 10.1016/S1097-2765(01)00262-3; Yoshida Y, 2003, CELL MOL LIFE SCI, V60, P1998, DOI 10.1007/s00018-003-3176-7	47	84	86	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17816	17827		10.1074/jbc.M701841200	http://dx.doi.org/10.1074/jbc.M701841200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17420252	hybrid			2022-12-27	WOS:000247084500055
J	Khalimonchuk, O; Bird, A; Winge, DR				Khalimonchuk, Oleh; Bird, Amanda; Winge, Dennis R.			Evidence for a pro-oxidant intermediate in the assembly of cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-OXIDASE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; HUMAN SCO1; TRANSLATIONAL ACTIVATOR; CU(I)-BINDING PROTEIN; CRYSTAL-STRUCTURE; YEAST SCO1; COX11; EXPRESSION	The hydrogen peroxide sensitivity of cells lacking two proteins, Sco1 and Cox11, important in the assembly of cytochrome c oxidase (CcO), is shown to arise from the transient accumulation of a pro-oxidant heme A-Cox1 stalled intermediate. The peroxide sensitivity of these cells is abrogated by a reduction in either Cox1 expression or heme A formation but exacerbated by either enhanced Cox1 expression or heme A production arising from overexpression of COX15. Sco1 and Cox11 are implicated in the formation of the Cu-A and Cu-B sites of CcO, respectively. The respective wild-type genes suppress the peroxide sensitivities of sco1 Delta and cox11 Delta cells, but no cross-complementation is seen with noncognate genes. Copper-binding mutant alleles of Sco1 and Cox11 that are nonfunctional in promoting the assembly of CcO are functional in suppressing the peroxide sensitivity of their respective null mutants. Likewise, human Sco1 that is nonfunctional in yeast CcO assembly is able to suppress the peroxide sensitivity of yeast sco1 Delta cells. Thus, a disconnect exists between the respiratory capacity of cells and hydrogen peroxide sensitivity. Hydrogen peroxide sensitivity of sco1 Delta and cox11 Delta cells is abrogated by overexpression of a novel mitochondrial ATPase Afg1 that promotes the degradation of CcO mitochondrially encoded subunits. Studies on the hydrogen peroxide sensitivity in CcO assembly mutants reveal new aspects of the CcO assembly process.	Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Bird, Amanda Jane/ABD-2295-2021; Winge, Dennis/G-3611-2010; Khalimonchuk, Oleh/AAM-1194-2021	Bird, Amanda Jane/0000-0002-1846-7050; Khalimonchuk, Oleh/0000-0002-3972-8678	NIEHS NIH HHS [ES03817] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003817, R37ES003817] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abajian C, 2006, J BIOL INORG CHEM, V11, P459, DOI 10.1007/s00775-006-0096-7; Balatri E, 2003, STRUCTURE, V11, P1431, DOI 10.1016/j.str.2003.10.004; Banci L, 2006, P NATL ACAD SCI USA, V103, P8595, DOI 10.1073/pnas.0601375103; Banting GS, 2006, EUKARYOT CELL, V5, P568, DOI 10.1128/EC.5.3.568-578.2006; Barrientos A, 2004, EMBO J, V23, P3472, DOI 10.1038/sj.emboj.7600358; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; Barros MH, 2002, FEBS LETT, V516, P119, DOI 10.1016/S0014-5793(02)02514-0; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; Carlson EJ, 2006, EMBO J, V25, P4557, DOI 10.1038/sj.emboj.7601307; Carr HS, 2005, J BIOL CHEM, V280, P22664, DOI 10.1074/jbc.M414077200; Carr HS, 2003, ACCOUNTS CHEM RES, V36, P309, DOI 10.1021/ar0200807; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; Chinenov YV, 2000, J MOL MED, V78, P239, DOI 10.1007/s001090000110; Cobine PA, 2006, BBA-MOL CELL RES, V1763, P759, DOI 10.1016/j.bbamcr.2006.03.002; DAUM G, 1982, J BIOL CHEM, V257, P3028; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; FIJIKI Y, 1982, J CELL BIOL, V93, P97; Fiori A, 2005, MOL MICROBIOL, V56, P1689, DOI 10.1111/j.1365-2958.2005.04658.x; Fontanesi F, 2006, AM J PHYSIOL-CELL PH, V291, pC1129, DOI 10.1152/ajpcell.00233.2006; Halawani D, 2006, MOL CELL, V22, P713, DOI 10.1016/j.molcel.2006.06.003; Hansen J, 2000, MOL GEN GENET, V263, P535, DOI 10.1007/s004380051199; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Horan S, 2005, BIOCHEM J, V390, P703, DOI 10.1042/BJ20050598; Horng YC, 2005, J BIOL CHEM, V280, P34113, DOI 10.1074/jbc.M506801200; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Khalimonchuk E, 2005, MITOCHONDRION, V5, P363, DOI 10.1016/j.mito.2005.08.002; Khalimonchuk O, 2005, CURR GENET, V47, P223, DOI 10.1007/s00294-005-0569-1; Khalimonchuk O, 2006, EUKARYOT CELL, V5, P997, DOI 10.1128/EC.00092-06; LEE YJ, 1992, YEAST, V8, P787, DOI 10.1002/yea.320080912; MULERO JJ, 1993, MOL BIOL CELL, V4, P1327, DOI 10.1091/mbc.4.12.1327; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; POUTRE CG, 1987, GENETICS, V115, P637; Pungartnik C, 1999, CURR GENET, V36, P124, DOI 10.1007/s002940050481; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Seib KL, 2003, FEBS LETT, V546, P411, DOI 10.1016/S0014-5793(03)00632-X; Smith D, 2005, J BIOL CHEM, V280, P17652, DOI 10.1074/jbc.C500061200; Souza RL, 2000, J BIOL CHEM, V275, P14898, DOI 10.1074/jbc.275.20.14898; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Williams JC, 2005, J BIOL CHEM, V280, P15202, DOI 10.1074/jbc.M410705200; Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200; Ye QL, 2005, BIOCHEMISTRY-US, V44, P2934, DOI 10.1021/bi0480537; Zambrano A, 2007, MOL BIOL CELL, V18, P523, DOI 10.1091/mbc.E06-09-0803	47	94	98	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17442	17449		10.1074/jbc.M702379200	http://dx.doi.org/10.1074/jbc.M702379200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430883	Green Published, hybrid			2022-12-27	WOS:000247084500014
J	Barends, TRM; Bultema, JB; Kaper, T; van der Maarel, MJEC; Dijkhuizen, L; Dijkstra, BW				Barends, Thomas R. M.; Bultema, Jelle B.; Kaper, Thijs; van der Maarel, Marc J. E. C.; Dijkhuizen, Lubbert; Dijkstra, Bauke W.			Three-way stabilization of the covalent intermediate in amylomaltase, an alpha-amylase-like transglycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE CYCLIC GLUCANS; THERMUS-AQUATICUS; ESCHERICHIA-COLI; CYCLODEXTRIN GLYCOSYLTRANSFERASE; GLYCOSYL HYDROLASES; STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; ENZYME; STARCH; CYCLOAMYLOSE	Amylomaltases are glycosyl hydrolases belonging to glycoside hydrolase family 77 that are capable of the synthesis of large cyclic glucans and the disproportionation of oligosaccharides. Using protein crystallography, we have generated a flip book movie of the amylomaltase catalytic cycle in atomic detail. The structures include a covalent glycosyl enzyme intermediate and a covalent intermediate in complex with an analogue of a cosubstrate and show how the structures of both enzyme and substrate respond to the changes required by the catalytic cycle as it proceeds. Notably, the catalytic nucleophile changes conformation dramatically during the reaction. Also, Gln- 256 on the 250s loop is involved in orienting the substrate in the + 1 site. The absence of a suitable base in the covalent intermediate structure explains the low hydrolysis activity.	Univ Groningen, Lab Biophys Chem, NL-9747 AG Groningen, Netherlands; Univ Groningen, TNO, Ctr Carbohydrate Bioproc, NL-9751 NN Haren, Netherlands; Univ Groningen, Microbiol Lab, NL-9751 NN Haren, Netherlands	University of Groningen; Netherlands Organization Applied Science Research; University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Lab Biophys Chem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.w.dijkstra@rug.nl	Dijkhuizen, Lubbert/E-9454-2014; Dijkhuizen, Lubbert/K-3539-2019; Dijkstra, Bauke W./H-4308-2019	Dijkhuizen, Lubbert/0000-0003-2312-7162; Dijkstra, Bauke W./0000-0001-9731-6586				Bhuiyan SH, 2003, J MOL CATAL B-ENZYM, V22, P45, DOI 10.1016/S1381-1177(03)00005-5; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DeLano W.L, PYMOL MOL GRAPHICS S; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1996, BIOCHEM J, V316, P16959; *INT UN PUR APPL C, 1980, PURE APPL CHEM, V53, P1901; Jensen MH, 2004, BIOCHEMISTRY-US, V43, P3104, DOI 10.1021/bi0357762; Kaper T, 2004, BIOCHEM SOC T, V32, P279, DOI 10.1042/BST0320279; Kaper T, 2005, APPL ENVIRON MICROB, V71, P5098, DOI 10.1128/AEM.71.9.5098-5106.2005; Kaper T, 2007, BIOCHEMISTRY-US, V46, P5261, DOI 10.1021/bi602408j; KURIKI T, 1999, PROG BIOPHYS MOL BIO, V67; LIEBL W, 1992, EUR J BIOCHEM, V207, P81, DOI 10.1111/j.1432-1033.1992.tb17023.x; Lovering AL, 2005, J BIOL CHEM, V280, P2105, DOI 10.1074/jbc.M410468200; McPherson A, 2001, PROTEIN SCI, V10, P418, DOI 10.1110/ps.32001; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mosi R, 1997, BIOCHEMISTRY-US, V36, P9927, DOI 10.1021/bi970618u; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Noguchi S, 1998, J MOL BIOL, V278, P231, DOI 10.1006/jmbi.1998.1674; Numao S, 2003, J BIOL CHEM, V278, P48074, DOI 10.1074/jbc.M309249200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALMER TN, 1976, EUR J BIOCHEM, V69, P105, DOI 10.1111/j.1432-1033.1976.tb10863.x; PEAT S, 1956, J CHEM SOC, P44, DOI 10.1039/jr9560000044; PEAT S, 1953, NATURE, V172, P158, DOI 10.1038/172158a0; Przylas I, 2000, J MOL BIOL, V296, P873, DOI 10.1006/jmbi.1999.3503; Przylas I, 2000, EUR J BIOCHEM, V267, P6903, DOI 10.1046/j.1432-1033.2000.01790.x; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Strater N, 2002, BIOLOGIA, V57, P93; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; Takaha T, 1996, J BIOL CHEM, V271, P2902, DOI 10.1074/jbc.271.6.2902; Terada Y, 1999, APPL ENVIRON MICROB, V65, P910; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van der Maarel MJEC, 2005, STARCH-STARKE, V57, P465, DOI 10.1002/star.200500409	37	58	59	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17242	17249		10.1074/jbc.M701444200	http://dx.doi.org/10.1074/jbc.M701444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17420245	hybrid, Green Published			2022-12-27	WOS:000246946500057
J	Dissanayake, SK; Wade, M; Johnson, CE; O'Connell, MP; Leotlela, PD; French, AD; Shah, KV; Hewitt, KJ; Rosenthal, DT; Indig, FE; Jiang, Y; Nickoloff, BJ; Taub, DD; Trent, JM; Moon, RT; Bittner, M; Weeraratna, AT				Dissanayake, Samudra K.; Wade, Michael; Johnson, Carrie E.; O'Connell, Michael P.; Leotlela, Poloko D.; French, Amanda D.; Shah, Kavita V.; Hewitt, Kyle J.; Rosenthal, Devin T.; Indig, Fred E.; Jiang, Yuan; Nickoloff, Brian J.; Taub, Dennis D.; Trent, Jeffrey M.; Moon, Randall T.; Bittner, Michael; Weeraratna, Ashani T.			The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; MALIGNANT-MELANOMA; MOLECULAR CLASSIFICATION; KISS-1 EXPRESSION; FRIZZLED HOMOLOGS; GENE-EXPRESSION; CARCINOMA-CELLS; DOWN-REGULATION; PROTEIN; INVASION	We have shown that Wnt5A increases the motility of melanoma cells. To explore cellular pathways involving Wnt5A, we compared gain-of-function (WNT5A stable transfectants) versus loss-of-function (siRNA knockdown) of WNT5A by microarray analysis. Increasing WNT5A suppressed the expression of several genes, which were re-expressed after small interference RNA-mediated knockdown of WNT5A. Genes affected by WNT5A include KISS-1, a metastasis suppressor, and CD44, involved in tumor cell homing during metastasis. This could be validated at the protein level using both small interference RNA and recombinant Wnt5A (rWnt5A). Among the genes up-regulated by WNT5A was the gene vimentin, associated with an epithelial to mesenchymal transition (EMT), which involves decreases in E-cadherin, due to up-regulation of the transcriptional repressor, Snail. rWnt5A treatment increases Snail and vimentin expression, and decreases E-cadherin, even in the presence of dominant-negativeTCF4, suggesting that this activation is independent of Wnt/ss-catenin signaling. Because Wnt5A can signal via protein kinase C (PKC), the role of PKC in Wnt5A- mediated motility and EMT was also assessed using PKC inhibition and activation studies. Treating cells expressing low levels of Wnt5A with phorbol ester increased Snail expression inhibiting PKC in cells expressing high levels of Wnt5A	NIA, Immunol Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; NIA, Res Resources Branch, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Washington, Howard Hughes Med Inst, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Inst Stem Cell & Regenerat Med, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Translat Genom Res Inst, Phoenix, AZ 85004 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Loyola University Chicago; Translational Genomics Research Institute	Weeraratna, AT (corresponding author), NIA, Immunol Lab, Gerontol Res Ctr, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	weerarat@grc.nia.nih.gov	Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019; Hewitt, Kyle/S-6512-2019; Shah, Kavita/Y-9755-2019; O'Connell, Michael/F-9236-2017	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Shah, Kavita/0000-0002-0451-1305; O'Connell, Michael/0000-0002-8615-7660	Intramural NIH HHS [Z01 AG000442-04] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [Z01AG000615, Z01AG000764, Z01AG000442] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; Chin D, 2002, BIOCHEMISTRY-US, V41, P14001, DOI 10.1021/bi025640o; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; De Wit Peter E. J., 1996, Current Opinion in Oncology, V8, P143, DOI 10.1097/00001622-199603000-00012; Dhar DK, 2004, INT J CANCER, V111, P868, DOI 10.1002/ijc.20357; Dietrich A, 1997, EUR J CANCER, V33, P926, DOI 10.1016/S0959-8049(96)00512-6; FAASSEN AE, 1993, J CELL SCI, V105, P501; Fink-Puches R, 1993, Exp Dermatol, V2, P17, DOI 10.1111/j.1600-0625.1993.tb00194.x; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Ikeguchi M, 2004, CLIN CANCER RES, V10, P1379, DOI 10.1158/1078-0432.CCR-1519-02; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Jonsson M, 1998, BRIT J CANCER, V78, P430, DOI 10.1038/bjc.1998.511; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Kuphal S, 2005, MELANOMA RES, V15, P305, DOI 10.1097/00008390-200508000-00012; Lahn MM, 2004, MELANOMA RES, V14, P85, DOI 10.1097/00008390-200404000-00002; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; LEOTLELA PD, 2006, IN PRESS ONCOGENE; Lewis TB, 2005, CANCER-AM CANCER SOC, V104, P1678, DOI 10.1002/cncr.21372; Li SY, 2005, INT J ONCOL, V27, P1329; MAPELLI E, 1994, INT J CANCER, V57, P281, DOI 10.1002/ijc.2910570225; Maya R, 2000, ONCOGENE, V19, P3213, DOI 10.1038/sj.onc.1203658; MCMAHON AP, 1989, DEVELOPMENT, V107, P161; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; NUSSE R, 1985, PROC R SOC SER B-BIO, V226, P3, DOI 10.1098/rspb.1985.0075; Oka M, 2005, CANCER METAST REV, V24, P287, DOI 10.1007/s10555-005-1578-8; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PARKER C, 1992, MELANOMA RES, V2, P337, DOI 10.1097/00008390-199212000-00007; Sanchez-Carbayo M, 2003, AM J PATHOL, V162, P609, DOI 10.1016/S0002-9440(10)63854-0; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Sionov RV, 1998, CELL ADHES COMMUN, V6, P503, DOI 10.3109/15419069809010798; Stathatos N, 2005, J CLIN ENDOCR METAB, V90, P5432, DOI 10.1210/jc.2005-0963; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Tzircotis G, 2006, ONCOGENE, V25, P7401, DOI 10.1038/sj.onc.1209724; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107; Yoshikawa N, 2003, LIFE SCI, V72, P1377, DOI 10.1016/S0024-3205(02)02407-4	48	285	301	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17259	17271		10.1074/jbc.M700075200	http://dx.doi.org/10.1074/jbc.M700075200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17426020	hybrid, Green Accepted			2022-12-27	WOS:000246946500059
J	Lorca, GL; Ezersky, A; Lunin, VV; Walker, JR; Altamentova, S; Evdokimova, E; Vedadi, M; Bochkarev, A; Savchenko, A				Lorca, Graciela L.; Ezersky, Alexandra; Lunin, Vladimir V.; Walker, John R.; Altamentova, Svetlana; Evdokimova, Elena; Vedadi, Masoud; Bochkarev, Alexey; Savchenko, Alexei			Glyoxylate and pyruvate are antagonistic effectors of the Escherichia coli IclR transcriptional regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; METABOLIC FLUX ANALYSIS; C-13-LABELING EXPERIMENTS; ISOCITRATE DEHYDROGENASE; ACETATE OPERON; PROTEIN; GENE; BINDING; EXPRESSION; REPRESSOR	The Escherichia coli isocitrate lyase regulator (IclR) regulates the expression of the glyoxylate bypass operon ( aceBAK). Founding member of a large family of common fold transcriptional regulators, IclR comprises a DNA binding domain that interacts with the operator sequence and a C-terminal domain ( C-IclR) that binds a hitherto unknown small molecule. We screened a chemical library of more than 150 metabolic scaffolds using a high-throughput protein stability assay to identify molecules that bind IclR and then tested the active compounds in in vitro assays of operator binding. Glyoxylate and pyruvate, identified by this method, bound the C-IclR domain with KD values of 0.9 +/- 0.2 and 156.2 +/- 7.9 mu M, as defined by isothermal titration calorimetry. Both compounds altered IclR interactions with operator DNA in electrophoretic mobility shift assays but showed an antagonistic effect. Glyoxylate disrupted the formation of the IclR/operator complex in vitro by favoring the inactive dimeric state of the protein, whereas pyruvate increased the binding of IclR to the aceBAK promoter by stabilizing the active tetrameric form of the protein. Structures of the C-IclR domain alone and in complex with each effector were determined at 2.3 A, confirming the binding of both molecules in the effector recognition site previously characterized for the other representative of the family, the E. coli AllR regulator. Site-directed mutagenesis demonstrated the importance of hydrophobic patch formed by Met- 146, Leu-154, Leu-220, and Leu-143 in interactions with effector molecules. In general, our strategy of combining chemical screens with functional assays and structural studies has uncovered two small molecules with antagonistic effects that regulate the IclR-dependent transcription of the aceBAK operon.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L6, Canada; Ontario Ctr Struct Prot, Toronto, ON M5G 1LG, Canada; Canada Struct Genom Consortium, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Lorca, GL (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	glorca@ufl.edu; alexei.savchenko@utoronto.ca		/0000-0002-5255-895X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62414-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arias-Barrau E, 2004, J BACTERIOL, V186, P5062, DOI 10.1128/jb.186.15.5062-5077.2004; Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carver TE, 2005, J BIOL CHEM, V280, P11704, DOI 10.1074/jbc.M413278200; CHUNG T, 1988, J BACTERIOL, V170, P386, DOI 10.1128/jb.170.1.386-392.1988; CORTAY JC, 1991, EMBO J, V10, P675, DOI 10.1002/j.1460-2075.1991.tb07996.x; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; Cusa E, 1999, J BACTERIOL, V181, P7479, DOI 10.1128/JB.181.24.7479-7484.1999; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DIMARCO AA, 1993, J BACTERIOL, V175, P4499, DOI 10.1128/JB.175.14.4499-4506.1993; ELMANSKI EM, 1983, J GEN MICROBIOL, V132, P797; Epelbaum S, 1998, J BACTERIOL, V180, P4056, DOI 10.1128/JB.180.16.4056-4067.1998; Evans G, 2001, J APPL CRYSTALLOGR, V34, P82, DOI 10.1107/S0021889800014655; Gerischer U, 1998, J BACTERIOL, V180, P1512, DOI 10.1128/JB.180.6.1512-1524.1998; Gloss LM, 1997, BIOCHEMISTRY-US, V36, P5612, DOI 10.1021/bi970056e; Gorelik M, 2006, PROTEIN SCI, V15, P1506, DOI 10.1110/ps.062146906; Guazzaroni MAE, 2005, J BIOL CHEM, V280, P20887, DOI 10.1074/jbc.M500783200; Gui LZ, 1996, J BACTERIOL, V178, P4704, DOI 10.1128/jb.178.15.4704-4709.1996; Gui LZ, 1996, J BACTERIOL, V178, P321, DOI 10.1128/jb.178.1.321-324.1996; Kao KC, 2005, J BIOL CHEM, V280, P36079, DOI 10.1074/jbc.M508202200; KORNBERG HL, 1957, BIOCHIM BIOPHYS ACTA, V24, P651, DOI 10.1016/0006-3002(57)90268-8; KORNBERG HL, 1966, BIOCHEM J, V99, P1; KORNBERG HL, 1967, B SOC CHIM BIOL, V49, P1479; KREBS A, 1980, CAN J BIOCHEM CELL B, V58, P309, DOI 10.1139/o80-041; LAPORTE DC, 1984, J BIOL CHEM, V259, P4068; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MALOY SR, 1982, J BACTERIOL, V149, P173, DOI 10.1128/JB.149.1.173-180.1982; Nasser W, 2007, ANAL BIOANAL CHEM, V387, P381, DOI 10.1007/s00216-006-0702-0; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Nobeli I, 2006, BIOESSAYS, V28, P534, DOI 10.1002/bies.20414; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; ORNSTON LN, 1969, J BACTERIOL, V98, P1098, DOI 10.1128/JB.98.3.1098-1108.1969; Pan B, 1996, J BACTERIOL, V178, P3982, DOI 10.1128/jb.178.13.3982-3984.1996; Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1089/108705701753364922; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pellicer MT, 1999, J BIOL CHEM, V274, P1745, DOI 10.1074/jbc.274.3.1745; Peng LF, 2004, FEMS MICROBIOL LETT, V235, P17, DOI 10.1016/j.femsle.2004.04.003; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Phue JN, 2005, BIOTECHNOL BIOENG, V90, P805, DOI 10.1002/bit.20478; Ponce E, 1998, BIOTECHNOL BIOENG, V58, P292, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<292::AID-BIT25>3.0.CO;2-D; Popp R, 2002, J BACTERIOL, V184, P1988, DOI 10.1128/JB.184.7.1988-1997.2002; Ramos JL, 2005, MICROBIOL MOL BIOL R, V69, P326, DOI 10.1128/MMBR.69.2.326-356.2005; RAMSEIER TM, 1993, J MOL BIOL, V234, P28, DOI 10.1006/jmbi.1993.1561; Repik A, 2000, MOL MICROBIOL, V36, P806, DOI 10.1046/j.1365-2958.2000.01910.x; Resnik E, 1996, J BACTERIOL, V178, P2715, DOI 10.1128/jb.178.9.2715-2717.1996; REVERCHON S, 1991, MOL MICROBIOL, V5, P2203, DOI 10.1111/j.1365-2958.1991.tb02150.x; Rintoul MR, 2002, J MOL BIOL, V324, P599, DOI 10.1016/S0022-2836(02)01134-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; Sebaihia M, 2006, J BACTERIOL, V188, P6002, DOI 10.1128/JB.01927-05; SENISTERRA G, 2003, Patent No. 03071269; Senisterra GA, 2006, J BIOMOL SCREEN, V11, P940, DOI 10.1177/1087057106294699; SHRAKE A, 1990, J BIOL CHEM, V265, P5055; Siddiquee KA, 2004, FEMS MICROBIOL LETT, V235, P25, DOI 10.1016/j.femsle.2004.04.004; Siddiquee KA, 2004, APPL MICROBIOL BIOT, V63, P407, DOI 10.1007/s00253-003-1357-9; Silhavy T. J., 1984, EXPT GENE FUSIONS; Skubak P, 2004, ACTA CRYSTALLOGR D, V60, P2196, DOI 10.1107/S0907444904019079; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; Steiner P, 1998, GENE, V220, P31, DOI 10.1016/S0378-1119(98)00418-1; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P45, DOI 10.1107/S0907444902018048; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; Torres B, 2003, J BIOL CHEM, V278, P27575, DOI 10.1074/jbc.M303245200; Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Vedadi M, 2006, P NATL ACAD SCI USA, V103, P15835, DOI 10.1073/pnas.0605224103; VOGELS GD, 1976, BACTERIOL REV, V40, P403, DOI 10.1128/MMBR.40.2.403-468.1976; Walker JR, 2006, J MOL BIOL, V358, P810, DOI 10.1016/j.jmb.2006.02.034; WALSH K, 1985, J BIOL CHEM, V260, P8430; WEBER PC, 1995, ACTA CRYSTALLOGR D, V51, P590, DOI 10.1107/S0907444995001405; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yamamoto K, 2003, MOL MICROBIOL, V47, P183, DOI 10.1046/j.1365-2958.2003.03287.x; Zhang HB, 2002, P NATL ACAD SCI USA, V99, P4638, DOI 10.1073/pnas.022056699; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200; Zhang ZG, 2005, J BACTERIOL, V187, P980, DOI 10.1128/JB.187.3.980-990.2005	81	63	65	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16476	16491		10.1074/jbc.M610838200	http://dx.doi.org/10.1074/jbc.M610838200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426033	hybrid			2022-12-27	WOS:000246794300055
J	Murata, T; Lin, MI; Stan, RV; Bauer, PM; Yu, J; Sessa, WC				Murata, Takahisa; Lin, Michelle I.; Stan, Radu V.; Bauer, Phillip Michael; Yu, Jun; Sessa, William C.			Genetic evidence supporting caveolae microdomain regulation of calcium entry in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; OPERATED CA2+ INFLUX; OXIDE SYNTHASE ENOS; NITRIC-OXIDE; CATION CHANNEL; SMOOTH-MUSCLE; TRPC CHANNELS; MICROVASCULAR PERMEABILITY; TRISPHOSPHATE RECEPTOR; SIGNALING COMPLEX	Various cellular signals initiate calcium entry into cells, and there is evidence that lipid rafts and caveolae may concentrate proteins that regulate transmembrane calcium fluxes. Here, using mice deficient in caveolin-1 (Cav-1) and Cav-1 knock-out reconstituted with endothelium-specific Cav-1, we show that Cav-1 is essential for calcium entry in endothelial cells and governs the localization and protein-protein interactions between transient receptor channels C4 and C1. Thus, Cav-1 is required for calcium entry in vascular endothelial cells and perhaps other specialized cell types containing caveolae.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Program Vasc Cell Signaling & Therapeut, New Haven, CT 06536 USA; Dartmouth Med Coll, Dept Pathol, Lebanon, NH 03756 USA	Yale University; Yale University; Dartmouth College	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.	william.sessa@yale.edu	Stan, Radu/AAE-7574-2021; Sessa, William C/B-6844-2011	Stan, Radu/0000-0003-2969-1725; Sessa, William C/0000-0001-5759-1938; Murata, Takahisa/0000-0002-3328-0796	NHLBI NIH HHS [R01 HL 57665, R01 HL 61371, P01 HL 70295, N01-HV-28186, R01 HL64793] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061371, P01HL070295, R01HL064793, R01HL057665] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmmed GU, 2005, PFLUG ARCH EUR J PHY, V451, P131, DOI 10.1007/s00424-005-1461-z; Bauer PM, 2005, P NATL ACAD SCI USA, V102, P204, DOI 10.1073/pnas.0406092102; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Flockerzi V, 2005, PFLUG ARCH EUR J PHY, V451, P81, DOI 10.1007/s00424-005-1443-1; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GABELLA G, 1971, J CELL SCI, V8, P601; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Isshiki M, 2002, J CELL SCI, V115, P475; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; Kan H, 1997, J PHARMACOL EXP THER, V282, P113; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kwiatek AM, 2006, MOL PHARMACOL, V70, P1174, DOI 10.1124/mol.105.021741; Lee-Kwon W, 2005, AM J PHYSIOL-CELL PH, V288, pC942, DOI 10.1152/ajpcell.00417.2004; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; MONCADA S, 1991, PHARMACOL REV, V43, P109; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Murata T, 2002, J BIOL CHEM, V277, P44085, DOI 10.1074/jbc.M205934200; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Ong HL, 2002, BIOCHEM J, V364, P641, DOI 10.1042/BJ20020061; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Poteser M, 2006, J BIOL CHEM, V281, P13588, DOI 10.1074/jbc.M512205200; Razani B, 2002, BIOCHEMISTRY-US, V41, P7914, DOI 10.1021/bi020043n; Razani B, 2002, MOL CELL BIOL, V22, P2329, DOI 10.1128/MCB.22.7.2329-2344.2002; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Rey O, 2006, J BIOL CHEM, V281, P38730, DOI 10.1074/jbc.M605956200; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Sinkins WG, 2004, J BIOL CHEM, V279, P34521, DOI 10.1074/jbc.M401156200; Stamboulian S, 2005, DEV BIOL, V286, P326, DOI 10.1016/j.ydbio.2005.08.006; Strubing C, 2003, J BIOL CHEM, V278, P39014, DOI 10.1074/jbc.M306705200; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Vandebrouck A, 2007, FASEB J, V21, P608, DOI 10.1096/fj.06-6683com; Yip H, 2004, HISTOCHEM CELL BIOL, V122, P553, DOI 10.1007/s00418-004-0720-y; Yoshida T, 2006, NAT CHEM BIOL, V2, P596, DOI 10.1038/nchembio821; Yu J, 2006, J CLIN INVEST, V116, P1284, DOI 10.1172/JCI27100; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	53	117	119	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16631	16643		10.1074/jbc.M607948200	http://dx.doi.org/10.1074/jbc.M607948200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17416589	hybrid			2022-12-27	WOS:000246794300069
J	Kong, C; Su, X; Chen, PI; Stahl, PD				Kong, Chen; Su, Xiong; Chen, Pin-I; Stahl, Philip D.			Rin1 interacts with signal-transducing adaptor molecule (STAM) and mediates epidermal growth factor receptor trafficking and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; DOWN-REGULATION; UBIQUITIN ISOPEPTIDASE; ENDOSOMAL TRAFFICKING; MULTIVESICULAR-BODY; BINDING-PROTEIN; KINASE-ACTIVITY; RAB5; ENDOCYTOSIS; COMPLEX	Rin1, the prototype of a new family of multidomain Rab5 exchange factors, has been shown to play an important role in the endocytosis of the epidermal growth factor receptor (EGFR). Herein, we examined the role of Rin1 in the down-regulation of EGFR following EGF stimulation. We observed that overexpression of Rin1 accelerates EGFR degradation in EGF-stimulated cells. In concordance, depletion of endogenous Rin1 by RNA interference resulted in a substantial reduction of EGFR degradation. We showed that Rin1 interacts with signal-transducing adaptor molecule 2 (STAM2), a protein that associates with hepatocyte growth factor-regulated substrate and plays a key role in the endosomal sorting machinery. Green fluorescent protein (GFP)-Rin1 co-localizes with hemagglutinin (HA)-STAM2 and with endogenous hepatocyte growth factor-regulated substrate. Furthermore, wild type STAM2, but not a deletion mutant lacking the SH3 domain, co-immunoprecipitates with endogenous Rin1. This interaction is dependent on the proline-rich domain (PRD) of Rin1 as Rin1 Delta PRD, a mutant lacking the PRD, does not interact with STAM2. Moreover, EGFR degradation was not accelerated by expression of the Rin1 Delta PRD mutant. Together these results suggest that Rin1 regulates EGFR degradation in cooperation with STAM, defining a novel role for Rin1 in regulating endosomal trafficking.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid, St Louis, MO 63110 USA.	pstahl@cellbiology.wustl.edu	Stahl, Philip/D-6315-2012		NIGMS NIH HHS [2R01GM42259-31] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bache KG, 2006, MOL BIOL CELL, V17, P2513, DOI 10.1091/mbc.E05-10-0915; Barbieri MA, 2004, EUR J CELL BIOL, V83, P305, DOI 10.1078/0171-9335-00381; Barbieri MA, 2003, J BIOL CHEM, V278, P32027, DOI 10.1074/jbc.M304324200; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Hierro A, 2004, NATURE, V431, P221, DOI 10.1038/nature02914; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Hu HL, 2005, CURR BIOL, V15, P815, DOI 10.1016/j.cub.2005.03.049; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Husnjak K, 2006, NAT CELL BIOL, V8, P787, DOI 10.1038/ncb0806-787; Kajiho H, 2003, J CELL SCI, V116, P4159, DOI 10.1242/jcs.00718; Kanazawa C, 2003, BIOCHEM BIOPH RES CO, V309, P848, DOI 10.1016/j.bbrc.2003.08.078; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kimura T, 2006, J BIOL CHEM, V281, P10598, DOI 10.1074/jbc.M510531200; Komada M, 2005, J BIOCHEM, V137, P1, DOI 10.1093/jb/mvi001; Lakadamyali M, 2006, CELL, V124, P997, DOI 10.1016/j.cell.2005.12.038; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mizuno E, 2004, J BIOCHEM, V135, P385, DOI 10.1093/jb/mvh046; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Stahl Philip D, 2002, Sci STKE, V2002, ppe32, DOI 10.1126/stke.2002.141.pe32; Stetak A, 2006, EMBO J, V25, P2347, DOI 10.1038/sj.emboj.7601137; Su X, 2006, J BIOL CHEM, V281, P27982, DOI 10.1074/jbc.M602873200; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Yamada M, 2002, MOL CELL BIOL, V22, P8648, DOI 10.1128/MCB.22.24.8648-8658.2002; Zheng B, 2004, MOL BIOL CELL, V15, p322A, DOI 10.1091/mbc.e04-06-0446	42	32	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15294	15301		10.1074/jbc.M611538200	http://dx.doi.org/10.1074/jbc.M611538200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17403676	hybrid			2022-12-27	WOS:000246589000068
J	Ramesh, A; Savva, CG; Holzenburg, A; Sacchettini, JC				Ramesh, Arati; Savva, Christos G.; Holzenburg, Andreas; Sacchettini, James C.			Crystal structure of Rsr, an ortholog of the antigenic Ro protein, links conformational flexibility to RNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5S RIBOSOMAL-RNA; DEINOCOCCUS-RADIODURANS; ELECTRON-DENSITY; A-DOMAIN; AUTOANTIGEN; SYSTEM; IRRADIATION; VALIDATION; SOFTWARE; INSIGHTS	Ro ribonucleoproteins are a class of antigenic ribonucleoproteins associated with rheumatic autoimmune diseases like systemic lupus erythematosus and Sjogrens syndrome in humans. Ro ribonucleoproteins are mostly composed of the 60-kDa Ro protein and small cytoplasmic RNAs, called Y RNAs, of unknown function. In eukaryotes, where Ro has been found to associate with damaged or mutant RNAs, it has been suggested that Ro may play a role in RNA quality control. In the radiation-resistant bacterium Deinococcus radiodurans and some eukaryotes, Ro has also been implicated in cell survival following UV damage. Here we present the first high resolution structure of a prokaryotic Ro ortholog, Rsr from D. radiodurans. The structure has been solved to 1.9 angstrom resolution and shows distinct differences when compared with the eukaryotic apo- and RNA-bound Ro structures. Rsr is composed of two domains: a helical RNA binding domain and a mixed "von Willebrand factor A-like" domain containing a divalent metal binding site. Although the individual domains of Rsr are similar to the eukaryotic Ro, significantly large differences are seen at the interface of the two domains. Since this interface communicates with the conserved central cavity of Ro, which is implicated in RNA binding, changes at this interface could potentially influence RNA binding by Ro. Although the apo- Rsr protein is monomeric, Rsr binds Y RNA to form multimers of similar to 12 molecules of a 1: 1 Rsr-Y RNA complex. Rsr binds D. radiodurans Y RNA with low nanomolar affinity, comparable with previously characterized eukaryotic Ro orthologs.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Struct Biol, College Stn, TX 77843 USA; Texas A&M Univ, Microscopy & Imaging Ctr, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	sacchett@tamu.edu		Ramesh, Arati/0000-0001-8655-0051				ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; BOIRE G, 1990, J CLIN INVEST, V85, P1182, DOI 10.1172/JCI114551; Chen XG, 2000, GENE DEV, V14, P777; Chen XG, 2004, J MOL MED, V82, P232, DOI 10.1007/s00109-004-0529-0; Chen XG, 2003, CURR BIOL, V13, P2206, DOI 10.1016/j.cub.2003.11.028; Conti E, 2006, CURR OPIN STRUC BIOL, V16, P237, DOI 10.1016/j.sbi.2006.03.010; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Cox MM, 2005, NAT REV MICROBIOL, V3, P882, DOI 10.1038/nrmicro1264; Farris AD, 1999, NUCLEIC ACIDS RES, V27, P1070, DOI 10.1093/nar/27.4.1070; Fuchs G, 2006, NAT STRUCT MOL BIOL, V13, P1002, DOI 10.1038/nsmb1156; Ioerger TR, 2003, METHOD ENZYMOL, V374, P244, DOI 10.1016/S0076-6879(03)74012-9; Jacob J, 1999, BIOPHYS J, V76, P1367, DOI 10.1016/S0006-3495(99)77298-X; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P6367, DOI 10.1073/pnas.0401506101; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Muzzolini L, 2007, PLOS BIOL, V5, P157, DOI 10.1371/journal.pbio.0050020; OBRIEN CA, 1994, GENE DEV, V8, P2891, DOI 10.1101/gad.8.23.2891; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Reddy V, 2003, ACTA CRYSTALLOGR D, V59, P2200, DOI 10.1107/S0907444903020316; Rosenhouse-Dantsker A, 2006, BIOPHYS J, V91, P2860, DOI 10.1529/biophysj.105.080242; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Shi H, 1996, RNA, V2, P769; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Stein AJ, 2005, CELL, V121, P529, DOI 10.1016/j.cell.2005.03.009; Tebbe B, 1997, LUPUS, V6, P96, DOI 10.1177/096120339700600204; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; VANHEEL M, 1989, OPTIK, V82, P114; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VONMUHLEN CA, 1995, SEMIN ARTHRITIS RHEU, V24, P323, DOI 10.1016/S0049-0172(95)80004-2; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Xue DH, 2003, P NATL ACAD SCI USA, V100, P7503, DOI 10.1073/pnas.0832411100; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	38	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14960	14967		10.1074/jbc.M611163200	http://dx.doi.org/10.1074/jbc.M611163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17392270	hybrid			2022-12-27	WOS:000246589000034
J	Sogaard, TMM; Svejstrup, JQ				Sogaard, T. Max M.; Svejstrup, Jesper Q.			Hyperphosphorylation of the C-terminal repeat domain of RNA polymerase II facilitates dissociation of its complex with mediator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING-KINASE; UBIQUITIN-PROTEIN LIGASE; SACCHAROMYCES-CEREVISIAE; FCP1 PHOSPHATASE; GENE-EXPRESSION; FISSION YEAST; LARGE SUBUNIT; IN-VITRO; TRANSCRIPTION; HOLOENZYME	The Mediator complex associates with RNA polymerase II (RNAPII) at least partly via the RNAPII C-terminal repeat domain (CTD). This association greatly stimulates the CTD kinase activity of general transcription factor TFIIH, and subsequent CTD phosphorylation is involved in triggering promoter clearance. Here, highly purified proteins and a protein dissociation assay were used to investigate whether the RNAPII.Mediator complex (holo-RNAPII) can be disrupted by CTD phosphorylation, thereby severing one of the bonds that stabilize promoter-associated initiation complexes. We report that CTD phosphorylation by the serine 5-specific TFIIH complex, or its kinase module TFIIK, is indeed sufficient to dissociate holo-RNAPII. Surprisingly, phosphorylation by the CTD serine 2-specific kinase CTDK1 also results in dissociation. Moreover, the Mediator-induced stimulation of CTD phosphorylation previously reported for TFIIH is also observed with CTDK1 kinase. An unrelated CTD-binding protein, Rsp5, is capable of stimulating this CTD kinase activity as well. These data shed new light on mechanisms that drive the RNAPII transcription cycle and suggest a mechanism for the enhancement of CTD kinase activity by the Mediator complex.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Svejstrup, JQ (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.	j.svejstrup@cancer.org.uk		Sogaard, Teit Max Moscote/0000-0001-6224-4818; Svejstrup, Jesper/0000-0003-4964-6147				Andrau JC, 2006, MOL CELL, V22, P179, DOI 10.1016/j.molcel.2006.03.023; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Borggrefe T, 2001, J BIOL CHEM, V276, P47150, DOI 10.1074/jbc.M109581200; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Davis JA, 2002, MOL CELL, V10, P409, DOI 10.1016/S1097-2765(02)00598-1; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Guidi BW, 2004, J BIOL CHEM, V279, P29114, DOI 10.1074/jbc.M404426200; Hallberg M, 2004, P NATL ACAD SCI USA, V101, P3370, DOI 10.1073/pnas.0400221101; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; Jones JC, 2004, J BIOL CHEM, V279, P24957, DOI 10.1074/jbc.M402218200; Kang JS, 2001, J BIOL CHEM, V276, P42003, DOI 10.1074/jbc.M105961200; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kong SE, 2005, J BIOL CHEM, V280, P4299, DOI 10.1074/jbc.M411071200; Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Lee KM, 2005, MOL BIOL CELL, V16, P2734, DOI 10.1091/mbc.E04-11-0982; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Liu Y, 2004, MOL CELL BIOL, V24, P1721, DOI 10.1128/MCB.24.4.1721-1735.2004; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Morris DP, 1997, METHODS, V12, P264, DOI 10.1006/meth.1997.0478; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 2002, GENE DEV, V16, P1339, DOI 10.1101/gad.987602; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; Pei Y, 2006, MOL CELL BIOL, V26, P777, DOI 10.1128/MCB.26.3.777-788.2006; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Sakurai H, 1998, J BIOL CHEM, V273, P9534, DOI 10.1074/jbc.273.16.9534; Somesh BP, 2005, CELL, V121, P913, DOI 10.1016/j.cell.2005.04.010; SOMESH BP, 2007, IN PRESS CELL; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 2004, BBA-GENE STRUCT EXPR, V1677, P64, DOI 10.1016/j.bbaexp.2003.10.012; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Takagi Y, 2006, MOL CELL, V23, P355, DOI 10.1016/j.molcel.2006.06.007; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; Zhu XF, 2006, MOL CELL, V22, P169, DOI 10.1016/j.molcel.2006.03.032	51	86	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14113	14120		10.1074/jbc.M701345200	http://dx.doi.org/10.1074/jbc.M701345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17376774	hybrid			2022-12-27	WOS:000246245800021
J	Ao, ZJ; Huang, GY; Yao, H; Xu, ZK; Labine, M; Cochrane, AW; Yao, XJ				Ao, Zhujun; Huang, Guanyou; Yao, Han; Xu, Zaikun; Labine, Meaghan; Cochrane, Alan W.; Yao, Xiaojian			Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL DNA FLAP; HIV-1 INTEGRASE; REVERSE TRANSCRIPTION; LOCALIZATION SIGNAL; NONDIVIDING CELLS; VIRION INCORPORATION; GENETIC ANALYSES; MATRIX PROTEIN; INFECTION; BETA	Similar to all other viruses, human immunodeficiency virus type 1 ( HIV-1) depends heavily on cellular factors for its successful replication. In this study we have investigated the interaction of HIV-1 integrase (IN) with several host nuclear import factors using co-immunoprecipitation assays. Our results indicate that IN interacts specifically with host importin 7 (Imp7) in vivo, but does not interact with importin 8 (Imp8) or importin alpha(Rch1). In contrast, another HIV-1 karyophilic protein MAp17, which is capable of binding Rch1, fails to interact with Imp7, suggesting that IN and Map17 may interact with different cellular pathways during HIV-1 replication. Genetic analysis revealed that the C-terminal domain of IN is the region responsible for interaction between IN with Imp7, and an IN mutant (K240A, K244A/ R263A, K264A) disrupted the Imp7 binding ability of the protein, indicating that both regions ((235)WKGPAKLLWKG and (262)RRKAK) within the C-terminal domain of IN are required for efficient IN/Imp7 interaction. Using a vesicular stomatitis virus G glycoprotein pseudotyped HIV single-cycle replication system, we showed that the IN/Imp7 interaction-deficient mutant was unable to mediate viral replication and displayed impairment at both viral reverse transcription and nuclear import steps. Moreover, transient knockdown of Imp7 in both HIV-1 producing and target cells resulted in a 2.5 - 3.5-fold inhibition of HIV infection. Altogether, our results indicate that HIV-1 IN specifically interacts with Imp7, and this viral/cellular protein interaction contributes to efficient HIV-1 infection.	Univ Manitoba, Fac Med, Dept Med Microbiol, Lab Mol Human Retrovirol, Winnipeg, MB R3E 0W3, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3G 1J4, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Manitoba; Universite de Montreal; University of Toronto	Yao, XJ (corresponding author), Univ Manitoba, Fac Med, Dept Med Microbiol, Lab Mol Human Retrovirol, Winnipeg, MB R3E 0W3, Canada.	yao2@cc.umanitoba.ca		Yao, Xiaojian/0000-0002-5022-1309				Ao Z, 2004, J VIROL, V78, P3170, DOI 10.1128/JVI.78.6.3170-3177.2004; Ao ZJ, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-62; Armon-Omer A, 2004, J MOL BIOL, V336, P1117, DOI 10.1016/j.jmb.2003.11.057; Bauerle M, 2002, J BIOL CHEM, V277, P32480, DOI 10.1074/jbc.M202765200; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; Bukrinsky M, 2004, MOL MED, V10, P1; Bukrinsky MI, 1998, MOL MED, V4, P138, DOI 10.1007/BF03401911; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Busschots K, 2005, J BIOL CHEM, V280, P17841, DOI 10.1074/jbc.M411681200; Ciuffi A, 2005, NAT MED, V11, P1287, DOI 10.1038/nm1329; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; Dean KA, 2001, J CELL SCI, V114, P3479; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Emiliani S, 2005, J BIOL CHEM, V280, P25517, DOI 10.1074/jbc.M501378200; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; Fassati A, 2003, EMBO J, V22, P3675, DOI 10.1093/emboj/cdg357; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Fridell RA, 1997, J CELL SCI, V110, P1325; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Hearps AC, 2006, BIOCHEM J, V398, P475, DOI 10.1042/BJ20060466; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Ikeda T, 2004, J VIROL, V78, P11563, DOI 10.1128/JVI.78.21.11563-11573.2004; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Lu R, 2005, J VIROL, V79, P10356, DOI 10.1128/JVI.79.16.10356-10368.2005; Lu R, 2004, J VIROL, V78, P12735, DOI 10.1128/JVI.78.23.12735-12746.2004; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Nakajima N, 2001, J VIROL, V75, P7944, DOI 10.1128/JVI.75.17.7944-7955.2001; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Petit C, 2000, J VIROL, V74, P7119, DOI 10.1128/JVI.74.15.7119-7126.2000; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; Pluymers Wim, 2001, Current Drug Targets - Infectious Disorders, V1, P133, DOI 10.2174/1568005014606044; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Sirven A, 2000, BLOOD, V96, P4103; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vandegraaff N, 2006, VIROLOGY, V346, P415, DOI 10.1016/j.virol.2005.11.022; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Vodicka Marie A., 2001, Somatic Cell and Molecular Genetics, V26, P35, DOI 10.1023/A:1021022629126; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Yao XJ, 1999, GENE THER, V6, P1590, DOI 10.1038/sj.gt.3300988; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhu K, 2004, J VIROL, V78, P5045, DOI 10.1128/JVI.78.10.5045-5055.2004; Zielske SP, 2005, J VIROL, V79, P11541, DOI 10.1128/JVI.79.17.11541-11546.2005	58	85	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13456	13467		10.1074/jbc.M610546200	http://dx.doi.org/10.1074/jbc.M610546200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360709	hybrid			2022-12-27	WOS:000246060300035
J	Gerbino, A; Fistetto, G; Colella, M; Hofer, AM; Debellis, L; Caroppo, R; Curci, S				Gerbino, Andrea; Fistetto, Gregorio; Colella, Matilde; Hofer, Aldebaran M.; Debellis, Lucantonio; Caroppo, Rosa; Curci, Silvana			Real time measurements of water flow in amphibian gastric glands - Modulation via the extracellular Ca2+-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; CHANNEL-RELATED PROTEIN; ACID-SECRETION; PARIETAL-CELLS; ALKALINE SECRETION; APICAL MEMBRANE; OXYNTIC CELLS; K+ CHANNEL; OXYNTOPEPTIC CELLS; OSMOTIC FLOW	The mechanisms for the formation of the osmotic gradient driving water movements in the gastric gland and its modulation via the extracellular Ca2+-sensing receptor (CaR) were investigated. Real time measurements of net water flux in the lumen of single gastric glands of the intact amphibian stomach were performed using ion-selective double-barreled microelectrodes. Water movement was measured by recording changes in the concentration of impermeant TEA(+) ions ([TEA(+)](gl)) with TEA(+)-sensitive microelectrodes inserted in the lumen of individual gastric glands. Glandular K+ (K-gl(+)) and H+ (pH(gl)) were also measured by using K+- and H+-sensitive microelectrodes, respectively. Stimulation with histamine significantly decreased [TEA](gl), indicating net water flow toward the gland lumen. This response was inhibited by the H+/K+- ATPase inhibitor, SCH 28080. Histamine also elicited a significant and reversible increase in [K+](gl) that was blocked by chromanol 293B, a blocker of KCQN1 K+ channels. Histamine failed to induce net water flow in the presence of chromanol 293B. In the "resting state," stimulation of CaR with diverse agonists resulted in significant increase in [TEA](gl). CaR activation also significantly reduced histamine-induced water secretion and apical K+ transport. Our data validate the strong link between histamine-stimulated acid secretion and water transport. We also show that cAMP-dependent [K+](gl) elevation prior to the onset of acid secretion generates the osmotic gradient initially driving water into the gastric glands and that CaR activation inhibits this process, probably through reduction of intracellular cAMP levels.	Vet Affairs Boston Healthcare Syst, W Roxbury, MA 02132 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, W Roxbury, MA 02132 USA; Brigham & Womens Hosp, W Roxbury, MA 02132 USA; Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Universita degli Studi di Bari Aldo Moro	Curci, S (corresponding author), Vet Affairs Boston Healthcare Syst, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.	scurci@rics.bwh.harvard.edu	Gerbino, Andrea/Y-6526-2018; Colella, Matilde/G-9246-2011	Gerbino, Andrea/0000-0002-2839-0130; Colella, Matilde/0000-0002-9584-7030; Debellis, Lucantonio/0000-0002-7571-0969; CAROPPO, Rosa/0000-0002-8773-8985				BERGLINDH T, 1980, AM J PHYSIOL, V238, P165; Bijvelds MJC, 2005, AM J PHYSIOL-GASTR L, V289, pG870, DOI 10.1152/ajpgi.00226.2005; Bleich M, 1997, PFLUG ARCH EUR J PHY, V434, P499, DOI 10.1007/s004240050427; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Brown EM, 2000, ANNU REV NUTR, V20, P507, DOI 10.1146/annurev.nutr.20.1.507; Caroppo R, 2004, J CELL BIOL, V166, P111, DOI 10.1083/jcb.200310145; Caroppo R, 2001, EMBO J, V20, P6316, DOI 10.1093/emboj/20.22.6316; Chattopadhyay N, 1996, AM J PHYSIOL-RENAL, V271, pF736, DOI 10.1152/ajprenal.1996.271.3.F736; CHEBABO SR, 1995, J PHYSIOL-LONDON, V487, P685, DOI 10.1113/jphysiol.1995.sp020910; CHEW CS, 1980, AM J PHYSIOL, V238, P312; CUPPOLETTI J, 1993, AM J PHYSIOL, V264, pC1609, DOI 10.1152/ajpcell.1993.264.6.C1609; CUPPOLETTI J, 1984, J BIOL CHEM, V259, P4952; DEBELLIS L, 1990, AM J PHYSIOL, V258, pG631, DOI 10.1152/ajpgi.1990.258.4.G631; DEBELLIS L, 1994, PFLUG ARCH EUR J PHY, V428, P655, DOI 10.1007/BF00374590; Debellis L, 2001, AM J PHYSIOL-GASTR L, V281, pG1440, DOI 10.1152/ajpgi.2001.281.6.G1440; DEBELLIS L, 1992, PFLUG ARCH EUR J PHY, V422, P253, DOI 10.1007/BF00376210; Debellis L, 1998, J PHYSIOL-LONDON, V513, P235, DOI 10.1111/j.1469-7793.1998.235by.x; Dedek K, 2001, PFLUG ARCH EUR J PHY, V442, P896, DOI 10.1007/s004240100609; DEMAREST JR, 1989, SCIENCE, V245, P402, DOI 10.1126/science.2474200; DIETZEL I, 1980, EXP BRAIN RES, V40, P432; DURBIN RP, 1979, AM J PHYSIOL, V236, pE63, DOI 10.1152/ajpendo.1979.236.1.E63; DURBIN RP, 1956, J GEN PHYSIOL, V39, P535, DOI 10.1085/jgp.39.4.535; FINKELSTEIN A, 1987, DISTINGUISHED LECTUR, V4, P1; FLEMSTROM G, 1977, AM J PHYSIOL, V233, pE1, DOI 10.1152/ajpendo.1977.233.1.E1; FLEMSTROM G, 1982, AM J PHYSIOL, V242, P183; FORTE JG, 1975, J PHYSIOL-LONDON, V244, P33, DOI 10.1113/jphysiol.1975.sp010783; Forte JG, 1996, TRENDS CELL BIOL, V6, P45, DOI 10.1016/0962-8924(96)81009-9; FORTE JG, 1980, ANNU REV PHYSIOL, V42, P111, DOI 10.1146/annurev.ph.42.030180.000551; Fujita A, 2002, J PHYSIOL-LONDON, V540, P85, DOI 10.1113/jphysiol.2001.013439; Fujiwara K, 1996, HISTOCHEM CELL BIOL, V106, P465, DOI 10.1007/s004180050065; Grahammer F, 2001, GASTROENTEROLOGY, V120, P1363, DOI 10.1053/gast.2001.24053; Hebert SC, 2004, CELL CALCIUM, V35, P239, DOI 10.1016/j.ceca.2003.10.015; HEINZ E, 1954, PHYSIOL REV, V34, P643, DOI 10.1152/physrev.1954.34.4.643; Heitzmann D, 2004, J PHYSIOL-LONDON, V561, P547, DOI 10.1113/jphysiol.2004.075168; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; Hofer AM, 2005, J CELL SCI, V118, P855, DOI 10.1242/jcs.01705; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; HOGBEN CAM, 1955, AM J PHYSIOL, V180, P641; HOLM L, 1990, J INTERN MED S, V732, P91; Lambrecht NWG, 2005, PHYSIOL GENOMICS, V21, P81, DOI 10.1152/physiolgenomics.00212.2004; LOGSDON CD, 1982, AM J PHYSIOL, V242, pG388, DOI 10.1152/ajpgi.1982.242.4.G388; MALINOWSKA DH, 1983, AM J PHYSIOL, V245, pG573, DOI 10.1152/ajpgi.1983.245.4.G573; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; MALINOWSKA DH, 2004, AM J PHYSIOL, V286, pG495; Masyuk AI, 2002, GASTROENTEROLOGY, V122, P545, DOI 10.1053/gast.2002.31035; McDaniel N, 2005, AM J PHYSIOL-GASTR L, V289, pG550, DOI 10.1152/ajpgi.00095.2005; Mizukawa Y, 2002, AM J PHYSIOL-CELL PH, V282, pC786, DOI 10.1152/ajpcell.00239.2001; MOODY FG, 1969, AM J PHYSIOL, V217, P255, DOI 10.1152/ajplegacy.1969.217.1.255; Nakahari T, 1997, EXP PHYSIOL, V82, P55, DOI 10.1113/expphysiol.1997.sp004015; NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981; NICHOLSON C, 1993, J NEUROSCI METH, V48, P199, DOI 10.1016/0165-0270(93)90092-6; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; Ochi Y, 2005, LIFE SCI, V77, P2040, DOI 10.1016/j.lfs.2005.04.006; OKADA Y, 1984, J PHYSIOL-LONDON, V354, P109, DOI 10.1113/jphysiol.1984.sp015366; ORKAND RK, 1984, NEUROSCI LETT, V45, P273, DOI 10.1016/0304-3940(84)90238-6; POWELL DW, 1964, AM J PHYSIOL, V207, P868, DOI 10.1152/ajplegacy.1964.207.4.868; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; REENSTRA WW, 1990, AM J PHYSIOL, V259, pG850, DOI 10.1152/ajpgi.1990.259.5.G850; REHM WS, 1970, J THEOR BIOL, V27, P433, DOI 10.1016/S0022-5193(70)80008-X; REHM WS, 1953, AM J PHYSIOL, V175, P473, DOI 10.1152/ajplegacy.1953.175.3.473; Richter C, 1998, BIOCHEM J, V335, P481, DOI 10.1042/bj3350481; RUIZ MC, 1993, AM J PHYSIOL, V265, pG934, DOI 10.1152/ajpgi.1993.265.5.G934; SACHS G, 1976, J BIOL CHEM, V251, P7690; Sachs G, 1997, ANNU REV PHYSIOL, V59, P243, DOI 10.1146/annurev.physiol.59.1.243; Schubert ML, 2005, CURR OPIN GASTROEN, V21, P636, DOI 10.1097/01.mog.0000181713.89281.14; STANFIELD PR, 1983, REV PHYSIOL BIOCH P, V97, P1, DOI 10.1007/BFb0035345; UEDA S, 1989, BIOCHIM BIOPHYS ACTA, V1012, P254, DOI 10.1016/0167-4889(89)90105-5; VanHouten J, 2004, J CLIN INVEST, V113, P598, DOI 10.1172/JCI200418776; VILLEGAS L, 1971, AM J PHYSIOL, V220, P1282, DOI 10.1152/ajplegacy.1971.220.5.1282; VILLEGAS L, 1982, BIOCHIM BIOPHYS ACTA, V685, P249, DOI 10.1016/0005-2736(82)90064-5; VILLEGAS L, 1974, AM J PHYSIOL, V226, P1338, DOI 10.1152/ajplegacy.1974.226.6.1338; VILLEGAS L, 1968, AM J PHYSIOL, V214, P997, DOI 10.1152/ajplegacy.1968.214.5.997; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; Wang KS, 2000, AM J PHYSIOL-GASTR L, V279, pG448, DOI 10.1152/ajpgi.2000.279.2.G448; WOLOSIN JM, 1984, AM J PHYSIOL, V246, pG537; Yao XB, 2003, ANNU REV PHYSIOL, V65, P103, DOI 10.1146/annurev.physiol.65.072302.114200; ZEUTHEN T, 1994, J PHYSIOL-LONDON, V478, P203, DOI 10.1113/jphysiol.1994.sp020243; ZHNG EB, 1996, GASTROINTESTINAL HEP, P91	82	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13477	13486		10.1074/jbc.M610585200	http://dx.doi.org/10.1074/jbc.M610585200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17363364	hybrid			2022-12-27	WOS:000246060300037
J	Granier, S; Kim, S; Shafer, AM; Ratnala, VRP; Fung, JJ; Zare, RN; Kobilka, B				Granier, Sebastien; Kim, Samuel; Shafer, Aaron M.; Ratnala, Venkata R. P.; Fung, Juan Jose; Zare, Richard N.; Kobilka, Brian			Structure and conformational changes in the C-terminal domain of the beta(2)-adrenoceptor - Insights from fluorescence resonance energy transfer studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; LIGHT-DEPENDENT CHANGES; BETA-2-ADRENERGIC RECEPTOR; PALMITOYLATION SITES; CYTOPLASMIC END; LIVING CELLS; HELIX VII; ACTIVATION; RHODOPSIN	The C terminus of the beta(2)-adrenoceptor (AR) interacts with G protein-coupled receptor kinases and arrestins in an agonist-dependent manner, suggesting that conformational changes induced by ligands in the transmembrane domains are transmitted to the C terminus. We used fluorescence resonance energy transfer (FRET) to examine ligand-induced structural changes in the distance between two positions on the beta(2)-AR C terminus and cysteine 265 (Cys-265) at the cytoplasmic end of transmembrane domain 6. The donor fluorophore FlAsH ( Fluorescein Arsenical Helix binder) was attached to a CCPGCC motif introduced at position 351-356 in the proximal C terminus or at the distal C terminus. An acceptor fluorophore, Alexa Fluor 568, was attached to Cys-265. FRET analyses revealed that the average distances between Cys-265 and the proximal and distal FlAsH sites were 57 and 62 A, respectively. These relatively large distances suggest that the C terminus is in an extended, relatively unstructured conformation. Nevertheless, we observed ligand-specific changes in FRET. All ligands induced an increase in FRET between the proximal C-terminal FlAsH site and Cys-265. Ligands that have been shown to induce arrestin-dependent ERK activation, including the catecholamine agonists and the inverse agonist ICI118551, led to a decrease in FRET between the distal FlAsH site and Cys-265, whereas other ligands had no effect or induced a small increase in FRET. Taken together the results provide new insight into the structure of the C terminus of the beta(2)-AR as well as ligand-induced conformational changes that may be relevant to arrestin-dependent regulation and signaling.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Chem, Stanford, CA 94305 USA	Stanford University; Stanford University	Kobilka, B (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Rm B157 Beckman Ctr,279 Campus Dr, Stanford, CA 94305 USA.	kobilka@stanford.edu	Kim, Samuel C/ABF-6326-2021; Granier, Sebastien/J-1089-2016; Zare, Richard N./A-8410-2009	Kim, Samuel C/0000-0001-5237-6358; Zare, Richard/0000-0001-5266-4253; Kobilka, Brian/0000-0001-5958-3990	NINDS NIH HHS [R37NS28471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028471] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Benovic Jeffrey L., 2002, Journal of Allergy and Clinical Immunology, V110, pS229, DOI 10.1067/mai.2002.129370; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; CHEN RF, 1965, SCIENCE, V150, P1593, DOI 10.1126/science.150.3703.1593; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Griffin BA, 2000, METHOD ENZYMOL, V327, P565; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; Ha TJ, 1999, P NATL ACAD SCI USA, V96, P893, DOI 10.1073/pnas.96.3.893; Hoffmann C, 2005, NAT METHODS, V2, P171, DOI 10.1038/NMETH742; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Magde D, 2002, PHOTOCHEM PHOTOBIOL, V75, P327, DOI 10.1562/0031-8655(2002)075<0327:FQYATR>2.0.CO;2; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Tompa P, 2005, TRENDS BIOCHEM SCI, V30, P484, DOI 10.1016/j.tibs.2005.07.008; Trester-Zedlitz M, 2005, BIOCHEMISTRY-US, V44, P6133, DOI 10.1021/bi0475469; Yao XJ, 2006, NAT CHEM BIOL, V2, P417, DOI 10.1038/nchembio801	31	134	141	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13895	13905		10.1074/jbc.M611904200	http://dx.doi.org/10.1074/jbc.M611904200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17347144	Green Submitted, hybrid			2022-12-27	WOS:000246060300079
J	Basler, M; Knapp, O; Masin, J; Fiser, R; Maier, E; Benz, R; Sebo, P; Osicka, R				Basler, Marek; Knapp, Oliver; Masin, Jiri; Fiser, Radovan; Maier, Elke; Benz, Roland; Sebo, Peter; Osicka, Radim			Segments crucial for membrane translocation and pore-forming activity of Bordetella adenylate cyclase toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-INVASIVE ACTIVITY; ESCHERICHIA-COLI; HEMOLYTIC ACTIVITIES; FATTY-ACYLATION; TARGET-CELLS; PERTUSSIS; CALMODULIN; IDENTIFICATION; SECRETION; PROTEIN	Bordetella adenylate cyclase toxin-hemolysin ( CyaA, AC-Hly, or ACT) permeabilizes cell membranes by forming small cation-selective ( hemolytic) pores and subverts cellular signaling by delivering into host cells an adenylate cyclase ( AC) enzyme that converts ATP to cAMP. Both AC delivery and pore formation were previously shown to involve a predicted amphipathic alpha-helix(502-522) containing a pair of negatively charged Glu(509) and Glu(516) residues. Another predicted transmembrane alpha-helix(565-591) comprises a Glu(570) and Glu(581) pair. We examined the roles of these glutamates in the activity of CyaA. Substitutions of Glu(516) increased specific hemolytic activity of CyaA by two different molecular mechanisms. Replacement of Glu(516) by positively charged lysine residue ( E516K) increased the propensity of CyaA to form pores, whereas proline ( E516P) or glutamine ( E516Q) substitutions extended the lifetime of open single pore units. All three substitutions also caused a drop of pore selectivity for cations. Substitutions of Glu(570) and Glu(581) by helix-breaking proline or positively charged lysine residue reduced ( E570K, E581P) or ablated ( E570P, E581K) AC membrane translocation. Moreover, E570P, E570K, and E581P substitutions down-modulated also the specific hemolytic activity of CyaA. In contrast, the E581K substitution enhanced the hemolytic activity of CyaA 4 times, increasing both the frequency of formation and lifetime of toxin pores. Negative charge at position 570, but not at position 581, was found to be essential for cation selectivity of the pore, suggesting a role of Glu(570) in ion filtering inside or close to pore mouth. The pairs of glutamate residues in the predicted transmembrane segments of CyaA thus appear to play a key functional role in membrane translocation and pore-forming activities of CyaA.	Acad Sci Czech Republ, Inst Microbiol, CZ-14220 Prague 4, Czech Republic; Charles Univ Prague, Fac Sci, Dept Genet & Microbiol, CZ-12844 Prague 2, Czech Republic; Univ Wurzburg, Theodor Boveri Inst, Biozentrum, Lehrstuhl Biotechnol, D-97074 Wurzburg, Germany	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Charles University Prague; University of Wurzburg	Osicka, R (corresponding author), Acad Sci Czech Republ, Inst Microbiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.	osicka@biomed.cas.cz	Osicka, Radim/H-6776-2014; Basler, Marek/A-3559-2012; Fiser, Radovan/E-4908-2012; SEBO, Peter/F-7423-2011; Masin, Jiri/H-3125-2014; SEBO, Peter/N-2043-2019	Osicka, Radim/0000-0003-2626-5456; Basler, Marek/0000-0001-5414-2088; Fiser, Radovan/0000-0003-4516-0086; SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; Masin, Jiri/0000-0001-6258-4599; Benz, Roland/0000-0002-9510-9265				BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Basar T, 1999, J BIOL CHEM, V274, P10777, DOI 10.1074/jbc.274.16.10777; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P239; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GOODWIN MS, 1990, INFECT IMMUN, V58, P3445, DOI 10.1128/IAI.58.10.3445-3447.1990; GORDON VM, 1989, J BIOL CHEM, V264, P14792; Gray M, 1998, J BIOL CHEM, V273, P18260, DOI 10.1074/jbc.273.29.18260; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; Harvill ET, 1999, INFECT IMMUN, V67, P1493, DOI 10.1128/IAI.67.3.1493-1500.1999; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; Karimova G, 1998, P NATL ACAD SCI USA, V95, P12532, DOI 10.1073/pnas.95.21.12532; KHELEF N, 1992, MICROB PATHOGENESIS, V12, P227, DOI 10.1016/0882-4010(92)90057-U; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; LADANT D, 1988, J BIOL CHEM, V263, P2612; MASURE HR, 1990, BIOCHEMISTRY-US, V29, P140, DOI 10.1021/bi00453a017; Osickova A, 1999, J BIOL CHEM, V274, P37644; OTERO AS, 1995, J BIOL CHEM, V270, P9695, DOI 10.1074/jbc.270.17.9695; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; SEBO P, 1993, MOL MICROBIOL, V9, P999, DOI 10.1111/j.1365-2958.1993.tb01229.x; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; SZABO G, 1994, J BIOL CHEM, V269, P22496; WEISS J, 1986, BIOCHEM BIOPH RES CO, V136, P463, DOI 10.1016/0006-291X(86)90463-8; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	41	58	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12419	12429		10.1074/jbc.M611226200	http://dx.doi.org/10.1074/jbc.M611226200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17347146	hybrid			2022-12-27	WOS:000245942800010
J	Pucci, B; De Felice, M; Rocco, M; Esposito, F; De Falco, M; Esposito, L; Rossi, M; Pisani, FM				Pucci, Biagio; De Felice, Mariarita; Rocco, Monia; Esposito, Francesco; De Falco, Mariarosaria; Esposito, Luca; Rossi, Mose; Pisani, Francesca M.			Modular organization of the Sulfolobus solfataricus mini-chromosome maintenance protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE ACTIVITY; MCM HELICASE; BIOCHEMICAL-ANALYSIS; ARCHAEAL MCM; COMPLEX; POLYMORPHISM	Mini-chromosome maintenance ( MCM) proteins form ring-like hexameric complexes that are commonly believed to act as the replicative DNA helicase at the eukaryotic/archaeal DNA replication fork. Because of their simplified composition with respect to the eukaryotic counterparts, the archaeal MCM complexes represent a good model system to use in analyzing the structural/functional relationships of these important replication factors. In this study the domain organization of the MCM-like protein from Sulfolobus solfataricus ( Sso MCM) has been dissected by trypsin partial proteolysis. Three truncated derivatives of Sso MCM corresponding to protease-resistant domains were produced as soluble recombinant proteins and purified: the N-terminal domain ( N-ter, residues 1-268); a fragment comprising the AAA+ and C-terminal domains ( AAA+-C-ter, residues 269-686); and the C-terminal domain ( C-ter, residues 504-686). All of the purified recombinant proteins behaved as monomers in solution as determined by analytical gel filtration chromatography, suggesting that the polypeptide chain integrity is required for stable oligomerization of Sso MCM. However, the AAA+-C-ter derivative, which includes the AAA+ motor domain and retains ATPase activity, was able to form dimers in solution when ATP was present, as analyzed by size exclusion chromatography and glycerol gradient sedimentation analyses. Interestingly, the AAA+-C-ter protein could displace oligonucleotides annealed to M13 single-stranded DNA although with a reduced efficiency in comparison with the full-sized Sso MCM. The implications of these findings for understanding the DNA helicase mechanism of the MCM complex are discussed.	CNR, Ist Biochim Prot, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Pisani, FM (corresponding author), CNR, Ist Biochim Prot, Via P Castellino 111, I-80131 Naples, Italy.	fm.pisani@ibp.cnr.it	Pisani, Francesca M./AAX-4025-2020; Pucci, Biagio/AAS-7502-2021; pucci, biagio/AAA-9268-2020	pucci, biagio/0000-0003-4502-1748				Barry ER, 2007, NUCLEIC ACIDS RES, V35, P988, DOI 10.1093/nar/gkl1117; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; Chen YJ, 2005, J MOL BIOL, V346, P389, DOI 10.1016/j.jmb.2004.11.076; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Costa A, 2006, NUCLEIC ACIDS RES, V34, P5829, DOI 10.1093/nar/gkl708; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; ERZBERGER JP, 2006, ANNU REV BIOPH BIOM, V85, P91; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; GABROWSKI B, 2003, ANNU REV MICROBIOL, V57, P487; Gomez-Llorente Y, 2005, J BIOL CHEM, V280, P40909, DOI 10.1074/jbc.M509760200; Grainge I, 2003, NUCLEIC ACIDS RES, V31, P4888, DOI 10.1093/nar/gkg662; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kasiviswanathan R, 2004, J BIOL CHEM, V279, P28358, DOI 10.1074/jbc.M403202200; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McGeoch AT, 2005, NAT STRUCT MOL BIOL, V12, P756, DOI 10.1038/nsmb974; Moyer SE, 2006, P NATL ACAD SCI USA, V103, P10236, DOI 10.1073/pnas.0602400103; Pape T, 2003, EMBO REP, V4, P1079, DOI 10.1038/sj.embor.7400010; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pucci B, 2004, J BIOL CHEM, V279, P49222, DOI 10.1074/jbc.M408967200; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; You ZY, 1999, MOL CELL BIOL, V19, P8003; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	31	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12574	12582		10.1074/jbc.M610953200	http://dx.doi.org/10.1074/jbc.M610953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337732	hybrid			2022-12-27	WOS:000245942800026
J	Wang, Y; Zhan, QM				Wang, Yang; Zhan, Qimin			Cell cycle-dependent expression of centrosomal ninein-like protein in human cells is regulated by the anaphase-promoting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE ASSEMBLY CHECKPOINT; MEDIATED DEGRADATION; AURORA-B; INSTABILITY; CDC20; PLK1; DESTRUCTION; NLP; COMPLEX/CYCLOSOME; DUPLICATION	The recently identified centrosome protein Nlp (ninein-like protein) is a key regulator in centrosome maturation, which contributes to chromosome segregation and cytokinesis. However, the mechanism(s) controlling Nlp expression remains largely unknown. Here we have shown that Nlp expression is cell cycle-dependent with a peak at G(2)/M transition in human cells. Nlp is a short-lived protein and degraded by the proteasome via the anaphase-promoting cyclosome complex (APC/c) pathway. It interacts with the APC/c through the APC2 or Cdc27 subunits and is ubiquitinated. Following treatment with proteasome inhibitors, its protein level is elevated. Nlp binds in vivo to the degradation-targeting proteins Cdh1 and Cdc20, and overexpression of Cdh1 and Cdc20 enhances Nlp degradation. Using point mutations of the two putative degradation signals in Nlp, we have found that its degradation requires intact KEN-box and D-box. Interestingly, the Lys-Glu-Asn-D-box-mutated Nlp exhibits a much stronger capability of inducing anchorage-independent growth and multinuclearity compared with the wild type Nlp. Taken together, these findings indicate that Nlp expression is cell cycle-dependent and regulated by APC-mediated protein degradation.	Chinese Acad Med Sci, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhan, QM (corresponding author), Chinese Acad Med Sci, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.	Zhanqimin@pumc.edu.cn	Wang, Yang/A-1849-2010	Wang, Yang/0000-0001-9385-7393				Casenghi M, 2005, J CELL SCI, V118, P5101, DOI 10.1242/jcs.02622; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; de Gramont A, 2006, CELL CYCLE, V5, P2168, DOI 10.4161/cc.5.18.3219; Deng CX, 2001, MUTAT RES-FUND MOL M, V477, P183, DOI 10.1016/S0027-5107(01)00119-1; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Eytan E, 2006, P NATL ACAD SCI USA, V103, P2081, DOI 10.1073/pnas.0510695103; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fry AM, 2006, CELL CYCLE, V5, P1487, DOI 10.4161/cc.5.14.3003; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Goto H, 2006, NAT CELL BIOL, V8, P180, DOI 10.1038/ncb1350; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Li JJ, 2006, PHARMACOL THERAPEUT, V111, P974, DOI 10.1016/j.pharmthera.2006.02.006; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Maki CG, 1996, CANCER RES, V56, P2649; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pfleger CM, 2000, GENE DEV, V14, P655; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; Salisbury JL, 2001, J MAMMARY GLAND BIOL, V6, P203, DOI 10.1023/A:1011312808421; Shao SJ, 2006, J BIOL CHEM, V281, P28943, DOI 10.1074/jbc.M600235200; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Stewart S, 2005, CANCER RES, V65, P8730, DOI 10.1158/0008-5472.CAN-05-1500; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	31	29	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17712	17719		10.1074/jbc.M701350200	http://dx.doi.org/10.1074/jbc.M701350200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17403670	hybrid			2022-12-27	WOS:000247084500044
J	Moretti, R; Thorson, JS				Moretti, Rocco; Thorson, Jon S.			Enhancing the latent nucleotide triphosphate flexibility of the glucose-1-phosphate thymidylyltransferase RmlA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE GLUCOSE PYROPHOSPHORYLASE; GDP-MANNOSE PYROPHOSPHORYLASE; BIOSYNTHETIC GENE-CLUSTER; IN-VITRO CHARACTERIZATION; CHEMOENZYMATIC SYNTHESIS; SUBSTRATE-SPECIFICITY; SUGAR NUCLEOTIDES; CATALYTIC PROMISCUITY; NATURAL-PRODUCTS; PURIFICATION	Nucleotidyltransferases are central to nearly all glycosylation-dependent processes and have been used extensively for the chemoenzymatic synthesis of sugar nucleotides. The determination of the NTP specificity of the model thymidylyltransferase RmlA revealed RmlA to utilize all eight naturally occurring NTPs with varying levels of catalytic efficiency, even in the presence of nonnative sugar-1-phosphates. Guided by structural models, active site engineering of RmlA led to alterations of the inherent pyrimidine/purine bias by up to three orders of magnitude. This study sets the stage for engineering single universal nucleotidyltransferases and also provides new catalysts for the synthesis of novel nucleotide diphosphosugars.	Univ Wisconsin, Sch Pharm, Pharmaceut Sci Div, Lab Biosynthet Chem, Madison, WI 53705 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Sch Pharm, Natl Cooperat Drug Discovery Grp, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Thorson, JS (corresponding author), Univ Wisconsin, Sch Pharm, Pharmaceut Sci Div, Lab Biosynthet Chem, 777 Highland Ave, Madison, WI 53705 USA.	jsthorson@pharmacy.wisc.edu	Thorson, Jon S/L-3696-2013	Thorson, Jon S/0000-0002-7148-0721	NCI NIH HHS [CA84374] Funding Source: Medline; NIAID NIH HHS [AI552218] Funding Source: Medline; NIGMS NIH HHS [GM07215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084374] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Albermann C, 2003, ORG LETT, V5, P933, DOI 10.1021/ol0341086; ALBRECHT GJ, 1966, J BIOL CHEM, V241, P2868; Amann S, 2001, CARBOHYD RES, V335, P23, DOI 10.1016/S0008-6215(01)00195-1; Aparicio JF, 2003, APPL MICROBIOL BIOT, V61, P179, DOI 10.1007/s00253-002-1183-5; Bae J, 2005, CHEMBIOCHEM, V6, P1963, DOI 10.1002/cbic.200500183; Barton WA, 2002, P NATL ACAD SCI USA, V99, P13397, DOI 10.1073/pnas.192468299; Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; Benson DA, 2006, NUCLEIC ACIDS RES, V34, pD16, DOI 10.1093/nar/gkj157; Borisova SA, 2006, ANGEW CHEM INT EDIT, V45, P2748, DOI 10.1002/anie.200503195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton C, 2006, GLYCOBIOLOGY, V16, p29R, DOI 10.1093/glycob/cwj016; CABIB E, 1965, J BIOL CHEM, V240, P2114; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Du LC, 2000, CHEM BIOL, V7, P623, DOI 10.1016/S1074-5521(00)00011-9; Elhalabi JM, 1999, CURR MED CHEM, V6, P93; Elling L, 1996, PHYTOCHEMISTRY, V42, P955, DOI 10.1016/0031-9422(96)00089-1; Fu X, 2005, ORG LETT, V7, P1513, DOI 10.1021/ol0501626; Fu X, 2003, NAT BIOTECHNOL, V21, P1467, DOI 10.1038/nbt909; Galm U, 2005, CHEM REV, V105, P739, DOI 10.1021/cr030117g; Griffith BR, 2005, CURR OPIN BIOTECH, V16, P622, DOI 10.1016/j.copbio.2005.10.002; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jiang JQ, 2003, CHEMBIOCHEM, V4, P443, DOI 10.1002/cbic.200200566; Jiang JQ, 2001, ANGEW CHEM INT EDIT, V40, P1502, DOI 10.1002/1521-3773(20010417)40:8<1502::AID-ANIE1502>3.0.CO;2-K; Jiang JQ, 2000, J AM CHEM SOC, V122, P6803, DOI 10.1021/ja001444y; KIMATA K, 1966, J BIOL CHEM, V241, P1099; KNOP JK, 1970, J BIOL CHEM, V245, P2499; Ko KS, 2005, J ORG CHEM, V70, P1919, DOI 10.1021/jo048424p; Kotake T, 2004, J BIOL CHEM, V279, P45728, DOI 10.1074/jbc.M408716200; Lairson LL, 2004, CHEM COMMUN, P2243, DOI 10.1039/b406490a; Lake MW, 2000, J BIOL CHEM, V275, P40211, DOI 10.1074/jbc.M007406200; LINDQUIST L, 1993, EUR J BIOCHEM, V211, P763, DOI 10.1111/j.1432-1033.1993.tb17607.x; Liu W, 2005, CHEM BIOL, V12, P293, DOI 10.1016/j.chembiol.2004.12.013; Mizanur RM, 2004, J AM CHEM SOC, V126, P15993, DOI 10.1021/ja046070d; Morrison J F, 1979, Methods Enzymol, V63, P257; Nedal A, 2004, APPL MICROBIOL BIOT, V64, P7, DOI 10.1007/s00253-003-1535-9; Ning BT, 2000, EUR J BIOCHEM, V267, P6866, DOI 10.1046/j.1432-1033.2000.01781.x; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PREISS J, 1964, J BIOL CHEM, V239, P3119; Rupprath C, 2005, CURR MED CHEM, V12, P1637, DOI 10.2174/0929867054367167; Sambrook J., 1989, MOL CLONING LAB MANU; Schwarz G, 2005, CELL MOL LIFE SCI, V62, P2792, DOI 10.1007/s00018-005-5269-y; SHEN L, 1965, J BIOL CHEM, V240, P2334; SMOOT JW, 1985, EUR J BIOCHEM, V148, P83, DOI 10.1111/j.1432-1033.1985.tb08810.x; Watt GM, 2000, TETRAHEDRON-ASYMMETR, V11, P621, DOI 10.1016/S0957-4166(99)00556-X; WeymouthWilson AC, 1997, NAT PROD REP, V14, P99, DOI 10.1039/np9971400099; WONG CH, 1995, PURE APPL CHEM, V67, P1609, DOI 10.1351/pac199567101609; Yang M, 2005, J AM CHEM SOC, V127, P9336, DOI 10.1021/ja051482n; Yang M, 2005, CHEMBIOCHEM, V6, P346, DOI 10.1002/cbic.200400100; Yoshikuni Y, 2006, NATURE, V440, P1078, DOI 10.1038/nature04607; Zea CJ, 2004, ANAL BIOCHEM, V328, P196, DOI 10.1016/j.ab.2004.01.019; Zhang CS, 2006, J AM CHEM SOC, V128, P16420, DOI 10.1021/ja065950k; Zhang CS, 2007, CHEMBIOCHEM, V8, P385, DOI 10.1002/cbic.200600509; Zhang CS, 2006, SCIENCE, V313, P1291, DOI 10.1126/science.1130028; Zhang ZL, 2005, J BIOL CHEM, V280, P9698, DOI 10.1074/jbc.M411211200	58	38	38	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16942	16947		10.1074/jbc.M701951200	http://dx.doi.org/10.1074/jbc.M701951200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17434871	hybrid			2022-12-27	WOS:000246946500027
J	Rao, R; Redha, R; Macias-Perez, I; Su, Y; Hao, CM; Zent, R; Breyer, MD; Pozzi, A				Rao, Reena; Redha, Reyadh; Macias-Perez, Ines; Su, Yan; Hao, Chuanming; Zent, Roy; Breyer, Matthew D.; Pozzi, Ambra			Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; GROWTH-FACTOR; PROSTANOID RECEPTORS; TUMOR ANGIOGENESIS; EPITHELIAL-CELLS; P42/44 MAPK; EXPRESSION; EP4; CYCLOOXYGENASE-2; PHOSPHORYLATION	Prostaglandin E2 (PGE(2)), a major product of cyclooxygenase, exerts its functions by binding to four G protein-coupled receptors (EP1-4) and has been implicated in modulating angiogenesis. The present study examined the role of the EP4 receptor in regulating endothelial cell proliferation, migration, and tubulogenesis. Primary pulmonary microvascular endothelial cells were isolated from EP4(flox/flox) mice and were rendered null for the EP4 receptor with adenoCre virus. Whereas treatment with PGE(2) or the EP4 selective agonists PGE(1)-OH and ONO-AE1-329 induced migration, tubulogenesis, ERK activation and cAMP production in control adenovirus-transduced endothelial EP4(flox/flox) cells, no effects were seen in adenoCre-transduced EP4(flox/flox) cells. The EP4 agonist-induced endothelial cell migration was inhibited by ERK, but not PKA inhibitors, defining a functional link between PGE(2)-induced endothelial cell migration and EP4-mediated ERK signaling. Finally, PGE2, as well as PGE1-OH and ONO-AE1 -329, also promoted angiogenesis in an in vivo sponge assay providing evidence that the EP4 receptor mediates de novo vascularization in vivo.	Vanderbilt Univ, Dept Med, Div Nephrol, Med Ctr N, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vet Affairs Hosp, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Pozzi, A (corresponding author), Vanderbilt Univ, Dept Med, Div Nephrol, Med Ctr N, B3109, Nashville, TN 37232 USA.	pozzi@vanderbilt.edu		Breyer, Matthew/0000-0003-1880-371X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074116, R01DK069921, R01DK074359] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK74116, R01-DK074359, R01-DK 69921] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408; Aoudjit L, 2006, AM J PHYSIOL-RENAL, V290, pF1534, DOI 10.1152/ajprenal.00267.2005; Axelsson Hans, 2005, Angiogenesis, V8, P339; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Calipel A, 2006, J BIOL CHEM, V281, P9238, DOI 10.1074/jbc.M600228200; Chen KH, 2003, CURR EYE RES, V26, P363, DOI 10.1076/ceyr.26.5.363.15442; Ehses JA, 2002, J BIOL CHEM, V277, P37088, DOI 10.1074/jbc.M205055200; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x; Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Hunger-Glaser I, 2003, J BIOL CHEM, V278, P22631, DOI 10.1074/jbc.M210876200; Inoue H, 2002, BRIT J PHARMACOL, V136, P287, DOI 10.1038/sj.bjp.0704705; Kamiyama M, 2006, ONCOGENE, V25, P7019, DOI 10.1038/sj.onc.1209694; Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com; Li RC, 2004, CIRC RES, V94, P759, DOI 10.1161/01.RES.0000121568.40692.97; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mendez M, 2005, AM J PHYSIOL-HEART C, V288, pH2111, DOI 10.1152/ajpheart.00838.2004; Muller M, 2006, ENDOCRINOLOGY, V147, P3356, DOI 10.1210/en.2005-1429; Namkoong S, 2005, EXP MOL MED, V37, P588, DOI 10.1038/emm.2005.72; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Pavlovic S, 2006, J BIOL CHEM, V281, P3321, DOI 10.1074/jbc.M506846200; Pearce HR, 2003, J GASTROEN HEPATOL, V18, P1180, DOI 10.1046/j.1440-1746.2003.03152.x; Pozzi A, 2005, J BIOL CHEM, V280, P27138, DOI 10.1074/jbc.M501730200; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Qian JY, 2006, AM J PHYSIOL-HEART C, V290, pH1740, DOI 10.1152/ajpheart.00904.2005; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Rosch S, 2005, BIOCHEM BIOPH RES CO, V338, P1171, DOI 10.1016/j.bbrc.2005.10.051; Schneider A, 2004, GENESIS, V40, P7, DOI 10.1002/gene.20048; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Sun HS, 2003, ENDOCRINOLOGY, V144, P3934, DOI 10.1210/en.2003-0289; Sung YM, 2005, CANCER RES, V65, P9304, DOI 10.1158/0008-5472.CAN-05-1015; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yang L, 2006, CANCER RES, V66, P9665, DOI 10.1158/0008-5472.CAN-06-1271	41	111	119	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16959	16968		10.1074/jbc.M701214200	http://dx.doi.org/10.1074/jbc.M701214200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17401137	hybrid			2022-12-27	WOS:000246946500029
J	Shiokawa, D; Matsushita, T; Shika, Y; Shimizu, M; Maeda, M; Tanuma, SI				Shiokawa, Daisuke; Matsushita, Tokiyoshi; Shika, Yukari; Shimizu, Mamoru; Maeda, Masahiro; Tanuma, Sei-ichi			DNase X is a glycosylphosphatidylinositol-anchored membrane enzyme that provides a barrier to endocytosis-mediated transfer of a foreign gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HELICAL PEPTIDES; LIPID RAFTS; DEPENDENT ENDOCYTOSIS; MAMMALIAN-CELLS; PLASMID DNA; HUMAN XQ28; NAKED DNA; PROTEINS; EXPRESSION; ENDOSOMES	DNase X is the first mammalian DNase to be isolated that is homologous to DNase I. In this study, we have examined its function using a novel monoclonal antibody and showed it to be expressed on the cell surface as a glycosylphosphatidylinositol-anchored membrane protein. High level expression was observed in human muscular tissues and in myotubes obtained in vitro from RD rhabdomyosarcoma cells. We observed that RD myotubes incorporated a foreign gene, lacZ, by endocytosis but that expression of the encoded coding product, beta-galactosidase, was strongly inhibited. Overexpression of DNase X inhibited endocytosis-mediated gene transfer, whereas knockdown of DNase X with small interfering RNA had the opposite effect. These results reveal that DNase X provides a cell surface barrier to endocytosis-mediated gene transfer.	Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Biochem, Noda, Chiba 2788510, Japan; Immunobiol Labs Co Ltd, Res & Dev Dept, Fujioka, Gunma 3750005, Japan; Tokyo Univ Sci, Genome & Drug Res Ctr, Noda, Chiba 2788510, Japan	Tokyo University of Science; Immuno-Biological Laboratories Co. Ltd.; Tokyo University of Science	Tanuma, SI (corresponding author), Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Biochem, 2641 Yamazaki, Noda, Chiba 2788510, Japan.	tanuma@rs.noda.tus.ac.jp						Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Balicki D, 2002, P NATL ACAD SCI USA, V99, P7467, DOI 10.1073/pnas.102168299; CAMPBELL VW, 1980, J BIOL CHEM, V255, P3726; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; Coy JF, 1996, CELL DEATH DIFFER, V3, P199; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Herweijer H, 2003, GENE THER, V10, P453, DOI 10.1038/sj.gt.3301983; Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; KINEBUCHI M, 1991, J IMMUNOL, V146, P3721; Liu F, 2001, Mol Interv, V1, P168; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MOORE S, 1981, ENZYMES A, V14, P281; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Niidome T, 1997, J BIOL CHEM, V272, P15307, DOI 10.1074/jbc.272.24.15307; Ohmori N, 1998, BIOCHEM BIOPH RES CO, V245, P259, DOI 10.1006/bbrc.1998.8408; PARRISH JE, 1995, HUM MOL GENET, V4, P1557, DOI 10.1093/hmg/4.9.1557; Pergolizzi R, 1996, GENE, V168, P267, DOI 10.1016/0378-1119(95)00741-5; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; PRICE PA, 1975, J BIOL CHEM, V250, P1981; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Sandgren S, 2004, J BIOL CHEM, V279, P17951, DOI 10.1074/jbc.M311440200; Sawamura D, 2002, CLIN EXP DERMATOL, V27, P480, DOI 10.1046/j.1365-2230.2002.01101.x; Shiokawa D, 2005, BIOCHEM J, V392, P511, DOI 10.1042/BJ20051114; Shiokawa D, 2001, BIOCHEMISTRY-US, V40, P143, DOI 10.1021/bi001041a; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	32	24	25	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17132	17140		10.1074/jbc.M610428200	http://dx.doi.org/10.1074/jbc.M610428200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17416904	hybrid			2022-12-27	WOS:000246946500046
J	Jain, AK; Jaiswal, AK				Jain, Abhinav K.; Jaiswal, Anil K.			GSK-3 beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDOREDUCTASE-1 GENE-EXPRESSION; ELEMENT-MEDIATED EXPRESSION; CUL3-BASED E3 LIGASE; TRANSCRIPTION FACTOR; ANTIOXIDANT INDUCTION; NRF2; PHOSPHORYLATION; ACTIVATION; PROTEIN; KEAP1	NF-E2-related factor 2 (Nrf2) regulates expression and coordinated induction of a battery of chemoprotective genes in response to oxidative and electrophilic stress. This leads to protection against oxidative stress and neoplastic diseases. Nuclear import and export of Nrf2 play a significant role in control of nuclear levels of Nrf2 and thus the expression of Nrf2 downstream genes. Tyrosine kinase Fyn phosphorylates tyrosine 568 of Nrf2 that leads to the nuclear export of Nrf2. In this study, we investigated the upstream factor(s) in regulation of Fyn and Fyn-mediated nuclear export of Nrf2. The investigations shed light on a novel mechanism of Nrf2 regulation in response to oxidative stress. We demonstrate that GSK-3 beta acts upstream of Fyn kinase in control of nuclear export of Nrf2. Chemical and short interfering RNA-mediated inhibition of GSK-3 beta led to nuclear accumulation of Nrf2 and transcriptional activation of the Nrf2 downstream gene nqo1. Chemical and short interfering RNA inhibition of GSK-3 beta and Fyn individually and in combination revealed that both kinases follow the same pathway to regulate nuclear export of Nrf2. We further demonstrate that hydrogen peroxide phosphorylates tyrosine 216 of GSK-3 beta. This leads to activation of GSK-3 beta. The activated GSK-3 beta phosphorylates Fyn at threonine residue( s). Phosphorylated Fyn accumulates in the nucleus and phosphorylates Nrf2 at tyrosine 568. This leads to nuclear export, ubiquitination, and degradation of Nrf2.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	ajaiswal@bcm.tmc.edu	Jain, Abhinav K/A-2540-2013	Jain, Abhinav/0000-0003-3268-514X	NIEHS NIH HHS [R01 ES012265] Funding Source: Medline; NIGMS NIH HHS [R01 GM47466] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jain AK, 2006, J BIOL CHEM, V281, P12132, DOI 10.1074/jbc.M511198200; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Kannan S, 2006, CANCER RES, V66, P8421, DOI 10.1158/0008-5472.CAN-06-1181; Karapetian RN, 2005, MOL CELL BIOL, V25, P1089, DOI 10.1128/MCB.25.3.1089-1099.2005; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Strachan GD, 2005, BIOCHEM BIOPH RES CO, V336, P490, DOI 10.1016/j.bbrc.2005.08.127; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248	22	351	370	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16502	16510		10.1074/jbc.M611336200	http://dx.doi.org/10.1074/jbc.M611336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403689	hybrid			2022-12-27	WOS:000246794300057
J	Xu, Y; Fang, F; Dhar, SK; St Clair, WH; Kasarskis, EJ; St Clair, DK				Xu, Yong; Fang, Fang; Dhar, Sanjit K.; St Clair, William H.; Kasarskis, Edward J.; St Clair, Daret K.			The role of a single-stranded nucleotide loop in transcriptional regulation of the human sod2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SYNERGISTIC ACTIVATION; TRANSGENIC MICE; CANCER-CELLS; FACTOR-ALPHA; DNA; NUCLEOPHOSMIN; MECHANISM	Manganese superoxide dismutase (MnSOD), a mitochondrial antioxidant enzyme, is necessary for survival of aerobic life. Previously, we demonstrated that a Sp1-based promoter is essential for constitutive transcription and a NF-kappa B-based intronic enhancer is responsible for cytokine-mediated induction. Here we show that nucleophosmin (NPM), a RNA-binding protein, binds to an 11G single-stranded loop in the promoter region and serves to integrate the Sp1 and NF-kappa B responses. Disruption of the loop structure causes a reduction of both constitutive and inductive transcription due to loss of the binding motif for NPM. Interaction of NF-kappa B.NPM.Sp1 facilitated by binding of NPM to the loop structure in the promoter region appears to comprise the basic complex for the transcriptional stimulation. These results suggest a novel molecular mechanism for communication between the enhancer and the GC-rich promoter.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.	dstc100@uky.edu			NATIONAL CANCER INSTITUTE [R01CA073599, R01CA049797, R29CA049797] Funding Source: NIH RePORTER; NCI NIH HHS [CA 73599, R01 CA073599-09A1, R01 CA049797-17, R01 CA073599, R01 CA049797, CA 49797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ameres SL, 2005, EMBO J, V24, P358, DOI 10.1038/sj.emboj.7600531; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Bertolino E, 2002, MOL CELL, V10, P397, DOI 10.1016/S1097-2765(02)00597-X; Boeger H, 2005, FEBS LETT, V579, P899, DOI 10.1016/j.febslet.2004.11.027; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Granger SW, 1998, J VIROL, V72, P8961, DOI 10.1128/JVI.72.11.8961-8970.1998; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; IKEDA K, 1993, GENE, V136, P341; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Josson S, 2006, ONCOGENE, V25, P1554, DOI 10.1038/sj.onc.1209186; Keller JN, 1998, J NEUROSCI, V18, P687; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Kiningham KK, 2001, BIOCHEM J, V353, P147, DOI 10.1042/bj3530147; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; MARLHENS F, 1985, BIOCHEM BIOPH RES CO, V129, P300, DOI 10.1016/0006-291X(85)91437-8; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; OBERLEY LW, 1979, CANCER RES, V39, P1141; Oberley LW, 1986, FREE RADICALS AGING, P325; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Porntadavity S, 2001, DNA CELL BIOL, V20, P473, DOI 10.1089/104454901316976109; Rahman I, 2002, BIOCHEM PHARMACOL, V64, P935, DOI 10.1016/S0006-2952(02)01153-X; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; St Clair D, 2005, BIOMED PHARMACOTHER, V59, P209, DOI 10.1016/j.biopha.2005.03.004; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Swaminathan V, 2005, MOL CELL BIOL, V25, P7534, DOI 10.1128/MCB.25.17.7534-7545.2005; Tamada H, 2006, MOL CELL BIOL, V26, P1259, DOI 10.1128/MCB.26.4.1259-1271.2006; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WANG DR, 1994, J BIOL CHEM, V269, P30994; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Xu Y, 2002, BIOCHEM J, V362, P401, DOI 10.1042/0264-6021:3620401; Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265; Yeh CC, 1998, DNA CELL BIOL, V17, P921, DOI 10.1089/dna.1998.17.921; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909	56	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15981	15994		10.1074/jbc.M608979200	http://dx.doi.org/10.1074/jbc.M608979200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426024	Green Accepted, hybrid			2022-12-27	WOS:000246794300007
J	Don, AS; Martinez-Lamenca, C; Webb, WR; Proia, RL; Roberts, E; Rosen, H				Don, Anthony S.; Martinez-Lamenca, Carolina; Webb, William R.; Proia, Richard L.; Roberts, Ed; Rosen, Hugh			Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOMODULATORY DRUG FTY720; 1-PHOSPHATE RECEPTOR AGONIST; MRL-LPR/LPR-MICE; ENDOPLASMIC-RETICULUM; KINASE TYPE-2; IN-VIVO; SACCHAROMYCES-CEREVISIAE; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE EGRESS; TUMOR-GROWTH	The clinical immunosuppressant FTY720 is a sphingosine analogue that, once phosphorylated by sphingosine kinase 2(Sphk2), is an agonist of multiple receptor subtypes for sphingosine 1-phosphate. Short exposures to FTY720 afford long term protection in lymphoproliferative and autoimmune disease models, presumably by inducing apoptosis in subsets of cells essential for pathogenesis. Sphingosine itself is pro-apoptotic, and apoptosis induced with FTY720 or sphingosine is thought to proceed independently of their phosphorylation. Following chemical mutagenesis of Jurkat cells we isolated mutants that are selectively resistant to FTY720 analogue AAL(R), as well as natural sphingolipid bases, including sphingosine. Cells lacking functional Sphk2 were resistant to apoptosis induced with AAL(R), indicating that apoptosis proceeds through AAL(R) phosphorylation. Phosphorylation of AAL(R) was also required for induction of lymphocyte apoptosis in mice, as apoptosis was not induced with the non-phosphorylatable chiral analogue, AAL(S). Apoptosis was induced in the spleen but not the thymus of mice administered 1 mg/ kg AAL(R), correlating with levels of AAL(R)-phosphate (AFD(R)) in organ extracts. AFD(R) did not induce apoptosis when added to the cell culture medium, indicating that it induces apoptosis through an intracellular target. NBD-labeled AAL(R) localized to the endoplasmic reticulum, and AAL(R) treatment resulted in elevated cytosolic calcium, Bax redistribution from cytosol to mitochondrial and endoplasmic reticulum membranes, and caspase-independent mitochondrial permeabilization in Jurkat cells. We therefore describe an apoptotic pathway triggered by intracellular accumulation of sphingolipid base phosphates and suggest that sphingoid base substrates for Sphk2 acting intracellularly could be useful in the treatment of lymphoproliferative diseases.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; NIDDK, NIH, Bethesda, MD 20892 USA	Scripps Research Institute; Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rosen, H (corresponding author), ICND118,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hrosen@scripps.edu	Don, Anthony Simon/AAE-9687-2021; Proia, Richard L/A-7908-2012	Don, Anthony Simon/0000-0003-1655-1184; Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056017, ZIADK056017] Funding Source: NIH RePORTER; NIAID NIH HHS [AI055509] Funding Source: Medline; PHS HHS [NIMH-074404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Azuma H, 2002, CANCER RES, V62, P1410; Bandhuvula P, 2005, J BIOL CHEM, V280, P33697, DOI 10.1074/jbc.C500294200; Billich A, 2004, ANAL BIOCHEM, V326, P114, DOI 10.1016/j.ab.2003.11.018; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2001, TRANSPLANT P, V33, P3078, DOI 10.1016/S0041-1345(01)02312-0; Chiba K, 1999, TRANSPLANT P, V31, P1230, DOI 10.1016/S0041-1345(98)01975-7; Chiba K, 2005, TRANSPL P, V37, P102, DOI 10.1016/j.transproceed.2004.12.286; Chiba K, 2005, PHARMACOL THERAPEUT, V108, P308, DOI 10.1016/j.pharmthera.2005.05.002; Chua CW, 2005, INT J CANCER, V117, P1039, DOI 10.1002/ijc.21243; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Cvijic ME, 2003, J IMMUNOL METHODS, V278, P293, DOI 10.1016/S0022-1759(03)00191-1; Ettmayer P, 2006, BIOORG MED CHEM LETT, V16, P84, DOI 10.1016/j.bmcl.2005.09.038; Hamaguchi A, 2003, J BIOL CHEM, V278, P41557, DOI 10.1074/jbc.M305294200; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; Heringdorf DMZ, 2004, J CELL BIOCHEM, V92, P937, DOI 10.1002/jcb.20107; Ho JWY, 2005, MOL CANCER THER, V4, P1430, DOI 10.1158/1535-7163.MCT-05-0021; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Lee WJ, 2004, EXP MOL MED, V36, P420, DOI 10.1038/emm.2004.54; Lepine S, 2004, J IMMUNOL, V173, P3783, DOI 10.4049/jimmunol.173.6.3783; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Matsuoka Y, 2003, BRIT J PHARMACOL, V138, P1303, DOI 10.1038/sj.bjp.0705182; Megidish T, 1999, BIOCHEMISTRY-US, V38, P3369, DOI 10.1021/bi982548c; Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005; Nagahara Y, 2000, IMMUNOPHARMACOLOGY, V48, P75, DOI 10.1016/S0162-3109(00)00181-8; Nagahara Y, 2000, J IMMUNOL, V165, P3250, DOI 10.4049/jimmunol.165.6.3250; Nagahara Y, 2002, BRIT J PHARMACOL, V137, P953, DOI 10.1038/sj.bjp.0704970; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Okazaki H, 2002, J RHEUMATOL, V29, P707; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Pernmpongkosol S, 2002, INT J CANCER, V98, P167, DOI 10.1002/ijc.10178; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101; Suzuki S, 1997, CLIN EXP IMMUNOL, V107, P103, DOI 10.1046/j.1365-2249.1997.d01-885.x; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; van Meer G, 2002, J BIOL CHEM, V277, P25855, DOI 10.1074/jbc.R200010200; Welsch CA, 2004, J BIOL CHEM, V279, P36720, DOI 10.1074/jbc.M406179200; Yasui H, 2005, CANCER RES, V65, P7478, DOI 10.1158/0008-5472.CAN-05-0850; Zemann B, 2006, BLOOD, V107, P1454, DOI 10.1182/blood-2005-07-2628; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6	50	65	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15833	15842		10.1074/jbc.M609124200	http://dx.doi.org/10.1074/jbc.M609124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400555	hybrid			2022-12-27	WOS:000246589600058
J	Edwards, MR; Haas, J; Panettieri, RA; Johnson, M; Johnston, SL				Edwards, Michael R.; Haas, Jennifer; Panettieri, Rey A., Jr.; Johnson, Malcolm; Johnston, Sebastian L.			Corticosteroids and beta(2) Agonists differentially regulate rhinovirus-induced interleukin-6 via distinct cis-acting elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; SMOOTH-MUSCLE-CELLS; AIRWAY EPITHELIAL-CELLS; HISTONE ACETYLTRANSFERASE ACTIVITY; RESPONSE ELEMENT; BINDING PROTEIN; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; ASTHMA EXACERBATIONS	Interleukin-6 (IL-6) is a proinflammatory cytokine up-regulated by rhinovirus infection during acute exacerbations of asthma and chronic obstructive pulmonary disease. The role of IL-6 during exacerbations is unclear; however, it is believed IL-6 could contribute to airway and systemic inflammation. In this study we investigate the effects of common asthma treatments fluticasone propionate and beta(2) agonists salmeterol and salbutamol on IL-6 production in BEAS-2B and primary bronchial epithelial cells. Salmeterol and salbutamol enhanced rhinovirus- and IL-1 beta-induced IL-6 production; however, fluticasone treatment caused a reduction of IL-6 protein and mRNA. Combined activity of salmeterol and fluticasone at equimolar concentrations had no effect on rhinovirus or IL-1 beta induction of IL-6. The induction of IL- 6 by salmeterol was dependent upon the beta 2 receptor and could also be induced by cAMP or cAMP-elevating agents forskolin and rolipram. Using transfection of IL-6 promoter reporter constructs, dominant negative mutants, and electromobility shift assays, it was found that NF-kappa B was the only transcription factor required for rhinovirus induction of IL-6 gene expression. Salmeterol caused an augmentation of rhinovirus- induced promoter activation via a mechanism dependent upon the c/EBP and/or CRE (cyclic AMP response element) cis-acting sites. The suppressive effect of FP was dependent upon distinct glucocorticoid response element sequences proximal to the transcriptional start site within the IL-6 promoter. The data demonstrate that beta(2) agonists can augment IL-6 expression by other stimuli in an additive manner via cyclic AMP and that the negative effect of steroids is mediated by glucocorticoid response elements within the IL-6 promoter.	Imperial Coll London, Wright Fleming Inst Infect & Immun, London W2 1PG, England; Univ Penn, UK MRC Ctr Allerg Mechan Asthma, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Imperial College London; University of Pennsylvania; University of Pennsylvania	Edwards, MR (corresponding author), St Marys Hosp, Imperial Coll, Dept Resp Med, Natl Heart Lung Inst, London Norfolk Pl, London W2 1PG, England.	michael.edwards@ic.ac.uk	panettieri, reynold/AAG-9485-2019; Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200; Edwards, Michael Robert/0000-0001-6837-0532	Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		ABBINANTENISSEN JM, 1995, AM J PHYSIOL-LUNG C, V268, pL601, DOI 10.1152/ajplung.1995.268.4.L601; Adcock IM, 1999, BRIT J PHARMACOL, V127, P1003, DOI 10.1038/sj.bjp.0702613; Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681; BOEGE U, 1991, VIROLOGY, V181, P1, DOI 10.1016/0042-6822(91)90464-M; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; Edwards MR, 2006, AM J RESP CELL MOL, V34, P616, DOI 10.1165/rcmb.2005-0385OC; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Flammer JR, 2006, BIOCHEMISTRY-US, V45, P9615, DOI 10.1021/bi052521a; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Funkhouser AW, 2004, PEDIATR RES, V55, P13, DOI 10.1203/01.PDR.0000099801.06360.AB; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Hermoso MA, 2004, MOL CELL BIOL, V24, P4743, DOI 10.1128/MCB.24.11.4743-4756.2004; HOLTKAMP W, 1995, J CLIN GASTROENTEROL, V20, P123, DOI 10.1097/00004836-199503000-00010; Hurst JR, 2006, AM J RESP CRIT CARE, V173, P71, DOI 10.1164/rccm.200505-704OC; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Johnston RA, 2005, AM J PHYSIOL-LUNG C, V288, pL390, DOI 10.1152/ajplung.00007.2004; Johnston SL, 1998, J IMMUNOL, V160, P6172; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kim J, 2000, J IMMUNOL, V165, P3384, DOI 10.4049/jimmunol.165.6.3384; Korn SH, 2001, EUR RESPIR J, V17, P1070, DOI 10.1183/09031936.01.00073301; Kuhn C, 2000, AM J RESP CELL MOL, V22, P289, DOI 10.1165/ajrcmb.22.3.3690; Laza-Stanca V, 2006, J VIROL, V80, P8248, DOI 10.1128/JVI.00162-06; Malkoski SP, 1999, MOL ENDOCRINOL, V13, P1629, DOI 10.1210/me.13.10.1629; McCauslin CS, 2006, J BIOL CHEM, V281, P17681, DOI 10.1074/jbc.M600207200; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; Papi A, 1999, J BIOL CHEM, V274, P30041, DOI 10.1074/jbc.274.42.30041; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pelaia G, 2003, LIFE SCI, V72, P1549, DOI 10.1016/S0024-3205(02)02446-3; Pizzichini MMM, 1998, AM J RESP CRIT CARE, V158, P1178, DOI 10.1164/ajrccm.158.4.9712082; Qiu Z, 2004, CLIN EXP ALLERGY, V34, P1321, DOI 10.1111/j.1365-2222.2004.02013.x; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Seemungal TAR, 2000, EUR RESPIR J, V16, P677, DOI 10.1034/j.1399-3003.2000.16d19.x; SPURRELL JC, 2005, AM J PHYSIOL, V28, pL85; Tao YX, 2001, J BIOL CHEM, V276, P2329, DOI 10.1074/jbc.C000526200; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Usmani OS, 2005, AM J RESP CRIT CARE, V172, P704, DOI 10.1164/rccm.200408-1041OC; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wardlaw SA, 2002, MOL PHARMACOL, V62, P326, DOI 10.1124/mol.62.2.326; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wilkinson TMA, 2006, AM J RESP CRIT CARE, V173, P871, DOI 10.1164/rccm.200509-1489OC; Wilkinson TMA, 2006, CHEST, V129, P317, DOI 10.1378/chest.129.2.317; XIGN Z, 1998, J CLIN IVESTIG, V101, P311; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	57	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15366	15375		10.1074/jbc.M701325200	http://dx.doi.org/10.1074/jbc.M701325200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17395587	hybrid, Green Published			2022-12-27	WOS:000246589600012
J	Jousse, C; Deval, C; Maurin, AC; Parry, L; Cherasse, Y; Chaveroux, C; Lefloch, R; Lenormand, P; Bruhat, A; Fafournoux, P				Jousse, Celine; Deval, Christiane; Maurin, Anne-Catherine; Parry, Laurent; Cherasse, Yoan; Chaveroux, Cedric; Lefloch, Renaud; Lenormand, Philippe; Bruhat, Alain; Fafournoux, Pierre			TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID DEPRIVATION; SENSING RESPONSE PATHWAY; TRANSLATIONAL CONTROL; INSULIN-RESISTANCE; EIF2-ALPHA KINASE; TRIBBLES HOMOLOG; PROTEIN; EXPRESSION; CHOP; BINDING	The integrated stress response (ISR) is defined as a highly conserved response to several stresses that converge to the induction of the activating transcription factor 4 (ATF4). Because an uncontrolled response may have deleterious effects, cells have elaborated several negative feedback loops that attenuate the ISR. In the present study, we describe how induction of the human homolog of Drosophila tribbles (TRB3) attenuates the ISR by a negative feedback mechanism. To investigate the role of TRB3 in the control of the ISR, we used the regulation of gene expression by amino acid limitation as a model. The enhanced production of ATF4 upon amino acid starvation results in the induction of a large number of target genes like CHOP (CAAT/enhancer-binding protein-homologous protein), asparagine synthetase (ASNS), or TRB3. We demonstrate that TRB3 overexpression inhibits the transcriptional induction of CHOP and ASNS whereas TRB3 silencing induces the expression of these genes both under normal and stressed conditions. In addition, transcriptional profiling experiments show that TRB3 affects the expression of many ISR-regulated genes. Our results also suggest that TRB3 and ATF4 belong to the same protein complex bound to the sequence involved in the ATF4-dependent regulation of gene expression by amino acid limitation. Collectively, our data identify TRB3 as a negative feedback regulator of the ATF4-dependent transcription and participates to the fine regulation of the ISR.	INRA, UMR 1019, Unite Nutr Humaine, F-63122 St Genes Champanelle, France; Ctr Antoine Lacassagne, CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06100 Nice, France	INRAE; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Fafournoux, P (corresponding author), INRA, UMR 1019, Unite Nutr Humaine, F-63122 St Genes Champanelle, France.	fpierre@clermont.inra.fr	Lenormand, Philippe/N-5996-2018; Cherasse, Yoan/F-8915-2010; Cherasse, Yoan/AAD-6442-2020	Cherasse, Yoan/0000-0002-6139-8193; Chaveroux, Cedric/0000-0002-4116-3354				Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; BRUHAT A, 2007, NUCL ACIDS RES; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corcoran CA, 2005, CANCER BIOL THER, V4, P1063, DOI 10.4161/cbt.4.10.2205; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hegedus Z, 2007, CELL SIGNAL, V19, P238, DOI 10.1016/j.cellsig.2006.06.010; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Matsushima R, 2006, J BIOL CHEM, V281, P29719, DOI 10.1074/jbc.M511636200; Maurin AC, 2005, CELL METAB, V1, P273, DOI 10.1016/j.cmet.2005.03.004; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ord D, 2005, BIOCHEM BIOPH RES CO, V330, P210, DOI 10.1016/j.bbrc.2005.02.149; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; Prudente S, 2005, DIABETES, V54, P2807, DOI 10.2337/diabetes.54.9.2807; Qi L, 2006, SCIENCE, V312, P1763, DOI 10.1126/science.1123374; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rorth P, 2000, MOL CELL, V6, P23; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Sok J, 1999, MOL CELL BIOL, V19, P495; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	41	122	125	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15851	15861		10.1074/jbc.M611723200	http://dx.doi.org/10.1074/jbc.M611723200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17369260	Green Published, hybrid			2022-12-27	WOS:000246589600060
J	Scoumanne, A; Chen, XB				Scoumanne, Ariane; Chen, Xinbin			The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEMETHYLATION; P53 ACTIVITY; COMPLEX; DOMAIN; IDENTIFICATION; ACETYLATION; REPRESSION; PROTEIN; FAMILY; GENES	The lysine-specific demethylase 1 (LSD1), a component of several histone deacetylase complexes, plays an important role in chromatin remodeling and transcriptional regulation. Here, we generated multiple cell lines in which LSD1 is inducibly expressed or knocked down and found that LSD1 is required for cell proliferation. In addition, we found that deficiency in LSD1 leads to a partial cell cycle arrest in G(2)/M and sensitizes cells to growth suppression induced by DNA damage or MDM2 inhibition in a p53-dependent manner. We also showed that LSD1 deficiency delays p53 stabilization induced by DNA damage, leading to a delayed induction of p21 and MDM2. Finally, we performed a microarray study and identified several novel LSD1 target genes, including S100A8, which encodes a calcium-binding protein, and DEK, a proto-oncogene. Taken together, we uncovered that LSD1 has a pro-oncogenic function by modulating pro-survival gene expression and p53 transcriptional activity.	Univ Calif Davis, Ctr Comparat Oncol, Davis, CA 95616 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of California System; University of California Davis; University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), Univ Calif Davis, Ctr Comparat Oncol, 2128 Tupper Hall, Davis, CA 95616 USA.	xbchen@ucdavis.edu			NATIONAL CANCER INSTITUTE [R01CA081237, R01CA076069, R01CA102188, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA081237, CA076069, CA102188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Kondoh N, 1999, CANCER RES, V59, P4990; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Roy S, 2007, J BIOL CHEM, V282, P4765, DOI 10.1074/jbc.M609588200; Scoumanne A, 2006, CANCER RES, V66, P6271, DOI 10.1158/0008-5472.CAN-06-0121; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; Waldmann T, 2004, GENE, V343, P1, DOI 10.1016/j.gene.2004.08.029; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	23	113	142	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15471	15475		10.1074/jbc.M701023200	http://dx.doi.org/10.1074/jbc.M701023200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17409384	hybrid			2022-12-27	WOS:000246589600022
J	Matsumura, S; Toyoshima, F; Nishida, E				Matsumura, Shigeru; Toyoshima, Fumiko; Nishida, Eisuke			Polo-like kinase 1 facilitates chromosome alignment during prometaphase through BubR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE KINASE; SPINDLE-CHECKPOINT PROTEINS; MITOTIC CHECKPOINT; CENP-E; BOX DOMAIN; AURORA-B; KINETOCHORE LOCALIZATION; BINDING DOMAIN; HUMAN-CELLS; HELA-CELLS	Plk1, an evolutionarily conserved M phase kinase, associates with not only spindle poles but also kinetochores during prometaphase. However, the role of Plk1 at kinetochores has been poorly understood. Here we show that BubR1 mediates the action of Plk1 at kinetochores for proper chromosome alignment. Our results show that BubR1 colocalizes with Plk1 at kinetochores of unaligned chromosomes and physically interacts with Plk1 in prometaphase cells. Down-regulation of Plk1 by small interfering RNA abolished the mobility-shifted, hyperphosphorylated form of BubR1 in the prometaphase-arrested cells. In addition, BubR1 was phosphorylated by Plk1 in vitro at two Plk1 consensus sites in the kinase domain of BubR1. The add-back of either wild-type BubR1 or BubR1 2E, in which the two Plk1 phosphorylation sites were replaced by glutamic acids, but not that of BubR1 2A, an unphosphorylatable mutant, rescued the chromosome alignment defects in BubR1-deficient cells. Moreover, when both Plk1 and BubR1 were down-regulated, the add-back of BubR1 2E, but not that of wild-type BubR1, rescued the chromosome alignment defects. These results taken together suggest that Plk1 facilitates chromosome alignment during prometaphase through BubR1.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp		Toyoshima, Fumiko/0000-0002-3698-0034				Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Ahonen LJ, 2005, CURR BIOL, V15, P1078, DOI 10.1016/j.cub.2005.05.026; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chan GK, 2005, TRENDS CELL BIOL, V15, P589, DOI 10.1016/j.tcb.2005.09.010; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hanisch A, 2006, MOL BIOL CELL, V17, P448, DOI 10.1091/mbc.E05-08-0801; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; King JM, 2000, J CELL SCI, V113, P3815; Kline-Smith SL, 2005, CURR OPIN CELL BIOL, V17, P35, DOI 10.1016/j.ceb.2004.12.009; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lampson MA, 2005, NAT CELL BIOL, V7, P93, DOI 10.1038/ncb1208; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Liu JJ, 2005, ONCOGENE, V24, P238, DOI 10.1038/sj.onc.1208220; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; Morrow CJ, 2005, J CELL SCI, V118, P3639, DOI 10.1242/jcs.02487; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; Qi W, 2006, MOL BIOL CELL, V17, P3705, DOI 10.1091/mbc.E06-03-0240; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 2001, J CELL SCI, V114, P4385; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167; Wong OK, 2005, J CELL BIOL, V170, P709, DOI 10.1083/jcb.200502163; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	46	75	84	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15217	15227		10.1074/jbc.M611053200	http://dx.doi.org/10.1074/jbc.M611053200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376779	hybrid			2022-12-27	WOS:000246589000061
J	Beuret, L; Flori, E; Denoyelle, C; Bille, K; Busca, R; Picardo, M; Bertolotto, C; Ballotti, R				Beuret, Laurent; Flori, Enrica; Denoyelle, Christophe; Bille, Karine; Busca, Roser; Picardo, Mauro; Bertolotto, Corine; Ballotti, Robert			Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA GENE-PRODUCT; TRANSCRIPTION FACTOR MITF; NF-KAPPA-B; C-MET; FACTOR/SCATTER FACTOR; MALIGNANT-MELANOMA; LINEAGE SURVIVAL; INVASIVE GROWTH; CARCINOMA-CELLS; DOWN-REGULATION	The MET proto-oncogene encodes for the hepatocyte growth factor (HGF) receptor, a plasma membrane tyrosine kinase that is involved in melanocyte growth and melanoma development. In mouse melanoma cells, Met expression is increased by alpha MSH via the activation of the cAMP pathway. However, the mechanism by which cAMP regulates MET and the biological consequences of this increase were not known. In the present report, we show that alpha MSH regulates MET expression in both human melanocytes and mouse melanoma cells through a transcriptional mechanism that requires MITF. Furthermore, the adenovirus driven expression of MITF is sufficient to increase MET in melanoma cells. Functional analysis of the MET promoter allows us to identify an E-box motif conserved in both human and mouse promoter that mediates the effect of MITF. Interestingly, up-regulation of MET expression by cAMP leads to an exacerbated HGF signaling and allows HGF to protect melanocytes and melanoma cells from apoptosis. Thus, physiological stimuli or pathological events that would induce MITF expression may lead to increased MET expression thereby favoring melanoma survival. These observations strengthen the roles of MITF and MET in melanoma development.	INSERM, U597, Equipe Labellisee Ligue Natl Contre Canc, F-06107 Nice, France; Univ Nice Sophia Antipolis, UFR Med, Nice, France; IRCCS, Lab Fisiopatol Cutanea, Ist Dermatol San Gallicano, I-00144 Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG)	Ballotti, R (corresponding author), INSERM, U597, Equipe Labellisee Ligue Natl Contre Canc, F-06107 Nice, France.	ballotti@unice.fr	Picardo, Mauro/A-6978-2011; Bertolotto-Ballotti, Corine/O-2155-2016; DENOYELLE, Christophe CD/K-6205-2015; BALLOTTI, Robert/F-8825-2013; Flori, Enrica/H-4417-2014; Bertolotto, Corine/AAF-6634-2021	Picardo, Mauro/0000-0003-4899-6639; DENOYELLE, Christophe CD/0000-0001-7153-8826; Flori, Enrica/0000-0002-9275-1041; Bertolotto, Corine/0000-0001-6971-7753; BALLOTTI, Robert/0000-0002-7322-4908				Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bolanos-Garcia VM, 2005, MOL CELL BIOCHEM, V276, P149, DOI 10.1007/s11010-005-3696-6; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chen QY, 1997, HEPATOLOGY, V26, P59; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Cruz J, 2003, ONCOLOGY-BASEL, V65, P72, DOI 10.1159/000071207; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; de la Serna IL, 2006, J BIOL CHEM, V281, P20233, DOI 10.1074/jbc.M512052200; Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318; Gaggioli C, 2003, PIGM CELL RES, V16, P374, DOI 10.1034/j.1600-0749.2003.00057.x; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Hamasuna R, 1999, INT J CANCER, V82, P274, DOI 10.1002/(SICI)1097-0215(19990719)82:2<274::AID-IJC19>3.0.CO;2-2; Kankuri E, 2005, CANCER RES, V65, P9914, DOI 10.1158/0008-5472.CAN-05-1559; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Kos L, 1999, PIGM CELL RES, V12, P13, DOI 10.1111/j.1600-0749.1999.tb00503.x; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; McGill GG, 2006, J BIOL CHEM, V281, P10365, DOI 10.1074/jbc.M513094200; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Noonan FP, 2000, CANCER RES, V60, P3738; Otsuka T, 1998, CANCER RES, V58, P5157; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Recio JA, 2003, CANCER RES, V63, P1576; Rusciano D, 1999, J CELL SCI, V112, P623; Seol DW, 2000, ONCOGENE, V19, P1132, DOI 10.1038/sj.onc.1203404; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; Stella MC, 2005, MOL CELL BIOL, V25, P3982, DOI 10.1128/MCB.25.10.3982-3996.2005; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Wu M, 2000, GENE DEV, V14, P301; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; Zhang XH, 2003, AM J PHYSIOL-RENAL, V284, pF82, DOI 10.1152/ajprenal.00200.2002	41	66	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14140	14147		10.1074/jbc.M611563200	http://dx.doi.org/10.1074/jbc.M611563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371876	hybrid			2022-12-27	WOS:000246245800024
J	Davis, AJ; Im, YJ; Dubin, JS; Tomer, KB; Boss, WF				Davis, Amanda J.; Im, Yang Ju; Dubin, Joshua S.; Tomer, Kenneth B.; Boss, Wendy F.			RETRACTED: Arabidopsis phosphatidylinositol phosphate kinase 1 binds F-actin and recruits phosphatidylinositol 4-kinase beta 1 to the actin cytoskeleton (Retracted article. See vol. 284, pg. 16060, 2009)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							PLECKSTRIN HOMOLOGY DOMAIN; POLLEN-TUBE GROWTH; ROOT HAIR-CELLS; PHOSPHOINOSITIDE METABOLISM; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; 5-KINASE; PROTEIN; ORGANIZATION; CYCLODEXTRINS	The actin cytoskeleton can be influenced by phospholipids and lipid-modifying enzymes. In animals the phosphatidylinositol phosphate kinases (PIPKs) are associated with the cytoskeleton through a scaffold of proteins; however, in plants such an interaction was not clear. Our approach was to determine which of the plant PIPKs interact with actin and determine whether the PIPK-actin interaction is direct. Our results indicate that AtPIPK1 interacts directly with actin and that the binding is mediated through a predicted linker region in the lipid kinase. AtPIPK1 also recruits AtPI4K beta 1 to the cytoskeleton. Recruitment of AtPI4K beta 1 to F-actin was dependent on the C-terminal catalytic domain of phosphatidylinositol-4-phosphate 5-kinase but did not require the presence of the N-terminal 251 amino acids, which includes 7 putative membrane occupation and recognition nexus motifs. In vivo studies confirm the interaction of plant lipid kinases with the cytoskeleton and suggest a role for actin in targeting PIPKs to the membrane.	N Carolina State Univ, Raleigh, NC 27695 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Boss, WF (corresponding author), N Carolina State Univ, Box 7649, Raleigh, NC 27695 USA.	wendy_boss@ncsu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050171, Z01ES050171] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABE S, 1992, J EXP BOT, V43, P941, DOI 10.1093/jxb/43.7.941; Boss Wendy E., 2006, V39, P181; CARRAWAY KL, 1992, CYTOSKELETON PRACTIC, P47; Davis AJ, 2004, J LIPID RES, V45, P1783, DOI 10.1194/jlr.D400005-JLR200; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dowd PE, 2006, PLANT CELL, V18, P1438, DOI 10.1105/tpc.106.041582; Downes CP, 2005, TRENDS CELL BIOL, V15, P259, DOI 10.1016/j.tcb.2005.03.008; Fauvelle F, 1997, J PHARM SCI, V86, P935, DOI 10.1021/js9602453; Gubbels MJ, 2006, J CELL SCI, V119, P2236, DOI 10.1242/jcs.02949; Hastie LE, 1998, J CELL BIOCHEM, V68, P511, DOI 10.1002/(SICI)1097-4644(19980315)68:4<511::AID-JCB10>3.0.CO;2-C; Heilmann I, 1999, PLANT PHYSIOL, V119, P1331, DOI 10.1104/pp.119.4.1331; Helling D, 2006, PLANT CELL, V18, P3519, DOI 10.1105/tpc.106.047373; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Im YJ, 2007, J BIOL CHEM, V282, P5443, DOI 10.1074/jbc.M611342200; Javierre I, 2002, J COLLOID INTERF SCI, V254, P120, DOI 10.1006/jcis.2002.8545; Kanzaki M, 2004, J BIOL CHEM, V279, P30622, DOI 10.1074/jbc.M401443200; KARUPPIAH N, 1995, BIOCHEM BIOPH RES CO, V211, P60, DOI 10.1006/bbrc.1995.1778; Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317; Kovar DR, 2000, PLANT CELL, V12, P583, DOI 10.1105/tpc.12.4.583; Kusner DJ, 2003, ARCH BIOCHEM BIOPHYS, V412, P231, DOI 10.1016/S0003-9861(03)00052-3; Lee MH, 2002, PLANT PHYSIOL, V129, P1507, DOI 10.1104/pp.003624; Mueller-Roeber B, 2002, PLANT PHYSIOL, V130, P22, DOI 10.1104/pp.004770; OWEN CH, 1992, J STRUCT BIOL, V109, P248, DOI 10.1016/1047-8477(92)90037-B; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Perera IY, 2005, FEBS LETT, V579, P3427, DOI 10.1016/j.febslet.2005.05.018; Preuss ML, 2006, J CELL BIOL, V172, P991, DOI 10.1083/jcb.200508116; Preuss ML, 2004, PLANT CELL, V16, P1589, DOI 10.1105/tpc.021634; Shimada H, 2004, PLANT CELL PHYSIOL, V45, P960, DOI 10.1093/pcp/pch130; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; SOMMARIN M, 1988, BIOCHIM BIOPHYS ACTA, V958, P268, DOI 10.1016/0005-2760(88)90185-3; Staiger CJ, 2006, CURR OPIN PLANT BIOL, V9, P554, DOI 10.1016/j.pbi.2006.09.013; Staiger CJ, 1997, TRENDS PLANT SCI, V2, P275, DOI 10.1016/S1360-1385(97)86350-9; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Stevenson-Paulik J, 2003, PLANT PHYSIOL, V132, P1053, DOI 10.1104/pp.103.021758; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; TAN Z, 1992, PLANT PHYSIOL, V100, P2116, DOI 10.1104/pp.100.4.2116; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Van Gestel K, 2002, J EXP BOT, V53, P659, DOI 10.1093/jexbot/53.369.659; Vincent P, 2005, J CELL BIOL, V168, P801, DOI 10.1083/jcb.200412074; Westergren T, 2001, BIOCHEM J, V359, P583, DOI 10.1042/0264-6021:3590583; XU P, 1992, PLANT CELL, V4, P941, DOI 10.1105/tpc.4.8.941; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yang SA, 2004, J BIOL CHEM, V279, P42331, DOI 10.1074/jbc.M404335200; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zhong RQ, 2004, PLANT CELL, V16, P3242, DOI 10.1105/tpc.104.027466	47	15	15	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14121	14131		10.1074/jbc.M611728200	http://dx.doi.org/10.1074/jbc.M611728200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17379598	hybrid			2022-12-27	WOS:000246245800022
J	Han, JH; Zhou, H; Li, ZZ; Xu, RM; Zhang, ZG				Han, Junhong; Zhou, Hui; Li, Zhizhong; Xu, Rui-Ming; Zhang, Zhiguo			The Rtt109-Vps75 histone acetyltransferase complex acetylates non-nucleosomal histone H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; H3K56 ACETYLATION; CELL-CYCLE; LYSINE-56; DNA; CHROMATIN; TRANSCRIPTION; REPLICATION; STABILITY; INTEGRITY	Acetylation of lysine 56 of histone H3 (H3-Lys-56) occurs in S phase and disappears during G(2)/M phase of the cell cycle. However, it is not clear how this modification is regulated during the progression of the cell cycle. We and others have shown that the histone acetyltransferase (AT) Rtt109 is the primary HAT responsible for acetylating H3-Lys-56 in budding yeast. Here we show that Rtt109 forms a complex with Vps75 and that both recombinant Rtt109-Vps75 complexes and native complexes purified from yeast cells acetylate H3 present in H3/H4/H2A/H2B core histones but not other histones. In addition, both recombinant and native Rtt109-Vps75 HAT complexes exhibited no detectable activity toward nucleosomal H3, suggesting that H3-Lys-56 acetylation is at least in part regulated by the inability of Rtt109-Vps75 complexes to acetylate nucleosomal H3 during G(2)/M phase of the cell cycle. Further, Rtt109 bound mutant H3/H4 tetramers composed of histones lacking their N-terminal tail domains less efficiently than wild-type H3/H4 tetramers, and Rtt109-Vps75 complexes displayed reduced HAT activity toward these mutant H3/H4 tetramers. Thus, the N termini of H3/H4 tetramers are required for efficient acetylation of H3 by the Rtt109-Vps75 complex. Taken together, these studies provide insights into how H3-Lys-56 acetylation is regulated during the cell cycle.	Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; NYU, Sch Med, Helen L & Martin S Kimmel Ctr Biol & Med, Skirball Inst Biomed,Struct Biol Program, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	Mayo Clinic; New York University; New York University	Zhang, ZG (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	Zhang.Zhiguo@mayo.edu	xu, rui/GRX-5734-2022; Han, Junhong/L-5264-2013	Han, Junhong/0000-0002-3371-8698				AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Driscoll R, 2007, SCIENCE, V315, P649, DOI 10.1126/science.1135862; English CM, 2005, BIOCHEMISTRY-US, V44, P13673, DOI 10.1021/bi051333h; Han JH, 2007, SCIENCE, V315, P653, DOI 10.1126/science.1133234; Hyland EA, 2005, MOL CELL BIOL, V25, P10060, DOI 10.1128/MCB.25.22.10060-10070.2005; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Levenstein ME, 2002, J BIOL CHEM, V277, P8749, DOI 10.1074/jbc.M111212200; Luger K, 2006, CHROMOSOME RES, V14, P5, DOI 10.1007/s10577-005-1026-1; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maas NL, 2006, MOL CELL, V23, P109, DOI 10.1016/j.molcel.2006.06.006; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Ozdemir A, 2005, J BIOL CHEM, V280, P25949, DOI 10.1074/jbc.C500181200; Pan XW, 2006, CELL, V124, P1069, DOI 10.1016/j.cell.2005.12.036; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Schneider J, 2006, J BIOL CHEM, V281, P37270, DOI 10.1074/jbc.C600265200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suter B, 2004, GENETICS, V167, P579, DOI 10.1534/genetics.103.024851; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; van Holde KE., 1989, SPRINGER SERIES MOL; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhang ZG, 1998, P NATL ACAD SCI USA, V95, P2807, DOI 10.1073/pnas.95.6.2807; Zhou H, 2006, BIOCHEMISTRY-US, V45, P2852, DOI 10.1021/bi0521083	28	82	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14158	14164		10.1074/jbc.M700611200	http://dx.doi.org/10.1074/jbc.M700611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369253	hybrid			2022-12-27	WOS:000246245800026
J	Scherner, O; Meurer, SK; Tihaa, L; Gressner, AM; Weiskirchen, R				Scherner, Olaf; Meurer, Steffen K.; Tihaa, Lidia; Gressner, Axel M.; Weiskirchen, Ralf			Endoglin differentially modulates antagonistic transforming growth factor-beta 1 and BMP-7 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; BONE MORPHOGENETIC PROTEIN-7; HEPATIC STELLATE CELLS; I RECEPTORS; OSTEOGENIC PROTEIN-1; ENDOTHELIAL-CELLS; OSTEOBLAST DIFFERENTIATION; MYOGENIC DIFFERENTIATION; EXTRACELLULAR-MATRIX	Transforming growth factor-beta 1 (TGF-beta 1) and BMP-7 (bone morphogenetic protein-7; OP-1) play central, antagonistic roles in kidney fibrosis, a setting in which the expression of endoglin (CD105), an accessory TGF-beta type III receptor, is increased. So far, endoglin is known as a negative regulator of TGF-beta/ALK-5 signaling. Here we analyzed the effect of BMP-7 on TGF-beta 1 signaling and the role of endoglin for both pathways in endoglin-deficient L6E9 cells. In this myoblastic cell line, TGF-beta 1 and BMPs are opposing cytokines, interfering with myogenic differentiation. Both induce specific target genes of which Id1 (for BMPs) and collagen I (for TGF-beta 1) are two examples. TGF-beta 1 activated two distinct type I receptors, ALK-5 and ALK-1, in these cells. Although the ALK-5/Smad3 signaling pathway mediated collagen I expression, ALK-1/Smad1/Smad5 signaling mediated a transient Id1 up-regulation. In contrast, BMP-7 exclusively activated Smad1/Smad5 resulting in a more prolonged Id1 expression. Although BMP-7 had no impact on collagen I abundance, it antagonized TGF-beta 1-induced collagen I expression and (CAGA) 12-MLP-Luc activity, effects that are mediated by the ALK-5/Smad3 pathway. Finally, we found that the transient overexpression of endoglin, previously shown to inhibit TGF-beta 1-induced ALK-5/Smad3 signaling, enhanced the BMP-7/Smad1/Smad5 pathway.	RWTH Univ Hosp, Inst Clin Chem & Pathobiochem, D-52074 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Weiskirchen, R (corresponding author), RWTH Univ Hosp, Inst Clin Chem & Pathobiochem, D-52074 Aachen, Germany.	rweiskirchen@ukaachen.de	Weiskirchen, Ralf/O-1734-2018	Weiskirchen, Ralf/0000-0003-3888-0931				ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Aoki H, 2001, J CELL SCI, V114, P1483; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ebisawa T, 1999, J CELL SCI, V112, P3519; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Gu K, 2004, CELLS TISSUES ORGANS, V176, P28, DOI 10.1159/000075025; Guo BQ, 2004, ANTICANCER RES, V24, P1337; HEINO J, 1990, J BIOL CHEM, V265, P10181; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hruska KA, 2000, AM J PHYSIOL-RENAL, V279, pF130, DOI 10.1152/ajprenal.2000.279.1.F130; Izumi N, 2006, AM J PHYSIOL-LUNG C, V290, pL120, DOI 10.1152/ajplung.00171.2005; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KINOSHITA K, 2006, GUT; Kollias HD, 2006, MOL CELL BIOL, V26, P6248, DOI 10.1128/MCB.00384-06; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Meurer SK, 2005, J BIOL CHEM, V280, P3078, DOI 10.1074/jbc.M405411200; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Newfeld SJ, 1999, GENETICS, V152, P783; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Obreo J, 2004, CELL PHYSIOL BIOCHEM, V14, P301, DOI 10.1159/000080340; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Park SH, 2005, J BIOCHEM MOL BIOL, V38, P9; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Rodriguez-Barbero A, 2001, BIOCHEM BIOPH RES CO, V282, P142, DOI 10.1006/bbrc.2001.4526; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SCHAFER S, 1987, HEPATOLOGY, V7, P680, DOI 10.1002/hep.1840070411; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sorensen LK, 2003, DEV BIOL, V261, P235, DOI 10.1016/S0012-1606(03)00158-1; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Tou LQ, 2003, MOL CELL ENDOCRINOL, V205, P121, DOI 10.1016/S0303-7207(03)00151-5; Vinals F, 2004, J BIOL CHEM, V279, P45766, DOI 10.1074/jbc.M408059200; Wang SN, 2004, J BIOL CHEM, V279, P23200, DOI 10.1074/jbc.M311998200; Weiskirchen R, 2000, BIOCHEM BIOPH RES CO, V274, P655, DOI 10.1006/bbrc.2000.3187; Wiercinska E, 2006, HEPATOLOGY, V43, P1032, DOI 10.1002/hep.21135; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	65	84	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13934	13943		10.1074/jbc.M611062200	http://dx.doi.org/10.1074/jbc.M611062200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17376778	hybrid			2022-12-27	WOS:000246245800003
J	Thorpe, C; Coppock, DL				Thorpe, Colin; Coppock, Donald L.			Generating disulfides in multicellular organisms: Emerging roles for a new flavoprotein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SULFHYDRYL OXIDASE QSOX; ENDOPLASMIC-RETICULUM; BOND FORMATION; EGG-WHITE; OXIDATIVE STRESS; LIVER-REGENERATION; THIOREDOXIN DOMAIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CELL-DEATH		Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Coriell Inst Med Res, Camden, NJ 08103 USA	University of Delaware; Coriell Institute for Medical Research	Thorpe, C (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	cthorpe@udel.edu			NIGMS NIH HHS [GM26643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benayoun B, 2001, J BIOL CHEM, V276, P13830, DOI 10.1074/jbc.M010933200; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; BIRNIE A, 2005, MOL CELLULAR BIOL HE; Brohawn SG, 2003, BIOCHEMISTRY-US, V42, P11074, DOI 10.1021/bi0301385; Chakravarthi S, 2006, EMBO REP, V7, P271, DOI 10.1038/sj.embor.7400645; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; Coppock DL, 2006, ANTIOXID REDOX SIGN, V8, P300, DOI 10.1089/ars.2006.8.300; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Essex DW, 2006, CURR DRUG TARGETS, V7, P1233, DOI 10.2174/138945006778559193; Farrell SR, 2005, BIOCHEMISTRY-US, V44, P1532, DOI 10.1021/bi0479555; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Gerber J, 2001, J BIOL CHEM, V276, P23486, DOI 10.1074/jbc.M100134200; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Gross E, 2006, P NATL ACAD SCI USA, V103, P299, DOI 10.1073/pnas.0506448103; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; Gruber CW, 2006, TRENDS BIOCHEM SCI, V31, P455, DOI 10.1016/j.tibs.2006.06.001; Haynes CM, 2004, MOL CELL, V15, P767, DOI 10.1016/j.molcel.2004.08.025; Hoober KL, 1999, BIOCHEMISTRY-US, V38, P3211, DOI 10.1021/bi9820816; Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759; Hoober KL, 1999, J BIOL CHEM, V274, P22147, DOI 10.1074/jbc.274.32.22147; Hoober KL, 1996, J BIOL CHEM, V271, P30510, DOI 10.1074/jbc.271.48.30510; Inaba K, 2006, CELL, V127, P789, DOI 10.1016/j.cell.2006.10.034; JANOLINO VG, 1975, J BIOL CHEM, V250, P2532; Jessop CE, 2004, BIOCHEM SOC T, V32, P655, DOI 10.1042/BST0320655; Jordan PA, 2006, ANTIOXID REDOX SIGN, V8, P312, DOI 10.1089/ars.2006.8.312; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; KIERMEIER F., 1967, Zeitschrift fur Lebensmittel-Untersuchung und -Forschung, V132, P342, DOI 10.1007/BF01045314; Kulp MS, 2006, J BIOL CHEM, V281, P876, DOI 10.1074/jbc.M511764200; LASH LH, 1983, ARCH BIOCHEM BIOPHYS, V225, P344, DOI 10.1016/0003-9861(83)90039-5; Mairet-Coello G, 2005, J COMP NEUROL, V484, P403, DOI 10.1002/cne.20411; Mairet-Coello G, 2004, J COMP NEUROL, V473, P334, DOI 10.1002/cne.20126; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Matthias LJ, 2003, ANTIOXID REDOX SIGN, V5, P133, DOI 10.1089/152308603321223621; Messens J, 2006, INT J BIOCHEM CELL B, V38, P1050, DOI 10.1016/j.biocel.2005.12.011; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Nakamoto H, 2004, BBA-MOL CELL RES, V1694, P111, DOI 10.1016/j.bbamcr.2004.02.012; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; OSTROWSKI MC, 1980, BIOCHEMISTRY-US, V19, P2639, DOI 10.1021/bi00553a016; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Radom J, 2006, BBA-GENE STRUCT EXPR, V1759, P225, DOI 10.1016/j.bbaexp.2006.04.008; Raje S, 2003, BIOCHEMISTRY-US, V42, P4560, DOI 10.1021/bi030003z; Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200; ROTH RA, 1981, J BIOL CHEM, V256, P4633; Rozhkova A, 2004, EMBO J, V23, P1709, DOI 10.1038/sj.emboj.7600178; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; SWAISGOOD H, 2003, FOOD SCI TECHNOL, V122, P539; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Tury A, 2006, CELL TISSUE RES, V323, P91, DOI 10.1007/s00441-005-0043-x; Tury A, 2004, J ENDOCRINOL, V183, P353, DOI 10.1677/joe.1.05842; Vala A, 2005, J MOL BIOL, V354, P952, DOI 10.1016/j.jmb.2005.09.076; van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P191, DOI 10.1080/10409230591008161; Wilkinson B, 2005, J BIOL CHEM, V280, P11483, DOI 10.1074/jbc.M414203200; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Wittke I, 2003, CANCER RES, V63, P7742; Wu CK, 2003, PROTEIN SCI, V12, P1109, DOI 10.1110/ps.0238103; Yamada H, 1989, Nihon Hifuka Gakkai Zasshi, V99, P499; Zanata SM, 2005, REDOX REP, V10, P319, DOI 10.1179/135100005X83699	62	64	65	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13929	13933		10.1074/jbc.R600037200	http://dx.doi.org/10.1074/jbc.R600037200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17353193	hybrid			2022-12-27	WOS:000246245800002
J	Rizwan, AN; Krick, W; Burckhardt, G				Rizwan, Ahsan N.; Krick, Wolfgang; Burckhardt, Gerhard			The chloride dependence of the human organic anion transporter 1 (hOAT1) is blunted by mutation of a single amino acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE-VESICLES; FUNCTIONAL-CHARACTERIZATION; CATION TRANSPORTERS; EXPRESSION CLONING; MOLECULAR-CLONING; LACTOSE PERMEASE; RAT-KIDNEY; OAT1; POLYMORPHISMS; SPECIFICITY	Organic anion transporter 1 (OAT1) is key for the secretion of organic anions in renal proximal tubules. These organic anions comprise endogenous as well as exogenous compounds including frequently used drugs of various chemical structures. The molecular basis for the polyspecificity of OAT1 is not known. Here we mutated a conserved positively charged arginine residue (Arg(466)) in the 11(th) transmembrane helix of human OAT1. The replacement by the positively charged lysine (R466K) did not impair expression of hOAT1 at the plasma membrane of Xenopus laevis oocytes but decreased the transport of p-aminohippurate (PAH) considerably. Extracellular glutarate inhibited and intracellular glutarate trans-stimulated wild type and mutated OAT1, suggesting for the mutant R466K an unimpaired interaction with dicarboxylates. However, when Arg(466) was replaced by the negatively charged aspartate (R466D), glutarate no longer interacted with the mutant. PAH uptake by wild type hOAT1 was stimulated in the presence of chloride, whereas the R466K mutant was chloride-insensitive. Likewise, the uptake of labeled glutarate or ochratoxin A was chloride-dependent in the wild type but not in R466K. Kinetic experiments revealed that chloride did not alter the apparent K-m for PAH but influenced V-max in wild type OAT1-expressing oocytes. In R466K mutants the apparent Km for PAH was similar to that of the wild type, but V-max was not changed by chloride removal. We conclude that Arg(466) influences the binding of glutarate, but not interaction with PAH, and interacts with chloride, which is a major determinant in substrate translocation.	Univ Gottingen, Abt Vegetat Physiol & Pathophysiol, Zentrum Physiol & Pathophysiol, D-37073 Gottingen, Germany	University of Gottingen	Burckhardt, G (corresponding author), Univ Gottingen, Abt Vegetat Physiol & Pathophysiol, Zentrum Physiol & Pathophysiol, Humboldtallee 23, D-37073 Gottingen, Germany.	gburckh@gwdg.de						Abramson J, 2004, CURR OPIN STRUC BIOL, V14, P413, DOI 10.1016/j.sbi.2004.07.005; Anzai N, 2006, J PHARMACOL SCI, V100, P411, DOI 10.1254/jphs.CRJ06006X; Bahn A, 2005, AM J PHYSIOL-CELL PH, V289, pC1075, DOI 10.1152/ajpcell.00619.2004; Bahn A, 2004, DRUG METAB DISPOS, V32, P424, DOI 10.1124/dmd.32.4.424; Bahn A, 2004, BIOCHIMIE, V86, P133, DOI 10.1016/j.biochi.2003.12.001; Bleasby K, 2005, J PHARMACOL EXP THER, V314, P923, DOI 10.1124/jpet.105.084301; Burckhardt BC, 2003, REV PHYSIOL BIOCH P, V146, P95, DOI 10.1007/s10254-002-0003-8; Burckhardt G, 2000, AM J PHYSIOL-RENAL, V278, pF853, DOI 10.1152/ajprenal.2000.278.6.F853; Feng B, 2001, BIOCHEMISTRY-US, V40, P5511, DOI 10.1021/bi002841o; Fujita Tomoe, 2005, Pharmacogenet Genomics, V15, P201, DOI 10.1097/01213011-200504000-00003; Gorboulev V, 1999, MOL PHARMACOL, V56, P1254, DOI 10.1124/mol.56.6.1254; Hagos Y, 2007, J AM SOC NEPHROL, V18, P430, DOI 10.1681/ASN.2006040415; Hong M, 2004, J BIOL CHEM, V279, P31478, DOI 10.1074/jbc.M404686200; Hong M, 2007, BIOCHEM J, V401, P515, DOI 10.1042/BJ20061171; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; Kimura H, 2002, J PHARMACOL EXP THER, V301, P293, DOI 10.1124/jpet.301.1.293; Koepsell H, 2004, PFLUG ARCH EUR J PHY, V447, P666, DOI 10.1007/s00424-003-1089-9; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; Perry JL, 2006, J BIOL CHEM, V281, P38071, DOI 10.1074/jbc.M608834200; Popp C, 2005, MOL PHARMACOL, V67, P1600, DOI 10.1124/mol.104.008839; PRITCHARD JB, 1988, AM J PHYSIOL, V255, pF597, DOI 10.1152/ajprenal.1988.255.4.F597; Race JE, 1999, BIOCHEM BIOPH RES CO, V255, P508, DOI 10.1006/bbrc.1998.9978; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Tanaka K, 2004, BIOCHEM J, V380, P283, DOI 10.1042/BJ20031724; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Uwai Y, 1998, FEBS LETT, V438, P321, DOI 10.1016/S0014-5793(98)01328-3; Wolff NA, 2003, J AM SOC NEPHROL, V14, P1959, DOI 10.1097/01.ASN.0000079040.55124.25; Wolff NA, 1997, FEBS LETT, V417, P287, DOI 10.1016/S0014-5793(97)01304-5; Wolff NA, 2001, J AM SOC NEPHROL, V12, P2012, DOI 10.1681/ASN.V12102012; Xu G, 2005, KIDNEY INT, V68, P1491, DOI 10.1111/j.1523-1755.2005.00612.x; Xu W, 2006, J BIOL CHEM, V281, P31178, DOI 10.1074/jbc.M605664200; Zhang XH, 2005, J BIOL CHEM, V280, P34813, DOI 10.1074/jbc.M506342200	34	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13402	13409		10.1074/jbc.M609849200	http://dx.doi.org/10.1074/jbc.M609849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353191	hybrid			2022-12-27	WOS:000246060300029
J	Saxena, NK; Vertino, PM; Anania, FA; Sharma, D				Saxena, Neeraj K.; Vertino, Paula M.; Anania, Frank A.; Sharma, Dipali			Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED KINASE; FEMALE MICE; D1; TRANSCRIPTION; EXPRESSION; INDUCTION; OVEREXPRESSION; TRANSFORMATION; REQUIREMENT; TRANSDUCER	Numerous epidemiological studies documented that obesity is a risk factor for breast cancer development in postmenopausal women. Leptin, the key player in the regulation of energy balance and body weight control also acts as a growth factor on certain organs in both normal and disease state. In this study, we analyzed the role of leptin and the molecular mechanism(s) underlying its action in breast cancer cells that express both short and long isoforms of leptin receptor. Leptin increased MCF7 cell population in the S-phase of the cell cycle along with a robust increase in CYCLIN D1 expression. Also, leptin induced Stat3-phosphorylation-dependent proliferation of MCF7 cells as blocking Stat3 phosphorylation with a specific inhibitor, AG490, abolished leptin-induced proliferation. Using deletion constructs of CYCLIN D1 promoter and chromatin immunoprecipitation assay, we show that leptin induced increase in CYCLIN D1 promoter activity is mediated through binding of activated Stat3 at the Stat binding sites and changes in histone acetylation and methylation. We also show specific involvement of coactivator molecules, histone acetyltransferase SRC1, and mediator complex in leptin-mediated regulation of CYCLIN D1 promoter. Importantly, silencing of SRC1 and Med1 abolished the leptin induced increase in CYCLIN D1 expression and MCF7 cell proliferation. Intriguingly, recruitment of both SRC1 and Med1 was dependent on phosphorylated Stat3 as AG490 treatment inhibited leptin-induced recruitment of these coactivators to CYCLIN D1 promoter. Our data suggest that CYCLIN D1 may be a target gene for leptin mediated growth stimulation of breast cancer cells and molecular mechanisms involve activated Stat3-mediated recruitment of distinct coactivator complexes.	Emory Univ, Sch Med, Div Digest Dis, Dept Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Div Digest Dis, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Sharma, D (corresponding author), 1701 Uppergate Dr, Atlanta, GA 30322 USA.	dsharma@emory.edu			NATIONAL CANCER INSTITUTE [R01CA077337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062092, R01DK062092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA012933] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA077337-07, R01 CA077337-06A1, R01 CA077337] Funding Source: Medline; NIAAA NIH HHS [AA 12933, R21 AA012933, R21 AA012933-02] Funding Source: Medline; NIDDK NIH HHS [R56 DK062092, DK 062092, R01 DK062092, R01 DK062092-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 2004, PHYSIOL BEHAV, V81, P223, DOI 10.1016/j.physbeh.2004.02.014; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Bahrenberg G, 2002, MOL ENDOCRINOL, V16, P859, DOI 10.1210/me.16.4.859; Berclaz G, 2004, ANN ONCOL, V15, P875, DOI 10.1093/annonc/mdh222; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burdelya L, 2002, MOL CANCER THER, V1, P893; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cleary MP, 2004, EXP BIOL MED, V229, P182, DOI 10.1177/153537020422900207; Cleary MP, 2003, BREAST CANCER RES TR, V77, P205, DOI 10.1023/A:1021891825399; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Dizdar O, 2004, MED HYPOTHESES, V63, P790, DOI 10.1016/j.mehy.2004.01.046; Flajollet S, 2006, J BIOL CHEM, V281, P20338, DOI 10.1074/jbc.M603023200; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Gertler A, 2006, TRENDS ENDOCRIN MET, V17, P372, DOI 10.1016/j.tem.2006.09.006; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Han SW, 2003, ONCOL REP, V10, P141; Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467-789X.2001.00042.x; Housa D, 2006, PHYSIOL RES, V55, P233, DOI 10.33549/physiolres.930848; Huang L, 2000, Cell Res, V10, P81, DOI 10.1038/sj.cr.7290038; Ishikawa M, 2004, CLIN CANCER RES, V10, P4325, DOI 10.1158/1078-0432.CCR-03-0749; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Kenny FS, 1999, CLIN CANCER RES, V5, P2069; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; Manabe Y, 2003, J PATHOL, V201, P221, DOI 10.1002/path.1430; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Misra P, 2002, J BIOL CHEM, V277, P48745, DOI 10.1074/jbc.M208829200; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Palamara Kerri L, 2006, Cardiol Rev, V14, P238, DOI 10.1097/01.crd.0000233903.57946.fd; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761; Saxena NK, 2004, FASEB J, V18, P1612, DOI 10.1096/fj.04-1847fje; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; SHARMA D, 2006, ENDOCR-RELAT CANCER, V13, P1; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sulkowska M, 2006, PATHOL ONCOL RES, V12, P69, DOI 10.1007/BF02893446; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Xi SC, 2005, ONCOGENE, V24, P970, DOI 10.1038/sj.onc.1208316	55	159	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13316	13325		10.1074/jbc.M609798200	http://dx.doi.org/10.1074/jbc.M609798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344214	Green Accepted, hybrid			2022-12-27	WOS:000246060300019
J	Xia, SH; Forman, LW; Faller, DV				Xia, Shuhua; Forman, Lora W.; Faller, Douglas V.			Protein kinase C delta is required for survival of cells expressing activated p21(RAS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-INDUCED APOPTOSIS; CANCER CELLS; SIGNALING PATHWAYS; PREMATURE SENESCENCE; MEDIATED APOPTOSIS; PKC ISOFORMS; T-CELLS; INHIBITION; GROWTH; PHOSPHORYLATION	Inhibition of protein kinase C (PKC) activity in transformed cells and tumor cells containing activated p21(RAS) results in apoptosis. To investigate the pro-apoptotic pathway induced by the p21RAS oncoprotein, we first identified the specific PKC isozyme necessary to prevent apoptosis in the presence of activated p21(RAS). Dominant-negative mutants of PKC, short interfering RNA vectors, and PKC isozyme-specific chemical inhibitors directed against the PKC delta isozyme demonstrated that PKC delta plays a critical role in p21(RAS)- mediated apoptosis. An activating p21(RAS) mutation, or activation of the phosphatidylinositol 3-kinase (PI3K) Ras effector pathway, increased the levels of PKC delta protein and activity in cells, whereas inhibition of p21RAS activity decreased the expression of the PKC delta protein. Activation of the Akt survival pathway by oncogenic Ras required PKC delta activity. Akt activity was dramatically decreased after PKC delta suppression in cells containing activated p21(RAS). Conversely, constitutively activated Akt rescued cells from apoptosis induced by PKC delta inhibition. Collectively, these findings demonstrate that p21(RAS), through its downstream effector PI3K, induces PKC delta expression and that this increase in PKC delta activity, acting through Akt, is required for cell survival. The p21RAS effector molecule responsible for the initiation of the apoptotic signal after suppression of PKC delta activity was also determined to be PI3K. PI3K (p110(CAAX), where AA is aliphatic amino acid) was sufficient for induction of apoptosis after PKC delta inhibition. Thus, the same p21(RAS) effector, PI3K, is responsible for delivering both a pro-apoptotic signal and a survival signal, the latter being mediated by PKC delta and Akt. Selective suppression of PKC delta activity and consequent induction of apoptosis is a potential strategy for targeting of tumor cells containing an activated p21(RAS).	Boston Univ, Sch Med, Canc Res Ctr, Boston, MA 02118 USA	Boston University	Faller, DV (corresponding author), Boston Univ, Sch Med, Canc Res Ctr, K-701,715 Albany St, Boston, MA 02118 USA.	dfaller@bu.edu			NCI NIH HHS [R41 CA141908, CA108100, CA112102, R41 CA108100, R01 CA112102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112102, R41CA141908, R41CA108100] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Ahn JY, 2006, EMBO J, V25, P2083, DOI 10.1038/sj.emboj.7601111; Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Brodie C, 1998, MOL BRAIN RES, V56, P108, DOI 10.1016/S0169-328X(98)00035-7; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen CY, 2001, CELL GROWTH DIFFER, V12, P297; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; Chou CK, 2006, LIFE SCI, V78, P1823, DOI 10.1016/j.lfs.2005.08.039; Clark AS, 2003, CANCER RES, V63, P780; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gil-Perotin S, 2006, J NEUROSCI, V26, P1107, DOI 10.1523/JNEUROSCI.3970-05.2006; Gonzalez-Guerrico AM, 2005, J BIOCHEM MOL BIOL, V38, P639; Hiraragi H, 2005, J VIROL, V79, P9449, DOI 10.1128/JVI.79.15.9449-9457.2005; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jung JW, 2005, CANCER LETT, V225, P199, DOI 10.1016/j.canlet.2004.11.029; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kiley SC, 1999, CANCER RES, V59, P3230; Klampfer L, 2005, ONCOGENE, V24, P3932, DOI 10.1038/sj.onc.1208552; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 2006, J BIOL CHEM, V281, P3237, DOI 10.1074/jbc.M512167200; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Liou JS, 2004, J CELL PHYSIOL, V198, P277, DOI 10.1002/jcp.10409; Liou JS, 2000, J BIOL CHEM, V275, P39001, DOI 10.1074/jbc.M007154200; Majumder S., 1997, Indian Journal of Experimental Biology, V35, P162; McCracken MA, 2003, MOL CANCER THER, V2, P273; Mecklenbrauker I, 2004, NATURE, V431, P456, DOI 10.1038/nature02955; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Nakada M, 2005, AM J PATHOL, V167, P565, DOI 10.1016/S0002-9440(10)62998-7; Okhrimenko H, 2005, J BIOL CHEM, V280, P23643, DOI 10.1074/jbc.M501374200; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Stice LL, 2002, EXP CELL RES, V275, P17, DOI 10.1006/excr.2002.5482; SUN C, 2000, J STOMATOLOGY, V18, P237; Thimmaiah KN, 2003, CANCER RES, V63, P364; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Whang YE, 2004, VITAM HORM, V67, P409; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Zhang JD, 2005, J CELL BIOCHEM, V96, P522, DOI 10.1002/jcb.20535	62	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13199	13210		10.1074/jbc.M610225200	http://dx.doi.org/10.1074/jbc.M610225200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350960	hybrid, Green Accepted			2022-12-27	WOS:000246060300008
J	Selth, L; Svejstrup, JQ				Selth, Luke; Svejstrup, Jesper Q.			Vps75, a new yeast member of the NAP histone chaperone family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME ASSEMBLY PROTEIN-1; SACCHAROMYCES-CEREVISIAE; DNA; ACETYLATION; SCREEN; H2B	Homologues of nucleosome assembly protein 1 ( NAP1) are found throughout eukaryotes. Here we identify and characterize a new NAP family histone chaperone from budding yeast, named Vps75. Purified Vps75 preferentially binds histone H3/H4 tetramers and is capable of assembling nucleosomes in vitro. In vivo, Vps75 is associated with the chromatin of both active and inactive genes and telomeres. Others have previously reported that Vps75 forms a complex with Rtt109, required for acetylation of histone H3 lysine 56 ( H3 Lys- 56). Cells lacking RTT109 are sensitive to hydroxyurea, pointing to a role in replication. We show that VPS75 is not required for H3 Lys- 56 acetylation and that vps75 Delta cells are insensitive to hydroxyurea, suggesting that although Rtt109 and Vps75 associate and are likely to be functionally connected, they also have separate roles.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Svejstrup, JQ (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, Blanche Lane, S Mimms EN6 3LD, Herts, England.	j.svejstrup@cancer.org.uk	Selth, Luke/AAH-4823-2021	Selth, Luke/0000-0002-4686-1418; Svejstrup, Jesper/0000-0003-4964-6147				Askree SH, 2004, P NATL ACAD SCI USA, V101, P8658, DOI 10.1073/pnas.0401263101; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Kristjuhan A, 2004, EMBO J, V23, P4243, DOI 10.1038/sj.emboj.7600433; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Li MF, 1999, J MOL BIOL, V293, P1067, DOI 10.1006/jmbi.1999.3207; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Luger K, 2006, CHROMOSOME RES, V14, P5, DOI 10.1007/s10577-005-1026-1; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; McBryant SJ, 2003, J BIOL CHEM, V278, P44574, DOI 10.1074/jbc.M305636200; Mosammaparast N, 2002, EMBO J, V21, P6527, DOI 10.1093/emboj/cdf647; NELSON T, 1979, P NATL ACAD SCI USA, V76, P5510, DOI 10.1073/pnas.76.11.5510; Park YJ, 2006, P NATL ACAD SCI USA, V103, P1248, DOI 10.1073/pnas.0508002103; Park YJ, 2006, BIOCHEM CELL BIOL, V84, P549, DOI 10.1139/O06-088; Ricke RM, 2005, BIOL PROCED ONLINE, V7, P60, DOI 10.1251/bpo106; Schneider J, 2006, J BIOL CHEM, V281, P37270, DOI 10.1074/jbc.C600265200; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Wittmeyer J, 2004, METHOD ENZYMOL, V377, P322; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011	21	62	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12358	12362		10.1074/jbc.C700012200	http://dx.doi.org/10.1074/jbc.C700012200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17344218	hybrid			2022-12-27	WOS:000245942800003
J	Doucet, N; Savard, PY; Pelletier, JN; Gagne, SM				Doucet, Nicolas; Savard, Pierre-Yves; Pelletier, Joelle N.; Gagne, Stephane M.			NMR investigation of Tyr(105) mutants in TEM-1 beta-lactamase - Dynamics are correlated with function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALCOHOL-DEHYDROGENASE; MODEL-FREE APPROACH; ANISOTROPIC ROTATIONAL DIFFUSION; MAGNETIC-RESONANCE RELAXATION; SITE LOOP MOTION; TRIOSEPHOSPHATE ISOMERASE; BACKBONE DYNAMICS; ESCHERICHIA-COLI; ACTIVE-SITE; DIHYDROFOLATE-REDUCTASE	The existence of coupled residue motions on various time scales in enzymes is now well accepted, and their detailed characterization has become an essential element in understanding the role of dynamics in catalysis. To this day, a handful of enzyme systems has been shown to rely on essential residue motions for catalysis, but the generality of such phenomena remains to be elucidated. Using NMR spectroscopy, we investigated the electronic and dynamic effects of several mutations at position 105 in TEM-1 beta-lactamase, an enzyme responsible for antibiotic resistance. Even in absence of substrate, our results show that the number and magnitude of short and long range effects on H-1-N-15 chemical shifts are correlated with the catalytic efficiencies of the various Y105X mutants investigated. In addition, N-15 relaxation experiments on mutant Y105D show that several active-site residues of TEM-1 display significantly altered motions on both picosecond-nanosecond and microsecond-millisecond time scales despite many being far away from the site of mutation. The altered motions among various active-site residues in mutant Y105D may account for the observed decrease in catalytic efficiency, therefore suggesting that short and long range residue motions could play an important catalytic role in TEM-1 beta-lactamase. These results support previous observations suggesting that internal motions play a role in promoting protein function.	Univ Montreal, Dept Chim, Montreal, PQ H3C 3J7, Canada; Univ Laval, Dept Biochim & Microbiol & CREFSIP, Quebec City, PQ G1K 7P4, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Laval University; Universite de Montreal	Gagne, SM (corresponding author), Univ Montreal, Dept Chim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	stephane.gagne@rsvs.ulaval.ca						Agarwal PK, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-2; Agarwal PK, 2004, BIOCHEMISTRY-US, V43, P10605, DOI 10.1021/bi0495228; Agarwal PK, 2002, P NATL ACAD SCI USA, V99, P2794, DOI 10.1073/pnas.052005999; Agarwal PK, 2000, J AM CHEM SOC, V122, P4803, DOI 10.1021/ja994456w; Akke M, 2002, CURR OPIN STRUC BIOL, V12, P642, DOI 10.1016/S0959-440X(02)00369-X; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; Beach H, 2005, J AM CHEM SOC, V127, P9167, DOI 10.1021/ja0514949; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Billeter SR, 2001, J AM CHEM SOC, V123, P11262, DOI 10.1021/ja011384b; Carnevale V, 2006, J AM CHEM SOC, V128, P9766, DOI 10.1021/ja060896t; Clarkson MW, 2006, BIOCHEMISTRY-US, V45, P7693, DOI 10.1021/bi060652l; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Colby TD, 1998, BIOCHEMISTRY-US, V37, P9295, DOI 10.1021/bi973184b; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Derreumaux P, 1998, BIOPHYS J, V74, P72, DOI 10.1016/S0006-3495(98)77768-9; Desamero R, 2003, BIOCHEMISTRY-US, V42, P2941, DOI 10.1021/bi026994i; Doucet N, 2004, J BIOL CHEM, V279, P46295, DOI 10.1074/jbc.M407606200; Eisenmesser EZ, 2005, NATURE, V438, P117, DOI 10.1038/nature04105; EPSTEIN DM, 1995, BIOCHEMISTRY-US, V34, P11037, DOI 10.1021/bi00035a009; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gagne SM, 1998, J MOL BIOL, V278, P667, DOI 10.1006/jmbi.1998.1723; Garcia-Viloca M, 2004, SCIENCE, V303, P186, DOI 10.1126/science.1088172; Guallar V, 2004, J MOL BIOL, V337, P227, DOI 10.1016/j.jmb.2003.11.016; Hammes-Schiffer S, 2002, BIOCHEMISTRY-US, V41, P13335, DOI 10.1021/bi0267137; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; Jarymowycz VA, 2006, CHEM REV, V106, P1624, DOI 10.1021/cr040421p; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kern D, 2003, CURR OPIN STRUC BIOL, V13, P748, DOI 10.1016/j.sbi.2003.10.008; Kovrigin EL, 2006, BIOCHEMISTRY-US, V45, P2636, DOI 10.1021/bi0525066; Kovrigin EL, 2006, J AM CHEM SOC, V128, P7724, DOI 10.1021/ja061435a; LENFANT F, 1991, J BIOL CHEM, V266, P17187; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; Maveyraud L, 1998, J AM CHEM SOC, V120, P9748, DOI 10.1021/ja9818001; Meroueh SO, 2005, J AM CHEM SOC, V127, P15397, DOI 10.1021/ja051592u; Meroueh SO, 2002, J AM CHEM SOC, V124, P9422, DOI 10.1021/ja026547q; Neet KE, 1998, J BIOL CHEM, V273, P25527, DOI 10.1074/jbc.273.40.25527; NICHOLSON LK, 1992, BIOCHEMISTRY-US, V31, P5253, DOI 10.1021/bi00138a003; Osborne MJ, 2001, BIOCHEMISTRY-US, V40, P9846, DOI 10.1021/bi010621k; Pawley NH, 2001, J BIOMOL NMR, V20, P149, DOI 10.1023/A:1011249816560; QUENOUILLE MH, 1949, J ROY STAT SOC B, V11, P68; Radkiewicz JL, 2000, J AM CHEM SOC, V122, P225, DOI 10.1021/ja9913838; Rozovsky S, 2001, J MOL BIOL, V310, P259, DOI 10.1006/jmbi.2001.4672; Rozovsky S, 2001, J MOL BIOL, V310, P271, DOI 10.1006/jmbi.2001.4673; Sabbagh Y, 1998, ANTIMICROB AGENTS CH, V42, P2319, DOI 10.1128/AAC.42.9.2319; Savard PY, 2006, BIOCHEMISTRY-US, V45, P11414, DOI 10.1021/bi060414q; Savard PY, 2004, J BIOMOL NMR, V29, P433, DOI 10.1023/B:JNMR.0000032503.96942.68; Sosa-Peinado A, 2000, PROTEIN EXPRES PURIF, V19, P235, DOI 10.1006/prep.2000.1243; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Tjandra N, 1996, J BIOMOL NMR, V8, P273, DOI 10.1007/BF00410326; Tousignant A, 2004, CHEM BIOL, V11, P1037, DOI 10.1016/j.chembiol.2004.06.007; Vakulenko SB, 1999, J BIOL CHEM, V274, P23052, DOI 10.1074/jbc.274.33.23052; Wand AJ, 2001, NAT STRUCT BIOL, V8, P926, DOI 10.1038/nsb1101-926; Wand AJ, 2001, SCIENCE, V293; Wang XJ, 2002, J BIOL CHEM, V277, P32149, DOI 10.1074/jbc.M204212200; Xu XP, 2001, J BIOMOL NMR, V21, P321, DOI 10.1023/A:1013324104681; Zhu G, 2000, J MAGN RESON, V143, P423, DOI 10.1006/jmre.2000.2022	63	28	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2007	282	29					21448	21459		10.1074/jbc.M609777200	http://dx.doi.org/10.1074/jbc.M609777200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	190GP	17426035	hybrid			2022-12-27	WOS:000248047500072
J	Gendron, C; Kashiwagi, M; Lim, NH; Enghild, JJ; Thogersen, IB; Hughes, C; Caterson, B; Nagase, H				Gendron, Christi; Kashiwagi, Masahide; Lim, Ngee Han; Enghild, Jan J.; Thogersen, Ida B.; Hughes, Clare; Caterson, Bruce; Nagase, Hideaki			Proteolytic activities of human ADAMTS-5 - Comparative studies with ADAMTS-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; IN-VITRO; INTERGLOBULAR DOMAIN; CARTILAGE EXPLANTS; AGGRECANASE-1 ADAMTS-4; MONOCLONAL-ANTIBODIES; ARTICULAR-CARTILAGE; BINDING PROPERTIES; CLEAVAGE; METALLOPROTEINASES	Aggrecanases have been characterized as proteinases that cleave the Glu(373)-Ala(374) bond of the aggrecan core protein, and they are multidomain metalloproteinases belonging to the ADAMTS (adamalysin with thrombospondin type 1 motifs) family. The first aggrecanases discovered were ADAMTS-4 (aggrecanase 1) andADAMTS-5 (aggrecanase 2). They contain a zinc catalytic domain followed by non-catalytic ancillary domains, including a disintegrin domain, a thrombospondin domain, a cysteine-rich domain, and a spacer domain. In the case of ADAMTS-5, a second thrombospondin domain follows the spacer domain. We previously reported that the non-catalytic domains of ADAMTS-4 influence both its extracellular matrix interaction and proteolytic abilities. Here we report the effects of these domains of ADAMTS-5 on the extracellular matrix interaction and proteolytic activities and compare them with those of ADAMTS-4. Although the spacer domain was critical for ADAMTS-4 localization in the matrix, the cysteine-rich domain influenced ADAMTS-5 localization. Similar to previous reports of other ADAMTS family members, very little proteolytic activity was detected with the ADAMTS-5 catalytic domain alone. The sequential inclusion of each carboxyl-terminal domain enhanced its activity against aggrecan, carboxymethylated transferrin, fibromodulin, decorin, biglycan, and fibronectin. Both ADAMTS-4 and -5 had a broad optimal activity at pH 7.0-9.5. Aggrecanolytic activities were sensitive to the NaCl concentration, but activities on non-aggrecan substrates, e. g. carboxymethylated transferrin, were not affected. Although ADAMTS-4 and ADAMTS-5 had similar general proteolytic activities, the aggrecanase activity of ADAMTS-5 was at least 1,000-fold greater than that of ADAMTS-4 under physiological conditions. Our studies suggest that ADAMTS-5 is a major aggrecanase in cartilage metabolism and pathology.	Univ London Imperial Coll Sci & Technol, Kennedy Inst, Div Rheumatol, London W6 8LH, England; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark; Univ Cardiff Wales, Sch Biosci, Connect Tissue Labs, Cardiff CF1 3US, Wales	Imperial College London; University of Oxford; Aarhus University; Cardiff University	Nagase, H (corresponding author), Kennedy Inst, 1 Aspenlea Rd,Hammersmith, London W6 8LH, England.	h.nagase@imperial.ac.uk	Hughes, Clare E/A-4526-2010; Lim, Ngee Han/B-4226-2011; Caterson, Bruce/A-8085-2010	Lim, Ngee Han/0000-0002-8520-7857; Enghild, Jan Johannes/0000-0001-9292-9172; Caterson, Bruce/0000-0001-6016-0661; Hughes, Clare/0000-0003-4726-5877	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Bau B, 2002, ARTHRITIS RHEUM, V46, P2648, DOI 10.1002/art.10531; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; CATERSON B, 1985, FED PROC, V44, P386; Colige A, 2005, J BIOL CHEM, V280, P34397, DOI 10.1074/jbc.M506458200; Collins-Racie LA, 2004, MATRIX BIOL, V23, P219, DOI 10.1016/j.matbio.2004.05.004; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Gendron C, 2003, FEBS LETT, V555, P431, DOI 10.1016/S0014-5793(03)01295-X; Glasson SS, 2004, ARTHRITIS RHEUM-US, V50, P2547, DOI 10.1002/art.20558; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; Heathfield TF, 2004, J BIOL CHEM, V279, P6286, DOI 10.1074/jbc.M307765200; Held-Feindt J, 2006, INT J CANCER, V118, P55, DOI 10.1002/ijc.21258; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kevorkian L, 2004, ARTHRITIS RHEUM-US, V50, P131, DOI 10.1002/art.11433; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Little CB, 2005, ARTHRITIS RHEUM-US, V52, P1461, DOI 10.1002/art.21022; Llamazares M, 2003, J BIOL CHEM, V278, P13382, DOI 10.1074/jbc.M211900200; Majerus EM, 2005, J BIOL CHEM, V280, P21773, DOI 10.1074/jbc.M502529200; Malfait AM, 2002, J BIOL CHEM, V277, P22201, DOI 10.1074/jbc.M200431200; Melching LI, 2006, OSTEOARTHR CARTILAGE, V14, P1147, DOI 10.1016/j.joca.2006.05.014; Nagase H, 2003, ARTHRITIS RES THER, V5, P94, DOI 10.1186/ar630; Patwari P, 2005, OSTEOARTHR CARTILAGE, V13, P269, DOI 10.1016/j.joca.2004.10.023; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Roughley PJ, 2003, BIOCHEM J, V375, P183, DOI 10.1042/BJ20030609; Ruoslahti E, 1978, Ann N Y Acad Sci, V312, P178, DOI 10.1111/j.1749-6632.1978.tb16802.x; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soejima K, 2003, BLOOD, V102, P3232, DOI 10.1182/blood-2003-03-0908; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Stewart MC, 2006, OSTEOARTHR CARTILAGE, V14, P392, DOI 10.1016/j.joca.2005.11.009; Sztrolovics R, 1999, BIOCHEM J, V339, P571, DOI 10.1042/0264-6021:3390571; Tao ZY, 2005, BLOOD, V106, P141, DOI 10.1182/blood-2004-11-4188; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2004, J BIOL CHEM, V279, P17554, DOI 10.1074/jbc.M313041200; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; Wainwright SD, 2006, MATRIX BIOL, V25, P317, DOI 10.1016/j.matbio.2006.03.006; WYCKOFF M, 1977, ANAL BIOCHEM, V78, P459, DOI 10.1016/0003-2697(77)90107-5; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405; Zeng WL, 2006, BBA-GEN SUBJECTS, V1760, P517, DOI 10.1016/j.bbagen.2006.01.013; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200	52	203	213	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18294	18306		10.1074/jbc.M701523200	http://dx.doi.org/10.1074/jbc.M701523200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17430884	hybrid			2022-12-27	WOS:000247302000036
J	Pochetti, G; Godio, C; Mitro, N; Caruso, D; Galmozzi, A; Scurati, S; Loiodice, F; Fracchiolla, G; Tortorella, P; Laghezza, A; Lavecchia, A; Novellino, E; Mazza, F; Crestani, M				Pochetti, Giorgio; Godio, Cristina; Mitro, Nico; Caruso, Donatella; Galmozzi, Andrea; Scurati, Samuele; Loiodice, Fulvio; Fracchiolla, Giuseppe; Tortorella, Paolo; Laghezza, Antonio; Lavecchia, Antonio; Novellino, Ettore; Mazza, Fernando; Crestani, Maurizio			Insights into the mechanism of partial agonism - Crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIDIABETIC THIAZOLIDINEDIONE; FATTY-ACIDS; PPAR-ALPHA; SELECTIVITY; REVEALS; CRYSTALLOGRAPHY; TRANSCRIPTION; DETERMINANTS; RECRUITMENT; SPECIFICITY	The peroxisome proliferator-activated receptors (PPARs) are transcriptional regulators of glucose and lipid metabolism. They are activated by natural ligands, such as fatty acids, and are also targets of synthetic antidiabetic and hypolipidemic drugs. By using cell-based reporter assays, we studied the transactivation activity of two enantiomeric ureidofibrate-like derivatives. In particular, we show that the R-enantiomer, (R)-1, is a full agonist of PPAR gamma, whereas the S-enantiomer, (S)-1, is a less potent partial agonist. Most importantly, we report the x-ray crystal structures of the PPAR gamma ligand binding domain complexed with the R- and the S- enantiomer, respectively. The analysis of the two crystal structures shows that the different degree of stabilization of the helix 12 induced by the ligand determines its behavior as full or partial agonist. Another crystal structure of the PPAR gamma center dot( S)-1 complex, only differing in the soaking time of the ligand, is also presented. The comparison of the two structures of the complexes with the partial agonist reveals significant differences and is suggestive of the possible coexistence in solution of transcriptionally active and inactive forms of helix 12 in the presence of a partial agonist. Mutation analysis confirms the importance of Leu(465), Leu(469), and Ile(472) in the activation by (R)-1 and underscores the key role of Gln(286) in the PPAR gamma activity.	CNR, Ist Cristallog, Area Ric ROMA 1, Monterotondo Stn, I-00016 Rome, Italy; Univ Milan, Lab Giovanni Galli Biochim & Biol Mol Lipidi & Sp, Dipartimento Sci Farmacol, I-20133 Milan, Italy; Univ Bari, Dipartimento Farmacochim, I-70125 Bari, Italy; Univ Naples Federico II, Dipartimento Chim Farmaceut, I-80131 Naples, Italy; Univ Aquila, Dipartimento Chim Ingn Chim & Mat, I-67010 Laquila, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Di Cristallografia (IC-CNR); University of Milan; Universita degli Studi di Bari Aldo Moro; University of Naples Federico II; University of L'Aquila	Pochetti, G (corresponding author), CNR, Ist Cristallog, Area Ric ROMA 1, Monterotondo Stn, Sede Monterotondo,Via Salaria Km 29-300, I-00016 Rome, Italy.	giorgio.pochetti@ic.cnr.it	caruso, donatella/A-3332-2014; FRACCHIOLLA, Giuseppe/P-3899-2015; pochetti, giorgio/AAU-7069-2020; Lavecchia, Antonio/P-9476-2017; Laghezza, Antonio/F-7420-2014	caruso, donatella/0000-0003-2115-778X; FRACCHIOLLA, Giuseppe/0000-0003-4991-3962; Lavecchia, Antonio/0000-0002-2181-8026; Novellino, Ettore/0000-0002-2181-2142; Mitro, Nico/0000-0002-5000-3619; Laghezza, Antonio/0000-0001-6221-6155; Godio, Cristina/0000-0003-2639-6368; Crestani, Maurizio/0000-0001-9230-1078				Arakawa K, 2004, CLIN EXP PHARMACOL P, V31, P8, DOI 10.1111/j.1440-1681.2004.03954.x; Benko S, 2003, J BIOL CHEM, V278, P43797, DOI 10.1074/jbc.M306199200; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Berger JP, 2005, TRENDS PHARMACOL SCI, V26, P244, DOI 10.1016/j.tips.2005.03.003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgermeister E, 2006, MOL ENDOCRINOL, V20, P809, DOI 10.1210/me.2005-0171; Cronet P, 2001, STRUCTURE, V9, P699, DOI 10.1016/S0969-2126(01)00634-7; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Ebdrup S, 2003, J MED CHEM, V46, P1306, DOI 10.1021/jm021027r; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gangloff M, 2001, J BIOL CHEM, V276, P15059, DOI 10.1074/jbc.M009870200; Hellal-Levy C, 2000, MOL ENDOCRINOL, V14, P1210, DOI 10.1210/me.14.8.1210; Hulin B, 1996, CURR PHARM DESIGN, V2, P85; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; Kallenberger BC, 2003, NAT STRUCT BIOL, V10, P136, DOI 10.1038/nsb892; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Love JD, 2002, J BIOL CHEM, V277, P11385, DOI 10.1074/jbc.M110869200; Lu IL, 2006, J MED CHEM, V49, P2703, DOI 10.1021/jm051129s; Nagy L, 2004, TRENDS BIOCHEM SCI, V29, P317, DOI 10.1016/j.tibs.2004.04.006; Nettles KW, 2005, ANNU REV PHYSIOL, V67, P309, DOI 10.1146/annurev.physiol.66.032802.154710; Nettles KW, 2004, MOL CELL, V13, P317, DOI 10.1016/S1097-2765(04)00054-1; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Ostberg T, 2004, J BIOL CHEM, V279, P41124, DOI 10.1074/jbc.M401552200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sauerberg P, 2002, J MED CHEM, V45, P789, DOI 10.1021/jm010964g; Schoonjans K, 2000, LANCET, V355, P1008, DOI 10.1016/S0140-6736(00)90002-3; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Takada I, 2000, MOL ENDOCRINOL, V14, P733, DOI 10.1210/me.14.5.733; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001	39	100	103	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17314	17324		10.1074/jbc.M702316200	http://dx.doi.org/10.1074/jbc.M702316200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17403688	hybrid			2022-12-27	WOS:000246946500065
J	Wang, LW; Dlugosz, M; Somerville, RPT; Raed, M; Haltiwanger, RS; Apte, SS				Wang, Lauren W.; Dlugosz, Malgosia; Somerville, Robert P. T.; Raed, Mona; Haltiwanger, Robert S.; Apte, Suneel S.			O-fucosylation of thrombospondin type 1 repeats in ADAMTS-like-1/punctin-1 regulates secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-LIKE; ADAMTS FAMILY; EXTRACELLULAR-MATRIX; C-MANNOSYLATION; LIGAND-BINDING; LINKED FUCOSE; GDP-FUCOSE; GLYCOSYLATION; PROTEIN; NOTCH	The ADAMTS superfamily contains several metalloproteases (ADAMTS proteases) as well as ADAMTS-like molecules that lack proteolytic activity. Their common feature is the presence of one or more thrombospondin type-1 repeats (TSRs) within a characteristic modular organization. ADAMTS like-1/punctin-1 has four TSRs. Previously, O-fucosylation on Ser or Thr mediated by the endoplasmic reticulum-localized enzyme protein-O-fucosyltransferase 2 (POFUT2) was described for TSRs of thrombospondin-1, properdin, and F-spondin within the sequence Cys-Xaa(1)-Xaa(2)- Ser/Thr)-Cys-Xaa-Xaa-Gly (where the fucosylated residue is underlined). On mass spectrometric analysis of tryptic peptides from recombinant secreted human punctin-1, the appropriate peptides from TSR2, TSR3, and TSR4 were found to bear either a fucose monosaccharide (TSR3, TSR4) or a fucose-glucose disaccharide (TSR2, TSR3, TSR4). Although mass spectral analysis did not unambiguously identify the relevant peptide from TSR1, metabolic labeling of cells expressing TSR1 and the cysteine-rich module led to incorporation of [H-3] fucose into this construct. Mutation of the putative modified Ser/Thr residues in TSR2, TSR3, and TSR4 led to significantly decreased levels of secreted punctin-1. Similarly, expression of punctin-1 in Lec-13 cells that are deficient in conversion of GDP-mannose to GDP-fucose substantially decreased the levels of secreted protein, which were restored upon culture in the presence of exogenous L-fucose. In addition, mutation of the single N-linked oligosaccharide in punctin-1 led to decreased levels of secreted punctin-1. Taken together, the data define a critical role for N-glycosylation and O-fucosylation in the biosynthesis of punctin-1. From a broad perspective, these data suggest that O-fucosylation may be a widespread post-translational modification in members of the ADAMTS superfamily with possible regulatory consequences.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Cleveland Clinic Foundation; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave,ND20, Cleveland, OH 44195 USA.	aptes@ccf.org		Apte, Suneel/0000-0001-8441-1226	NIAMS NIH HHS [AR49930] Funding Source: Medline; NIGMS NIH HHS [GM61126] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049930, R56AR049930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Dagoneau N, 2004, AM J HUM GENET, V75, P801, DOI 10.1086/425231; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Hall NG, 2003, MATRIX BIOL, V22, P501, DOI 10.1016/S0945-053X(03)00075-1; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; Hirohata S, 2002, J BIOL CHEM, V277, P12182, DOI 10.1074/jbc.M109665200; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Huxley-Jones J, 2005, INT J BIOCHEM CELL B, V37, P1838, DOI 10.1016/j.biocel.2005.03.009; Kozma K, 2006, J BIOL CHEM, V281, P36742, DOI 10.1074/jbc.M605912200; Kramerova IA, 2000, DEVELOPMENT, V127, P5475; KUMAR R, 1989, MOL CELL BIOL, V9, P5713, DOI 10.1128/MCB.9.12.5713; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Lee NV, 2006, EMBO J, V25, P5270, DOI 10.1038/sj.emboj.7601400; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200; Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Nardi JB, 2001, J INSECT PHYSIOL, V47, P997, DOI 10.1016/S0022-1910(01)00074-9; Nita-Lazar A, 2006, METHOD ENZYMOL, V417, P93, DOI 10.1016/S0076-6879(06)17008-1; Nita-Lazar Aleksandra, 2006, V347, P57; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Rampal R, 2005, J BIOL CHEM, V280, P42454, DOI 10.1074/jbc.M509552200; Rampal R, 2005, J BIOL CHEM, V280, P32133, DOI 10.1074/jbc.M506104200; Rao C, 2003, DEVELOPMENT, V130, P4665, DOI 10.1242/dev.00668; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; Sato T, 2006, GLYCOBIOLOGY, V16, P1194, DOI 10.1093/glycob/cwl035; Shao L, 2003, J BIOL CHEM, V278, P7775, DOI 10.1074/jbc.M212221200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; STANLEY P, 1985, MOL CELL BIOL, V5, P923, DOI 10.1128/MCB.5.5.923; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Varki A., 1999, ESSENTIALS GLYCOBIOL; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Xu AG, 2005, J BIOL CHEM, V280, P30158, DOI 10.1074/jbc.M505569200	44	58	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17024	17031		10.1074/jbc.M701065200	http://dx.doi.org/10.1074/jbc.M701065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17395588	hybrid			2022-12-27	WOS:000246946500035
J	Yang, Z; Webb, TI; Lynch, JW				Yang, Zhe; Webb, Timothy I.; Lynch, Joseph W.			Closed-state cross-linking of adjacent beta 1 Subunits in alpha 1 beta 1 GABA(a) receptors via introduced 6 ' cysteines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR CHANNEL; GAMMA-AMINOBUTYRIC-ACID; GABA(A) RECEPTORS; GATING MECHANISM; PROTEIN MOBILITY; ION-CHANNEL; PORE; GLYCINE; SEGMENT; GATE	The pore structural changes associated with Cys-loop receptor gating are currently the subject of considerable interest. Several functional approaches have shown that surface exposure of pore-lining side chains does not change significantly during activation. However, a disulfide trapping study on alpha 1(T6 ' C) beta 1(T6 ' C) gamma-aminobutyric acid type A (GABA(A)) receptors (GABA(A)Rs), which showed that adjacent beta subunits cross-link in the open state only, concluded that channel gating is mediated by beta subunits contra-rotating through a summed angle of similar to 120(o). Such a large rotation is not easily reconciled with other evidence. The present study initially sought to investigate an observation that appeared inconsistent with the rotation model: namely that alpha 1(T6 ' C) beta 1(T6 ' C) GABA(A)Rs expressed in HEK293 cells form 6 ' cysteine-mediated disulfide bonds in the closed state. On the basis of electrophysiological and Western blotting experiments, we conclude that adjacent beta(T6 ' C) subunits dimerise efficiently in the closed state via cross-links between their respective 6 ' cysteines and that this locks the channels closed. This questions the beta. subunit contra-rotation model of activation and raises the question of how the closed state cross-links form. We propose that beta subunit 6 ' cysteines move into sufficiently close proximity for disulfide formation via relatively large amplitude random thermal motions that appear to be a unique feature of beta subunits. Because dimerized channels are locked closed, we conclude either that the spontaneous beta subunit movements or asymmetries in the movements of adjacent beta subunits during activation are essential for pore opening. Our results identify a novel feature of GABA(A)R gating that may be important for understanding its activation mechanism.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland	Lynch, JW (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	j.lynch@uq.edu.au	Lynch, Joseph/C-8636-2009; Webb, Timothy I/H-6941-2015	Webb, Timothy I/0000-0002-6263-6296				Chen LG, 2006, P NATL ACAD SCI USA, V103, P5185, DOI 10.1073/pnas.0600370103; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; Cymes GD, 2005, NATURE, V438, P975, DOI 10.1038/nature04293; Goren EN, 2004, J BIOL CHEM, V279, P11198, DOI 10.1074/jbc.M314050200; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; Horenstein J, 2005, J BIOL CHEM, V280, P1573, DOI 10.1074/jbc.M410881200; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; Mitra A, 2005, P NATL ACAD SCI USA, V102, P15069, DOI 10.1073/pnas.0505090102; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Paas Y, 2005, P NATL ACAD SCI USA, V102, P15877, DOI 10.1073/pnas.0507599102; Panicker S, 2002, J NEUROSCI, V22, P1629, DOI 10.1523/JNEUROSCI.22-05-01629.2002; Shan Q, 2002, J BIOL CHEM, V277, P44845, DOI 10.1074/jbc.M208647200; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1	21	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16803	16810		10.1074/jbc.M611555200	http://dx.doi.org/10.1074/jbc.M611555200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17405880	hybrid			2022-12-27	WOS:000246946500012
J	Bocharov, EV; Pustovalova, YE; Pavlov, KV; Volynsky, PE; Goncharuk, MV; Ermolyuk, YS; Karpunin, DV; Schulga, AA; Kirpichnikov, MP; Efremov, RG; Maslennikov, IV; Arseniev, AS				Bocharov, Eduard V.; Pustovalova, Yulia E.; Pavlov, Konstantin V.; Volynsky, Pavel E.; Goncharuk, Marina V.; Ermolyuk, Yaroslav S.; Karpunin, Dmitry V.; Schulga, Alexey A.; Kirpichnikov, Michail P.; Efremov, Roman G.; Maslennikov, Innokenty V.; Arseniev, Alexander S.			Unique dimeric structure of BNip3 transmembrane domain suggests membrane permeabilization as a cell death trigger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDIMENSIONAL NMR EXPERIMENTS; BCL-2 FAMILY; MITOCHONDRIAL PERMEABILITY; OUTER-MEMBRANE; PROTEIN; CHANNEL; HYDROPHOBICITY; APOPTOSIS; DYNAMICS; NECROSIS	BNip3 is a prominent representative of apoptotic Bcl-2 proteins with rather unique properties initiating an atypical programmed cell death pathway resembling both necrosis and apoptosis. Many Bcl-2 family proteins modulate the permeability state of the outer mitochondrial membrane by forming homo-and hetero-oligomers. The structure and dynamics of the homodimeric transmembrane domain of BNip3 were investigated with the aid of solution NMR in lipid bicelles and molecular dynamics energy relaxation in an explicit lipid bilayer. The right-handed parallel helix-helix structure of the domain with a hydrogen bond-rich His-Ser node in the middle of the membrane, accessibility of the node for water, and continuous hydrophilic track across the membrane suggest that the domain can provide an ion-conducting pathway through the membrane. Incorporation of the BNip3 transmembrane domain into an artificial lipid bilayer resulted in pH-dependent conductivity increase. A possible biological implication of the findings in relation to triggering necrosis-like cell death by BNip3 is discussed.	Russian Acad Sci, Struct Biol Lab, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Russian Acad Sci, Ingn Prot Lab, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Russian Acad Sci, Lab Neuroreceptors & Neuroregulators, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Russian Acad Sci, Lab Bioelectrochem, Frumkin Inst Phys Chem & Electrochem, Moscow 119991, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Russian Academy of Sciences; Frumkin Institute of Physical Chemistry & Electrochemistry	Bocharov, EV (corresponding author), Russian Acad Sci, Struct Biol Lab, Shemyakin Ovchinnikov Inst Bioorgan Chem, Ul Miklukho Maklaya 16-10, Moscow 117997, Russia.	bon@nmr.ru; aars@nmr.ru	Pavlov, Konstantin/T-6515-2017; Schulga, Alexey/T-3856-2018; Pustovalova, Yulia/AAB-1221-2021; Volynsky, Pavel/A-8360-2014; Maslennikov, Innokentiy/I-2524-2012; Pavlov, Konstantin V./Y-8481-2018; Roman, Efremov/A-7460-2014; Goncharuk, Marina/V-1558-2018	Pavlov, Konstantin/0000-0003-1637-8000; Schulga, Alexey/0000-0003-3425-0828; Pustovalova, Yulia/0000-0003-3024-1764; Volynsky, Pavel/0000-0002-0471-4188; Pavlov, Konstantin V./0000-0003-1637-8000; Roman, Efremov/0000-0002-5474-4721; Maslennikov, Innokentiy/0000-0003-4292-5821				Andersson A, 2005, LANGMUIR, V21, P7702, DOI 10.1021/la0513003; Aouacheria A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Bathori G, 2006, J BIOL CHEM, V281, P17347, DOI 10.1074/jbc.M600906200; Bocharov EV, 2004, J BIOL CHEM, V279, P17697, DOI 10.1074/jbc.M313384200; Carmeliet E, 1999, PHYSIOL REV, V79, P917, DOI 10.1152/physrev.1999.79.3.917; Cavanagh J, 2007, PROTEIN NMR SPECTROSCOPY: PRINCIPLES AND PRACTICE, 2ND EDITION, P1; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Daragan VA, 1997, PROG NUCL MAG RES SP, V31, P63, DOI 10.1016/S0079-6565(97)00006-X; Decoursey TE, 2003, PHYSIOL REV, V83, P475, DOI 10.1152/physrev.00028.2002; EFREMOV RG, 1995, J PHYS CHEM-US, V99, P10658, DOI 10.1021/j100026a033; Fernandez C, 2002, P NATL ACAD SCI USA, V99, P13533, DOI 10.1073/pnas.212515099; Frazier DP, 2006, ANTIOXID REDOX SIGN, V8, P1625, DOI 10.1089/ars.2006.8.1625; Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guntert P, 2003, PROG NUCL MAG RES SP, V43, P105, DOI 10.1016/S0079-6565(03)00021-9; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Kass I, 2005, STRUCTURE, V13, P1789, DOI 10.1016/j.str.2005.08.022; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee H, 2006, MOL CELLS, V21, P1; Lemasters JJ, 2006, BBA-MOL BASIS DIS, V1762, P181, DOI 10.1016/j.bbadis.2005.10.006; Lemeshko SV, 2004, MOL CELL BIOCHEM, V256, P127, DOI 10.1023/B:MCBI.0000009864.77216.00; Li XX, 2005, BIOPHYS J, V88, P2577, DOI 10.1529/biophysj.104.049403; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; O'Rourke B, 2007, ANNU REV PHYSIOL, V69, P19, DOI 10.1146/annurev.physiol.69.031905.163804; Orekhov VY, 1995, APPL MAGN RESON, V9, P581, DOI 10.1007/BF03162365; Pavlovic D, 2003, P NATL ACAD SCI USA, V100, P6104, DOI 10.1073/pnas.1031527100; Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001; Porcelli AM, 2005, BIOCHEM BIOPH RES CO, V326, P799, DOI 10.1016/j.bbrc.2004.11.105; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; SKLENAR V, 1995, J MAGN RESON SER A, V114, P132, DOI 10.1006/jmra.1995.1119; Skulachev VP, 2006, APOPTOSIS, V11, P473, DOI 10.1007/s10495-006-5881-9; Sulistijo ES, 2006, J MOL BIOL, V364, P974, DOI 10.1016/j.jmb.2006.09.065; Sulistijo ES, 2003, J BIOL CHEM, V278, P51950, DOI 10.1074/jbc.M308429200; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Walters RFS, 2006, P NATL ACAD SCI USA, V103, P13658, DOI 10.1073/pnas.0605878103; Webster KA, 2005, J MOL CELL CARDIOL, V38, P35, DOI 10.1016/j.yjmcc.2004.11.007; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	47	115	116	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16256	16266		10.1074/jbc.M701745200	http://dx.doi.org/10.1074/jbc.M701745200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17412696	hybrid			2022-12-27	WOS:000246794300033
J	D'Andrea-Merrins, M; Chang, L; Lam, AD; Ernst, SA; Stuenkel, EL				D'Andrea-Merrins, Matthew; Chang, Louise; Lam, Alice D.; Ernst, Stephen A.; Stuenkel, Edward L.			Munc18c interaction with syntaxin 4 monomers and SNARE complex intermediates in GLUT4 vesicle trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; 3T3-L1 ADIPOCYTES; IN-VIVO; INSULIN; PROTEIN; TRANSLOCATION; CELLS; COMPARTMENTS; SPECIFICITY; INHIBITION	In the process of insulin-stimulated GLUT4 vesicle exocytosis, Munc18c has been proposed to control SNARE complex formation by inactivating syntaxin 4 in a self-associated conformation. Using in vivo fluorescence resonance energy transfer in 3T3L1 adipocytes, co-immunoprecipitation, and in vitro binding assays, we provide data to indicate that Munc18c also associates with nearly equal affinity to a mutant of syntaxin 4 in a constitutively open ( unfolded) state ( L173A/E174A; LE). To bind to the open conformation of syntaxin 4, we found that Munc18c requires an interaction with the N terminus of syntaxin 4, which resembles Sly1 interaction with the N terminus of ER/Golgi syntaxins. However, both N and C termini of syntaxin 4 are required for Munc18c binding, since a mutation in the syntaxin 4 SNARE domain ( I241A) reduces the interaction, irrespective of syntaxin 4 conformation. Using an optical reporter for syntaxin 4-SNARE pairings in vivo, we demonstrate that Munc18c blocks recruitment of SNAP23 to wild type syntaxin 4 yet associates with syntaxin 4(LE)-SNAP23 Q-SNARE complexes. Fluorescent imaging of GLUT4 vesicles in 3T3L1 adipocytes revealed that syntaxin 4(LE) expressed with Munc18c bypasses the requirement of insulin for GLUT4 vesicle plasma membrane docking. This effect was attenuated by reducing the Munc18c-syntaxin 4(LE) interaction with the I241A mutation, indicating that Munc18c facilitates vesicle docking. Therefore, in contradiction to previous models, our data indicates that the conformational "opening" of syntaxin 4 rather than the dissociation of Munc18c is the critical event required for GLUT4 vesicle docking.	Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Andrea-Merrins, M (corresponding author), Univ Michigan, Dept Mol & Integrat Physiol, 7744 MSII,1153 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	mmerrins@umich.edu		Stuenkel, Edward/0000-0001-8225-5725; Chang, Louise/0000-0001-5501-4774; Merrins, Matthew J./0000-0003-1599-9227	NIDDK NIH HHS [DK60591, DK61618] Funding Source: Medline; NINDS NIH HHS [NS039914, NS053978] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060591, R01DK061618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039914, R01NS053978] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001; Bose A, 2004, MOL CELL BIOL, V24, P5447, DOI 10.1128/MCB.24.12.5447-5458.2004; Bryant NJ, 2003, J CELL BIOL, V161, P691, DOI 10.1083/jcb.200212078; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Dugani CB, 2005, EMBO REP, V6, P1137, DOI 10.1038/sj.embor.7400584; Dulubova I, 2003, P NATL ACAD SCI USA, V100, P32, DOI 10.1073/pnas.232701299; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Gonzalez E, 2006, MOL BIOL CELL, V17, P4484, DOI 10.1091/mbc.E06-07-0585; Hodgkinson CP, 2005, DIABETOLOGIA, V48, P1627, DOI 10.1007/s00125-005-1819-y; Hoppe A, 2002, BIOPHYS J, V83, P3652, DOI 10.1016/S0006-3495(02)75365-4; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Kanda H, 2005, J CLIN INVEST, V115, P291, DOI 10.1172/JCI200522681; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Liu J, 2004, J BIOL CHEM, V279, P55924, DOI 10.1074/jbc.M410024200; Lizunov VA, 2005, J CELL BIOL, V169, P481, DOI 10.1083/jcb.200412069; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Thurmond DC, 2000, EMBO J, V19, P3565, DOI 10.1093/emboj/19.14.3565; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Vogel K, 2000, J BIOL CHEM, V275, P2959, DOI 10.1074/jbc.275.4.2959; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Widberg CH, 2003, J BIOL CHEM, V278, P35093, DOI 10.1074/jbc.M304261200; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9	38	38	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16553	16566		10.1074/jbc.M610818200	http://dx.doi.org/10.1074/jbc.M610818200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17412693	hybrid			2022-12-27	WOS:000246794300062
J	Hamilton, SR; Fard, SF; Paiwand, FF; Tolg, C; Veiseh, M; Wang, C; McCarthy, JB; Bissell, MJ; Koropatnick, J; Turley, EA				Hamilton, Sara R.; Fard, Shireen F.; Paiwand, Frouz F.; Tolg, Cornelia; Veiseh, Mandana; Wang, Chao; McCarthy, James B.; Bissell, Mina J.; Koropatnick, James; Turley, Eva A.			The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; MAP KINASE; EPITHELIAL-CELLS; BINDING-PROTEIN; PROGNOSTIC-SIGNIFICANCE; MEDIATED MOTILITY; TUMOR PROGRESSION; FACTOR-BETA; EXPRESSION	CD44 is an integral hyaluronan receptor that can promote or inhibit motogenic signaling in tumor cells. Rhamm is a nonintegral cell surface hyaluronan receptor (CD168) and intracellular protein that promotes cell motility in culture. Here we describe an autocrine mechanism utilizing cell surface RhammCD44 interactions to sustain rapid basal motility in invasive breast cancer cell lines that requires endogenous hyaluronan synthesis and the formation of Rhamm-CD44-ERK1,2 complexes. Motile/invasive MDA-MB-231 and Ras-MCF10A cells produce more endogenous hyaluronan, cell surface CD44 and Rhamm, an oncogenic Rhamm isoform, and exhibit more elevated basal activation of ERK1,2 than less invasive MCF7 and MCF10A breast cancer cells. Furthermore, CD44, Rhamm, and ERK1,2 uniquely co-immunoprecipitate and co-localize in MDA-MB-231 and Ras-MCF10A cells. Combinations of anti-CD44, anti-Rhamm antibodies, and a MEK1 inhibitor (PD098059) had less-than-additive blocking effects, suggesting the action of all three proteins on a common motogenic signaling pathway. Collectively, these results show that cell surface Rhamm and CD44 act together in a hyaluronan-dependent autocrine mechanism to coordinate sustained signaling through ERK1,2, leading to high basal motility of invasive breast cancer cells. Therefore, an effect of CD44 on tumor cell motility may depend in part on its ability to partner with additional proteins, such as cell surface Rhamm.	Canc Res Labs, London Reg Canc Program, London, ON N6A 4L6, Canada; Univ Western Ontario, London, ON N6A 4L6, Canada; Hosp Sick Children, Dept Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Univ Minnesota, Ctr Comprehens Canc, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Lawrence Berkeley Natl Labs, Div Life Sci, Berkeley, CA 94720 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Minnesota System; University of Minnesota Twin Cities; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Turley, EA (corresponding author), Canc Res Labs, London Reg Canc Program, Rm A4-931,790 Commissioners Rd E, London, ON N6A 4L6, Canada.	eva.turley@lhsc.on.ca		Koropatnick, James/0000-0001-6144-5941; Hamilton, Sara/0000-0001-6062-2037	NCI NIH HHS [R01 CA064786, R01 CA057621-07, U54 CA126552, R01 CA064786-07, R01 CA057621, U54 CA126552-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064786, R01CA057621, U54CA126552] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Adamia Sophia, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P3, DOI 10.2174/1568006053005056; Agnantis NJ, 2004, IN VIVO, V18, P481; Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; Allen LF, 2003, SEMIN ONCOL, V30, P105, DOI 10.1053/j.seminoncol.2003.08.012; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Assmann V, 1999, J CELL SCI, V112, P3943; Assmann V, 1998, J CELL SCI, V111, P1685; Auvinen P, 2005, HISTOPATHOLOGY, V47, P420, DOI 10.1111/j.1365-2559.2005.02220.x; Bakkers J, 2004, DEVELOPMENT, V131, P525, DOI 10.1242/dev.00954; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; Boldt S, 2004, CURR PHARM DESIGN, V10, P1885, DOI 10.2174/1381612043384420; Bourguignon LYW, 2005, J BIOL CHEM, V280, P11961, DOI 10.1074/jbc.M411985200; Bourguignon LYW, 2002, J BIOL CHEM, V277, P39703, DOI 10.1074/jbc.M204320200; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; CARNENISCH TD, 2000, J CLIN INVEST, V106, P349; DELOSTOYOS J, 1989, BLOOD, V74, P751; Diaz LK, 2005, CLIN CANCER RES, V11, P3309, DOI 10.1158/1078-0432.CCR-04-2184; Eccles SA, 2005, CURR OPIN GENET DEV, V15, P77, DOI 10.1016/j.gde.2004.12.001; Edward M, 2005, CARCINOGENESIS, V26, P1215, DOI 10.1093/carcin/bgi064; Entschladen F, 2004, LANCET ONCOL, V5, P254, DOI 10.1016/S1470-2045(04)01431-7; Florquin S, 2003, KIDNEY INT, V64, pS15, DOI 10.1046/j.1523-1755.64.s86.4.x; GALLUZZO E, 1995, EUR J IMMUNOL, V25, P2932, DOI 10.1002/eji.1830251033; Ge L, 2004, J BIOL CHEM, V279, P55419, DOI 10.1074/jbc.M410312200; Goebeler M, 1996, J CELL SCI, V109, P1957; Gotte M, 2006, CANCER RES, V66, P10233, DOI 10.1158/0008-5472.CAN-06-1464; Goueffic Y, 2006, CARDIOVASC RES, V72, P339, DOI 10.1016/j.cardiores.2006.07.017; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; Hall CL, 1996, ONCOGENE, V13, P2213; Hall CL, 2001, MATRIX BIOL, V20, P183, DOI 10.1016/S0945-053X(01)00133-0; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; Hofmann M, 1998, J CELL SCI, V111, P1673; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126; Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491; Khan SA, 2005, CLIN EXP METASTAS, V22, P663, DOI 10.1007/s10585-006-9007-0; Kondoh K, 2005, CHROMOSOMA, V114, P86, DOI 10.1007/s00412-005-0341-9; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kuida K, 2004, J BIOCHEM, V135, P653, DOI 10.1093/jb/mvh078; Lokeshwar V, 1999, PROSTATE CANCER P D, V2, pS21, DOI 10.1038/sj.pcan.4500346; Lopez JI, 2005, CANCER RES, V65, P6755, DOI 10.1158/0008-5472.CAN-05-0863; Lynn BD, 2001, J COMP NEUROL, V439, P315, DOI 10.1002/cne.1353; Ma W, 2005, CLIN ONCOL-UK, V17, P258, DOI 10.1016/j.clon.2005.02.007; Marhaba R, 2004, J MOL HISTOL, V35, P211; Martinez-Carpio PA, 1999, CANCER LETT, V147, P25, DOI 10.1016/S0304-3835(99)00261-X; Maxwell CA, 2003, MOL BIOL CELL, V14, P2262, DOI 10.1091/mbc.E02-07-0377; Mohapatra S, 1996, J EXP MED, V183, P1663, DOI 10.1084/jem.183.4.1663; Morris SF, 2001, EUR J SURG ONCOL, V27, P527, DOI 10.1053/ejso.2001.1167; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Naor D, 2002, CRIT REV CL LAB SCI, V39, P527, DOI 10.1080/10408360290795574; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Navolanic PM, 2003, INT J ONCOL, V22, P237; Nedvetzki S, 2004, P NATL ACAD SCI USA, V101, P18081, DOI 10.1073/pnas.0407378102; OCHIENG J, 1991, INVAS METAST, V11, P38; Pilarski LM, 1999, BLOOD, V93, P2918; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Ponti D, 2006, EUR J CANCER, V42, P1219, DOI 10.1016/j.ejca.2006.01.031; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; Rom J, 2006, PATHOL RES PRACT, V202, P125, DOI 10.1016/j.prp.2005.12.002; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Savani RC, 2000, AM J RESP CELL MOL, V23, P475, DOI 10.1165/ajrcmb.23.4.3944; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; SAVANI RC, 1995, J CLIN INVEST, V95, P1158, DOI 10.1172/JCI117764; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Sleeman JP, 1996, CANCER RES, V56, P3134; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; SOULE HD, 1990, CANCER RES, V50, P6075; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Thanakit Voranuch, 2005, J Med Assoc Thai, V88 Suppl 4, pS30; Tolg C, 2006, J CELL BIOL, V175, P1017, DOI 10.1083/jcb.200511027; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; Tzircotis G, 2005, J CELL SCI, V118, P5119, DOI 10.1242/jcs.02629; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Udabage L, 2005, CANCER RES, V65, P6139, DOI 10.1158/0008-5472.CAN-04-1622; Vial E, 2004, ANN NY ACAD SCI, V1030, P208, DOI 10.1196/annals.1329.027; Wang C, 1998, CLIN CANCER RES, V4, P567; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Watanabe O, 2005, J EXP CLIN CANC RES, V24, P75; Weber GF, 2002, CANCER RES, V62, P2281; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Wells A, 2000, ADV CANCER RES, V78, P31; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702; Zaman A, 2005, AM J RESP CELL MOL, V33, P447, DOI 10.1165/rcmb.2004-0333OC; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342	95	201	214	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16667	16680		10.1074/jbc.M702078200	http://dx.doi.org/10.1074/jbc.M702078200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392272	hybrid, Green Accepted			2022-12-27	WOS:000246794300072
J	Pathak, HB; Arnold, JJ; Wiegand, PN; Hargittai, MRS; Cameron, CE				Pathak, Harsh B.; Arnold, Jamie J.; Wiegand, Phillip N.; Hargittai, Michele R. S.; Cameron, Craig E.			Picornavirus genome replication - Assembly and organization of the VPg uridylylation ribonucleoprotein (initiaion) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; STEM-LOOP-D; POLIOVIRUS RNA; POSITIVE-STRAND; NEGATIVE-STRAND; ELEMENT CRE; 5' END; PROTEIN; IDENTIFICATION; 3D(POL)	All picornaviruses have a protein, VPg, covalently linked to the 5 '- ends of their genomes. Uridylylated VPg (VPg- pUpU) is thought to serve as the protein primer for RNA synthesis. VPgpUpU can be produced in vitro by the viral polymerase, 3Dpol, in a reaction in which a single adenylate residue of a stem- loop structure, termed oriI, templates processive incorporation of UMPinto VPg by using a "slide-back" mechanism. This reaction is greatly stimulated by viral precursor protein 3CD or its processed derivative, 3C; both contain RNA-binding and protease activities. We show that the 3C domain encodes specificity for oriI, and the 3D domain enhances the overall affinity for oriI. Thus, 3C(D) stimulation exhibits an RNA length dependence. By using a minimal system to evaluate the mechanism of VPg uridylylation, we show that the active complex contains polymerase, oriI, and 3C(D) at stoichiometry of 1:1:2. Dimerization of 3C(D) is supported by physical and structural data. Polymerase recruitment to and retention in this complex require a proteinprotein interaction between the polymerase and 3C(D). Physical and functional data for this interaction are provided for three picornaviruses. VPg association with this complex is weak, suggesting that formation of a complex containing all necessary components of the reaction is rate- limiting for the reaction. We suggest that assembly of this complex in vivo would be facilitated by use of precursor proteins instead of processed proteins. These data provide a glimpse into the organization of the ribonucleoprotein complex that catalyzes this key step in picornavirus genome replication.	Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 201, University Pk, PA 16802 USA.	cec9@psu.edu			NIAID NIH HHS [AI053531, R01 AI053531, R56 AI053531, R37 AI053531, R01 AI053531-05] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI053531, R01AI053531] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Arnold JJ, 2004, BIOCHEMISTRY-US, V43, P5138, DOI 10.1021/bi035213q; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060; Boerner JE, 2005, J VIROL, V79, P7803, DOI 10.1128/JVI.79.12.7803-7811.2005; Carroll SS, 1996, METHOD ENZYMOL, V275, P365; Cheney IW, 2003, J VIROL, V77, P7434, DOI 10.1128/JVI.77.13.7434-7443.2003; DILDINE SL, 1992, J VIROL, V66, P4364, DOI 10.1128/JVI.66.7.4364-4376.1992; Du ZH, 2004, BIOCHEMISTRY-US, V43, P11959, DOI 10.1021/bi048973p; Gerber K, 2001, J VIROL, V75, P10979, DOI 10.1128/JVI.75.22.10979-10990.2001; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000; Goodfellow IG, 2003, J GEN VIROL, V84, P2359, DOI 10.1099/vir.0.19132-0; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Headey SJ, 2007, RNA, V13, P351, DOI 10.1261/rna.313707; Herold J, 2000, J VIROL, V74, P6394, DOI 10.1128/JVI.74.14.6394-6400.2000; Huang LY, 2005, J BIOL CHEM, V280, P36417, DOI 10.1074/jbc.M508175200; Knowlton KU, 1996, J VIROL, V70, P7811, DOI 10.1128/JVI.70.11.7811-7818.1996; Lobert PE, 1999, P NATL ACAD SCI USA, V96, P11560, DOI 10.1073/pnas.96.20.11560; Marcotte LL, 2007, J VIROL, V81, P3583, DOI 10.1128/JVI.02306-06; Mason PW, 2002, J VIROL, V76, P9686, DOI 10.1128/JVI.76.19.9686-9694.2002; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McKnight KL, 1998, RNA, V4, P1569, DOI 10.1017/S1355838298981006; Morasco BJ, 2003, J VIROL, V77, P5136, DOI 10.1128/JVI.77.9.5136-5144.2003; Mosimann SC, 1997, J MOL BIOL, V273, P1032, DOI 10.1006/jmbi.1997.1306; Murray KE, 2003, J VIROL, V77, P4739, DOI 10.1128/JVI.77.8.4739-4750.2003; Nayak A, 2005, J VIROL, V79, P7698, DOI 10.1128/JVI.79.12.7698-7706.2005; Nayak A, 2006, J VIROL, V80, P9865, DOI 10.1128/JVI.00561-06; Ohlenschlager O, 2004, STRUCTURE, V12, P237, DOI 10.1016/j.str.2004.01.014; Parsley TB, 1997, RNA, V3, P1124; Pathak HB, 2002, J BIOL CHEM, V277, P31551, DOI 10.1074/jbc.M204408200; PATHAK HB, 2006, THESIS PENNSYLVANIA, P173; Paul Aniko V., 2002, P227; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 2003, J BIOL CHEM, V278, P43951, DOI 10.1074/jbc.M307441200; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Racaniello V.R., 2001, FIELDS VIROLOGY, P455; Rieder E, 2000, J VIROL, V74, P10371, DOI 10.1128/JVI.74.22.10371-10380.2000; Rieder E, 2003, J GEN VIROL, V84, P2203, DOI 10.1099/vir.0.19013-0; ROHLL JB, 1994, J VIROL, V68, P4384, DOI 10.1128/JVI.68.7.4384-4391.1994; Thiviyanathan V, 2004, P NATL ACAD SCI USA, V101, P12688, DOI 10.1073/pnas.0403079101; van Ooij MJM, 2006, J GEN VIROL, V87, P103, DOI 10.1099/vir.0.81297-0; Xiang WK, 1998, J VIROL, V72, P6732, DOI 10.1128/JVI.72.8.6732-6741.1998; Yang Y, 2004, J BIOL CHEM, V279, P12659, DOI 10.1074/jbc.M312992200; Yang Y, 2002, J VIROL, V76, P7485, DOI 10.1128/JVI.76.15.7485-7494.2002; Yin J, 2003, J VIROL, V77, P5152, DOI 10.1128/JVI.77.9.5152-5166.2003; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	48	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16202	16213		10.1074/jbc.M610608200	http://dx.doi.org/10.1074/jbc.M610608200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392285	Green Accepted, hybrid			2022-12-27	WOS:000246794300028
J	Wiradjaja, F; Ooms, LM; Tahirovic, S; Kuhne, E; Devenish, RJ; Munn, AL; Piper, RC; Mayinger, P; Mitchell, CA				Wiradjaja, Fenny; Ooms, Lisa M.; Tahirovic, Sabina; Kuhne, Ellie; Devenish, Rodney J.; Munn, Alan L.; Piper, Robert C.; Mayinger, Peter; Mitchell, Christina A.			Inactivation of the phosphoinositide phosphatases Sac1p and Inp54p leads to accumulation of phosphatidylinositol 4,5-bisphosphate on vacuole membranes and vacuolar fusion defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; YEAST SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID TRANSFER PROTEIN; PLASMA-MEMBRANE; CELL-GROWTH; GENE; GOLGI; MUTATIONS; MUTANTS	Phosphoinositides direct membrane trafficking, facilitating the recruitment of effectors to specific membranes. In yeast phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) is proposed to regulate vacuolar fusion; however, in intact cells this phosphoinositide can only be detected at the plasma membrane. In Saccharomyces cerevisiae the 5-phosphatase, Inp54p, dephosphorylates PtdIns(4,5)P-2 forming PtdIns(4)P, a substrate for the phosphatase Sac1p, which hydrolyzes (PtdIns(4) P). We investigated the role these phosphatases in regulating PtdIns(4,5) P-2 subcellular distribution. PtdIns(4,5)P-2 bioprobes exhibited loss of plasma membrane localization and instead labeled a subset of fragmented vacuoles in Delta sac1 Delta inp54 and sac1(ts) Delta inp54 mutants. Furthermore, sac1(ts) Delta inp54 mutants exhibited vacuolar fusion defects, which were rescued by latrunculin A treatment, or by inactivation of Mss4p, a PtdIns(4)P 5-kinase that synthesizes plasma membrane PtdIns(4,5)P-2. Under these conditions PtdIns(4,5)P-2 was not detected on vacuole membranes, and vacuole morphology was normal, indicating vacuolar PtdIns(4,5)P-2 derives from Mss4p-generated plasma membrane PtdIns(4,5)P-2. Delta sac1 Delta inp54 mutants exhibited delayed carboxypeptidase Y sorting, cargo-selective secretion defects, and defects in vacuole function. These studies reveal PtdIns(4,5)P-2 hydrolysis by lipid phosphatases governs its spatial distribution, and loss of phosphatase activity may result in PtdIns(4,5)P-2 accumulation on vacuole membranes leading to vacuolar fragmentation/fusion defects.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Heidelberg Univ, ZMBH, D-69120 Heidelberg, Germany; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA	Monash University; Ruprecht Karls University Heidelberg; University of Queensland; University of Iowa; Oregon Health & Science University	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3800, Australia.	Christina.Mitchell@md.monash.edu.au	Ooms, Lisa/AGZ-7420-2022	Mitchell, Christina A/0000-0001-9372-3192; Ooms, Lisa Michelle/0000-0002-8918-9932; Piper, Robert/0000-0001-9995-5699	NIGMS NIH HHS [GM071569] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Belgareh-Touze N, 2002, MOL BIOL CELL, V13, P1694, DOI 10.1091/mbc.01-12-0597; Boeddinghaus C, 2002, J CELL BIOL, V157, P79, DOI 10.1083/jcb.200112098; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Faulhammer F, 2005, J CELL BIOL, V168, P185, DOI 10.1083/jcb.200407118; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Han GS, 2002, J BIOL CHEM, V277, P47709, DOI 10.1074/jbc.M207996200; Haucke V, 2005, BIOCHEM SOC T, V33, P1285, DOI 10.1042/BST0331285; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Hongay C, 2002, EMBO J, V21, P4114, DOI 10.1093/emboj/cdf415; Hughes WE, 1999, YEAST, V15, P1111, DOI 10.1002/(SICI)1097-0061(199908)15:11<1111::AID-YEA440>3.0.CO;2-H; Hughes WE, 2000, J BIOL CHEM, V275, P801, DOI 10.1074/jbc.275.2.801; Kochendorfer KU, 1999, EMBO J, V18, P1506, DOI 10.1093/emboj/18.6.1506; LaGrassa TJ, 2005, J CELL BIOL, V168, P401, DOI 10.1083/jcb.200407141; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Mayer A, 2000, MOL BIOL CELL, V11, P807, DOI 10.1091/mbc.11.3.807; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; Munn AL, 1999, MOL BIOL CELL, V10, P3943, DOI 10.1091/mbc.10.11.3943; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOVICK P, 1989, GENETICS, V121, P659; O'Malley CJ, 2001, BIOCHEM J, V355, P805, DOI 10.1042/bj3550805; Ooms LM, 2000, MOL CELL BIOL, V20, P9376, DOI 10.1128/MCB.20.24.9376-9390.2000; Parrish WR, 2004, MOL BIOL CELL, V15, P3567, DOI 10.1091/mbc.E04-03-0209; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rivas MP, 1999, MOL BIOL CELL, V10, P2235, DOI 10.1091/mbc.10.7.2235; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Rohde HM, 2003, J BIOL CHEM, V278, P52689, DOI 10.1074/jbc.M307983200; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; Rudge SA, 2004, MOL BIOL CELL, V15, P24, DOI 10.1091/mbc.E03-05-0297; Schorr M, 2001, CURR BIOL, V11, P1421, DOI 10.1016/S0960-9822(01)00449-3; Seeley ES, 2002, MOL BIOL CELL, V13, P782, DOI 10.1091/mbc.01-10-0512; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; Stolz LE, 1998, GENETICS, V148, P1715; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Tahirovic S, 2005, TRAFFIC, V6, P116, DOI 10.1111/j.1600-0854.2004.00255.x; Ungermann C, 1999, P NATL ACAD SCI USA, V96, P11194, DOI 10.1073/pnas.96.20.11194; Ungewickell A, 2005, P NATL ACAD SCI USA, V102, P18854, DOI 10.1073/pnas.0509740102; Ungewickell AJ, 1999, P NATL ACAD SCI USA, V96, P13342, DOI 10.1073/pnas.96.23.13342; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; WILSBACH K, 1993, EMBO J, V12, P3049, DOI 10.1002/j.1460-2075.1993.tb05974.x; Wiradjaja F, 2001, J BIOL CHEM, V276, P7643, DOI 10.1074/jbc.M010471200; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8; Zhang XL, 1998, J BIOL CHEM, V273, P1574, DOI 10.1074/jbc.273.3.1574; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	62	14	14	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16295	16307		10.1074/jbc.M701038200	http://dx.doi.org/10.1074/jbc.M701038200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392273	hybrid			2022-12-27	WOS:000246794300037
J	Yang, GD; Yang, W; Wu, LY; Wang, R				Yang, Guangdong; Yang, Wei; Wu, Lingyun; Wang, Rui			H2S, endoplasmic reticulum stress, and apoptosis of insulin-secreting beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATHIONINE-GAMMA-LYASE; OXIDE-INDUCED APOPTOSIS; HYDROGEN-SULFIDE; MAP KINASES; ER STRESS; ACTIVATION; P38; RAT; INHIBITION; RELEASE	Cystathionine gamma-lyase ( CSE) is a key enzyme in the transsulfuration pathway, which uses L-cysteine to produce hydrogen sulfide (H2S). Functional changes of pancreatic beta cells induced by endogenous H2S have been reported, but the effect of the CSE/ H2S system on pancreatic beta cell survival has not been known. In this study, we demonstrate that H2S at physiologically relevant concentrations induced apoptosis of INS-1E cells, an insulin-secreting beta cell line. Transfection of INS-1E cells with a recombinant defective adenovirus containing the CSE gene (Ad-CSE) resulted in a significant increase in CSE expression and H2S production. Ad-CSE transfection also stimulated apoptosis. The other two end products of CSE-catalyzed enzymatic reaction, ammonium and pyruvate, had no effects on INS-1E cell apoptosis, indicating that overexpression of CSE may stimulate INS-1E cell apoptosis via increased endogenous production of H2S. Both exogenous H2S ( 100 mu M) and Ad-CSE transfection inhibited ERK1/2 but activated p38 MAPK. Interestingly, BiP and CHOP, two indicators of endoplasmic reticulum ( ER) stress, were up-regulated in H2S- and CSE-mediated apoptosis in INS-1E cells. After suppressing CHOP mRNA expression, H2S- induced apoptosis of INS-1E cells was significantly decreased. Inhibition of p38 MAPK, but not of ERK1/2, inhibited the expression of BiP and CHOP and decreased H2S- stimulated apoptosis, suggesting that p38 MAPK activation functions upstream of ER stress to initiate H2S-induced apoptosis. It is concluded that H2S induces apoptosis of insulin-secreting beta cells by enhancing ER stress via p38 MAPK activation. Our findings may help unmask a novel role of CSE/ H2S system in regulating pancreatic functions under physiological condition and in diabetes.	Lakehead Univ, Fac Sci & Environm Studies, Dept Biol, Thunder Bay, ON P7B 5E1, Canada; Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 5E5, Canada	Lakehead University; University of Saskatchewan; University of Saskatchewan	Wang, R (corresponding author), Lakehead Univ, Fac Sci & Environm Studies, Dept Biol, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.	rwang@lakeheadu.ca	Wang, Rui/C-7824-2012; Yang, Guangdong/G-4129-2011	Wang, Rui/0000-0003-3825-3620; 				Cao Y, 2006, AM J PHYSIOL-CELL PH, V291, pC503, DOI 10.1152/ajpcell.00547.2005; Deplancke B, 2003, FASEB J, V17, P1310, DOI 10.1096/fj.02-0883fje; DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; Halleck MM, 1997, CELL STRESS CHAPERON, V2, P31, DOI 10.1379/1466-1268(1997)002<0031:TMRTRS>2.3.CO;2; Harding HP, 2002, DIABETES, V51, pS455, DOI 10.2337/diabetes.51.2007.S455; Jeon HK, 2005, CELL BIOL TOXICOL, V21, P115, DOI 10.1007/s10565-005-0148-8; JIA X, 2004, CAN J CARDIOL SD, V20, P56; Kaneko Y, 2006, DIABETES, V55, P1391, DOI 10.2337/db05-1082; Lipson KL, 2006, CURR MOL MED, V6, P71, DOI 10.2174/156652406775574613; Mariggio MA, 1998, IMMUNOPHARM IMMUNOT, V20, P399, DOI 10.3109/08923979809034822; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; Rinaldi L, 2006, LAB INVEST, V86, P391, DOI 10.1038/labinvest.3700391; Rose P, 2005, WORLD J GASTROENTERO, V11, P3990, DOI 10.3748/wjg.v11.i26.3990; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schicho R, 2006, GASTROENTEROLOGY, V131, P1542, DOI 10.1053/j.gastro.2006.08.035; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; Song RP, 2002, AM J RESP CELL MOL, V27, P603, DOI 10.1165/rcmb.4851; Steegborn C, 1999, J BIOL CHEM, V274, P12675, DOI 10.1074/jbc.274.18.12675; Tongers J, 2004, CARDIOVASC RES, V63, P545, DOI 10.1016/j.cardiores.2004.04.015; VALITUTTI S, 1990, ANN ALLERGY, V65, P463; Veldman BAJ, 2005, DIABETIC MED, V22, P301, DOI 10.1111/j.1464-5491.2005.01415.x; Wang HY, 2005, J CELL SCI, V118, P3905, DOI 10.1242/jcs.02513; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Wang R., 2006, LAB INVEST, V86, P324; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wijekoon EP, 2005, DIABETES, V54, P3245, DOI 10.2337/diabetes.54.11.3245; Wu LY, 2004, P NATL ACAD SCI USA, V101, P7094, DOI 10.1073/pnas.0402004101; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto T, 2006, NEUROSCI LETT, V392, P170, DOI 10.1016/j.neulet.2005.09.012; Yang G, 2006, FASEB J, V20, P553, DOI 10.1096/fj.05-4712fje; Yang GD, 2004, FASEB J, V18, P1782, DOI 10.1096/fj.04-2279fje; Yang GD, 2004, J BIOL CHEM, V279, P49199, DOI 10.1074/jbc.M408997200; Yang W, 2005, J PHYSIOL-LONDON, V569, P519, DOI 10.1113/jphysiol.2005.097642; Yusuf M, 2005, BIOCHEM BIOPH RES CO, V333, P1146, DOI 10.1016/j.bbrc.2005.06.021; Zhao WM, 2003, CAN J PHYSIOL PHARM, V81, P848, DOI 10.1139/Y03-077; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	47	163	177	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16567	16576		10.1074/jbc.M700605200	http://dx.doi.org/10.1074/jbc.M700605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430888	hybrid			2022-12-27	WOS:000246794300063
J	Ghoneim, C; Soula-Rothhut, M; Blanchevoye, C; Martiny, L; Antonicelli, F; Rothhut, B				Ghoneim, Christelle; Soula-Rothhut, Mahdhia; Blanchevoye, Charlotte; Martiny, Laurent; Antonicelli, Frank; Rothhut, Bernard			Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; UPSTREAM STIMULATORY FACTOR-2; SCATTER FACTOR; CARCINOMA-CELLS; PAPILLARY CARCINOMA; EMBRYO FIBROBLASTS; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; RESPONSE ELEMENT; FACTOR RECEPTOR	Hepatocyte growth factor (HGF) plays a major role in the pathogenesis of a variety of human epithelial tumors including papillary carcinoma of the thyroid. Previous reports demonstrated that HGF, acting through the Met receptor, repressed thrombospondin-1 (TSP-1) expression. To study the mechanisms by which HGF down-regulated TSP-1 expression, we transiently transfected a panel of deleted human TSP-1 promoter reporter plasmids into papillary thyroid carcinoma cells. Weidentified a region between -1210 and -1123 bp relative to the transcription start site that is responsive to HGF treatment and harbors a cAMP-responsive element (CRE) at position -1199 (TGACGTCC). Overexpression of various members of the CRE-binding protein family identified activating transcription factor-1 (ATF-1) as the transcription factor responsible for HGF-induced repression of TSP-1 promoter activity. This inhibition was associated with a concomitant increase in the abundance of nuclear ATF-1 protein. Gel shift and antibody supershift studies indicated that ATF-1 was involved in DNA binding to the TSP-1-CRE site. Finally, we utilized small hairpin RNA to target ATF-1 and showed that these small interfering RNA constructs significantly inhibited ATF-1 expression at both the RNA and the protein level. ATF-1 knockdown prevented HGF-induced down-regulation of TSP-1 promoter activity and protein expression and also reduced HGF-dependent tumor cell invasion. Taken together, our results indicate that HGF-induced down-regulation of TSP-1 expression is mediated by the interaction of ATF-1 with the CRE binding site in the TSP-1 promoter and that this transcription factor plays a crucial role for tumor invasiveness in papillary carcinoma of the thyroid triggered by HGF.	URCA, CNRS, UMR 6198, Biochem Lab, F-51687 Reims, France; URCA, CNRS, Unite Matrice Extracellulaire & Regulat Cellulair, F-51687 Reims, France; URCA, CNRS, Dept Dermatol, F-51687 Reims, France	Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne	Rothhut, B (corresponding author), URCA, CNRS, UMR 6198, Biochem Lab, Moulin Housse, F-51687 Reims, France.	bernard.rothhut@univ-reims.fr	MARTINY, Laurent/ABI-5531-2020	Rothhut, Bernard/0000-0001-6467-8134				Antonicelli F, 2004, AM J PHYSIOL-LUNG C, V286, pL1319, DOI 10.1152/ajplung.00329.2003; Belfiore A, 1997, J CLIN ENDOCR METAB, V82, P2322, DOI 10.1210/jc.82.7.2322; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; Castle VP, 1997, LAB INVEST, V77, P51; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dejong V, 1999, ONCOGENE, V18, P3143, DOI 10.1038/sj.onc.1202654; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; Eccles N, 1996, MOL CELL ENDOCRINOL, V117, P247, DOI 10.1016/0303-7207(95)03757-8; ELLIS MJC, 1995, MOL ENDOCRINOL, V9, P255, DOI 10.1210/me.9.2.255; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; Gourdon L, 1999, FEBS LETT, V459, P9, DOI 10.1016/S0014-5793(99)01203-X; Guillemot L, 2001, J BIOL CHEM, V276, P39394, DOI 10.1074/jbc.M103862200; Gutierrez LS, 2003, CARCINOGENESIS, V24, P199, DOI 10.1093/carcin/24.2.199; Heckert LL, 2000, MOL ENDOCRINOL, V14, P1836, DOI 10.1210/me.14.11.1836; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; Hsu SC, 1996, CANCER RES, V56, P5684; HUGO C, 1995, KIDNEY INT, V48, P1846, DOI 10.1038/ki.1995.483; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kim SA, 2001, MOL CELL BIOCHEM, V216, P21, DOI 10.1023/A:1011022822077; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORANDI V, 1994, J CELL PHYSIOL, V160, P367, DOI 10.1002/jcp.1041600218; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Salnikow K, 1997, CANCER RES, V57, P5060; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SANTOS OFP, 1993, DEV BIOL, V159, P535, DOI 10.1006/dbio.1993.1262; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Scarpino S, 2005, J PATHOL, V205, P50, DOI 10.1002/path.1675; Scarpino S, 1999, J PATHOL, V189, P570; SCHWARTEWALDHOF.I, 2000, P NATL ACAD SCI USA, V97, P9264; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Soula-Rothhut M, 2005, EXP CELL RES, V304, P187, DOI 10.1016/j.yexcr.2004.10.026; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TUSZYNSKI GP, 1987, CANCER RES, V47, P4130; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Wang SX, 2004, J BIOL CHEM, V279, P34311, DOI 10.1074/jbc.M401629200; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	56	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15490	15497		10.1074/jbc.M610586200	http://dx.doi.org/10.1074/jbc.M610586200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17409099	hybrid			2022-12-27	WOS:000246589600025
J	Poncelet, AC; Schnaper, HW; Tan, RY; Liu, YH; Runyan, CE				Poncelet, Anne-Christine; Schnaper, H. William; Tan, Ruoyun; Liu, Youhua; Runyan, Constance E.			Cell phenotype-specific down-regulation of Smad3 involves decreased gene activation as well as protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; MESENCHYMAL TRANSITION; RENAL FIBROSIS; MYOFIBROBLAST TRANSITION; SIGNALING PATHWAY; UBIQUITIN LIGASE; I RECEPTOR; EXPRESSION; MECHANISMS	Signaling by transforming growth factor-beta (TGF-beta),a regulator of several biological processes, including renal fibrosis, is mediated, in part, by the Smad proteins. Tight control of Smad level and activity is critical for proper TGF-beta biological functions. Here, we have investigated the mechanisms involved in regulating Smad3 expression. In human glomerular mesangial cells, Smad3 protein levels were specifically reduced by 24 h of TGF-beta 1 treatment, whereas Smad2 and Smad4 levels were not. TGF-beta 1 increased endogenous Smad3 ubiquitination, and proteasome inhibitor treatment blocked TGF-beta 1-mediated Smad3 down-regulation resulting in accumulation of ubiquitinated Smad3. These data support the concept that Smad3 down-regulation occurs via degradation by the ubiquitin/proteasome machinery. However, changes in Smad3 protein levels were also paralleled by changes in Smad3 mRNA expression. TGF-beta 1 did not decrease Smad3 mRNA stability, but it significantly inhibited Smad3 promoter activity. In renal tubular epithelial cells, decreased Smad3 levels were observed only after exposure to TGF-beta 1 for longer time periods (5-7 days) that paralleled epithelial-to-mesenchymal transition, as determined by increased expression of smooth muscle alpha-actin and decreased expression of E-cadherin. Decline in Smad3 expression also occurred in kidneys after unilateral ureteral obstruction, a model of tubulointerstitial fibrosis associated with TGF-beta up-regulation and epithelial-to-mesenchymal transition. Our data show for the first time that TGF-beta 1 modulates the expression of a receptor-activated Smad at both the protein and transcriptional level. Smad3 down-regulation could represent a feedback loop controlling TGF-beta signaling in a cell phenotype-specific manner.	Univ Washington, Sch Med, Dept Med, UW Med S Lake Union, Seattle, WA 98109 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	University of Washington; University of Washington Seattle; Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Poncelet, AC (corresponding author), Univ Washington, Sch Med, Dept Med, UW Med S Lake Union, 815 Mercer St,Box 358050,Rm 254, Seattle, WA 98109 USA.	annechr@u.washington.edu		Liu, Youhua/0000-0002-4740-805X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK064074, R01DK061408, R21DK053576, R01DK049362] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK049362, R01 DK49362, R01 DK061408, K01 DK64074] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Bottinger EP, 2002, J AM SOC NEPHROL, V13, P2600, DOI 10.1097/01.ASN.0000033611.79556.AE; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fan JM, 1999, KIDNEY INT, V56, P1455, DOI 10.1046/j.1523-1755.1999.00656.x; Felici A, 2003, EMBO J, V22, P4465, DOI 10.1093/emboj/cdg428; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Flanders KC, 2004, INT J EXP PATHOL, V85, P47, DOI 10.1111/j.0959-9673.2004.00377.x; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Inazaki K, 2004, KIDNEY INT, V66, P597, DOI 10.1111/j.1523-1755.2004.00779.x; Inoue Y, 2004, J INTERF CYTOK RES, V24, P43, DOI 10.1089/107999004772719909; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kelley TJ, 2001, AM J RESP CELL MOL, V25, P732, DOI 10.1165/ajrcmb.25.6.4574; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Lan HY, 2003, J AM SOC NEPHROL, V14, P1535, DOI 10.1097/01.ASN.0000067632.04658.B8; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Liu YH, 2006, KIDNEY INT, V69, P213, DOI 10.1038/sj.ki.5000054; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; Roberts AB, 2006, CYTOKINE GROWTH F R, V17, P19, DOI 10.1016/j.cytogfr.2005.09.008; Roberts AB, 2003, ANN NY ACAD SCI, V995, P1, DOI 10.1111/j.1749-6632.2003.tb03205.x; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Runyan CE, 2003, AM J PHYSIOL-RENAL, V285, pF413, DOI 10.1152/ajprenal.00082.2003; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Xin H, 2005, J BIOL CHEM, V280, P20842, DOI 10.1074/jbc.M412275200; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhao Y, 2002, BIOCHEM BIOPH RES CO, V294, P319, DOI 10.1016/S0006-291X(02)00471-0	49	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15534	15540		10.1074/jbc.M701991200	http://dx.doi.org/10.1074/jbc.M701991200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400544	hybrid			2022-12-27	WOS:000246589600030
J	Davies, SL; Ozawa, A; McCormick, WD; Dvorak, MM; Ward, DT				Davies, Sarah L.; Ozawa, Ai; McCormick, Wanda D.; Dvorak, Melita M.; Ward, Donald T.			Protein kinase C-mediated phosphorylation of the calcium-sensing receptor is stimulated by receptor activation and attenuated by calyculin-sensitive phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PARATHYROID CELLS; CA2+-SENSING RECEPTOR; CA-0(2+)-SENSING RECEPTOR; CAR; EXPRESSION; SECRETION; RELEASE; CLONING; POTENT	The agonist sensitivity of the calcium-sensing receptor ( CaR) can be altered by protein kinase C ( PKC), with CaR residue Thr(888) contributing significantly to this effect. To determine whether CaRT888 is a substrate for PKC and whether receptor activation modulates such phosphorylation, a phospho-specific antibody against this residue was raised ( CaRpT888). In HEK-293 cells stably expressing CaR ( CaR-HEK), but not in cells expressing the mutant receptor CaRT888A, phorbol ester ( PMA) treatment increased CaRp(T888) immunoreactivity as observed by immunoblotting and immunofluorescence. Raising extracellular Ca2+ concentration from 0.5 to 2.5 mM increased CaRT888 phosphorylation, an effect that was potentiated stereoselectively by the calcimimetic NPS R-467. These responses were mimicked by 5 mM extracellular Ca2+ and abolished by the calcilytic NPS-89636 and also by PKC inhibition or chronic PMA pretreatment. Whereas CaRT888A did exhibit increased apparent agonist sensitivity, by converting intracellular Ca2+ ( Ca-i(2+)) oscillations to sustained plateau responses in some cells, we still observed Ca-i(2+) oscillations in a significant number of cells. This suggests that CaRT888 contributes significantly to CaR regulation but is not the exclusive determinant of CaR-induced Ca-i(2+) oscillations. Finally, dephosphorylation of CaRT888 was blocked by the protein phosphatase 1/2A inhibitor calyculin, a treatment that also inhibited Ca-i(2+) oscillations. In addition, calyculin/PMA cotreatment increased CaRT888 phosphorylation in bovine parathyroid cells. Therefore, CaRT888 is a substrate for receptor-induced, PKC-mediated feedback phosphorylation and can be dephosphorylated by a calyculin-sensitive phosphatase.	Univ Manchester, Fac Life Sci, Manchester M13 9PL, Lancs, England; Univ Calif San Francisco, Dept Endocrinol, San Francisco, CA 94121 USA	University of Manchester; University of California System; University of California San Francisco	Ward, DT (corresponding author), Univ Manchester, Core Technol Facil, Floor 2,46 Grafton St, Manchester M13 9NT, Lancs, England.	d.ward@manchester.ac.uk		McCormick, Wanda/0000-0002-6287-7321; Ward, Donald/0000-0003-1342-9458	Biotechnology and Biological Sciences Research Council [BBS/B/04986] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; CHARTIER L, 1991, CELL MOTIL CYTOSKEL, V18, P26, DOI 10.1002/cm.970180104; Davies SL, 2006, AM J PHYSIOL-CELL PH, V290, pC1543, DOI 10.1152/ajpcell.00482.2005; Dvorak MM, 2004, P NATL ACAD SCI USA, V101, P5140, DOI 10.1073/pnas.0306141101; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; HOSOYA N, 1993, J CELL SCI, V105, P883; Jiang YF, 2002, J BIOL CHEM, V277, P50543, DOI 10.1074/jbc.M205798200; LI YM, 1993, BIOCHEM PHARMACOL, V46, P1435, DOI 10.1016/0006-2952(93)90109-A; MEMBRENO L, 1989, ENDOCRINOLOGY, V124, P789, DOI 10.1210/endo-124-2-789; Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P141, DOI 10.1113/jphysiol.1993.sp019764; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P163, DOI 10.1113/jphysiol.1993.sp019765; RACKE RFK, 1994, BIOCHEM BIOPH RES CO, V267, pE429; Sakwe AM, 2004, EXP CELL RES, V297, P560, DOI 10.1016/j.yexcr.2004.03.039; Tanaka M, 2004, BIOORG MED CHEM LETT, V14, P5171, DOI 10.1016/j.bmcl.2004.07.061; Ward DT, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015623.73739.B8; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; Young SH, 2002, J BIOL CHEM, V277, P46871, DOI 10.1074/jbc.M207083200	23	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15048	15056		10.1074/jbc.M607469200	http://dx.doi.org/10.1074/jbc.M607469200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376781	hybrid			2022-12-27	WOS:000246589000044
J	Kim, JG; Son, YJ; Yun, CH; Kim, YI; Nam-Goong, IS; Park, JH; Park, SK; Ojeda, SR; D'Elia, AV; Damante, G; Lee, BJ				Kim, Jae Geun; Son, Young June; Yun, Chang Ho; Kim, Young Il; Nam-Goong, Il Seong; Park, Jun Heon; Park, Sang Kyu; Ojeda, Sergio R.; D'Elia, Angela Valentina; Damante, Giuseppe; Lee, Byung Ju			Thyroid transcription factor-1 facilitates cerebrospinal fluid formation by regulating aquaporin-1 synthesis in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTONICITY-RESPONSIVE ELEMENT; DNA-BINDING PROTEINS; CHOROID-PLEXUS; THYROGLOBULIN PROMOTER; GENE-TRANSCRIPTION; LUNG MORPHOGENESIS; AQP1 EXPRESSION; WATER CHANNELS; TTF-1; HOMEODOMAIN	In the brain, aquaporin-1 ( AQP-1), a water channel for high osmotic water permeability, is mainly expressed in the apical membrane of the ventricular choroid plexus and regulates formation of cerebrospinal fluid ( CSF). Although the physiology of AQP-1 has been the subject of several publications, much less is known about the trans-acting factors involved in the control of AQP-1 gene expression. Here we report that TTF-1, a homeodomain-containing transcriptional regulator, is coexpressed with AQP-1 in the rat brain choroid plexus and enhances AQP-1 gene transcription by binding to conserved core TTF-1-binding motifs in the 5'-flanking region of the AQP-1 gene. Intracerebroventricular administration of an antisense TTF-1 oligodeoxynucleotide significantly decreased AQP-1 synthesis and reduced CSF formation. In addition, blockade of TTF-1 synthesis increased survival of the animals following acute water intoxication-induced brain edema. These results suggest that TTF-1 is physiologically involved in the transcriptional control of AQP-1, which is required for CSF formation.	Univ Ulsan, Coll Nat Sci, Dept Biol Sci, Ulsan 680749, South Korea; Ulsan Univ Hosp, Dept Internal Med, Ulsan 682060, South Korea; Ulsan Univ Hosp, Dept Pediat, Ulsan 682060, South Korea; Oregon Hlth & Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA; Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy	University of Ulsan; University of Ulsan; Ulsan University Hospital; University of Ulsan; Ulsan University Hospital; Oregon Health & Science University; Oregon National Primate Research Center; University of Udine	Lee, BJ (corresponding author), Univ Ulsan, Coll Nat Sci, Dept Biol Sci, Ulsan 680749, South Korea.	bjlee@ulsan.ac.kr	Damante, Giuseppe/AAC-5200-2022	Damante, Giuseppe/0000-0003-2312-4009; NAM-GOONG, IL SEONG/0000-0002-0492-0467	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD018185, R01HD025123] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00163] Funding Source: Medline; NICHD NIH HHS [HD25123, U54 HD18185] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Brown PD, 2004, NEUROSCIENCE, V129, P957, DOI 10.1016/j.neuroscience.2004.07.003; Cadnapaphornchai MA, 2000, AM J MED, V109, P688, DOI 10.1016/S0002-9343(00)00622-7; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAVSON H, 1982, J NEUROBIOL, V13, P293, DOI 10.1002/neu.480130402; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; Griesdale DEG, 2004, SURG NEUROL, V61, P418, DOI 10.1016/j.surneu.2003.10.047; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Gunnarson E, 2004, NEUROSCIENCE, V129, P947, DOI 10.1016/j.neuroscience.2004.08.022; Halford SE, 2004, NUCLEIC ACIDS RES, V32, P3040, DOI 10.1093/nar/gkh624; Han ZQ, 2000, BIOCHEM BIOPH RES CO, V273, P328, DOI 10.1006/bbrc.2000.2944; Johanson CE, 1999, AM J PHYSIOL-CELL PH, V276, pC82, DOI 10.1152/ajpcell.1999.276.1.C82; Kim MS, 2002, J BIOL CHEM, V277, P36863, DOI 10.1074/jbc.M206443200; Kramer SG, 1999, DEVELOPMENT, V126, P191; KUHN R, 1991, MOL CELL BIOL, V11, P4642, DOI 10.1128/MCB.11.9.4642; Kumbrink J, 2005, J BIOL CHEM, V280, P42785, DOI 10.1074/jbc.M511079200; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lee BJ, 2001, MOL CELL NEUROSCI, V17, P107, DOI 10.1006/mcne.2000.0933; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; Masseguin C, 2000, J APPL PHYSIOL, V88, P843, DOI 10.1152/jappl.2000.88.3.843; MOON C, 1997, AM J PHYSIOL-CELL PH, V273, pC1562; Nakamura K, 2001, DEV BRAIN RES, V130, P159, DOI 10.1016/S0165-3806(01)00226-7; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Oshio K, 2003, ACT NEUR S, V86, P525; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Pellizzari L, 1999, BIOCHEM J, V337, P253, DOI 10.1042/0264-6021:3370253; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Ray MK, 1996, MOL CELL BIOL, V16, P2056; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; Son YJ, 2003, J BIOL CHEM, V278, P27043, DOI 10.1074/jbc.M303157200; Speake T, 2003, BBA-BIOMEMBRANES, V1609, P80, DOI 10.1016/S0005-2736(02)00658-2; Umenishi F, 2003, J BIOL CHEM, V278, P15765, DOI 10.1074/jbc.M209980200; Umenishi F, 1996, DNA CELL BIOL, V15, P475, DOI 10.1089/dna.1996.15.475; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V293, P913, DOI 10.1016/S0006-291X(02)00316-9; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V292, P771, DOI 10.1006/bbrc.2002.6709; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Wu Q, 1998, AM J PHYSIOL-CELL PH, V275, pC1565, DOI 10.1152/ajpcell.1998.275.6.C1565; Zhang CL, 2006, NUCLEIC ACIDS RES, V34, P2238, DOI 10.1093/nar/gkl248; Zhang D, 2002, J GEN PHYSIOL, V119, P561, DOI 10.1085/jgp.20028597	44	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14923	14931		10.1074/jbc.M701411200	http://dx.doi.org/10.1074/jbc.M701411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17371871	hybrid			2022-12-27	WOS:000246589000030
J	Pagan, JK; Arnold, J; Hanchard, KJ; Kumar, R; Bruno, T; Jones, MJK; Richard, DJ; Forrest, A; Spurdle, A; Verdin, E; Crossley, M; Fanciulli, M; Chenevix-Trench, G; Young, DB; Khanna, KK				Pagan, Julia K.; Arnold, Jeremy; Hanchard, Kim J.; Kumar, Raman; Bruno, Tiziana; Jones, Mathew J. K.; Richard, Derek J.; Forrest, Alistair; Spurdle, Amanda; Verdin, Eric; Crossley, Merlin; Fanciulli, Maurizio; Chenevix-Trench, Georgia; Young, David B.; Khanna, Kum Kum			A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II HISTONE DEACETYLASES; TERMINAL-BINDING-PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITIONS; CO-REPRESSOR; E-CADHERIN; ANKYRIN-REPEAT; ACETYLATION; IDENTIFICATION; ASSOCIATION; ACTIVATION	Corepressors play a crucial role in negative gene regulation and are defective in several diseases. BCoR is a corepressor for the BCL6 repressor protein. Here we describe and functionally characterize BCoR-L1, a homolog of BCoR. When tethered to a heterologous promoter, BCoR-L1 is capable of strong repression. Like other corepressors, BCoR-L1 associates with histone deacetylase ( HDAC) activity. Specifically, BCoR-L1 coprecipitates with the Class II HDACs, HDAC4, HDAC5, and HDAC7, suggesting that they are involved in its role as a transcriptional repressor. BCoR-L1 also interacts with the CtBP corepressor through a CtBP-interacting motif in its amino terminus. Abrogation of the CtBP binding site within BCoR-L1 partially relieves BCoR-L1-mediated transcriptional repression. Furthermore, BCoR-L1 is located on the E-cadherin promoter, a known CtBP-regulated promoter, and represses the E-cadherin promoter activity in a reporter assay. The inhibition of BCoR-L1 expression by RNA-mediated interference results in derepression of E-cadherin in cells that do not normally express E-cadherin, indicating that BCoR-L1 contributes to the repression of an authentic endogenous CtBP target.	Queensland Inst Med Res, Herston, Qld 4029, Australia; Univ Queensland, Royal Brisbane Hosp, Sch Med, Cent Clin Div, Herston, Qld 4029, Australia; Inst Med & Vet Sci, Hanson Inst, Breast Canc Genet Grp, Adelaide, SA 5000, Australia; Regina Elena Inst Canc Res, I-00158 Rome, Italy; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Hanson Institute; Institute Medical & Veterinary Science Australia; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Queensland; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of Sydney	Khanna, KK (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Herston, Qld 4029, Australia.		Chenevix-Trench, Georgia/AAV-2014-2020; Pagan, Julia/O-1929-2016; Khanna, Kum Kum/I-1747-2013; Spurdle, Amanda B/A-4978-2011; Verdin, Eric/AAB-7999-2019; Richard, Derek/J-1338-2012; bruno, tiziana/AAC-4913-2022; Kumar, Raman/AHE-0538-2022; fanciulli, maurizio/ABH-6745-2020; Crossley, Merlin/D-7888-2011; Forrest, Alistair/A-6597-2008	Chenevix-Trench, Georgia/0000-0002-1878-2587; Pagan, Julia/0000-0002-7079-6388; Spurdle, Amanda B/0000-0003-1337-7897; Richard, Derek/0000-0002-4839-8471; bruno, tiziana/0000-0003-0352-4523; Kumar, Raman/0000-0001-7976-8386; Crossley, Merlin/0000-0003-2057-3642; Forrest, Alistair/0000-0003-4543-1675; Khanna, Kum Kum/0000-0001-8650-5381; Jones, Mathew/0000-0003-2714-8411; Kumar, Raman Krishna/0000-0003-4343-0951; Verdin, Eric/0000-0003-3703-3183				Alpatov R, 2004, MOL CELL BIOL, V24, P10223, DOI 10.1128/MCB.24.23.10223-10235.2004; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Chinnadurai G, 2003, BIOESSAYS, V25, P9, DOI 10.1002/bies.10212; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7; Gabellini D, 2004, CURR OPIN GENET DEV, V14, P301, DOI 10.1016/j.gde.2004.04.010; Gabellini D, 2003, CURR OPIN GENET DEV, V13, P239, DOI 10.1016/S0959-437X(03)00050-9; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gearhart MD, 2006, MOL CELL BIOL, V26, P6880, DOI 10.1128/MCB.00630-06; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gorisch SM, 2005, J CELL SCI, V118, P5825, DOI 10.1242/jcs.02689; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Huynh KD, 2000, GENE DEV, V14, P1810; Jardin F, 2005, HEMATOLOGY, V10, P115, DOI 10.1080/10245330400026105; Jepsen K, 2002, J CELL SCI, V115, P689; Joo JH, 2005, MOL VIS, V11, P133; Kim JH, 2005, NAT STRUCT MOL BIOL, V12, P423, DOI 10.1038/nsmb924; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Marmorstein R, 2001, CURR OPIN GENET DEV, V11, P155, DOI 10.1016/S0959-437X(00)00173-8; McKinsey TA, 2006, MOL BIOL CELL, V17, P438, DOI 10.1091/mbc.E05-07-0612; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Plevin MJ, 2005, TRENDS BIOCHEM SCI, V30, P66, DOI 10.1016/j.tibs.2004.12.001; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thio SSC, 2004, NUCLEIC ACIDS RES, V32, P1836, DOI 10.1093/nar/gkh344; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Voss TC, 2005, J CELL SCI, V118, P3277, DOI 10.1242/jcs.02450; Wang AH, 2005, J BIOL CHEM, V280, P29117, DOI 10.1074/jbc.M500295200; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang QH, 2002, SCIENCE, V295, P1895; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	71	55	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15248	15257		10.1074/jbc.M700246200	http://dx.doi.org/10.1074/jbc.M700246200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17379597	Green Published, hybrid			2022-12-27	WOS:000246589000064
J	Takeuchi, K; Takahashi, H; Kawano, S; Shimada, I				Takeuchi, Koh; Takahashi, Hideo; Kawano, Seiko; Shimada, Ichio			Identification and characterization of the slowly exchanging pH-dependent conformational rearrangement in KcsA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL KCSA; LIVIDANS K+ CHANNEL; SELECTIVITY FILTER; CRYSTAL-STRUCTURE; MEMBRANE-PROTEIN; STRUCTURAL BASIS; VOLTAGE-SENSOR; ION PERMEATION; ACTIVATION; STOICHIOMETRY	Gating of ion channels is strictly regulated by physiological conditions as well as intra/extracellular ligands. To understand the underlying structures mediating ion channel gating, we investigated the pH-dependent gating of the K+ channel KcsA under near-physiological conditions, using solution-state NMR. In a series of (HN)-H-1-N-15-TROSY HSQC (transverse relaxation optimized spectroscopy-heteronuclear single quantum coherence) spectra measured at various pH values, significant chemical shift changes were detected between pH 3.9 and 5.2, reflecting a conformational rearrangement associated with the gating. The pH-dependent chemical shift changes were mainly observed for the resonances from the residues near the intracellular helix bundle, which has been considered to form the primary gate in the K+ channel, as well as the intracellular extension of the inner helix. The substitution of His-25 by Ala abolished this pH-dependent conformational rearrangement, indicating that the residue serves as a "pH-sensor" for the channel. Although the electrophysiological open probability of KcsA is less than 10%, the conformations of the intracellular helix bundle between the acidic and neutral conditions seem to be remarkably different. This supports the recently proposed "dual gating" properties of the K+ channel, in which the activation-coupled inactivation at the selectivity filter determines the channel open probability of the channel. Indeed, a pH-dependent chemical shift change was also observed for the signal from the Trp-67 indole, which is involved in a hydrogen bond network related to the activation-coupled inactivation. The slow kinetic parameter obtained for the intracellular bundle seems to fit better into the time scale for burst duration than very fast fluctuations within a burst period, indicating the existence of another gating element with faster kinetic properties.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Adv Ind Sci & Technol, Koto Ku, Biol Informat Res Ctr, Tokyo 1350064, Japan; Tokyo Med & Dent Univ, Dept Cardiovasc Dis, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); Tokyo Medical & Dental University (TMDU)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp	Takeuchi, Koh/B-4971-2010	Takeuchi, Koh/0000-0002-6227-4627				Bichet D, 2003, NAT REV NEUROSCI, V4, P957, DOI 10.1038/nrn1244; Chill JH, 2006, PROTEIN SCI, V15, P684, DOI 10.1110/ps.051954706; Cordero-Morales JF, 2006, NAT STRUCT MOL BIOL, V13, P311, DOI 10.1038/nsmb1069; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 2004, BIOPHYS J, V86, P2101, DOI 10.1016/S0006-3495(04)74269-1; Fiaux J, 2004, J BIOMOL NMR, V29, P289, DOI 10.1023/B:JNMR.0000032523.00554.38; Gao LZ, 2005, P NATL ACAD SCI USA, V102, P17630, DOI 10.1073/pnas.0505158102; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Irizarry SN, 2002, BIOCHEMISTRY-US, V41, P13653, DOI 10.1021/bi026393r; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kelly BL, 2003, NAT STRUCT BIOL, V10, P280, DOI 10.1038/nsb908; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lee HC, 2003, NEURON, V40, P527, DOI 10.1016/S0896-6273(03)00636-6; LeMasurier M, 2001, J GEN PHYSIOL, V118, P303, DOI 10.1085/jgp.118.3.303; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; Lohr F, 2003, J BIOMOL NMR, V25, P291, DOI 10.1023/A:1023084605308; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Lu T, 2001, NAT NEUROSCI, V4, P239, DOI 10.1038/85080; Molina ML, 2004, BIOCHEMISTRY-US, V43, P14924, DOI 10.1021/bi048889+; Oxenoid K, 2001, BIOCHEMISTRY-US, V40, P5111, DOI 10.1021/bi0029090; Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Takeuchi K, 2003, STRUCTURE, V11, P1381, DOI 10.1016/j.str.2003.10.003; Vinogradova O, 1998, J BIOMOL NMR, V11, P381, DOI 10.1023/A:1008289624496; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Yokogawa M, 2005, J AM CHEM SOC, V127, P12021, DOI 10.1021/ja0511772; Zheng J, 1997, J GEN PHYSIOL, V110, P101, DOI 10.1085/jgp.110.2.101; Zhou YF, 2003, J MOL BIOL, V333, P965, DOI 10.1016/j.jmb.2003.09.022; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	36	66	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15179	15186		10.1074/jbc.M608264200	http://dx.doi.org/10.1074/jbc.M608264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17360718	hybrid			2022-12-27	WOS:000246589000057
J	Kindrachuk, J; Potter, JE; Brownlie, R; Ficzycz, AD; Griebel, PJ; Mookherjee, N; Mutwiri, GK; Babiuk, LA; Napper, S				Kindrachuk, Jason; Potter, Jean E.; Brownlie, Robert; Ficzycz, Andrew D.; Griebel, Philip J.; Mookherjee, Neeloffer; Mutwiri, George K.; Babiuk, Lorne A.; Napper, Scott			Nucleic acids exert a sequence-independent cooperative effect on sequence-dependent activation of Toll-like receptor 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CPG-DNA; PATHOGEN RECOGNITION; CUTTING EDGE; IMMUNE CELLS; TLR9; BINDING; LEUKOCYTES; INDUCTION; BOVINE; MOTIFS	Toll-like receptor 9 (TLR9) activates the innate immune system in response to microbial DNA or mimicking oligodeoxynucleotides. Although cell stimulation experiments demonstrate the preferential activation of TLR9 by CpG-containing nucleic acids, direct binding investigations have reached contradictory conclusions with respect to the ability of this receptor to bind nucleic acids in a sequence-specific manner. To address this apparent discrepancy, we report the purification of the soluble ectodomain of human TLR9 with characterization of its ligand binding properties. We observe that TLR9 has a high degree of specificity in its ability to bind nucleic acids that contain CpG dinucleotides as well as higher order motifs that mediate species-specific activation. However, TLR9 is also functionally influenced by nucleic acids in a sequence-independent fashion as both stimulatory and nonstimulatory nucleic acids sensitize TLR9 for in vitro ligand binding as well as in vivo activation. We propose a model in which receptor activation is achieved in a sequence-dependent manner, and sensitivity is modulated by the absolute concentration of nucleic acids in a sequence-independent fashion. This model bears resemblance to that recently proposed for Toll in that activation is a two-step process in which formation of a ligand-bound monomer precedes formation of the activated dimer. In each model receptor sensitivity is determined within the second step with the crucial distinction that Toll undergoes negative cooperativity, whereas TLR9 is sensitized through a positive cooperative effect.	Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of Saskatchewan; University of British Columbia	Napper, S (corresponding author), Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada.	scott.napper@usask.ca		Kindrachuk, Jason/0000-0002-3305-7084; Mookherjee, Neeloffer/0000-0002-9350-4157				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Bauer M, 1999, IMMUNOLOGY, V97, P699, DOI 10.1046/j.1365-2567.1999.00811.x; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cornelie S, 2004, J BIOL CHEM, V279, P15124, DOI 10.1074/jbc.M313406200; de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Gay NJ, 2006, NAT REV IMMUNOL, V6, P693, DOI 10.1038/nri1916; GILKESON GS, 1995, J CLIN INVEST, V95, P1398, DOI 10.1172/JCI117793; GILKESON GS, 1993, CLIN IMMUNOL IMMUNOP, V68, P283, DOI 10.1006/clin.1993.1129; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hallman M, 2001, PEDIATR RES, V50, P315, DOI 10.1203/00006450-200109000-00004; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Ioannou XP, 2003, ANTISENSE NUCLEIC A, V13, P157, DOI 10.1089/108729003768247628; Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003; Jurk M, 2006, CHEMMEDCHEM, V1, P1007, DOI 10.1002/cmdc.200600064; Kirk P, 2005, IMMUNITY, V23, P347, DOI 10.1016/j.immuni.2005.09.008; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; KOWALSKI J, 1993, VACCINE, V11, P1100, DOI 10.1016/0264-410X(93)90069-A; Krieg AM, 1999, PHARMACOL THERAPEUT, V84, P113, DOI 10.1016/S0163-7258(99)00023-6; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lazarczyk M, 2005, EXPERT OPIN BIOL TH, V5, P525, DOI 10.1517/14712598.5.4.525; Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179; Mena A, 2003, OLIGONUCLEOTIDES, V13, P245, DOI 10.1089/154545703322460621; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; Roberts TL, 2005, J IMMUNOL, V174, P605, DOI 10.4049/jimmunol.174.2.605; ROUAS R, 2002, CANCER GENE THER, V9, P1; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Sester DP, 2000, J IMMUNOL, V165, P4165, DOI 10.4049/jimmunol.165.8.4165; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Vollmer J, 2004, EUR J IMMUNOL, V34, P251, DOI 10.1002/eji.200324032; Wagner H, 2006, J EXP MED, V203, P265, DOI 10.1084/jem.20052191; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Weber ANR, 2005, J BIOL CHEM, V280, P22793, DOI 10.1074/jbc.M502074200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Yasuda K, 2006, EUR J IMMUNOL, V36, P431, DOI 10.1002/eji.200535210	47	25	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13944	13953		10.1074/jbc.M608089200	http://dx.doi.org/10.1074/jbc.M608089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355967	hybrid			2022-12-27	WOS:000246245800004
J	Visser, F; Sun, LJ; Damaraju, V; Tackaberry, T; Peng, YS; Robins, MJ; Baldwin, SA; Young, JD; Cass, CE				Visser, Frank; Sun, Lijie; Damaraju, Vijaya; Tackaberry, Tracey; Peng, Yunshan; Robins, Morris J.; Baldwin, Stephen A.; Young, James D.; Cass, Carol E.			Residues 334 and 338 in transmembrane segment 8 of human equilibrative nucleoside transporter 1 are important determinants of inhibitor sensitivity, protein folding, and catalytic turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE-GUANOSINE TRANSPORTER; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-CHARACTERIZATION; INTRACELLULAR MEMBRANES; LEISHMANIA-DONOVANI; RECOMBINANT HUMAN; BINDING-SITES; S-6-(4-NITROBENZYL)-MERCAPTOPURINE RIBOSIDE; NITROBENZYLTHIOINOSINE BINDING; NUCLEOBASE TRANSPORT	Equilibrative nucleoside transporters (ENTs) are important for the metabolic salvage of nucleosides and the cellular uptake of antineoplastic and antiviral nucleoside analogs. Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. Random mutagenesis and screening by functional complementation for inhibitor-resistant mutants in yeast revealed mutations at Phe334 and Asn-338. Both residues are predicted to lie in transmembrane segment 8 (TM 8), which contains residues that are highly conserved in the ENT family. F334Y displayed increased V-max values that were attributed to increased rates of catalytic turnover, and N338Q and N338C displayed altered membrane distributions that appeared to be because of protein folding defects. Mutations of Phe-334 or Asn-338 impaired interactions with dilazep and dipyridamole, whereas mutations of Asn-338 impaired interactions with draflazine and soluflazine. A helical wheel projection of TM 8 predicted that Phe-334 and Asn-338 lie in close proximity to other highly conserved and/or hydrophilic residues, suggesting that they form part of a structurally important region that influences interactions with inhibitors, protein folding, and rates of conformational change during the transport cycle.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Membrane Prot Res Grp, Edmonton, AB, Canada; Univ Alberta, Dept Oncol, Edmonton, AB, Canada; Univ Alberta, Dept Physiol, Edmonton, AB, Canada; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Alberta; Brigham Young University; University of Leeds	Cass, CE (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	carol.cass@cancerboard.ab.ca	Cass, Carol E/F-5861-2010		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; Arastu-Kapur S, 2005, J BIOL CHEM, V280, P2213, DOI 10.1074/jbc.M408224200; Arastu-Kapur S, 2003, J BIOL CHEM, V278, P33327, DOI 10.1074/jbc.M305141200; Baldwin SA, 2005, J BIOL CHEM, V280, P15880, DOI 10.1074/jbc.M414337200; Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2; BARCLAY BJ, 1982, CAN J BIOCHEM CELL B, V60, P172, DOI 10.1139/o82-023; Barnes K, 2006, CIRC RES, V99, P510, DOI 10.1161/01.RES.0000238359.18495.42; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Endres CJ, 2005, MOL PHARMACOL, V67, P837, DOI 10.1124/mol.104.008102; Endres CJ, 2004, BIOCHEM J, V380, P131, DOI 10.1042/BJ20031880; GATI WP, 1989, MOL PHARMACOL, V36, P134; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Greener A, 1996, Methods Mol Biol, V57, P375, DOI 10.1385/0-89603-332-5:375; GRENSON M, 1969, EUR J BIOCHEM, V11, P249, DOI 10.1111/j.1432-1033.1969.tb00767.x; GRIFFITH DA, 1990, BIOCHEM PHARMACOL, V40, P2297, DOI 10.1016/0006-2952(90)90726-2; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HAMMOND JR, 1991, MOL PHARMACOL, V39, P771; Hammond JR, 2000, N-S ARCH PHARMACOL, V361, P373, DOI 10.1007/s002100000214; Hogue DL, 1996, J BIOL CHEM, V271, P9801, DOI 10.1074/jbc.271.16.9801; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; IJZERMAN AP, 1989, EUR J PHARM-MOLEC PH, V172, P273, DOI 10.1016/0922-4106(89)90057-6; JAMIESON GP, 1993, CYTOMETRY, V14, P32, DOI 10.1002/cyto.990140107; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P31, DOI 10.1113/jphysiol.1982.sp014099; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; JARVIS SM, 1983, BIOCHEM J, V216, P661, DOI 10.1042/bj2160661; Jennings LL, 1998, DRUG DEVELOP RES, V45, P277, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<277::AID-DDR26>3.0.CO;2-7; JONES KW, 1993, EUR J PHARM-MOLEC PH, V246, P97, DOI 10.1016/0922-4106(93)90085-N; King KM, 2006, MOL PHARMACOL, V69, P346, DOI 10.1124/mol.105.015768; Kong W, 2004, CURR DRUG METAB, V5, P63, DOI 10.2174/1389200043489162; KOREN R, 1983, BIOCHEM J, V216, P299, DOI 10.1042/bj2160299; SenGupta DJ, 2004, BIOCHEM PHARMACOL, V67, P453, DOI 10.1016/j.bcp.2003.09.018; SenGupta DJ, 2002, BIOCHEMISTRY-US, V41, P1512, DOI 10.1021/bi015833w; Spratlin J, 2004, CLIN CANCER RES, V10, P6956, DOI 10.1158/1078-0432.CCR-04-0224; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Valdes R, 2006, J BIOL CHEM, V281, P22647, DOI 10.1074/jbc.M602366200; Vasudevan G, 2001, P NATL ACAD SCI USA, V98, P6092, DOI 10.1073/pnas.101537298; Vickers MF, 2000, J BIOL CHEM, V275, P25931, DOI 10.1074/jbc.M000239200; Vickers MF, 2004, NUCLEOS NUCLEOT NUCL, V23, P361, DOI 10.1081/NCN-120028333; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; Visser F, 2005, J BIOL CHEM, V280, P11025, DOI 10.1074/jbc.M410348200; Visser F, 2005, MOL PHARMACOL, V67, P1291, DOI 10.1124/mol.104.005884; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200; Yao SYM, 2001, MOL MEMBR BIOL, V18, P161, DOI 10.1080/09687680110048318; Yao SYM, 2001, BIOCHEM J, V353, P387, DOI 10.1042/0264-6021:3530387; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Zhang J, 2006, BIOCHEM J, V394, P389, DOI 10.1042/BJ20051476; Zhang J, 2003, MOL PHARMACOL, V64, P1512, DOI 10.1124/mol.64.6.1512	55	34	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14148	14157		10.1074/jbc.M701735200	http://dx.doi.org/10.1074/jbc.M701735200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17379602	hybrid			2022-12-27	WOS:000246245800025
J	Zhu, SM; Si, ML; Wu, HL; Mo, YY				Zhu, Shuomin; Si, Min-Liang; Wu, Hailong; Mo, Yin-Yuan			MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; BREAST-CANCER; RT-PCR; EXPRESSION; CELLS; RNA; PROTEIN; CDNA; RAS; ORGANIZATION	MicroRNAs are small noncoding RNA molecules that control expression of target genes. Our previous studies show that mir-21 is overexpressed in tumor tissues compared with the matched normal tissues. Moreover, suppression of mir-21 by antisense oligonucleotides inhibits tumor cell growth both in vitro and in vivo. However, it remains largely unclear as to how mir-21 affects tumor growth, because our understanding of mir-21 targets is limited. In this study, we performed two-dimensional differentiation in-gel electrophoresis of tumors treated with anti-mir-21 and identified the tumor suppressor tropomyosin 1 (TPM1) as a potential mir-21 target. In agreement with this, there is a putative mir-21 binding site at the 3'-untranslated region (3'-UTR) of TPM1 variants V1 and V5. Thus, we cloned the 3'-UTR of TPM1 into a luciferase reporter and found that although mir-21 down-regulated the luciferase activity, anti-mir-21 up-regulated it. Moreover, deletion of the mir-21 binding site abolished the effect of mir-21 on the luciferase activity, suggesting that this mir-21 binding site is critical. Western blot with the cloned TPM1-V1 plus the 3'-UTR indicated that TPM1 protein level was also regulated by mir-21, whereas real-time quantitative reverse transcription-PCR revealed no difference at the mRNA level, suggesting translational regulation. Finally, overexpression of TPM1 in breast cancer MCF-7 cells suppressed anchor-age-independent growth. Thus, down-regulation of TPM1 by mir-21 may explain, at least in part, why suppression of mir-21 can inhibit tumor growth, further supporting the notion that mir-21 functions as an oncogene.	So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA	Southern Illinois University System; Southern Illinois University	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 801 N Rutledge,POB 19626, Springfield, IL 62794 USA.	ymo@siumed.edu	Mo, Yin-Yuan/B-6141-2011; zhu, shoumin/F-4564-2011; Mo, Yin-Yuan/R-8255-2019; Vickers, Michael M/E-4095-2010		NATIONAL CANCER INSTITUTE [R01CA102630] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102630, CA102630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen GA, 2004, J PATHOL, V202, P321, DOI 10.1002/path.1524; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; FINLAY TH, 1993, ENDOCRINOLOGY, V133, P996, DOI 10.1210/en.133.3.996; Fitzgerald K, 2005, CURR OPIN DRUG DISC, V8, P557; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lao KQ, 2006, BIOCHEM BIOPH RES CO, V343, P85, DOI 10.1016/j.bbrc.2006.02.106; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; Mo YY, 1999, EXP CELL RES, V252, P50, DOI 10.1006/excr.1999.4616; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Sanvito F, 2000, CANCER RES, V60, P510; SI ML, 2006, IN PRESS ONCOGENE; Smalheiser Neil R., 2006, V342, P115, DOI 10.1385/1-59745-123-1:115; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Varga AE, 2005, ONCOGENE, V24, P5043, DOI 10.1038/sj.onc.1208688; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444	47	868	991	3	77	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14328	14336		10.1074/jbc.M611393200	http://dx.doi.org/10.1074/jbc.M611393200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17363372	hybrid			2022-12-27	WOS:000246245800044
J	Li, DL; Sinha, KK; Hay, MA; Rinaldi, CR; Saunthararajah, Y; Nucifora, G				Li, Donglan; Sinha, Kislay K.; Hay, Maher A.; Rinaldi, Ciro R.; Saunthararajah, Yogen; Nucifora, Giuseppina			RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; AML1 GENE; MYELOID-LEUKEMIA; MYELODYSPLASTIC SYNDROME; TRANSCRIPTION FACTORS; FUSION PROTEIN; CBF-BETA; REPRESSION	RUNX1 (AML1, CBF alpha 2, PEBP2 alpha B) is a transcription factor essential for the establishment of the hematopoietic stem cell. It is generally thought that RUNX1 exists as a monomer that regulates hematopoietic differentiation by interacting with tissue-specific factors and its DNA consensus through its N terminus. RUNX1 is frequently altered in human leukemia by gene fusions or point mutations. In general, these alterations do not affect the N terminus of the protein, and it is unclear how they consistently lead to hematopoietic transformation and leukemia. Here we report that RUNX1 homodimerizes through a mechanism involving C terminus-C terminus interaction. This RUNX1-RUNX1 interaction regulates the activity of the protein in reporter gene assays and modulates its ability to induce hematopoietic differentiation of hematopoietic cell lines. The promoters of genes regulated by RUNX1 often contain multiple RUNX1 binding sites. This arrangement suggests that RUNX1 could homodimerize to bring and hold together distant chromatin sites and factors and that if the dimerization region is removed by gene fusions or is altered by point mutations, as observed in leukemia, the ability of RUNX1 to regulate differentiation could be impaired.	Univ Illinois, Dept Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Nucifora, G (corresponding author), Univ Illinois, Dept Med, Coll Med Res Bldg,M-C 737,909 S Wolcott Ave, Chicago, IL 60612 USA.	nucifora@uic.edu		Sinha, Kislay/0000-0002-6978-4611; Abdul-Hay, Maher/0000-0003-1041-7689	NCI NIH HHS [CA96448] Funding Source: Medline; NHLBI NIH HHS [R01 HL72691, HL79580, HL 082935] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096448] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082935, R01HL079580, R01HL072691] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Busson-Le Coniat M, 2001, GENE CHROMOSOME CANC, V32, P244, DOI 10.1002/gcc.1188; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Chi YQ, 2003, J BIOL CHEM, V278, P49806, DOI 10.1074/jbc.M309645200; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Frank R, 1995, ONCOGENE, V11, P2667; Gutierrez S, 2004, J BIOL CHEM, V279, P43581, DOI 10.1074/jbc.M408335200; Harada H, 2004, BLOOD, V103, P2316, DOI 10.1182/blood-2003-09-3074; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Liu YZ, 2006, CANCER CELL, V9, P249, DOI 10.1016/j.ccr.2006.03.012; McLean TW, 1996, BLOOD, V88, P4252; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Mikhail FM, 2006, J CELL PHYSIOL, V207, P582, DOI 10.1002/jcp.20538; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Miller JD, 2001, BLOOD, V97, P2248, DOI 10.1182/blood.V97.8.2248; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Niini T, 2000, HAEMATOLOGICA, V85, P362; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; PEPLING ME, 1995, P NATL ACAD SCI USA, V92, P9087, DOI 10.1073/pnas.92.20.9087; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Saunthararajah Y, 2006, CRIT REV EUKAR GENE, V16, P183, DOI 10.1615/CritRevEukarGeneExpr.v16.i2.60; Senyuk V, 2005, CANCER RES, V65, P7603, DOI 10.1158/0008-5472.CAN-05-0412; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Soulier J, 2003, LEUKEMIA, V17, P1679, DOI 10.1038/sj.leu.2403000; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Uchida H, 1997, J IMMUNOL, V158, P2251; Vradii D, 2005, P NATL ACAD SCI USA, V102, P7174, DOI 10.1073/pnas.0502130102; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	57	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13542	13551		10.1074/jbc.M700074200	http://dx.doi.org/10.1074/jbc.M700074200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355962	hybrid			2022-12-27	WOS:000246060300043
J	Pino, MF; Kim, KA; Shelton, KD; Lindner, J; Odili, S; Li, CH; Collins, HW; Shiota, M; Matschinsky, FM; Magnuson, MA				Pino, Maria F.; Kim, Kyoung-Ah; Shelton, Kathy D.; Lindner, Jill; Odili, Stella; Li, Changhong; Collins, Heather W.; Shiota, Masakazu; Matschinsky, Franz M.; Magnuson, Mark A.			Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL GLUCOKINASE; YOUNG TYPE-2 MODY-2; DIABETES-MELLITUS; LIVER GLUCOKINASE; TRANSGENIC MICE; FRUCTOSE 1-PHOSPHATE; INSULIN-SECRETION; RAT-LIVER; GENE; HOMEOSTASIS	To better understand how glucokinase (GK) missense mutations associated with human glycemic diseases perturb glucose homeostasis, we generated and characterized mice with either an activating (A456V) or inactivating (K414E) mutation in the gk gene. Animals with these mutations exhibited alterations in their blood glucose concentration that were inversely related to the relative activity index of GK. Moreover, the threshold for glucose-stimulated insulin secretion from islets with either the activating or inactivating mutation were left- or right-shifted, respectively. However, we were surprised to find that mice with the activating mutation had markedly reduced amounts of hepatic GK activity. Further studies of bacterially expressed mutant enzymes revealed that GK(A456V) is as stable as the wild type enzyme, whereas GK(K414E) is thermolabile. However, the ability of GK regulatory protein to inhibit GK(A456V) was found to be less than that of the wild type enzyme, a finding consistent with impaired hepatic nuclear localization. Taken together, this study indicates that it is necessary to have knowledge of both thermolability and the interactions of mutant GK enzymes with GK regulatory protein when attempting to predict in vivo glycemic phenotypes based on the measurement of enzyme kinetics.	Vanderbilt Univ, Sch Med, Ctr Stem Cell Biol, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Stem Cell Biol, Nashville, TN 37232 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Diabet, Philadelphia, PA 19104 USA	Vanderbilt University; Vanderbilt University; University of Pennsylvania; University of Pennsylvania	Magnuson, MA (corresponding author), Vanderbilt Univ, Sch Med, Ctr Stem Cell Biol, Dept Physiol & Mol Biophys, 802 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.	mark.magnuson@vanderbilt.edu	Lindner, Jill/K-5511-2012; Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Lindner, Jill/0000-0002-8897-7494; Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022122, R01DK022122] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42502, DK 22122] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BEDOYA FJ, 1986, J BIOL CHEM, V261, P760; Brocklehurst KJ, 2004, BIOCHEM J, V378, P693, DOI 10.1042/BJ20031414; Burke CV, 1999, BIOCHEM J, V342, P345, DOI 10.1042/0264-6021:3420345; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; Christesen HBT, 2002, DIABETES, V51, P1240, DOI 10.2337/diabetes.51.4.1240; Cuesta-Munoz AL, 2004, DIABETES, V53, P2164, DOI 10.2337/diabetes.53.8.2164; DAVIES DR, 1990, EUR J BIOCHEM, V192, P283, DOI 10.1111/j.1432-1033.1990.tb19225.x; Davis EA, 1999, DIABETOLOGIA, V42, P1175, DOI 10.1007/s001250051289; de la Iglesia N, 1999, FEBS LETT, V456, P332, DOI 10.1016/S0014-5793(99)00971-0; Desai UJ, 2001, DIABETES, V50, P2287, DOI 10.2337/diabetes.50.10.2287; DETHEUX M, 1991, EUR J BIOCHEM, V200, P553, DOI 10.1111/j.1432-1033.1991.tb16218.x; Farrelly D, 1999, P NATL ACAD SCI USA, V96, P14511, DOI 10.1073/pnas.96.25.14511; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; Gloyn AL, 2003, HUM MUTAT, V22, P353, DOI 10.1002/humu.10277; Gloyn AL, 2005, J BIOL CHEM, V280, P14105, DOI 10.1074/jbc.M413146200; Gloyn AL, 2003, DIABETES, V52, P2433, DOI 10.2337/diabetes.52.9.2433; Grimsby J, 2000, J BIOL CHEM, V275, P7826, DOI 10.1074/jbc.275.11.7826; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; Heredia VV, 2006, J BIOL CHEM, V281, P40201, DOI 10.1074/jbc.M607987200; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; JETTON TL, 1994, J BIOL CHEM, V269, P3641; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; Kamata K, 2004, STRUCTURE, V12, P429, DOI 10.1016/j.str.2004.02.005; Kesavan P, 1997, BIOCHEM J, V322, P57, DOI 10.1042/bj3220057; LABOSKY PA, 1994, CIBA F SYMP, V182, P157; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Li CH, 2004, J BIOL CHEM, V279, P13393, DOI 10.1074/jbc.M311502200; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Miller SP, 1999, DIABETES, V48, P1645, DOI 10.2337/diabetes.48.8.1645; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Sagen JV, 2006, DIABETES, V55, P1713, DOI 10.2337/db05-1513; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; Shiota C, 1999, J BIOL CHEM, V274, P37125, DOI 10.1074/jbc.274.52.37125; Shiota M, 2001, DIABETES, V50, P622, DOI 10.2337/diabetes.50.3.622; STOFFEL M, 1992, NAT GENET, V2, P153, DOI 10.1038/ng1092-153; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; Terauchi Y, 2007, J CLIN INVEST, V117, P246, DOI 10.1172/JCI17645; Toyoda Y, 2001, HORM METAB RES, V33, P329, DOI 10.1055/s-2001-15418; TOYODA Y, 1994, BIOCHEM BIOPH RES CO, V204, P252, DOI 10.1006/bbrc.1994.2452; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VANDERCAMMEN A, 1992, BIOCHEM J, V286, P253, DOI 10.1042/bj2860253; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VANSCHAFTINGEN E, 1992, ADV ENZYME REGUL, V32, P133; Velho G, 1997, DIABETOLOGIA, V40, P217, DOI 10.1007/s001250050666; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Zelent D, 2006, DIABETES, V55, P1923, DOI 10.2337/db06-0151	55	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13906	13916		10.1074/jbc.M610094200	http://dx.doi.org/10.1074/jbc.M610094200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353190	hybrid			2022-12-27	WOS:000246060300080
J	Zhang, F; Yim, YI; Scarselletta, S; Norton, M; Eisenberg, E; Greene, LE				Zhang, Fang; Yim, Yang-In; Scarselletta, Sarah; Norton, Mark; Eisenberg, Evan; Greene, Lois E.			Clathrin adaptor GGA1 polymerizes clathrin into tubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; VHS DOMAINS; ENDOSOME TRANSPORT; GAMMA-ADAPTIN; PROTEINS; AP-1; TGN; LOCALIZATION; TRAFFICKING; RECEPTORS	GGAs, a class of monomeric clathrin adaptors, are involved in the sorting of cargo at the trans-Golgi network of eukaryotic cells. They are modular structures consisting of the VHS, the GAT, hinge, and GAEdomains, which have been shown to interact directly with cargo, ARF, clathrin, and accessory proteins, respectively. Previous studies have shown that GGAs interact with clathrin both in solution and in the cell, but it has yet been shown whether they assemble clathrin. We find that GGA1 promoted assembly of clathrin with complete assembly achieved when one GGA1 molecule is bound per heavy chain. In the presence of excess GGA1, we obtained the unusual stoichiometry of five GGA1s per heavy chain, and even at this stoichiometry the binding was not saturated. The assembled structures were mostly baskets, but similar to 10% of the structures were tubular with an average length of 180 similar to 40 nm and width of similar to 50 nm. The truncated GGA1 fragment consisting of the hinge+GAE domains bound to clathrin with similar affinity as the full-length molecule and polymerized clathrin into baskets. Unlike the full-length molecule, this fragment saturated the lattices at one molecule per heavy chain and assembled clathrin only into baskets. The separated hinge and GAE domains bound much weaker to clathrin than the intact molecule, and these domains do not significantly polymerize clathrin into baskets. We conclude that clathrin adaptor GGA1 is a clathrin assembly protein, but it is unique in its ability to polymerize clathrin into tubules.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Greene, LE (corresponding author), NHLBI, Cell Biol Lab, NIH, 50 S Dr,Rm 2737,MSC 8017, Bethesda, MD 20892 USA.	greenel@helix.nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000516, ZIAHL000516] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bai HD, 2004, J BIOL CHEM, V279, P17411, DOI 10.1074/jbc.M401158200; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Boman AL, 2001, J CELL SCI, V114, P3413; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Costaguta G, 2001, MOL BIOL CELL, V12, P1885, DOI 10.1091/mbc.12.6.1885; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Doray B, 2002, P NATL ACAD SCI USA, V99, P8072, DOI 10.1073/pnas.082235699; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GREENE LE, 1990, J BIOL CHEM, V265, P6682; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hirst J, 2001, MOL BIOL CELL, V12, P3573, DOI 10.1091/mbc.12.11.3573; Knuehl C, 2006, TRAFFIC, V7, P1688, DOI 10.1111/j.1600-0854.2006.00499.x; Ma YC, 2002, J BIOL CHEM, V277, P49267, DOI 10.1074/jbc.M203695200; Nakayama K, 2003, CELL STRUCT FUNCT, V28, P431, DOI 10.1247/csf.28.431; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Polishchuk RS, 2006, TRAFFIC, V7, P1092, DOI 10.1111/j.1600-0854.2006.00453.x; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Scott PM, 2004, NAT CELL BIOL, V6, P252, DOI 10.1038/ncb1107; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Waguri S, 2003, MOL BIOL CELL, V14, P142, DOI 10.1091/mbc.E02-06-0338; Zhao XH, 2001, J CELL SCI, V114, P353; Zhu YX, 2001, METHOD ENZYMOL, V329, P379	28	12	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13282	13289		10.1074/jbc.M700936200	http://dx.doi.org/10.1074/jbc.M700936200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344219	hybrid			2022-12-27	WOS:000246060300016
J	Muller, D; Karle, A; Meibburger, B; Hofig, I; Stork, R; Kontermann, RE				Mueller, Dafne; Karle, Anette; Meissburger, Bettina; Hoefig, Ines; Stork, Roland; Kontermann, Roland E.			Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LYMPHOMA XENOGRAFTS; ANTIGEN-BINDING; TUMOR-GROWTH; PROTEIN; FRAGMENTS; DIABODY; COSTIMULATION; INHIBITION; INTERFERON; PEGYLATION	Recombinant bispecific antibodies such as tandem scFv molecules ( taFv), diabodies ( Db), or single chain diabodies ( scDb) have shown to be able to retarget T lymphocytes to tumor cells, leading to their destruction. However, therapeutic efficacy is hampered by a short serum half-life of these small molecules having molecule masses of 50-60 kDa. Thus, improvement of the pharmacokinetic properties of small bispecific antibody formats is required to enhance efficacy in vivo. In this study, we generated several recombinant bispecific antibody-albumin fusion proteins and analyzed these molecules for biological activity and pharmacokinetic properties. Three recombinant antibody formats were produced by fusing two different scFv molecules, bispecific scDb or taFv molecules, respectively, to human serum albumin ( HSA). These constructs ( scFv(2)-HSA, scDb-HSA, taFv-HSA), directed against the tumor antigen carcinoembryonic antigen ( CEA) and the T cell receptor complex molecule CD3, retained full binding capacity to both antigens compared with unfused scFv, scDb, and taFv molecules. Tumor antigen-specific retargeting and activation of T cells as monitored by interleukin-2 release was observed for scDb, scDb-HSA, taFv-HSA, and to a lesser extent for scFv2-HSA. T cell activation could be further enhanced by a target cell-specific costimulatory signal provided by a B7-DbCEA fusion protein. Furthermore, we could demonstrate that fusion to serum albumin strongly increases circulation time of recombinant bispecific antibodies. In addition, our comparative study indicates that single chain diabody-albumin fusion proteins seem to be the most promising format for further studying cytotoxic activities in vitro and in vivo.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Kontermann, RE (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandeing 31, D-70569 Stuttgart, Germany.	roland.kontermann@izi.uni-stuttgart.de	Hoefig, Ines/P-2483-2014; Kontermann, Roland E./F-9263-2014	Hoefig, Ines/0000-0001-8319-8507; Mueller, Dafne/0000-0002-1544-3475				Alt M, 1999, FEBS LETT, V454, P90, DOI 10.1016/S0014-5793(99)00782-6; Bailon P, 2001, BIOCONJUGATE CHEM, V12, P195, DOI 10.1021/bc000082g; BALAN V, 2006, BIOCONJUGATE CHEM, V17, P68; Blanco B, 2003, J IMMUNOL, V171, P1070, DOI 10.4049/jimmunol.171.2.1070; Blanco B, 2002, CANCER GENE THER, V9, P275, DOI 10.1038/sj.cgt.7700438; Chapman AP, 1999, NAT BIOTECHNOL, V17, P780, DOI 10.1038/11717; Chapman AP, 2002, ADV DRUG DELIVER REV, V54, P531, DOI 10.1016/S0169-409X(02)00026-1; Chaudhury C, 2006, BIOCHEMISTRY-US, V45, P4983, DOI 10.1021/bi052628y; Chaudhury C, 2003, J EXP MED, V197, P315, DOI 10.1084/jem.20021829; CHESTER KA, 1994, LANCET, V343, P455, DOI 10.1016/S0140-6736(94)92695-6; Chuang VTG, 2002, PHARMACEUT RES, V19, P569; Cochlovius B, 2000, J IMMUNOL, V165, P888, DOI 10.4049/jimmunol.165.2.888; Dennis MS, 2002, J BIOL CHEM, V277, P35035, DOI 10.1074/jbc.M205854200; Dreier T, 2003, J IMMUNOL, V170, P4397, DOI 10.4049/jimmunol.170.8.4397; Duttaroy A, 2005, DIABETES, V54, P251, DOI 10.2337/diabetes.54.1.251; Gerstmayer B, 1997, J IMMUNOL, V158, P4584; GRUBER M, 1994, J IMMUNOL, V152, P5368; Huhalov A, 2004, Q J NUCL MED MOL IM, V48, P279; Kipriyanov SM, 1999, J MOL BIOL, V293, P41, DOI 10.1006/jmbi.1999.3156; Kontermann RE, 2005, ACTA PHARMACOL SIN, V26, P1, DOI 10.1111/j.1745-7254.2005.00008.x; Kontermann RE, 1997, IMMUNOTECHNOLOGY, V3, P137, DOI 10.1016/S1380-2933(97)00010-9; Korn Tina, 2001, P619; Kragh-Hansen U, 2002, BIOL PHARM BULL, V25, P695, DOI 10.1248/bpb.25.695; Kubetzko S, 2005, MOL PHARMACOL, V68, P1439, DOI 10.1124/mol.105.014910; Kubetzko S, 2006, J BIOL CHEM, V281, P35186, DOI 10.1074/jbc.M604127200; Marvin JS, 2005, ACTA PHARMACOL SIN, V26, P649, DOI 10.1111/j.1745-7254.2005.00119.x; Melder RJ, 2005, CANCER IMMUNOL IMMUN, V54, P535, DOI 10.1007/s00262-004-0624-7; MULLER D, 2007, HDB THERAPEUTIC ANTI, V2, P345; Osborn BL, 2002, EUR J PHARMACOL, V456, P149, DOI 10.1016/S0014-2999(02)02644-4; Osborn BL, 2002, J PHARMACOL EXP THER, V303, P540, DOI 10.1124/jpet.102.037002; PEDLEY RB, 1994, BRIT J CANCER, V70, P1126, DOI 10.1038/bjc.1994.459; Peipp M, 2002, BIOCHEM SOC T, V30, P507, DOI 10.1042/bst0300507; Schlereth B, 2005, CANCER RES, V65, P2882, DOI 10.1158/0008-5472.CAN-04-2637; Smith BJ, 2001, BIOCONJUGATE CHEM, V12, P750, DOI 10.1021/bc010003g; Sung C, 2003, J INTERF CYTOK RES, V23, P25, DOI 10.1089/10799900360520423; van Spriel AB, 2000, IMMUNOL TODAY, V21, P391, DOI 10.1016/S0167-5699(00)01659-5; Volkel T, 2001, PROTEIN ENG, V14, P815, DOI 10.1093/protein/14.10.815; Yang K, 2003, PROTEIN ENG, V16, P761, DOI 10.1093/protein/gzg093; ZHU ZP, 1995, J IMMUNOL, V155, P1903	39	181	229	6	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12650	12660		10.1074/jbc.M700820200	http://dx.doi.org/10.1074/jbc.M700820200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17347147	hybrid			2022-12-27	WOS:000245942800034
J	Lingueglia, E				Lingueglia, Eric			Acid-sensing ion channels in sensory perception	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ROOT GANGLION NEURONS; MECHANOSENSORY TERMINALS; RETINAL FUNCTION; TOUCH SENSATION; PROTEIN PICK1; GATED CURRENT; ASIC3; MICE; CONTRIBUTES; CURRENTS	Acid-activated currents blocked by amiloride have been reported for a long time in most neurons of the mammalian brain as well as in sensory neurons (1). A decade ago, Waldmann and colleagues (2) were the first to clone the ion channels underlying these currents, which have been called acid-sensing ion channels (ASICs).2 ASICs are neuronal voltage-insensitive cationic channels activated by extracellular protons. They belong to the ENaC/DEG (epithelial amiloride-sensitive Na+ channel and degenerin) family of ion channels (3). ASICs share the same overall structure with other members of this family, which is characterized by two hydrophobic transmembrane regions flanking a large extracellular domain representing more than 50% of the protein and comprising many conserved cysteines (Fig. 1). Functional ASICs probably assemble as tetramers, as proposed for two other channels of the ENaC/DEG family, i.e. ENaC and FaNaC (the invertebrate FMRF-amide-activated Na+ channel). The ASIC family in mammals (ASICs have also been cloned from toadfish, lamprey, shark, and zebrafish) comprises four different genes encoding seven isoforms (4, 5) (Fig. 1). ASICs are widely expressed in neurons of both the central and the peripheral nervous system but have also been detected in non-neuronal tissues including testis (human ASIC3), pituitary gland (ASIC4), lung epithelial cells (ASIC3), and bone (ASIC1-3) (Table 1).	Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lingueglia, E (corresponding author), Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.	lingueglia@ipmc.cnrs.fr	LINGUEGLIA, Eric/F-5509-2013	LINGUEGLIA, Eric/0000-0003-3902-3405				Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; BOUNOUTAS A, 2007, PFLUGERS ARCH; Brockway LM, 2002, AM J PHYSIOL-CELL PH, V283, pC126, DOI 10.1152/ajpcell.00457.2001; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Chen XM, 2006, J GEN PHYSIOL, V127, P267, DOI 10.1085/jgp.200509409; Deval E, 2006, J BIOL CHEM, V281, P1796, DOI 10.1074/jbc.M509669200; Deval E, 2004, J BIOL CHEM, V279, P19531, DOI 10.1074/jbc.M313078200; DeVries SH, 2001, NEURON, V32, P1107, DOI 10.1016/S0896-6273(01)00535-9; Diochot S, 2007, TOXICON, V49, P271, DOI 10.1016/j.toxicon.2006.09.026; Donier E, 2005, J BIOL CHEM, V280, P38666, DOI 10.1074/jbc.M505981200; Drew LJ, 2004, J PHYSIOL-LONDON, V556, P691, DOI 10.1113/jphysiol.2003.058693; Dube GR, 2005, PAIN, V117, P88, DOI 10.1016/j.pain.2005.05.021; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; Ettaiche M, 2004, J NEUROSCI, V24, P1005, DOI 10.1523/JNEUROSCI.4698-03.2004; Ettaiche M, 2006, J NEUROSCI, V26, P5800, DOI 10.1523/JNEUROSCI.0344-06.2006; Gao J, 2005, NEURON, V48, P635, DOI 10.1016/j.neuron.2005.10.011; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; Hildebrand MS, 2004, HEARING RES, V190, P149, DOI 10.1016/S0378-5955(04)00015-2; Hruska-Hageman AM, 2004, J BIOL CHEM, V279, P46962, DOI 10.1074/jbc.M405874200; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Jones NG, 2004, J NEUROSCI, V24, P10974, DOI 10.1523/JNEUROSCI.2619-04.2004; Jones RCW, 2005, J NEUROSCI, V25, P10981, DOI 10.1523/JNEUROSCI.0703-05.2005; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; Leffler A, 2006, NEUROSCIENCE, V139, P699, DOI 10.1016/j.neuroscience.2005.12.020; Lilley S, 2004, J NEUROSCI, V24, P1013, DOI 10.1523/JNEUROSCI.3191-03.2004; Lingueglia E, 2006, PEPTIDES, V27, P1138, DOI 10.1016/j.peptides.2005.06.037; Mogil JS, 2005, J NEUROSCI, V25, P9893, DOI 10.1523/JNEUROSCI.2019-05.2005; Molliver DC, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-35; Page AJ, 2005, GUT, V54, P1408, DOI 10.1136/gut.2005.071084; Peng BG, 2004, J NEUROSCI, V24, P10167, DOI 10.1523/JNEUROSCI.3196-04.2004; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2004, J BIOL CHEM, V279, P53886, DOI 10.1074/jbc.M407708200; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Richter TA, 2004, J NEUROSCI, V24, P4088, DOI 10.1523/JNEUROSCI.0653-04.2004; Roza C, 2004, J PHYSIOL-LONDON, V558, P659, DOI 10.1113/jphysiol.2004.066001; Shimada S, 2006, ARCH HISTOL CYTOL, V69, P227, DOI 10.1679/aohc.69.227; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Sluka KA, 2007, PAIN, V129, P102, DOI 10.1016/j.pain.2006.09.038; STEEN KH, 1995, NEUROSCI LETT, V199, P29, DOI 10.1016/0304-3940(95)12002-L; Su XF, 2006, J BIOL CHEM, V281, P36960, DOI 10.1074/jbc.M608002200; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Ugawa S, 2002, J CLIN INVEST, V110, P1185, DOI 10.1172/JCI200215709; Voilley Nicolas, 2004, Current Drug Targets - Inflammation and Allergy, V3, P71, DOI 10.2174/1568010043483980; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Wetzel C, 2007, NATURE, V445, P206, DOI 10.1038/nature05394; Wu LJ, 2004, J BIOL CHEM, V279, P43716, DOI 10.1074/jbc.M403557200; Xie JH, 2003, J NEUROPHYSIOL, V89, P2459, DOI 10.1152/jn.00707.2002; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Yagi J, 2006, CIRC RES, V99, P501, DOI 10.1161/01.RES.0000238388.79295.4c	54	240	250	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17325	17329		10.1074/jbc.R700011200	http://dx.doi.org/10.1074/jbc.R700011200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430882	hybrid			2022-12-27	WOS:000247084500001
J	Wang, JH; Zhang, Z; Palzkill, T; Chow, DC				Wang, Jihong; Zhang, Zhen; Palzkill, Timothy; Chow, Dar-Chone			Thermodynamic investigation of the role of contact residues of beta-lactamase-inhibitory protein for binding to TEM-1 beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTHERMAL TITRATION CALORIMETRY; LIGAND-BINDING; INTERFACE; RECOGNITION; COMPLEXES; AFFINITY	We have determined the thermodynamics of binding for the interaction between TEM-1 beta-lactamase and a set of alanine substituted contact residue mutants of beta-lactamase-inhibitory protein ( BLIP) using isothermal titration calorimetry. The binding enthalpies for these interactions are highly temperature dependent, with negative binding heat capacity changes ranging from -800 to -271 cal mol(-1) K-1. The isoenthalpic temperatures ( at which the binding enthalpy is zero) of these interactions range from 5 to 38 C. The changes in isoenthalpic temperature were used as an indicator of the changes in enthalpy and entropy driving forces, which in turn are related to hydrophobic and hydrophilic interactions. A contact residue of BLIP is categorized as a canonical residue if its alanine substitution mutant exhibits a change of isoenthalpic temperature matching the change of hydrophobicity because of the mutation. A contact position exhibiting a change in isoenthalpic temperature that does not match the change in hydrophobicity is categorized as an anti-canonical residue. Our experimental results reveal that the majority of residues where alanine substitution results in a loss of affinity are canonical ( 7 of 10), and about half of the residues where alanine substitutions have a minor effect are canonical. The interactions between TEM-1 beta-lactamase and BLIP canonical contact residues contribute directly to binding free energy, suggesting potential anchoring sites for binding partners. The anti-canonical behavior of certain residues may be the result of mutation-induced modifications such as structural rearrangements affecting contact residue configurations. Structural inspection of BLIP suggests that the Lys(74) side chain electrostatically holds BLIP loop 2 in position to bind to TEM-1 beta-lactamase, explaining a large loss of entropy-driven binding energy of the K74A mutant and the resulting anti-canonical behavior. The anticanonical behavior of the W150A mutant may also be due to structural rearrangements. Finally, the affinity enhancing effect of the contact residue mutant Y50A may be due to energetic coupling interactions between Asp(49) and His(41).	Univ Houston, Dept Chem, Houston, TX 77204 USA; Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	University of Houston System; University of Houston; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Chow, DC (corresponding author), Univ Houston, Dept Chem, Univ Pk, Houston, TX 77204 USA.	dchow@mail.uh.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032956, R37AI032956] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32956] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK SD, 1991, ANAL BIOCHEM, V193, P72, DOI 10.1016/0003-2697(91)90045-U; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Brooijmans N, 2002, PROTEINS, V48, P645, DOI 10.1002/prot.10139; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DORAN JL, 1990, J BACTERIOL, V172, P4909, DOI 10.1128/jb.172.9.4909-4918.1990; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Majiduddin FK, 2002, INT J MED MICROBIOL, V292, P127, DOI 10.1078/1438-4221-00198; Nooren IMA, 2003, J MOL BIOL, V325, P991, DOI 10.1016/S0022-2836(02)01281-0; Nooren IMA, 2003, EMBO J, V22, P3486, DOI 10.1093/emboj/cdg359; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Reynolds KA, 2006, J BIOL CHEM, V281, P26745, DOI 10.1074/jbc.M603878200; Rudgers GW, 2001, PROTEIN ENG, V14, P487, DOI 10.1093/protein/14.7.487; Rudgers GW, 2001, ANTIMICROB AGENTS CH, V45, P3279, DOI 10.1128/AAC.45.12.3279-3286.2001; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s; Velazquez-Campoy Adrian, 2004, Methods Mol Biol, V261, P35; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zhang YL, 1998, ANAL BIOCHEM, V261, P139, DOI 10.1006/abio.1998.2738; Zhang Z, 2004, J BIOL CHEM, V279, P42860, DOI 10.1074/jbc.M406157200; Zhang Z, 2003, J BIOL CHEM, V278, P45706, DOI 10.1074/jbc.M308572200	32	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17676	17684		10.1074/jbc.M611548200	http://dx.doi.org/10.1074/jbc.M611548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430899	hybrid			2022-12-27	WOS:000247084500040
J	Adams, CM				Adams, Christopher M.			Role of the transcription factor ATF4 in the anabolic actions of insulin and the anti-anabolic actions of glucocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING RESPONSE PATHWAY; GENE-EXPRESSION; AMINO-ACID; HEPATIC GLUCONEOGENESIS; MAMMALIAN TARGET; SKELETAL-MUSCLE; PROTEIN; RAPAMYCIN; CELLS; MICE	In most mammalian cells, insulin and glucocorticoids promote anabolism and catabolism, respectively. Whereas the opposing effects of insulin and glucocorticoids on catabolic gene expression have been explained at the molecular level, comparatively little is known about how these hormones alter anabolic gene expression. These studies identify ATF4 as an anabolic transcription factor that is repressed by glucocorticoids and induced by insulin. Insulin-mediated induction of ATF4 required the mammalian target of rapamycin complex 1, was required for the activation of a genetic program for the cellular uptake of essential amino acids and the synthesis of nonessential amino acids and aminoacyl-tRNAs, and was coupled to the repression of Foxo-dependent genes needed for protein and lipid catabolism. These results suggest that ATF4 plays a central role in hormonal regulation of amino acid and protein anabolism by coupling amino acid uptake and synthesis, as well as the generation of charged tRNAs, to mammalian target of rapamycin complex 1-mediated mRNA translation.	Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA	University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Adams, CM (corresponding author), Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.	christopher-adams@uiowa.edu		Adams, Christopher/0000-0002-5795-7212				Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Adams CM, 2004, J BIOL CHEM, V279, P52772, DOI 10.1074/jbc.M410302200; BERDANIER CD, 1979, J NUTR, V109, P1766, DOI 10.1093/jn/109.10.1766; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; EAGLE HARRY, 1955, JOUR BIOL CHEM, V214, P839; Foster DW, 1996, TXB ENDOCRINE PHYSL, P309; Furuyama T, 2003, BIOCHEM J, V375, P365, DOI 10.1042/BJ20030022; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hall RK, 2000, J BIOL CHEM, V275, P30169, DOI 10.1074/jbc.M004898200; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hyde R, 2003, BIOCHEM J, V373, P1, DOI 10.1042/BJ20030405; Jousse C, 2004, BIOCHEM BIOPH RES CO, V313, P447, DOI 10.1016/j.bbrc.2003.07.020; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145; Kimball SR, 2005, SEMIN CELL DEV BIOL, V16, P21, DOI 10.1016/j.semcdb.2004.11.009; KLEBANOV S, 1995, J GERONTOL A-BIOL, V50, pB78, DOI 10.1093/gerona/50A.2.B78; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Kwon HS, 2004, DIABETES, V53, P899, DOI 10.2337/diabetes.53.4.899; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Lassot I, 2005, J BIOL CHEM, V280, P41537, DOI 10.1074/jbc.M505294200; LEUNG K, 1975, ANNU REV PHYSIOL, V37, P245, DOI 10.1146/annurev.ph.37.030175.001333; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; Lopez AB, 2007, BIOCHEM J, V402, P163, DOI 10.1042/BJ20060941; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; PRATT WB, 1966, J BIOL CHEM, V241, P5244; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; SABATINO F, 1991, J GERONTOL, V46, pB171, DOI 10.1093/geronj/46.5.B171; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; SARRAJ JA, 2005, BIOL CHEM, V386, P873; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Wang HM, 2006, J BIOL CHEM, V281, P39128, DOI 10.1074/jbc.M610023200; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200	46	128	131	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16744	16753		10.1074/jbc.M610510200	http://dx.doi.org/10.1074/jbc.M610510200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17430894	hybrid			2022-12-27	WOS:000246946500006
J	Ihara, M; Koyama, H; Uchimura, Y; Saitoh, H; Kikuchi, A				Ihara, Motomasa; Koyama, Hirofumi; Uchimura, Yasuhiro; Saitoh, Hisato; Kikuchi, Akira			Noncovalent binding of small ubiquitin-related modifier (SUMO) protease to SUMO is necessary for enzymatic activities and cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; BETA-CATENIN; DEPENDENT ACTIVATION; YEAST; ISOPEPTIDASE; PROTEINS; ULP1; SPECIFICITY; CONJUGATION; AUTOPHAGY	SUMO proteases possess two enzymatic activities to hydrolyze the C-terminal region of SUMOs ( hydrolase activity) and to remove SUMO from SUMO-conjugated substrates ( isopeptidase activity). SUMO proteases bind to SUMOs noncovalently, but the physiological roles of the binding in the functions of SUMO proteases are not well understood. In this study we found that SUMO proteases ( Axam, SENP1, and yeast Ulp1) show different preferences for noncovalent binding to various SUMOs ( SUMO-1, -2, -3, and yeast Smt3) and that the hydrolase and isopeptidase activities of SUMO proteases are dependent on their binding to SUMOs through salt bridge. Expression of Smt3 suppressed the phenotype of yeast mutant lacking smt3, which exhibits growth arrest, and the binding of Ulp1 to Smt3 was essential for this rescue activity. Although expression of an Smt3 mutant ( smt3R64E(GG)), which conjugates to substrate but loses the ability to bind to Ulp1, rescued the phenotype of yeast lacking smt3 partially, the mutant cells showed an increment in the doubling time and a delay of desumoylation of Smt3-conjugated Cdc3. These results indicate that the noncovalent binding of SUMO protease to SUMO through salt bridge is essential for the enzymatic activities and that the balance between sumoylation and desumoylation is important for cell growth control.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Kumamoto Univ, Inst Mol Embryol Genet, Dept Regulat Med, Kumamoto 8600811, Japan	Hiroshima University; Kumamoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@hiroshima-u.ac.jp						Amar N, 2006, EMBO REP, V7, P635, DOI 10.1038/sj.embor.7400698; Bailey D, 2002, J GEN VIROL, V83, P2951, DOI 10.1099/0022-1317-83-12-2951; Ihara M, 2005, MOL CELL BIOL, V25, P3506, DOI 10.1128/MCB.25.9.3506-3518.2005; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kadoya T, 2002, MOL CELL BIOL, V22, P3803, DOI 10.1128/MCB.22.11.3803-3819.2002; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 2003, J CELL BIOL, V160, P1069, DOI 10.1083/jcb.200212052; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; Ohsumi Y, 2004, SEMIN CELL DEV BIOL, V15, P231, DOI 10.1016/j.semcdb.2003.12.004; Panse VG, 2003, NAT CELL BIOL, V5, P21, DOI 10.1038/ncb893; Reverter D, 2004, STRUCTURE, V12, P1519, DOI 10.1016/j.str.2004.05.023; Rose MD., 1990, METHODS YEAST GENETI; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Shen LN, 2006, BIOCHEM J, V397, P279, DOI 10.1042/BJ20052030; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Uchimura Y, 2004, FEBS LETT, V564, P85, DOI 10.1016/S0014-5793(04)00321-7; Xu Z, 2005, BIOCHEM J, V386, P325, DOI 10.1042/BJ20041210; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	30	20	25	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16465	16475		10.1074/jbc.M610723200	http://dx.doi.org/10.1074/jbc.M610723200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428805	hybrid			2022-12-27	WOS:000246794300054
J	Kunita, R; Otomo, A; Mizumura, H; Suzuki-Utsunomiya, K; Hadano, S; Ikeda, JE				Kunita, Ryota; Otomo, Asako; Mizumura, Hikaru; Suzuki-Utsunomiya, Kyoko; Hadano, Shinji; Ikeda, Joh-E			The Rab5 activator ALS2/alsin acts as a novel Rac1 effector through Rac1-activated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HEREDITARY SPASTIC PARALYSIS; ALS2 GENE; SIGNAL-TRANSDUCTION; HOMOLOGY DOMAIN; PROTEIN; RECEPTOR; MUTATION; RHO; GTPASES	Mutations in the ALS2 gene cause a number of recessive motor neuron diseases, indicating that the ALS2 protein ( ALS2/ alsin) is vital for motor neurons. ALS2 acts as a guanine nucleotide exchange factor ( GEF) for Rab5 ( Rab5GEF) and is involved in endosome dynamics. However, the spatiotemporal regulation of the ALS2-mediated Rab5 activation is unclear. Here we identified an upstream activator for ALS2 and showed a functional significance of the ALS2 activation in endosome dynamics. ALS2 preferentially interacts with activated Rac1. In the cells activated Rac1 recruits cytoplasmic ALS2 to membrane ruffles and subsequently to nascent macropinosomes via Rac1-activated macropinocytosis. At later endocytic stages macropinosomal ALS2 augments fusion of the ALS2-localized macropinosomes with the transferrin-positive endosomes, depending on the ALS2-associated Rab5GEF activity. These results indicate that Rac1 promotes the ALS2 membranous localization, thereby rendering ALS2 active via Rac1-activated endocytosis. Thus, ALS2 is a novel Rac1 effector and is involved in Rac1-activated macropinocytosis. All together, loss of ALS2 may perturb macropinocytosis and/or the following membrane trafficking, which gives rise to neuronal dysfunction in the ALS2-linked motor neuron diseases.	Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan; Japan Sci & Technol Agcy, Solut Oriented Res Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Tokai Univ, Inst Med Sci, Dept Mol Neurosci, Isehara, Kanagawa 2591193, Japan; Univ Ottawa, Fac Med, Dept Paediat, Ottawa, ON K1H 8M5, Canada	Tokai University; Japan Science & Technology Agency (JST); Tokai University; University of Ottawa	Ikeda, JE (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan.	jeikeda3@is.icc.u-tokai.ac.jp	Hadano, Shinji/ABA-5052-2021; Otomo, Asako/AAA-6374-2019	Hadano, Shinji/0000-0002-4997-3968; Otomo, Asako/0000-0002-7849-4309				Araki N, 2006, CELL STRUCT FUNCT, V31, P145, DOI 10.1247/csf.06029; Baird D, 2005, CURR BIOL, V15, P1, DOI 10.1016/j.cub.2004.12.040; Barbieri MA, 2003, J BIOL CHEM, V278, P32027, DOI 10.1074/jbc.M304324200; Barbieri MA, 1998, J BIOL CHEM, V273, P25850, DOI 10.1074/jbc.273.40.25850; Brown B, 2001, J LAW MED ETHICS, V29, P166; Cai HB, 2005, J NEUROSCI, V25, P7567, DOI 10.1523/JNEUROSCI.1645-05.2005; Carney DS, 2006, TRENDS CELL BIOL, V16, P27, DOI 10.1016/j.tcb.2005.11.001; Cheng L, 2004, J BIOL CHEM, V279, P12786, DOI 10.1074/jbc.M313099200; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Devon RS, 2006, P NATL ACAD SCI USA, V103, P9595, DOI 10.1073/pnas.0510197103; Devon RS, 2003, CLIN GENET, V64, P210, DOI 10.1034/j.1399-0004.2003.00138.x; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; Gros-Louis F, 2003, ANN NEUROL, V53, P144, DOI 10.1002/ana.10422; Hadano S, 2006, HUM MOL GENET, V15, P233, DOI 10.1093/hmg/ddi440; Hamasaki M, 2004, ANAT REC PART A, V277A, P298, DOI 10.1002/ar.a.20027; Hunker CM, 2006, EXP CELL RES, V312, P1106, DOI 10.1016/j.yexcr.2005.12.021; Hunker CM, 2006, BIOCHEM BIOPH RES CO, V340, P967, DOI 10.1016/j.bbrc.2005.12.099; Im YJ, 2007, J BIOL CHEM, V282, P5443, DOI 10.1074/jbc.M611342200; Jacquier A, 2006, ANN NEUROL, V60, P105, DOI 10.1002/ana.20886; Kalia M, 2006, MOL BIOL CELL, V17, P3689, DOI 10.1091/mbc.E05-10-0980; Kanekura K, 2005, J BIOL CHEM, V280, P4532, DOI 10.1074/jbc.M410508200; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kirkham M, 2005, BBA-MOL CELL RES, V1746, P349, DOI 10.1016/j.bbamcr.2005.11.005; Kress JA, 2005, ANN NEUROL, V58, P800, DOI 10.1002/ana.20665; Kunita R, 2004, J BIOL CHEM, V279, P38626, DOI 10.1074/jbc.M406120200; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Lesca G, 2003, NEUROLOGY, V60, P674, DOI 10.1212/01.WNL.0000048207.28790.25; Li GP, 1997, J BIOL CHEM, V272, P10337; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Otomo A, 2003, HUM MOL GENET, V12, P1671, DOI 10.1093/hmg/ddg184; Panzeri C, 2006, BRAIN, V129, P1710, DOI 10.1093/brain/awl104; Pelkmans L, 2004, CELL, V118, P767, DOI 10.1016/j.cell.2004.09.003; Pfeffer S, 2004, NAT REV MOL CELL BIO, V5, P886, DOI 10.1038/nrm1500; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sato M, 2005, NAT CELL BIOL, V7, P559, DOI 10.1038/ncb1261; Su X, 2006, J BIOL CHEM, V281, P27982, DOI 10.1074/jbc.M602873200; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Takeshima H, 2000, MOL CELL, V6, P11, DOI 10.1016/S1097-2765(00)00003-4; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Topp JD, 2004, J BIOL CHEM, V279, P24612, DOI 10.1074/jbc.M313504200; Tudor EL, 2005, J BIOL CHEM, V280, P34735, DOI 10.1074/jbc.M506216200; Yamanaka K, 2003, P NATL ACAD SCI USA, V100, P16041, DOI 10.1073/pnas.2635267100; Yamanaka K, 2006, ANN NEUROL, V60, P95, DOI 10.1002/ana.20888; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	52	61	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16599	16611		10.1074/jbc.M610682200	http://dx.doi.org/10.1074/jbc.M610682200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17409386	hybrid			2022-12-27	WOS:000246794300066
J	Michaluk, P; Kolodziej, L; Mioduszewska, B; Wilczynski, GM; Dzwonek, J; Jaworski, J; Gorecki, DC; Ottersen, OP; Kaczmarek, L				Michaluk, Piotr; Kolodziej, Lukasz; Mioduszewska, Barbara; Wilczynski, Grzegorz M.; Dzwonek, Joanna; Jaworski, Jacek; Gorecki, Dariusz C.; Ottersen, Ole Petter; Kaczmarek, Leszek			beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; NMDA RECEPTORS; MATRIX-METALLOPROTEINASE-9; EXPRESSION; BRAIN; MEMBRANE; KINASE; BIOSYNTHESIS	Matrix metalloproteinase-9 has recently emerged as an important molecule in control of extracellular proteolysis in the synaptic plasticity. However, no synaptic targets for its enzymatic activity had been identified before. In this report, we show that beta-dystroglycan comprises such a neuronal activity-driven target for matrix metalloproteinase-9. This notion is based on the following observations. (i) Recombinant, autoactivating matrix metalloproteinase-9 produces limited proteolytic cleavage of beta-dystroglycan. (ii) In neuronal cultures, beta-dystroglycan proteolysis occurs in response to stimulation with either glutamate or bicuculline and is blocked by tissue inhibitor of metalloproteinases-1, a metalloproteinase inhibitor. (iii) beta-Dystroglycan degradation is also observed in the hippocampus in vivo in response to seizures but not in the matrix metalloproteinase 9 knock-out mice. (iv) beta-Dystroglycan cleavage correlates in time with increased matrix metalloproteinase-9 activity. (v) Finally, beta-dystroglycan and matrix metalloproteinase-9 colocalize in postsynaptic elements in the hippocampus. In conclusion, our data identify the beta-dystroglycan as a first matrix metalloproteinase-9 substrate digested in response to enhanced synaptic activity. This demonstration may help to understand the possible role of both proteins in neuronal functions, especially in synaptic plasticity, learning, and memory.	Nencki Inst, Dept Mol & Cellular Neurobiol, PL-02093 Warsaw, Poland; Nencki Inst, Dept Neurophysiol, PL-02093 Warsaw, Poland; Univ Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Int Inst Mol & Cell biol, PL-02109 Warsaw, Poland; Int Inst Mol & Cell Biol, Lab Mol & Cellular Neurobiol, PL-02109 Warsaw, Poland; Univ Portsmouth, Sch Pharm & Biomed Sci, Inst Biomed Sci & Biomol Sci, Portsmouth PO1 2DT, Hants, England; Univ Oslo, Ctr Mol Biol & Neurosci, Inst Basic Med Sci, N-0317 Oslo, Norway	Polish Academy of Sciences; Polish Academy of Sciences; Utrecht University; Utrecht University; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; University of Portsmouth; University of Oslo	Kaczmarek, L (corresponding author), Nencki Inst, Dept Mol & Cellular Neurobiol, Pasteura 3, PL-02093 Warsaw, Poland.	l.kaczmarek@nencki.gov.pl	Kolodziej, Lukas/J-2978-2014; Kaczmarek, Leszek/B-6171-2008; Michaluk, Piotr/AAR-5238-2021; Kaczmarek, Leszek/AHA-0076-2022	Kolodziej, Lukas/0000-0002-0400-7918; Kaczmarek, Leszek/0000-0002-7207-3490; Michaluk, Piotr/0000-0003-2306-3314; Kaczmarek, Leszek/0000-0002-7207-3490; Wilczynski, Grzegorz/0000-0001-6667-0291; Dzwonek, Joanna/0000-0002-3834-2175; Gorecki, Dariusz/0000-0003-3584-1654; Kolodziej, Lukasz/0000-0002-9814-9158; Jaworski, Jacek/0000-0001-8760-7865	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Barresi R, 2006, J CELL SCI, V119, P199, DOI 10.1242/jcs.02814; Bruno MA, 2006, P NATL ACAD SCI USA, V103, P6735, DOI 10.1073/pnas.0510645103; CALABRESI P, 1990, J NEUROPHYSIOL, V63, P651, DOI 10.1152/jn.1990.63.4.651; Cavaldesi M, 1999, J NEUROCHEM, V72, P1648, DOI 10.1046/j.1471-4159.1999.721648.x; Culligan Kevin, 2002, Journal of Biomedicine and Biotechnology, V2, P31, DOI 10.1155/S1110724302000347; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; Dzwonek J, 2004, FEBS LETT, V567, P129, DOI 10.1016/j.febslet.2004.03.070; Fisher KE, 2002, BIOCHEMISTRY-US, V41, P8289, DOI 10.1021/bi012076t; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Gorecki DC, 1999, MOL CELL NEUROSCI, V13, P218, DOI 10.1006/mcne.1999.0740; Gorecki DC, 1998, NEUROSCIENCE, V84, P467, DOI 10.1016/S0306-4522(97)00562-9; Helbecque N, 2003, NEUROSCI LETT, V350, P181, DOI 10.1016/S0304-3940(03)00905-4; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hnia K, 2006, NEUROSCIENCE, V141, P607, DOI 10.1016/j.neuroscience.2006.04.043; Holt KH, 2000, FEBS LETT, V468, P79, DOI 10.1016/S0014-5793(00)01195-9; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Ivanov A, 2006, J PHYSIOL-LONDON, V572, P789, DOI 10.1113/jphysiol.2006.105510; Kaczmarek L, 2002, EMBO J, V21, P6643, DOI 10.1093/emboj/cdf676; Matsumura K, 2005, NEUROMUSCULAR DISORD, V15, P336, DOI 10.1016/j.nmd.2005.01.007; Matsumura K, 2003, NEUROMUSCULAR DISORD, V13, P796, DOI 10.1016/S0960-8966(03)00139-1; Meighan SE, 2006, J NEUROCHEM, V96, P1227, DOI 10.1111/j.1471-4159.2005.03565.x; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Montanaro F, 2003, NEURON, V37, P193, DOI 10.1016/S0896-6273(03)00032-1; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; OKULSKI P, 2007, IN PRESS BIOL PSYCHI; REVAH F, 1996, PROTOCOLS GENE TRANS, P81; Sadatmansoori S, 2001, PROTEIN EXPRES PURIF, V23, P447, DOI 10.1006/prep.2001.1542; Spence HJ, 2004, EMBO REP, V5, P484, DOI 10.1038/sj.embor.7400140; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Takumi Y, 1999, NAT NEUROSCI, V2, P618, DOI 10.1038/10172; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; WILCZYNSKI GM, IN PRESS REGULATION; Woessner J.F., 2000, PROTEIN PROFILE SER; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yamada H, 2001, HUM MOL GENET, V10, P1563, DOI 10.1093/hmg/10.15.1563; Yang YC, 2003, J NEUROSCI, V23, P4072; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6; Zagulska-Szymczak S, 2001, NEUROCHEM INT, V38, P485, DOI 10.1016/S0197-0186(00)00101-7; Zhong D, 2006, BIOCHEM BIOPH RES CO, V345, P867, DOI 10.1016/j.bbrc.2006.05.004	46	156	159	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16036	16041		10.1074/jbc.M700641200	http://dx.doi.org/10.1074/jbc.M700641200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426029	hybrid			2022-12-27	WOS:000246794300011
J	Rezvani, HR; Dedieu, S; North, S; Belloc, F; Rossignol, R; Letellier, T; de Verneuil, H; Taieb, A; Mazurier, F				Rezvani, Hamid Reza; Dedieu, Sophie; North, Sophie; Belloc, Francis; Rossignol, Rodrigue; Letellier, Thierry; de Verneuil, Hubert; Taieb, Alain; Mazurier, Frederic			Hypoxia-inducible factor-1 alpha, a key factor in the keratinocyte response to UVB exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET-B IRRADIATION; ACTIVATED PROTEIN-KINASE; FACTOR-I; ANTIOXIDANT ENZYMES; INDUCED APOPTOSIS; OXIDATIVE STRESS; GENE-EXPRESSION; DOWN-REGULATION; FACTOR 1-ALPHA; NITRIC-OXIDE	Hypoxia-inducible factor-1 (HIF-1) is a major transcription factor sensitive to oxygen levels, which responds to stress factors under both hypoxic and nonhypoxic conditions. UV irradiation being a common stressor of skin, we looked at the effect of UVB on HIF-1 alpha expression in keratinocytes. We found that UVB induces a biphasic HIF-1 alpha variation through reactive oxygen species ( ROS) generation. Whereas rapid production of cytoplasmic ROS down-regulates HIF-1 alpha expression, delayed mitochondrial ROS generation results in its up-regulation. Indeed, activation of p38 MAPK and JNK1 mediated by mitochondrial ROS were required for HIF-1 alpha phosphorylation and accumulation after UVB irradiation. Our experiments also revealed a key role of HIF-1 alpha in mediating UVB-induced apoptosis. We conclude that the broad impact of the HIF- 1 transcription factor on gene expression could make it a key regulator of UV-responsive genes and photocarcinogenesis.	INSERM, U876, F-33000 Bordeaux, France; Univ Bordeaux, F-33000 Bordeaux, France; INSERM, U668, F-33000 Bordeaux, France; Ctr Hosp Univ Bordeaux, Dept Dermatol, Natl Reference Ctr Rare Skin Dis, Hop St Andre, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux	Mazurier, F (corresponding author), INSERM, U876, F-33000 Bordeaux, France.	mazurier@u-bordeaux2.fr	Mazurier, FrÃ©dÃ©ric/O-1619-2018; TAIEB, ALAIN/AAB-1085-2021; Rezvani, Hamid Reza/G-3734-2013	Rezvani, Hamid Reza/0000-0001-8067-1338; Mazurier, Frederic/0000-0002-6984-7096				Assefa Z, 2005, BBA-REV CANCER, V1755, P90, DOI 10.1016/j.bbcan.2005.04.001; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Beak SM, 2004, BIOCHIMIE, V86, P425, DOI 10.1016/j.biochi.2004.06.010; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; Bell EL, 2005, MITOCHONDRION, V5, P322, DOI 10.1016/j.mito.2005.06.005; Blaudschun R, 2000, FEBS LETT, V474, P195, DOI 10.1016/S0014-5793(00)01605-7; BODE AM, 2003, SCI STKE, pRE2; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Brenneisen P, 1998, J BIOL CHEM, V273, P5279, DOI 10.1074/jbc.273.9.5279; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Comerford KM, 2004, CANCER RES, V64, P9057, DOI 10.1158/0008-5472.CAN-04-1919; Corre S, 2004, J BIOL CHEM, V279, P51226, DOI 10.1074/jbc.M409768200; Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fandrey J, 2006, CARDIOVASC RES, V71, P642, DOI 10.1016/j.cardiores.2006.05.005; Garmyn M, 1997, J PHOTOCH PHOTOBIO B, V37, P125, DOI 10.1016/S1011-1344(96)07340-X; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Heck DE, 2004, TOXICOL APPL PHARM, V195, P288, DOI 10.1016/j.taap.2003.09.028; Hildesheim J, 2004, J INVEST DERMATOL, V122, P497, DOI 10.1111/j.1523-1747.2004.22229.x; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Kietzmann T, 2005, SEMIN CELL DEV BIOL, V16, P474, DOI 10.1016/j.semcdb.2005.03.010; Kietzmann T, 2003, THROMB HAEMOSTASIS, V89, P666; Kim MS, 2006, J INVEST DERMATOL, V126, P2697, DOI 10.1038/sj.jid.5700463; Kwon SJ, 2005, CLIN CANCER RES, V11, P7607, DOI 10.1158/1078-0432.CCR-05-0981; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Maalouf S, 2002, MOL CARCINOGEN, V34, P121, DOI 10.1002/mc.10055; Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1; Matsumura Yasuhiro, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S146239940200532X; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; McArdle F, 2002, FREE RADICAL BIO MED, V33, P1355, DOI 10.1016/S0891-5849(02)01042-0; Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891-5849(02)01045-6; Mildner M, 1999, PHOTOCHEM PHOTOBIOL, V70, P674, DOI 10.1562/0031-8655(1999)070<0674:UAURDR>2.3.CO;2; Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; PUNNONEN K, 1991, PHOTODERMATOL PHOTO, V8, P3; Rezvani HR, 2007, CANCER GENE THER, V14, P174, DOI 10.1038/sj.cgt.7701000; Rezvani HR, 2006, J BIOL CHEM, V281, P17999, DOI 10.1074/jbc.M600536200; Rossignol F, 2002, GENE, V299, P135, DOI 10.1016/S0378-1119(02)01049-1; Ryan HE, 2000, CANCER RES, V60, P4010; Sander CS, 2004, INT J DERMATOL, V43, P326, DOI 10.1111/j.1365-4632.2004.02222.x; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SHINDO Y, 1994, PHOTODERMATOL PHOTO, V10, P183; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Tyrrell RM, 1995, BIOCHEM SOC SYMP, P47, DOI 10.1042/bss0610047; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zhong H, 1999, CANCER RES, V59, P5830	56	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16413	16422		10.1074/jbc.M611397200	http://dx.doi.org/10.1074/jbc.M611397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17400550	hybrid			2022-12-27	WOS:000246794300049
J	Clements, A; Tull, D; Jenney, AW; Farn, JL; Kim, SH; Bishop, RE; McPhee, JB; Hancock, REW; Hartland, EL; Pearse, MJ; Wijburg, OLC; Jackson, DC; McConville, MJ; Strugnell, RA				Clements, Abigail; Tull, Dedreia; Jenney, Adam W.; Farn, Jacinta L.; Kim, Sang-Hyun; Bishop, Russell E.; McPhee, Joseph B.; Hancock, Robert E. W.; Hartland, Elizabeth L.; Pearse, Martin J.; Wijburg, Odilia L. C.; Jackson, David C.; McConville, Malcolm J.; Strugnell, Richard A.			Secondary acylation of Klebsiella pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDES; GRAM-NEGATIVE BACILLI; OUTER-MEMBRANE STABILITY; INTENSIVE-CARE UNITS; LIPID-A COMPONENT; O SIDE-CHAIN; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; PSEUDOMONAS-AERUGINOSA; BACTERIAL-RESISTANCE	Klebsiella pneumoniae is an important cause of nosocomial Gram-negative sepsis. Lipopolysaccharide (LPS) is considered to be a major virulence determinant of this encapsulated bacterium and most mutations to the lipid A anchor of LPS are conditionally lethal to the bacterium. We studied the role of LPS acylation in K. pneumoniae disease pathogenesis by using a mutation of lpxM (msbB/waaN), which encodes the enzyme responsible for late secondary acylation of immature lipid A molecules. A K. pneumoniae B5055 (K2:O1) lpxM mutant was found to be attenuated for growth in the lungs in a mouse pneumonia model leading to reduced lethality of the bacterium. B5055 Delta lpxM exhibited similar sensitivity to phagocytosis or complement-mediated lysis than B5055, unlike the non-encapsulated mutant B5055nm. In vitro, B5055 Delta lpxM showed increased permeability of the outer membrane and an increased susceptibility to certain antibacterial peptides suggesting that in vivo attenuation may be due in part to sensitivity to antibacterial peptides present in the lungs of BALB/c mice. These data support the view that lipopolysaccharide acylation plays a important role in providing Gram-negative bacteria some resistance to structural and innate defenses and especially the antibacterial properties of detergents (e. g. bile) and cationic defensins.	Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; Univ Melbourne, CRC Vaccine Technol, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; CSL Ltd, Parkville, Vic 3052, Australia; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z4, Canada; Monash Univ, Dept Microbiol, CRC Vaccine Technol, Clayton, Vic 3800, Australia; Univ Melbourne, Australian Bacterial Pathogenesis Program, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia	University of Melbourne; University of Melbourne; University of Melbourne; CSL; University of Toronto; University of British Columbia; Monash University; University of Melbourne	Strugnell, RA (corresponding author), Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia.	rastru@unimelb.edu.au	Hancock, Robert E. W./E-1145-2013; McPhee, Joseph/AAG-5382-2019; Hartland, Elizabeth/O-2569-2014	Hancock, Robert E. W./0000-0001-5989-8503; Hartland, Elizabeth/0000-0003-4254-2863; Strugnell, Richard/0000-0003-0614-5641; Clements, Abigail/0000-0003-2285-777X; Tull, Dedreia/0000-0003-2546-6707; McPhee, Joseph/0000-0002-6844-755X; Jackson, David/0000-0001-7255-270X	Canadian Institutes of Health Research [84329-1] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Alvarez D, 2000, INFECT IMMUN, V68, P953, DOI 10.1128/IAI.68.2.953-955.2000; Amsterdam D, 1996, ANTIBIOTICS LAB MED, V4, P52; Bader MW, 2003, MOL MICROBIOL, V50, P219, DOI 10.1046/j.1365-2958.2003.03675.x; BENNER SA, 1994, J MOL BIOL, V235, P926, DOI 10.1006/jmbi.1994.1049; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; Campos MA, 2004, INFECT IMMUN, V72, P7107, DOI 10.1128/IAI.72.12.7107-7114.2004; Cortes G, 2002, INFECT IMMUN, V70, P2583, DOI 10.1128/IAI.70.5.2583-2590.2002; d'Hauteville H, 2002, J IMMUNOL, V168, P5240, DOI 10.4049/jimmunol.168.10.5240; DARVEAU RP, 1992, J CLIN INVEST, V90, P447, DOI 10.1172/JCI115880; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Friedrich C, 1999, ANTIMICROB AGENTS CH, V43, P1542, DOI 10.1128/AAC.43.7.1542; Frirdich E, 2005, J ENDOTOXIN RES, V11, P133, DOI 10.1179/096805105X46592; Frirdich E, 2005, J BIOL CHEM, V280, P27604, DOI 10.1074/jbc.M504987200; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guzman-Verri C, 2002, P NATL ACAD SCI USA, V99, P12375, DOI 10.1073/pnas.192439399; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hanberger H, 1999, JAMA-J AM MED ASSOC, V281, P67, DOI 10.1001/jama.281.1.67; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Hancock REW, 1997, J MED MICROBIOL, V46, P1; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; HIGHSMITH AK, 1985, INFECT CONT HOSP EP, V6, P75, DOI 10.1017/S0195941700062640; Jia WY, 2004, J BIOL CHEM, V279, P44966, DOI 10.1074/jbc.M404963200; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; KOHASHI O, 1992, MICROBIOL IMMUNOL, V36, P369, DOI 10.1111/j.1348-0421.1992.tb02036.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCEFIELD RC, 1962, IMMUNOLOGY, V89, P307; LEHMANN V, 1978, EUR J BIOCHEM, V86, P487, DOI 10.1111/j.1432-1033.1978.tb12332.x; Maneval WE, 1941, STAIN TECHNOL, V16, P13, DOI 10.3109/10520294109106189; Manterola L, 2005, J BACTERIOL, V187, P5631, DOI 10.1128/JB.187.16.5631-5639.2005; McManus MC, 1997, AM J HEALTH-SYST PH, V54, P1420, DOI 10.1093/ajhp/54.12.1420; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; MERINO S, 1992, INFECT IMMUN, V60, P2529, DOI 10.1128/IAI.60.6.2529-2535.1992; Moskowitz SM, 2004, J BACTERIOL, V186, P575, DOI 10.1128/JB.186.2.575-579.2004; Murray SR, 2001, J BACTERIOL, V183, P5554, DOI 10.1128/JB.183.19.5554-5561.2001; Nesper J, 2001, INFECT IMMUN, V69, P435, DOI 10.1128/IAI.69.1.435-445.2001; Neuhauser MM, 2003, JAMA-J AM MED ASSOC, V289, P885, DOI 10.1001/jama.289.7.885; Post DMB, 2003, INFECT IMMUN, V71, P647, DOI 10.1128/IAI.71.2.647-655.2003; Pristovsek P, 1999, J MED CHEM, V42, P4604, DOI 10.1021/jm991031b; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; Regue M, 2005, J BACTERIOL, V187, P4198, DOI 10.1128/JB.187.12.4198-4206.2005; SCHINDLER M, 1979, BIOCHEMISTRY-US, V18, P4425, DOI 10.1021/bi00587a024; Sforza S, 2004, J MASS SPECTROM, V39, P378, DOI 10.1002/jms.598; Shankar-Sinha S, 2004, INFECT IMMUN, V72, P1423, DOI 10.1128/IAI.72.3.1423-1430.2004; SIDORCZYK Z, 1983, EUR J BIOCHEM, V137, P15, DOI 10.1111/j.1432-1033.1983.tb07789.x; SIMOONSSMIT AM, 1984, J MED MICROBIOL, V17, P67, DOI 10.1099/00222615-17-1-67; Somerville JE, 1999, INFECT IMMUN, V67, P6583; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Steeghs L, 2001, EMBO J, V20, P6937, DOI 10.1093/emboj/20.24.6937; THARANATHAN RN, 1978, EUR J BIOCHEM, V84, P385, DOI 10.1111/j.1432-1033.1978.tb12179.x; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Vinogradov E, 2001, CARBOHYD RES, V335, P291, DOI 10.1016/S0008-6215(01)00216-6; WEISS J, 1982, INFECT IMMUN, V38, P1149, DOI 10.1128/IAI.38.3.1149-1153.1982; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WILLIAMS P, 1983, J GEN MICROBIOL, V129, P2181; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yin N, 2003, J AM CHEM SOC, V125, P2426, DOI 10.1021/ja0284456; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U; Zhang LJ, 2000, ANTIMICROB AGENTS CH, V44, P3317, DOI 10.1128/AAC.44.12.3317-3321.2000; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	61	86	88	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15569	15577		10.1074/jbc.M701454200	http://dx.doi.org/10.1074/jbc.M701454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17371870	Green Accepted, hybrid			2022-12-27	WOS:000246589600034
J	Nyalendo, C; Michaud, M; Beaulieu, E; Roghi, C; Murphy, G; Gingras, D; Beliveau, R				Nyalendo, Carine; Michaud, Marisol; Beaulieu, Edith; Roghi, Christian; Murphy, Gilian; Gingras, Denis; Beliveau, Richard			Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573 - Role in endothelial and tumor cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE; MT1-MMP; CAVEOLAE; CANCER; SURFACE; OLIGOMERIZATION; ANGIOGENESIS; LOCALIZATION; PROTEOLYSIS; INHIBITION	Membrane type 1 matrix metalloproteinase (MT1-MMP) is a transmembrane MMP that plays important roles in migratory processes underlying tumor invasion and angiogenesis. In addition to its matrix degrading activity, MT1-MMP also contains a short cytoplasmic domain whose involvement in cell locomotion seems important but remains poorly understood. In this study, we show that MT1-MMP is phosphorylated on the unique tyrosine residue located within this cytoplasmic sequence (Tyr(573)) and that this phosphorylation requires the kinase Src. Using phosphospecific antibodies recognizing MT1-MMP phosphorylated on Tyr(573), we observed that tyrosine phosphorylation of the enzyme is rapidly induced upon stimulation of tumor and endothelial cells with the platelet-derived chemoattractant sphingosine-1-phosphate, suggesting a role in migration triggered by this lysophospholipid. Accordingly, overexpression of a nonphosphorylable MT1-MMP mutant (Y573F) blocked sphingosine-1-phosphate-induced migration of Human umbilical vein endothelial cells and HT-1080 (human fibrosarcoma) cells and failed to stimulate migration of cells lacking the enzyme (bovine aortic endothelial cells). Altogether, these findings strongly suggest that the Src-dependent tyrosine phosphorylation of MT1-MMP plays a key role in cell migration and further emphasize the importance of the cytoplasmic domain of the enzyme in this process.	Univ Quebec, Ctr Cancerol Charles Bruneau, Mol Med Lab, Hop St Justine, Montreal, PQ H3T 1C5, Canada; Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England	Universite de Montreal; University of Quebec; University of Quebec Montreal; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Beliveau, R (corresponding author), St Justine UQAM, Ctr Cancerol Charles Bruneau, Mol Med Lab, 3175,Chemin Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	molmed@recherche-ste-justine.qc.ca	Roghi, Christian/F-3228-2012	Roghi, Christian/0000-0002-4109-6382				Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Beardsley A, 2005, J BIOL CHEM, V280, P3541, DOI 10.1074/jbc.M409040200; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; Follows ER, 2001, BIOCHEM J, V359, P427, DOI 10.1042/0264-6021:3590427; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; Haas TL, 2005, CAN J PHYSIOL PHARM, V83, P1, DOI 10.1139/Y04-120; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Koo HM, 2002, MOL CELLS, V13, P118; Koshikawa N, 2005, J BIOL CHEM, V280, P88, DOI 10.1074/jbc.M411824200; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Langlois S, 2004, BLOOD, V103, P3020, DOI 10.1182/blood-2003-08-2968; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Mandell JW, 2003, AM J PATHOL, V163, P1687, DOI 10.1016/S0002-9440(10)63525-0; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pilorget A, 2005, J CEREBR BLOOD F MET, V25, P1171, DOI 10.1038/sj.jcbfm.9600117; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1997, J CELL SCI, V110, P589; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Uekita T, 2004, J BIOL CHEM, V279, P12734, DOI 10.1074/jbc.M309957200; van Hinsbergh VWM, 2006, ARTERIOSCL THROM VAS, V26, P716, DOI 10.1161/01.ATV.0000209518.58252.17; WU JZ, 1994, BIOCHEMISTRY-US, V33, P14825, DOI 10.1021/bi00253a022; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	46	107	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15690	15699		10.1074/jbc.M608045200	http://dx.doi.org/10.1074/jbc.M608045200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17389600	hybrid			2022-12-27	WOS:000246589600045
J	Banchio, C; Lingrell, S; Vance, DE				Banchio, Claudia; Lingrell, Susanne; Vance, Dennis E.			Sp-1 binds promoter elements that are regulated by retinoblastoma and regulate CTP: Phosphocholine cytidylyltransferase-alpha transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE SYNTHESIS; GENE-PRODUCT; S-PHASE; CTPPHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN-KINASE; FATTY-ACIDS; RB PROTEIN; CELL-CYCLE; RAT-LIVER; EXPRESSION	The retinoblastoma (Rb) protein is implicated in transcriptional regulation of at least five cellular genes. Co-transfection of Rb and truncated promoter constructs has defined a discrete element (retinoblastoma control element (RCE)) within the promoters of each of these genes as being necessary for Rb-mediated transcriptional control. In the present report we demonstrate that two RCEs identified within the CTP: phosphocholine cytidylyltransferase-alpha (CT alpha) proximal promoter are essential to promote transcription. Mutations that abolished each RCE markedly decreased CT alpha transcription. Co-transfection of Rb and truncated promoter constructs demonstrated that Rb regulates CT alpha expression by different mechanisms depending on the phase of the cell cycle. The regulation of CT alpha expression by Rb required both the Sp1 and the RCEs. Maximal expression occurred when both Rb and Sp1 were overexpressed. Moreover, RCEs were required for Rb association with the DNA. This regulatory mechanism alters CT alpha activity and thereafter changes PC availability and cell physiology. This is the first report demonstrating not only that surrounding Sp1 binding sites alter regulation mediated by Rb, but also that the expression of a gene involved in PC biosynthesis shares a common regulatory pathway with genes responsible for cell growth and differentiation.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Ciencias Biol,Biol Div, Area Biol,Consejo Nacl Invest Cient & Tecn,Inst M, RA-2002 Rosario, Argentina	University of Alberta; University of Alberta; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario	Banchio, C (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada.	banchio@ibr.gov.ar; dennis.vance@ualberta.ca						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Bakovic M, 2000, J LIPID RES, V41, P583; Banchio C, 2004, J BIOL CHEM, V279, P40220, DOI 10.1074/jbc.M406468200; Banchio C, 2006, J BIOL CHEM, V281, P10010, DOI 10.1074/jbc.M513503200; Banchio C, 2003, J BIOL CHEM, V278, P32457, DOI 10.1074/jbc.M304810200; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CREAGH SC, 1990, PHYS REV A, V42, P1907, DOI 10.1103/PhysRevA.42.1907; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Hellwinkel OJC, 2005, J GENE MED, V7, P407, DOI 10.1002/jgm.684; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V795, P433, DOI 10.1016/0005-2760(84)90169-3; PELECH SL, 1983, J BIOL CHEM, V258, P6782; PELECH SL, 1981, J BIOL CHEM, V256, P8283; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Sabah M, 2006, APPL IMMUNOHISTO M M, V14, P397, DOI 10.1097/01.pai.0000190176.06200.68; Safinya CR, 2001, CURR OPIN STRUC BIOL, V11, P440, DOI 10.1016/S0959-440X(00)00230-X; Sesca E, 1996, BIOCHEM BIOPH RES CO, V229, P158, DOI 10.1006/bbrc.1996.1773; Simpson D, 2000, MOL VIS, V6, P178; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WEINBERG RA, 1992, CANCER SURV, V12, P43	45	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14827	14835		10.1074/jbc.M700527200	http://dx.doi.org/10.1074/jbc.M700527200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17384411	hybrid			2022-12-27	WOS:000246589000018
J	Ellyard, JI; Simson, L; Bezos, A; Johnston, K; Freeman, C; Parish, CR				Ellyard, Julia I.; Simson, Ljubov; Bezos, Anna; Johnston, Kellie; Freeman, Craig; Parish, Christopher R.			Eotaxin selectively binds heparin - An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED EOSINOPHIL INFILTRATION; PLASMINOGEN-PLASMIN SYSTEM; MOLECULAR-WEIGHT HEPARIN; MAST-CELL TRYPTASE; ALLERGIC INFLAMMATION; GLYCOSAMINOGLYCAN BINDING; SULFATE PROTEOGLYCANS; RECEPTOR-BINDING; GUINEA-PIGS; CHEMOKINES	An important feature of chemokines is their ability to bind to the glycosaminoglycan (GAG) side chains of proteoglycans, predominately heparin and heparan sulfate. To date, all chemokines tested bind to immobilized heparin in vitro, as well as cell surface heparan sulfate in vitro and in vivo. These interactions play an important role in modulating the action of chemokines by facilitating the formation of stable chemokine gradients within the vascular endothelium and directing leukocyte migration, by protecting chemokines from proteolysis, by inducing chemokine oligomerization, and by facilitating transcytosis. Despite the importance of eotaxin in eosinophil differentiation and recruitment being well established, little is known about the interaction between eotaxin and GAGs and the functional consequences of such an interaction. Here we report that eotaxin binds selectively to immobilized heparin with high affinity ( Kd = 1.23 x 10(-8) M), but not to heparan sulfate or a range of other GAGs. The interaction of eotaxin with heparin does not promote eotaxin oligomerization but protects eotaxin from proteolysis directly by plasmin and indirectly by cathepsin G and elastase. In vivo, co-administration of eotaxin and heparin is able to significantly enhance eotaxin-mediated eosinophil recruitment in a mouse air-pouch model. Furthermore, when heparin is coadministered with eotaxin at a concentration that does not normally result in eosinophil infiltration, eosinophil recruitment occurs. In contrast, heparin does not enhance eotaxin-mediated eosinophil chemotaxis in vitro, suggesting protease protection or haptotactic gradient formation as the mechanism by which heparin enhances eotaxin action in vivo. These results suggest a role for mast cell-derived heparin in the recruitment of eosinophils, reinforcing Th2 polarization of inflammatory responses.	Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Acton, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research	Parish, CR (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canc & Vasc Biol Grp, Bldg 54,Garran Rd, Acton, ACT 0200, Australia.	christopher.parish@anu.edu.au	Simson, Ljubov/C-2954-2009	Parish, Christopher/0000-0001-7740-0430				Abraham WM, 2002, AM J PHYSIOL-LUNG C, V282, pL193, DOI 10.1152/ajplung.00429.2001; Ahmed T, 1997, AM J RESP CRIT CARE, V155, P1848, DOI 10.1164/ajrccm.155.6.9196085; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Buckland KF, 2003, BRIT J PHARMACOL, V140, P1117, DOI 10.1038/sj.bjp.0705530; Conroy DM, 2001, RESP RES, V2, P150, DOI 10.1186/rr52; Cook EB, 2004, ANN ALLERG ASTHMA IM, V92, P65, DOI 10.1016/S1081-1206(10)61712-7; Crown SE, 2006, J BIOL CHEM, V281, P25438, DOI 10.1074/jbc.M601518200; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Culley FJ, 2003, EUR J IMMUNOL, V33, P1302, DOI 10.1002/eji.200323509; Das AM, 1998, J LEUKOCYTE BIOL, V64, P156, DOI 10.1002/jlb.64.2.156; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Ferland C, 2004, J IMMUNOL, V173, P4417, DOI 10.4049/jimmunol.173.7.4417; Ferland C, 2001, J LEUKOCYTE BIOL, V69, P772; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Freeman C, 2005, J BIOL CHEM, V280, P8842, DOI 10.1074/jbc.M410769200; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; He SH, 1997, J IMMUNOL, V159, P6216; He SH, 1998, BRIT J PHARMACOL, V125, P1491, DOI 10.1038/sj.bjp.0702223; He SH, 2004, ACTA PHARMACOL SIN, V25, P1677; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Johnson Z, 2005, CYTOKINE GROWTH F R, V16, P625, DOI 10.1016/j.cytogfr.2005.04.006; Johnson Z, 2004, J IMMUNOL, V173, P5776, DOI 10.4049/jimmunol.173.9.5776; Jones AL, 2004, J BIOL CHEM, V279, P38267, DOI 10.1074/jbc.M406027200; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kita H, 1996, J EXP MED, V183, P2421, DOI 10.1084/jem.183.6.2421; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LAWMAN MJP, 1984, J IMMUNOL METHODS, V69, P197, DOI 10.1016/0022-1759(84)90318-1; Ley K, 2003, MICROCIRCULATION, V10, P289, DOI 10.1038/sj.mn.7800194; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; Mattes J, 2003, J EXP MED, V197, P387, DOI 10.1084/jem.20021683; Middleton J, 2002, BLOOD, V100, P3853, DOI 10.1182/blood.V100.12.3853; Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Oliveira SHP, 2002, BLOOD, V100, P4291, DOI 10.1182/blood.V100.13.4291; Pang LH, 2006, J IMMUNOL, V176, P3788, DOI 10.4049/jimmunol.176.6.3788; Parish CR, 2006, NAT REV IMMUNOL, V6, P633, DOI 10.1038/nri1918; PARISH CR, 1991, BIOCHIM BIOPHYS ACTA, V1073, P56, DOI 10.1016/0304-4165(91)90182-G; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Piliponsky AM, 2002, MOL IMMUNOL, V38, P1369, DOI 10.1016/S0161-5890(02)00090-1; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Sadir R, 2004, J BIOL CHEM, V279, P43854, DOI 10.1074/jbc.M405392200; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; Seeds EAM, 1995, PULM PHARMACOL, V8, P97, DOI 10.1006/pulp.1995.1012; Seeds EAM, 2001, PULM PHARMACOL THER, V14, P111, DOI 10.1006/pupt.2000.0277; Shakoory B, 2004, J INTERF CYTOK RES, V24, P271, DOI 10.1089/107999004323065057; Simson L, 2007, J IMMUNOL, V178, P4222, DOI 10.4049/jimmunol.178.7.4222; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; Temkin V, 2002, J IMMUNOL, V169, P2662, DOI 10.4049/jimmunol.169.5.2662; Teran LM, 2000, IMMUNOL TODAY, V21, P235, DOI 10.1016/S0167-5699(00)01634-0; Tomimori Y, 2002, LAB INVEST, V82, P789, DOI 10.1097/01.LAB.0000018827.78602.F4; Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i; Wang LC, 2005, NAT IMMUNOL, V6, P902, DOI 10.1038/ni1233; Wang QL, 2000, JPN J PHARMACOL, V82, P326; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WIEDERMANN CJ, 1993, CURR BIOL, V3, P735, DOI 10.1016/0960-9822(93)90020-O; Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9; Yu YH, 2005, J BIOL CHEM, V280, P32200, DOI 10.1074/jbc.M505738200	66	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15238	15247		10.1074/jbc.M608046200	http://dx.doi.org/10.1074/jbc.M608046200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17384413	hybrid			2022-12-27	WOS:000246589000063
J	Johannessen, M; Delghandi, MP; Rykx, A; Dragset, M; Vandenheede, JR; Van Lint, J; Moens, U				Johannessen, Mona; Delghandi, Marit Pedersen; Rykx, An; Dragset, Marte; Vandenheede, Jackie R.; Van Lint, Johan; Moens, Ugo			Protein kinase D induces transcription through direct phosphorylation of the cAMP-response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ACTIVATION LOOP PHOSPHORYLATION; SOMATOSTATIN GENE-TRANSCRIPTION; SIGNAL-TRANSDUCTION PATHWAY; C-MU; PROTEOLYTIC CLEAVAGE; CARDIAC-HYPERTROPHY; NUCLEAR EXPORT; NIH 3T3-CELLS; PHORBOL ESTER	Protein kinase D (PKD), a family of serine/threonine kinases, can be activated by a multitude of stimuli in a protein kinase C-dependent or -independent manner. PKD is involved in signal transduction pathways controlling cell proliferation, apoptosis, motility, and protein trafficking. Despite its versatile functions, few genuine in vivo substrates for PKD have been identified. In this study we demonstrate that the transcription factor cAMP-response element-binding protein (CREB) is a direct substrate for PKD. PKD1 and CREB interact in cells, and activated PKD1 provokes CREB phosphorylation at Ser-133 both in vitro and in vivo. A constitutive active mutant of PKD1 stimulates GAL4-CREB- mediated transcription in a Ser-133-dependent manner, activates CRE-responsive promoters, and increases the expression of CREB target genes. PKD1 also enhances transcription mediated by two other members of the CREB family, ATF-1 and CREM. Our results describe a novel mechanism for PKD-induced signaling through activation of the transcription factor CREB and suggest that stimulus-induced phosphorylation of CREB, reported to be mediated by protein kinase C, may involve downstream activated PKD.	Univ Tromso, Inst Med Biol, Dept Microbiol & Virol, N-9037 Tromso, Norway; Katholieke Univ Leuven, Fac Med, Dept Mol Cell Biol, B-3000 Louvain, Belgium	UiT The Arctic University of Tromso; KU Leuven	Moens, U (corresponding author), Univ Tromso, Inst Med Biol, Dept Microbiol & Virol, N-9037 Tromso, Norway.	ugom@fagmed.uit.no	Van Lint, Johan/P-9073-2019	Van Lint, Johan/0000-0002-0275-571X				Anel AMD, 2005, J CELL BIOL, V169, P83, DOI 10.1083/jcb.200412089; Arnold R, 2005, MOL CELL BIOL, V25, P2364, DOI 10.1128/MCB.25.6.2364-2383.2005; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; Darragh J, 2005, BIOCHEM J, V390, P749, DOI 10.1042/BJ20050196; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Elliott MR, 2003, J IMMUNOL, V171, P3636, DOI 10.4049/jimmunol.171.7.3636; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Fass DM, 2003, J BIOL CHEM, V278, P43014, DOI 10.1074/jbc.M305905200; FOSS KB, 1994, EUR J BIOCHEM, V220, P217, DOI 10.1111/j.1432-1033.1994.tb18617.x; Ghanekar Y, 2005, TRENDS CELL BIOL, V15, P511, DOI 10.1016/j.tcb.2005.08.001; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; Guha S, 2002, CANCER RES, V62, P1632; Hanks SK, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-5-111; Harrison BC, 2006, MOL CELL BIOL, V26, P3875, DOI 10.1128/MCB.26.10.3875-3888.2006; Hausser A, 2005, NAT CELL BIOL, V7, P880, DOI 10.1038/ncb1289; Haworth RS, 2004, CIRC RES, V95, P1091, DOI 10.1161/01.RES.0000149299.34793.3c; Hurd C, 2003, BIOCHEM BIOPH RES CO, V302, P800, DOI 10.1016/S0006-291X(03)00268-7; Hurd C, 2002, ONCOGENE, V21, P2154, DOI 10.1038/sj.onc.1205290; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Jaggi M, 2005, CANCER RES, V65, P483; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Johannessen M, 2004, CELL SIGNAL, V16, P1187, DOI 10.1016/j.cellsig.2004.03.009; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Matthews SA, 2006, MOL CELL BIOL, V26, P1569, DOI 10.1128/MCB.26.4.1569-1577.2006; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Moens MJU, 2007, FRONT BIOSCI-LANDMRK, V12, P1814; Montminy M, 1996, METABOLISM, V45, P4, DOI 10.1016/S0026-0495(96)90068-2; Morel E, 2005, CIRC RES, V97, P1296, DOI 10.1161/01.RES.0000194325.31359.86; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Nelson TJ, 2005, J MOL CELL CARDIOL, V39, P479, DOI 10.1016/j.yjmcc.2005.05.004; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PAGANO JS, 1969, PROG IMMUNOBIOL STAN, V3, P152; Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Romero DG, 2006, ENDOCRINOLOGY, V147, P6046, DOI 10.1210/en.2006-0794; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Saeki K, 1999, BIOCHEM J, V338, P49, DOI 10.1042/0264-6021:3380049; Seternes OM, 2002, MOL CELL BIOL, V22, P6931, DOI 10.1128/MCB.22.20.6931-6945.2002; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shiga H, 2005, J NEUROSCI RES, V80, P767, DOI 10.1002/jnr.20513; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, J BIOL CHEM, V278, P17969, DOI 10.1074/jbc.M213224200; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vantus T, 2004, CELL SIGNAL, V16, P703, DOI 10.1016/j.cellsig.2003.11.009; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 2004, J BIOL CHEM, V279, P27482, DOI 10.1074/jbc.M402875200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wang QMJ, 2006, TRENDS PHARMACOL SCI, V27, P317, DOI 10.1016/j.tips.2006.04.003; Wang Y, 2004, J BIOL CHEM, V279, P53674, DOI 10.1074/jbc.M410331200; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Webb BLJ, 2000, BRIT J PHARMACOL, V130, P1433, DOI 10.1038/sj.bjp.0703452; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	79	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14777	14787		10.1074/jbc.M610669200	http://dx.doi.org/10.1074/jbc.M610669200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389598	hybrid			2022-12-27	WOS:000246589000013
J	Saether, T; Berge, T; Ledsaak, M; Matre, V; Alm-Kristiansen, AH; Dahle, O; Aubry, F; Gabrielsen, OS				Saether, Thomas; Berge, Tone; Ledsaak, Marit; Matre, Vilborg; Alm-Kristiansen, Anne Hege; Dahle, Oyvind; Aubry, Florence; Gabrielsen, Odd Stokke			The chromatin remodeling factor Mi-2 alpha acts as a novel co-activator for human c-Myb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; RET FINGER PROTEIN; T-CELL DEVELOPMENT; V-MYB; TRANSCRIPTION FACTORS; HEMATOPOIETIC-CELLS; MI-2 AUTOANTIGEN; GENE-EXPRESSION; HISTONE H3; COMPLEX	The c-Myb protein belongs to a group of early hematopoietic transcription factors that are important for progenitor generation and proliferation. These factors have been hypothesized to participate in establishing chromatin patterns specific for hematopoietic genes. In a two-hybrid screening we identified the chromatin remodeling factor Mi-2 alpha as an interaction partner for human c-Myb. The main interacting domains were mapped to the N-terminal region of Mi-2 alpha and the DNA-binding domain of c-Myb. Surprisingly, functional analysis revealed that Mi-2 alpha, previously studied as a subunit in the NuRD corepressor complex, enhanced c-Myb-dependent reporter activation. Consistently, knock-down of endogenous Mi-2 alpha in c-Myb-expressing K562 cells, led to down-regulation of the c-Myb target genes NMU and ADA. When wild-type and helicase-dead Mi-2 alpha were compared, the Myb-Mi-2 alpha co-activation appeared to be independent of the ATPase/DNA helicase activity of Mi-2 alpha. The rationale for the unexpected co-activator function seems to lie in a dual function of Mi-2 alpha, by which this factor is able to repress transcription in a helicase-dependent and activate in a helicase-independent fashion, as revealed by Gal4-tethering experiments. Interestingly, desumoylation of c-Myb potentiated the Myb-Mi-2 alpha transactivational co-operation, as did co-transfection with p300.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; Univ Rennes 1, INSERM, U625, GERHM, F-35042 Rennes, France	University of Oslo; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Gabrielsen, OS (corresponding author), Univ Oslo, Dept Mol Biosci, POB 1041, N-0316 Oslo, Norway.	o.s.gabrielsen@imbv.uio.no	Aubry, Florence/I-2746-2015					Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Andersson KB, 2003, J BIOL CHEM, V278, P3816, DOI 10.1074/jbc.M209404200; Aubry F, 1998, EUR J BIOCHEM, V254, P558, DOI 10.1046/j.1432-1327.1998.2540558.x; Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BONNER JJ, 1991, GENE, V104, P113, DOI 10.1016/0378-1119(91)90475-Q; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Brackertz M, 2006, NUCLEIC ACIDS RES, V34, P397, DOI 10.1093/nar/gkj437; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Carpinelli MR, 2004, P NATL ACAD SCI USA, V101, P6553, DOI 10.1073/pnas.0401496101; Dahle O, 2004, EXP CELL RES, V297, P118, DOI 10.1016/j.yexcr.2004.03.014; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Eberharter A, 2004, J CELL SCI, V117, P3707, DOI 10.1242/jcs.01175; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; ESS KC, 1995, MOL CELL BIOL, V15, P5707; Feng Q, 2003, CURR TOP MICROBIOL, V274, P269; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Georgopoulos K, 2002, NAT REV IMMUNOL, V2, P162, DOI 10.1038/nri747; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hong W, 2005, EMBO J, V24, P2367, DOI 10.1038/sj.emboj.7600703; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Le Guezennec X, 2006, MOL CELL BIOL, V26, P843, DOI 10.1128/MCB.26.3.843-851.2006; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Matre V, 2003, BIOCHEM J, V372, P851, DOI 10.1042/BJ20030057; Miranda GA, 2002, MOL IMMUNOL, V38, P1151, DOI 10.1016/S0161-5890(02)00007-X; Mo XM, 2005, GENE DEV, V19, P2447, DOI 10.1101/gad.355405; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Navarro P, 1997, BBA-PROTEIN STRUCT M, V1343, P187, DOI 10.1016/S0167-4838(97)00108-8; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; Sandberg ML, 2005, DEV CELL, V8, P153, DOI 10.1016/j.devcel.2004.12.015; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Shetzline SE, 2004, BLOOD, V104, P1833, DOI 10.1182/blood-2003-10-3577; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Shimono K, 2005, J BIOL CHEM, V280, P39436, DOI 10.1074/jbc.M507356200; Shimono Y, 2003, J BIOL CHEM, V278, P51638, DOI 10.1074/jbc.M309198200; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Thomas MD, 2005, IMMUNITY, V23, P275, DOI 10.1016/j.immuni.2005.08.005; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Williams CJ, 2004, IMMUNITY, V20, P719, DOI 10.1016/j.immuni.2004.05.005; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3	60	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13994	14005		10.1074/jbc.M700755200	http://dx.doi.org/10.1074/jbc.M700755200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17344210	hybrid			2022-12-27	WOS:000246245800009
J	Jeong, CH; Lee, HJ; Cha, JH; Kim, JH; Kim, KR; Kim, JH; Yoon, DK; Kim, KW				Jeong, Chul-Ho; Lee, Hyo-Jong; Cha, Jong-Ho; Kim, Jeong Hun; Kim, Kwang Rok; Kim, Ji-Hye; Yoon, Dae-Kwan; Kim, Kyu-Won			Hypoxia-inducible factor-1 alpha inhibits self-renewal of mouse embryonic stem cells in vitro via negative regulation of the leukemia inhibitory factor-STAT3 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; O-2 HOMEOSTASIS; FACTOR 1-ALPHA; EXPRESSION; DIFFERENTIATION; HIF-1-ALPHA; PLURIPOTENCY; ACTIVATION; APOPTOSIS; NANOG	During mammalian embryogenesis, the early embryo grows in a relatively hypoxic environment due to a restricted supply of oxygen. The molecular mechanisms underlying modulation of self-renewal and differentiation of mouse embryonic stem cells (mESCs) under such hypoxic conditions remain to be established. Here, we show that hypoxia inhibits mESC self-renewal and induces early differentiation in vitro, even in the presence of leukemia inhibitory factor (LIF). These effects are mediated by down-regulation of the LIF-STAT3 signaling pathway. Under conditions of hypoxia, hypoxia-inducible factor-1 alpha (HIF-1 alpha) suppresses transcription of LIF-specific receptor (LIFR) by directly binding to the reverse hypoxia-responsive element located in the LIFR promoter. Ectopic expression and small interference RNA knockdown of HIF-1 alpha verified the inhibitory effect on LIFR transcription. Our findings collectively suggest that hypoxia-induced in vitro differentiation of mESCs is triggered, at least in part, by the HIF-1 alpha-mediated suppression of LIF-STAT3 signaling.	Seoul Natl Univ, Coll Pharm, ResInst Pharmaceut Sci, Neurovasc Coordinat Res Ctr, Seoul 151742, South Korea; Seoul Natl Univ Hosp, Dept Ophthalmol & Visual Sci, Coll Med, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Seoul Artificial eye Ctr, Clin Res Inst, Seoul 110744, South Korea; Korea Res Inst Chem Technol, Div Med Sci, Taejon 305600, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Korea Research Institute of Chemical Technology (KRICT)	Kim, KW (corresponding author), Seoul Natl Univ, Coll Pharm, ResInst Pharmaceut Sci, Neurovasc Coordinat Res Ctr, Seoul 151742, South Korea.	qwonkim@plaza.snu.ac.kr	Kim, Jeong Hun/J-2748-2012; Kim, Kyu Won/AAJ-7213-2020	Lee, Hyo-Jong/0000-0003-4826-7954				Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 1997, BIOCHEM J, V328, P879, DOI 10.1042/bj3280879; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; D'Ippolito G, 2006, BONE, V39, P513, DOI 10.1016/j.bone.2006.02.061; Duval D, 2004, CELL DEATH DIFFER, V11, P331, DOI 10.1038/sj.cdd.4401337; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102; FICHER P, 1993, J REPROD FERTIL, V99, P673; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lee YM, 2001, DEV DYNAM, V220, P175, DOI 10.1002/1097-0177(20010201)220:2<175::AID-DVDY1101>3.0.CO;2-F; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Nichols J, 1996, MECH DEVELOP, V57, P123, DOI 10.1016/0925-4773(96)00531-X; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Pampfer S, 1999, CELL DEATH DIFFER, V6, P533, DOI 10.1038/sj.cdd.4400516; Ramirez-Bergeron DL, 2004, DEVELOPMENT, V131, P4623, DOI 10.1242/dev.01310; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Smith A G, 1992, Semin Cell Biol, V3, P385, DOI 10.1016/1043-4682(92)90010-S; Suzuki A, 2006, P NATL ACAD SCI USA, V103, P10294, DOI 10.1073/pnas.0506945103; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tighe AP, 2004, J CELL PHYSIOL, V198, P223, DOI 10.1002/jcp.10424; Viswanathan S, 2003, BIOTECHNOL BIOENG, V84, P505, DOI 10.1002/bit.10799; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje	34	75	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13672	13679		10.1074/jbc.M700534200	http://dx.doi.org/10.1074/jbc.M700534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360716	hybrid			2022-12-27	WOS:000246060300057
J	Spiller, S; Dreher, S; Meng, GX; Grabiec, A; Thomas, W; Hartung, T; Pfeffer, K; Hochrein, H; Brade, H; Bessler, W; Wagner, H; Kirschning, CJ				Spiller, Stephan; Dreher, Stefan; Meng, Guangxun; Grabiec, Alina; Thomas, Winston; Hartung, Thomas; Pfeffer, Klaus; Hochrein, Hubertus; Brade, Helmut; Bessler, Wolfgang; Wagner, Hermann; Kirschning, Carsten J.			Cellular recognition of trimyristoylated peptide or enterobacterial lipopolysaccharide via both TLR2 and TLR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; PORPHYROMONAS-GINGIVALIS LIPOPOLYSACCHARIDE; NECROSIS-FACTOR RECEPTOR; NF-KAPPA-B; ESCHERICHIA-COLI; STAPHYLOCOCCUS-AUREUS; MURINE MACROPHAGES; INDUCED ACTIVATION; LIPOTEICHOIC ACID; WALL COMPONENTS	Evidence for specific and direct bacterial product recognition through toll-like receptors (TLRs) has been emphasized recently. We analyzed lipopeptide analogues and enterobacterial lipopolysaccharide (eLPS) for their potential to activate cells through TLR2 and TLR4. Whereas bacterial protein palmitoylated at its N-terminal cysteine and N-terminal peptides derived thereof are known to induce TLR2-mediated cell activation, a synthetic acyl-hexapeptide mimicking a bacterial lipoprotein subpopulation for which N-terminal trimyristoylation is characteristic (Myr(3)CSK(4)) activated cells not only through TLR2 but also through TLR4. Conversely, highly purified eLPS triggered cell activation through over-expressed TLR2 in the absence of TLR4 expression if CD14 was coexpressed. Accordingly, TLR2(-/-) macrophages prepared upon gene targeting responded to Myr3CSK4 challenge, whereas TLR2(-/-)/TLR4(d/d) cells were unresponsive. Through interferon-gamma (IFN gamma) priming, macrophages lacking expression of functional TLR4 and/or MD-2 acquired sensitivity to eLPS, whereas TLR2/TLR4 double deficient cells did not. Not only TLR2(-/-) mice but also TLR4(-/-) mice were resistant to Myr(3)CSK(4) challenge-induced fatal shock. D-galactosamine- sensitized mice expressing defective TLR4 or lacking TLR4 expression acquired susceptibility to eLPS-driven toxemia upon IFN gamma priming, whereas double deficient mice did not. Immunization toward ovalbumin using Myr(3)CSK(4) asadjuvant was ineffective in TLR2(-/-)/TLR4(-/-) mice yet effective in wild-type, TLR2(-/-), or TLR4(-/-) mice as shown by analysis of ovalbumin- specific serum Ig concentration. A compound such as Myr(3)CSK(4) whose stimulatory activity is mediated by both TLR2 and TLR4 might constitute a preferable adjuvant. On the other hand, simultaneous blockage of both of the two TLRs might effectively inhibit infection- induced pathology.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; Deltagen Inc, San Carlos, CA 94025 USA; Commiss European, Joint Res Ctr, Inst Hlth & Consumer Protect, I-21020 Ispra, Italy; Univ Dusseldorf, Inst Med Microbiol, D-40225 Dusseldorf, Germany; Bavarian Nord GmbH, D-82152 Munich, Germany; Res Ctr Borstel, Dept Immune Chem & Biochem Microbiol, D-23845 Borstel, Germany; Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany	Technical University of Munich; European Commission Joint Research Centre; EC JRC ISPRA Site; Heinrich Heine University Dusseldorf; Bavarian Nordic; Forschungszentrum Borstel; University of Freiburg	Kirschning, CJ (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Trogerstr 30, D-81675 Munich, Germany.	carsten.kirschning@lrz.tum.de	Hochrein, Hubertus/L-3697-2013	Hochrein, Hubertus/0000-0001-9904-1934; Pfeffer, Klaus/0000-0002-5652-6330; 孟, 广勋/0000-0002-4253-9675				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Bessler W G, 1997, Behring Inst Mitt, P390; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791; Buwitt-Beckmann U, 2006, J BIOL CHEM, V281, P9049, DOI 10.1074/jbc.M512525200; COLIGAN JE, 1990, CURRENT PROTOCOLS IM; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Darveau RP, 2004, INFECT IMMUN, V72, P5041, DOI 10.1128/IAI.72.9.5041-5051.2004; DING AH, 1995, J LEUKOCYTE BIOL, V57, P174, DOI 10.1002/jlb.57.1.174; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; ENGLEMAN EG, 2004, SCI STKE, pPE28; Fan XL, 1999, INFECT IMMUN, V67, P2964, DOI 10.1128/IAI.67.6.2964-2968.1999; GALANOS C, 1979, ZBL BAKT-INT J MED M, V243, P226; Golenbock DT, 2001, NAT IMMUNOL, V2, P286, DOI 10.1038/86289; Grabiec A, 2004, J BIOL CHEM, V279, P48004, DOI 10.1074/jbc.M405311200; HANTKE K, 1973, EUR J BIOCHEM, V34, P284, DOI 10.1111/j.1432-1033.1973.tb02757.x; Heit A, 2003, J IMMUNOL, V170, P2802, DOI 10.4049/jimmunol.170.6.2802; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hochrein H, 2002, HUM IMMUNOL, V63, P1103, DOI 10.1016/S0198-8859(02)00748-6; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hu XY, 2006, IMMUNITY, V24, P563, DOI 10.1016/j.immuni.2006.02.014; KASAI N, 1986, INFECT IMMUN, V51, P43, DOI 10.1128/IAI.51.1.43-48.1986; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kirschning CJ, 2001, INT J MED MICROBIOL, V291, P251, DOI 10.1078/1438-4221-00128; Lee HK, 2002, J IMMUNOL, V168, P4012, DOI 10.4049/jimmunol.168.8.4012; MANTHEY CL, 1994, J IMMUNOL, V153, P2653; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Meier A, 2003, CELL MICROBIOL, V5, P561, DOI 10.1046/j.1462-5822.2003.00301.x; MELCHERS F, 1975, J EXP MED, V142, P473, DOI 10.1084/jem.142.2.473; Meng GX, 2004, J CLIN INVEST, V113, P1473, DOI 10.1172/JCI200420762; Meng GX, 2003, J BIOL CHEM, V278, P39822, DOI 10.1074/jbc.M304766200; Mokuno Y, 2000, J IMMUNOL, V165, P931, DOI 10.4049/jimmunol.165.2.931; Morath S, 2002, J EXP MED, V195, P1635, DOI 10.1084/jem.20020322; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Muroi M, 2003, INFECT IMMUN, V71, P3221, DOI 10.1128/IAI.71.6.3221-3226.2003; Muroi M, 2002, INFECT IMMUN, V70, P6043, DOI 10.1128/IAI.70.11.6043-6047.2002; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nahori MA, 2005, J IMMUNOL, V175, P6022, DOI 10.4049/jimmunol.175.9.6022; Ogura Y, 2006, CELL, V126, P659, DOI 10.1016/j.cell.2006.08.002; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Poltorak A, 2001, J IMMUNOL, V167, P2106, DOI 10.4049/jimmunol.167.4.2106; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Suda Y, 1999, BIOCHEM BIOPH RES CO, V257, P327, DOI 10.1006/bbrc.1999.0464; Sun DX, 2006, NAT IMMUNOL, V7, P375, DOI 10.1038/ni1308; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tanamoto K, 1999, INFECT IMMUN, V67, P3399, DOI 10.1128/IAI.67.7.3399-3402.1999; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VOGEL SN, 1982, IMMUNOBIOLOGY, V160, P479, DOI 10.1016/S0171-2985(82)80010-7; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; WIESMULLER KH, 1983, H-S Z PHYSIOL CHEM, V364, P593, DOI 10.1515/bchm2.1983.364.1.593; Wolfs TGAM, 2002, J IMMUNOL, V168, P1286, DOI 10.4049/jimmunol.168.3.1286	60	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13190	13198		10.1074/jbc.M610340200	http://dx.doi.org/10.1074/jbc.M610340200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353199	hybrid			2022-12-27	WOS:000246060300007
J	Llarrull, LI; Fabiane, SM; Kowalski, JM; Bennett, B; Sutton, BJ; Vila, AJ				Llarrull, Leticia I.; Fabiane, Stella M.; Kowalski, Jason M.; Bennett, Brian; Sutton, Brian J.; Vila, Alejandro J.			Asp-120 locates Zn2 for optimal metallo-ss-lactamase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC BETA-LACTAMASE; BACILLUS-CEREUS; CRYSTAL-STRUCTURE; STENOTROPHOMONAS-MALTOPHILIA; SPECTROSCOPIC CHARACTERIZATION; STRUCTURAL DETERMINANTS; ANTIBIOTIC-RESISTANCE; CATALYTIC MECHANISM; SUBSTRATE-BINDING; SITE	Metallo-beta-lactamases are zinc-dependent hydrolases that inactivate beta-lactam antibiotics, rendering bacteria resistant to them. Asp-120 is fully conserved in all metallo-beta-lactamases and is central to catalysis. Several roles have been proposed for Asp-120, but so far there is no agreed consensus. We generated four site-specifically substituted variants of the enzyme BcII from Bacillus cereus as follows: D120N, D120E, D120Q, and D120S. Replacement of Asp-120 by other residues with very different metal ligating capabilities severely impairs the lactamase activity without abolishing metal binding to the mutated site. A kinetic study of these mutants indicates that Asp-120 is not the proton donor, nor does it play an essential role in nucleophilic activation. Spectroscopic and crystallographic analysis of D120S BcII, the least active mutant bearing the weakest metal ligand in the series, reveals that this enzyme is able to accommodate a dinuclear center and that perturbations in the active site are limited to the Zn2 site. It is proposed that the role of Asp-120 is to act as a strong Zn2 ligand, locating this ion optimally for substrate binding, stabilization of the development of a partial negative charge in the beta-lactam nitrogen, and protonation of this atom by a zinc-bound water molecule.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Celular, Dept Quim Biol Area Biofis, RA-2000 Rosario, Argentina; Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England; Med Coll Wisconsin, Nat Biomed EPR Ctr, Dept Biophys, Milwaukee, WI 53226 USA	National University of Rosario; University of London; King's College London; Medical College of Wisconsin	Vila, AJ (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Inst Biol Celular, Dept Quim Biol Area Biofis, Suipacha 531,S2002LRK, RA-2000 Rosario, Argentina.	vila@ibr.gov.ar		Vila, Alejandro/0000-0002-7978-3233	NCRR NIH HHS [RR001980] Funding Source: Medline; NIAID NIH HHS [AI056231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056231] Funding Source: NIH RePORTER; Medical Research Council [G0400503B] Funding Source: researchfish	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARIK S, 1996, SITE DIRECTED MUTAGE, P203; BENNETT B, 1994, EUR J BIOCHEM, V225, P321, DOI 10.1111/j.1432-1033.1994.00321.x; Bienvenue DL, 2003, BIOCHEMISTRY-US, V42, P10756, DOI 10.1021/bi034845+; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; Breece RM, 2005, J BIOL CHEM, V280, P11074, DOI 10.1074/jbc.M412582200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Crawford PA, 2005, BIOCHEMISTRY-US, V44, P5168, DOI 10.1021/bi047463s; CRICCO JA, 2002, THESIS U ROSARIO ROS; Crowder MW, 2006, ACCOUNTS CHEM RES, V39, P721, DOI 10.1021/ar0400241; Dal Peraro M, 2004, J AM CHEM SOC, V126, P12661, DOI 10.1021/ja048071b; Dal Peraro M, 2003, INORG CHEM, V42, P4245, DOI 10.1021/ic026059j; Dal Peraro M, 2002, J BIOL INORG CHEM, V7, P704, DOI 10.1007/s00775-002-0346-2; Dal Peraro M, 2007, J AM CHEM SOC, V129, P2808, DOI 10.1021/ja0657556; Davies AM, 2005, BIOCHEMISTRY-US, V44, P4841, DOI 10.1021/bi047709t; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; Fast W, 2001, BIOCHEMISTRY-US, V40, P1640, DOI 10.1021/bi001860v; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; Garau G, 2005, ANTIMICROB AGENTS CH, V49, P2778, DOI 10.1128/AAC.49.7.2778-2784.2005; Garau G, 2005, J MOL BIOL, V345, P785, DOI 10.1016/j.jmb.2004.10.070; Garcia-Saez I, 2003, J BIOL CHEM, V278, P23868, DOI 10.1074/jbc.M301062200; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; Garrity JD, 2004, J BIOL CHEM, V279, P920, DOI 10.1074/jbc.M309852200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JNT CCP4 ESF EAMCB N, V26, P27; LLARRULL LI, 2001, BIOCELL, V25, P62; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; Murphy TA, 2006, J MOL BIOL, V357, P890, DOI 10.1016/j.jmb.2006.01.003; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; Page MI, 1998, CHEM COMMUN, P1609, DOI 10.1039/a803578d; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Park H, 2005, J AM CHEM SOC, V127, P4232, DOI 10.1021/ja042607b; Paul-Soto R, 1998, FEBS LETT, V438, P137, DOI 10.1016/S0014-5793(98)01289-7; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Prosperi-Meys C, 2002, CELL MOL LIFE SCI, V59, P2136, DOI 10.1007/s000180200013; Rasia RM, 2004, J BIOL CHEM, V279, P26046, DOI 10.1074/jbc.M311373200; Rasia RM, 2002, BIOCHEMISTRY-US, V41, P1853, DOI 10.1021/bi010933n; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SENY D, 2002, BIOCHEM J, V363, P687; Spencer J, 2005, J AM CHEM SOC, V127, P14439, DOI 10.1021/ja0536062; Spencer J, 2001, J BIOL CHEM, V276, P33638, DOI 10.1074/jbc.M105550200; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Sulton D, 2005, J BIOL CHEM, V280, P35528, DOI 10.1074/jbc.M501251200; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; Walsh TR, 2005, CLIN MICROBIOL REV, V18, P306, DOI 10.1128/CMR.18.2.306-325.2005; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wilke MS, 2005, CURR OPIN MICROBIOL, V8, P525, DOI 10.1016/j.mib.2005.08.016; Xu DG, 2006, J BIOL CHEM, V281, P8740, DOI 10.1074/jbc.M512517200; Yamaguchi Y, 2005, J BIOL CHEM, V280, P20824, DOI 10.1074/jbc.M414314200; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524; Yang YJ, 1999, J BIOL CHEM, V274, P15706, DOI 10.1074/jbc.274.22.15706	59	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18276	18285		10.1074/jbc.M700742200	http://dx.doi.org/10.1074/jbc.M700742200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17426028	hybrid, Green Submitted			2022-12-27	WOS:000247302000034
J	Lejard, V; Brideau, G; Blais, F; Salingcarnboriboon, R; Wagner, G; Roehrl, MHA; Noda, M; Duprez, D; Houillier, P; Rossert, J				Lejard, Veronique; Brideau, Gaelle; Blais, Frederic; Salingcarnboriboon, Ruchanee; Wagner, Gerhard; Roehrl, Michael H. A.; Noda, Masaki; Duprez, Delphine; Houillier, Pascal; Rossert, Jerome			Scleraxis and NFATc regulate the expression of the pro-alpha 1(I) collagen gene in tendon fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; TRANSGENIC MICE; TRANSCRIPTION FACTOR; CONNECTIVE-TISSUE; CARDIAC VALVES; REPORTER GENES; BONE-FORMATION; NF-ATC; CELLS; PROMOTER	The combinatorial action of separate cis-acting elements controls the cell-specific expression of type I collagen genes. In particular, we have shown that two short elements located between -3.2 and -2.3 kb and named TSE1 and TSE2 are needed for expression of the mouse COL1a1 gene in tendon fibroblasts. In this study, we analyzed the trans-acting factors binding to TSE1 and TSE2. Gel shift experiments showed that scleraxis ( SCX), which is a basic helix-loop-helix transcription factor that is expressed selectively in tendon fibroblasts, binds TSE2, preferentially as a SCX/E47 heterodimer. In transfection experiments, overexpression of SCX and E47 strongly enhanced the activity of reporter constructs harboring either four copies of TSE2 cloned upstream of the COL1a1 minimal promoter or a 3.2-kb segment of the COL1a1 proximal promoter. Analysis of TSE1 showed that it contains a consensus binding site for NFATc transcription factors. This led us to show that the NFATc4 gene is expressed in tendons of developing mouse limbs and in TT-D6 cells, a cell line that has characteristics of tendon fibroblasts. In gel shift assays, TSE1 bound NFATc proteins present in nuclear extracts from TT-D6 cells. In transfection experiments, overexpression of NFATc transactivated a reporter construct harboring four copies of TSE1 cloned upstream of the COL1a1 minimal promoter. By contrast, inhibition of the nuclear translocation of NFATc proteins in TT-D6 cells strongly inhibited the expression of the COL1a1 gene. Taken together, these results suggest that SCX and NFATc4 cooperate to activate the COL1a1 gene specifically in tendon fibroblasts.	Inst Biomed Cordeliers, INSERM U652, F-75006 Paris, France; Univ Paris 06, F-75005 Paris, France; Univ Paris 05, F-75006 Paris, France; CNRS, UMR 7622, F-75005 Paris, France; Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pharmacol, Tokyo 1010062, Japan; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol & Lab Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Tokyo Medical & Dental University (TMDU); Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Rossert, J (corresponding author), Inst Biomed Cordeliers, INSERM U652, 15 Rue Ecole Med, F-75006 Paris, France.	jerome.rossert@egp.aphp.fr	Ampornaramveth, Ruchanee Salingcarnboriboon/U-1638-2019; Houillier, Pascal/AAD-4903-2019; Roehrl, Michael/AAU-8506-2020; Duprez, Delphine/K-1856-2017	Houillier, Pascal/0000-0003-4953-6917; Roehrl, Michael/0000-0003-4892-1098; Duprez, Delphine/0000-0003-0248-7417				Akiyama H, 2004, P NATL ACAD SCI USA, V101, P6502, DOI 10.1073/pnas.0401711101; Bonnin MA, 2005, MECH DEVELOP, V122, P573, DOI 10.1016/j.mod.2004.11.005; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Brent AE, 2003, CELL, V113, P235, DOI 10.1016/S0092-8674(03)00268-X; Carlberg Alyssa L., 2000, Molecular Cell Biology Research Communications, V3, P82, DOI 10.1006/mcbr.2000.0195; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Edom-Vovard F, 2004, DEV DYNAM, V229, P449, DOI 10.1002/dvdy.10481; Edom-Vovard F, 2002, DEV BIOL, V247, P351, DOI 10.1006/dbio.2002.0707; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hoffmann A, 2006, J CLIN INVEST, V116, P940, DOI 10.1172/JCI22689; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Lange AW, 2006, DEV BIOL, V292, P407, DOI 10.1016/j.ydbio.2006.01.017; Lincoln J, 2006, DEV BIOL, V294, P292, DOI 10.1016/j.ydbio.2006.03.027; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu Y, 1997, J BIOL CHEM, V272, P29880, DOI 10.1074/jbc.272.47.29880; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; OLIVER G, 1995, DEVELOPMENT, V121, P693; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Roehrl MHA, 2004, P NATL ACAD SCI USA, V101, P7554, DOI 10.1073/pnas.0401835101; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Salingcarnboriboon R, 2003, EXP CELL RES, V287, P289, DOI 10.1016/S0014-4827(03)00107-1; Schweitzer R, 2001, DEVELOPMENT, V128, P3855; Shukunami C, 2005, BIOCHEM BIOPH RES CO, V333, P299, DOI 10.1016/j.bbrc.2005.05.133; Shukunami C, 2006, DEV BIOL, V298, P234, DOI 10.1016/j.ydbio.2006.06.036; Terraz C, 2002, J BIOL CHEM, V277, P19019, DOI 10.1074/jbc.M200125200; Terraz C, 2001, J BIOL CHEM, V276, P37011, DOI 10.1074/jbc.M104185200; Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974	41	179	185	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17665	17675		10.1074/jbc.M610113200	http://dx.doi.org/10.1074/jbc.M610113200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430895	hybrid			2022-12-27	WOS:000247084500039
J	Ndonwi, M; Broze, GJ; Agah, S; Schmidt, AE; Bajaj, SP				Ndonwi, Matthew; Broze, George J., Jr.; Agah, Sayeh; Schmidt, Amy E.; Bajaj, S. Paul			Substitution of the gla domain in factor x with that of protein C impairs its interaction with factor VIIa/tissue factor - Lack of comparable effect by similar substitution in factor IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-FACTOR-VIIA; BLOOD-COAGULATION FACTOR; TISSUE FACTOR REGION; SITE-DIRECTED MUTAGENESIS; FACTOR PATHWAY INHIBITOR; RUSSELLS VIPER VENOM; CRYSTAL-STRUCTURE; STUART FACTOR; SUBSTRATE RECOGNITION; CHRISTMAS-FACTOR	We previously reported that the first epidermal growth factor-like (EGF1) domain in factor X (FX) or factor IX (FIX) plays an important role in the factor VIIa/tissue factor (FVIIa/TF)induced coagulation. To assess the role of gamma-carboxyglutamic acid (Gla) domains of FX and FIX in FVIIa/TF induced coagulation, we studied four new and two previously described replacement mutants: FXPCGla and FIXPCGla (Gla domain replaced with that of protein C), FXPCEGF1 and FIXPCEGF1 ( EGF1 domain replaced with that of protein C), as well as FXPCGla/EGF1 and FIXPCGla/EGF1 (both Gla and EGF1 domains replaced with those of protein C). FVIIa/TF activation of each FX mutant and the corresponding reciprocal activation of FVII/TF by each FXa mutant were impaired. In contrast, FVIIa/TF activation of FIXPCGla was minimally affected, and the reciprocal activation of FVII/TF by FIXa(PCGla) was normal; however, both reactions were impaired for the FIXPCEGF1 and FIXPCGla/EGF1 mutants. Predictably, FXIa activation of FIXPCEGF1 was normal, whereas it was impaired for the FIXPCGla and FIXPCGla/EGF1 mutants. Molecular models reveal that alternate interactions exist for the Gla domain of protein C such that it is comparable with FIX but not FX in its binding to FVIIa/TF. Further, additional interactions exist for the EGF1 domain of FX, which are not possible for FIX. Importantly, a seven-residue insertion in the EGF1 domain of protein C prevents its interaction with FVIIa/TF. Cumulatively, our data provide a molecular framework demonstrating that the Gla and EGF1 domains of FX interact more strongly with FVIIa/TF than the corresponding domains in FIX.	Univ Calif Los Angeles, Orthoped Hosp, Prot Sci Lab, Dept Orthopaed Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Washington Univ, Sch Med, Jewish Hosp, Div Hematol, St Louis, MO 63110 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Saint Louis University; Barnes-Jewish Hospital; Washington University (WUSTL)	Bajaj, SP (corresponding author), Univ Calif Los Angeles, Orthoped Hosp, Prot Sci Lab, Dept Orthopaed Surg, Box 951795, Los Angeles, CA 90095 USA.	pbajaj@mednet.ucla.edu			NHLBI NIH HHS [HL 34462, HL 70369, HL 36365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL036365, R01HL070369, R55HL036365, R01HL034462, R01HL036365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aktimur A, 2003, J BIOL CHEM, V278, P7981, DOI 10.1074/jbc.M212748200; Bajaj SP, 2006, J BIOL CHEM, V281, P24873, DOI 10.1074/jbc.M509971200; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Butenas S, 1996, BIOCHEMISTRY-US, V35, P1904, DOI 10.1021/bi951768c; BYLUND DB, 1993, AM J PHYSIOL, V265, pL421, DOI 10.1152/ajplung.1993.265.5.L421; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; Carlsson K, 2003, EUR J BIOCHEM, V270, P2576, DOI 10.1046/j.1432-1033.2003.03625.x; Chen SWW, 2002, THROMB HAEMOSTASIS, V88, P74; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V6, P68; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DeLano W.L, PYMOL MOL GRAPHICS S; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4892, DOI 10.1021/bi00776a003; Greenberg D L, 2001, HEMOSTASIS THROMBOSI, P21; Halfman C J, 1981, Methods Enzymol, V74 Pt C, P481; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelley RF, 2004, BIOCHEMISTRY-US, V43, P1223, DOI 10.1021/bi035738i; Kirchhofer D, 2000, BIOCHEMISTRY-US, V39, P7380, DOI 10.1021/bi000182+; Kirchhofer D, 2001, BIOCHEMISTRY-US, V40, P675, DOI 10.1021/bi002013v; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; Lu G, 2004, J BIOL CHEM, V279, P17241, DOI 10.1074/jbc.M312827200; MASYS DR, 1982, BLOOD, V60, P1143; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; Mizuno H, 2001, P NATL ACAD SCI USA, V98, P7230, DOI 10.1073/pnas.131179698; MORRISSEY JH, 2001, HEMOSTASIS THROMBOSI, P89; Ndonwi M, 2005, J THROMB HAEMOST, V3, P112, DOI 10.1111/j.1538-7836.2004.01051.x; Norledge BV, 2003, PROTEINS, V53, P640, DOI 10.1002/prot.10445; Oganesyan V, 2002, J BIOL CHEM, V277, P24851, DOI 10.1074/jbc.C200163200; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; RAO LV, 1995, BIOCHEMISTRY-US, V34, P6310; RAO LVM, 1985, BLOOD, V65, P218; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; Shikamoto Y, 2003, J BIOL CHEM, V278, P24090, DOI 10.1074/jbc.M300650200; Smith SA, 2004, J THROMB HAEMOST, V2, P1155, DOI 10.1111/j.1538-7836.2004.00772.x; Thiec F, 2003, J BIOL CHEM, V278, P10393, DOI 10.1074/jbc.M212144200; Venkateswarlu D, 2003, J THROMB HAEMOST, V1, P2577, DOI 10.1111/j.1538-7836.2003.00421.x; WARNCRAMER BJ, 1985, BIOCHEM BIOPH RES CO, V133, P417, DOI 10.1016/0006-291X(85)90922-2; Waters EK, 2006, J BIOL CHEM, V281, P26062, DOI 10.1074/jbc.M604915200; Wirehn J, 2005, BIOCHEMISTRY-US, V44, P6755, DOI 10.1021/bi047388l; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHONG DG, 1993, BIOTECHNIQUES, V15, P874; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574; Zhong DG, 2002, J BIOL CHEM, V277, P3622, DOI 10.1074/jbc.M111202200	58	12	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15632	15644		10.1074/jbc.M701908200	http://dx.doi.org/10.1074/jbc.M701908200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17387172	hybrid			2022-12-27	WOS:000246589600040
J	Uematsu, S; Akira, S				Uematsu, Satoshi; Akira, Shizuo			Toll-like receptors and type I interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							IFN-REGULATORY FACTOR-3; TANK-BINDING KINASE-1; KAPPA-B KINASE; INNATE IMMUNE RECOGNITION; CUTTING EDGE; STRANDED-RNA; ANTIVIRAL RESPONSE; ADAPTER MOLECULE; ALPHA PRODUCTION; MYD88	Toll-like receptors (TLRs) are key molecules of the innate immune systems, which detect conserved structures found in a broad range of pathogens and trigger innate immune responses. Asubset of TLRs recognizes viral components and induces antiviral responses. Whereas TLR4 recognizes viral components at the cell surface, TLR3, TLR7, TLR8, and TLR9 recognize viral nucleic acids on endosomal membrane. After ligand recognition, these members activate their intrinsic signaling pathways and induce type I interferon. In this review, we discuss the recent findings of the viral recognition by TLRs and their signaling pathways.	Osaka Univ, Dept Host Def, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; ERATO, Japan Sci & Technol Corp, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Akira, S (corresponding author), Osaka Univ, Dept Host Def, Res Inst Microbial Dis, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	sakira@biken.osaka-u.ac.jp						Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Gohda J, 2004, J IMMUNOL, V173, P2913, DOI 10.4049/jimmunol.173.5.2913; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hemmi H, 2003, J IMMUNOL, V170, P3059, DOI 10.4049/jimmunol.170.6.3059; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Hoshino K, 2006, NATURE, V440, P949, DOI 10.1038/nature04641; Hoshino K, 1999, J IMMUNOL, V162, P3749; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Ishii KJ, 2006, TRENDS IMMUNOL, V27, P525, DOI 10.1016/j.it.2006.09.002; Ito T, 2002, J EXP MED, V195, P1507, DOI 10.1084/jem.20020207; Johnsen IB, 2006, EMBO J, V25, P3335, DOI 10.1038/sj.emboj.7601222; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lee HK, 2006, IMMUNITY, V24, P153, DOI 10.1016/j.immuni.2005.12.012; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Matsui K, 2006, J IMMUNOL, V177, P5785, DOI 10.4049/jimmunol.177.9.5785; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; McGettrick AF, 2006, P NATL ACAD SCI USA, V103, P9196, DOI 10.1073/pnas.0600462103; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Negishi H, 2006, P NATL ACAD SCI USA, V103, P15136, DOI 10.1073/pnas.0607181103; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rassa JC, 2002, P NATL ACAD SCI USA, V99, P2281, DOI 10.1073/pnas.042355399; Rowe DC, 2006, P NATL ACAD SCI USA, V103, P6299, DOI 10.1073/pnas.0510041103; Saitoh T, 2006, NAT IMMUNOL, V7, P598, DOI 10.1038/ni1347; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Sasai M, 2005, J IMMUNOL, V174, P27, DOI 10.4049/jimmunol.174.1.27; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shinohara ML, 2006, NAT IMMUNOL, V7, P498, DOI 10.1038/ni1327; Su XQ, 2006, EUR J IMMUNOL, V36, P199, DOI 10.1002/eji.200535415; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takeshita F, 2005, EUR J IMMUNOL, V35, P2477, DOI 10.1002/eji.200526151; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yang K, 2005, IMMUNITY, V23, P465, DOI 10.1016/j.immuni.2005.09.016	57	344	387	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15319	15323		10.1074/jbc.R700009200	http://dx.doi.org/10.1074/jbc.R700009200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17395581	hybrid			2022-12-27	WOS:000246589600006
J	Barthelme, D; Scheele, U; Dinkelaker, S; Janoschka, A; MacMillan, F; Albers, SV; Driessen, AJM; Stagni, MS; Bill, E; Meyer-Klaucke, W; Schunemann, V; Tampe, R				Barthelme, Dominik; Scheele, Urte; Dinkelaker, Stephanie; Janoschka, Adam; MacMillan, Fraser; Albers, Sonja-Verena; Driessen, Arnold J. M.; Stagni, Marco Salamone; Bill, Eckhard; Meyer-Klaucke, Wolfram; Schuenemann, Volker; Tampe, Robert			Structural organization of essential iron-sulfur clusters in the evolutionarily highly conserved ATP-binding cassette protein ABCE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEON SULFOLOBUS-SOLFATARICUS; ENZYME ENDONUCLEASE-III; RNASE-L-INHIBITOR; 4FE-4S CLUSTERS; FNR PROTEIN; DNA-BINDING; BIOGENESIS; TRANSPORTERS; FERREDOXIN; MOSSBAUER	The ABC protein ABCE1, formerly named RNase L inhibitor RLI1, is one of the most conserved proteins in evolution and is expressed in all organisms except eubacteria. Because of its fundamental role in translation initiation and/or ribosome biosynthesis, ABCE1 is essential for life. Its molecular mechanism has, however, not been elucidated. In addition to two ABC ATPase domains, ABCE1 contains a unique N-terminal region with eight conserved cysteines, predicted to coordinate iron-sulfur clusters. Here we present detailed information on the type and on the structural organization of the Fe-S clusters in ABCE1. Based on biophysical, biochemical, and yeast genetic analyses, ABCE1 harbors two essential diamagnetic [4Fe-4S](2+) clusters with different electronic environments, one ferredoxin-like (CPXnCX2CX2C; Cys at positions 4-7) and one unique ABCE1-type cluster (CXPX2CX3CXnCP; Cys at positions 1, 2, 3, and 8). Strikingly, only seven of the eight conserved cysteines coordinating the Fe-S clusters are essential for cell viability. Mutagenesis of the cysteine at position 6 yielded a functional ABCE1 with the ferredoxin-like Fe-S cluster in a paramagnetic [3Fe-4S](+) state. Notably, a lethal mutation of the cysteine at position 4 can be rescued by ligand swapping with an adjacent, extra cysteine conserved among all eukaryotes.	Univ Frankfurt, Inst Biochem, Bioctr, D-60439 Frankfurt, Germany; Univ Kaiserslautern, Dept Phys, D-67663 Kaiserslautern, Germany; Univ Frankfurt, Inst Phys & Theoret Chem, D-60439 Frankfurt, Germany; Univ Groningen, Dept Mol Microbiol, NL-9751 NN Haren, Netherlands; DESY, Outstn Hamburg, European Mol Biol Lab, D-22603 Hamburg, Germany; Max Planck Inst Bioinorgan Chem, D-45470 Mulheim, Germany	Goethe University Frankfurt; University of Kaiserslautern; Goethe University Frankfurt; University of Groningen; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society	Tampe, R (corresponding author), Univ Frankfurt, Inst Biochem, Bioctr, Max von Laue Str 9, D-60439 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015; Barthelme, Dominik/E-8452-2010; Albers, Sonja-Verena/H-1213-2012; Albers, Sonja-Verena/H-8689-2019; Salomone-Stagni, Marco/F-4458-2010; MacMillan, Fraser/B-7619-2011; MacMillan, Fraser/AAM-4483-2020; Driessen, Arnold J.M./D-1876-2012; Schünemann, Volker/C-6603-2016; Meyer-Klaucke, Wolfram/G-1148-2010	Tampé, Robert/0000-0002-0403-2160; Albers, Sonja-Verena/0000-0003-2459-2226; MacMillan, Fraser/0000-0002-2410-4790; MacMillan, Fraser/0000-0002-2410-4790; Driessen, Arnold J.M./0000-0001-9258-9104				Agarwalla S, 2004, J BIOL CHEM, V279, P34123, DOI 10.1074/jbc.M405702200; Albers SV, 2006, APPL ENVIRON MICROB, V72, P102, DOI 10.1128/AEM.72.1.102-111.2006; Albers SV, 2003, J BACTERIOL, V185, P3918, DOI 10.1128/JB.185.13.3918-3925.2003; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Braz ASK, 2004, J MOL EVOL, V59, P20, DOI 10.1007/s00239-004-2600-4; Busch JLH, 1997, BIOCHEM J, V323, P95, DOI 10.1042/bj3230095; Chen ZQ, 2006, J BIOL CHEM, V281, P7452, DOI 10.1074/jbc.M510603200; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Elsasser C, 2002, J AM CHEM SOC, V124, P12606, DOI 10.1021/ja027348+; EMPTAGE MH, 1980, J BIOL CHEM, V255, P1793; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; GEORGE GN, 1989, BIOCHEM J, V259, P597, DOI 10.1042/bj2590597; Hopfner KP, 2003, CURR OPIN STRUC BIOL, V13, P249, DOI 10.1016/S0959-440X(03)00037-X; Howard JB, 2006, P NATL ACAD SCI USA, V103, P17088, DOI 10.1073/pnas.0603978103; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Jonuscheit M, 2003, MOL MICROBIOL, V48, P1241, DOI 10.1046/j.1365-2958.2003.03509.x; Karcher A, 2005, STRUCTURE, V13, P649, DOI 10.1016/j.str.2005.02.008; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Korbas M, 2006, J BIOL CHEM, V281, P30804, DOI 10.1074/jbc.M605306200; Korbas M, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2209954; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Lill R, 2005, IUBMB LIFE, V57, P701, DOI 10.1080/15216540500305860; Lill R, 2006, ANNU REV CELL DEV BI, V22, P457, DOI 10.1146/annurev.cellbio.22.010305.104538; Martusewitsch E, 2000, J BACTERIOL, V182, P2574, DOI 10.1128/JB.182.9.2574-2581.2000; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; ORMEJOHNSON WH, 1982, IRON SULFUR PROTEINS, P67; Pierrel F, 2004, J BIOL CHEM, V279, P47555, DOI 10.1074/jbc.M408562200; Porello SL, 1998, BIOCHEMISTRY-US, V37, P6465, DOI 10.1021/bi972433t; SCHLEPER C, 1992, P NATL ACAD SCI USA, V89, P7645, DOI 10.1073/pnas.89.16.7645; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Schunemann V, 2000, REP PROG PHYS, V63, P263, DOI 10.1088/0034-4885/63/3/202; Seemann M, 2005, J BIOL INORG CHEM, V10, P131, DOI 10.1007/s00775-004-0619-z; Stout CD, 2001, HDB METALLOPROTEINS, P560; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Tilley GJ, 2001, BIOCHEM J, V360, P717, DOI 10.1042/0264-6021:3600717; van der Does C, 2004, BIOL CHEM, V385, P927, DOI 10.1515/BC.2004.121; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; Zhao ZY, 2004, BIOCHEM BIOPH RES CO, V323, P104, DOI 10.1016/j.bbrc.2004.08.068; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; Zimmerman C, 2002, NATURE, V415, P88, DOI 10.1038/415088a	45	96	98	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14598	14607		10.1074/jbc.M700825200	http://dx.doi.org/10.1074/jbc.M700825200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355973	hybrid, Green Published			2022-12-27	WOS:000246245800073
J	Norgett, EE; Borthwick, KJ; Al-Lamki, RS; Su, Y; Smith, AN; Karet, FE				Norgett, Elizabeth E.; Borthwick, Katherine J.; Al-Lamki, Rafia S.; Su, Ya; Smith, Annabel N.; Karet, Fiona E.			V-1 and V-0 domains of the human H+-ATPase are linked by an interaction between the G and a subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; V-ATPASE; MOLECULAR-CLONING; COATED VESICLE; C-SUBUNIT; G VMA10P; VACUOLAR; KIDNEY; MUTATIONS; ISOFORMS	The specialized H+-ATPases found in the inner ear and acid-handling cells in the renal collecting duct differ from those at other sites, as they contain tissue-specific subunits, such as a4 and B1, and in the kidney, C2, d2, and G3 as well. These subunits replace the ubiquitously expressed forms. Previously, we have shown that, in major organs of both mouse and man, G3 subunit expression is limited to the kidney. Here we have shown widespread transcription of murine G3 in specific segments of microdissected nephron, and demonstrated additional G3 expression in epithelial fragments from human inner ear. We raised a polyclonal G3-specific antibody, which specifically detects G3 from human, mouse, and rat kidney lysates, and displays no cross-reactivity with G1 or G2. However, immunolocalization using this antibody on human and mouse kidney sections was unachievable, suggesting epitope masking. Phage display analysis and subsequent enzyme-linked immunosorbent assay, using the G3 antibody epitope peptide as bait, identified a possible interaction between the G3 subunit and the a4 subunit of the H+-ATPase. This interaction was verified by successfully using purified, immobilized full-length G3 to pull down the a4 subunit from human kidney membrane preparations. This confirms that a4 and G3 are component subunits of the same proton pump and explains the observed epitope masking. This interaction was also found to be a more general feature of human H+-ATPases, as similar G1/a1, G3/a1, and G1/a4 interactions were also demonstrated. These interactions represent a novel link between the V-1 and V-0 domains in man, which is known to be required for H+-ATPase assembly and regulation.	Univ Cambridge, Dept Med Genet, Cambridge CB2 0XY, England; Univ Cambridge, Dept Med, Cambridge CB2 0XY, England; Univ Cambridge, Div Renal Med, Cambridge CB2 0XY, England	University of Cambridge; University of Cambridge; University of Cambridge	Karet, FE (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Box 139, Cambridge CB2 0XY, England.	fek1000@cam.ac.uk		Karet, Fiona/0000-0002-2457-2869	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arata Y, 2002, BBA-BIOENERGETICS, V1555, P71, DOI 10.1016/S0005-2728(02)00257-8; Armbruster A, 2003, FEBS LETT, V546, P395, DOI 10.1016/S0014-5793(03)00643-4; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; HO MN, 1993, J BIOL CHEM, V268, P18286; Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200; Jones RPO, 2005, BIOCHEMISTRY-US, V44, P3933, DOI 10.1021/bi048402x; KANE PM, 1995, J BIOL CHEM, V270, P17025; Karet FE, 1999, AM J HUM GENET, V65, P1656, DOI 10.1086/302679; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Pietrement C, 2006, BIOL REPROD, V74, P185, DOI 10.1095/biolreprod.105.043752; Smith AN, 2005, J AM SOC NEPHROL, V16, P1245, DOI 10.1681/ASN.2004090761; Smith AN, 2002, GENE, V297, P169, DOI 10.1016/S0378-1119(02)00884-3; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Stover EH, 2002, J MED GENET, V39, P796, DOI 10.1136/jmg.39.11.796; Sun-Wada GH, 2003, J BIOL CHEM, V278, P44843, DOI 10.1074/jbc.M307197200; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Yokoyama K, 2003, J BIOL CHEM, V278, P42686, DOI 10.1074/jbc.M305853200	27	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14421	14427		10.1074/jbc.M701226200	http://dx.doi.org/10.1074/jbc.M701226200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360703	hybrid			2022-12-27	WOS:000246245800055
J	Wozniak, RJ; Boyer, ME; Grass, JA; Lee, Y; Bresnick, EH				Wozniak, Ryan J.; Boyer, Meghan E.; Grass, Jeffrey A.; Lee, Youngsook; Bresnick, Emery H.			Context-dependent gata factor function - Combinatorial requirements for transcriptional control in hematopoietic and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; GENE-EXPRESSION; ADHESION MOLECULE-1; BINDING PROTEINS; FACTOR INTERPLAY; ACTIVATION; MECHANISMS; COMPLEX; HEMANGIOBLAST; SCL/TAL-1	GATA factors are fundamental components of developmentally important transcriptional networks. By contrast to common mechanisms in which transacting factors function directly at promoters, the hematopoietic GATA factors GATA-1 and GATA-2 often assemble dispersed complexes over broad chromosomal regions. For example, GATA-1 and GATA-2 occupy five conserved regions over similar to 100 kb of the Gata2 locus in the transcriptionally repressed and active states, respectively, in erythroid cells. Since it is unknown whether the individual complexes exert qualitatively distinct or identical functions to regulate Gata2 transcription in vivo, we compared the activity of the -3.9 and +9.5 kb sites of the Gata2 locus in transgenic mice. The +9.5 site functioned as an autonomous enhancer in the endothelium and fetal liver of embryonic day 11 embryos, whereas the -3.9 site lacked such activity. Mechanistic studies demonstrated critical requirements for a GATA motif and a neighboring E-box within the +9.5 site for enhancer activity in endothelial and hematopoietic cells. Surprisingly, whereas this GATA-E-box composite motif was sufficient for enhancer activity in an erythroid precursor cell line, its enhancer function in primary human endothelial cells required additional regulatory modules. These results identify the first molecular determinant of Gata2 transcription in vascular endothelium, composed of a core enhancer module active in both endothelial and hematopoietic cells and regulatory modules preferentially required in endothelial cells.	Univ Wisconsin, Sch Med & Publ Hlth, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med & Publ Hlth, Dept Anat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	ehbresni@wisc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067050, T32HL007936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068634, R56DK068634] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07936, HL67050] Funding Source: Medline; NIDDK NIH HHS [DK68634] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anguita E, 2004, EMBO J, V23, P2841, DOI 10.1038/sj.emboj.7600274; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bresnick EH, 2005, J CELL PHYSIOL, V205, P1, DOI 10.1002/jcp.20393; Bresnick EH, 2006, PROG NUCLEIC ACID RE, V81, P435, DOI 10.1016/S0079-6603(06)81011-1; Cantor AB, 2005, SEMIN CELL DEV BIOL, V16, P117, DOI 10.1016/j.semcdb.2004.10.006; Chan WYI, 2007, BLOOD, V109, P1908, DOI 10.1182/blood-2006-05-023226; Choi K, 1998, DEVELOPMENT, V125, P725; Craven SE, 2004, DEVELOPMENT, V131, P1165, DOI 10.1242/dev.01024; D'Souza SL, 2005, BLOOD, V105, P3862, DOI 10.1182/blood-2004-09-3611; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; Friedle H, 2002, J BIOL CHEM, V277, P23872, DOI 10.1074/jbc.M201831200; Fujiwara Y, 2004, BLOOD, V103, P583, DOI 10.1182/blood-2003-08-2870; Gottgens B, 2002, EMBO J, V21, P3039, DOI 10.1093/emboj/cdf286; Grass JA, 2003, P NATL ACAD SCI USA, V100, P8811, DOI 10.1073/pnas.1432147100; Grass JA, 2006, MOL CELL BIOL, V26, P7056, DOI 10.1128/MCB.01033-06; Ikonomi P, 2000, GENE, V261, P277, DOI 10.1016/S0378-1119(00)00510-2; Im H, 2005, P NATL ACAD SCI USA, V102, P17065, DOI 10.1073/pnas.0506164102; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Kobayashi-Osaki M, 2005, MOL CELL BIOL, V25, P7005, DOI 10.1128/MCB.25.16.7005-7020.2005; Lahlil R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEONARD M, 1993, BLOOD, V82, P1071; Lugus JJ, 2007, DEVELOPMENT, V134, P393, DOI 10.1242/dev.02731; Mann RS, 2002, CURR OPIN GENET DEV, V12, P592, DOI 10.1016/S0959-437X(02)00344-1; Martowicz ML, 2005, J BIOL CHEM, V280, P1724, DOI 10.1074/jbc.M406038200; McGrath KE, 2005, EXP HEMATOL, V33, P1021, DOI 10.1016/j.exphem.2005.06.012; Mikkola HKA, 2006, DEVELOPMENT, V133, P3733, DOI 10.1242/dev.02568; MIKKOLA HK, 2005, NATURE, V421, P547; Minami T, 2004, J BIOL CHEM, V279, P20626, DOI 10.1074/jbc.M308730200; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Minami T, 2001, J BIOL CHEM, V276, P5395, DOI 10.1074/jbc.M008798200; Minegishi N, 1999, BLOOD, V93, P4196, DOI 10.1182/blood.V93.12.4196.412k23_4196_4207; Nardelli J, 1999, DEV BIOL, V210, P305, DOI 10.1006/dbio.1999.9278; NG YK, 1994, DEVELOPMENT, V120, P3257; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; NUDEL U, 1977, P NATL ACAD SCI USA, V74, P1100, DOI 10.1073/pnas.74.3.1100; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pal S, 2004, J BIOL CHEM, V279, P31348, DOI 10.1074/jbc.M403475200; Pal S, 2004, P NATL ACAD SCI USA, V101, P980, DOI 10.1073/pnas.0307612100; Pan JL, 1998, J BIOL CHEM, V273, P10058, DOI 10.1074/jbc.273.16.10058; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Umetani M, 2001, ARTERIOSCL THROM VAS, V21, P917, DOI 10.1161/01.ATV.21.6.917; Vyas P, 1999, DEVELOPMENT, V126, P2799; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007; Xu ZX, 2003, MOL CELL BIOL, V23, P7585, DOI 10.1128/MCB.23.21.7585-7599.2003; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; ZON LI, 1993, BLOOD, V81, P3234	62	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14665	14674		10.1074/jbc.M700792200	http://dx.doi.org/10.1074/jbc.M700792200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17347142	hybrid			2022-12-27	WOS:000246245800080
J	Lu, CY; Egawa, T; Wainwright, LM; Poole, RK; Yeh, SR				Lu, Changyuan; Egawa, Tsuyoshi; Wainwright, Laura M.; Poole, Robert K.; Yeh, Syun-Ru			Structural and functional properties of a truncated hemoglobin from a food-borne pathogen Campylobacter jejuni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; DIMERIC BACTERIAL HEMOGLOBIN; LIGAND-BINDING PROPERTIES; HYDROGEN-BOND NETWORK; AMINO-ACID-SEQUENCE; DISTAL HEME POCKET; MYCOBACTERIUM-TUBERCULOSIS; OXYGEN-BINDING; CARBON-MONOXIDE; VITREOSCILLA HEMOGLOBIN	Campylobacter jejuni contains two hemoglobins, Cgb and Ctb. Cgb has been suggested to perform an NO detoxification reaction to protect the bacterium against NO attack. On the other hand, the physiological function of Ctb, a class III truncated hemoglobin, remains unclear. By using CO as a structural probe, resonance Raman data show that the distal heme pocket of Ctb exhibits a positive electrostatic potential. In addition, two ligand-related vibrational modes, v(Fe-O2) and v(O-O), were identified in the oxy derivative, with frequencies at 542 and 1132 cm(-1), respectively, suggesting the presence of an intertwined H-bonding network surrounding the heme-bound ligand, which accounts for its unusually high oxygen affinity ( 222 mu m(-1)). Mutagenesis studies of various distal mutants suggest that the heme-bound dioxygen is stabilized by H-bonds donated from the Tyr(B10) and Trp(G8) residues, which are highly conserved in the class III truncated hemoglobins; furthermore, an additional H-bond donated from the His(E7) to the Tyr(B10) further regulates these H-bonding interactions by restricting the conformational freedom of the phenolic side chain of the Tyr( B10). Taken together, the data suggest that it is the intricate balance of the H-bonding interactions that determines the unique ligand binding properties of Ctb. The extremely high oxygen affinity of Ctb makes it unlikely to function as an oxygen transporter; on the other hand, the distal heme environment of Ctb is surprisingly similar to that of cytochrome c peroxidase, suggesting a role of Ctb in performing a peroxidase or P450-type of oxygen chemistry.	Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	Yeshiva University; Albert Einstein College of Medicine; University of Sheffield	Yeh, SR (corresponding author), Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	syeh@aecom.yu.edu		Yeh, Syun-Ru/0000-0002-9858-386X	Biotechnology and Biological Sciences Research Council [BB/E010504/1] Funding Source: Medline; NHLBI NIH HHS [HL65465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER; BBSRC [BB/E010504/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bolognesi M, 1999, J MOL BIOL, V291, P637, DOI 10.1006/jmbi.1999.2975; COUTURE M, 1994, MOL GEN GENET, V243, P185, DOI 10.1007/BF00280316; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Coyle CM, 2003, BIOCHEMISTRY-US, V42, P4896, DOI 10.1021/bi026395b; CRAMM R, 1994, J BIOL CHEM, V269, P7349; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Dikshit KL, 1998, ARCH BIOCHEM BIOPHYS, V349, P161, DOI 10.1006/abbi.1997.0432; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; Egawa T, 2005, J INORG BIOCHEM, V99, P72, DOI 10.1016/j.jinorgbio.2004.10.017; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; Elvers KT, 2004, J BACTERIOL, V186, P5332, DOI 10.1128/JB.186.16.5332-5341.2004; Elvers KT, 2005, MOL MICROBIOL, V57, P735, DOI 10.1111/j.1365-2958.2005.04723.x; Frey AD, 2003, FEMS MICROBIOL REV, V27, P525, DOI 10.1016/S0168-6445(03)00056-1; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Giangiacomo L, 2005, J BIOL CHEM, V280, P9192, DOI 10.1074/jbc.M407267200; Giangiacomo L, 2001, BIOCHEMISTRY-US, V40, P9311, DOI 10.1021/bi0101143; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Iijima M, 2000, CELL STRUCT FUNCT, V25, P47, DOI 10.1247/csf.25.47; Ishikawa H, 2001, BIOPHYS J, V80, P1507, DOI 10.1016/S0006-3495(01)76123-1; IWAASA H, 1992, J MOL BIOL, V227, P948, DOI 10.1016/0022-2836(92)90236-D; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; Kaur R, 2002, APPL ENVIRON MICROB, V68, P152, DOI 10.1128/AEM.68.1.152-160.2002; Kundu S, 2004, BIOCHEMISTRY-US, V43, P6241, DOI 10.1021/bi049848g; LAMBRIGHT DG, 1989, J MOL BIOL, V207, P289, DOI 10.1016/0022-2836(89)90456-7; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; Milani M, 2005, J INORG BIOCHEM, V99, P97, DOI 10.1016/j.jinorgbio.2004.10.035; Milani M, 2003, P NATL ACAD SCI USA, V100, P5766, DOI 10.1073/pnas.1037676100; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; MILLER MA, 1994, NAT STRUCT BIOL, V1, P524, DOI 10.1038/nsb0894-524; Moens L, 1996, MOL BIOL EVOL, V13, P324, DOI 10.1093/oxfordjournals.molbev.a025592; Mukai M, 2002, BIOCHEMISTRY-US, V41, P3897, DOI 10.1021/bi0156409; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; Nardini M, 2006, J BIOL CHEM, V281, P37803, DOI 10.1074/jbc.M607254200; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; Ouellet H, 2003, BIOCHEMISTRY-US, V42, P5764, DOI 10.1021/bi0270337; Park KW, 2002, J BIOL CHEM, V277, P33334, DOI 10.1074/jbc.M203820200; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; Pesce A, 2004, J BIOL CHEM, V279, P33662, DOI 10.1074/jbc.M403597200; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; Ramandeep, 2001, J BIOL CHEM, V276, P24781, DOI 10.1074/jbc.M009808200; RAMSDEN J, 1989, BIOCHEMISTRY-US, V28, P3125, DOI 10.1021/bi00434a001; Schlichting I, 2000, CURR OPIN STRUC BIOL, V10, P744, DOI 10.1016/S0959-440X(00)00158-5; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Spiro TG, 2005, J INORG BIOCHEM, V99, P34, DOI 10.1016/j.jinorgbio.2004.09.026; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Takaya N, 1997, FEBS LETT, V414, P545, DOI 10.1016/S0014-5793(97)01069-7; Tarricone C, 1997, PROTEINS, V27, P154, DOI 10.1002/(SICI)1097-0134(199701)27:1<154::AID-PROT15>3.0.CO;2-M; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TILTON RF, 1988, J MOL BIOL, V199, P195, DOI 10.1016/0022-2836(88)90389-0; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; VINOGRADOV SN, 1992, COMP BIOCHEM PHYS B, V103, P759, DOI 10.1016/0305-0491(92)90193-U; Vogel KM, 1999, J AM CHEM SOC, V121, P9915, DOI 10.1021/ja990042r; Vogel KM, 2000, INORG CHIM ACTA, V297, P11, DOI 10.1016/S0020-1693(99)00253-4; Wainwright LM, 2006, BIOCHEMISTRY-US, V45, P6003, DOI 10.1021/bi052247k; Wajcman H, 2002, CR BIOL, V325, P1159, DOI 10.1016/S1631-0691(02)01537-8; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; Wang J., 1996, METHODS NITRIC OXIDE, P427; Watts RA, 2001, P NATL ACAD SCI USA, V98, P10119, DOI 10.1073/pnas.191349198; WEBSTER DA, 1966, J BIOL CHEM, V241, P3308; WEBSTER DA, 1988, ADV INORG BIOCHEM, V7, P245; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Wu GH, 2003, ADV MICROB PHYSIOL, V47, P255, DOI 10.1016/S0065-2911(03)47005-7; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	80	58	60	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13627	13636		10.1074/jbc.M609397200	http://dx.doi.org/10.1074/jbc.M609397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339325	hybrid			2022-12-27	WOS:000246060300052
J	Miao, F; Wu, XW; Zhang, LX; Yuan, YC; Riggs, AD; Natarajan, R				Miao, Feng; Wu, Xiwei; Zhang, Lingxiao; Yuan, Yate-Ching; Riggs, Arthur D.; Natarajan, Rama			Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG ISLANDS; GENE-EXPRESSION; CODING REGIONS; ACTIVE GENES; END-PRODUCTS; H3 LYSINE-9; PATTERNS; COMPLICATIONS; TRANSCRIPTION; CHROMATIN	Aberrant histone lysine methylation patterns that change chromatin structure can promote dysregulated gene transcription and disease progression. Diabetic conditions such as high glucose (HG) are known to alter key pathologic pathways. However, their impact on cellular histone lysine methylation is unknown. We hypothesized that chronic HG can induce aberrant changes in histone H3 lysine 4 and lysine 9 dimethylation (H3K4me2 and H3K9me2) within target cells. Chromatin immunoprecipitation linked to microarrays (ChIP-on-chip) is currently a widely used approach for acquiring genome-wide information on histone modifications. We adopted this approach to profile and compare the variations in H3K4me2 and H3K9me2 in human gene coding and CpG island regions in THP-1 monocytes cultured in normal glucose and HG. Subsequently, we identified key relevant candidate genes displaying differential changes in H3K4me2 and H3K9me2 in HG versus normal glucose and also validated them with follow-up conventional ChIPs. Relevance to human diabetes was demonstrated by noting that H3K9me2 at the coding and promoter regions of two candidate genes was significantly greater in blood monocytes of diabetic patients relative to normal controls similar to the THP-1 data. In addition, regular mRNA profiling with cDNA arrays revealed correlations between mRNA and H3K9me2 levels. These novel results show histone methylation variations, for the first time, under diabetic conditions at a genome-wide level.	Beckman Res Inst City Hope, Dept Diabet, Duarte, CA 91010 USA; Beckman Res Inst City Hope, Dept Biomed Informat, Duarte, CA 91010 USA; Beckman Res Inst City Hope, Dept Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Natarajan, R (corresponding author), Beckman Res Inst City Hope, Dept Diabet, 1500 E Duarte Rd, Duarte, CA 91010 USA.	RNatarajan@coh.org		Riggs, Arthur/0000-0002-8184-5288	NCRR NIH HHS [M01RR00043] Funding Source: Medline; NIDDK NIH HHS [R01 DK065073] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065073] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Ishii H, 1998, J MOL MED, V76, P21, DOI 10.1007/s109-1998-8101-y; KLIPPERAURBACH Y, 1995, MED HYPOTHESES, V45, P486, DOI 10.1016/0306-9877(95)90228-7; Klose RJ, 2006, NATURE, V442, P312, DOI 10.1038/nature04853; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005; Miao F, 2004, J BIOL CHEM, V279, P18091, DOI 10.1074/jbc.M311786200; Millar CB, 2006, NAT REV MOL CELL BIO, V7, P657, DOI 10.1038/nrm1986; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Shanmugam N, 2003, DIABETES, V52, P1256, DOI 10.2337/diabetes.52.5.1256; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Sims RJ, 2006, GENE DEV, V20, P2779, DOI 10.1101/gad.1468206; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Steffes MW, 2003, JAMA-J AM MED ASSOC, V290, P2159, DOI 10.1001/jama.290.16.2159; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; van Steensel B, 2005, NAT GENET, V37, pS18, DOI 10.1038/ng1559; Werman A, 2004, P NATL ACAD SCI USA, V101, P2434, DOI 10.1073/pnas.0308705101; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	43	135	144	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13854	13863		10.1074/jbc.M609446200	http://dx.doi.org/10.1074/jbc.M609446200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339327	hybrid			2022-12-27	WOS:000246060300075
J	Sakurai, H; Takemori, Y				Sakurai, Hiroshi; Takemori, Yukiko			Interaction between heat shock transcription factors (HSFs) and divergent binding sequences - Binding specificities of yeast HSFS and human HSF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR ACTIVATES TRANSCRIPTION; GENOME-WIDE ANALYSIS; DNA-BINDING; FACTOR CONTAINS; SCHIZOSACCHAROMYCES-POMBE; GENE-EXPRESSION; IN-VIVO; STRESS; FAMILY; DOMAIN	The target genes of the heat shock transcription factor (HSF)contain a cis- acting sequence, the heat shock element (HSE), which consists of multiple inverted repeats of the sequence 5'-nGAAn-3'. Using data acquired in this and a previous study, we have identified the HSEs in 59 of 62 target genes of Saccharomyces cerevisiae Hsf1. The Hsf1 protein recognizes continuous and discontinuous repeats of the nGAAn unit; the nucleotide sequences and configuration of the units diverge slightly among functional HSEs. When Schizosaccharomyces pombe HSF was expressed in S. cerevisiae cells, heat shock induced S. pombe HSF to bind to various HSE types, which properly activated transcription from almost all target genes, suggesting that the S. pombe genome also contains divergent HSEs. Human HSF1 induced the heat shock response via HSEs with continuous units in S. cerevisiae cells but failed to do so via HSEs with discontinuous units. Binding of human HSF1 to the discontinuous type of HSE was observed in vitro but was significantly inhibited in vivo. These results show that human HSF1 recognizes HSEs in a slightly different way than yeast HSFs and suggest that the configuration of the unit is an important determinant for HSF-HSE interactions.	Kanazawa Univ, Grad Sch Med Sci, Div Hlth Sci, Kanazawa, Ishikawa 9200942, Japan	Kanazawa University	Sakurai, H (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Div Hlth Sci, 5-11-80 Kodatsuno, Kanazawa, Ishikawa 9200942, Japan.	sakurai@kenroku.kanazawa-u.ac.jp	SAKURAI, Hiroshi/L-3693-2015	Sakurai, Hiroshi/0000-0002-0336-2301				Aguilera J, 2001, CURR GENET, V39, P273, DOI 10.1007/s002940100213; Ahn SG, 2001, GENE DEV, V15, P2134, DOI 10.1101/gad.894801; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; Boscheinen O, 1997, MOL GEN GENET, V255, P322, DOI 10.1007/s004380050503; Chen TX, 2002, P NATL ACAD SCI USA, V99, P1200, DOI 10.1073/pnas.032681299; Chen ZD, 1998, NUCLEIC ACIDS RES, V26, P1126, DOI 10.1093/nar/26.4.1126; Corey LL, 2003, GENE DEV, V17, P1392, DOI 10.1101/gad.1071803; CUNNIFF NFA, 1993, J BIOL CHEM, V268, P8317; Erkine AM, 1996, MOL CELL BIOL, V16, P7004; Erkine AM, 1999, MOL CELL BIOL, V19, P1627; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; FLICK KE, 1994, J BIOL CHEM, V269, P12475; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; GALLO GJ, 1991, MOL CELL BIOL, V11, P281, DOI 10.1128/MCB.11.1.281; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GROSS DS, 1993, EMBO J, V12, P3931, DOI 10.1002/j.1460-2075.1993.tb06071.x; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; Hashikawa N, 2006, J BIOL CHEM, V281, P3936, DOI 10.1074/jbc.M510827200; Hashikawa N, 2004, MOL CELL BIOL, V24, P3648, DOI 10.1128/MCB.24.9.3648-3659.2004; HASHIKAWA N, 2007, J BIOL CHEM, DOI DOI 10.1074/JBC.M908890199; Imazu H, 2005, EUKARYOT CELL, V4, P1050, DOI 10.1128/EC.4.6.1050-1056.2005; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; Liu Xiao-Dong, 1996, Genes and Development, V10, P592, DOI 10.1101/gad.10.5.592; Manuel M, 2002, EUR J BIOCHEM, V269, P2527, DOI 10.1046/j.1432-1033.2002.02917.x; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; PEDERSON DS, 1994, MOL CELL BIOL, V14, P189, DOI 10.1128/MCB.14.1.189; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Sakurai H, 2003, GENES CELLS, V8, P951, DOI 10.1046/j.1356-9597.2003.00689.x; Sakurai H, 2001, BIOCHEM BIOPH RES CO, V285, P696, DOI 10.1006/bbrc.2001.5234; Saltsman KA, 1999, MOL GEN GENET, V261, P161, DOI 10.1007/s004380050953; Santoro N, 1998, MOL CELL BIOL, V18, P6340, DOI 10.1128/MCB.18.11.6340; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; SILAR P, 1991, MOL CELL BIOL, V11, P1232, DOI 10.1128/MCB.11.3.1232; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; Tachibana T, 2002, J BIOL CHEM, V277, P22140, DOI 10.1074/jbc.M201267200; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; Trinklein ND, 2004, CELL STRESS CHAPERON, V9, P21, DOI 10.1379/1466-1268(2004)009<0021:TRABOH>2.0.CO;2; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Voellmy R, 2004, CELL STRESS CHAPERON, V9, P122, DOI 10.1379/CSC-14R.1; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; Yamamoto A, 2006, BIOCHEM BIOPH RES CO, V346, P1324, DOI 10.1016/j.bbrc.2006.06.057; YANG WM, 1991, MOL CELL BIOL, V11, P3676, DOI 10.1128/MCB.11.7.3676; YOUNG MR, 1993, MOL CELL BIOL, V13, P5637, DOI 10.1128/MCB.13.9.5637	63	37	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13334	13341		10.1074/jbc.M611801200	http://dx.doi.org/10.1074/jbc.M611801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17347150	hybrid			2022-12-27	WOS:000246060300021
J	Yang, DH; Cai, KQ; Roland, IH; Smith, ER; Xu, XX				Yang, Dong-Hua; Cai, Kathy Q.; Roland, Isabelle H.; Smith, Elizabeth R.; Xu, Xiang-Xi			Disabled-2 is an epithelial surface positioning gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; PRIMITIVE ENDODERM; SIGNALING PATHWAY; VISCERAL ENDODERM; PARIETAL ENDODERM; RETINOIC ACID; CELL-ADHESION; MOUSE; DAB2; OVARIAN	The formation of the primitive endoderm layer on the surface of the inner cell mass is one of the earliest epithelial morphogenesis in mammalian embryos. In mouse embryos deficient of Disabled2 (Dab2), the primitive endoderm cells lose the ability to position on the surface, resulting in defective morphogenesis. Embryonic stem cells lacking Dab2 are also unable to position on the surface of cell aggregates and fail to form a primitive endoderm outer layer in the embryoid bodies. The cellular function of Dab2, a cargo-selective adaptor, in mediating endocytic trafficking of clathrin-coated vesicles is well established. We show here that Dab2 mediates directional trafficking and polarized distribution of cell surface proteins such as megalin and E-cadherin and propose that loss of polarity is the underlying mechanism for the loss of epithelial cell surface positioning in Dab2-deficient embryos and embryoid bodies. Thus, the findings indicate that Dab2 is a surface positioning gene and suggest a novel mechanism of epithelial cell surface targeting.	Fox Chase Canc Ctr, Ovarian Canc & Tumor Cell Biol Programs, Dept Med Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Ovarian Canc & Tumor Cell Biol Programs, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Xiangxi.Xu@fccc.edu			NCI NIH HHS [CA75389, CA79716, CA006927, R01 CA095071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079716, P30CA006927, R01CA095071, R01CA075389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON ED, 1979, CELL, V16, P953, DOI 10.1016/0092-8674(79)90110-7; Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Bielinska M, 1999, INT J DEV BIOL, V43, P183; BIRCHMEIER W, 1999, EPITHELIAL MORPHOGEN; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Capo-chichi CD, 2005, DEV BIOL, V286, P574, DOI 10.1016/j.ydbio.2005.07.037; Chazaud C, 2006, DEV CELL, V10, P615, DOI 10.1016/j.devcel.2006.02.020; CLARK WH, 1995, ACTA ONCOL, V34, P3, DOI 10.3109/02841869509093632; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; FOWLER KJ, 1990, EXP CELL RES, V191, P194, DOI 10.1016/0014-4827(90)90005-U; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GUETHHALLONET C, 1994, DEVELOPMENT, V120, P3289; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Kamikura DM, 2003, GENE DEV, V17, P2798, DOI 10.1101/gad.1136103; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Liebl EC, 2003, DEVELOPMENT, V130, P3217, DOI 10.1242/dev.00545; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Matthews P, 2000, SIGHT SOUND, V10, P42; Maurer ME, 2005, J CELL SCI, V118, P5345, DOI 10.1242/jcs.02650; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2002, EMBO J, V21, P1555, DOI 10.1093/emboj/21.7.1555; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Nagai J, 2005, AM J PHYSIOL-RENAL, V289, pF569, DOI 10.1152/ajprenal.00292.2004; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Rice DS, 1998, DEVELOPMENT, V125, P3719; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; Rossant J, 2003, PHILOS T ROY SOC B, V358, P1341, DOI 10.1098/rstb.2003.1329; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Wolpert L., 2002, PRINCIPLES DEV; Yang DH, 2002, DEV BIOL, V251, P27, DOI 10.1006/dbio.2002.0810; Yang DH, 2002, CANCER-AM CANCER SOC, V94, P2380, DOI 10.1002/cncr.10497; Yang DH, 2006, AM J PATHOL, V169, P258, DOI 10.2353/ajpath.2006.060036	53	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13114	13122		10.1074/jbc.M611356200	http://dx.doi.org/10.1074/jbc.M611356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17339320	hybrid			2022-12-27	WOS:000245942800079
J	Lin, Q; Weis, S; Yang, G; Weng, YH; Helston, R; Rish, K; Smith, A; Bordner, J; Polte, T; Gaunitz, F; Dennery, PA				Lin, Qing; Weis, Sebastian; Yang, Guang; Weng, Yi-Hao; Helston, Rachel; Rish, Kimberly; Smith, Ann; Bordner, Jessica; Polte, Tobias; Gaunitz, Frank; Dennery, Phyllis A.			Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; MOUSE HEPATOMA-CELLS; HYDROGEN-PEROXIDE; OXIDANT STRESS; MU-CALPAIN; GENE; INDUCTION; EXPORT; PROLIFERATION; PATHWAY	Heme oxygenase-1 (HO-1), the rate-limiting enzyme in heme degradation, is an integral membrane protein of the smooth endoplasmic reticulum. However, we detected an HO-1 immunoreactive signal in the nucleus of cultured cells after exposure to hypoxia and heme or heme/hemopexin. Under these conditions, a faster migrating HO-1 immunoreactive band was enriched in nuclear extracts, suggesting that HO-1 was cleaved to allow nuclear entry. This was confirmed by the absence of immunoreactive signal with an antibody against the C terminus and the lack of a C-terminal sequence by gas chromatography-mass spectrometry. Incubation with leptomycin B prior to hypoxia abolished nuclear HO-1 and the faster migrating band on Western analysis, suggesting that this process was facilitated by CRM1. Furthermore, preincubation with a cysteine protease inhibitor prevented nuclear entry of green fluorescent protein-labeled HO-1, demonstrating that protease-mediated C-terminal cleavage was also necessary for nuclear transport of HO-1. Nuclear localization was also associated with reduction of HO activity. HO-1 protein, whether it was enzymatically active or not, mediated activation of oxidant-responsive transcription factors, including activator protein-1. Nevertheless, nuclear HO-1 protected cells against hydrogen peroxide-mediated injury equally as well as cytoplasmic HO-1. We speculate that nuclear localization of HO-1 protein may serve to up-regulate genes that promote cytoprotection against oxidative stress.	Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Stanford Univ, Dept Pediat, Palo Alto, CA 94305 USA; Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA; Univ Leipzig, Interdisziplinares Zentrum, D-04107 Leipzig, Germany	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Stanford University; University of Missouri System; University of Missouri Kansas City; Leipzig University	Dennery, PA (corresponding author), Childrens Hosp, Div Neonatol, 34th & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	dennery@email.chop.edu	Weis, Sebastian/P-9016-2014; Gaunitz, Frank/A-2641-2008; Dennery, Phyllis/GQG-9113-2022	Weis, Sebastian/0000-0003-3201-2375; Gaunitz, Frank/0000-0001-6628-0605; Dennery, Phyllis/0000-0001-5745-1855; Helston, Rachel/0000-0001-6022-6755	NHLBI NIH HHS [HL 58752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Alam J, 2003, CURR PHARM DESIGN, V9, P2499, DOI 10.2174/1381612033453730; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1989, J BIOL CHEM, V264, P6371; APPLEGATE LA, 1991, CANCER RES, V51, P974; Bhattacharya A, 2003, CANCER RES, V63, P8167; BRODERSEN R, 1979, J BIOL CHEM, V254, P2364; Chen M, 2005, BIOCHEM BIOPH RES CO, V330, P714, DOI 10.1016/j.bbrc.2005.03.029; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Dennery PA, 1998, J CLIN INVEST, V101, P1001, DOI 10.1172/JCI448; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; Hajdena-Dawson Monica, 2003, Mol Imaging, V2, P138, DOI 10.1162/153535003322556886; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Hori R, 2002, J BIOL CHEM, V277, P10712, DOI 10.1074/jbc.M107749200; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Jager R, 2003, MOL CANCER RES, V1, P921; KEYSE SM, 1990, CARCINOGENESIS, V11, P787, DOI 10.1093/carcin/11.5.787; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kim HP, 2004, FASEB J, V18, P1080, DOI 10.1096/fj.03-1391com; Kitchin KT, 2001, J IMMUNOL METHODS, V247, P153, DOI 10.1016/S0022-1759(00)00325-2; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kravets A, 2004, J BIOL CHEM, V279, P19916, DOI 10.1074/jbc.M314251200; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lischka P, 2006, J VIROL, V80, P10274, DOI 10.1128/JVI.00995-06; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MORGAN WT, 1988, J BIOL CHEM, V263, P8226; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u; Pae HO, 2004, J IMMUNOL, V172, P4744, DOI 10.4049/jimmunol.172.8.4744; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046; Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; SMITH A, 1988, BIOCHEM J, V256, P941, DOI 10.1042/bj2560941; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Taille C, 2003, J BIOL CHEM, V278, P27160, DOI 10.1074/jbc.M300364200; Tsutsumi S, 2003, CANCER RES, V63, P4882; Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501-4513.2005; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802; Weng YH, 2003, J BIOL CHEM, V278, P50999, DOI 10.1074/jbc.M307644200; Wilks A, 1998, BIOCHEMISTRY-US, V37, P2889, DOI 10.1021/bi972720x; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yan JL, 2004, NAT STRUCT MOL BIOL, V11, P901, DOI 10.1038/nsmb819; Yang G, 2004, J CLIN INVEST, V114, P669, DOI 10.1172/JCI200419300; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; YOSHIDA T, 1991, EUR J BIOCHEM, V199, P729, DOI 10.1111/j.1432-1033.1991.tb16177.x; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7803; ZHANG J, 1992, J CLIN INVEST, V90, P1193, DOI 10.1172/JCI115980; Zhang XC, 2005, J BIOL CHEM, V280, P8714, DOI 10.1074/jbc.M408092200	61	313	323	4	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2007	282	28					20621	20633		10.1074/jbc.M607954200	http://dx.doi.org/10.1074/jbc.M607954200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	187AI	17430897	hybrid			2022-12-27	WOS:000247819300065
J	Koller-Eichhorn, R; Marquardt, T; Gail, R; Wittinghofer, A; Kostrewa, D; Kutay, U; Kambach, C				Koller-Eichhorn, Roland; Marquardt, Tobias; Gail, Robert; Wittinghofer, Alfred; Kostrewa, Dirk; Kutay, Ulrike; Kambach, Christian			Human OLA1 defines an ATPase subfamily in the Obg family of GTP-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; P-LOOP; SWITCH; RAS; TRANSLATION; VALIDATION; EVOLUTION; GTPASES; YCHF; P21	Purine nucleotide-binding proteins build the large family of P-loop GTPases and related ATPases, which perform essential functions in all kingdoms of life. The Obg family comprises a group of ancient GTPases belonging to the TRAFAC (for translation factors) class and can be subdivided into several distinct protein subfamilies. The founding member of one of these subfamilies is the bacterial P-loop NTPase YchF, which had so far been assumed to act as GTPase. We have biochemically characterized the human homologue of YchF and found that it binds and hydrolyzes ATP more efficiently than GTP. For this reason, we have termed the protein hOLA1, for human Obg-like ATPase 1. Further biochemical characterization of YchF proteins from different species revealed that ATPase activity is a general but previously missed feature of the YchF subfamily of Obg-like GTPases. To explain ATP specificity of hOLA1, we have solved the x-ray structure of hOLA1 bound to the nonhydrolyzable ATP analogue AMPPCP. Our structural data help to explain the altered nucleotide specificity of YchF homologues and identify the Ola1/YchF subfamily of the Obg-related NTPases as an exceptional example of a single protein subfamily, which has evolved altered nucleotide specificity within a distinct protein family of GTPases.	ETH, Inst Biochem, CH-8093 Zurich, Switzerland; Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Max Planck Society	Kutay, U (corresponding author), ETH, Inst Biochem, Schafmattstr 18, CH-8093 Zurich, Switzerland.	ulrike.kutay@bc.biol.ethz.ch; christian.kambach@psi.ch						Buglino J, 2002, STRUCTURE, V10, P1581, DOI 10.1016/S0969-2126(02)00882-1; Caldon CE, 2003, CURR OPIN MICROBIOL, V6, P135, DOI 10.1016/S1369-5274(03)00037-7; Caldon CE, 2001, MOL MICROBIOL, V41, P289, DOI 10.1046/j.1365-2958.2001.02536.x; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Danese I, 2004, INFECT IMMUN, V72, P5783, DOI 10.1128/IAI.72.10.5783-5790.2004; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Lin B, 1999, J BACTERIOL, V181, P5825, DOI 10.1128/JB.181.18.5825-5832.1999; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Michel B, 2005, DEV CELL, V8, P300, DOI 10.1016/j.devcel.2005.02.002; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P21; Morimoto T, 2002, MICROBIOL-SGM, V148, P3539, DOI 10.1099/00221287-148-11-3539; NUR EKMS, 1992, MOL BIOL CELL, V3, P1437; Paduch M, 2001, ACTA BIOCHIM POL, V48, P829; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Schwarzenbacher R, 2004, ACTA CRYSTALLOGR D, V60, P1229, DOI 10.1107/S0907444904010145; Sikora AE, 2006, BIOCHEM BIOPH RES CO, V339, P1165, DOI 10.1016/j.bbrc.2005.11.129; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Teplyakov A, 2003, J BACTERIOL, V185, P4031, DOI 10.1128/JB.185.14.4031-4037.2003; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; WELSH KM, 1994, J BACTERIOL, V176, P7161, DOI 10.1128/JB.176.23.7161-7168.1994; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	32	68	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19928	19937		10.1074/jbc.M700541200	http://dx.doi.org/10.1074/jbc.M700541200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17430889	hybrid, Green Published			2022-12-27	WOS:000247650600067
J	Kirmse, R; Portet, S; Mucke, N; Aebi, U; Herrmann, H; Langowski, J				Kirmse, Robert; Portet, Stephanie; Muecke, Norbert; Aebi, Ueli; Herrmann, Harald; Langowski, Jorg			A quantitative kinetic model for the in vitro assembly of intermediate filaments from tetrameric vimentin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; ACTIN; ARCHITECTURE; NUCLEATION; PROTEINS; DYNAMICS; ELEMENTS; DISEASE; UNITS	In vitro assembly of intermediate filament proteins is a very rapid process. It starts without significant delay by lateral association of tetramer complexes into unit-length filaments (ULFs) after raising the ionic strength from low salt to physiological conditions ( 100 mM KCl). We employed electron and scanning force microscopy complemented by mathematical modeling to investigate the kinetics of in vitro assembly of human recombinant vimentin. From the average length distributions of the resulting filaments measured at increasing assembly times we simulated filament assembly and estimated specific reaction rate parameters. We modeled eight different potential pathways for vimentin filament elongation. Comparing the numerical with the experimental data we conclude that a two-step mechanism involving rapid formation of ULFs followed by ULF and filament annealing is the most robust scenario for vimentin assembly. These findings agree with the first two steps of the previously proposed three-step assembly model (Herrmann, H., and Aebi, U. ( 1998) Curr. Opin. Struct. Biol. 8, 177 - 185). In particular, our modeling clearly demonstrates that end-to-end annealing of ULFs and filaments is obligatory for forming long filaments, whereas tetramer addition to filament ends does not contribute significantly to filament elongation.	German Canc Res Ctr, Div Biophys Macromol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Mol Genet, D-69120 Heidelberg, Germany; Univ Manitoba, Dept Math, Winnipeg, MB R3T 2N2, Canada; Univ Basel, Inst Biol Struct, CH-4056 Basel, Switzerland	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Manitoba; University of Basel	Langowski, J (corresponding author), German Canc Res Ctr, Div Biophys Macromol, D-69120 Heidelberg, Germany.	jl@dkfz.de	Langowski, Jörg/A-1843-2011	Langowski, Jörg/0000-0001-8600-0666; Portet, Stephanie/0000-0002-8802-8184; Mucke, Norbert/0000-0002-0683-4386				Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Ando S, 2004, BBA-PROTEINS PROTEOM, V1702, P53, DOI 10.1016/j.bbapap.2004.07.008; Andrianantoandro E, 2006, MOL CELL, V24, P13, DOI 10.1016/j.molcel.2006.08.006; Bar H, 2004, J STRUCT BIOL, V148, P137, DOI 10.1016/j.jsb.2004.04.003; Bar H, 2005, P NATL ACAD SCI USA, V102, P15099, DOI 10.1073/pnas.0504568102; Chang L, 2006, J CELL BIOL, V172, P747, DOI 10.1083/jcb.200511033; FARDEAU M, 2007, HUM MUTAT, V28, P374; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Goldfarb LG, 2004, BRAIN, V127, P723, DOI 10.1093/brain/awh033; Helfand BT, 2004, J CELL SCI, V117, P133, DOI 10.1242/jcs.00936; Helfand BT, 2003, J CELL SCI, V116, P2345, DOI 10.1242/jcs.00526; Herrmann H, 2004, ANNU REV BIOCHEM, V73, P749, DOI 10.1146/annurev.biochem.73.011303.073823; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Herrmann H, 1999, J MOL BIOL, V286, P1403, DOI 10.1006/jmbi.1999.2528; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Herrmann H, 2003, INT REV CYTOL, V223, P83; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; Kaminska A, 2004, HUM GENET, V114, P306, DOI 10.1007/s00439-003-1057-7; Kerssemakers JWJ, 2006, NATURE, V442, P709, DOI 10.1038/nature04928; Mucke N, 2005, J STRUCT BIOL, V150, P268, DOI 10.1016/j.jsb.2005.02.012; Mucke N, 2004, J MOL BIOL, V340, P97, DOI 10.1016/j.jmb.2004.04.039; Mucke N, 2004, J MOL BIOL, V335, P1241, DOI 10.1016/j.jmb.2003.11.038; Omary MB, 2006, TRENDS BIOCHEM SCI, V31, P383, DOI 10.1016/j.tibs.2006.05.008; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; Oosawa F, 2000, GENES CELLS, V5, P9, DOI 10.1046/j.1365-2443.2000.00304.x; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; OOSAWA F, 1975, THERMODYNAMICS POLYM, P41; PARRY DAD, 1995, INTERMEDIATE FILAMEN; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Pollard Thomas D, 2002, Harvey Lect, V98, P1; Prahlad V, 1998, J CELL BIOL, V143, P159, DOI 10.1083/jcb.143.1.159; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; Sokolova AV, 2006, P NATL ACAD SCI USA, V103, P16206, DOI 10.1073/pnas.0603629103; STEINERT PM, 1982, BIOCHEMISTRY-US, V21, P177, DOI 10.1021/bi00530a030; TIMASHEFF SN, 1980, ANNU REV BIOCHEM, V49, P565, DOI 10.1146/annurev.bi.49.070180.003025; VOTER WA, 1984, J BIOL CHEM, V259, P430; WEGNER A, 1975, BIOPHYS CHEM, V3, P215, DOI 10.1016/0301-4622(75)80013-5	37	64	64	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18563	18572		10.1074/jbc.M701063200	http://dx.doi.org/10.1074/jbc.M701063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17403663	hybrid			2022-12-27	WOS:000247302000061
J	Kuttner-Kondo, L; Hourcade, DE; Anderson, VE; Muqim, N; Mitchell, L; Soares, DC; Barlow, PN; Medof, ME				Kuttner-Kondo, Lisa; Hourcade, Dennis E.; Anderson, Vernon E.; Muqim, Nasima; Mitchell, Lynne; Soares, Dinesh C.; Barlow, Paul N.; Medof, M. Edward			Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT CONTROL PROTEIN; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; MEMBRANE COFACTOR PROTEIN; RECEPTOR-TYPE 1; HERPESVIRUS HUMAN-HERPESVIRUS-8; REGULATORY ACTIVITY; FUNCTIONAL DOMAINS; ALPHA-CHAIN; INHIBITOR; CD35	Focused complement activation on foreign targets depends on regulatory proteins that decay the bimolecular C3 convertases. Although this process is central to complement control, how the convertases engage and disassemble is not established. The second and third complement control protein (CCP) modules of the cell surface regulator, decay-accelerating factor (DAF, CD55), comprise the simplest structure mediating this activity. Positioning the functional effects of 31 substitution mutants of DAF CCP2 to - 4 on partial structures was previously reported. In light of the high resolution crystal structure of the DAF four-CCP functional region, we now reexamine the effects of these and 40 additional mutations. Moreover, we map six monoclonal antibody epitopes and overlap their effects with those of the amino acid substitutions. The data indicate that the interaction of DAF with the convertases is mediated predominantly by two patches similar to 13 angstrom apart, one centered around Arg(69) and Arg(96) on CCP2 and the other around Phe(148) and Leu(171) on CCP3. These patches on the same face of the adjacent modules bracket an intermodular linker of critical length ( 16 angstrom). Although the key DAF residues in these patches are present or there are conservative substitutions in all other C3 convertase regulators that mediate decay acceleration and/or provide factor I-cofactor activity, the linker region is highly conserved only in the former. Intra-CCP regions also differ. Linker region comparisons suggest that the active CCPs of the decay accelerators are extended, whereas those of the cofactors are tilted. Intra-CCP comparisons suggest that the two classes of regulators bind different regions on their respective ligands.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Univ Edinburgh, Sch Chem, Inst Struct & Mol Biol, Edinburgh EH9 3JJ, Midlothian, Scotland	Case Western Reserve University; Case Western Reserve University; Washington University (WUSTL); University of Edinburgh	Medof, ME (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, 2085 Adelbert Rd,RM 301, Cleveland, OH 44106 USA.	mxm16@po.cwru.edu	Soares, Dinesh C/A-4425-2012; Barlow, Paul N/G-2853-2011	Soares, Dinesh C/0000-0001-7557-0495; Anderson, Vernon Emmett/0000-0002-1699-7621	Medical Research Council [G0001089] Funding Source: Medline; NIAID NIH HHS [R01 AI23598, R01 AI05143] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER; MRC [G0001089] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Bhella D, 2004, J BIOL CHEM, V279, P8325, DOI 10.1074/jbc.M311334200; Blom AM, 2000, MOL IMMUNOL, V37, P445, DOI 10.1016/S0161-5890(00)00059-6; Blom AM, 2003, J BIOL CHEM, V278, P43437, DOI 10.1074/jbc.M306620200; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; Brodbeck WG, 1997, TRANSFUS CLIN BIOL, V4, P125, DOI 10.1016/S1246-7820(97)80026-2; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; COYNE KE, 1992, J IMMUNOL, V149, P2906; Hourcade DE, 1999, IMMUNOPHARMACOLOGY, V42, P167, DOI 10.1016/S0162-3109(99)00005-3; IIDA K, 1981, J EXP MED, V153, P1138, DOI 10.1084/jem.153.5.1138; KIM YU, 1995, J EXP MED, V181, P151, DOI 10.1084/jem.181.1.151; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; Kraus DM, 2006, J IMMUNOL, V176, P4419, DOI 10.4049/jimmunol.176.7.4419; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; Krych-Goldberg M, 1999, J BIOL CHEM, V274, P31160, DOI 10.1074/jbc.274.44.31160; Krych-Goldberg M, 2005, J IMMUNOL, V175, P4528, DOI 10.4049/jimmunol.175.7.4528; Krych-Goldberg M, 2001, IMMUNOL REV, V180, P112, DOI 10.1034/j.1600-065X.2001.1800110.x; Kuttner-Kondo LA, 2001, J IMMUNOL, V167, P2164, DOI 10.4049/jimmunol.167.4.2164; Liszewski MK, 2006, J IMMUNOL, V176, P3725, DOI 10.4049/jimmunol.176.6.3725; Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200; LUBLIN DM, 1986, J IMMUNOL, V137, P1629; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; Mark L, 2004, J BIOL CHEM, V279, P45093, DOI 10.1074/jbc.M407558200; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MORGAN BP, 1999, COMPLEMENT REGULATOR, P1; Mullick J, 2005, J VIROL, V79, P12382, DOI 10.1128/JVI.79.19.12382-12393.2005; Mullick J, 2005, J VIROL, V79, P5850, DOI 10.1128/JVI.79.9.5850-5856.2005; Mullick J, 2003, J VIROL, V77, P3878, DOI 10.1128/JVI.77.6.3878-3881.2003; Rosengard AM, 2002, P NATL ACAD SCI USA, V99, P8808, DOI 10.1073/pnas.112220499; Sfyroera G, 2005, J IMMUNOL, V174, P2143, DOI 10.4049/jimmunol.174.4.2143; Singh AK, 2006, J BIOL CHEM, V281, P23119, DOI 10.1074/jbc.M603085200; Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4; Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19; STAFFORD HA, 1988, P NATL ACAD SCI USA, V85, P880, DOI 10.1073/pnas.85.3.880; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; Williams P, 2003, J BIOL CHEM, V278, P10691, DOI 10.1074/jbc.M212561200; Zhang L, 2006, BIOPHYS J, V90, P3106, DOI 10.1529/biophysj.105.068130	41	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18552	18562		10.1074/jbc.M611650200	http://dx.doi.org/10.1074/jbc.M611650200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17395591	hybrid			2022-12-27	WOS:000247302000060
J	Kicinska, A; Swida, A; Bednarczyk, P; Koszela-Piotrowska, I; Choma, K; Dolowy, K; Szewczyk, A; Jarmuszkiewicz, W				Kicinska, Anna; Swida, Aleksandra; Bednarczyk, Piotr; Koszela-Piotrowska, Izabela; Choma, Katarzyna; Dolowy, Krzysztof; Szewczyk, Adam; Jarmuszkiewicz, Wieslawa			ATP-sensitive potassium channel in mitochondria of the eukaryotic microorganism Acanthamoeba castellanii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; PLANT-MITOCHONDRIA; PERMEABILITY TRANSITION; ALTERNATIVE OXIDASE; HEART-MITOCHONDRIA; INNER MEMBRANE; STEADY-STATE; OPENERS; 5-HYDROXYDECANOATE; IDENTIFICATION	We describe the existence of a potassium ion transport mechanism in the mitochondrial inner membrane of a lower eukaryotic organism, Acanthamoeba castellanii. We found that substances known to modulate potassium channel activity influenced the bioenergetics of A. castellanii mitochondria. In isolated mitochondria, the rate of resting respiration is increased by about 10% in response to potassium channel openers, i.e. diazoxide and BMS-191095, during succinate-, malate-, or NADH-sustained respiration. This effect is strictly dependent on the presence of potassium ions in an incubation medium and is reversed by glibenclamide (a potassium channel blocker). Diazoxide and BMS-191095 also caused a slight but statistically significant depolarization of mitochondrial membrane potential (measured with a TPP+- specific electrode), regardless of the respiratory substrate used. The resulting steady state value of membrane potential was restored after treatment with glibenclamide or 1 mM ATP. Additionally, the electrophysiological properties of potassium channels present in the A. castellanii inner mitochondrial membrane are described in the reconstituted system, using black lipid membranes. Conductance from 90 +/- 7 to 166 +/- 10 picosiemens, inhibition by 1mM ATP/ Mg2+ or glibenclamide, and activation by diazoxide were observed. These results suggest that an ATP- sensitive potassium channel similar to that of mammalian mitochondria is present in A. castellanii mitochondria.	Adam Mickiewicz Univ, Lab Bioenerget, PL-61614 Poznan, Poland; M Nencki Inst Expt Biol, Lab Intracellular Ion Channels, PL-02093 Warsaw, Poland; Agr Univ Warsaw, Dept Biophys, PL-02766 Warsaw, Poland	Adam Mickiewicz University; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Warsaw University of Life Sciences	Jarmuszkiewicz, W (corresponding author), Adam Mickiewicz Univ, Lab Bioenerget, Umultowska 89, PL-61614 Poznan, Poland.	wiesiaj@amu.edu.pl	Bednarczyk, Piotr/B-4973-2018; Dolowy, Krzysztof/AGG-0462-2022	Bednarczyk, Piotr/0000-0002-7125-0715; Dolowy, Krzysztof/0000-0003-3673-0542; Kicinska, Anna/0000-0003-4293-762X; Szewczyk, Adam/0000-0001-5519-260X; Jarmuszkiewicz, Wieslawa/0000-0001-8550-8337				Ardehali H, 2005, J MOL CELL CARDIOL, V39, P7, DOI 10.1016/j.yjmcc.2004.12.003; Ardehali H, 2004, P NATL ACAD SCI USA, V101, P11880, DOI 10.1073/pnas.0401703101; Bajgar R, 2001, J BIOL CHEM, V276, P33369, DOI 10.1074/jbc.M103320200; Bednarczyk P, 2004, J MEMBRANE BIOL, V199, P63, DOI 10.1007/s00232-004-0676-9; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Cancherini DV, 2003, AM J PHYSIOL-RENAL, V285, pF1291, DOI 10.1152/ajprenal.00103.2003; Dahlem YA, 2004, BBA-BIOENERGETICS, V1656, P46, DOI 10.1016/j.bbabio.2004.01.003; Debska G, 2002, BBA-BIOENERGETICS, V1556, P97, DOI 10.1016/S0005-2728(02)00340-7; Debska G, 2001, BRAIN RES, V892, P42, DOI 10.1016/S0006-8993(00)03187-5; Drose S, 2006, J BIOL CHEM, V281, P23733, DOI 10.1074/jbc.M602570200; Garlid KD, 2003, BBA-BIOENERGETICS, V1606, P23, DOI 10.1016/S0005-2728(03)00108-7; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Garlid KD, 2006, AM J PHYSIOL-HEART C, V291, pH152, DOI 10.1152/ajpheart.01233.2005; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Grover GJ, 2001, J PHARMACOL EXP THER, V297, P1184; Hille B, 2001, SELECTIVE PERMEABILI, P441; Hordejuk R, 2004, MOL MEMBR BIOL, V21, P307, DOI 10.1080/10647440400003899; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Jaburek M, 1998, J BIOL CHEM, V273, P13578; Jarmuszkiewicz W, 1997, FEBS LETT, V411, P110, DOI 10.1016/S0014-5793(97)00676-5; Jarmuszkiewicz W, 1998, J BIOL CHEM, V273, P10174, DOI 10.1074/jbc.273.17.10174; Jarmuszkiewicz W, 2001, BIOSCIENCE REP, V21, P213, DOI 10.1023/A:1013656510245; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kopustinskiene DM, 2003, J BIOENERG BIOMEMBR, V35, P141, DOI 10.1023/A:1023746103401; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; Mackenzie S, 1999, PLANT CELL, V11, P571, DOI 10.1105/tpc.11.4.571; Mannhold R, 2006, CURR TOP MED CHEM, V6, P1031, DOI 10.2174/156802606777323647; O'Rourke B, 2007, ANNU REV PHYSIOL, V69, P19, DOI 10.1146/annurev.physiol.69.031905.163804; Pastore D, 1999, J BIOL CHEM, V274, P26683, DOI 10.1074/jbc.274.38.26683; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Ruy F, 2004, J BIOENERG BIOMEMBR, V36, P195, DOI 10.1023/B:JOBB.0000023623.70126.04; Sluse FE, 2002, HANDBOOK OF PLANT GROWTH: PH AS THE MASTER VARIABLE, P173; Suzuki M, 1997, BIOCHEM BIOPH RES CO, V241, P693, DOI 10.1006/bbrc.1997.7891; Szewczyk A, 2006, BBA-BIOENERGETICS, V1757, P715, DOI 10.1016/j.bbabio.2006.05.002; Tsujimoto Y, 2006, BBA-BIOENERGETICS, V1757, P1297, DOI 10.1016/j.bbabio.2006.03.017; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; Wojtkowska M, 2005, J BIOENERG BIOMEMBR, V37, P261, DOI 10.1007/s10863-005-6636-y; Zhou M, 1999, MOL BRAIN RES, V74, P15, DOI 10.1016/S0169-328X(99)00232-6	38	47	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17433	17441		10.1074/jbc.M701496200	http://dx.doi.org/10.1074/jbc.M701496200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430885	hybrid			2022-12-27	WOS:000247084500013
J	Bandyopadhyay, B; Li, GB; Yin, HS; Kuret, J				Bandyopadhyay, Bhaswati; Li, Guibin; Yin, Haishan; Kuret, Jeff			Tau aggregation and toxicity in a cell culture model of tauopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED-HELICAL FILAMENTS; GLYCOGEN-SYNTHASE KINASE-3-BETA; UBIQUITIN-PROTEASOME SYSTEM; ALZHEIMERS-DISEASE; PHOSPHORYLATED-TAU; NEUROFIBRILLARY TANGLES; CONFORMATIONAL-CHANGES; MEDIATED CYTOTOXICITY; COGNITIVE IMPAIRMENT; MICROTUBULE-BINDING	Intracellular aggregation of the microtubule-associated protein tau into filamentous inclusions is a defining characteristic of Alzheimer disease. Because appearance of tau-aggregate bearing lesions correlates with both cognitive decline and neurodegeneration, it has been hypothesized that tau aggregation may be directly toxic to cells that harbor them. Testing this hypothesis in cell culture has been complicated by the resistance of full-length tau isoforms to aggregation over experimentally tractable time periods. To overcome this limitation, a small-molecule agonist of the tau aggregation reaction, Congo red, was used to drive aggregation within HEK-293 cells expressing full-length tau isoform htau40. Formation of detergent-insoluble aggregates was both time and agonist concentration dependent. At 10 mu M Congo red, detergent-insoluble aggregates appeared with pseudo-first order kinetics and a half-life of approximately 5 days. By 7 days in culture, total tau levels increased 2-fold, with -30% of total tau converted into detergent-insoluble aggregates. Agonist addition also led to rapid losses in the tubulin binding activity of tau, although tau was not hyperphosphorylated as judged by occupancy of phosphorylation sites Ser(396)/ Ser(404). Tau aggregation was associated with decreased viability as detected by ToPro-3 uptake. The results, which establish a new approach for analysis of tau aggregation in cells independent of tau hyperphosphorylation, suggest that conformational changes associated with aggregation are incompatible with microtubule binding, and that toxicity associated with intracellular tau aggregation is not acute but develops over a period of days.	Ohio State Univ, Dept Mol & Cellular Biochem, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kuret, J (corresponding author), 1060 Carmack Rd, Columbus, OH 43210 USA.	kuret.3@osu.edu	Li, Guibin/E-3507-2011		NIA NIH HHS [AG14452] Funding Source: Medline; NINDS NIH HHS [P30-NS045758] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS045758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014452] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Andorfer C, 2005, J NEUROSCI, V25, P5446, DOI 10.1523/JNEUROSCI.4637-04.2005; Apostol BL, 2003, P NATL ACAD SCI USA, V100, P5950, DOI 10.1073/pnas.2628045100; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Bao YP, 2004, J MED GENET, V41, P47, DOI 10.1136/jmg.2003.014548; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bennett EJ, 2005, MOL CELL, V17, P351, DOI 10.1016/j.molcel.2004.12.021; BERLIN CM, 1965, MOL PHARMACOL, V1, P149; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Chambard JM, 2003, J PHYSIOL-LONDON, V550, P667, DOI 10.1113/jphysiol.2003.039321; Chirita C, 2004, BIOCHEMISTRY-US, V43, P2879, DOI 10.1021/bi036094h; Chirita CN, 2005, BIOCHEMISTRY-US, V44, P5862, DOI 10.1021/bi0500123; David DC, 2002, J NEUROCHEM, V83, P176, DOI 10.1046/j.1471-4159.2002.01137.x; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; DiTella MC, 1996, J CELL SCI, V109, P467; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; Evans DB, 2000, J BIOL CHEM, V275, P24977, DOI 10.1074/jbc.M000808200; Falke E, 2003, AM J PATHOL, V163, P1615, DOI 10.1016/S0002-9440(10)63518-3; Ghoshal N, 2002, EXP NEUROL, V177, P475, DOI 10.1006/exnr.2002.8014; GOLDSTEIN A, PRINCIPLES DRUG ACTI; GRAY EG, 1987, NEUROPATH APPL NEURO, V13, P91, DOI 10.1111/j.1365-2990.1987.tb00174.x; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Guillozet-Bongaarts AL, 2005, NEUROBIOL AGING, V26, P1015, DOI 10.1016/j.neurobiolaging.2004.09.019; HAMOS JE, 1989, NEUROLOGY, V39, P355, DOI 10.1212/WNL.39.3.355; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Hyman BT, 2005, BBA-MOL BASIS DIS, V1739, P150, DOI 10.1016/j.bbadis.2004.06.015; Ikegami S, 2000, NEUROSCI LETT, V279, P129, DOI 10.1016/S0304-3940(99)00964-7; Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x; KHATOON S, 1992, J NEUROCHEM, V59, P750, DOI 10.1111/j.1471-4159.1992.tb09432.x; KHATOON S, 1994, FEBS LETT, V351, P80, DOI 10.1016/0014-5793(94)00829-9; Khlistunova I, 2006, J BIOL CHEM, V281, P1205, DOI 10.1074/jbc.M507753200; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Kim YS, 2003, J BIOL CHEM, V278, P10842, DOI 10.1074/jbc.M212540200; Kimura T, 1996, DEMENTIA, V7, P177, DOI 10.1159/000106875; King ME, 2001, AM J PATHOL, V158, P1481, DOI 10.1016/S0002-9440(10)64099-0; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; KsiezakReding H, 1996, AM J PATHOL, V149, P639; Kuret J, 2005, MICROSC RES TECHNIQ, V67, P141, DOI 10.1002/jemt.20187; Kuret J, 1997, J NEUROCHEM, V69, P2506; Lee VMY, 1999, METHOD ENZYMOL, V309, P81; Lee-MacAry AE, 2001, J IMMUNOL METHODS, V252, P83, DOI 10.1016/S0022-1759(01)00336-2; Li GB, 2004, J BIOL CHEM, V279, P15938, DOI 10.1074/jbc.M314116200; LOPRESTI P, 1995, P NATL ACAD SCI USA, V92, P10369, DOI 10.1073/pnas.92.22.10369; Lu PJ, 1999, NATURE, V399, P784; Lund ET, 2001, J NEUROCHEM, V76, P1221, DOI 10.1046/j.1471-4159.2001.00130.x; Margittai M, 2004, P NATL ACAD SCI USA, V101, P10278, DOI 10.1073/pnas.0401911101; Mitchell TW, 2000, J HISTOCHEM CYTOCHEM, V48, P1627, DOI 10.1177/002215540004801206; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Morfini G, 2005, TRENDS MOL MED, V11, P64, DOI 10.1016/j.molmed.2004.12.002; Necula M, 2004, ANAL BIOCHEM, V329, P238, DOI 10.1016/j.ab.2004.02.023; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Sergeant N, 2003, NEUROSCIENCE, V117, P293, DOI 10.1016/S0306-4522(02)00747-9; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200; Tint I, 1998, J NEUROSCI, V18, P8660; Vila-Ortiz GJ, 2001, CELL MOL NEUROBIOL, V21, P535, DOI 10.1023/A:1013823524302; Vogelsberg-Ragaglia V, 2000, MOL BIOL CELL, V11, P4093, DOI 10.1091/mbc.11.12.4093; Wilkinson RW, 2001, J IMMUNOL METHODS, V258, P183, DOI 10.1016/S0022-1759(01)00474-4; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Wogulis M, 2005, J NEUROSCI, V25, P1071, DOI 10.1523/JNEUROSCI.2381-04.2005; Wyman J, 1990, BINDING LINKAGE FUNC; Yasojima K, 1999, BRAIN RES, V831, P301, DOI 10.1016/S0006-8993(99)01486-9	76	105	111	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16454	16464		10.1074/jbc.M700192200	http://dx.doi.org/10.1074/jbc.M700192200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428800	hybrid			2022-12-27	WOS:000246794300053
J	Leach, MR; Zhang, JW; Zamble, DB				Leach, Michael R.; Zhang, Jie Wei; Zamble, Deborah B.			The role of complex formation between the Escherichia coli hydrogenase accessory factors HypB and SlyD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASES; METAL-BINDING; HELICOBACTER-PYLORI; BRADYRHIZOBIUM-JAPONICUM; PROLYL ISOMERASE; ACTIVE-SITE; MUTATIONAL ANALYSIS; CHAPERONE FUNCTION; NIFE-HYDROGENASES; NICKEL-BINDING	The Escherichia coli protein SlyD is a member of the FK-506-binding protein family of peptidylprolyl isomerases. In addition to its peptidylprolyl isomerase domain, SlyD is composed of a molecular chaperone domain and a C-terminal tail rich in potential metal-binding residues. SlyD interacts with the [NiFe]-hydrogenase accessory protein HypB and contributes to nickel insertion during biosynthesis of the hydrogenase metallocenter. This study examines the HypB-SlyD complex and its significance in hydrogenase activation. Protein variants were prepared to delineate the interface between HypB and SlyD. Complex formation requires the HypB linker region located between the high affinity N-terminal Ni(II) site and the GTPase domain of the protein. In the case of SlyD, the deletion of a short loop in the chaperone domain abrogates the interaction with HypB. Mutations in either protein that disrupt complex formation in vitro also result in deficient hydrogenase production in vivo, indicating that the contact between HypB and SlyD is important for hydrogenase maturation. Surprisingly, SlyD stimulates release of nickel from the high affinity Ni(II)-binding site of HypB, an activity that is also disrupted by mutations that affect complex formation. Furthermore, a SlyD truncation lacking the C-terminal metal-binding tail still interacts with HypB but is deficient in stimulating metal release and is not functional in vivo. These results suggest that SlyD could activate metal release from HypB during metallation of the [NiFe] hydrogenase.	Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada	University of Toronto	Zamble, DB (corresponding author), Univ Toronto, Dept Chem, 80 St George St, Toronto, ON M5S 3H6, Canada.	dzamble@chem.utoronto.ca		Zamble, Deborah/0000-0002-8976-3375				Arie JP, 2001, MOL MICROBIOL, V39, P199, DOI 10.1046/j.1365-2958.2001.02250.x; Atanassova A, 2005, J BACTERIOL, V187, P4689, DOI 10.1128/JB.187.14.4689-4697.2005; BALLANTINE SP, 1985, J BACTERIOL, V163, P454, DOI 10.1128/JB.163.2.454-459.1985; Barik S, 2006, CELL MOL LIFE SCI, V63, P2889, DOI 10.1007/s00018-006-6215-3; BEGG YA, 1977, FEMS MICROBIOL LETT, V2, P47, DOI 10.1111/j.1574-6968.1977.tb00905.x; Bernhardt TG, 2002, MOL MICROBIOL, V45, P99, DOI 10.1046/j.1365-2958.2002.02984.x; Blokesch M, 2004, EUR J BIOCHEM, V271, P3428, DOI 10.1111/j.1432-1033.2004.04280.x; Blokesch M, 2004, J BACTERIOL, V186, P2603, DOI 10.1128/JB.186.9.2603-2611.2004; Blokesch M, 2002, BIOCHEM SOC T, V30, P674, DOI 10.1042/BST0300674; Blokesch M, 2004, J MOL BIOL, V344, P155, DOI 10.1016/j.jmb.2004.09.040; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Casalot L, 2001, TRENDS MICROBIOL, V9, P228, DOI 10.1016/S0966-842X(01)02009-1; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; Furutani M, 2000, BIOCHEMISTRY-US, V39, P453, DOI 10.1021/bi9911076; Gasper R, 2006, J BIOL CHEM, V281, P27492, DOI 10.1074/jbc.M600809200; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Ge RG, 2006, BIOCHEM J, V393, P285, DOI 10.1042/BJ20051160; GILBERT JV, 1995, INFECT IMMUN, V63, P2682, DOI 10.1128/IAI.63.7.2682-2688.1995; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Hottenrott S, 1997, J BIOL CHEM, V272, P15697, DOI 10.1074/jbc.272.25.15697; Hube M, 2002, J BACTERIOL, V184, P3879, DOI 10.1128/JB.184.14.3879-3885.2002; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; JACOBI A, 1992, ARCH MICROBIOL, V158, P444; Janowski B, 1997, ANAL BIOCHEM, V252, P299, DOI 10.1006/abio.1997.2330; Kansau I, 1996, MOL MICROBIOL, V22, P1013, DOI 10.1046/j.1365-2958.1996.01536.x; Kuchar J, 2004, CHEM REV, V104, P509, DOI 10.1021/cr020613p; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Leach MR, 2005, BIOCHEMISTRY-US, V44, P12229, DOI 10.1021/bi050993j; Loscher S, 2005, FEBS LETT, V579, P4287, DOI 10.1016/j.febslet.2005.06.063; LUTZ S, 1991, MOL MICROBIOL, V5, P123, DOI 10.1111/j.1365-2958.1991.tb01833.x; MAIER RJ, 2007, BIOMETALS; MAIER T, 1993, J BACTERIOL, V175, P630, DOI 10.1128/JB.175.3.630-635.1993; MAIER T, 1995, EUR J BIOCHEM, V230, P133, DOI 10.1111/j.1432-1033.1995.tb20543.x; McCafferty DG, 1997, BIOCHEMISTRY-US, V36, P10498, DOI 10.1021/bi970543u; Mehta N, 2003, J BACTERIOL, V185, P726, DOI 10.1128/JB.185.3.726-734.2003; Mendel S, 2006, MICROBIOL-SGM, V152, P2959, DOI 10.1099/mic.0.28776-0; Olson JW, 1997, MOL MICROBIOL, V24, P119, DOI 10.1046/j.1365-2958.1997.3251690.x; Olson JW, 2001, MOL MICROBIOL, V39, P176, DOI 10.1046/j.1365-2958.2001.02244.x; Olson JW, 2000, J BACTERIOL, V182, P1702, DOI 10.1128/JB.182.6.1702-1705.2000; Reissmann S, 2003, SCIENCE, V299, P1067, DOI 10.1126/science.1080972; REY L, 1994, J BACTERIOL, V176, P6066, DOI 10.1128/jb.176.19.6066-6073.1994; Rodrigue A, 2005, J BACTERIOL, V187, P2912, DOI 10.1128/JB.187.8.2912-2916.2005; ROOF WD, 1994, J BIOL CHEM, V269, P2902; Roof WD, 1997, MOL MICROBIOL, V25, P1031, DOI 10.1046/j.1365-2958.1997.5201884.x; Rowe JL, 2005, J BACTERIOL, V187, P6317, DOI 10.1128/JB.187.18.6317-6323.2005; Sanokawa-Akakura R, 2004, J BIOL CHEM, V279, P27845, DOI 10.1074/jbc.C400118200; Scholz C, 2006, BIOCHEMISTRY-US, V45, P20, DOI 10.1021/bi051922n; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; Suzuki R, 2003, J MOL BIOL, V328, P1149, DOI 10.1016/S0022-2836(03)00379-6; WAUGH R, 1986, BIOCHIMIE, V68, P157, DOI 10.1016/S0300-9084(86)81080-X; Winter G, 2005, FEBS LETT, V579, P4292, DOI 10.1016/j.febslet.2005.06.064; WULFING C, 1994, J BIOL CHEM, V269, P2895; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang JW, 2005, J BIOL CHEM, V280, P4360, DOI 10.1074/jbc.M411799200	55	67	74	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16177	16186		10.1074/jbc.M610834200	http://dx.doi.org/10.1074/jbc.M610834200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426034	hybrid			2022-12-27	WOS:000246794300026
J	Nomikos, M; Mulgrew-Nesbitt, A; Pallavi, P; Mihalyne, G; Zaitseva, I; Swann, K; Lai, FA; Murray, D; McLaughlin, S				Nomikos, Michail; Mulgrew-Nesbitt, Anna; Pallavi, Payal; Mihalyne, Gyongyi; Zaitseva, Irina; Swann, Karl; Lai, F. Anthony; Murray, Diana; McLaughlin, Stuart			Binding of phosphoinositide-specific phospholipase C-zeta (PLC-zeta) to phospholipid membranes - Potential role of an unstructured cluster of basic residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGGERS CA2+ OSCILLATIONS; EGG ACTIVATION; HIGH-AFFINITY; SPERM FACTOR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ELECTROSTATIC SEQUESTRATION; INOSITOL TRISPHOSPHATE; NUCLEAR TRANSLOCATION; CALCIUM OSCILLATIONS; KINASE SUBSTRATE	Phospholipase C- zeta ( PLC- zeta) is a sperm- specific enzyme that initiates the Ca2+ oscillations in mammalian eggs that activate embryo development. It shares considerable sequence homology with PLC-delta 1, but lacks the PH domain that anchors PLC-delta 1 to phosphatidylinositol 4,5-bisphosphate, PIP2. Thus it is unclear how PLC-zeta interacts with membranes. The linker region between the X and Y catalytic domains of PLC-zeta, however, contains a cluster of basic residues not present in PLC-zeta 1. Application of electrostatic theory to a homology model of PLC-zeta suggests this basic cluster could interact with acidic lipids. We measured the binding of catalytically competent mouse PLC-zeta to phospholipid vesicles: for 2: 1 phosphatidylcholine/phosphatidylserine (PC/ PS) vesicles, the molar partition coefficient, K, is too weak to be of physiological significance. Incorporating 1% PIP2 into the 2: 1 PC/ PS vesicles increases K about 10-fold, to 5 X 103 M-1, a biologically relevant value. Expressed fragments corresponding to the PLC- zeta X-Y linker region also bind with higher affinity to polyvalent than monovalent phosphoinositides on nitrocellulose filters. A peptide corresponding to the basic cluster (charge = +7) within the linker region, PLC-zeta-( 374-385), binds to PC/ PS vesicles with higher affinity than PLC-zeta, but its binding is less sensitive to incorporating PIP2. The acidic residues flanking this basic cluster in PLC-zeta may account for both these phenomena. FRET experiments suggest the basic cluster could not only anchor the protein to the membrane, but also enhance the local concentration of PIP2 adjacent to the catalytic domain.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Cardiff Univ, Sch Med, Wales Heart Res Inst, Cell Signaling Lab, Cardiff CF14 4XN, S Glam, Wales; Cardiff Univ, Sch Med, Dept Obstet & Gynaecol, Cardiff CF14 4XN, S Glam, Wales; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cardiff University; Cardiff University; Cornell University	McLaughlin, S (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	stuart.mclaughlin@stonybrook.edu		Swann, Karl/0000-0002-4355-1449; Lai, Tony/0000-0003-2852-8547; Nomikos, Michail/0000-0001-9761-6327	NIGMS NIH HHS [GM24971] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024971, R37GM024971] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Audhya A, 2003, EMBO J, V22, P4223, DOI 10.1093/emboj/cdg397; Behnia R, 2005, NATURE, V438, P597, DOI 10.1038/nature04397; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; Berney C, 2003, BIOPHYS J, V84, P3992, DOI 10.1016/S0006-3495(03)75126-1; Brind S, 2000, DEV BIOL, V223, P251, DOI 10.1006/dbio.2000.9728; Buser CA, 1998, METH MOL B, V84, P267; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; Cox LJ, 2002, REPRODUCTION, V124, P611, DOI 10.1530/rep.0.1240611; Downes CP, 2005, TRENDS CELL BIOL, V15, P259, DOI 10.1016/j.tcb.2005.03.008; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fujimoto S, 2004, DEV BIOL, V274, P370, DOI 10.1016/j.ydbio.2004.07.025; Gallagher K, 1998, BIOPHYS J, V75, P769, DOI 10.1016/S0006-3495(98)77566-6; Gambhir A, 2004, BIOPHYS J, V86, P2188, DOI 10.1016/S0006-3495(04)74278-2; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Grobler JA, 1996, PROTEIN SCI, V5, P680; Halet G, 2002, J CELL SCI, V115, P2139; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P349, DOI 10.1038/nrm1100; JOENS KT, 2000, BIOCHEM J, V346, P743; Jones KT, 1998, FEBS LETT, V437, P297, DOI 10.1016/S0014-5793(98)01254-X; Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Kouchi Z, 2005, J BIOL CHEM, V280, P21015, DOI 10.1074/jbc.M412123200; Kouchi Z, 2004, J BIOL CHEM, V279, P10408, DOI 10.1074/jbc.M313801200; Kuroda K, 2006, J BIOL CHEM, V281, P27794, DOI 10.1074/jbc.M603473200; Kurokawa M, 2004, BIOL CELL, V96, P37, DOI 10.1016/j.biolcel.2003.11.003; Larman MG, 2004, J CELL SCI, V117, P2513, DOI 10.1242/jcs.01109; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Malcuit C, 2006, J CELL PHYSIOL, V206, P565, DOI 10.1002/jcp.20471; McLaughlin S, 2005, NATURE, V438, P605, DOI 10.1038/nature04398; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Murray D, 1998, BIOCHEMISTRY-US, V37, P2145, DOI 10.1021/bi972012b; Murray D, 2002, CURR TOP MEMBR, V52, P277; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nomikos M, 2005, J BIOL CHEM, V280, P31011, DOI 10.1074/jbc.M500629200; Okada M, 2005, FEBS LETT, V579, P4949, DOI 10.1016/j.febslet.2005.07.082; Okeley NM, 2004, J BIOL CHEM, V279, P21833, DOI 10.1074/jbc.M313469200; Parrington J, 2002, REPRODUCTION, V123, P31, DOI 10.1530/rep.0.1230031; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Petrey D, 2003, PROTEINS, V53, P430, DOI 10.1002/prot.10550; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rice A, 2000, DEV BIOL, V228, P125, DOI 10.1006/dbio.2000.9929; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Saunders CM, 2007, BIOCHEM SOC SYMP, V74, P23, DOI 10.1042/BSS2007c03; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Stallings JD, 2005, J BIOL CHEM, V280, P22060, DOI 10.1074/jbc.M413813200; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Swann K, 2006, SEMIN CELL DEV BIOL, V17, P264, DOI 10.1016/j.semcdb.2006.03.009; Swann K, 2004, REPRODUCTION, V127, P431, DOI 10.1530/rep.1.00169; Wang JY, 2002, J BIOL CHEM, V277, P34401, DOI 10.1074/jbc.M203954200; Wang JY, 2004, BIOPHYS J, V86, P1969, DOI 10.1016/S0006-3495(04)74260-5; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200; Winters MJ, 2005, MOL CELL, V20, P21, DOI 10.1016/j.molcel.2005.08.020; Wu H, 2001, BIOL REPROD, V64, P1338, DOI 10.1095/biolreprod64.5.1338; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Yoda A, 2004, DEV BIOL, V268, P245, DOI 10.1016/j.ydbio.2003.12.028	67	80	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16644	16653		10.1074/jbc.M701072200	http://dx.doi.org/10.1074/jbc.M701072200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430887	hybrid			2022-12-27	WOS:000246794300070
J	Ojala, JRM; Pikkarainen, T; Tuuttila, A; Sandalova, T; Tryggvason, K				Ojala, Juha R. M.; Pikkarainen, Timo; Tuuttila, Ari; Sandalova, Tatyana; Tryggvason, Karl			Crystal structure of the cysteine-rich domain of scavenger receptor MARCO reveals the presence of a basic and an acidic cluster that both contribute to ligand recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIA-BINDING; SRCR DOMAIN; ANTIBACTERIAL PROTEIN; CLONING; ANCIENT; IDENTIFICATION; CONFORMATION; EXPRESSION; SEQUENCE; PROGRAM	MARCO is a trimeric class A scavenger receptor of macrophages and dendritic cells that recognizes polyanionic particles and pathogens. The distal, scavenger receptor cysteine-rich (SRCR) domain of the extracellular part of this receptor has been implicated in ligand binding. To provide a structural basis for understanding the ligand-binding mechanisms of MARCO, we have determined the crystal structure of the mouse MARCO SRCR domain. The recombinant SRCR domain purified as monomeric and dimeric forms, and their structures were determined at 1.78 and 1.77A resolution, respectively. The monomer has a compact globular fold with a twisted five-stranded antiparallel beta-sheet and a long loop covering a single beta-helix, whereas the dimer is formed via beta-strand swapping of two monomers, thus containing a large eight- stranded beta-sheet. Calculation of the surface electrostatic potential revealed that the beta-sheet region with several arginines forms a basic cluster. Unexpectedly, an acidic cluster was found in the long loop region. In the monomer, the acidic cluster is involved in metal ion binding. Studies with cells expressing various SRCR domain mutants showed that all of the arginines of the basic cluster are involved in ligand binding, suggesting a cooperative binding mechanism. Ligand binding is also dependent on the acidic cluster and Ca2+ ions whose depletion appears to affect ligand binding at least by modulating the electrostatic potential or relative domain orientation. We propose that the SRCR domain dimerization can contribute to the recognition of large ligands by providing a means for the MARCO receptor oligomerization.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Tryggvason, K (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, Scheeles Vag 2,B1, S-17177 Stockholm, Sweden.	karl.tryggvason@ki.se		Ojala, Juha/0000-0003-2018-6124; Sandalova, Tatyana/0000-0002-7694-6420				ACTON S, 1993, J BIOL CHEM, V268, P3530; Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; Arredouani MS, 2004, CELL MOL BIOL, V50, P657; Arredouani MS, 2005, J IMMUNOL, V175, P6058, DOI 10.4049/jimmunol.175.9.6058; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bikker FJ, 2004, J BIOL CHEM, V279, P47699, DOI 10.1074/jbc.M406095200; Bikker FJ, 2002, J BIOL CHEM, V277, P32109, DOI 10.1074/jbc.M203788200; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen YY, 2006, J BIOL CHEM, V281, P12767, DOI 10.1074/jbc.M513628200; DeLano W.L, PYMOL MOL GRAPHICS S; DOI T, 1993, J BIOL CHEM, V268, P2126; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Elshourbagy MA, 2000, EUR J BIOCHEM, V267, P919, DOI 10.1046/j.1432-1327.2000.01077.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; HANZAWA H, 1990, FEBS LETT, V269, P413, DOI 10.1016/0014-5793(90)81206-4; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; Jiang Y, 2006, J BIOL CHEM, V281, P9058, DOI 10.1074/jbc.M507874200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2005, LECT NOTES COMPUT SC, V3695, P163; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kvell K, 2006, BIOCHEM BIOPH RES CO, V341, P1193, DOI 10.1016/j.bbrc.2006.01.083; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Louie GV, 1997, MOL CELL, V1, P67, DOI 10.1016/S1097-2765(00)80008-8; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakamura K, 2001, BIOCHEM BIOPH RES CO, V280, P1028, DOI 10.1006/bbrc.2000.4210; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pikkarainen T, 1999, J BIOL CHEM, V274, P10975, DOI 10.1074/jbc.274.16.10975; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Rast JP, 2006, SCIENCE, V314, P952, DOI 10.1126/science.1134301; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Sankala M, 2002, J BIOL CHEM, V277, P33378, DOI 10.1074/jbc.M204494200; Santiago-Garcia J, 2003, J BIOL CHEM, V278, P6942, DOI 10.1074/jbc.M208358200; Sarraj MA, 2005, DEV DYNAM, V234, P1026, DOI 10.1002/dvdy.20594; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Sarrias MR, 2005, J BIOL CHEM, V280, P35391, DOI 10.1074/jbc.M505042200; Somoza JR, 2003, STRUCTURE, V11, P1123, DOI 10.1016/S0969-2126(03)00148-5; Takeuchi K, 2004, J BIOL CHEM, V279, P4981, DOI 10.1074/jbc.M307815200; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; vanderLaan LJW, 1997, IMMUNOL LETT, V57, P203, DOI 10.1016/S0165-2478(97)00077-1	58	76	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16654	16666		10.1074/jbc.M701750200	http://dx.doi.org/10.1074/jbc.M701750200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17405873	hybrid			2022-12-27	WOS:000246794300071
J	Purusharth, RI; Madhuri, B; Ray, MK				Purusharth, Rajyaguru Ichchhashankar; Madhuri, Bollapalli; Ray, Malay Kumar			Exoribonuclease R in Pseudomonas syringae is essential for growth at low temperature and plays a novel role in the 3 ' end processing of 16 and 5S ribosomal RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DECAY; ESCHERICHIA-COLI; RIBOSOMAL-RNA; POLYNUCLEOTIDE PHOSPHORYLASE; QUALITY-CONTROL; RIBONUCLEASE-E; IN-VIVO; BACTERIUM; DEGRADATION; DEGRADOSOME	The (3 ' -> 5 ') exoribonuclease RNase R interacts with the endoribonuclease RNase E in the degradosome of the coldadapted bacterium Pseudomonas syringae Lz4W. We now present evidence that the RNase R is essential for growth of the organism at low temperature (4 degrees C). Mutants of P. syringae with inactivated rnr gene (encoding RNase R) are cold-sensitive and die upon incubation at 4 degrees C, a phenotype that can be complemented by expressing RNase R in trans. Overexpressing polyribonucleotide phosphorylase in the rnr mutant does not rescue the cold sensitivity. This is different from the situation in Escherichia coli, where rnr mutants show normal growth, but pnp (encoding polyribonucleotide phosphorylase) and rnr double mutants are nonviable. Interestingly, RNaseRis not cold-inducible in P. syringae. Remarkably, however, rnr mutants of P. syringae at low temperature (4 degrees C) accumulate 16 and 5 S ribosomal RNA (rRNA) that contain untrimmed extra ribonucleotide residues at the 3 ' ends. This suggests a novel role for RNase R in the rRNA 3 ' end processing. Unprocessed 16 S rRNA accumulates in the polysome population, which correlates with the inefficient protein synthesis ability of mutant. An additional role of RNase R in the turnover of transfer- messenger RNA was identified from our observation that the rnr mutant accumulates transfer-messenger RNA fragments in the bacterium at 4 degrees C. Taken together our results establish that the processive RNase R is crucial for RNA metabolism at low temperature in the coldadapted Antarctic P. syringae.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Ray, MK (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	malay@ccmb.res.in		RAJYAGURU, PURUSHARTH/0000-0003-3794-418X				Altman Sidney, 1995, P67; Bessarab DA, 1998, P NATL ACAD SCI USA, V95, P3157, DOI 10.1073/pnas.95.6.3157; Bidle KA, 1999, J BACTERIOL, V181, P2330, DOI 10.1128/JB.181.8.2330-2337.1999; Bollenbach TJ, 2005, NUCLEIC ACIDS RES, V33, P2751, DOI 10.1093/nar/gki576; Cairrao F, 2003, MOL MICROBIOL, V50, P1349, DOI 10.1046/j.1365-2958.2003.03766.x; Charollais J, 2003, MOL MICROBIOL, V48, P1253, DOI 10.1046/j.1365-2958.2003.03513.x; Chen CL, 2005, J BIOL CHEM, V280, P34393, DOI 10.1074/jbc.C500333200; Cheng ZF, 2005, MOL CELL, V17, P313, DOI 10.1016/j.molcel.2004.11.048; Cheng ZF, 2003, P NATL ACAD SCI USA, V100, P6388, DOI 10.1073/pnas.1231041100; Cheng ZF, 1998, J BIOL CHEM, V273, P14077, DOI 10.1074/jbc.273.23.14077; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; Favaro R, 2003, J BACTERIOL, V185, P5279, DOI 10.1128/JB.185.17.5279-5286.2003; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; Goverde RLJ, 1998, MOL MICROBIOL, V28, P555, DOI 10.1046/j.1365-2958.1998.00816.x; Held W.A., 1974, RIBOSOMES, P193; Hinds J, 1999, MICROBIOL-UK, V145, P519, DOI 10.1099/13500872-145-3-519; Hong SJ, 2005, MOL MICROBIOL, V57, P565, DOI 10.1111/j.1365-2958.2005.04709.x; Jager S, 2001, NUCLEIC ACIDS RES, V29, P4581, DOI 10.1093/nar/29.22.4581; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Khemici V, 2004, MOL MICROBIOL, V51, P777, DOI 10.1046/j.1365-2958.2003.03862.x; Lee K, 2003, MOL MICROBIOL, V48, P349, DOI 10.1046/j.1365-2958.2003.03435.x; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; Li ZW, 1999, RNA, V5, P139, DOI 10.1017/S1355838299981669; Li ZW, 1999, EMBO J, V18, P2878, DOI 10.1093/emboj/18.10.2878; Liou GG, 2001, P NATL ACAD SCI USA, V98, P63, DOI 10.1073/pnas.011535498; Purusharth RI, 2005, J BIOL CHEM, V280, P14572, DOI 10.1074/jbc.M413507200; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1016/S0168-6445(99)00012-1; Ray MK, 1999, CURR MICROBIOL, V38, P143, DOI 10.1007/PL00006778; Regha K, 2005, GENETICS, V170, P1473, DOI 10.1534/genetics.104.038943; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SRIVASTAVA AK, 1990, ANNU REV MICROBIOL, V44, P105, DOI 10.1146/annurev.mi.44.100190.000541; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770; WIREMAN JW, 1974, NATURE, V247, P552, DOI 10.1038/247552a0; Zangrossi S, 2000, MOL MICROBIOL, V36, P1470, DOI 10.1046/j.1365-2958.2000.01971.x	36	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16267	16277		10.1074/jbc.M605588200	http://dx.doi.org/10.1074/jbc.M605588200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17405875	hybrid			2022-12-27	WOS:000246794300034
J	Stack, CM; Donnelly, S; Lowther, J; Xu, WB; Collins, PR; Brinen, LS; Dalton, JP				Stack, Colin M.; Donnelly, Sheila; Lowther, Jonathan; Xu, Weibo; Collins, Peter R.; Brinen, Linda S.; Dalton, John P.			The major secreted cathepsin L1 protease of the liver fluke, Fasciola hepatica - A Leu(-12) to Pro(-12) replacement in the nonconserved C-terminal region of the prosegment prevents complete enzyme autoactivation and allows definition of the molecular events in prosegment removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROCATHEPSIN-B; L IN-VITRO; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; CYSTEINE PROTEASES; CRYSTAL-STRUCTURE; BORDETELLA-PERTUSSIS; PAPAIN PRECURSOR; PICHIA-PASTORIS; CLEAVAGE SITES	A protease secreted by the parasitic helminth Fasciola hepatica, a 37-kDa procathepsin L1 (FheproCL1), autocatalytically processes and activates to its mature enzyme (FheCL1) over a wide pH range of 7.3 to 4.0, although activation is more rapid at low pH. Maturation initiates with cleavages of a small proportion of molecules within the central region of the prosegment, possibly by intramolecular events. However, activation to fully mature enzymes is achieved by a precise intermolecular cleavage at a Leu (-12)-Ser(-11) down arrow His(-)10 sequence within the nonconserved C-terminal region of the prosegment. The importance of this cleavage site in enzyme activation was demonstrated using an active site variant FheproCL1Gly(26) ( Cys(26) to Gly(26)) and a double variant FheproCL1Pro(-12)/Gly(26) ( Leu (-)12 to Pro(-12)), and although both of these variants cannot autocatalytically process, the former is susceptible to trans-processing at a Leu(-12)-Ser-11 down arrow His-10 sequence by pre- activated FheCL1, but the latter is not. Another F. hepatica secreted protease FheCL2, which, unlike FheCL1, can readily accept proline in the S2 subsite of its active site, can trans-process the double variant FheproCL1Pro(-12)/Gly(26) by cleavage at the Pro (-12) -Ser(-11 down arrow)2His(-10) sequence. Furthermore, the autoactivation of a variant enzyme with a single replacement, FheproCL1Pro(-12), was very slow but was increased 40-fold in the presence of FheCL2. These studies provide a molecular insight into the regulation of FheproCL1 autocatalysis.	Univ Technol Sydney, Inst Biotechnol Infect Dis, Fac Sci, Sydney, NSW 2007, Australia; Dublin City Univ, Sch Biotechnol, Dublin 9, Ireland; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of Technology Sydney; Dublin City University; University of California System; University of California San Francisco	Dalton, JP (corresponding author), Univ Technol Sydney, Inst Biotechnol Infect Dis, Fac Sci, Bldg 4,Thomas & Harris St,, Sydney, NSW 2007, Australia.	john.dalton@uts.edu.au	Stack, Colin M/D-4601-2009; Dalton, John/K-4457-2014; Donnelly, Sheila/H-7733-2014	Donnelly, Sheila/0000-0003-2005-3698; Stack, Colin/0000-0002-7539-7677	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andrews SJ, 1999, FASCIOLOSIS, P1; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; Baker KC, 1996, PROTEIN ENG, V9, P525, DOI 10.1093/protein/9.6.525; Brady MT, 1999, INFECT IMMUN, V67, P5372, DOI 10.1128/IAI.67.10.5372-5378.1999; BRINDLEY PJ, 2004, HDB PROTEOLYTIC ENZY, P1305; Brix K, 2001, BIOL CHEM, V382, P717, DOI 10.1515/BC.2001.087; Cappetta M, 2002, BIOL CHEM, V383, P1215, DOI 10.1515/BC.2002.134; Collins PR, 2004, J BIOL CHEM, V279, P17038, DOI 10.1074/jbc.M308831200; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Dalton JP, 2004, CAN J ZOOL, V82, P211, DOI [10.1139/z03-213, 10.1139/Z03-213]; Dalton JP, 2003, INT J PARASITOL, V33, P621, DOI 10.1016/S0020-7519(03)00057-2; Dalton JP, 1996, INFECT IMMUN, V64, P5066, DOI 10.1128/IAI.64.12.5066-5074.1996; DeLano W.L, PYMOL MOL GRAPHICS S; DOWD AJ, 1994, EUR J BIOCHEM, V223, P91, DOI 10.1111/j.1432-1033.1994.tb18969.x; Dowd AJ, 1997, MOL BIOCHEM PARASIT, V88, P163, DOI 10.1016/S0166-6851(97)00090-X; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Friedrichs B, 2003, J CLIN INVEST, V111, P1733, DOI 10.1172/JCI200315990; Guay J, 2000, EUR J BIOCHEM, V267, P6311, DOI 10.1046/j.1432-1327.2000.01730.x; Guo YL, 2000, FEBS LETT, V469, P203, DOI 10.1016/S0014-5793(00)01281-3; Halton DW, 1997, INT J PARASITOL, V27, P693, DOI 10.1016/S0020-7519(97)00011-8; HALTON DW, 1967, PARASITOLOGY, V57, P639, DOI 10.1017/S003118200007311X; Higgins DR, 1998, METH MOL B, V103, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ishidoh K, 1998, BIOL CHEM, V379, P131; ISHIDOH K, 1994, FEBS LETT, V352, P281, DOI 10.1016/0014-5793(94)00924-4; Jerala R, 1998, J BIOL CHEM, V273, P11498, DOI 10.1074/jbc.273.19.11498; Linder S, 1996, BIOTECHNIQUES, V20, P980; MACH L, 1994, J BIOL CHEM, V269, P13036; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MASON RW, 1992, BIOCHEM BIOPH RES CO, V189, P1659, DOI 10.1016/0006-291X(92)90268-P; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; Mulcahy G, 1998, VACCINE, V16, P932, DOI 10.1016/S0264-410X(97)00289-2; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; O'Neill SM, 2001, PARASITE IMMUNOL, V23, P541, DOI 10.1046/j.1365-3024.2001.00411.x; Ogino T, 1999, J BIOCHEM-TOKYO, V126, P78, DOI 10.1093/oxfordjournals.jbchem.a022439; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Quraishi O, 2001, J BIOL CHEM, V276, P8118, DOI 10.1074/jbc.M005851200; Riese RJ, 2000, CURR OPIN IMMUNOL, V12, P107, DOI 10.1016/S0952-7915(99)00058-8; Roche L, 1997, EUR J BIOCHEM, V245, P373, DOI 10.1111/j.1432-1033.1997.t01-1-00373.x; Roche L, 1999, MOL BIOCHEM PARASIT, V98, P271, DOI 10.1016/S0166-6851(98)00164-9; Rozman J, 1999, FEBS LETT, V459, P358, DOI 10.1016/S0014-5793(99)01302-2; Sajid M, 2003, MOL BIOCHEM PARASIT, V131, P65, DOI 10.1016/S0166-6851(03)00194-4; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; Sivaraman J, 1999, PROTEIN SCI, V8, P283; Tepel C, 2000, J CELL SCI, V113, P4487; Tort J, 1999, ADV PARASIT, V43, P161, DOI 10.1016/S0065-308X(08)60243-2; Turk B, 1999, EUR J BIOCHEM, V259, P926, DOI 10.1046/j.1432-1327.1999.00145.x; Turk D, 2003, ACTA CRYSTALLOGR D, V59, P203, DOI 10.1107/S0907444902021479; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; VERNET T, 1993, PROTEIN ENG, V6, P213, DOI 10.1093/protein/6.2.213; Wiederanders B, 2003, CURR PROTEIN PEPT SC, V4, P309, DOI 10.2174/1389203033487081	56	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16532	16543		10.1074/jbc.M611501200	http://dx.doi.org/10.1074/jbc.M611501200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403677	hybrid			2022-12-27	WOS:000246794300060
J	Wang, H; Lu, YF; Huang, WQ; Papoutsakis, ET; Fuhrken, P; Eklund, EA				Wang, Hao; Lu, YuFeng; Huang, Weiqi; Papoutsakis, E. Terry; Fuhrken, Peter; Eklund, Elizabeth A.			HoxA10 activates transcription of the gene encoding mitogen-activated protein kinase phosphatase 2 (Mkp2) in myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HEMATOPOIETIC-CELLS; N-TERMINAL KINASE; DNA-BINDING; MYELOGENOUS LEUKEMIA; EXPRESSION; DIFFERENTIATION; APOPTOSIS; SUBPOPULATIONS; INTERRUPTION; REPRESSION	HoxA10 is a homeodomain transcription factor that is frequently overexpressed in human acute myeloid leukemia. In murine bone marrow transplantation studies, HoxA10 overexpression induces a myeloproliferative disorder with accumulation of mature phagocytes in the peripheral blood and tissues. Over time, differentiation block develops in these animals, resulting in acute myeloid leukemia. In immature myeloid cells, HoxA10 represses transcription of some genes that confer the mature phagocyte phenotype. Therefore, overexpressed HoxA10 blocks differentiation by repressing myeloid-specific gene transcription in differentiating myeloid cells. In contrast, target genes involved in myeloproliferation due to HoxA10 overexpression have not been identified. To identify such genes, we screened aCpGisland microarray with HoxA10 co-immunoprecipitating chromatin. We identified the DUSP4 gene, which encodes mitogen-activated protein kinase phosphatase 2 (Mkp2), as a HoxA10 target gene. We analyzed the DUSP4 5 '- flank and identified two proximal-promoter cis elements that are activated by HoxA10. We find that DUSP4 transcription and Mkp2 expression decrease during normal myelopoiesis. However, this down-regulation is impaired in myeloid cells overexpressing HoxA10. In hematopoietic cells, c-Jun N-terminal kinases (Jnk) are the preferred substrates for Mkp2. Therefore, Mkp2 inhibits apoptosis by dephosphorylating (inactivating) Jnk. Consistent with this, HoxA10 overexpression decreases apoptosis in differentiating myeloid cells. Therefore, our studies identify a mechanism by which overexpressed HoxA10 contributes to inappropriate cell survival during myelopoiesis.	Northwestern Univ, Fineberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA; Jesse Brown Vet Affairs Med Ctr, Chicago, IL 60612 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Eklund, EA (corresponding author), Northwestern Univ, Fineberg Sch Med, 710 N Fairbanks Ct,Olson 8524, Chicago, IL 60611 USA.	e-eklund@northwestern.edu	Papoutsakis, Eleftherios/B-7612-2009; Papoutsakis, Eleftherios T/A-5254-2010; Huang, Weiqi/E-4341-2010	Wang, Hao/0000-0003-2131-0377				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; Bei L, 2005, J BIOL CHEM, V280, P12359, DOI 10.1074/jbc.M408138200; Buske C, 2001, BLOOD, V97, P2286, DOI 10.1182/blood.V97.8.2286; Cadalbert L, 2005, CELL SIGNAL, V17, P1254, DOI 10.1016/j.cellsig.2005.01.003; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Daftary GS, 2002, MOL ENDOCRINOL, V16, P571, DOI 10.1210/me.16.3.571; Dai Y, 2005, BLOOD, V105, P1706, DOI 10.1182/blood-2004-07-2767; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Eklund EA, 2002, J BIOL CHEM, V277, P36878, DOI 10.1074/jbc.M203917200; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Hawkins SM, 2001, J BIOL CHEM, V276, P44472, DOI 10.1074/jbc.M104193200; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; LARRICK JW, 1980, J IMMUNOL, V125, P6; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LEVY R, 1990, J IMMUNOL, V145, P2595; Lindsey S, 2005, J IMMUNOL, V175, P5269, DOI 10.4049/jimmunol.175.8.5269; LOWNEY P, 1991, NUCLEIC ACIDS RES, V19, P3443, DOI 10.1093/nar/19.12.3443; Lu YF, 2003, J BIOL CHEM, V278, P47792, DOI 10.1074/jbc.M305885200; Mc Gee MM, 2002, J BIOL CHEM, V277, P18383, DOI 10.1074/jbc.M112058200; Oberley MJ, 2003, METHOD ENZYMOL, V371, P577; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	27	32	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16164	16176		10.1074/jbc.M610556200	http://dx.doi.org/10.1074/jbc.M610556200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430893	hybrid			2022-12-27	WOS:000246794300025
J	Hosoda, K; Matsuura, T; Kita, H; Ichihashi, N; Tsukada, K; Yomo, T				Hosoda, Kazufumi; Matsuura, Tomoaki; Kita, Hiroshi; Ichihashi, Norikazu; Tsukada, Koji; Yomo, Tetsuya			Kinetic analysis of the entire RNA amplification process by Q beta replicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; COLIPHAGE Q-BETA; PHAGE-Q-BETA; ESCHERICHIA-COLI; TRANSCRIPTION INITIATION; PROTEIN INTERACTIONS; EF-TS; TEMPLATE; POLYMERASE; BINDING	The kinetics of the RNA replication reaction by Q beta replicase were investigated. Q beta replicase is an RNA-dependent RNA polymerase responsible for replicating the RNA genome of coliphage Q beta and plays a key role in the life cycle of the Q beta phage. Although the RNA replication reaction using this enzyme has long been studied, a kinetic model that can describe the entire RNA amplification process has yet to be determined. In this study, we propose a kinetic model that is able to account for the entire RNA amplification process. The key to our proposed kinetic model is the consideration of nonproductive binding (i.e. binding of an enzyme to the RNA where the enzyme cannot initiate the reaction). By considering nonproductive binding and the notable enzyme inactivation we observed, the previous observations that remained unresolved could also be explained. Moreover, based on the kinetic model and the experimental results, we determined rate and equilibrium constants using template RNAs of various lengths. The proposed model and the obtained constants provide important information both for understanding the basis of Q beta phage amplification and the applications using Q beta replicase.	Osaka Univ, Dept Bioinformat Engn, Grad Sch Informat Sci & Technol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Biotechnol, Grad Sch Engn, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, Complex Syst Biol Project, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yomo, T (corresponding author), Osaka Univ, Dept Bioinformat Engn, Grad Sch Informat Sci & Technol, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.	yomo@ist.osaka-u.ac.jp	Matsuura, Tomoaki/W-6086-2019; Ichihashi, Norikazu/AAY-6897-2020; matsuura, tomoaki/O-7368-2018	Matsuura, Tomoaki/0000-0003-1015-6781; matsuura, tomoaki/0000-0003-1015-6781				Abramson Richard D., 1993, Current Opinion in Biotechnology, V4, P41, DOI 10.1016/0958-1669(93)90030-Z; ALBE KR, 1990, J THEOR BIOL, V143, P163, DOI 10.1016/S0022-5193(05)80266-8; Alberts B., 2002, MOL BIOL CELL, P191; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; AXELROD VD, 1991, VIROLOGY, V184, P595, DOI 10.1016/0042-6822(91)90430-J; BIEBRICHER CK, 1984, BIOCHEMISTRY-US, V23, P3186, DOI 10.1021/bi00309a012; BIEBRICHER CK, 1986, NATURE, V321, P89, DOI 10.1038/321089a0; BIEBRICHER CK, 1981, J MOL BIOL, V148, P391, DOI 10.1016/0022-2836(81)90183-2; BIEBRICHER CK, 1983, BIOCHEMISTRY-US, V22, P2544, DOI 10.1021/bi00279a036; BLUMENTHAL T, 1977, BIOCHIM BIOPHYS ACTA, V478, P201, DOI 10.1016/0005-2787(77)90183-6; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; Brown D, 1996, P NATL ACAD SCI USA, V93, P11558, DOI 10.1073/pnas.93.21.11558; BROWN D, 1995, BIOCHEMISTRY-US, V34, P14775, DOI 10.1021/bi00045a019; CALENDAR R, 2006, BACTERIOPHAGES, P175; Chetverin AB, 1997, CELL, V88, P503, DOI 10.1016/S0092-8674(00)81890-5; CHETVERIN AB, 1991, J MOL BIOL, V222, P3, DOI 10.1016/0022-2836(91)90729-P; CHETVERIN AB, 1995, PROG NUCLEIC ACID RE, V51, P225, DOI 10.1016/S0079-6603(08)60880-6; EIGEN M, 1991, BIOCHEMISTRY-US, V30, P11005, DOI 10.1021/bi00110a001; Fersht A., 1999, STRUCTURE MECH PROTE, P114; HARUNA I, 1965, P NATL ACAD SCI USA, V54, P579, DOI 10.1073/pnas.54.2.579; Inokuchi Y, 1997, J BIOL CHEM, V272, P15339, DOI 10.1074/jbc.272.24.15339; INOKUCHI Y, 1994, J BIOCHEM-TOKYO, V116, P1275, DOI 10.1093/oxfordjournals.jbchem.a124675; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; KACIAN DL, 1972, P NATL ACAD SCI USA, V69, P3038, DOI 10.1073/pnas.69.10.3038; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Kim H, 2004, BIOTECHNOL BIOENG, V88, P148, DOI 10.1002/bit.20226; Kita H, 2006, J BIOSCI BIOENG, V101, P421, DOI 10.1263/jbb.101.421; Klovins J, 1998, RNA, V4, P948, DOI 10.1017/S1355838298980177; KNUTH DE, 1992, AM MATH MON, V99, P403, DOI 10.2307/2325085; KONDO M, 1972, EUR J BIOCHEM, V24, P530, DOI 10.1111/j.1432-1033.1972.tb19715.x; Kopsidas G, 2006, IMMUNOL LETT, V107, P163, DOI 10.1016/j.imlet.2006.09.004; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LANGOWSKI J, 1980, NUCLEIC ACIDS RES, V8, P4727, DOI 10.1093/nar/8.20.4727; LIN SY, 1970, NATURE, V228, P1184, DOI 10.1038/2281184a0; LIZARDI PM, 1988, BIO-TECHNOL, V6, P1197, DOI 10.1038/nbt1088-1197; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; Messias AC, 2004, ACCOUNTS CHEM RES, V37, P279, DOI 10.1021/ar030034m; MILLS DR, 1979, P NATL ACAD SCI USA, V76, P2232, DOI 10.1073/pnas.76.5.2232; MILLS DR, 1978, CELL, V15, P541, DOI 10.1016/0092-8674(78)90022-3; MILLS DR, 1967, P NATL ACAD SCI USA, V58, P217, DOI 10.1073/pnas.58.1.217; MOROZOV IY, 1993, P NATL ACAD SCI USA, V90, P9325, DOI 10.1073/pnas.90.20.9325; Nakaishi T, 2002, J BIOSCI BIOENG, V93, P322, DOI 10.1263/jbb.93.322; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; Ortin J, 2006, ANNU REV MICROBIOL, V60, P305, DOI 10.1146/annurev.micro.60.080805.142248; PALMENBERG A, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1371, DOI 10.1073/pnas.71.4.1371; Preuss R, 1997, J MOL BIOL, V273, P600, DOI 10.1006/jmbi.1997.1343; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; Schuppli D, 1997, P NATL ACAD SCI USA, V94, P10239, DOI 10.1073/pnas.94.19.10239; Susa M, 2002, J BIOL CHEM, V277, P15407, DOI 10.1074/jbc.M112481200; THOMA JA, 1960, J AM CHEM SOC, V82, P3329, DOI 10.1021/ja01498a025; Tretheway DM, 2001, J VIROL, V75, P11373, DOI 10.1128/JVI.75.23.11373-11383.2001; Tyagi S, 1996, P NATL ACAD SCI USA, V93, P5395, DOI 10.1073/pnas.93.11.5395; Ugarov VI, 2003, J BIOL CHEM, V278, P44139, DOI 10.1074/jbc.M305992200; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WERNER M, 1991, BIOCHEMISTRY-US, V30, P5832, DOI 10.1021/bi00238a004; Yoshinari S, 2000, VIROLOGY, V271, P363, DOI 10.1006/viro.2000.0334; ZAMORA H, 1995, BIOCHEMISTRY-US, V34, P1261, DOI 10.1021/bi00004a020	58	21	21	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15516	15527		10.1074/jbc.M700307200	http://dx.doi.org/10.1074/jbc.M700307200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17412690	hybrid			2022-12-27	WOS:000246589600028
J	Matsumura, K; Higashida, K; Ishida, H; Hata, Y; Yamamoto, K; Shigeta, M; Mizuno-Horikawa, Y; Wang, XC; Miyoshi, E; Gu, JG; Taniguchi, N				Matsumura, Kengo; Higashida, Katsuya; Ishida, Hiroki; Hata, Yoji; Yamamoto, Kenji; Shigeta, Masaki; Mizuno-Horikawa, Yoko; Wang, Xiangchun; Miyoshi, Eiji; Gu, Jianguo; Taniguchi, Naoyuki			Carbohydrate binding specificity of a fucose-specific lectin from aspergillus oryzae - A novel probe for core fucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-III; ALEURIA-AURANTIA LECTIN; HEPATOCELLULAR-CARCINOMA; RALSTONIA-SOLANACEARUM; CRYSTAL-STRUCTURE; FUNGAL LECTIN; CELL-LINES; RECOGNITION; HEPATOMA; PHYTOHEMAGGLUTININ	The alpha 1,6-fucosyl residue (core fucose) of glycoproteins is widely distributed in mammalian tissues and is altered under pathological conditions. A probe that specifically detects core fucose is important for understanding the role of this oligosaccharide structure. Aleuria aurantia lectin (AAL) and Lens culimaris agglutinin-A (LCA) have been often used as carbohydrate probes for core fucose in glycoproteins. Here we show, by using surface plasmon resonance (SPR) analysis, that Aspergillus oryzae L-fucose-specific lectin (AOL) has strongest preference for the alpha 1,6-fucosylated chain among alpha 1,2-, alpha 1,3-, alpha 1,4-, and alpha 1,6-fucosylated pyridylaminated (PA)-sugar chains. These results suggest that AOL is a novel probe for detecting core fucose in glycoproteins on the surface of animal cells. A comparison of the carbohydrate-binding specificity of AOL, AAL, and LCA by SPR showed that the irreversible binding of AOL to the alpha 1,2-fucosylated PA-sugar chain (H antigen) relative to the alpha 1,6-fucosylated chain was weaker than that of AAL, and that the interactions of AOL and AAL with alpha 1,6- fucosylated glycopeptide (FGP), which is considered more similar to in vivo glycoproteins than PA-sugar chains, were similar to their interactions with the alpha 1,6-fucosylated PA-sugar chain. Furthermore, positive staining of AOL, but not AAL, was completely abolished in the cultured embryo fibroblast (MEF) cells obtained from alpha 1,6- fucosyltransferase (Fut8) knock-out mice, as assessed by cytological staining. Taken together, these results suggest that AOL is more suitable for detecting core fucose than AAL or LCA.	Gekkeikan Sake Co Ltd, Inst Res, Fushimi Ku, Kyoto 6128361, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Sakyo Ku, Kyoto 6068502, Japan; Osaka Univ, Dept Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan; Tohoku Pharmaceut Univ, Div Regulatory Glycobiol, Inst Mol Biomembrane & Glycobiol, Aoba Ku, Sendai, Miyagi 9818558, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Dis Glycom, Suita, Osaka 5650871, Japan	Kyoto University; Osaka University; Tohoku Medical & Pharmaceutical University; Osaka University	Matsumura, K (corresponding author), Gekkeikan Sake Co Ltd, Inst Res, Fushimi Ku, 300 Katahara Cho, Kyoto 6128361, Japan.	kengo@gekkeikan.co.jp	Gu, Jianguo/ABC-9257-2020; Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Fujihashi M, 2003, BIOCHEMISTRY-US, V42, P11093, DOI 10.1021/bi034983z; FUKUMORI F, 1990, J BIOCHEM-TOKYO, V107, P190, DOI 10.1093/oxfordjournals.jbchem.a123024; HUTCHINSON WL, 1991, HEPATOLOGY, V13, P683, DOI 10.1002/hep.1840130412; Inamori K, 2004, J BIOL CHEM, V279, P2337, DOI 10.1074/jbc.C300480200; Ishida H, 2002, BIOSCI BIOTECH BIOCH, V66, P1002, DOI 10.1271/bbb.66.1002; KOCHIBE N, 1980, BIOCHEMISTRY-US, V19, P2841, DOI 10.1021/bi00554a004; Kostlanova N, 2005, J BIOL CHEM, V280, P27839, DOI 10.1074/jbc.M505184200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MIYOSHI E, 1995, J BIOL CHEM, V270, P28311; Noda K, 2003, CANCER RES, V63, P6282; Oda Y, 2003, J BIOL CHEM, V278, P32439, DOI 10.1074/jbc.M305181200; OHNO M, 1992, INT J CANCER, V51, P315, DOI 10.1002/ijc.2910510223; PEREIRA MEA, 1974, BIOCHEMISTRY-US, V13, P3184, DOI 10.1021/bi00712a029; Seko A, 1997, BBA-GEN SUBJECTS, V1335, P23, DOI 10.1016/S0304-4165(96)00118-3; Stelck S, 1999, GLYCOBIOLOGY, V9, P1171, DOI 10.1093/glycob/9.11.1171; STEPHAN EB, 1996, GLYCOCONJ J, V13, P585; Sudakevitz D, 2002, J BIOCHEM, V132, P353, DOI 10.1093/oxfordjournals.jbchem.a003230; TOYOSHIMA S, 1970, BIOCHIM BIOPHYS ACTA, V221, P514, DOI 10.1016/0005-2795(70)90222-9; Vijayan M, 1999, CURR OPIN STRUC BIOL, V9, P707, DOI 10.1016/S0959-440X(99)00034-2; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; WATKINS WM, 1952, NATURE, V169, P825, DOI 10.1038/169825a0; Wimmerova M, 2003, J BIOL CHEM, V278, P27059, DOI 10.1074/jbc.M302642200; YAMASHITA K, 1985, J BIOL CHEM, V260, P4688	26	140	149	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15700	15708		10.1074/jbc.M701195200	http://dx.doi.org/10.1074/jbc.M701195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17383961	hybrid			2022-12-27	WOS:000246589600046
J	Zhu, TN; He, HJ; Kole, S; D'Souza, T; Agarwal, R; Morin, PJ; Bernier, M				Zhu, Tie-Nian; He, Hua-Jun; Kole, Sutapa; D'Souza, Theresa; Agarwal, Rachana; Morin, Patrice J.; Bernier, Michel			Filamin A-mediated down-regulation of the exchange factor Ras-GRF1 correlates with decreased matrix metalloproteinase-9 expression in human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MATRIX METALLOPROTEINASE-2 AND-9; GTPASE-ACTIVATING PROTEIN; DEPENDENT ACTIVATION; GENE-EXPRESSION; METASTATIC MELANOMA; KINASE ACTIVATION; CANCER CELLS; GELATINASE-B; KAPPA-B	The actin-binding protein filamin A (FLNa) is associated with diverse cellular processes such as cell motility and signaling through its scaffolding properties. Here we examine the effect of FLNa on the regulation of signaling pathways that control the expression of matrix metalloproteinases (MMPs). The lack of FLNa in human M2 melanoma cells was associated with constitutive and phorbol ester-induced expression and secretion of active MMP-9 in the absence of MMP-2 up-regulation. M2 cells displayed stronger MMP-9 production and activity than their M2A7 counterparts where FLNa had been stably reintroduced. Using an MMP-9 promoter construct (pMMP-9-Luc), in vitro kinase assays, and genetic and pharmacological approaches, we demonstrate that FLNa mediated transcriptional down-regulation of pMMP-9-Luc by suppressing the constitutive hyperactivity of the Ras/MAPK extracellular signal-regulated kinase (ERK) cascade. Experimental evidence indicated that this phenomenon was associated with destabilization and ubiquitylation of Ras-GRF1, a guanine nucleotide exchange factor that activates H-Ras by facilitating the release of GDP. Ectopic expression of Ras-GRF1 was accompanied by ERK activation and elevated levels of MMP-9 in M2A7 cells, whereas a catalytically inactive dominant negative Ras-GRF1, which prevented ERK activation, reduced MMP-9 expression in M2 cells. Our results indicate that expression of FLNa regulates constitutive activation of the Ras/ERK pathway partly through a Ras-GRF1 mechanism to modulate the production of MMP-9.	NIA, Diabet Sect, NIH, Clin Invest Lab, Baltimore, MD 21224 USA; NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bernier, M (corresponding author), NIA, Diabet Sect, NIH, Clin Invest Lab, Box 23,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	Bernierm@mail.nih.gov	Bernier, Michel/AAO-3983-2021; Bernier, Michel/Y-7139-2019	Bernier, Michel/0000-0002-5948-368X; 	NATIONAL INSTITUTE ON AGING [Z01AG000512, ZIAAG000395, Z01AG000892, Z01AG000395, ZIAAG000892] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Anilkumar G, 2003, CANCER RES, V63, P2645; Arozarena I, 2004, MOL CELL BIOL, V24, P1516, DOI 10.1128/MCB.24.4.1516-1530.2004; Arozarena I, 2000, J BIOL CHEM, V275, P26441, DOI 10.1074/jbc.M002992200; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Curtis I, 2001, EMBO REP, V2, P277, DOI 10.1093/embo-reports/kve072; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feng YY, 2004, NAT CELL BIOL, V6, P1034, DOI 10.1038/ncb1104-1034; Forlani G, 2006, FEBS J, V273, P2127, DOI 10.1111/j.1742-4658.2006.05226.x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Garreau H, 1996, BIOL CELL, V86, P93, DOI 10.1016/0248-4900(96)84771-X; Gollob JA, 2005, CANCER RES, V65, P8869, DOI 10.1158/0008-5472.CAN-05-1387; Guerrero C, 1996, ONCOGENE, V12, P1097; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Ho LL, 2002, EUR J PHARMACOL, V453, P149, DOI 10.1016/S0014-2999(02)02340-3; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Johansson N, 2000, HISTOL HISTOPATHOL, V15, P225, DOI 10.14670/HH-15.225; Kaneda A, 2002, CANCER RES, V62, P6645; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kato Y, 2005, J BIOL CHEM, V280, P10938, DOI 10.1074/jbc.M411313200; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; La Porta CAM, 1998, ANTICANCER RES, V18, P2591; Lai WC, 2003, J IMMUNOL, V170, P6244, DOI 10.4049/jimmunol.170.12.6244; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Leaner VD, 2005, MOL CELL BIOL, V25, P3324, DOI 10.1128/MCB.25.8.3324-3337.2005; Liabakk NB, 1996, CANCER RES, V56, P190; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lypowy J, 2005, J BIOL CHEM, V280, P25717, DOI 10.1074/jbc.M414266200; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; MacDougall JR, 1999, BRIT J CANCER, V80, P504, DOI 10.1038/sj.bjc.6690385; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Nikkola J, 2005, CLIN CANCER RES, V11, P5158, DOI 10.1158/1078-0432.CCR-04-2478; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Palmer HG, 2003, CANCER RES, V63, P7799; Parrini E, 2006, BRAIN, V129, P1892, DOI 10.1093/brain/awl125; Parsons SL, 1998, BRIT J CANCER, V78, P1495, DOI 10.1038/bjc.1998.712; Popp O, 2003, BIOL CHEM, V384, P951, DOI 10.1515/BC.2003.107; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Robertson SP, 2003, NAT GENET, V33, P487, DOI 10.1038/ng1119; SATO H, 1993, ONCOGENE, V8, P395; Satyamoorthy K, 2003, CANCER RES, V63, P756; Scott MGH, 2006, MOL CELL BIOL, V26, P3432, DOI 10.1128/MCB.26.9.3432-3445.2006; Spallarossa P, 2006, CARDIOVASC RES, V69, P736, DOI 10.1016/j.cardiores.2005.08.009; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; Tsubokawa T, 2006, STROKE, V37, P1888, DOI 10.1161/01.STR.0000227259.15506.24; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Woo CH, 2004, J IMMUNOL, V173, P6973, DOI 10.4049/jimmunol.173.11.6973; Wu CY, 2004, J NEUROCHEM, V90, P1477, DOI 10.1111/j.1471-4159.2004.02682.x; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x	72	48	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14816	14826		10.1074/jbc.M611430200	http://dx.doi.org/10.1074/jbc.M611430200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389601	hybrid			2022-12-27	WOS:000246589000017
J	Hammond, CL; Marchan, R; Krance, SM; Ballatori, N				Hammond, Christine L.; Marchan, Rosemarie; Krance, Suzanne M.; Ballatori, Nazzareno			Glutathione export during apoptosis requires functional multidrug resistance-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; REDUCED GLUTATHIONE; GSH EXTRUSION; OUTWARD TRANSLOCATION; ERYTHROCYTE-MEMBRANE; MOLECULAR-CLONING; EXECUTION PHASE; LEUKOTRIENE C-4; P-GLYCOPROTEIN; CELLS	GSH is released in cells undergoing apoptosis, and the present study indicates that the multidrug resistance-associated proteins (MRPs/ABCC) are responsible for this GSH release. Jurkat cells released similar to 75-80% of their total intracellular GSH during both Fas antibody- and staurosporine-induced apoptosis. In contrast, Raji cells, a lymphocyte cell line that is deficient in phosphatidylserine externalization, did not release GSH during apoptosis, and other apoptotic features appeared more slowly in these cells. Jurkat and Raji cell lines expressed comparable MRP and OATP/SLCO (organic anion-transporting polypeptide) mRNA levels, and MRP1 protein levels; however, differences existed in MRP1 localization and function. In Jurkat cells, MRP1 was largely localized to the plasma membrane, and these cells exported the MRP substrate calcein. Calcein release was enhanced during apoptosis. In contrast, Raji cells had little MRP1 at the plasma membrane and did not export calcein under basal or apoptotic conditions, indicating that these cells lack functional MRPs at the plasma membrane. GSH release in Jurkat cells undergoing apoptosis was inhibited by the organic anion transport inhibitors MK571, sulfinpyrazone, and probenecid, supporting a role for the MRP transporters in this process. Furthermore, when MRP1 expression was decreased with RNA interference, GSH release was lower under both basal and apoptotic conditions, providing direct evidence that MRP1 is involved in GSH export.	Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA	University of Rochester	Ballatori, N (corresponding author), Univ Rochester, Sch Med, Dept Environm Med, 575 Elmwood Ave,Box EHSC, Rochester, NY 14642 USA.	Ned_Ballatori@urmc.rochester.edu		Marchan, Rosemarie/0000-0003-4414-1633	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048823, R01DK067214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247, R01ES006484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48823, DK067214] Funding Source: Medline; NIEHS NIH HHS [ES01247, ES06484, ES07026] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALMQUIST KC, 1995, CANCER RES, V55, P102; Ballatori N, 2005, TOXICOL APPL PHARM, V204, P238, DOI 10.1016/j.taap.2004.09.008; Briz O, 2006, J BIOL CHEM, V281, P30326, DOI 10.1074/jbc.M602048200; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Cha SH, 2001, MOL PHARMACOL, V59, P1277, DOI 10.1124/mol.59.5.1277; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; De Nicola M, 2006, BIOCHEM PHARMACOL, V72, P1405, DOI 10.1016/j.bcp.2006.06.009; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; FELLER N, 1995, FEBS LETT, V368, P385, DOI 10.1016/0014-5793(95)00677-2; Forsberg AJ, 2004, ANTIOXID REDOX SIGN, V6, P203, DOI 10.1089/152308604322899279; Franco R, 2006, J BIOL CHEM, V281, P29542, DOI 10.1074/jbc.M602500200; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; Gennuso F, 2004, P NATL ACAD SCI USA, V101, P2470, DOI 10.1073/pnas.0308452100; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; GRANT CE, 1994, CANCER RES, V54, P357; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hammond CL, 2004, TOXICOL APPL PHARM, V195, P12, DOI 10.1016/j.taap.2003.10.008; Hammond CL, 2001, J HEPATOL, V34, P946, DOI 10.1016/S0168-8278(01)00037-X; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Kamp D, 1998, BBA-BIOMEMBRANES, V1372, P91, DOI 10.1016/S0005-2736(98)00049-2; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; LEIER I, 1994, J BIOL CHEM, V269, P27807; Letschert K, 2005, J PHARMACOL EXP THER, V313, P549, DOI 10.1124/jpet.104.081224; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Masuda S, 1999, MOL PHARMACOL, V55, P743; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nies AT, 2001, INT J CANCER, V94, P492, DOI 10.1002/ijc.1498; Pohl A, 2002, BIOCHEM J, V365, P259, DOI 10.1042/BJ20011880; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Rius M, 2003, HEPATOLOGY, V38, P374, DOI 10.1053/jhep.2003.50331; Romsicki Y, 2001, BIOCHEMISTRY-US, V40, P6937, DOI 10.1021/bi0024456; Shen HX, 1996, BIOCHEMISTRY-US, V35, P5719, DOI 10.1021/bi960098n; Sohnius A, 2003, MOL MEMBR BIOL, V20, P299, DOI 10.1080/0968768031000114033; Sugiyama D, 2001, J PHARMACOL EXP THER, V298, P316; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Van Luyn MJA, 1998, INT J CANCER, V76, P55, DOI 10.1002/(SICI)1097-0215(19980330)76:1<55::AID-IJC10>3.3.CO;2-O; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; Versantvoort CHM, 1995, INT J CANCER, V63, P855, DOI 10.1002/ijc.2910630617; Wielinga PR, 2003, J BIOL CHEM, V278, P17664, DOI 10.1074/jbc.M212723200; Woehlecke H, 2003, BIOCHEM J, V376, P489, DOI 10.1042/BJ20030886	51	88	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14337	14347		10.1074/jbc.M611019200	http://dx.doi.org/10.1074/jbc.M611019200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374608	hybrid			2022-12-27	WOS:000246245800045
J	Meary, F; Metral, S; Ferreira, C; Eladari, D; Colin, Y; Lecomte, MC; Nicolas, G				Meary, Fleur; Metral, Sylvain; Ferreira, Chrystophe; Eladari, Dominique; Colin, Yves; Lecomte, Marie-Christine; Nicolas, Gael			A mutant alpha II-spectrin designed to resist calpain and caspase cleavage questions the functional importance of this process in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROAGGREGATIVE ESCHERICHIA-COLI; DEPENDENT PROTEASE-I; MEMBRANE SKELETON; CALMODULIN-BINDING; BRAIN SPECTRIN; APOPTOSIS; FODRIN; CALCIUM; SITE; PHOSPHORYLATION	alpha- and beta-spectrins are components of molecular scaffolds located under the lipid bilayer and named membrane skeletons. Disruption of these scaffolds through mutations in spectrins demonstrated that they are involved in the membrane localization or the maintenance of proteins associated with them. The ubiquitous alpha II-spectrin chain bears in its central region a unique domain that is sensitive to several proteases such as calpains or caspases. The conservation of this region in vertebrates suggests that the proteolysis of alpha II-spectrin by these enzymes could be involved in important functions. To assess the role of alpha II-spectrin cleavage in vivo, we generated a murine model in which the exons encoding the region defining this cleavage sensitivity were disrupted by gene targeting. Surprisingly, homozygous mice expressing this mutant alpha II-spectrin appeared healthy, bred normally, and had no histological anomaly. Remarkably, the mutant alpha II-spectrin assembles correctly into the membrane skeleton, thus challenging the notion that this region is required for the stable biogenesis of the membrane skeleton in nonerythroid cells. Our finding also argues against a critical role of this particular alpha II-spectrin cleavage in either major cellular functions or in normal development.	Inst Natl Transfus Sanguine, INSERM, U665, F-75015 Paris, France; Univ Paris 07, F-75005 Paris, France; Univ Paris 07, Inst Fed Rech Claude Bernard, F-75018 Paris, France; INSERM, U652, F-75006 Paris, France; Hop Necker Enfants Malad, Dept Physiol, AP HP, F-75006 Paris, France; Univ Paris 05, Fac Med Rene Descartes, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Nicolas, G (corresponding author), Inst Natl Transfus Sanguine, INSERM, U665, 6 Rue Alexandre Cabanel, F-75015 Paris, France.	gnicolas@idf.inserm.fr	METRAL, Sylvain/P-5833-2017; NICOLAS, Gaël/X-9555-2019; NICOLAS, Gaël/D-7611-2013; colin, yves/O-1910-2017	METRAL, Sylvain/0000-0001-6244-8546; NICOLAS, Gaël/0000-0002-1671-8274; NICOLAS, Gaël/0000-0002-1671-8274; colin, yves/0000-0001-5196-4254; Ferreira, Chrystophe/0000-0002-1990-278X; Meary, Fleur/0000-0002-5356-4649; Eladari, Dominique/0000-0003-1067-0844				Bignone PA, 2003, BIOCHEM J, V374, P613, DOI 10.1042/BJ20030507; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; Canizalez-Roman A, 2003, MOL MICROBIOL, V48, P947, DOI 10.1046/j.1365-2958.2003.03492.x; Chen HQ, 2007, J BIOL CHEM, V282, P4124, DOI 10.1074/jbc.M610231200; Delaunay J, 2007, BLOOD REV, V21, P1, DOI 10.1016/j.blre.2006.03.005; FOWLER VM, 1992, J CELL BIOL, V119, P1559, DOI 10.1083/jcb.119.6.1559; GEDDES JW, 1995, NEUROBIOL AGING, V16, P651, DOI 10.1016/0197-4580(95)00062-J; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; Harwood SM, 2005, ANN CLIN BIOCHEM, V42, P415, DOI 10.1258/000456305774538238; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Ikeda Y, 2006, NAT GENET, V38, P184, DOI 10.1038/ng1728; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; Lee A, 2001, J BIOL CHEM, V276, P20735, DOI 10.1074/jbc.M009723200; LEE JK, 1993, J CELL BIOL, V123, P1797, DOI 10.1083/jcb.123.6.1797; Leneuve P, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng021; LETO TL, 1989, J BIOL CHEM, V264, P5826; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; Lynch G, 2007, NEUROPHARMACOLOGY, V52, P12, DOI 10.1016/j.neuropharm.2006.07.027; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mohindas N, 2006, TRANSFUS CLIN BIOL, V13, P29, DOI 10.1016/j.tracli.2006.02.017; Navarro-Garcia F, 2004, INFECT IMMUN, V72, P3609, DOI 10.1128/IAI.72.6.3609-3621.2004; Nedrelow JH, 2003, J BIOL CHEM, V278, P7735, DOI 10.1074/jbc.M210988200; Nicolas G, 2002, MOL CELL BIOL, V22, P3527, DOI 10.1128/MCB.22.10.3527-3536.2002; Norman KR, 2002, J CELL BIOL, V157, P665, DOI 10.1083/jcb.200111051; Ozkan ED, 1997, P NATL ACAD SCI USA, V94, P4137, DOI 10.1073/pnas.94.8.4137; Parkinson NJ, 2001, NAT GENET, V29, P61, DOI 10.1038/ng710; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Praitis V, 2005, DEV BIOL, V283, P157, DOI 10.1016/j.ydbio.2005.04.002; Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955; Rubera I, 2004, J AM SOC NEPHROL, V15, P2050, DOI 10.1097/01.ASN.0000133023.89251.01; Simonovic M, 2006, J BIOL CHEM, V281, P34333, DOI 10.1074/jbc.M604613200; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Williams ST, 2003, APOPTOSIS, V8, P353, DOI 10.1023/A:1024168901003; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618	38	19	19	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14226	14237		10.1074/jbc.M700028200	http://dx.doi.org/10.1074/jbc.M700028200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374614	hybrid			2022-12-27	WOS:000246245800033
J	Little, R; Martinez-Argudo, I; Perry, S; Dixon, R				Little, Richard; Martinez-Argudo, Isabel; Perry, Susan; Dixon, Ray			Role of the H domain of the histidine kinase-like protein NifL in signal transmission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NIFL; NITROGEN REGULATOR-II; TERMINAL GAF DOMAIN; FUNCTIONAL DISSECTION; FIXATION; REDOX; MUTATIONS; ACTIVATOR; SYSTEM; 2-OXOGLUTARATE	The NifL protein from Azotobacter vinelandii senses both the redox and fixed nitrogen status to regulate nitrogen fixation by controlling the activity of the transcriptional activator NifA. NifL has a domain architecture similar to that of the cytoplasmic histidine protein kinases. It contains two N-terminal PAS domains and a C-terminal transmitter region containing a conserved histidine residue ( H domain) and a nucleotide binding GHKL domain corresponding to the catalytic core of the histidine kinases. Despite these similarities, NifL does not exhibit kinase activity and regulates its partner NifA by direct protein-protein interactions rather than phosphorylation. NifL senses the redox status via a FAD co-factor located within the PAS1 domain and responds to the nitrogen status by interaction with the signal transduction protein GlnK, which binds to the GHKL domain. The ability of NifL to inhibit NifA is antagonized by the binding of 2-oxoglutarate to the N-terminal GAF domain of NifA. In this study we have performed site-directed mutagenesis of the H domain of NifL to examine its role in signal transmission. Our results suggest that this domain plays a major role in transmission of signals perceived by the PAS1 and GHKL domains to ensure that NifL achieves the required conformation necessary to inhibit the 2-oxoglutarate-bound form of NifA. Some of the substitutions discriminate the redox and fixed nitrogen sensing functions of NifL implying that the conformational requirements and/or domain interactions necessary for NifA inhibition differ with respect to the signal input.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dixon, R (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England.	ray.dixon@bbsrc.ac.uk	Martinez, Isabel/R-4803-2019	Martinez, Isabel/0000-0001-5067-1791; Dixon, Ray/0000-0002-6348-639X	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000016] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ATKINSON MR, 1992, J BACTERIOL, V174, P4538, DOI 10.1128/JB.174.14.4538-4548.1992; AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994; Dixon R, 2004, NAT REV MICROBIOL, V2, P621, DOI 10.1038/nrmicro954; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Hefti MH, 2001, ANAL BIOCHEM, V295, P180, DOI 10.1006/abio.2001.5214; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; Jiang P, 2000, BIOCHEMISTRY-US, V39, P13433, DOI 10.1021/bi000794u; KAMBEROV ES, 1994, J BIOL CHEM, V269, P28294; Kramer G, 1999, P NATL ACAD SCI USA, V96, P604, DOI 10.1073/pnas.96.2.604; Little R, 2000, EMBO J, V19, P6041, DOI 10.1093/emboj/19.22.6041; Little R, 2003, J BIOL CHEM, V278, P28711, DOI 10.1074/jbc.M301992200; Little R, 2002, J BIOL CHEM, V277, P15472, DOI 10.1074/jbc.M112262200; Macheroux P, 1998, BIOCHEM J, V332, P413, DOI 10.1042/bj3320413; Marina A, 2005, EMBO J, V24, P4247, DOI 10.1038/sj.emboj.7600886; Martinez-Argudo I, 2004, P NATL ACAD SCI USA, V101, P16316, DOI 10.1073/pnas.0405312101; Martinez-Argudo I, 2004, MOL MICROBIOL, V52, P1731, DOI 10.1111/j.1365-2958.2004.04089.x; Martinez-Argudo I, 2004, J BACTERIOL, V186, P601, DOI 10.1128/JB.186.3.601-610.2004; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Money T, 1999, J BACTERIOL, V181, P4461, DOI 10.1128/JB.181.15.4461-4468.1999; Perry S, 2005, J MOL BIOL, V346, P935, DOI 10.1016/j.jmb.2004.12.033; Qin L, 2003, J BACTERIOL, V185, P3429, DOI 10.1128/JB.185.11.3429-3435.2003; Reyes-Ramirez F, 2002, J BACTERIOL, V184, P6777, DOI 10.1128/JB.184.24.6777-6785.2002; Reyes-Ramirez F, 2001, J BACTERIOL, V183, P3076, DOI 10.1128/JB.183.10.3076-3082.2001; Rudnick P, 2002, J BACTERIOL, V184, P812, DOI 10.1128/JB.184.3.812-820.2002; Soderback E, 1998, MOL MICROBIOL, V28, P179, DOI 10.1046/j.1365-2958.1998.00788.x; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wolanin PM, 2002, GENOME BIOL, V3; WOODLEY P, 1994, MOL MICROBIOL, V13, P619, DOI 10.1111/j.1365-2958.1994.tb00456.x; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	34	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13429	13437		10.1074/jbc.M610827200	http://dx.doi.org/10.1074/jbc.M610827200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355964	hybrid			2022-12-27	WOS:000246060300032
J	Dai, QY; Sheng, ZY; Geiger, JH; Castellino, FJ; Prorok, M				Dai, Qiuyun; Sheng, Zhenyu; Geiger, James H.; Castellino, Francis J.; Prorok, Mary			Helix-helix interactions between homo- and heterodimeric gamma-carboxyglutamate-containing conantokin peptides and their derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR ANTAGONIST; COILED-COILS; CALCIUM; BINDING	The conantokins are a family of small, naturally occurring gamma-carboxyglutamate ( Gla)-rich peptides that specifically antagonize the N-methyl-D-aspartate ( NMDA) subtype of ionotropic glutamate receptor. One member of this family, conantokin-G ( con-G), undergoes Ca2+-mediated self-assembly to form an antiparallel helical dimer. Subunit interactions in this complex are incumbent upon intermolecular Ca2+ bridging of Gla residues spaced at i, i + 4, i + 7, i + 11 intervals within the monomer. Herein, we further probe the molecular determinants governing such helix-helix interactions. Select variants were synthesized to evaluate the contributions of non-Gla residues to conantokin self-association. Con-G dimerization was shown to be exothermic and accompanied by positive heat capacity changes. Using positional Gla variants of conantokin-R ( con-R), a non-dimerizing conantokin, i, i + 4, i + 7, i + 11 Gla spacing alone was shown to be insufficient for self-assembly. The Ca2+-dependent antiparallel heterodimerization of con-G and con-T( K7 gamma), two peptides that harbor optimal Gla spacing, was established. Last, the effects of covalently constrained con-G dipeptides on NMDA-evoked current in HEK293 cells expressing combinations of NR1a, NR1b, NR2A, and NR2B subunits of the NMDA receptor were investigated. The antiparallel dipeptide was unique in its ability to potentiate current at NR1a/2A receptors and, like monomeric con-G, was inhibitory at NR1a/2B and NR1b/2B combinations. In contrast, the parallel species was completely inactive at all subunit combinations tested. These results suggest that, under physiological Ca2+ concentrations, equilibrium levels of con-G dimer most likely exist in an antiparallel orientation and exert effects on NMDA receptor activity that differ from the monomer.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Wm Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	University of Notre Dame; University of Notre Dame; Michigan State University	Prorok, M (corresponding author), Univ Notre Dame, Dept Chem & Biochem, 230 Raclin Carmichael Hall, Notre Dame, IN 46556 USA.	mprorok@nd.edu		Dai, Qiuyun/0000-0003-2062-8332; Geiger, James/0000-0002-9443-4488	NHLBI NIH HHS [HL019982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blandl T, 1999, J PEPT RES, V53, P453, DOI 10.1034/j.1399-3011.1999.00042.x; Buczek O, 2005, CELL MOL LIFE SCI, V62, P3067, DOI 10.1007/s00018-005-5283-0; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Chen ZG, 1998, J BIOL CHEM, V273, P16248, DOI 10.1074/jbc.273.26.16248; Cnudde SE, 2007, J AM CHEM SOC, V129, P1586, DOI 10.1021/ja065722q; COLPITTS TL, 1993, INT J PEPT PROT RES, V41, P567; Dai QY, 2004, BIOCHEMISTRY-US, V43, P13225, DOI 10.1021/bi048796s; Dai QY, 2004, J MOL BIOL, V336, P731, DOI 10.1016/j.jmb.2003.12.027; De Crescenzo G, 2003, BIOCHEMISTRY-US, V42, P1754, DOI 10.1021/bi0268450; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Jimenez EC, 2002, EPILEPSY RES, V51, P73, DOI 10.1016/S0920-1211(02)00101-8; Klein RC, 2001, J BIOL CHEM, V276, P26860, DOI 10.1074/jbc.M102428200; Klein RC, 1999, NEUROPHARMACOLOGY, V38, P1819, DOI 10.1016/S0028-3908(99)00065-9; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Li T, 2000, J BIOL CHEM, V275, P18291, DOI 10.1074/jbc.M001790200; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; McClain DL, 2001, J MOL BIOL, V313, P371, DOI 10.1006/jmbi.2001.5044; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MONERA OD, 1993, J BIOL CHEM, V268, P19218; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Prorok M, 1998, J BIOL CHEM, V273, P19573, DOI 10.1074/jbc.273.31.19573; Prorok M, 2001, CURR DRUG TARGETS, V2, P313, DOI 10.2174/1389450013348542; Ragnarsson L, 2006, J NEUROCHEM, V96, P283, DOI 10.1111/j.1471-4159.2005.03574.x; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P6906, DOI 10.1021/bi970321w; Rishavy MA, 2005, J BIOL CHEM, V280, P34870, DOI 10.1074/jbc.M504345200; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; White HS, 2000, J PHARMACOL EXP THER, V292, P425	31	20	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12641	12649		10.1074/jbc.M609087200	http://dx.doi.org/10.1074/jbc.M609087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17347154	hybrid			2022-12-27	WOS:000245942800033
J	Furland, NE; Zanetti, SR; Oresti, GM; Maldonado, EN; Aveldano, MI				Furland, Natalia E.; Zanetti, Samanta R.; Oresti, Gerardo M.; Maldonado, Eduardo N.; Aveldano, Marta I.			Ceramides and sphingomyelins with high proportions of very long-chain polyunsaturated fatty acids in mammalian germ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONGEVITY ASSURANCE GENES; DIPOLYUNSATURATED PHOSPHATIDYLCHOLINES; APOPTOSIS; RAT; TESTIS; SPERMATOGENESIS; CRYPTORCHIDISM; RETINA; IDENTIFICATION; SPERMATOGONIA	Very long-chain polyunsaturated fatty acids (VLCPUFA) have previously been shown to be components of sphingomyelin (SM) of mammalian testis and spermatozoa. Here we examined the fatty acids of testicular ceramide (Cer) in comparison with those of SM in some mammals with a special focus on the rat testis. In bull, cat, dog, rabbit, mouse, and rat, VLCPUFA were found in both testicular lipids, Cer having a higher percentage of VLCPUFA than SM. Rat testis had the highest percentage of VLCPUFA in both lipids, the major ones being 28:4n-6 and 30:5n-6. VLCPUFA-containing SM and Cer occurred in cells located in the seminiferous tubules, where germ cells had a higher percentage of these species than Sertoli cells. Seminiferous tubule fractionation showed that SM and Cer of mitochondria and lysosomes had mostly saturates and negligible VLCPUFA, the latter being important in the SM and Cer of microsomes and other membrane fractions. VLCPUFA were absent from the SM and Cer of rat prepuberal testis, increased with the onset of spermatogenesis to account for nearly 15 and 40% of the total fatty acids of testicular SM and Cer, respectively, remained at those levels throughout the adult life of fertile rats and tended to decrease at advanced ages. Four conditions that lead to selective death of germ cells in vivo, namely experimental cryptorchidism, post-ischemic reperfusion, focalized x-ray irradiation and treatments with the antineoplasic drug doxorubicin, caused the VLCPUFA to disappear from the testicular SM and Cer of adult fertile rats, showing that these lipids are specific traits of spermatogenic cells.	Univ Nacl Sur, Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim, RA-8000 Bahia Blanca, Buenos Aires, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of the South	Aveldano, MI (corresponding author), Consejo Nacl Invest Cient & Tecn, Ctr Reg Invest Basicas & Aplicadas Bahia Blanca, INIBIBB, CC 857, RA-8000 Bahia Blanca, Buenos Aires, Argentina.	avelda@criba.edu.ar	Maldonado, Eduardo/AAN-3907-2020	Maldonado, Eduardo/0000-0002-5285-3027				Antollini SS, 2002, J LIPID RES, V43, P1440, DOI 10.1194/jlr.M200057-JLR200; Anway MD, 2003, BIOL REPROD, V68, P996, DOI 10.1095/biolreprod.102.008045; AVELDANO MI, 1993, J BIOL CHEM, V268, P11663; AVELDANO MI, 1987, J BIOL CHEM, V262, P1180; AVELDANO MI, 1987, J BIOL CHEM, V262, P1172; Barqawi A, 2004, ASIAN J ANDROL, V6, P47; BECKMAN JK, 1979, LIPIDS, V14, P262, DOI 10.1007/BF02533912; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Blauer M, 1999, BIOL REPROD, V60, P588, DOI 10.1095/biolreprod60.3.588; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN ER, 1994, LIPIDS, V29, P825, DOI 10.1007/BF02536249; Christie W.W., 2003, LIPID ANAL; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Dufau M L, 1975, Methods Enzymol, V39, P252; Farooqui SM, 1997, BIOCHEM BIOPH RES CO, V236, P407, DOI 10.1006/bbrc.1997.6954; Furland NE, 2007, J BIOL CHEM, V282, P18151, DOI 10.1074/jbc.M700709200; Furland NE, 2003, LIPIDS, V38, P73, DOI 10.1007/s11745-003-1033-9; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Henriksen K, 1996, J ANDROL, V17, P394; Hikim APS, 1999, REV REPROD, V4, P38; Ito K, 1997, J VET MED SCI, V59, P353, DOI 10.1292/jvms.59.353; Kangasniemi M, 1996, BIOL REPROD, V54, P1200, DOI 10.1095/biolreprod54.6.1200; Kato Masashi, 2001, Journal of Toxicological Sciences, V26, P51, DOI 10.2131/jts.26.51; Kocak I, 2002, ASIAN J ANDROL, V4, P183; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Linn SC, 2001, BIOCHEM SOC T, V29, P831, DOI 10.1042/0300-5127:0290831; Mizutani Y, 2006, BIOCHEM J, V398, P531, DOI 10.1042/BJ20060379; Osawa Y, 2005, J BIOL CHEM, V280, P27879, DOI 10.1074/jbc.M503002200; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; POULOS A, 1987, BIOCHEM J, V248, P961, DOI 10.1042/bj2480961; Ramstedt B, 1999, EUR J BIOCHEM, V266, P997, DOI 10.1046/j.1432-1327.1999.00938.x; ROBINSON BS, 1992, J BIOL CHEM, V267, P1746; ROTSTEIN NP, 1987, LIPIDS, V22, P253, DOI 10.1007/BF02533988; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Saether T, 2003, BIOL REPROD, V69, P117, DOI 10.1095/biolreprod.102.014035; Shetty G, 2004, ENDOCRINOLOGY, V145, P4461, DOI 10.1210/en.2004-0440; Shinoda K, 1999, ARCH TOXICOL, V73, P274, DOI 10.1007/s002040050617; SINGH H, 1994, J BIOL CHEM, V269, P21388; Suomalainen L, 2003, J CLIN ENDOCR METAB, V88, P5572, DOI 10.1210/jc.2003-030776; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; Tilly JL, 1999, CHEM PHYS LIPIDS, V102, P149, DOI 10.1016/S0009-3084(99)00083-3; TURNER TT, 1993, BIOL REPROD, V49, P401, DOI 10.1095/biolreprod49.2.401; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Vietzke JP, 2001, LIPIDS, V36, P299, DOI 10.1007/s11745-001-0721-9; ZANATO VF, 1994, BRAZ J MED BIOL RES, V27, P1273; Ziulkoski AL, 2001, BIOCHEM BIOPH RES CO, V281, P971, DOI 10.1006/bbrc.2001.4440	52	53	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18141	18150		10.1074/jbc.M700708200	http://dx.doi.org/10.1074/jbc.M700708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17392276	hybrid			2022-12-27	WOS:000247302000020
J	Conner, M; Hawtin, SR; Simms, J; Wootten, D; Lawson, Z; Conner, AC; Parslow, RA; Wheatley, M				Conner, Matthew; Hawtin, Stuart R.; Simms, John; Wootten, Denise; Lawson, Zoe; Conner, Alex C.; Parslow, Rosemary A.; Wheatley, Mark			Systematic analysis of the entire second extracellular loop of the V-1a vasopressin receptor - Key residues, conserved throughout a G-protein-coupled receptor family, identified	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; HIGH-AFFINITY BINDING; OXYTOCIN RECEPTOR; AGONIST BINDING; N-TERMINUS; MOLECULAR CHARACTERIZATION; CHEMOKINE RECEPTOR; HORMONE-RECEPTOR; DISULFIDE BOND; V1A RECEPTORS	The roles of extracellular residues of G-protein-coupled receptors (GPCRs) are not well defined compared with residues in transmembrane helices. Nevertheless, it has been established that extracellular domains of both peptide-GPCRs and amine-GPCRs incorporate functionally important residues. Extracellular loop 2 (ECL2) has attracted particular interest, because the x-ray structure of bovine rhodopsin revealed that ECL2 projects into the binding crevice within the transmembrane bundle. Our study provides the first comprehensive investigation into the role of the individual residues comprising the entire ECL2 domain of a small peptide-GPCR. Using the V-1a vasopressin receptor, systematic substitution of all of the ECL2 residues by Ala generated 30 mutant receptors that were characterized pharmacologically. The majority of these mutant receptor constructs (24 in total) had essentially wild-type ligand binding and intracellular signaling characteristics, indicating that these residues are not critical for normal receptor function. However, four aromatic residues Phe(189), Trp(206), Phe(209), and Tyr(218) are important for agonist binding and receptor activation and are highly conserved throughout the neurohypophysial hormone subfamily of peptide-GPCRs. Located in the middle of ECL2, juxtaposed to the highly conserved disulfide bond, Trp(206) and Phe(209) project into the binding crevice. Indeed, Phe(209) is part of the Cys-X-X-X-Ar (where Ar is an aromatic residue) motif, which is well conserved in both peptide-GPCRs and amine-GPCRs. In contrast, Phe(189) and Tyr(218), located at the extreme ends of ECL2, may be important for determining the position of the ECL2 cap over the binding crevice. This study provides mechanistic insight into the roles of highly conserved ECL2 residues.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Wheatley, M (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	m.wheatley@bham.ac.uk	Wootten, Denise/ABD-5703-2021	Wootten, Denise/0000-0003-4563-1642; Simms, John/0000-0002-4675-0902; Wheatley, Mark/0000-0001-6261-5682	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Baneres JL, 2005, J BIOL CHEM, V280, P20253, DOI 10.1074/jbc.M412009200; Birnbaumer R, 1999, ARCH MED RES, V30, P465, DOI 10.1016/S0188-4409(99)00063-6; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Cavalli A, 1996, FEBS LETT, V399, P9, DOI 10.1016/S0014-5793(96)01286-0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Cook JVF, 1997, ENDOCRINOLOGY, V138, P2800, DOI 10.1210/en.138.7.2800; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; Ding XQ, 2002, MOL PHARMACOL, V61, P1041, DOI 10.1124/mol.61.5.1041; Elling CE, 2000, BIOCHEMISTRY-US, V39, P667, DOI 10.1021/bi991777b; Fourmy D, 2002, PHARMACOL TOXICOL, V91, P313, DOI 10.1034/j.1600-0773.2002.910608.x; Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629; Gnagey AL, 1999, MOL PHARMACOL, V56, P1245, DOI 10.1124/mol.56.6.1245; Hawtin SR, 2005, FEBS LETT, V579, P349, DOI 10.1016/j.febslet.2004.10.108; Hawtin SR, 2005, MOL ENDOCRINOL, V19, P2871, DOI 10.1210/me.2005-0148; Hawtin SR, 2002, MOL ENDOCRINOL, V16, P600, DOI 10.1210/me.16.3.600; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Hawtin SR, 2001, BIOCHEM J, V357, P73, DOI 10.1042/0264-6021:3570073; Hawtin SR, 2000, BIOCHEMISTRY-US, V39, P13524, DOI 10.1021/bi0013400; Hawtin SR, 2006, J BIOL CHEM, V281, P38478, DOI 10.1074/jbc.M607639200; Hibert M, 1999, J RECEPT SIGNAL TR R, V19, P589, DOI 10.3109/10799899909036674; HOWL J, 1995, GEN PHARMACOL-VASC S, V26, P1143, DOI 10.1016/0306-3623(95)00016-T; Howl J, 1997, FASEB J, V11, P582, DOI 10.1096/fasebj.11.7.9212082; Howl J, 1996, BIOCHEM J, V317, P577, DOI 10.1042/bj3170577; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Kleinau G, 2007, J BIOL CHEM, V282, P518, DOI 10.1074/jbc.M606176200; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; Lequin O, 2002, J BIOL CHEM, V277, P22386, DOI 10.1074/jbc.M110614200; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Li SH, 2001, J BIOL CHEM, V276, P7968, DOI 10.1074/jbc.M010482200; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; NODA K, 1994, J BIOL CHEM, V269, P6743; Ott TR, 2002, MOL ENDOCRINOL, V16, P1079, DOI 10.1210/me.16.5.1079; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Patel AB, 2004, P NATL ACAD SCI USA, V101, P10048, DOI 10.1073/pnas.0402848101; Patel AB, 2005, J MOL BIOL, V347, P803, DOI 10.1016/j.jmb.2005.01.069; Pellegrini M, 2001, J BIOL CHEM, V276, P22862, DOI 10.1074/jbc.M101057200; Ruan KH, 2001, BIOCHEMISTRY-US, V40, P275, DOI 10.1021/bi001867c; Scarselli M, 2007, J BIOL CHEM, V282, P7385, DOI 10.1074/jbc.M610394200; SCHMIDT A, 1991, FEBS LETT, V282, P77, DOI 10.1016/0014-5793(91)80448-C; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SHARIF M, 1992, NATURE, V357, P279, DOI 10.1038/357279a0; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Thibonnier M, 2001, ANNU REV PHARMACOL, V41, P175, DOI 10.1146/annurev.pharmtox.41.1.175; Wesley VJ, 2002, BIOCHEMISTRY-US, V41, P5086, DOI 10.1021/bi015990v; Wurch T, 2000, J NEUROCHEM, V75, P1180, DOI 10.1046/j.1471-4159.2000.0751180.x; Zeng FY, 1999, J NEUROCHEM, V72, P2404, DOI 10.1046/j.1471-4159.1999.0722404.x; Zhang L, 2002, BIOCHEMISTRY-US, V41, P61, DOI 10.1021/bi0117955; Zhao MM, 1996, MOL PHARMACOL, V50, P1118; Zhou NM, 2001, J BIOL CHEM, V276, P42826, DOI 10.1074/jbc.M106582200	56	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17405	17412		10.1074/jbc.M702151200	http://dx.doi.org/10.1074/jbc.M702151200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17403667	Green Accepted, hybrid			2022-12-27	WOS:000247084500010
J	Kim, HT; Kim, KP; Lledias, F; Kisselev, AF; Scaglione, KM; Skowyra, D; Gygi, SP; Goldberg, AL				Kim, Hyoung Tae; Kim, Kwang Pyo; Lledias, Fernando; Kisselev, Alexei F.; Scaglione, K. Matthew; Skowyra, Dorota; Gygi, Steven P.; Goldberg, Alfred L.			Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUBIQUITIN CHAINS; MULTIUBIQUITIN CHAIN; RING FINGER; DNA-REPAIR; 26S PROTEASOME; DEGRADATION; COMPLEX; SUBSTRATE; DOMAIN; LYSINE	It is generally assumed that a specific ubiquitin ligase (E3) links protein substrates to polyubiquitin chains containing a single type of isopeptide linkage, and that chains composed of linkages through Lys(48), but not through Lys(63), target proteins for proteasomal degradation. However, when we carried out a systematic analysis of the types of ubiquitin (Ub) chains formed by different purified E3s and Ub-conjugating enzymes (E2s), we found, using Ub mutants and mass spectrometry, that the U-box E3, CHIP, and Ring finger E3s, MuRF1 and Mdm2, with the E2, UbcH5, form a novel type of Ub chain that contains all seven possible linkages, but predominantly Lys(48), Lys(63), and Lys(11) linkages. Also, these heterogeneous chains contain forks (bifurcations), where two Ub molecules are linked to the adjacent lysines at Lys(6) + Lys(11), Lys(27) + Lys(29), or Lys(29) + Lys(33) on the preceding Ub molecule. However, the HECT domain E3s, E6AP and Nedd4, with the same E2, UbcH5, form homogeneous chains exclusively, either Lys48 chains (E6AP) or Lys(63) chains (Nedd4). Furthermore, with other families of E2s, CHIP and MuRF1 synthesize homogeneous Ub chains on the substrates. Using the dimeric E2, UbcH13/ Uev1a, they attach Lys(63) chains, but with UbcH1 (E2-25K), MuRF1 synthesizes Lys(48) chains on the substrate. We then compared the capacity of the forked heterogeneous chains and homogeneous chains to support proteasomal degradation. When troponin I was linked by MuRF1 to a Lys(48)-Ub chain or, surprisingly, to a Lys(63)-Ub chain, troponin I was degraded rapidly by pure 26S proteasomes. However, when linked to the mixed forked chains, troponin I was degraded quite poorly, and its polyUb chain, especially the forked linkages, was disassembled slowly by proteasome- associated isopeptidases. Because these Ring finger and U- box E3s with UbcH5 target proteins for degradation in vivo, but Lys(63) chains do not, cells probably contain additional factors that prevent formation of such nondegradable Ub- conjugates and that protect proteins linked to Lys(63)-Ub chains from proteasomal degradation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA; St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Konkuk Univ, Dept Mol Biotechnol, Inst Biomed Sci, Seoul 143701, South Korea	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Saint Louis University; Konkuk University	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	alfred_goldberg@hms.harvard.edu	Kim, Kwang Pyo/AAG-1815-2020	Scaglione, Kenneth/0000-0002-3858-9418; Lledias, Fernando/0000-0002-2141-8727; Kim, Hyoung Tae/0000-0002-0270-2749	NIGMS NIH HHS [R01 GM051923, R01 GM051923-12, R01 GM65267, R01 GM065267] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065267, R01GM051923] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Babbitt SE, 2005, CELL, V121, P553, DOI 10.1016/j.cell.2005.03.028; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Brzovic PS, 2006, MOL CELL, V21, P873, DOI 10.1016/j.molcel.2006.02.008; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; Coux O, 1998, J BIOL CHEM, V273, P8820, DOI 10.1074/jbc.273.15.8820; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Gazdoiu S, 2005, P NATL ACAD SCI USA, V102, P15053, DOI 10.1073/pnas.0507646102; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1991, J BIOL CHEM, V266, P5104; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kedar V, 2004, P NATL ACAD SCI USA, V101, P18135, DOI 10.1073/pnas.0404341102; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Merkley N, 2004, J BIOL CHEM, V279, P47139, DOI 10.1074/jbc.M409576200; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Park KC, 1997, ARCH BIOCHEM BIOPHYS, V347, P78, DOI 10.1006/abbi.1997.0311; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Petroski MD, 2005, CELL, V123, P1107, DOI 10.1016/j.cell.2005.09.033; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Wang M, 2005, EMBO J, V24, P4324, DOI 10.1038/sj.emboj.7600895; Wang M, 2006, EMBO J, V25, P1710, DOI 10.1038/sj.emboj.7601061; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023	60	337	357	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17375	17386		10.1074/jbc.M609659200	http://dx.doi.org/10.1074/jbc.M609659200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17426036	hybrid			2022-12-27	WOS:000247084500007
J	Feinberg, H; Taylor, ME; Weis, WI				Feinberg, Hadar; Taylor, Maureen E.; Weis, William I.			Scavenger receptor C-type lectin binds to the leukocyte cell surface glycan Lewis(x) by a novel mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CRYSTAL-STRUCTURE; LIGAND-BINDING; DC-SIGN; RECOGNITION; OLIGOSACCHARIDES; DOMAIN; ARRAY	The scavenger receptor C-type lectin (SRCL) is unique in the family of class A scavenger receptors, because in addition to binding sites for oxidized lipoproteins it also contains a C-type carbohydrate-recognition domain (CRD) that interacts with specific glycans. Both human and mouse SRCL are highly specific for the Lewis(x) trisaccharide, which is commonly found on the surfaces of leukocytes and some tumor cells. Structural analysis of the CRD of mouse SRCL in complex with Lewisx and mutagenesis show the basis for this specificity. The interaction between mouse SRCL and Lewisx is analogous to the way that selectins and DC-SIGN bind to related fucosylated glycans, but the mechanism of the interaction is novel, because it is based on a primary galactose-binding site similar to the binding site in the asialoglycoprotein receptor. Crystals of the human receptor lacking bound calcium ions reveal an alternative conformation in which a glycan ligand would be released during receptor-mediated endocytosis.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94306 USA; Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94306 USA; Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England	Stanford University; Stanford University; Imperial College London	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, 299 Campus Dr, W Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Taylor, Maureen/0000-0001-8300-4987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116, R01GM050565] Funding Source: NIH RePORTER; NIGMS NIH HHS [U54 GM062116, GM62116, R01 GM050565, GM50565] Funding Source: Medline; Wellcome Trust [075565] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		ASA D, 1992, GLYCOBIOLOGY, V2, P395, DOI 10.1093/glycob/2.5.395; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coombs PJ, 2006, GLYCOBIOLOGY, V16, p1C, DOI 10.1093/glycob/cwj126; Coombs PJ, 2005, J BIOL CHEM, V280, P22993, DOI 10.1074/jbc.M504197200; Elola MT, 2007, BREAST CANCER RES TR, V101, P161, DOI 10.1007/s10549-006-9286-9; Feinberg H, 2000, J BIOL CHEM, V275, P35176, DOI 10.1074/jbc.M005557200; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Meier M, 2000, J MOL BIOL, V300, P857, DOI 10.1006/jmbi.2000.3853; NAKAMURA K, 2001, BIOCHEM BIOPH RES CO, V280, P183; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Perret S, 2005, BIOCHEM J, V389, P325, DOI 10.1042/BJ20050079; Poget SF, 2001, BIOCHEMISTRY-US, V40, P10966, DOI 10.1021/bi002698z; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Walker JR, 2004, BIOCHEMISTRY-US, V43, P3783, DOI 10.1021/bi035871a; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301	24	45	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17250	17258		10.1074/jbc.M701624200	http://dx.doi.org/10.1074/jbc.M701624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17420244	hybrid, Green Accepted			2022-12-27	WOS:000246946500058
J	Kalamajski, S; Aspberg, A; Oldberg, A				Kalamajski, Sebastian; Aspberg, Anders; Oldberg, Ake			The decorin sequence SYIRIADTNIT binds collagen type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; SMALL PROTEOGLYCAN; TARGETED DISRUPTION; CORE; FIBROMODULIN; BIGLYCAN; LUMICAN; IDENTIFICATION; EXPRESSION; HOMOLOGY	Decorin belongs to the small leucine-rich repeat proteoglycan family, interacts with fibrillar collagens, and regulates the assembly, structure, and biomechanical properties of connective tissues. The decorin-collagen type I-binding region is located in leucine-rich repeats 5-6. Site-directed mutagenesis of this 54-residue-long collagen-binding sequence identifies Arg-207 and Asp-210 in leucine-rich repeat 6 as crucial for the binding to collagen. The synthetic peptide SYIRIADTNIT, which includes Arg-207 and Asp-210, inhibits the binding of full-length recombinant decorin to collagen in vitro. These collagen-binding amino acids are exposed on the exterior of the beta-sheet-loop structure of the leucine-rich repeat. This resembles the location of interacting residues in other leucine-rich repeat proteins.	Lund Univ, Dept Expt Med Sci, BMC B12, SE-22184 Lund, Sweden; Univ Copenhagen, Dept Mol Biol, DK-2100 Copenhagen, Denmark	Lund University; University of Copenhagen	Oldberg, A (corresponding author), Lund Univ, Dept Expt Med Sci, BMC B12, SE-22184 Lund, Sweden.	Ake.Oldberg@med.lu.se		Kalamajski, Sebastian/0000-0002-6600-9302; Aspberg, Anders/0000-0002-6588-6944				Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Chen CZ, 1997, P NATL ACAD SCI USA, V94, P1761, DOI 10.1073/pnas.94.5.1761; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Kvist AJ, 2006, J BIOL CHEM, V281, P33127, DOI 10.1074/jbc.M607892200; Liu XH, 2005, BIOCHEM BIOPH RES CO, V338, P1342, DOI 10.1016/j.bbrc.2005.10.096; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Nareyeck G, 2004, EUR J BIOCHEM, V271, P3389, DOI 10.1111/j.1432-1033.2004.04273.x; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Parthiban V, 2006, NUCLEIC ACIDS RES, V34, pW239, DOI 10.1093/nar/gkl190; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Scott PG, 2004, P NATL ACAD SCI USA, V101, P15633, DOI 10.1073/pnas.0402976101; Shimizu A, 2004, J BIOL CHEM, V279, P16285, DOI 10.1074/jbc.M307230200; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746	33	59	63	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16062	16067		10.1074/jbc.M700073200	http://dx.doi.org/10.1074/jbc.M700073200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426031	hybrid			2022-12-27	WOS:000246794300014
J	Munoz-Espin, D; Fuertes, MA; Jimenez, M; Villar, L; Alonso, C; Rivas, G; Salas, M; Meijer, WJJ				Munoz-Espin, Daniel; Fuertes, Miguel A.; Jimenez, Mercedes; Villar, Laurentino; Alonso, Carlos; Rivas, German; Salas, Margarita; Meijer, Wilfried J. J.			Structural and functional analysis of phi 29 p16.7C dimerization mutants - Identification of a novel aromatic cage dimerization motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; DNA-REPLICATION; CELL-MEMBRANE; RNA-POLYMERASE; ASSOCIATION; ULTRACENTRIFUGATION; VISUALIZATION; MODEL	Prokaryotic DNA replication is compartmentalized at the cellular membrane. The Bacillus subtilis phage phi 29-encoded membrane protein p16.7 is one of the few proteins known to be involved in the organization of prokaryotic membrane-associated DNA replication. The functional DNA binding domain of p16.7 is constituted by its C-terminal half, p16.7C, which forms high affinity dimers in solution and which can form higher order oligomers. Recently, the solution and crystal structures of p16.7C and the crystal structure of the p16.7C-DNA complex have been solved. Here, we have studied the p16.7C dimerization process and the structural and functional roles of p16.7 residues Trp-116 and Asn-120 and its last nine C-terminal amino acids, which form an extended tail. The results obtained show that transition of folded dimers into unfolded monomers occurs without stable intermediates and that both Trp-116 and the C-terminal tail are important for dimerization and functionality of p16.7C. Residue Trp-116 is involved in formation of a novel aromatic cage dimerization motif, which we call "Pro cage." Finally, whereas residue Asn-120 plays a minor role in p16.7C dimerization, we show that it is critical for both oligomerization and DNA binding, providing further evidence that DNA binding and oligomerization of p16.7C are coupled processes.	Univ Autonoma Madrid, CSIC, Ctr Mol Biol, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain; CSIC, Ctr Invest Biol, E-28040 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Mol Biol, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain.	msalas@cbm.uam.es	Salas, Margarita/J-9873-2014; Rivas, German/AFL-7528-2022; Rivas, German/AAG-7458-2022; Jimenez Sarmiento, Mercedes/K-2691-2014	Salas, Margarita/0000-0001-5939-3441; Rivas, German/0000-0003-3450-7478; Rivas, German/0000-0003-3450-7478; Jimenez Sarmiento, Mercedes/0000-0003-2006-1903; Meijer, Wilfried/0000-0003-1842-0049				Albert A, 2005, J BIOL CHEM, V280, P42486, DOI 10.1074/jbc.C500429200; Asensio JL, 2005, J BIOL CHEM, V280, P20730, DOI 10.1074/jbc.M501687200; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Cole JL, 2004, METHOD ENZYMOL, V384, P212; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; Firshein W, 1997, MOL MICROBIOL, V23, P1, DOI 10.1046/j.1365-2958.1997.2061569.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; Howlett GJ, 2006, CURR OPIN CHEM BIOL, V10, P430, DOI 10.1016/j.cbpa.2006.08.017; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; IVARIE RD, 1973, VIROLOGY, V52, P351, DOI 10.1016/0042-6822(73)90330-9; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kruppa GH, 2003, RAPID COMMUN MASS SP, V17, P155, DOI 10.1002/rcm.885; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lobley A, 2001, BIOPHYS J, V80, p373A; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Lyle JM, 2002, SCIENCE, V296, P2218, DOI 10.1126/science.1070585; MAO D, 1982, BIOCHEMISTRY-US, V21, P4960, DOI 10.1021/bi00263a020; Meijer WJJ, 2001, MOL MICROBIOL, V39, P731, DOI 10.1046/j.1365-2958.2001.02260.x; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Munoz-Espin D, 2004, J BIOL CHEM, V279, P50437, DOI 10.1074/jbc.M403297200; Neidigh JW, 2002, NAT STRUCT BIOL, V9, P425, DOI 10.1038/nsb798; Noirot-Gros MF, 2002, P NATL ACAD SCI USA, V99, P8342, DOI 10.1073/pnas.122040799; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rivas G, 2003, BIOCHEM SOC T, V31, P1015; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Serna-Rico A, 2002, J BIOL CHEM, V277, P6733, DOI 10.1074/jbc.M109312200; Serna-Rico A, 2003, EMBO J, V22, P2297, DOI 10.1093/emboj/cdg221; Shao X, 1997, BIOCHEMISTRY-US, V36, P9941, DOI 10.1021/bi9707786; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Sueoka N, 1998, PROG NUCLEIC ACID RE, V59, P35; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	1	2	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16521	16531		10.1074/jbc.M611778200	http://dx.doi.org/10.1074/jbc.M611778200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426023	hybrid, Green Published			2022-12-27	WOS:000246794300059
J	Sharma, SM; Bronisz, A; Hu, R; Patel, K; Mansky, KC; Sif, S; Ostrowski, MC				Sharma, Sudarshana M.; Bronisz, Agnieszka; Hu, Rong; Patel, Krupen; Mansky, Kim C.; Sif, Said; Ostrowski, Michael C.			MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA TRANSCRIPTION FACTOR; FACTOR FAMILY; TERMINAL DIFFERENTIATION; NUCLEAR FACTOR; C-FOS; EXPRESSION; ACTIVATION; RECEPTOR; MOUSE; CELLS	Transcription factors NFATc1, PU.1, and MITF collaborate to regulate specific genes in response to colony-stimulating factor-1 (CSF-1) and receptor activator of NF-kappa B ligand (RANKL) signaling during osteoclast differentiation. However, molecular details concerning timing and mechanism of specific events remain ill-defined. In bone marrow-derived precursors, CSF-1 alone promoted assembly of MITF-PU.1 complexes at osteoclast target gene promoters like cathepsin K and acid 5 phosphatase without increasing gene expression. The combination of RANKL and CSF-1 concurrently increased the levels of MAPK-phosphorylated forms of MITF, p38 MAPK, and SWI/SNF chromatin-remodeling complexes bound to these target promoters and markedly increased expression of the genes. NFATc1 was subsequently recruited to complexes at the promoters during terminal stages of osteoclast differentiation. Genetic analysis of Mitf and Pu.1 in mouse models supported the critical interaction of these genes in osteoclast differentiation. The results define MITF and PU.1 as nuclear effectors that integrate CSF-1/RANKL signals during osteoclast differentiation to initiate expression of target genes, whereas a complex that includes NFATc1 may act to maintain target gene expression in differentiated cells.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Minnesota, Div Orthodont, Dept Dev & Surg Sci, Sch Dent, Minneapolis, MN 55455 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Minnesota System; University of Minnesota Twin Cities	Ostrowski, MC (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 37OA Tzagoumis Med Res Facil,420 W 12th Ave, Columbus, OH 43210 USA.	michael.ostrowski@osumc.edu	Sharma, Sudarshana Mangalore/AAI-2475-2019; Bronisz, Agnieszka/M-3485-2019; Bronisz, Agnieszka/G-5980-2019; Ostrowski, Michael/H-3108-2011	Bronisz, Agnieszka/0000-0002-5841-1051; Bronisz, Agnieszka/0000-0002-5841-1051; Sif, Said/0000-0001-6268-1145; Mansky, Kim/0000-0002-2826-5030; Sharma, Sudarshana/0000-0002-9745-0061; Ostrowski, Michael/0000-0003-2948-6297	NIAMS NIH HHS [R01-AR-0447129, R01 AR044719] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044719] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Bronisz A, 2006, MOL BIOL CELL, V17, P3897, DOI 10.1091/mbc.E06-05-0470; Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012; de la Serna IL, 2006, J BIOL CHEM, V281, P20233, DOI 10.1074/jbc.M512052200; Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hershey CL, 2004, BONE, V34, P689, DOI 10.1016/j.bone.2003.08.014; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P295; Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200; Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Sankar U, 2004, J BONE MINER RES, V19, P1339, DOI 10.1359/JBMR.040321; So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	33	135	138	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15921	15929		10.1074/jbc.M609723200	http://dx.doi.org/10.1074/jbc.M609723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403683	hybrid			2022-12-27	WOS:000246589600067
J	Shimizu, R; Trainor, CD; Nishikawa, K; Kobayashi, M; Ohneda, K; Yamamoto, M				Shimizu, Ritsuko; Trainor, Cecelia D.; Nishikawa, Keizo; Kobayashi, Makoto; Ohneda, Kinuko; Yamamoto, Masayuki			GATA-1 self-association controls erythroid development in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; CREB-BINDING PROTEIN; DNA-BINDING; ZINC-FINGER; HEMATOPOIETIC TRANSCRIPTION; GENE; DIFFERENTIATION; ACETYLATION; DOMAIN; EXPRESSION	GATA-1 is the key transcription factor for the development of the erythroid, megakaryocytic, eosinophilic, and mast cell lineages. GATA-1 possesses the ability to self-associate, and this characteristic has been suggested to be important for GATA-1 function. To elucidate the roles self-associated GATA-1 plays during hematopoietic cell development in vivo, in this study we prepared GATA-1 mutants in which three lysine residues potentially contributing to the self-association (Lys-245, Lys-246, and Lys-312) are substituted in combination with alanines. Of the mutants, 3KA harboring alanine substitutions in all three lysines showed reduced self-association activity without considerable interference in the modification of GATA-1 by acetylation. We generated transgenic mouse lines that express these GATA-1 mutants utilizing the Gata1 hematopoietic regulatory domain, and crossed the mice to Gata1 knockdown (GATA-1.05) mutant mice. Although NKA (K245A and K246A) and CKA (K312A) mutants almost fully rescued the GATA-1.05 mice from anemia and embryonic lethality, the 3KA mutant only partially rescued the GATA-1.05 mutant mice. Even with the higher than endogenous level expression, GATA-1.05/Y::3KA embryos were prone to die at various stages in mid-to-late gestation. Live birth and an anemic phenotype were restored in some embryos depending on the expression level of the 3KA transgene. The expression of the transferrin receptor and heme biosynthesis enzymes was impaired in the yolk sac and liver of the 3KA-rescued embryos. Immature erythroid cells with insufficient expression of the transferrin receptor accumulated in the livers of 3KA-rescued embryos. These results provide the first convincing line of evidence that the self-association of GATA-1 is important for proper mammalian erythroid development in vivo.	Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Japan Sci & Technol Agcy, Explorat Res Adv Technol Environm Response Projec, Tsukuba, Ibaraki 3058577, Japan; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University of Tsukuba; University of Tsukuba; Japan Science & Technology Agency (JST); University of Tsukuba; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Yamamoto, M (corresponding author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Tennoudai 1-1-1, Tsukuba, Ibaraki 3058577, Japan.	masi@tara.tsukuba.ac.jp	Kobayashi, Makoto/B-2537-2008; Shimizu, Ritsuko/A-4877-2010; Ohneda, Kinuko/AAC-8822-2019; Yamamoto, Masayuki/A-4873-2010	Kobayashi, Makoto/0000-0001-6660-450X; Shimizu, Ritsuko/0000-0001-6672-7606; Yamamoto, Masayuki/0000-0002-9073-9436	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK011005, ZIADK011005] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Ghirlando R, 2000, J BIOL CHEM, V275, P28152; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Hung HL, 1999, MOL CELL BIOL, V19, P3496; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Ito T, 2000, GENE DEV, V14, P1899; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kobayashi M, 2001, DEVELOPMENT, V128, P2341; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Lamonica JM, 2006, BLOOD, V108, P3736, DOI 10.1182/blood-2006-07-032847; Levy JE, 1999, NAT GENET, V21, P396, DOI 10.1038/7727; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; Newton A, 2001, J BIOL CHEM, V276, P35794, DOI 10.1074/jbc.M106256200; Nishikawa K, 2003, MOL CELL BIOL, V23, P8295, DOI 10.1128/MCB.23.22.8295-8305.2003; Nishimura S, 2000, MOL CELL BIOL, V20, P713, DOI 10.1128/MCB.20.2.713-723.2000; Ohneda K, 2002, GENES CELLS, V7, P1243, DOI 10.1046/j.1365-2443.2002.00595.x; Onodera K, 1997, P NATL ACAD SCI USA, V94, P4487, DOI 10.1073/pnas.94.9.4487; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Shimizu R, 2005, SEMIN CELL DEV BIOL, V16, P129, DOI 10.1016/j.semcdb.2004.11.001; Shimizu R, 2004, MOL CELL BIOL, V24, P10814, DOI 10.1128/MCB.24.24.10814-10825.2004; Shimizu R, 2004, BLOOD, V103, P2560, DOI 10.1182/blood-2003-07-2514; Shimizu R, 2001, EMBO J, V20, P5250, DOI 10.1093/emboj/20.18.5250; Suzuki N, 2003, BLOOD, V102, P3575, DOI 10.1182/blood-2003-04-1154; Takahashi S, 2000, BLOOD, V96, P910, DOI 10.1182/blood.V96.3.910.015k29_910_916; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wassarman P. M., 1993, METHODS ENZYMOLOGY G, V225, P747; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Zhang P, 2000, BLOOD, V96, P2641	47	24	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15862	15871		10.1074/jbc.M701936200	http://dx.doi.org/10.1074/jbc.M701936200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17374603	hybrid			2022-12-27	WOS:000246589600061
J	Andersen, DS; Leevers, SJ				Andersen, Ditte S.; Leevers, Sally J.			The essential Drosophila ATP-binding cassette domain protein, pixie, binds the 40 S ribosome in an ATP-dependent manner and is required for translation initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNASE-L INHIBITOR; 2-5A/RNASE L PATHWAY; EIF3; BIOGENESIS; COMPLEX; GENE	The Drosophila gene, pixie, is an essential gene required for normal growth and translation. Pixie is the fly ortholog of human RLI, which was first identified as an RNase L inhibitor, and yeast Rli1p, which has recently been shown to play a role in translation initiation and ribosome biogenesis. These proteins are all soluble ATP-binding cassette proteins with two N-terminal iron-sulfur clusters. Here we demonstrate that Pixie can be isolated from cells in complex with eukaryotic translation initiation factor 3 and ribosomal proteins of the small subunit. In addition, our analysis of polysome profiles reveals that double-stranded RNA interference-mediated depletion of Pixie results in an increase in empty 80 S ribosomes and a corresponding decrease in polysomes. Thus Pixie is required for normal levels of translation initiation. We also find that Pixie associates with the 40 S subunit on sucrose density gradients in an ATP-dependent manner. Our observations are consistent with Pixie playing a catalytic role in the assembly of complexes required for translation initiation. Thus, the function of this soluble ATP-binding cassette domain protein family in translation initiation has been conserved from yeast through to higher eukaryotes.	Canc Res UK London Res Inst, Growth Regulat Lab, London WC2A 3PX, England	Cancer Research UK	Leevers, SJ (corresponding author), Canc Res UK London Res Inst, Growth Regulat Lab, POB 123,44 Lincolns Inn Fields, London WC2A 3PX, England.	sally.leevers@cancer.org.uk		Andersen, Ditte/0000-0003-1209-6102				Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Chen ZQ, 2006, J BIOL CHEM, V281, P7452, DOI 10.1074/jbc.M510603200; Coelho CMA, 2005, DEVELOPMENT, V132, P5411, DOI 10.1242/dev.02148; Coelho CMA, 2005, GENETICS, V171, P597, DOI 10.1534/genetics.105.045021; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; Gabaldon T, 2004, CELL MOL LIFE SCI, V61, P930, DOI 10.1007/s00018-003-3387-y; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hinnebusch AG, 2006, TRENDS BIOCHEM SCI, V31, P553, DOI 10.1016/j.tibs.2006.08.005; Kerr ID, 2004, BIOCHEM BIOPH RES CO, V315, P166, DOI 10.1016/j.bbrc.2004.01.044; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Kolupaeva VG, 2005, RNA, V11, P470, DOI 10.1261/rna.7215305; Lambertsson A, 1998, ADV GENET, V38, P69, DOI 10.1016/S0065-2660(08)60142-X; Lasko P, 2000, J CELL BIOL, V150, pF51, DOI 10.1083/jcb.150.2.F51; Le Roy F, 2005, NAT STRUCT MOL BIOL, V12, P505, DOI 10.1038/nsmb944; Martinand C, 1998, EUR J BIOCHEM, V254, P248, DOI 10.1046/j.1432-1327.1998.2540248.x; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; Zachariou A, 2003, EMBO J, V22, P6642, DOI 10.1093/emboj/cdg617; Zhao ZY, 2004, BIOCHEM BIOPH RES CO, V323, P104, DOI 10.1016/j.bbrc.2004.08.068	24	55	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14752	14760		10.1074/jbc.M701361200	http://dx.doi.org/10.1074/jbc.M701361200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17392269	hybrid			2022-12-27	WOS:000246589000010
J	Graham, ME; Anggono, V; Bache, N; Larsen, MR; Craft, GE; Robinson, PJ				Graham, Mark E.; Anggono, Victor; Bache, Nicolai; Larsen, Martin R.; Craft, George E.; Robinson, Phillip J.			The in vivo phosphorylation sites of rat brain dynamin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; MEDIATED ENDOCYTOSIS; MASS-SPECTROMETRY; SH3 DOMAIN; DEPOLARIZATION; SYNAPTOSOMES; CDK5; MICROCOLUMNS	Dynamin I (dynI) is phosphorylated in synaptosomes at Ser(774) and Ser(778) by cyclin-dependent kinase 5 to regulate recruitment of syndapin I for synaptic vesicle endocytosis, and in PC12 cells on Ser(857). Hierarchical phosphorylation of Ser(774) precedes phosphorylation of Ser(778). In contrast, Thr(780) phosphorylation by cdk5 has been reported as the sole site (Tomizawa, K., Sunada, S., Lu, Y. F., Oda, Y., Kinuta, M., Ohshima, T., Saito, T., Wei, F. Y., Matsushita, M., Li, S. T., Tsutsui, K., Hisanaga, S. I., Mikoshiba, K., Takei, K., and Matsui, H. (2003) J. Cell Biol. 163, 813-824). To resolve the discrepancy and to better understand the biological roles of dynI phosphorylation, we undertook a systematic identification of all phosphorylation sites in rat brain nerve terminal dynI. Using phosphoamino acid analysis, exclusively phospho-serine residues were found. Thr(780) phosphorylation was not detectable. Mutation of Ser(774), Ser(778), and Thr(780) confirmed that Thr(780) phosphorylation is restricted to in vitro conditions. Mass spectrometry of P-32-labeled phosphopeptides separated by two-dimensional mapping revealed seven in vivo phosphorylation sites: Ser(774), Ser(778), Ser(822), Ser(851), Ser(857), Ser(512), and Ser(347). Quantification of P-32 radiation in each phosphopeptide showed that Ser(774) and Ser(778) were the major sites (up to 69% of the total), followed by Ser(851) and Ser(857) (12%), and Ser(853) (2%). Phosphorylation of Ser(851) and Ser(857) was restricted to the long tail splice variant dynIxa and was not hierarchical. Co-purified, P-32- labeled dynIII was phosphorylated at Ser(759), Ser(763), and Ser(853). Ser(853) is homologous to Ser(851) in dynIxa. The results identify all major and several minor phosphorylation sites in dynI and provide the first measure of their relative abundance and relative responses to depolarization. The multiple phospho-sites suggest subtle regulation of synaptic vesicle endocytosis by new protein kinases and new protein-protein interactions. The homologous dynI and dynIII phosphorylation indicates a high mechanistic similarity. The results suggest a unique role for the long splice variants of dynI and dynIII in nerve terminals.	Childrens Med Res Inst, Cell Signaling Unit, Wentworthville, NSW 2145, Australia; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	Children's Medical Research Institute - Australia; University of Southern Denmark	Robinson, PJ (corresponding author), Childrens Med Res Inst, Cell Signaling Unit, Locked Bag 23, Wentworthville, NSW 2145, Australia.	probinson@cmri.com.au	Graham, Mark E/A-6480-2014; Robinson, Phillip J/G-4008-2011; Anggono, Victor/J-2750-2013; Larsen, Martin Rossel/F-1411-2015	Graham, Mark E/0000-0002-7290-1217; Robinson, Phillip J/0000-0002-7878-0313; Anggono, Victor/0000-0002-4062-4884; Larsen, Martin Rossel/0000-0001-6203-0123				Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Anggono V, 2006, NAT NEUROSCI, V9, P752, DOI 10.1038/nn1695; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Gray NW, 2003, CURR BIOL, V13, P510, DOI 10.1016/S0960-9822(03)00136-2; HOSOYA H, 1994, BIOCHEM BIOPH RES CO, V202, P1127, DOI 10.1006/bbrc.1994.2045; Huang Y, 2004, BIOCHEMISTRY-US, V43, P10173, DOI 10.1021/bi036060+; Kapp EA, 2003, ANAL CHEM, V75, P6251, DOI 10.1021/ac034616t; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; Larsen MR, 2004, MOL CELL PROTEOMICS, V3, P456, DOI 10.1074/mcp.M300105-MCP200; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MEISENHELDER J, 1999, CURRENT PROTOCOLS PR; Nguyen C, 2003, J CELL BIOL, V163, P697, DOI 10.1083/jcb.200310038; Powell KA, 2000, J BIOL CHEM, V275, P11610, DOI 10.1074/jbc.275.16.11610; Ramachandran R, 2007, EMBO J, V26, P559, DOI 10.1038/sj.emboj.7601491; ROBINSON PJ, 1983, NEUROSCI LETT, V43, P85, DOI 10.1016/0304-3940(83)90133-7; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SAKAMOTO Y, 1988, J CHROMATOGR, V442, P69, DOI 10.1016/S0021-9673(00)94457-1; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; SIHRA TS, 1993, J NEUROCHEM, V61, P1220, DOI 10.1111/j.1471-4159.1993.tb13612.x; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Yoshimura Y, 2000, MOL BRAIN RES, V81, P118, DOI 10.1016/S0169-328X(00)00170-4	29	42	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14695	14707		10.1074/jbc.M609713200	http://dx.doi.org/10.1074/jbc.M609713200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376771	hybrid			2022-12-27	WOS:000246589000005
J	Nagai, N; Habuchi, H; Kitazume, S; Toyoda, H; Hashimoto, Y; Kimata, K				Nagai, Naoko; Habuchi, Hiroko; Kitazume, Shinobu; Toyoda, Hidenao; Hashimoto, Yasuhiro; Kimata, Koji			Regulation of heparan sulfate 6-O-sulfation by beta-secretase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FIBROBLAST-GROWTH-FACTOR; HAMSTER OVARY CELLS; ALZHEIMERS-DISEASE; EXPRESSION PATTERNS; LEADER PEPTIDASE; FIBRIL FORMATION; CLEAVAGE; 6-O-SULFOTRANSFERASE; BINDING	The enzymes involved in glycosaminoglycan chain biosynthesis are mostly Golgi resident proteins, but some are secreted extracellularly. For example, the activities of heparan sulfate 6-O-sulfotransferase ( HS6ST) and heparan sulfate 3-O-sulfotransferase are detected in the serum as well in the medium of cell lines. However, the biological significance of this is largely unknown. Here we have investigated by means of monitoring green fluorescent protein ( GFP) fluorescence how C-terminally GFP-tagged HS6STs that are stably expressed in CHO-K1 cell lines are secreted/shed. Brefeldin A and monensin treatments revealed that the N-terminal hydrophobic domain of HS6ST3 is processed in the endoplasmic reticulum or cis/medial Golgi. Treatment of HS6ST3-GFP-expressing cells with various protease inhibitors revealed that the cell-permeable beta-secretase inhibitor N-benzyloxycarbonyl-Val-Leu-leucinal ( Z-VLL-CHO) specifically inhibits HS6ST secretion, although this effect was specific for HS6ST3 but not for HS6ST1 and HS6ST2. However, Z-VLL-CHO treatment did not increase the molecular size of the HS6ST3-GFP that accumulated in the cell. Z-VLL-CHO treatment also induced the intracellular accumulation of SP-HS6ST3(-TMD)-GFP, a modified secretory form of HS6ST3 that has the preprotrypsin leader sequence as its N-terminal hydrophobic domain. Diminishment of beta-secretase activity by coexpressing the amyloid precursor protein of a Swedish mutant, a potent beta-secretase substrate, also induced intracellular HS6ST3-GFP accumulation. Moreover, Z-VLL-CHO treatment increased the 6-O-sulfate ( 6S) levels of HS, especially in the disaccharide unit of hexuronic acid-GlcNS( 6S). Thus, the HS6ST3 enzyme in the Golgi apparatus and therefore the 6-O sulfation of heparan sulfates in the cell are at least partly regulated by beta-secretase via an indirect mechanism.	Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan; RIKEN Frontier Res Syst, Glycochain Funct Lab, Wako, Saitama 3511098, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Lab Bioanalyt Chem, Inage Ku, Chiba 2638522, Japan	Aichi Medical University; RIKEN; Chiba University	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Nagakute, Aichi 4801195, Japan.	kimata@amugw.aichi-med-u.ac.jp						Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bink RJ, 2003, J BIOL CHEM, V278, P31118, DOI 10.1074/jbc.M213124200; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Canevari L, 2004, NEUROCHEM RES, V29, P637, DOI 10.1023/B:NERE.0000014834.06405.af; Castillo GM, 1997, J NEUROCHEM, V69, P2452; Chen E, 2005, DEV BIOL, V284, P364, DOI 10.1016/j.ydbio.2005.05.032; Cuello AC, 2005, BRAIN PATHOL, V15, P66; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; DIERSTEIN R, 1986, EMBO J, V5, P427, DOI 10.1002/j.1460-2075.1986.tb04228.x; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; FIKES JD, 1990, J BIOL CHEM, V265, P3417; FOLKMAN J, 1988, AM J PATHOL, V130, P393; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Habuchi H, 2003, BIOCHEM J, V371, P131, DOI 10.1042/BJ20021259; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; Kamimura K, 2001, J BIOL CHEM, V276, P17014, DOI 10.1074/jbc.M011354200; Karamyshev AL, 1998, J MOL BIOL, V277, P859, DOI 10.1006/jmbi.1997.1617; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kotani N, 2005, J BIOCHEM, V137, P315, DOI 10.1093/jb/mvi034; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lindahl B, 1999, J BIOL CHEM, V274, P30631, DOI 10.1074/jbc.274.43.30631; McLaurin J, 1999, AMYLOID, V6, P233, DOI 10.3109/13506129909007334; Nagai N, 2004, J CELL SCI, V117, P3331, DOI 10.1242/jcs.01191; Nogami K, 2004, J BIOL CHEM, V279, P8219, DOI 10.1074/jbc.M307304200; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SNOW AD, 1990, AM J PATHOL, V137, P1253; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	44	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14942	14951		10.1074/jbc.M610691200	http://dx.doi.org/10.1074/jbc.M610691200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17363373	hybrid			2022-12-27	WOS:000246589000032
J	Chan, SJ; Nakagawa, S; Steiner, DF				Chan, Shu Jin; Nakagawa, Satoe; Steiner, Donald F.			Complementation analysis demonstrates that insulin cross-links both alpha subunits in a truncated insulin receptor dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BINDING DOMAIN; EXTRACELLULAR DOMAIN; STRUCTURAL BASIS; LIGAND-BINDING; AFFINITY; EPITOPES; FRAGMENT; KINASE	The insulin receptor is a homodimer composed of two alpha beta half receptors. Scanning mutagenesis studies have identified key residues important for insulin binding in the L1 domain (amino acids 1-150) and C-terminal region (amino acids 704 - 719) of the alpha subunit. However, it has not been shown whether insulin interacts with these two sites within the same alpha chain or whether it cross-links a site from each alpha subunit in the dimer to achieve high affinity binding. Here we have tested the contralateral binding mechanism by analyzing truncated insulin receptor dimers (midi-hIRs) that contain complementary mutations in each alpha subunit. Midi-hIRs containing Ala(14), Ala(64), or Gly(714) mutations were fused with Myc or FLAG epitopes at the C terminus and were expressed separately by transient transfection. Immunoblots showed that R14A + FLAG, F64A + FLAG, and F714G+Myc mutant midi-hIRs were expressed in the medium but insulin binding activity was not detected. However, after co-transfection with R14A+FLAG/ F714G+Myc or F64A + FLAG/ F714G+Myc, hybrid dimers were obtained with a marked increase in insulin binding activity. Competitive displacement assays revealed that the hybrid mutant receptors bound insulin with the same affinity as wild type and also displayed curvilinear Scatchard plots. In addition, when hybrid mutant midi-hIR was covalently cross-linked with I-125(A14)-insulin and reduced, radiolabeled monomer was immunoprecipitated only with anti-FLAG, demonstrating that insulin was bound asymmetrically. These results demonstrate that a single insulin molecule can contact both alpha subunits in the insulin receptor dimer during high affinity binding and this property may be an important feature for receptor signaling.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Steiner, DF (corresponding author), Univ Chicago, Dept Med, 5820 E 58th St, Chicago, IL 60637 USA.	dfsteine@uchicago.edu			NIDDK NIH HHS [P60 DK020595, R01 DK013914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013914, P60DK020595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; Brandt J, 2001, J BIOL CHEM, V276, P12378, DOI 10.1074/jbc.M009402200; CUATRECASAS P, 1972, J BIOL CHEM, V247, P1980; De Meyts P, 2004, BIOESSAYS, V26, P1351, DOI 10.1002/bies.20151; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McKern NM, 2006, NATURE, V443, P218, DOI 10.1038/nature05106; OSIGO H, 2002, CELL, V110, P775; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SHAFFER L, 1994, EUR J BIOCHEM, V221, P1127; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Wan ZL, 2005, BIOCHEMISTRY-US, V44, P5000, DOI 10.1021/bi047585k; Whittaker J, 2005, J BIOL CHEM, V280, P20932, DOI 10.1074/jbc.M411320200; Whittaker J, 2002, J BIOL CHEM, V277, P47380, DOI 10.1074/jbc.M208371200	21	30	34	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13754	13758		10.1074/jbc.M700724200	http://dx.doi.org/10.1074/jbc.M700724200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339314	hybrid			2022-12-27	WOS:000246060300065
J	Herbert, AP; Deakin, JA; Schmidt, CQ; Blaum, BS; Egan, C; Ferreira, VP; Pangburn, MK; Lyon, M; Uhrin, D; Barlow, PN				Herbert, Andrew P.; Deakin, Jon A.; Schmidt, Christoph Q.; Blaum, Barbel S.; Egan, Claire; Ferreira, Viviana P.; Pangburn, Michael K.; Lyon, Malcolm; Uhrin, Dusan; Barlow, Paul N.			Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; C-REACTIVE PROTEIN; HEPARIN-BINDING DOMAIN; SHORT CONSENSUS REPEAT; ALTERNATIVE PATHWAY; STRONG ASSOCIATION; NMR-SPECTROSCOPY; VARIANT; COMMON; Y402H	A common single nucleotide polymorphism in the factor H gene predisposes to age-related macular degeneration. Factor H blocks the alternative pathway of complement on self-surfaces bearing specific polyanions, including the glycosaminoglycan chains of proteoglycans. Factor H also binds C-reactive protein, potentially contributing to noninflammatory apoptotic processes. The at risk sequence contains His ( rather than Tyr) at position 402 (384 in the mature protein), in the seventh of the 20 complement control protein (CCP) modules (CCP7) of factor H. We expressed both His402 and Tyr(402) variants of CCP7, CCP7,8, and CCP6-8. We determined structures of His(402) and Tyr(402) CCP7 and showed them to be nearly identical. The side chains of His/Tyr(402) have similar, solvent-exposed orientations far from interfaces with CCP6 and -8. Tyr(402) CCP7 bound significantly more tightly than His(402) CCP7 to a heparin affinity column as well as to defined-length sulfated heparin oligosaccharides employed in gel mobility shift assays. This observation is consistent with the position of the 402 side chain on the edge of one of two glycosaminoglycan-binding surface patches on CCP7 that we inferred on the basis of chemical shift perturbation studies with a sulfated heparin tetrasaccharide. According to surface plasmon resonance measurements, Tyr(402) CCP6-8 binds significantly more tightly than His(402) CCP6-8 to immobilized C-reactive protein. The data support a causal link between H402Y and age-related macular degeneration in which variation at position 402 modulates the response of factor H to age-related changes in the glycosaminoglycan composition and apoptotic activity of the macula.	Univ Edinburgh, Sch Chem, Edinburgh Biomol NMR Unit, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Manchester, Paterson Inst Canc Res, Canc Res Uk Glyco Oncol Grp, Manchester M20 4BX, Lancs, England; Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75703 USA	University of Edinburgh; University of Edinburgh; Paterson Institute for Cancer Research; University of Manchester; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Barlow, PN (corresponding author), Univ Edinburgh, Chem Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Paul.Barlow@ed.ac.uk	Barlow, Paul N/G-2853-2011; Herbert, Andrew P/C-4755-2008; Herbert, Andy P/F-6693-2010	Herbert, Andrew P/0000-0002-4549-6965; Herbert, Andy P/0000-0002-4549-6965; Ferreira, Viviana/0000-0001-8923-5671; Blaum, Baerbel/0000-0003-4312-8912; Lyon, Malcolm/0000-0001-9575-6879	Medical Research Council [G0001089] Funding Source: Medline; NIDDK NIH HHS [DK35081] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035081, R01DK035081] Funding Source: NIH RePORTER; MRC [G0001089] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200; Cordier F, 2003, J AM CHEM SOC, V125, P15750, DOI 10.1021/ja038616m; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750; Habeck Michael, 2004, Methods Mol Biol, V278, P379; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Herbert AP, 2006, J BIOL CHEM, V281, P16512, DOI 10.1074/jbc.M513611200; Jarva H, 1999, J IMMUNOL, V163, P3957; Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9; Kirkitadze MD, 1999, FEBS LETT, V459, P133, DOI 10.1016/S0014-5793(99)01205-3; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; KUHN S, 1995, J IMMUNOL, V155, P5663; Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831; Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871; Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269; Lyon M, 2004, J BIOL CHEM, V279, P43560, DOI 10.1074/jbc.M408510200; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; Nabuurs SB, 2003, J AM CHEM SOC, V125, P12026, DOI 10.1021/ja035440f; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, FOLD DES, V2, pS53, DOI 10.1016/S1359-0278(97)00064-3; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Nowak JZ, 2006, PHARMACOL REP, V58, P353; Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103; Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x; Ormsby RJ, 2006, MOL IMMUNOL, V43, P1624, DOI 10.1016/j.molimm.2005.09.012; ORMSBY RJ, 2007, MOL IMMUNOL, V44, P224; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8; Provis Jan M, 2005, Clin Exp Optom, V88, P269; QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442; RIPOCHE J, 1986, BIOSCIENCE REP, V6, P65, DOI 10.1007/BF01145180; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141; SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285; Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19; Sue SC, 2004, J MOL BIOL, V343, P1365, DOI 10.1016/j.jmb.2004.09.014; Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; Verdugo ME, 1997, EXP EYE RES, V65, P231, DOI 10.1006/exer.1997.0325; Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426; Zipfel PF, 2007, MOL IMMUNOL, V44, P3850, DOI 10.1016/j.molimm.2007.06.149	62	90	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18960	18968		10.1074/jbc.M609636200	http://dx.doi.org/10.1074/jbc.M609636200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17360715	hybrid			2022-12-27	WOS:000247475300038
J	Crepaldi, L; Lackner, C; Corti, C; Ferraguti, F				Crepaldi, Luca; Lackner, Carmen; Corti, Corrado; Ferraguti, Francesco			Transcriptional activators and repressors for the neuron-specific expression of a metabotropic glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; D-ASPARTATE RECEPTORS; MICE LACKING MGLUR1; NERVE GROWTH-FACTOR; SPLICE VARIANTS; MESSENGER-RNA; FACTOR-I; DIFFERENTIAL DISTRIBUTION; FUNCTIONAL-ANALYSIS; RAT	Metabotropic glutamate receptor 1 (mGlu1) has a discrete distribution in the central nervous system restricted to neurons. Its expression undergoes important changes during development and in response to physiological and pathological modifications. Here, we have determined the structure of the mGlu1 gene and demonstrated that mGlu1 transcription takes places at alternative first exons. Moreover, we have identified active promoter regions upstream from the two most expressed first exons by means of luciferase reporter gene assays performed in primary cerebellar granule neurons. Targeted mutations of active elements constituting the core promoter and electrophoretic mobility shift assays demonstrated that the factors thyroid transcription factor-1 and CCAAT/enhancer-binding proteins beta act synergistically to promote mGlu1 transcription. We have also elucidated the molecular bases for the neuron-specific expression of mGlu1 identifying a neural restrictive silencing element and a regulatory factor for X box element, which suppressed mGlu1 expression in nonneuronal cells. These results reveal the molecular bases for cell-and context-specific expression of an important glutamate receptor critically involved in synaptogenesis, neuronal differentiation, synaptic transmission, and plasticity.	Innsburck Med Univ, Dept Pharmacol, A-6020 Innsbruck, Austria; GlaxoSmithKline Med Res Ctr, Dept Psychiat, I-37135 Verona, Italy; GlaxoSmithKline Med Res Ctr, Biol Ctr Excellence Drug Discovery, I-37135 Verona, Italy	Medical University of Innsbruck; GlaxoSmithKline; GlaxoSmithKline	Ferraguti, F (corresponding author), Innsburck Med Univ, Dept Pharmacol, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	francesco.ferraguti@i-med.ac.at		Corti, Corrado/0000-0002-7876-9114; Ferraguti, Francesco/0000-0002-3843-5857				ARONICA E, 1993, MOL PHARMACOL, V44, P981; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Berthele A, 1998, NEUROSCIENCE, V85, P733, DOI 10.1016/S0306-4522(97)00670-2; BESSHO Y, 1993, J NEUROCHEM, V60, P253, DOI 10.1111/j.1471-4159.1993.tb05845.x; Bingle CD, 1997, INT J BIOCHEM CELL B, V29, P1471, DOI 10.1016/S1357-2725(97)00007-1; Borges K, 2001, J BIOL CHEM, V276, P25929, DOI 10.1074/jbc.M009105200; Bruce AW, 2004, P NATL ACAD SCI USA, V101, P10458, DOI 10.1073/pnas.0401827101; Chew LJ, 2001, J BIOL CHEM, V276, P42162, DOI 10.1074/jbc.M101895200; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Corti C, 2003, J BIOL CHEM, V278, P33105, DOI 10.1074/jbc.M212380200; Corti C, 2001, BIOCHEM BIOPH RES CO, V286, P381, DOI 10.1006/bbrc.2001.5391; Ferraguti F, 2004, HIPPOCAMPUS, V14, P193, DOI 10.1002/hipo.10163; Ferraguti F, 1998, J COMP NEUROL, V400, P391; Ferraguti F, 2006, CELL TISSUE RES, V326, P483, DOI 10.1007/s00441-006-0266-5; Gill SS, 1999, BRAIN RES BULL, V48, P143, DOI 10.1016/S0361-9230(98)00154-3; Gu YC, 2000, J BIOL CHEM, V275, P34252, DOI 10.1074/jbc.M004520200; Kane MD, 1998, NEUROSCI LETT, V252, P1, DOI 10.1016/S0304-3940(98)00484-4; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; KURAMOTO T, 1994, GENOMICS, V19, P358, DOI 10.1006/geno.1994.1069; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Laurie DJ, 1996, EUR J PHARMACOL, V296, pR1, DOI 10.1016/0014-2999(95)00868-3; Lee BJ, 2001, MOL CELL NEUROSCI, V17, P107, DOI 10.1006/mcne.2000.0933; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liu AG, 2003, J BIOL CHEM, V278, P26423, DOI 10.1074/jbc.M211165200; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Lopez-Bendito G, 2002, CEREB CORTEX, V12, P625, DOI 10.1093/cercor/12.6.625; Ma KW, 2006, J BIOL CHEM, V281, P21250, DOI 10.1074/jbc.M600521200; Marin YE, 2004, J MOL MED, V82, P735, DOI 10.1007/s00109-004-0566-8; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nakayama A, 2003, J BIOL CHEM, V278, P233, DOI 10.1074/jbc.M209574200; Nord M, 2000, ANN NY ACAD SCI, V923, P154; Ovcharenko I, 2005, GENOME RES, V15, P184, DOI 10.1101/gr.3007205; Reynolds PR, 2005, J BIOL CHEM, V280, P32548, DOI 10.1074/jbc.M502231200; Rich A, 2003, NAT REV GENET, V4, P566, DOI 10.1038/nrg1115; Schwartz S, 2003, NUCLEIC ACIDS RES, V31, P3518, DOI 10.1093/nar/gkg579; SHIGEMOTO R, 1992, J COMP NEUROL, V322, P121, DOI 10.1002/cne.903220110; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Stadler F, 2005, J NEUROCHEM, V94, P324, DOI 10.1111/j.1471-4159.2005.03190.x; Stephan D, 1996, NEUROPHARMACOLOGY, V35, P1649, DOI 10.1016/S0028-3908(96)00108-6; Sterneck E, 1998, J NEUROCHEM, V70, P2424; Storring JM, 1999, J NEUROCHEM, V72, P2238, DOI 10.1046/j.1471-4159.1999.0722238.x; Suzuki K, 1998, ENDOCRINOLOGY, V139, P3014, DOI 10.1210/en.139.6.3014; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Toshiyuki N, 2004, MOL BRAIN RES, V125, P47, DOI 10.1016/j.molbrainres.2004.03.017; TRENCKNER E, 1991, CULTURING NERVE CELL; WANG K, 1995, J VIROL, V69, P2873, DOI 10.1128/JVI.69.5.2873-2880.1995; Werner T, 2003, FASEB J, V17, P1228, DOI 10.1096/fj.02-0955rev; Zhu H, 1999, MOL BRAIN RES, V73, P93, DOI 10.1016/S0169-328X(99)00239-9	51	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17877	17889		10.1074/jbc.M700149200	http://dx.doi.org/10.1074/jbc.M700149200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430891	hybrid			2022-12-27	WOS:000247084500061
J	Gold, VAM; Robson, A; Clarke, AR; Collinson, I				Gold, Vicki A. M.; Robson, Alice; Clarke, Anthony R.; Collinson, Ian			Allosteric regulation of SecA - Magnesium-mediated control of conformation and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN TRANSLOCATION; BACILLUS-SUBTILIS SECA; COLI PLASMA-MEMBRANE; ATP-BINDING-SITE; X-RAY-STRUCTURE; ESCHERICHIA-COLI; DIMERIC SECA; PREPROTEIN TRANSLOCATION; ACIDIC PHOSPHOLIPIDS; CONDUCTING CHANNEL	In bacteria, the SecA protein associates with a ubiquitous protein channel SecYEG where it drives the post-translational secretion of pre-proteins across the plasma membrane. The high-resolution structures of both proteins have been determined in their resting states; however, the mechanism that couples ATP hydrolysis to active transport of substrate proteins through the membrane is not well understood. An analysis of the steady-state ATPase activity of the enzyme reveals that there is an allosteric binding site for magnesium distinct from that associated with hydrolysis of ATP. We have demonstrated that this regulation involves a large conformational change to the SecA dimer, which exerts a strong influence on the turnover and affinity for ATP, as well as the affinity for ADP. The strong inhibitory influence of magnesium on the ATPase activity can be countered by cardiolipin and conditions that promote protein translocation.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Collinson, I (corresponding author), Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England.	ian.collinson@bristol.ac.uk		Gold, Vicki/0000-0002-6908-0745; Collinson, Ian/0000-0002-3931-0503; Robson, Alice/0000-0003-3338-2626	Biotechnology and Biological Sciences Research Council [BB/C503538/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ahn T, 1998, J BIOL CHEM, V273, P21692, DOI 10.1074/jbc.273.34.21692; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BRENZA JM, 1985, BIOCHEM PHARMACOL, V34, P4291, DOI 10.1016/0006-2952(85)90287-4; BREUKINK E, 1993, FEBS LETT, V331, P19, DOI 10.1016/0014-5793(93)80289-7; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Collinson I, 2001, EMBO J, V20, P2462, DOI 10.1093/emboj/20.10.2462; de Keyzer J, 2005, J BIOL CHEM, V280, P35255, DOI 10.1074/jbc.M506157200; DEMELER B, 2005, COMPREHENSIVE DATA A, P210; denBlaauwen T, 1997, FEBS LETT, V416, P35, DOI 10.1016/S0014-5793(97)01142-3; Ding HY, 2003, BIOCHEMISTRY-US, V42, P8729, DOI 10.1021/bi0342057; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Duong F, 2003, EMBO J, V22, P4375, DOI 10.1093/emboj/cdg418; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; Fak JJ, 2004, BIOCHEMISTRY-US, V43, P7307, DOI 10.1021/BI0357208; Fekkes P, 1999, BIOCHEMISTRY-US, V38, P5111, DOI 10.1021/bi982818r; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; Froschauer EM, 2004, FEMS MICROBIOL LETT, V237, P49, DOI 10.1016/j.femsle.2004.06.013; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; Hunt JF, 2002, SCIENCE, V297, P2018, DOI 10.1126/science.1074424; Jilaveanu LB, 2006, J BACTERIOL, V188, P335, DOI 10.1128/JB.188.1.335-338.2006; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; Or E, 2005, J BIOL CHEM, V280, P9097, DOI 10.1074/jbc.M413947200; Or E, 2002, EMBO J, V21, P4470, DOI 10.1093/emboj/cdf471; Osborne AR, 2004, P NATL ACAD SCI USA, V101, P10937, DOI 10.1073/pnas.0401742101; Papanikolau Y, 2007, J MOL BIOL, V366, P1545, DOI 10.1016/j.jmb.2006.12.049; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; Sharma V, 2003, P NATL ACAD SCI USA, V100, P2243, DOI 10.1073/pnas.0538077100; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Smith MA, 2005, J BACTERIOL, V187, P6454, DOI 10.1128/JB.187.18.6454-6465.2005; SQUIRE PG, 1979, ARCH BIOCHEM BIOPHYS, V196, P165, DOI 10.1016/0003-9861(79)90563-0; Tam PCK, 2005, EMBO J, V24, P3380, DOI 10.1038/sj.emboj.7600804; Tomkiewicz D, 2006, J BIOL CHEM, V281, P15709, DOI 10.1074/jbc.M600205200; Tziatzios C, 2004, J MOL BIOL, V340, P513, DOI 10.1016/j.jmb.2004.04.076; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Does C, 2003, METHOD ENZYMOL, V372, P86; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; Vassylyev DG, 2006, J MOL BIOL, V364, P248, DOI 10.1016/j.jmb.2006.09.061; Woodbury RL, 2002, PROTEIN SCI, V11, P875, DOI 10.1110/ps.4090102; Zimmer J, 2006, J MOL BIOL, V364, P259, DOI 10.1016/j.jmb.2006.08.044	47	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17424	17432		10.1074/jbc.M702066200	http://dx.doi.org/10.1074/jbc.M702066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17416585	hybrid			2022-12-27	WOS:000247084500012
J	Li, H; Yao, J; Tong, XT; Guo, ZH; Wu, Y; Sun, L; Pan, N; Wu, HM; Xu, T; Ding, JP				Li, Hui; Yao, Jing; Tong, Xiaotian; Guo, Zhaohua; Wu, Ying; Sun, Liang; Pan, Na; Wu, Houming; Xu, Tao; Ding, Jiuping			Interaction sites between the Slo1 pore and the NH2 terminus of the beta(2) subunit, probed with a three-residue sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SHAKER K-CHANNELS; BK CHANNELS; INACTIVATION GATE; AUXILIARY SUBUNIT; CRYSTAL-STRUCTURE; CHROMAFFIN CELLS; MOLECULAR-BASIS; VOLTAGE; CA2+	Calcium- and voltage-gated (BK) K+ channels encoded by Slo1 play an essential role in nervous systems. Although it shares many common features with voltage-dependent KV channels, the BK channel exhibits differences in gating and inactivation. Using a mutant in which FWI replaces three residues (FIW) in the NH2 terminus of wild-type beta 2-subunits, in conjunction with alanine-scanning mutagenesis of the Slo1 S6 segment, we identify that the NH2 terminus of beta 2-subunits interacts with the residues near the cytosolic superficial mouth of BK channels during inactivation. The cytosolic blockers did not share the sites with NH2 terminus of beta 2-subunits. A novel blocking-inactivating scheme was proposed to account for the observed noncompetition inactivation. Our results also suggest that the residue Ile-323 plays a dual role in interacting with the NH2 terminus of beta 2-subunits and modulating the gating of BK channels.	Huazhong Univ Sci & Technol, Inst Biochem & Biophys, Coll Life Sci & Technol, Wuhan 430074, Hubei, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai 200032, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS	Xu, T (corresponding author), Huazhong Univ Sci & Technol, Inst Biochem & Biophys, Coll Life Sci & Technol, Wuhan 430074, Hubei, Peoples R China.	xutao@ibp.ac.cn; jpding@mail.hust.edu.cn	Xu, Tao/G-5474-2010; Sun, Liang/D-4857-2018	Yao, Jing/0000-0003-1844-3988; Sun, Liang/0000-0002-7817-5121				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Bentrop D, 2001, J BIOL CHEM, V276, P42116, DOI 10.1074/jbc.M107118200; Benzinger GR, 2006, J GEN PHYSIOL, V127, P119, DOI 10.1085/jgp.200509425; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gao YD, 2003, PROTEINS, V52, P146, DOI 10.1002/prot.10341; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; LAGRUTTA A, 1994, J BIOL CHEM, V269, P20347; Li WY, 2004, J GEN PHYSIOL, V124, P43, DOI 10.1085/jgp.200409067; Lingle C J, 1996, Ion Channels, V4, P261; Lingle CJ, 2001, J GEN PHYSIOL, V117, P583, DOI 10.1085/jgp.117.6.583; Lippiat JD, 2000, J PHYSIOL-LONDON, V529, P131, DOI 10.1111/j.1469-7793.2000.00131.x; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SAKMANN B, 1995, SINGLE CHANNEL RECOR, P408; Solaro CR, 1997, BIOPHYS J, V73, P819, DOI 10.1016/S0006-3495(97)78114-1; Uebele VN, 2000, J BIOL CHEM, V275, P23211, DOI 10.1074/jbc.M910187199; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wallner M, 1999, P NATL ACAD SCI USA, V96, P4137, DOI 10.1073/pnas.96.7.4137; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Xia XM, 2003, J GEN PHYSIOL, V121, P125, DOI 10.1085/jgp.20028667; Xia XM, 1999, J NEUROSCI, V19, P5255, DOI 10.1523/jneurosci.19-13-05255.1999; Xia XM, 2000, J NEUROSCI, V20, P4890; Zeng XH, 2003, NAT STRUCT BIOL, V10, P448, DOI 10.1038/nsb932; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	34	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17720	17728		10.1074/jbc.M607063200	http://dx.doi.org/10.1074/jbc.M607063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430898	hybrid			2022-12-27	WOS:000247084500045
J	Mori, H; Shukunami, C; Furuyama, A; Notsu, H; Nishizaki, Y; Hiraki, Y				Mori, Hajime; Shukunami, Chisa; Furuyama, Akiko; Notsu, Hiroyuki; Nishizaki, Yuriko; Hiraki, Yuji			Immobilization of bioactive fibroblast growth factor-2 into cubic proteinous microcrystals (Bombyx mori cypovirus polyhedra) that are insoluble in a physiological cellular environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROGENIC DIFFERENTIATION; HEPARIN; FGF; EXPRESSION; BINDING	The supramolecular architecture of the extracellular matrix and the disposition of its specific accessory molecules give rise to variable heterotopic signaling cues for single cells. Here we have described the successful occlusion of human fibroblast growth factor-2 (FGF-2) into the cubic inclusion bodies (FGF-2 polyhedra) of the Bombyx mori cytoplasmic polyhedrosis virus (BmCPV). The polyhedra are proteinous cubic crystals of several microns in size that are insoluble in the extracellular milieu. Purified FGF-2 polyhedra were found to stimulate proliferation and phosphorylation of p44/p42 mitogen-activated protein kinase in cultured fibroblasts. Moreover, cellular responses were blocked by a synthetic inhibitor of the FGF signaling pathway, SU5402, suggesting that FGF-2 polyhedra indeed act through FGF receptors. Furthermore, FGF-2 polyhedra retained potent growth stimulatory properties even after desiccation. We have demonstrated that BmCPV polyhedra microcrystals that occlude extracellular signaling proteins are a novel and versatile tool that can be employed to analyze cellular behavior at the single cell level.	Kyoto Univ, Dept Cellular Differences, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Inst Technol, Insect Biomed Res Ctr, Sakyo Ku, Kyoto 6068585, Japan; Prot Crystal Corp, Chuo Ku, Osaka 5410053, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan	Kyoto University; Kyoto Institute of Technology; Japan Science & Technology Agency (JST)	Hiraki, Y (corresponding author), Kyoto Univ, Dept Cellular Differences, Inst Frontier Med Sci, Sakyo Ku, 53 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	hiraki@frontier.kyoto-u.ac.jp	Shukunami, Chisa/G-2887-2019	Shukunami, Chisa/0000-0001-5616-6761; Mori, Hajime/0000-0001-9219-6140				Belloncik S, 1998, VIRUSES, P337; Coulibaly F, 2007, NATURE, V446, P97, DOI 10.1038/nature05628; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; Hosokawa Y, 2007, BIOMED MICRODEVICES, V9, P105, DOI 10.1007/s10544-006-9001-y; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; Ikeda K, 2006, PROTEOMICS, V6, P54, DOI 10.1002/pmic.200500022; Ikeda K, 1998, ARCH VIROL, V143, P241, DOI 10.1007/s007050050283; Ikeda K, 2001, J VIROL, V75, P988, DOI 10.1128/JVI.75.2.988-995.2001; L'Hote CGM, 2005, EXP CELL RES, V304, P417, DOI 10.1016/j.yexcr.2004.11.012; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MORI H, 1993, J GEN VIROL, V74, P99, DOI 10.1099/0022-1317-74-1-99; Ramirez F, 2003, MATRIX BIOL, V22, P101, DOI 10.1016/S0945-053X(03)00002-7; ROHRMANN GF, 1986, J GEN VIROL, V67, P1499, DOI 10.1099/0022-1317-67-8-1499; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shimizu A, 2001, J BIOL CHEM, V276, P11031, DOI 10.1074/jbc.M003535200; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Thisse B, 2005, DEV BIOL, V287, P390, DOI 10.1016/j.ydbio.2005.09.011; VEMURI S, 1994, J PHARM PHARMACOL, V46, P481, DOI 10.1111/j.2042-7158.1994.tb03831.x	22	31	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17289	17296		10.1074/jbc.M608106200	http://dx.doi.org/10.1074/jbc.M608106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17430896	hybrid			2022-12-27	WOS:000246946500062
J	Ricketts, LM; Dlugosz, M; Luther, KB; Haltiwanger, RS; Majerus, EM				Ricketts, Lindsay M.; Dlugosz, Malgosia; Luther, Kelvin B.; Haltiwanger, Robert S.; Majerus, Elaine M.			O-fucosylation is required for ADAMTS13 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOSPONDIN TYPE-1 REPEATS; VON-WILLEBRAND-FACTOR; GROWTH FACTOR-LIKE; THROMBOTIC THROMBOCYTOPENIC PURPURA; HAMSTER OVARY CELLS; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; GDP-FUCOSE; MOLECULAR-CLONING; PROTEIN O-FUCOSYL-TRANSFERASE-1	ADAMTS13 is a plasma metalloproteinase that cleaves von Willebrand factor to smaller, less thrombogenic forms. Deficiency of ADAMTS13 activity in plasma leads to thrombotic thrombocytopenic purpura. ADAMTS13 contains eight thrombospondin type 1 repeats (TSR), seven of which contain a consensus sequence for the direct addition of fucose to the hydroxyl group of serine or threonine. Mass spectral analysis of tryptic peptides derived from human ADAMTS13 indicate that at least six of the TSRs are modified with an O-fucose disaccharide. Analysis of [H-3] fucose metabolically incorporated into ADAMTS13 demonstrated that the disaccharide has the structure glucose-beta 1,3-fucose. Mutation of the modified serine to alanine in TSR2, TSR5, TSR7, and TSR8 reduced the secretion of ADAMTS13. Mutation of more than one site dramatically reduced secretion regardless of the sites mutated. When the expression of protein O-fucosyltransferase 2 (POFUT2), the enzyme that transfers fucose to serines in TSRs, was reduced using siRNA, the secretion of ADAMTS13 decreased. A similar outcome was observed when ADAMTS13 was expressed in a cell line unable to synthesize the donor for fucose addition, GDP-fucose. Although overexpression of POFUT2 did not affect the secretion of wild-type ADAMTS13, it did increase the secretion of the ADAMTS13 TSR1,2 double mutant but not that of ADAMTS13 TSR1-8 mutant. Together these findings indicate that O-fucosylation is functionally significant for secretion of ADAMTS13.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Majerus, EM (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S Euclid Ave,Box 8125, St Louis, MO 63110 USA.	emajerus@im.wustl.edu		Luther, Kelvin/0000-0001-9438-9675	NATIONAL CANCER INSTITUTE [R01CA123071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061126] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA123071-01A1, R01 CA123071] Funding Source: Medline; NIGMS NIH HHS [GM61126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; CHANEY W, 1986, J BIOL CHEM, V261, P551; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; de Peredo AG, 2002, MOL CELL PROTEOMICS, V1, P11, DOI 10.1074/mcp.M100011-MCP200; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hofsteenge J, 2001, J BIOL CHEM, V276, P6485, DOI 10.1074/jbc.M008073200; Imperiali B, 1999, CURR OPIN CHEM BIOL, V3, P643, DOI 10.1016/S1367-5931(99)00021-6; Kozma K, 2006, J BIOL CHEM, V281, P36742, DOI 10.1074/jbc.M605912200; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; LIEBLER DC, 2002, INTRO PROTEOMICS TOO, P89; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200; Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; Majerus EM, 2005, J BIOL CHEM, V280, P21773, DOI 10.1074/jbc.M502529200; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morais VA, 2006, BBA-MOL BASIS DIS, V1762, P802, DOI 10.1016/j.bbadis.2006.06.018; Moussalli M, 1999, J BIOL CHEM, V274, P32539, DOI 10.1074/jbc.274.46.32539; Nita-Lazar A, 2006, METHOD ENZYMOL, V417, P93, DOI 10.1016/S0076-6879(06)17008-1; OConnor SE, 1996, CHEM BIOL, V3, P803, DOI 10.1016/S1074-5521(96)90064-2; Ohyama C, 1998, J BIOL CHEM, V273, P14582, DOI 10.1074/jbc.273.23.14582; Okajima T, 2005, SCIENCE, V307, P1599, DOI 10.1126/science.1108995; Okajima T, 2002, CELL, V111, P893, DOI 10.1016/S0092-8674(02)01114-5; Purvis AR, 2004, J BIOL CHEM, V279, P49982, DOI 10.1074/jbc.M408727200; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Rampal R, 2005, J BIOL CHEM, V280, P32133, DOI 10.1074/jbc.M506104200; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; Sato T, 2006, GLYCOBIOLOGY, V16, P1194, DOI 10.1093/glycob/cwl035; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P969, DOI 10.1016/j.biocel.2003.12.011; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200; Wang Y, 1996, GLYCOBIOLOGY, V6, P837, DOI 10.1093/glycob/6.8.837; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200; Zhou WH, 2005, J BIOL CHEM, V280, P39934, DOI 10.1074/jbc.M504919200	52	81	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17014	17023		10.1074/jbc.M700317200	http://dx.doi.org/10.1074/jbc.M700317200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17395589	hybrid			2022-12-27	WOS:000246946500034
J	Blobaum, AL; Marnett, LJ				Blobaum, Anna L.; Marnett, Lawrence J.			Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERAPEUTIC ARTHRITIS RESEARCH; RANDOMIZED CONTROLLED-TRIAL; COX-2; IBUPROFEN; NAPROXEN; TARGET	Lumiracoxib is the first example of a marketed COX-2 inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo. However, the molecular basis of its COX-2 inhibition has not been completely defined. Using standard assays, lumiracoxib was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified human COX-2. The extent of COX-2 inhibition plateaued at around 50% and suggested that the inhibitor may be reversibly bound to the enzyme. Kinetic studies with lumiracoxib demonstrated that it was a time-dependent and slowly reversible inhibitor of human COX-2 that exhibited at least two binding steps during inhibition. Derivatives of lumiracoxib were synthesized with or without the methyl group on the phenylacetic acid ring and with various substitutions on the lower aniline ring. Inhibition studies demonstrated that the methyl group on the phenylacetic acid ring is required for COX-2 selectivity. The chemical identity and position of the substituents on the lower aniline ring were important in determining the potency and extent of COX inhibition as well as COX-2 selectivity. Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs. Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency. Taken together with a recent crystal structure of a lumiracoxib-COX- 2 complex, the kinetic analyses presented herein of the inhibition of mutant COX-2s by lumiracoxib allows the definition of the molecular basis of COX-2 inhibition.	Vanderbilt Univ, Sch Med, Dept Biochem, AB Hancock Jr Mem Lab Canc Res,Inst Chem Biol,Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, AB Hancock Jr Mem Lab Canc Res,Inst Chem Biol,Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, AB Hancock Jr Mem Lab Canc Res,Inst Chem Biol,Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, AB Hancock Jr Mem Lab Canc Res,Inst Chem Biol,Ctr, 23rd Ave S Pierce, Nashville, TN 37232 USA.	larry.marnett@vanderbilt.edu			NATIONAL CANCER INSTITUTE [T32CA009582, F32CA119629, R01CA089450] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009582, CA09582, CA119629, CA89450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acemoglu M, 2004, TETRAHEDRON, V60, P11571, DOI 10.1016/j.tet.2004.09.064; BROOKS CD, 1999, Patent No. 5863946; CLARK K, 2004, AM CHEM SOC, P22; Esser R, 2005, BRIT J PHARMACOL, V144, P538, DOI 10.1038/sj.bjp.0706078; Farkouh ME, 2004, LANCET, V364, P675, DOI 10.1016/S0140-6736(04)16894-3; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lyseng-Williamson KA, 2004, DRUGS, V64, P2237, DOI 10.2165/00003495-200464190-00008; MOSER P, 1990, J MED CHEM, V33, P2358, DOI 10.1021/jm00171a008; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Prusakiewicz JJ, 2004, BIOCHEMISTRY-US, V43, P15439, DOI 10.1021/bi048534q; Rowlinson SW, 2003, J BIOL CHEM, V278, P45763, DOI 10.1074/jbc.M305481200; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Schnitzer TJ, 2004, LANCET, V364, P665, DOI 10.1016/S0140-6736(04)16893-1; Sorbera LA, 2002, DRUG FUTURE, V27, P740, DOI 10.1358/dof.2002.027.08.692497; Tannenbaum H, 2004, DRUGS, V64, P2247, DOI 10.2165/00003495-200464190-00010	16	35	36	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16379	16390		10.1074/jbc.M609883200	http://dx.doi.org/10.1074/jbc.M609883200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17434872	hybrid			2022-12-27	WOS:000246794300046
J	Mizuta, T; Shimizu, S; Matsuoka, Y; Nakagawa, T; Tsujimoto, Y				Mizuta, Takeshi; Shimizu, Shigeomi; Matsuoka, Yousuke; Nakagawa, Takashi; Tsujimoto, Yoshihide			A Bax/Bak-independent mechanism of cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; INDUCED NEURONAL DEATH; CELL-DEATH; SERINE-PROTEASE; ARACHIDONIC-ACID; APOPTOSIS; BAX; BCL-2; FAMILY; INHIBITORS	Bax and Bak are multidomain pro-apoptotic members of the Bcl- 2 family of proteins that regulate mitochondria-mediated apoptosis by direct modulation of mitochondrial membrane permeability. Since double-knock-out mouse embryonic fibroblasts with deficiency of Bax and Bak are resistant to multiple apoptotic stimuli, Bax and Bak are considered to be an essential gateway for various apoptotic signals. Here we showed that the combination of calcium ionophore A23187 and arachidonic acid induced cytochrome c release and caspase-dependent death of double-knock-out mouse embryonic fibroblasts, indicating that other mechanisms of cytochrome c release exist. Furthermore, A23187/arachidonic acid (ArA)induced caspase-dependent death was significantly suppressed by the treatment of several serine protease inhibitors including 4-(2-aminoethyl) benzenesulfonylfluoride and L-1-chloro- 3-(4-tosylamido)-4-phenyl-2-butanone but not the overexpression of anti-apoptotic Bcl- 2 family of proteins or the inhibition of mitochondrial membrane permeability transition. These results indicate that there are at least two mechanisms of cytochrome c release leading to caspase activation, a Bax/Bak-dependent mechanism and a Bax/Bak- independent, but serine protease(s)-dependent, mechanism.	Osaka Univ, Sch Med, Dept Med Genet, Lab Mol Genet, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, Solut Oritented Res Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Med Genet, Lab Mol Genet, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp	Nakagawa, Takashi/F-3015-2010	Nakagawa, Takashi/0000-0001-5539-7605				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Brune B, 2003, CELL DEATH DIFFER, V10, P864, DOI 10.1038/sj.cdd.4401261; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; de Bruin EC, 2003, CELL DEATH DIFFER, V10, P1204, DOI 10.1038/sj.cdd.4401296; DILISA F, 1985, BIOCHEM BIOPH RES CO, V131, P968, DOI 10.1016/0006-291X(85)91334-8; Egger L, 2003, CELL DEATH DIFFER, V10, P1188, DOI 10.1038/sj.cdd.4401288; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; HAMEM R, 1998, CELL, V94, P339; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2003, J NEUROSCI, V23, P11112; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; MARKWARDT F, 1974, BIOCHEM PHARMACOL, V23, P2247, DOI 10.1016/0006-2952(74)90554-1; MATSUOKA Y, 1994, J CELL SCI, V107, P693; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Pompeia C, 2003, CELL BIOCHEM FUNCT, V21, P97, DOI 10.1002/cbf.1012; Rideout HJ, 2001, NEUROSCIENCE, V107, P339, DOI 10.1016/S0306-4522(01)00322-0; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolf BB, 2002, CURR BIOL, V12, pR177, DOI 10.1016/S0960-9822(02)00736-4; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	28	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16623	16630		10.1074/jbc.M611060200	http://dx.doi.org/10.1074/jbc.M611060200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17409097	hybrid			2022-12-27	WOS:000246794300068
J	Takagi, Y; Sindkar, S; Ekonomidis, D; Hall, MP; Ho, CK				Takagi, Yuko; Sindkar, Shalaka; Ekonomidis, Dimitra; Hall, Megan P.; Ho, C. Kiong			Trypanosoma brucei encodes a bifunctional capping enzyme essential for cap 4 formation on the spliced leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE N-7 METHYLTRANSFERASE; INDUCIBLE EXPRESSION SYSTEM; CARBOXYL-TERMINAL DOMAIN; PRE-MESSENGER-RNA; POLYMERASE-II; VACCINIA VIRUS; ENCEPHALITOZOON-CUNICULI; 5'-CAPPING ENZYME; (GUANINE-7-)METHYLTRANSFERASE COMPLEX; SACCHAROMYCES-CEREVISIAE	The 5' end of kinetoplastid mRNA possesses a hypermethylated cap 4 structure, which is derived from standard m7GpppN (cap 0) with additional methylations at seven sites within the first four nucleosides on the spliced leader RNA. In addition to TbCe1 guanylyltransferase and TbCmt1 (guanine N-7) methyltransferase, Trypanosoma brucei encodes a second cap 0 forming enzyme. TbCgm1 (T. brucei cap guanylyltransferase-methyltransferase) is a novel bifunctional capping enzyme consisting of an amino-terminal guanylyltransferase domain and a carboxyl-terminal methyltransferase domain. Recombinant TbCgm1 transfers the GMP to spliced leader RNA (SL RNA) via a covalent enzyme-GMP intermediate, and methylates the guanine N-7 position of the GpppN-terminated RNA to form cap 0 structure. The two domains can function autonomously in vitro. TbCGM1 is essential for parasite growth. Silencing of TbCGM1 by RNA interference increased the abundance of uncapped SL RNA and lead to accumulation of hypomethylated SL RNA. In contrast, silencing of TbCE1 and TbCMT1 did not affect parasite growth or SL RNA capping. We conclude that TbCgm1 specifically cap SL RNA, and cap 0 is a prerequisite for subsequent methylation events leading to the formation of mature SL RNA.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ho, CK (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.	kiongho@buffalo.edu	Takagi, Yuko/M-3283-2018; Ho, KIong/GPP-6051-2022	Takagi, Yuko/0000-0002-4567-0986; /0000-0002-7300-5027				Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Arhin GK, 2006, MOL BIOCHEM PARASIT, V147, P137, DOI 10.1016/j.molbiopara.2006.01.011; Arhin GK, 2006, RNA, V12, P53, DOI 10.1261/rna.2223406; BANGS JD, 1992, J BIOL CHEM, V267, P9805; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; CHAPMAN AB, 1994, J BIOL CHEM, V269, P4754; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Dong HP, 2007, J VIROL, V81, P4412, DOI 10.1128/JVI.02455-06; EVERS R, 1989, NUCLEIC ACIDS RES, V17, P3403, DOI 10.1093/nar/17.9.3403; Fabrega C, 2004, MOL CELL, V13, P77, DOI 10.1016/S1097-2765(03)00522-7; FANTONI A, 1994, MOL CELL BIOL, V14, P2021, DOI 10.1128/MCB.14.3.2021; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; GUNZL A, 1995, J BIOL CHEM, V270, P17287, DOI 10.1074/jbc.270.29.17287; Hakansson K, 1998, P NATL ACAD SCI USA, V95, P1505, DOI 10.1073/pnas.95.4.1505; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Hall MP, 2006, NUCLEIC ACIDS RES, V34, P5594, DOI 10.1093/nar/gkl573; Hall MP, 2006, RNA, V12, P488, DOI 10.1261/rna.2250606; Hausmann S, 2005, J BIOL CHEM, V280, P20404, DOI 10.1074/jbc.M501073200; Hausmann S, 2005, J BIOL CHEM, V280, P12077, DOI 10.1074/jbc.M412063200; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; Ho CK, 2001, J BIOL CHEM, V276, P46182, DOI 10.1074/jbc.M108706200; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1996, J VIROL, V70, P6658, DOI 10.1128/JVI.70.10.6658-6664.1996; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Hodel AE, 1998, MOL CELL, V1, P443, DOI 10.1016/S1097-2765(00)80044-1; Hodel AE, 1997, NAT STRUCT BIOL, V4, P350, DOI 10.1038/nsb0597-350; Li HJ, 2005, MOL CELL BIOL, V25, P2216, DOI 10.1128/MCB.25.6.2216-2226.2005; Liang XH, 2003, EUKARYOT CELL, V2, P830, DOI 10.1128/EC.2.5.830-840.2003; Lockless SW, 1998, BIOCHEMISTRY-US, V37, P8564, DOI 10.1021/bi980178m; Marchetti MA, 1998, NUCLEIC ACIDS RES, V26, P3591, DOI 10.1093/nar/26.15.3591; MARTIN SA, 1975, J BIOL CHEM, V250, P9330; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MCNALLY KP, 1992, MOL CELL BIOL, V12, P4844, DOI 10.1128/MCB.12.11.4844; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; Ogino T, 2007, MOL CELL, V25, P85, DOI 10.1016/j.molcel.2006.11.013; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; PUGH CSG, 1978, J BIOL CHEM, V253, P4075; Saha N, 1999, J BIOL CHEM, V274, P16553, DOI 10.1074/jbc.274.23.16553; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; Silva E, 1998, MOL CELL BIOL, V18, P4612, DOI 10.1128/MCB.18.8.4612; SMITH JL, 1989, J BIOL CHEM, V264, P18091; Takagi T, 2003, J BIOL CHEM, V278, P14174, DOI 10.1074/jbc.M212101200; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; VENKATESAN S, 1980, J BIOL CHEM, V255, P903; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wickstead B, 2002, MOL BIOCHEM PARASIT, V125, P211, DOI 10.1016/S0166-6851(02)00238-4; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; Zamudio JR, 2006, EUKARYOT CELL, V5, P905, DOI 10.1128/EC.00080-06; Zheng SS, 2006, J BIOL CHEM, V281, P35904, DOI 10.1074/jbc.M607292200	64	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15995	16005		10.1074/jbc.M701569200	http://dx.doi.org/10.1074/jbc.M701569200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17416901	hybrid			2022-12-27	WOS:000246794300008
J	Torgersen, ML; Walchli, S; Grimmer, S; Skanland, SS; Sandvig, K				Torgersen, Maria L.; Walchli, Sebastien; Grimmer, Stine; Skanland, Sigrid S.; Sandvig, Kirsten			Protein kinase C delta is activated by Shiga toxin and regulates its transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROGRADE TRANSPORT; GLOBOTRIAOSYL CERAMIDE; EARLY/RECYCLING ENDOSOMES; TYROSINE SULFATION; GOLGI-APPARATUS; B-SUBUNIT; ALPHA; CLATHRIN; BINDING; CELLS	Protein kinase C (PKC) isozymes regulate different vesicular trafficking steps in the recycling or degradative pathways. However, a possible role of these kinases in the retrograde pathway from endosomes to the Golgi complex has previously not been investigated. We report here the involvement of a specific PKC isozyme, PKC delta, in the intracellular transport of the glycolipid-binding Shiga toxin (Stx), which utilizes the retrograde pathway to intoxicate cells. Upon binding to cells, Stx was shown to specifically activate PKC delta and not PKC alpha. The involvement of PKC delta and PKC alpha in the retrograde transport of Stx was then monitored biochemically and by immunofluorescence after inhibition or depletion of the isozymes. PKC delta, but not PKC alpha, was shown to selectively regulate the endosome-to-Golgi transport of StxB. Upon inhibition or knockdown of PKC delta, StxB molecules colocalized less with giantin and more with EEA1, indicating that the molecules were accumulated in endosomes, unable to reach the Golgi complex. The inhibition of Golgi transport of Stx was reflected by a strong reduction in the toxic effect, demonstrating that transport of Stx to the cytosol is dependent on PKC delta activity. These results are in agreement with our previous data, which show that Stx is able to stimulate its own transport.	Univ Oslo, Inst Canc Res, Fac Div, Norwegian Radium Hosp, N-0310 Oslo, Norway; Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway	University of Oslo; University of Oslo	Sandvig, K (corresponding author), Univ Oslo, Inst Canc Res, Fac Div, Norwegian Radium Hosp, N-0310 Oslo, Norway.	ksandvig@radium.uio.no	Torgersen, Maria Lyngaas L/F-3492-2017; Skånland, Sigrid S/AAW-4817-2021; Torgersen, Maria Lyngaas/O-6240-2019	Torgersen, Maria Lyngaas L/0000-0003-2616-7194; Torgersen, Maria Lyngaas/0000-0003-2616-7194; Skanland, Sigrid S./0000-0003-1630-356X; Walchli, Sebastien/0000-0001-5869-1746				Alvi F, 2007, CELL MOL LIFE SCI, V64, P263, DOI 10.1007/s00018-006-6363-5; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Badizadegan K, 2004, AM J PHYSIOL-CELL PH, V287, pC1453, DOI 10.1152/ajpcell.00189.2004; Bonifacino JS, 2006, NAT REV MOL CELL BIO, V7, P568, DOI 10.1038/nrm1985; Cabell CH, 1996, P ASSOC AM PHYSICIAN, V108, P37; Chen YW, 2004, TRAFFIC, V5, P577, DOI 10.1111/j.1600-0854.2004.00202.x; Cherla RP, 2003, FEMS MICROBIOL LETT, V228, P159, DOI 10.1016/S0378-1097(03)00761-4; Chu JJH, 2006, VIROLOGY, V349, P463, DOI 10.1016/j.virol.2006.01.022; Falguieres T, 2001, MOL BIOL CELL, V12, P2453, DOI 10.1091/mbc.12.8.2453; Falguieres T, 2006, FEBS J, V273, P5205, DOI 10.1111/j.1742-4658.2006.05516.x; Foster GH, 2000, INFECT IMMUN, V68, P5183, DOI 10.1128/IAI.68.9.5183-5189.2000; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; FUJISE A, 1994, J BIOL CHEM, V269, P31642; Hehnly H, 2006, MOL BIOL CELL, V17, P4379, DOI 10.1091/mbc.E06-04-0310; Hermoso M, 2004, J BIOL CHEM, V279, P17681, DOI 10.1074/jbc.M304506200; Hettema EH, 2003, EMBO J, V22, P548, DOI 10.1093/emboj/cdg062; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Inoue R, 2005, BIOCHEM BIOPH RES CO, V330, P1314, DOI 10.1016/j.bbrc.2005.03.117; Ishiki M, 2005, ENDOCRINOLOGY, V146, P5071, DOI 10.1210/en.2005-0850; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Iversen TG, 2001, MOL BIOL CELL, V12, P2099, DOI 10.1091/mbc.12.7.2099; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; Kermorgant S, 2004, EMBO J, V23, P3721, DOI 10.1038/sj.emboj.7600396; Koss M, 2006, J IMMUNOL, V176, P1218, DOI 10.4049/jimmunol.176.2.1218; Larsson C, 2006, CELL SIGNAL, V18, P276, DOI 10.1016/j.cellsig.2005.07.010; Lauvrak SU, 2006, MOL BIOL CELL, V17, P1096, DOI 10.1091/mbc.E05-08-0766; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; LEITINGER B, 1994, J BIOL CHEM, V269, P8115; Li J, 2005, J BIOL CHEM, V280, P8351, DOI 10.1074/jbc.M409431200; Liedtke CM, 2003, AM J PHYSIOL-CELL PH, V284, pC487, DOI 10.1152/ajpcell.00357.2002; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Llado A, 2004, MOL BIOL CELL, V15, P4877, DOI 10.1091/mbc.E04-02-0127; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Morgan A, 2005, BIOCHEM SOC T, V33, P1341, DOI 10.1042/BST0331341; Mori T, 2000, EXP HEMATOL, V28, P1260, DOI 10.1016/S0301-472X(00)00538-5; Murata K, 2006, BBA-MOL BASIS DIS, V1762, P835, DOI 10.1016/j.bbadis.2006.07.004; Oliva JL, 2005, GROWTH FACTORS, V23, P245, DOI 10.1080/08977190500366043; Perego C, 2002, BIOCHEM BIOPH RES CO, V294, P127, DOI 10.1016/S0006-291X(02)00448-5; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Saint-Pol A, 2004, DEV CELL, V6, P525, DOI 10.1016/S1534-5807(04)00100-5; Sandvig K, 2005, GENE THER, V12, P865, DOI 10.1038/sj.gt.3302525; SANDVIG K, 1981, BIOCHEM J, V194, P821, DOI 10.1042/bj1940821; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; Sandvig K, 2001, TOXICON, V39, P1629, DOI 10.1016/S0041-0101(01)00150-7; Seaman MNJ, 2005, TRENDS CELL BIOL, V15, P68, DOI 10.1016/j.tcb.2004.12.004; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; SU GF, 1992, INFECT IMMUN, V60, P3345, DOI 10.1128/IAI.60.8.3345-3359.1992; Tai GH, 2004, MOL BIOL CELL, V15, P4011, DOI 10.1091/mbc.e03-12-0876; Takenouchi H, 2004, J CELL SCI, V117, P3911, DOI 10.1242/jcs.01246; Tapia JA, 2006, BBA-MOL CELL RES, V1763, P25, DOI 10.1016/j.bbamcr.2005.10.007; Torgersen ML, 2005, FEBS J, V272, P4103, DOI 10.1111/j.1742-4658.2005.04835.x; Utskarpen A, 2006, TRAFFIC, V7, P663, DOI 10.1111/j.1600-0854.2006.00418.x; Weinberger A, 2005, MOL BIOL CELL, V16, P4918, DOI 10.1091/mbc.E05-02-0101; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Yang H, 2002, HYPERTENSION, V39, P567, DOI 10.1161/hy0202.103052	61	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16317	16328		10.1074/jbc.M610886200	http://dx.doi.org/10.1074/jbc.M610886200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403690	hybrid			2022-12-27	WOS:000246794300039
J	Roy, LM; Jaruga, P; Wood, TG; McCullough, AK; Dizdaroglu, M; Lloyd, RS				Roy, Laura M.; Jaruga, Pawel; Wood, Thomas G.; McCullough, Amanda K.; Dizdaroglu, Miral; Lloyd, R. Stephen			Human polymorphic variants of the NEIL1 DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; OXIDATIVELY DAMAGED DNA; HUMAN-POPULATION; FREE-RADICALS; PROTEIN; CANCER; GENES; DISEASE; RISK; 2,6-DIAMINO-4-HYDROXY-5-FORMAMIDOPYRIMIDINE	In mammalian cells, the repair of DNA bases that have been damaged by reactive oxygen species is primarily initiated by a series of DNA glycosylases that include OGG1, NTH1, NEIL1, and NEIL2. To explore the functional significance of NEIL1, we recently reported that neil1 knock-out and heterozygotic mice develop the majority of symptoms of metabolic syndrome (Vartanian,V., Lowell, B., Minko, I. G., Wood, T. G., Ceci, J. D., George, S., Ballinger, S. W., Corless, C. L., McCullough, A. K., and Lloyd, R. S. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 1864 1869). To determine whether this phenotype could be causally related to human disease susceptibility, we have characterized four polymorphic variants of human NEIL1. Although three of the variants (S82C, G83D, and D252N) retained near wild type levels of nicking activity on abasic (AP) site-containing DNA, G83D did not catalyze the wild type beta,delta-elimination reaction but primarily yielded the beta-elimination product. The AP nicking activity of the C136R variant was significantly reduced. Glycosylase nicking activities were measured on both thymine glycol-containing oligonucleotides and gamma-irradiated genomic DNA using gas chromatography/mass spectrometry. Two of the polymorphic variants (S82C and D252N) showed near wild type enzyme specificity and kinetics, whereas G83D was devoid of glycosylase activity. Although insufficient quantities of C136R could be obtained to carry out gas chromatography/ mass spectrometry analyses, this variant was also devoid of the ability to incise thymine glycol-containing oligonucleotide, suggesting that it may also be glycosylase-deficient. Extrapolation of these data suggests that individuals who are heterozygous for these inactive variant neil1 alleles may be at increased risk for metabolic syndrome.	Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Dept Mol & Med Genet, Portland, OR 97239 USA; Univ Maryland Baltimore Cty, Dept Chem & Biochem Engn, Baltimore, MD 21250 USA; Nicholas Copernicus Univ, Coll Med, Dept Clin Biochem, PL-85092 Bydgoszcz, Poland; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	Oregon Health & Science University; University System of Maryland; University of Maryland Baltimore County; Nicolaus Copernicus University; Ludwik Rydygier Collegium Medicum; University of Texas System; University of Texas Medical Branch Galveston; National Institute of Standards & Technology (NIST) - USA	Lloyd, RS (corresponding author), Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Dept Mol & Med Genet, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	lloydst@ohsu.edu	Wood, Thomas/GWZ-2481-2022; Wood, Thomas/B-6172-2012; Jaruga, Pawel/M-4378-2015	Wood, Thomas/0000-0001-8962-8571; Lloyd, R. Stephen/0000-0001-7273-372X; Jaruga, Pawel/0000-0001-9192-6084	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075974, R56DK075974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK075974] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Broderick P, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-243; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P93; Dizdaroglu M, 2000, BIOCHEMISTRY-US, V39, P5586, DOI 10.1021/bi9927787; Dizdaroglu M, 2003, MUTAT RES-FUND MOL M, V531, P109, DOI 10.1016/j.mrfmmm.2003.07.003; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Doublie S, 2004, P NATL ACAD SCI USA, V101, P10284, DOI 10.1073/pnas.0402051101; Evans MD, 2004, MUTAT RES-REV MUTAT, V567, P1, DOI 10.1016/j.mrrev.2003.11.001; Fishel ML, 2007, MUTAT RES-FUND MOL M, V614, P24, DOI 10.1016/j.mrfmmm.2006.06.007; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Hadi MZ, 2000, NUCLEIC ACIDS RES, V28, P3871, DOI 10.1093/nar/28.20.3871; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hegde V, 2001, J BIOL CHEM, V276, P27591, DOI 10.1074/jbc.M101213200; Jaruga P, 2004, BIOCHEMISTRY-US, V43, P15909, DOI 10.1021/bi048162l; Jaruga P, 2002, BIOCHEMISTRY-US, V41, P3703, DOI 10.1021/bi016004d; Jaruga P, 2002, PHOTOCHEM PHOTOBIOL, V75, P85, DOI 10.1562/0031-8655(2002)075<0085:CVPDGE>2.0.CO;2; Kalam MA, 2006, NUCLEIC ACIDS RES, V34, P2305, DOI 10.1093/nar/gkl099; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; Lunn RM, 2000, CARCINOGENESIS, V21, P551, DOI 10.1093/carcin/21.4.551; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; McCullough AK, 2001, BIOCHEMISTRY-US, V40, P561, DOI 10.1021/bi002404+; Mohrenweiser HW, 1998, MUTAT RES-FUND MOL M, V400, P15, DOI 10.1016/S0027-5107(98)00059-1; Mohrenweiser HW, 2003, MUTAT RES-FUND MOL M, V526, P93, DOI 10.1016/S0027-5107(03)00049-6; Parsons JL, 2005, NUCLEIC ACIDS RES, V33, P4849, DOI 10.1093/nar/gki816; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Shinmura K, 2004, CARCINOGENESIS, V25, P2311, DOI 10.1093/carcin/bgh267; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vartanian V, 2006, P NATL ACAD SCI USA, V103, P1864, DOI 10.1073/pnas.0507444103; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wiederholt CJ, 2002, J AM CHEM SOC, V124, P7278, DOI 10.1021/ja026522r; Xi T, 2004, GENOMICS, V83, P970, DOI 10.1016/j.ygeno.2003.12.016	31	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15790	15798		10.1074/jbc.M610626200	http://dx.doi.org/10.1074/jbc.M610626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17389588	hybrid			2022-12-27	WOS:000246589600054
J	Kikkawa, Y; Sasaki, T; Nguyen, MT; Nomizu, M; Mitaka, T; Miner, JH				Kikkawa, Yamato; Sasaki, Takako; Nguyen, Mai Tuyet; Nomizu, Motoyoshi; Mitaka, Toshihiro; Miner, Jeffrey H.			The LG1-3 tandem of laminin alpha 5 harbors the binding sites of lutheran/basal cell adhesion molecule and alpha 3 beta 1/alpha 6 beta 1 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP GLYCOPROTEIN; GLOMERULAR-BASEMENT-MEMBRANE; IN-VIVO; ENDOTHELIAL-CELLS; G-DOMAIN; DYSTROGLYCAN-BINDING; GLOBULAR DOMAIN; HUMAN TISSUES; LG MODULES; B-CAM	The laminin-type globular (LG) domains of laminin alpha chains have been implicated in various cellular interactions that are mediated through receptors such as integrins, alpha-dystroglycan, syndecans, and the Lutheran blood group glycoprotein (Lu). Lu, an Ig superfamily transmembrane receptor specific for laminin alpha 5, is also known as basal cell adhesion molecule (B-CAM). Although Lu/B-CAM binds to the LG domain of laminin alpha 5, the binding site has not been precisely defined. To better delineate this binding site, we produced a series of recombinant laminin trimers containing modified alpha chains, such that all or part of alpha 5LG was replaced with analogous segments of human laminin alpha 1LG. In solid phase binding assays using a soluble Lu (Lu-Fc) composed of the Lu extracellular domain and human IgG1 Fc, we found that Lu bound to Mr5G3, a recombinant laminin containing alpha 5 domains LN through LG3 fused to human laminin alpha 1LG4-5. However, Lu/B-CAM did not bind other recombinant laminins containing alpha 5LG3 unless alpha 5LG1-2 was also present. A recombinant alpha 5LG1-3 tandem lacking the laminin coiled coil (LCC) domain did not reproduce the activity of Lu/B-CAM binding. Therefore, proper structure of the alpha 5LG1-3 tandem with the LCC domain was essential for the binding of Lu/BCAM to laminin alpha 5. Our results also suggest that the binding site for Lu/B-CAM on laminin alpha 5 may overlap with that of integrins alpha 3 beta 1 and alpha 6 beta 1.	Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Clin Biochem, Hachioji, Tokyo 1920392, Japan; Washington Univ, Sch Med, Div Renal, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Pathophysiol, Sapporo, Hokkaido 0608556, Japan; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Tokyo University of Pharmacy & Life Sciences; Washington University (WUSTL); Washington University (WUSTL); Sapporo Medical University; Max Planck Society	Kikkawa, Y (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Clin Biochem, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	kikkawa@ps.toyaku.ac.jp	Kikkawa, Yamato/D-1503-2010; Mitaka, Toshihiro/K-9424-2013	Mitaka, Toshihiro/0000-0001-9467-4871	NIDDK NIH HHS [R01DK064687] Funding Source: Medline; NIGMS NIH HHS [R01GM060432] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060432] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernemann TM, 2000, J CUTAN PATHOL, V27, P108, DOI 10.1034/j.1600-0560.2000.027003108.x; Bolcato-Bellemin AL, 2003, DEV BIOL, V260, P376, DOI 10.1016/S0012-1606(03)00254-9; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; Doi M, 2002, J BIOL CHEM, V277, P12741, DOI 10.1074/jbc.M111228200; El Nemer W, 1998, J BIOL CHEM, V273, P16686; El Nemer W, 2001, J BIOL CHEM, V276, P23757, DOI 10.1074/jbc.M102978200; ELION EA, 1998, CURRENT PROTOCOLS MO, V1; Eyler CE, 2006, TRANSFUSION, V46, P668, DOI 10.1111/j.1537-2995.2006.00779.x; Fukumoto S, 2006, J BIOL CHEM, V281, P5008, DOI 10.1074/jbc.M509295200; Garbe JHO, 2002, BIOCHEM J, V362, P213, DOI 10.1042/0264-6021:3620213; Gauthier E, 2005, J BIOL CHEM, V280, P30055, DOI 10.1074/jbc.M503293200; Hasenson S, 2005, EXP EYE RES, V81, P415, DOI 10.1016/j.exer.2005.02.015; Hines PC, 2003, BLOOD, V101, P3281, DOI 10.1182/blood-2001-12-0289; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Ido H, 2006, MATRIX BIOL, V25, P112, DOI 10.1016/j.matbio.2005.10.003; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; Kikkawa Y, 2005, CONNECT TISSUE RES, V46, P193, DOI 10.1080/03008200500344074; Kikkawa Y, 2003, J CELL BIOL, V161, P187, DOI 10.1083/jcb.200211121; Kikkawa Y, 2002, J BIOL CHEM, V277, P44864, DOI 10.1074/jbc.M208731200; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; Kikkawa Y, 2006, DEV BIOL, V296, P265, DOI 10.1016/j.ydbio.2006.04.463; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; Li J, 2003, EMBO J, V22, P2400, DOI 10.1093/emboj/cdg239; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Moulson CL, 2001, DEV DYNAM, V222, P101, DOI 10.1002/dvdy.1169; Murphy MM, 2005, BLOOD, V105, P3322, DOI 10.1182/blood-2004-07-2881; Nguyen NM, 2002, DEV BIOL, V246, P231, DOI 10.1006/dbio.2002.0658; Nguyet NM, 2005, DEV BIOL, V282, P111, DOI 10.1016/j.ydbio.2005.02.031; Nishiuchi R, 2003, J BIOCHEM, V134, P497, DOI 10.1093/jb/mvg185; PARSONS SF, 1995, P NATL ACAD SCI USA, V92, P5496, DOI 10.1073/pnas.92.12.5496; Sasaki T, 2001, FEBS LETT, V509, P181, DOI 10.1016/S0014-5793(01)03167-2; Schon M, 2000, J INVEST DERMATOL, V115, P1047, DOI 10.1046/j.1523-1747.2000.00189.x; Shannon MB, 2006, J AM SOC NEPHROL, V17, P1913, DOI 10.1681/ASN.2005121298; Shimizu H, 1999, J BIOL CHEM, V274, P11995, DOI 10.1074/jbc.274.17.11995; Sterk LMT, 2002, J CELL SCI, V115, P1161; Suzuki N, 2005, CONNECT TISSUE RES, V46, P142, DOI 10.1080/03008200591008527; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Udani M, 1998, J CLIN INVEST, V101, P2550, DOI 10.1172/JCI1204; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Vainionpaa N, 2006, AM J PHYSIOL-CELL PH, V290, pC764, DOI 10.1152/ajpcell.00285.2005; Virtanen I, 2000, EXP CELL RES, V257, P298, DOI 10.1006/excr.2000.4883; Yu H, 2003, BIOCHEM J, V371, P289, DOI 10.1042/BJ20021500; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	46	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14853	14860		10.1074/jbc.M611706200	http://dx.doi.org/10.1074/jbc.M611706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17383963	hybrid			2022-12-27	WOS:000246589000021
J	Xhemalce, B; Miller, KM; Driscoll, R; Masumoto, H; Jackson, SP; Kouzarides, T; Verreault, A; Arcangioli, B				Xhemalce, Blerta; Miller, Kyle M.; Driscoll, Robert; Masumoto, Hiroshi; Jackson, Stephen P.; Kouzarides, Tony; Verreault, Alain; Arcangioli, Benoit			Regulation of histone H3 lysine 56 acetylation in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; ASSEMBLY FACTOR ASF1; SACCHAROMYCES-CEREVISIAE; S-PHASE; FISSION YEAST; H3K56 ACETYLATION; CELL-CYCLE; H3; CHROMATIN; REPAIR	In Saccharomyces cerevisiae, acetylation of lysine 56 ( Lys-56) in the globular domain of histone H3 plays an important role in response to genotoxic agents that interfere with DNA replication. However, the regulation and biological function of this modification are poorly defined in other eukaryotes. Here we show that Lys-56 acetylation in Schizosaccharomyces pombe occurs transiently during passage through S-phase and is normally removed in G2. Genotoxic agents that cause DNA double strand breaks during replication elicit a delay in deacetylation of histone H3 Lys-56. In addition, mutant cells that cannot acetylate Lys-56 are acutely sensitive to genotoxic agents that block DNA replication. Moreover, we show that Spbc342.06cp, a previously uncharacterized open reading frame, encodes the functional homolog of S. cerevisiae Rtt109, and that this protein acetylates H3 Lys-56 both in vitro and in vivo. Altogether, our results indicate that both the regulation of histone H3 Lys-56 acetylation by its histone acetyltransferase and histone deacetylase and its role in the DNA damage response are conserved among two distantly related yeast model organisms.	Inst Pasteur, Unite Dynam Genome, F-75724 Paris 15, France; Univ Montreal, Inst Rech Immunol & Cancerol, Montreal, PQ H3C 3J7, Canada; Wellcome Trust & Canc Res, Cambridge CB2 1QN, England; Dept Pathol, Cambridge CB2 1QN, England; Univ Cambridge, Wellcome Trust & Canc Res, Gurdon Inst, Cambridge CB2 1QN, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QN, England; Osaka Univ, Grad Sch Frontier Sci, Labs Biomol Networks, Suita, Osaka 5650871, Japan	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Montreal; University of Cambridge; University of Cambridge; Osaka University	Arcangioli, B (corresponding author), Inst Pasteur, Unite Dynam Genome, 25 Rue Dr Roux, F-75724 Paris 15, France.	barcan@pasteur.fr	Dry, Kate/I-2328-2014; Jackson, Stephen Philip/R-4548-2019	Jackson, Stephen Philip/0000-0001-9317-7937; Xhemalce, Blerta/0000-0002-0517-9607; Miller, Kyle/0000-0002-4544-0013; Kouzarides, Tony/0000-0002-8918-4162				Adkins MW, 2007, J BIOL CHEM, V282, P1334, DOI 10.1074/jbc.M608025200; Arcangioli B, 2000, EMBO REP, V1, P145, DOI 10.1093/embo-reports/kvd023; Benson LJ, 2006, J BIOL CHEM, V281, P9287, DOI 10.1074/jbc.M512956200; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Collins SR, 2007, NATURE, V446, P806, DOI 10.1038/nature05649; Dalgaard LZ, 1999, NATURE, V400, P181, DOI 10.1038/22139; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Djupedal I, 2005, GENE DEV, V19, P2301, DOI 10.1101/gad.344205; Driscoll R, 2007, SCIENCE, V315, P649, DOI 10.1126/science.1135862; Emili A, 2001, MOL CELL, V7, P13, DOI 10.1016/S1097-2765(01)00150-2; Franco AA, 2005, GENE DEV, V19, P1365, DOI 10.1101/gad.1305005; Freeman-Cook LL, 1999, MOL BIOL CELL, V10, P3171, DOI 10.1091/mbc.10.10.3171; Groth A, 2005, MOL CELL, V17, P301, DOI 10.1016/j.molcel.2004.12.018; Han JH, 2007, SCIENCE, V315, P653, DOI 10.1126/science.1133234; Holmes AM, 2005, MOL CELL BIOL, V25, P303, DOI 10.1128/MCB.25.1.303-311.2005; Hu FH, 2001, GENE DEV, V15, P1061, DOI 10.1101/gad.873201; Hyland EA, 2005, MOL CELL BIOL, V25, P10060, DOI 10.1128/MCB.25.22.10060-10070.2005; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; Kats ES, 2006, P NATL ACAD SCI USA, V103, P3710, DOI 10.1073/pnas.0511102103; Kaykov A, 2004, CURR BIOL, V14, P1924, DOI 10.1016/j.cub.2004.10.026; Koc A, 2004, J BIOL CHEM, V279, P223, DOI 10.1074/jbc.M303952200; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lewis LK, 2005, NUCLEIC ACIDS RES, V33, P4928, DOI 10.1093/nar/gki806; Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869; Maas NL, 2006, MOL CELL, V23, P109, DOI 10.1016/j.molcel.2006.06.006; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Mellone BG, 2003, CURR BIOL, V13, P1748, DOI 10.1016/j.cub.2003.09.031; Miller KM, 2006, CELL CYCLE, V5, P2561, DOI 10.4161/cc.5.22.3501; MORENO S, 1989, J CELL SCI, P1; Nakayama J, 2001, EMBO J, V20, P2857, DOI 10.1093/emboj/20.11.2857; Ozdemir A, 2005, J BIOL CHEM, V280, P25949, DOI 10.1074/jbc.C500181200; Ozdemir A, 2006, CELL CYCLE, V5, P2602, DOI 10.4161/cc.5.22.3473; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Prado F, 2004, EMBO REP, V5, P497, DOI 10.1038/sj.embor.7400128; Ramey CJ, 2004, MOL CELL BIOL, V24, P10313, DOI 10.1128/MCB.24.23.10313-10327.2004; Recht J, 2006, P NATL ACAD SCI USA, V103, P6988, DOI 10.1073/pnas.0601676103; Redon C, 2006, GENETICS, V172, P67, DOI 10.1534/genetics.105.046128; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Schneider J, 2006, J BIOL CHEM, V281, P37270, DOI 10.1074/jbc.C600265200; Sipiczki M, 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-2-reviews1011, DOI 10.1186/GB-2000-1-2-REVIEWS1011]; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Tomschik M, 2005, P NATL ACAD SCI USA, V102, P3278, DOI 10.1073/pnas.0500189102; Umehara T, 2002, GENES CELLS, V7, P59, DOI 10.1046/j.1356-9597.2001.00493.x; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; Vengrova S, 2004, GENE DEV, V18, P794, DOI 10.1101/gad.289404; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Ye JX, 2005, MOL CELL, V18, P123, DOI 10.1016/j.molcel.2005.02.031; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6; Zhou H, 2006, BIOCHEMISTRY-US, V45, P2852, DOI 10.1021/bi0521083	50	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15040	15047		10.1074/jbc.M701197200	http://dx.doi.org/10.1074/jbc.M701197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17369611	hybrid			2022-12-27	WOS:000246589000043
J	Funa, N; Awakawa, T; Horinouchi, S				Funa, Nobutaka; Awakawa, Takayoshi; Horinouchi, Sueharu			Pentaketide resorcylic acid synthesis by type III polyketide synthase from Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-ORYZAE; BIOSYNTHESIS; METABOLITES; IDENTIFICATION; SUPERFAMILY; FAMILY	Type III polyketide synthases (PKSs) are responsible for aromatic polyketide synthesis in plants and bacteria. Genome analysis of filamentous fungi has predicted the presence of fungal type III PKSs, although none have thus far been functionally characterized. In the genome of Neurospora crassa, a single open reading frame, NCU04801.1, annotated as a type III PKS was found. In this report, we demonstrate that NCU04801.1 is a novel type III PKS catalyzing the synthesis of pentaketide alkylresorcylic acids. NCU04801.1, hence named 2'-oxoalkylresorcylic acid synthase (ORAS), preferred stearoyl-CoA as a starter substrate and condensed four molecules of malonyl-CoA to give a pentaketide intermediate. For ORAS to yield pentaketide alkylresorcylic acids, aldol condensation and aromatization of the intermediate, which is still attached to the enzyme, are presumably followed by hydrolysis for release of the product as a resorcylic acid. ORAS is the first type III PKS that synthesizes pentaketide resorcylic acids.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.	asuhori@mail.ecc.u-tokyo.ac.jp						Austin MB, 2004, CHEM BIOL, V11, P1179, DOI 10.1016/j.chembiol.2004.05.024; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; Eckermann C, 2003, PHYTOCHEMISTRY, V62, P271, DOI 10.1016/S0031-9422(02)00554-X; Filip P, 2002, Z NATURFORSCH C, V57, P1004; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Funa N, 2006, P NATL ACAD SCI USA, V103, P6356, DOI 10.1073/pnas.0511227103; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Keller NP, 2005, NAT REV MICROBIOL, V3, P937, DOI 10.1038/nrmicro1286; KUSHWAHA SC, 1976, LIPIDS, V11, P778, DOI 10.1007/BF02533055; Langfelder K, 2003, FUNGAL GENET BIOL, V38, P143, DOI 10.1016/S1087-1845(02)00526-1; Machida M, 2005, NATURE, V438, P1157, DOI 10.1038/nature04300; Ninomiya Y, 2004, P NATL ACAD SCI USA, V101, P12248, DOI 10.1073/pnas.0402780101; Saeed A, 2003, HELV CHIM ACTA, V86, P377, DOI 10.1002/hlca.200390038; Sankaranarayanan R, 2004, NAT STRUCT MOL BIOL, V11, P894, DOI 10.1038/nsmb809; Saxena P, 2003, J BIOL CHEM, V278, P44780, DOI 10.1074/jbc.M306714200; Schweizer E, 2004, MICROBIOL MOL BIOL R, V68, P501, DOI 10.1128/MMBR.68.3.501-517.2004; SEITZ LM, 1992, J AGR FOOD CHEM, V40, P1541, DOI 10.1021/jf00021a014; Seshime Y, 2005, BIOCHEM BIOPH RES CO, V331, P253, DOI 10.1016/j.bbrc.2005.03.160; Shen B, 2003, CURR OPIN CHEM BIOL, V7, P285, DOI 10.1016/S1367-5931(03)00020-6; Suzuki Y, 1998, PHYTOCHEMISTRY, V47, P1247, DOI 10.1016/S0031-9422(97)00720-6; Sweeney MJ, 1999, FEMS MICROBIOL LETT, V175, P149, DOI 10.1111/j.1574-6968.1999.tb13614.x; Tobert JA, 2003, NAT REV DRUG DISCOV, V2, P517, DOI 10.1038/nrd1112; Yang SW, 2006, J ANTIBIOT, V59, P190, DOI 10.1038/ja.2006.27; Zarnowski R, 2000, Z NATURFORSCH C, V55, P846	24	103	107	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14476	14481		10.1074/jbc.M701239200	http://dx.doi.org/10.1074/jbc.M701239200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374612	hybrid			2022-12-27	WOS:000246245800061
J	Vandenberg, RJ; Shaddick, K; Ju, PC				Vandenberg, Robert J.; Shaddick, Kim; Ju, Pengchu			Molecular basis for substrate discrimination by glycine transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; CHROMOSOMAL LOCALIZATION; CLONING; EXPRESSION; INHIBITOR; GLYT2; GENE; TYPE-1	Glycine is an inhibitory neurotransmitter in the spinal cord and brain stem, where it acts on strychnine-sensitive glycine receptors, and is also an excitatory neurotransmitter throughout the brain and spinal cord, where it acts on the N-methyl-D-aspartate family of receptors. There are two Na+/Cl--dependent glycine transporters, GLYT1 and GLYT2, which control extracellular glycine concentrations and these transporters show differences in substrate selectivity and blocker sensitivity. A bacterial Na+-dependent leucine transporter (LeuT(Aa)) has recently been crystallized and its structure determined. When the amino acid residues within the leucine binding site of LeuT(Aa) are aligned with residues of the two glycine transporters there are a number of identical residues and also some key differences. In this report, we demonstrate that the LeuT(Aa) structure represents a good working model of the Na+/Cl--dependent neurotransmitters and that differences in substrate selectivity can be attributed to a single difference of a glycine residue in transmembrane domain 6 of GLYT1 for a serine residue at the corresponding position of GLYT2.	Univ Sydney, Biomed Res Inst, Dept Pharmacol, Sydney, NSW 2006, Australia	University of Sydney	Vandenberg, RJ (corresponding author), Univ Sydney, Biomed Res Inst, Dept Pharmacol, Sydney, NSW 2006, Australia.	robv@med.usyd.edu.au	Vandenberg, Robert John/E-6018-2016	Vandenberg, Robert John/0000-0003-1523-4814				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Atkinson BN, 2001, MOL PHARMACOL, V60, P1414, DOI 10.1124/mol.60.6.1414; Aubrey KR, 2000, MOL PHARMACOL, V58, P129, DOI 10.1124/mol.58.1.129; Aubrey KR, 2001, BRIT J PHARMACOL, V134, P1429, DOI 10.1038/sj.bjp.0704381; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KIM KM, 1994, MOL PHARMACOL, V45, P608; Kinney GG, 2003, J NEUROSCI, V23, P7586; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LIU QR, 1993, J BIOL CHEM, V268, P22802; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; Morrow JA, 1998, FEBS LETT, V439, P334, DOI 10.1016/S0014-5793(98)01390-8; Nunez E, 2005, NEUROPHARMACOLOGY, V49, P922, DOI 10.1016/j.neuropharm.2005.07.010; Otis TS, 1998, J NEUROSCI, V18, P7099; Pearlman RJ, 2003, J NEUROCHEM, V84, P592, DOI 10.1046/j.1471-4159.2003.01549.x; Rees MI, 2006, NAT GENET, V38, P801, DOI 10.1038/ng1814; Roux MJ, 2000, NEURON, V25, P373, DOI 10.1016/S0896-6273(00)80901-0; Ryan RM, 2004, J BIOL CHEM, V279, P20742, DOI 10.1074/jbc.M304433200; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; Vandenberg RJ, 1998, BRIT J PHARMACOL, V123, P1593, DOI 10.1038/sj.bjp.0701776; Xu TX, 2005, NEUROREPORT, V16, P1227, DOI 10.1097/00001756-200508010-00019; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; ZAFRA F, 1995, J NEUROSCI, V15, P3952	23	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14447	14453		10.1074/jbc.M609158200	http://dx.doi.org/10.1074/jbc.M609158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17383967	hybrid			2022-12-27	WOS:000246245800058
J	McCole, DF; Truong, A; Bunz, M; Barrett, KE				McCole, Declan F.; Truong, Anh; Bunz, Michael; Barrett, Kim E.			Consequences of direct Versus indirect activation of epidermal growth factor receptor in intestinal epithelial cells are dictated by protein-tyrosine phosphatase 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CHLORIDE SECRETION; FACTOR-ALPHA BIND; EGF-RECEPTOR; TRANSFORMING GROWTH; COLON-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-MECHANISM; COUPLED RECEPTORS; PHOSPHOLIPASE-C; ERBB RECEPTORS	The epidermal growth factor receptor (EGFR) is an integral regulator of many cellular functions. EGFR also acts as a central conduit for extracellular signals involving direct activation of the receptor by EGFR ligands or indirect activation by G protein-coupled receptor (GPCR)-stimulated transactivation of the EGFR. We have previously shown that EGFR negatively regulates epithelial chloride secretion as a result of transforming growth factor-alpha-mediated EGFR transactivation in response to muscarinic GPCR activation. Here we show that direct activation of the EGFR by EGFR ligands produces a different pattern of EGFR tyrosine phosphorylation and downstream phosphatidylinositol 3-kinase recruitment than GPCR-stimulated transactivation of the EGFR occurring via paracrine EGFR ligand release. Moreover, we demonstrate that this differential signaling and its consequences depend on protein-tyrosine phosphatase 1B activity. Thus protein-tyrosine phosphatase 1B governs differential recruitment of signaling pathways involved in EGFR regulation of epithelial ion transport. Our findings furthermore establish how divergent signaling outcomes can arise from the activation of a single receptor.	Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	McCole, DF (corresponding author), Univ Calif San Diego, Div Gastroenterol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dmccole@ucsd.edu	McCole, Declan/AAL-2454-2020; Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Barrett KE, 1998, AM J PHYSIOL-CELL PH, V274, pC958, DOI 10.1152/ajpcell.1998.274.4.C958; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARTLIDGE SA, 1989, BRIT J CANCER, V60, P657, DOI 10.1038/bjc.1989.334; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; Darmoul D, 2004, MOL CANCER RES, V2, P514; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; DeYulia GJ, 2005, BIOCHEM BIOPH RES CO, V334, P38, DOI 10.1016/j.bbrc.2005.06.056; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 1999, J BIOL CHEM, V274, P33449, DOI 10.1074/jbc.274.47.33449; LABURTHE M, 1989, AM J PHYSIOL, V256, pG443, DOI 10.1152/ajpgi.1989.256.3.G443; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; Lenferink AEG, 1998, BIOCHEM J, V336, P147, DOI 10.1042/bj3360147; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MaleckaPanas E, 1997, HEPATO-GASTROENTEROL, V44, P435; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; McCole DF, 2005, GASTROENTEROLOGY, V129, P591, DOI 10.1053/j.gastro.2005.06.004; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; MILARSKI KL, 1993, J BIOL CHEM, V268, P26364; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; Playford RJ, 1996, GUT, V39, P262, DOI 10.1136/gut.39.2.262; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VAJANAPHANICH M, 1995, J CLIN INVEST, V96, P386, DOI 10.1172/JCI118046; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAHAWISAN R, 1986, J PHARM PHARMACOL, V38, P150, DOI 10.1111/j.2042-7158.1986.tb04533.x; Wang DG, 2002, ONCOGENE, V21, P2785, DOI 10.1038/sj.onc.1205375; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang ZY, 1996, J BIOL CHEM, V271, P5386, DOI 10.1074/jbc.271.10.5386	52	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13303	13315		10.1074/jbc.M700424200	http://dx.doi.org/10.1074/jbc.M700424200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339316	hybrid			2022-12-27	WOS:000246060300018
J	Uchida, Y; Hama, H; Alderson, NL; Douangpanya, S; Wang, Y; Crumrine, DA; Elias, PM; Holleran, WM				Uchida, Yoshikazu; Hama, Hiroko; Alderson, Nathan L.; Douangpanya, Sounthala; Wang, Yu; Crumrine, Debra A.; Elias, Peter M.; Holleran, Walter M.			Fatty acid 2-hydroxylase, encoded by FA2H, accounts for differentiation-associated increase in 2-OH Ceramides during keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN KERATINOCYTES; STRATUM-CORNEUM CERAMIDES; EPIDERMAL PERMEABILITY BARRIER; LIPID ENVELOPE CLE; HARLEQUIN ICHTHYOSIS; ATOPIC-DERMATITIS; PIG EPIDERMIS; ALPHA-HYDROXYLATION; FAMILY-MEMBERS; HUMAN-SKIN	Ceramides in mammalian stratum corneum comprise a heterogeneous mixture of molecular species that subserve the epidermal permeability barrier, an essential function for survival in a terrestrial environment. In addition to a variation of sphingol species, hydroxylation of the amide-linked fatty acids contributes to the diversity of epidermal ceramides. Fatty acid 2-hydroxylase, encoded by the gene FA2H, the mammalian homologue of FAH1 in yeast, catalyzes the synthesis of 2-hydroxy fatty acid-containing sphingolipids. We assessed here whether FA2H accounts for 2-hydroxyceramide/2-hydroxyglucosylceramide synthesis in epidermis. Reverse transcription-PCR and Western immunoblots demonstrated that FA2H is expressed in cultured human keratinocytes and human epidermis, with FA2H expression and fatty acid 2-hydroxylase activity increased with differentiation. FA2H-siRNA suppressed 2-hydroxylase activity and decreased 2-hydroxyceramide/2-hydroxyglucosylceramide levels, demonstrating that FA2H accounts for synthesis of these sphingolipids in keratinocytes. Whereas FA2H expression and 2-hydroxy free fatty acid production increased early in keratinocyte differentiation, production of 2-hydroxyceramides/2-hydroxyglucosylceramides with longer chain amide-linked fatty acids (>= C24) increased later. Keratinocytes transduced with FA2H-siRNA contained abnormal epidermal lamellar bodies and did not form the normal extracellular lamellar membranes required for the epidermal permeability barrier. These results reveal that 1) differentiation-dependent up-regulation of ceramide synthesis and fatty acid elongation is accompanied by up-regulation of FA2H; 2) 2-hydroxylation of fatty acid by FA2H occurs prior to generation of ceramides/glucosylceramides; and 3) 2-hydroxyceramides/2-hydroxyglucosylceramides are required for epidermal lamellar membrane formation. Thus, late differentiation-linked increases in FA2H expression are essential for epidermal permeability barrier homeostasis.	Vet Affairs Med Ctr, Dermatol Serv & Res Unit, San Francisco, CA 94121 USA; Univ Calif San Francisco, Sch Med, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94121 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Medical University of South Carolina	Uchida, Y (corresponding author), Vet Affairs Med Ctr, Dermatol Serv & Res Unit, 4150 Clement St, San Francisco, CA 94121 USA.	uchiday@derm.ucsf.edu		Uchida, Yoshikazu/0000-0002-4980-3416	NCRR NIH HHS [RR17677] Funding Source: Medline; NIAMS NIH HHS [AR19098, AR39448, AR050629] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448, R01AR019098, R01AR050629] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAHAM W, 1985, J LIPID RES, V26, P761; Akiyama M, 2005, J CLIN INVEST, V115, P1777, DOI 10.1172/JCI24834; Alderson NL, 2006, J LIPID RES, V47, P2772, DOI 10.1194/jlr.M600362-JLR200; Alderson NL, 2005, J LIPID RES, V46, P1569, DOI 10.1194/jlr.D500013-JLR200; Alderson NL, 2004, J BIOL CHEM, V279, P48562, DOI 10.1074/jbc.M406649200; Behne M, 2000, J INVEST DERMATOL, V114, P185, DOI 10.1046/j.1523-1747.2000.00846.x; Bleck O, 1999, J INVEST DERMATOL, V113, P894, DOI 10.1046/j.1523-1747.1999.00809.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bouwstra JA, 1998, J LIPID RES, V39, P186; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; de Jager MW, 2003, CHEM PHYS LIPIDS, V124, P123, DOI 10.1016/S0009-3084(03)00050-1; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P1619; Di Nardo A, 1998, ACTA DERM-VENEREOL, V78, P27; Eckhardt M, 2005, BIOCHEM J, V388, P245, DOI 10.1042/BJ20041451; Elias PM, 2000, J INVEST DERMATOL, V115, P765, DOI 10.1046/j.1523-1747.2000.00124-5.x; ELIAS PM, 1991, ADV LIPID RES, V24, P1; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; Hamanaka S, 2005, BRIT J DERMATOL, V152, P426, DOI 10.1111/J.1365-2133.2004.06333.X; Hamanaka S, 2002, J INVEST DERMATOL, V119, P416, DOI 10.1046/j.1523-1747.2002.01836.x; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Holleran WM, 2006, FEBS LETT, V580, P5456, DOI 10.1016/j.febslet.2006.08.039; HOLLERAN WM, 1991, J LIPID RES, V32, P1151; HOLLERAN WM, 1994, J CLIN INVEST, V93, P1756, DOI 10.1172/JCI117160; HOSHI M, 1973, J NEUROCHEM, V21, P709, DOI 10.1111/j.1471-4159.1973.tb06017.x; HOSHI M, 1973, J BIOL CHEM, V248, P4123; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; Houben E, 2006, J LIPID RES, V47, P1063, DOI 10.1194/jlr.M600001-JLR200; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; Jansen BJH, 2003, J INVEST DERMATOL, V121, P1433, DOI 10.1046/j.1523-1747.2003.12636.x; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; Kelsell DP, 2005, AM J HUM GENET, V76, P794; KISHIMOTO Y, 1963, J LIPID RES, V4, P139; Magnoni C, 2002, TOXICOL IN VITRO, V16, P349, DOI 10.1016/S0887-2333(02)00024-3; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MELNIK B, 1988, BRIT J DERMATOL, V119, P547, DOI 10.1111/j.1365-2133.1988.tb03262.x; Mitchell AG, 1997, J BIOL CHEM, V272, P28281, DOI 10.1074/jbc.272.45.28281; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; MOTTA S, 1993, BIOCHIM BIOPHYS ACTA, V1182, P147, DOI 10.1016/0925-4439(93)90135-N; Ohvo-Rekila H, 2002, PROG LIPID RES, V41, P66, DOI 10.1016/S0163-7827(01)00020-0; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PITTELKOW MR, 1986, MAYO CLIN PROC, V61, P771, DOI 10.1016/S0025-6196(12)64815-0; PONEC M, 1988, J LIPID RES, V29, P949; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; ROBSON KJ, 1994, J LIPID RES, V35, P2060; Sando GN, 1996, J BIOL CHEM, V271, P22044, DOI 10.1074/jbc.271.36.22044; Schmuth M, 2000, J INVEST DERMATOL, V115, P459, DOI 10.1046/j.1523-1747.2000.00081.x; Stewart ME, 1999, J LIPID RES, V40, P1434; Uchida Y, 2003, J INVEST DERMATOL, V120, P662, DOI 10.1046/j.1523-1747.2003.12098.x; Uchida Y, 2002, J LIPID RES, V43, P1293, DOI 10.1194/jlr.M100442-JLR200; Uchida Y, 2001, J INVEST DERMATOL, V117, P1307, DOI 10.1046/j.0022-202x.2001.01555.x; Uchida Y, 2000, J LIPID RES, V41, P2071; Vasireddy V, 2007, HUM MOL GENET, V16, P471, DOI 10.1093/hmg/ddl480; Veiga MP, 2001, BIOCHEMISTRY-US, V40, P2614, DOI 10.1021/bi0019803; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; WERTZ PW, 1983, J LIPID RES, V24, P1135; WERTZ PW, 1983, J LIPID RES, V24, P759; YAMAMOTO A, 1991, ARCH DERMATOL RES, V283, P219, DOI 10.1007/BF01106105	61	52	54	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13211	13219		10.1074/jbc.M611562200	http://dx.doi.org/10.1074/jbc.M611562200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355976	hybrid			2022-12-27	WOS:000246060300009
J	Gloster, TM; Ibatullin, FM; Macauley, K; Eklof, JM; Roberts, S; Turkenburg, JP; Bjornvad, ME; Jorgensen, PL; Danielsen, S; Johansen, KS; Borchert, TV; Wilson, KS; Brumer, H; Davies, GJ				Gloster, Tracey M.; Ibatullin, Farid M.; Macauley, Katherine; Eklof, Jens M.; Roberts, Shirley; Turkenburg, Johan P.; Bjornvad, Mads E.; Jorgensen, Per Lina; Danielsen, Steffen; Johansen, Katja S.; Borchert, Torben V.; Wilson, Keith S.; Brumer, Harry; Davies, Gideon J.			Characterization and three-dimensional structures of two distinct bacterial xyloglucanases from families GH5 and GH12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL WALL COMPOSITION; CELLULOSE SURFACES; CRYSTAL-STRUCTURES; ENDOGLUCANASE; OLIGOSACCHARIDES; CLONING; REVEAL; BIOSYNTHESIS; EXPRESSION; SUBSTRATE	The plant cell wall is a complex material in which the cellulose microfibrils are embedded within a mesh of other polysaccharides, some of which are loosely termed "hemicellulose." One such hemicellulose is xyloglucan, which displays a beta-1,4-linked D-glucose backbone substituted with xylose, galactose, and occasionally fucose moieties. Both xyloglucan and the enzymes responsible for its modification and degradation are finding increasing prominence, reflecting both the drive for enzymatic biomass conversion, their role in detergent applications, and the utility of modified xyloglucans for cellulose fiber modification. Here we present the enzymatic characterization and three-dimensional structures in ligand free and xyloglucan- oligosaccharide complexed forms of two distinct xyloglucanases from glycoside hydrolase families GH5 and GH12. The enzymes, Paenibacillus pabuli XG5 and Bacillus licheniformis XG12, both display open active center grooves grafted upon their respective (beta/alpha)(8) and beta-jelly roll folds, in which the side chain decorations of xyloglucan may be accommodated. For the beta-jelly roll enzyme topology of GH12, binding of xylosyl and pendant galactosyl moieties is tolerated, but the enzymeis similarly competent in the degradation of unbranched glucans. In the case of the (beta/alpha)(8) GH5 enzyme, kinetically productive interactions are made with both xylose and galactose substituents, as reflected in both a high specific activity on xyloglucan and the kinetics of a series of aryl glycosides. The differential strategies for the accommodation of the side chains of xyloglucan presumably facilitate the action of these microbial hydrolases in milieus where diverse and differently substituted substrates may be encountered.	AlbaNova Univ Ctr, Sch Biotechnol, Royal Inst Technol, S-10691 Stockholm, Sweden; Novozymes A S, DK-2880 Bagsvaerd, Denmark	Royal Institute of Technology; Novozymes	Brumer, H (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	harry@biotech.kth.se; davies@ysbl.york.ac.uk	Ibatullin, Farid/B-2705-2012; Davies, Gideon J/A-9042-2011; Johansen, Katja/J-7939-2016; Johansen, Katja/E-9740-2013	Davies, Gideon J/0000-0002-7343-776X; Johansen, Katja/0000-0002-7587-5990; Ibatullin, Farid/0000-0002-7660-4172; Wilson, Keith/0000-0002-3581-2194; McAuley, Katherine/0000-0002-9545-072X; Turkenburg, Johan/0000-0001-6992-6838	Biotechnology and Biological Sciences Research Council [BB/D522511/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blanco A, 1998, APPL MICROBIOL BIOT, V50, P48, DOI 10.1007/s002530051255; Brumer H, 2004, J AM CHEM SOC, V126, P5715, DOI 10.1021/ja0316770; Brummell DA, 2006, FUNCT PLANT BIOL, V33, P103, DOI 10.1071/FP05234; Buckeridge MS, 1997, CARBOHYD RES, V303, P233, DOI 10.1016/S0008-6215(97)00161-4; Buckeridge MS, 2000, PLANT PHYSIOL BIOCH, V38, P141, DOI 10.1016/S0981-9428(00)00162-5; Carpita N., 2000, BIOCH MOL BIOL PLANT, P52; Chanliaud E, 2004, PLANT J, V38, P27, DOI 10.1111/j.1365-313X.2004.02018.x; CLAEYSSENS M, 1992, BIORESOURCE TECHNOL, V39, P143, DOI 10.1016/0960-8524(92)90133-I; Cosgrove DJ, 2005, NAT REV MOL CELL BIO, V6, P850, DOI 10.1038/nrm1746; Crennell SJ, 2002, J MOL BIOL, V320, P883, DOI 10.1016/S0022-2836(02)00446-1; DAPRANO A, 1968, P NATL ACAD SCI USA, V61, P1183, DOI 10.1073/pnas.61.4.1183; Davies GJ, 2005, CURR OPIN STRUC BIOL, V15, P637, DOI 10.1016/j.sbi.2005.10.008; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; Demain AL, 2005, MICROBIOL MOL BIOL R, V69, P124, DOI 10.1128/MMBR.69.1.124-154.2005; DUCROS V, 1995, STRUCTURE, V3, P939, DOI 10.1016/S0969-2126(01)00228-3; Ducros VMA, 2003, CHEM BIOL, V10, P619, DOI 10.1016/S1074-5521(03)00143-1; Dunand C, 2000, PLANT SCI, V151, P183, DOI 10.1016/S0168-9452(99)00217-4; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Faure R, 2006, J ORG CHEM, V71, P5151, DOI 10.1021/jo0525682; FRY SC, 1993, PHYSIOL PLANTARUM, V89, P1; FRY SC, 1989, J EXP BOT, V40, P1, DOI 10.1093/jxb/40.1.1; Greffe L, 2005, GLYCOBIOLOGY, V15, P437, DOI 10.1093/glycob/cwi013; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Hoffman M, 2005, CARBOHYD RES, V340, P1826, DOI 10.1016/j.carres.2005.04.016; Jia ZH, 2005, CARBOHYD RES, V340, P1818, DOI 10.1016/j.carres.2005.04.015; Johansson P, 2004, PLANT CELL, V16, P874, DOI 10.1105/tpc.020065; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lonnberg H, 2006, BIOMACROMOLECULES, V7, P2178, DOI 10.1021/bm060178z; Martinez-Fleites C, 2006, J BIOL CHEM, V281, P24922, DOI 10.1074/jbc.M603583200; Miyazaki S, 1998, J CONTROL RELEASE, V56, P75, DOI 10.1016/S0168-3659(98)00079-0; Miyazaki S, 2003, DRUG DEV IND PHARM, V29, P113, DOI 10.1081/DDC-120016718; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nelson N, 1944, J BIOL CHEM, V153, P375; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park YW, 1997, BIOCHEM BIOPH RES CO, V241, P636, DOI 10.1006/bbrc.1997.7747; Pauly M, 1999, PLANT J, V20, P629, DOI 10.1046/j.1365-313X.1999.00630.x; Pauly M, 1999, GLYCOBIOLOGY, V9, P93, DOI 10.1093/glycob/9.1.93; Popper ZA, 2004, NEW PHYTOL, V164, P165, DOI 10.1111/j.1469-8137.2004.01146.x; Popper ZA, 2003, ANN BOT-LONDON, V91, P1, DOI 10.1093/aob/mcg013; Rao P S, 1973, IND GUMS; Reiter WD, 2002, CURR OPIN PLANT BIOL, V5, P536, DOI 10.1016/S1369-5266(02)00306-0; SAARILAHTI HT, 1990, GENE, V90, P9, DOI 10.1016/0378-1119(90)90433-R; Sandgren M, 2004, J MOL BIOL, V342, P1505, DOI 10.1016/j.jmb.2004.07.098; Scheible WR, 2004, CURR OPIN PLANT BIOL, V7, P285, DOI 10.1016/j.pbi.2004.03.006; Shankaracharya NB, 1998, J FOOD SCI TECH MYS, V35, P193; Shirakawa M, 1998, FOOD HYDROCOLLOID, V12, P25, DOI 10.1016/S0268-005X(98)00052-6; Sims IM, 1996, CARBOHYD RES, V293, P147, DOI 10.1016/0008-6215(96)00142-5; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; Stiernstedt J, 2006, BIOMACROMOLECULES, V7, P2147, DOI 10.1021/bm060100i; Sulzenbacher G, 1997, BIOCHEMISTRY-US, V36, P16032, DOI 10.1021/bi972407v; Sulzenbacher G, 1999, BIOCHEMISTRY-US, V38, P4826, DOI 10.1021/bi982648i; Thompson DS, 2005, J EXP BOT, V56, P2275, DOI 10.1093/jxb/eri247; TULL D, 1994, BIOCHEMISTRY-US, V33, P6363, DOI 10.1021/bi00186a041; Vargas-Rechia C, 1998, PLANT PHYSIOL, V116, P1013, DOI 10.1104/pp.116.3.1013; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Vincken JP, 1997, CARBOHYD RES, V298, P299, DOI 10.1016/S0008-6215(96)00325-4; Vincken JP, 1997, PLANT PHYSIOL, V114, P9, DOI 10.1104/pp.114.1.9; Vincken JP, 1996, CARBOHYD POLYM, V29, P75, DOI 10.1016/0144-8617(95)00149-2; Wolfenden R, 1998, J AM CHEM SOC, V120, P6814, DOI 10.1021/ja9813055; Yaoi K, 2005, APPL ENVIRON MICROB, V71, P7670, DOI 10.1128/AEM.71.12.7670-7678.2005; Yaoi K, 2004, STRUCTURE, V12, P1209, DOI 10.1016/j.str.2004.04.020; Zhou Q, 2006, CARBOHYD POLYM, V63, P449, DOI 10.1016/j.carbpol.2005.09.015; Zhou Q, 2005, MACROMOLECULES, V38, P3547, DOI 10.1021/ma047712k	68	92	92	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19177	19189		10.1074/jbc.M700224200	http://dx.doi.org/10.1074/jbc.M700224200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17376777	hybrid			2022-12-27	WOS:000247475300059
J	Hansson, M; Dupuis, T; Stromquist, R; Andersson, B; Vener, AV; Carlberg, I				Hansson, Maria; Dupuis, Tiphaine; Stromquist, Ragna; Andersson, Bertil; Vener, Alexander V.; Carlberg, Inger			The mobile thylakoid phosphoprotein TSP9 interacts with the light-harvesting complex II and the peripheries of both photosystems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; STATE TRANSITIONS; CHLOROPLAST PHOSPHOPROTEINS; PHOTOSYNTHETIC MEMBRANES; 3-DIMENSIONAL STRUCTURE; ARABIDOPSIS-THALIANA; STRUCTURAL-CHANGES; ANTENNA; ORGANIZATION; POLYPEPTIDES	The localization of the plant-specific thylakoid-soluble phosphoprotein of 9 kDa, TSP9, within the chloroplast thylakoid membrane of spinach has been established by the combined use of fractionation, immunoblotting, cross-linking, and mass spectrometry. TSP9 was found to be exclusively confined to the thylakoid membranes, where it is enriched in the stacked grana membrane domains. After mild solubilization of the membranes, TSP9 migrated together with the major light-harvesting antenna (LHCII) of photosystem II (PSII) and with PSII-LHCII supercomplexes upon separation of the protein complexes by either native gel electrophoresis or sucrose gradient centrifugation. Studies with a cleavable cross-linking agent revealed the interaction of TSP9 with both major and minor LHCII proteins as identified by mass spectrometric sequencing. Cross-linked complexes that in addition to TSP9 contain the peripheral PSII subunits CP29, CP26, and PsbS, which form the interface between LHCII and the PSII core, were found. Our observations also clearly suggest an interaction of TSP9 with photosystem I (PSI) as shown by both immunodetection and mass spectrometry. Sequencing identified the peripheral PSI subunits PsaL, PsaF, and PsaE, originating from cross-linked protein complexes of around 30 kDa that also contained TSP9. The distribution of TSP9 among the cross-linked forms was found to be sensitive to conditions such as light exposure. An association of TSP9 with LHCII as well as the peripheries of the photosystems suggests its involvement in regulation of photosynthetic light harvesting.	[Hansson, Maria; Andersson, Bertil; Vener, Alexander V.] Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden; [Dupuis, Tiphaine; Stromquist, Ragna; Andersson, Bertil; Carlberg, Inger] Linkoping Univ, Div Cell Biol, SE-58185 Linkoping, Sweden	Stockholm University; Linkoping University	Carlberg, I (corresponding author), Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs Nat Sci, SE-10691 Stockholm, Sweden.	ingerc@dbb.su.se	Andersson, Bertil/C-9328-2009					ALBERTSSON PA, 1990, FEBS LETT, V273, P36, DOI 10.1016/0014-5793(90)81045-P; Allen JF, 2003, SCIENCE, V299, P1530, DOI 10.1126/science.1082833; ANDERSSON B, 1976, BIOCHIM BIOPHYS ACTA, V423, P122, DOI 10.1016/0005-2728(76)90106-7; Antonkine ML, 2003, J MOL BIOL, V327, P671, DOI 10.1016/S0022-2836(03)00145-1; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Baena-Gonzalez E, 1999, PLANTA, V208, P196, DOI 10.1007/s004250050550; BENNETT J, 1987, FEBS LETT, V210, P22, DOI 10.1016/0014-5793(87)81290-5; BENNETT J, 1980, EUR J BIOCHEM, V104, P85, DOI 10.1111/j.1432-1033.1980.tb04403.x; Bergantino E, 2003, P NATL ACAD SCI USA, V100, P15265, DOI 10.1073/pnas.2533072100; BHALLA P, 1987, ARCH BIOCHEM BIOPHYS, V252, P97, DOI 10.1016/0003-9861(87)90012-9; Boekema EJ, 1999, BIOCHEMISTRY-US, V38, P2233, DOI 10.1021/bi9827161; Carlberg I, 1999, BIOCHEMISTRY-US, V38, P3197, DOI 10.1021/bi982506o; Carlberg I, 2003, P NATL ACAD SCI USA, V100, P757, DOI 10.1073/pnas.0235452100; CARLBERG I, 1992, BIOCHIM BIOPHYS ACTA, V1099, P111, DOI 10.1016/0304-4173(92)90015-7; Ciambella C, 2005, PROTEOMICS, V5, P746, DOI 10.1002/pmic.200401129; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; Depege N, 2003, SCIENCE, V299, P1572, DOI 10.1126/science.1081397; DOUCE R, 1973, J BIOL CHEM, V248, P7215; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Froehlich JE, 2003, J PROTEOME RES, V2, P413, DOI 10.1021/pr034025j; Fromme P, 2003, FEBS LETT, V555, P40, DOI 10.1016/S0014-5793(03)01124-4; Haldrup A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7; Hammer MF, 1997, PLANT PHYSIOL, V113, P227, DOI 10.1104/pp.113.1.227; Hankamer B, 2001, J STRUCT BIOL, V135, P262, DOI 10.1006/jsbi.2001.4405; Hansson M, 2003, MOL CELL PROTEOMICS, V2, P550, DOI 10.1074/mcp.M300050-MCP200; Holt NE, 2004, BIOCHEMISTRY-US, V43, P8281, DOI 10.1021/bi0494020; Horton P, 2005, J EXP BOT, V56, P365, DOI 10.1093/jxb/eri023; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Jolley C, 2005, J BIOL CHEM, V280, P33627, DOI 10.1074/jbc.M500937200; Kargul J, 2005, FEBS J, V272, P4797, DOI 10.1111/j.1742-4658.2005.04894.x; Kouril R, 2005, BIOCHEMISTRY-US, V44, P10935, DOI 10.1021/bi051097a; Kugler M, 1997, PHOTOSYNTH RES, V53, P35, DOI 10.1023/A:1005882406718; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Lindahl M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P321; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; MICHEL H, 1991, J BIOL CHEM, V266, P17584; MUNCH S, 1988, CURR GENET, V14, P511, DOI 10.1007/BF00521277; Nilsson A, 1997, J BIOL CHEM, V272, P18350, DOI 10.1074/jbc.272.29.18350; Niyogi KK, 2005, J EXP BOT, V56, P375, DOI 10.1093/jxb/eri056; Pascal AA, 2005, NATURE, V436, P134, DOI 10.1038/nature03795; Rintamaki E, 1996, J BIOL CHEM, V271, P14870, DOI 10.1074/jbc.271.25.14870; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Shevchenko A, 2002, MOL BIOTECHNOL, V20, P107, DOI 10.1385/MB:20:1:107; Snyders S, 2001, J BIOL CHEM, V276, P32169, DOI 10.1074/jbc.M102539200; Snyders S, 1999, J BIOL CHEM, V274, P9137, DOI 10.1074/jbc.274.14.9137; Song JK, 2006, BIOCHEMISTRY-US, V45, P15633, DOI 10.1021/bi062148m; Suorsa M, 2004, EUR J BIOCHEM, V271, P96, DOI 10.1046/j.1432-1033.2003.03906.x; Takahashi H, 2006, P NATL ACAD SCI USA, V103, P477, DOI 10.1073/pnas.0509952103; Turkina MV, 2006, MOL CELL PROTEOMICS, V5, P1412, DOI 10.1074/mcp.M600066-MCP200; Uversky VN, 2005, J MOL RECOGNIT, V18, P343, DOI 10.1002/jmr.747; Vainonen JP, 2005, J BIOL CHEM, V280, P33679, DOI 10.1074/jbc.M505729200; Vener AV, 2006, ADV PHOTO RESPIRAT, V21, P107; Vener AV, 2001, J BIOL CHEM, V276, P6959, DOI 10.1074/jbc.M009394200; Vener AV, 1999, BIOCHEMISTRY-US, V38, P14955, DOI 10.1021/bi990971v; Walcher W, 2003, ANAL CHEM, V75, P6775, DOI 10.1021/ac034866+; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623; Yakushevska AE, 2003, BIOCHEMISTRY-US, V42, P608, DOI 10.1021/bi027109z; Yakushevska AE, 2001, EUR J BIOCHEM, V268, P6020, DOI 10.1046/j.0014-2956.2001.02505.x; Zhang SP, 2004, J BIOL CHEM, V279, P3180, DOI 10.1074/jbc.M311640200	66	18	18	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16214	16222		10.1074/jbc.M605833200	http://dx.doi.org/10.1074/jbc.M605833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17400553	hybrid			2022-12-27	WOS:000246794300029
J	Montecinos, V; Guzman, P; Barra, V; Villagran, M; Munoz-Montesino, C; Sotomayor, K; Escobar, E; Godoy, A; Mardones, L; Sotomayor, P; Guzman, C; Vasquez, O; Gallardo, V; van Zundert, B; Bono, MR; Onate, SA; Bustamante, M; Carcamo, JG; Rivas, CI; Vera, JC				Montecinos, Viviana; Guzman, Paula; Barra, Valeria; Villagran, Marcelo; Munoz-Montesino, Carola; Sotomayor, Kirsty; Escobar, Elizabeth; Godoy, Alejandro; Mardones, Lorena; Sotomayor, Paula; Guzman, Catherine; Vasquez, Osman; Gallardo, Victoria; van Zundert, Brigitte; Bono, Maria Rosa; Onate, Sergio A.; Bustamante, Marcelo; Carcamo, Juan G.; Rivas, Coralia I.; Vera, Juan Carlos			Vitamin C is an essential antioxidant that enhances survival of oxidatively stressed human vascular endothelial cells in the presence of a vast molar excess of glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMMENDED DIETARY ALLOWANCE; BLOOD-BRAIN-BARRIER; ASCORBIC-ACID; DEHYDROASCORBIC ACID; THIOREDOXIN REDUCTASE; TRANSPORT; EXPRESSION; ACCUMULATION; IDENTIFICATION; GLUTAREDOXIN	Cellular glutathione levels may exceed vitamin C levels by 10-fold, generating the question about the real antioxidant role that low intracellular concentrations of vitamin C can play in the presence of a vast molar excess of glutathione. We characterized the metabolism of vitamin C and its relationship with glutathione in primary cultures of human endothelial cells oxidatively challenged by treatment with hydrogen peroxide or with activated cells undergoing the respiratory burst, and analyzed the manner in which vitamin C interacts with glutathione to increase the antioxidant capacity of cells. Our data indicate that: (i) endothelial cells express transporters for reduced and oxidized vitamin C and accumulate ascorbic acid with participation of glutathione-dependent dehydroascorbic acid reductases, (ii) although increased intracellular levels of vitamin C or glutathione caused augmented resistance to oxidative stress, 10-times more glutathione than vitamin C was required, (iii) full antioxidant protection required the simultaneous presence of intracellular and extracellular vitamin C at concentrations normally found in vivo, and (iv) intracellular vitamin C cooperated in enhancing glutathione recovery after oxidative challenge thus providing cells with enhanced survival potential, while extracellular vitamin C was recycled through a mechanism involving the simultaneous neutralization of oxidant species. Therefore, in endothelial cells under oxidative challenge, vitamin C functions as an essential cellular antioxidant even in the presence of a vast molar excess of glutathione.	Univ Concepcion, Dept Fisiopatol, Fac Ciencias Biol, Concepcion, Chile; Univ Chile, Fac Ciencias, Dept Bioquim, Santiago, Chile; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Univ Catolica Santisima Concepcion, Fac Med, Concepcion, Chile; Univ Austral Chile, Fac Ciencias, Inst Bioquim, Valdivia, Chile	Universidad de Concepcion; Universidad de Chile; Roswell Park Cancer Institute; Universidad Catolica de la Santisima Concepcion; Universidad Austral de Chile	Vera, JC (corresponding author), Univ Concepcion, Dept Fisiopatol, Fac Ciencias Biol, Barrio Univ S-N,Casilla 160C, Concepcion, Chile.	juvera@udec.cl	Mardones, Lorena/Z-4896-2019; Godoy, Alejandro/GPS-4942-2022; Bono, Maria/G-7461-2014; Villagran, Marcelo/AAP-1171-2020	Mardones, Lorena/0000-0001-8037-4296; Villagran, Marcelo/0000-0003-3645-5659; Munoz, Carola/0000-0003-1851-0167; Carcamo, Juan Guillermo/0000-0002-2595-4375; Escobar Sagredo, Maria Elizabeth/0000-0002-9706-4312				Baekkevold ES, 1999, LAB INVEST, V79, P327; Best KA, 2005, MOL CELL BIOCHEM, V271, P43, DOI 10.1007/s11010-005-3442-0; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Carr AC, 1999, AM J CLIN NUTR, V69, P1086; Castro A, 1996, EUR J CELL BIOL, V70, P61; Duelli R, 2001, NEWS PHYSIOL SCI, V16, P71; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Godoy A, 2007, J BIOL CHEM, V282, P615, DOI 10.1074/jbc.M608300200; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Koshiishi I, 1998, BBA-GEN SUBJECTS, V1425, P209, DOI 10.1016/S0304-4165(98)00073-7; Levine M, 2001, P NATL ACAD SCI USA, V98, P9842, DOI 10.1073/pnas.171318198; Liang WJ, 2001, MOL MEMBR BIOL, V18, P87, DOI 10.1080/09687680120706; Linster CL, 2007, FEBS J, V274, P1, DOI 10.1111/j.1742-4658.2006.05607.x; Lovering AL, 2004, CANCER RES, V64, P1802, DOI 10.1158/0008-5472.CAN-03-2847; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MARTENSSON J, 1993, P NATL ACAD SCI USA, V90, P317, DOI 10.1073/pnas.90.1.317; Martin A, 1997, ARTERIOSCL THROM VAS, V17, P1583, DOI 10.1161/01.ATV.17.8.1583; Maulen NP, 2003, J BIOL CHEM, V278, P9035, DOI 10.1074/jbc.M205119200; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; May JM, 2003, BBA-MOL CELL RES, V1640, P153, DOI 10.1016/S0167-4889(03)00043-0; May JM, 2001, BIOCHEM PHARMACOL, V62, P873, DOI 10.1016/S0006-2952(01)00736-5; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MRTENSSON J, 1991, P NATL ACAD SCI USA, V88, P4656, DOI 10.1073/pnas.88.11.4656; Nualart FJ, 2003, J BIOL CHEM, V278, P10128, DOI 10.1074/jbc.M210686200; Padayatty SJ, 2003, J AM COLL NUTR, V22, P18, DOI 10.1080/07315724.2003.10719272; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; Regina A, 1997, BBA-GEN SUBJECTS, V1335, P135, DOI 10.1016/S0304-4165(96)00131-6; Rivas CI, 1998, BLOOD, V91, P1037, DOI 10.1182/blood.V91.3.1037.1037_1037_1043; Rivas CI, 1997, J BIOL CHEM, V272, P5814, DOI 10.1074/jbc.272.9.5814; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Seno T, 2004, J VASC RES, V41, P345, DOI 10.1159/000080525; Simpson IA, 2001, J BIOL CHEM, V276, P12725, DOI 10.1074/jbc.M010897200; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Tsukimori K, 2005, HYPERTENSION, V46, P696, DOI 10.1161/01.HYP.0000184197.11226.71; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wang YH, 1997, P NATL ACAD SCI USA, V94, P13816, DOI 10.1073/pnas.94.25.13816; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Wilson JX, 2005, ANNU REV NUTR, V25, P105, DOI 10.1146/annurev.nutr.25.050304.092647; Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.3.489	45	63	64	4	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15506	15515		10.1074/jbc.M608361200	http://dx.doi.org/10.1074/jbc.M608361200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403685	hybrid			2022-12-27	WOS:000246589600027
J	Papadopulos, A; Vehring, S; Lopez-Montero, I; Kutschenko, L; Stockl, M; Devaux, PF; Kozlov, M; Pomorski, T; Herrmann, A				Papadopulos, Andreas; Vehring, Stefanie; Lopez-Montero, Ivan; Kutschenko, Lara; Stoeckl, Martin; Devaux, Philippe F.; Kozlov, Michael; Pomorski, Thomas; Herrmann, Andreas			Flippase activity detected with unlabeled lipids by shape changes of giant unilamellar vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; RAPID TRANSBILAYER MOVEMENT; SPIN-LABELED LIPIDS; PHOSPHATIDYLCHOLINE VESICLES; PHOSPHOLIPID-VESICLES; CYTOPLASMIC MEMBRANE; PROTEINS; ASYMMETRY; TRANSLOCATION; FLOP	Transbilayer movement of phospholipids in biological membranes is mediated by energy-dependent and energy-independent flippases. Available methods for detection of flippase mediated transversal flip-flop are essentially based on spin-labeled or fluorescent lipid analogues. Here we demonstrate that shape change of giant unilamellar vesicles (GUVs) can be used as a new tool to study the occurrence and time scale of flippase-mediated transbilayer movement of unlabeled phospholipids. Insertion of lipids into the external leaflet created an area difference between the two leaflets that caused the formation of a bud-like structure. Under conditions of negligible flip-flop, the bud was stable. Upon reconstitution of the energy-independent flippase activity of the yeast endoplasmic reticulum into GUVs, the initial bud formation was reversible, and the shapes were recovered. This can be ascribed to a rapid flip-flop leading to relaxation of the monolayer area difference. Theoretical analysis of kinetics of shape changes provides self-consistent determination of the flip-flop rate and further kinetic parameters. Based on that analysis, the half-time of phospholipid flip-flop in the presence of endoplasmic reticulum proteins was found to be on the order of few minutes. In contrast, GUVs reconstituted with influenza virus protein formed stable buds. The results argue for the presence of specific membrane proteins mediating rapid flip-flop.	Humboldt Univ, Mat Nat Wissensch Fak 1, Inst Biol Biophys, D-10115 Berlin, Germany; Inst Biol Physicochim, F-75005 Paris, France; Tel Aviv Univ, Dept Physiol & Pharmacol, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Humboldt University of Berlin; Tel Aviv University; Sackler Faculty of Medicine	Pomorski, T (corresponding author), Humboldt Univ, Mat Nat Wissensch Fak 1, Inst Biol Biophys, Invalidenstr 42, D-10115 Berlin, Germany.	thomas.pomorski@rz.hu-berlin.de; andreas.herrmann@rz.hu-berlin.de	López-Montero, Iván/A-5263-2017; Stöckl, Martin T/I-6554-2016; Pomorski, Thomas Günther/G-4804-2014; Stöckl, Martin/AAM-6743-2020	López-Montero, Iván/0000-0001-8131-6063; Stöckl, Martin T/0000-0001-7986-9291; Pomorski, Thomas Günther/0000-0002-4889-0829; Stöckl, Martin/0000-0001-7986-9291; Papadopulos, Andreas/0000-0002-3376-1979				ADAMSON AW, 1990, PHYS CHEM SURFACES, P548; ALBERTY RA, 1983, PHYS CHEM, P275; ANGELOVA MI, 1992, PROG COLL POL SCI S, V89, P127; BERNDL K, 1990, EUROPHYS LETT, V13, P659, DOI 10.1209/0295-5075/13/7/015; BHAMIDIPATI SP, 1995, BIOCHEMISTRY-US, V34, P5666, DOI 10.1021/bi00016a043; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN SD, 1993, BIOCHIM BIOPHYS ACTA, V1168, P13, DOI 10.1016/0005-2760(93)90260-G; Buton X, 1996, J BIOL CHEM, V271, P6651, DOI 10.1074/jbc.271.12.6651; DEKRUYFF B, 1977, BIOCHIM BIOPHYS ACTA, V465, P443, DOI 10.1016/0005-2736(77)90263-2; Devaux PF, 2002, CHEM PHYS LIPIDS, V116, P115, DOI 10.1016/S0009-3084(02)00023-3; Eckford PDW, 2005, BIOCHEM J, V389, P517, DOI 10.1042/BJ20050047; FARGE E, 1992, BIOPHYS J, V61, P347, DOI 10.1016/S0006-3495(92)81841-6; Fellmann P, 1994, Methods Mol Biol, V27, P161; Girard P, 2004, BIOPHYS J, V87, P419, DOI 10.1529/biophysj.104.040360; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; Holthuis JCM, 2005, NAT REV MOL CELL BIO, V6, P209, DOI 10.1038/nrm1591; HOPE MJ, 1989, BIOCHEMISTRY-US, V28, P4181, DOI 10.1021/bi00436a009; Hrafnsdottir S, 1997, BIOCHEMISTRY-US, V36, P4969, DOI 10.1021/bi962513h; John K, 2002, BIOPHYS J, V83, P1525, DOI 10.1016/S0006-3495(02)73922-2; Kol MA, 2004, BIOCHEMISTRY-US, V43, P2673, DOI 10.1021/bi036200f; Kol MA, 2003, J BIOL CHEM, V278, P24586, DOI 10.1074/jbc.M301875200; KORNBERG RD, 1971, BIOCHEMISTRY-US, V10, P1111; Kubelt J, 2002, BIOCHEMISTRY-US, V41, P5605, DOI 10.1021/bi0118714; Leventis R, 2001, BIOPHYS J, V81, P2257, DOI 10.1016/S0006-3495(01)75873-0; Lopez-Montero I, 2005, J BIOL CHEM, V280, P25811, DOI 10.1074/jbc.M412052200; Marx U, 2000, BIOPHYS J, V78, P2628, DOI 10.1016/S0006-3495(00)76807-X; Mathivet L, 1996, BIOPHYS J, V70, P1112, DOI 10.1016/S0006-3495(96)79693-5; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; MUI BLS, 1995, BIOPHYS J, V69, P930, DOI 10.1016/S0006-3495(95)79967-2; Nicolson T, 2000, FEBS LETT, V476, P277, DOI 10.1016/S0014-5793(00)01684-7; Pohl A, 2005, BBA-MOL CELL BIOL L, V1733, P29, DOI 10.1016/j.bbalip.2004.12.007; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; ROUSER G, 1970, LIPIDS, V5, P496; Tanaka T, 2004, LANGMUIR, V20, P9526, DOI 10.1021/la049481g; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Vishwakarma RA, 2005, ORG BIOMOL CHEM, V3, P1275, DOI 10.1039/b500300h; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	38	47	47	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15559	15568		10.1074/jbc.M604740200	http://dx.doi.org/10.1074/jbc.M604740200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17369612	hybrid			2022-12-27	WOS:000246589600033
J	Wei, Q; Yokota, C; Semenov, MV; Doble, B; Woodgett, J; He, X				Wei, Qiou; Yokota, Chika; Semenov, Mikhail V.; Doble, Brad; Woodgett, Jim; He, Xi			R-spondin1 is a high affinity ligand for LRP6 and induces LRP6 phosphorylation and beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN-5; DUAL-KINASE MECHANISM; DISHEVELLED PHOSPHORYLATION; NEGATIVE REGULATOR; REPEAT DOMAIN; WNT PROTEINS; R-SPONDIN; PATHWAY; AXIN; ACTIVATION	R-spondin proteins are newly identified secreted molecules that activate beta-catenin signaling. However, the mechanism of R-spondin action and its relationship with Wnt signaling remain unclear. Here we show that human R-spondin1 (hRspo1) is a high affinity ligand for the Wnt co-receptor LRP6 (K-d = 1.2 nM). hRspo1 induces glycogen synthase kinase 3-dependent phosphorylation and activation of LRP6. DKK1, an LRP6 antagonist, inhibits hRspo1-induced LRP6 phosphorylation. We further demonstrate that hRspo1 synergizes with Frizzled5 in Xenopus axis induction assays and induces the phosphorylation of Dishevelled, a cytoplasmic component downstream of Frizzled function. Our study reveals interesting similarity and distinction between Wnt and R-spondin signaling.	Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Neurol,Program Neurobiol, Boston, MA 02115 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Harvard University; Boston Children's Hospital; Harvard Medical School; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	He, X (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Neurol,Program Neurobiol, 300 Longwood Ave, Boston, MA 02115 USA.	Xi.He@childrens.harvard.edu	Doble, Bradley/V-7848-2019; Woodgett, Jim/F-1087-2010; Doble, Brad/L-7551-2016	Doble, Bradley/0000-0002-0260-2983; Woodgett, Jim/0000-0003-3731-5797; Doble, Brad/0000-0002-0260-2983				Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Chen JZ, 2002, MOL BIOL REP, V29, P287, DOI 10.1023/A:1020479301379; Darras S, 1997, DEVELOPMENT, V124, P4275; Flanagan JG, 2000, METHOD ENZYMOL, V327, P19, DOI 10.1016/S0076-6879(00)27264-9; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Kamata T, 2004, BBA-GENE STRUCT EXPR, V1676, P51, DOI 10.1016/j.bbaexp.2003.10.009; Kato Y, 1999, J NEUROSCI, V19, P9364; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kim KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/cc.5.1.2305; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Nam JS, 2006, J BIOL CHEM, V281, P13247, DOI 10.1074/jbc.M508324200; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Rulifson EJ, 2000, MOL CELL, V6, P117, DOI 10.1016/S1097-2765(00)00013-7; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Semenov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tolwinski NS, 2004, PLOS BIOL, V2, P486, DOI 10.1371/journal.pbio.0020095; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200; Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	48	153	171	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15903	15911		10.1074/jbc.M701927200	http://dx.doi.org/10.1074/jbc.M701927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400545	hybrid			2022-12-27	WOS:000246589600065
J	Lanzetti, L; Margaria, V; Melander, F; Virgili, L; Lee, MH; Bartek, J; Jensen, S				Lanzetti, Letizia; Margaria, Valentina; Melander, Fredrik; Virgili, Laura; Lee, Myung-Hee; Bartek, Jiri; Jensen, Sanne			Regulation of the Rab5 GTPase-activating protein RN-tre by the dual specificity phosphatase Cdc14A in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC EXIT; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; CYCLE PROGRESSION; BINDING PROTEIN; BUDDING-YEAST; AURORA-B; MITOSIS; CYTOKINESIS; SPINDLE	The Cdc14 family of dual specificity phosphatases regulates key mitotic events in the eukaryotic cell cycle. Although extensively characterized in yeast, little is known about the function of mammalian Cdc14 family members. Here we report a genetic substrate-trapping system designed to identify substrates of the human Cdc14A (hCdc14A) phosphatase. Using this approach, we identify RN-tre, a GTPase-activating protein for the Rab5 GTPase, as a novel physiological target of hCdc14A. As a Rab5 GTPase-activating protein, RN-tre has previously been implicated in control of intracellular membrane trafficking. We find that RN-tre forms a stable complex with the catalytically inactive hCdc14A C278S mutant but not with the wild type protein in human cells, indicative of a substrate/enzyme interaction. In support, we show that RN-tre is regulated by cell cycle-dependent phosphorylation peaking at mitosis, which can be antagonized by hCdc14A activity in vitro as well as in vivo. Furthermore, we show that RN-tre phosphorylation is critical for efficient hCdc14A association and that RN-tre binding can be displaced by tungstate, a competitive inhibitor that binds to the active site of hCdc14A. Consistent with the preference of hCdc14A for phosphorylations mediated by proline-directed kinases, we find that RN-tre is a direct substrate of cyclin-dependent kinase. Finally, phosphorylation of RN-tre appears to finely modulate its catalytic activity. Our findings reveal a novel connection between the cell cycle machinery and the endocytic pathway.	Univ Turin, Ist Ric Cura Canc, Dipartimento Sci Oncol, Turin 10060, Italy; Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Danish Canc Soc, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark	University of Turin; Danish Cancer Society; Danish Cancer Society	Jensen, S (corresponding author), Evolva AS, Bulowsuej 25, DK-1870 Frederiksberg, Denmark.	sannej@evolva.com	Bartek, Jiri/G-5870-2014	margaria, valentina/0000-0001-6125-4926; Melander, Fredrik/0000-0002-3670-6633; LANZETTI, Letizia/0000-0001-7541-5524				Albert S, 1999, J BIOL CHEM, V274, P33186, DOI 10.1074/jbc.274.47.33186; Azzam R, 2004, SCIENCE, V305, P516, DOI 10.1126/science.1099402; Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Brill LM, 2004, ANAL CHEM, V76, P2763, DOI 10.1021/ac035352d; Cho HP, 2005, MOL CELL BIOL, V25, P4541, DOI 10.1128/MCB.25.11.4541-4551.2005; Cueille N, 2001, J CELL SCI, V114, P2649; Esteban V, 2006, CELL CYCLE, V5, P2894, DOI 10.4161/cc.5.24.3566; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fukada M, 2005, METHODS, V35, P54, DOI 10.1016/j.ymeth.2004.07.008; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Gray CH, 2003, EMBO J, V22, P3524, DOI 10.1093/emboj/cdg348; Gruneberg U, 2004, J CELL BIOL, V166, P167, DOI 10.1083/jcb.200403084; Gruneberg U, 2002, J CELL BIOL, V158, P901, DOI 10.1083/jcb.200202054; Haas AK, 2005, NAT CELL BIOL, V7, P887, DOI 10.1038/ncb1290; Higuchi T, 2005, NATURE, V433, P171, DOI 10.1038/nature03240; Jensen S, 2002, J CELL SCI, V115, P4977, DOI 10.1242/jcs.00189; Jensen S, 2002, CURR BIOL, V12, pR221, DOI 10.1016/S0960-9822(02)00756-X; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Lanzetti L, 2004, NATURE, V429, P309, DOI 10.1038/nature02542; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Matoskova B, 1996, ONCOGENE, V12, P2679; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; Miserey-Lenkei S, 2006, EMBO J, V25, P278, DOI 10.1038/sj.emboj.7600929; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Pereira G, 2002, J CELL BIOL, V157, P367, DOI 10.1083/jcb.200112085; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502; SAGER PR, 1984, CELL, V39, P275, DOI 10.1016/0092-8674(84)90005-9; Saito RM, 2004, NAT CELL BIOL, V6, P777, DOI 10.1038/ncb1154; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Schweitzer JK, 2005, J BIOL CHEM, V280, P41628, DOI 10.1074/jbc.M504497200; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stegmeier F, 2004, ANNU REV GENET, V38, P203, DOI 10.1146/annurev.genet.38.072902.093051; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Thompson HM, 2004, NAT CELL BIOL, V6, P335, DOI 10.1038/ncb1112; Trautmann S, 2001, CURR BIOL, V11, P931, DOI 10.1016/S0960-9822(01)00268-8; Traverso EE, 2001, J BIOL CHEM, V276, P21924, DOI 10.1074/jbc.M011689200; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Wolfe BA, 2004, EMBO J, V23, P919, DOI 10.1038/sj.emboj.7600103; WOODMAN PG, 1993, MOL BIOL CELL, V4, P541, DOI 10.1091/mbc.4.5.541; YANG WQ, 2003, CURR TOP MED CHEM, V3, P739; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang ZY, 1997, BIOCHEMISTRY-US, V36, P1362, DOI 10.1021/bi9624043	53	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15258	15270		10.1074/jbc.M700914200	http://dx.doi.org/10.1074/jbc.M700914200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17371873	hybrid			2022-12-27	WOS:000246589000065
J	Su, G; Blaine, SA; Qiao, DH; Friedl, A				Su, Gui; Blaine, Stacy A.; Qiao, Dianhua; Friedl, Andreas			Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; PROSTATE EPITHELIAL-CELLS; GROWTH-FACTOR; SOLUBLE SYNDECAN-1; TUMOR MICROENVIRONMENT; MITOGENIC ACTIVITY; PROGNOSTIC-FACTOR; INTEGRIN ACTIVITY; CARCINOMA CELLS; CORE PROTEIN	The cell surface heparan sulfate proteoglycan syndecan-1 is induced in stromal fibroblasts of breast carcinomas and participates in a reciprocal feedback loop, which stimulates carcinoma cell growth in vitro and in vivo. To define the molecular mechanism of carcinoma growth stimulation, a three-dimensional co-culture model was developed that combines T47D breast carcinoma cells with immortalized human mammary fibroblasts in collagen gels. By silencing endogenous syndecan-1 induction with short interfering RNA and expressing mutant murine syndecan-1 constructs, it was determined that carcinoma cell mitogenesis required proteolytic shedding of syndecan-1 from the fibroblast surface. The paracrine growth signal was mediated by the syndecan-1 heparan sulfate chains rather than the ectodomain of the core protein and required fibroblast growth factor 2 and stroma-derived factor 1. This paracrine pathway may provide an opportunity for the therapeutic disruption of stroma-epithelial signaling.	Univ Wisconsin, Dept Pathol & Lab Med, Clin Sci Ctr K4812, Madison, WI 53792 USA; Dept Vet Affairs Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Clin Sci Ctr K4812, 600 Highland Ave, Madison, WI 53792 USA.	afriedl@wisc.edu			NATIONAL CANCER INSTITUTE [R01CA107012] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA107012-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Baba F, 2006, BREAST CANCER RES TR, V98, P91, DOI 10.1007/s10549-005-9135-2; Barbareschi M, 2003, CANCER-AM CANCER SOC, V98, P474, DOI 10.1002/cncr.11515; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; BROUTYBOYE D, 1993, ANTICANCER RES, V13, P1087; Brule S, 2006, GLYCOBIOLOGY, V16, P488, DOI 10.1093/glycob/cwj098; Burbach BJ, 2003, MATRIX BIOL, V22, P163, DOI 10.1016/S0945-053X(03)00009-X; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; Dhodapkar MV, 1999, LEUKEMIA LYMPHOMA, V34, P35, DOI 10.3109/10428199909083378; Dillon C, 2004, J MAMMARY GLAND BIOL, V9, P207, DOI 10.1023/B:JOMG.0000037163.56461.1e; Ding K, 2005, J CELL BIOL, V171, P729, DOI 10.1083/jcb.200508010; Elenius V, 2004, J BIOL CHEM, V279, P41928, DOI 10.1074/jbc.M404506200; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Feng SJ, 1997, CANCER RES, V57, P5369; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Gudjonsson T, 2002, J CELL SCI, V115, P39; Hornby A E, 1995, EXS, V74, P249; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Joensuu H, 2002, CANCER RES, V62, P5210; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Langford JK, 2005, J BIOL CHEM, V280, P3467, DOI 10.1074/jbc.M412451200; Langford JK, 1998, J BIOL CHEM, V273, P29965, DOI 10.1074/jbc.273.45.29965; Lee PHA, 2004, J BIOL CHEM, V279, P48640, DOI 10.1074/jbc.M407241200; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lovell R, 2005, BRIT J HAEMATOL, V130, P542, DOI 10.1111/j.1365-2141.2005.05647.x; Maeda T, 2006, ONCOGENE, V25, P1408, DOI 10.1038/sj.onc.1209168; Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008-5472.CAN-03-2439; MALI M, 1994, J BIOL CHEM, V269, P27795; Mathe M, 2006, ORAL ONCOL, V42, P493, DOI 10.1016/j.oraloncology.2005.10.003; McQuade KJ, 2006, J CELL SCI, V119, P2445, DOI 10.1242/jcs.02970; Mukunyadzi P, 2003, MODERN PATHOL, V16, P796, DOI 10.1097/01.MP.0000081731.17549.53; Mundhenke C, 2002, AM J PATHOL, V160, P185, DOI 10.1016/S0002-9440(10)64362-3; Netelenbos T, 2002, J LEUKOCYTE BIOL, V72, P353; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Sadlonova A, 2005, BREAST CANCER RES, V7, pR46, DOI 10.1186/bcr949; SANANTONIO JD, 1994, GLYCOBIOLOGY, V4, P327; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shimazu A, 1999, J DENT RES, V78, P1791, DOI 10.1177/00220345990780120501; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; Stanley MJ, 1999, AM J CLIN PATHOL, V112, P377; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; Wang ZH, 2005, BIOCHEMISTRY-US, V44, P12355, DOI 10.1021/bi050620i; Wozniak MA, 2005, BIOL PROCED ONLINE, V7, P144, DOI 10.1251/bpo112; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610; Yu HM, 2005, LAB CHIP, V5, P1089, DOI 10.1039/b504403k	56	98	100	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14906	14915		10.1074/jbc.M611739200	http://dx.doi.org/10.1074/jbc.M611739200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17344212	hybrid			2022-12-27	WOS:000246589000028
J	Kilpatrick, EL; Hildebrandt, JD				Kilpatrick, Eric L.; Hildebrandt, John D.			Sequence dependence and differential expression of G gamma 5 subunit isoforms of the heterotrimeric G proteins variably processed after prenylation in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA DIMERS; RAS; INHIBITORS	Between 1 and 2% of proteins coded for in the human genome, including all G protein gamma subunits, are predicted to be prenylated. Subsequently, prenylated proteins are proteolytically cleaved at the C terminus and carboxymethylated. These reactions are generally obligatory events required for functional expression of prenylated proteins. The biological role of prenyl substrates has made these reactions significant targets for anticancer drug development. Understanding the enzymology of this pathway will be key to success for this strategy. When G gamma 1, -2, -4, -10, -11, -12, and -13 were expressed in HEK293 cells they were completely processed according to the current understanding of the prenylation reaction. In contrast, G gamma 5 was processed to two forms; a minor one, fully processed as predicted, and a major one that was prenylated without further processing. When the Ca(1)a(2)X motif of G gamma 5, CSFL, was exchanged for that of G gamma 2, CAIL, G gamma 5 was completely processed. Conversely, G gamma 2-SFL was incompletely processed. Differential processing of G gamma 5 was found due to the presence of an aromatic amino acid in its Ca(1)a(2)X motif. Retrieving endogenous G gamma subunits from HEK293 or Neuro-2a cells with FLAG-G beta constructs identified multiple G gamma subunits by mass spectrometry in either cell, but in both cases the most prominent one was G gamma 5 expressed without C-terminal processing after prenylation. This work indicates that post-prenylation reactions can generate multiple products determined by the C-terminal Ca(1)a(2)X motif. Within the human genome 10% of predicted prenylated proteins have aromatic amino acids in their Ca(1)a(2)X sequence and would likely generate the prenylation pattern described here.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29464 USA	Medical University of South Carolina	Hildebrandt, JD (corresponding author), Med Univ S Carolina, Dept Pharmacol, 173 Ashley Ave, Charleston, SC 29464 USA.	hildebjd@musc.edu			NIDDK NIH HHS [DK37219] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Cook LA, 2006, MOL CELL PROTEOMICS, V5, P671, DOI 10.1074/mcp.M500223-MCP200; Cook LA, 1998, BIOCHEMISTRY-US, V37, P12280, DOI 10.1021/bi980230e; Cook LA, 2001, PROTEIN SCI, V10, P2548, DOI 10.1110/ps.ps.26401; Dingus J, 2005, BIOCHEMISTRY-US, V44, P11882, DOI 10.1021/bi0504254; Dolence JM, 2000, BIOCHEMISTRY-US, V39, P4096, DOI 10.1021/bi9923611; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; Hamilton MH, 2003, P NATL ACAD SCI USA, V100, P5081, DOI 10.1073/pnas.0831228100; HEILMEYER LMG, 1992, P NATL ACAD SCI USA, V89, P9554, DOI 10.1073/pnas.89.20.9554; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HORI Y, 1991, ONCOGENE, V6, P515; Jang GF, 1998, BIOCHEMISTRY-US, V37, P4473, DOI 10.1021/bi972289b; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Leung GK, 2001, J BIOL CHEM, V276, P29051, DOI 10.1074/jbc.M102908200; McIntire WE, 2006, BIOCHEMISTRY-US, V45, P11616, DOI 10.1021/bi0604882; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Morgan MA, 2003, LEUKEMIA, V17, P1482, DOI 10.1038/sj.leu.2403024; Morishita R, 1999, J NEUROCHEM, V73, P2369, DOI 10.1046/j.1471-4159.1999.0732369.x; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Pei JM, 2001, TRENDS BIOCHEM SCI, V26, P275, DOI 10.1016/S0968-0004(01)01813-8; Roskoski R, 2003, BIOCHEM BIOPH RES CO, V303, P1, DOI 10.1016/S0006-291X(03)00323-1; Rowinsky EK, 2006, J CLIN ONCOL, V24, P2981, DOI 10.1200/JCO.2006.05.9808; Rusinol AE, 2006, J CELL SCI, V119, P3265, DOI 10.1242/jcs.03156; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; WILCOX MD, 1994, J BIOL CHEM, V269, P12508; WILCOX MD, 1995, BIOCHEM BIOPH RES CO, V212, P367, DOI 10.1006/bbrc.1995.1979; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Wright LP, 2006, J LIPID RES, V47, P883, DOI 10.1194/jlr.R600004-JLR200; Young SG, 2005, J LIPID RES, V46, P2531, DOI 10.1194/jlr.R500011-JLR200; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	42	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14038	14047		10.1074/jbc.M701338200	http://dx.doi.org/10.1074/jbc.M701338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17353195	hybrid			2022-12-27	WOS:000246245800013
J	Lagergren, A; Mansson, R; Zetterblad, J; Smith, E; Basta, B; Bryder, D; Akerblad, P; Sigvardsson, M				Lagergren, Anna; Mansson, Robert; Zetterblad, Jenny; Smith, Emma; Basta, Barbro; Bryder, David; Akerblad, Peter; Sigvardsson, Mikael			The Cxcl12, Periostin, and Ccl9 genes are direct targets for early B-cell factor in OP-9 stroma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; TRANSCRIPTION FACTORS; INTERLEUKIN-7 RECEPTOR; MICE LACKING; NEURONAL DIFFERENTIATION; LYMPHOCYTE EXPANSION; HEMATOPOIETIC STEM; EXPRESSION; PROMOTER; EBF	The development of blood cells from hematopoietic stem cells in the bone marrow is dependent on communication with bone marrow stroma cells, making these cells central for the appropriate regulation of hematopoiesis. To identify transcription factors that may play a role in gene regulation in stroma cells, we performed comparative gene expression analysis of fibroblastic NIH3T3 cells, unable to support hematopoiesis in vitro, and OP-9 stroma cells, highly efficient in this regard. These experiments revealed that transcription factors of the early B cell factor (EBF) family were highly expressed in OP-9 cells as compared with the NIH3T3 cells. To identify potential targets genes for EBF proteins in stroma cells, we overexpressed EBF in fibroblasts and analyzed the pattern of induced genes by microarray analysis. This revealed that EBF was able to up-regulate expression of among others the Cxcl12, Ccl9, and Periostin genes. The identification of relevant promoters revealed that they all contained functional EBF binding sites able to interact with EBF in OP-9 cells. Furthermore, ectopic expression of a dominant negative EBF protein or antisense EBF-1 RNA in OP-9 stroma cells resulted in reduced expression of these target genes. These data suggest that EBF proteins might have dual roles in hematopoiesis acting both as intrinsic regulators of B-lymphopoiesis and as regulators of genes in bone marrow stroma cells.	Lund Univ, Lund Stemcell Ctr, Dept Hematopoet Stem Cell Biol, S-22184 Lund, Sweden; AstraZeneca R&D, Dept Mol Pharmacol, S-43183 Molndal, Sweden; Linkoping Univ, Univ Hlth Sci, Dept Biomed & Surg, S-58185 Linkoping, Sweden	Lund University; AstraZeneca; Linkoping University	Sigvardsson, M (corresponding author), Lund Univ, Lund Stemcell Ctr, Dept Hematopoet Stem Cell Biol, BMC B12, S-22184 Lund, Sweden.	mikael.sigvardsson@stemcell.lu.se	Mansson, Robert/D-4372-2014; Bryder, David/Q-6292-2019	Mansson, Robert/0000-0003-0738-0328; Bryder, David/0000-0002-8761-4237; Smith, Emma/0000-0003-0609-4864; Sigvardsson, Mikael/0000-0001-8527-7276				Akerblad P, 2005, PHYSIOL GENOMICS, V23, P206, DOI 10.1152/physiolgenomics.00015.2005; Akerblad P, 1999, MOL CELL BIOL, V19, P392; Akerblad P, 2002, MOL CELL BIOL, V22, P8015, DOI 10.1128/MCB.22.22.8015-8025.2002; Akerblad P, 1999, J IMMUNOL, V163, P5453; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Corradi A, 2003, DEVELOPMENT, V130, P401, DOI 10.1242/dev.00215; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dubois L, 2001, MECH DEVELOP, V108, P3, DOI 10.1016/S0925-4773(01)00486-5; Egawa T, 2001, IMMUNITY, V15, P323, DOI 10.1016/S1074-7613(01)00185-6; Garcia-Dominguez M, 2003, DEVELOPMENT, V130, P6013, DOI 10.1242/dev.00840; Garel S, 1999, DEVELOPMENT, V126, P5285; Garel S, 1997, DEV DYNAM, V210, P191, DOI 10.1002/(SICI)1097-0177(199711)210:3<191::AID-AJA1>3.0.CO;2-B; Gisler R, 2002, J IMMUNOL, V168, P5130, DOI 10.4049/jimmunol.168.10.5130; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; Jimenez MA, 2007, MOL CELL BIOL, V27, P743, DOI 10.1128/MCB.01557-06; Kieslinger M, 2005, DEV CELL, V9, P757, DOI 10.1016/j.devcel.2005.10.009; Kieusseian A, 2006, BLOOD, V107, P492, DOI 10.1182/blood-2005-02-0529; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; Lagergren A, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-80; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liberg D, 2002, MOL CELL BIOL, V22, P8389, DOI 10.1128/MCB.22.24.8389-8397.2002; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Mansson R, 2004, J BIOL CHEM, V279, P17905, DOI 10.1074/jbc.M400589200; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; SALCEDO R, 1995, CELL IMMUNOL, V160, P165, DOI 10.1016/0008-8749(95)80023-C; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992-4003.2004; Sicurella C, 2001, BLOOD CELL MOL DIS, V27, P470, DOI 10.1006/bcmd.2001.0407; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Sigvardsson M, 2002, MOL CELL BIOL, V22, P8539, DOI 10.1128/MCB.22.24.8539-8551.2002; Sigvardsson M, 2000, MOL CELL BIOL, V20, P3640, DOI 10.1128/MCB.20.10.3640-3654.2000; Sitnicka E, 2003, J EXP MED, V198, P1495, DOI 10.1084/jem.20031152; Smith EMK, 2005, BLOOD, V106, P1995, DOI 10.1182/blood-2004-12-4744; Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001; TRAVIS A, 1993, MOL CELL BIOL, V13, P3392, DOI 10.1128/MCB.13.6.3392; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Vieira Paulo, 2004, Methods Mol Biol, V271, P67; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wang SS, 1997, J NEUROSCI, V17, P4149; Wang SS, 2002, MOL CELL NEUROSCI, V20, P404, DOI 10.1006/mcne.2002.1138; Yoshioka N, 2002, EXP CELL RES, V279, P91, DOI 10.1006/excr.2002.5590; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	52	24	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14454	14462		10.1074/jbc.M610263200	http://dx.doi.org/10.1074/jbc.M610263200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374609	hybrid			2022-12-27	WOS:000246245800059
J	Tanaka, S; Narita, S; Tokuda, H				Tanaka, Shin-ya; Narita, Shin-ichiro; Tokuda, Hajime			Characterization of the Pseudomonas aeruginosa Lol system as a lipoprotein sorting mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MEMBRANE LOCALIZATION; ABC TRANSPORTER; CYTOPLASMIC MEMBRANE; SECRETORY PROTEINS; CELL-ENVELOPE; TRANSLOCATION; DETACHMENT; RELEASE; PEPTIDOGLYCAN	Escherichia coli lipoproteins are localized to either the inner or the outer membrane depending on the residue that is present next to the N- terminal acylated Cys. Asp at position 2 causes the retention of lipoproteins in the inner membrane. In contrast, the accompanying study ( 9) revealed that the residues at positions 3 and 4 determine the membrane specificity of lipoproteins in Pseudomonas aeruginosa. Since the five Lol proteins involved in the sorting of E. coli lipoproteins are conserved in P. aeruginosa, we examined whether or not the Lol proteins of P. aeruginosa are also involved in lipoprotein sorting but utilize different signals. The genes encoding LolCDE, LolA, and LolB homologues were cloned and expressed. The LolCDE homologue thus purified was reconstituted into proteoliposomes with lipoproteins. When incubated in the presence of ATP and a LolA homologue, the reconstituted LolCDE homologue released lipoproteins, leading to the formation of a LolA-lipoprotein complex. Lipoproteins were then incorporated into the outer membrane depending on a LolB homologue. As revealed in vivo, lipoproteins with Lys and Ser at positions 3 and 4, respectively, remained in proteoliposomes. On the other hand, E. coli LolCDE released lipoproteins with this signal and transferred them to LolA of not only E. coli but also P. aeruginosa. These results indicate that Lol proteins are responsible for the sorting of lipoproteins to the outer membrane of P. aeruginosa, as in the case of E. coli, but respond differently to inner membrane retention signals.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	htokuda@iam.u-tokyo.ac.jp		Narita, Shin-ichiro/0000-0001-9425-2943				Akama H, 2004, J BIOL CHEM, V279, P25939, DOI 10.1074/jbc.C400164200; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Fukuda A, 2002, J BIOL CHEM, V277, P43512, DOI 10.1074/jbc.M206816200; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; Hara T, 2003, J BIOL CHEM, V278, P40408, DOI 10.1074/jbc.M307836200; Ikegami A, 2005, BIOSCI BIOTECH BIOCH, V69, P1595, DOI 10.1271/bbb.69.1595; Ito Y, 2006, MOL MICROBIOL, V62, P1064, DOI 10.1111/j.1365-2958.2006.05378.x; KLEIN JR, 1991, MOL GEN GENET, V230, P230, DOI 10.1007/BF00290673; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Masuda K, 2002, P NATL ACAD SCI USA, V99, P7390, DOI 10.1073/pnas.112085599; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miyamoto A, 2001, BIOCHEM BIOPH RES CO, V287, P1125, DOI 10.1006/bbrc.2001.5705; MIZUNO T, 1979, J BIOCHEM-TOKYO, V86, P991, DOI 10.1093/oxfordjournals.jbchem.a132631; Narita S, 2006, FEBS LETT, V580, P1164, DOI 10.1016/j.febslet.2005.10.038; Narita SI, 2007, J BIOL CHEM, V282, P13372, DOI 10.1074/jbc.M611839200; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Schulze RJ, 2006, MOL MICROBIOL, V59, P1473, DOI 10.1111/j.1365-2958.2006.05039.x; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; TANI K, 1990, J BIOL CHEM, V265, P17341; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yokota N, 1999, J BIOL CHEM, V274, P30995, DOI 10.1074/jbc.274.43.30995; YOKOTA N, 1999, J BIOL CHEM, V279, P25939; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506	31	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13379	13384		10.1074/jbc.M611840200	http://dx.doi.org/10.1074/jbc.M611840200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350955	hybrid			2022-12-27	WOS:000246060300026
J	Fuller, GLJ; Williams, JAE; Tomlinson, MG; Eble, JA; Hanna, SL; Pohlmann, S; Suzuki-Inoue, K; Ozaki, Y; Watson, SP; Pearce, AC				Fuller, Gemma L. J.; Williams, Jennifer A. E.; Tomlinson, Michael G.; Eble, Johannes A.; Hanna, Sheri L.; Pohlmann, Stefan; Suzuki-Inoue, Katsue; Ozaki, Yukio; Watson, Steve P.; Pearce, Andrew C.			The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; IMMUNODEFICIENCY-VIRUS TYPE-1; TANDEM SH2 DOMAINS; ANTIGEN-RECEPTOR; PLATELET ACTIVATION; INTEGRIN ALPHA(2)BETA(1); PHOSPHOLIPASE C-GAMMA-2; GLYCOPROTEIN-VI; ZAP-70 BIND; SYK	The two lectin receptors, CLEC-2 and Dectin-1, have been shown to signal through a Syk-dependent pathway, despite the presence of only a single YXXL in their cytosolic tails. In this study, we show that stimulation of CLEC-2 in platelets and in two mutant cell lines is dependent on the YXXL motif and on proteins that participate in signaling by immunoreceptor tyrosine-based activation motif receptors, including Src, Syk, and Tec family kinases, and on phospholipase C gamma. Strikingly, mutation of either Src homology (SH) 2 domain of Syk blocks signaling by CLEC-2 despite the fact that it has only a single YXXL motif. Furthermore, signaling by CLEC-2 is only partially dependent on the BLNK/ SLP-76 family of adapter proteins in contrast to that of immunoreceptor tyrosinebased activation motif receptors. The C-type lectin receptor, Dectin-1, which contains a YXXL motif preceded by the same four amino acids as for CLEC-2 ( DEDG), signals like CLEC-2 and also requires the two SH2 domains of Syk and is only partially dependent on the BLNK/SLP-76 family of adapters. In marked contrast, the C-type lectin receptor, DCSIGN, which has a distinct series of amino acids preceding a single YXXL, signals independent of this motif. A mutational analysis of the DEDG sequence of CLEC-2 revealed that the glycine residue directly upstream of the YXXL tyrosine is important for CLEC-2 signaling. These results demonstrate that CLEC-2 and Dectin-1 signal through a single YXXL motif that requires the tandem SH2 domains of Syk but is only partially dependent on the SLP- 76/ BLNK family of adapters.	Univ Birmingham, Biomed Res Inst, Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England; Muenster Univ Hosp, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Yamanashi Univ, Dept Clin Lab & Med, Yamanashi 4093898, Japan	University of Birmingham; University of Munster; University of Pennsylvania; University of Erlangen Nuremberg; University of Yamanashi	Pearce, AC (corresponding author), Univ Birmingham, Biomed Res Inst, Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England.	a.c.pearce@bham.ac.uk	Pöhlmann, Stefan/H-2395-2011; Watson, Stephen P/Q-6292-2016	Pöhlmann, Stefan/0000-0001-6086-9136; Watson, Stephen P/0000-0002-7846-7423; Tomlinson, Michael/0000-0002-1189-0091	MRC [G0400247] Funding Source: UKRI; British Heart Foundation [PG/02/036/13595] Funding Source: Medline; Medical Research Council [G0400247] Funding Source: Medline; Wellcome Trust [073107] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Atkinson BT, 2003, BLOOD, V102, P3592, DOI 10.1182/blood-2003-04-1142; Bori-Sanz T, 2003, J BIOL CHEM, V278, P35914, DOI 10.1074/jbc.M301826200; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Caparros E, 2006, BLOOD, V107, P3950, DOI 10.1182/blood-2005-03-1252; Chaipan C, 2006, J VIROL, V80, P8951, DOI 10.1128/JVI.00136-06; Chung CH, 2001, BIOCHEM BIOPH RES CO, V285, P689, DOI 10.1006/bbrc.2001.5228; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Colonna M, 2000, EUR J IMMUNOL, V30, P697; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Drickamer K, 2002, BIOCHEM SOC SYMP, V69, P59; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUANG TF, 1995, BIOCHEM J, V309, P1021, DOI 10.1042/bj3091021; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Levi M, 2005, HEMATOLOGY, V10, P129, DOI 10.1080/10245330512331390177; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Lin J, 2001, J CELL SCI, V114, P243; Liu HH, 2006, ACTA PHYS-CHIM SIN, V22, P868, DOI 10.3866/PKU.WHXB20060720; Navdaev A, 2001, J BIOL CHEM, V276, P20882, DOI 10.1074/jbc.M101585200; Pao LI, 1998, J IMMUNOL, V160, P3305; Pearce AC, 2004, J BIOL CHEM, V279, P53955, DOI 10.1074/jbc.M410355200; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001; Qi RM, 1999, BBA-MOL CELL RES, V1451, P353, DOI 10.1016/S0167-4889(99)00105-6; Quek LS, 2000, BLOOD, V96, P4246; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Scaradavou A, 2002, BLOOD REV, V16, P73, DOI 10.1054/blre.2001.0188; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; Sobanov Y, 2001, EUR J IMMUNOL, V31, P3493, DOI 10.1002/1521-4141(200112)31:12<3493::AID-IMMU3493>3.0.CO;2-9; Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Suzuki-Inoue K, 2006, BLOOD, V107, P542, DOI 10.1182/blood-2005-05-1994; Suzuki-Inoue K, 2003, BLOOD, V102, P1367, DOI 10.1182/blood-2003-01-0029; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Tomlinson MG, 2004, MOL CELL BIOL, V24, P2455, DOI 10.1128/MCB.24.6.2455-2466.2004; Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Wang LD, 2003, IMMUNOLOGY, V110, P411, DOI 10.1111/j.1365-2567.2003.01756.x; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Watson SP, 2005, J THROMB HAEMOST, V3, P1752, DOI 10.1111/j.1538-7836.2005.01429.x; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Woodside DG, 2002, J BIOL CHEM, V277, P39401, DOI 10.1074/jbc.M207657200; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413	64	165	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12397	12409		10.1074/jbc.M609558200	http://dx.doi.org/10.1074/jbc.M609558200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17339324	Green Accepted, hybrid			2022-12-27	WOS:000245942800008
J	Philip, F; Sengupta, P; Scarlata, S				Philip, Finly; Sengupta, Parijat; Scarlata, Suzanne			Signaling through a G protein-coupled receptor and its corresponding G protein follows a stoichiometrically limited model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; RESONANCE ENERGY-TRANSFER; BRADYKININ B-2 RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; LATERAL MOBILITY; ACTIVATION; MEMBRANE; DYNAMICS; CELLS; TRAFFICKING	The bradykinin receptor is a G protein-coupled receptor (GPCR) that is coupled to the G alpha(q) family of heterotrimeric G proteins. In general, a GPCR can exert intracellular signals either by transiently associating with multiple diffusing G protein subunits or by activating a G protein that is stably bound to the receptor, thus generating a signal that is limited by the stoichiometry of the complex. Here we have distinguished between these models by monitoring the association of type 2 bradykinin receptor (B2R) and the G alpha(q)/G beta gamma heterotrimer in living human embryonic kidney 293 cells expressing fluorescent-tagged proteins. Stable B2R-G alpha(.)(q)G beta gamma complexes are observed in resting cells by fluorescence resonance energy transfer from either G alpha(q)-eCFP or eCFP-G beta gamma to B2R-eYFP. Stimulating the cells with bradykinin causes detachment of B2R from the G protein subunits as the receptor internalizes into early endosomes, with a corresponding elimination of B2R-G protein fluorescence resonance energy transfer because G alpha(q) and its associated G beta gamma remain on the plasma membrane. Single point and scanning fluorescence correlation spectroscopy measurements show that a portion of B2R molecules diffuses with a mobility corresponding to dimers or small oligomers, whereas a second fraction diffuses in higher order molecular assemblies. Our studies support a model in which receptors are pre-coupled with their corresponding G proteins in the basal state of cells thereby limiting the response to an external signal to a defined stoichiometry that allows for a rapid and directed cellular response.	SUNY Stony Brook, Med Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Scarlata, S (corresponding author), SUNY Stony Brook, Med Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	Suzanne.Scarlata@sunysb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53132] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1994, MOL BIOL CELL, P734; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BERLAND KM, 1995, BIOPHYS J, V68, P694, DOI 10.1016/S0006-3495(95)80230-4; BLANKAT A, 2000, MOL CELL BIOL, V20, P6837; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Briddon SJ, 2004, P NATL ACAD SCI USA, V101, P4673, DOI 10.1073/pnas.0400420101; Brock R, 1998, BIOPHYS J, V75, P2547, DOI 10.1016/S0006-3495(98)77699-4; Chen Y, 1999, METHODS, V19, P234, DOI 10.1006/meth.1999.0854; Chen Y, 1999, BIOPHYS J, V77, P553, DOI 10.1016/S0006-3495(99)76912-2; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dowal L, 2006, J BIOL CHEM, V281, P23999, DOI 10.1074/jbc.M512330200; Haasemann M, 1998, J CELL SCI, V111, P917; Hegener O, 2004, BIOCHEMISTRY-US, V43, P6190, DOI 10.1021/bi035928t; HENIS YI, 1982, P NATL ACAD SCI-BIOL, V79, P2907, DOI 10.1073/pnas.79.9.2907; Herrmann R, 2004, J BIOL CHEM, V279, P24283, DOI 10.1074/jbc.M311166200; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; Hynes TR, 2004, J BIOL CHEM, V279, P44101, DOI 10.1074/jbc.M405151200; Kang SK, 2002, BIOCHEM BIOPH RES CO, V293, P383, DOI 10.1016/S0006-291X(02)00197-3; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; Lamb ME, 2002, BIOCHEMISTRY-US, V41, P14340, DOI 10.1021/bi020231d; Lamb ME, 2001, BIOCHEM J, V355, P741, DOI 10.1042/bj3550741; Liang W, 2004, J CELL SCI, V117, P723, DOI 10.1242/jcs.00878; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; Maier C, 2005, J CELL SCI, V118, P3353, DOI 10.1242/jcs.02462; Maiti S, 1997, P NATL ACAD SCI USA, V94, P11753, DOI 10.1073/pnas.94.22.11753; Meissner O, 2003, BIOCHEMISTRY-US, V42, P1667, DOI 10.1021/bi0263356; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; Myung CS, 2006, MOL PHARMACOL, V69, P877, DOI 10.1124/mol.105.018994; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; PETERS R, 1988, FEBS LETT, V234, P1, DOI 10.1016/0014-5793(88)81290-0; Philip F, 2004, BIOCHEMISTRY-US, V43, P11691, DOI 10.1021/bi049381+; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Ricupero DA, 1997, BIOCHEM J, V327, P803; Riven I, 2006, NEURON, V51, P561, DOI 10.1016/j.neuron.2006.08.017; Ruan QQ, 2004, BIOPHYS J, V87, P1260, DOI 10.1529/biophysj.103.036483; Ruan QQ, 2002, BIOPHYS J, V83, P3177, DOI 10.1016/S0006-3495(02)75320-4; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383; Sengupta P, 2002, METHODS, V27, P374, DOI 10.1016/S1046-2023(02)00096-8; SMRCKA AV, 2003, USE GREEN FLUORESCEN, P223; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	46	78	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19203	19216		10.1074/jbc.M701558200	http://dx.doi.org/10.1074/jbc.M701558200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17420253	hybrid			2022-12-27	WOS:000247475300061
J	Haince, JF; Kozlov, S; Dawson, VL; Dawson, TM; Hendzel, MJ; Lavin, MF; Poirier, GG				Haince, Jean-Francois; Kozlov, Sergei; Dawson, Valina L.; Dawson, Ted M.; Hendzel, Michael J.; Lavin, Martin F.; Poirier, Guy G.			Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-H2AX FOCI FORMATION; STRAND BREAK REPAIR; CELL-CYCLE ARREST; IONIZING-RADIATION; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; PROTEOMIC APPROACH; ACTIVATES ATM; PARP-1; POLYMERASE	Poly(ADP- ribosyl)ation is a post-translational modification that is instantly stimulated by DNA strand breaks creating a unique signal for the modulation of protein functions in DNA repair and cell cycle checkpoint pathways. Here we report that lack of poly( ADP- ribose) synthesis leads to a compromised response to DNA damage. Deficiency in poly( ADP- ribosyl) ation metabolism induces profound cellular sensitivity to DNA-damaging agents, particularly in cells deficient for the protein kinase ataxia telangiectasia mutated ( ATM). At the biochemical level, we examined the significance of poly( ADP- ribose) synthesis on the regulation of early DNA damage-induced signaling cascade initiated by ATM. Using potent PARP inhibitors and PARP-1 knock-out cells, we demonstrate a functional interplay between ATM and poly( ADP- ribose) that is important for the phosphorylation of p53, SMC1, and H2AX. For the first time, we demonstrate a functional and physical interaction between the major DSB signaling kinase, ATM and poly( ADP- ribosyl) ation by PARP-1, a key enzyme of chromatin remodeling. This study suggests that poly( ADP- ribose) might serve as a DNA damage sensory molecule that is critical for early DNA damage signaling.	CHU Laval, Fac Med, Hlth & Environm Unit, Quebec City, PQ G1V 4G2, Canada; Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Alberta, Fac Med, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada	Laval University; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Alberta; University of Alberta	Poirier, GG (corresponding author), CHU Laval, Fac Med, Hlth & Environm Unit, 2705 Blvd Laurier,RC-9700, Quebec City, PQ G1V 4G2, Canada.	guy.poirier@crchul.ulaval.ca	Kozlov, Sergei/M-2067-2014; Kozlov, Sergei/T-9779-2019; Hendzel, Michael/C-3391-2009; Lavin, Martin F/F-5961-2014; Dawson, Valina/Y-9757-2019	Kozlov, Sergei/0000-0001-6183-7339; Hendzel, Michael/0000-0002-9603-7945; Lavin, Martin F/0000-0002-5940-4769; Poirier, Guy/0000-0002-4869-1424; Dawson, Valina/0000-0002-2915-3970	NINDS NIH HHS [NS39148] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS039148] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamson AW, 2002, J BIOL CHEM, V277, P38222, DOI 10.1074/jbc.M204409200; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Beardsley DI, 2005, MOL PHARMACOL, V68, P1049, DOI 10.1124/mol.105.013888; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chalmers A, 2004, INT J RADIAT ONCOL, V58, P410, DOI 10.1016/j.ijrobp.2003.09.053; Chang P, 2005, NAT CELL BIOL, V7, P1133, DOI 10.1038/ncb1322; Chang P, 2004, NATURE, V432, P645, DOI 10.1038/nature03061; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Du YC, 2006, MOL CELL PROTEOMICS, V5, P1033, DOI 10.1074/mcp.M500327-MCP200; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Fang Y, 2006, ONCOGENE, V25, P3598, DOI 10.1038/sj.onc.1209392; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fernandes N, 2005, J BIOL CHEM, V280, P15158, DOI 10.1074/jbc.M412065200; Gagne JP, 2003, BIOCHEM J, V371, P331, DOI 10.1042/BJ20021675; Goodarzi AA, 2004, DNA REPAIR, V3, P753, DOI 10.1016/j.dnarep.2004.03.041; Haince JF, 2005, TRENDS MOL MED, V11, P456, DOI 10.1016/j.molmed.2005.08.003; Hochegger H, 2006, EMBO J, V25, P1305, DOI 10.1038/sj.emboj.7601015; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; JACOBSON EL, 1985, CARCINOGENESIS, V6, P711, DOI 10.1093/carcin/6.5.711; Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lavin MF, 2005, MUTAT RES-FUND MOL M, V569, P123, DOI 10.1016/j.mrfmmm.2004.04.020; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Malanga M, 2005, BIOCHEM CELL BIOL, V83, P354, DOI 10.1139/o05-038; Malanga M, 2004, J BIOL CHEM, V279, P5244, DOI 10.1074/jbc.C300437200; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Menissier-de Murcia J, 2001, MOL CELL BIOL, V21, P1828; Noel G, 2006, MOL CANCER THER, V5, P564, DOI 10.1158/1535-7163.MCT-05-0418; O'Driscoll M, 2006, NAT REV GENET, V7, P45, DOI 10.1038/nrg1746; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Plummer ER, 2006, CURR OPIN PHARMACOL, V6, P364, DOI 10.1016/j.coph.2006.02.004; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Stojic L, 2005, CELL CYCLE, V4, P473, DOI 10.4161/cc.4.3.1528; Takahashi A, 2005, CANCER LETT, V229, P171, DOI 10.1016/j.canlet.2005.07.016; Tartier L, 2003, MUTAGENESIS, V18, P411, DOI 10.1093/mutage/geg015; Valenzuela MT, 2002, ONCOGENE, V21, P1108, DOI 10.1038/sj.onc.1205169; Wang XJ, 1998, ONCOGENE, V17, P2819, DOI 10.1038/sj.onc.1202216; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Young DB, 2005, J BIOL CHEM, V280, P27587, DOI 10.1074/jbc.M411689200; Yu YK, 2006, TOXICOL IN VITRO, V20, P959, DOI 10.1016/j.tiv.2006.01.004; Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200	60	203	215	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16441	16453		10.1074/jbc.M608406200	http://dx.doi.org/10.1074/jbc.M608406200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428792	hybrid			2022-12-27	WOS:000246794300052
J	Stalder, L; Muhlemann, O				Stalder, Lukas; Muehlemann, Oliver			Transcriptional silencing of nonsense codon-containing immunoglobulin mu genes requires translation of its mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUALITY-CONTROL; MEDIATED DECAY; TERMINATION; EXPRESSION; COMPLEX; BINDING; YEAST; EXON; UPF1	Eukaryotes have evolved quality control mechanisms that prevent the expression of genes in which the protein coding potential is crippled by the presence of a premature translation-termination codon (PTC). In addition to nonsense-mediated mRNA decay (NMD), a well documented posttranscriptional consequence of the presence of a PTC in an mRNA, we recently reported the transcriptional silencing of PTC-containing immunoglobulin (Ig) mu and gamma minigenes when they are stably integrated into the genome of HeLa cells. Here we demonstrate that this transcriptional silencing of PTC-containing Ig-mu constructs requires active translation of the cognate mRNA, as it is not observed under conditions where translation of the PTC-containing mRNA is inhibited through an iron-responsive element in the 5'-untranslated region. Furthermore, RNA interference-mediated depletion of the essential NMD factor Upf1 not only abolishes NMD but also reduces the extent of nonsense-mediated transcriptional gene silencing (NMTGS). Collectively, our data indicate that NMTGS and NMD are linked, relying on the same mechanism for PTC recognition, and that the NMTGS pathway branches from the NMD pathway at a step after Upf1 function.	Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland	University of Bern	Stalder, L (corresponding author), Univ Bern, Inst Cell Biol, Baltzerstr 4, CH-3012 Bern, Switzerland.	oliver.muehlemann@izb.unibe.ch						Amrani N, 2004, NATURE, V432, P112, DOI 10.1038/nature03060; Amrani N, 2006, NAT REV MOL CELL BIO, V7, P415, DOI 10.1038/nrm1942; Arciga-Reyes L, 2006, PLANT J, V47, P480, DOI 10.1111/j.1365-313X.2006.02802.x; Behm-Ansmant I, 2006, GENE DEV, V20, P391, DOI 10.1101/gad.1407606; Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; Buhler M, 2005, MOL CELL, V18, P307, DOI 10.1016/j.molcel.2005.03.030; Buhler M, 2004, NUCLEIC ACIDS RES, V32, P3304, DOI 10.1093/nar/gkh651; Buhler M, 2006, NAT STRUCT MOL BIOL, V13, P462, DOI 10.1038/nsmb1081; Domeier ME, 2000, SCIENCE, V289, P1928, DOI 10.1126/science.289.5486.1928; Fasken MB, 2005, NAT STRUCT MOL BIOL, V12, P482, DOI 10.1038/nsmb945; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; He F, 2003, MOL CELL, V12, P1439, DOI 10.1016/S1097-2765(03)00446-5; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; Kashima I, 2006, GENE DEV, V20, P355, DOI 10.1101/gad.1389006; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Mendell JT, 2004, NAT GENET, V36, P1073, DOI 10.1038/ng1429; Paillusson A, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni052; Peters AHFM, 2005, CURR OPIN CELL BIOL, V17, P230, DOI 10.1016/j.ceb.2005.02.006; Rehwinkel A, 2005, RNA, V11, P1530, DOI 10.1261/rna.2160905; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; Wittmann J, 2006, MOL CELL BIOL, V26, P1272, DOI 10.1128/MCB.26.4.1272-1287.2006	25	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16079	16085		10.1074/jbc.M610595200	http://dx.doi.org/10.1074/jbc.M610595200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428806	hybrid			2022-12-27	WOS:000246794300016
J	Valente, L; Nishikura, K				Valente, Louis; Nishikura, Kazuko			RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSCRIPTOME; INTERFERON ACTION; CANDIDATE ENZYME; EDITING ENZYME; DSRNA-BINDING; 2 FORMS; GLUR-B; ADAR2; DOMAIN; INOSINE	RNA editing that converts adenosine to inosine in double-stranded RNA (dsRNA) is mediated by adenosine deaminases acting on RNA (ADAR). ADAR1 and ADAR2 form respective homodimers, and this association is essential for their enzymatic activities. In this investigation, we set out experiments aiming to determine whether formation of the homodimer complex is mediated by an amino acid interface made through protein-protein interactions of two monomers or via binding of the two subunits to a dsRNA substrate. Point mutations were created in the dsRNA binding domains (dsRBDs) that abolished all RNA binding, as tested for two classes of ADAR ligands, long and short dsRNA. The mutant ADAR dimer complexes were intact, as demonstrated by their ability to co-purify in a sequential affinity-tagged purification and also by their elution at the dimeric fraction position on a size fractionation column. Our results demonstrated ADAR dimerization independent of their binding to dsRNA, establishing the importance of protein-protein interactions for dimer formation. As expected, these mutant ADARs could no longer perform their catalytic function due to the loss in substrate binding. Surprisingly, a chimeric dimer consisting of one RNA binding mutant monomer and a wild type partner still abolished its ability to bind and edit its substrate, indicating that ADAR dimers require two subunits with functional dsRBDs for binding to a dsRNA substrate and then for editing activity to occur.	Wistar Inst Anat & Biol, Dept Gene Express & Regulat, Philadelphia, PA 19104 USA	The Wistar Institute	Valente, L (corresponding author), Wistar Inst Anat & Biol, Dept Gene Express & Regulat, Philadelphia, PA 19104 USA.	lvalente@wistar.org			NATIONAL CANCER INSTITUTE [P01CA072765, T32CA009171] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040536] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009171, T32 CA09171, P01 CA072765, P01 CA072765-050002] Funding Source: Medline; NHLBI NIH HHS [R01 HL070045-04, R01 HL070045] Funding Source: Medline; NIGMS NIH HHS [R01 GM040536, R01 GM040536-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athanasiadis A, 2004, PLOS BIOL, V2, P2144, DOI 10.1371/journal.pbio.0020391; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Blow M, 2004, GENOME RES, V14, P2379, DOI 10.1101/gr.2951204; Blow MJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r27; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Chilibeck KA, 2006, J BIOL CHEM, V281, P16530, DOI 10.1074/jbc.M511831200; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; DeCerbo J, 2005, CURR OPIN CELL BIOL, V17, P302, DOI 10.1016/j.ceb.2005.04.008; Gallo A, 2003, EMBO J, V22, P3421, DOI 10.1093/emboj/cdg327; Gerber A, 1997, RNA, V3, P453; Hallegger M, 2006, RNA, V12, P1993, DOI 10.1261/rna.125506; Hartner JC, 2004, J BIOL CHEM, V279, P4894, DOI 10.1074/jbc.M311347200; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Hoopengardner B, 2003, SCIENCE, V301, P832, DOI 10.1126/science.1086763; Hough RF, 1999, NUCLEIC ACIDS RES, V27, P3424, DOI 10.1093/nar/27.17.3424; Jaikaran DCJ, 2002, J BIOL CHEM, V277, P37624, DOI 10.1074/jbc.M204126200; Kawahara Y, 2007, SCIENCE, V315, P1137, DOI 10.1126/science.1138050; Kim DDY, 2004, GENOME RES, V14, P1719, DOI 10.1101/gr.2855504; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; Levanon EY, 2004, NAT BIOTECHNOL, V22, P1001, DOI 10.1038/nbt996; Liu Y, 1996, J VIROL, V70, P1961, DOI 10.1128/JVI.70.3.1961-1968.1996; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304; Maas Stefan, 2006, RNA Biol, V3, P1; Macbeth MR, 2005, SCIENCE, V309, P1534, DOI 10.1126/science.1113150; Macbeth MR, 2004, RNA, V10, P1563, DOI 10.1261/rna.7920904; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Morse DP, 1999, P NATL ACAD SCI USA, V96, P6048, DOI 10.1073/pnas.96.11.6048; Nishikura K, 2006, NAT REV MOL CELL BIO, V7, P919, DOI 10.1038/nrm2061; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Poulsen H, 2006, RNA, V12, P1350, DOI 10.1261/rna.2314406; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Reenan RA, 2001, TRENDS GENET, V17, P53, DOI 10.1016/S0168-9525(00)02169-7; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Sansam CL, 2003, P NATL ACAD SCI USA, V100, P14018, DOI 10.1073/pnas.2336131100; Schmauss C, 2003, NEUROSCIENTIST, V9, P237, DOI 10.1177/1073858403253669; Stefl R, 2006, STRUCTURE, V14, P345, DOI 10.1016/j.str.2005.11.013; Toth AM, 2006, PROG NUCLEIC ACID RE, V81, P369, DOI 10.1016/S0079-6603(06)81010-X; Wang QD, 2004, J BIOL CHEM, V279, P4952, DOI 10.1074/jbc.M310162200; Xu M, 2006, MOL BIOL CELL, V17, P3211, DOI 10.1091/mbc.E06-02-0162; Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041; Yang WD, 2005, J BIOL CHEM, V280, P3946, DOI 10.1074/jbc.M407876200	48	86	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16054	16061		10.1074/jbc.M611392200	http://dx.doi.org/10.1074/jbc.M611392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428802	hybrid, Green Accepted			2022-12-27	WOS:000246794300013
J	Winter, JM; Moffitt, MC; Zazopoulos, E; McAlpine, JB; Dorrestein, PC; Moore, BS				Winter, Jaclyn M.; Moffitt, Michelle C.; Zazopoulos, Emmanuel; McAlpine, James B.; Dorrestein, Pieter C.; Moore, Bradley S.			Molecular basis for chloronium-mediated meroterpene cyclization - Cloning, sequencing, and heterologous expression of the napyradiomycin biosynthetic gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGUS CURVULARIA-INAEQUALIS; COMPLETE GENOME SEQUENCE; VANADIUM CHLOROPEROXIDASE; FURAQUINOCIN-A; SYNTHASE GENE; STREPTOMYCES; ACTINOMYCETE; BROMOPEROXIDASE; IDENTIFICATION; ALIGNMENT	Structural inspection of the bacterial meroterpenoid antibiotics belonging to the napyradiomycin family of chlorinated dihydroquinones suggests that the biosynthetic cyclization of their terpenoid subunits is initiated via a chloronium ion. The vanadium-dependent haloperoxidases that catalyze such reactions are distributed in fungi and marine algae and have yet to be characterized from bacteria. The cloning and sequence analysis of the 43-kb napyradiomycin biosynthetic cluster ( nap) from Streptomyces aculeolatus NRRL 18422 and from the undescribed marine sediment-derived Streptomyces sp. CNQ-525 revealed 33 open reading frames, three of which putatively encode vanadium-dependent chloroperoxidases. Heterologous expression of the CNQ-525-based nap biosynthetic cluster in Streptomyces albus produced at least seven napyradiomycins, including the new analog 2-deschloro-2-hydroxy-A80915C. These data not only revealed the molecular basis behind the biosynthesis of these novel meroterpenoid natural products but also resulted in the first in vivo verification of vanadium-dependent haloperoxidases.	Univ Calif San Diego, Ctr Marine Biotechnol & Biomed, Scripps Inst Oceanog, La Jolla, CA 92037 USA; Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of California System; University of California San Diego	Moore, BS (corresponding author), Univ Calif San Diego, Ctr Marine Biotechnol & Biomed, Scripps Inst Oceanog, 8655 Discovery Way, La Jolla, CA 92037 USA.	bsmoore@ucsd.edu	Dorrestein, Pieter/ABF-2930-2020; Moffitt, Michelle/C-2471-2014; Dorrestein, Pieter/D-5012-2012	Moffitt, Michelle/0000-0001-9872-3175; Moore, Bradley/0000-0002-4652-1253; Winter, Jaclyn/0000-0001-6273-5377	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM067550] Funding Source: NIH RePORTER; NIAID NIH HHS [AI52445] Funding Source: Medline; NIGMS NIH HHS [GM067550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlert J, 2002, SCIENCE, V297, P1173, DOI 10.1126/science.1072105; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Banskota AH, 2006, J ANTIBIOT, V59, P168, DOI 10.1038/ja.2006.24; Barnett P, 1998, J BIOL CHEM, V273, P23381, DOI 10.1074/jbc.273.36.23381; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; Butler A, 2004, NAT PROD REP, V21, P180, DOI 10.1039/b302337k; Carter-Franklin JN, 2004, J AM CHEM SOC, V126, P15060, DOI 10.1021/ja047925p; FUKUDA DS, 1990, J ANTIBIOT, V43, P623, DOI 10.7164/antibiotics.43.623; Funa N, 2005, J BIOL CHEM, V280, P14514, DOI 10.1074/jbc.M500190200; FUNAYAMA S, 1990, J ORG CHEM, V55, P1132, DOI 10.1021/jo00291a003; GOMI S, 1987, J ANTIBIOT, V40, P740, DOI 10.7164/antibiotics.40.740; Haagen Y, 2006, CHEMBIOCHEM, V7, P2016, DOI 10.1002/cbic.200600338; Hofrichter M, 2006, APPL MICROBIOL BIOT, V71, P276, DOI 10.1007/s00253-006-0417-3; IDEDA M, 2003, APPL MICROBIOL BIOT, V62, P99; Ikeda H, 2003, NAT BIOTECHNOL, V21, P526, DOI 10.1038/nbt820; Ishikawa J, 2004, P NATL ACAD SCI USA, V101, P14925, DOI 10.1073/pnas.0406410101; Ishikawa J, 1999, FEMS MICROBIOL LETT, V174, P251, DOI 10.1111/j.1574-6968.1999.tb13576.x; Kalaitzis JA, 2003, ORG LETT, V5, P4449, DOI 10.1021/ol035748b; Kawasaki T, 2006, J BACTERIOL, V188, P1236, DOI 10.1128/JB.188.4.1236-1244.2006; Kawasaki T, 2004, J ANTIBIOT, V57, P739, DOI 10.7164/antibiotics.57.739; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kuzuyama T, 2005, NATURE, V435, P983, DOI 10.1038/nature03668; Littlechild J, 2002, J MOL RECOGNIT, V15, P291, DOI 10.1002/jmr.590; Liu W, 2002, SCIENCE, V297, P1170, DOI 10.1126/science.1072110; Lombo F, 2006, CHEMBIOCHEM, V7, P366, DOI 10.1002/cbic.200500325; Mongodin EF, 2005, P NATL ACAD SCI USA, V102, P18147, DOI 10.1073/pnas.0509073102; Moore BS, 2006, NAT PROD REP, V23, P615, DOI 10.1039/b508781n; Nierman WC, 2004, P NATL ACAD SCI USA, V101, P14246, DOI 10.1073/pnas.0403306101; Otsuka M, 2004, ANTIMICROB AGENTS CH, V48, P3468, DOI 10.1128/AAC.48.9.3468-3476.2004; Raugei S, 2006, J PHYS CHEM B, V110, P3747, DOI 10.1021/jp054901b; Renirie R, 2000, J BIOL CHEM, V275, P11650, DOI 10.1074/jbc.275.16.11650; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHIN-YA K, 1990, Tetrahedron Letters, V31, P6025, DOI 10.1016/S0040-4039(00)98019-5; SHIOMI K, 1987, J ANTIBIOT, V40, P1740, DOI 10.7164/antibiotics.40.1740; SHIOMI K, 1987, J ANTIBIOT, V40, P1213, DOI 10.7164/antibiotics.40.1213; SHIOMI K, 1986, J ANTIBIOT, V39, P494, DOI 10.7164/antibiotics.39.494; Soria-Mercado IE, 2005, J NAT PROD, V68, P904, DOI 10.1021/np058011z; Soria-Mercado IE, 2004, ACTA CRYSTALLOGR E, V60, pO1627, DOI 10.1107/S1600536804020094; Takagi M, 2000, J BACTERIOL, V182, P4153, DOI 10.1128/JB.182.15.4153-4157.2000; Takahashi S, 1999, J BACTERIOL, V181, P1256, DOI 10.1128/JB.181.4.1256-1263.1999; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vaillancourt FH, 2006, CHEM REV, V106, P3364, DOI 10.1021/cr050313i; VANPEE HK, 1996, ANNU REV MICROBIOL, V50, P275; VANPEE HK, 2003, CHEMOSPHERE, V52, P200; VANSCHIJNDEL JWPM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P249, DOI 10.1016/0167-4838(93)90221-C; VITLER H, 1984, PHYTOCHEMISTRY, V23, P387; Wendt-Pienkowski E, 2005, J AM CHEM SOC, V127, P16442, DOI 10.1021/ja054376u	48	123	128	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16362	16368		10.1074/jbc.M611046200	http://dx.doi.org/10.1074/jbc.M611046200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392281	hybrid			2022-12-27	WOS:000246794300044
J	Kong, XG; Alvarez-Castelao, B; Lin, Z; Castano, JG; Caro, J				Kong, Xianguo; Alvarez-Castelao, Beatriz; Lin, Zhao; Castano, Jose G.; Caro, Jaime			Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTORS; TARGET GENES; UBIQUITIN; TRANSCRIPTION; HIF-2-ALPHA; HIF-1-ALPHA; COMPLEX; FAMILY; VHL; HYDROXYLATION	The transcriptional activator complex HIF-1 plays a key role in the long term adaptation of cells and tissues to their hypoxic microenvironment by stimulating the expression of genes involved in angiogenesis and glycolysis. The expression of the HIF-1 complex is regulated by the levels of its HIF-alpha subunits that are degraded under normoxic conditions by the ubiquitin-proteasome system. Whereas this pathway of HIF-alpha protein degradation has been well characterized, little is known of their turnover during prolonged hypoxic conditions. Herein, we describe a pathway by which HIF-1 alpha and HIF-2 alpha proteins are constitutively degraded during hypoxia by the proteasome system, although without requirement of prior ubiquitylation. The constitutive/hypoxic degradation of HIF-alpha proteins is independent of the presence of VHL, binding to DNA, or the formation of a transcriptionally active HIF-1 complex. These results are further strengthened by the demonstration that HIF-alpha proteins are directly degraded in a reconstituted in vitro assay by the proteasome. Finally, we demonstrate that the persistent down-regulation of HIF-1 alpha during prolonged hypoxia is mainly caused by a decreased production of the protein without change in its degradation rate. This constitutive, ubiquitin-independent proteasomal degradation pathway of HIF-alpha proteins has to be taken into account in understanding the biology as well as in the development of therapeutic interventions of highly hypoxic tumors.	Thomas Jefferson Univ, Cardeza Fdn, Philadelphia, PA 19107 USA; UAM, Fac Med, CSIC, Dept Bioquim, Madrid, Spain; UAM, Inst Invest Biomed Alberto Sols, CSIC, Fac Med, Madrid, Spain	Jefferson University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Caro, J (corresponding author), Thomas Jefferson Univ, Cardeza Fdn, 1015 Walnut St, Philadelphia, PA 19107 USA.	jaime.caro@jefferson.edu	alvarez-castelao, beatriz/W-1707-2018	alvarez-castelao, beatriz/0000-0001-7505-1855; G. Castano, Jose/0000-0002-6579-8442	NATIONAL CANCER INSTITUTE [R01CA089212] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA089212] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez-Castelao B, 2005, FEBS LETT, V579, P4797, DOI 10.1016/j.febslet.2005.07.060; ARRIBAS J, 1990, J BIOL CHEM, V265, P13969; Asher G, 2005, MOL CELL, V17, P645, DOI 10.1016/j.molcel.2005.01.020; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Brahimi-Horn Christiane, 2006, Bull Cancer, V93, pE73; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gruber M, 2006, CURR OPIN HEMATOL, V13, P169, DOI 10.1097/01.moh.0000219663.88409.35; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hoyt MA, 2004, CELL MOL LIFE SCI, V61, P1596, DOI 10.1007/s00018-004-4133-9; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Lee H, 2006, J BIOL CHEM, V281, P26876, DOI 10.1074/jbc.M605366200; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Lipford JR, 2005, NATURE, V438, P113, DOI 10.1038/nature04098; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Schmidt M, 2005, BIOL CHEM, V386, P725, DOI 10.1515/BC.2005.085; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200	35	60	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15498	15505		10.1074/jbc.M700704200	http://dx.doi.org/10.1074/jbc.M700704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403672	hybrid			2022-12-27	WOS:000246589600026
J	Yong, WD; Bao, SD; Chen, HY; Li, DP; Sanchez, ER; Shou, W				Yong, Weidong; Bao, Shideng; Chen, Hanying; Li, Dapei; Sanchez, Edwin R.; Shou, Weinian			Mice lacking protein phosphatase 5 are defective in ataxia telangiectasia mutated (ATM)-mediated cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT; DNA-DAMAGE; SERINE/THREONINE PHOSPHATASE; TPR DOMAIN; IN-VITRO; ACTIVATION; ATM; PP5; PROTEIN-PHOSPHATASE-5; IDENTIFICATION	Protein phosphatase 5 (Ppp5), a tetratricopeptide repeat domain protein, has been implicated in multiple cellular functions, including cellular proliferation, migration, differentiation and survival, and cell cycle checkpoint regulation via the ataxia telangiectasia mutated/ATM and Rad3-related (ATM/ATR) signal pathway. However, the physiological functions of Ppp5 have not been reported. To confirm the role of Ppp5 in cell cycle checkpoint regulation, we generated Ppp5-deficient mice and isolated mouse embryonic fibroblast (MEF) cells from Ppp5-deficient and littermate control embryos. Although Ppp5-deficient mice can survive through embryonic development and postnatal life and MEF cells from the Ppp5-deficient mice maintain normal replication checkpoint induced by hydroxyurea, Ppp5-deficient MEF cells display a significant defect in G(2)/M DNA damage checkpoint in response to ionizing radiation (IR). To determine whether this defect in IR-induced G(2)/M checkpoint is due to altered ATM-mediated signaling, we measured ATM kinase activity and ATM-mediated downstream events. Our data demonstrated that IR-induced ATM kinase activity is attenuated in Ppp5-deficient MEFs. Phosphorylation levels of two known ATM substrates, Rad17 and Chk2, were significantly reduced in Ppp5-deficient MEFs in response to IR. Furthermore, DNA damage-induced Rad17 nuclear foci were dramatically reduced in Ppp5-deficient MEFs. These results demonstrate a direct regulatory linkage between Ppp5 and activation of the ATM-mediated G(2)/M DNA damage check-point pathway in vivo.	Indiana Univ, Herman B Wells Ctr Pediat Res, Dept Pediat, Sect Pediat Cardiol,Sch Med, Indianapolis, IN 46202 USA; Univ Colorado, Hlth Sci Ctr, Dept Radiat Oncol, Aurora, CO 80011 USA; Univ Colorado, Hlth Sci Ctr, Dept Neurosurg, Aurora, CO 80011 USA; Univ Toledo, Coll Med, Dept Physiol & Pharmacol, Toledo, OH 43614 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University System of Ohio; University of Toledo	Shou, W (corresponding author), Indiana Univ, Herman B Wells Ctr Pediat Res, Dept Pediat, Sect Pediat Cardiol,Sch Med, R4-368,1044 W Walnut, Indianapolis, IN 46202 USA.	wshou@iupui.edu			NHLBI NIH HHS [R01 HL081092, R01 HL081092-01A2] Funding Source: Medline; NIDDK NIH HHS [R01 DK043867, R01 DK070127, R01 DK073402, DK73402, DK70127, DK43867, R01 DK073402-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073402, R01DK043867, R29DK043867, R01DK070127] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; Gentile S, 2006, P NATL ACAD SCI USA, V103, P5202, DOI 10.1073/pnas.0600080103; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kang H, 2001, BIOCHEMISTRY-US, V40, P10485, DOI 10.1021/bi010999i; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kobayashi M, 2004, GENES CELLS, V9, P291, DOI 10.1111/j.1356-9597.2004.00728.x; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; Post SM, 2003, NUCLEIC ACIDS RES, V31, P5568, DOI 10.1093/nar/gkg765; Ramsey AJ, 2002, BIOCHEMISTRY-US, V41, P5625, DOI 10.1021/bi016090h; Shiloh Y, 2004, NAT CELL BIOL, V6, P923, DOI 10.1038/ncb1004-923; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; von Kriegsheim A, 2006, NAT CELL BIOL, V8, P1011, DOI 10.1038/ncb1465; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yang J, 2005, EMBO J, V24, P1, DOI 10.1038/sj.emboj.7600496; Zhang J, 2005, MOL CELL BIOL, V25, P9910, DOI 10.1128/MCB.25.22.9910-9919.2005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	30	45	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14690	14694		10.1074/jbc.C700019200	http://dx.doi.org/10.1074/jbc.C700019200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376776	Green Accepted, hybrid			2022-12-27	WOS:000246589000004
J	Mexal, S; Jenkins, PM; Lautner, MA; Iacob, E; Crouch, EL; Stitzel, JA				Mexal, Sharon; Jenkins, Paul M.; Lautner, Meeghan A.; Iacob, Eli; Crouch, Eric L.; Stitzel, Jerry A.			alpha-7 Nicotinic receptor gene promoter polymorphisms in inbred mice affect expression in a cell type-specific fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUNGAROTOXIN-BINDING; MESSENGER-RNA; MOUSE STRAINS; SUBUNIT GENE; CLONAL LINE; DBA/2 MICE; RAT-BRAIN; SCHIZOPHRENIA; SITES; LINKAGE	Inbred mouse strains display significant differences in their levels of brain alpha 7 nicotinic acetylcholine receptor (alpha 7 nAChR) expression, as measured by binding of the alpha 7-selective antagonist alpha-bungarotoxin. Variations in alpha-bungarotoxin binding have been shown to correlate with an animal's sensitivity to nicotine-induced seizures and sensory gating. In two inbred mouse strains, C3H/2Ibg (C3H) and DBA/2Ibg (DBA/2), the interstrain binding differences are linked to a restriction length polymorphism in the alpha 7 nAChR gene, Chrna7. Despite this finding, the molecular mechanism(s) through which genetic variability in Chrna7 may contribute to alpha 7 nAChR expression differences remains unknown. However, studies of the human alpha 7 nAChR gene (CHRNA7) previously have demonstrated that CHRNA7 promoter polymorphisms are associated with differences in promoter activity as well as differences in sensory processing. In the present study, a 947-base pair region of the Chrna7 promoter was cloned from both the C3H and DBA/2 inbred mouse strains in an attempt to identify polymorphisms that may underlie alpha 7 nAChR differential expression. Sequence analysis of these fragments identified 14 single nucleotide polymorphisms (SNPs). A combination of two of these SNPs affects promoter activity in an in vitro luciferase reporter assay. These results suggest a mechanism through which the Chrna7 promoter genotype may influence interstrain variations in alpha 7 nAChR expression.	Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA; Univ Colorado, Dept Integrat Physiol, Boulder, CO 80309 USA; Univ Michigan, Med Ctr, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Michigan System; University of Michigan	Stitzel, JA (corresponding author), Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA.	stitzel@colorado.edu	Jenkins, Paul/C-9098-2015	Jenkins, Paul/0000-0002-4207-5823; STITZEL, JERRY/0000-0001-8161-6525	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH068582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014369, T32DA017637] Funding Source: NIH RePORTER; NIDA NIH HHS [DA017637, DA014369] Funding Source: Medline; NIMH NIH HHS [5 P50 MH068582] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adams CE, 2006, BRAIN RES, V1122, P27, DOI 10.1016/j.brainres.2006.08.113; Adams CE, 2003, DEV BRAIN RES, V143, P137, DOI 10.1016/S0165-3806(03)00106-8; Adams CE, 2001, BRAIN RES, V922, P180, DOI 10.1016/S0006-8993(01)03115-8; Boyd R. T., 1998, Society for Neuroscience Abstracts, V24, P834; Bullock AE, 1997, BEHAV NEUROSCI, V111, P1353, DOI 10.1037/0735-7044.111.6.1353; Campos-Caro A, 2001, DNA CELL BIOL, V20, P657, DOI 10.1089/104454901753340640; Cauley K, 1996, J NEUROBIOL, V30, P303, DOI 10.1002/(SICI)1097-4695(199606)30:2<303::AID-NEU11>3.0.CO;2-K; Criado M, 1997, J NEUROSCI, V17, P6554; Danthi S, 2006, NEUROSCI LETT, V400, P63, DOI 10.1016/j.neulet.2006.02.067; Freedman R, 1997, P NATL ACAD SCI USA, V94, P587, DOI 10.1073/pnas.94.2.587; FREEDMAN R, 1995, BIOL PSYCHIAT, V38, P22, DOI 10.1016/0006-3223(94)00252-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Leonard S, 2002, ARCH GEN PSYCHIAT, V59, P1085, DOI 10.1001/archpsyc.59.12.1085; LUKAS RJ, 1993, MOL CELL NEUROSCI, V4, P1, DOI 10.1006/mcne.1993.1001; MARKS MJ, 1989, PHARMACOL BIOCHEM BE, V33, P679, DOI 10.1016/0091-3057(89)90407-3; Marks MJ, 1996, MOL BRAIN RES, V39, P207, DOI 10.1016/0169-328X(96)00027-7; McDonough J, 1997, J NEUROSCI, V17, P2273; Quik M, 1996, J NEUROCHEM, V67, P145; Shin DH, 2001, BRAIN RES, V892, P203, DOI 10.1016/S0006-8993(00)03300-X; Stevens KE, 1996, NEUROPSYCHOPHARMACOL, V15, P152, DOI 10.1016/0893-133X(95)00178-G; Stitzel JA, 1996, MOL BRAIN RES, V43, P30, DOI 10.1016/S0169-328X(96)00149-0; Virginio C, 2002, EUR J PHARMACOL, V445, P153, DOI 10.1016/S0014-2999(02)01750-8; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8	24	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13220	13227		10.1074/jbc.M610694200	http://dx.doi.org/10.1074/jbc.M610694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360707	hybrid			2022-12-27	WOS:000246060300010
J	Tsuji, T; Sheehy, N; Gautier, VW; Hayakawa, H; Sawa, H; Hall, WW				Tsuji, Takahiro; Sheehy, Noreen; Gautier, Virginie W.; Hayakawa, Hitoshi; Sawa, Hirofumi; Hall, William W.			The nuclear import of the human T lymphotropic virus type I (HTLV-1) tax protein is carrier- and energy-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LEUKEMIA-VIRUS; NF-KAPPA-B; BETA-CATENIN; TRANSCRIPTION FACTOR; LOCALIZATION SIGNAL; PORE COMPLEX; NUCLEOCYTOPLASMIC TRAFFICKING; SUBCELLULAR-DISTRIBUTION; RECEPTOR; RAN	HTLV-1 is the etiologic agent of the adult T cell leukemia-lymphoma (ATLL). The viral regulatory protein Tax plays a central role in leukemogenesis as a transcriptional transactivator of both viral and cellular gene expression, and this requires Tax activity in both the cytoplasm and the nucleus. In the present study, we have investigated the mechanisms involved in the nuclear localization of Tax. Employing a GFP fusion expression system and a range of Tax mutants, we could confirm that the N-terminal 60 amino acids, and specifically residues within the zinc finger motif in this region, are important for nuclear localization. Using an in vitro nuclear import assay, it could be demonstrated that the transportation of Tax to the nucleus required neither energy nor carrier proteins. Specific and direct binding between Tax and p62, a nucleoporin with which the importin beta family of proteins have been known to interact was also observed. The nuclear import activity of wild type Tax and its mutants and their binding affinity for p62 were also clearly correlated, suggesting that the entry of Tax into the nucleus involves a direct interaction with nucleoporins within the nuclear pore complex (NPC). The nuclear export of Tax was also shown to be carrier independent. It could be also demonstrated that Tax it self may have a carrier function and that the NF-kappa B subunit p65 could be imported into the nucleus by Tax. These studies suggest that Tax could alter the nucleocytoplasmic distribution of cellular proteins, and this could contribute to the deregulation of cellular processes observed in HTLV-1 infection.	Univ Coll Dublin, Sch Med & Med Sci, Ctr Res Infect Dis, Dublin 4, Ireland; Hokkaido Univ, Res Ctr, Dept Mol Pathobiol, Sapporo, Hokkaido 0600818, Japan; Hokkaido Univ, Res Ctr, Century COE Program Zoonosis Control 21st, Kita Ku, Sapporo, Hokkaido 0600818, Japan	University College Dublin; Hokkaido University; Hokkaido University	Hall, WW (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Ctr Res Infect Dis, Dublin 4, Ireland.	william.hall@ucd.ie	Sawa, Hirofumi/AAW-8816-2021; Gautier, virginie/K-4057-2012; Sawa, Hirofumi/F-6954-2012	Gautier, virginie/0000-0003-1862-2644; Sawa, Hirofumi/0000-0003-2569-2755; Sheehy, Noreen/0000-0001-5004-0228				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Alefantis T, 2005, J BIOL CHEM, V280, P17353, DOI 10.1074/jbc.M409851200; Arnold M, 2006, J BIOL CHEM, V281, P20883, DOI 10.1074/jbc.M602189200; Asally M, 2005, EXP CELL RES, V308, P357, DOI 10.1016/j.yexcr.2005.05.011; Azran I, 2005, ONCOGENE, V24, P4521, DOI 10.1038/sj.onc.1208645; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; Delhaye S, 2004, J VIROL, V78, P4357, DOI 10.1128/JVI.78.8.4357-4362.2004; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Fagerlund R, 2005, J BIOL CHEM, V280, P15942, DOI 10.1074/jbc.M500814200; FELDHERR C, 1995, MOL CELL BIOL, V15, P7043; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gatza ML, 2006, J VIROL, V80, P6657, DOI 10.1128/JVI.02270-05; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Gustin KE, 2003, VIRUS RES, V95, P35, DOI 10.1016/S0168-1702(03)00165-5; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Harhaj NS, 2007, J BIOL CHEM, V282, P4185, DOI 10.1074/jbc.M611031200; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Koike M, 2004, J BIOL CHEM, V279, P34038, DOI 10.1074/jbc.M405821200; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Lam MHC, 2002, MOL ENDOCRINOL, V16, P390, DOI 10.1210/me.16.2.390; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Marg A, 2004, J CELL BIOL, V165, P823, DOI 10.1083/jcb.200403057; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Meertens L, 2004, J BIOL CHEM, V279, P43307, DOI 10.1074/jbc.M400497200; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; Muranyi W, 2002, SCIENCE, V297, P854, DOI 10.1126/science.1071506; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Pandya K, 2002, J BIOL CHEM, V277, P16304, DOI 10.1074/jbc.M200866200; Peloponese JM, 2006, IMMUNOL RES, V34, P1, DOI 10.1385/IR:34:1:1; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; Stewart M, 2003, SCIENCE, V302, P1513, DOI 10.1126/science.1092863; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; SUZUKI T, 1994, ONCOGENE, V9, P3099; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200; YAMADA S, 1995, CANCER RES, V55, P2524; Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhong HL, 2005, J BIOL CHEM, V280, P10675, DOI 10.1074/jbc.M412878200	80	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13875	13883		10.1074/jbc.M611629200	http://dx.doi.org/10.1074/jbc.M611629200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344183	hybrid			2022-12-27	WOS:000246060300077
J	Lun, SC; Bishai, WR				Lun, Shichun; Bishai, William R.			Characterization of a novel cell wall-anchored protein with carboxylesterase activity required for virulence in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESSENTIAL GENES; LIPOPROTEIN; EXPRESSION; MECHANISM; INHIBITION; SMEGMATIS; ESTERASES; SURVIVAL; LATENCY	Pooled mutant competition assays have shown that the Mycobacterium tuberculosis MT2282 gene (Rv2224c, annotated as encoding a proteinase) is required for bacterial survival in mice. To understand the mechanism of this requirement, we conducted a genetic and biochemical study of the MT2282 gene and its product. MT2282 encodes a member of the microbial esterase/lipase family with active site consensus sequences of G-X-S-X-G, and we have concluded that the MT2282 protein is, in fact, a cell wall-associated carboxylesterase rather than a proteinase, as initially annotated. The MT2282 gene product preferentially hydrolyzes ester bonds of substrates with intermediate carbon chain length. Purified MT2282 is a monomer with enzymatic catalysis properties that fit in the Michaelis-Menten kinetic model. Esterase activity was inhibited by paraoxon and dichlorvos. Replacement of Ser(215), Asp(450), and His(477) by Ala in the consensus motifs completely abolishes esterase activity, suggesting that Ser(215)-Asp(450)-His(477) forms a catalytic triad with Ser(215) as an active site residue. To evaluate the role of the MT2282 in pathogenesis, the gene was deleted from the M. tuberculosis genome. BALB/c mouse aerosol infections showed reduced colony-forming unit loads in lungs and spleens and less lung pathology for the Delta MT2282 mutant. High dose intravenous infection of mice with the mutant resulted in a significantly delayed time to death compared with the wild type or complemented mutant. These results indicate that MT2282 encodes a cell wall-associated carboxylesterase, which is required for full virulence of M. tuberculosis. We propose that MT2282 (Rv2224c) and its adjacent paralogous gene MT2281 (Rv2223c) be named caeA and caeB respectively, for carboxylesterase A and B.	Johns Hopkins Univ, Sch Med, Ctr TB Res, Dept Med, Baltimore, MD 21231 USA	Johns Hopkins University	Bishai, WR (corresponding author), Johns Hopkins Univ, Sch Med, Ctr TB Res, Dept Med, 1550 Orleans St, Baltimore, MD 21231 USA.	wbishai@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036973, R01AI043846, R01AI036973, R01AI037856] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37856, AI43846, AI36973] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 2006, CURRENT PROTOCOLS MO, V2; Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Chen P, 2000, INFECT IMMUN, V68, P5575, DOI 10.1128/IAI.68.10.5575-5580.2000; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Dannenberg AM, 2006, PATHOGENESIS OF HUMAN PULMONARY TUBERCULOSIS: INSIGHTS FROM THE RABBIT MODEL, P1; Draper P, 2005, TUBERCULOSIS AND THE TUBERCLE BACILLUS, P261; Dubnau E, 2002, INFECT IMMUN, V70, P2787, DOI 10.1128/IAI.70.6.2787-2795.2002; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Fojan P, 2000, BIOCHIMIE, V82, P1033, DOI 10.1016/S0300-9084(00)01188-3; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; KHULLER GK, 1982, AUST J EXP BIOL MED, V60, P541, DOI 10.1038/icb.1982.58; Kinsella RJ, 2003, P NATL ACAD SCI USA, V100, P10320, DOI 10.1073/pnas.1737230100; KLEIN P, 1988, PROTEIN ENG, V2, P15, DOI 10.1093/protein/2.1.15; KONDO E, 1977, JPN J MED SCI BIOL, V30, P171, DOI 10.7883/yoken1952.30.171; Lamichhane G, 2005, INFECT IMMUN, V73, P2533, DOI 10.1128/IAI.73.4.2533-2540.2005; Lamichhane G, 2003, P NATL ACAD SCI USA, V100, P7213, DOI 10.1073/pnas.1231432100; LANZ WW, 1973, J BACTERIOL, V113, P1170, DOI 10.1128/JB.113.3.1170-1176.1973; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; Liu P, 2004, J MOL BIOL, V342, P551, DOI 10.1016/j.jmb.2004.06.069; MATTAR S, 1994, J BIOL CHEM, V269, P14939; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Nuermberger EL, 2004, AM J RESP CRIT CARE, V170, P1131, DOI 10.1164/rccm.200407-885OC; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Pai RK, 2003, J IMMUNOL, V171, P175, DOI 10.4049/jimmunol.171.1.175; Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5; PATEL D, 1991, BIOCHEM PHARMACOL, V42, P1577, DOI 10.1016/0006-2952(91)90427-7; Pethe K, 2004, P NATL ACAD SCI USA, V101, P13642, DOI 10.1073/pnas.0401657101; Post FA, 2001, INFECT IMMUN, V69, P1433, DOI 10.1128/IAI.69.3.1433-1439.2001; Qamra R, 2006, BIOCHEMISTRY-US, V45, P6997, DOI 10.1021/bi0606445; Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837; Rosenfeld CA, 2006, TOXICOL SCI, V90, P460, DOI 10.1093/toxsci/kfj094; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Sassetti CM, 2001, P NATL ACAD SCI USA, V98, P12712, DOI 10.1073/pnas.231275498; Sinha S, 2005, MICROBIOL-SGM, V151, P2411, DOI 10.1099/mic.0.27799-0; Sun RG, 2004, MOL MICROBIOL, V52, P25, DOI 10.1111/j.1365-2958.2003.03958.x; Trivedi OA, 2005, MOL CELL, V17, P631, DOI 10.1016/j.molcel.2005.02.009; Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001; Vergne I, 2005, P NATL ACAD SCI USA, V102, P4033, DOI 10.1073/pnas.0409716102; WAYNE LG, 1994, EUR J CLIN MICROBIOL, V13, P908, DOI 10.1007/BF02111491; YOUNG DB, 1991, RES MICROBIOL, V142, P55, DOI 10.1016/0923-2508(91)90097-T	43	63	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18348	18356		10.1074/jbc.M700035200	http://dx.doi.org/10.1074/jbc.M700035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17428787	hybrid			2022-12-27	WOS:000247302000041
J	Ishima, R; Torchia, DA; Louis, JM				Ishima, Rieko; Torchia, Dennis A.; Louis, John M.			Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 PROTEASE; HUMAN-IMMUNODEFICIENCY; POL POLYPROTEIN; STABILITY; KINETICS; MECHANISM; PEPTIDES; PROTEINS; INHIBITION; SUBSTRATE	An experimental protocol for folding the mature human immunodeficiency virus-1 (HIV- 1) protease is presented that facilitates NMR studies at a low protein concentration of similar to 20 mu M. Under these conditions, NMRspectra show that the mature protease lacking its terminal beta-sheet residues 1-4 and 96-99 (PR5-95) exhibits a stable monomer fold spanning the region 10-90 that is similar to that of the single subunit of the wild-type dimer and the dimer bearing a D25N mutation (PRD25N). Urea- induced unfolding monitored both by changes in H-1- N-15 heteronuclear single quantum correlation spectra and by protein fluorescence indicates that although PR5-95 monomer displays a transition profile similar to that of the PRD25N dimer ( 50% unfolded (U-50) = similar to 1.9 M), extending the protease with 4 residues ( SFNF) of its N- terminally flanking sequence in the Gag-Pol precursor ((PRD25N)-P-SFNF) decreases the stability of the fold (U-50 = similar to 1.5 M). Assigned backbone chemical shifts were used to elucidate differences in the stability of the PRT26A (U50 = 2.5 M) and (PRD25N)-P-SFNF monomers and compared with PRD25N/T26A monomer. Discernible differences in the backbone chemical shifts were observed for N- terminal protease residues 3-6 of (PRD25N)-P-SFNF that may relate to the increase in the equilibrium dissociation constant ( Kd) and the very low catalytic activity of the protease prior to its autoprocessing at its N terminus from the Gag- Pol precursor.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA; NIDCR, Mol Struct Biol Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Louis, JM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Rm B2-29,LCP, Bethesda, MD 20892 USA.	johnl@intra.niddk.nih.gov		Louis, John M/0000-0002-0052-1899	Intramural NIH HHS [Z99 DK999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bowman MJ, 2002, BIOPOLYMERS, V66, P126, DOI 10.1002/bip.10232; Cherry E, 1998, J MOL BIOL, V284, P43, DOI 10.1006/jmbi.1998.1968; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRANT SK, 1992, BIOCHEMISTRY-US, V31, P9491, DOI 10.1021/bi00154a023; Ishima R, 2003, J BIOL CHEM, V278, P43311, DOI 10.1074/jbc.M307549200; Ishima R, 2001, J BIOL CHEM, V276, P49110, DOI 10.1074/jbc.M108136200; Katoh E, 2003, PROTEIN SCI, V12, P1376, DOI 10.1110/ps.0300703; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; Kovalevsky AY, 2006, J MOL BIOL, V363, P161, DOI 10.1016/j.jmb.2006.08.007; Lam PYS, 1996, J MED CHEM, V39, P3514, DOI 10.1021/jm9602571; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; Louis J M, 2000, Adv Pharmacol, V49, P111; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; Louis JM, 2003, J BIOL CHEM, V278, P6085, DOI 10.1074/jbc.M209726200; Louis JM, 1999, NAT STRUCT BIOL, V6, P868; Louis JM, 1999, J BIOL CHEM, V274, P23437, DOI 10.1074/jbc.274.33.23437; MILDNER AM, 1994, BIOCHEMISTRY-US, V33, P9405, DOI 10.1021/bi00198a005; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; Park SH, 2000, NAT BIOTECHNOL, V18, P847, DOI 10.1038/78451; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; Rodriguez-Barrios F, 2004, CURR TOP MED CHEM, V4, P991, DOI 10.2174/1568026043388529; ROSE JR, 1993, J BIOL CHEM, V268, P11939; Sluis-Cremer N, 2004, INT J BIOCHEM CELL B, V36, P1836, DOI 10.1016/j.biocel.2004.02.020; Sluis-Cremer N, 2002, EUR J BIOCHEM, V269, P5103, DOI 10.1046/j.1432-1033.2002.03216.x; Strisovsky K, 2000, PROTEIN SCI, V9, P1631, DOI 10.1110/ps.9.9.1631; Szeltner Z, 1996, J BIOL CHEM, V271, P5458, DOI 10.1074/jbc.271.10.5458; Temesgen Z, 2006, EXPERT OPIN PHARMACO, V7, P1541, DOI 10.1517/14656566.7.12.1541; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; Vondrasek J, 1997, NAT STRUCT BIOL, V4, P8, DOI 10.1038/nsb0197-8; WEBER IT, 1990, J BIOL CHEM, V265, P10492; Wondrak EM, 1996, BIOCHEMISTRY-US, V35, P12957, DOI 10.1021/bi960984y; Wondrak EM, 1996, J BIOL CHEM, V271, P4477, DOI 10.1074/jbc.271.8.4477; ZHANG ZY, 1991, J BIOL CHEM, V266, P15591	36	49	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17190	17199		10.1074/jbc.M701304200	http://dx.doi.org/10.1074/jbc.M701304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17412697	hybrid			2022-12-27	WOS:000246946500052
J	Outchkourov, N; Vermunt, A; Jansen, J; Kaan, A; Roeffen, W; Teelen, K; Lasonder, E; Braks, A; van de Vegte-Bolmer, M; Qiu, LY; Sauerwein, R; Stunnenberg, HG				Outchkourov, Nikolay; Vermunt, Adriaan; Jansen, Josephine; Kaan, Anita; Roeffen, Will; Teelen, Karina; Lasonder, Edwin; Braks, Anneke; van de Vegte-Bolmer, Marga; Qiu, Li Yan; Sauerwein, Robert; Stunnenberg, Hendrik G.			Epitope analysis of the malaria surface antigen Pfs48/45 identifies a subdomain that elicits transmission blocking antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; MONOCLONAL-ANTIBODIES; VACCINE CANDIDATE; PROTEIN; PFS230; EXPRESSION; REACTIVITY; TARGET	Pfs48/45, a member of a Plasmodium-specific protein family, displays conformation-dependent epitopes and is an important target for malaria transmission-blocking (TB) immunity. To design a recombinant Pfs48/45-based TB vaccine, we analyzed the conformational TB epitopes of Pfs48/ 45. The Pfs48/ 45 protein was found to consist of a C-terminal six-cysteine module recognized by anti-epitope I antibodies, a middle four-cysteine module recognized by anti-epitopes IIb and III, and an N-terminal module recognized by anti-epitope V antibodies. Refolding assays identified that a fragment of 10 cysteines (10C), comprising the middle four-cysteine and the C-terminal six-cysteine modules, possesses superior refolding capacity. The refolded and partially purified 10C conformer elicited antibodies in mice that targeted at least two of the TB epitopes (I and III). The induced antibodies could block the fertilization of Plasmodium falciparum gametes in vivo in a concentration-dependent manner. Our results provide important insight into the structural organization of the Pfs48/45 protein and experimental support for a Pfs48/45-based subunit vaccine.	Radboud Univ Nijmegen, Dept Biol Mol, NCMLS, NL-6500 HB Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Stunnenberg, HG (corresponding author), Radboud Univ Nijmegen, Dept Biol Mol, NCMLS, M850-3-79,POB 9101, NL-6500 HB Nijmegen, Netherlands.	h.stunnenberg@ncmls.ru.nl	Sauerwein, Robert/C-8519-2013; Roeffen, W.F.G./L-4607-2015; Stunnenberg, Hendrik G./D-6875-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576; Lasonder, Edwin/0000-0003-2582-3444				CARTER R, 1990, PARASITE IMMUNOL, V12, P587, DOI 10.1111/j.1365-3024.1990.tb00990.x; CARTER R, 1995, MOL BIOCHEM PARASIT, V71, P203, DOI 10.1016/0166-6851(94)00054-Q; Carter R, 2000, NAT MED, V6, P241, DOI 10.1038/73062; Carter R, 2001, VACCINE, V19, P2309, DOI 10.1016/S0264-410X(00)00521-1; Gerloff DL, 2005, P NATL ACAD SCI USA, V102, P13598, DOI 10.1073/pnas.0502378102; Harlow E., 1988, ANTIBODIES LAB MANUA; Kaslow DC, 2002, CHEM IMMUNOL, V80, P287; KOCKEN CHM, 1993, MOL BIOCHEM PARASIT, V61, P59, DOI 10.1016/0166-6851(93)90158-T; Kubler-Kielb J, 2007, P NATL ACAD SCI USA, V104, P293, DOI 10.1073/pnas.0609885104; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Lensen A, 1996, T ROY SOC TROP MED H, V90, P20, DOI 10.1016/S0035-9203(96)90464-2; Milek RLB, 1998, PARASITE IMMUNOL, V20, P377, DOI 10.1046/j.1365-3024.1998.00171.x; PONNUDURAI T, 1989, PARASITOLOGY, V98, P165, DOI 10.1017/S0031182000062065; PONNUDURAI T, 1987, T ROY SOC TROP MED H, V81, P491, DOI 10.1016/0035-9203(87)90172-6; Roeffen W, 1996, PARASITE IMMUNOL, V18, P103, DOI 10.1046/j.1365-3024.1996.d01-54.x; ROEFFEN W, 1995, AM J TROP MED HYG, V52, P60, DOI 10.4269/ajtmh.1995.52.60; Roeffen W, 2001, EXP PARASITOL, V97, P45, DOI 10.1006/expr.2000.4586; Roeffen WFG, 2001, J BIOL CHEM, V276, P19807, DOI 10.1074/jbc.M100562200; Schneider P, 2007, AM J TROP MED HYG, V76, P470, DOI 10.4269/ajtmh.2007.76.470; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; TARGETT GAT, 1990, IMMUNOL LETT, V25, P77, DOI 10.1016/0165-2478(90)90095-8; van Dijk MR, 2005, P NATL ACAD SCI USA, V102, P12194, DOI 10.1073/pnas.0500925102; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460; VERMEULEN AN, 1985, DEV BIOL STAND, V62, P91; Williamson KC, 2003, PARASITE IMMUNOL, V25, P351, DOI 10.1046/j.1365-3024.2003.00643.x; Wu YM, 2006, P NATL ACAD SCI USA, V103, P18243, DOI 10.1073/pnas.0608545103	27	59	62	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17148	17156		10.1074/jbc.M700948200	http://dx.doi.org/10.1074/jbc.M700948200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17426022	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000246946500048
J	Smith, BD; Sanders, JL; Porubsky, PR; Lushington, GH; Stout, CD; Scott, EE				Smith, Brian D.; Sanders, Jason L.; Porubsky, Patrick R.; Lushington, Gerald H.; Stout, C. David; Scott, Emily E.			Structure of the human lung cytochrome P450 2A13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO-SPECIFIC CARCINOGEN; AMINO-ACID-RESIDUES; METABOLIC-ACTIVATION; HUMAN CYP2A13; GENETIC POLYMORPHISMS; HYDROXYLASE-ACTIVITY; AFLATOXIN B-1; IDENTIFICATION; EXPRESSION; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE	The human lung cytochrome P450 2A13 (CYP2A13) activates the nicotine- derived procarcinogen 4-( methylnitrosamino)- 1(3-pyridyl)-1-butanone (NNK) into DNA- altering compounds that cause lung cancer. Another cytochrome P450, CYP2A6, is also present in human lung, but at much lower levels. Although these two enzymes are 93.5% identical, CYP2A13 metabolizes NNK with much lower K-m values than does CYP2A6. To investigate the structural differences between these two enzymes the structure of CYP2A13 was determined to 2.35 angstrom A by x- ray crystallography and compared with structures of CYP2A6. As expected, the overall CYP2A13 and CYP2A6 structures are very similar with an average root mean square deviation of 0.5 angstrom for the C alpha atoms. Like CYP2A6, the CYP2A13 active site cavity is small and highly hydrophobic with a cluster of Phe residues composing the active site roof. Active site residue Asn(297) is positioned to hydrogen bond with an adventitious ligand, identified as indole. Amino acid differences between CYP2A6 and CYP2A13 at positions 117, 300, 301, and 208 relate to different orientations of the ligand plane in the two protein structures and may underlie the significant variations observed in binding and catalysis of many CYP2A ligands. In addition, docking studies suggest that residues 365 and 366 may also contribute to differences in NNK metabolism.	Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA; Univ Kansas, Mol Graph & Modeling Lab, Lawrence, KS 66045 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Kansas; University of Kansas; Scripps Research Institute	Scott, EE (corresponding author), 1251 Wescoe Hall Dr, Lawrence, KS 66045 USA.	eescott@ku.edu	Lushington, Gerald/AAH-3205-2020; Lushington, Gerald/P-8421-2019	Lushington, Gerald/0000-0001-5821-4253; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708, P20RR016475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061545, R01GM076343] Funding Source: NIH RePORTER; NCRR NIH HHS [RR016475, RR017708] Funding Source: Medline; NIGMS NIH HHS [GM61545, GM076343] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMERICAN CANCER SOCIETY, 2007, CANC FACTS FIG; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Crawford EL, 1998, CARCINOGENESIS, V19, P1867, DOI 10.1093/carcin/19.10.1867; Fukami T, 2007, DRUG METAB DISPOS, V35, P335, DOI 10.1124/dmd.106.011064; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Gillam EMJ, 2000, BIOCHEMISTRY-US, V39, P13817, DOI 10.1021/bi001229u; He XY, 2006, INT J CANCER, V118, P2665, DOI 10.1002/ijc.21665; He XY, 2004, DRUG METAB DISPOS, V32, P1516, DOI 10.1124/dmd.104.001370; He XY, 2004, ARCH BIOCHEM BIOPHYS, V427, P143, DOI 10.1016/j.abb.2004.03.016; IWASAKI M, 1995, BIOCHEMISTRY-US, V34, P5054, DOI 10.1021/bi00015a016; IWASAKI M, 1993, BIOCHEM J, V291, P569, DOI 10.1042/bj2910569; Jalas JR, 2003, DRUG METAB DISPOS, V31, P1199, DOI 10.1124/dmd.31.10.1199; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LINDBERG RLP, 1992, PHARMACOGENETICS, V2, P32, DOI 10.1097/00008571-199202000-00006; Mace K, 1998, EUR J CANCER, V34, P914, DOI 10.1016/S0959-8049(98)00034-3; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Patten CJ, 1996, ARCH BIOCHEM BIOPHYS, V333, P127, DOI 10.1006/abbi.1996.0373; Pelkonen P, 1997, CHEM RES TOXICOL, V10, P85, DOI 10.1021/tx960078m; Rarey M, 1997, J COMPUT AID MOL DES, V11, P369, DOI 10.1023/A:1007913026166; Raunio H, 1998, Arch Toxicol Suppl, V20, P465; Scott EE, 2001, ARCH BIOCHEM BIOPHYS, V395, P57, DOI 10.1006/abbi.2001.2574; Su T, 2000, CANCER RES, V60, P5074; TURNER JM, 1961, BIOCHEM J, V78, P790, DOI 10.1042/bj0780790; Uno T, 1997, BIOCHEMISTRY-US, V36, P3193, DOI 10.1021/bi962654j; Wang HJ, 2003, CANCER RES, V63, P8057; Wang SL, 2006, TOXICOL SCI, V94, P38, DOI 10.1093/toxsci/kfl081; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Wester MR, 2002, METHOD ENZYMOL, V357, P73; Yano JK, 2005, NAT STRUCT MOL BIOL, V12, P822, DOI 10.1038/nsmb971; Zhang XL, 2002, J PHARMACOL EXP THER, V302, P416, DOI 10.1124/jpet.302.2.416; Zhu LR, 2006, DRUG METAB DISPOS, V34, P1672, DOI 10.1124/dmd.106.011049	35	81	86	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17306	17313		10.1074/jbc.M702361200	http://dx.doi.org/10.1074/jbc.M702361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428784	hybrid			2022-12-27	WOS:000246946500064
J	Koo, BH; Longpre, JM; Somerville, RPT; Alexander, JP; Leduc, R; Apte, SS				Koo, Bon-Hun; Longpre, Jean-Michel; Somerville, Robert P. T.; Alexander, J. Preston; Leduc, Richard; Apte, Suneel S.			Regulation of ADAMTS9 secretion and enzymatic activity by its propeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING ENZYME; TRANS-GOLGI NETWORK; CYSTEINE SWITCH; GENE FAMILY; CAENORHABDITIS-ELEGANS; PRECURSOR PROTEINS; IN-VIVO; METALLOPROTEASE; ACTIVATION; MATRIX	ADAMTS9 is a secreted, cell-surface-binding metalloprotease that cleaves the proteoglycans versican and aggrecan. Unlike most precursor proteins, the ADAMTS9 zymogen (proADAMTS9) is resistant to intracellular processing. Instead, proADAMTS9 is processed by furin at the cell surface. Here, we investigated the role of the ADAMTS9 propeptide in regulating its secretion and proteolytic activity. Removal of the propeptide abrogated secretion of the ADAMTS9 catalytic domain, and secretion was inefficiently restored by expression of the propeptide in trans. Substitution of Ala for Asn residues within each of three consensus N-linked glycosylation sites in the propeptide abrogated ADAMTS9 secretion. Thus, the propeptide is an intramolecular chaperone whose glycosylation is critical for secretion of the mature enzyme. In addition to two previously identified furin-processing sites (Arg(74)down arrow and Arg(287)down arrow) the ADAMTS9 propeptide was also furin-processed at Arg209. Substitution of Ala for Arg(74), Arg(209), and Arg(287) resulted in secretion of an unprocessed zymogen. Unexpectedly, versican incubated with cells expressing this pro-ADAMTS9 was processed to a greater extent than when incubated with cells expressing wild-type, furin-processable ADAMTS9. Moreover, cells and medium treated with the proprotein convertase inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone had greater versicancleaving activity than untreated cells. Following furin processing of pro-ADAMTS9, propeptide fragments maintained a non-covalent association with the catalytic domain. Collectively, these observations suggest that, unlike other metalloproteases, furin processing of the ADAMTS9 propeptide reduces its catalytic activity. Thus, the propeptide is a key functional domain of ADAMTS9, mediating an unusual regulatory mechanism that may have evolved to ensure maximal activity of this protease at the cell surface.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Orthopaed Res Ctr, Cleveland, OH 44195 USA; Triple Point Biol, Forest Grove, OR 97116 USA; Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Sherbrooke	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.	aptes@ccf.org		Apte, Suneel/0000-0001-8441-1226	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR049930, R01AR049930] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR49930] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; Cao J, 2005, J BIOL CHEM, V280, P10974, DOI 10.1074/jbc.M412370200; Cao J, 2000, J BIOL CHEM, V275, P29648, DOI 10.1074/jbc.M001920200; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Dagoneau N, 2004, AM J HUM GENET, V75, P801, DOI 10.1086/425231; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; Gauster M, 2005, J LIPID RES, V46, P977, DOI 10.1194/jlr.M400500-JLR200; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Gonzales PE, 2004, J BIOL CHEM, V279, P31638, DOI 10.1074/jbc.M401311200; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Jungers KA, 2005, GENE EXPR PATTERNS, V5, P609, DOI 10.1016/j.modgep.2005.03.004; Koo BH, 2006, J BIOL CHEM, V281, P12485, DOI 10.1074/jbc.M511083200; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Lazure C, 2002, CURR PHARM DESIGN, V8, P511, DOI 10.2174/1381612023395691; Lee NV, 2005, J BIOL CHEM, V280, P34796, DOI 10.1074/jbc.M506980200; Leonard JD, 2005, BIOCHEM J, V387, P797, DOI 10.1042/BJ20041727; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Liu YJ, 2006, ONCOGENE, V25, P2452, DOI 10.1038/sj.onc.1209287; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Longpre JM, 2004, J BIOL CHEM, V279, P33237, DOI 10.1074/jbc.M313151200; Majerus EM, 2003, J BIOL CHEM, V278, P46643, DOI 10.1074/jbc.M309872200; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Rao C, 2003, DEVELOPMENT, V130, P4665, DOI 10.1242/dev.00668; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Somerville RPT, 2004, J BIOL CHEM, V279, P51208, DOI 10.1074/jbc.M409036200; Somerville RPT, 2004, J BIOL CHEM, V279, P35159, DOI 10.1074/jbc.M402380200; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417; Torres-Collado AX, 2006, J BIOL CHEM, V281, P17827, DOI 10.1074/jbc.M513465200; Tortorella MD, 2005, ARCH BIOCHEM BIOPHYS, V444, P34, DOI 10.1016/j.abb.2005.09.018; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; Wewer UM, 2006, J BIOL CHEM, V281, P9418, DOI 10.1074/jbc.M513580200; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	42	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16146	16154		10.1074/jbc.M610161200	http://dx.doi.org/10.1074/jbc.M610161200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403680	hybrid			2022-12-27	WOS:000246794300023
J	Mendillo, ML; Putnam, CD; Kolodner, RD				Mendillo, Marc L.; Putnam, Christopher D.; Kolodner, Richard D.			Escherichia coli MutS tetramerization domain structure reveals that stable dimers but not tetramers are essential for DNA mismatch repair in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY SOLUTION SCATTERING; SMALL-ANGLE SCATTERING; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; MUTATION AVOIDANCE; PROTEIN-STRUCTURE; MALTOSE-BINDING; ATP HYDROLYSIS; PROGRAM; COMPLEX	The Escherichia coli mispair-binding protein MutS forms dimers and tetramers in vitro, although the functional form in vivo is under debate. Here we demonstrate that the MutS tetramer is extended in solution using small angle x-ray scattering and the crystal structure of the C-terminal 34 amino acids of MutS containing the tetramer-forming domain fused to maltose-binding protein ( MBP). Wild-type C-terminal MBP fusions formed tetramers and could bind MutS and MutS-MutL-DNA complexes. In contrast, D835R and R840E mutations predicted to disrupt tetrameric interactions only allowed dimerization of MBP. A chromosomal MutS truncation mutation eliminating the dimerization/tetramerization domain eliminated mismatch repair, whereas the tetramer-disrupting MutS D835R and R840E mutations only modestly affected MutS function. These results demonstrate that dimerization but not tetramerization of the MutS C terminus is essential for mismatch repair.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Canc, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	rkolodner@ucsd.edu	Classen, Scott/AAY-8176-2020	Putnam, Christopher/0000-0002-6145-1265; Mendillo, Marc/0000-0001-8128-0128	NCI NIH HHS [CA92584] Funding Source: Medline; NIGMS NIH HHS [R01 GM050006, GM50006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; AU KG, 1992, J BIOL CHEM, V267, P12142; Baitinger C, 2003, J BIOL CHEM, V278, P49505, DOI 10.1074/jbc.M308738200; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Biswas I, 1999, J BIOL CHEM, V274, P23673, DOI 10.1074/jbc.274.33.23673; Bjornson KP, 2003, J BIOL CHEM, V278, P34667, DOI 10.1074/jbc.M305513200; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calmann MA, 2005, J BACTERIOL, V187, P6577, DOI 10.1128/JB.187.18.6577-6579.2005; Calmann MA, 2005, NUCLEIC ACIDS RES, V33, P1193, DOI 10.1093/nar/gki263; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Doniach S, 2001, CHEM REV, V101, P1763, DOI 10.1021/cr990071k; Duan XQ, 2001, J MOL BIOL, V306, P1115, DOI 10.1006/jmbi.2001.4456; Feng G, 1996, J BACTERIOL, V178, P2388, DOI 10.1128/jb.178.8.2388-2396.1996; FENG G, 1995, BIOTECHNIQUES, V19, P956; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Iyer RR, 2006, CHEM REV, V106, P302, DOI 10.1021/cr0404794; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Junop MS, 2003, DNA REPAIR, V2, P387, DOI 10.1016/S1568-7864(02)00245-8; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lamers MH, 2004, J BIOL CHEM, V279, P43879, DOI 10.1074/jbc.M406380200; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; de Saro FJL, 2006, J BIOL CHEM, V281, P14340, DOI 10.1074/jbc.M601264200; Luria SE, 1943, GENETICS, V28, P491; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Manelyte L, 2006, NUCLEIC ACIDS RES, V34, P5270, DOI 10.1093/nar/gkl489; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MILLER J, 1992, SHORT COURSE BACTERI, P81; MOORE PB, 1980, J APPL CRYSTALLOGR, V13, P168, DOI 10.1107/S002188988001179X; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Poteete AR, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-22; Selmane T, 2003, J MOL BIOL, V334, P949, DOI 10.1016/j.jmb.2003.10.010; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; Stanislawska-Sachadyn A, 2003, PROTEIN EXPRES PURIF, V28, P69, DOI 10.1016/S1046-5928(02)00649-6; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Takamatsu S, 1996, NUCLEIC ACIDS RES, V24, P640, DOI 10.1093/nar/24.4.640; Telmer PG, 2003, J BIOL CHEM, V278, P34555, DOI 10.1074/jbc.M301004200; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	54	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16345	16354		10.1074/jbc.M700858200	http://dx.doi.org/10.1074/jbc.M700858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426027	hybrid			2022-12-27	WOS:000246794300042
J	Kim, D; Kim, MA; Cho, IH; Kim, MS; Lee, S; Jo, EK; Choi, SY; Park, K; Kim, JS; Akira, S; Na, HS; Oh, SB; Lee, SJ				Kim, Donghoon; Kim, Myung Ah; Cho, Ik-Hyun; Kim, Mi Sun; Lee, Soojin; Jo, Eun-Kyeong; Choi, Se-Young; Park, Kyungpyo; Kim, Joong Soo; Akira, Shizuo; Na, Heung Sik; Oh, Seog Bae; Lee, Sung Joong			A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTOR-4; ROOT GANGLION NEURONS; NEUROPATHIC PAIN; MECHANICAL ALLODYNIA; TACTILE ALLODYNIA; DORSAL-HORN; WALLERIAN DEGENERATION; ENDOGENOUS LIGAND; GENE-EXPRESSION	The activation of spinal cord glial cells has been implicated in the development of neuropathic pain upon peripheral nerve injury. The molecular mechanisms underlying glial cell activation, however, have not been clearly elucidated. In this study, we found that damaged sensory neurons induce the expression of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and inducible nitric-oxide synthase genes in spinal cord glial cells, which is implicated in the development of neuropathic pain. Studies using primary glial cells isolated from toll-like receptor 2 knock-out mice indicate that damaged sensory neurons activate glial cells via toll-like receptor 2. In addition, behavioral studies using toll-like receptor 2 knock-out mice demonstrate that the expression of toll-like receptor 2 is required for the induction of mechanical allodynia and thermal hyperalgesia due to spinal nerve axotomy. The nerve injury-induced spinal cord microglia and astrocyte activation is reduced in the toll-like receptor 2 knock-out mice. Similarly, the nerve injury-induced pro-inflammatory gene expression in the spinal cord is also reduced in the toll-like receptor 2 knock-out mice. These data demonstrate that toll-like receptor 2 contributes to the nerve injury-induced spinal cord glial cell activation and subsequent pain hypersensitivity.	Seoul Natl Univ, Program Mol & Cellular Neurosci, Dent Res Inst, BK21, Seoul 110749, South Korea; Seoul Natl Univ, Dept Oral Physiol, Sch Dent, Seoul 110749, South Korea; Korea Univ, Coll Med, Dept Physiol, Med Sci Res Ctr, Seoul 136705, South Korea; Chungnam Natl Univ, Dept Microbiol, Taejon 301747, South Korea; Osaka Univ, Dept Host Def, Suita, Osaka 5650871, Japan	Seoul National University (SNU); Seoul National University (SNU); Korea University; Korea University Medicine (KU Medicine); Chungnam National University; Osaka University	Oh, SB (corresponding author), Seoul Natl Univ, Program Mol & Cellular Neurosci, Dent Res Inst, BK21, Seoul 110749, South Korea.	odolbae@snu.ac.kr; sjlee87@snu.ac.kr	Akira, Shizuo/C-3134-2009; OH, Seog Bae/AAQ-2478-2020; Cho, Ik-Hyun/A-9348-2014	Choi, Se-Young/0000-0001-7534-5167; Lee, Soojin/0000-0002-0383-5025; Eun-Kyeong, Jo/0000-0001-7191-0587				Aronica E, 2005, NEUROSCIENCE, V130, P927, DOI 10.1016/j.neuroscience.2004.10.024; Arruda JL, 2000, BRAIN RES, V879, P216, DOI 10.1016/S0006-8993(00)02807-9; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Broom DC, 2004, NEUROSCIENCE, V124, P891, DOI 10.1016/j.neuroscience.2004.01.003; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Coggeshall RE, 2001, J COMP NEUROL, V435, P276, DOI 10.1002/cne.1029; Colburn RW, 1999, EXP NEUROL, V157, P289, DOI 10.1006/exnr.1999.7065; Colburn RW, 1997, J NEUROIMMUNOL, V79, P163, DOI 10.1016/S0165-5728(97)00119-7; Coyle DE, 1998, GLIA, V23, P75; Csillik B, 2003, ANN ANAT, V185, P303, DOI 10.1016/S0940-9602(03)80050-X; DeLeo JA, 1996, J INTERF CYTOK RES, V16, P695, DOI 10.1089/jir.1996.16.695; ECCLESTON PA, 1984, DEV BRAIN RES, V16, P1, DOI 10.1016/0165-3806(84)90056-7; Falchi M, 2001, DRUG EXP CLIN RES, V27, P97; FRANCEL PC, 1987, J NEUROCHEM, V48, P1624, DOI 10.1111/j.1471-4159.1987.tb05711.x; GARRISON CJ, 1991, BRAIN RES, V565, P1, DOI 10.1016/0006-8993(91)91729-K; Guo LH, 2005, J NEUROIMMUNOL, V163, P120, DOI 10.1016/j.jneuroim.2005.03.007; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; Honore P, 2006, BEHAV BRAIN RES, V167, P355, DOI 10.1016/j.bbr.2005.09.024; Jin SX, 2003, J NEUROSCI, V23, P4017; Karanth S, 2006, EXP NEUROL, V202, P161, DOI 10.1016/j.expneurol.2006.05.024; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; KNYIHARCSILLIK E, 1989, CELL TISSUE RES, V258, P515; Ledeboer A, 2005, PAIN, V115, P71, DOI 10.1016/j.pain.2005.02.009; Lee H, 2006, BIOCHEM BIOPH RES CO, V350, P742, DOI 10.1016/j.bbrc.2006.09.108; Levy D, 1998, EUR J NEUROSCI, V10, P1846, DOI 10.1046/j.1460-9568.1998.00186.x; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUBERNAROD J, 1994, J IMMUNOL, V152, P819; Ma WY, 2002, BRAIN RES, V937, P94, DOI 10.1016/S0006-8993(02)02593-3; Milligan ED, 2004, EUR J NEUROSCI, V20, P2294, DOI 10.1111/j.1460-9568.2004.03709.x; Nishino J, 2004, EMBO J, V23, P1998, DOI 10.1038/sj.emboj.7600202; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Polgar E, 2005, J NEUROSCI, V25, P6658, DOI 10.1523/JNEUROSCI.1490-05.2005; Schafers M, 2003, J NEUROSCI, V23, P2517; Schenker M, 2003, EXP NEUROL, V184, P225, DOI 10.1016/S0014-4886(03)00255-3; Scholz J, 2005, J NEUROSCI, V25, P7317, DOI 10.1523/JNEUROSCI.1526-05.2005; Shi TJS, 2001, NEUROSCIENCE, V105, P249, DOI 10.1016/S0306-4522(01)00148-8; Sommer C, 2001, BRAIN RES, V913, P86, DOI 10.1016/S0006-8993(01)02743-3; Sung CS, 2004, BRAIN RES, V1015, P145, DOI 10.1016/j.brainres.2004.04.068; SVENSSON M, 1993, J NEUROSCI RES, V35, P373, DOI 10.1002/jnr.490350404; Tabuchi S, 2000, NEUROCHEM RES, V25, P573, DOI 10.1023/A:1007542532395; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tanga FY, 2005, P NATL ACAD SCI USA, V102, P5856, DOI 10.1073/pnas.0501634102; Tanga FY, 2004, NEUROCHEM INT, V45, P397, DOI 10.1016/j.neuint.2003.06.002; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Wilson ADH, 2003, BRIT J PLAST SURG, V56, P732, DOI 10.1016/j.bjps.2003.08.005; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	59	234	239	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14975	14983		10.1074/jbc.M607277200	http://dx.doi.org/10.1074/jbc.M607277200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17355971	hybrid			2022-12-27	WOS:000246589000036
J	Yatsenko, AS; Gray, EE; Shcherbata, HR; Patterson, LB; Sood, VD; Kucherenko, MM; Baker, D; Ruohola-Baker, H				Yatsenko, Andriy S.; Gray, Elizabeth E.; Shcherbata, Halyna R.; Patterson, Larissa B.; Sood, Vanita D.; Kucherenko, Mariya M.; Baker, David; Ruohola-Baker, Hannele			A putative Src homology 3 domain binding motif but not the C-terminal dystrophin WW domain binding motif is required for dystroglycan function in cellular polarity in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR AGGREGATION; CONGENITAL MUSCULAR-DYSTROPHIES; BETA-DYSTROGLYCAN; INTEGRIN ACTIVATION; TYROSINE PHOSPHORYLATION; NEUROMUSCULAR-JUNCTION; EPITHELIAL-CELLS; SKELETAL-MUSCLE; TALIN; COMPLEX	The conserved dystroglycan-dystrophin (Dg(.)Dys) complex connects the extracellular matrix to the cytoskeleton. In humans as well as Drosophila, perturbation of this complex results in muscular dystrophies and brain malformations and in some cases cellular polarity defects. However, the regulation of the Dg(.)Dys complex is poorly understood in any cell type. We now find that in loss-of-function and overexpression studies more than half (34 residues) of the Dg proline-rich conserved C-terminal regions can be truncated without significantly compromising its function in regulating cellular polarity in Drosophila. Notably, the truncation eliminates the WW domain binding motif at the very C terminus of the protein thought to mediate interactions with dystrophin, suggesting that a second, internal WW binding motif can also mediate this interaction. We confirm this hypothesis by using a sensitive fluorescence polarization assay to show that both WW domain binding sites of Dg bind to Dys in humans (K-d = 7.6 and 81 mu M, respectively) and Drosophila (K-d = 16 and 46 mu M, respectively). In contrast to the large deletion mentioned above, a single proline to an alanine point mutation within a predicted Src homology 3 domain (SH3) binding site abolishes Dg function in cellular polarity. This suggests that an SH3-containing protein, which has yet to be identified, functionally interacts with Dg.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Ivan Franko Natl Univ, UA-79005 Lvov, Ukraine	University of Washington; University of Washington Seattle; Ministry of Education & Science of Ukraine; Ivan Franko National University Lviv	Ruohola-Baker, H (corresponding author), Univ Washington, Dept Biochem, HSB-591,Box 357350, Seattle, WA 98195 USA.	hannele@u.washington.edu	Baker, David/K-8941-2012; Shcherbata, Halyna/J-5712-2017; Yatsenko, Andriy/D-1895-2018	Baker, David/0000-0001-7896-6217; Shcherbata, Halyna/0000-0002-3855-0345; Kucherenko, Mariya/0000-0002-8637-2037; Sood, Vanita/0000-0001-6714-3725; Yatsenko, Andriy/0000-0001-8730-5744				Barresi R, 2006, J CELL SCI, V119, P199, DOI 10.1242/jcs.02814; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Calderwood DA, 2004, BIOCHEM SOC T, V32, P434, DOI 10.1042/BST0320434; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Cohn RD, 2005, NEUROMUSCULAR DISORD, V15, P207, DOI 10.1016/j.nmd.2004.11.005; Cohn RD, 2002, CELL, V110, P639, DOI 10.1016/S0092-8674(02)00907-8; Davies KE, 2006, NAT REV MOL CELL BIO, V7, P762, DOI 10.1038/nrm2024; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Heathcote RD, 2000, DEV BIOL, V227, P595, DOI 10.1006/dbio.2000.9906; Henry MD, 2001, HUM PATHOL, V32, P791, DOI 10.1053/hupa.2001.26468; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Ilsley JL, 2002, CELL SIGNAL, V14, P183, DOI 10.1016/S0898-6568(01)00236-4; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kahl J, 2003, J NEUROSCI, V23, P392, DOI 10.1523/JNEUROSCI.23-02-00392.2003; Kato Y, 2002, J BIOL CHEM, V277, P10173, DOI 10.1074/jbc.M110490200; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; Lapidos KA, 2004, CIRC RES, V94, P1023, DOI 10.1161/01.RES.0000126574.61061.25; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Liu SC, 2000, J CELL SCI, V113, P3563; Martens P, 2003, GLOBAL ENVIRON CHANG, V13, P75, DOI 10.1016/S0959-3780(02)00089-4; Martin PT, 2003, J NEUROCYTOL, V32, P915, DOI 10.1023/B:NEUR.0000020632.41508.83; Martin-Rendon E, 2003, TRENDS PHARMACOL SCI, V24, P178, DOI 10.1016/S0165-6147(03)00050-6; Moore SA, 2002, NATURE, V418, P422, DOI 10.1038/nature00838; Muntoni F, 2004, CURR OPIN NEUROL, V17, P205, DOI 10.1097/00019052-200404000-00020; Muschler J, 2002, CANCER RES, V62, P7102; Pignoni F, 1997, DEVELOPMENT, V124, P271; Poulton JS, 2006, P NATL ACAD SCI USA, V103, P12775, DOI 10.1073/pnas.0603817103; Rentschler S, 1999, BIOL CHEM, V380, P431, DOI 10.1515/BC.1999.057; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Schneider M, 2006, DEVELOPMENT, V133, P3805, DOI 10.1242/dev.02549; Sgambato A, 2005, J CELL PHYSIOL, V205, P163, DOI 10.1002/jcp.20411; Shcherbata HR, 2007, EMBO J, V26, P481, DOI 10.1038/sj.emboj.7601503; Sotgia F, 2001, BIOCHEMISTRY-US, V40, P14585, DOI 10.1021/bi011247r; Spence HJ, 2004, EMBO REP, V5, P484, DOI 10.1038/sj.embor.7400140; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; TAPLEY P, 1989, ONCOGENE, V4, P325; Tracey WD, 2000, GENETICS, V154, P273; Tremblay MR, 2006, J BIOL CHEM, V281, P13365, DOI 10.1074/jbc.M600912200; van der Plas MC, 2006, J NEUROSCI, V26, P333, DOI 10.1523/JNEUROSCI.4069-05.2006; Van Doren M, 1998, CURR BIOL, V8, P243; Weir ML, 2006, J CELL SCI, V119, P4047, DOI 10.1242/jcs.03103; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Zhou YW, 2006, BIOCHEMISTRY-US, V45, P2042, DOI 10.1021/bi0519957	49	17	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15159	15169		10.1074/jbc.M608800200	http://dx.doi.org/10.1074/jbc.M608800200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17355978	hybrid, Green Published			2022-12-27	WOS:000246589000055
J	Ji, ZY; Mei, FC; Xie, JW; Cheng, XD				Ji, Zhenyu; Mei, Fang C.; Xie, Jingwu; Cheng, Xiaodong			Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA RECEPTOR; K-RAS MUTATIONS; DUCTAL ADENOCARCINOMA; EPITHELIAL-CELLS; GENE-MUTATIONS; GLI PROTEINS; IN-VITRO; GROWTH; INHIBITION; EXPRESSION	Hedgehog (Hh) signaling is deregulated in multiple human cancers including pancreatic ductal adenocarcinoma (PDA). Because KRAS mutation represents one of the earliest genetic alterations and occurs almost universally in PDA, we hypothesized that oncogenic KRAS promotes pancreatic tumorigenesis in part through activation of the Hh pathway. Here, we report that oncogenic KRAS activates hedgehog signaling in PDA cells, utilizing a downstream effector pathway mediated by RAF/MEK/MAPK but not phosphatidylinositol 3-kinase (PI3K)/AKT. Oncogenic KRAS transformation of human pancreatic ductal epithelial cells increases GLI transcriptional activity, an effect that is inhibited by the MEK-specific inhibitors U0126 and PD98059, but not by the PI3K-specific inhibitor wortmannin. Inactivation of KRAS activity by a small interfering RNA specific for oncogenic KRAS inhibits GLI activity and GLI1 expression in PDA cell lines with activating KRAS mutation; the MEK inhibitors U0126 and PD98059 elicit a similar response. In addition, expression of the constitutively active form of BRAFE600, but not myr-AKT, blocks the inhibitory effects of KRAS knockdown on Hh signaling. Finally, suppressing GLI activity leads to a selective attenuation of the oncogenic transformation activity of mutant KRAS-expressing PDA cells. These results demonstrate that oncogenic KRAS, through RAF/MEK/MAPK signaling, is directly involved in the activation of the hedgehog pathway in PDA cells and that collaboration between these two signaling pathways may play an important role in PDA progression.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol,Sch Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol,Sch Med, 301 Univ Blvd, Galveston, TX 77555 USA.	xcheng@utmb.edu	Cheng, Xiaodong/O-8176-2019	Cheng, Xiaodong/0000-0002-3479-1694	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM066170] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; BOS JL, 1989, CANCER RES, V49, P4682; Brunner TB, 2005, CANCER RES, V65, P8433, DOI 10.1158/0008-5472.CAN-05-0158; CALDAS C, 1994, CANCER RES, V54, P3568; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; FRIESS H, 1993, CANCER RES, V53, P2704; Furukawa T, 1996, AM J PATHOL, V148, P1763; Goggins M, 1998, CANCER RES, V58, P5329; Goggins M, 1996, CANCER RES, V56, P5360; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jansen B, 1999, P NATL ACAD SCI USA, V96, P14019, DOI 10.1073/pnas.96.24.14019; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kayed H, 2004, INT J CANCER, V110, P668, DOI 10.1002/ijc.20194; Klein WM, 2002, MODERN PATHOL, V15, P441, DOI 10.1038/modpathol.3880544; KLIMSTRA DS, 1994, AM J PATHOL, V145, P1547; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Luttges J, 1999, CANCER-AM CANCER SOC, V85, P1703; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Mei FC, 2005, FASEB J, V19, P497, DOI 10.1096/fj.05-4586fje; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Moskaluk CA, 1997, CANCER RES, V57, P2140; Nieuwenhuis E, 2005, CLIN GENET, V67, P193, DOI 10.1111/j.1399-0004.2004.00360.x; Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Sahin F, 2003, MODERN PATHOL, V16, P686, DOI 10.1097/01.MP.0000075645.97329.86; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Yamano M, 2000, AM J PATHOL, V156, P2123, DOI 10.1016/S0002-9440(10)65083-3; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222	47	230	243	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14048	14055		10.1074/jbc.M611089200	http://dx.doi.org/10.1074/jbc.M611089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17353198	hybrid			2022-12-27	WOS:000246245800014
J	Sasaki, M; Nie, LH; Maki, CG				Sasaki, Mark; Nie, Linghu; Maki, Carl G.			MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; CELL-CYCLE ARREST; MUTANT P53; IN-VIVO; MONOCLONAL-ANTIBODY; CANCER-THERAPY; UBIQUITINATION; STABILIZATION; MUTATIONS	p53 protein conformation is an important determinant of its localization and activity. Changes in p53 conformation can be monitored by reactivity with wild-type conformation-specific (pAb-1620) or mutant conformation-specific (pAb-240) p53 antibodies. Wild-type p53 accumulated in a mutant (pAb-240 reactive) form when its proteasome-dependent degradation was blocked during recovery from stress treatment and in cells co-expressing p53 and MDM2. This suggests that conformational change precedes wild-type p53 degradation by the proteasome. MDM2 binding to the p53 N terminus could induce a conformational change in wild-type p53. Interestingly, this conformational change was opposed by heat-shock protein 90 and did not require the MDM2 RING-finger domain and p53 ubiquitination. Finally, ubiquitinated p53 accumulated in a pAb-240 reactive form when p53 degradation was blocked by proteasome inhibition, and a p53-ubiquitin fusion protein displayed a mutant-only conformation in MDM2-null cells. These results support a model in which MDM2 binding induces a conformational change that is opposed by heat-shock protein 90 and precedes p53 ubiquitination. The covalent attachment of ubiquitin may "lock" p53 in a mutant conformation in the absence of MDM2-binding and prior to its degradation by the proteasome.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave,MC1105,Rm G06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu			NCI NIH HHS [R01 CA080918] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beliakoff J, 2004, ANTI-CANCER DRUG, V15, P651, DOI 10.1097/01.cad.0000136876.11928.be; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Geyer RK, 2000, CELL GROWTH DIFFER, V11, P149; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Joseph TW, 2003, FASEB J, V17, P1622, DOI 10.1096/fj.02-0931com; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kuo PL, 2005, CANCER LETT, V223, P293, DOI 10.1016/j.canlet.2004.09.046; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Maki CG, 1996, CANCER RES, V56, P2649; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller P, 2005, J BIOL CHEM, V280, P6682, DOI 10.1074/jbc.M412767200; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Shimizu H, 2006, BIOCHEM J, V397, P355, DOI 10.1042/BJ20051521; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103	35	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14626	14634		10.1074/jbc.M610514200	http://dx.doi.org/10.1074/jbc.M610514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17363365	hybrid			2022-12-27	WOS:000246245800076
J	Endo, M; Ohashi, K; Mizuno, K				Endo, Mitsuharu; Ohashi, Kazumasa; Mizuno, Kensaku			LIM kinase and slingshot are critical for neurite extension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN DEPOLYMERIZING FACTOR; GROWTH CONE MOTILITY; COFILIN PHOSPHORYLATION; NEURONAL DIFFERENTIATION; CYTOSKELETAL DYNAMICS; REGULATES COFILIN; PROTEIN-KINASE; PHOSPHATASE; FAMILY; CELLS	Cofilin and its closely related protein, actin-depolymerizing factor (ADF), are key regulators of actin cytoskeleton dynamics that have been implicated in growth cone motility and neurite extension. Cofilin/ADF are inactivated by LIM kinase (LIMK)catalyzed phosphorylation and reactivated by Slingshot (SSH)catalyzed dephosphorylation. Here we examined the roles of cofilin/ADF, LIMKs (LIMK1 and LIMK2), and SSHs (SSH1 and SSH2) in nerve growth factor (NGF)-induced neurite extension. Knockdown of cofilin/ADF by RNA interference almost completely inhibited NGF-induced neurite extension from PC12 cells, and double knockdown of SSH1/SSH2 significantly suppressed both NGF-induced cofilin/ADF dephosphorylation and neurite extension from PC12 cells, thus indicating that cofilin/ADF and their activating phosphatases SSH1/SSH2 are critical for neurite extension. Interestingly, NGF stimulated the activities of both LIMK1 and LIMK2 in PC12 cells, and suppression of LIMK1/LIMK2 expression or activity significantly reduced NGF-induced neurite extension from PC12 cells or chick dorsal root ganglion (DRG) neurons. Inhibition of LIMK1/LIMK2 activity reduced actin filament assembly in the peripheral region of the growth cone of chick DRG neurons. These results suggest that proper regulation of cofilin/ADF activities through control of phosphorylation by LIMKs and SSHs is critical for neurite extension and that LIMKs regulate actin filament assembly at the tip of the growth cone.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan	Tohoku University	Mizuno, K (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan.	kmizuno@biology.tohoku.ac.jp	Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; Birkenfeld J, 2001, J NEUROCHEM, V78, P924, DOI 10.1046/j.1471-4159.2001.00500.x; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Endo M, 2003, J NEUROSCI, V23, P2527; Gehler S, 2004, J NEUROSCI, V24, P10741, DOI 10.1523/JNEUROSCI.2836-04.2004; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Higuchi O, 1997, ONCOGENE, V14, P1819, DOI 10.1038/sj.onc.1201020; Hsieh SHK, 2006, J NEUROSCI, V26, P1006, DOI 10.1523/JNEUROSCI.2806-05.2006; Kaji N, 2003, J BIOL CHEM, V278, P33450, DOI 10.1074/jbc.M305802200; Lee-Hoeflich ST, 2004, EMBO J, V23, P4792, DOI 10.1038/sj.emboj.7600418; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Meberg PJ, 2000, J NEUROSCI, V20, P2459; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Nagata-Ohashi K, 2004, J CELL BIOL, V165, P465, DOI 10.1083/jcb.200401136; Nishita M, 2005, J CELL BIOL, V171, P349, DOI 10.1083/jcb.200504029; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Ohta Y, 2003, GENES CELLS, V8, P811, DOI 10.1046/j.1365-2443.2003.00678.x; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Rosenblatt J, 1998, NATURE, V393, P739, DOI 10.1038/31597; Rosso S, 2004, MOL BIOL CELL, V15, P3433, DOI 10.1091/mbc.E03-05-0328; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Tursun B, 2005, GENE DEV, V19, P2307, DOI 10.1101/gad.1340605; Wang Y, 2005, J BIOL CHEM, V280, P12683, DOI 10.1074/jbc.M411494200; Yang EJ, 2004, J BIOL CHEM, V279, P8903, DOI 10.1074/jbc.M311913200; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	36	101	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13692	13702		10.1074/jbc.M610873200	http://dx.doi.org/10.1074/jbc.M610873200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360713	hybrid			2022-12-27	WOS:000246060300059
J	Lee, JH; Tate, CM; You, JS; Skalnik, DG				Lee, Jeong-Heon; Tate, Courtney M.; You, Jin-Sam; Skalnik, David G.			Identification and characterization of the human Set1B histone H3-Lys(4) methyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; H3 LYSINE-4; DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; ALL-1 GENE; MLL GENE; METHYLATION; COMPASS	We previously identified a mammalian Set1A complex analogous to the yeast Set1/COMPASS histone H3-Lys4 methyltransferase complex ( Lee, J.- H., and Skalnik, D. G. (2005) J. Biol. Chem. 280, 41725-41731). Data base analysis indicates that human Set1A protein shares 39% identity with an uncharacterized SET domain protein, KIAA1076, hereafter denoted Set1B. Immunoprecipitation and mass spectrometry reveal that Set1B associates with a similar to 450 kDa complex that contains all five noncatalytic components of the Set1A complex, including CFP1, Rbbp5, Ash2, Wdr5, and Wdr82. These data reveal two human protein complexes that differ only in the identity of the catalytic histone methyltransferase. In vitro assays demonstrate that the Set1B complex is a histone methyltransferase that produces trimethylated histone H3 at Lys(4). Both Set1A and Set1B are widely expressed. Inducible expression of the carboxyl terminus of either Set1A or Set1B decreases steady-state levels of both endogenous Set1A and Set1B protein, but does not alter the expression of the non-catalytic components of the Set1 complexes. A 123-amino acid fragment upstream of the Set1A SET domain is necessary for interaction with CFP1, Ash2, Rbbp5, and Wdr5. This protein domain is also required to mediate feedback inhibition of Set1A and Set1B expression, which is a consequence of reduced Set1A and Set1B stability when not associated with the methyltransferase complex. Confocal microscopy reveals that Set1A and Set1B each localize to a largely non-overlapping set of euchromatic nuclear speckles, suggesting that Set1A and Set1B each bind to a unique set of target genes and thus make non-redundant contributions to the epigenetic control of chromatin structure and gene expression.	Indiana Univ, Sch Med, Wells Ctr Pediat Res, Sect Pediat Hematol Oncol,Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Ctr Appl Prot Sci, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Skalnik, DG (corresponding author), Canc Res Bldg,Rm 327,1044 W Walnut St, Indianapolis, IN 46202 USA.	dskalnik@iupui.edu			NIAID NIH HHS [T32 AI060519] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayton P, 2001, GENESIS, V30, P201, DOI 10.1002/gene.1066; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Glaser S, 2006, DEVELOPMENT, V133, P1423, DOI 10.1242/dev.02302; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Han ZF, 2006, MOL CELL, V22, P137, DOI 10.1016/j.molcel.2006.03.018; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lee JH, 2005, J BIOL CHEM, V280, P41725, DOI 10.1074/jbc.M508312200; Lee JH, 2004, GENESIS, V38, P32, DOI 10.1002/gene.10250; Lee JH, 2002, J BIOL CHEM, V277, P42259, DOI 10.1074/jbc.M205054200; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	34	174	187	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13419	13428		10.1074/jbc.M609809200	http://dx.doi.org/10.1074/jbc.M609809200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355966	hybrid			2022-12-27	WOS:000246060300031
J	Sato, O; Li, XD; Ikebe, M				Sato, Osamu; Li, Xiang-dong; Ikebe, Mitsuo			Myosin Va becomes a low duty ratio motor in the inhibited form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-MEROMYOSIN; TAIL DOMAIN; UNCONVENTIONAL MYOSIN; MELANOSOME TRANSPORT; FLUORESCENT-PROBE; ATPASE ACTIVITY; ACTIN-BINDING; SMOOTH-MUSCLE; PROCESSIVITY; ACTOMYOSIN	Vertebrate myosin Va is a typical processive motor with high duty ratio. Recent studies have revealed that the actin-activated ATPase activity of the full-length myosin Va (M5aFull) is inhibited at a low [Ca2+], which is due to the formation of a folded conformation of M5aFull. To clarify the underlying inhibitory mechanism, we analyzed the actin-activated ATP hydrolysis mechanism of the M5aFull at the inhibited and the activated states, respectively. Marked differences were found in the hydrolysis, Pi release, and ADP release steps between the activated and the inhibited states. The kinetic constants of these steps of the activated state were similar to those of the unregulated S1 construct, in which the rate-limiting step was the ADP release step. On the other hand, the P-i release rate from acto-M5aFull was decreased in EGTA by > 1,000-fold, which makes this step the rate-limiting step for the actin-activated ATP hydrolysis cycle of M5aFull. The ADP off rate from acto-M5aFull was decreased by similar to 10-fold, and the equilibrium between the prehydrolysis state and the post hydrolysis state was shifted toward the former state in the inhibited state of M5aFull. Because of these changes, M5aFull spends a majority of the ATP hydrolysis cycling time in the weak actin binding state. The present results indicate that M5aFull molecules at a low [Ca2+] is inhibited as a cargo transporter not only due to the decrease in the cross-bridge cycling rate but also due to the decrease in the duty ratio thus being dissociated from actin.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Mitsuo.ikebe@umassmed.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR048526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006103] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41653, AR048526] Funding Source: Medline; NIDCD NIH HHS [DC006103] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Evans LL, 1997, J CELL SCI, V110, P439; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Hannemann DE, 2005, BIOCHEMISTRY-US, V44, P8826, DOI 10.1021/bi0473509; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Homma K, 2005, J BIOL CHEM, V280, P29381, DOI 10.1074/jbc.M504779200; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langford GM, 2002, TRAFFIC, V3, P859, DOI 10.1034/j.1600-0854.2002.31202.x; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Li XD, 2005, J BIOL CHEM, V280, P17815, DOI 10.1074/jbc.M413295200; Li XD, 2004, BIOCHEM BIOPH RES CO, V315, P538, DOI 10.1016/j.bbrc.2004.01.084; Li XD, 2006, J BIOL CHEM, V281, P21789, DOI 10.1074/jbc.M602957200; Liu J, 2006, NATURE, V442, P208, DOI 10.1038/nature04719; Lu HL, 2006, J BIOL CHEM, V281, P31987, DOI 10.1074/jbc.M605181200; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Olivares AO, 2006, J BIOL CHEM, V281, P31326, DOI 10.1074/jbc.M603898200; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; Provance DW, 1996, P NATL ACAD SCI USA, V93, P14554, DOI 10.1073/pnas.93.25.14554; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rodriguez OC, 2002, J CELL SCI, V115, P991; Rogers SL, 1999, J CELL BIOL, V146, P1265, DOI 10.1083/jcb.146.6.1265; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Sato O, 2004, J BIOL CHEM, V279, P28844, DOI 10.1074/jbc.M314332200; Sellers J. R., 1999, MYOSINS; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Thirumurugan K, 2006, NATURE, V442, P212, DOI 10.1038/nature04865; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; Vale RD, 2003, J CELL BIOL, V163, P445, DOI 10.1083/jcb.200308093; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Wang F, 2004, J BIOL CHEM, V279, P2333, DOI 10.1074/jbc.C300488200; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Wu XF, 1997, J CELL SCI, V110, P847; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v	52	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13228	13239		10.1074/jbc.M610766200	http://dx.doi.org/10.1074/jbc.M610766200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17363376	hybrid			2022-12-27	WOS:000246060300011
J	Ahmed, AH; Loh, AP; Jane, DE; Oswald, RE				Ahmed, H. Ahmed; Loh, Adrienne P.; Jane, David E.; Oswald, Robert E.			Dynamics of the S1S2 glutamate binding domain of GluR2 measured using F-19 NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PARTIAL AGONIST ACTION; GATED ION CHANNELS; AMPA RECEPTORS; CONFORMATIONAL-CHANGES; CHEMICAL EXCHANGE; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; MECHANISM; CORE	Ionotropic glutamate receptors mediate the majority of vertebrate excitatory synaptic transmission. Although the structure of the GluR2 binding domain (S1S2) is well known (agonist binding site between two lobes), little is known about the time scales of conformational transitions or the relationship between dynamics and function. (FNMR)-F-19 (F-19-labeled tryptophan) spectroscopy was used to monitor motions in the S1S2 domain bound to ligands with varying efficacy and in the apo state. One tryptophan (Trp-671) undergoes chemical exchange in some but not all agonists, consistent with mu s-ms motion. The dynamics can be correlated to ligand affinity, and a likely source of the motion is a peptide bond capable of transiently forming hydrogen bonds across the lobe interface. Another tryptophan (Trp767) appears to monitor motions of the relative positions of the lobes and suggests that the relative orientation in the apo- and antagonist-bound forms can exchange between at least two conformations on the ms time scale.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Univ Wisconsin, Dept Chem, La Crosse, WI 54601 USA; Univ Bristol, Sch Med Sci, Ctr Synapt Plast, Dept Pharmacol, Bristol BS8 1TD, Avon, England	Cornell University; University of Wisconsin System; University of Bristol	Oswald, RE (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	reo1@cornell.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068935] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM068935] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Armstrong N, 2006, CELL, V127, P85, DOI 10.1016/j.cell.2006.08.037; Arvola M, 1996, J BIOL CHEM, V271, P15527, DOI 10.1074/jbc.271.26.15527; Asztely F, 1996, MOL NEUROBIOL, V12, P1, DOI 10.1007/BF02740744; Auerbach A, 2005, P NATL ACAD SCI USA, V102, P1408, DOI 10.1073/pnas.0406787102; CARVER JP, 1972, J MAGN RESON, V6, P89, DOI 10.1016/0022-2364(72)90090-X; DAVIS DG, 1994, J MAGN RESON SER B, V104, P266, DOI 10.1006/jmrb.1994.1084; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W.L, PYMOL MOL GRAPHICS S; Dingledine R, 1999, PHARMACOL REV, V51, P7; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holm MM, 2005, P NATL ACAD SCI USA, V102, P12053, DOI 10.1073/pnas.0505522102; Inanobe A, 2005, NEURON, V47, P71, DOI 10.1016/j.neuron.2005.05.022; Jane DE, 1997, J MED CHEM, V40, P3645, DOI 10.1021/jm9702387; JEN J, 1978, J MAGN RESON, V30, P111, DOI 10.1016/0022-2364(78)90229-9; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Jin RS, 2005, J NEUROSCI, V25, P9027, DOI 10.1523/JNEUROSCI.2567-05.2005; Jin RS, 2003, BIOCHEMISTRY-US, V42, P5201, DOI 10.1021/bi020632t; Jin RS, 2002, BIOCHEMISTRY-US, V41, P15635, DOI 10.1021/bi020583k; Kasper C, 2006, J MOL BIOL, V357, P1184, DOI 10.1016/j.jmb.2006.01.024; Lawrence JJ, 2003, MOL PHARMACOL, V64, P269, DOI 10.1124/mol.64.2.269; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; LUZ Z, 1963, J CHEM PHYS, V39, P366, DOI 10.1063/1.1734254; Madden DR, 2000, EUR J BIOCHEM, V267, P4281; Mayer ML, 2006, NATURE, V440, P456, DOI 10.1038/nature04709; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; Oswald RE, 2004, ADV PROTEIN CHEM, V68, P313; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; Ramanoudjame G, 2006, P NATL ACAD SCI USA, V103, P10473, DOI 10.1073/pnas.0603225103; REEVES LW, 1971, CAN J CHEMISTRY, V49, P3683, DOI 10.1139/v71-615; Robert A, 2005, J NEUROSCI, V25, P3752, DOI 10.1523/JNEUROSCI.0188-05.2005; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Rzeski W, 2001, P NATL ACAD SCI USA, V98, P6372, DOI 10.1073/pnas.091113598; Salopek-Sondi B, 2002, PROTEIN ENG, V15, P855, DOI 10.1093/protein/15.11.855; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Sutcliffe MJ, 1998, METHOD ENZYMOL, V293, P589; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Valentine ER, 2005, BIOCHEMISTRY-US, V44, P3410, DOI 10.1021/bi047984f; Weston MC, 2006, J NEUROSCI, V26, P7650, DOI 10.1523/JNEUROSCI.1519-06.2006; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; Zemsky J, 1999, PROTEINS, V37, P709	50	42	43	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12773	12784		10.1074/jbc.M610077200	http://dx.doi.org/10.1074/jbc.M610077200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337449	hybrid			2022-12-27	WOS:000245942800048
J	Brinsmade, SR; Escalante-Semerena, JC				Brinsmade, Shaun R.; Escalante-Semerena, Jorge C.			In vivo and in vitro analyses of single-mino acid variants of the Salmonella enterica phosphotransacetylase enzyme provide insights into the function of its N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COENZYME-A; RIBOSOMAL-PROTEIN MODIFICATION; ESCHERICHIA-COLI-B; SEROVAR TYPHIMURIUM; METHANOSARCINA-THERMOPHILA; DETHIOBIOTIN SYNTHETASE; LARGE-INTESTINE; MUTANT LACKING; GLOBAL SIGNAL; ACETATE	The function of the N-terminal domain ( similar to 350 residues) of the Pta ( phosphotransacetylase) enzyme of Salmonella enterica is unclear. Results from in vivo genetic and in vitro studies suggest that the N-terminal domain of Pta is a sensor for NADH and pyruvate. We isolated 10 single-amino acid variants of Pta that, unlike the wild-type protein, supported growth of a strain of S. enterica devoid of Acs ( acetyl-CoA synthetase; AMP-forming) activity on 10 mM acetate. All mutations were mapped within the N-terminal domain of the protein. Kinetic analyses of the wild type and three variant Pta proteins showed that two of the variant proteins were faster enzymes ( k(cat) 2.5-3-fold > k(cat) Pta(WT). Results from sedimentation equilibrium experiments are consistent with Pta(WT) being a trimer. Pta variants formed more hexamer than the Pta(WT) protein. NADH inhibited Pta(WT) activity by inducing a conformational change detectable by limited trypsin proteolysis; NADH did not inhibit variant protein Pta(R252H). Pyruvate stimulated Pta(WT) activity, and its effect was potentiated in the variants, being most pronounced on Pta(R252H).	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.	escalante@bact.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062203] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM62203, R01 GM062203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATLAS R, 1995, HDB MEDIA ENV MICROB, P5; Atteia A, 2006, J BIOL CHEM, V281, P9909, DOI 10.1074/jbc.M507862200; Bender CL, 1999, MICROBIOL MOL BIOL R, V63, P266, DOI 10.1128/MMBR.63.2.266-292.1999; BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; Bertani G, 2004, J BACTERIOL, V186, P595, DOI 10.1128/JB.186.3.595-600.2004; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinsmade SR, 2005, J BACTERIOL, V187, P8039, DOI 10.1128/JB.187.23.8039-8046.2005; Brinsmade SR, 2004, J BACTERIOL, V186, P1890, DOI 10.1128/JB.186.6.1890-1892.2004; BROWN TDK, 1977, J GEN MICROBIOL, V102, P327, DOI 10.1099/00221287-102-2-327; Canovas M, 2003, BIOTECHNOL BIOENG, V84, P686, DOI 10.1002/bit.10822; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; Chang DE, 1999, J BACTERIOL, V181, P6656, DOI 10.1128/JB.181.21.6656-6663.1999; CLARK DP, 1996, CELLULAR MOL BIOL, P343; CUMBERLIDGE AG, 1979, J MOL BIOL, V131, P169, DOI 10.1016/0022-2836(79)90072-X; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; El-Mansi M, 2006, CURR OPIN MICROBIOL, V9, P173, DOI 10.1016/j.mib.2006.02.002; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Epelbaum S, 1998, J BACTERIOL, V180, P4056, DOI 10.1128/JB.180.16.4056-4067.1998; Fink Pamela S., 1993, P307; Frodyma M, 2000, J BACTERIOL, V182, P236, DOI 10.1128/JB.182.1.236-240.2000; Galperin MY, 2000, PROTEINS, V41, P238, DOI 10.1002/1097-0134(20001101)41:2<238::AID-PROT80>3.0.CO;2-L; Gehring AM, 1996, BIOCHEMISTRY-US, V35, P579, DOI 10.1021/bi952275a; Gupta S, 2005, BBA-PROTEINS PROTEOM, V1750, P112, DOI 10.1016/j.bbapap.2005.02.004; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HONG JS, 1971, P NATL ACAD SCI USA, V68, P3158, DOI 10.1073/pnas.68.12.3158; HOWARD BV, 1974, J BIOL CHEM, V249, P7912; HUANG WJ, 1995, BIOCHEMISTRY-US, V34, P10985, DOI 10.1021/bi00035a004; ISONO K, 1980, MOL GEN GENET, V177, P645; Iyer PP, 2001, J BACTERIOL, V183, P4244, DOI 10.1128/JB.183.14.4244-4250.2001; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JETER RM, 1984, J BACTERIOL, V159, P206, DOI 10.1128/JB.159.1.206-213.1984; Ke J, 2000, PLANT PHYSIOL, V123, P497, DOI 10.1104/pp.123.2.497; Kimura S, 2001, J BIOCHEM, V130, P481, DOI 10.1093/oxfordjournals.jbchem.a003010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu Y, 2007, J BACTERIOL, V189, P1589, DOI 10.1128/JB.01151-06; LUNDIE LL, 1989, J BIOL CHEM, V264, P18392; Macfarlane GT, 1997, SCAND J GASTROENTERO, V32, P3, DOI 10.1080/00365521.1997.11720708; MARGOLIS SA, 1986, ANAL CHEM, V58, P2504, DOI 10.1021/ac00125a033; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; MCCLEARY WR, 1993, J BACTERIOL, V175, P2793, DOI 10.1128/JB.175.10.2793-2798.1993; Palacios S, 2003, J BACTERIOL, V185, P2802, DOI 10.1128/JB.185.9.2802-2810.2003; Poot RA, 1997, FEBS LETT, V401, P175, DOI 10.1016/S0014-5793(96)01467-6; PRUSS BM, 1994, MOL MICROBIOL, V12, P973; Pruss BM, 1998, ARCH MICROBIOL, V170, P141, DOI 10.1007/s002030050626; RADIKA K, 1984, ARCH BIOCHEM BIOPHYS, V233, P272, DOI 10.1016/0003-9861(84)90626-X; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rubio A, 2002, J BACTERIOL, V184, P2827, DOI 10.1128/JB.184.10.2827-2832.2002; SASSE J, 1991, CURRENT PROTOCOLS MO; SCHEPPACH W, 1991, CLIN SCI, V80, P177, DOI 10.1042/cs0800177; SCHMIEGER H, 1973, MOL GEN GENET, V120, P181, DOI 10.1007/BF00267246; SCHMIEGER H, 1971, MOL GEN GENET, V110, P378, DOI 10.1007/BF00438281; Segel I.H., 1975, ENZYME KINETICS; SHAW WV, 1992, SCI PROGRESS-UK, V76, P565; SHIMIZU M, 1969, BIOCHIM BIOPHYS ACTA, V191, P550, DOI 10.1016/0005-2744(69)90348-9; Shivers RP, 2006, MOL MICROBIOL, V62, P811, DOI 10.1111/j.1365-2958.2006.05410.x; Shivers RP, 2005, MOL MICROBIOL, V56, P1549, DOI 10.1111/j.1365-2958.2005.04634.x; Starai VJ, 2004, CELL MOL LIFE SCI, V61, P2020, DOI 10.1007/s00018-004-3448-x; Starai VJ, 2004, J MOL BIOL, V340, P1005, DOI 10.1016/j.jmb.2004.05.010; SUZUKI T, 1969, BIOCHIM BIOPHYS ACTA, V191, P559, DOI 10.1016/0005-2744(69)90349-0; TALGOY MM, 1979, CAN J BIOCHEM CELL B, V57, P822, DOI 10.1139/o79-102; TANAKA S, 1989, MOL GEN GENET, V217, P289, DOI 10.1007/BF02464895; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; Vetting MW, 2004, CHEM BIOL, V11, P565, DOI 10.1016/j.chembiol.2004.03.017; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WINSTON SE, 1990, CURRENT PROTOCOLS MO; Wolfe AJ, 2005, MICROBIOL MOL BIOL R, V69, P12, DOI 10.1128/MMBR.69.1.12-50.2005; Wolfe AJ, 2003, MOL MICROBIOL, V48, P977, DOI 10.1046/j.1365-2958.2003.03457.x	69	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12629	12640		10.1074/jbc.M611439200	http://dx.doi.org/10.1074/jbc.M611439200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17339319	hybrid			2022-12-27	WOS:000245942800032
J	Fratti, RA; Wickner, W				Fratti, Rutilio A.; Wickner, William			Distinct targeting and fusion functions of the PX and SNARE domains of yeast vacuolar Vam7p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEX RING DOMAIN; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; ALPHA-SNAP; DOCKING; PROTEIN; COMPLEX; SEC17P; PURIFICATION	Regulated membrane fusion requires organelle tethering, enrichment of selected proteins and lipids at the fusion site, bilayer distortion, and lipid rearrangement. Yeast vacuole homotypic fusion requires regulatory lipids (ergosterol, diacylglycerol, and phosphoinositides), the Rab family GTPase Ypt7p, the multisubunit Ypt7p-effector complex HOPS (homotypic fusion and vacuole protein sorting), and four SNAREs. One SNARE, Vam7p, has an N-terminal PX domain which binds to phosphatidylinositol 3-phosphate (PI(3)P) and to HOPS and a C-terminal SNARE domain but no apolar membrane anchor. We have exploited an in vitro reaction of vacuole fusion to analyze the functions of each domain, removing the PX domain or mutating it to abolish its PI(3) P affinity. Lowering the PI(3) P affinity of the PX domain, or even deleting the PX domain, affects the fusion K-m for Vam7p but not the maximal fusion rate. Fusion driven by the SNARE domain alone is strikingly enhanced by the PLC inhibitor U73122 through enhanced binding of Vam7p SNARE domain to vacuoles, and the further addition of Plc1p blocks this U73122 effect. The PX domain, through its affinities for phosphoinositides and HOPS, is thus exclusively required for enhancing the targeting of Vam7p rather than for execution of the Vam7p functions in HOPS.SNARE complex assembly and fusion.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Wickner, W (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	Bill.Wickner@dartmouth.edu						Boeddinghaus C, 2002, J CELL BIOL, V157, P79, DOI 10.1083/jcb.200112098; Bone N, 1998, CURR BIOL, V8, P135, DOI 10.1016/S0960-9822(98)00060-8; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Collins KM, 2005, EMBO J, V24, P1775, DOI 10.1038/sj.emboj.7600658; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Fratti RA, 2004, J CELL BIOL, V167, P1087, DOI 10.1083/jcb.200409068; GARRETT MD, 1995, METHOD ENZYMOL, V257, P232; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Jun Y, 2004, J BIOL CHEM, V279, P53186, DOI 10.1074/jbc.M411363200; Jun Y, 2006, EMBO J, V25, P5260, DOI 10.1038/sj.emboj.7601413; Marcus SL, 2001, FEBS LETT, V494, P201, DOI 10.1016/S0014-5793(01)02356-0; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Slusarewicz P, 1997, P NATL ACAD SCI USA, V94, P5582, DOI 10.1073/pnas.94.11.5582; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; Stroupe C, 2006, EMBO J, V25, P1579, DOI 10.1038/sj.emboj.7601051; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Thorngren N, 2004, EMBO J, V23, P2765, DOI 10.1038/sj.emboj.7600286; Ungermann C, 2000, P NATL ACAD SCI USA, V97, P8889, DOI 10.1073/pnas.160269997; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551	30	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13133	13138		10.1074/jbc.M700584200	http://dx.doi.org/10.1074/jbc.M700584200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17347148	hybrid			2022-12-27	WOS:000245942800081
J	Iinuma, T; Shiga, A; Nakamoto, K; O'Brien, MB; Aridor, M; Arimitsu, N; Tagaya, M; Tani, K				Iinuma, Takayuki; Shiga, Akiko; Nakamoto, Koji; O'Brien, Matthew B.; Aridor, Meir; Arimitsu, Nagisa; Tagaya, Mitsuo; Tani, Katsuko			Mammalian Sec16/p250 plays a role in membrane traffic from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITIONAL ER ORGANIZATION; COPII-COATED VESICLE; DE-NOVO FORMATION; EXIT SITES; GOLGI-APPARATUS; SEC23P-INTERACTING PROTEIN; CARGO SELECTION; PICHIA-PASTORIS; SUBUNIT INTERACTIONS; PHOSPHOLIPASE A(1)	Coat protein complex II ( COPII)-coated vesicles/carriers, which mediate export of proteins from the endoplasmic reticulum ( ER), are formed at special ER subdomains in mammals, termed ER exit sites or transitional ER. The COPII coat consists of a small GTPase, Sar1, and two protein complexes, Sec23-Sec24 and Sec13-Sec31. Sec23-Sec24 and Sec13-Sec31 appear to constitute the inner and the outermost layers of the COPII coat, respectively. We previously isolated two mammalian proteins ( p125 and p250) that bind to Sec23. p125 was found to be a mammalian-specific, phospholipase A(1)-like protein that participates in the organization of ER exit sites. Here we show that p250 is encoded by the KIAA0310 clone and has sequence similarity to yeast Sec16 protein. Although KIAA0310p was found to be localized at ER exit sites, subcellular fractionation revealed its predominant presence in the cytosol. Cytosolic KIAA0310p was recruited to ER membranes in a manner dependent on Sar1. Depletion of KIAA0310p mildly caused disorganization of ER exit sites and delayed protein transport from the ER, suggesting its implication in membrane traffic out of the ER. Overexpression of KIAA0310p affected ER exit sites in a manner different from that of p125. Binding experiments suggested that KIAA0310p interacts with both the inner and the outermost layer coat complexes, whereas p125 binds principally to the inner layer complex. Our results suggest that KIAA0310p, a mammalian homologue of yeast Sec16, builds up ER exit sites in cooperation with p125 and plays a role in membrane traffic from the ER.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Tokyo University of Pharmacy & Life Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Tani, K (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan.	tani@ls.toyaku.ac.jp			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062318, R56DK062318] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK062318, DK062318] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Aridor M, 2000, J BIOL CHEM, V275, P35673, DOI 10.1074/jbc.C000449200; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bevis BJ, 2002, NAT CELL BIOL, V4, P750, DOI 10.1038/ncb852; Bhattacharyya D, 2007, MOL BIOL CELL, V18, P839, DOI 10.1091/mbc.E06-08-0707; Bielli A, 2005, J CELL BIOL, V171, P919, DOI 10.1083/jcb.200509095; Blumental-Perry A, 2006, DEV CELL, V11, P671, DOI 10.1016/j.devcel.2006.09.001; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Connerly PL, 2005, CURR BIOL, V15, P1439, DOI 10.1016/j.cub.2005.06.065; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; Giraudo CG, 2003, MOL BIOL CELL, V14, P3753, DOI 10.1091/mbc.E03-02-0101; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Higgs HN, 1998, J BIOL CHEM, V273, P5468, DOI 10.1074/jbc.273.10.5468; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kondylis V, 2003, J CELL BIOL, V162, P185, DOI 10.1083/jcb.200301136; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Matsuoka K, 2001, P NATL ACAD SCI USA, V98, P13705, DOI 10.1073/pnas.241522198; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mironov AA, 2003, DEV CELL, V5, P583, DOI 10.1016/S1534-5807(03)00294-6; Misawa H, 2001, INT J MOL MED, V8, P513; Mizoguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P144, DOI 10.1006/bbrc.2000.3846; Morsomme P, 2002, DEV CELL, V2, P307, DOI 10.1016/S1534-5807(02)00133-8; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Nakajima K, 2002, J BIOL CHEM, V277, P11329, DOI 10.1074/jbc.M111092200; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Okazaki N, 2003, DNA RES, V10, P35, DOI 10.1093/dnares/10.1.35; Pathre P, 2003, EMBO J, V22, P4059, DOI 10.1093/emboj/cdg390; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rossanese OW, 1999, J CELL BIOL, V145, P69, DOI 10.1083/jcb.145.1.69; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; ROWE T, 1995, METHOD ENZYMOL, V257, P49; Sawada N, 2005, INT J MOL MED, V16, P1049; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; Shimoi W, 2005, J BIOL CHEM, V280, P10141, DOI 10.1074/jbc.M409673200; Soderholm J, 2004, DEV CELL, V6, P649, DOI 10.1016/S1534-5807(04)00129-7; Stagg SM, 2006, NATURE, V439, P234, DOI 10.1038/nature04339; Stephens DJ, 2004, J CELL SCI, V117, P3635, DOI 10.1242/jcs.01269; Stephens DJ, 2003, EMBO REP, V4, P210, DOI 10.1038/sj.embor.embor736; Supek F, 2002, J CELL BIOL, V158, P1029, DOI 10.1083/jcb.200207053; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; Tani K, 1999, J BIOL CHEM, V274, P20505, DOI 10.1074/jbc.274.29.20505; Tani K, 1999, FEBS LETT, V447, P247, DOI 10.1016/S0014-5793(99)00303-8; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Watson P, 2006, TRAFFIC, V7, P1678, DOI 10.1111/j.1600-0854.2006.00493.x; Weissman JT, 2001, TRAFFIC, V2, P465, DOI 10.1034/j.1600-0854.2001.20704.x; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Zeuschner D, 2006, NAT CELL BIOL, V8, P377, DOI 10.1038/ncb1371	56	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17632	17639		10.1074/jbc.M611237200	http://dx.doi.org/10.1074/jbc.M611237200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17428803	hybrid			2022-12-27	WOS:000247084500035
J	Kriek, M; Martins, F; Leonardi, R; Fairhurst, SA; Lowe, DJ; Roach, PL				Kriek, Marco; Martins, Filipa; Leonardi, Roberta; Fairhurst, Shirley A.; Lowe, David J.; Roach, Peter L.			Thiazole synthase from Escherichia coli - An investigation of the substrates and purified proteins required for activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC RIBONUCLEOTIDE REDUCTASE; ELECTRON-PARAMAGNETIC-RESONANCE; ADENOSYL-L-METHIONINE; THIAMIN BIOSYNTHESIS; LYSINE 2,3-AMINOMUTASE; BACILLUS-SUBTILIS; PHOSPHATE MOIETY; BIOTIN SYNTHASE; IRON; IDENTIFICATION	Thiamine is biosynthesized by combining two heterocyclic precursors. In Escherichia coli and other anaerobes, one of the heterocycles, 4-methyl-5-(beta-hydroxyethyl) thiazole phosphate, is biosynthesized from 1-deoxyxylulose-5-phosphate, tyrosine, and cysteine. Genetic evidence has identified thiH, thiG, thiS, and thiF as essential for thiazole biosynthesis in E. coli. In this paper, we describe the measurement of the thiazole phosphate-forming reaction using purified protein components. The activity is shown to require four proteins isolated as heterodimers: ThiGH and ThiFS. Reconstitution of the [4Fe-4S] cluster in ThiH was essential for activity, as was the use of ThiS in the thiocarboxylate form. Spectroscopic studies with ThiGH strongly suggested that S-adenosylmethionine ( AdoMet) bound to the [4Fe-4S] cluster, which became more susceptible to reduction to the +1 state. Assays of thiazole phosphate formation showed that, in addition to the proteins, Dxp, tyrosine, AdoMet, and a reductant were required. The analysis showed that no more than 1 mol eq of thiazole phosphate was formed per ThiGH. Furthermore, for each mole of thiazole-P formed, 1 eq of AdoMet and 1 eq of tyrosine were utilized, and 1 eq of 5'-deoxyadenosine was produced. These results demonstrate that ThiH is a member of the "radical-AdoMet" family and support a mechanistic hypothesis in which AdoMet is reductively cleaved to yield a highly reactive 5'-deoxyadenosyl radical. This radical is proposed to abstract the phenolic hydrogen atom from tyrosine, and the resultant substrate radical cleaves to yield dehydroglycine, which is required by ThiG for the thiazole cyclization reaction.	Univ Southampton, Sch Chem, Biol Chem Sect, Southampton SO17 1BJ, Hants, England; John Innes Ctr, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	University of Southampton; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Roach, PL (corresponding author), Univ Southampton, Sch Chem, Biol Chem Sect, Southampton SO17 1BJ, Hants, England.	plr2@soton.ac.uk	Roach, Peter/AAW-7071-2021; Roach, Peter/C-6248-2013	Roach, Peter/0000-0001-9880-2877				ANDERSAG H, 1937, CHEM BER           B, V70, P2035; BACKSTROM AD, 1995, J AM CHEM SOC, V117, P2351, DOI 10.1021/ja00113a025; Begley TP, 1999, ARCH MICROBIOL, V171, P293, DOI 10.1007/s002030050713; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; Cavazza C, 2006, STRUCTURE, V14, P217, DOI 10.1016/j.str.2005.10.013; Chatterjee A, 2006, J AM CHEM SOC, V128, P7158, DOI 10.1021/ja061413o; Chatterjee A, 2006, ANGEW CHEM INT EDIT, V45, P3507, DOI 10.1002/anie.200504614; Cicchillo RM, 2004, BIOCHEMISTRY-US, V43, P6378, DOI 10.1021/bi049528x; Dorrestein PC, 2004, CHEM BIOL, V11, P1373, DOI 10.1016/j.chembiol.2004.08.009; Dorrestein PC, 2004, J AM CHEM SOC, V126, P3091, DOI 10.1021/ja039616p; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Gerrits J, 1997, METHOD ENZYMOL, V279, P74; HEWITSON KS, 2000, THESIS OXFORD U; Hinckley GT, 2006, BIOCHEMISTRY-US, V45, P3219, DOI 10.1021/bi0519497; Iwig DF, 2004, BIOCHEMISTRY-US, V43, P13496, DOI 10.1021/bi048693+; KAWASAKI T, 1969, J BIOCHEM-TOKYO, V65, P407, DOI 10.1093/oxfordjournals.jbchem.a129028; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawhorn BG, 2004, ORG BIOMOL CHEM, V2, P2538, DOI 10.1039/b405429f; LEDER IG, 1975, METABOLIC PATHWAYS, V7, P57; Lehmann C, 2006, BIOCHEMISTRY-US, V45, P11, DOI 10.1021/bi051502y; Leonardi R, 2004, J BIOL CHEM, V279, P17054, DOI 10.1074/jbc.M312714200; Leonardi R, 2003, FEBS LETT, V539, P95, DOI 10.1016/S0014-5793(03)00204-7; Lieder KW, 1998, BIOCHEMISTRY-US, V37, P2578, DOI 10.1021/bi972417w; Liu A, 2000, J BIOL CHEM, V275, P12367, DOI 10.1074/jbc.275.17.12367; Martinez-Gomez NC, 2004, J BIOL CHEM, V279, P40505, DOI 10.1074/jbc.M403985200; NEWELL PC, 1966, BIOCHEM J, V100, P517, DOI 10.1042/bj1000517; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Ollagnier-de-Choudens S, 2002, FEBS LETT, V532, P465, DOI 10.1016/S0014-5793(02)03733-X; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; Park JH, 2004, J BACTERIOL, V186, P1571, DOI 10.1128/JB.186.5.1571-1573.2004; Park JH, 2003, BIOCHEMISTRY-US, V42, P12430, DOI 10.1021/bi034902z; Pohl M, 2004, CURR OPIN BIOTECH, V15, P335, DOI 10.1016/j.copbio.2004.06.002; PUGH CSG, 1978, J BIOL CHEM, V253, P4075; Serganov A, 2006, NATURE, V441, P1167, DOI 10.1038/nature04740; Settembre EC, 2003, BIOCHEMISTRY-US, V42, P2971, DOI 10.1021/bi026916v; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Spenser ID, 1997, ANGEW CHEM INT EDIT, V36, P1033; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Taylor SV, 1998, J ORG CHEM, V63, P2375, DOI 10.1021/jo971933p; Taylor SV, 1998, J BIOL CHEM, V273, P16555, DOI 10.1074/jbc.273.26.16555; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Wright CM, 2006, CHEM COMMUN, P3104, DOI 10.1039/b604040c; Xi J, 2001, P NATL ACAD SCI USA, V98, P8513, DOI 10.1073/pnas.141226698; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	47	70	74	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17413	17423		10.1074/jbc.M700782200	http://dx.doi.org/10.1074/jbc.M700782200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17403671	hybrid			2022-12-27	WOS:000247084500011
J	Song, YJ; Benison, G; Nyarko, A; Hays, TS; Barbar, E				Song, Yujuan; Benison, Gregory; Nyarko, Afua; Hays, Thomas S.; Barbar, Elisar			Potential role for phosphorylation in differential regulation of the assembly of dynein light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DYNEIN; INTERMEDIATE CHAIN; TCTEX-1; LC8; PROTEIN; DIMERIZATION; RECEPTOR; LIGHT-CHAIN-1; DIMER; TRANSPORT	The homodimeric light chains LC8 and Tctex-1 are integral parts of the microtubule motor cytoplasmic dynein, as they directly associate with dynein intermediate chain IC and various cellular cargoes. These light chains appear to regulate assembly of the dynein complex by binding to and promoting dimerization of IC. In addition, both LC8 and Tctex-1 play roles in signaling, apoptosis, and neuronal development that are independent of their function in dynein, but it is unclear how these various activities are modulated. Both light chains undergo specific phosphorylation, and here we present biochemical and NMR analyses of phosphomimetic mutants that indicate how phosphorylation may regulate light chain function. For both LC8 and Tctex-1, phosphorylation promotes dissociation from IC while retaining their binding activity with other non- dynein proteins. Although LC8 and Tctex-1 are homologs having a common fold, their reduced affinity for IC upon phosphorylation arises by different mechanisms. In the case of Tctex-1, phosphorylation directly masks the IC binding site at the dimer interface, whereas for LC8, phosphorylation dissociates the dimer and indirectly eliminates the binding site. This modulation of the monomer-dimer equilibrium by phosphorylation provides a novel mechanism for discrimination among LC8 binding partners.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	Oregon State University; University of Minnesota System; University of Minnesota Twin Cities	Barbar, E (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.	barbare@science.oregonstate.edu	Nyarko, Afua/R-9872-2019	Barbar, Elisar/0000-0003-4892-5259	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044757] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbar E, 2001, BIOCHEMISTRY-US, V40, P1596, DOI 10.1021/bi002278+; Benison G, 2006, J MOL BIOL, V362, P1082, DOI 10.1016/j.jmb.2006.08.006; Campbell KS, 1998, J IMMUNOL, V161, P1728; Chuang JZ, 2005, DEV CELL, V9, P75, DOI 10.1016/j.devcel.2005.04.003; DeLano W.L, PYMOL MOL GRAPHICS S; Fan JS, 2001, J MOL BIOL, V306, P97, DOI 10.1006/jmbi.2000.4374; Ilangovan U, 2005, J MOL BIOL, V352, P338, DOI 10.1016/j.jmb.2005.07.002; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jin QY, 2005, CELL SIGNAL, V17, P1363, DOI 10.1016/j.cellsig.2005.02.004; Kaiser FJ, 2003, HUM MOL GENET, V12, P1349, DOI 10.1093/hmg/ddg145; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; Li MG, 2004, MOL BIOL CELL, V15, P3005, DOI 10.1091/mbc.E04-01-0013; Liang J, 1999, NAT STRUCT BIOL, V6, P735; Lo KWH, 2006, J BIOL CHEM, V281, P9552, DOI 10.1074/jbc.M511721200; Lo KWH, 2005, J BIOL CHEM, V280, P8172, DOI 10.1074/jbc.M411408200; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Machado RD, 2003, HUM MOL GENET, V12, P3277, DOI 10.1093/hmg/ddg365; Makokha M, 2002, BIOCHEMISTRY-US, V41, P4302, DOI 10.1021/bi011970h; Mueller S, 2002, J BIOL CHEM, V277, P7897, DOI 10.1074/jbc.M111937200; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; Nyarko A, 2005, BIOCHEMISTRY-US, V44, P14248, DOI 10.1021/bi0512694; Nyarko A, 2004, BIOCHEMISTRY-US, V43, P15595, DOI 10.1021/bi048451+; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Raux H, 2000, J VIROL, V74, P10212, DOI 10.1128/JVI.74.21.10212-10216.2000; Rayala SK, 2005, EMBO REP, V6, P538, DOI 10.1038/sj.embor.7400417; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Song J, 2005, J MOL BIOL, V354, P1043, DOI 10.1016/j.jmb.2005.10.017; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Talbott M, 2006, BIOCHEMISTRY-US, V45, P6793, DOI 10.1021/bi0600345; Tang Q, 2002, MOL BIOL CELL, V13, P4484, DOI 10.1091/mbc.e02-05-0245; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Wang L, 2004, BIOCHEMISTRY-US, V43, P4611, DOI 10.1021/bi036328x; Williams JC, 2005, J BIOL CHEM, V280, P21981, DOI 10.1074/jbc.M414643200; Wu HW, 2005, STRUCTURE, V13, P213, DOI 10.1016/j.str.2004.11.013; Yang ZB, 2005, J BIOL CHEM, V280, P654, DOI 10.1074/jbc.M408486200	36	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17272	17279		10.1074/jbc.M610445200	http://dx.doi.org/10.1074/jbc.M610445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428790	hybrid			2022-12-27	WOS:000246946500060
J	Taylor, DM; Gibbs, BF; Kabashi, E; Minotti, S; Durham, HD; Agar, JN				Taylor, David M.; Gibbs, Bernard F.; Kabashi, Edor; Minotti, Sandra; Durham, Heather D.; Agar, Jeffrey N.			Tryptophan 32 potentiates aggregation and cytotoxicity of a copper/zinc superoxide dismutase mutant associated with familial amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADVANCED GLYCATION ENDPRODUCTS; MOLECULAR-WEIGHT COMPLEXES; CATION-PI INTERACTIONS; EXPRESSING HUMAN SOD1; MOTOR-NEURONS; CU,ZN-SUPEROXIDE DISMUTASE; HYALINE INCLUSIONS; TRANSGENIC MICE; MASS-SPECTROMETRY; OXIDATIVE DAMAGE	One familial form of the neurodegenerative disease, amyotrophic lateral sclerosis, is caused by gain-of-function mutations in the gene encoding copper/zinc superoxide dismutase (SOD-1). This study provides in vivo evidence that normally occurring oxidative modification to SOD-1 promotes aggregation and toxicity of mutant proteins. The oxidation of Trp-32 was identified as a normal modification being present in both wild-type enzyme and SOD-1 with the disease-causing mutation, G93A, isolated from erythrocytes. Mutating Trp-32 to a residue with a slower rate of oxidative modification, phenylalanine, decreased both the cytotoxicity of mutant SOD-1 and its propensity to form cytoplasmic inclusions in motor neurons of dissociated mouse spinal cord cultures.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; McGill Univ, Sheldon Biotechnol Ctr, Montreal, PQ H3A 2B4, Canada; Brandeis Univ, Dept Chem, Waltham, MA 02454 USA	McGill University; McGill University; Brandeis University	Durham, HD (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	heather.durham@mcgill.ca; agar@brandeis.edu	Kabashi, Edor/C-5408-2014	Kabashi, Edor/0000-0003-4118-251X; Agar, Jeffery/0000-0003-2645-1873				Andrus PK, 1998, J NEUROCHEM, V71, P2041; Aoki M, 2005, NEUROPATHOLOGY, V25, P365, DOI 10.1111/j.1440-1789.2005.00611.x; Batulan Z, 2003, J NEUROSCI, V23, P5789; Batulan Z, 2005, CELL STRESS CHAPERON, V10, P185, DOI 10.1379/CSC-30R.1; Batulan Z, 2006, NEUROBIOL DIS, V24, P213, DOI 10.1016/j.nbd.2006.06.017; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Boillee S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bredesen DE, 1997, ANN NEUROL, V42, P135, DOI 10.1002/ana.410420202; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Choi J, 2006, J BIOL CHEM, V281, P10816, DOI 10.1074/jbc.M509079200; Choi J, 2005, J BIOL CHEM, V280, P11648, DOI 10.1074/jbc.M414327200; Chou SM, 1996, J CHEM NEUROANAT, V10, P249, DOI 10.1016/0891-0618(96)00137-8; Claiborne A, 2001, ADV PROTEIN CHEM, V58, P215; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Johnson KA, 2000, ANAL CHEM, V72, P1410, DOI 10.1021/ac991183e; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Jonsson PA, 2006, BRAIN, V129, P451, DOI 10.1093/brain/awh704; Kabashi E, 2006, BBA-MOL BASIS DIS, V1762, P1038, DOI 10.1016/j.bbadis.2006.06.006; Kato S, 1999, ACTA NEUROPATHOL, V97, P260, DOI 10.1007/s004010050983; Kato S, 2001, NEUROPATHOLOGY, V21, P67, DOI 10.1046/j.1440-1789.2001.00359.x; Kato S, 2000, ACTA NEUROPATHOL, V100, P490, DOI 10.1007/s004010000226; Kurahashi T, 2001, J AM CHEM SOC, V123, P9268, DOI 10.1021/ja015953r; Lei QP, 1998, ANAL CHEM, V70, P1838, DOI 10.1021/ac971181z; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; Okado-Matsumoto A, 2001, ANAL BIOCHEM, V298, P337, DOI 10.1006/abio.2001.5385; PAPAYANNOPOULOS IA, 1995, MASS SPECTROM REV, V14, P49, DOI 10.1002/mas.1280140104; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Poon HF, 2005, FREE RADICAL BIO MED, V39, P453, DOI 10.1016/j.freeradbiomed.2005.03.030; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Roy J, 1998, J NEUROSCI, V18, P9673; Shaw BF, 2007, TRENDS BIOCHEM SCI, V32, P78, DOI 10.1016/j.tibs.2006.12.005; Shibata N, 1999, ACTA NEUROPATHOL, V97, P240, DOI 10.1007/s004010050980; SHIBATA N, 1994, NEUROSCI LETT, V179, P149, DOI 10.1016/0304-3940(94)90956-3; Shibata N, 1996, DEV NEUROSCI-BASEL, V18, P492, DOI 10.1159/000111445; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Shibata N, 2002, ACTA NEUROPATHOL, V104, P171, DOI 10.1007/s00401-002-0537-5; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; Takata I, 1996, BIOCHEM BIOPH RES CO, V219, P243, DOI 10.1006/bbrc.1996.0212; Taylor DM, 2004, NEUROTOXICOLOGY, V25, P779, DOI 10.1016/j.neuro.2004.02.002; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200; Wang J, 2002, NEUROBIOL DIS, V9, P139, DOI 10.1006/nbdi.2001.0471; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; Zhang H, 2004, FREE RADICAL BIO MED, V37, P2018, DOI 10.1016/j.freeradbiomed.2004.08.026; Zhang H, 2003, J BIOL CHEM, V278, P24078, DOI 10.1074/jbc.M302051200	58	54	56	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16329	16335		10.1074/jbc.M610119200	http://dx.doi.org/10.1074/jbc.M610119200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17389599	hybrid			2022-12-27	WOS:000246794300040
J	Wang, R; Yin, YJ; Wang, F; Li, M; Feng, J; Zhang, HM; Zhang, JP; Liu, SJ; Chang, WR				Wang, Rui; Yin, Ya-Jie; Wang, Feng; Li, Mei; Feng, Jie; Zhang, Hong-Mei; Zhang, Ji-Ping; Liu, Shuang-Jiang; Chang, Wen-Rui			Crystal structures and site-directed mutagenesis of a mycothiol-dependent enzyme reveal a novel folding and molecular basis for mycothiol-mediated maleylpyruvate isomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTALLOGRAPHIC STRUCTURE DETERMINATION; MYCOBACTERIUM-SMEGMATIS MUTANTS; CORYNEBACTERIUM-GLUTAMICUM; BIOSYNTHESIS; SOFTWARE; PROGRAM; THIOL; IDENTIFICATION; TUBERCULOSIS; ANTIBIOTICS	Mycothiol (MSH) is the major low molecular mass thiols in many Gram- positive bacteria such as Mycobacterium tuberculosis and Corynebacterium glutamicum. The physiological roles of MSH are believed to be equivalent to those of GSH in Gramnegative bacteria, but current knowledge of MSH is limited to detoxification of alkalating chemicals and protection from host cell defense/killing systems. Recently, an MSH-dependent maleylpyruvate isomerase (MDMPI) was discovered from C. glutamicum, and this isomerase represents one example of many putative MSH-dependent enzymes that take MSH as cofactor. In this report, fourteen mutants of MDMPI were generated. The wild type and mutant (H52A) MDMPIs were crystallized and their structures were solved at 1.75 and 2.05 A resolution, respectively. The crystal structures reveal that this enzyme contains a divalent metal- binding domain and a C-terminal domain possessing a novel folding pattern (alpha beta alpha beta beta alpha fold). The divalent metal-binding site is composed of residues His(52), Glu(144), and His(148) and is located at the bottom of a surface pocket. Combining the structural and site- directed mutagenesis studies, it is proposed that this surface pocket including the metal ion and MSH moiety formed the putative catalytic center.	Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resource, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Univ, Beijing 100049, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Chang, WR (corresponding author), Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resource, Beijing 100080, Peoples R China.	wrchang@sun5.ibp.ac.cn	Liu, Shuang-Jiang/E-5756-2013	Li, Mei/0000-0002-1742-2360				Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchmeier NA, 2003, MOL MICROBIOL, V47, P1723, DOI 10.1046/j.1365-2958.2003.03416.x; Buchmeier NA, 2006, J BACTERIOL, V188, P6245, DOI 10.1128/JB.00393-06; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Feng J, 2006, J BIOL CHEM, V281, P10778, DOI 10.1074/jbc.M513192200; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Newton GL, 2006, J BIOL CHEM, V281, P33910, DOI 10.1074/jbc.M604724200; Newton GL, 2002, ARCH MICROBIOL, V178, P388, DOI 10.1007/s00203-002-0469-4; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Newton GL, 1999, BIOCHEM BIOPH RES CO, V255, P239, DOI 10.1006/bbrc.1999.0156; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Polekhina G, 2001, BIOCHEMISTRY-US, V40, P1567, DOI 10.1021/bi002249z; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shen XH, 2005, APPL ENVIRON MICROB, V71, P3442, DOI 10.1128/AEM.71.7.3442-3452.2005; SPIES HSC, 1994, EUR J BIOCHEM, V224, P203, DOI 10.1111/j.1432-1033.1994.tb20013.x; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766	26	20	20	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16288	16294		10.1074/jbc.M610347200	http://dx.doi.org/10.1074/jbc.M610347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428791	hybrid			2022-12-27	WOS:000246794300036
J	Neeper, MP; Liu, Y; Hutchinson, TL; Wang, Y; Flores, CM; Qin, N				Neeper, Michael P.; Liu, Yi; Hutchinson, Tasha L.; Wang, Yan; Flores, Christopher M.; Qin, Ning			Activation properties of heterologously expressed mammalian TRPV2 - Evidence for species dependence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN-RECEPTOR HOMOLOG; VANILLOID RECEPTOR-1; CATION CHANNEL; SPLICE VARIANT; ION-CHANNEL; RAT; TRANSLOCATION; SENSITIVITY; STIMULI; LACKING	TRPV2 has been proposed as a potential pain target, in part due to its relatedness to the nociceptor TRPV1 and to its reported activation by noxious high temperatures (> 52 degrees C). However, TRPV2 responses to heat as well as to the nonselective agonist 2-aminoethoxydiphenyl borate (2-APB) have not been universally reproduced in other laboratories, leading to debate about the activation properties of this channel. Here, we report the expression of rat, mouse, and human TRPV2 in HEK293 cells and the differential properties of their responses to heat and 2-APB. Expression of mouse or rat TRPV2 in HEK293 cells resulted in robust channel activation when induced by either temperature (> 53 degrees C) or 2-APB. By contrast, expression of human TRPV2 did not lead to detectable activation by either of these stimuli. Human TRPV2 protein was expressed at levels comparable with those of rat TRPV2, exhibited similar surface localization and responded to a novelly identified TRPV2 agonist, Delta(9)-tetrahydrocannabinol, indicating that human TRPV2 is functionally expressed on the cell surface. Studies using deletion mutants and chimeras between rat and human TRPV2 indicated that both amino- and carboxyl-cytoplasmic termini of rat TRPV2 are important for responses to heat and 2-APB but can be supplied in trans to form an active channel. The present study not only confirms and extends previous reports demonstrating that rat and mouse TRPV2 respond to 2-APB and noxious heat but also indicates that further investigation will be required to elucidate TRPV2 activation and regulatory mechanisms.	Johnson & Johnson Pharmaceut Res & Dev LLC, Analges Team, E Coast Res & Early Dev, Spring House, PA 19477 USA	Johnson & Johnson; Johnson & Johnson USA	Qin, N (corresponding author), Johnson & Johnson Pharmaceut Res & Dev LLC, Analges Team, E Coast Res & Early Dev, Welsch & McKean Rd,POB 776, Spring House, PA 19477 USA.	nqin@prdus.jnj.com						Bandell M, 2006, NAT NEUROSCI, V9, P493, DOI 10.1038/nn1665; Bender FLP, 2005, CELL PHYSIOL BIOCHEM, V15, P183, DOI 10.1159/000083651; Benham CD, 2003, CELL CALCIUM, V33, P479, DOI 10.1016/S0143-4160(03)00063-0; Boels K, 2001, J CELL SCI, V114, P3599; Brauchi S, 2006, J NEUROSCI, V26, P4835, DOI 10.1523/JNEUROSCI.5080-05.2006; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chung MK, 2004, J BIOL CHEM, V279, P21569, DOI 10.1074/jbc.M401872200; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Gaudet AD, 2004, BRAIN RES, V1017, P155, DOI 10.1016/j.brainres.2004.05.045; Gavva NR, 2004, J BIOL CHEM, V279, P20283, DOI 10.1074/jbc.M312577200; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Lewinter RD, 2004, J COMP NEUROL, V470, P400, DOI 10.1002/cne.20024; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liu Y, 2006, EUR J PHARMACOL, V530, P23, DOI 10.1016/j.ejphar.2005.11.033; Liu Y, 2006, EPILEPSY RES, V70, P263, DOI 10.1016/j.eplepsyres.2006.03.007; Muraki K, 2003, CIRC RES, V93, P829, DOI 10.1161/01.RES.0000097263.10220.0C; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Shimosato G, 2005, PAIN, V119, P225, DOI 10.1016/j.pain.2005.10.002; Stokes AJ, 2005, J CELL BIOCHEM, V94, P669, DOI 10.1002/jcb.20331; Stokes AJ, 2004, J EXP MED, V200, P137, DOI 10.1084/jem.20032082; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Tian W, 2006, AM J PHYSIOL-RENAL, V290, pF117, DOI 10.1152/ajprenal.00143.2005; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Wang HB, 2005, NEURON, V46, P9, DOI 10.1016/j.neuron.2005.03.011; Wirkner K, 2005, NEUROREPORT, V16, P997, DOI 10.1097/00001756-200506210-00023	32	123	124	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15894	15902		10.1074/jbc.M608287200	http://dx.doi.org/10.1074/jbc.M608287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17395593	hybrid			2022-12-27	WOS:000246589600064
J	Du, JM; Wang, H; Zhong, C; Peng, BZ; Zhang, ML; Li, BH; Huo, S; Guo, YJ; Ding, JP				Du, Jiamu; Wang, Hao; Zhong, Chen; Peng, Baozhen; Zhang, Meilan; Li, Bohua; Huo, Sheng; Guo, Yajun; Ding, Jianping			Structural basis for recognition of CD20 by therapeutic antibody rituximab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; FINE SPECIFICITY; LYMPHOMA; REDISTRIBUTION; EPITOPES; SEQUENCE	Rituximab is a widely used monoclonal antibody drug for treating certain lymphomas and autoimmune diseases. To understand the molecular mechanism of recognition of human CD20 by Rituximab, we determined the crystal structure of the Rituximab Fab in complex with a synthesized peptide comprising the CD20 epitope ( residues 163-187) at 2.6-angstrom resolution. The combining site of the Fab consists of four complementarity determining regions that form a large, deep pocket to accommodate the epitope peptide. The bound peptide assumes a unique cyclic conformation that is constrained by a disulfide bond and a rigid proline residue ( Pro(172)). The (170)ANPS(173) motif of CD20 is deeply embedded into the pocket on the antibody surface and plays an essential role in the recognition and binding of Rituximab. The antigen-antibody interactions involve both hydrogen bonds and van der Waals contacts and display a high degree of structural and chemical complementarity. These results provide a molecular basis for the specific recognition of CD20 by Rituximab as well as valuable information for development of improved antibody drugs with better specificity and higher affinity.	Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; Second Mil Med Univ, Int Joint Canc Inst, Shanghai 200433, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Naval Medical University	Ding, JP (corresponding author), 800 Xiang Yin Rd, Shanghai 200433, Peoples R China.	jpding@sibs.ac.cn	Li, Bo/AAA-8968-2020; Du, Jiamu/G-3308-2010; Du, Jiamu/I-1334-2013	Li, Bo/0000-0002-7294-6888; Du, Jiamu/0000-0002-1337-0786; ding, jian ping/0000-0001-7029-7346				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; ANDERSON DR, 1998, Patent No. 5843439; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banfield MJ, 1997, PROTEINS, V29, P161, DOI 10.1002/(SICI)1097-0134(199710)29:2<161::AID-PROT4>3.0.CO;2-G; Binder M, 2006, BLOOD, V108, P1975, DOI 10.1182/blood-2006-04-014639; Boye J, 2003, ANN ONCOL, V14, P520, DOI 10.1093/annonc/mdg175; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Chan HTC, 2003, CANCER RES, V63, P5480; Check E, 2004, NATURE, V428, P786, DOI 10.1038/428786b; Cohen Y, 2004, AUTOIMMUN REV, V3, P111, DOI 10.1016/S1568-9972(03)00083-1; Cragg Mark S., 2005, V8, P140; Cragg MS, 2003, BLOOD, V101, P1045, DOI 10.1182/blood-2002-06-1761; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; DeLano W, 2002, PYMOL 0 99; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Ernst JA, 2005, BIOCHEMISTRY-US, V44, P15150, DOI 10.1021/bi0511078; Garber K, 2003, J NATL CANCER I, V95, P189, DOI 10.1093/jnci/95.3.189; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keating M, 2000, SEMIN ONCOL, V27, P86; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Leget Gail A., 1998, Current Opinion in Oncology, V10, P548, DOI 10.1097/00001622-199811000-00012; Li HD, 2003, J BIOL CHEM, V278, P42427, DOI 10.1074/jbc.M308802200; Martin ACR, 1996, PROTEINS, V25, P130, DOI 10.1002/(SICI)1097-0134(199605)25:1<130::AID-PROT11>3.3.CO;2-Y; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McLaughlin P, 2000, SEMIN ONCOL, V27, P37, DOI 10.1053/sonc.2000.20438; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perosa F, 2006, BLOOD, V107, P1070, DOI 10.1182/blood-2005-04-1769; Polyak MJ, 2002, BLOOD, V99, P3256, DOI 10.1182/blood.V99.9.3256; PRESS OW, 1994, BLOOD, V83, P1390; REFF ME, 1994, BLOOD, V83, P435; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; Smith MR, 2003, ONCOGENE, V22, P7359, DOI 10.1038/sj.onc.1206939; Stanfield RL, 2006, J MOL BIOL, V357, P1566, DOI 10.1016/j.jmb.2006.01.023; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; STASHENKO P, 1980, J IMMUNOL, V125, P1678; Teeling JL, 2006, J IMMUNOL, V177, P362, DOI 10.4049/jimmunol.177.1.362; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4	42	86	103	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15073	15080		10.1074/jbc.M701654200	http://dx.doi.org/10.1074/jbc.M701654200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17395584	hybrid			2022-12-27	WOS:000246589000047
J	Guo, ZF; Eisenberg, D				Guo, Zhefeng; Eisenberg, David			The mechanism of the amyloidogenic conversion of T7 endonuclease I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN STABILITY; FIBRIL FORMATION; THERMODYNAMIC STABILITY; CONFORMATIONS; AGGREGATION; SOLUBILITY; MODULATION; PRECURSORS; DISEASE	Amyloid fibrils are associated with a range of human disorders. Understanding the conversion of amyloidogenic proteins from their soluble forms to amyloid fibrils is critical for developing effective therapeutics. Previously we showed that T7 endonuclease I forms amyloid-like fibrils. Here we study the mechanism of the amyloidogenic conversion of T7 endonuclease I. We show that T7 endonuclease I forms fibrils at pH 6.8, but not at pH 6.0 or 8.0. The amyloidogenicity at pH 6.8 is not correlated with thermodynamic stability, unfolding cooperativity, or solubility. Thermal melting experiments at various pH values show that the protein has a distinctive thermal transition at pH 6.8. The transition at pH 6.8 has a lower transition temperature than the unfolding transitions observed at pH 6.0 and 8.0 and leads to a beta-rich conformation instead of an unfolded state. Electron microscopy shows that the thermal transition at pH 6.8 results in fibril formation. The thermal transition at pH 6.8 leads to a protein state that is not accessible at pH 6.0 or 8.0, showing that the existence of the amyloidogenic conformation of T7 endonuclease I depends sensitively on solution conditions. Therefore, we propose that fibrillizing proteins need to be "prepared" for fibrillization. Preparation may consist of amino acid replacements or changing solution conditions and may require retention of some aspects of native structure. In this model, some amyloid-enhancing mutations decrease protein stability, whereas others have little effect.	Univ Calif Los Angeles, Howard Hughes Med Inst, DOE Inst Genom & Proteom, Inst Mol Biol, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; United States Department of Energy (DOE); University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, DOE Inst Genom & Proteom, Inst Mol Biol, Box 951570, Los Angeles, CA 90095 USA.	david@mbi.ucla.edu	Guo, Zhefeng/A-2069-2013	Guo, Zhefeng/0000-0003-1992-7255				ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416; Baldwin RL, 1996, BIOPHYS J, V71, P2056, DOI 10.1016/S0006-3495(96)79404-3; Calamai M, 2005, BIOPHYS J, V89, P4201, DOI 10.1529/biophysj.105.068726; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; Chow MKM, 2004, J BIOL CHEM, V279, P47643, DOI 10.1074/jbc.M405799200; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Dumoulin M, 2005, J MOL BIOL, V346, P773, DOI 10.1016/j.jmb.2004.11.020; Eakin CM, 2006, NAT STRUCT MOL BIOL, V13, P202, DOI 10.1038/nsmb1068; Eakin CM, 2004, BIOCHEMISTRY-US, V43, P7808, DOI 10.1021/bi049792q; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Guo ZF, 2006, P NATL ACAD SCI USA, V103, P8042, DOI 10.1073/pnas.0602607103; Hadden JM, 2001, NAT STRUCT BIOL, V8, P62; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hosszu LLP, 2004, J BIOL CHEM, V279, P28515, DOI 10.1074/jbc.M313762200; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Jahn TR, 2006, NAT STRUCT MOL BIOL, V13, P195, DOI 10.1038/nsmb1058; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kim YS, 2000, J BIOL CHEM, V275, P1570, DOI 10.1074/jbc.275.3.1570; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Morel B, 2006, J MOL BIOL, V356, P453, DOI 10.1016/j.jmb.2005.11.062; Pedersen JS, 2004, J MOL BIOL, V341, P575, DOI 10.1016/j.jmb.2004.06.020; Plakoutsi G, 2005, J MOL BIOL, V351, P910, DOI 10.1016/j.jmb.2005.06.043; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Schmittschmitt JP, 2003, PROTEIN SCI, V12, P2374, DOI 10.1110/ps.03152903; Soldi G, 2005, BIOPHYS J, V89, P4234, DOI 10.1529/biophysj.105.067538; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Westermark P, 2005, FEBS J, V272, P5942, DOI 10.1111/j.1742-4658.2005.05024.x	37	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14968	14974		10.1074/jbc.M609514200	http://dx.doi.org/10.1074/jbc.M609514200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17360710	hybrid			2022-12-27	WOS:000246589000035
J	Lee, SA; Jung, M				Lee, Sung A.; Jung, Mira			The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase C delta and JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOMEGALOVIRUS REPLICATION; SIGNAL-TRANSDUCTION; PROTEOLYTIC CLEAVAGE; DNA-DAMAGE; HA-RAS; POLY(ADP-RIBOSE) POLYMERASE; DEPENDENT APOPTOSIS; ANTIVIRAL ACTIVITY; CANCER CELLS; JUN	Sangivamycin has shown a potent antiproliferative activity against a variety of human cancers. However, little is known about the mechanism of action underlying its antitumor activity. Here we demonstrate that sangivamycin has differential antitumor effects in drug-sensitive MCF7/wild type (WT) cells, causing growth arrest, and in multidrug-resistant MCF7/adriamycin-resistant (ADR) human breast carcinoma cells, causing massive apoptotic cell death. Comparisons between the effects of sangivamycin on these two cell lines allowed us to identify the mechanism underlying the apoptotic antitumor effect. Fluorescence-activated cell sorter analysis indicated that sangivamycin induced cell cycle arrest in the G(2)/M phase in MCF7/ADR cells. A marked induction of c-Jun expression as well as phosphorylation of c-Jun and JNK was observed after sangivamycin treatment of MCF7/ADR cells but not MCF7/WT cells. Sangivamycin also induced cleavage of lamin A and poly(ADP-ribose) polymerase (PARP) in MCF7/ADR cells, probably via activation of caspase-6, -7, and -9. Pretreatment with a caspase-9-specific inhibitor or pan-caspase inhibitor abolished sangivamycin-induced cleavage of lamin A and PARP but not sangivamycin induction of c-Jun expression and phosphorylation. Pretreatment of MCF7/ADR cells with SP600125, a specific inhibitor of JNK, or with rottlerin, a specific inhibitor of protein kinase C delta (PKC delta), significantly reduced the sangivamycin-induced apoptosis and almost completely abolished sangivamycin-induced phosphorylation of c-Jun and cleavage of lamin A and PARP. Transfection of MCF7/ADR cells with PKC delta small interfering RNAs or PKC delta antibody or rottlerin pretreatment significantly suppressed the phosphorylation of JNK. Taken together, our data suggest that sangivamycin induces mitochondria-mediated apoptotic cell death of MCF7/ADR cells via activation of JNK in a protein kinase C delta-dependent manner.	Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20057 USA	Georgetown University	Jung, M (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20057 USA.	jungm@georgetown.edu			NCI NIH HHS [P02 CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amellem O, 1997, EXP CELL RES, V232, P361, DOI 10.1006/excr.1997.3497; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; BERGSTROM DE, 1984, J MED CHEM, V27, P285, DOI 10.1021/jm00369a010; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Biron KK, 2002, ANTIMICROB AGENTS CH, V46, P2365, DOI 10.1128/AAC.46.8.2365-2372.2002; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; CAVINS JOHN A., 1967, CANCER CHEMOTHER REP, V51, P197; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN MB, 1985, MOL PHARMACOL, V27, P349; Dal Pra I, 2000, EXP CELL RES, V255, P171, DOI 10.1006/excr.1999.4789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Ding YL, 2005, BIOORG MED CHEM LETT, V15, P725, DOI 10.1016/j.bmcl.2004.11.019; Drew L, 2002, CLIN CANCER RES, V8, P3922; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; EMOTO Y, 1996, BLOOD, V87, P1991; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Gelis C, 2005, PHOTOCHEM PHOTOBIOL, V81, P975, DOI 10.1562/2004-08-05-RA-262R.1; GLAZER RI, 1981, BIOCHEM PHARMACOL, V30, P2697, DOI 10.1016/0006-2952(81)90540-2; Goldberg M, 1999, CRIT REV EUKAR GENE, V9, P285, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.130; GOUBOUT JP, 2002, J BIOL CHEM, V277, P2554; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HARDESTY CT, 1974, CANCER RES, V34, P1005; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kim MK, 2005, CANCER LETT, V223, P239, DOI 10.1016/j.canlet.2004.10.045; Koszalka GW, 2002, ANTIMICROB AGENTS CH, V46, P2373, DOI 10.1128/AAC.46.8.2373-2380.2002; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LEE SA, 1992, CANCER RES, V52, P3750; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; LESZCZYNSKI D, 1995, ONCOL RES, V7, P471; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Migawa MT, 2005, J MED CHEM, V48, P3840, DOI 10.1021/jm0402014; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Molinari M, 1996, ONCOGENE, V13, P2077; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; Okorokov AL, 1997, ONCOL RES, V9, P267; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; OLTVAI ZN, 1993, CELL, V74, P619; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Osada H, 1997, BIOORGAN MED CHEM, V5, P193, DOI 10.1016/S0968-0896(96)00207-6; OSADA H, 1989, J ANTIBIOT, V42, P102, DOI 10.7164/antibiotics.42.102; PALCZEWSKI K, 1990, BIOCHEMISTRY-US, V29, P6276, DOI 10.1021/bi00478a024; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Ravelo AG, 2004, CURR TOP MED CHEM, V4, P241; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; RITCH PS, 1981, CANCER RES, V41, P1784; ROBINS RK, 1985, MED RES REV, V5, P273, DOI 10.1002/med.2610050302; SAFFER JD, 1981, MOL PHARMACOL, V20, P211; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Testolin L, 1997, EXP CELL RES, V230, P220, DOI 10.1006/excr.1996.3419; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TURK SR, 1987, ANTIMICROB AGENTS CH, V31, P544, DOI 10.1128/AAC.31.4.544; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis S, 2003, J CELL SCI, V116, P4053, DOI 10.1242/jcs.00754; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	79	17	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15271	15283		10.1074/jbc.M701362200	http://dx.doi.org/10.1074/jbc.M701362200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17371872	hybrid			2022-12-27	WOS:000246589000066
J	Nagle, CA; An, J; Shiota, M; Torres, TP; Cline, GW; Liu, ZX; Wang, SL; Catlin, RL; Shulman, GI; Newgard, CB; Coleman, RA				Nagle, Cynthia A.; An, Jie; Shiota, Masakazu; Torres, Tracy P.; Cline, Gary W.; Liu, Zhen-Xiang; Wang, Shuli; Catlin, ReEtta L.; Shulman, Gerald I.; Newgard, Christopher B.; Coleman, Rosalind A.			Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE-1; SKELETAL-MUSCLE; FATTY-ACIDS; GLYCOGEN-SYNTHESIS; SAFFLOWER OIL; FISH-OIL; LIVER; TRIACYLGLYCEROL; ACTIVATION	Fatty liver is commonly associated with insulin resistance and type 2 diabetes, but it is unclear whether triacylglycerol accumulation or an excess flux of lipid intermediates in the pathway of triacyglycerol synthesis are sufficient to cause insulin resistance in the absence of genetic or diet-induced obesity. To determine whether increased glycerolipid flux can, by itself, cause hepatic insulin resistance, we used an adenoviral construct to overexpress glycerol-sn-3-phosphate acyltransferase-1 (Ad-GPAT1), the committed step in de novo triacylglycerol synthesis. After 5-7 days, food intake, body weight, and fat pad weight did not differ between Ad-GPAT1 and Ad-enhanced green fluorescent protein control rats, but the chow-fed Ad-GPAT1 rats developed fatty liver, hyperlipidemia, and insulin resistance. Liver was the predominant site of insulin resistance; Ad-GPAT1 rats had 2.5-fold higher hepatic glucose output than controls during a hyperinsulinemic-euglycemic clamp. Hepatic diacylglycerol and lysophosphatidate were elevated in Ad-GPAT1 rats, suggesting a role for these lipid metabolites in the development of hepatic insulin resistance, and hepatic protein kinase C is an element of was activated, providing a potential mechanism for insulin resistance. Ad-GPAT1-treated rats had 50% lower hepatic NF-kappa B activity and no difference in expression of tumor necrosis factor-alpha and interleukin-beta, consistent with hepatic insulin resistance in the absence of increased hepatic inflammation. Glycogen synthesis and uptake of 2-deoxyglucose were reduced in skeletal muscle, suggesting mild peripheral insulin resistance associated with a higher content of skeletal muscle triacylglycerol. These results indicate that increased flux through the pathway of hepatic de novo triacylglycerol synthesis can cause hepatic and systemic insulin resistance in the absence of obesity or a lipogenic diet.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27704 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Vanderbilt University; Howard Hughes Medical Institute; Yale University; Yale University	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, CB 7461, Chapel Hill, NC 27599 USA.	rcoleman@unc.edu	Adiels, Martin/C-9278-2011; Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987, R56DK056598, R56DK060667, R01DK060667, P01DK058398, P30DK056350, R01DK056598, R01DK040936, U24DK059635] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056598, P30 DK034987, R01 DK040936, DK56598, P30 DK34987, P01 DK058398, R56 DK056598, U24 DK059635, DK-58398, R56 DK060667, P30 DK056350, U24 DK59635, DK-40936, R01 DK056598-25, P30 DK056350-050001, R01 DK060667, DK60667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An J, 2004, NAT MED, V10, P268, DOI 10.1038/nm995; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; BECKER TC, 2004, METHOD CELL BIOL, V43, P161; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Cao JS, 2006, P NATL ACAD SCI USA, V103, P19695, DOI 10.1073/pnas.0609140103; Chitturi S, 2002, HEPATOLOGY, V35, P373, DOI 10.1053/jhep.2002.30692; COLEMAN RA, 1983, J BIOL CHEM, V258, P450; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; den Boer M, 2004, ARTERIOSCL THROM VAS, V24, P644, DOI 10.1161/01.ATV.0000116217.57583.6e; DONNELLY R, 1994, ENDOCRINOLOGY, V1135, P874; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Goudriaan JR, 2003, J LIPID RES, V44, P2270, DOI 10.1194/jlr.M300143-JLR200; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Gutierrez-Juarez R, 2006, J CLIN INVEST, V116, P1686, DOI 10.1172/JCI26991; Haluzik M, 2004, ENDOCRINOLOGY, V145, P3258, DOI 10.1210/en.2004-0219; Hammond LE, 2005, J BIOL CHEM, V280, P25629, DOI 10.1074/jbc.M503181200; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; Hegarty BD, 2003, ACTA PHYSIOL SCAND, V178, P373, DOI 10.1046/j.1365-201X.2003.01162.x; Ide T, 2004, MED SCI MONITOR, V10, pBR388; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; JERKINS AA, 1995, J BIOL CHEM, V270, P1416, DOI 10.1074/jbc.270.38.22135; Jucker BM, 1999, DIABETES, V48, P134, DOI 10.2337/diabetes.48.1.134; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS189, DOI 10.1055/s-2001-18581; Lam TKT, 2002, AM J PHYSIOL-ENDOC M, V283, pE682, DOI 10.1152/ajpendo.00038.2002; Lewin TM, 2005, AM J PHYSIOL-ENDOC M, V288, pE835, DOI 10.1152/ajpendo.00300.2004; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Linden D, 2004, J LIPID RES, V45, P1279, DOI 10.1194/jlr.M400010-JLR200; Linden D, 2006, FASEB J, V20, P434, DOI 10.1096/fj.05-4568com; Man WC, 2006, J LIPID RES, V47, P1928, DOI 10.1194/jlr.M600172-JLR200; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Neschen S, 2005, CELL METAB, V2, P55, DOI 10.1016/j.cmet.2005.06.006; Neschen S, 2002, AM J PHYSIOL-ENDOC M, V282, pE395, DOI 10.1152/ajpendo.00414.2001; NEWGARD CB, 1984, J BIOL CHEM, V259, P6958; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Onishi Y, 2003, BIOCHEM BIOPH RES CO, V303, P788, DOI 10.1016/S0006-291X(03)00407-8; Pedrini MT, 2005, DIABETOLOGIA, V48, P756, DOI 10.1007/s00125-005-1684-8; Petersen KF, 2002, AM J CARDIOL, V90, p11G; Qu X, 1999, J ENDOCRINOL, V162, P207, DOI 10.1677/joe.0.1620207; Reusch JEB, 2002, AM J CARDIOL, V90, p19G; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; SAUEL VT, 2007, J CLIN INVEST, V117, P739; SHIN DH, 1991, J BIOL CHEM, V266, P23834; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Younossi ZM, 2002, HEPATOLOGY, V35, P746, DOI 10.1053/jhep.2002.32483; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200	51	95	98	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14807	14815		10.1074/jbc.M611550200	http://dx.doi.org/10.1074/jbc.M611550200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389595	Green Accepted, hybrid, Green Submitted			2022-12-27	WOS:000246589000016
J	Kang, S; Bennett, CN; Gerin, I; Rapp, LA; Hankenson, KD; MacDougald, OA				Kang, Sona; Bennett, Christina N.; Gerin, Isabelle; Rapp, Lauren A.; Hankenson, Kurt D.; MacDougald, Ormond A.			Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; BROWN ADIPOCYTE DIFFERENTIATION; HIGH-BONE-MASS; BETA-CATENIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PROMOTES OSTEOGENESIS; 3T3-L1 CELLS; PPAR-GAMMA; IN-VITRO	Mesenchymal precursor cells have the potential to differentiate into several cell types, including adipocytes and osteoblasts. Activation of Wnt/beta-catenin signaling shifts mesenchymal cell fate toward osteoblastogenesis at the expense of adipogenesis; however, molecular mechanisms by which Wnt signaling alters mesenchymal cell fate have not been fully investigated. Our prior work indicates that multipotent precursors express adipogenic and osteoblastogenic transcription factors at physiological levels and that ectopic expression of Wnt10b in bipotential ST2 cells suppresses expression of CCAAT/enhancer-binding protein alpha (C/EBP alpha) and peroxisome proliferator-activated receptor gamma (PPAR gamma) and increases expression of Runx2, Dlx5, and osterix. Here, we demonstrate that transient activation of Wnt/beta-catenin signaling rapidly suppresses C/EBP alpha and PPAR gamma, followed by activation of osteoblastogenic transcription factors. Enforced expression of C/EBP alpha or PPAR gamma partially rescues lipid accumulation and decreases mineralization in ST2 cells expressing Wnt10b, suggesting that suppression of C/EBP alpha and PPAR gamma is required for Wnt/beta-catenin to alter cell fate. Furthermore, knocking down expression of C/EBP alpha, PPAR gamma, or both greatly reduces adipogenic potential and causes spontaneous osteoblastogenesis in ST2 cells and mouse embryonic fibroblasts, suggesting that Wnt signaling alters the fate of mesenchymal precursor cells primarily by suppressing C/EBP alpha and PPAR gamma.	Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Med Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Orthoped Surg, Med Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	MacDougald, OA (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Med Ctr, 1301 E Catherine Rd, Ann Arbor, MI 48109 USA.	macdouga@umich.edu	Hankenson, Kurt/AFS-9417-2022; Hankenson, Kurt/ABI-1547-2020	Hankenson, Kurt/0000-0001-6361-143X; MacDougald, Ormond/0000-0001-6907-7960	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062876, R56DK062876] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK62876] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acampora D, 1999, DEVELOPMENT, V126, P3795; Akerblad P, 2002, MOL CELL BIOL, V22, P8015, DOI 10.1128/MCB.22.22.8015-8025.2002; Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Backesjo CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; BILLS CE, 1971, JOHNS HOPKINS MED J, V128, P194; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Chen Z, 2005, CELL METAB, V1, P93, DOI 10.1016/j.cmet.2004.12.009; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Cock TA, 2004, EMBO REP, V5, P1007, DOI 10.1038/sj.embor.7400254; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200; Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gummow BM, 2003, J BIOL CHEM, V278, P26572, DOI 10.1074/jbc.M212677200; Hankenson KD, 2002, J BONE MINER RES, V17, P415, DOI 10.1359/jbmr.2002.17.3.415; Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564; Ichida F, 2004, J BIOL CHEM, V279, P34015, DOI 10.1074/jbc.M403621200; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200; Kanazawa A, 2005, DIABETOLOGIA, V48, P1315, DOI 10.1007/s00125-005-1797-0; Kang S, 2005, MOL CELL BIOL, V25, P1272, DOI 10.1128/MCB.25.4.1272-1282.2005; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kennell JA, 2003, MOL CELL BIOL, V23, P5366, DOI 10.1128/MCB.23.15.5366-5375.2003; Khan E, 2003, J LAB CLIN MED, V142, P29, DOI 10.1016/S0022-2143(03)00058-1; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Liu JJ, 2006, MOL CELL BIOL, V26, P5827, DOI 10.1128/MCB.00441-06; Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nanbu-Wakao R, 2002, MOL ENDOCRINOL, V16, P1565, DOI 10.1210/me.16.7.1565; Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756-3282(00)00317-3; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Olson LE, 2006, CELL, V125, P593, DOI 10.1016/j.cell.2006.02.046; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pearl LH, 2002, CURR OPIN STRUC BIOL, V12, P761, DOI 10.1016/S0959-440X(02)00386-X; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schwartz AV, 2006, J CLIN ENDOCR METAB, V91, P3349, DOI 10.1210/jc.2005-2226; Shimba S, 2005, P NATL ACAD SCI USA, V102, P12071, DOI 10.1073/pnas.0502383102; Shimba S, 2004, J BIOL CHEM, V279, P40946, DOI 10.1074/jbc.M400840200; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Soroceanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723; Suh JM, 2006, CELL METAB, V3, P25, DOI 10.1016/j.cmet.2005.11.012; Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102; ter Brugge PJ, 2003, CLIN ORAL IMPLAN RES, V14, P472, DOI 10.1034/j.1600-0501.2003.00886.x; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tong Q, 2005, MOL CELL BIOL, V25, P706, DOI 10.1128/MCB.25.2.706-715.2005; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Tseng YH, 2005, NAT CELL BIOL, V7, P601, DOI 10.1038/ncb1259; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Wiesenthal V, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj029; Wu JH, 2005, BIOCHEMISTRY-US, V44, P11098, DOI 10.1021/bi050166i; Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677-4684.2004	82	309	336	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14515	14524		10.1074/jbc.M700030200	http://dx.doi.org/10.1074/jbc.M700030200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17351296	hybrid			2022-12-27	WOS:000246245800065
J	Marechal, A; Mattioli, TA; Stuehr, DJ; Santolini, J				Marechal, Amandine; Mattioli, Tony A.; Stuehr, Dennis J.; Santolini, Jerome			Activation of peroxynitrite by inducible nitric-oxide synthase - A direct source of nitrative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE NITRATION; CARBON-DIOXIDE; MEDIATED OXIDATION; NITROGEN MONOXIDE; MECHANISM; CHEMISTRY; INACTIVATION; MYOGLOBIN; PTERIN; HEME	In mammals, nitric oxide (NO) is an essential biological mediator that is exclusively synthesized by nitric-oxide synthases (NOSs). However, NOSs are also directly or indirectly responsible for the production of peroxynitrite, a well known cytotoxic agent involved in numerous pathophysiological processes. Peroxynitrite reactivity is extremely intricate and highly depends on activators such as hemoproteins. NOSs present, therefore, the unique ability to both produce and activate peroxynitrite, which confers upon them a major role in the control of peroxynitrite bioactivity. We report here the first kinetic analysis of the interaction between peroxynitrite and the oxygenase domain of inducible NOS (iNOSoxy). iNOSoxy binds peroxynitrite and accelerates its decomposition with a second order rate constant of 22 x 10(4) m(-1)s(-1) at pH 7.4. This reaction is pH-dependent and is abolished by the binding of substrate or product. Peroxynitrite activation is correlated with the observation of a new iNOS heme intermediate with specific absorption at 445 nm. iNOSoxy modifies peroxynitrite reactivity and directs it toward one-electron processes such as nitration or one-electron oxidation. Taken together our results suggest that, upon binding to iNOSoxy, peroxynitrite undergoes homolytic cleavage with build-up of an oxo-ferryl intermediate and concomitant release of a NO2. radical. Successive cycles of peroxynitrite activation were shown to lead to iNOSoxy autocatalytic nitration and inhibition. The balance between peroxynitrite activation and self-inhibition of iNOSoxy may determine the contribution of NOSs to cellular oxidative stress.	CEA Saclay, Lab Stress Oxydant & Detoxicat, iBiTec S, F-91191 Gif Sur Yvette, France; Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; Cleveland Clinic Foundation	Santolini, J (corresponding author), CEA Saclay, Lab Stress Oxydant & Detoxicat, iBiTec S, F-91191 Gif Sur Yvette, France.	jerome.santolini@cea.fr	MARECHAL, Amandine/AAF-7931-2020	MARECHAL, Amandine/0000-0003-3460-3806; Santolini, Jerome/0000-0001-8919-112X				AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ANDERSEN HJ, 1992, J AGR FOOD CHEM, V40, P1741, DOI 10.1021/jf00022a004; Arnold EV, 1996, METHOD ENZYMOL, V269, P41; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bonini MG, 2001, J BIOL CHEM, V276, P9749, DOI 10.1074/jbc.M008456200; Bredt DS, 2003, J CELL SCI, V116, P9, DOI 10.1242/jcs.00183; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daiber A, 2000, EUR J BIOCHEM, V267, P6729, DOI 10.1046/j.1432-1033.2000.01768.x; Daiber A, 2004, BIOCHEM BIOPH RES CO, V317, P873, DOI 10.1016/j.bbrc.2004.03.122; Daiber A, 2002, METHOD ENZYMOL, V359, P379; Daiber A, 2000, J INORG BIOCHEM, V81, P213, DOI 10.1016/S0162-0134(00)00110-0; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; Garcin ED, 2004, J BIOL CHEM, V279, P37918, DOI 10.1074/jbc.M406204200; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Ghosh DK, 2003, FRONT BIOSCI-LANDMRK, V8, pD193, DOI 10.2741/959; Goldstein S, 2005, CHEM REV, V105, P2457, DOI 10.1021/cr0307087; Herold S, 2005, COMP BIOCHEM PHYS A, V142, P124, DOI 10.1016/j.cbpb.2005.06.009; Herold S, 2005, BIOCHEMISTRY-US, V44, P6223, DOI 10.1021/bi0475929; Herold S, 2003, BIOCHEMISTRY-US, V42, P14036, DOI 10.1021/bi0350349; Herold S, 2003, CHEM RES TOXICOL, V16, P390, DOI 10.1021/tx025595l; Herold S, 2002, BIOCHEMISTRY-US, V41, P13460, DOI 10.1021/bi026046h; Herold S, 1998, FEBS LETT, V439, P85, DOI 10.1016/S0014-5793(98)01345-3; Herold S, 2001, J AM CHEM SOC, V123, P4085, DOI 10.1021/ja010111d; Huhmer AFR, 1996, CHEM RES TOXICOL, V9, P484, DOI 10.1021/tx950152l; Huhmer AFR, 1997, CHEM RES TOXICOL, V10, P618, DOI 10.1021/tx960188t; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Ishimura Y, 2005, BIOCHEM BIOPH RES CO, V338, P543, DOI 10.1016/j.bbrc.2005.07.202; Koppenol WH, 1998, FREE RADICAL BIO MED, V25, P385, DOI 10.1016/S0891-5849(98)00093-8; Koppenol WH, 2001, REDOX REP, V6, P339, DOI 10.1179/135100001101536517; Lee JB, 1998, J AM CHEM SOC, V120, P7493, DOI 10.1021/ja980507y; Lee JB, 1998, J AM CHEM SOC, V120, P6053, DOI 10.1021/ja9801036; Li HY, 2005, J INORG BIOCHEM, V99, P293, DOI 10.1016/j.jinorgbio.2004.10.016; Lincoln J, 1997, NITRIC OXIDE HLTH DI; Lowenstein CJ, 2004, J CELL SCI, V117, P2865, DOI 10.1242/jcs.01166; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mehl M, 1999, NITRIC OXIDE-BIOL CH, V3, P142, DOI 10.1006/niox.1999.0217; Meli R, 2002, J BIOL INORG CHEM, V7, P31, DOI 10.1007/s007750100262; Meunier B, 2004, CHEM REV, V104, P3947, DOI 10.1021/cr020443g; Mungrue IN, 2004, J CELL SCI, V117, P2627, DOI 10.1242/jcs.01187; NAKAJIMA R, 1985, BIOCHEM BIOPH RES CO, V128, P1, DOI 10.1016/0006-291X(85)91635-3; Negrerie M, 1999, J BIOL CHEM, V274, P24694, DOI 10.1074/jbc.274.35.24694; Panda K, 2002, J BIOL CHEM, V277, P31020, DOI 10.1074/jbc.M203749200; Pasquet JPEE, 1996, BIOCHIMIE, V78, P785, DOI 10.1016/S0300-9084(97)82537-0; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; Rosen GM, 2002, CHEM REV, V102, P1191, DOI 10.1021/cr010187s; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Sessa WC, 2004, J CELL SCI, V117, P2427, DOI 10.1242/jcs.01165; Shimanovich R, 2001, ARCH BIOCHEM BIOPHYS, V387, P307, DOI 10.1006/abbi.2000.2247; Stern MK, 1996, J AM CHEM SOC, V118, P8735, DOI 10.1021/ja961279f; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Titheradge MA, 1998, METH MOL B, V100, P83; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200; Zou MH, 2000, ARCH BIOCHEM BIOPHYS, V376, P149, DOI 10.1006/abbi.2000.1699	70	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14101	14112		10.1074/jbc.M609237200	http://dx.doi.org/10.1074/jbc.M609237200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17369257	hybrid			2022-12-27	WOS:000246245800020
J	Pandey, SK; Yu, XX; Watts, LM; Michael, MD; Sloop, KW; Rivard, AR; Leedom, TA; Manchem, VP; Samadzadeh, L; Mckay, RA; Monia, BP; Bhanot, S				Pandey, Sanjay K.; Yu, Xing Xian; Watts, Lynnetta M.; Michael, M. Dodson; Sloop, Kyle W.; Rivard, Amber R.; Leedom, Thomas A.; Manchem, Vara Prasad; Samadzadeh, Laura; McKay, Robert A.; Monia, Brett P.; Bhanot, Sanjay			Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; LMW-PTP; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; NEGATIVE REGULATOR; GLYCOGEN-SYNTHESIS; DIABETIC MICE; HUMAN-DISEASE; RESISTANCE; GLUCOSE	To investigate the role of low molecular weight protein-tyrosine phosphatase (LMW-PTP) in glucose metabolism and insulin action, a specific antisense oligonucleotide ( ASO) was used to reduce its expression both in vitro and in vivo. Reduction of LMW-PTP expression with the ASO in cultured mouse hepatocytes and in liver and fat tissues of diet-induced obese (DIO) mice and ob/ob mice led to increased phosphorylation and activity of key insulin signaling intermediates, including insulin receptor-beta subunit, phosphatidylinositol 3-kinase, and Akt in response to insulin stimulation. The ASO-treated DIO and ob/ob animals showed improved insulin sensitivity, which was reflected by a lowering of both plasma insulin and glucose levels and improved glucose and insulin tolerance in DIO mice. The treatment did not decrease body weight or increase metabolic rate. These data demonstrate that LMW-PTP is a key negative regulator of insulin action and a potential novel target for the treatment of insulin resistance and type 2 diabetes.	ISIS Pharmaceut, Antisense Drug Discovery, Metab Dis Program, Carlsbad, CA 92008 USA; Lilly Res Labs, Endocrine Discovery, Indianapolis, IN 46285 USA	Isis Pharmaceuticals Inc; Eli Lilly	Pandey, SK (corresponding author), ISIS Pharmaceut, Antisense Drug Discovery, Metab Dis Program, 1896 Rutherford Rd, Carlsbad, CA 92008 USA.	spandey@isisph.com		Michael, Mervyn/0000-0002-0224-1065				Bazzano LA, 2005, J AM COLL NUTR, V24, P310, DOI 10.1080/07315724.2005.10719479; Bottini N, 2002, ARCH IMMUNOL THER EX, V50, P95; Bottini N, 2002, MOL GENET METAB, V77, P226, DOI 10.1016/S1096-7192(02)00120-8; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; Chiarugi P, 2002, J BIOL CHEM, V277, P37331, DOI 10.1074/jbc.M205203200; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dean NM, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P319; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Gum RJ, 2003, DIABETES, V52, P21, DOI 10.2337/diabetes.52.1.21; Iannaccone U, 2005, METABOLISM, V54, P891, DOI 10.1016/j.metabol.2005.02.002; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; Magherini F, 1998, FEBS LETT, V437, P263, DOI 10.1016/S0014-5793(98)01241-1; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Pandey SK, 1998, BIOCHEMISTRY-US, V37, P7006, DOI 10.1021/bi9726786; Ramponi G, 1997, INT J BIOCHEM CELL B, V29, P279, DOI 10.1016/S1357-2725(96)00109-4; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Sleeman MW, 2005, NAT MED, V11, P199, DOI 10.1038/nm1178; Srivastava AK, 1998, MOL CELL BIOCHEM, V182, P135, DOI 10.1023/A:1006857527588; Taddei ML, 2000, BIOCHEM BIOPH RES CO, V270, P564, DOI 10.1006/bbrc.2000.2456; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yu XX, 2005, HEPATOLOGY, V42, P362, DOI 10.1002/hep.20783; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	32	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14291	14299		10.1074/jbc.M609626200	http://dx.doi.org/10.1074/jbc.M609626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17353188	hybrid			2022-12-27	WOS:000246245800040
J	Ceccarelli, DFJ; Blasutig, IM; Goudreault, M; Li, ZQ; Ruston, J; Pawson, T; Sicheri, F				Ceccarelli, Derek F. J.; Blasutig, Ivan M.; Goudreault, Marilyn; Li, Zhiqin; Ruston, Julie; Pawson, Tony; Sicheri, Frank			Non-canonical interaction of phosphoinositides with pleckstrin homology domains of Tiam1 and ArhGAP9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH DOMAIN; STRUCTURAL BASIS; DIFFRACTION DATA; MEMBRANE; BINDING; RAC; RECOGNITION; COMPLEX; KINASE; IDENTIFICATION	Pleckstrin homology (PH) domains are phosphoinositide (PI)-binding modules that target proteins to membrane surfaces. Here we define a family of PH domain proteins, including Tiam1 and ArhGAP9, that demonstrates specificity for PI(4,5)P-2, as well as for PI(3,4,5) P-3 and PI(3,4)P-2, the products of PI 3-kinase. These PH domain family members utilize a noncanonical phosphoinositide binding pocket related to that employed by beta- spectrin. Crystal structures of the PH domain of ArhGAP9 in complex with the headgroups of Ins(1,3,4)P-3, Ins(1,4,5)P-3, and Ins(1,3,5)P-3 reveal how two adjacent phosphate positions in PI(3,4)P-2, PI(4,5)P-2, and PI(3,4,5)P-3 are accommodated through flipped conformations of the bound phospholipid. We validate the non-canonical site of phosphoinositide interaction by showing that binding pocket mutations, which disrupt phosphoinositide binding in vitro, also disrupt membrane localization of Tiam1 in cells. We posit that the diversity in PI interaction modes displayed by PH domains contributes to their versatility of use in biological systems.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Syst Biol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Syst Biol, Toronto, ON M5G 1X5, Canada.	pawson@mshri.on.ca; sicheri@mshri.on.ca	Sicheri, Frank/F-8856-2013; Pawson, Tony J/E-4578-2013	Blasutig, Ivan/0000-0001-7310-2647; Ceccarelli, Derek/0000-0002-2674-9234				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balla T, 2005, J CELL SCI, V118, P2093, DOI 10.1242/jcs.02387; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlton JG, 2005, TRENDS CELL BIOL, V15, P540, DOI 10.1016/j.tcb.2005.08.005; Cozier GE, 2004, CURR TOP MICROBIOL, V282, P49; Cronin TC, 2004, EMBO J, V23, P3711, DOI 10.1038/sj.emboj.7600388; Di Lello P, 2005, BIOCHEMISTRY-US, V44, P7678, DOI 10.1021/bi050099s; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; DiNitto JP, 2006, BBA-MOL CELL BIOL L, V1761, P850, DOI 10.1016/j.bbalip.2006.04.008; DINITTO JP, 2003, SCI STKE, pRE16, DOI DOI 10.1126/STKE.2132003RE16; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Furukawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P643, DOI 10.1006/bbrc.2001.5022; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Mertens AE, 2003, FEBS LETT, V546, P11, DOI 10.1016/S0014-5793(03)00435-6; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Ten Klooster JP, 2006, BIOCHEM J, V397, P39, DOI 10.1042/BJ20051957; Teo HL, 2006, CELL, V125, P99, DOI 10.1016/j.cell.2006.01.047; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368; ZHANG P, 1995, STRUCTURE, V3, P1185, DOI 10.1016/S0969-2126(01)00254-4	46	75	77	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13864	13874		10.1074/jbc.M700505200	http://dx.doi.org/10.1074/jbc.M700505200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339315	hybrid			2022-12-27	WOS:000246060300076
J	Grodnitzky, JA; Syed, N; Kimber, MJ; Day, TA; Donaldson, JG; Hsu, WH				Grodnitzky, Justin A.; Syed, Nasser; Kimber, Michael J.; Day, Tim A.; Donaldson, Julie G.; Hsu, Walter H.			Somatostatin receptors signal through EFA6A-ARF6 to activate phospholipase D in clonal beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; NUCLEOTIDE EXCHANGE FACTOR; SMOOTH-MUSCLE-CELLS; GTP-BINDING PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INSULIN-SECRETION; PLASMA-MEMBRANE; P115 RHOGEF; ARF6; STIMULATION	Somatostatin (SS) is a peptide hormone that inhibits insulin secretion in beta-cells by activating its G(i/o)-coupled receptors. Our previous work indicated that a beta gamma-dimer of G(i/o) coupled to SS receptors can activate phospholipase D1 ( PLD1) ( Cheng, H., Grodnitzky, J. A., Yibchok-anun, S., Ding, J., and Hsu, W. H. (2005) Mol. Pharmacol. 67, 2162-2172). The aim of the present study was to elucidate the mechanisms underlying SS-induced PLD activation. We demonstrated the presence of ADP-ribosylation factor Arf1 and Arf6 in clonal beta-cells, HIT-T15. We also determined that the activation of PLD1 was mediated through Arf6. Overexpression of dominant-negative (dn) Arf6 mutant, Arf6( T27N), and suppression of mRNA levels using siRNA, both abolished SS-induced PLD activation, while overexpression of wild type Arf6 further enhanced this PLD activation. In contrast, overexpression of dn-Arf1 mutant Arf1(T31N) or dn-Arf5 mutant Arf5(T31N) failed to reduce SS-induced PLD activation. These findings suggested that Arf6, but not Arf1 or Arf5, mediates the effect of SS. We further determined the involvement of the Arf6 guanine nucleotide exchange factor (GEF) EFA6A, a GEF previously thought to be found predominantly in the brain, in the activation of PLD1 in HIT-T15 cells. Using Northern and Western blot analyses, both mRNA and protein of EFA6A were found in these cells. Overexpression of dn-EFA6A mutant, EFA6A( E242K), and suppression of mRNA levels using siRNA, both abolished SS-induced PLD activation, whereas overexpression of dn-EFA6B mutant, EFA6B( E651K), failed to reduce SS-induced PLD activation. In addition, overexpression of dn-ARNO mutant, ARNO(E156K), another GEF of Arf6, had no effect on SS-induced activation of PLD. Taken together, these results suggest that SS signals through EFA6A to activate Arf6-PLD cascade.	Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Iowa State University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hsu, WH (corresponding author), Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA.	whsu@iastate.edu		Day, Tim/0000-0002-9037-6540	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000517, Z01HL000517] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; Andresen BT, 2001, HYPERTENSION, V37, P635, DOI 10.1161/01.HYP.37.2.635; ANGING WF, 2005, REV MED PHYSL, P85; Bhattacharya M, 2004, J NEUROSCI, V24, P8752, DOI 10.1523/JNEUROSCI.3155-04.2004; Bollag WB, 2002, MOL CELL ENDOCRINOL, V192, P7, DOI 10.1016/S0303-7207(02)00134-X; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; Cheng H, 2005, MOL PHARMACOL, V67, P2162, DOI 10.1124/mol.104.010470; Cheng H, 2002, LIFE SCI, V71, P927, DOI 10.1016/S0024-3205(02)01774-5; Choi S, 2006, J NEUROSCI, V26, P4811, DOI 10.1523/JNEUROSCI.4182-05.2006; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; Cui Y, 1997, J INVEST MED, V45, P388; Derrien V, 2002, J CELL SCI, V115, P2867; Divecha N, 2000, EMBO J, V19, P5440, DOI 10.1093/emboj/19.20.5440; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Du GW, 2004, MOL BIOL CELL, V15, P1024, DOI 10.1091/mbc.E03-09-0673; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fahimi-Vahid M, 2002, J MOL CELL CARDIOL, V34, P441, DOI 10.1006/jmcc.2002.1525; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Foster DA, 2003, MOL CANCER RES, V1, P789; GUPTA S, 1995, ENDOCRINOLOGY, V136, P3794, DOI 10.1210/en.136.9.3794; HA KS, 1994, BIOCHEM J, V303, P55, DOI 10.1042/bj3030055; HADCOCK JR, 1994, MOL PHARMACOL, V45, P410; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; HOU CF, 1994, J BIOL CHEM, V269, P10357; HSU WH, 1991, J BIOL CHEM, V266, P837; Hughes WE, 2004, J BIOL CHEM, V279, P27534, DOI 10.1074/jbc.M403012200; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Karschin A, 1995, NEUROREPORT, V7, P121, DOI 10.1097/00001756-199512000-00029; Kato Y, 1997, PROSTAGLANDINS, V54, P475, DOI 10.1016/S0090-6980(97)00061-0; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lawrence JTR, 2003, P NATL ACAD SCI USA, V100, P13320, DOI 10.1073/pnas.2232129100; Lee SD, 2000, NEUROSCI LETT, V294, P130, DOI 10.1016/S0304-3940(00)01563-9; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Macia E, 2001, J BIOL CHEM, V276, P24925, DOI 10.1074/jbc.M103284200; METZ SA, 1990, BIOCHEM J, V270, P427, DOI 10.1042/bj2700427; Mitchell R, 2003, J BIOL CHEM, V278, P33818, DOI 10.1074/jbc.M305825200; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MIWA M, 1995, BIOCHEM CELL BIOL, V73, P191, DOI 10.1139/o95-023; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Niedergang F, 2003, J CELL BIOL, V161, P1143, DOI 10.1083/jcb.200210069; Niu JX, 2003, CIRC RES, V93, P848, DOI 10.1161/01.RES.0000097607.14733.0C; O'Luanaigh N, 2002, MOL BIOL CELL, V13, P3730, DOI 10.1091/mbc.E02-04-0213; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; REISINE T, 1995, ENDOCR REV, V16, P427, DOI 10.1210/er.16.4.427; Robertson DN, 2003, MOL PHARMACOL, V64, P1239, DOI 10.1124/mol.64.5.1239; Sakagami H, 2004, EUR J NEUROSCI, V19, P863, DOI 10.1111/j.0953-816X.2004.03195.x; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251	63	7	9	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13410	13418		10.1074/jbc.M701940200	http://dx.doi.org/10.1074/jbc.M701940200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353194	Green Submitted, hybrid			2022-12-27	WOS:000246060300030
J	Grosfeld, A; Stolze, IP; Cockman, ME; Pugh, CW; Edelmann, M; Kessler, B; Bullock, AN; Ratcliffe, PJ; Masson, N				Grosfeld, Alexandra; Stolze, Ineke P.; Cockman, Matthew E.; Pugh, Christopher W.; Edelmann, Mariola; Kessler, Benedikt; Bullock, Alex N.; Ratcliffe, Peter J.; Masson, Norma			Interaction of hydroxylated collagen IV with the von Hippel-Lindau tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; PROTEIN; COMPLEX; GROWTH; PVHL; HYDROXYPROLINE; UBIQUITYLATION; TUMORIGENESIS; ANGIOGENESIS; TRAFFICKING	The von Hippel-Lindau tumor suppressor (pVHL) targets hydroxylated alpha-subunits of hypoxia-inducible factor (HIF) for ubiquitin-mediated proteasomal destruction through direct interaction with the hydroxyproline binding pocket in its beta-domain. Although disruption of this process may contribute to VHL-associated tumor predisposition by up-regulation of HIF target genes, genetic and biochemical analyses support the existence of additional functions, including a role in the assembly of extracellular matrix. In an attempt to delineate these pathways, we searched for novel pVHL-binding proteins. Here we report a direct, hydroxylation-dependent interaction with alpha-chains of collagen IV. Interaction with pVHL was also observed with fibrillar collagen chains, but not the folded collagen triple helix. The interaction was suppressed by a wide range of tumor-associated mutations, including those that do not disturb the regulation of HIF, supporting a role in HIF- independent tumor suppressor functions.	Univ Oxford, Oxford OX3 7BN, England	University of Oxford	Masson, N (corresponding author), Univ Oxford, Henry Wellcome Bldg Mol Physiol, Oxford OX3 7BN, England.	nmasson@well.ox.ac.uk	Grosfeld, Alexandra/AAH-3510-2020; Cockman, Matthew/V-9619-2019; Kessler, Benedikt/AAY-8614-2021; Grosfeld, Alexandra/R-1404-2017	Cockman, Matthew/0000-0002-3310-4821; Kessler, Benedikt/0000-0002-8160-2446; Grosfeld, Alexandra/0000-0002-9508-036X; Pugh, Chris/0000-0002-5170-1662; Edelmann, Mariola/0000-0003-0459-7716; Ratcliffe, Peter/0000-0002-2853-806X	Medical Research Council [G116/127] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G116/127] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barry RE, 2004, TRENDS MOL MED, V10, P466, DOI 10.1016/j.molmed.2004.07.008; Batycka M, 2006, RAPID COMMUN MASS SP, V20, P2074, DOI 10.1002/rcm.2563; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; Canty EG, 2005, J CELL SCI, V118, P1341, DOI 10.1242/jcs.01731; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Esteban-Barragan MA, 2002, CANCER RES, V62, P2929; Fitzgerald J, 1999, J BIOL CHEM, V274, P27392, DOI 10.1074/jbc.274.39.27392; Gotkin MG, 2004, EXP CELL RES, V296, P307, DOI 10.1016/j.yexcr.2004.01.029; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Zimmer M, 2004, MOL CANCER RES, V2, P89	27	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13264	13269		10.1074/jbc.M611648200	http://dx.doi.org/10.1074/jbc.M611648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339318	hybrid			2022-12-27	WOS:000246060300014
J	Wang, ZX; Teh, CHL; Kueh, JLL; Lufkin, T; Robson, P; Stanton, LW				Wang, Zheng-Xu; Teh, Christina Hui-Leng; Kueh, Jacqueline L. L.; Lufkin, Thomas; Robson, Paul; Stanton, Lawrence W.			Oct4 and sox2 directly regulate expression of another pluripotency transcription factor, Zfp206, in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SELF-RENEWAL; ENHANCER; COMPLEX; NANOG; OCTAMER; OCT-3/4; SITES	It is well known that Oct4 and Sox2 play an important role in the maintenance of embryonic stem cell pluripotency. These transcription factors bind to regulatory regions within hundreds of target genes to control their expression. Zfp206 is a recently characterized transcription factor that has a role in maintaining stem cell pluripotency. We have demonstrated here that Zfp206 is a direct downstream target of Oct4 and Sox2. Two composite sox-oct binding sites have been identified within the first intron of Zfp206. We have demonstrated binding of Oct4 and Sox2 to this region. In addition, we have shown that Oct4 or Sox2 alone can activate transcription via one of these sox-oct elements, although the presence of both Oct4 and Sox2 gave rise to a synergistic effect. These studies extend our understanding of the transcriptional network that operates to regulate the differentiation potential of embryonic stem cells.	Genome Inst Singapore, Dept Stem Cell & Dev Biol, Singapore 138672, Singapore; Jin Cheng Hosp Lan Zhou, Dept Gen Surg, Lanzhou 730050, Gansu, Peoples R China; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore	Stanton, LW (corresponding author), Genome Inst Singapore, Dept Stem Cell & Dev Biol, 60 Biopolis St, Singapore 138672, Singapore.	stantonl@gis.a-star.edu.sg	Lufkin, Thomas/AAG-7476-2019; Robson, Paul/A-3464-2009; Lufkin, Thomas/B-5352-2011	Lufkin, Thomas/0000-0002-7902-4771; Robson, Paul/0000-0002-0191-3958; Lufkin, Thomas/0000-0002-7902-4771				Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Botquin V, 1998, GENE DEV, V12, P2073, DOI 10.1101/gad.12.13.2073; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brandenberger R, 2004, NAT BIOTECHNOL, V22, P707, DOI 10.1038/nbt971; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Catena R, 2004, J BIOL CHEM, V279, P41846, DOI 10.1074/jbc.M405514200; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; Furusawa T, 2006, BIOL REPROD, V75, P555, DOI 10.1095/biolreprod.105.049502; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Matin MM, 2004, STEM CELLS, V22, P659, DOI 10.1634/stemcells.22-5-659; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Palmqvist L, 2005, STEM CELLS, V23, P663, DOI 10.1634/stemcells.2004-0157; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Remenyi A, 2003, GENE DEV, V17, P2048, DOI 10.1101/gad.269303; Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Sharov AA, 2003, PLOS BIOL, V1, P410, DOI 10.1371/journal.pbio.0000074; Tanaka TS, 2002, GENOME RES, V12, P1921, DOI 10.1101/gr.670002; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200; Yoshikawa T, 2006, GENE EXPR PATTERNS, V6, P213, DOI 10.1016/j.modgep.2005.06.003; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zhang W, 2006, NUCLEIC ACIDS RES, V34, P4780, DOI 10.1093/nar/gkl631	30	54	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12822	12830		10.1074/jbc.M611814200	http://dx.doi.org/10.1074/jbc.M611814200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17344211	hybrid			2022-12-27	WOS:000245942800054
J	Xiao, JN; Luo, XB; Lin, HX; Zhang, Y; Lu, YJ; Wang, N; Zhang, YQ; Yang, BF; Wang, ZG				Xiao, Jiening; Luo, Xiaobin; Lin, Huixian; Zhang, Ying; Lu, Yanjie; Wang, Ning; Zhang, Yiqiang; Yang, Baofeng; Wang, Zhiguo			MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERVAL; MORTALITY; PREDICTORS; DISPERSION; BINDING; RABBIT; DEATH; GENE	We have previously found that the ether-a-go-go related gene (ERG), a long QT syndrome gene encoding a key K+ channel (I-Kr) in cardiac cells, is severely depressed in its expression at the protein level but not at the mRNA level in diabetic subjects. The mechanisms underlying the disparate alterations of ERG protein and mRNA, however, remained unknown. Wereport here a remarkable overexpression of miR-133 in hearts from a rabbit model of diabetes, and in parallel the expression of serum response factor ( SRF), which is known to be a transactivator of miR-133, was also robustly increased. Delivery of exogenous miR-133 into the rabbit myocytes and cell lines produced posttranscriptional repression of ERG, down-regulating ERG protein level without altering its transcript level and caused substantial depression of IKr, an effect abrogated by the miR-133 antisense inhibitor. Functional inhibition or gene silencing of SRF down- regulated miR-133 expression and increased IKr density. Repression of ERG by miR-133 likely underlies the differential changes ofERGprotein and transcript thereby depression of IKr, and contributes to repolarization slowing thereby QT prolongation and the associated arrhythmias, in diabetic hearts. Our study provided the first evidence for the pathological role of miR-133 in adult hearts and thus expanded our understanding of the cellular function and pathophysiological roles of miRNAs.	Harbin Med Univ, Dept Pharmacol, State Prov Key Labs Biomed Pharmaceut, Heilongjiang 150086, Peoples R China; Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Harbin Med Univ, Cardiovasc Res Inst, Heilongjiang 150086, Peoples R China	Harbin Medical University; Universite de Montreal; Universite de Montreal; Harbin Medical University	Yang, BF (corresponding author), Harbin Med Univ, Dept Pharmacol, State Prov Key Labs Biomed Pharmaceut, Heilongjiang 150086, Peoples R China.	yangbf@ems.hrbmu.edu.cn; wz@gmail.com	Wang, Zhiguo/GRS-4339-2022; wang, zhiguo/AAN-4182-2021	Wang, Zhiguo/0000-0002-0811-2045; 				Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Cardoso CRL, 2003, STROKE, V34, P2187, DOI 10.1161/01.STR.0000085084.15144.66; Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Choy AM, 1997, CIRCULATION, V96, P2149; Christensen PK, 2000, SCAND J CLIN LAB INV, V60, P323, DOI 10.1080/003655100750046486; Janse MJ, 2004, CARDIOVASC RES, V61, P208, DOI 10.1016/j.cardiores.2003.11.018; Jones EMC, 2004, J BIOL CHEM, V279, P44690, DOI 10.1074/jbc.M408344200; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Li GR, 2002, AM J PHYSIOL-HEART C, V283, pH1031, DOI 10.1152/ajpheart.00105.2002; Lu XG, 1998, J GERONTOL A-BIOL, V53, pB3, DOI 10.1093/gerona/53A.1.B3; LUO X, 2007, IN PRESS J CELL PHYS; Nelson TJ, 2005, J MOL CELL CARDIOL, V39, P479, DOI 10.1016/j.yjmcc.2005.05.004; Okin PM, 2004, DIABETES, V53, P434, DOI 10.2337/diabetes.53.2.434; Rana BS, 2005, HEART, V91, P44, DOI 10.1136/hrt.2003.017632; RENNECKE J, 2005, PLOS BIOL, V3, pE85; Rossing P, 2001, DIABETIC MED, V18, P199, DOI 10.1046/j.1464-5491.2001.00446.x; Sawicki PT, 1996, DIABETOLOGIA, V39, P77; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Taylor A, 1997, MOL CELL BIOCHEM, V169, P61, DOI 10.1023/A:1006898812618; Tsuji Y, 2000, CARDIOVASC RES, V48, P300, DOI 10.1016/S0008-6363(00)00180-2; Veglio M, 2004, J ENDOCRINOL INVEST, V27, P175, DOI 10.1007/BF03346265; Veglio M, 2002, J INTERN MED, V251, P317, DOI 10.1046/j.1365-2796.2002.00955.x; Wang HZ, 2002, CANCER RES, V62, P4843; Wang ZG, 1999, CIRC RES, V84, P551, DOI 10.1161/01.RES.84.5.551; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782; ZHANG Y, 2006, AM J PHYSIOL, V291, P1446; Zhang YQ, 2007, CELL PHYSIOL BIOCHEM, V19, P225, DOI 10.1159/000100642; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	29	197	250	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12363	12367		10.1074/jbc.C700015200	http://dx.doi.org/10.1074/jbc.C700015200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17344217	Green Published, hybrid			2022-12-27	WOS:000245942800004
J	Cendron, L; Berni, R; Folli, C; Ramazzina, I; Percudani, R; Zanotti, G				Cendron, Laura; Berni, Rodolfo; Folli, Claudia; Ramazzina, Ileana; Percudani, Riccardo; Zanotti, Giuseppe			The structure of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase provides insights into the mechanism of uric acid degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSTHYRETIN-RELATED PROTEIN; CRYSTAL-STRUCTURE; PRODUCT; 5-HYDROXYISOURATE; CRYSTALLOGRAPHY; IDENTIFICATION; PATHWAY; ENZYME	The complete degradation of uric acid to (S)-allantoin, as recently elucidated, involves three enzymatic reactions. Inactivation by pseudogenization of the genes of the pathway occurred during hominoid evolution, resulting in a high concentration of urate in the blood and susceptibility to gout. Here, we describe the 1.8 angstrom resolution crystal structure of the homodimeric 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase, which catalyzes the last step in the urate degradation pathway, for both ligand-free enzyme and enzyme in complex with the substrate analogs (R)-allantoin and guanine. Each monomer comprises ten alpha-helices, grouped into two domains and assembled in a novel fold. The structure and the mutational analysis of the active site have allowed us to identify some residues that are essential for catalysis, among which His-67 and Glu-87 appear to play a particularly significant role. Glu-87 may facilitate the exit of the carboxylate group because of electrostatic repulsion that destabilizes the ground state of the substrate, whereas His-67 is likely to be involved in a protonation step leading to the stereoselective formation of the (S)-allantoin enantiomer as reaction product. The structural and functional characterization of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase can provide useful information in view of the potential use of this enzyme in the enzymatic therapy of gout.	Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Padua, Dept Chem, Inst Chim Biomol Consiglio Nazl Ric, Sect Padua, I-35131 Padua, Italy; Venetian Inst Mol Med, I-35127 Padua, Italy	University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Padua; Veneto Institute Molecular Medicine	Percudani, R (corresponding author), Univ Parma, Dept Biochem & Mol Biol, Viale Sci 23-A, I-43100 Parma, Italy.	riccardo.percudani@unipr.it; giuseppe.zanotti@unipd.it	cendron, Laura/A-5202-2014; percudani, riccardo/B-4872-2011	percudani, riccardo/0000-0001-8452-1062; Berni, Rodolfo/0000-0002-1839-0479; Cendron, Laura/0000-0002-0125-0461; Ramazzina, Ileana/0000-0003-1009-2917; Zanotti, Giuseppe/0000-0002-0945-6501				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Begley TP, 2004, CURR OPIN CHEM BIOL, V8, P508, DOI 10.1016/j.cbpa.2004.08.004; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Colloc'h N, 2000, PROTEINS, V39, P142, DOI 10.1002/(SICI)1097-0134(20000501)39:2<142::AID-PROT4>3.0.CO;2-X; Colloch N, 1997, NAT STRUCT BIOL, V4, P947, DOI 10.1038/nsb1197-947; DeLano W.L, PYMOL MOL GRAPHICS S; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gabison L, 2006, FEBS LETT, V580, P2087, DOI 10.1016/j.febslet.2006.03.007; Hennebry SC, 2006, J MOL BIOL, V359, P1389, DOI 10.1016/j.jmb.2006.04.057; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P116; Jung DK, 2006, P NATL ACAD SCI USA, V103, P9790, DOI 10.1073/pnas.0600523103; Kahn K, 1997, J AM CHEM SOC, V119, P5435, DOI 10.1021/ja970375t; KHAN K, 1997, BIOCHEMISTRY-US, V36, P4731; Laskowski RA, 2005, NUCLEIC ACIDS RES, V33, pW89, DOI 10.1093/nar/gki414; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee Susan J, 2006, Curr Rheumatol Rep, V8, P224, DOI 10.1007/s11926-996-0029-z; Lee Y, 2005, FEBS LETT, V579, P4769, DOI 10.1016/j.febslet.2005.07.056; Lundberg E, 2006, J STRUCT BIOL, V155, P445, DOI 10.1016/j.jsb.2006.04.002; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Miller BG, 2002, ANNU REV BIOCHEM, V71, P847, DOI 10.1146/annurev.biochem.71.110601.135446; MODRIC N, 1992, TETRAHEDRON LETT, V33, P6691, DOI 10.1016/S0040-4039(00)61021-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OLEARY MH, 1992, ENZYMES, V20, P235; Ramazzina I, 2006, NAT CHEM BIOL, V2, P144, DOI 10.1038/nchembio768; Sarma AD, 1999, J BIOL CHEM, V274, P33863, DOI 10.1074/jbc.274.48.33863; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; VOGELS GD, 1976, BACTERIOL REV, V40, P403, DOI 10.1128/MMBR.40.2.403-468.1976; Wu N, 2000, P NATL ACAD SCI USA, V97, P2017, DOI 10.1073/pnas.050417797; Zanotti G, 2006, J MOL BIOL, V363, P1, DOI 10.1016/j.jmb.2006.07.079	33	37	40	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18182	18189		10.1074/jbc.M701297200	http://dx.doi.org/10.1074/jbc.M701297200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17428786	hybrid			2022-12-27	WOS:000247302000024
J	Furland, NE; Oresti, GM; Antollini, SS; Venturino, A; Maldonado, EN; Aveldano, MI				Furland, Natalia E.; Oresti, Gerardo M.; Antollini, Silvia S.; Venturino, Andres; Maldonado, Eduardo N.; Aveldano, Marta I.			Very long-chain polyunsaturated fatty acids are the major acyl groups of sphingomyelins and ceramides in the head of mammalian spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID RAFTS; ACROSOME REACTION; DIPOLYUNSATURATED PHOSPHATIDYLCHOLINES; DISPLACES CHOLESTEROL; PLASMA-MEMBRANE; SPERM; CAPACITATION; FERTILIZATION; ASSOCIATION; ACTIVATION	Very long-chain (C24 to C34) polyunsaturated fatty acids (VLCPUFA) are important constituents of sphingomyelin (SM) and ceramide (Cer) in testicular germ cells. In the present paper we focused on the SM and Cer and their fatty acids in spermatozoa and their main regions, heads and tails. In bull and ram spermatozoa, SM was the third most abundant phospholipid and VLCPUFA were the major acyl groups (similar to 70%) of SM and Cer. In rat epididymal spermatozoa the SM/Cer ratio was low in the absence of and could be maintained high in the presence of the cation chelator EDTA, added to the medium used for sperm isolation. This fact points to the occurrence of an active divalent cation-dependent sphingomyelinase. Bull and rat sperm had an uneven head-tail distribution of phospholipid, with virtually all the VLCPUFA-rich SM located at the head, the lower SM content in the rat being determined by the lower sperm head/tail size ratio. Most of the SM from bull sperm heads was readily solubilized with 1% Triton X-100 at 4 degrees C. The detergent-soluble SM fraction was richer in VLCPUFA than the nonsoluble fraction and richer in saturated fatty acids. Cer was produced at the expense of SM, thus decreasing severalfold the SM/Cer ratio in rat spermatozoa incubated for 2 h in presence of the sperm-capacitating agents, calcium, bicarbonate, and albumin. The generation of Cer from SM in the sperm head surface may be an early step among the biochemical and biophysical changes known to take place in the spermatozoon in the physiological events preceding fertilization.	Univ Nacl Sur, Inst Invest Bioquim, Consejo Natl Invest Cient & Tecn, RA-8000 Bahia Blanca, Argentina; Univ Nacl Comahue, Consejo Natl Invest Cient & Tecn, Lab Teriogenol, RA-8300 Neuquen, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of the South; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Universidad Nacional del Comahue	Aveldano, MI (corresponding author), Consejo Nacl Invest Cient & Tecn, Ctr Reg Invest Basicas & Aplicadas Bahia Blanca, INIBIBB, CC 857, RA-8000 Bahia Blanca, Buenos Aires, Argentina.	avelda@criba.edu.ar	Maldonado, Eduardo/AAN-3907-2020	Maldonado, Eduardo/0000-0002-5285-3027				Antollini SS, 2002, J LIPID RES, V43, P1440, DOI 10.1194/jlr.M200057-JLR200; Aveldano MI, 1995, ARCH BIOCHEM BIOPHYS, V324, P331, DOI 10.1006/abbi.1995.0046; AVELDANO MI, 1992, BIOCHEM J, V283, P235, DOI 10.1042/bj2830235; AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024; AVELDANO MI, 1987, J BIOL CHEM, V262, P1180; AVELDANO MI, 1987, J BIOL CHEM, V262, P1172; BALDI E, 2001, FRONT BIOSCI, V5, P110; Barenholz Y, 2004, SUB CELL BIOCHEM, V37, P167; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN ER, 1994, LIPIDS, V29, P825, DOI 10.1007/BF02536249; CHRISTIE WW, 1982, LIPID ANAL, P51; Contreras FX, 2005, BIOPHYS J, V88, P348, DOI 10.1529/biophysj.104.050690; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; Cross NL, 2000, BIOL REPROD, V63, P1129, DOI 10.1095/biolreprod63.4.1129; Cross NL, 2004, BIOL REPROD, V71, P1367, DOI 10.1095/biolreprod.104.030502; DAVIS BK, 1981, P NATL ACAD SCI-BIOL, V78, P7560, DOI 10.1073/pnas.78.12.7560; DESNOYERS L, 1992, J BIOL CHEM, V267, P10149; Fisch JD, 1998, HUM REPROD, V13, P1248, DOI 10.1093/humrep/13.5.1248; Flesch FM, 2000, BBA-REV BIOMEMBRANES, V1469, P197, DOI 10.1016/S0304-4157(00)00018-6; Furland NE, 2007, J BIOL CHEM, V282, P18141, DOI 10.1074/jbc.M700708200; Gitlits VM, 2000, EUR J CELL BIOL, V79, P104, DOI 10.1078/S0171-9335(04)70012-6; HINKOVSKA VT, 1987, BIOCHEM CELL BIOL, V65, P525, DOI 10.1139/o87-067; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Holopainen JM, 2001, BIOPHYS J, V80, P765, DOI 10.1016/S0006-3495(01)76056-0; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; HOROWITZ JA, 1984, J BIOL CHEM, V259, P832; Jacobson K, 2007, NAT CELL BIOL, V9, P7, DOI 10.1038/ncb0107-7; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Larson JL, 1999, MOL REPROD DEV, V52, P445, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;445::AID-MRD14&gt;3.0.CO;2-6; Li XM, 2000, BIOPHYS J, V78, P1921, DOI 10.1016/S0006-3495(00)76740-3; London M, 2004, J BIOL CHEM, V279, P9997, DOI 10.1074/jbc.M309992200; Martin RE, 2005, INVEST OPHTH VIS SCI, V46, P1147, DOI 10.1167/iovs.04-1207; Martinez P, 1996, FRONT BIOSCI, V1, P103; Murase T, 2004, J REPROD DEVELOP, V50, P667, DOI 10.1262/jrd.50.667; NIKOLOPOULOU M, 1986, LIPIDS, V21, P566, DOI 10.1007/BF02534053; NIKOLOPOULOU M, 1986, ARCH BIOCHEM BIOPHYS, V250, P30, DOI 10.1016/0003-9861(86)90698-3; Nixon B, 2006, BIOL REPROD, V74, P275, DOI 10.1095/biolreprod.105.044644; POULOS A, 1987, BIOCHEM J, V248, P961, DOI 10.1042/bj2480961; Ramstedt B, 1999, BIOPHYS J, V76, P908, DOI 10.1016/S0006-3495(99)77254-1; ROBINSON BS, 1992, J BIOL CHEM, V267, P1746; ROLDAN ERS, 1994, J BIOL CHEM, V269, P23583; Roldan ERS, 1996, FEBS LETT, V396, P227, DOI 10.1016/0014-5793(96)01110-6; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Sleight SB, 2005, BIOL REPROD, V73, P721, DOI 10.1095/biolreprod.105.041533; Therien I, 2001, BIOL REPROD, V65, P41, DOI 10.1095/biolreprod65.1.41; TOYODA Y, 1974, J REPROD FERTIL, V36, P9, DOI 10.1530/jrf.0.0360009; van Gestel RA, 2005, MOL HUM REPROD, V11, P583, DOI 10.1093/molehr/gah200; WILLIAMS RM, 1991, BIOL REPROD, V44, P1080, DOI 10.1095/biolreprod44.6.1080; Wolfe CA, 1998, BIOL REPROD, V59, P1506, DOI 10.1095/biolreprod59.6.1506; Yanagimachi R., 1994, P189; Yu CJ, 2005, J LIPID RES, V46, P1678, DOI 10.1194/jlr.M500060-JLR200	51	61	64	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18151	18161		10.1074/jbc.M700709200	http://dx.doi.org/10.1074/jbc.M700709200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17392275	Green Published, hybrid			2022-12-27	WOS:000247302000021
J	Johnson, BJ; Cohen, J; Welford, RW; Pearson, AR; Schulten, K; Klinman, JP; Wilmot, CM				Johnson, Bryan J.; Cohen, Jordi; Welford, Richard W.; Pearson, Arwen R.; Schulten, Klaus; Klinman, Judith P.; Wilmot, Carrie M.			Exploring molecular oxygen pathways in Hansenula polymorpha copper-containing amine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINONE COFACTOR BIOGENESIS; OXIDATIVE HALF-REACTION; PASTORIS LYSYL OXIDASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; LIGAND MIGRATION; BOVINE SERUM; CATALYTIC MECHANISM; ADHESION PROTEIN-1; ESCHERICHIA-COLI	The accessibility of large substrates to buried enzymatic active sites is dependent upon the utilization of proteinaceous channels. The necessity of these channels in the case of small substrates is questionable because diffusion through the protein matrix is often assumed. Copper amine oxidases contain a buried protein-derived quinone cofactor and a mononuclear copper center that catalyze the conversion of two substrates, primary amines and molecular oxygen, to aldehydes and hydrogen peroxide, respectively. The nature of molecular oxygen migration to the active site in the enzyme from Hansenula polymorpha is explored using a combination of kinetic, x-ray crystallographic, and computational approaches. A crystal structure of H. polymorpha amine oxidase in complex with xenon gas, which serves as an experimental probe for molecular oxygen binding sites, reveals buried regions of the enzyme suitable for transient molecular oxygen occupation. Calculated O-2 free energy maps using copper amine oxidase crystal structures in the absence of xenon correspond well with later experimentally observed xenon sites in these systems, and allow the visualization of O-2 migration routes of differing probabilities within the protein matrix. Site-directed mutagenesis designed to block individual routes has little effect on overall k(cat)/K-m (O-2), supporting multiple dynamic pathways for molecular oxygen to reach the active site.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Illinois, Beckman Inst, Urbana, IL 61801 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Illinois System; University of Illinois Urbana-Champaign; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Wilmot, CM (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	wilmo004@umn.edu	Schulten, Klaus/D-5561-2009	Pearson, Arwen/0000-0001-8499-7490	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025765, T32GM008700, R01GM025765, R01GM066569] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR005969, P41-RR05969] Funding Source: Medline; NIGMS NIH HHS [R37 GM025765, GM-66569, R01 GM025765, GM-25765, T32 GM008700, R01 GM066569-05, R01 GM066569, GM-008700] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Airenne TT, 2005, PROTEIN SCI, V14, P1964, DOI 10.1110/ps.051438105; Bourgeois D, 2003, P NATL ACAD SCI USA, V100, P8704, DOI 10.1073/pnas.1430900100; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; Chiu YC, 2006, BIOCHEMISTRY-US, V45, P4105, DOI 10.1021/bi052464l; Cohen J, 2005, STRUCTURE, V13, P1321, DOI 10.1016/j.str.2005.05.013; Cohen J, 2006, BIOPHYS J, V91, P1844, DOI 10.1529/biopbysj.106.085746; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; CRUIKSHANK DWJ, 2006, INT TABLES CRYSTALLO, P403; Darnault C, 2003, NAT STRUCT BIOL, V10, P271, DOI 10.1038/nsb912; DeLano WL, 2002, PYMOL USERS MANUAL; Dooley DM, 1998, J AM CHEM SOC, V120, P2599, DOI 10.1021/ja970312a; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; Dooley DM, 1999, J BIOL INORG CHEM, V4, P1, DOI 10.1007/s007750050283; Dove JE, 2001, ADV PROTEIN CHEM, V58, P141; DRUMMOND JT, 1994, BIOCHEMISTRY-US, V33, P3732, DOI 10.1021/bi00178a033; DuBois JL, 2004, METHOD ENZYMOL, V378, P17; Duff AP, 2006, ACTA CRYSTALLOGR D, V62, P1073, DOI 10.1107/S0907444906026333; Duff AP, 2004, J MOL BIOL, V344, P599, DOI 10.1016/j.jmb.2004.09.075; Duff AP, 2003, BIOCHEMISTRY-US, V42, P15148, DOI 10.1021/bi035338v; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Goto Y, 2002, BIOCHEMISTRY-US, V41, P13637, DOI 10.1021/bi0204591; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; Hevel JM, 1999, BIOCHEMISTRY-US, V38, P3683, DOI 10.1021/bi982199m; Hirota S, 2001, BIOCHEMISTRY-US, V40, P15789, DOI 10.1021/bi011631o; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5; Jakobsson E, 2005, ACTA CRYSTALLOGR D, V61, P1550, DOI 10.1107/S0907444905028805; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; Kim M, 2002, NAT STRUCT BIOL, V9, P591, DOI 10.1038/nsb824; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; Knapp MJ, 2003, BIOCHEMISTRY-US, V42, P11466, DOI 10.1021/bi0300884; Kumar V, 1996, STRUCTURE, V4, P943, DOI 10.1016/S0969-2126(96)00101-3; Lewis EA, 2004, CHEM REV, V104, P1047, DOI 10.1021/cr020633r; Li RB, 1998, STRUCTURE, V6, P293, DOI 10.1016/S0969-2126(98)00033-1; Lunelli M, 2005, J MOL BIOL, V346, P991, DOI 10.1016/j.jmb.2004.12.038; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Medda R, 1999, FEBS LETT, V453, P1, DOI 10.1016/S0014-5793(99)00675-4; Medda R, 2006, BIOCHIMIE, V88, P827, DOI 10.1016/j.biochi.2006.01.011; Mills SA, 2000, J AM CHEM SOC, V122, P9897, DOI 10.1021/ja000325f; Mills SA, 2002, BIOCHEMISTRY-US, V41, P10577, DOI 10.1021/bi0200864; Mure M, 2002, BIOCHEMISTRY-US, V41, P9269, DOI 10.1021/bi020246b; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Okajima T, 2005, BIOCHEMISTRY-US, V44, P12041, DOI 10.1021/bi051070r; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padiglia A, 2001, EUR J BIOCHEM, V268, P4686, DOI 10.1046/j.1432-1327.2001.02390.x; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Plastino J, 1999, BIOCHEMISTRY-US, V38, P8204, DOI 10.1021/bi9826660; Samuels NM, 2005, BIOCHEMISTRY-US, V44, P14308, DOI 10.1021/bi051176m; Schmidt M, 2005, P NATL ACAD SCI USA, V102, P11704, DOI 10.1073/pnas.0504932102; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; Schwartz B, 2001, BIOCHEMISTRY-US, V40, P2954, DOI 10.1021/bi0021378; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; Su QJ, 1998, BIOCHEMISTRY-US, V37, P12513, DOI 10.1021/bi981103l; Takahashi K, 2006, BIOCHEMISTRY-US, V45, P4683, DOI 10.1021/bi0521893; Whittington DA, 2001, BIOCHEMISTRY-US, V40, P3476, DOI 10.1021/bi0022487; Wilce MCJ, 1997, BIOCHEMISTRY-US, V36, P16116, DOI 10.1021/bi971797i; Wilmot CM, 1999, SCIENCE, V286, P1724, DOI 10.1126/science.286.5445.1724; Wilmot CM, 1997, BIOCHEMISTRY-US, V36, P1608, DOI 10.1021/bi962205j	62	67	69	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17767	17776		10.1074/jbc.M701308200	http://dx.doi.org/10.1074/jbc.M701308200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17409383	Green Accepted, hybrid			2022-12-27	WOS:000247084500050
J	Luttichau, HR; Johnsen, AH; Jurlander, J; Rosenkilde, MM; Schwartz, TW				Luttichau, Hans R.; Johnsen, Anders H.; Jurlander, Jesper; Rosenkilde, Mette M.; Schwartz, Thue W.			Kaposi sarcoma-associated herpes virus targets the lymphotactin receptor with both a broad spectrum antagonist vCCL2 and a highly selective and potent agonist vCCL3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CHEMOKINE LYMPHOTACTIN; HHV8 ASSOCIATED DISEASES; NATURAL-KILLER-CELLS; CD8(+) T-CELLS; VMIP-I; MOLLUSCUM CONTAGIOSUM; GENE-EXPRESSION; XCR1 RECEPTOR; IDENTIFICATION; PROTEIN	Large DNA viruses such as herpesvirus and poxvirus encode proteins that target and exploit the chemokine system of their host. These proteins have the potential to block or change the orchestrated recruitment of leukocytes to sites of viral infection. The genome of Kaposi sarcoma-associated herpes virus (KSHV) encodes three chemokine-like proteins named vCCL1, vCCL2, and vCCL3. In this study vCCL3 was probed in parallel with vCCL1 and vCCL2 against a panel of the 18 classified human chemokine receptors. In calcium mobilization assays vCCL1 acted as a selective CCR8 agonist, whereas vCCL2 was found to act as a broad spectrum chemokine antagonist of human chemokine receptors, including the lymphotactin receptor. In contrast vCCL3 was found to be a highly selective agonist for the human lymphotactin receptor XCR1. The potency of vCCL3 was found to be 10-fold higher than the endogenous human XCL1 chemokine in respect to phosphatidylinositol turnover and calcium mobilization as well as chemotaxis. High expression of XCR1 was found in placenta and neutrophils by real-time PCR. These data are consistent with reports of different expression profiles for vCCL2 and vCCL3 during the life cycle of KSHV, indicate a novel, sophisticated exploitation by the virus of specifically the lymphotactin receptor by both agonist and antagonist mechanisms, and suggest a unique physiological importance of this (somewhat overlooked) chemokine receptor.	Panum Inst, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Rigshosp, Dept Haematol, DK-2100 Copenhagen, Denmark; 7TM Pharma AS, DK-2970 Horsholm, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Luttichau, HR (corresponding author), Panum Inst, Mol Pharmacol Lab, 18-6,Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	hrl@molpharm.dk		Rosenkilde, Mette Marie/0000-0001-9600-3254; Luttichau, Hans Rudolf/0000-0002-5428-4075; Schwartz, Thue W./0000-0002-0261-6904				Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Borthwick NJ, 1997, IMMUNOLOGY, V90, P272, DOI 10.1046/j.1365-2567.1997.00154.x; Cairns CM, 2001, J IMMUNOL, V167, P57, DOI 10.4049/jimmunol.167.1.57; Carfi A, 1999, P NATL ACAD SCI USA, V96, P12379, DOI 10.1073/pnas.96.22.12379; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; Dewin DR, 2006, J IMMUNOL, V176, P544, DOI 10.4049/jimmunol.176.1.544; Dong C, 2005, J IMMUNOL METHODS, V302, P136, DOI 10.1016/j.jim.2005.05.008; Dorner B, 1997, J BIOL CHEM, V272, P8817, DOI 10.1074/jbc.272.13.8817; Endres MJ, 1999, J EXP MED, V189, P1993, DOI 10.1084/jem.189.12.1993; Ghirnikar RS, 2000, J NEUROSCI RES, V59, P63, DOI 10.1002/(SICI)1097-4547(20000101)59:1<63::AID-JNR8>3.0.CO;2-W; Giancarlo B, 1996, EUR J IMMUNOL, V26, P3238, DOI 10.1002/eji.1830261260; Haque NS, 2001, BLOOD, V97, P39, DOI 10.1182/blood.V97.1.39; Hedrick JA, 1997, J IMMUNOL, V158, P1533; HENG MCY, 1989, AM J DERMATOPATH, V11, P248, DOI 10.1097/00000372-198906000-00009; Hengge UR, 2002, LANCET INFECT DIS, V2, P281, DOI 10.1016/S1473-3099(02)00263-3; Hengge UR, 2002, LANCET INFECT DIS, V2, P344, DOI 10.1016/S1473-3099(02)00288-8; Houssiau F, 1996, J IMMUNOL, V157, P2570; Huang H, 2001, BIOCHEM BIOPH RES CO, V281, P378, DOI 10.1006/bbrc.2001.4363; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kostenis E, 2001, TRENDS PHARMACOL SCI, V22, P560, DOI 10.1016/S0165-6147(00)01810-1; Kuloglu ES, 2001, BIOCHEMISTRY-US, V40, P12486, DOI 10.1021/bi011106p; Lindow M, 2003, TRENDS PHARMACOL SCI, V24, P126, DOI 10.1016/S0165-6147(03)00033-6; Lindow M, 2003, J VIROL, V77, P7393, DOI 10.1128/JVI.77.13.7393-7400.2003; Louahed J, 2003, EUR J IMMUNOL, V33, P494, DOI 10.1002/immu.200310025; Lu M, 2004, J VIROL, V78, P13637, DOI 10.1128/JVI.78.24.13637-13652.2004; Luttichau HR, 2003, J BIOL CHEM, V278, P10928, DOI 10.1074/jbc.M211329200; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Maghazachi AA, 1997, FASEB J, V11, P765, DOI 10.1096/fasebj.11.10.9271361; MULLER S, 1995, EUR J IMMUNOL, V25, P1744, DOI 10.1002/eji.1830250638; Murphy PM, 2000, PHARMACOL REV, V52, P145; Najarro P, 2003, J GEN VIROL, V84, P3325, DOI 10.1099/vir.0.19591-0; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; Peterson FC, 2004, J BIOL CHEM, V279, P12598, DOI 10.1074/jbc.M311633200; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Seet BT, 2003, P NATL ACAD SCI USA, V100, P15137, DOI 10.1073/pnas.2336648100; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Spinetti G, 2003, J LEUKOCYTE BIOL, V73, P201, DOI 10.1189/jlb.0302105; Stine JT, 2000, BLOOD, V95, P1151, DOI 10.1182/blood.V95.4.1151.004k37_1151_1157; Yoshida T, 1998, J BIOL CHEM, V273, P16551, DOI 10.1074/jbc.273.26.16551	49	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17794	17805		10.1074/jbc.M702001200	http://dx.doi.org/10.1074/jbc.M702001200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17403668	hybrid			2022-12-27	WOS:000247084500053
J	Garg, H; Joshi, A; Freed, EO; Blumenthal, R				Garg, Himanshu; Joshi, Anjali; Freed, Eric O.; Blumenthal, Robert			Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CD4 T-CELLS; ENVELOPE GLYCOPROTEIN; MEMBRANE-FUSION; IN-VIVO; TYPE-1 ENVELOPE; INFLUENZA HEMAGGLUTININ; VIROLOGICAL SYNAPSE; PROTEASE INHIBITOR; CYTOPLASMIC TAIL	The loss of CD4(+) T cells in HIV-1 infections is hypothesized to be caused by apoptosis of bystander cells mediated by cell surface-expressed HIV-1 Env glycoprotein. However, the mechanism by which Env mediates this process remains controversial. Specifically, the role of HIV-1 gp120 binding to CD4 and CXCR4 versus the fusion process mediated by gp41 remains unresolved. Env-induced apoptosis in bystander cells has been shown to be gp41-dependent and correlates with the redistribution of membrane lipids between Env-expressing cells and target cells (hemifusion). Using a rational mutagenesis approach aimed at targeting Env function via the gp41 subunit, we examined the role of HIV gp41 in bystander apoptosis. A mutation in the fusion domain of gp41 (V513E) resulted in a fusion-defective Env that failed to induce apoptosis. A mutation in the gp41 N-terminal helix (G547D) reduced cell fusion capacity and apoptosis; conversely, an Env mutant with a deletion of the gp41 cytoplasmic tail (Ct Del) enhanced both cell-to-cell fusion and apoptosis. Most significantly, an Env mutant containing a substitution in the loop region of gp41 (D589L) mediated transfer of lipids (hemifusion) to bystander cells but was defective in cell-to-cell and to a lesser degree virus-to-cell fusion. This mutant was still able to induce apoptosis in bystander cells. Hence, we have provided the first direct evidence that gp41-mediated hemifusion is both required and sufficient for induction of apoptosis in bystander cells. These results may help to explain the mechanism of HIV-1 Env-induced T cell depletion.	NCI, Membrane Struct & Funct Sect, Canc Res Ctr, Nanobiol Program,NIH, Frederick, MD 21702 USA; NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blumenthal, R (corresponding author), NCI, Membrane Struct & Funct Sect, Canc Res Ctr, Nanobiol Program,NIH, Frederick, MD 21702 USA.	blumen@helix.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010776, Z01BC010777, ZIABC010777, Z01BC010775, Z01BC010776, Z01BC008303, ZIABC010775, ZIABC008303] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Aquaro S, 2006, J ANTIMICROB CHEMOTH, V58, P714, DOI 10.1093/jac/dkl306; Bar S, 2004, J VIROL, V78, P811, DOI 10.1128/JVI.78.2.811-820.2004; Biard-Piechaczyk M, 2000, VIROLOGY, V268, P329, DOI 10.1006/viro.1999.0151; Blanco J, 2003, VIROLOGY, V305, P318, DOI 10.1006/viro.2002.1764; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; CAO J, 1994, J VIROL, V68, P4662, DOI 10.1128/JVI.68.7.4662-4668.1994; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; Cao J, 1996, J VIROL, V70, P1340, DOI 10.1128/JVI.70.3.1340-1354.1996; Castedo M, 2003, ANN NY ACAD SCI, V1010, P19, DOI 10.1196/annals.1299.004; Castedo M, 1995, EUR J IMMUNOL, V25, P3277, DOI 10.1002/eji.1830251212; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Chernomordik LV, 2005, CELL, V123, P375, DOI 10.1016/j.cell.2005.10.015; Chinnaiyan AM, 1997, NAT MED, V3, P333, DOI 10.1038/nm0397-333; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Etemad-Moghadam B, 2000, J VIROL, V74, P4433, DOI 10.1128/JVI.74.9.4433-4440.2000; Etemad-Moghadam B, 2001, J VIROL, V75, P5646, DOI 10.1128/JVI.75.12.5646-5655.2001; Ferri KF, 2000, ANN NY ACAD SCI, V926, P149; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Garg H, 2006, J LEUKOCYTE BIOL, V79, P351, DOI 10.1189/jlb.0805430; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; Jekle A, 2003, J VIROL, V77, P5846, DOI 10.1128/JVI.77.10.5846-5854.2003; Jolly C, 2005, J VIROL, V79, P12088, DOI 10.1128/JVI.79.18.12088-12094.2005; Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kinomoto M, 2005, J VIROL, V79, P5996, DOI 10.1128/JVI.79.10.5996-6004.2005; Labonte JA, 2000, J VIROL, V74, P10690, DOI 10.1128/JVI.74.22.10690-10698.2000; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; MACHO A, 1995, BLOOD, V86, P2481; Meissner EG, 2006, J VIROL, V80, P11019, DOI 10.1128/JVI.01382-06; Miro S, 2005, ANTIVIR THER, V10, P945; Murakami T, 2000, P NATL ACAD SCI USA, V97, P343, DOI 10.1073/pnas.97.1.343; Perfettini JL, 2005, CELL DEATH DIFFER, V12, P916, DOI 10.1038/sj.cdd.4401584; Piguet V, 2004, J CLIN INVEST, V114, P605, DOI 10.1172/JCI200422812; Reeves JD, 2005, J VIROL, V79, P4991, DOI 10.1128/JVI.79.8.4991-4999.2005; Roggero R, 2001, J VIROL, V75, P7637, DOI 10.1128/JVI.75.16.7637-7650.2001; Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wyss S, 2005, J VIROL, V79, P12231, DOI 10.1128/JVI.79.19.12231-12241.2005; Yang XZ, 2005, J VIROL, V79, P12132, DOI 10.1128/JVI.79.19.12132-12147.2005	43	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16899	16906		10.1074/jbc.M701701200	http://dx.doi.org/10.1074/jbc.M701701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17416587	hybrid			2022-12-27	WOS:000246946500022
J	Higa, MM; Alam, SL; Sundquist, WI; Ullman, KS				Higa, Meda M.; Alam, Steven L.; Sundquist, Wesley I.; Ullman, Katharine S.			Molecular characterization of the ran-binding zinc finger domain of Nup153	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA EXPORT; NUCLEOPORIN NUP153; ENVELOPE BREAKDOWN; IMPORTIN-BETA; J-COUPLINGS; NUCLEOCYTOPLASMIC TRANSPORT; UBIQUITIN INTERACTIONS; CRYSTAL-STRUCTURE; SH3 DOMAIN	The nuclear pore complex is the gateway for selective traffic between the nucleus and cytoplasm. To learn how building blocks of the pore can create specific docking sites for transport receptors and regulatory factors, we have studied a zinc finger module present in multiple copies within the nuclear pores of higher eukaryotes. All four zinc fingers of human Nup153 were found to bind the small GTPase Ran with dissociation constants ranging between 5 and 40 mu M. In addition a fragment of Nup153 encompassing the four tandem zinc fingers was found to bind Ran with similar affinity. NMR structural studies revealed that a representative Nup153 zinc finger adopts the same zinc ribbon structure as the previously characterized Npl4 NZF module. Ran binding was mediated by a three-amino acid motif (Leu(13)/Val(14)/Asn(25)) located within the two zinc coordination loops. Nup153 ZnFs bound GDP and GTP forms of Ran with similar affinities, indicating that this interaction is not influenced by a nucleotide-dependent conformational switch. Taken together, these studies elucidate the Ran-binding interface on Nup153 and, more broadly, provide insight into the versatility of this zinc finger binding module.	Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Ullman, KS (corresponding author), Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, 2000 Circle Hope Dr, Salt Lake City, UT 84112 USA.	alam@biochem.utah.edu; katharine.ullman@hci.utah.edu		Ullman, Katharine/0000-0003-3693-2830	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051174, R01AI045405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM082545, T32GM007464, R01GM061275] Funding Source: NIH RePORTER; NCI NIH HHS [CA42014] Funding Source: Medline; NIAID NIH HHS [R01 AI051174, R01 AI45405] Funding Source: Medline; NIGMS NIH HHS [T32 GM07464, R01 GM061275, R01 GM61275, R01 GM061275-07, P50 GM082545] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Arrigoni R, 2006, FEBS LETT, V580, P6233, DOI 10.1016/j.febslet.2006.10.027; Ball JR, 2005, CHROMOSOMA, V114, P319, DOI 10.1007/s00412-005-0019-3; Bastos R, 1996, J CELL BIOL, V134, P1141, DOI 10.1083/jcb.134.5.1141; BAX A, 1994, METHOD ENZYMOL, V239, P79; BAX A, 1994, J BIOMOL NMR, V4, P787, DOI 10.1007/BF00398409; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Bernad R, 2004, MOL CELL BIOL, V24, P2373, DOI 10.1128/MCB.24.6.2373-2384.2004; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Braslavsky CIV, 2000, BIOCHEMISTRY-US, V39, P11629, DOI 10.1021/bi001010f; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; DeLano W.L, PYMOL MOL GRAPHICS S; Devos D, 2006, P NATL ACAD SCI USA, V103, P2172, DOI 10.1073/pnas.0506345103; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Forler D, 2004, MOL CELL BIOL, V24, P1155, DOI 10.1128/MCB.24.3.1155-1167.2004; Gebauer D, 2004, BIOCHEMISTRY-US, V43, P14873, DOI 10.1021/bi049498y; Gill DJ, 2007, EMBO J, V26, P600, DOI 10.1038/sj.emboj.7601501; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hulo N, 2006, NUCLEIC ACIDS RES, V34, pD227, DOI 10.1093/nar/gkj063; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lim RYH, 2006, CHROMOSOMA, V115, P15, DOI 10.1007/s00412-005-0037-1; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Liu J, 2003, DEV CELL, V5, P487, DOI 10.1016/S1534-5807(03)00262-4; Madrid AS, 2006, CHROMOSOMA, V115, P98, DOI 10.1007/s00412-005-0043-3; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Moroianu J, 1997, P NATL ACAD SCI USA, V94, P9699, DOI 10.1073/pnas.94.18.9699; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Plambeck CA, 2003, J BIOL CHEM, V278, P22805, DOI 10.1074/jbc.M301896200; Porter FW, 2006, P NATL ACAD SCI USA, V103, P12417, DOI 10.1073/pnas.0605375103; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; Prunuske AJ, 2006, MOL BIOL CELL, V17, P760, DOI 10.1091/mbc.E05-06-0485; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Salina D, 2003, J CELL BIOL, V162, P991, DOI 10.1083/jcb.200304080; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; Schwartz TU, 2005, CURR OPIN STRUC BIOL, V15, P221, DOI 10.1016/j.sbi.2005.03.003; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Singh BB, 1999, J BIOL CHEM, V274, P37370, DOI 10.1074/jbc.274.52.37370; Slupsky CM, 1998, BIOCHEM CELL BIOL, V76, P379, DOI 10.1139/bcb-76-2-3-379; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Teo HL, 2006, CELL, V125, P99, DOI 10.1016/j.cell.2006.01.047; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; VUISTER GW, 1993, J BIOMOL NMR, V3, P297, DOI 10.1007/BF00212516; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P6464, DOI 10.1021/ja00093a069; Yaseen NR, 1999, J BIOL CHEM, V274, P26493, DOI 10.1074/jbc.274.37.26493; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516; Yu GW, 2006, PROTEIN SCI, V15, P384, DOI 10.1110/ps.051927306; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	70	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17090	17100		10.1074/jbc.M702715200	http://dx.doi.org/10.1074/jbc.M702715200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17426026	hybrid			2022-12-27	WOS:000246946500042
J	Ma, CL; Remani, S; Sun, JK; Kotaria, R; Mayor, JA; Walters, DE; Kaplan, RS				Ma, Chunlong; Remani, Sreevidya; Sun, Jiakang; Kotaria, Rusudan; Mayor, June A.; Walters, D. Eric; Kaplan, Ronald S.			Identification of the substrate binding sites within the yeast mitochondrial citrate transport protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BOVINE HEART-MITOCHONDRIA; TRANSMEMBRANE DOMAIN-III; FATTY-ACID SYNTHESIS; SECONDARY STRUCTURE; REACTION-MECHANISM; ADP/ATP CARRIER; TRICARBOXYLATE CARRIER; TRANSLOCATION PATHWAY; LIKELY COMPRISE	The objective of the present investigation was to identify the substrate binding site(s) within the yeast mitochondrial citrate transport protein (CTP). Our strategy involved kinetically characterizing 30 single-Cys CTP mutants that we had previously constructed based on their hypothesized importance in the structure-based mechanism of this carrier. As part of these studies, a modified transport assay was developed that permitted, for the first time, the accurate determination of Km values that were elevated > 100-fold compared with the Cys- less control value. We identified 10 single-Cys CTP mutants that displayed sharply elevated Km values ( i. e. 5 to > 300-fold). Each of these mutants displayed Vmax values that were reduced by >= 98% and resultant catalytic efficiencies that were reduced by >= 99.9%. Importantly, superposition of this functional data onto the three-dimensional homology- modeled CTP structure, which we previously had developed, revealed that nine of these ten residues form two topographically distinct clusters. Additional modeling showed that: (i) each cluster is capable of forming numerous hydrogen bonds with citrate and (ii) the two clusters are sufficiently distant from one another such that citrate is unlikely to interact with all of these residues at the same time. We deduced from these findings that the CTP contains at least two citrate binding sites per monomer, which are located at increasing depths within the translocation pathway. The identification of these sites, combined with an initial assessment of the citrate- amino acid side- chain interactions that may occur at these sites, substantiallyextendsourunderstanding of CTP functioning at the molecular level.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Kaplan, RS (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	Ronald.Kaplan@rosalindfranklin.edu	Ma, Chunlong/AAT-7097-2021; Walters, D. Eric/C-9626-2010; Mayor, June/AAP-1544-2021	Walters, D. Eric/0000-0002-1513-3522; KAPLAN, RONALD/0000-0001-9164-0297	NIGMS NIH HHS [GM-054642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISACCIA F, 1993, BIOCHIM BIOPHYS ACTA, V1142, P139, DOI 10.1016/0005-2728(93)90095-W; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNENGR.H, 1973, FEBS LETT, V36, P130, DOI 10.1016/0014-5793(73)80353-9; Cascio M, 2004, J BIOENERG BIOMEMBR, V36, P429, DOI 10.1023/B:JOBB.0000047325.48943.71; CONOVER TE, 1987, TRENDS BIOCHEM SCI, V12, P88, DOI 10.1016/0968-0004(87)90042-9; DIERKS T, 1988, BIOCHIM BIOPHYS ACTA, V943, P231, DOI 10.1016/0005-2736(88)90555-X; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; Eriks LR, 2003, ANAL BIOCHEM, V323, P234, DOI 10.1016/j.ab.2003.09.002; Gouaux E, 2005, SCIENCE, V310, P1461, DOI 10.1126/science.1113666; Guan L, 2006, ANNU REV BIOPH BIOM, V35, P67, DOI 10.1146/annurev.biophys.35.040405.102005; Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8; INDIVERI C, 1991, EUR J BIOCHEM, V198, P339, DOI 10.1111/j.1432-1033.1991.tb16021.x; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kaplan RS, 2000, J BIOL CHEM, V275, P12009, DOI 10.1074/jbc.275.16.12009; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KAPLAN RS, 1990, J BIOL CHEM, V265, P13379; KAPLAN RS, 1995, J BIOL CHEM, V270, P4108, DOI 10.1074/jbc.270.8.4108; Kihira Y, 2006, J BIOCHEM, V139, P575, DOI 10.1093/jb/mvj052; Kotaria R, 1999, J BIOENERG BIOMEMBR, V31, P543, DOI 10.1023/A:1005460810527; Ma CL, 2006, BBA-BIOENERGETICS, V1757, P1271, DOI 10.1016/j.bbabio.2006.06.011; Ma CL, 2005, J BIOL CHEM, V280, P2331, DOI 10.1074/jbc.M411474200; Ma CL, 2004, J BIOL CHEM, V279, P1533, DOI 10.1074/jbc.M310866200; Mackerell AD, 2004, J COMPUT CHEM, V25, P1400, DOI 10.1002/jcc.20065; Michaelis L, 1913, BIOCHEM Z, V49, P333; Miller C, 2006, NATURE, V440, P484, DOI 10.1038/nature04713; Nury H, 2006, ANNU REV BIOCHEM, V75, P713, DOI 10.1146/annurev.biochem.75.103004.142747; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Robinson AJ, 2006, P NATL ACAD SCI USA, V103, P2617, DOI 10.1073/pnas.0509994103; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; SHOICHET BK, 1992, J COMPUT CHEM, V13, P380, DOI 10.1002/jcc.540130311; Walters DE, 2004, BIOPHYS J, V87, P907, DOI 10.1529/biophysj.104.042127; WATSON JA, 1970, J BIOL CHEM, V245, P5993; Xu Y, 2000, J BIOL CHEM, V275, P7117, DOI 10.1074/jbc.275.10.7117; XU Y, 1995, BIOCHEM BIOPH RES CO, V207, P783, DOI 10.1006/bbrc.1995.1255	35	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17210	17220		10.1074/jbc.M611268200	http://dx.doi.org/10.1074/jbc.M611268200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17400551	hybrid			2022-12-27	WOS:000246946500054
J	Guazzaroni, ME; Gallegos, MT; Ramos, JL; Krell, T				Guazzaroni, Maria-Eugenia; Gallegos, Maria-Trinidad; Ramos, Juan L.; Krell, Tino			Different modes of binding of mono- and biaromatic effectors to the transcriptional regulator - Role in differential derepression from its cognate operator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG EFFLUX PUMP; PSEUDOMONAS-PUTIDA DOT-T1E; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; STRUCTURAL BASIS; MUTATIONAL ANALYSIS; PROTEIN; INDOLE; EXPRESSION	Members of the IclR family of regulators exhibit a highly conserved effector recognition domain and interact with a limited number of effectors. In contrast with most IclR family members, TtgV, the transcriptional repressor of the TtgGHI efflux pump, exhibits multidrug recognition properties. A three-dimensional model of the effector domain of TtgV was generated based on the available three- dimensional structure of several IclR members, and a series of point mutants was created. Using isothermal titration calorimetry, we determined the binding parameters of the most efficient effectors for TtgV and its mutant variants. All mutants bound biaromatic compounds with higher affinity than the wild-type protein, whereas monoaromatic compounds were bound with lower affinity. This tendency was particularly pronounced for mutants F134A and H200A. TtgVF134A bound 4-nitrotoluene with an affinity 13- old lower than that of TtgV (17.4 +/- 0.6 mu M). This mutant bound 1-naphthol with an affinity of 5.7 mu M, which is seven times as great as that of TtgV (40 mu M). The TtgVV223A mutant bound to DNA with the same affinity as the wild- type TtgV protein, but it remained bound to the target operator in the presence of effectors, suggesting that Val-223 could be part of an intra- TtgV signal recognition pathway. Thermodynamic analyses of the binding of effectors to TtgV and to its mutants in complex with their target DNA revealed that the binding of biaromatic compounds resulted in a more efficient release of the repressor protein than the binding of monoaromatics. The physiological significance of these findings is discussed.	CSIC, Estac Expt Zaidin, Dept Environm Protect, E-18008 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)	Ramos, JL (corresponding author), CSIC, Estac Expt Zaidin, Dept Environm Protect, Calle Prof Albareda,Numero 1, E-18008 Granada, Spain.	jlramos@eez.csic.es	Guazzaroni, María Eugenia MEG/E-2599-2013; Krell, Tino/G-7296-2015; Gallegos, María-Trinidad M.T./K-6501-2014; Guazzaroni, María-Eugenia/Y-9268-2019	Guazzaroni, María Eugenia MEG/0000-0002-4657-3731; Krell, Tino/0000-0002-9040-3166; Gallegos, María-Trinidad M.T./0000-0001-7633-8807; Guazzaroni, María-Eugenia/0000-0002-4657-3731; Ramos, Juan L./0000-0002-8731-7435				AHMED M, 1994, J BIOL CHEM, V28, P506; Arias-Barrau E, 2004, J BACTERIOL, V186, P5062, DOI 10.1128/jb.186.15.5062-5077.2004; Brady GP, 2000, J COMPUT AID MOL DES, V14, P383, DOI 10.1023/A:1008124202956; CLAUS G, 1983, SYST APPL MICROBIOL, V4, P169, DOI 10.1016/S0723-2020(83)80046-0; Combet C, 2002, BIOINFORMATICS, V18, P213, DOI 10.1093/bioinformatics/18.1.213; Desrosiers DC, 2005, J MOL BIOL, V354, P375, DOI 10.1016/j.jmb.2005.09.045; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; Duque E, 2001, MOL MICROBIOL, V39, P1100, DOI 10.1046/j.1365-2958.2001.02310.x; Fasolini M, 2003, J BIOL CHEM, V278, P21092, DOI 10.1074/jbc.M301781200; Friemann R, 2005, J MOL BIOL, V348, P1139, DOI 10.1016/j.jmb.2005.03.052; Garbe TR, 2000, ARCH MICROBIOL, V173, P78, DOI 10.1007/s002030050012; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Guazzaroni MAE, 2005, J BIOL CHEM, V280, P20887, DOI 10.1074/jbc.M500783200; Guazzaroni ME, 2004, J BACTERIOL, V186, P2921, DOI 10.1128/JB.186.10.2921-2927.2004; Hirakawa H, 2005, MOL MICROBIOL, V55, P1113, DOI 10.1111/j.1365-2958.2004.04449.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Kahramanoglou C, 2006, J BACTERIOL, V188, P3199, DOI 10.1128/JB.188.9.3199-3207.2006; KAMATH AV, 1990, APPL ENVIRON MICROB, V56, P275, DOI 10.1128/AEM.56.1.275-280.1990; Kawamura-Sato K, 1999, FEMS MICROBIOL LETT, V179, P345, DOI 10.1016/S0378-1097(99)00433-4; Kok RG, 1998, J BACTERIOL, V180, P5058, DOI 10.1128/JB.180.19.5058-5069.1998; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Krell T, 2006, PROTEIN SCI, V15, P1207, DOI 10.1110/ps.051857206; MADSEN EL, 1988, APPL ENVIRON MICROB, V54, P74, DOI 10.1128/AEM.54.1.74-78.1988; Molina-Henares AJ, 2006, FEMS MICROBIOL REV, V30, P157, DOI 10.1111/j.1574-6976.2005.00008.x; Mosqueda G, 2000, J BACTERIOL, V182, P937, DOI 10.1128/JB.182.4.937-943.2000; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Ramos JL, 2002, ANNU REV MICROBIOL, V56, P743, DOI 10.1146/annurev.micro.56.012302.161038; RAMOS JL, 1986, P NATL ACAD SCI USA, V83, P8467, DOI 10.1073/pnas.83.22.8467; RAMOS JL, 1995, J BACTERIOL, V177, P3911, DOI 10.1128/jb.177.14.3911-3916.1995; Reed WL, 1999, J MOL BIOL, V294, P417, DOI 10.1006/jmbi.1999.3224; Rintoul MR, 2002, J MOL BIOL, V324, P599, DOI 10.1016/S0022-2836(02)01134-8; Rojas A, 2003, J BACTERIOL, V185, P4755, DOI 10.1128/JB.185.16.4755-4763.2003; Rojas A, 2001, J BACTERIOL, V183, P3967, DOI 10.1128/JB.183.13.3967-3973.2001; Salto R, 1998, J BACTERIOL, V180, P600, DOI 10.1128/JB.180.3.600-604.1998; Sazinsky MH, 2004, J BIOL CHEM, V279, P30600, DOI 10.1074/jbc.M400710200; Scholz O, 2003, J MOL BIOL, V329, P217, DOI 10.1016/S0022-2836(03)00427-3; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2004, EMBO J, V23, P2923, DOI 10.1038/sj.emboj.7600288; SNELL EE, 1975, ADV ENZYMOL RAMB, V42, P287; Soisson SM, 1997, SCIENCE, V276, P421, DOI 10.1126/science.276.5311.421; Su CC, 2006, J BACTERIOL, V188, P7290, DOI 10.1128/JB.00684-06; Teran W, 2006, J BIOL CHEM, V281, P7102, DOI 10.1074/jbc.M511095200; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; Walker JR, 2006, J MOL BIOL, V358, P810, DOI 10.1016/j.jmb.2006.02.034; Zgurskaya HI, 2000, J BACTERIOL, V182, P4264, DOI 10.1128/JB.182.15.4264-4267.2000; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6; ZHOU LM, 1990, J BACTERIOL, V172, P3707, DOI 10.1128/jb.172.7.3707-3710.1990	52	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16308	16316		10.1074/jbc.M610032200	http://dx.doi.org/10.1074/jbc.M610032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17416591	hybrid			2022-12-27	WOS:000246794300038
J	May, MJ; Madge, LA				May, Michael J.; Madge, Lisa A.			Caspase inhibition sensitizes inhibitor of NF-kappa B kinase beta-deficient fibroblasts to caspase-independent cell death via the generation of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA-INDUCED APOPTOSIS; IKK-ALPHA; GENE-EXPRESSION; ENDOTHELIAL-CELLS; JNK ACTIVATION; TARGET GENES; RECEPTOR; REVEALS; BAX	Cells lacking functional NF-kappa B die after ligation of some tumor necrosis factor (TNF) receptor family members through failure to express NF-kappa B-dependent anti-apoptotic genes. NF-kappa B activation requires the I kappa B kinase (IKK) complex containing two catalytic subunits named IKK alpha and IKK beta that regulate distinct NF-kappa B pathways. IKK beta is critical for classical signaling that induces pro- inflammatory and anti-apoptotic gene profiles, whereas IKK alpha regulates the non-canonical pathway involved in lymphoid organogenesis and B- cell development. To determine whether IKK alpha and IKK alpha differentially function in rescuing cells from death induced by activators of the classical and non-canonical pathways, we analyzed death after ligation of the TNF and lymphotoxin-receptors, respectively. Using murine embryonic fibroblasts (MEFs) lacking each of the IKKs, the caspase inhibitor benzyloxycarbonyl- Val-Ala-Asp-fluoromethyl ketone, and dominant negative Fas-associated death domain protein, we found that deletion of these kinases sensitized MEFs to distinct cell death pathways. MEFs lacking IKK alpha were sensitized to death in response to both cytokines that was entirely caspase-dependent, demonstrating that IKK beta functions in this process. Surprisingly, death of IKK beta(-/-) MEFs was not blocked by caspase inhibition, demonstrating that IKK beta negatively regulates caspase-independent cell death (CICD). CICD was strongly activated by both TNF and lymphotoxin-beta receptor ligation in IKK beta(-/-) MEFs and was accompanied by loss of mitochondrial membrane potential and the generation of reactive oxygen species. CICD was inhibited by the anti- oxidant butylated hydroxyanosole and overexpression of Bcl-2, neither of which blocked caspase-dependent apoptosis. Our findings, therefore, demonstrate that both IKK alpha and IKK beta regulate cytokineinduced apoptosis, and IKK beta additionally represses reactive oxygen species- and mitochondrial- dependent CICD.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	May, MJ (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St,OVH 200E, Philadelphia, PA 19104 USA.	maym@vet.upenn.edu		May, Michael/0000-0002-2485-3716	NHLBI NIH HHS [1R01HL080612-01A1, R01 HL080612, R01 HL080612-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; CHINNAIYAN AM, 1995, CELL, V81, P512; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Elliott MJ, 1999, CANCER CHEMOTH PHARM, V44, P1, DOI 10.1007/s002800050938; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kuai J, 2003, J BIOL CHEM, V278, P14363, DOI 10.1074/jbc.M208672200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Luedde T, 2005, J CLIN INVEST, V115, P849, DOI 10.1172/JCI200523493; Madge LA, 2003, J BIOL CHEM, V278, P21295, DOI 10.1074/jbc.M212837200; Massa PE, 2005, J BIOL CHEM, V280, P14057, DOI 10.1074/jbc.M414401200; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Okuno S, 1998, J BIOL CHEM, V273, P34272, DOI 10.1074/jbc.273.51.34272; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Thon L, 2005, FASEB J, V19, P1945, DOI 10.1096/fj.05-3726com; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	47	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16105	16116		10.1074/jbc.M611115200	http://dx.doi.org/10.1074/jbc.M611115200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430892	hybrid, Green Accepted			2022-12-27	WOS:000246794300019
J	Si, J; Fu, XY; Behar, J; Wands, J; Beer, DG; Souza, RF; Spechler, SJ; Lambeth, D; Cao, WB				Si, Jin; Fu, Xiaoying; Behar, Jose; Wands, Jack; Beer, David G.; Souza, Rhonda F.; Spechler, Stuart J.; Lambeth, David; Cao, Weibiao			NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappa B in Barrett's esophageal adenocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H SYNTHASE-2; SELECTIVE-INHIBITION; COX-2 INHIBITORS; CAT ESOPHAGEAL; APOPTOSIS; CANCER; PURIFICATION; CONTRACTION; INCREASES; REFLUX	We have shown that the NADPH oxidase NOX5-S may play an important role in the progression from Barrett's esophagus to esophageal adenocarcinoma (EA) by increasing cell proliferation and decreasing apoptosis. However, the mechanism of the acid-induced NOX5-S-mediated increase in cell proliferation is not known. We found that, in SEG1 EA cells, the acid- induced increase in prostaglandin E-2 (PGE(2)) production was mediated by activation of cyclooxygenase-2 (COX2) but not by COX1. Acid treatment increased intracellular Ca2+, and a blockade of intracellular Ca2+ increase inhibited the acid-induced increase in COX2 expression and PGE(2) production. Knockdown of NOX5-S or NF-kappa B1 p50 by their small interfering RNA significantly inhibited acid- induced COX2 expression and PGE(2) production in SEG1 cells. Acid treatment significantly decreased I kappa B alpha and increased luciferase activity when SEG1 cells were transfected with an NF-kappa B in vivo activation reporter plasmid, pNF-kappa B-Luc. In a novel Barrett's cell line overexpressing NOX5-S, I kappa B alpha was significantly reduced, and luciferase activity increased when these Barrett's cells were transfected with pNF-kappa B-Luc. Overexpression of NOX5-S in Barrett's cells significantly increased H2O2 production, COX2 expression, PGE(2) production, and thymidine incorporation. The increase in thymidine incorporation occurring in NOX5-S-overexpressing Barrett's cells or induced by acid treatment in SEG1 EA cells was significantly decreased by COX2 inhibitors or small interfering RNA. We conclude that acid-induced COX2 expression and PGE(2) production depend on an increase in cytosolic Ca2+ and sequential activation of NOX5-S and NF-kappa B in SEG1 cells. COX2-derived PGE(2) production may contribute to NOX5-S-mediated cell proliferation in SEG1 cells.	Brown Univ, Dept Med, Sch Med, Providence, RI 02903 USA; Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA; Univ Michigan, Sch Med, Dept Surg, Sect Gen Thorac Surg, Ann Arbor, MI 48109 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Vet Affairs Med Ctr, Div Gastroenterol, Dallas, TX 76235 USA; Univ Texas, SW Med Ctr, Dallas, TX 76235 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Michigan System; University of Michigan; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cao, WB (corresponding author), Brown Univ, Dept Med, Sch Med, 55 Claverick St,Rm 337, Providence, RI 02903 USA.	wcao@hotmail.com			NCRR NIH HHS [P20 RR17695] Funding Source: Medline; NIDDK NIH HHS [R21 DK073327-01, R21 DK073327] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073327] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Barbieri SS, 2004, FREE RADICAL BIO MED, V37, P156, DOI 10.1016/j.freeradbiomed.2004.04.020; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brar SS, 2003, AM J PHYSIOL-CELL PH, V285, pC353, DOI 10.1152/ajpcell.00525.2002; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Buttar NS, 2002, GASTROENTEROLOGY, V122, P1101, DOI 10.1053/gast.2002.32371; Cao W, 2001, AM J PHYSIOL-CELL PH, V280, pC980, DOI 10.1152/ajpcell.2001.280.4.C980; Cao WB, 2004, AM J PHYSIOL-GASTR L, V286, pG833, DOI 10.1152/ajpgi.00414.2003; Cao WB, 2003, AM J PHYSIOL-GASTR L, V285, pG86, DOI 10.1152/ajpgi.00156.2002; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; Farhadi A, 2002, AM J GASTROENTEROL, V97, P22; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Fu XY, 2006, J BIOL CHEM, V281, P20368, DOI 10.1074/jbc.M603353200; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gu Y, 2003, J BIOL CHEM, V278, P17210, DOI 10.1074/jbc.M210314200; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Habeeb AG, 2000, DRUG DEVELOP RES, V51, P273, DOI 10.1002/ddr.9; HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4; Hughes SJ, 1997, CANCER RES, V57, P5571; Johnson JL, 1995, ARCH BIOCHEM BIOPHYS, V324, P26, DOI 10.1006/abbi.1995.9934; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kim H, 2005, J BIOL CHEM, V280, P21237, DOI 10.1074/jbc.M413842200; Kim R, 1997, CANCER EPIDEM BIOMAR, V6, P369; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Liu XH, 1998, CANCER RES, V58, P4245; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Morales CP, 2003, GUT, V52, P327, DOI 10.1136/gut.52.3.327; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; Paik JH, 2000, J BIOL CHEM, V275, P28173; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; Shaheen NJ, 2005, GASTROENTEROLOGY, V128, P1554, DOI 10.1053/j.gastro.2005.03.032; Shirvani VN, 2000, GASTROENTEROLOGY, V118, P487, DOI 10.1016/S0016-5085(00)70254-X; Sooriakumaran P, 2006, POSTGRAD MED J, V82, P242, DOI 10.1136/pgmj.2005.042234; Souza RF, 2000, CANCER RES, V60, P5767; Souza RF, 2004, AM J PHYSIOL-GASTR L, V287, pG743, DOI 10.1152/ajpgi.00144.2004; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; Trier J S, 1980, Methods Cell Biol, V21B, P365; Tsai SH, 2002, J CELL BIOCHEM, V84, P750, DOI 10.1002/jcb.10096; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wild CP, 2003, NAT REV CANCER, V3, P676, DOI 10.1038/nrc1166; Yan XJ, 2002, BIOL REPROD, V66, P1667, DOI 10.1095/biolreprod66.6.1667; Zimmermann KC, 1999, CANCER RES, V59, P198	52	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16244	16255		10.1074/jbc.M700297200	http://dx.doi.org/10.1074/jbc.M700297200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403674	hybrid			2022-12-27	WOS:000246794300032
J	Moulson, CL; Lin, MH; White, JM; Newberry, EP; Davidson, NO; Miner, JH				Moulson, Casey L.; Lin, Meei-Hua; White, J. Michael; Newberry, Elizabeth P.; Davidson, Nicholas O.; Miner, Jeffrey H.			Keratinocyte-specific expression of fatty acid transport protein 4 rescues the wrinkle-free phenotype in Slc27a4/Fatp4 mutant mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID TRANSPORT; HUMAN INVOLUCRIN PROMOTER; PERMEABILITY BARRIER FUNCTION; RESTRICTIVE DERMOPATHY; HARLEQUIN ICHTHYOSIS; TETRAPLOID CELLS; LAMIN-A; MOUSE; PROTEIN-4; SKIN	FATP4 (fatty acid transport protein 4; also known as SLC27A4) is the most widely expressed member of a family of six long chain fatty acid transporters. FATP4 is highly expressed in enterocytes and has therefore been proposed to be a major importer of dietary fatty acids. Two independent mutations in Fatp4 cause mice to be born with thick, tight, shiny, "wrinkle-free" skin and a defective skin barrier; they die within hours of birth from dehydration and restricted movements. In contrast, induced keratinocyte-specific deficiency of FATP4 in adult mice causes only mild skin abnormalities. Therefore, whether the loss of FATP4 from skin or a systemic gestational metabolic defect causes the severe skin defects and neonatal lethality remain important unanswered questions. To investigate the basis for the phenotype, we first generated wild-type tetraploid/mutant diploid aggregates that should lead to rescue of any abnormalities caused by loss of FATP4 from the placenta. However, the skin phenotype was not ameliorated. We then generated transgenic mice expressing exogenous FATP4 either widely or specifically in suprabasal keratinocytes, and we bred the transgenes onto the Fatp4(-/-) background. Both modes of FATP4 expression led to rescue of the neonatally lethal skin defects, and the resulting mice were viable and fertile. Keratinocyte expression of an FATP4 variant with mutations in the acyl-CoA synthetase domain did not provide any degree of rescue. We conclude that expression of FATP4 with an intact acyl-CoA synthetase domain in suprabasal keratinocytes is necessary for normal skin development and that FATP4 functions in establishing the cornified envelope.	Washington Univ, Sch Med, Div Renal, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Gastroenterol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Miner, JH (corresponding author), Washington Univ, Sch Med, Div Renal, Dept Internal Med, 660 S Euclid Ave,Box 8126, St Louis, MO 63110 USA.	minerj@wustl.edu		White, James Michael/0000-0001-5110-6567	NCRR NIH HHS [C06RR015502, P41RR000954] Funding Source: Medline; NHLBI NIH HHS [R37HL038180] Funding Source: Medline; NIAMS NIH HHS [R01 AR049269-02, R01 AR049269-03, R01AR049269, R01 AR049269-01A1, R01 AR049269] Funding Source: Medline; NIDDK NIH HHS [P60DK020579, P30 DK056341-06, P30DK056341, P30 DK056341-07, P30 DK056341, K01DK075811, R01DK056260, P30DK052574] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015502, P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, P30DK056341, P30DK052574, K01DK075811, R01DK056260] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama M, 2005, J CLIN INVEST, V115, P1777, DOI 10.1172/JCI24834; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Black PN, 2003, MICROBIOL MOL BIOL R, V67, P454, DOI 10.1128/MMBR.67.3.454-472.2003; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cameron DJ, 2007, INT J BIOL SCI, V3, P111; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CARROLL JM, 1992, J CELL SCI, V103, P925; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; DiRusso CC, 2005, J BIOL CHEM, V280, P16829, DOI 10.1074/jbc.M409598200; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; ELIAS PM, 1978, LAB INVEST, V39, P574; FOUNDATION N, 1969, NUTR REV, V27, P85; Gimeno RE, 2003, J BIOL CHEM, V278, P49512, DOI 10.1074/jbc.M309759200; Goto Y, 2002, INT J DEV BIOL, V46, P741; Hadjantonakis Anna-Katerina, 2002, BMC Biotechnol, V2, P11, DOI 10.1186/1472-6750-2-11; Haggarty P, 2004, EUR J CLIN NUTR, V58, P1559, DOI 10.1038/sj.ejcn.1602016; Hall AM, 2005, J BIOL CHEM, V280, P11948, DOI 10.1074/jbc.M412629200; Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200; Han XL, 2001, ANAL BIOCHEM, V295, P88, DOI 10.1006/abio.2001.5178; Herrera E, 2002, PLACENTA, V23, pS9, DOI 10.1053/plac.2002.0771; Herrmann T, 2005, J INVEST DERMATOL, V125, P1228, DOI 10.1111/j.0022-202X.2005.23972.x; Herrmann T, 2003, J CELL BIOL, V161, P1105, DOI 10.1083/jcb.200207080; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hovnanian A, 2005, J CLIN INVEST, V115, P1708, DOI 10.1172/JCI25736; JAMES RM, 1995, DEV BIOL, V167, P213, DOI 10.1006/dbio.1995.1018; Larque E, 2006, EARLY HUM DEV, V82, P697, DOI 10.1016/j.earlhumdev.2006.02.001; Lewis SE, 2001, J BIOL CHEM, V276, P37042, DOI 10.1074/jbc.M105556200; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Li WM, 2007, INT J BIOL SCI, V3, P120; Milger K, 2006, J CELL SCI, V119, P4678, DOI 10.1242/jcs.03280; MIYAZAKI J, 1989, GENE, V79, P269; Moulson CL, 2003, P NATL ACAD SCI USA, V100, P5274, DOI 10.1073/pnas.0431186100; Moulson CL, 2005, J INVEST DERMATOL, V125, P913, DOI 10.1111/j.0022-202X.2005.23846.x; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; Navarro CL, 2004, HUM MOL GENET, V13, P2493, DOI 10.1093/hmg/ddh265; Navarro CL, 2005, HUM MOL GENET, V14, P1503, DOI 10.1093/hmg/ddi159; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; PROTTEY C, 1976, BRIT J DERMATOL, V94, P579, DOI 10.1111/j.1365-2133.1976.tb05151.x; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Rossant J., 2002, MOUSE DEV PATTERNING, P155; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schmuth M, 2005, J INVEST DERMATOL, V125, P1174, DOI 10.1111/j.0022-202X.2005.23934.x; Stahl A, 2004, PFLUG ARCH EUR J PHY, V447, P722, DOI 10.1007/s00424-003-1106-z; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Stuhlsatz-Krouper SM, 1999, PROSTAG LEUKOTR ESS, V60, P285, DOI 10.1016/S0952-3278(99)80001-5; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; Sundberg JP., 1994, HDB MOUSE MUTATIONS, P57; Tanaka M, 2000, METH MOL B, V158, P135; Vasireddy V, 2007, HUM MOL GENET, V16, P471, DOI 10.1093/hmg/ddl480; VERGROESEN AJ, 1976, BIBL NUTR DIET, P19	53	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15912	15920		10.1074/jbc.M701779200	http://dx.doi.org/10.1074/jbc.M701779200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17401141	hybrid			2022-12-27	WOS:000246589600066
J	Onofri, F; Messa, M; Matafora, V; Bonanno, G; Corradi, A; Bachi, A; Valtorta, F; Benfenati, F				Onofri, Franco; Messa, Mirko; Matafora, Vittoria; Bonanno, Giambattista; Corradi, Anna; Bachi, Angela; Valtorta, Flavia; Benfenati, Fabio			Synapsin phosphorylation by Src tyrosine kinase enhances Src activity in synaptic vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; NEUROTRANSMITTER RELEASE; F-ACTIN; GLUTAMATE RELEASE; NERVE-TERMINALS; FAMILY KINASES; SH2 DOMAINS; C-SRC; PROTEIN; SYNAPTOSOMES	Synapsins are synaptic vesicle-associated phosphoproteins implicated in the regulation of neurotransmitter release. Synapsin I is the major binding protein for the SH3 domain of the kinase c-Src in synaptic vesicles. Its binding leads to stimulation of synaptic vesicle-associated c-Src activity. We investigated the mechanism and role of Src activation by synapsins on synaptic vesicles. We found that synapsin is tyrosine phosphorylated by c-Src in vitro and on intact synaptic vesicles independently of its phosphorylation state on serine. Mass spectrometry revealed a single major phosphorylation site at Tyr(301), which is highly conserved in all synapsin isoforms and orthologues. Synapsin tyrosine phosphorylation triggered its binding to the SH2 domains of Src or Fyn. However, synapsin selectively activated and was phosphorylated by Src, consistent with the specific enrichment of c-Src in synaptic vesicles over Fyn or n-Src. The activity of Src on synaptic vesicles was controlled by the amount of vesicle-associated synapsin, which is in turn dependent on synapsin serine phosphorylation. Synaptic vesicles depleted of synapsin in vitro or derived from synapsin null mice exhibited greatly reduced Src activity and tyrosine phosphorylation of other synaptic vesicle proteins. Disruption of the Src-synapsin interaction by internalization of either the Src SH3 or SH2 domains into synaptosomes decreased synapsin tyrosine phosphorylation and concomitantly increased neurotransmitter release in response to Ca(2+-)ionophores. We conclude that synapsin is an endogenous substrate and activator of synaptic vesicle-associated c-Src and that regulation of Src activity on synaptic vesicles participates in the regulation of neurotransmitter release by synapsin.	Univ Genoa, Dept Expt Med, I-16132 Genoa, Italy; Italian Inst Technol, Cent Lab, Dept Neurosci & Brain Technol, I-16163 Genoa, Italy; Ist Sci San Raffaele, I-20132 Milan, Italy; San Raffaele Vita Salute Univ, I-20132 Milan, Italy; Italian Inst Technol, Unit Mol Neurosci, I-20132 Milan, Italy	University of Genoa; Istituto Italiano di Tecnologia - IIT; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Istituto Italiano di Tecnologia - IIT	Benfenati, F (corresponding author), Via Benedetto XV N3, I-16132 Genoa, Italy.	benfenat@unige.it	bachi, angela/B-3527-2015; Corradi, Anna/AAC-5209-2022; Bonanno, Giambattista/C-5856-2008; Flavia, Valtorta/F-3450-2012	bachi, angela/0000-0003-4842-6556; Flavia, Valtorta/0000-0001-9556-4746; matafora, vittoria/0000-0002-4311-998X; Bonanno, Giambattista/0000-0003-3744-5786	Telethon [GGP05134] Funding Source: Medline	Telethon(Fondazione Telethon)		Areces LB, 2004, EUR J MASS SPECTROM, V10, P383, DOI 10.1255/ejms.601; Ashton AC, 2000, J NEUROCHEM, V74, P1979, DOI 10.1046/j.1471-4159.2000.0741979.x; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; Baldelli P., 2006, MOL MECH EXOCYTOSIS, P1; Baldwin ML, 2006, NEUROCHEM INT, V49, P80, DOI 10.1016/j.neuint.2006.01.002; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; Benfenati F, 1999, PHILOS T R SOC B, V354, P243, DOI 10.1098/rstb.1999.0376; Bonanomi D, 2005, J NEUROSCI, V25, P7299, DOI 10.1523/JNEUROSCI.1573-05.2005; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CECCALDI PE, 1995, J CELL BIOL, V128, P905, DOI 10.1083/jcb.128.5.905; Charpantier E, 2005, J NEUROSCI, V25, P9836, DOI 10.1523/JNEUROSCI.3497-05.2005; Cheetham JJ, 2001, BIOCHEM J, V354, P57, DOI 10.1042/0264-6021:3540057; Chi P, 2003, NEURON, V38, P69, DOI 10.1016/S0896-6273(03)00151-X; Chi P, 2001, NAT NEUROSCI, V4, P1187, DOI 10.1038/nn756; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; Esser L, 1998, EMBO J, V17, P977, DOI 10.1093/emboj/17.4.977; Giovedi S, 2004, J BIOL CHEM, V279, P43769, DOI 10.1074/jbc.M404168200; Gitler D, 2004, J NEUROSCI, V24, P11368, DOI 10.1523/JNEUROSCI.3795-04.2004; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; Hayashi T, 2004, J NEUROSCI, V24, P6152, DOI 10.1523/JNEUROSCI.0799-04.2004; Hilfiker S, 2005, J NEUROSCI, V25, P2658, DOI 10.1523/JNEUROSCI.4278-04.2005; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Hosaka M, 1999, J BIOL CHEM, V274, P16747, DOI 10.1074/jbc.274.24.16747; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; JENSEN ES, 1998, P 11 INT WORLD FERT, V2, P89; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kalia LV, 2004, ONCOGENE, V23, P8007, DOI 10.1038/sj.onc.1208158; Kao HT, 1999, J EXP ZOOL, V285, P360, DOI 10.1002/(SICI)1097-010X(19991215)285:4<360::AID-JEZ4>3.3.CO;2-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Nielander HB, 1997, EUR J NEUROSCI, V9, P2712, DOI 10.1111/j.1460-9568.1997.tb01700.x; Ohnishi H, 2001, P NATL ACAD SCI USA, V98, P10930, DOI 10.1073/pnas.191368198; OKADA M, 1991, J BIOL CHEM, V266, P24249; Onofri F, 2000, J BIOL CHEM, V275, P29857, DOI 10.1074/jbc.M006018200; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Purcell AL, 2003, TRENDS NEUROSCI, V26, P625, DOI 10.1016/j.tins.2003.09.005; Raiteri M, 2000, J NEUROCHEM, V74, P423, DOI 10.1046/j.1471-4159.2000.0740423.x; RIGAUDY P, 1994, DNA CELL BIOL, V13, P585, DOI 10.1089/dna.1994.13.585; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; Schenk U, 2005, J NEUROSCI, V25, P1654, DOI 10.1523/JNEUROSCI.3074-04.2005; Sheinerman FB, 2003, J MOL BIOL, V334, P823, DOI 10.1016/j.jmb.2003.09.075; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shyu KG, 2005, NEUROREPORT, V16, P1969, DOI 10.1097/01.wnr.0000189758.57164.85; SIOW YL, 1992, BIOCHEMISTRY-US, V31, P4268, DOI 10.1021/bi00132a017; Stefani G, 1997, J PHYSIOL-LONDON, V504, P501, DOI 10.1111/j.1469-7793.1997.501bd.x; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; Stigliani S, 2003, J NEUROCHEM, V85, P409, DOI 10.1046/j.1471-4159.2003.01689.x; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Vaccaro P, 1997, MOL BRAIN RES, V52, P1, DOI 10.1016/S0169-328X(97)00219-2; Valtorta F, 2004, BIOESSAYS, V26, P445, DOI 10.1002/bies.20012; Wang SJ, 2003, NEUROREPORT, V14, P1519, DOI 10.1097/00001756-200308060-00024; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	69	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15754	15767		10.1074/jbc.M701051200	http://dx.doi.org/10.1074/jbc.M701051200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400547	hybrid			2022-12-27	WOS:000246589600051
J	Soltani, CE; Hotze, EM; Johnson, AE; Tweten, RK				Soltani, Casie E.; Hotze, Eileen M.; Johnson, Arthur E.; Tweten, Rodney K.			Specific protein-membrane contacts are required for prepore and pore assembly by a cholesterol-dependent cytolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE BETA-HAIRPINS; THIOL-ACTIVATED CYTOLYSIN; TOXIN PERFRINGOLYSIN-O; CLOSTRIDIUM-PERFRINGENS; THETA-TOXIN; CONFORMATIONAL-CHANGES; TRYPTOPHAN RESIDUES; LIPOSOMAL MEMBRANES; BINDING CYTOLYSIN; MECHANISM	Three short hydrophobic loops and a conserved undecapeptide at the tip of domain 4 (D4) of the cholesterol-dependent cytolysins (CDCs) mediate the binding of the CDC monomers to cholesterol-rich cell membranes. But intermedilysin (ILY), from Streptococcus intermedius, does not bind to cholesterol-rich membranes unless they contain the human protein CD59. This observation suggested that the D4 loops, which include loops L1-L3 and the undecapeptide, of ILY were no longer required for its cell binding. However, we show here that membrane insertion of the D4 loops is required for the cytolysis by ILY. Receptor binding triggers changes in the structure of ILY that are necessary for oligomerization, but membrane insertion of the D4 loops is critical for oligomer assembly and pore formation. Defects that prevent membrane insertion of the undecapeptide also block assembly of the prepore oligomer, while defects in the membrane insertion of the L1-L3 loops prevent the conversion of the prepore oligomer to the pore complex. These studies reveal that pore formation by ILY, and probably other CDCs, is affected by an intricate and coupled sequence of interactions between domain 4 and the membrane.	Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Dept Mol & Cellular Med, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem & Biochem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biophys, College Stn, TX 77843 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Tweten, RK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, BMSB 1053, Oklahoma City, OK 73104 USA.	Rod-Tweten@ouhsc.edu	Johnson, Arthur E/G-3457-2012		NIAID NIH HHS [R01 AI037657, R37 AI037657, AI037657] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI037657, R01AI037657] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alouf JE, 2000, INT J MED MICROBIOL, V290, P351; ALOUF JE, 1999, BACTERIAL TOXINS COM; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Czajkowsky DM, 2004, EMBO J, V23, P3206, DOI 10.1038/sj.emboj.7600350; Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862; Giddings KS, 2003, P NATL ACAD SCI USA, V100, P11315, DOI 10.1073/pnas.2033520100; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; Heuck AP, 2000, MOL CELL, V6, P1233, DOI 10.1016/S1097-2765(00)00119-2; Heuck AP, 2003, J BIOL CHEM, V278, P31218, DOI 10.1074/jbc.M303151200; Hotze EM, 2002, J BIOL CHEM, V277, P11597, DOI 10.1074/jbc.M111039200; Hotze EM, 2001, J BIOL CHEM, V276, P8261, DOI 10.1074/jbc.M009865200; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P27, DOI DOI 10.1016/0263-7855(96)00018-5; Iwamoto M, 1997, BBA-BIOMEMBRANES, V1327, P222, DOI 10.1016/S0005-2736(97)00061-8; IWAMOTO M, 1987, EUR J BIOCHEM, V167, P425, DOI 10.1111/j.1432-1033.1987.tb13355.x; Nagamune H, 2004, MICROBIOL IMMUNOL, V48, P677, DOI 10.1111/j.1348-0421.2004.tb03479.x; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Nakamura M, 1998, J BIOCHEM, V123, P1145; OHNOIWASHITA Y, 1991, J BIOCHEM-TOKYO, V110, P369, DOI 10.1093/oxfordjournals.jbchem.a123588; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Polekhina G, 2005, P NATL ACAD SCI USA, V102, P600, DOI 10.1073/pnas.0403229101; Ramachandran R, 2004, NAT STRUCT MOL BIOL, V11, P697, DOI 10.1038/nsmb793; Ramachandran R, 2005, P NATL ACAD SCI USA, V102, P7139, DOI 10.1073/pnas.0500556102; Ramachandran R, 2002, NAT STRUCT BIOL, V9, P823, DOI 10.1038/nsb855; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; SekinoSuzuki N, 1996, EUR J BIOCHEM, V241, P941, DOI 10.1111/j.1432-1033.1996.00941.x; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Shimada Y, 2002, EUR J BIOCHEM, V269, P6195, DOI 10.1046/j.1432-1033.2002.03338.x; Tilley SJ, 2005, CELL, V121, P247, DOI 10.1016/j.cell.2005.02.033	31	65	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15709	15716		10.1074/jbc.M701173200	http://dx.doi.org/10.1074/jbc.M701173200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17412689	Green Accepted, hybrid			2022-12-27	WOS:000246589600047
J	Sudo, Y; Furutani, Y; Spudich, JL; Kandori, H				Sudo, Yuki; Furutani, Yuji; Spudich, John L.; Kandori, Hideki			Early photocycle structural changes in a bacteriorhodopsin mutant engineered to transmit photosensory signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY-RHODOPSIN-II; INTERNAL WATER-MOLECULES; PROTONATED SCHIFF-BASE; OUT-OF-PLANE; PHARAONIS PHOBORHODOPSIN; RETINAL CHROMOPHORE; PRIMARY PHOTOPRODUCT; CHARGED RESIDUES; HYDROGEN-BONDS; TRANSDUCER	Bacteriorhodopsin ( BR) and sensory rhodopsin II (SRII) function as a light-driven proton pump and a receptor for negative phototaxis in haloarchaeal membranes, respectively. SRII transmits light signals through changes in protein-protein interaction with its transducer HtrII. Recently, we converted BR by three mutations into a form capable of transmitting photosignals to HtrII to mediate phototaxis responses. The BR triple mutant (BR-T) provides an opportunity to identify structural changes necessary to activate HtrII by comparing light-induced infrared spectral changes of BR, BR-T, and SRII. The hydrogen out-of-plane (HOOP) vibrations of the BR-T were very similar to those of SRII, indicating that they are distributed more extensively along the retinal chromophore than in BR, as in SRII. On the other hand, the bands of the protein moiety in BR-T are similar to those of BR, indicating that they are not specific to photosensing. The alteration of the O-H stretching vibration of Thr-204 in SRII, which we had previously shown to be essential for signal relay to HtrII, occurs also in BR-T. In addition, 1670(+)/1664(-)cm(-1) bands attributable to a distorted alpha-helix were observed in BR-T in a HtrII-dependent manner, as is seen in SRII. Thus, we identified similarities and dissimilarities of BR-T to BR and SRII. The results suggest signaling function of the structural changes of the HOOP vibrations, the O-H stretching vibration of the Thr-215 residue, and a distorted alpha-helix for the signal generation. We also succeeded in measurements of L minus initial state spectra of BR- T, which are the first FTIR spectra of L intermediates among sensory rhodopsins.	Univ Texas, Hlth Sci Ctr, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Nagoya Inst Technol, Dept Mat Sci & Engn, Showa Ku, Nagoya, Aichi 4668555, Japan	University of Texas System; University of Texas Health Science Center Houston; Nagoya Institute of Technology	Spudich, JL (corresponding author), Univ Texas, Hlth Sci Ctr, Ctr Membrane Biol, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	John.L.Spudich@uth.tmc.edu; kandori@nitech.ac.jp	Furutani, Yuji/J-8337-2019; Sudo, Yuki/AGY-0493-2022	Furutani, Yuji/0000-0001-5284-8773; Sudo, Yuki/0000-0001-8155-9356	NIGMS NIH HHS [R37GM27750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergo V, 2004, BIOCHEMISTRY-US, V43, P9075, DOI 10.1021/bi0361968; Bergo V, 2003, J BIOL CHEM, V278, P36556, DOI 10.1074/jbc.M303719200; Bergo VB, 2005, J BIOL CHEM, V280, P28365, DOI 10.1074/jbc.M505555200; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRIGGS W, 2004, HDB PHOTOSENSORY REC, P1; Furutani Y, 2005, PHOTOCH PHOTOBIO SCI, V4, P661, DOI 10.1039/b416698a; Furutani Y, 2005, BIOCHEMISTRY-US, V44, P2909, DOI 10.1021/bi047893i; Furutani Y, 2003, BIOCHEMISTRY-US, V42, P4837, DOI 10.1021/bi034317y; Furutani Y, 2006, BIOCHEMISTRY-US, V45, P11836, DOI 10.1021/bi0610597; Gordeliy VI, 2002, NATURE, V419, P484, DOI 10.1038/nature01109; Kamada K, 2006, BIOCHEMISTRY-US, V45, P4859, DOI 10.1021/bi060047i; Kamo N, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1277, DOI 10.1023/A:1013187403599; Kandori H, 2000, P NATL ACAD SCI USA, V97, P4643, DOI 10.1073/pnas.080064797; Kandori H, 2002, J PHYS CHEM A, V106, P2091, DOI 10.1021/jp012447f; Kandori H, 2001, BIOCHEMISTRY-US, V40, P15693, DOI 10.1021/bi011621n; Kandori H, 2002, BIOCHEMISTRY-US, V41, P4554, DOI 10.1021/bi0120749; Kandori H, 2002, BIOCHEMISTRY-US, V41, P6026, DOI 10.1021/bi025585j; Kandori H, 2001, BIOCHEMISTRY-US, V40, P9238, DOI 10.1021/bi0103819; Kandori H, 2000, J AM CHEM SOC, V122, P11745, DOI 10.1021/ja0032069; Kandori H, 1999, BIOCHEMISTRY-US, V38, P9676, DOI 10.1021/bi990713y; Kandori H, 2000, BBA-BIOENERGETICS, V1460, P177, DOI 10.1016/S0005-2728(00)00138-9; Klare JP, 2004, FEBS LETT, V564, P219, DOI 10.1016/S0014-5793(04)00193-0; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MAEDA A, 1991, PHOTOCHEM PHOTOBIOL, V54, P911, DOI 10.1111/j.1751-1097.1991.tb02111.x; Oesterhelt D, 1974, Methods Enzymol, V31, P667; PALINGS I, 1989, BIOCHEMISTRY-US, V28, P1498, DOI 10.1021/bi00430a012; Perazzona B, 1996, J BACTERIOL, V178, P6475, DOI 10.1128/jb.178.22.6475-6478.1996; Shibata M, 2003, J AM CHEM SOC, V125, P13312, DOI 10.1021/ja037343s; Shibata N, 2005, BIOCHEMISTRY-US, V44, P7406, DOI 10.1021/bi050122+; Shimono K, 2003, BIOCHEMISTRY-US, V42, P7801, DOI 10.1021/bi034284m; SIEBERT F, 1983, EUR J BIOCHEM, V130, P565, DOI 10.1111/j.1432-1033.1983.tb07187.x; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Spudich JL, 2006, TRENDS MICROBIOL, V14, P480, DOI 10.1016/j.tim.2006.09.005; Sudo Y, 2006, J MOL BIOL, V357, P1274, DOI 10.1016/j.jmb.2006.01.061; Sudo Y, 2005, J AM CHEM SOC, V127, P16036, DOI 10.1021/ja056203a; Sudo Y, 2005, BIOCHEMISTRY-US, V44, P6144, DOI 10.1021/bi047573z; Sudo Y, 2004, BIOCHEMISTRY-US, V43, P13748, DOI 10.1021/bi048803c; Sudo Y, 2003, BIOCHEMISTRY-US, V42, P14166, DOI 10.1021/bi035678g; Sudo Y, 2002, BIOPHYS J, V83, P427, DOI 10.1016/S0006-3495(02)75180-1; Sudo Y, 2001, PHOTOCHEM PHOTOBIOL, V74, P489, DOI 10.1562/0031-8655(2001)074<0489:PPBTIC>2.0.CO;2; Sudo Y, 2006, P NATL ACAD SCI USA, V103, P16129, DOI 10.1073/pnas.0607467103; Sudo Y, 2006, J BIOL CHEM, V281, P34239, DOI 10.1074/jbc.M605907200; Tanimoto T, 2004, BIOCHEMISTRY-US, V43, P9439, DOI 10.1021/bi049368p; Tanimoto T, 2003, BIOCHEMISTRY-US, V42, P2300, DOI 10.1021/bi026990d; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Yamazaki Y, 1996, BIOCHEMISTRY-US, V35, P4063, DOI 10.1021/bi9524530; Yang CS, 2004, J BIOL CHEM, V279, P42970, DOI 10.1074/jbc.M406504200	49	26	28	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15550	15558		10.1074/jbc.M701271200	http://dx.doi.org/10.1074/jbc.M701271200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17387174	hybrid			2022-12-27	WOS:000246589600032
J	Bayburt, TH; Leitz, AJ; Xie, GF; Oprian, DD; Sligar, SG				Bayburt, Timothy H.; Leitz, Andrew J.; Xie, Guifu; Oprian, Daniel D.; Sligar, Stephen G.			Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; GTP-BINDING PROTEIN; METARHODOPSIN-II; LIGHT-SCATTERING; DIMERS; CYTOCHROME-P450; RECONSTITUTION; NANODISCS; COMPLEX; ENERGY	Nanodiscs are nanometer scale planar membranes of controlled size that are rendered soluble in aqueous solution via an encircling amphipathic membrane scaffold protein "belt" (Bayburt, T. H., Grinkova, Y. V., and Sligar, S. G. (2002) Nano. Lett. 2, 853-856). Integral membrane proteins can be self-assembled into the Nanodisc bilayer with defined stoichiometry, which allows an unprecedented opportunity to investigate the nature of the oligomerization state of a G-protein-coupled receptor and its coupling to heterotrimeric G-proteins. We generated Nanodiscs having one and two rhodopsins present in the 10-nm-diameter lipid bilayer domain. Efficient transducin activation and isolation of a high affinity transducin-metarhodopsin II complex was demonstrated for a monodisperse and monomeric receptor. A population of Nanodiscs containing two rhodopsins was generated using an increased ratio of receptor to membrane scaffold protein in the self-assembly mixture. The two-rhodopsin population was isolated and purified by density gradient centrifugation. Interestingly, in this case, only one of the two receptors present in the Nanodisc was able to form a stable metarhodopsin II-G-protein complex. Thus there is clear evidence that a monomeric rhodopsin is capable of full coupling to transducin. Importantly, presumably due to steric interactions, it appears that only a single receptor in the Nanodiscs containing two rhodopsins can interact with G-protein. These results have important implications for the stoichiometry of receptor-G-protein coupling and cross talk in signaling pathways.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA	University of Illinois System; University of Illinois Urbana-Champaign; Brandeis University	Sligar, SG (corresponding author), Univ Illinois, Dept Biochem, 116 Morrill Hall,505 S Goodwin, Urbana, IL 61801 USA.	s-sligar@uiuc.edu			NATIONAL EYE INSTITUTE [R01EY007965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033775, R41GM075362] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baas BJ, 2004, ARCH BIOCHEM BIOPHYS, V430, P218, DOI 10.1016/j.abb.2004.07.003; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bayburt TH, 2003, PROTEIN SCI, V12, P2476, DOI 10.1110/ps.03267503; Bayburt TH, 2002, NANO LETT, V2, P853, DOI 10.1021/nl025623k; Bayburt TH, 2006, ARCH BIOCHEM BIOPHYS, V450, P215, DOI 10.1016/j.abb.2006.03.013; BENNETT N, 1985, J BIOL CHEM, V260, P4156; Boldog T, 2006, P NATL ACAD SCI USA, V103, P11509, DOI 10.1073/pnas.0604988103; BOROCHOVNEORI H, 1983, BIOCHEMISTRY-US, V22, P206, DOI 10.1021/bi00270a030; Chabre M, 2005, BIOCHEMISTRY-US, V44, P9395, DOI 10.1021/bi050720o; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CROUCH R, 1975, P NATL ACAD SCI USA, V72, P1538, DOI 10.1073/pnas.72.4.1538; Denisov IG, 2005, J PHYS CHEM B, V109, P15580, DOI 10.1021/jp051385g; Denisov IG, 2004, J AM CHEM SOC, V126, P3477, DOI 10.1021/ja0393574; Duan H, 2004, ARCH BIOCHEM BIOPHYS, V424, P141, DOI 10.1016/j.abb.2004.02.010; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; EMEIS D, 1981, FEBS LETT, V136, P201, DOI 10.1016/0014-5793(81)80618-7; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2006, CURR OPIN STRUC BIOL, V16, P252, DOI 10.1016/j.sbi.2006.03.013; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Funari SS, 2001, P NATL ACAD SCI USA, V98, P8938, DOI 10.1073/pnas.161160998; Gibson SK, 1998, BIOCHEMISTRY-US, V37, P11393, DOI 10.1021/bi980933w; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Jastrzebska B, 2006, J BIOL CHEM, V281, P11917, DOI 10.1074/jbc.M600422200; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; Leitz AJ, 2006, BIOTECHNIQUES, V40, P601, DOI 10.2144/000112169; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; Mansoor SE, 2006, P NATL ACAD SCI USA, V103, P3060, DOI 10.1073/pnas.0511010103; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; Medina R, 2004, J BIOL CHEM, V279, P39565, DOI 10.1074/jbc.M402446200; Mesnier D, 2004, J BIOL CHEM, V279, P49664, DOI 10.1074/jbc.M404941200; Milligan G, 2005, FEBS J, V272, P2914, DOI 10.1111/j.1742-4658.2005.04731.x; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Suda K, 2004, MOL MEMBR BIOL, V21, P435, DOI 10.1080/09687860400020291; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; TAYA K, 2002, T MAT RES SOC JPN, V27, P605; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697	46	290	297	0	39	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14875	14881		10.1074/jbc.M701433200	http://dx.doi.org/10.1074/jbc.M701433200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17395586	hybrid			2022-12-27	WOS:000246589000024
J	Liscombe, DK; Facchini, PJ				Liscombe, David K.; Facchini, Peter J.			Molecular cloning and characterization of tetrahydroprotoberberine cis-N- methyltransferase, an enzyme involved in alkaloid biosynthesis in opium poppy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPAVER-SOMNIFERUM; CDNA CLONING; O-METHYLTRANSFERASE; SUSPENSION-CULTURES; CRYSTAL-STRUCTURES; GENE-EXPRESSION; ACCUMULATION; (S)-STYLOPINE; LOCALIZATION; PURIFICATION	S-Adenosyl-L-methionine: tetrahydroprotoberberine cis-N-methyltransferase (EC 2.1.1.122) catalyzes the conversion of (S)-stylopine to the quaternary ammonium alkaloid, (S)-cis-N-methylstylopine, as a key step in the biosynthesis of protopine and benzophenanthridine alkaloids in plants. A full-length cDNA encoding a protein exhibiting 45 and 48% amino acid identity with coclaurine N-methyltransferase from Papaver somniferum (opium poppy) and Coptis japonica, respectively, was identified in an elicitor-treated opium poppy cell culture expressed sequence tag data base. Phylogenetic analysis showed that the protein belongs to a unique clade of enzymes that includes coclaurine N-methyltransferase, the predicated translation products of the Arabidopsis thaliana genes, At4g33110 and At4g33120, and bacterial S-adenosyl-L-methionine-dependent cyclopropane fatty acid synthases. Expression of the cDNA in Escherichia coli produced a recombinant enzyme able to convert the protoberberine alkaloids stylopine, canadine, and tetrahydropalmatine to their corresponding N-methylated derivatives. However, the protoberberine alkaloids tetrahydroxyberbine and scoulerine, and simple isoquinoline, benzylisoquinoline, and pavine alkaloids were not accepted as substrates, demonstrating the strict specificity of the enzyme. The apparent K-m values for (R,S)-stylopine and S-adenosyl-L-methionine were 0.6 and 11.5 mu M, respectively. TNMT gene transcripts and enzyme activity were detected in opium poppy seedlings and all mature plant organs and were induced in cultured opium poppy cells after treatment with a fungal elicitor. The enzyme was detected in cell cultures of other members of the Papaveraceae but not in species of related plant families that do not accumulate protopine and benzophenanthridine alkaloids.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Facchini, PJ (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.	pfacchin@ucalgary.ca		Facchini, Peter/0000-0002-7693-290X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anaya AL, 2006, FRONT BIOSCI-LANDMRK, V11, P2354, DOI 10.2741/1975; BATTERSBY AR, 1968, J CHEM SOC C, P2163, DOI 10.1039/j39680002163; BAUER W, 1989, TETRAHEDRON LETT, V30, P5257, DOI 10.1016/S0040-4039(01)93756-6; BAUER W, 1991, PHYTOCHEMISTRY, V30, P2953, DOI 10.1016/S0031-9422(00)98230-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDERWOOD JM, 1971, PHYTOCHEMISTRY, V10, P682, DOI 10.1016/S0031-9422(00)94724-1; CASTILLO P, 1986, SYNTHESIS-STUTTGART, V10, P839; CHEN CY, 1968, CAN J CHEMISTRY, V46, P2501, DOI 10.1139/v68-410; Cheng SH, 1998, METH MOL B, V86, P27; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Choi KB, 2002, J BIOL CHEM, V277, P830, DOI 10.1074/jbc.M106405200; Choi KB, 2001, PHYTOCHEMISTRY, V56, P649, DOI 10.1016/S0031-9422(00)00481-7; CHRZANOWSKA M, 1995, J NAT PRODUCTS, V58, P401, DOI 10.1021/np50117a008; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Facchini P, 2005, CAN J BOT, V83, P1189, DOI 10.1139/b05-094; Facchini Peter J., 2007, Phytochemistry Reviews, V6, P97, DOI 10.1007/s11101-006-9042-0; Facchini PJ, 2003, PHYTOCHEMISTRY, V64, P177, DOI 10.1016/S0031-9422(03)00292-9; Facchini PJ, 2001, ANNU REV PLANT PHYS, V52, P29, DOI 10.1146/annurev.arplant.52.1.29; Facchini PJ, 1996, PLANT PHYSIOL, V111, P687, DOI 10.1104/pp.111.3.687; FACCHINI PJ, 1994, J BIOL CHEM, V269, P26684; Ferrer JL, 2005, PLANT PHYSIOL, V137, P1009, DOI 10.1104/pp.104.048751; Frick S, 2005, J NAT PROD, V68, P666, DOI 10.1021/np0496643; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; Huang CYF, 2002, J BIOL CHEM, V277, P34367, DOI 10.1074/jbc.M202468200; Huang FC, 2000, PHYTOCHEMISTRY, V53, P555, DOI 10.1016/S0031-9422(99)00600-7; Ibrahim RK, 1998, PLANT MOL BIOL, V36, P1, DOI 10.1023/A:1005939803300; Ikezawa N, 2003, J BIOL CHEM, V278, P38557, DOI 10.1074/jbc.M302470200; Larsson KAE, 2006, PHYTOCHEMISTRY, V67, P2002, DOI 10.1016/j.phytochem.2006.06.036; Liscombe DK, 2005, PHYTOCHEMISTRY, V66, P1374, DOI 10.1016/j.phytochem.2005.04.029; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; MCOMIE JFW, 1968, TETRAHEDRON, V24, P2289, DOI 10.1016/0040-4020(68)88130-X; Morishige T, 2000, J BIOL CHEM, V275, P23398, DOI 10.1074/jbc.M002439200; Morishige T, 2002, EUR J BIOCHEM, V269, P5659, DOI 10.1046/j.1432-1033.2002.03275.x; NARASIMHAN NS, 1983, TETRAHEDRON, V39, P1975, DOI 10.1016/S0040-4020(01)91915-5; Nuccio ML, 2000, J BIOL CHEM, V275, P14095, DOI 10.1074/jbc.275.19.14095; OHASHI M, 1963, J AM CHEM SOC, V85, P2807, DOI 10.1021/ja00901a030; OKEEFE BR, 1994, PLANT PHYSIOL, V105, P395, DOI 10.1104/pp.105.1.395; Ounaroon A, 2003, PLANT J, V36, P808, DOI 10.1046/j.1365-313X.2003.01928.x; Paraskevas S, 2005, Int J Dent Hyg, V3, P162, DOI 10.1111/j.1601-5037.2005.00145.x; Pauli HH, 1998, PLANT J, V13, P793, DOI 10.1046/j.1365-313X.1998.00085.x; Raman SB, 2003, PLANT PHYSIOL, V132, P1642, DOI 10.1104/pp.103.020453; RUEFFER M, 1990, PHYTOCHEMISTRY, V29, P3727, DOI 10.1016/0031-9422(90)85321-6; RUEFFER M, 1987, TETRAHEDRON LETT, V28, P5307, DOI 10.1016/S0040-4039(00)96715-7; Samanani N, 2005, PLANT CELL, V17, P915, DOI 10.1105/tpc.104.028654; Samanani N, 2004, PLANT J, V40, P302, DOI 10.1111/j.1365-313X.2004.02210.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmeller T, 1997, PHYTOCHEMISTRY, V44, P257, DOI 10.1016/S0031-9422(96)00545-6; SCHUMACHER HM, 1988, PLANT CELL REP, V7, P43, DOI 10.1007/BF00272975; Suzuki K, 1999, PLANT CELL PHYSIOL, V40, P289, DOI 10.1093/oxfordjournals.pcp.a029540; TAKESHITA N, 1995, PLANT CELL PHYSIOL, V36, P29; TANAHASHI T, 1990, PHYTOCHEMISTRY, V29, P1113, DOI 10.1016/0031-9422(90)85414-B; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; Ye KQ, 1998, P NATL ACAD SCI USA, V95, P1601, DOI 10.1073/pnas.95.4.1601; Ying ZT, 1999, J BIOL CHEM, V274, P36750, DOI 10.1074/jbc.274.51.36750; Ziegler J, 2005, PLANTA, V222, P458, DOI 10.1007/s00425-005-1550-4; Zubieta C, 2002, PLANT CELL, V14, P1265, DOI 10.1105/tpc.001412; Zubieta C, 2001, NAT STRUCT BIOL, V8, P271, DOI 10.1038/85029; Zulak KG, 2007, PLANTA, V225, P1085, DOI 10.1007/s00425-006-0419-5	60	80	95	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14741	14751		10.1074/jbc.M611908200	http://dx.doi.org/10.1074/jbc.M611908200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389594	hybrid			2022-12-27	WOS:000246589000009
J	Taylor, RC; Brumatti, G; Ito, S; Hengartner, MO; Derry, WB; Martin, SJ				Taylor, Rebecca C.; Brumatti, Gabriela; Ito, Shu; Hengartner, Michael O.; Derry, W. Brent; Martin, Seamus J.			Establishing a blueprint for CED-3-dependent killing through identification of multiple substrates for this protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; MYOSIN LIGHT-CHAIN; CAENORHABDITIS-ELEGANS; C-ELEGANS; GENE CED-3; GRANZYME-B; ROCK-I; APOPTOSIS; ACTIVATION; CALRETICULIN	Genetic studies have established that the cysteine protease CED-3 plays a central role in coordinating programmed cell death in Caenorhabditis elegans. However, it remains unclear how CED-3 activation results in cell death because few substrates for this protease have been described. We have used a global proteomics approach to seek substrates for CED-3 and have identified 22 worm proteins that undergo CED-3-dependent proteolysis. Proteins that were found to be substrates for CED-3 included the cytoskeleton proteins actin, myosin light chain, and tubulin, as well as proteins involved in ATP synthesis, cellular metabolism, and chaperone function. We estimate that similar to 3% of the C. elegans proteome is susceptible to CED-3-dependent proteolysis. Notably, the endoplasmic reticulum chaperone calreticulin, which has been implicated in the recognition of apoptotic cells by phagocytes, was cleaved by CED-3 and was also cleaved by human caspases during apoptosis. Inhibitors of caspase activity blocked the appearance of calreticulin on the surface of apoptotic cells, suggesting a mechanism for the surface display of calreticulin during apoptosis. Further analysis of these substrates is likely to yield important insights into the mechanism of killing by CED-3 and its human caspase counterparts.	Trinity Coll Dublin, Mol Cell Biol Lab, Smurfit Inst Genet, Dublin 2, Ireland; Univ Toronto, Program Dev Biol, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med & Mol Genet, Toronto, ON M5G 1X8, Canada; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	Trinity College Dublin; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Zurich	Martin, SJ (corresponding author), Trinity Coll Dublin, Mol Cell Biol Lab, Smurfit Inst Genet, Dublin 2, Ireland.	martinsj@tcd.ie	Derry, Brent/CAF-4503-2022; Hengartner, Michael O/E-6235-2011	Hengartner, Michael/0000-0002-7584-596X; Derry, Brent/0000-0002-1977-8475; Taylor, Rebecca/0000-0003-3429-3123; Martin, Seamus/0000-0002-8539-3143				Adrain C, 2006, J BIOL CHEM, V281, P8118, DOI 10.1074/jbc.M509361200; Adrain C, 2004, J BIOL CHEM, V279, P36923, DOI 10.1074/jbc.M402638200; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Kim SY, 2004, MOL BIOTECHNOL, V27, P1, DOI 10.1385/MB:27:1:01; Lettre G, 2006, NAT REV MOL CELL BIO, V7, P97, DOI 10.1038/nrm1836; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Moretti A, 2002, P NATL ACAD SCI USA, V99, P11860, DOI 10.1073/pnas.182373099; Moss DK, 2006, J CELL SCI, V119, P2362, DOI 10.1242/jcs.02959; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Shaham S, 1999, GENETICS, V153, P1655; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Syntichaki P, 2005, CURR BIOL, V15, P1249, DOI 10.1016/j.cub.2005.05.057; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Van Damme P, 2005, NAT METHODS, V2, P771, DOI 10.1038/NMETH792; Won J, 2003, J BIOL CHEM, V278, P19347, DOI 10.1074/jbc.M213098200; Xu KL, 2001, NEURON, V31, P957, DOI 10.1016/S0896-6273(01)00432-9; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yan N, 2005, NATURE, V437, P831, DOI 10.1038/nature04002; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	35	29	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15011	15021		10.1074/jbc.M611051200	http://dx.doi.org/10.1074/jbc.M611051200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17371877	Green Accepted, hybrid			2022-12-27	WOS:000246589000040
J	Ojima, K; Ono, Y; Doi, N; Yoshioka, K; Kawabata, Y; Labeit, S; Sorimachi, H				Ojima, Koichi; Ono, Yasuko; Doi, Naoko; Yoshioka, Katsuhide; Kawabata, Yukiko; Labeit, Siegfried; Sorimachi, Hiroyuki			Myogenic stage, sarcomere length, and protease activity modulate localization of muscle-specific calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHY TYPE 2A; ALPHA-ACTININ-BINDING; TITIN KINASE DOMAIN; Z-I-BODIES; MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; Z-DISC; MOLECULAR-STRUCTURE; STRIATED-MUSCLE; TERMINAL REGION	p94/calpain 3 is a Ca2+-binding intracellular protease predominantly expressed in skeletal muscles. p94 binds to the N2A and M-line regions of connectin/titin and localizes in the Z-bands. Genetic evidence showing that compromised p94 proteolytic activity leads to muscular dystrophy (limb-girdle muscular dystrophy type 2A) indicates the importance of p94 function in myofibrils. Here we show that a series of p94 splice variants is expressed immediately after muscle differentiation and differentially change localization during myofibrillogenesis. We found that the endogenous N-terminal ( but not C-terminal) domain of p94 was not only localized in the Z-bands but also directly bound to sarcomeric alpha-actinin. These data suggest the incorporation of proteolytic N-terminal fragments of p94 into the Z-bands. In myofibrils localization of exogenously expressed p94 shifted from the M-line to N2A as the sarcomere lengthens beyond similar to 2.6 and 2.8 mu m for wild-type and protease-inactive p94, respectively. These data demonstrate for the first time that p94 proteolytic activity is involved in responses to muscle conditions, which may explain why p94 inactivation causes limb-girdle muscular dystrophy.	Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Tokyo 1138613, Japan; Japan Sci & Technol Agcy, JST, CREST, Kawaguchi 3320012, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Univ Klinikum Mannheim, Inst Anasthesiol & Operat Intens Med, D-68167 Mannheim, Germany	Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); University of Tokyo; Ruprecht Karls University Heidelberg	Sorimachi, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Enzymat Regulat Cell Funct, Tokyo 1138613, Japan.	sorimach@rinshoken.or.jp	Sorimachi, Hiroyuki/Q-6956-2017; Sorimachi, Hiroyuki/C-6448-2009	Sorimachi, Hiroyuki/0000-0001-9509-6727; Sorimachi, Hiroyuki/0000-0001-9509-6727; Ojima, Koichi/0000-0002-5973-1073				Bang ML, 2001, J CELL BIOL, V153, P413, DOI 10.1083/jcb.153.2.413; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; Farkas A, 2003, BIOL CHEM, V384, P945, DOI 10.1515/BC.2003.106; Frey N, 2002, J BIOL CHEM, V277, P13998, DOI 10.1074/jbc.M200712200; GOLL DE, 1991, J BIOL CHEM, V266, P8501; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gregorio CC, 1998, J CELL BIOL, V143, P1013, DOI 10.1083/jcb.143.4.1013; Hackman P, 2002, AM J HUM GENET, V71, P492, DOI 10.1086/342380; Haravuori H, 2001, NEUROLOGY, V56, P869, DOI 10.1212/WNL.56.7.869; Herasse M, 1999, MOL CELL BIOL, V19, P4047; Holtzer H, 1997, CELL STRUCT FUNCT, V22, P83, DOI 10.1247/csf.22.83; Kawabata Y, 2003, FEBS LETT, V555, P623, DOI 10.1016/S0014-5793(03)01324-3; Kinbara K, 1997, ARCH BIOCHEM BIOPHYS, V342, P99, DOI 10.1006/abbi.1997.0108; Kramerova I, 2005, HUM MOL GENET, V14, P2125, DOI 10.1093/hmg/ddi217; Kramerova I, 2004, HUM MOL GENET, V13, P1373, DOI 10.1093/hmg/ddh153; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; MARUYAMA K, 1976, J BIOCHEM-TOKYO, V80, P405, DOI 10.1093/oxfordjournals.jbchem.a131291; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; Obermann WMJ, 1997, EMBO J, V16, P211, DOI 10.1093/emboj/16.2.211; Obermann WMJ, 1996, J CELL BIOL, V134, P1441, DOI 10.1083/jcb.134.6.1441; Ohtsuka H, 1997, FEBS LETT, V401, P65, DOI 10.1016/S0014-5793(96)01432-9; Ojima K, 1999, J CELL SCI, V112, P4101; Ojima K, 2004, BIOCHEM BIOPH RES CO, V321, P1050, DOI 10.1016/j.bbrc.2004.07.069; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; Ono Y, 2006, J BIOL CHEM, V281, P18519, DOI 10.1074/jbc.M601029200; Poussard S, 1996, CELL GROWTH DIFFER, V7, P1461; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Richard I, 2000, J CELL BIOL, V151, P1583, DOI 10.1083/jcb.151.7.1583; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Sato N, 2003, MOL CELL BIOL, V23, P6662, DOI 10.1128/MCB.23.18.6662-6671.2003; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1997, J MOL BIOL, V270, P688, DOI 10.1006/jmbi.1997.1145; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; Spencer MJ, 2002, P NATL ACAD SCI USA, V99, P8874, DOI 10.1073/pnas.132269299; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Tagawa K, 2000, HUM MOL GENET, V9, P1393, DOI 10.1093/hmg/9.9.1393; Takada F, 2001, P NATL ACAD SCI USA, V98, P1595, DOI 10.1073/pnas.041609698; Taveau M, 2003, MOL CELL BIOL, V23, P9127, DOI 10.1128/MCB.23.24.9127-9135.2003; TOKUYASU KT, 1987, J CELL BIOL, V105, P2795, DOI 10.1083/jcb.105.6.2795; Trombitas K, 1998, J CELL BIOL, V140, P853, DOI 10.1083/jcb.140.4.853; Trombitas K, 2003, BIOPHYS J, V85, P3142, DOI 10.1016/S0006-3495(03)74732-8; WANG K, 1979, P NATL ACAD SCI USA, V76, P3698, DOI 10.1073/pnas.76.8.3698; Wittt CC, 2004, J MOL BIOL, V336, P145, DOI 10.1016/j.jmb.2003.12.021; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807	48	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14493	14504		10.1074/jbc.M610806200	http://dx.doi.org/10.1074/jbc.M610806200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371879	hybrid			2022-12-27	WOS:000246245800063
J	Tringali, C; Lupo, B; Anastasia, L; Papini, N; Monti, E; Bresciani, R; Tettamanti, G; Venerando, B				Tringali, Cristina; Lupo, Barbara; Anastasia, Luigi; Papini, Nadia; Monti, Eugenio; Bresciani, Roberto; Tettamanti, Guido; Venerando, Bruno			Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; MEMBRANE-ASSOCIATED SIALIDASE; ABL TRANSFORMING ACTIVITY; CHRONIC MYELOID-LEUKEMIA; B16 MELANOMA-CELLS; SRC FAMILY KINASES; MOLECULAR-BIOLOGY; CANCER-THERAPY; OVEREXPRESSION; GANGLIOSIDES	Chronic myeloid leukemia is a hematopoietic stem cell cancer, originated by the perpetually "switched on" activity of the tyrosine kinase Bcr-Abl, leading to uncontrolled proliferation and insensitivity to apoptotic stimuli. The genetic phenotype of myeloid leukemic K562 cells includes the suppression of cytosolic sialidase Neu2. Neu2 transfection in K562 cells induced a marked decrease (-30% and -80%) of the mRNA of the antiapoptotic factors Bcl-XL and Bcl-2, respectively, and an almost total disappearance of Bcl-2 protein. In addition, gene expression and activity of Bcr-Abl underwent a 35% diminution, together with a marked decrease of Bcr-Abl-dependent Src and Lyn kinase activity. Thus, the antiapoptotic axis Bcr-Abl, Src, and Lyn, which stimulates the formation of Bcl-XL and Bcl- 2, was remarkably weakened. The ultimate consequences of these modifications were an increased susceptibility to apoptosis of K562 cells and a marked reduction of their proliferation rate. The molecular link between Neu2 activity and Bcr-Abl signaling pathway may rely on the desialylation of some cytosolic glycoproteins. In fact, three cytosolic glycoproteins, in the range 45 - 66 kDa, showed a 50 - 70% decrease of their sialic acid content upon Neu2 expression, supporting their possible role as modulators of the Bcr-Abl complex.	Univ Milan, Dept Med Chem Biochem & Biotechnol, I-20090 Milan, Italy; Univ Brescia, Dept Biomed Sci & Biotechnol, I-25153 Brescia, Italy	University of Milan; University of Brescia	Venerando, B (corresponding author), Univ Milan, Dept Med Chem Biochem & Biotechnol, Via Fratelli Cervi 93, I-20090 Milan, Italy.	bruno.venerando@unimi.it	Tringali, Cristina Alessandra/Q-7259-2017; papini, nadia/M-2425-2017; Anastasia, Luigi/AAN-1964-2020; Bresciani, Roberto/AAA-9728-2020	Tringali, Cristina Alessandra/0000-0002-0632-6197; papini, nadia/0000-0003-4066-4955; Anastasia, Luigi/0000-0002-0712-2161; Bresciani, Roberto/0000-0002-7881-7550; Lupo, Barbara/0000-0002-4383-6882; MONTI, Eugenio/0000-0002-4742-7445				Achyuthan KE, 2001, COMP BIOCHEM PHYS B, V129, P29, DOI 10.1016/S1096-4959(01)00372-4; Allende ML, 2002, CURR OPIN STRUC BIOL, V12, P587, DOI 10.1016/S0959-440X(02)00376-7; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bremer E, 2006, TRENDS MOL MED, V12, P382, DOI 10.1016/j.molmed.2006.06.002; CARTER HE, 1964, J BIOL CHEM, V239, P743; Chavas LMG, 2005, J BIOL CHEM, V280, P469, DOI 10.1074/jbc.M411506200; Chen R, 2006, CANCER RES, V66, P10959, DOI 10.1158/0008-5472.CAN-06-1216; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Dube DH, 2005, NAT REV DRUG DISCOV, V4, P477, DOI 10.1038/nrd1751; Fanzani A, 2003, FEBS LETT, V547, P183, DOI 10.1016/S0014-5793(03)00709-9; Fernandez-Luna JL, 2000, APOPTOSIS, V5, P315, DOI 10.1023/A:1009623222534; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hakomori S, 1996, CANCER RES, V56, P5309; Inokuchi Koiti, 2006, Journal of Nippon Medical School, V73, P178, DOI 10.1272/jnms.73.178; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Kato K, 2006, BIOCHEM J, V394, P647, DOI 10.1042/BJ20050737; Kato T, 2001, INT J CANCER, V92, P797, DOI 10.1002/ijc.1268; Lin CF, 2006, CURR MED CHEM, V13, P1609, DOI 10.2174/092986706777441986; Melo J, 2004, HEMATOL J, V5, pS183, DOI 10.1038/sj.thj.6200449; Meyn MA, 2006, J BIOL CHEM, V281, P30907, DOI 10.1074/jbc.M605902200; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Monti E, 1999, GLYCOBIOLOGY, V9, P1313, DOI 10.1093/glycob/9.12.1313; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; Papadopoulos K, 2006, SEMIN ONCOL, V33, P449, DOI 10.1053/j.seminoncol.2006.04.008; Papini N, 2004, J BIOL CHEM, V279, P16989, DOI 10.1074/jbc.M400881200; Pasternak G, 1998, J CANCER RES CLIN, V124, P643, DOI 10.1007/s004320050228; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Roginskaya V, 1999, LEUKEMIA, V13, P855, DOI 10.1038/sj.leu.2401429; Salesse S, 2003, MOL CANCER THER, V2, P173; Sato K, 1996, BIOCHEM BIOPH RES CO, V221, P826, DOI 10.1006/bbrc.1996.0681; Sawada M, 2002, INT J CANCER, V97, P180, DOI 10.1002/ijc.1598; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sonnino S, 1996, GLYCOBIOLOGY, V6, P479, DOI 10.1093/glycob/6.5.479-e; SONNINO S, 1984, J LIPID RES, V25, P620; TETTAMAN.G, 1973, BIOCHIM BIOPHYS ACTA, V296, P160, DOI 10.1016/0005-2760(73)90055-6; Tokuyama S, 1997, INT J CANCER, V73, P410, DOI 10.1002/(SICI)1097-0215(19971104)73:3<410::AID-IJC16>3.0.CO;2-G; Tringali C, 2004, J BIOL CHEM, V279, P3169, DOI 10.1074/jbc.M308381200; Tringali C, 2007, GLYCOCONJUGATE J, V24, P67, DOI 10.1007/s10719-006-9013-0; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017; Zhang YM, 2001, GLYCOCONJUGATE J, V18, P557, DOI 10.1023/A:1019682102486	53	46	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14364	14372		10.1074/jbc.M700406200	http://dx.doi.org/10.1074/jbc.M700406200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374613	hybrid			2022-12-27	WOS:000246245800048
J	Fan, DP; Qiu, SF; Overton, CD; Yancey, PG; Swift, LL; Jerome, WG; Linton, MF; Fazio, S				Fan, Daping; Qiu, Shenfeng; Overton, Cheryl D.; Yancey, Patricia G.; Swift, Larry L.; Jerome, W. Gray; Linton, MacRae F.; Fazio, Sergio			Impaired secretion of apolipoprotein E2 from macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; HUMAN-PLASMA-LIPOPROTEINS; APOE-DEFICIENT MICE; REDUCES ATHEROSCLEROSIS; CHOLESTEROL EFFLUX; GENE-TRANSFER; E ISOFORMS; A-I; EXPRESSION; PROTEIN	Human apoE is a multifunctional and polymorphic protein synthesized and secreted by liver, brain, and tissue macrophages. Here we show that apoE isoforms and mutants expressed through lentiviral transduction display cell-specific differences in secretion efficiency. Whereas apoE3, apoE4, and a natural mutant of apoE4 (apoE-Cys(142)) were efficiently secreted from macrophages, apoE2 and a non-natural apoE mutant (apoE-Cys(112)/Cys(142)) were retained in the perinuclear region and only minimally secreted. The secretory block for apoE2 in macrophages was not affected by the ablation of LDLR (low density lipoprotein receptor), ABCA-1, or SR-BI (scavenger receptor class B type I) but was released in the absence of low density lipoprotein receptor-related protein (LRP). In co-immunoprecipitation experiments, an anti-apoE antibody pulled down two times more LRP in apoE2-transduced macrophages than in apoE3-expressing macrophages. Non-reducing SDS-PAGE/Western blot analyses showed that macrophage apoE2 is mostly dimeric and multimeric, whereas apoE3 is predominantly monomeric. ApoE2 retention and multimer formation also occurred in human macrophages derived from the monocyte cell line THP-1. These results were specific for macrophages, as in transduced mouse primary hepatocytes: 1) ApoE2 was secreted as efficiently as apoE3 and apoE4; 2) all isoforms were exclusively in monomeric form; 3) there was no co-immunoprecipitation of apoE and LRP. A microsomal triglyceride transfer protein (MTP) inhibitor nearly deleted apoB100 secretion from hepatocytes without affecting apoE secretion. These data show that macrophages retain apoE2, a highly expressed protein carried by about 8% of the human population. Given the role of locally produced apoE in regulating cholesterol efflux, modulating inflammation, and controlling oxidative stress, this unique property of apoE2 may have important impacts on atherogenesis.	Vanderbilt Univ, Med Ctr, Atheroscelrosis Res Unit, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Div Cardiol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Fazio, S (corresponding author), Vanderbilt Univ, Med Ctr, Atheroscelrosis Res Unit, 2220 Pierce Ave,383 PRB, Nashville, TN 37232 USA.	sergio.fazio@vanderbilt.edu	Yancey, Patricia/ABB-5856-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059637] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-057986, R01 HL057986] Funding Source: Medline; NIDDK NIH HHS [DK59637] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya P, 2002, BBA-MOL CELL BIOL L, V1584, P9, DOI 10.1016/S1388-1981(02)00263-9; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; Braun NA, 2006, J LIPID RES, V47, P1176, DOI 10.1194/jlr.M500503-JLR200; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Duan HW, 1997, J BIOL CHEM, V272, P31156, DOI 10.1074/jbc.272.49.31156; Fazio S, 2002, J LIPID RES, V43, P1602, DOI 10.1194/jlr.M200108-JLR200; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; HAMILTON RL, 1990, J LIPID RES, V31, P1589; Hasty AH, 1999, CIRCULATION, V99, P2571, DOI 10.1161/01.CIR.99.19.2571; Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; Huang YD, 2004, J MOL NEUROSCI, V23, P189, DOI 10.1385/JMN:23:3:189; Huang ZH, 2004, J BIOL CHEM, V279, P29195, DOI 10.1074/jbc.M402631200; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Ishiguro H, 2001, J BIOL CHEM, V276, P36742, DOI 10.1074/jbc.M106027200; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Kitajima K, 2006, ARTERIOSCL THROM VAS, V26, P1852, DOI 10.1161/01.ATV.0000231520.26490.54; Kockx M, 2004, J BIOL CHEM, V279, P25966, DOI 10.1074/jbc.M401177200; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LaDu MJ, 2006, BIOCHEMISTRY-US, V45, P381, DOI 10.1021/bi051765s; Lin CY, 1999, J LIPID RES, V40, P1618; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; Lucic D, 2007, J LIPID RES, V48, P366, DOI 10.1194/jlr.M600259-JLR200; Lund-Katz S, 2001, J LIPID RES, V42, P894; Mabile L, 2003, J CELL BIOCHEM, V90, P766, DOI 10.1002/jcb.10697; Mahley RW, 1999, J LIPID RES, V40, P1933; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; MAZZONE T, 1989, J LIPID RES, V30, P1055; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; Overton CD, 2007, CIRC RES, V100, P670, DOI 10.1161/01.RES.0000260204.40510.aa; Raffai RL, 2003, J BIOL CHEM, V278, P11670, DOI 10.1074/jbc.M212873200; Ruiz J, 2005, J LIPID RES, V46, P1721, DOI 10.1194/jlr.M500114-JLR200; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; Tangirala RK, 2001, J BIOL CHEM, V276, P261, DOI 10.1074/jbc.M003324200; Tsukamoto K, 2000, MOL THER, V1, P189, DOI 10.1006/mthe.2000.0028; Tsukamoto K, 1997, J CLIN INVEST, V100, P107, DOI 10.1172/JCI119501; VOGEL T, 1994, J CELL BIOCHEM, V54, P299, DOI 10.1002/jcb.240540306; WEISGRABER KH, 1978, J BIOL CHEM, V253, P6281; WEISGRABER KH, 1991, J BIOL CHEM, V266, P12029; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Yoshida H, 2001, CIRCULATION, V104, P2820, DOI 10.1161/hc4801.100034; Zhao YW, 1999, J LIPID RES, V40, P1029; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585	64	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13746	13753		10.1074/jbc.M611754200	http://dx.doi.org/10.1074/jbc.M611754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17341585	hybrid			2022-12-27	WOS:000246060300064
J	Torres, M; Fernandez-Fuentes, N; Fiser, A; Casadevall, A				Torres, Marcela; Fernandez-Fuentes, Narcis; Fiser, Andras; Casadevall, Arturo			The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENTAL FLEXIBILITY; FINE SPECIFICITY; GENERATION; ISOTYPE; REPERTOIRE; DIVERSITY; RESIDUES; BINDING; RECOGNITION; ASSOCIATION	A central dogma in immunology is that antibody specificity is a function of the variable (V) region. However serological analysis of IgG(1), IgG(2a), and IgG(2b) switch variants of murine monoclonal antibody (mAb) 3E5 IgG(3) with identical V domains revealed apparent specificity differences for Cryptococcus neoformans glucuronoxylomannan (GXM). Kinetic and thermodynamic binding properties of mAbs 3E5 to a 12-mer peptide mimetic of GXM revealed differences in the affinity of these mAbs for a monovalent ligand, a result that implied that the constant (C) region affects the secondary structure of the antigen binding site, thus accounting for variations in specificity. Structural models of mAbs 3E5 suggested that isotype-related differences in binding resulted from amino acid sequence polymorphisms in the C region. This study implies that isotype switching is another mechanism for generating diversity in antigen binding and that isotype restriction of certain antibody responses may reflect structural constraints imposed by C region on V region binding. Furthermore, isotype affected the polyreactivity of V region identical antibodies, implying a role for C region in determining self-reactivity.	Albert Einstein Coll Med, Dept Immunol & Microbiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Casadevall, A (corresponding author), Albert Einstein Coll Med, Dept Immunol & Microbiol, 1300 Morris Pk Ave,Forchheimer Bldg,Rm 411, Bronx, NY 10461 USA.	casadeva@aecom.yu.edu		Fernandez-Fuentes, Narcis/0000-0002-6421-1080	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033774, R37AI033142, R01AI033142] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59842] Funding Source: Medline; NIAID NIH HHS [AI33142, AI33774] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amitai G, 2004, J MOL BIOL, V344, P1135, DOI 10.1016/j.jmb.2004.10.055; Beck A, 2005, J CHROMATOGR B, V819, P203, DOI 10.1016/j.jchromb.2004.06.052; Benson DA, 2006, NUCLEIC ACIDS RES, V34, pD16, DOI 10.1093/nar/gkj157; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boffey J, 2004, J NEUROIMMUNOL, V152, P98, DOI 10.1016/j.jneuroim.2004.04.002; CASADEVALL A, 1992, J INFECT DIS, V165, P1086, DOI 10.1093/infdis/165.6.1086; Chennubhotla C, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100075; Chong LT, 1999, P NATL ACAD SCI USA, V96, P14330, DOI 10.1073/pnas.96.25.14330; COOPER LJN, 1993, J IMMUNOL, V150, P2231; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DAVIS ME, 1991, METHOD ENZYMOL, V202, P473; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GREENSPAN NS, 1995, IMMUNOL TODAY, V16, P226, DOI 10.1016/0167-5699(95)80164-2; GREENSPAN NS, 1989, FASEB J, V3, P2203, DOI 10.1096/fasebj.3.10.2666233; Hande S, 1997, MOL IMMUNOL, V34, P1281, DOI 10.1016/S0161-5890(98)00005-4; JANIN J, 1995, BIOCHIMIE, V77, P497, DOI 10.1016/0300-9084(96)88166-1; JESKE DJ, 1984, J IMMUNOL, V133, P1090; KOZACK RE, 1995, BIOPHYS J, V68, P807, DOI 10.1016/S0006-3495(95)80257-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lavoie TB, 1999, MOL IMMUNOL, V36, P1189, DOI 10.1016/S0161-5890(99)00130-3; Lipschultz CA, 2002, J MOL RECOGNIT, V15, P44, DOI 10.1002/jmr.559; Lipschultz CA, 2000, METHODS, V20, P310, DOI 10.1006/meth.1999.0924; Luger E, 2001, EUR J IMMUNOL, V31, P2319, DOI 10.1002/1521-4141(200108)31:8<2319::AID-IMMU2319>3.0.CO;2-T; Manivel V, 2002, J IMMUNOL, V169, P888, DOI 10.4049/jimmunol.169.2.888; McCloskey N, 1996, IMMUNOLOGY, V88, P169, DOI 10.1111/j.1365-2567.1996.tb00001.x; McLean GR, 2002, J IMMUNOL, V169, P1379, DOI 10.4049/jimmunol.169.3.1379; MORAHAN G, 1983, NATURE, V301, P720, DOI 10.1038/301720a0; Okamoto A, 1999, BIOCHEMISTRY-US, V38, P1176, DOI 10.1021/bi981921d; Pritsch O, 2000, EUR J IMMUNOL, V30, P3387, DOI 10.1002/1521-4141(2000012)30:12<3387::AID-IMMU3387>3.0.CO;2-K; Rai BK, 2006, BIOINFORMATICS, V22, P2691, DOI 10.1093/bioinformatics/btl449; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Reitan SK, 2002, P NATL ACAD SCI USA, V99, P7588, DOI 10.1073/pnas.052150899; Reitan SK, 2001, EUR J IMMUNOL, V31, P2143, DOI 10.1002/1521-4141(200107)31:7<2143::AID-IMMU2143>3.0.CO;2-1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; Selzer T, 1999, J MOL BIOL, V287, P409, DOI 10.1006/jmbi.1999.2615; Selzer T, 2001, PROTEINS, V45, P190, DOI 10.1002/prot.1139; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SPIRA G, 1992, J IMMUNOL METHODS, V148, P121, DOI 10.1016/0022-1759(92)90165-P; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Torres M, 2005, J IMMUNOL, V174, P2132, DOI 10.4049/jimmunol.174.4.2132; VARELA FJ, 1991, IMMUNOL TODAY, V12, P159, DOI 10.1016/0167-5699(91)90081-4	45	101	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13917	13927		10.1074/jbc.M700661200	http://dx.doi.org/10.1074/jbc.M700661200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353196	hybrid			2022-12-27	WOS:000246060300081
J	Yang, Y; MacLeod, V; Miao, HQ; Theus, A; Zhan, FH; Shaughnessy, JD; Sawyer, J; Li, JP; Zcharia, E; Vlodavsky, I; Sanderson, RD				Yang, Yang; MacLeod, Veronica; Miao, Hua-Quan; Theus, Allison; Zhan, Fenghuang; Shaughnessy, John D., Jr.; Sawyer, Jeffrey; Li, Jin-Ping; Zcharia, Eyal; Vlodavsky, Israel; Sanderson, Ralph D.			Heparanase enhances syndecan-1 shedding - A novel mechanism for stimulation of tumor growth and metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE PROTEOGLYCANS; MYELOMA CELLS; BINDING; EXPRESSION; PROMOTES; IDENTIFICATION; RECEPTORS; ADHESION; PROTEIN; SERUM	When shed from the cell surface, the heparan sulfate proteoglycan syndecan-1 can facilitate the growth, angiogenesis, and metastasis of tumors. Here we report that tumor cell expression of heparanase, an enzyme known to be a potent promoter of tumor progression and metastasis, regulates both the level and location of syndecan-1 within the tumor microenvironment by enhancing its synthesis and subsequent shedding from the tumor cell surface. Heparanase regulation of syndecan-1 is detected in both human myeloma and breast cancer cell lines. This regulation requires the presence of active enzyme, because mutated forms of heparanase lacking heparan sulfate-degrading activity failed to influence syndecan-1 expression or shedding. Removal of heparan sulfate from the cell surface using bacterial heparitinase dramatically accelerated syndecan-1 shedding, suggesting that the effects of heparanase on syndecan-1 expression by tumor cells may be due, at least in part, to enzymatic removal or reduction in the size of heparan sulfate chains. Animals bearing tumors formed from cells expressing high levels of heparanase or animals transgenic for heparanase expression exhibited elevated levels of serum syndecan-1 as compared with controls, indicating that heparanase regulation of syndecan-1 expression and shedding can occur in vivo and impact cancer progression and perhaps other pathological states. These results reveal a new mechanism by which heparanase promotes an aggressive tumor phenotype and suggests that heparanase and syndecan-1 act synergistically to fine tune the tumor microenvironment and ensure robust tumor growth.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; ImClone Syst Inc, New York, NY 10014 USA; Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Little Rock, AR 72205 USA; Uppsala Univ, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	University of Alabama System; University of Alabama Birmingham; University of Arkansas System; University of Arkansas Medical Sciences; Eli Lilly; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Uppsala University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Sanderson, RD (corresponding author), Univ Alabama Birmingham, Dept Pathol, 814 SHEL,1530 3rd Ave S, Birmingham, AL 35294 USA.	sanderson@uab.edu			NCI NIH HHS [CA 103054, CA 055819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055819, R01CA103054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bendre MS, 2002, CANCER RES, V62, P5571; Borset M, 2000, BLOOD, V96, P2528; CHIANG MK, 1995, GROWTH FACTORS, V12, P1, DOI 10.3109/08977199509003208; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Dhodapkar MV, 1997, BRIT J HAEMATOL, V99, P368, DOI 10.1046/j.1365-2141.1997.3893203.x; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Goldschmidt O, 2003, FASEB J, V17, P1015, DOI 10.1096/fj.02-0773com; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Ilan N, 2006, INT J BIOCHEM CELL B, V38, P2018, DOI 10.1016/j.biocel.2006.06.004; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kelly T, 2003, CANCER RES, V63, P8749; Kram V, 2006, J CELL PHYSIOL, V207, P784, DOI 10.1002/jcp.20625; Li JP, 2005, P NATL ACAD SCI USA, V102, P6473, DOI 10.1073/pnas.0502287102; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Miao HQ, 2002, PROTEIN EXPRES PURIF, V26, P425, DOI 10.1016/S1046-5928(02)00558-2; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Sanderson RD, 2005, J CELL BIOCHEM, V96, P897, DOI 10.1002/jcb.20602; Sanderson RD, 2004, MATRIX BIOL, V23, P341, DOI 10.1016/j.matbio.2004.08.004; Sanderson RD, 2002, ANN HEMATOL, V81, P125, DOI 10.1007/s00277-002-0437-8; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Seidel C, 2000, BLOOD, V95, P388, DOI 10.1182/blood.V95.2.388; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Yang Y, 2005, BLOOD, V105, P1303, DOI 10.1182/blood-200406-2141; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610; Zcharia E, 2005, AM J PATHOL, V166, P999, DOI 10.1016/S0002-9440(10)62321-8; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458	33	215	225	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13326	13333		10.1074/jbc.M611259200	http://dx.doi.org/10.1074/jbc.M611259200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17347152	hybrid			2022-12-27	WOS:000246060300020
J	Bera, AK; Kuhn, RJ; Smith, JL				Bera, Aloke K.; Kuhn, Richard J.; Smith, Janet L.			Functional characterization of cis and trans activity of the flavivirus NS2B-NS3 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEST-NILE-VIRUS; YELLOW-FEVER VIRUS; SITE-DIRECTED MUTAGENESIS; NS3 SERINE-PROTEASE; NONSTRUCTURAL PROTEINS; VIRAL REPLICATION; CLEAVAGE SITE; IN-VITRO; DENGUE; DOMAIN	Flaviviruses are serious human pathogens for which treatments are generally lacking. The proteolytic maturation of the 375-kDa viral polyprotein is one target for antiviral development. The flavivirus serine protease consists of the N-terminal domain of the multifunctional nonstructural protein 3 (NS3) and an essential 40-residue cofactor (NS2B40) within viral protein NS2B. The NS2B-NS3 protease is responsible for all cytoplasmic cleavage events in viral polyprotein maturation. This study describes the first biochemical characterization of flavivirus protease activity using full-length NS3. Recombinant proteases were created by fusion of West Nile virus (WNV) NS2B40 to full-length WNV NS3. The protease catalyzed two autolytic cleavages. The NS2B/NS3 junction was cleaved before protein purification. A second site at Arg4592Gly460 within the C-terminal helicase region of NS3 was cleaved more slowly. Autolytic cleavage reactions also occurred in NS2B-NS3 recombinant proteins from yellow fever virus, dengue virus types 2 and 4, and Japanese encephalitis virus. Cis and trans cleavages were distinguished using a noncleavable WNV protease variant and two types of substrates as follows: an inactive variant of recombinant WNV NS2B-NS3, and cyan and yellow fluorescent proteins fused by a dodecamer peptide encompassing a natural cleavage site. With these materials, the autolytic cleavages were found to be intramolecular only. Autolytic cleavage of the helicase site was insensitive to protein dilution, confirming that autolysis is intramolecular. Formation of an active protease was found to require neither cleavage of NS2B from NS3 nor a free NS3 N terminus. Evidence was also obtained for product inhibition of the protease by the cleaved C terminus of NS2B.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Smith, JL (corresponding author), Univ Michigan, Inst Life Sci, 210 Washtenaw Ave, Ann Arbor, MI 48109 USA.	JanetSmith@umich.edu	Bera, Aloke Kumar/AAD-9541-2022; Kuhn, Richard/AAR-2722-2021	Kuhn, Richard/0000-0003-4148-1026	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055672] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI055672, P01 AI-055672] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIAS CF, 1993, VIROLOGY, V193, P888, DOI 10.1006/viro.1993.1198; Beasley DWC, 2005, J VIROL, V79, P8339, DOI 10.1128/JVI.79.13.8339-8347.2005; Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; CHAMBERS TJ, 1995, J VIROL, V69, P1600, DOI 10.1128/JVI.69.3.1600-1605.1995; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; Chappell KJ, 2006, J BIOL CHEM, V281, P38448, DOI 10.1074/jbc.M607641200; Chappell KJ, 2005, J BIOL CHEM, V280, P2896, DOI 10.1074/jbc.M409931200; Erbel P, 2006, NAT STRUCT MOL BIOL, V13, P372, DOI 10.1038/nsmb1073; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; Ganesh VK, 2005, BIOORGAN MED CHEM, V13, P257, DOI 10.1016/j.bmc.2004.09.036; Khumthong R, 2002, J BIOCHEM MOL BIOL, V35, P206; Kuhn RJ, 2003, ADV PROTEIN CHEM, V64, P363; Leung D, 2001, J BIOL CHEM, V276, P45762, DOI 10.1074/jbc.M107360200; Li J, 2005, J BIOL CHEM, V280, P28766, DOI 10.1074/jbc.M500588200; LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993; LIN C, 1993, VIROLOGY, V192, P596, DOI 10.1006/viro.1993.1076; Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; Nall TA, 2004, J BIOL CHEM, V279, P48535, DOI 10.1074/jbc.M406810200; NESTOROWICZ A, 1994, VIROLOGY, V199, P114, DOI 10.1006/viro.1994.1103; Niyomrattanakit P, 2006, BIOCHEM J, V397, P203, DOI 10.1042/BJ20051767; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; PUGACHEV KV, 1993, FEBS LETT, V328, P115, DOI 10.1016/0014-5793(93)80977-3; Shiryaev SA, 2006, BIOCHEM J, V393, P503, DOI 10.1042/BJ20051374; Teo KF, 1997, J GEN VIROL, V78, P337, DOI 10.1099/0022-1317-78-2-337; Wu JH, 2005, J VIROL, V79, P10268, DOI 10.1128/JVI.79.16.10268-10277.2005; Xu T, 2005, J VIROL, V79, P10278, DOI 10.1128/JVI.79.16.10278-10288.2005; Yusof R, 2000, J BIOL CHEM, V275, P9963, DOI 10.1074/jbc.275.14.9963	31	79	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12883	12892		10.1074/jbc.M611318200	http://dx.doi.org/10.1074/jbc.M611318200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337448	hybrid			2022-12-27	WOS:000245942800060
J	Paczkowski, FA; Sharpe, IA; Dutertre, S; Lewis, RJ				Paczkowski, Filip A.; Sharpe, Iain A.; Dutertre, Sebastien; Lewis, Richard J.			chi-conotoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NORADRENALINE TRANSPORTER; HUMAN DOPAMINE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; MONOAMINE TRANSPORTERS; COCAINE BINDING; MECHANISM; DESIPRAMINE; CONOPEPTIDE; EXPRESSION; RECEPTORS	Monoamine neurotransmitter transporters for norepinephrine (NE), dopamine and serotonin are important targets for antidepressants and analgesics. The conopeptide chi-MrIA is a noncompetitive and highly selective inhibitor of the NE transporter (NET) and is being developed as a novel intrathecal analgesic. We used site-directed mutagenesis to generate a suite of mutated transporters to identify two amino acids (Leu(469) and Glu(382)) that affected the affinity of chi-MrIA to inhibit [H-3] NE uptake through human NET. Residues that increased the Kd of a tricyclic antidepressant (nisoxetine) were also identified (Phe(207), Ser(225), His(296), Thr(381), and Asp(473)). Phe(207), Ser(225), His(296), and Thr(381) also affected the rate of NE transport without affecting NE Km. In a new model of NET constructed from the bLeuT crystal structure, chi-MrIA-interacting residues were located at the mouth of the transporter near residues affecting the binding of small molecule inhibitors.	Univ Queensland, Inst Mol Biosci QBP, Brisbane, Qld 4072, Australia	University of Queensland	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci QBP, Brisbane, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Lewis, Richard/T-8763-2019; Lewis, Richard J/E-8674-2013	Lewis, Richard/0000-0003-3470-923X; Lewis, Richard J/0000-0003-3470-923X; Dutertre, Sebastien/0000-0002-2945-1484				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Appell M, 2004, BIOCHEM PHARMACOL, V67, P293, DOI 10.1016/j.bcp.2003.09.013; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; Beuming T, 2006, MOL PHARMACOL, V70, P1630, DOI 10.1124/mol.106.026120; Bonisch H, 1999, J AUTON PHARMACOL, V19, P327; Bryan-Lluka LJ, 2003, J BIOL CHEM, V278, P40324, DOI 10.1074/jbc.M213101200; Dutertre S, 2004, EUR J BIOCHEM, V271, P2327, DOI 10.1111/j.1432-1033.2004.04147.x; EDVARDSEN O, 1994, MOL BRAIN RES, V27, P265, DOI 10.1016/0169-328X(94)90009-4; Gainetdinov RR, 2003, ANNU REV PHARMACOL, V43, P261, DOI 10.1146/annurev.pharmtox.43.050802.112309; Nielsen CK, 2005, PAIN, V118, P112, DOI 10.1016/j.pain.2005.08.002; Norregaard L, 2001, Curr Opin Drug Discov Devel, V4, P591; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Paczkowski FA, 2004, J NEUROCHEM, V88, P203, DOI 10.1046/j.1471-4159.2003.02149.x; Paczkowski FA, 2001, MOL BRAIN RES, V97, P32, DOI 10.1016/S0169-328X(01)00295-9; Petrek M, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-316; Rasmussen SGF, 2003, EUR J PHARMACOL, V479, P13, DOI 10.1016/j.ejphar.2003.08.053; Ravna AW, 2003, J COMPUT AID MOL DES, V17, P367, DOI 10.1023/A:1026116017725; Ravna AW, 2003, J PHARMACOL EXP THER, V307, P34, DOI 10.1124/jpet.103.054593; Ravna AW, 2001, J MOL GRAPH MODEL, V20, P133, DOI 10.1016/S1093-3263(01)00112-7; Roubert C, 2001, J BIOL CHEM, V276, P8254, DOI 10.1074/jbc.M009798200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Schroeter S, 2000, J COMP NEUROL, V420, P211; Sen N, 2005, NEUROPHARMACOLOGY, V49, P780, DOI 10.1016/j.neuropharm.2005.08.014; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; Sharpe IA, 2003, J BIOL CHEM, V278, P40317, DOI 10.1074/jbc.M213030200; Stahl SM, 2003, J CLIN PSYCHIAT, V64, P230; Sucic S, 2002, MOL BRAIN RES, V108, P40, DOI 10.1016/S0169-328X(02)00512-0; Sucic S, 2002, J NEUROCHEM, V81, P344, DOI 10.1046/j.1471-4159.2002.00826.x; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	34	45	47	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17837	17844		10.1074/jbc.M610813200	http://dx.doi.org/10.1074/jbc.M610813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17428804	Green Published, hybrid			2022-12-27	WOS:000247084500057
J	D'Haeze, W; Leoff, C; Freshour, G; Noel, KD; Carlson, RW				D'Haeze, Wim; Leoff, Christine; Freshour, Glenn; Noel, K. Dale; Carlson, Russell W.			Rhizobium etli CE3 bacteroid lipopolysaccharides are structurally similar but not identical to those produced by cultured CE3 bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-ANTIGENIC POLYSACCHARIDE; LIPID-A; SALMONELLA-TYPHIMURIUM; POLYMYXIN-RESISTANT; ESCHERICHIA-COLI; GENETIC-LOCUS; ROOT-NODULES; MUTANTS; EXPRESSION; DEFICIENT	Rhizobium etli CE3 bacteroids were isolated from Phaseolus vulgaris root nodules. The lipopolysaccharide (LPS) from the bacteroids was purified and compared with the LPS from laboratory-cultured R. etli CE3 and from cultures grown in the presence of anthocyanin. Comparisons were made of the O-chain polysaccharide, the core oligosaccharide, and the lipid A. Although LPS from CE3 bacteria and bacteroids are structurally similar, it was found that bacteroid LPS had specific modifications to both the O-chain polysaccharide and lipid A portions of their LPS. Cultures grown with anthocyanin contained modifications only to the O-chain polysaccharide. The changes to the O-chain polysaccharide consisted of the addition of a single methyl group to the 2-position of a fucosyl residue in one of the five O-chain trisaccharide repeat units. This same change occurred for bacteria grown in the presence of anthocyanin. This methylation change correlated with the inability of bacteroid LPS and LPS from anthocyanin-containing cultures to bind the monoclonal antibody JIM28. The core oligosaccharide region of bacteroid LPS and from anthocyanin-grown cultures was identical to that of LPS from normal laboratory-cultured CE3. The lipid A from bacteroids consisted exclusively of a tetraacylated species compared with the presence of both tetra-and pentaacylated lipid A from laboratory cultures. Growth in the presence of anthocyanin did not affect the lipid A structure. Purified bacteroids that could resume growth were also found to be more sensitive to the cationic peptides, poly-L-lysine, polymyxin-B, and melittin.	Univ Georgia, Comples Carbohydrate Res Ctr, Athens, GA 30602 USA; Marquette Univ, Dept Biol, Milwaukee, WI 53233 USA	University System of Georgia; University of Georgia; Marquette University	Carlson, RW (corresponding author), Univ Georgia, Comples Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA.	rcarlson@ccrc.uga.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banba M, 2001, MOL PLANT MICROBE IN, V14, P173, DOI 10.1094/MPMI.2001.14.2.173; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; Bechinger B, 2004, CRIT REV PLANT SCI, V23, P271, DOI 10.1080/07352680490452825; BHAT UR, 1992, J BACTERIOL, V174, P2230, DOI 10.1128/JB.174.7.2230-2235.1992; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Brewin NJ, 2004, CRIT REV PLANT SCI, V23, P293, DOI 10.1080/07352680490480734; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CARLSON RW, 1978, PLANT PHYSIOL, V62, P912, DOI 10.1104/pp.62.6.912; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CARRION M, 1990, J BACTERIOL, V172, P1725, DOI 10.1128/jb.172.4.1725-1731.1990; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; CHING TM, 1977, PLANT PHYSIOL, V60, P771, DOI 10.1104/pp.60.5.771; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; D'Haeze W, 2004, TRENDS MICROBIOL, V12, P555, DOI 10.1016/j.tim.2004.10.009; D'Haeze W, 2004, MOL MICROBIOL, V52, P485, DOI 10.1111/j.1365-2958.2004.03989.x; D'Haeze W, 2003, P NATL ACAD SCI USA, V100, P11789, DOI 10.1073/pnas.1333899100; D'Haeze W, 2002, GLYCOBIOLOGY, V12, p79R, DOI 10.1093/glycob/12.6.79R; DIEBOLD R, 1989, J BACTERIOL, V171, P4821, DOI 10.1128/jb.171.9.4821-4830.1989; Duelli DM, 2001, J BACTERIOL, V183, P6054, DOI 10.1128/JB.183.20.6054-6064.2001; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Forsberg LS, 2003, J BIOL CHEM, V278, P51347, DOI 10.1074/jbc.M309016200; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Fraysse N, 2003, EUR J BIOCHEM, V270, P1365, DOI 10.1046/j.1432-1033.2003.03492.x; Fraysse N, 2002, GLYCOBIOLOGY, V12, P741, DOI 10.1093/glycob/cwf078; Geurtsen J, 2005, J BIOL CHEM, V280, P8248, DOI 10.1074/jbc.M414235200; Gonzalez V, 2006, P NATL ACAD SCI USA, V103, P3834, DOI 10.1073/pnas.0508502103; Helander IM, 1996, EUR J BIOCHEM, V237, P272, DOI 10.1111/j.1432-1033.1996.0272n.x; Kannenberg EL, 2001, MOL MICROBIOL, V39, P379, DOI 10.1046/j.1365-2958.2001.02225.x; KANNENBERG EL, 1989, J BACTERIOL, V171, P4543, DOI 10.1128/jb.171.9.4543-4548.1989; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; LULLIEN V, 1987, PLANT MOL BIOL, V9, P469, DOI 10.1007/BF00015878; Ma Y, 2001, J BACTERIOL, V183, P250, DOI 10.1128/JB.183.1.250-256.2001; Mergaert P, 2006, P NATL ACAD SCI USA, V103, P5230, DOI 10.1073/pnas.0600912103; Noel KD, 2004, APPL ENVIRON MICROB, V70, P1537, DOI 10.1128/AEM.70.3.1537-1544.2004; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; Noel KD, 1996, MOL PLANT MICROBE IN, V9, P180, DOI 10.1094/MPMI-9-0180; Noel KD, 2000, J BACTERIOL, V182, P5317, DOI 10.1128/JB.182.19.5317-5324.2000; Noel KD., 1992, MOL SIGNALS PLANT MI, P341; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; REUHS BL, 1994, MOL PLANT MICROBE IN, V7, P240, DOI 10.1094/MPMI-7-0240; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; Reuhs BL, 2005, J BACTERIOL, V187, P6479, DOI 10.1128/JB.187.18.6479-6487.2005; Reynolds CM, 2006, J BIOL CHEM, V281, P21974, DOI 10.1074/jbc.M603527200; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Ridley BL, 2000, GLYCOBIOLOGY, V10, P1013, DOI 10.1093/glycob/10.10.1013; ROWLEY JC, 1975, ULTRAMICROSCOPY, V1, P151, DOI 10.1016/S0304-3991(75)80018-0; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; Tran AX, 2005, J BIOL CHEM, V280, P28186, DOI 10.1074/jbc.M505020200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; Vedam V, 2004, MOL PLANT MICROBE IN, V17, P283, DOI 10.1094/MPMI.2004.17.3.283; Vedam V, 2003, J BACTERIOL, V185, P1841, DOI 10.1128/JB.185.6.1841-1850.2003; WESTPHAL O, 1965, METHODS CARBOHYDR RE, V5, P91; Xi CW, 2000, P NATL ACAD SCI USA, V97, P11114, DOI 10.1073/pnas.210181097; YORK WS, 1986, METHOD ENZYMOL, V118, P3; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	63	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17101	17113		10.1074/jbc.M611669200	http://dx.doi.org/10.1074/jbc.M611669200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17420254	hybrid, Green Submitted			2022-12-27	WOS:000246946500043
J	Huh, YH; Ryu, JH; Chun, JS				Huh, Yun Hyun; Ryu, Je-Hwang; Chun, Jang-Soo			Regulation of type II collagen expression by histone deacetylase in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED PHENOTYPE; GENE-EXPRESSION; PROTEIN-KINASE; CARTILAGE; INHIBITION; OSTEOARTHRITIS; CHONDROGENESIS; MECHANISMS; REPRESSION; APOPTOSIS	Histone deacetylase (HDAC) regulates various cellular processes by modulating gene expression. Here, we investigated the role of HDAC in the expression of type II collagen, a marker of differentiated chondrocytes. We found that HDAC activity in primary articular chondrocytes decreases during dedifferentiation induced by serial monolayer culture and that the activity recovered during redifferentiation induced by three-dimensional culture in a cell pellet. Inhibition of HDAC with trichostatin A or PXD101 was sufficient to block type II collagen expression in primary culture chondrocytes. HDAC inhibition also blocked the redifferentiation of dedifferentiated chondrocytes by suppressing the synthesis and accumulation of type II collagen. HDAC inhibition promoted the expression of Wnt-5a, which is known to inhibit type II collagen expression, and knockdown of Wnt-5a blocked the ability of HDAC inhibitors to suppress type II collagen expression. In addition, the induction of Wnt-5a expression by HDAC inhibitors was associated with acetylation of the Wnt-5a promoter. Taken together, our results suggest that HDAC promotes type II collagen expression by suppressing the transcription of Wnt-5a.	Gwangju Inst Sci & Technol, Dept Life Sci, Res Ctr Biomol Nanotechnol, Kwangju 500712, South Korea	Gwangju Institute of Science & Technology (GIST)	Chun, JS (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, Res Ctr Biomol Nanotechnol, Kwangju 500712, South Korea.	jschun@gist.ac.kr						Aigner T, 2003, CURR OPIN RHEUMATOL, V15, P634, DOI 10.1097/00002281-200309000-00019; BENYA PD, 1977, BIOCHEMISTRY-US, V16, P865, DOI 10.1021/bi00624a009; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; Chung YL, 2003, MOL THER, V8, P707, DOI 10.1016/S1525-0016(03)00235-1; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Eyre DR, 2004, CLIN ORTHOP RELAT R, pS118, DOI 10.1097/01.blo.0000144855.48640.b9; Ghosh P, 2002, BIOGERONTOLOGY, V3, P85, DOI 10.1023/A:1015219716583; Hug BA, 2004, CELL, V119, P448, DOI 10.1016/j.cell.2004.10.023; Hwang SG, 2005, J BIOL CHEM, V280, P29780, DOI 10.1074/jbc.M411793200; Hwang SG, 2004, J BIOL CHEM, V279, P26597, DOI 10.1074/jbc.M401401200; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167-4889(90)90145-4; Li XH, 2006, CANCER RES, V66, P9323, DOI 10.1158/0008-5472.CAN-06-1578; Liu CJ, 2004, J BIOL CHEM, V279, P47081, DOI 10.1074/jbc.M405288200; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Monneret C, 2005, EUR J MED CHEM, V40, P1, DOI 10.1016/j.ejmech.2004.10.001; Mort JS, 2005, ARTHRITIS RES THER, V7, P155, DOI 10.1186/ar1781; Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Pillai R, 2004, DEV DYNAM, V231, P647, DOI 10.1002/dvdy.20168; Plumb JA, 2003, MOL CANCER THER, V2, P721; Ryu JH, 2006, J BIOL CHEM, V281, P22039, DOI 10.1074/jbc.M601804200; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell L., 1999, FRONT BIOSCI-LANDMRK, V4, P731; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; Shim JS, 2004, ONCOGENE, V23, P1704, DOI 10.1038/sj.onc.1207289; Suzuki F, 1996, CONNECT TISSUE RES, V35, P303, DOI 10.3109/03008209609029204; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Weston AD, 2002, J CELL BIOL, V158, P39, DOI 10.1083/jcb.200112029; Yoo EJ, 2006, J BIOL CHEM, V281, P6608, DOI 10.1074/jbc.M508982200; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Young DA, 2005, ARTHRITIS RES THER, V7, pR503, DOI 10.1186/ar1702	37	64	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17123	17131		10.1074/jbc.M700599200	http://dx.doi.org/10.1074/jbc.M700599200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428794	hybrid			2022-12-27	WOS:000246946500045
J	Tanner, MJ; Hanel, W; Gaffen, SL; Lin, X				Tanner, Matthew J.; Hanel, Walter; Gaffen, Sarah L.; Lin, Xin			CARMA1 coiled-coil domain is involved in the oligomerization and subcellular localization of CARMA1 and is required for T cell receptor-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL10; KINASE; PHOSPHORYLATION; LYMPHOCYTE; REGULATOR; MALT1; RECRUITMENT; CARD	T lymphocyte (T cell) activation and proliferation is induced by the activation of multiple signal transduction pathways. Earlier studies indicate that CARMA1, a Caspase Recruitment Domain (CARD) and Membrane-associated GUanylate Kinase domain (MAGUK)-containing scaffold protein, plays an essential role in NF-kappa B activation induced by the costimulation of T cell receptor (TCR) and CD28 molecules. However, the molecular mechanism by which CARMA1 mediates TCR-CD28 costimulation-induced NF-kappa B activation is not fully understood. Here we show that CARMA1 is constitutively oligomerized. This oligomerization of CARMA1 is through its Coiled-coil domain. Disruption of the predicted structure of the Coiled-coil domain of CARMA1 impaired its oligomerization and, importantly, abrogated CARMA1-mediated NF-kappa B activation. Interestingly, disruption of the CC1 domain abrogates CARMA1 localization, whereas disruption of the CC2 domain seems to inhibit CARMA1 self-association. Together, our results demonstrate that the oligomerization of CARMA1 is required for TCR-induced NF-kappa B activation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; SUNY Buffalo, Dept Microbiol & Immunol, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Oral Biol, Buffalo, NY 14214 USA	University of Texas System; UTMD Anderson Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Lin, X (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	xllin@mdanderson.org	Gaffen, Sarah L/B-1560-2009	Gaffen, Sarah L/0000-0001-8511-2041; Tanner, Matthew/0000-0002-4392-5535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049329, R21AI049329, R01AI050848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM065899, R01GM065899] Funding Source: NIH RePORTER; NIAID NIH HHS [AI049329, AI050848] Funding Source: Medline; NIGMS NIH HHS [GM065899] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Che TJ, 2004, J BIOL CHEM, V279, P15870, DOI 10.1074/jbc.M310599200; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Hara H, 2004, J EXP MED, V200, P1167, DOI 10.1084/jem.20032246; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Lin X, 2004, SEMIN IMMUNOL, V16, P429, DOI 10.1016/j.smim.2004.08.022; Matsumoto R, 2005, IMMUNITY, V23, P575, DOI 10.1016/j.immuni.2005.10.007; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Rawlings DJ, 2006, NAT REV IMMUNOL, V6, P799, DOI 10.1038/nri1944; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Schulze-Luehrmann J, 2006, IMMUNITY, V25, P701, DOI 10.1016/j.immuni.2006.10.010; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	26	44	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17141	17147		10.1074/jbc.M700169200	http://dx.doi.org/10.1074/jbc.M700169200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428801	hybrid			2022-12-27	WOS:000246946500047
J	Holmes, D; Knudsen, G; Mackey-Cushman, S; Su, LS				Holmes, Derek; Knudsen, Geoffry; Mackey-Cushman, Stephanie; Su, Lishan			FoxP3 enhances HIV-1 gene expression by modulating NF kappa B occupancy at the long terminal repeat in human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED SYNDROME; TRANSCRIPTIONAL ACTIVITY; IMMUNE DYSREGULATION; PERIPHERAL-BLOOD; SOOTY MANGABEYS; IN-VITRO; VIRUS; CD4(+); INFECTION; SIV	FoxP3 determines the development of CD4+ CD25+ regulatory T (Treg) cells and represses interleukin-2 (IL-2) expression in Treg cells. However, human immunodeficiency virus type 1 (HIV-1) infects and replicates efficiently in FoxP3+ Treg cells. We report that, while inhibiting IL-2 gene expression, FoxP3 enhances gene expression from HIV-1 long terminal repeat (LTR). This FoxP3 activity requires both the N- and C-terminal domains and is inactivated by human IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) mutations. FoxP3 enhances HIV-1 LTR via its specific NF kappa B binding sequences in an NF kappa B-dependent fashion in T cells but not in HEK293 cells. FoxP3 decreases level of histone acetylation at the interleukin-2 locus but not at the HIV-1 LTR. Although NF kappa B nuclear translocation is not altered, FoxP3 enhances NF kappa B-p65 binding to HIV-1 LTR. These data suggest that FoxP3 modulates gene expression in a promoter sequence-dependent fashion by modulating chromatin structure and NF kappa B activity. HIV-1 LTR has evolved to both highjack the T-cell activation pathway for expression and to resist FoxP3-mediated suppression of T-cell activation.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Su, LS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.	lsu@med.unc.edu			NIAID NIH HHS [R01 AI077454, 5T32AI07273, AI048407, T32 AI007273, R01 AI048407, R56 AI048407] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI048407, T32AI007273, R01AI048407, R01AI077454] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson J, 2005, J IMMUNOL, V174, P3143, DOI 10.4049/jimmunol.174.6.3143; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Apoil PA, 2005, JAIDS-J ACQ IMM DEF, V39, P381, DOI 10.1097/01.qai.0000169662.30783.2d; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Beilharz MW, 2004, J IMMUNOL, V172, P4917, DOI 10.4049/jimmunol.172.8.4917; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Boettler T, 2005, J VIROL, V79, P7860, DOI 10.1128/JVI.79.12.7860-7867.2005; Boyer O, 2004, BLOOD, V103, P3428, DOI 10.1182/blood-2003-07-2598; Brenchley JM, 2006, J VIROL, V80, P6801, DOI 10.1128/JVI.00070-06; Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004; Chen CX, 2006, J BIOL CHEM, V281, P36828, DOI 10.1074/jbc.M608848200; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Coffield VM, 2003, NAT BIOTECHNOL, V21, P1321, DOI 10.1038/nbt889; Cron RQ, 2000, CLIN IMMUNOL, V94, P179, DOI 10.1006/clim.1999.4831; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dittmer U, 2004, IMMUNITY, V20, P293, DOI 10.1016/S1074-7613(04)00054-8; Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407; Estes JD, 2006, J INFECT DIS, V193, P703, DOI 10.1086/500368; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Giffin MJ, 2003, NAT STRUCT BIOL, V10, P800, DOI 10.1038/nsb981; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GIORGI JV, 1993, ANN NY ACAD SCI, V677, P126, DOI 10.1111/j.1749-6632.1993.tb38771.x; GIORGI JV, 1987, J CLIN IMMUNOL, V7, P140, DOI 10.1007/BF00916008; GRANT C, 2006, PLOS PATHOG, V2, pS33; Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hornum Lars, 2004, Curr Diab Rep, V4, P135, DOI 10.1007/s11892-004-0069-6; Jiang Qi, 2006, BMC Immunol, V7, P6, DOI 10.1186/1471-2172-7-6; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; Joshi A, 2005, J VIROL, V79, P4965, DOI 10.1128/JVI.79.8.4965-4976.2005; Joshi A, 2004, VIROLOGY, V321, P307, DOI 10.1016/j.virol.2004.01.014; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069; Kovalev GI, 2001, J IMMUNOL, V167, P3285, DOI 10.4049/jimmunol.167.6.3285; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Montes M, 2006, AIDS, V20, P1669, DOI 10.1097/01.aids.0000238415.98194.38; Morse SS, 1999, J IMMUNOL, V162, P5309; Nilsson J, 2006, BLOOD, V108, P3808, DOI 10.1182/blood-2006-05-021576; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Silvestri G, 2005, J VIROL, V79, P4043, DOI 10.1128/JVI.79.7.4043-4054.2005; Silvestri G, 2005, J MED PRIMATOL, V34, P243, DOI 10.1111/j.1600-0684.2005.00122.x; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Sugimoto K, 2005, J VIROL, V79, P6976, DOI 10.1128/JVI.79.11.6976-6983.2005; Sugimoto K, 2003, HEPATOLOGY, V38, P1437, DOI 10.1016/j.hep.2003.09.026; Torgerson TR, 2002, CURR OPIN ALLERGY CL, V2, P481, DOI 10.1097/00130832-200212000-00002; Tsunemi S, 2005, AIDS, V19, P879, DOI 10.1097/01.aids.0000171401.23243.56; Udalova IA, 2002, P NATL ACAD SCI USA, V99, P8167, DOI 10.1073/pnas.102674699; Viguier M, 2004, J IMMUNOL, V173, P1444, DOI 10.4049/jimmunol.173.2.1444; Wang HY, 2004, IMMUNITY, V20, P107, DOI 10.1016/S1074-7613(03)00359-5; Weiss L, 2004, BLOOD, V104, P3249, DOI 10.1182/blood-2004-01-0365; Williams SA, 2006, EMBO J, V25, P139, DOI 10.1038/sj.emboj.7600900; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547	63	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15973	15980		10.1074/jbc.M702051200	http://dx.doi.org/10.1074/jbc.M702051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17416586	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000246794300006
J	Medvedev, AE; Piao, W; Shoenfelt, J; Rhee, SH; Chen, HY; Basu, S; Wahl, LM; Fenton, MJ; Vogel, SN				Medvedev, Andrei E.; Piao, Wenji; Shoenfelt, Joanna; Rhee, Sang Hoon; Chen, Haiyan; Basu, Subhendu; Wahl, Larry M.; Fenton, Matthew J.; Vogel, Stefanie N.			Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOUBLE-STRANDED-RNA; CONFERS LIPOPOLYSACCHARIDE RESPONSIVENESS; RECEPTOR-ASSOCIATED KINASE-1; BRUTONS TYROSINE KINASE; TOLL-LIKE RECEPTOR-2; HUMAN NK CELLS; ADAPTER MOLECULE; INNATE IMMUNITY; DOWN-REGULATION	In this study, we examined whether tyrosine phosphorylation of the Toll-IL-1 resistance (TIR) domain of Toll-like receptor (TLR) 4 is required for signaling and blocked in endotoxin tolerance. Introduction of the P712H mutation, responsible for lipopolysaccharide (LPS) unresponsiveness of C3H/HeJ mice, into the TIR domain of constitutively active mouse Delta TLR4 and mutation of the homologous P714 in human CD4-TLR4 rendered them signaling-incompetent and blocked TLR4 tyrosine phosphorylation. Mutations of tyrosine residues Y674A and Y680A within the TIR domains of CD4-TLR4 impaired its ability to elicit phosphorylation of p38 and JNK mitogen-activated protein kinases, I kappa B-alpha degradation, and activation of NF-kappa B and RANTES reporters. Likewise, full-length human TLR4 expressing Y674A or Y680A mutations showed suppressed capacities to mediate LPS-inducible cell activation. Signaling deficiencies of the Y674A and Y680A TLR4s correlated with altered MyD88-TLR4 interactions, increased associations with a short IRAK-1 isoform, and decreased amounts of activated IRAK-1 in complex with TLR4. Pretreatment of human embryonic kidney (HEK) 293/TLR4/MD-2 cells with protein tyrosine kinase or Src kinase inhibitors suppressed LPS-driven TLR4 tyrosine phosphorylation, p38 and NF-kappa B activation. TLR2 and TLR4 agonists induced TLR tyrosine phosphorylation in HEK293 cells overexpressing CD14, MD-2, and TLR4 or TLR2. Induction of endotoxin tolerance in HEK293/TLR4/MD-2 transfectants and in human monocytes markedly suppressed LPS-mediated TLR4 tyrosine phosphorylation and recruitment of Lyn kinase to TLR4, but did not affect TLR4-MD-2 interactions. Thus, our data demonstrate that TLR4 tyrosine phosphorylation is important for signaling and is impaired in endotoxin-tolerant cells, and suggest involvement of Lyn kinase in these processes.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; NIDCR, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Medvedev, AE (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.	amedvedev@som.umaryland.edu	Chen, Haiyan/HGB-6216-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059524, R01AI057490, R01AI044936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000456] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-059524, R01 AI044936, R01 AI044936-06, AI-057490, R01 AI057490, R01 AI059524-04, R01 AI057490-04, AI-44936, R01 AI059524] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe T, 2005, J VIROL, V79, P2847, DOI 10.1128/JVI.79.5.2847-2858.2005; Adib-Conquy M, 2002, J BIOL CHEM, V277, P27927, DOI 10.1074/jbc.M200705200; Akira S, 2004, CR BIOL, V327, P581, DOI 10.1016/j.crvi.2004.04.002; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Burns K, 2003, J EXP MED, V197, P263, DOI 10.1084/jem.20021790; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Chen LY, 2003, AM J PHYSIOL-LUNG C, V284, pL607, DOI 10.1152/ajplung.00116.2002; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; Dobrovolskaia MA, 2003, J IMMUNOL, V170, P508, DOI 10.4049/jimmunol.170.1.508; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; FAHMI H, 1993, CELL IMMUNOL, V150, P219, DOI 10.1006/cimm.1993.1191; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Goriely S, 2006, BLOOD, V107, P1078, DOI 10.1182/blood-2005-06-2416; Gray P, 2006, J BIOL CHEM, V281, P10489, DOI 10.1074/jbc.M508892200; Hart OM, 2005, J IMMUNOL, V175, P1636, DOI 10.4049/jimmunol.175.3.1636; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HENRICSON BE, 1995, MOL MED, V1, P428, DOI 10.1007/BF03401580; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Ingalls RR, 1997, J IMMUNOL, V159, P433; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Janssens S, 2002, CURR BIOL, V12, P467, DOI 10.1016/S0960-9822(02)00712-1; Johnsen IB, 2006, EMBO J, V25, P3335, DOI 10.1038/sj.emboj.7601222; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Li LW, 2003, J ENDOTOXIN RES, V9, P39, DOI 10.1179/096805103125001324; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; MCINTIRE FC, 1967, BIOCHEMISTRY-US, V6, P2363, DOI 10.1021/bi00860a011; Medvedev AE, 2005, J IMMUNOL, V174, P6587, DOI 10.4049/jimmunol.174.11.6587; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medvedev AE, 2003, J ENDOTOXIN RES, V9, P60, DOI 10.1179/096805103125001360; Medvedev AE, 2001, J IMMUNOL, V167, P2257, DOI 10.4049/jimmunol.167.4.2257; Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209; Medvedev AE, 2006, J ENDOTOXIN RES, V12, P133, DOI 10.1179/096805106X102255; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nimah M, 2005, SHOCK, V23, P80, DOI 10.1097/01.shk.0000145206.28812.60; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Ogawa H, 2003, J IMMUNOL, V170, P5956, DOI 10.4049/jimmunol.170.12.5956; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; Perera PY, 1997, J IMMUNOL, V158, P4422; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rallabhandi P, 2006, J IMMUNOL, V177, P322, DOI 10.4049/jimmunol.177.1.322; Rao N, 2005, MOL CELL BIOL, V25, P6521, DOI 10.1128/MCB.25.15.6521-6532.2005; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Ronni T, 2003, MOL CELL BIOL, V23, P2543, DOI 10.1128/MCB.23.7.2543-2555.2003; Ropert C, 2003, J IMMUNOL, V171, P1456, DOI 10.4049/jimmunol.171.3.1456; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Savedra R, 1996, J IMMUNOL, V157, P2549; Schade FU, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P751; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Seth RB, 2006, CELL RES, V16, P141, DOI 10.1038/sj.cr.7310019; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Sivori S, 2004, P NATL ACAD SCI USA, V101, P10116, DOI 10.1073/pnas.0403744101; Sly LM, 2004, IMMUNITY, V21, P227, DOI 10.1016/j.immuni.2004.07.010; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; Stuart LM, 2005, J CELL BIOL, V170, P477, DOI 10.1083/jcb.200501113; Tada H, 2005, INFECT IMMUN, V73, P7967, DOI 10.1128/IAI.73.12.7967-7976.2005; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Viriyakosol S, 2005, INFECT IMMUN, V73, P1553, DOI 10.1128/IAI.73.3.1553-1560.2005; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Vogel Stefanie N, 2003, Mol Interv, V3, P466, DOI 10.1124/mi.3.8.466; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986	89	152	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16042	16053		10.1074/jbc.M606781200	http://dx.doi.org/10.1074/jbc.M606781200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17392283	hybrid, Green Accepted			2022-12-27	WOS:000246794300012
J	Uemura, K; Kuzuya, A; Shimozono, Y; Aoyagi, N; Ando, K; Shimohama, S; Kinoshita, A				Uemura, Kengo; Kuzuya, Akira; Shimozono, Yoshiharu; Aoyagi, Nobuhisa; Ando, Koichi; Shimohama, Shun; Kinoshita, Ayae			GSK3 beta activity modifies the localization and function of presenilin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; BETA-CATENIN; N-CADHERIN; TAU-HYPERPHOSPHORYLATION; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; CLEAVAGE; ADHESION	Presenilin 1, a causative gene product of familial Alzheimer disease, has been reported to be localized mainly in the endoplasmic reticulum and Golgi membranes. However, endogenous Presenilin 1 also localizes at the plasma membrane as a biologically active molecule. Presenilin 1 interacts with N-cadherin/beta-catenin to form a trimeric complex at the synaptic site through its loop domain, whose serine residues ( serine 353 and 357) can be phosphorylated by glycogen synthase kinase 3 beta. Here, we demonstrate that cell-surface expression of Presenilin 1/gamma-secretase is enhanced by N-cadherin-based cell-cell contact. Physical interaction between Presenilin 1 and N-cadherin/beta-catenin plays an important role in this process. Glycogen synthase kinase 3 beta-mediated phosphorylation of Presenilin 1 reduces its binding to N-cadherin, thereby down-regulating its cell-surface expression. Moreover, reduction of the Presenilin 1 center dot N-cadherin center dot beta-catenin complex formation leads to an impaired activation of contact-mediated phosphatidylinositol 3-kinase/Akt cell survival signaling. Furthermore, phosphorylation of Presenilin 1 hinders epsilon-cleavage of N-cadherin, whereas epsilon-cleavage of APP remained unchanged. This is the first report that clarifies the regulatory mechanism of Presenilin 1/gamma-secretase with respect to its subcellular distribution and its differential substrate cleavage. Because the cleavage of various membrane proteins by Presenilin 1/gamma-cleavage is involved in cellular signaling, glycogen synthase kinase 3 beta-mediated phosphorylation of Presenilin 1 should be deeply associated with signaling functions. Our findings indicate that the abnormal activation of glycogen synthase kinase 3 beta can reduce neuronal viability and synaptic plasticity via modulating Presenilin 1/N-cadherin/beta-catenin interaction and thus have important implications in the pathophysiology of Alzheimer disease.	Kyoto Univ, Fac Med, Sch Hlth Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Horizontal Med Res Org, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Neurol, Kyoto 6068507, Japan; Sapporo Med Univ, Dept Neurol, Sapporo, Hokkaido 0608556, Japan	Kyoto University; Kyoto University; Kyoto University; Sapporo Medical University	Kinoshita, A (corresponding author), Kyoto Univ, Fac Med, Sch Hlth Sci, Sakyo Ku, 53 Shogoinkawahara Cho, Kyoto 6068507, Japan.	akinoshita@hs.med.kyoto-u.ac.jp		Shimozono, Yoshiharu/0000-0003-1422-530X				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Baki L, 2004, EMBO J, V23, P2586, DOI 10.1038/sj.emboj.7600251; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Bhat RV, 2004, J NEUROCHEM, V89, P1313, DOI 10.1111/j.1471-4159.2004.02422.x; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Chyung JH, 2005, J BIOL CHEM, V280, P4383, DOI 10.1074/jbc.M409272200; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Deng Y, 2006, J NEUROSCI, V26, P3845, DOI 10.1523/JNEUROSCI.5384-05.2006; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Kirschenbaum F, 2001, J BIOL CHEM, V276, P7366, DOI 10.1074/jbc.M004697200; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Li BL, 2004, TRANSGENIC RES, V13, P385, DOI 10.1023/B:TRAG.0000040039.44899.6f; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Murase S, 2002, NEURON, V35, P91, DOI 10.1016/S0896-6273(02)00764-X; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Twomey C, 2006, FEBS LETT, V580, P4015, DOI 10.1016/j.febslet.2006.06.035; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Uemura K, 2003, J NEUROSCI RES, V73, P166, DOI 10.1002/jnr.10641; Uemura K, 2006, NEUROSCI LETT, V402, P278, DOI 10.1016/j.neulet.2006.04.018; Uemura K, 2006, BIOCHEM BIOPH RES CO, V345, P951, DOI 10.1016/j.bbrc.2006.04.157; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x	35	65	69	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15823	15832		10.1074/jbc.M610708200	http://dx.doi.org/10.1074/jbc.M610708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17389597	hybrid			2022-12-27	WOS:000246589600057
J	Dogra, C; Hall, SL; Wedhas, N; Linkhart, TA; Kumar, A				Dogra, Charu; Hall, Susan L.; Wedhas, Nia; Linkhart, Thomas A.; Kumar, Ashok			Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes - Evidence for tweak- independent functions of Fn14 during myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; FIBROBLAST GROWTH FACTOR-INDUCIBLE-14; INHIBITS SKELETAL MYOGENESIS; NUCLEAR FACTOR-KAPPAB; NECROSIS-FACTOR-ALPHA; SIGNALING PATHWAYS; STEM-CELLS; MUSCLE DIFFERENTIATION; TNF SUPERFAMILY; WEAK INDUCER	Fibroblast growth factor-inducible 14 ( Fn14), distantly related to tumor necrosis factor receptor superfamily and a receptor for TWEAK cytokine, has been implicated in several biological responses. In this study, we have investigated the role of Fn14 in skeletal muscle formation in vitro. Flow cytometric and Western blot analysis revealed that Fn14 is highly expressed on myoblastic cell line C2C12 and mouse primary myoblasts. The expression of Fn14 was decreased upon differentiation of myoblasts into myotubes. Suppression of Fn14 expression using RNA interference inhibited the myotube formation in both C2C12 and primary myoblast cultures. Fn14 was required for the transactivation of skeletal alpha-actin promoter and the expression of specific muscle proteins such as myosin heavy chain fast type and creatine kinase. RNA interference-mediated knockdown of Fn14 receptor in C2C12 myoblasts decreased the levels of myogenic regulatory factors MyoD and myogenin upon induction of differentiation. Conversely, overexpression of MyoD increased differentiation in Fn14-knockdown C2C12 cultures. Suppression of Fn14 expression in C2C12 myoblasts also inhibited the differentiation-associated increase in the activity of serum response factor and RhoA GTPase. In addition, our data suggest that the role of Fn14 during myogenic differentiation could be independent of TWEAK cytokine. Collectively, our study suggests that the Fn14 receptor is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes.	Jerry L Pettis Mem Vet Adm Med Ctr, Lab Skeletal Muscle Physiol & Neurobiol, Loma Linda, CA 92357 USA; Loma Linda Univ, Sch Med, Loma Linda, CA 92350 USA	Loma Linda University	Kumar, A (corresponding author), Jerry L Pettis Mem Vet Adm Med Ctr, Lab Skeletal Muscle Physiol & Neurobiol, 11201 Benton St, Loma Linda, CA 92357 USA.	ashok.kumar2@va.gov		Kumar, Ashok/0000-0001-8571-2848	NIA NIH HHS [R01 AG029623, R01 AG029623-01, R01 AG129623] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG029623] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; Brown SAN, 2003, BIOCHEM J, V371, P395, DOI 10.1042/BJ20021730; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Delgado I, 2003, GENOMICS, V82, P109, DOI 10.1016/S0888-7543(03)00104-6; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Dhawan J, 2005, TRENDS CELL BIOL, V15, P666, DOI 10.1016/j.tcb.2005.10.007; Dogra C, 2006, J BIOL CHEM, V281, P10327, DOI 10.1074/jbc.M511131200; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; Girgenrath M, 2006, EMBO J, V25, P5826, DOI 10.1038/sj.emboj.7601441; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Horsley V, 2003, CELL, V113, P483, DOI 10.1016/S0092-8674(03)00319-2; Jakubowski A, 2005, J CLIN INVEST, V115, P2330, DOI 10.1172/JCI23486; Kumar A, 2004, FASEB J, V18, P1524, DOI 10.1096/fj.04-2414com; Kumar A, 2003, FASEB J, V17, P1800, DOI 10.1096/fj.02-1148com; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 2005, J BIOL CHEM, V280, P37782, DOI 10.1074/jbc.M505278200; Kuwahara K, 2005, MOL CELL BIOL, V25, P3173, DOI 10.1128/MCB.25.8.3173-3181.2005; Langen RCJ, 2004, FASEB J, V18, P227, DOI 10.1096/fj.03-0251com; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Meighan-Mantha RL, 1999, J BIOL CHEM, V274, P33166, DOI 10.1074/jbc.274.46.33166; Miller SM, 1998, MOL BIOL CELL, V9, p292A; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Pipes GCT, 2006, GENE DEV, V20, P1545, DOI 10.1101/gad.1428006; Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sabourin LA, 1999, J CELL BIOL, V144, P631, DOI 10.1083/jcb.144.4.631; Sartorelli V, 2005, CURR OPIN GENET DEV, V15, P528, DOI 10.1016/j.gde.2005.04.015; Schulze M, 2005, GENE DEV, V19, P1787, DOI 10.1101/gad.339305; Soulez M, 1996, MOL CELL BIOL, V16, P6065; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Tanabe K, 2003, J NEUROSCI, V23, P9675; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; Tran NL, 2005, J BIOL CHEM, V280, P3483, DOI 10.1074/jbc.M409906200; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Wagers AJ, 2005, CELL, V122, P659, DOI 10.1016/j.cell.2005.08.021; WARNER DO, 1992, AM REV RESPIR DIS, V145, P553, DOI 10.1164/ajrccm/145.3.553; Warren GL, 2002, FASEB J, V16, P1630, DOI 10.1096/fj.02-0187fje; Wedhas N, 2005, FASEB J, V19, P1986, DOI 10.1096/fj.05-4198com; Wei L, 2000, AM J PHYSIOL-HEART C, V278, pH1736, DOI 10.1152/ajpheart.2000.278.6.H1736; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Wiley SR, 2001, IMMUNITY, V15, P837, DOI 10.1016/S1074-7613(01)00232-1; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351; Wilson EM, 2003, J BIOL CHEM, V278, P41109, DOI 10.1074/jbc.C300299200; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yepes M, 2005, AM J PATHOL, V166, P511, DOI 10.1016/S0002-9440(10)62273-0; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	62	68	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15000	15010		10.1074/jbc.M608668200	http://dx.doi.org/10.1074/jbc.M608668200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17383968	hybrid, Green Accepted			2022-12-27	WOS:000246589000039
J	Lecuit, M; Sonnenburg, JL; Cossart, P; Gordon, JI				Lecuit, Marc; Sonnenburg, Justin L.; Cossart, Pascale; Gordon, Jeffrey I.			Functional genomic studies of the intestinal response to a foodborne enteropathogen in a humanized gnotobiotic mouse model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LISTERIA-MONOCYTOGENES; IMMUNE-RESPONSES; KAPPA-B; INTERNALIN; INFECTION; ACTIVATION; DIVERSITY	Members of the genus Listeria provide a model for defining host responses to invasive foodborne enteropathogens. Active translocation of Listeria monocytogenes across the gut epithelial barrier is mediated by interaction of bacterial internalin ( InlA) and its species-specific host receptor, E-cadherin, whereas translocation across Peyer's patches through M-cells is InlA-independent. To define microbial determinants and molecular correlates of the host response to translocation via these two routes, we colonized germ-free transgenic mice expressing the human enterocyte-associated E-cadherin receptor with wildtype ( WT) or mutant L. monocytogenes strains, or its nonpathogenic noninvasive relative Listeria innocua, or with Bacteroides thetaiotaomicron, a prominent gut symbiont. Mouse Gene-Chips, combined with Ingenuity Pathway software, were used to identify canonical signaling pathways that comprise the response to WT L. monocytogenes versus the other species. Gain- and loss-of-function experiments with L. innocua and L. monocytogenes, respectively, demonstrated that the 773-member transcriptional signature of the response to WT L. monocytogenes is largely conserved in the Delta inlA mutant. Internalin-dependent responses include down-regulation of gene networks involved in various aspects of lipid, amino acid, and energy metabolism and up-regulation of immunoinflammatory responses. The host response is markedly attenuated in a listeriolysin-deficient ( Delta hly) mutant despite its ability to be translocated to the lamina propria. Together, these studies establish that hly, rather than bacterial invasion of the lamina propria mediated by InlA, is a dominant determinant of the intensity of the host response to L. monocytogenes infection via the oral route.	Washington Univ, Sch Med, Ctr Genome Sci, St Louis, MO 63108 USA; Inst Pasteur, Bacteria Cell Interact Unit, INSERM U604, F-75015 Paris, France; INRA, USC2020, F-75015 Paris, France	Washington University (WUSTL); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE	Gordon, JI (corresponding author), Washington Univ, Sch Med, Ctr Genome Sci, 4444 Forest Pk Blvd,Campus 8510, St Louis, MO 63108 USA.	jgordon@wustl.edu	Lecuit, Marc/M-4126-2019; Lecuit, Marc/J-4073-2013	Lecuit, Marc/0000-0002-4491-1063; Lecuit, Marc/0000-0002-4491-1063	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boldogh IR, 2001, P NATL ACAD SCI USA, V98, P3162, DOI 10.1073/pnas.051494698; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dramsi S, 1998, INFECT IMMUN, V66, P4461; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Glaser P, 2001, SCIENCE, V294, P849; Havell EA, 1999, IMMUNOBIOLOGY, V201, P164, DOI 10.1016/S0171-2985(99)80056-4; Hooper LV, 2002, METHOD MICROBIOL, V31, P559, DOI 10.1016/S0580-9517(02)31030-4; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Jacquet C, 2004, J INFECT DIS, V189, P2094, DOI 10.1086/420853; Kayal S, 1999, MOL MICROBIOL, V31, P1709, DOI 10.1046/j.1365-2958.1999.01305.x; Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757; Lecuit M, 2004, P NATL ACAD SCI USA, V101, P6152, DOI 10.1073/pnas.0401434101; Lecuit M, 2001, SCIENCE, V292, P1722, DOI 10.1126/science.1059852; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; Lecuit M, 1997, INFECT IMMUN, V65, P5309, DOI 10.1128/IAI.65.12.5309-5319.1997; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Mansell A, 2001, J BIOL CHEM, V276, P43597, DOI 10.1074/jbc.M105202200; Marco AJ, 1997, MICROB PATHOGENESIS, V23, P255, DOI 10.1006/mpat.1997.0144; Nishikawa S, 1998, MICROBIOL IMMUNOL, V42, P325, DOI 10.1111/j.1348-0421.1998.tb02290.x; Olier M, 2002, MICROBIOL-SGM, V148, P1855, DOI 10.1099/00221287-148-6-1855; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; Pentecost M, 2006, PLOS PATHOG, V2, P29, DOI 10.1371/journal.ppat.0020003; Pizarro-Cerda J, 2006, J PATHOL, V208, P215, DOI 10.1002/path.1888; Pron B, 1998, INFECT IMMUN, V66, P747, DOI 10.1128/IAI.66.2.747-755.1998; Sabet C, 2005, INFECT IMMUN, V73, P6912, DOI 10.1128/IAI.73.10.6912-6922.2005; Serbina NV, 2003, IMMUNITY, V19, P891, DOI 10.1016/S1074-7613(03)00330-3; Slaghuis J, 2004, J INFECT DIS, V189, P393, DOI 10.1086/381206; Sonnenburg JL, 2005, SCIENCE, V307, P1955, DOI 10.1126/science.1109051; Stappenbeck TS, 2002, METHOD ENZYMOL, V356, P167; Tang P, 1996, INFECT IMMUN, V64, P2359, DOI 10.1128/IAI.64.6.2359-2361.1996; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029	36	60	63	1	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15065	15072		10.1074/jbc.M610926200	http://dx.doi.org/10.1074/jbc.M610926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389602	Green Published, hybrid			2022-12-27	WOS:000246589000046
J	Xu, R; Spencer, VA; Bissell, MJ				Xu, Ren; Spencer, Virginia A.; Bissell, Mina J.			Extracellular matrix-regulated gene expression requires cooperation of SWI/SNF and transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; BETA-CASEIN EXPRESSION; GLUCOCORTICOID-RECEPTOR; HISTONE ACETYLTRANSFERASE; STAT5; DIFFERENTIATION; ACTIVATION; INDUCTION; PROLACTIN; COMPLEXES	Extracellular cues play crucial roles in the transcriptional regulation of tissue-specific genes, but whether and how these signals lead to chromatin remodeling is not understood and subject to debate. Using chromatin immunoprecipitation assays and mammary-specific genes as models, we show here that extracellular matrix molecules and prolactin cooperate to induce histone acetylation and binding of transcription factors and the SWI/SNF complex to the beta- and gamma-casein promoters. Introduction of a dominant negative Brg1, an ATPase subunit of SWI/SNF complex, significantly reduced both beta- and gamma-casein expression, suggesting that SWI/SNF-dependent chromatin remodeling is required for transcription of mammary-specific genes. Chromatin immunoprecipitation analyses demonstrated that the ATPase activity of SWI/SNF is necessary for recruitment of RNA transcriptional machinery, but not for binding of transcription factors or for histone acetylation. Co-immunoprecipitation analyses showed that the SWI/SNF complex is associated with STAT5, CCAAT/enhancer-binding protein beta, and glucocorticoid receptor. Thus, extracellular matrix-and prolactin-regulated transcription of the mammary-specific casein genes requires the concerted action of chromatin remodeling enzymes and transcription factors.	Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Bissell, MJ (corresponding author), Lawrence Berkeley Natl Lab, Div Life Sci, 1 Cyclotron Rd,MS 977R225A, Berkeley, CA 94720 USA.	MJBissell@lbl.gov		Xu, Ren/0000-0002-3591-9522	NCI NIH HHS [R01 CA057621-13, R01 CA057621] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057621] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; BLUM JL, 1989, ENVIRON HEALTH PERSP, V80, P71, DOI 10.2307/3430733; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Carey M, 2005, MOL CELL, V17, P323, DOI 10.1016/j.molcel.2005.01.013; Chan HM, 2001, J CELL SCI, V114, P2363; Close MJ, 1997, J CELL SCI, V110, P2861; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Edwards GM, 1998, J BIOL CHEM, V273, P9495, DOI 10.1074/jbc.273.16.9495; Farkas G, 2000, GENE, V253, P117, DOI 10.1016/S0378-1119(00)00240-7; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Hill DA, 2004, J CELL BIOCHEM, V91, P987, DOI 10.1002/jcb.20003; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; Hsiao PW, 2002, BIOCHEM CELL BIOL, V80, P343, DOI 10.1139/O02-082; Jolivet G, 2001, J CELL BIOCHEM, V82, P371, DOI 10.1002/jcb.1166; Joseph J, 2004, ONCOGENE, V23, P6304, DOI 10.1038/sj.onc.1207852; Kabotyanski EB, 2006, MOL ENDOCRINOL, V20, P2355, DOI 10.1210/me.2006-0160; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kolb AF, 2002, BBA-GENE STRUCT EXPR, V1579, P101, DOI 10.1016/S0167-4781(02)00533-X; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Lechner J, 1997, J BIOL CHEM, V272, P20954, DOI 10.1074/jbc.272.33.20954; LEE EYHP, 1985, P NATL ACAD SCI USA, V82, P1419, DOI 10.1073/pnas.82.5.1419; Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941; LIN CQ, 1995, J CELL BIOL, V129, P1115, DOI 10.1083/jcb.129.4.1115; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Mukhopadhyay SS, 2001, MOL CELL BIOL, V21, P6859, DOI 10.1128/MCB.21.20.6859-6869.2001; Muller C, 2001, CURR OPIN GENET DEV, V11, P167, DOI 10.1016/S0959-437X(00)00175-1; Muller WG, 2001, J CELL BIOL, V154, P33, DOI 10.1083/jcb.200011069; Muschler J, 1999, MOL BIOL CELL, V10, P2817, DOI 10.1091/mbc.10.9.2817; Myers CA, 1998, MOL CELL BIOL, V18, P2184, DOI 10.1128/MCB.18.4.2184; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200; Novaro V, 2003, J CELL SCI, V116, P2975, DOI 10.1242/jcs.00523; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Pujuguet P, 2001, J CELL BIOCHEM, V83, P660, DOI 10.1002/jcb.1260; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; Rijnkels M, 1997, MAMM GENOME, V8, P9, DOI 10.1007/s003359900338; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Rosen JM, 1999, ANNU REV NUTR, V19, P407, DOI 10.1146/annurev.nutr.19.1.407; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Sun JM, 2003, METHODS, V31, P12, DOI 10.1016/S1046-2023(03)00083-5; VanLint C, 1996, GENE EXPRESSION, V5, P245; Weir ML, 2006, J CELL SCI, V119, P4047, DOI 10.1242/jcs.03103; Wyszomierski SL, 2001, MOL ENDOCRINOL, V15, P228, DOI 10.1210/me.15.2.228	56	74	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14992	14999		10.1074/jbc.M610316200	http://dx.doi.org/10.1074/jbc.M610316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387179	Green Accepted, Green Submitted, hybrid			2022-12-27	WOS:000246589000038
J	McNally, DJ; Aubry, AJ; Hui, JPM; Khieu, NH; Whitfield, D; Ewing, CP; Guerry, P; Brisson, JR; Logan, SM; Soo, EC				McNally, David J.; Aubry, Annie J.; Hui, Joseph P. M.; Khieu, Nam H.; Whitfield, Dennis; Ewing, Cheryl P.; Guerry, Patricia; Brisson, Jean-Robert; Logan, Susan M.; Soo, Evelyn C.			Targeted metabolomics analysis of Campylobacter coli VC167 reveals legionaminic acid derivatives as novel flagellar glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PNEUMOPHILA SEROGROUP-1 LIPOPOLYSACCHARIDE; O-CHAIN POLYSACCHARIDE; FUNCTIONAL-CHARACTERIZATION; LEGIONELLA-PNEUMOPHILA; NMR-SPECTROSCOPY; PSEUDAMINIC ACID; POSTTRANSLATIONAL MODIFICATION; HELICOBACTER-PYLORI; CHEMICAL STRUCTURES; ANTIBODY-RESPONSE	Glycosylation of Campylobacter flagellin is required for the biogenesis of a functional flagella filament. Recently, we used a targeted metabolomics approach using mass spectrometry and NMR to identify changes in the metabolic profile of wild type and mutants in the flagellar glycosylation locus, characterize novel metabolites, and assign function to genes to define the pseudaminic acid biosynthetic pathway in Campylobacter jejuni 81-176 (McNally, D. J., Hui, J. P., Aubry, A. J., Mui, K. K., Guerry, P., Brisson, J. R., Logan, S. M., and Soo, E. C. ( 2006) J. Biol. Chem. 281, 18489 - 18498). In this study, we use a similar approach to further define the glycome and metabolomic complement of nucleotide-activated sugars in Campylobacter coli VC167. Herein we demonstrate that, in addition to CMP-pseudaminic acid, C. coli VC167 also produces two structurally distinct nucleotide-activated nonulosonate sugars that were observed as negative ions at m/z 637 and m/z 651 (CMP-315 and CMP-329). Hydrophilic interaction liquid chromatography-mass spectrometry yielded suitable amounts of the pure sugar nucleotides for NMR spectroscopy using a cold probe. Structural analysis in conjunction with molecular modeling identified the sugar moieties as acetamidino and N-methylacetimidoyl derivatives of legionaminic acid (Leg5Am7Ac and Leg5AmNMe7Ac). Targeted metabolomic analyses of isogenic mutants established a role for the ptmA-F genes and defined two new ptm genes in this locus as legionaminic acid biosynthetic enzymes. This is the first report of legionaminic acid in Campylobacter sp. and the first report of legionaminic acid derivatives as modifications on a protein.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Inst Marine Biosci, Halifax, NS B3H 3Z1, Canada; USN, Med Res Ctr, Silver Spring, MD 20910 USA	National Research Council Canada; International Business Machines (IBM); National Research Council Canada; United States Department of Defense; United States Navy	Logan, SM (corresponding author), Natl Res Council Canada, Inst Biol Sci, Rm 3037,100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	susan.logan@nrc-cnrc.gc.ca; evelyn.soo@nrc-cnrc.gc.ca	Guerry, Patricia/A-8024-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043559] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43559] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALM RA, 1992, J BACTERIOL, V174, P4230, DOI 10.1128/JB.174.13.4230-4238.1992; ASPINALL GO, 1995, EUR J BIOCHEM, V231, P570, DOI 10.1111/j.1432-1033.1995.0570d.x; ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1017, DOI 10.1111/j.1432-1033.1993.tb17849.x; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; Blaser M. J., 1997, J INFECT DIS S2, V176, P103; BLASER MJ, 1984, INFECT IMMUN, V44, P292, DOI 10.1128/IAI.44.2.292-298.1984; Brisson JR, 2002, CAN J CHEM, V80, P949, DOI 10.1139/V02-114; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; Fouts DE, 2005, PLOS BIOL, V3, P72, DOI 10.1371/journal.pbio.0030015; Goon S, 2003, MOL MICROBIOL, V50, P659, DOI 10.1046/j.1365-2958.2003.03725.x; GUERRY P, 1991, J BACTERIOL, V173, P4757, DOI 10.1128/jb.173.15.4757-4764.1991; Guerry P, 2006, MOL MICROBIOL, V60, P299, DOI 10.1111/j.1365-2958.2006.05100.x; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; HARRIS LA, 1987, J BACTERIOL, V169, P5066, DOI 10.1128/jb.169.11.5066-5071.1987; HERMANSSON K, 1993, EUR J BIOCHEM, V212, P801, DOI 10.1111/j.1432-1033.1993.tb17721.x; Kenne L, 1988, CARBOHYD RES, V180, P285, DOI 10.1016/0008-6215(88)80085-5; Knirel YA, 2003, ADV CARBOHYD CHEM BI, V58, P371, DOI 10.1016/S0065-2318(03)58007-6; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Konkel ME, 2004, J BACTERIOL, V186, P3296, DOI 10.1128/JB.186.11.3296-3303.2004; Kooistra O, 2002, EUR J BIOCHEM, V269, P573, DOI 10.1046/j.0014-2956.2001.02684.x; Kooistra O, 2002, EUR J BIOCHEM, V269, P560, DOI 10.1046/j.0014-2956.2001.02683.x; LABIGNEROUSSEL A, 1988, J BACTERIOL, V170, P1704, DOI 10.1128/jb.170.4.1704-1708.1988; LINDBERG B, 1990, ADV CARBOHYD CHEM BI, V48, P279, DOI 10.1016/S0065-2318(08)60033-5; Logan SM, 2002, MOL MICROBIOL, V46, P587, DOI 10.1046/j.1365-2958.2002.03185.x; Luneberg E, 2000, INT J MED MICROBIOL, V290, P37; Luneberg E, 1998, J EXP MED, V188, P49, DOI 10.1084/jem.188.1.49; MARTIN PMV, 1989, INFECT IMMUN, V57, P2542, DOI 10.1128/IAI.57.8.2542-2546.1989; McNally DJ, 2006, J BIOL CHEM, V281, P18489, DOI 10.1074/jbc.M603777200; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; NACHAMKIN I, 1985, J CLIN MICROBIOL, V21, P33, DOI 10.1128/JCM.21.1.33-38.1985; Olivier NB, 2006, BIOCHEMISTRY-US, V45, P13659, DOI 10.1021/bi061456h; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; POWER ME, 1994, J BACTERIOL, V176, P3303, DOI 10.1128/jb.176.11.3303-3313.1994; Schirm M, 2005, ANAL CHEM, V77, P7774, DOI 10.1021/ac051316y; Schirm M, 2003, MOL MICROBIOL, V48, P1579, DOI 10.1046/j.1365-2958.2003.03527.x; Schoenhofen IC, 2006, GLYCOBIOLOGY, V16, p8C, DOI 10.1093/glycob/cwl010; Schoenhofen IC, 2006, J BIOL CHEM, V281, P723, DOI 10.1074/jbc.M511021200; Song YC, 2004, MOL MICROBIOL, V53, P541, DOI 10.1111/j.1365-2958.2004.04175.x; Soo EC, 2004, ANAL CHEM, V76, P619, DOI 10.1021/ac034875i; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Tsvetkov YE, 2001, CARBOHYD RES, V331, P233, DOI 10.1016/S0008-6215(01)00041-6; Tsvetkov YE, 2001, CARBOHYD RES, V335, P221, DOI 10.1016/S0008-6215(01)00235-X; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; VLIEGENTHART A, 1982, CELL BIOL MONOGR, P127; YAO RJ, 1993, GENE, V130, P127, DOI 10.1016/0378-1119(93)90355-7; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200	47	96	100	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14463	14475		10.1074/jbc.M611027200	http://dx.doi.org/10.1074/jbc.M611027200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371878	hybrid			2022-12-27	WOS:000246245800060
J	Nie, LH; Sasaki, M; Maki, CG				Nie, Linghu; Sasaki, Mark; Maki, Carl G.			Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; MONOCLONAL-ANTIBODY; MUTANT P53; MDM2; PROTEIN; DEGRADATION; MUTATIONS; CELLS; EXCLUSION; LIGASE	Wild-type p53 is a conformationally labile protein that undergoes nuclear-cytoplasmic shuttling. MDM2-mediated ubiquitination promotes p53 nuclear export by exposing or activating a nuclear export signal (NES) in the C terminus of p53. We observed that cancer-derived p53s with a mutant ( primary antibody 1620-/pAb240+) conformation localized in the cytoplasm to a greater extent and displayed increased susceptibility to ubiquitination than p53s with a more wild-type ( primary antibody 1620+/pAb240-) conformation. The cytoplasmic localization of mutant p53s required the C-terminal NES and an intact ubiquitination pathway. Mutant p53 ubiquitination occurred at lysines in both the DNA-binding domain (DBD) and C terminus. Interestingly, Lys to Arg mutations that inhibited ubiquitination restored nuclear localization to mutant p53 but had no apparent effect on p53 conformation. Further studies revealed that wild-type p53, like mutant p53, is ubiquitinated by MDM2 in both the DBD and C terminus and that ubiquitination in both regions contributes to its nuclear export. MDM2 binding can induce a conformational change in wild-type p53, but this conformational change is insufficient to promote p53 nuclear export in the absence of MDM2 ubiquitination activity. Taken together, these results support a stepwise model for mutant and wild-type p53 nuclear export. In this model, the conformational change induced by either the cancer-derived mutation or MDM2 binding precedes p53 ubiquitination. The addition of ubiquitin to DBD and C-terminal lysines then promotes nuclear export via the C-terminal NES.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave,MC1105,Rm G06, Chicago, IL 60637 USA.	cmaki@rover.uchicago.edu	Bhattacharyya, Debnath/A-3144-2016; Bandyopadhyay, Samir Kumar/AAR-8919-2020	Bhattacharyya, Debnath/0000-0003-0140-9644; Bandyopadhyay, Samir Kumar/0000-0002-4868-3459	NCI NIH HHS [R01 CA080918] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080918] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chan WM, 2006, MOL CANCER RES, V4, P15, DOI 10.1158/1541-7786.MCR-05-0097; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Inoue T, 2002, J BIOL CHEM, V277, P15053, DOI 10.1074/jbc.M200248200; Irwin MS, 2004, CELL CYCLE, V3, P319; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Rodriguez-Lopez AM, 2001, MOL PHARMACOL, V59, P135, DOI 10.1124/mol.59.1.135; Sasaki M, 2007, J BIOL CHEM, V282, P14626, DOI 10.1074/jbc.M610514200; Shimizu H, 2006, BIOCHEM J, V397, P355, DOI 10.1042/BJ20051521; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WesierskaGadek J, 1996, J CELL BIOCHEM, V62, P90, DOI 10.1002/(SICI)1097-4644(199607)62:1<90::AID-JCB10>3.0.CO;2-J; Yu GW, 2006, P NATL ACAD SCI USA, V103, P1227, DOI 10.1073/pnas.0510343103; ZENG GC, 1984, MOL CELL BIOL, V4, P1815, DOI 10.1128/MCB.4.9.1815; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	39	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14616	14625		10.1074/jbc.M610515200	http://dx.doi.org/10.1074/jbc.M610515200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17371868	hybrid			2022-12-27	WOS:000246245800075
J	Rebouissou, S; Imbeaud, S; Balabaud, C; Boulanger, V; Bertrand-Michel, J; Terce, F; Auffray, C; Bioulac-Sage, P; Zucman-Rossi, J				Rebouissou, Sandra; Imbeaud, Sandrine; Balabaud, Charles; Boulanger, Virginie; Bertrand-Michel, Justine; Terce, Francois; Auffray, Charles; Bioulac-Sage, Paulette; Zucman-Rossi, Jessica			HNF1 alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR 1-ALPHA; HEPATIC STEATOSIS; GENE-EXPRESSION; CANCER-CELLS; ALPHA-GENE; LIVER; ACID; INHIBITION; INSULIN; MICE	Biallelic inactivating mutations of the transcription factor 1 gene (TCF1), encoding hepatocyte nuclear factor 1 alpha (HNF1 alpha) were identified in 50% of hepatocellular adenomas (HCA) phenotypically characterized by a striking steatosis. To understand the molecular basis of this aberrant lipid storage, we performed a microarray transcriptome analysis validated by quantitative reverse transcription-PCR, Western blotting, and lipid profiling. In mutated HCA, we showed a repression of gluconeogenesis coordinated with an activation of glycolysis, citrate shuttle, and fatty acid synthesis predicting elevated rates of lipogenesis. Moreover, the strong down-regulation of liver fatty acid-binding protein suggests that impaired fatty acid trafficking may also contribute to the fatty phenotype. In addition, transcriptional profile analysis of the observed deregulated genes in non-HNF1 alpha-mutated HCA as well as in non-tumor livers allowed us to define a specific signature of the HNF1 alpha-mutated HCA. In these tumors, lipid composition was dramatically modified according to the transcriptional deregulations identified in the fatty acid synthetic pathway. Surprisingly, lipogenesis activation did not operate through sterol regulatory element-binding protein-1 (SREBP-1) and carbohydrate-response element-binding protein (ChREBP) that were repressed. We conclude that steatosis in HNF1 alpha-mutated HCA results mainly from an aberrant promotion of lipogenesis that is linked to HNF1 alpha inactivation and that is independent of both SREBP-1 and ChREBP activation. Finally, our findings have potential clinical implications since lipogenesis can be efficiently inhibited by targeted therapies.	INSERM, U674, Inst Univ Hematol, CEPH, F-75010 Paris, France; Univ Paris 07, Inst Univ Hematol, CEPH, F-75010 Paris, France; Univ Paris 06, CNRS, UMR 7091, Array S IMAGE,Genexpress, F-94800 Villejuif, France; INSERM, U889, F-33076 Bordeaux, France; Univ Bordeaux 2, F-33076 Bordeaux, France; CHU Bordeaux, Hop St Andre, Serv Hepatol, F-33076 Bordeaux, France; CHU Bordeaux, Hop Pellegrin, F-33076 Bordeaux, France; CHU Purpan, INSERM, F-31052 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; CHU Bordeaux; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Zucman-Rossi, J (corresponding author), INSERM, U674, Inst Univ Hematol, CEPH, 27 Rue Juliette Dodu, F-75010 Paris, France.	zucman@cephb.fr	j, zucman-rossi/AAV-3594-2021; Tercé, François/M-5863-2018; Rebouissou, Sandra/O-5938-2017; zucman-rossi, Jessica/B-5098-2009; Imbeaud, Sandrine/P-8780-2017	j, zucman-rossi/0000-0002-5687-0334; Tercé, François/0000-0003-4488-2167; Rebouissou, Sandra/0000-0003-0188-2271; zucman-rossi, Jessica/0000-0002-5687-0334; Imbeaud, Sandrine/0000-0001-8439-6732				Akiyama TE, 2000, J BIOL CHEM, V275, P27117; Bandsma RHJ, 2001, DIABETES, V50, P2591, DOI 10.2337/diabetes.50.11.2591; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Dentin R, 2005, J CLIN INVEST, V115, P2843, DOI 10.1172/JCI25256; EDMONDSON HA, 1976, NEW ENGL J MED, V294, P470, DOI 10.1056/NEJM197602262940904; Engelking LJ, 2004, J CLIN INVEST, V113, P1168, DOI 10.1172/JCI200420978; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; GORDON JI, 1985, J BIOL CHEM, V260, P1995; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Hiraiwa H, 2001, J BIOL CHEM, V276, P7963, DOI 10.1074/jbc.M010523200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Iizuka K, 2004, P NATL ACAD SCI USA, V101, P7281, DOI 10.1073/pnas.0401516101; Imbeaud S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni054; Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004; Ktistaki E, 1997, SCIENCE, V277, P109, DOI 10.1126/science.277.5322.109; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Matsusue K, 2003, J CLIN INVEST, V111, P737, DOI 10.1172/JCI200317223; Ntambi JM, 2004, PROG LIPID RES, V43, P91, DOI 10.1016/S0163-7827(03)00039-0; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Rebouissou S, 2005, HUM MOL GENET, V14, P603, DOI 10.1093/hmg/ddi057; Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124; Zhang YL, 2006, J BIOL CHEM, V281, P37603, DOI 10.1074/jbc.M604709200; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	31	93	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14437	14446		10.1074/jbc.M610725200	http://dx.doi.org/10.1074/jbc.M610725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17379603	hybrid, Green Submitted			2022-12-27	WOS:000246245800057
J	Liu, YA; Prasad, R; Beard, WA; Kedar, PS; Hou, EW; Shock, DD; Wilson, SH				Liu, Yuan; Prasad, Rajendra; Beard, William A.; Kedar, Padmini S.; Hou, Esther W.; Shock, David D.; Wilson, Samuel H.			Coordination of steps in single-nucleotide base excision repair mediated by apurinic/apyrimidinic endonuclease 1 and DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED HUMAN PROTEINS; CELL NUCLEAR ANTIGEN; ABASIC SITE REPAIR; POLY(ADP-RIBOSE) POLYMERASE-1; LIGASE I; DEGENERATIVE DISEASES; INDUCED CYTOTOXICITY; MAMMALIAN-CELLS; DAMAGE; ENZYMES	The individual steps in single-nucleotide base excision repair (SN-BER) are coordinated to enable efficient repair without accumulation of cytotoxic DNA intermediates. The DNA transactions and various proteins involved in SN-BER of abasic sites are well known in mammalian systems. Yet, despite a wealth of information on SN-BER, the mechanism of step-by-step coordination is poorly understood. In this study we conducted experiments toward understanding step-by-step coordination during BER by comparing DNA binding specificities of two major human SN-BER enzymes, apurinic/aprymidinic endonuclease 1 (APE) and DNA polymerase beta (Pol beta). It is known that these enzymes do not form a stable complex in solution. For each enzyme, we found that DNA binding specificity appeared sufficient to explain the sequential processing of BER intermediates. In addition, however, we identified at higher enzyme concentrations a ternary complex of APE center dot Pol beta center dot DNA that formed specifically at BER intermediates containing a 5'-deoxyribose phosphate group. Formation of this ternary complex was associated with slightly stronger Pol beta gap-filling and much stronger 5'-deoxyribose phosphate lyase activities than was observed with the Pol beta center dot DNA binary complex. These results indicate that step-by step coordination in SN-BER can rely on DNA binding specificity inherent in APE and Pol beta, although coordination also may be facilitated by APE center dot Pol beta center dot DNA ternary complex formation with appropriate enzyme expression levels or enzyme recruitment to sites of repair.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexander Dr,POB 12233,MD F3-01, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	Intramural NIH HHS [Z01 ES050158-11] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050159, Z01ES050158] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; Beard WA, 2004, J BIOL CHEM, V279, P31921, DOI 10.1074/jbc.M404016200; Beard WA, 2006, CHEM REV, V106, P361, DOI 10.1021/cr0404904; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Cistulli C, 2004, DNA REPAIR, V3, P581, DOI 10.1016/j.dnarep.2003.09.012; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianova II, 2004, NUCLEIC ACIDS RES, V32, P2550, DOI 10.1093/nar/gkh567; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Donny W, 2004, J BIOL CHEM, V279, P25268, DOI 10.1074/jbc.M400804200; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P169; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S; Horton JK, 2005, DNA REPAIR, V4, P1111, DOI 10.1016/j.dnarep.2005.05.011; Horton JK, 2005, J BIOL CHEM, V280, P15773, DOI 10.1074/jbc.M413841200; Horton JK, 2003, DNA REPAIR, V2, P27, DOI 10.1016/S1568-7864(02)00184-2; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Jackson EB, 2005, NUCLEIC ACIDS RES, V33, P3303, DOI 10.1093/nar/gki641; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lan L, 2004, P NATL ACAD SCI USA, V101, P13738, DOI 10.1073/pnas.0406048101; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; Lindahl T, 1975, Basic Life Sci, V5A, P31; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Liu Y, 2005, J BIOL CHEM, V280, P3665, DOI 10.1074/jbc.M412922200; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; LUTZ WK, 1990, MUTAT RES, V238, P287, DOI 10.1016/0165-1110(90)90020-C; Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Poulsen HE, 1998, FREE RADICAL RES, V29, P565, DOI 10.1080/10715769800300601; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Pratico D, 2005, NEUROBIOL AGING, V26, P581, DOI 10.1016/j.neurobiolaging.2004.09.020; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sokhansanj BA, 2002, NUCLEIC ACIDS RES, V30, P1817, DOI 10.1093/nar/30.8.1817; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Sukhanova MV, 2005, NUCLEIC ACIDS RES, V33, P1222, DOI 10.1093/nar/gki266; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Waris G, 2006, J CARCINOG, V5, P14, DOI [10.1186/1477-3163-5-14, DOI 10.1186/1477-3163-5-14]; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	57	110	116	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13532	13541		10.1074/jbc.M611295200	http://dx.doi.org/10.1074/jbc.M611295200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355977	Green Accepted, hybrid			2022-12-27	WOS:000246060300042
J	McMillan, BJ; McMillan, SN; Glover, E; Bradfield, CA				McMillan, Brian J.; McMillan, Susanne N.; Glover, Ed; Bradfield, Christopher A.			2,3,7,8-Tetrachlorodibenzo-p-dioxin induces premature activation of the KLF2 regulon during thymocyte development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; KRUPPEL-LIKE FACTOR-2; T-CELL QUIESCENCE; DEFICIENT MICE; AH-RECEPTOR; MOUSE; EXPRESSION; TRANSCRIPTION; TOXICITY; GENES	The environmental pollutant 2,3,7,8-tetrachlorodibenzo-p-dioxin ( TCDD, dioxin) causes numerous and diverse toxic events via activation of the aryl hydrocarbon receptor, including atrophy of the thymus. Exposure to TCDD induces acute thymocyte cell loss, which occurs concomitantly with proliferation arrest and premature emigration of triple negative ( TN; CD4(-), CD8(-), CD3(-)) T cell progenitors. In this report, we demonstrate that TCDD exposure results in dysregulation of KLF2 ( Kruppel-like factor 2) expression in developing thymocytes. The Klf2 gene encodes an Sp1-like zinc finger transcription factor that functions as a central regulator of T lymphocyte proliferation and trafficking. During normal thymocyte development, KLF2 is expressed exclusively in CD4 and CD8 single positive T cells and promotes a nonproliferative, promigratory phenotype. In mice exposed to TCDD, however, the Klf2 gene is prematurely expressed in TN thymocytes. Administration of a 100 mu g/kg dose of TCDD results in a similar to 15-fold induction of KLF2 as early as the TN2 ( CD44(+), CD25(+)) stage of development and immediately precedes acute cell loss in the TN3, TN4, and double positive ( CD4(+), CD8(+)) cell stages. Induction of KLF2 occurs within 12 h of TCDD exposure and is fully dependent on expression of the aryl hydrocarbon receptor. In addition, TCDD exposure alters the expression of several factors comprising the KLF2 regulon, including Edg1/S1P(1), beta(7)integrin, CD52, Cdkn2d( cyclin-dependent kinase inhibitor 2D), s100a4, and IL10R alpha. These findings indicate that the pollutant TCDD interferes with early thymopoeisis via ectopic expression of the KLF2 regulon.	Univ Wisconsin, McArdle Lab Canc Res, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bradfield, CA (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, Sch Med, 1400 Univ Ave, Madison, WI 53706 USA.	bradfield@oncology.wisc.edu			NATIONAL CANCER INSTITUTE [T32CA009135, P30CA014520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES005703, R01ES005703] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA009135, P30-CA014520] Funding Source: Medline; NIEHS NIH HHS [R01 ES005703, R37-ES05703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; BEATTY P, 1976, BIOCHEM BIOPH RES CO, V68, P197, DOI 10.1016/0006-291X(76)90029-2; Birnbaum LS, 2000, FOOD ADDIT CONTAM A, V17, P275, DOI 10.1080/026520300283351; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; Carlson CM, 2006, NATURE, V442, P299, DOI 10.1038/nature04882; Das H, 2006, P NATL ACAD SCI USA, V103, P6653, DOI 10.1073/pnas.0508235103; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; Dekker RJ, 2005, AM J PATHOL, V167, P609, DOI 10.1016/S0002-9440(10)63002-7; DEKKER RJ, 2006, BLOOD; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Frericks M, 2006, BIOL CHEM, V387, P1219, DOI 10.1515/BC.2006.151; Gill J, 2003, IMMUNOL REV, V195, P28, DOI 10.1034/j.1600-065X.2003.00077.x; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Gouedard C, 2004, MOL CELL BIOL, V24, P5209, DOI 10.1128/MCB.24.12.5209-5222.2004; Haaland RE, 2005, MOL IMMUNOL, V42, P627, DOI 10.1016/j.molimm.2004.09.012; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Laiosa MD, 2003, J IMMUNOL, V171, P4582, DOI 10.4049/jimmunol.171.9.4582; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; McMillan BJ, 2007, P NATL ACAD SCI USA, V104, P1412, DOI 10.1073/pnas.0607296104; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Parmar KM, 2006, J CLIN INVEST, V116, P49, DOI 10.1172/JCI24787; POLAND A, 1980, MOL PHARMACOL, V17, P86; Puthier D, 2004, J IMMUNOL, V173, P6109, DOI 10.4049/jimmunol.173.10.6109; Schecter A, 2006, ENVIRON RES, V101, P419, DOI 10.1016/j.envres.2005.12.003; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Staples JE, 1998, J IMMUNOL, V160, P3844; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; Svensson C, 2002, BIOCHEM BIOPH RES CO, V291, P1194, DOI 10.1006/bbrc.2002.6582; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; Temchura VV, 2005, EUR J IMMUNOL, V35, P2738, DOI 10.1002/eji.200425641; Tomita S, 2003, J IMMUNOL, V171, P4113, DOI 10.4049/jimmunol.171.8.4113; Vorderstrasse BA, 2001, TOXICOL APPL PHARM, V171, P157, DOI 10.1006/taap.2000.9122; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996	42	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12590	12597		10.1074/jbc.M611446200	http://dx.doi.org/10.1074/jbc.M611446200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337447	hybrid			2022-12-27	WOS:000245942800028
J	Pickersgill, L; Litherland, GJ; Greenberg, AS; Walker, M; Yeaman, SJ				Pickersgill, Laura; Litherland, Gary J.; Greenberg, Andrew S.; Walker, Mark; Yeaman, Stephen J.			Key role for ceramides in mediating insulin resistance in human muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SATURATED FATTY-ACIDS; NECROSIS-FACTOR-ALPHA; HUMAN SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAY; GLUCOSE-UPTAKE; PERILIPIN-A; DIACYLGLYCEROL; ACCUMULATION	Elevated non-esterified fatty acids, triglyceride, diacylglycerol, and ceramide have all been associated with insulin resistance in muscle. We set out to investigate the role of intramyocellular lipid metabolites in the induction of insulin resistance in human primary myoblast cultures. Muscle cells were subjected to adenovirus-mediated expression of perilipin or incubated with fatty acids for 18 h, prior to insulin stimulation and measurement of lipid metabolites and rates of glycogen synthesis. Adenovirus-driven perilipin expression lead to significant accumulation of triacylglycerol in myoblasts, without any detectable effect on insulin sensitivity, as judged by the ability of insulin to stimulate glycogen synthesis. Similarly, incubation of cells with the monounsaturated fatty acid oleate resulted in triacylglycerol accumulation without inhibiting insulin action. By contrast, the saturated fatty acid palmitate induced insulin resistance. Palmitate treatment caused less accumulation of triacylglycerol than did oleate but also induced significant accumulation of both diacylglycerol and ceramide. Insulin resistance was also caused by cell-permeable analogues of ceramide, and palmitate-induced resistance was blocked in the presence of inhibitors of de novo ceramide synthesis. Oleate co-incubation completely prevented the insulin resistance induced by palmitate. Our data are consistent with ceramide being the agent responsible for insulin resistance caused by palmitate exposure. Furthermore, the triacylglycerol derived from oleate was able to exert a protective role in sequestering palmitate, thus preventing its conversion to ceramide.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Tufts Univ, Obes & Metab Lab, Jean Mayer US Dept Agr, Human Nutr Res Ctr Aging, Boston, MA 02111 USA	Newcastle University - UK; Newcastle University - UK; Tufts University; United States Department of Agriculture (USDA)	Yeaman, SJ (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	S.J.Yeaman@ncl.ac.uk	Litherland, Gary J/K-9755-2015	Litherland, Gary/0000-0001-5264-0219	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050647] Funding Source: NIH RePORTER; NIDDK NIH HHS [IH DK50647] Funding Source: Medline; Wellcome Trust [066495/Z/01/A] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		Adams JM, 2004, DIABETES, V53, P25, DOI 10.2337/diabetes.53.1.25; Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020; Chavez JA, 2005, J BIOL CHEM, V280, P20148, DOI 10.1074/jbc.M412769200; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; CHEN KS, 1991, T ASSOC AM PHYSICIAN, V104, P206; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Halse R, 2001, DIABETES, V50, P720, DOI 10.2337/diabetes.50.4.720; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; Phillips SA, 2005, OBES RES, V13, P1321, DOI 10.1038/oby.2005.160; Powell DJ, 2004, BIOCHEM J, V382, P619, DOI 10.1042/BJ20040139; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Straczkowski M, 2004, DIABETES, V53, P1215, DOI 10.2337/diabetes.53.5.1215; Summers SA, 2006, PROG LIPID RES, V45, P42, DOI 10.1016/j.plipres.2005.11.002; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Thamer C, 2003, J CLIN ENDOCR METAB, V88, P1785, DOI 10.1210/jc.2002-021674; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	36	107	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12583	12589		10.1074/jbc.M611157200	http://dx.doi.org/10.1074/jbc.M611157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337731	hybrid			2022-12-27	WOS:000245942800027
J	Winter, AD; Eschenlauer, SCP; McCormack, G; Page, AP				Winter, Alan D.; Eschenlauer, Sylvain C. P.; McCormack, Gillian; Page, Antony P.			Loss of secretory pathway FK506-binding proteins results in cold-sensitive lethality and associate extracellular matrix defects in the nematode Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASES; BINDING-PROTEIN; FKBP FAMILY; GENE; CYCLOPHILINS; PROCOLLAGEN; COLLAGEN; CLONING; MEMBER; FK506	The FK506-binding proteins (FKBs) represent ubiquitous enzymes that catalyze the rate-limiting peptidyl prolyl cis-trans isomerization step in protein folding. The nematode Caenorhabditis elegans has eight FKBs, three of which (FKB-3, -4, and -5) have dual peptidyl prolyl cis-trans isomerase (PPIase) domains, signal peptides and ER retention signals. PPIase activity has been detected for recombinant FKB-3. Both FKB-3 and -5 are expressed in the exoskeleton-synthesizing hypodermis with transcript peaks that correspond to the molting and collagen synthesis cycles. FKB-4 is expressed at a low level throughout development. No phenotypes were observed in deletion mutants in each of the secretory pathway FKBs. Combined triple and fkb-4, -5 double deletion mutants were however found to arrest at 12 degrees C, but developed normally at 15-25 degrees C. This cold sensitive larval lethal effect was not maternally derived, occurred during embryogenesis, and could be rescued following the transgenic introduction of a wild type copy of either fkb-4 or fkb-5. The temperature-sensitive defects also affected molting, cuticle collagen expression, hypodermal seam cell morphology, and the structural integrity of the cuticular extracellular matrix. This study establishes that the secretory pathway FK506-binding PPIase enzymes are essential for normal nematode development, collagen biogenesis, and the formation of an intact exoskeleton under adverse physiological conditions.	Univ Glasgow, Fac Vet Med, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland; Wellcome Ctr Mol Parasitol, Glasgow G12 8TA, Lanark, Scotland	University of Glasgow	Page, AP (corresponding author), Univ Glasgow, Fac Vet Med, Inst Comparat Med, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	a.page@vet.gla.ac.uk			MRC [G117/476] Funding Source: UKRI; Medical Research Council [G117/476] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BARSTEAD RJ, 1999, C ELEGANS PRACTICAL, P97; Bell A, 2006, INT J PARASITOL, V36, P261, DOI 10.1016/j.ijpara.2005.11.003; BIRD DM, 1989, MOL CELL BIOL, V9, P4119, DOI 10.1128/MCB.9.10.4119; BRENNER S, 1974, GENETICS, V77, P71; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; Hao LM, 2006, DEV BIOL, V290, P323, DOI 10.1016/j.ydbio.2005.11.028; Johnstone IL, 1996, EMBO J, V15, P3633, DOI 10.1002/j.1460-2075.1996.tb00732.x; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KRAMER JM, 1997, C ELEGANS, V2, P471; McMahon L, 2003, MOL BIOL CELL, V14, P1366, DOI 10.1091/mbc.E02-08-0479; Mello C, 1995, METHOD CELL BIOL, V48, P451; Page AP, 1996, BIOCHEM J, V317, P179, DOI 10.1042/bj3170179; Page AP, 2003, ADV PARASIT, V53, P85, DOI 10.1016/S0065-308X(03)53003-2; Patterson CE, 2000, MOL BIOL CELL, V11, P3925, DOI 10.1091/mbc.11.11.3925; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SMITH T, 1995, J BIOL CHEM, V270, P18323, DOI 10.1074/jbc.270.31.18323; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; Suzuki Y, 2004, EUR J BIOCHEM, V271, P1372, DOI 10.1111/j.1432-1033.2004.04049.x; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Yu H, 2001, J MOL BIOL, V314, P1017, DOI 10.1006/jmbi.2000.5210; Zeng BF, 1998, BIOCHEM J, V330, P109, DOI 10.1042/bj3300109	27	12	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12813	12821		10.1074/jbc.M700274200	http://dx.doi.org/10.1074/jbc.M700274200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17339317	hybrid, Green Accepted			2022-12-27	WOS:000245942800053
J	Sharon, M; Witt, S; Glasmacher, E; Baumeister, W; Robinson, CV				Sharon, Michal; Witt, Susanne; Glasmacher, Elke; Baumeister, Wolfgang; Robinson, Carol V.			Mass spectrometry reveals the missing links in the assembly pathway of the bacterial 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20S PROTEASOME BIOGENESIS; MACROMOLECULAR ASSEMBLIES; THERMOPLASMA-ACIDOPHILUM; RHODOCOCCUS PROTEASOME; 26S PROTEASOME; ACTIVE-SITES; DISSOCIATION; DEGRADATION; MATURATION; COMPLEX	The 20 S proteasome is an essential proteolytic particle, responsible for degrading short-lived and abnormal intracellular proteins. The 700-kDa assembly is comprised of 14 alpha-type and 14 beta-type subunits, which form a cylindrical architecture composed of four stacked heptameric rings (alpha(7)beta(7)beta(7)alpha(7)). The formation of the 20 S proteasome is a complex process that involves a cascade of folding, assembly, and processing events. To date, the understanding of the assembly pathway is incomplete due to the experimental challenges of capturing short-lived intermediates. In this study, we have applied a real-time mass spectrometry approach to capture transient species along the assembly pathway of the 20 S proteasome from Rhodococcus erythropolis. In the course of assembly, we observed formation of an early alpha/beta-heterodimer as well as an unprocessed half-proteasome particle. Formation of mature holoproteasomes occurred in concert with the disappearance of half-proteasomes. We also analyzed the beta-subunits before and during assembly and reveal that those with longer propeptides are incorporated into half- and full proteasomes more rapidly than those that are heavily truncated. To characterize the preholo-proteasome, formed by docking of two unprocessed half- proteasomes and not observed during assembly of wild type subunits, we trapped this intermediate using a beta-subunit mutational variant. In summary, this study provides evidence for transient intermediates in the assembly pathway and reveals detailed insight into the cleavage sites of the propeptide.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Max Planck Inst Biochem, Dept Mol Struct Biol, D-82152 Martinsried, Germany	University of Cambridge; Max Planck Society	Baumeister, W (corresponding author), GSF Inst Mol Immunol, Marchioninistr 25, D-81377 Munich, Germany.	baumeist@biochem.mpg.de; cvr24@cam.ac.uk	Glasmacher, Elke/B-8939-2015	Glasmacher, Elke/0000-0003-1265-2543; Sharon, Michal/0000-0003-3933-0595; robinson, carol/0000-0001-7829-5505				Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Benesch JL, 2006, CURR OPIN STRUC BIOL, V16, P245, DOI 10.1016/j.sbi.2006.03.009; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Chernushevich IV, 2004, ANAL CHEM, V76, P1754, DOI 10.1021/ac035406j; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; Fandrich M, 2000, P NATL ACAD SCI USA, V97, P14151, DOI 10.1073/pnas.240326597; Gerards WLH, 1998, CELL MOL LIFE SCI, V54, P253, DOI 10.1007/s000180050147; Groll M, 2003, J MOL BIOL, V327, P75, DOI 10.1016/S0022-2836(03)00080-9; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1994, EUR J BIOCHEM, V223, P1061, DOI 10.1111/j.1432-1033.1994.tb19084.x; Heinemeyer W, 2004, CELL MOL LIFE SCI, V61, P1562, DOI 10.1007/s00018-004-4130-z; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hernandez H, 2007, NAT PROTOC, V2, P715, DOI 10.1038/nprot.2007.73; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kruger E, 2001, BIOCHIMIE, V83, P289, DOI 10.1016/S0300-9084(01)01241-X; Kwon YD, 2004, J MOL BIOL, V335, P233, DOI 10.1016/j.jmb.2003.08.029; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Loo JA, 2005, J AM SOC MASS SPECTR, V16, P998, DOI 10.1016/j.jasms.2005.02.017; Maupin-Furlow JA, 1998, J BACTERIOL, V180, P1480, DOI 10.1128/JB.180.6.1480-1487.1998; Mayr U, 1998, J STRUCT BIOL, V124, P179, DOI 10.1006/jsbi.1998.4068; Nagy I, 1998, J BACTERIOL, V180, P5448, DOI 10.1128/JB.180.20.5448-5453.1998; Remaut H, 2006, MOL CELL, V22, P831, DOI 10.1016/j.molcel.2006.05.033; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 2001, ENZYMES, V22, P335; Sharon M, 2006, J BIOL CHEM, V281, P9569, DOI 10.1074/jbc.M511951200; Sobott F, 2003, INT J MASS SPECTROM, V230, P193, DOI 10.1016/j.ijms.2003.09.008; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7; van den Heuvel RH, 2004, CURR OPIN CHEM BIOL, V8, P519, DOI 10.1016/j.cbpa.2004.08.006; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wilson HL, 2000, J BACTERIOL, V182, P1680, DOI 10.1128/JB.182.6.1680-1692.2000; Witt S, 2006, STRUCTURE, V14, P1179, DOI 10.1016/j.str.2006.05.019; Zuhl F, 1997, FEBS LETT, V418, P189, DOI 10.1016/S0014-5793(97)01370-7; Zuhl F, 1997, FEBS LETT, V400, P83, DOI 10.1016/S0014-5793(96)01403-2; ZWICK LP, 1994, NAT STRUCT BIOL, V1, P765; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7	38	40	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18448	18457		10.1074/jbc.M701534200	http://dx.doi.org/10.1074/jbc.M701534200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17430901	hybrid			2022-12-27	WOS:000247302000051
J	Ditsworth, D; Zong, WX; Thompson, CB				Ditsworth, Dara; Zong, Wei-Xing; Thompson, Craig B.			Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY GROUP BOX-1; CHROMATIN PROTEIN HMGB1; GLYCATION END-PRODUCTS; ADP-RIBOSYLATION; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE-1; NEURITE OUTGROWTH; HUMAN TELOMERES; NECROTIC CELLS; INTACT-CELLS	Necrotic cells release inflammatory mediators that activate cytokine production from innate immune cells. One mediator of this activation is high mobility group box 1 protein (HMGB1). HMGB1 is normally a chromatin-associated protein and is sequestered at condensed chromatin during apoptosis. How it is released from chromatin during necrotic cell death is not known. Here we show that after DNA-alkylating damage, the activation of poly(ADP)-ribose polymerase (PARP) regulates the translocation of HMGB1 from the nucleus to the cytosol. This displaced HMGB1 is subject to release if the cell then loses plasma membrane integrity as a result of necrosis. Both full-length HMGB1 and a truncated form of HMGB1 lacking the highly conserved glutamate-rich C-terminal tail can induce macrophage activation and tumor necrosis factor-alpha production. However, displacement of HMGB1 from the nucleus following PARP activation requires the presence of the glutamate-rich C-terminal tail. Although the C-terminal tail is not the sole substrate for PARP modification of HMGB1, it appears to be required to destabilize HMGB1 association with chromatin following PARP-dependent chromatin modifications. These data suggest that PARP-dependent nuclear-to-cytosolic translocation of HMGB1 serves to establish the ability of cells to release this potent inflammatory mediator upon subsequent necrotic death.	Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Thompson, CB (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, 421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu			NATIONAL CANCER INSTITUTE [K01CA098092] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA098092, K01 CA098092-04, K01 CA098092-02, K01 CA098092-03, K01 CA098092-06, K01 CA098092-01A2, K01 CA098092-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTHAUS FR, 1992, J CELL SCI, V102, P663; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Bakondi E, 2002, J HISTOCHEM CYTOCHEM, V50, P91, DOI 10.1177/002215540205000110; Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje; BERGERON S, 2005, J BIOL CHEM; Bianchi ME, 2004, TRENDS CELL BIOL, V14, P287, DOI 10.1016/j.tcb.2004.04.004; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Bonaldi T, 2002, EMBO J, V21, P6865, DOI 10.1093/emboj/cdf692; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Dumitriu IE, 2005, J IMMUNOL, V174, P7506, DOI 10.4049/jimmunol.174.12.7506; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Knapp S, 2004, BIOCHEMISTRY-US, V43, P11992, DOI 10.1021/bi049364k; Li BM, 2004, J BIOL CHEM, V279, P13659, DOI 10.1074/jbc.M311606200; Li JH, 2004, J IMMUNOL METHODS, V289, P211, DOI 10.1016/j.jim.2004.04.019; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Muller S, 2001, BIOCHEMISTRY-US, V40, P10254, DOI 10.1021/bi0100900; OGATA N, 1980, J BIOL CHEM, V255, P7610; OGATA N, 1980, J BIOL CHEM, V255, P7616; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; POIRIER GG, 1982, EUR J BIOCHEM, V127, P437; Rovere-Querini P, 2004, EMBO REP, V5, P825, DOI 10.1038/sj.embor.7400205; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Skoberne M, 2004, TRENDS MOL MED, V10, P251, DOI 10.1016/j.molmed.2004.04.001; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; TANUMA S, 1983, J BIOL CHEM, V258, P4067; TANUMA SI, 1985, ARCH BIOCHEM BIOPHYS, V237, P38, DOI 10.1016/0003-9861(85)90251-6; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Thorslund T, 2005, MOL CELL BIOL, V25, P7625, DOI 10.1128/MCB.25.17.7625-7636.2005; Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yung TMC, 2004, J BIOL CHEM, V279, P39686, DOI 10.1074/jbc.M402729200; ZHANG J, 1993, BIOCHEMISTRY-US, V32, P2228, DOI 10.1021/bi00060a014; Zhang YB, 2005, CELL, V122, P693, DOI 10.1016/j.cell.2005.06.027; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	48	160	163	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17845	17854		10.1074/jbc.M701465200	http://dx.doi.org/10.1074/jbc.M701465200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430886	Green Accepted, hybrid			2022-12-27	WOS:000247084500058
J	Wallden, K; Stenmark, P; Nyman, T; Flodin, S; Graslund, S; Loppnau, P; Bianchi, V; Nordlund, P				Wallden, Karin; Stenmark, Pal; Nyman, Tomas; Flodin, Susanne; Graslund, Susanne; Loppnau, Peter; Bianchi, Vera; Nordlund, P.			Crystal structure of human cytosolic 5 '-nucleotidase II - Insights into allosteric regulation and substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTRANSFERASE ACTIVITY; 5-NUCLEOTIDASE; RESISTANCE; CLONING; ENZYME; IMP; PHOSPHORYLATION; OVEREXPRESSION; SPECIFICITY; EXPRESSION	Cytosolic 5'-nucleotidase II catalyzes the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates and regulates the IMP and GMP pools within the cell. It possesses phosphotransferase activity and thereby also catalyzes the reverse reaction. Both reactions are allosterically activated by adenine-based nucleotides and 2,3-bisphosphoglycerate. We have solved structures of cytosolic 5'-nucleotidase II as native protein (2.2 angstrom) and in complex with adenosine (1.5 angstrom) and beryllium trifluoride (2.15 angstrom). The tetrameric enzyme is structurally similar to enzymes of the haloacid dehalogenase (HAD) superfamily, including mitochondrial 5'(3')-deoxyribonucleotidase and cytosolic 5'-nucleotidase III but possesses additional regulatory regions that contain two allosteric effector sites. At effector site 1 located near a subunit interface we modeled diadenosine tetraphosphate with one adenosine moiety in each subunit. This efficiently glues the tetramer subunits together in pairs. The model shows why diadenosine tetraphosphate but not diadenosine triphosphate activates the enzyme and supports a role for cN-II during apoptosis when the level of diadenosine tetraphosphate increases. We have also modeled 2,3-bisphosphoglycerate in effector site 1 using one phosphate site from each subunit. By comparing the structure of cytosolic 5'-nucleotidase II with that of mitochondrial 5'(3')deoxyribonucleotidase in complex with dGMP, we identified residues involved in substrate recognition.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Struct Genom Consortium, S-17177 Stockholm, Sweden; Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada; Univ Padua, Dept Biol, I-35131 Padua, Italy; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; University of Toronto; Structural Genomics Consortium; University of Padua; Karolinska Institutet	Nordlund, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	Par.Nordlund@ki.se	Gräslund, Susanne/ABB-6339-2020	Wallden, Karin/0000-0002-7391-1003; Graslund, Susanne/0000-0003-0077-8333; Stenmark, Pal/0000-0003-4777-3417	Telethon [GGP05001] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Telethon(Fondazione Telethon); Wellcome Trust(Wellcome TrustEuropean Commission)		Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Allegrini S, 1997, BIOCHEM J, V328, P483, DOI 10.1042/bj3280483; Amici A, 1997, FEBS LETT, V419, P263, DOI 10.1016/S0014-5793(97)01464-6; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; Bitto E, 2006, J BIOL CHEM, V281, P20521, DOI 10.1074/jbc.M602000200; Bretonnet AS, 2005, FEBS LETT, V579, P3363, DOI 10.1016/j.febslet.2005.05.014; CARSON DA, 1991, BIOCHIM BIOPHYS ACTA, V1091, P22, DOI 10.1016/0167-4889(91)90216-K; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ericsson UB, 2006, ANAL BIOCHEM, V357, P289, DOI 10.1016/j.ab.2006.07.027; Galmarini CM, 2003, BRIT J HAEMATOL, V122, P53, DOI 10.1046/j.1365-2141.2003.04386.x; Garcia-Gil M, 2003, NEUROSCIENCE, V117, P811, DOI 10.1016/S0306-4522(02)00836-9; Himo F, 2005, J PHYS CHEM B, V109, P20004, DOI 10.1021/jp0546150; HOGLUND L, 1990, J BIOL CHEM, V265, P6589; Hunsucker SA, 2005, PHARMACOL THERAPEUT, V107, P1, DOI 10.1016/j.pharmthera.2005.01.003; ITOH R, 1967, BIOCHIM BIOPHYS ACTA, V146, P151, DOI 10.1016/0005-2744(67)90081-2; ITOH R, 1993, COMP BIOCHEM PHYS B, V105, P13, DOI 10.1016/0305-0491(93)90163-Y; JOHNSON MA, 1989, MOL PHARMACOL, V36, P291; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kisselev LL, 1998, FEBS LETT, V427, P157, DOI 10.1016/S0014-5793(98)00420-7; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESFEAMCB; Lotfi K, 2001, BRIT J HAEMATOL, V113, P339, DOI 10.1046/j.1365-2141.2001.02751.x; Marques AFP, 1998, J NEUROCHEM, V71, P1241; Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OKA J, 1994, BIOCHEM BIOPH RES CO, V205, P917, DOI 10.1006/bbrc.1994.2752; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pesi R, 1998, BIOL CHEM, V379, P699, DOI 10.1515/bchm.1998.379.6.699; PESI R, 1994, ARCH BIOCHEM BIOPHYS, V312, P75, DOI 10.1006/abbi.1994.1282; Pesi R, 2000, NEUROREPORT, V11, P1827, DOI 10.1097/00001756-200006260-00006; PINTO RM, 1986, BIOCHEM BIOPH RES CO, V138, P261, DOI 10.1016/0006-291X(86)90274-3; Rampazzo C, 2000, J BIOL CHEM, V275, P5409, DOI 10.1074/jbc.275.8.5409; Rampazzo C, 1999, EUR J BIOCHEM, V261, P689, DOI 10.1046/j.1432-1327.1999.00320.x; Randitelli S, 1996, INT J BIOCHEM CELL B, V28, P711, DOI 10.1016/1357-2725(95)00171-9; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Rinaldo-Matthis A, 2002, NAT STRUCT BIOL, V9, P779, DOI 10.1038/nsb846; Schirmer M, 1998, EXP HEMATOL, V26, P1223; Spychala J, 1999, EUR J BIOCHEM, V259, P851, DOI 10.1046/j.1432-1327.1999.00099.x; SPYCHALA J, 1988, J BIOL CHEM, V263, P18759; Suzuki NN, 2004, STRUCTURE, V12, P751, DOI 10.1016/j.str.2004.02.038; TOZZI MG, 1991, ARCH BIOCHEM BIOPHYS, V291, P212, DOI 10.1016/0003-9861(91)90125-3; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vartanian A, 1997, FEBS LETT, V415, P160, DOI 10.1016/S0014-5793(97)01086-7; Vartanian AA, 2003, BIOCHEM PHARMACOL, V65, P227, DOI 10.1016/S0006-2952(02)01481-8; Wallden K, 2005, STRUCTURE, V13, P1081, DOI 10.1016/j.str.2005.04.023; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; WORKU Y, 1982, BIOCHEM J, V205, P503, DOI 10.1042/bj2050503; Wu JZ, 2005, ANTIMICROB AGENTS CH, V49, P2164, DOI 10.1128/AAC.49.6.2164-2171.2005; Yamamoto S, 2007, INT J HEMATOL, V85, P108, DOI 10.1532/IJH97.06177	52	58	61	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17828	17836		10.1074/jbc.M700917200	http://dx.doi.org/10.1074/jbc.M700917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17405878	hybrid			2022-12-27	WOS:000247084500056
J	Charrier, L; Yan, YT; Nguyen, HTT; Dalmasso, G; Laboisse, CL; Gewirtz, AT; Sitaraman, SV; Merlin, D				Charrier, Laetitia; Yan, Yutao; Nguyen, Hang Thi Thu; Dalmasso, Guillaume; Laboisse, Christian L.; Gewirtz, Andrew T.; Sitaraman, Shanthi V.; Merlin, Didier			ADAM-15/metargidin mediates homotypic aggregation of human T lymphocytes and heterotypic interactions of T lymphocytes with intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; INFLAMMATORY-BOWEL-DISEASE; ADHESION MOLECULE-1 ICAM-1; CROHNS-DISEASE; CELIAC-DISEASE; E-CADHERIN; INTEGRIN ALPHA(E)BETA(7); GENE-EXPRESSION; N-CADHERIN; FAMILY	Intestinal epithelial cells (IEC) play an immunoregulatory role in the intestine. This role involves cell-cell interactions with intraepithelial lymphocytes that may also play a role in some enteropathies. The discovery of the RGD motif-containing protein ADAM-15 (a disintegrin and metalloprotease-15) raises the question of its involvement in these cell-cell interactions. Cell adhesion assays were performed using the Jurkat E6.1 T cell line as a model of T lymphocytes and Caco2-BBE monolayers as a model of intestinal epithelia. Our results show that an anti-ADAM- 15 ectodomain antibody inhibited the attachment of Jurkat cells on Caco2-BBE monolayers. Overexpression of ADAM-15 in Caco2-BBE cells enhanced Jurkat cell binding, and overexpression of ADAM-15 in Jurkat cells enhanced their aggregation. Mutagenesis experiments showed that both the mutation of ADAM-15 RGD domain or the deletion of its cytoplasmic tail decreased these cell-cell interactions. Moreover, wound-healing experiments showed that epithelial ADAM-15 mediated Jurkat cell adhesion to Caco2-BBE cells enhances the mechanisms of wound repair. We also found that ADAM-15 mediated aggregation of Jurkat cells increases the expression of tumor necrosis factor-alpha mRNA. These results demonstrate the following: 1) ADAM-15 is involved in heterotypic adhesion of intraepithelial lymphocytes to IEC as well as in homotypic aggregation of T cells; 2) both the RGD motif and the cytoplasmic tail of ADAM-15 are involved for these cell-cell interactions; and 3) ADAM-15-mediated cell-cell interactions are involved in mechanisms of epithelial restitution and production of pro-inflammatory mediators. Altogether these findings point to ADAM-15 as a possible therapeutic target for prevention of inappropriate T cell activation involved in some pathologies.	Emory Univ, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; INSERM, U539, F-44035 Nantes, France	Emory University; Emory University; Institut National de la Sante et de la Recherche Medicale (Inserm)	Charrier, L (corresponding author), Emory Univ, Dept Med, Div Digest Dis, 615 Michael st, Atlanta, GA 30322 USA.	lcharri@emory.edu	Dalmasso, Guillaume/N-2443-2018; Nguyen, Hang/N-2441-2018	Dalmasso, Guillaume/0000-0002-3433-870X; Nguyen, Hang/0000-0001-7431-5126	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055850, R01DK061417, R56DK061941, R01DK061941, R24DK064399] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK061417, DK55850, R24-DK064399, DK061941] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agace WW, 2000, CURR OPIN CELL BIOL, V12, P563, DOI 10.1016/S0955-0674(00)00132-0; BEAULIEU JF, 1992, J CELL SCI, V102, P427; Borley NR, 2000, J PATHOL, V190, P196; Brand S, 2006, AM J PHYSIOL-GASTR L, V290, pG827, DOI 10.1152/ajpgi.00513.2005; Buyse M, 2003, AM J PATHOL, V163, P1969, DOI 10.1016/S0002-9440(10)63555-9; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CEPEK KL, 1993, J IMMUNOL, V150, P3459; Charrier L, 2005, AM J PHYSIOL-GASTR L, V288, pG346, DOI 10.1152/ajpgi.00262.2004; Desloges N, 1998, J CELL BIOCHEM, V71, P536; Dignass AU, 1996, EXP CELL RES, V225, P422, DOI 10.1006/excr.1996.0193; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; FERGUSON A, 1976, ACTA PAEDIATR SCAND, V65, P541, DOI 10.1111/j.1651-2227.1976.tb04929.x; Fujimura Y, 1996, GUT, V38, P724, DOI 10.1136/gut.38.5.724; FUKUSHIMA K, 1991, GASTROENTEROLOGY, V101, P670, DOI 10.1016/0016-5085(91)90524-O; HALSTENSEN TS, 1989, SCAND J IMMUNOL, V30, P665, DOI 10.1111/j.1365-3083.1989.tb02474.x; HALSTENSEN TS, 1990, EUR J IMMUNOL, V20, P1825, DOI 10.1002/eji.1830200829; HASKARD D, 1986, J IMMUNOL, V137, P2901; Herren B, 2001, EXP CELL RES, V271, P152, DOI 10.1006/excr.2001.5353; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Higgins JMG, 2000, J BIOL CHEM, V275, P25652, DOI 10.1074/jbc.M001228200; Hogg N, 2003, J CELL SCI, V116, P4695, DOI 10.1242/jcs.00876; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; KAISERLIAN D, 1991, EUR J IMMUNOL, V21, P2415, DOI 10.1002/eji.1830211018; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; Kawamura-Kodama K, 1999, J INVEST DERMATOL, V112, P62, DOI 10.1046/j.1523-1747.1999.00479.x; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; LAZENBY AJ, 1989, HUM PATHOL, V20, P18, DOI 10.1016/0046-8177(89)90198-6; Liu X, 2003, J BIOL CHEM, V278, P23672, DOI 10.1074/jbc.M302777200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lussier C, 2000, MICROSC RES TECHNIQ, V51, P169; Makagiansar IT, 2002, MOL CELL BIOCHEM, V233, P1, DOI 10.1023/A:1015556625038; MAKI M, 1991, GUT, V32, P1412, DOI 10.1136/gut.32.11.1412; MENTZER SJ, 1986, J IMMUNOL, V137, P108; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Mosnier JF, 2006, LAB INVEST, V86, P1064, DOI 10.1038/labinvest.3700465; Naganuma M, 2002, AM J GASTROENTEROL, V97, P1741; Nath D, 1999, J CELL SCI, V112, P579; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; RICKERT RR, 1980, J CLIN GASTROENTEROL, V2, P11, DOI 10.1097/00004836-198003000-00003; ROBERTS K, 1993, EUR J IMMUNOL, V23, P1630, DOI 10.1002/eji.1830230735; ROSS IN, 1981, Q J MED, V50, P435; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; Sanders DSA, 2005, J CLIN PATHOL, V58, P568, DOI 10.1136/jcp.2004.021840; Sitaraman S, 2004, FASEB J, V18, P696, DOI 10.1096/fj.03-0422fje; SPENCER J, 1989, GUT, V30, P339, DOI 10.1136/gut.30.3.339; SPITS H, 1986, SCIENCE, V232, P403, DOI 10.1126/science.3485822; Taraszka KS, 2000, J EXP MED, V191, P1555, DOI 10.1084/jem.191.9.1555; VINAYAK VK, 1991, MICROB PATHOGENESIS, V10, P343, DOI 10.1016/0882-4010(91)90079-P; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wu E, 1997, BIOCHEM BIOPH RES CO, V235, P437, DOI 10.1006/bbrc.1997.6714; Yusuf-Makagiansar H, 2001, INFLAMMATION, V25, P203, DOI 10.1023/A:1011044616170; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	56	22	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16948	16958		10.1074/jbc.M700158200	http://dx.doi.org/10.1074/jbc.M700158200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17416588	hybrid			2022-12-27	WOS:000246946500028
J	Zhu, JW; Yu, D; Zeng, XC; Zhou, K; Zhan, X				Zhu, Jianwei; Yu, Dan; Zeng, Xian-Chun; Zhou, Kang; Zhan, Xi			Receptor-mediated endocytosis involves tyrosine phosphorylation of cortactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; COATED-PIT INVAGINATION; ACTIN POLYMERIZATION; IN-VITRO; CONSTITUTIVE INTERNALIZATION; DEPENDENT ENDOCYTOSIS; TRANSFERRIN RECEPTORS; SIGNALING PATHWAY; DYNAMIC ACTIN; CLATHRIN	Efficient internalization of cell surface receptors requires actin polymerization mediated by Arp2/3 complex and cortactin, a prominent substrate of the protein-tyrosine kinase Src. However, the significance of cortactin tyrosine phosphorylation in endocytosis is unknown. We found that overexpression of a cortactin mutant deficient in tyrosine phosphorylation decreased transferrin uptake. Suppression of cortactin expression by RNA interference also reduced transferrin internalization. Such inhibition was effectively rescued by overexpressing wild-type cortactin but not a cortactin mutant deficient in tyrosine phosphorylation or a mutant with deletion of the Src homology 3 domain. Likewise, purified phosphorylation-null cortactin failed to restore the formation of clathrin-coated vesicles in a cortactin-depleted cell extract. In vitro analysis revealed that Src-mediated phosphorylation enhanced the association of cortactin with dynamin-2 in a tyrosine phosphorylation-dependent manner. Quantitative analysis demonstrated that Src enhances the affinity of cortactin for dynamin-2 by more than 3-fold. On the other hand, Src-treated dynamin-2 had no effect on its interaction with cortactin. These data indicate that Src kinase is implicated in clathrin-mediated endocytosis by phosphorylation of cortactin.	Univ Maryland, Sch Med, Dept Pathol, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA; Nantong Univ, Affiliated Hosp, Nantong 226001, Peoples R China; Univ Maryland, Sch Med, Dept Pathol, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Penn State Univ, Biochem Microbiol & Mol Biol Program, University Pk, PA 16802 USA	University System of Maryland; University of Maryland Baltimore; Nantong University; University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Zhan, X (corresponding author), Univ Maryland, Sch Med, Dept Pathol, Ctr Vasc & Inflammatory Dis, 800 W Baltimore St, Baltimore, MD 21201 USA.	xzhan@som.umaryland.edu		Zeng, Xian-Chun/0000-0003-2675-2596	NATIONAL CANCER INSTITUTE [R01CA091984, R01CA113809] Funding Source: NIH RePORTER; NCI NIH HHS [CA091984, CA113809] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; AJIOKA RS, 1986, P NATL ACAD SCI USA, V83, P6445, DOI 10.1073/pnas.83.17.6445; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Broudy VC, 1999, BLOOD, V94, P1979; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; Chao C, 2005, J BIOL CHEM, V280, P33368, DOI 10.1074/jbc.M506337200; Cheng L, 1997, GENE THER, V4, P1013, DOI 10.1038/sj.gt.3300507; Conner SD, 2002, J CELL BIOL, V156, P921, DOI 10.1083/jcb.200108123; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; GEORGIEVAHANSON V, 1988, J NEUROCHEM, V50, P307, DOI 10.1111/j.1471-4159.1988.tb13265.x; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; He H, 1998, MOL CELL BIOL, V18, P3829, DOI 10.1128/MCB.18.7.3829; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; HOLEN I, 1995, BIOCHEM J, V311, P317, DOI 10.1042/bj3110317; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Huang ZY, 2006, J LEUKOCYTE BIOL, V80, P1553, DOI 10.1189/jlb.0106019; Ihara Y, 2002, BIOCHEM BIOPH RES CO, V297, P353, DOI 10.1016/S0006-291X(02)02195-2; Illes A, 2006, CELL SIGNAL, V18, P830, DOI 10.1016/j.cellsig.2005.07.012; Kaksonen M, 2000, J CELL SCI, V113, P4421; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Korolchuk V, 2003, BIOCHEM SOC T, V31, P857, DOI 10.1042/BST0310857; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Li YS, 2001, CANCER RES, V61, P6906; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; MAA MC, 1992, ONCOGENE, V7, P2429; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Merrifield CJ, 2005, CELL, V121, P593, DOI 10.1016/j.cell.2005.03.015; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Qualmann B, 2002, INT REV CYTOL, V220, P93; SALAMERO J, 1995, EUR J IMMUNOL, V25, P2757, DOI 10.1002/eji.1830251007; Sauvonnet N, 2005, J CELL BIOL, V168, P155, DOI 10.1083/jcb.200406174; Schmid RS, 2000, J NEUROSCI, V20, P4177; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; Tehrani S, 2006, MOL BIOL CELL, V17, P2882, DOI 10.1091/mbc.E06-03-0187; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Webb BA, 2007, EUR J CELL BIOL, V86, P189, DOI 10.1016/j.ejcb.2007.01.003; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zhu JW, 2005, J CELL SCI, V118, P807, DOI 10.1242/jcs.01668	57	41	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16086	16094		10.1074/jbc.M701997200	http://dx.doi.org/10.1074/jbc.M701997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17420251	hybrid			2022-12-27	WOS:000246794300017
J	Nojima, T; Hirose, T; Kimura, H; Hagiwara, M				Nojima, Takayuki; Hirose, Tetsuro; Kimura, Hiroshi; Hagiwara, Masatoshi			The interaction between cap-binding complex and RNA export factor is required for intronless mRNA export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXON JUNCTION COMPLEX; NONSENSE-MEDIATED DECAY; GENOME-WIDE ANALYSIS; NUCLEAR EXPORT; POLYMERASE-II; BIOCHEMICAL-ANALYSIS; TREX COMPLEX; THO COMPLEX; IN-VIVO; PROTEIN	RNA export factor (REF) is a component of the exon junction complex (EJC) that is deposited onmRNAin a splicing- dependent manner, and targets spliced mRNA for export. In this study, analysis of the RNA- binding protein complexes revealed thatREFassociates with beta-globin mRNAat the region other than the EJC deposition site. Comparison between RNA polymerase II and T7 transcription and further analysis showed that the deposition of REF apart from the EJC is dependent on the 5' cap structure, but not splicing. Excess amounts of m(7)GpppG cap analog reduced REF binding to intronless mRNA, and a co- immunoprecipitation experiment revealed that REF interacts with the cap- binding protein CBP20. The export of Cy3-labeled intronless beta- globinmRNA from nuclei of HeLa cells was enhanced by co-injection of CBP20 and REF. Thus, REF recruited by CBP20 may play a stimulatory role to export the capped intronless mRNAs.	Tokyo Med & Dent Univ, Gene Express Lab, Sch Biomed Sci, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Dept Funct Genom, Inst Med Res, Bunkyo Ku, Tokyo 1138510, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama, Japan; Kyoto Univ, Grad Sch Med, HMRO, Nucl Funct & Dynam Unit,Sakyo Ku, Kyoto 6068501, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); Kyoto University	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Gene Express Lab, Sch Biomed Sci, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138510, Japan.	m.hagiwara.end@mri.tmd.ac.jp	Hirose, Tetsuro/P-7367-2018; Kimura, Hiroshi/B-9524-2015	Hirose, Tetsuro/0000-0003-1068-5464; Kimura, Hiroshi/0000-0003-0854-083X; Nojima, Takayuki/0000-0003-1236-4162				Abruzzi KC, 2004, EMBO J, V23, P2620, DOI 10.1038/sj.emboj.7600261; Chan CC, 2004, RNA, V10, P200, DOI 10.1261/rna.5230104; Chavez S, 2001, MOL CELL BIOL, V21, P7054, DOI 10.1128/MCB.21.20.7054-7064.2001; Chen IHB, 2002, J VIROL, V76, P12877, DOI 10.1128/JVI.76.24.12877-12889.2002; Cheng H, 2006, CELL, V127, P1389, DOI 10.1016/j.cell.2006.10.044; Chiu YL, 2002, MOL CELL, V10, P585, DOI 10.1016/S1097-2765(02)00630-5; Custodio N, 2004, RNA, V10, P622, DOI 10.1261/rna.5258504; Das R, 2006, GENE DEV, V20, P1100, DOI 10.1101/gad.1397406; Degot S, 2004, J BIOL CHEM, V279, P33702, DOI 10.1074/jbc.M402754200; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Gornemann J, 2005, MOL CELL, V19, P53, DOI 10.1016/j.molcel.2005.05.007; Herold A, 2003, EMBO J, V22, P2472, DOI 10.1093/emboj/cdg233; Hirose T, 2004, P NATL ACAD SCI USA, V101, P17976, DOI 10.1073/pnas.0408435102; Hirose Y, 2000, GENE DEV, V14, P1415; Howe KJ, 2002, BBA-GENE STRUCT EXPR, V1577, P308, DOI 10.1016/S0167-4781(02)00460-8; Huang YQ, 1999, EMBO J, V18, P1642, DOI 10.1093/emboj/18.6.1642; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Jimeno S, 2002, EMBO J, V21, P3526, DOI 10.1093/emboj/cdf335; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Koffa MD, 2001, EMBO J, V20, P5769, DOI 10.1093/emboj/20.20.5769; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO REP, V2, P1119, DOI 10.1093/embo-reports/kve245; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Li C, 2003, MOL CELL BIOL, V23, P7363, DOI 10.1128/MCB.23.20.7363-7376.2003; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205; Masuyama K, 2004, GENE DEV, V18, P2074, DOI 10.1101/gad.1216204; Moteki S, 2002, MOL CELL, V10, P599, DOI 10.1016/S1097-2765(02)00660-3; Neugebauer KM, 2002, J CELL SCI, V115, P3865, DOI 10.1242/jcs.00073; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Ohno M, 2002, MOL CELL, V9, P659, DOI 10.1016/S1097-2765(02)00454-9; Palacios IM, 2004, NATURE, V427, P753, DOI 10.1038/nature02351; Rehwinkel J, 2004, NAT STRUCT MOL BIOL, V11, P558, DOI 10.1038/nsmb759; Reichert VL, 2002, GENE DEV, V16, P2778, DOI 10.1101/gad.1030602; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Sakashita E, 2004, MOL CELL BIOL, V24, P1174, DOI 10.1128/MCB.24.3.1174-1187.2004; Shibuya T, 2004, NAT STRUCT MOL BIOL, V11, P346, DOI 10.1038/nsmb750; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; Tange TO, 2005, RNA, V11, P1869, DOI 10.1261/rna.2155905; Tokunaga K, 2006, GENES CELLS, V11, P305, DOI 10.1111/j.1365-2443.2006.00936.x; Wang ZY, 1997, P NATL ACAD SCI USA, V94, P6688, DOI 10.1073/pnas.94.13.6688; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	58	75	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15645	15651		10.1074/jbc.M700629200	http://dx.doi.org/10.1074/jbc.M700629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17363367	hybrid			2022-12-27	WOS:000246589600041
J	Rennefahrt, UEE; Deacon, SW; Parker, SA; Devarajan, K; Beeser, A; Chernoff, J; Knapp, S; Turk, BE; Peterson, JR				Rennefahrt, Ulrike E. E.; Deacon, Sean W.; Parker, Sirlester A.; Devarajan, Karthik; Beeser, Alexander; Chernoff, Jonathan; Knapp, Stefan; Turk, Benjamin E.; Peterson, Jeffrey R.			Specificity profiling of Pak kinases allows identification of novel phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; DEPENDENT PROTEIN-KINASE; TUMOR-SUPPRESSOR GENE; P21-ACTIVATED KINASES; SERINE/THREONINE KINASE; PEPTIDE SPECIFICITY; WIDE PREDICTION; BETA-PIX; ACTIVATION; PATHWAY	The p21-activated kinases (Paks) serve as effectors of the Rho family GTPases Rac and Cdc42. The six human Paks are divided into two groups based on sequence similarity. Group I Paks (Pak1 to -3) phosphorylate a number of substrates linking this group to regulation of the cytoskeleton and both proliferative and anti-apoptotic signaling. Group II Paks (Pak4 to -6) are thought to play distinct functional roles, yet their few known substrates are also targeted by Group I Paks. To determine if the two groups recognize distinct target sequences, we used a degenerate peptide library method to comprehensively characterize the consensus phosphorylation motifs of Group I and II Paks. Wefind that Pak1 and Pak2 exhibit virtually identical substrate specificity that is distinct from that of Pak4. Based on structural comparisons and mutagenesis, we identified two key amino acid residues that mediate the distinct specificities of Group I and II Paks and suggest a structural basis for these differences. These results implicate, for the first time, residues from the small lobe of a kinase in substrate selectivity. Finally, we utilized the Pak1 consensus motif to predict a novel Pak1 phosphorylation site in Pix (Pak-interactive exchange factor) and demonstrate that Pak1 phosphorylates this site both in vitro and in cultured cells. Collectively, these results elucidate the specificity of Pak kinases and illustrate a general method for the identification of novel sites phosphorylated by Paks.	Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Oxford, Ctr Struct Genom, Botnar Res Ctr, Oxford OX3 7LD, England	Fox Chase Cancer Center; Yale University; University of Oxford	Peterson, JR (corresponding author), Fox Chase Canc Ctr, Div Basic Sci, 333 Cottman Ave, Philadelphia, PA 19111 USA.	jeffrey.Peterson@fccc.edu	Knapp, Stefan/AAG-2347-2019; Chernoff, Jonathan/I-7631-2014	Knapp, Stefan/0000-0001-5995-6494; Chernoff, Jonathan/0000-0002-4803-7836; Peterson, Jeffrey/0000-0002-0604-718X	NATIONAL CANCER INSTITUTE [P30CA006927, T32CA009035] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009035, CA006927] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Ballif BA, 2004, MOL CELL PROTEOMICS, V3, P1093, DOI 10.1074/mcp.M400085-MCP200; Beeser A, 2005, J BIOL CHEM, V280, P36609, DOI 10.1074/jbc.M502306200; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Budovskaya YV, 2005, P NATL ACAD SCI USA, V102, P13933, DOI 10.1073/pnas.0501046102; Bullock AN, 2005, J BIOL CHEM, V280, P41675, DOI 10.1074/jbc.M510711200; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; Cammarano MS, 2005, MOL CELL BIOL, V25, P9532, DOI 10.1128/MCB.25.21.9532-9542.2005; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Eswaran J, 2007, STRUCTURE, V15, P201, DOI 10.1016/j.str.2007.01.001; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fu Z, 2005, MOL CELL BIOL, V25, P6047, DOI 10.1128/MCB.25.14.6047-6064.2005; Fujii K, 2004, P NATL ACAD SCI USA, V101, P13744, DOI 10.1073/pnas.0401881101; Gnesutta N, 2003, MOL CELL BIOL, V23, P7838, DOI 10.1128/MCB.23.21.7838-7848.2003; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Gringel A, 2006, J CELL PHYSIOL, V209, P568, DOI 10.1002/jcp.20777; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Hutti JE, 2004, NAT METHODS, V1, P27, DOI 10.1038/NMETH708; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; Kang CM, 2005, GENE DEV, V19, P1692, DOI 10.1101/gad.1311105; Kaur R, 2005, J BIOL CHEM, V280, P3323, DOI 10.1074/jbc.M406701200; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lei M, 2005, STRUCTURE, V13, P769, DOI 10.1016/j.str.2005.03.007; Li XF, 2005, J BIOL CHEM, V280, P41192, DOI 10.1074/jbc.M506884200; Lu YB, 2003, J BIOL CHEM, V278, P10374, DOI 10.1074/jbc.M205875200; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Peterson JR, 2001, P NATL ACAD SCI USA, V98, P10624, DOI 10.1073/pnas.201393198; Pirruccello M, 2006, J MOL BIOL, V361, P312, DOI 10.1016/j.jmb.2006.06.017; Qu J, 2003, MOL CELL BIOL, V23, P7122, DOI 10.1128/MCB.23.20.7122-7133.2003; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; ten Klooster JP, 2006, J CELL BIOL, V172, P759, DOI 10.1083/jcb.200509096; TRAFNY EAM, 1994, PROTEIN SCI, V3, P176; Tuazon PT, 1997, BIOCHEMISTRY-US, V36, P16059, DOI 10.1021/bi9717845; Turk BE, 2006, NAT PROTOC, V1, P375, DOI 10.1038/nprot.2006.57; Wang RA, 2006, ONCOGENE, V25, P2931, DOI 10.1038/sj.onc.1209309; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zenke FT, 2004, J BIOL CHEM, V279, P18392, DOI 10.1074/jbc.M400084200; Zheng HY, 2005, MOL CELL PROTEOMICS, V4, P721, DOI 10.1074/mcp.M400077-MCP200; Zhu GZ, 2005, J BIOL CHEM, V280, P36372, DOI 10.1074/jbc.M505031200; Zhu GZ, 2005, J BIOL CHEM, V280, P10743, DOI 10.1074/jbc.M413159200; Zhu GZ, 2005, CELL CYCLE, V4, P52, DOI 10.4161/cc.4.1.1353	60	101	102	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15667	15678		10.1074/jbc.M700253200	http://dx.doi.org/10.1074/jbc.M700253200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17392278	hybrid			2022-12-27	WOS:000246589600043
J	Samson, T; Will, C; Knoblauch, A; Sharek, L; von der Mark, K; Burridge, K; Wixler, V				Samson, Thomas; Will, Carola; Knoblauch, Alexander; Sharek, Lisa; von der Mark, Klaus; Burridge, Keith; Wixler, Viktor			Def-6, a guanine nucleotide exchange factor for Rac1, interacts with the skeletal muscle integrin chain alpha 7A and influences myoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-7-BETA-1 INTEGRIN; CELL-ADHESION; BINDING-PROTEIN; RHO-GTPASES; EXPRESSION PATTERNS; CYTOPLASMIC DOMAINS; MUSCULAR-DYSTROPHY; LAMININ; RECEPTOR; MIGRATION	Integrin alpha 7 beta 1 is the major laminin binding integrin receptor of muscle cells. The alpha 7 chain occurs in several splice isoforms, of which alpha 7A and alpha 7B differ in their intracellular domains only. The fact that the expression of alpha 7A and alpha 7B is tightly regulated during skeletal muscle development suggests different and distinct roles for both isoforms. However, so far, functional properties and interacting proteins were described for the alpha 7B chain only. Using a yeast two-hybrid screen, we have found that Def-6, a guanine nucleotide exchange factor for Rac1, binds to the intracellular domain of the alpha 7A subunit. The specificity of the Def-6-alpha 7A interaction has been shown by direct yeast two-hybrid binding assays and coprecipitation experiments. This is the first description of an alpha 7A-specific and -exclusive interaction, because Def-6 did not bind to any other tested integrin cytoplasmic domain. Interestingly, the binding of Def-6 to alpha 7A was abolished, when cells were cotransfected with an Src-related kinase, which is known to phosphorylate Def-6 and stimulate its exchange activity. We found expression of Def-6 was not only restricted to T-lymphocytes as described thus far but in a more widespread manner, including different muscle tissues. In cells, Def-6 is seen in newly forming cell protrusions and focal adhesions, and its localization partially overlaps with the alpha 7A integrin receptor. C2C12 myoblasts overexpressing Def-6 show a delay of Rac1 inactivation during myogenic differentiation and abnormal myotube formation. Thus, our data suggest a role for Def-6 in the fine regulation of Rac1 during myogenesis with the integrin alpha 7A chain guiding this regulation in a spatio-temporal manner.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ Klinikum Munster, Inst Mol Virol, Zentrum Mol Biol Entzundung, D-48149 Munster, Germany; Univ Erlangen Nurnberg, Nikolaus Fiebiger Zentrum, D-91054 Erlangen, Germany	University of North Carolina; University of North Carolina Chapel Hill; University of Munster; University of Erlangen Nuremberg	Samson, T (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, CB 7295, Chapel Hill, NC 27599 USA.	thomas_samson@med.unc.edu	von+der+Mark, Klaus/AAJ-1443-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Borggrefe T, 1999, EUR J IMMUNOL, V29, P1812, DOI 10.1002/(SICI)1521-4141(199906)29:06<1812::AID-IMMU1812>3.0.CO;2-J; Borggrefe T, 2001, EUR J IMMUNOL, V31, P2467, DOI 10.1002/1521-4141(200108)31:8<2467::AID-IMMU2467>3.0.CO;2-P; Bryan BA, 2005, MOL CELL BIOL, V25, P11089, DOI 10.1128/MCB.25.24.11089-11101.2005; Bryan BA, 2005, CELL MOL LIFE SCI, V62, P1547, DOI 10.1007/s00018-005-5029-z; Burkin DJ, 1999, CELL TISSUE RES, V296, P183, DOI 10.1007/s004410051279; Burkin DJ, 1998, J CELL BIOL, V143, P1067, DOI 10.1083/jcb.143.4.1067; Chen EH, 2003, CELL, V114, P751, DOI 10.1016/S0092-8674(03)00720-7; Coghill ID, 2003, J BIOL CHEM, V278, P24139, DOI 10.1074/jbc.M213259200; COLLO G, 1993, J BIOL CHEM, V268, P19019; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fanzo JC, 2006, J CLIN INVEST, V116, P703, DOI 10.1172/JCI24096; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Ginsberg MH, 2005, CURR OPIN CELL BIOL, V17, P509, DOI 10.1016/j.ceb.2005.08.010; Gross B, 2002, EUR J IMMUNOL, V32, P1121; Gupta S, 2003, J BIOL CHEM, V278, P43541, DOI 10.1074/jbc.M308960200; Gupta S, 2003, HUM IMMUNOL, V64, P389, DOI 10.1016/S0198-8859(03)00024-7; Heller H, 2001, J BIOL CHEM, V276, P37307, DOI 10.1074/jbc.M103195200; Hotfilder M, 1999, BRIT J HAEMATOL, V106, P335, DOI 10.1046/j.1365-2141.1999.01551.x; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JULLIEN P, 1994, EUR J BIOCHEM, V224, P589, DOI 10.1111/j.1432-1033.1994.00589.x; Kaariainen M, 2002, AM J PATHOL, V161, P1023, DOI 10.1016/S0002-9440(10)64263-0; Kaartinen V, 2001, DEVELOPMENT, V128, P4217; Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646; Li J, 2003, DEV BIOL, V261, P209, DOI 10.1016/S0012-1606(03)00304-X; Markowitz D G, 1988, Trans Assoc Am Physicians, V101, P212; Mavrakis KJ, 2004, EXP CELL RES, V294, P335, DOI 10.1016/j.yexcr.2003.12.004; Mayer U, 2003, J BIOL CHEM, V278, P14587, DOI 10.1074/jbc.R200022200; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; Mielenz D, 2001, J BIOL CHEM, V276, P13417, DOI 10.1074/jbc.M011481200; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nawrotzki R, 2003, HUM MOL GENET, V12, P483, DOI 10.1093/hmg/ddg047; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rosoff WJ, 2002, J CELL PHYSIOL, V193, P328, DOI 10.1002/jcp.10182; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Samson T, 2004, J BIOL CHEM, V279, P28641, DOI 10.1074/jbc.M312894200; Schober S, 2000, EXP CELL RES, V255, P303, DOI 10.1006/excr.2000.4806; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; SONG WK, 1993, J CELL SCI, V106, P1139; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Tanaka Y, 2003, IMMUNITY, V18, P403, DOI 10.1016/S1074-7613(03)00054-2; Taylor MV, 2002, CURR BIOL, V12, pR224, DOI 10.1016/S0960-9822(02)00757-1; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Velling T, 1996, DEV DYNAM, V207, P355, DOI 10.1002/(SICI)1097-0177(199612)207:4<355::AID-AJA1>3.0.CO;2-G; Vignier N, 1999, BIOCHEM BIOPH RES CO, V260, P357, DOI 10.1006/bbrc.1999.0916; von der Mark H, 2002, J BIOL CHEM, V277, P6012, DOI 10.1074/jbc.M102188200; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; Weston C, 2000, J CELL BIOL, V150, P205, DOI 10.1083/jcb.150.1.205; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; Yao CC, 1996, J BIOL CHEM, V271, P25598, DOI 10.1074/jbc.271.41.25598; Ziober BL, 1997, MOL BIOL CELL, V8, P1723, DOI 10.1091/mbc.8.9.1723; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773	63	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15730	15742		10.1074/jbc.M611197200	http://dx.doi.org/10.1074/jbc.M611197200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403664	hybrid, Green Published			2022-12-27	WOS:000246589600049
J	Capul, AA; Barron, T; Dobson, DE; Turco, SJ; Beverley, SM				Capul, Althea A.; Barron, Tamara; Dobson, Deborah E.; Turco, Salvatore J.; Beverley, Stephen M.			Two functionally divergent UDP-Gal nucleotide sugar transporters participate in phosphoglycan synthesis in Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE TRANSPORTER; SIALIC ACID TRANSPORTER; SAND FLY INTERACTIONS; PROTOZOAN PARASITE LEISHMANIA; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; DONOVANI LIPOPHOSPHOGLYCAN; SACCHAROMYCES-CEREVISIAE; GALACTOSE TRANSPORTER; TRYPANOSOMA-BRUCEI	In the protozoan parasite Leishmania, abundant surface and secreted molecules, such as lipophosphoglycan (LPG) and proteophosphoglycans (PPGs), contain extensive galactose in the form of phosphoglycans (PGs) based on (Gal-Man-PO4) repeating units. PGs are synthesized in the parasite Golgi apparatus and require transport of cytoplasmic nucleotide sugar precursors to the Golgi lumen by nucleotide sugar transporters (NSTs). GDP-Man transport is mediated by the LPG2 gene product, and here we focused on transporters for UDP-Gal. Data base mining revealed 12 candidate NST genes in the L. major genome, including LPG2 as well as a candidate endoplasmic reticulum UDP-glucose transporter (HUT1L) and several pseudogenes. Gene knock-out studies established that two genes (LPG5A and LPG5B) encoded UDP-Gal NSTs. Although the single lpg5A(-) and lpg5B(-) mutants produced PGs, an lpg5A(-)/5B(-) double mutant was completely deficient. PG synthesis was restored in the lpg5A(-)/5B(-) mutant by heterologous expression of the human UDP-Gal transporter, and heterologous expression of LPG5A and LPG5B rescued the glycosylation defects of the mammalian Lec8 mutant, which is deficient in UDP-Gal uptake. Interestingly, the LPG5A and LPG5B functions overlap but are not equivalent, since the lpg5A(-) mutant showed a partial defect in LPG but not PPG phosphoglycosylation, whereas the lpg5B(-) mutant showed a partial defect in PPG but not LPG phosphoglycosylation. Identification of these key NSTs in Leishmania will facilitate the dissection of glycoconjugate synthesis and its role(s) in the parasite life cycle and further our understanding of NSTs generally.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA	Washington University (WUSTL); University of Kentucky	Beverley, SM (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave,Box 8230, St Louis, MO 63110 USA.	beverley@borcim.wustl.edu		Beverley, Stephen/0000-0001-5319-0811	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031078] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI031078-15, R01 AI031078, AI31078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Barron TL, 2006, BBA-GEN SUBJECTS, V1760, P710, DOI 10.1016/j.bbagen.2005.10.007; BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Beverley SM, 2005, EUKARYOT CELL, V4, P1147, DOI 10.1128/EC.4.6.1147-1154.2005; Beverley SM, 2003, NAT REV GENET, V4, P11, DOI 10.1038/nrg980; BEVERLEY SM, 1987, P NATL ACAD SCI USA, V84, P484, DOI 10.1073/pnas.84.2.484; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ AK, 1993, P NATL ACAD SCI USA, V90, P1599, DOI 10.1073/pnas.90.4.1599; D'Alessio C, 2003, J BIOL CHEM, V278, P22379, DOI 10.1074/jbc.M300892200; DEIBARRA AAL, 1982, PARASITOLOGY, V85, P523, DOI 10.1017/S0031182000056304; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; Dobson DE, 2003, J BIOL CHEM, V278, P28840, DOI 10.1074/jbc.M302728200; Dobson DE, 2003, J BIOL CHEM, V278, P15523, DOI 10.1074/jbc.M301568200; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; GOTTLIEB M, 1982, MOL CELL BIOL, V2, P76, DOI 10.1128/MCB.2.1.76; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Handford M, 2006, BRAZ J MED BIOL RES, V39, P1149, DOI 10.1590/S0100-879X2006000900002; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Ilg T, 2000, PARASITOL TODAY, V16, P489, DOI 10.1016/S0169-4758(00)01791-9; Ilg T, 2001, J BIOL CHEM, V276, P4988, DOI 10.1074/jbc.M008030200; Ishida N, 1999, J BIOCHEM, V126, P68, DOI 10.1093/oxfordjournals.jbchem.a022437; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Ivens AC, 1998, GENOME RES, V8, P135, DOI 10.1101/gr.8.2.135; Kabuss R, 2005, GLYCOBIOLOGY, V15, P905, DOI 10.1093/glycob/cwi085; Kainuma M, 2001, YEAST, V18, P533, DOI 10.1002/yea.708; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; Kawakita M, 1998, J BIOCHEM, V123, P777; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Mahoney AB, 1999, BIOCHEMISTRY-US, V38, P9813, DOI 10.1021/bi990741g; Martinez-Duncker I, 2003, BIOCHIMIE, V85, P245, DOI 10.1016/S0300-9084(03)00046-4; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; Montgomery J, 2002, MOL BIOCHEM PARASIT, V121, P75, DOI 10.1016/S0166-6851(02)00024-5; Naderer T, 2004, CURR MOL MED, V4, P649, DOI 10.2174/1566524043360069; Nakanishi H, 2001, YEAST, V18, P543, DOI 10.1002/yea.707; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; Parodi AJ, 1998, BRAZ J MED BIOL RES, V31, P601, DOI 10.1590/S0100-879X1998000500002; Peters C, 1997, EUR J IMMUNOL, V27, P2666, DOI 10.1002/eji.1830271028; Piani A, 1999, MICROBES INFECT, V1, P589, DOI 10.1016/S1286-4579(99)80058-6; Puthenveedu MA, 2005, CURR OPIN CELL BIOL, V17, P369, DOI 10.1016/j.ceb.2005.06.006; Reyes F, 2006, J BIOL CHEM, V281, P9145, DOI 10.1074/jbc.M512210200; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; Rogers ME, 2004, NATURE, V430, P463, DOI 10.1038/nature02675; Roper JR, 2005, J BIOL CHEM, V280, P19728, DOI 10.1074/jbc.M502370200; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; Sacks DL, 2001, CELL MICROBIOL, V3, P189, DOI 10.1046/j.1462-5822.2001.00115.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shakarian AM, 2000, EXP PARASITOL, V95, P79, DOI 10.1006/expr.2000.4511; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Spath GF, 2003, SCIENCE, V301, P1241, DOI 10.1126/science.1087499; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; Sprong H, 2003, MOL BIOL CELL, V14, DOI 10.1091/mbc.E03-03-0130; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; TOLSON DL, 1989, MOL BIOCHEM PARASIT, V35, P109, DOI 10.1016/0166-6851(89)90113-8; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; Wallace IM, 2006, NUCLEIC ACIDS RES, V34, P1692, DOI 10.1093/nar/gkl091; WANG WC, 1988, J BIOL CHEM, V263, P4576; Wiese M, 1998, EMBO J, V17, P2619, DOI 10.1093/emboj/17.9.2619; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; Zhao W, 2006, J BIOL CHEM, V281, P31106, DOI 10.1074/jbc.M605564200	72	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14006	14017		10.1074/jbc.M610869200	http://dx.doi.org/10.1074/jbc.M610869200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17347153	Green Accepted, hybrid			2022-12-27	WOS:000246245800010
J	Gloyd, M; Ghirlando, R; Matthews, LA; Guarne, A				Gloyd, Melanie; Ghirlando, Rodolfo; Matthews, Lindsay A.; Guarne, Alba			MukE and MukF form two distinct high affinity complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA INTERACTIONS; SMC PROTEINS; BACTERIAL; KLEISINS; HINGE; ULTRACENTRIFUGATION; ARCHITECTURE; CHROMOSOMES; ACTIVATION	The MukBFE complex is essential for chromosome segregation and condensation in Escherichia coli. MukB is functionally related to the structural maintenance of chromosomes (SMC) proteins. Similar to SMCs, MukB requires accessory proteins (MukE and MukF) to form a functional complex for DNA segregation. MukF is a member of the kleisin family, which includes proteins that commonly mediate the interaction between SMCs and other accessory proteins, suggesting that the similarities between the MukBFE and the SMC complexes extend beyond MukB. Although SMCs have been carefully studied, little is known about the roles of their accessory components. In the present work, we characterize the oligomeric states of MukE and MukF using size exclusion chromatography and analytical ultracentrifugation. MukE self-associates to form dimers (K-D 18 +/- 3 mu M), which in turn interact with the MukF dimer to form two distinct high affinity complexes having 2: 2 and 2: 4 stoichiometries (F: E). Intermediate complexes are not found, and thus we propose that the equilibrium between these two complexes determines the formation of a functional MukBFE with stoichiometry 2:2:2.	McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	McMaster University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Guarne, A (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, HSC 4N57A,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	guarnea@mcmaster.ca	Ghirlando, Rodolfo/A-8880-2009		Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK033007, ZIADK033007] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi S, 2003, J BACTERIOL, V185, P3690, DOI 10.1128/JB.185.13.3690-3695.2003; Dervyn E, 2004, MOL MICROBIOL, V51, P1629, DOI 10.1111/j.1365-2958.2003.03951.x; Fennell-Fezzie R, 2005, EMBO J, V24, P1921, DOI 10.1038/sj.emboj.7600680; Haering CH, 2004, MOL CELL, V15, P951, DOI 10.1016/j.molcel.2004.08.030; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hirano M, 2006, MOL CELL, V21, P175, DOI 10.1016/j.molcel.2005.11.026; Hirano M, 2004, EMBO J, V23, P2664, DOI 10.1038/sj.emboj.7600264; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano T, 2005, CURR BIOL, V15, pR265, DOI 10.1016/j.cub.2005.03.037; Hopfner KP, 2003, CURR OPIN STRUC BIOL, V13, P249, DOI 10.1016/S0959-440X(03)00037-X; Kim JS, 2006, PROTEINS, V62, P322, DOI 10.1002/prot.20751; Lehmann AR, 2005, DNA REPAIR, V4, P309, DOI 10.1016/j.dnarep.2004.07.009; Matoba K, 2005, BIOCHEM BIOPH RES CO, V333, P694, DOI 10.1016/j.bbrc.2005.05.163; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; Petrushenko ZM, 2006, J BIOL CHEM, V281, P34208, DOI 10.1074/jbc.M606723200; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Tao WT, 2000, MOL MICROBIOL, V38, P392, DOI 10.1046/j.1365-2958.2000.02138.x; Volkov A, 2003, MOL CELL BIOL, V23, P5638, DOI 10.1128/MCB.23.16.5638-5650.2003; Wang Q, 2006, J BACTERIOL, V188, P4431, DOI 10.1128/JB.00313-06; Yamanaka K, 1996, MOL GEN GENET, V250, P241; Yamazoe M, 1999, EMBO J, V18, P5873, DOI 10.1093/emboj/18.21.5873	26	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14373	14378		10.1074/jbc.M701402200	http://dx.doi.org/10.1074/jbc.M701402200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355972	hybrid			2022-12-27	WOS:000246245800049
J	Martens, LK; Kirschner, KM; Warnecke, C; Scholz, H				Martens, Lina K.; Kirschner, Karin M.; Warnecke, Christina; Scholz, Holger			Hypoxia-inducible factor-1 (HIF-1) is a transcriptional activator of the TrkB neurotrophin receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; TYROSINE PROTEIN-KINASE; WILMS-TUMOR SUPPRESSOR; AFFINITY NGF RECEPTOR; NERVE GROWTH-FACTOR; FACTOR (HIF)-1-ALPHA; ERYTHROPOIETIN GENE; MESSENGER-RNA; UP-REGULATION; EXPRESSION	Neurotrophins and their cognate receptors play a pivotal role in the development and function of the nervous system. High expression levels of the neurotrophin receptor TrkB and its ligands in neuroblastomas are associated with an unfavorable outcome. We report here that NTRK2, which encodes the TrkB receptor tyrosine kinase, is an oxygen-regulated gene, whose expression is stimulated by the hypoxia-inducible factor-1 (HIF-1). TrkB mRNA and protein levels were elevated nearly 30-fold in neuroblastoma-derived Kelly cells in hypoxia (1% O-2) versus normoxia (21% O-2). A luciferase reporter construct containing approximate to 2.1 kilobases of the human TrkB promoter was activated about 6-fold both in hypoxia and after stimulation with the hypoxia mimetic 2,2'-dipyridyl (100 mu M) at 21% O-2. Luciferase activity in the presence of 2,2'-dipyridyl was reduced significantly upon small interfering RNA knockdown of HIF-1 alpha but not of HIF-2 alpha. Accordingly, hypoxia failed to stimulate the TrkB promoter in mouse embryonic fibroblasts that lacked HIF-1 alpha. The hypoxia-responsive promoter region could be mapped to three HIF-1 binding elements that were located between -923 and -879 bp relative to the transcription start site. The migration of cultured neuroblastoma cells was increased similar to 2-fold upon incubation at 1 versus 21% O-2. This effect of hypoxia was abrogated with the tyrosine kinase inhibitor K252a (200 mu M). Our findings indicate that transcription of the NTRK2 gene is stimulated at low oxygen tension through a HIF-1-dependent mechanism. In conclusion, enhanced expression of TrkB could represent a critical switch for the previously reported dedifferentiation of neuroblastoma cells under hypoxic conditions.	Charite Univ Med Berlin, Inst Vegetav Physiol, D-10117 Berlin, Germany; Univ Erlangen Nurnberg, Div Nephrol & Hypertens, D-91054 Erlangen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Erlangen Nuremberg	Scholz, H (corresponding author), Tucholskystr 2, D-10117 Berlin, Germany.	holger.scholz@charite.de	Sciesielski, Lina/G-3716-2017	Sciesielski, Lina/0000-0003-3458-0309; Kirschner, Karin/0000-0003-0226-8636				Aoyama M, 2001, CANCER LETT, V164, P51, DOI 10.1016/S0304-3835(00)00715-1; Arevalo JC, 2006, CELL MOL LIFE SCI, V63, P1523, DOI 10.1007/s00018-006-6010-1; Baltensperger H, 1997, J BIOL CHEM, V272, P10151; Behar TN, 1997, EUR J NEUROSCI, V9, P2561, DOI 10.1111/j.1460-9568.1997.tb01685.x; Bernhardt WM, 2006, KIDNEY INT, V69, P114, DOI 10.1038/sj.ki.5000062; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Dame C, 2006, BLOOD, V107, P4282, DOI 10.1182/blood-2005-07-2889; Desmet CJ, 2006, CELL MOL LIFE SCI, V63, P755, DOI 10.1007/s00018-005-5490-8; Donovan MJ, 2000, DEVELOPMENT, V127, P4531; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Eide FF, 1996, J NEUROSCI, V16, P3123; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Fandrey J, 2006, CARDIOVASC RES, V71, P642, DOI 10.1016/j.cardiores.2006.05.005; Frede S, 2005, CANCER RES, V65, P4690, DOI 10.1158/0008-5472.CAN-04-3877; Hedborg F, 2003, FASEB J, V17, P598, DOI 10.1096/fj.02-0390com; HEDBORG F, 1995, EUR J CANCER, V31A, P435, DOI 10.1016/0959-8049(95)00025-E; Ho R, 2002, CANCER RES, V62, P6462; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jaboin J, 2002, CANCER RES, V62, P6756; Jogi A, 2004, EXP CELL RES, V295, P469, DOI 10.1016/j.yexcr.2004.01.013; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Kermani P, 2005, J CLIN INVEST, V115, P653, DOI 10.1172/JCI200522655; Kirschner KM, 2006, J BIOL CHEM, V281, P31930, DOI 10.1074/jbc.M602668200; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOGNER P, 1993, CANCER RES, V53, P2044; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Li ZJ, 2005, CANCER RES, V65, P2070, DOI 10.1158/0008-5472.CAN-04-3606; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789; Narumiya S, 1998, BRAIN RES, V797, P278, DOI 10.1016/S0006-8993(98)00385-0; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; Polleux F, 2002, DEVELOPMENT, V129, P3147; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Rosenberger C, 2005, KIDNEY INT, V67, P531, DOI 10.1111/j.1523-1755.2005.67110.x; Ryan HE, 2000, CANCER RES, V60, P4010; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Sowter HM, 2003, CANCER RES, V63, P6130; Stolze I, 2002, BLOOD, V100, P2623, DOI 10.1182/blood-2001-12-0169; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Wagner KD, 2001, J AM SOC NEPHROL, V12, P1188, DOI 10.1681/ASN.V1261188; Wagner KD, 2003, GENE, V305, P217, DOI 10.1016/S0378-1119(02)01231-3; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12	63	69	72	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14379	14388		10.1074/jbc.M609857200	http://dx.doi.org/10.1074/jbc.M609857200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374610	hybrid			2022-12-27	WOS:000246245800050
J	White, TA; Krishnan, N; Becker, DF; Tanner, JJ				White, Tommi A.; Krishnan, Navasona; Becker, Donald F.; Tanner, John J.			Structure and kinetics of monofunctional proline dehydrogenase from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN REDOX STATE; PUTA PROTEIN; P53-INDUCED GENE-6; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DNA-BINDING; OXIDASE; APOPTOSIS; MEMBRANE; DOMAIN	Proline dehydrogenase (PRODH) and Delta(1)-pyrroline-5-carboxylate dehydrogenase (P5CDH) catalyze the two-step oxidation of proline to glutamate. They are distinct monofunctional enzymes in all eukaryotes and some bacteria but are fused into bifunctional enzymes known as proline utilization A (PutA) in other bacteria. Here we report the first structure and biochemical data for a monofunctional PRODH. The 2.0-angstrom resolution structure of Thermus thermophilus PRODH reveals a distorted (beta alpha)(8) barrel catalytic core domain and a hydrophobic alpha-helical domain located above the carboxyl-terminal ends of the strands of the barrel. Although the catalytic core is similar to that of the PutA PRODH domain, the FAD conformation of T. thermophilus PRODH is remarkably different and likely reflects unique requirements for membrane association and communication with P5CDH. Also, the FAD of T. thermophilus PRODH is highly solvent-exposed compared with PutA due to a 4-angstrom shift of helix 8. Structure-based sequence analysis of the PutA/PRODH family led us to identify nine conserved motifs involved in cofactor and substrate recognition. Biochemical studies show that the midpoint potential of the FAD is -75 mV and the kinetic parameters for proline are K-m =27 mM and k(cat) = 13 s(-1). 3,4-Dehydro-L-proline was found to be an efficient substrate, and L-tetrahydro-2-furoic acid is a competitive inhibitor (K-I = 1.0 mM). Finally, we demonstrate that T. thermophilus PRODH reacts with O-2 producing superoxide. This is significant because superoxide production underlies the role of human PRODH in p53-mediated apoptosis, implying commonalities between eukaryotic and bacterial monofunctional PRODHs.	Univ Missouri, Dept Chem, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Nebraska, Redox Biol Ctr, Dept Biochem, Lincoln, NE 68588 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Nebraska System; University of Nebraska Lincoln	Tanner, JJ (corresponding author), Univ Missouri, Dept Chem, Columbia, MO 65211 USA.	tannerjj@missouri.edu		White, Tommi/0000-0001-7283-3755; Tanner, John/0000-0001-8314-113X	NIGMS NIH HHS [R01 GM061068, GM061068, GM065546, R01 GM061068-07, R01 GM065546, R01 GM065546-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061068, R01GM065546] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS E, 1980, ANNU REV BIOCHEM, V49, P1005, DOI 10.1146/annurev.bi.49.070180.005041; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Becker DF, 2001, BIOCHEMISTRY-US, V40, P4714, DOI 10.1021/bi0019491; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bottoms CA, 2002, PROTEIN SCI, V11, P2125, DOI 10.1110/ps.0213502; BROWN ED, 1992, J BIOL CHEM, V267, P13086; BROWN ED, 1993, J BIOL CHEM, V268, P8972; CHEN CC, 1986, J BIOL CHEM, V261, P2599; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Donald SP, 2001, CANCER RES, V61, P1810; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Gu D, 2004, J BIOL CHEM, V279, P31171, DOI 10.1074/jbc.M403701200; Hu CAA, 2007, MOL CELL BIOCHEM, V295, P85, DOI 10.1007/s11010-006-9276-6; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; Inagaki E, 2006, J MOL BIOL, V362, P490, DOI 10.1016/j.jmb.2006.07.048; Krishnan N, 2006, J BACTERIOL, V188, P1227, DOI 10.1128/JB.188.4.1227-1235.2006; Krishnan N, 2005, BIOCHEMISTRY-US, V44, P9130, DOI 10.1021/bi050629k; Larson JD, 2006, PROTEIN SCI, V15, P2630, DOI 10.1110/ps.062425706; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee YH, 2003, NAT STRUCT BIOL, V10, P109, DOI 10.1038/nsb885; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; MENZEL R, 1981, J BIOL CHEM, V256, P9762; MEZL VA, 1976, ANAL BIOCHEM, V74, P430, DOI 10.1016/0003-2697(76)90223-2; Miles EW, 1999, J BIOL CHEM, V274, P12193, DOI 10.1074/jbc.274.18.12193; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; MUROPASTOR AM, 1995, J BIOL CHEM, V270, P9819, DOI 10.1074/jbc.270.17.9819; MuroPastor AM, 1997, J BACTERIOL, V179, P2788, DOI 10.1128/jb.179.8.2788-2791.1997; Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Phang J. M., 2001, METABOLIC MOL BASES, P1821; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; STANKOVICH MT, 1980, ANAL BIOCHEM, V109, P295, DOI 10.1016/0003-2697(80)90652-1; Surber MW, 1998, ARCH BIOCHEM BIOPHYS, V354, P281, DOI 10.1006/abbi.1998.0697; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsuge H, 2005, J BIOL CHEM, V280, P31045, DOI 10.1074/jbc.C500234200; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; Vinod MP, 2002, BIOCHEMISTRY-US, V41, P6525, DOI 10.1021/bi025706f; Walden H, 2001, J MOL BIOL, V306, P745, DOI 10.1006/jmbi.2000.4433; White TA, 2005, ACTA CRYSTALLOGR F, V61, P737, DOI 10.1107/S1744309105019779; Winn MD, 2003, METHOD ENZYMOL, V374, P300, DOI 10.1016/S0076-6879(03)74014-2; WOOD JM, 1981, J BACTERIOL, V146, P895, DOI 10.1128/JB.146.3.895-901.1981; Zhang M, 2004, BIOCHEMISTRY-US, V43, P12539, DOI 10.1021/bi048737e; Zhang WM, 2007, BIOCHEMISTRY-US, V46, P483, DOI 10.1021/bi061935g; Zhang WM, 2004, BIOCHEMISTRY-US, V43, P13165, DOI 10.1021/bi048596g; Zhu WD, 2003, BIOCHEMISTRY-US, V42, P5469, DOI 10.1021/bi0272196; Zhu WD, 2002, ARCH BIOCHEM BIOPHYS, V408, P131, DOI 10.1016/S0003-9861(02)00535-0	58	83	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14316	14327		10.1074/jbc.M700912200	http://dx.doi.org/10.1074/jbc.M700912200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17344208	Green Accepted, hybrid			2022-12-27	WOS:000246245800043
J	Becker, HM; Deitmer, JW				Becker, Holger M.; Deitmer, Joachim W.			Carbonic anhydrase II increases the activity of the human electrogenic Na+/HCO3- cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-BICARBONATE COTRANSPORT; INTRACELLULAR PH REGULATION; RENAL PROXIMAL TUBULE; NA+-HCO3-COTRANSPORTER; HYDROPHOBIC POCKET; O-18 EXCHANGE; GLIAL-CELLS; TRANSPORT; OOCYTES; CLONING	Several acid/ base-coupled membrane transporters, such as the electrogenic sodium-bicarbonate cotransporter (NBCe1), have been shown to bind to different carbonic anhydrase isoforms to create a "transport metabolon." We have expressed NBCe1 derived from human kidney in oocytes of Xenopus leavis and determined its transport activity by recording the membrane current in voltage clamp, and the cytosolic H+ and Na+ concentrations using ion-selective microelectrodes. When carbonic anhydrase isoform II (CAII) had been injected into oocytes, the membrane current and the rate of cytosolic Na+ rise, indicative for NBCe1 activity, increased significantly with the amount of injected CAII (2-200 ng). The CAII inhibitor ethoxyzolamide reversed the effects of CAII on the NBCe1 activity. Co-expressing wild-type CAII or NH2-terminal mutant CAII together with NBCe1 provided similar results, whereas co-expressing the catalytically inactive CAII mutant V143Y had no effect on NBCe1 activity. Mass spectrometric analysis and the rate of cytosolic H+ change following addition of CO2/HCO3- confirmed the catalytic activity of injected and expressed CAII in oocytes. Our results show that the transport capacity of NBCe1 is enhanced by the catalytic activity of CAII, in line with the notion that CAII forms a transport metabolon with NBCe1.	Tech Univ Kaiserslautern, Fachbereich Biol, Abt Allgemeine Zool, D-67653 Kaiserslautern, Germany	University of Kaiserslautern	Becker, HM (corresponding author), Tech Univ Kaiserslautern, Fachbereich Biol, Abt Allgemeine Zool, POB 3049, D-67653 Kaiserslautern, Germany.	h.becker@biologie.uni-kl.de	Becker, Holger/AAB-4322-2020					ALEXANDER RS, 1991, BIOCHEMISTRY-US, V30, P11064, DOI 10.1021/bi00110a008; Alvarez BV, 2003, BIOCHEMISTRY-US, V42, P12321, DOI 10.1021/bi0353124; BADGER MR, 1989, PLANT PHYSIOL, V89, P51, DOI 10.1104/pp.89.1.51; Becker HM, 2004, J BIOL CHEM, V279, P28057, DOI 10.1074/jbc.M402401200; Becker HM, 2004, BIOPHYS J, V86, P235, DOI 10.1016/S0006-3495(04)74099-0; Becker HM, 2005, J BIOL CHEM, V280, P39882, DOI 10.1074/jbc.M503081200; Bevensee MO, 1997, J GEN PHYSIOL, V110, P467, DOI 10.1085/jgp.110.4.467; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; Broer S, 1998, BIOCHEM J, V333, P167, DOI 10.1042/bj3330167; BRUNE T, 1994, PFLUG ARCH EUR J PHY, V429, P64, DOI 10.1007/BF02584031; BURG M, 1977, AM J PHYSIOL, V233, pF307, DOI 10.1152/ajprenal.1977.233.4.F307; Choi I, 1999, AM J PHYSIOL-CELL PH, V276, pC576, DOI 10.1152/ajpcell.1999.276.3.C576; DEITMER JW, 1987, J PHYSIOL-LONDON, V388, P261, DOI 10.1113/jphysiol.1987.sp016614; DEITMER JW, 1989, J PHYSIOL-LONDON, V411, P179, DOI 10.1113/jphysiol.1989.sp017567; DEITMER JW, 1991, J GEN PHYSIOL, V98, P637, DOI 10.1085/jgp.98.3.637; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; Gross E, 2002, J PHYSIOL-LONDON, V544, P679, DOI 10.1113/jphysiol.2002.029777; Heyer M, 1999, PFLUG ARCH EUR J PHY, V438, P322, DOI 10.1007/s004240050916; Li XJ, 2002, J BIOL CHEM, V277, P36085, DOI 10.1074/jbc.M111952200; Loiselle FB, 2004, AM J PHYSIOL-CELL PH, V286, pC1423, DOI 10.1152/ajpcell.00382.2003; Lu J, 2006, J BIOL CHEM, V281, P19241, DOI 10.1074/jbc.M602181200; McMurtrie HL, 2004, J ENZYM INHIB MED CH, V19, P231, DOI 10.1080/14756360410001704443; NAKOUL NL, 1998, AM J PHYSIOL, V274, pC543; Piermarini PM, 2007, J BIOL CHEM, V282, P1409, DOI 10.1074/jbc.M608261200; Pushkin A, 2004, J PHYSIOL-LONDON, V559, P55, DOI 10.1113/jphysiol.2004.065110; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SASAKI S, 1989, AM J PHYSIOL, V257, pF947, DOI 10.1152/ajprenal.1989.257.6.F947; Schmitt BM, 1999, AM J PHYSIOL-RENAL, V276, pF27, DOI 10.1152/ajprenal.1999.276.1.F27; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; SEKI G, 1992, PFLUG ARCH EUR J PHY, V422, P60, DOI 10.1007/BF00381514; SILVERMAN DN, 1982, METHOD ENZYMOL, V87, P732; Sterling D, 2001, JOP, V2, P165; SULTEMEYER DF, 1990, PLANT PHYSIOL, V94, P1250, DOI 10.1104/pp.94.3.1250; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430	35	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13508	13521		10.1074/jbc.M700066200	http://dx.doi.org/10.1074/jbc.M700066200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17353189	hybrid			2022-12-27	WOS:000246060300040
J	Purohit, V; Roques, BP; Kim, B; Bambara, RA				Purohit, Vandana; Roques, Bernard P.; Kim, Baek; Bambara, Robert A.			Mechanisms that prevent template inactivation by HIV-1 reverse transcriptase RNase H cleavages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 NUCLEOCAPSID PROTEIN; ACID-CHAPERONE ACTIVITY; STRONG STOP TRANSFER; DNA STRAND TRANSFER; IN-VITRO; RETROVIRAL RECOMBINATION; GENETIC-RECOMBINATION; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE	The RNase H activity of human immunodeficiency virus, type 1 ( HIV-1) reverse transcriptase ( RT) cleaves the viral genome concomitant with minus strand synthesis. We previously analyzed RT-mediated pausing and RNase H cleavage on a hairpin-containing RNA template system and reported that RT generated 3' end-directed primary and secondary cuts while paused at the base of the hairpin during synthesis. Here, we report that all of the prominent cleavage products observed during primer extension on this template correlated with pause induced cuts. Products that persisted throughout the reaction corresponded to secondary cuts, about eight nucleotides in from the DNA primer terminus. This distance allows little overlap of intact template with the primer terminus. We considered whether secondary cuts could inactivate further synthesis by promoting dissociation of the primer from the template. As anticipated, 3' end-directed secondary cuts decreased primer extendibility. This provides a plausible mechanism to explain the persistence of secondary cut products in our hairpin template system. Improving the efficiency of synthesis by increasing the concentration of dNTPs or addition of nucleocapsid protein ( NC) reduced pausing and the generation of pause related secondary cuts on this template. Further studies reveal that 3' end-directed primary and secondary cleavages were also generated when synthesis was stalled by the presence of 3'-azido-3'-deoxythymidine at the primer terminus, possibly contributing to 3'-azido-3'-deoxythymidine inhibition. Considered together, the data reveal a role for NC and other factors that enhance DNA synthesis in the prevention of RNase H cleavages that could be detrimental to viral replication.	Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Paris 05, Unite Pharmacochim Mol & Struct, INSERM U266,UFR Sci Pharmaceut & Biol, CNRS,UMR 8600, F-75270 Paris 06, France	University of Rochester; University of Rochester; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bambara, RA (corresponding author), 601 Elmwood Ave, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007232] Funding Source: NIH RePORTER; NIDA NIH HHS [T32-DA07232] Funding Source: Medline; NIGMS NIH HHS [GM49573] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archer RH, 2000, J VIROL, V74, P8390, DOI 10.1128/JVI.74.18.8390-8401.2000; Archer RH, 2001, BIOCHEMISTRY-US, V40, P4087, DOI 10.1021/bi002328a; Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Bampi C, 2004, INT J BIOCHEM CELL B, V36, P1668, DOI 10.1016/j.biocel.2004.02.024; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; Chen Y, 2003, J BIOL CHEM, V278, P38368, DOI 10.1074/jbc.M305700200; Chen Y, 2003, J BIOL CHEM, V278, P8006, DOI 10.1074/jbc.M210959200; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; Derebail SS, 2004, J BIOL CHEM, V279, P47446, DOI 10.1074/jbc.M408927200; DESTEFANO JJ, 1995, ARCH VIROL, V140, P1775, DOI 10.1007/BF01384341; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Diamond TL, 2004, J BIOL CHEM, V279, P51545, DOI 10.1074/jbc.M408573200; Druillennec S, 1999, J BIOL CHEM, V274, P11283, DOI 10.1074/jbc.274.16.11283; Drummond JE, 1997, AIDS RES HUM RETROV, V13, P533, DOI 10.1089/aid.1997.13.533; Emini E. A., 1997, P637; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Galetto R, 2004, J BIOL CHEM, V279, P36625, DOI 10.1074/jbc.M405476200; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; Hanson MN, 2005, J MOL BIOL, V353, P772, DOI 10.1016/j.jmb.2005.08.065; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; KATI WM, 1992, J BIOL CHEM, V267, P25988; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LANDAULT C, 2006, J VIROL, V80, P2483; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; Negroni M, 1999, J MOL BIOL, V286, P15, DOI 10.1006/jmbi.1998.2460; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Nikolenko GN, 2005, P NATL ACAD SCI USA, V102, P2093, DOI 10.1073/pnas.0409823102; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; Purohit V, 2005, J BIOL CHEM, V280, P40534, DOI 10.1074/jbc.M507839200; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Schultz SJ, 2004, J MOL BIOL, V344, P635, DOI 10.1016/j.jmb.2004.09.081; Smith CM, 1999, J VIROL, V73, P6573, DOI 10.1128/JVI.73.8.6573-6581.1999; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Telesnitsky A., 1997, P121; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; WOHRL BM, 1991, J MOL BIOL, V220, P801, DOI 10.1016/0022-2836(91)90119-Q; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YOU JC, 1994, J BIOL CHEM, V269, P31491; Zhang WH, 2002, J VIROL, V76, P7473, DOI 10.1128/JVI.76.15.7473-7484.2002	63	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12598	12609		10.1074/jbc.M700043200	http://dx.doi.org/10.1074/jbc.M700043200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17337733	hybrid			2022-12-27	WOS:000245942800029
J	Faccio, R; Takeshita, S; Colaianni, G; Chappel, J; Zallone, A; Teitelbaum, SL; Ross, FP				Faccio, Roberta; Takeshita, Sunao; Colaianni, Graziana; Chappel, Jean; Zallone, Alberta; Teitelbaum, Steven L.; Ross, F. Patrick			M-CSF regulates the cytoskeleton via recruitment of a multimeric signaling complex to c-Fms Tyr-559/697/721	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; OSTEOCLAST CYTOSKELETON; GROWTH-FACTOR; PI-3 KINASE; MACROPHAGE; CBL; PODOSOMES	M-CSF is known to induce cytoskeletal reorganization in macrophages and osteoclasts by activation of phosphatidylinositol 3-kinase (PI3K) and c-Src, but the detailed mechanisms remain unclear. We find, unexpectedly, that tyrosine (Tyr) to phenylalanine (Phe) mutation of Tyr-721, the PI3K binding site in the M-CSF receptor c-Fms, fails to suppress cytoskeletal remodeling or actin ring formation. In contrast, mutation of c-Fms Tyr-559 to Phe blocks M-CSF-induced cytoskeletal reorganization by inhibiting formation of a Src Family Kinase SFK(.)cCbl (.) PI3K complex and the downstream activation of Vav3 and Rac, two key mediators of actin remodeling. Using an add-back approach in which specific Tyr residues are reinserted into c-Fms inactivated by the absence of all seven functionally important Tyr residues, we find that Tyr-559 is necessary but not sufficient to transduce M-CSF-dependent cytoskeletal reorganization. Furthermore, this same add-back approach identifies important roles for Tyr-697 and Tyr-721 in collaborating with Tyr-559 to recruit a multimeric signaling complex that can transduce signals from c-Fms to the actin cytoskeleton.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA; Univ Bari, Sch Med, Dept Human Anat, I-70100 Bari, Italy; Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Bone & Joint Dis, Aichi 4748522, Japan	Washington University (WUSTL); Washington University (WUSTL); Universita degli Studi di Bari Aldo Moro; National Center for Geriatrics & Gerontology	Ross, FP (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	rossf@wustl.edu		Colaianni, Graziana/0000-0001-8501-5399; Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR48853, AR52921, AR48812, AR46852, AR46523, AR32788] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046523, R37AR046523, R01AR048812, R01AR048853, R01AR032788, R01AR046852] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BOOCOCK CA, 1989, J CELL SCI, V93, P447; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.e04-12-1117; Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood-2003-04-1259; Caveggion E, 2003, J CELL PHYSIOL, V195, P276, DOI 10.1002/jcp.10236; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Chiusaroli R, 2003, DEV BIOL, V261, P537, DOI 10.1016/S0012-1606(03)00299-9; Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924; Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194; Feldner JC, 2002, EXP CELL RES, V272, P93, DOI 10.1006/excr.2001.5385; Feng X, 2002, ENDOCRINOLOGY, V143, P4868, DOI 10.1210/en.2002-220467; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733; GAVAZZI I, 1989, J CELL SCI, V94, P85; Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; Hurst IR, 2004, J BONE MINER RES, V19, P499, DOI 10.1359/JBMR.0301238; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Jones GE, 2003, EXP CELL RES, V290, P120, DOI 10.1016/S0014-4827(03)00318-5; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779-6798.2000; LOTZE MT, 2003, CYTOKINE HDB, P545; Marks D C, 1999, Mol Cell Biol Res Commun, V1, P144, DOI 10.1006/mcbr.1999.0123; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Munugalavadla V, 2005, BLOOD, V106, P103, DOI 10.1182/blood-2004-10-4041; Nakagawa H, 2001, J CELL SCI, V114, P1555; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nakamura I, 2003, J ELECTRON MICROSC, V52, P527, DOI 10.1093/jmicro/52.6.527; Palacio S, 2001, EUR J ENDOCRINOL, V144, P431, DOI 10.1530/eje.0.1440431; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Pfaff M, 2001, J CELL SCI, V114, P2775; Pilkington MF, 1998, J BONE MINER RES, V13, P688, DOI 10.1359/jbmr.1998.13.4.688; Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016; Razzouk S, 1999, EUR J CELL BIOL, V78, P249, DOI 10.1016/S0171-9335(99)80058-2; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rohde CM, 2004, J BIOL CHEM, V279, P43448, DOI 10.1074/jbc.M314170200; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STICKEL SK, 1987, J CELL BIOL, V104, P1521, DOI 10.1083/jcb.104.6.1521; Takenawa T, 2001, J CELL SCI, V114, P1801; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Takeshita S, 2007, J BIOL CHEM, V282, P18980, DOI 10.1074/jbc.M610938200; Tallquist M, 2004, CYTOKINE GROWTH F R, V15, P205, DOI 10.1016/j.cytogfr.2004.03.003; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Vedham V, 2005, MOL CELL BIOL, V25, P4211, DOI 10.1128/MCB.25.10.4211-4220.2005; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wells CM, 2004, J CELL SCI, V117, P1259, DOI 10.1242/jcs.00997	60	38	39	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18991	18999		10.1074/jbc.M610937200	http://dx.doi.org/10.1074/jbc.M610937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17420256	hybrid			2022-12-27	WOS:000247475300041
J	Takeshita, S; Faccio, R; Chappel, J; Zheng, L; Feng, X; Weber, JD; Teitelbaum, SL; Ross, FP				Takeshita, Sunao; Faccio, Roberta; Chappel, Jean; Zheng, Ling; Feng, Xu; Weber, Jason D.; Teitelbaum, Steven L.; Ross, F. Patrick			c-Fms tyrosine 559 is a major mediator of M-CSF-induced proliferation of primary macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; BINDING-SITE; V-FMS; KINASE; PROTEIN; ACTIVATION; SRC; DIFFERENTIATION	The molecular mechanisms by which binding of monocyte/macrophage colony-stimulating factor to its receptor c-Fms promotes replication in primary macrophages are incompletely understood, as all previous studies involved overexpression of receptor mutants in transformed cells not endogenously expressing the receptor. To address this issue we retrovirally expressed, in bone marrow-derived macrophages, a chimeric receptor containing a range of tyrosine to phenylalanine mutations in the c-Fms cytoplasmic tail. We measured incorporation of bromodeoxyuridine as a marker of proliferation and phosphorylation of ERKs, Akt, and the receptor itself. Our data indicate that tyrosine 559 is the major mediator of receptor activation and cell death, intracellular signaling, and cell proliferation and that the tyrosine residues at positions 697 and 807 play lesser roles in these events. Importantly, we find that activation of the ERK and Akt pathways is necessary but not sufficient for induction of macrophage proliferation. Using specific small molecule inhibitors we find that a combination of the Src family kinase, phosphatidylinositol 3-kinase/Akt, phospholipase C, and ERK pathways mediates macrophage proliferation in response to M-CSF.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Bone & Joint Dis, Aichi 4748522, Japan; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Center for Geriatrics & Gerontology; University of Alabama System; University of Alabama Birmingham	Ross, FP (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	rossf@wustl.edu		Teitelbaum, Steven/0000-0002-4054-6679; Weber, Jason/0000-0002-1069-6983	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032788, R37AR046523, R01AR046523, R01AR048812, R01AR048853, R01AR046852] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32788, AR48853, AR46523, AR48812, AR46852] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Bunney TD, 2006, TRENDS CELL BIOL, V16, P640, DOI 10.1016/j.tcb.2006.10.007; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Faccio R, 2007, J BIOL CHEM, V282, P18991, DOI 10.1074/jbc.M610937200; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; Feng X, 2002, ENDOCRINOLOGY, V143, P4868, DOI 10.1210/en.2002-220467; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Heo JS, 2006, AM J PHYSIOL-CELL PH, V290, pC123, DOI 10.1152/ajpcell.00142.2005; Hong L, 2004, MOL CELL BIOL, V24, P1401, DOI 10.1128/MCB.24.3.1401-1410.2004; Hubbard SR, 2002, CURR OPIN STRUC BIOL, V12, P735, DOI 10.1016/S0959-440X(02)00383-4; Jaworowski A, 1999, J BIOL CHEM, V274, P15127, DOI 10.1074/jbc.274.21.15127; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; LOTZE MT, 2003, CYTOKINE HDB, P545; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marks D C, 1999, Mol Cell Biol Res Commun, V1, P144, DOI 10.1006/mcbr.1999.0123; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Rohde CM, 2004, J BIOL CHEM, V279, P43448, DOI 10.1074/jbc.M314170200; Rohrschneider LR, 1997, MOL REPROD DEV, V46, P96; Roussel MF, 1997, MOL REPROD DEV, V46, P11, DOI 10.1002/(SICI)1098-2795(199701)46:1<11::AID-MRD3>3.0.CO;2-U; ROUSSEL MF, 1990, MOL CELL BIOL, V10, P2407, DOI 10.1128/MCB.10.5.2407; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tan BL, 2003, J BIOL CHEM, V278, P11686, DOI 10.1074/jbc.M207068200; Tari AM, 2001, SEMIN ONCOL, V28, P142, DOI 10.1053/sonc.2001.28555; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Zhou P, 2006, J IMMUNOL, V177, P8777, DOI 10.4049/jimmunol.177.12.8777	46	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18980	18990		10.1074/jbc.M610938200	http://dx.doi.org/10.1074/jbc.M610938200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17420255	hybrid			2022-12-27	WOS:000247475300040
J	Bonner, A; Perrier, C; Corthesy, B; Perkins, SJ				Bonner, Alexandra; Perrier, Clementine; Corthesy, Blaise; Perkins, Stephen J.			Solution structure of human secretory component and implications for biological function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY; POLYMERIC IG; NEUTRON-SCATTERING; ANALYTICAL ULTRACENTRIFUGATION; STREPTOCOCCUS-PNEUMONIAE; IMMUNOGLOBULIN-A; BINDING; ANTIGEN; PURIFICATION; EXPRESSION	Secretory component (SC) in association with polymeric IgA (pIgA) forms secretory IgA, the major antibody active at mucosal surfaces. SC also exists in the free form, with innate-like neutralizing properties against pathogens. Free SC consists of five glycosylated variable (V)-type Ig domains (D1-D5), whose structure was determined by x-ray and neutron scattering, ultracentrifugation, and modeling. With a radius of gyration of 3.53-3.63 nm, a length of 12.5 nm, and a sedimentation coefficient of 4.0 S, SC possesses an unexpected compact structure. Constrained scattering modeling based on up to 13,000 trial models shows that SC adopts a J-shaped structure in which D4 and D5 are folded back against D2 and D3. The seven glycosylation sites are located on one side of SC, leaving known IgAbinding motifs free to interact with pIgA. This work represents the first analysis of the three-dimensional structure of full-length free SC and paves the way to a better understanding of the association between SC and its potential ligands, i. e. pIgA and pathogenic-associated motifs.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; CHU Vaudois, Serv Immunol & Allergie, CH-1011 Lausanne, Switzerland	University of London; University College London; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Perkins, SJ (corresponding author), UCL, Dept Biochem & Mol Biol, Darwin Bldg,Gower St, London WC1E 6BT, England.	s.perkins@medsch.ucl.ac.uk	Perrier, Clementine/A-3925-2011					Almogren A, 2007, IMMUNOLOGY, V120, P273, DOI 10.1111/j.1365-2567.2006.02498.x; BAKOS MA, 1991, J IMMUNOL, V147, P3419; BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; BAKOS MA, 1991, J IMMUNOL, V146, P162; Boehm MK, 1999, J MOL BIOL, V286, P1421, DOI 10.1006/jmbi.1998.2556; Boehm MK, 2000, FEBS LETT, V475, P11, DOI 10.1016/S0014-5793(00)01612-4; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Braathen R, 2006, J BIOL CHEM, V281, P7075, DOI 10.1074/jbc.M508509200; BRANDTZAEG P, 1995, APMIS, V103, P1, DOI 10.1111/j.1699-0463.1995.tb01073.x; Corthesy B, 1996, J BIOL CHEM, V271, P33670, DOI 10.1074/jbc.271.52.33670; COYNE RS, 1994, J BIOL CHEM, V269, P31620; Crottet P, 1999, BIOCHEM J, V341, P299, DOI 10.1042/0264-6021:3410299; Crottet P, 1998, J IMMUNOL, V161, P5445; Crottet P, 1999, J BIOL CHEM, V274, P31456, DOI 10.1074/jbc.274.44.31456; Dallas SD, 1998, J MED MICROBIOL, V47, P879, DOI 10.1099/00222615-47-10-879; Elm C, 2004, J BIOL CHEM, V279, P6296, DOI 10.1074/jbc.M310528200; FALLGREENGEBAUER E, 1993, BIOL CHEM H-S, V374, P1023, DOI 10.1515/bchm3.1993.374.7-12.1023; FERKOL T, 1995, J CLIN INVEST, V95, P493, DOI 10.1172/JCI117690; Furtado PB, 2004, J MOL BIOL, V338, P921, DOI 10.1016/j.jmb.2004.03.007; Hamburger AE, 2004, STRUCTURE, V12, P1925, DOI 10.1016/j.str.2004.09.006; Heenan RK, 1997, J APPL CRYSTALLOGR, V30, P1140, DOI 10.1107/S0021889897002173; Hexham JM, 1999, J EXP MED, V189, P747, DOI 10.1084/jem.189.4.747; Hu YL, 2005, J MOL BIOL, V350, P553, DOI 10.1016/j.jmb.2005.04.031; Hughes GJ, 1997, FEBS LETT, V410, P443, DOI 10.1016/S0014-5793(97)00629-7; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; Lu L, 2003, J BIOL CHEM, V278, P48178, DOI 10.1074/jbc.M306906200; Lullau E, 1996, J BIOL CHEM, V271, P16300, DOI 10.1074/jbc.271.27.16300; MACH JP, 1970, NATURE, V228, P1278, DOI 10.1038/2281278a0; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MCRORIE DK, 1993, SELF ASSOCIATING SYS, P9; Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8; Nezlin R, 1998, IMMUNOGLOBULINS, P3, DOI 10.1016/B978-012517970-6/50001-1; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PERKINS SJ, 1988, BIOCHEM J, V254, P313, DOI 10.1042/bj2540313; Perkins SJ, 1998, INT J BIOL MACROMOL, V22, P1, DOI 10.1016/S0141-8130(97)00088-3; Perkins SJ, 2001, BIOPHYS CHEM, V93, P129, DOI 10.1016/S0301-4622(01)00216-2; Perrier C, 2006, J BIOL CHEM, V281, P14280, DOI 10.1074/jbc.M512958200; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; STERNBERG MJE, 1996, PROTEIN STRUCTURE PR, P111; Sun Z, 2005, J MOL BIOL, V353, P155, DOI 10.1016/j.jmb.2005.07.072; White KD, 2002, J EXP MED, V196, P551, DOI 10.1084/jem.20020581	45	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16969	16980		10.1074/jbc.M701281200	http://dx.doi.org/10.1074/jbc.M701281200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428798	hybrid			2022-12-27	WOS:000246946500030
J	Bassermann, F; von Klitzing, C; Illert, AL; Munch, S; Morris, SW; Pagano, M; Peschel, C; Duyster, J				Bassermann, Florian; von Klitzing, Christine; Illert, Anna Lena; Muench, Silvia; Morris, Stephan W.; Pagano, Michele; Peschel, Christian; Duyster, Justus			Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G(2)/M involves cyclin B1/Cdk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; SCF UBIQUITIN-LIGASE; XENOPUS EGG EXTRACTS; F-BOX PROTEINS; MITOTIC REGULATION; SOMATIC WEE1; BETA-TRCP; KINASE; INHIBITOR; MITOSIS	Nuclear interaction partner of ALK (NIPA) is an F-box-containing protein that defines a nuclear skp1 cullin F-box (SCF)type ubiquitin E3 ligase (SCFNIPA) implicated in the regulation of mitotic entry. The SCFNIPA complex targets nuclear cyclin B1 for ubiquitination in interphase, whereas phosphorylation of NIPA in late G(2) phase and mitosis inactivates the complex to allow for accumulation of cyclin B1. Here, we identify the region of NIPA that mediates binding to its substrate cyclin B1. In addition to the recently described serine residue 354, we specify 2 new residues, Ser-359 and Ser-395, implicated in the phosphorylation process at G(2)/M within this region. Moreover, we found cyclin B1/Cdk1 to phosphorylate NIPA at Ser-395 in mitosis. Mutation of both Ser-359 and Ser-395 impaired effective inactivation of the SCFNIPA complex, resulting in reduced levels of mitotic cyclin B1. These data are compatible with a process of sequential NIPA phosphorylation where cyclin B1/Cdk1 amplifies phosphorylation of NIPA once an initial phosphorylation event has dissociated the SCFNIPA complex. Thus, cyclin B1/Cdk1 may contribute to the regulation of its own abundance in early mitosis.	Tech Univ Munich, Dept Internal Med 3, D-81675 Munich, Germany; St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	Technical University of Munich; University of Munich; St Jude Children's Research Hospital; St Jude Children's Research Hospital; New York University; New York University	Duyster, J (corresponding author), Tech Univ Munich, Dept Internal Med 3, Ismaningerstr 22, D-81675 Munich, Germany.	justus.duyster@lrz.tum.de	Illert, Anna L/G-8127-2019	pagano, michele/0000-0003-3210-2442	NCI NIH HHS [R21-CA125173, R37-CA76584, CA 69129] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline; PHS HHS [21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA125173, R01CA069129, R37CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bassermann F, 2005, CELL CYCLE, V4, P1515, DOI 10.4161/cc.4.11.2192; Bassermann F, 2005, CELL, V122, P45, DOI 10.1016/j.cell.2005.04.034; Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; D'Angiolella V, 2003, GENE DEV, V17, P2520, DOI 10.1101/gad.267603; Desai A, 1999, METHOD CELL BIOL, V61, P385; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; Ouyang T, 2003, J BIOL CHEM, V278, P30028, DOI 10.1074/jbc.M300883200; Rauh NR, 2005, NATURE, V437, P1048, DOI 10.1038/nature04093; Schmidt A, 2005, GENE DEV, V19, P502, DOI 10.1101/gad.320705; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	36	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15965	15972		10.1074/jbc.M610819200	http://dx.doi.org/10.1074/jbc.M610819200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17389604	hybrid			2022-12-27	WOS:000246794300005
J	Marino, F; Chen, ZW; Ergenekan, CE; Bush-Pelc, LA; Mathews, FS; Di Cera, E				Marino, Francesca; Chen, Zhi-Wei; Ergenekan, Can E.; Bush-Pelc, Leslie A.; Mathews, F. Scott; Di Cera, Enrico			Structural basis of Na plus activation mimicry in murine thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOVALENT CATION SPECIFICITY; SODIUM-BINDING-SITE; CRYSTAL-STRUCTURE; PROTEIN-C; THERMODYNAMIC LINKAGE; ALLOSTERIC REGULATION; POTENT ANTICOAGULANT; MOLECULAR-BASIS; RESIDUE 225; CA2+ SITE	Unlike human thrombin, murine thrombin lacks Na+ activation due to the charge reversal substitution D222K in the Na+ binding loop. However, the enzyme is functionally stabilized in a Na+- bound form and is highly active toward physiologic substrates. The structural basis of this peculiar property is unknown. Here, we present the 2.2 A resolution x-ray crystal structure of murine thrombin in the absence of inhibitors and salts. The enzyme assumes an active conformation, with Ser-195, Glu-192, and Asp-189 oriented as in the Na+-bound fast form of human thrombin. Lys-222 completely occludes the pore of entry to the Na+ binding site and positions its side chain inside the pore, with the N+ atom H-bonded to the backbone oxygen atoms of Lys-185, Asp-186b, and Lys-186d. The same architecture is observed in the 1.75 A resolution structure of a thrombin chimera in which the human enzyme carries all residues defining the Na+ pore in the murine enzyme. These findings demonstrate that Na+ activation in thrombin is linked to the architecture of the Na+ pore. The molecular strategy of Na+ activation mimicry unraveled for murine thrombin is relevant to serine proteases and enzymes activated by monovalent cations in general.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	enrico@wustl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058141, R01HL073813, R29HL049413, R01HL049413] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49413, HL73813, HL58141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; Bah A, 2006, J BIOL CHEM, V281, P40049, DOI 10.1074/jbc.M608600200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bajaj SP, 2006, J BIOL CHEM, V281, P24873, DOI 10.1074/jbc.M509971200; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BODE W, 1992, PROTEIN SCI, V1, P426; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush LA, 2006, J BIOL CHEM, V281, P7183, DOI 10.1074/jbc.M512082200; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; Carrell CJ, 2006, BIOPHYS CHEM, V121, P177, DOI 10.1016/j.bpc.2005.12.008; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DEGEN SJF, 1995, THROMB HAEMOSTASIS, V73, P203; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; Di Cera E, 2007, PHYS CHEM CHEM PHYS, V9, P1292, DOI 10.1039/b616819a; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Feistritzer C, 2006, J BIOL CHEM, V281, P20077, DOI 10.1074/jbc.M600506200; Fuhrmann CN, 2006, J AM CHEM SOC, V128, P9086, DOI 10.1021/ja057721o; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; Gopalakrishna K, 2006, THROMB HAEMOSTASIS, V95, P936, DOI 10.1160/TH06-03-0156; Gruber A, 2006, J THROMB HAEMOST, V4, P392, DOI 10.1111/j.1538-7836.2006.01760.x; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; He XH, 1999, J BIOL CHEM, V274, P4970, DOI 10.1074/jbc.274.8.4970; Henriksen RA, 1998, BLOOD, V91, P2026, DOI 10.1182/blood.V91.6.2026.2026_2026_2031; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; Ishikawa K, 2002, STRUCTURE, V10, P877, DOI 10.1016/S0969-2126(02)00779-7; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Krem MM, 1999, J BIOL CHEM, V274, P28063, DOI 10.1074/jbc.274.40.28063; Laughlin LT, 1997, ARCH BIOCHEM BIOPHYS, V348, P262, DOI 10.1006/abbi.1997.0448; Mengwasser KE, 2005, J BIOL CHEM, V280, P26997, DOI 10.1074/jbc.M502678200; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; Nogami K, 2005, J BIOL CHEM, V280, P18476, DOI 10.1074/jbc.M412778200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page MJ, 2006, THROMB HAEMOSTASIS, V95, P920, DOI 10.1160/TH06-05-0239; Page MJ, 2006, PHYSIOL REV, V86, P1049, DOI 10.1152/physrev.00008.2006; Page MJ, 2006, BIOCHEMISTRY-US, V45, P2987, DOI 10.1021/bi052481a; Papaconstantinou ME, 2005, J BIOL CHEM, V280, P29393, DOI 10.1074/jbc.C500248200; Petrovan RJ, 2000, BIOCHEMISTRY-US, V39, P14457, DOI 10.1021/bi0009486; Pineda AO, 2004, BIOPHYS CHEM, V112, P253, DOI 10.1016/j.bpc.2004.07.027; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Prasad S, 2004, J BIOL CHEM, V279, P10103, DOI 10.1074/jbc.M312614200; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Rouy S, 2006, BRIT J HAEMATOL, V132, P770, DOI 10.1111/j.1365-2141.2005.05920.x; Roy DB, 2001, PROTEINS, V43, P315, DOI 10.1002/prot.1042; Schmidt AE, 2002, J BIOL CHEM, V277, P28987, DOI 10.1074/jbc.M201892200; Stanchev H, 2006, THROMB HAEMOSTASIS, V95, P195; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; Sun WY, 1998, P NATL ACAD SCI USA, V95, P7597, DOI 10.1073/pnas.95.13.7597; Sun WY, 2001, THROMB HAEMOSTASIS, V85, P651, DOI 10.1055/s-0037-1615648; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; Underwood MC, 2000, J BIOL CHEM, V275, P36876, DOI 10.1074/jbc.M001386200; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Wilbanks SM, 1998, BIOCHEMISTRY-US, V37, P7456, DOI 10.1021/bi973046m; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; Yun TH, 2003, J BIOL CHEM, V278, P48112, DOI 10.1074/jbc.M306925200; Zhang B, 2004, J THROMB HAEMOST, V2, P1564, DOI 10.1111/j.1538-7836.2004.00857.x	66	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16355	16361		10.1074/jbc.M701323200	http://dx.doi.org/10.1074/jbc.M701323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428793	hybrid			2022-12-27	WOS:000246794300043
J	Papp, S; Fadel, MP; Kim, H; McCulloch, CA; Opas, M				Papp, Sylvia; Fadel, Marc P.; Kim, Hugh; McCulloch, Christopher A.; Opas, Michal			Calreticulin affects fibronectin-based cell-substratum adhesion via the regulation of c-Src activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; TYROSINE KINASES; ENDOPLASMIC-RETICULUM; FOCAL ADHESIONS; CYTOPLASMIC DOMAIN; MATRIX ADHESIONS; SARCOPLASMIC-RETICULUM; EXPRESSION; VINCULIN; GENE	Calreticulin is an endoplasmic reticulum Ca2+-storage protein, which influences gene expression and cell adhesion. In this study, we show that calreticulin induces fibronectin gene expression and matrix deposition, leading to differences in cell spreading and focal adhesion formation in cells differentially expressing calreticulin. We further show that these effects of calreticulin occur via a c-Src-regulated pathway and that c-Src activity is inversely related to calreticulin abundance. Since c-Src is an important regulator of focal contact turnover, we investigated the effect of c-Src inhibition on cells differentially expressing calreticulin. Inhibition of c-Src rescued the poorly adhesive phenotype of the calreticulin-underexpressing cells in that they became well spread, commenced formation of numerous focal contacts, and deposited a rich fibronectin matrix. Importantly, we show that c-Src activity is dependent on releasable Ca2+ from the endoplasmic reticulum, thus implicating Ca2+ sensitive pathways that are affected by calreticulin in cell-substratum adhesion. We propose that calreticulin affects fibronectin synthesis and matrix assembly via the regulation of fibronectin gene expression. In parallel, calcium-dependent effects of calreticulin on c-Src activity influence the formation and/or stability of focal contacts, which are instrumental in matrix assembly and remodeling.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Opas, M (corresponding author), Univ Toronto, Lab Med & Pathobiol, 1 Kings Coll Circle,Med Sci Bldg,Rm 6326, Toronto, ON M5S 1A8, Canada.	m.opas@utoronto.ca						Ballestrem C, 2006, J CELL SCI, V119, P866, DOI 10.1242/jcs.02794; Barker TH, 2004, J BIOL CHEM, V279, P23510, DOI 10.1074/jbc.M402169200; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Bedard K, 2005, INT REV CYTOL, V245, P91, DOI 10.1016/S0074-7696(05)45004-4; Breitenlechner CB, 2005, J MOL BIOL, V353, P222, DOI 10.1016/j.jmb.2005.08.023; BRICKELL PM, 1991, INT J EXP PATHOL, V72, P97; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Campbell ID, 2004, TRENDS BIOCHEM SCI, V29, P429, DOI 10.1016/j.tibs.2004.06.005; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Cary LA, 1996, J CELL SCI, V109, P1787; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; Datta A, 2002, J BIOL CHEM, V277, P3943, DOI 10.1074/jbc.M109536200; DEAN DC, 1989, AM J RESP CELL MOL, V1, P5, DOI 10.1165/ajrcmb/1.1.5; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; Fadel MP, 2001, J BIOL CHEM, V276, P27083, DOI 10.1074/jbc.M101676200; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FLIEGEL L, 1989, BIOCHIM BIOPHYS ACTA, V982, P1, DOI 10.1016/0005-2736(89)90166-1; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; Goldmann WH, 1998, EXP CELL RES, V239, P235, DOI 10.1006/excr.1997.3915; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; ILLC D, 1995, NATURE, V377, P539; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Jung J, 2006, CALCIUM BINDING PROT, V1, P67; Katz BZ, 2003, J BIOL CHEM, V278, P29115, DOI 10.1074/jbc.M212396200; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; KELLIE S, 1991, J CELL SCI, V99, P207; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; KWON HJ, 1992, CANCER RES, V52, P6926; Lin EH, 2004, EXP CELL RES, V293, P1, DOI 10.1016/j.yexcr.2003.09.008; LIU NG, 1994, J BIOL CHEM, V269, P28635; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; Maher PA, 2000, EXP CELL RES, V260, P189, DOI 10.1006/excr.2000.5009; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; ROHRSCHNEIDER L, 1985, MOL CELL BIOL, V5, P3097, DOI 10.1128/MCB.5.11.3097; ROHRSCHNEIDER L, 1981, COLD SPRING HARB SYM, V46, P953; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sanders EJ, 2005, EXP EYE RES, V81, P551, DOI 10.1016/j.exer.2005.03.013; Sanders EJ, 2002, HISTOCHEM J, V34, P161, DOI 10.1023/A:1020994515099; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; Sechler JL, 1996, CELL ADHES COMMUN, V4, P413, DOI 10.3109/15419069709004458; SENGER DR, 1983, AM J PHYSIOL, V245, pC144, DOI 10.1152/ajpcell.1983.245.1.C144; Shen JS, 2005, METHODS, V35, P382, DOI 10.1016/j.ymeth.2004.10.011; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Szabo E., 2006, J APPL BIOMED, V4, P45; TAPLEY P, 1989, ONCOGENE, V4, P325; Volberg T, 2001, J CELL SCI, V114, P2279; Wierzbicka-Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670; WU CY, 1993, J BIOL CHEM, V268, P21883; Zaidel-Bar R, 2004, BIOCHEM SOC T, V32, P416, DOI 10.1042/BST0320416; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zhang ZY, 2004, MOL BIOL CELL, V15, P4234, DOI 10.1091/mbc.E04-03-0264; Zou JX, 2002, J BIOL CHEM, V277, P1824, DOI 10.1074/jbc.M103133200	76	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16585	16598		10.1074/jbc.M701011200	http://dx.doi.org/10.1074/jbc.M701011200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17389592	hybrid			2022-12-27	WOS:000246794300065
J	Zhang, FJ; Strom, AL; Fukada, K; Lee, S; Hayward, LJ; Zhu, HN				Zhang, Fujian; Strom, Anna-Lena; Fukada, Kei; Lee, Sangmook; Hayward, Lawrence J.; Zhu, Haining			Interaction between familial amyotrophic lateral sclerosis (ALS)-linked SOD1 mutants and the dynein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALS-LINKED SOD1; MOTOR-NEURON DEGENERATION; FAST AXONAL-TRANSPORT; SUPEROXIDE-DISMUTASE MUTANTS; COPPER-BINDING-SITE; TRANSGENIC MICE; MOUSE MODEL; MUTATION; DISEASE; PROTEINS	Amyotrophic lateral sclerosis ( ALS) is a neurodegenerative disorder characterized by progressive motor neuron death. More than 90 mutations in the copper-zinc superoxide dismutase (SOD1) gene cause a subset of familial ALS. Toxic properties have been proposed for the ALS-linked SOD1 mutants, but the nature of the toxicity has not been clearly specified. Cytoplasmic inclusion bodies containing mutant SOD1 and a number of other proteins are a pathological hallmark of mutant SOD1-mediated familial ALS, but whether such aggregates are toxic to motor neurons remains unclear. In this study, we identified a dynein subunit as a component of the mutant SOD1-containing high molecular weight complexes using proteomic techniques. We further demonstrated interaction and colocalization between dynein and mutant SOD1, but not normal SOD1, in cultured cells and also in G93A and G85R transgenic rodent tissues. Moreover, the interaction occurred early, prior to the onset of symptoms in the ALS animal models and increased over the disease progression. Motor neurons with long axons are particularly susceptible to defects in axonal transport. Our results demonstrate a direct "gain-of-interaction" between mutant SOD1 and dynein, which may provide insights into the mechanism by which mutant SOD1 could contribute to a defect in retrograde axonal transport or other dynein functions. The aberrant interaction is potentially critical to the formation of mutant SOD1 aggregates as well as the toxic cascades leading to motor neuron degeneration in ALS.	Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA	University of Kentucky; University of Massachusetts System; University of Massachusetts Worcester	Zhu, HN (corresponding author), 741 S Limestone St, Lexington, KY 40536 USA.	haining@uky.edu	Zhu, Haining/A-6076-2008	Zhu, Haining/0000-0001-5498-6694; Hayward, Lawrence/0000-0003-0579-0358	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES012025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044170, R01NS049126] Funding Source: NIH RePORTER; NIEHS NIH HHS [R21-ES12025] Funding Source: Medline; NINDS NIH HHS [R01-NS49126, R01-NS44170, R01 NS044170] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BREUER AC, 1987, NEUROLOGY, V37, P738, DOI 10.1212/WNL.37.5.738; BREUER AC, 1988, CELL MOTIL CYTOSKEL, V10, P321, DOI 10.1002/cm.970100136; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruns CK, 2007, EMBO J, V26, P855, DOI 10.1038/sj.emboj.7601528; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Fukada K, 2004, MOL CELL PROTEOMICS, V3, P1211, DOI 10.1074/mcp.M400094-MCP200; Fukada K, 2001, EUR J NEUROSCI, V14, P2032, DOI 10.1046/j.0953-816x.2001.01828.x; Gaudette M, 2000, AMYOTROPH LATERAL SC, V1, P83, DOI 10.1080/14660820050515377; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Guzik BW, 2004, CURR OPIN CELL BIOL, V16, P443, DOI 10.1016/j.ceb.2004.06.002; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Holzbaur ELF, 2004, TRENDS CELL BIOL, V14, P233, DOI 10.1016/j.tcb.2004.03.009; Howland DS, 2002, P NATL ACAD SCI USA, V99, P1604, DOI 10.1073/pnas.032539299; Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Kieran D, 2005, J CELL BIOL, V169, P561, DOI 10.1083/jcb.200501085; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; Ligon LA, 2005, NEUROREPORT, V16, P533, DOI 10.1097/00001756-200504250-00002; Liu J, 2004, NEURON, V43, P5, DOI 10.1016/j.neuron.2004.06.016; Lu XN, 2005, MOL CELL PROTEOMICS, V4, P1948, DOI 10.1074/mcp.M500138-MCP200; Menzies FM, 2002, BRAIN, V125, P1522, DOI 10.1093/brain/awf167; Munch C, 2004, NEUROLOGY, V63, P724, DOI 10.1212/01.WNL.0000134608.83927.B1; Pasinelli P, 2004, NEURON, V43, P19, DOI 10.1016/j.neuron.2004.06.021; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Pun S, 2006, NAT NEUROSCI, V9, P408, DOI 10.1038/nn1653; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066; Sasaki S, 1996, NEUROLOGY, V47, P535, DOI 10.1212/WNL.47.2.535; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Teuchert M, 2006, EXP NEUROL, V198, P271, DOI 10.1016/j.expneurol.2005.12.005; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Wang J, 2003, HUM MOL GENET, V12, P2753, DOI 10.1093/hmg/ddg312; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Wang LJ, 2002, J NEUROSCI, V22, P6920; Warita H, 1999, BRAIN RES, V819, P120, DOI 10.1016/S0006-8993(98)01351-1; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zhang B, 1997, J CELL BIOL, V139, P1307, DOI 10.1083/jcb.139.5.1307; Zhang FJ, 2006, BBA-GEN SUBJECTS, V1760, P404, DOI 10.1016/j.bbagen.2005.11.024; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	48	134	136	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16691	16699		10.1074/jbc.M609743200	http://dx.doi.org/10.1074/jbc.M609743200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403682	hybrid			2022-12-27	WOS:000246794300074
J	Hothersall, J; Wu, J; Rahman, AS; Shields, JA; Haddock, J; Johnson, N; Cooper, SM; Stephens, ER; Cox, RJ; Crosby, J; Willis, CL; Simpson, TJ; Thomas, CM				Hothersall, Joanne; Wu, Ji'en; Rahman, Ayesha S.; Shields, Jennifer A.; Haddock, James; Johnson, Nicola; Cooper, Sian M.; Stephens, Elton R.; Cox, Russell J.; Crosby, John; Willis, Christine L.; Simpson, Thomas J.; Thomas, Christopher M.			Mutational analysis reveals that all tailoring region genes are required for production of polyketide antibiotic mupirocin by pseudomonas fluorescens - Pseudomonic acid B biosynthesis precedes pseudomonic acid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN REPB; ORIGIN-BINDING ACTIVITY; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; COMBINATORIAL BIOSYNTHESIS; IDENTIFICATION; CLUSTER; TRANSFORMATION; MUTAGENESIS; RESISTANCE	The Pseudomonas fluorescens mupirocin biosynthetic cluster encodes six proteins involved in polyketide biosynthesis and 26 single polypeptides proposed to perform largely tailoring functions. In-frame deletions in the tailoring open reading frames demonstrated that all are required for mupirocin production. A bidirectional promoter region was identified between mupF, which runs counter to other open reading frames and its immediate neighbor macpC, implying the 74-kb cluster consists of two transcriptional units. mupD/E and mupJ/K must be cotranscribed as pairs for normal function implying co-assembly during translation. MupJ and K belong to a widely distributed enzyme pair implicated, with MupH, in methyl addition. Deletion of mupF, a putative ketoreductase, produced a mupirocin analogue with a C-7 ketone. Deletion of mupC, a putative dienoyl CoA reductase, generated an analogue whose structure indicated that MupC is also implicated in control of the oxidation state around the tetrahydropyran ring of monic acid. Double mutants with Delta mupC and Delta mupO, Delta mupU, Delta mupV, or Delta macpE produced pseudomonic acid B but not pseudomonic acid A, as do the mupO, U, V, and macpE mutants, indicating that MupC must work after MupO, U, and V.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England	University of Birmingham; University of Bristol	Thomas, CM (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	c.m.thomas@bham.ac.uk	Cox, Russell John/F-9190-2015; Wu, Ji'En/A-6967-2012; Simpson, Thomas J/P-5058-2015	Cox, Russell John/0000-0002-1844-0157; 	Biotechnology and Biological Sciences Research Council [BBS/B/07071, B20055] Funding Source: Medline; Engineering and Physical Sciences Research Council [GR/S78124/01] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		ALBERTINI AM, 1995, MICROBIOL-SGM, V141, P299, DOI 10.1099/13500872-141-2-299; Basu A, 2004, J BACTERIOL, V186, P335, DOI 10.1128/JB.186.2.335-342.2004; Basu A, 2002, J BACTERIOL, V184, P2204, DOI 10.1128/JB.184.8.2204-2214.2002; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRUSILOW WSA, 1993, MOL MICROBIOL, V9, P419, DOI 10.1111/j.1365-2958.1993.tb01703.x; Butcher RA, 2007, P NATL ACAD SCI USA, V104, P1506, DOI 10.1073/pnas.0610503104; Calderone CT, 2006, P NATL ACAD SCI USA, V103, P8977, DOI 10.1073/pnas.0603148103; CHAIN EB, 1974, J CHEM SOC CHEM COMM, P847, DOI 10.1039/c39740000847; CHAIN EB, 1977, J CHEM SOC PERK T, V1, P294; CHAIN EB, 1977, J CHEM SOC P1, V1, P318; Chen XH, 2006, J BACTERIOL, V188, P4024, DOI 10.1128/JB.00052-06; CLAYTON JP, 1980, TETRAHEDRON LETT, V21, P881, DOI 10.1016/S0040-4039(00)71533-4; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; Cooper SM, 2005, CHEM BIOL, V12, P825, DOI 10.1016/j.chembiol.2005.05.015; Cooper SM, 2005, CHEM COMMUN, P1179, DOI 10.1039/b414781b; Edwards DJ, 2004, CHEM BIOL, V11, P817, DOI 10.1016/j.chembiol.2004.03.030; El-Sayed AK, 2001, MICROBIOL-SGM, V147, P2127, DOI 10.1099/00221287-147-8-2127; El-Sayed AK, 2003, CHEM BIOL, V10, P419, DOI 10.1016/S1074-5521(03)00091-7; FELINE TC, 1977, J CHEM SOC T, V1, P309; Gu LC, 2006, J AM CHEM SOC, V128, P9014, DOI 10.1021/ja0626382; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HUGHES J, 1978, BIOCHEM J, V176, P305, DOI 10.1042/bj1760305; HUMBERT R, 1989, J BACTERIOL, V171, P1435, DOI 10.1128/jb.171.3.1435-1444.1989; Julien B, 2006, CHEM BIOL, V13, P1277, DOI 10.1016/j.chembiol.2006.10.004; Kahn M, 1979, Methods Enzymol, V68, P268; MARTIN FMN, 1989, J CHEM SOC P, V1, P207; MOIR A, 1979, J GEN MICROBIOL, V111, P165, DOI 10.1099/00221287-111-1-165; OHANLON PJ, 1983, J CHEM SOC P, V1, P2655; RAO R, 1988, J BIOL CHEM, V263, P15957; Rix U, 2002, NAT PROD REP, V19, P542, DOI 10.1039/b103920m; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P4563; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; VandeCasteele M, 1997, COMP BIOCHEM PHYS A, V118, P463, DOI 10.1016/S0300-9629(97)00007-8; Weissman KJ, 2005, NAT REV MICROBIOL, V3, P925, DOI 10.1038/nrmicro1287; Weitnauer G, 2001, CHEM BIOL, V8, P569, DOI 10.1016/S1074-5521(01)00040-0; WHATLING CA, 1995, MICROBIOL-UK, V141, P973, DOI 10.1099/13500872-141-4-973; WU JE, 2007, CHEM COMMUN; Xu J, 2005, MICROBIOL-SGM, V151, P2515, DOI 10.1099/mic.0.28138-0; Yanagisawa T, 2003, J BIOL CHEM, V278, P25887, DOI 10.1074/jbc.M302633200; Zhu LL, 2005, J ORG CHEM, V70, P631, DOI 10.1021/jo0483623	42	30	30	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15451	15461		10.1074/jbc.M701490200	http://dx.doi.org/10.1074/jbc.M701490200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17383964	hybrid			2022-12-27	WOS:000246589600020
J	Lerch, TF; Shimasaki, S; Woodruff, TK; Jardetzky, TS				Lerch, Thomas F.; Shimasaki, Shunichi; Woodruff, Teresa K.; Jardetzky, Theodore S.			Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MORPHOGENETIC PROTEIN; TGF-BETA; GROWTH-FACTOR; SULFATE-BINDING; INHIBITION; COMPLEX; EXPRESSION; PROTEOGLYCANS; MEMBRANE; INSIGHTS	Follistatin (FS) regulates transforming growth factor-beta superfamily ligands and is necessary for normal embryonic and ovarian follicle development. Follistatin is expressed as two splice variants (FS288 and FS315). Previous studies indicated differences in heparin binding between FS288 and FS315, potentially influencing the physiological functions and locations of these isoforms. We have determined the structure of the FS315-activin A complex and quantitatively compared heparin binding by the two isoforms. The FS315 complex structure shows that both isoforms inhibit activin similarly, but FS315 exhibits movements within follistatin domain 3 (FSD3) apparently linked to binding of the C-terminal extension. Surprisingly, the binding affinities of FS288 and FS315 for heparin are similar at lower ionic strengths with FS315 binding decreasing more sharply as a function of salt concentration. When bound to activin, FS315 binds heparin similarly to the FS288 isoform, consistent with the structure of the complex, in which the acidic residues of the C-terminal extension cannot interact with the heparin-binding site. Activin-induced binding of heparin is unique to the FS315 isoform and may stimulate clearance of FS315 complexes.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Calif San Diego, Sch Med, Dept Reprod Med, La Jolla, CA 92093 USA; Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA	Northwestern University; University of California System; University of California San Diego; Northwestern University; Feinberg School of Medicine	Jardetzky, TS (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Cook Hall,Rm 4133,2205 Tech Dr, Evanston, IL 60208 USA.	tedj@northwestern.edu		Woodruff, Teresa/0000-0002-1197-3399	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD041857] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD041857] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abe Y, 2004, GROWTH FACTORS, V22, P105, DOI 10.1080/08977190410001704688; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cook RW, 2005, J BIOL CHEM, V280, P40177, DOI 10.1074/jbc.M504591200; Glister C, 2004, REPRODUCTION, V127, P239, DOI 10.1530/rep.1.00090; Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Gumienny TL, 2002, TRENDS ENDOCRIN MET, V13, P295, DOI 10.1016/S1043-2760(02)00615-X; Harrington AE, 2006, EMBO J, V25, P1035, DOI 10.1038/sj.emboj.7601000; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Hashimoto O, 2000, CELL SIGNAL, V12, P565, DOI 10.1016/S0898-6568(00)00099-1; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Innis CA, 2003, J BIOL CHEM, V278, P39969, DOI 10.1074/jbc.M211284200; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; INOUYE S, 1992, MOL CELL ENDOCRINOL, V90, P1, DOI 10.1016/0303-7207(92)90094-M; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Knight PG, 2006, REPRODUCTION, V132, P191, DOI 10.1530/rep.1.01074; Kogure K, 1996, HEPATOLOGY, V24, P361; Lee PY, 2002, J VIROL, V76, P6302, DOI 10.1128/JVI.76.12.6302-631-.2002; Lerch TF, 2007, MOL CELL ENDOCRINOL, V267, P1, DOI 10.1016/j.mce.2006.10.018; Lin SJ, 2006, REPRODUCTION, V132, P179, DOI 10.1530/rep.1.01072; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MICHEL U, 1990, BIOCHEM BIOPH RES CO, V173, P401, DOI 10.1016/S0006-291X(05)81072-1; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; Otsuka F, 2001, BIOCHEM BIOPH RES CO, V289, P961, DOI 10.1006/bbrc.2001.6103; Phillips DJ, 2000, J CLIN ENDOCR METAB, V85, P2411, DOI 10.1210/jc.85.7.2411; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Rider CC, 2006, BIOCHEM SOC T, V34, P458, DOI 10.1042/BST0340458; Roehrl MHA, 2004, BIOCHEMISTRY-US, V43, P16056, DOI 10.1021/bi048233g; Schneyer AL, 2004, J CLIN ENDOCR METAB, V89, P5067, DOI 10.1210/jc.2004-0162; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SHIMONAKA M, 1991, ENDOCRINOLOGY, V128, P3313, DOI 10.1210/endo-128-6-3313; Sidis Y, 2005, ENDOCRINOLOGY, V146, P130, DOI 10.1210/en.2004-1041; Sidis Y, 2006, ENDOCRINOLOGY, V147, P3586, DOI 10.1210/en.2006-0089; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SUGINO K, 1993, J BIOL CHEM, V268, P15579; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; Whitman M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.64.re1; Woodruff TK, 1998, BIOCHEM PHARMACOL, V55, P953, DOI 10.1016/S0006-2952(97)00477-2; Yamamoto TS, 2000, INT J DEV BIOL, V44, P341; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375	50	56	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15930	15939		10.1074/jbc.M700737200	http://dx.doi.org/10.1074/jbc.M700737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17409095	hybrid			2022-12-27	WOS:000246589600068
J	Szollosi, A; Nenquin, M; Henquin, JC				Szollosi, Andras; Nenquin, Myriam; Henquin, Jean-Claude			Overnight culture unmasks glucose-induced insulin secretion in mouse islets lacking ATP-sensitive K+ channels by improving the triggering Ca2+ signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; AMPLIFYING PATHWAYS; B-CELLS; KNOCKOUT MICE; OSCILLATIONS; RELEASE; MECHANISMS; CAMP; EXOCYTOSIS; RECEPTOR	A current model ascribes glucose-induced insulin secretion to the interaction of a triggering pathway (K-ATP channel-dependent Ca2+ influx and rise in cytosolic [Ca2+](c)) and an amplifying pathway (K-ATP channel-independent augmentation of secretion without further increase of [Ca2+](c)). However, several studies of sulfonylurea receptor 1 null mice (Sur1KO) failed to measure significant effects of glucose in their islets lacking KATP channels. We addressed this issue that challenges the model. Compared with controls, fresh Sur1KO islets showed slightly elevated basal [Ca2+](c) and insulin secretion. In 15mM glucose, the absolute rate of secretion was similar to 3- fold lower in Sur1KO than control islets, with only poor increase above base line. Overnight culture of Sur1KO islets in 10 mM glucose (not in 5 mM) augmented basal insulin secretion and considerably improved the response to 15 mM glucose, which reached higher values than in control islets, in which culture had little impact. Glucose stimulation during KCl depolarization showed that the amplifying pathway is functional in fresh and cultured Sur1KO islets. The differences in insulin secretion between fresh and cultured Sur1KO islets and between Sur1KO and control islets were not attributable to differences in insulin content, glucose oxidation rate, or synchronization of [Ca2+](c) oscillations. The unmasking of glucose-induced insulin secretion in beta-cells lacking K-ATP channels is paradoxically due to improvement in the production of a triggering signal (elevated [Ca2+](c)). The results show that K-ATP channels are not the only transducer of glucose effects on [Ca2+](c) in beta-cells. They explain controversies in the literature and refute arguments raised against the model implicating an amplifying pathway in glucose-induced insulin secretion.-	Univ Louvain, Unite Endocrinol & Metab, Fac Med, B-1200 Brussels, Belgium	Universite Catholique Louvain	Henquin, JC (corresponding author), Univ Louvain, Unite Endocrinol & Metab, Fac Med, UCL 55-30,Ave Hippocrate 55, B-1200 Brussels, Belgium.	henquin@endo.ucl.ac.be	Szollosi, Andras/P-4278-2019; Szollosi, Andras/J-5097-2013	Szollosi, Andras/0000-0002-5570-4609; 				Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aizawa T, 2002, DIABETES, V51, pS96, DOI 10.2337/diabetes.51.2007.S96; Anello M, 1999, BRIT J PHARMACOL, V127, P1883, DOI 10.1038/sj.bjp.0702731; Ashcroft FM, 2005, J CLIN INVEST, V115, P2047, DOI 10.1172/JCI25495; Bratanova-Tochkova TK, 2002, DIABETES, V51, pS83, DOI 10.2337/diabetes.51.2007.S83; Doliba NM, 2006, AM J PHYSIOL-ENDOC M, V291, pE525, DOI 10.1152/ajpendo.00579.2005; Doliba NM, 2004, AM J PHYSIOL-ENDOC M, V286, pE834, DOI 10.1152/ajpendo.00292.2003; Dufer M, 2004, DIABETOLOGIA, V47, P488, DOI 10.1007/s00125-004-1348-0; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Gilon P, 2002, DIABETES, V51, pS144, DOI 10.2337/diabetes.51.2007.S144; GILON P, 1994, DIABETOLOGIA, V37, P1007, DOI 10.1007/BF00400464; Haspel D, 2005, DIABETOLOGIA, V48, P913, DOI 10.1007/s00125-005-1720-8; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HENQUIN JC, 1976, AM J PHYSIOL, V231, P713, DOI 10.1152/ajplegacy.1976.231.3.713; Jonas JC, 1998, DIABETES, V47, P1266, DOI 10.2337/diabetes.47.8.1266; Kasai H, 2002, DIABETES, V51, pS19, DOI 10.2337/diabetes.51.2007.S19; Li CH, 2004, J BIOL CHEM, V279, P13393, DOI 10.1074/jbc.M311502200; MacDonald PE, 2005, PHILOS T R SOC B, V360, P2211, DOI 10.1098/rstb.2005.1762; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Matschinsky FM, 2006, DIABETES, V55, P1; Munoz A, 2005, ENDOCRINOLOGY, V146, P5514, DOI 10.1210/en.2005-0637; Nakazaki M, 2002, DIABETES, V51, P3440, DOI 10.2337/diabetes.51.12.3440; Nenquin M, 2004, J BIOL CHEM, V279, P32316, DOI 10.1074/jbc.M402076200; Ravier MA, 2005, DIABETES, V54, P1798, DOI 10.2337/diabetes.54.6.1798; Ravier MA, 2002, FEBS LETT, V530, P215, DOI 10.1016/S0014-5793(02)03491-9; Rocheleau JV, 2006, PLOS BIOL, V4, P221, DOI 10.1371/journal.pbio.0040026; Sato Y, 1999, ENDOCRINOLOGY, V140, P2252, DOI 10.1210/en.140.5.2252; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 2000, DIABETES, V49, P311, DOI 10.2337/diabetes.49.3.311; Shiota C, 2005, AM J PHYSIOL-ENDOC M, V289, pE570, DOI 10.1152/ajpendo.00102.2005; Shiota C, 2002, J BIOL CHEM, V277, P37176, DOI 10.1074/jbc.M206757200; Straub SG, 2002, DIABETES-METAB RES, V18, P451, DOI 10.1002/dmrr.329; Szollosi A, 2007, J BIOL CHEM, V282, P1747, DOI 10.1074/jbc.M609875200	37	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14768	14776		10.1074/jbc.M701382200	http://dx.doi.org/10.1074/jbc.M701382200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389589	hybrid			2022-12-27	WOS:000246589000012
J	Campbell, EJ; Owen, CA				Campbell, Edward J.; Owen, Caroline A.			The sulfate groups of chondroitin sulfate- and heparan sulfate-containing proteoglycans in neutrophil plasma membranes are novel binding sites for human leukocyte elastase and cathepsin G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MUCUS PROTEINASE-INHIBITOR; CELL-SURFACE; CATALYTIC-ACTIVITY; ALPHA-1-PROTEINASE INHIBITOR; ACTIVATED NEUTROPHILS; SERINE PROTEINASES; BOUND ELASTASE; BFGF RELEASE; FACTOR FGF	Human leukocyte elastase (HLE) and cathepsin G (CG) are expressed at high levels on the surface of activated human neutrophils (PMN) in catalytically active but inhibitor-resistant forms having the potential to contribute to tissue injury. Herein we have investigated the mechanisms by which HLE and CG bind to PMN plasma membranes. I-125-Labeled HLE and CG bind to PMN at 0 degrees C in a saturable and reversible manner (KD = 5.38 and 4.36 x 10(-7) M and 11.5 and 8.1 x 10(6) binding sites/cell, respectively). Incubation of PMN with radiolabeled HLE and CG in the presence of a 200-fold molar excess of unlabeled HLE, CG, myeloperoxidase, lactoferrin, proteinase 3, phenylmethylsulfonyl fluoride (PMSF)-inactivated HLE, or PMSF-inactivated CG inhibited binding of radiolabeled ligands. This indicates that these PMN granule proteins share binding sites on PMN and that functional active sites of HLE and CG are not required for their binding to PMN. The sulfate groups of heparan sulfate-and chondroitin sulfate-containing proteoglycans are the PMN binding sites for HLE and CG since binding of HLE and CG to PMN was inhibited by incubating PMN with 1) trypsin, chondroitinase ABC, and heparitinases, but not other glycanases, and 2) purified chondroitin sulfates, heparan sulfate, and other sulfated molecules, but not with non-sulfated glycans. Thus, heparan sulfate-and chondroitin sulfate-containing proteoglycans are low affinity, high volume PMN surface binding sites for HLE and CG, which are well suited to bind high concentrations of active serine proteinases released from degranulating PMN.	Harvard Univ, Div Pulm & Crit Care Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Univ Utah, Hlth Sci Ctr, Dept Internal Med, Salt Lake City, UT 84132 USA; Intermt Hlth Care, Salt Lake City, UT 84132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Utah System of Higher Education; University of Utah; Intermountain Healthcare	Owen, CA (corresponding author), Harvard Univ, Div Pulm & Crit Care Med, Brigham & Womens Hosp, Sch Med, 5 Francis St,905 Thorn Bldg, Boston, MA 02115 USA.	cowen@rics.bwh.harvard.edu	Owen, Caroline/H-5925-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063137, R01HL086814] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL063137, HL63137, HL086814, R01 HL086814] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott RE, 1998, ARCH SURG-CHICAGO, V133, P1002, DOI 10.1001/archsurg.133.9.1002; Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; ANTONILLI L, 1993, INT J CLIN PHARM RES, V13, P11; BANGALORE N, 1994, BIOL CHEM H-S, V375, P659, DOI 10.1515/bchm3.1994.375.10.659; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BIRGENS HS, 1983, BRIT J HAEMATOL, V54, P383, DOI 10.1111/j.1365-2141.1983.tb02113.x; BIRGENS HS, 1984, SCAND J HAEMATOL, V33, P275; BODE W, 1986, EMBO J, V5, P2453, DOI 10.1002/j.1460-2075.1986.tb04521.x; BOYUM A, 1963, SCAND J CLIN LAB S97, V21, P77; Buczek-Thomas JA, 1999, J BIOL CHEM, V274, P25167, DOI 10.1074/jbc.274.35.25167; Cai TQ, 1996, J EXP MED, V184, P1213, DOI 10.1084/jem.184.4.1213; Campbell EJ, 2000, J IMMUNOL, V165, P3366, DOI 10.4049/jimmunol.165.6.3366; CAMPBELL EJ, 1982, P NATL ACAD SCI-BIOL, V79, P6941, DOI 10.1073/pnas.79.22.6941; Chan SCH, 2003, AM J RESP CRIT CARE, V168, P192, DOI 10.1164/rccm.200208-829OC; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; DILLON TJ, 1990, CLIN CHEM, V36, P392; DWENGER A, 1986, J CLIN CHEM CLIN BIO, V24, P299; ERMOLIEFF J, 1994, J BIOL CHEM, V269, P29502; Ermolieff J, 1998, BIOCHEM J, V330, P1369, DOI 10.1042/bj3301369; FALLER B, 1992, BIOCHEMISTRY-US, V31, P8285, DOI 10.1021/bi00150a023; FALLER B, 1992, BIOL CHEM H-S, V373, P503, DOI 10.1515/bchm3.1992.373.2.503; FROMMHERZ KJ, 1991, J BIOL CHEM, V266, P15356; HORNEBECK W, 1994, PATHOL RES PRACT, V190, P895; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; Kostoulas G, 1997, BIOL CHEM, V378, P1481, DOI 10.1515/bchm.1997.378.12.1481; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARTODAM RR, 1979, PREP BIOCHEM, V9, P15, DOI 10.1080/00327487908061669; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Owen CA, 1998, J IMMUNOL, V160, P1436; OWEN CA, 1995, J IMMUNOL, V155, P5803; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; OWEN CA, 1997, AM J PHYSIOL, V272, P385; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; Petersen F, 1998, J IMMUNOL, V161, P4347; Powers J ., 1980, CIBA FDN S, V75, P51; PRYZWANSKY KB, 1979, CELL, V18, P1025, DOI 10.1016/0092-8674(79)90215-0; QUERINJE.P, 1971, EUR J BIOCHEM, V20, P420, DOI 10.1111/j.1432-1033.1971.tb01408.x; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; REDINI F, 1988, BIOCHEM PHARMACOL, V37, P4257, DOI 10.1016/0006-2952(88)90604-1; RINDLERLUDWIG R, 1978, NEUTRAL PROTEASES HU, P138; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Salek-Ardakani S, 2000, BLOOD, V96, P1879, DOI 10.1182/blood.V96.5.1879.h8001879_1879_1888; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT W, 1978, NEUTRAL PROTEASES HU, P77; Shapiro SD, 2003, AM J PATHOL, V163, P2329, DOI 10.1016/S0002-9440(10)63589-4; Takeyama K, 1998, AM J PHYSIOL-LUNG C, V275, pL294, DOI 10.1152/ajplung.1998.275.2.L294; TWUMASI DY, 1977, J BIOL CHEM, V252, P1917; Volpi N, 1996, BBA-GEN SUBJECTS, V1290, P299, DOI 10.1016/0304-4165(96)00033-5	57	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14645	14654		10.1074/jbc.M608346200	http://dx.doi.org/10.1074/jbc.M608346200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17384412	hybrid			2022-12-27	WOS:000246245800078
J	DeKoter, RP; Schweitzer, BL; Kamath, MB; Jones, D; Tagoh, H; Bonifer, C; Hildeman, DA; Huang, KJ				DeKoter, Rodney P.; Schweitzer, Brock L.; Kamath, Meghana B.; Jones, Darrel; Tagoh, Hiromi; Bonifer, Constanze; Hildeman, David A.; Huang, Kelly J.			Regulation of the interleukin-7 receptor alpha promoter by the Ets transcription factors PU.1 and GA-binding protein in developing B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON LYMPHOID PROGENITORS; MURINE INTERLEUKIN-7; GAMMA CHAIN; BONE-MARROW; INITIATOR ACTIVITY; GENE-EXPRESSION; DEFICIENT MICE; IL-7 RECEPTOR; CORE PROMOTER; T-CELLS	Signaling through the IL-7 receptor (IL-7R) is required for development and maintenance of the immune system. The receptor for IL-7 is heterodimeric, consisting of a common gamma chain (gamma c, encoded by Il2rg) and an alpha subunit (IL-7R alpha, encoded by Il7r). The Il7r gene is expressed specifically in the immune system in a developmental stage-specific manner. It is not known how the Il7r gene is transcriptionally regulated during B cell development. The goal of this study is to elucidate the function of the Il7r promoter region in developing B cells. Using a combination of 5' rapid amplification of cDNA ends analysis, transient transfection assays, and DNase I hypersensitivity mapping, we identified the location of the Il7r promoter. Using a combination of electrophoretic mobility shift analysis, chromatin immunoprecipitation experiments, and RNA interference experiments, we found that the Ets transcription factors PU.1 and GA-binding protein (GABP) activate the Il7r promoter by interacting with a highly conserved Ets binding site. In committed B lineage cells, GABP can promote Il7r transcription in the absence of PU.1. However, the results of retroviral gene transfer experiments suggest that PU.1 is uniquely required to initiate transcription of the Il7r locus at the earliest stages of progenitor B cell generation. In summary, these results suggest that Il7r transcription is regulated by both PU.1 and GABP in developing B cells.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; Univ Leeds, St James Univ Hosp, Div Expt Hematol, LIMM, Leeds LS9 7TF, W Yorkshire, England	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Saint James's University Hospital; University of Leeds	DeKoter, RP (corresponding author), 231 Albert Sabin Way,MSB 3256, Cincinnati, OH 45267 USA.	dekoterp@ucmail.uc.edu	Hildeman, David/AAA-1757-2020; Tagoh, Hiromi/B-2954-2009; DeKoter, Rodney/A-9415-2009; Hildeman, David/I-4884-2015; Bonifer, Constanze/B-3000-2009	Hildeman, David/0000-0002-0421-8483; Tagoh, Hiromi/0000-0001-9905-6992; DeKoter, Rodney/0000-0002-9201-1983; Hildeman, David/0000-0002-0421-8483; Bonifer, Constanze/0000-0002-4267-0825; Schweitzer, Brock/0000-0003-0178-5594	NIAID NIH HHS [AI052175, R56 AI057753, AI057753, R01 AI052175, R01 AI057753] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052175, R56AI057753, R01AI057753] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Chinenov Y, 2000, J BIOL CHEM, V275, P7749, DOI 10.1074/jbc.275.11.7749; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dias S, 2005, J EXP MED, V201, P971, DOI 10.1084/jem.20042393; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; Giliani S, 2005, IMMUNOL REV, V203, P110, DOI 10.1111/j.0105-2896.2005.00234.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; Hildeman D, 1997, J VIROL, V71, P9672, DOI 10.1128/JVI.71.12.9672-9678.1997; Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood-2005-03-0860; JACOBSEN FW, 1994, J IMMUNOL, V153, P270; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KONDO M, 1994, EUR J IMMUNOL, V24, P2026, DOI 10.1002/eji.1830240914; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Lee HC, 2005, J IMMUNOL, V174, P7800, DOI 10.4049/jimmunol.174.12.7800; Lefevre P, 2005, J BIOL CHEM, V280, P27552, DOI 10.1074/jbc.M502422200; Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727; Maki K, 1996, P NATL ACAD SCI USA, V93, P7172, DOI 10.1073/pnas.93.14.7172; Medina KL, 2004, DEV CELL, V7, P607, DOI 10.1016/j.devcel.2004.08.006; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; PLEIMAN CM, 1991, MOL CELL BIOL, V11, P3052, DOI 10.1128/MCB.11.6.3052; Polli M, 2005, BLOOD, V106, P2083, DOI 10.1182/blood-2005-01-0283; Ristevski S, 2004, MOL CELL BIOL, V24, P5844, DOI 10.1128/MCB.24.13.5844-5849.2004; ROLINK A, 1993, BLOOD, V81, P2290; Rosmarin  AG, 2004, BLOOD CELL MOL DIS, V32, P143, DOI 10.1016/j.bcmd.2003.09.005; Schweitzer BL, 2006, J IMMUNOL, V177, P2195, DOI 10.4049/jimmunol.177.4.2195; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Van de Wiele CJV, 2004, J IMMUNOL, V172, P4235, DOI 10.4049/jimmunol.172.7.4235; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Xue HH, 2004, NAT IMMUNOL, V5, P1036, DOI 10.1038/ni1117; Ye M, 2005, J EXP MED, V202, P1411, DOI 10.1084/jem.20051089; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	41	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14194	14204		10.1074/jbc.M700377200	http://dx.doi.org/10.1074/jbc.M700377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17392277	hybrid, Green Accepted			2022-12-27	WOS:000246245800030
J	Narita, K; Chien, J; Mullany, SA; Staub, J; Qian, X; Lingle, WL; Shridhar, V				Narita, Keishi; Chien, Jeremy; Mullany, Sally A.; Staub, Julie; Qian, Xiang; Lingle, Wilma L.; Shridhar, Viji			Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HEPARAN-SULFATE; ACTIVATION; CARCINOMA; ERK	Heparan sulfate (HS) glycosaminoglycans are the oligosaccharide chains of heparan sulfate proteoglycans. The sulfation of HS glycosaminoglycan residues is required for its interaction with various heparin-binding growth factors to promote their biological activities to activate their high affinity receptor tyrosine kinases. We have identified HS glycosaminoglycan-6-O-endosulfatase HSulf-1 as a down-regulated gene in ovarian, breast, and several other cancer cell lines. Here we have shown that HSulf-1 inhibits autocrine activation of the EGFR-ERK ( epidermal growth factor receptor-extracellular signal-regulated kinase) pathway induced by serum withdrawal in MDA-MB-468 breast cancer cells. Short hairpin RNA-mediated down-regulation of HSulf-1 in HSulf-1 clonal lines of MDA-MB-468 led to a significant increase in autocrine activation of ERK compared with vector only control. The autocrine signaling was also inhibited with neutralization antibodies against amphiregulin and HB-EGF, the heparin-binding growth factor family of the EGF superfamily. Furthermore, HSulf-1-mediated inhibition of autocrine signaling was associated with reduced cyclin D1 levels, leading to decreased S phase fraction and increased G(2)-M fraction, as well as increased cell death. Finally, evaluation of HSulf-1 expression levels in primary invasive breast tumors by RNA in situ hybridization indicated that HSulf-1 is down-regulated in the majority (60%) of tumors, with a predominant association with lobular histology. These data suggest a potential role of HSulf-1 down-regulation in mammary carcinogenesis.	Mayo Clin, Coll Med, Ctr Canc, Dept Lab Med & Expt Pathol, Rochester, MN 55905 USA	Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin, Coll Med, Ctr Canc, Dept Lab Med & Expt Pathol, 200 1st St,SW, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Seal, Sudipta/A-7698-2012; Narita, Keishi/E-3539-2010; Xiangyang, Qian/Q-5174-2019; Chien, Jeremy/AID-8939-2022	Narita, Keishi/0000-0002-7602-8523; Chien, Jeremy/0000-0003-4744-8374	NATIONAL CANCER INSTITUTE [R01CA106954] Funding Source: NIH RePORTER; NCI NIH HHS [CA106954-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agranovich MS, 2005, RUSS J MATH PHYS, V12, P1; Arpino G, 2004, BREAST CANCER RES, V6, pR149, DOI 10.1186/bcr767; Bottini A, 2006, J CLIN ONCOL, V24, P3623, DOI 10.1200/JCO.2005.04.5773; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Dubey S, 2006, LANCET ONCOL, V7, P416, DOI 10.1016/S1470-2045(06)70693-3; Evron E, 2001, CANCER RES, V61, P2782; Gururaj AE, 2006, CLIN CANCER RES, V12, p1001S, DOI 10.1158/1078-0432.CCR-05-2110; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; Johnston SRD, 2006, CLIN CANCER RES, V12, p1061S, DOI 10.1158/1078-0432.CCR-05-2125; Johnston SRD, 2005, J STEROID BIOCHEM, V95, P173, DOI 10.1016/j.jsbmb.2005.04.004; Kansra S, 2004, MOL BIOL CELL, V15, P4299, DOI 10.1091/mbc.E04-03-0233; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; Ma L, 1998, INT J CANCER, V78, P112, DOI 10.1002/(SICI)1097-0215(19980925)78:1<112::AID-IJC18>3.0.CO;2-D; Ma L, 2001, J PATHOL, V194, P413, DOI 10.1002/path.902; Mullen P, 2004, METH MOLEC MED, V88, P247; Narita K, 2006, CANCER RES, V66, P6025, DOI 10.1158/0008-5472.CAN-05-3582; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Qian X, 2004, DIAGN MOL PATHOL, V13, P9, DOI 10.1097/00019606-200403000-00002; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yin F, 2001, ANTICANCER RES, V21, P413	28	67	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14413	14420		10.1074/jbc.M611395200	http://dx.doi.org/10.1074/jbc.M611395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17363371	hybrid			2022-12-27	WOS:000246245800054
J	Pang, DJ; Hayday, AC; Bijlmakers, MJ				Pang, Dick John; Hayday, Adrian C.; Bijlmakers, Marie-Jose			CD8 raft localization is induced by its assembly into CD8 alpha beta heterodimers, not CD8 alpha alpha homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-ACTIVATION; TYROSINE-PROTEIN-KINASE; GPI-ANCHORED PROTEINS; CLASS-I MOLECULE; MEMBRANE MICRODOMAINS; CORECEPTOR FUNCTION; LIPID RAFTS; BETA-CHAIN; DETERGENT-RESISTANT; ANTIGEN RECEPTOR	The coreceptor CD8 is expressed as a CD8 alpha beta heterodimer on major histocompatibility complex class I-restricted TCR alpha beta T cells, and as a CD8 alpha alpha homodimer on subsets of memory T cells, intraepithelial lymphocytes, natural killer cells, and dendritic cells. Although the role of CD8 alpha alpha is not well understood, it is increasingly clear that this protein is not a functional homologue of CD8 alpha beta On major histocompatibility complex class I-restricted T cells, CD8 alpha beta is a more efficient TCR coreceptor than CD8 alpha alpha. This property has for the mouse protein been attributed to the recruitment of CD8 alpha beta into lipid rafts, which is dependent on CD8 beta palmitoylation. Here, these divergent distributions of CD8 alpha beta and CD8 alpha alpha are demonstrated for the human CD8 proteins as well. However, although palmitoylation of both CD8 alpha and CD8 beta chains was detected, this modification did not contribute to raft localization. In contrast, arginines in the cytoplasmic domain are crucial for raft localization of CD8 beta beta. Most strikingly, the assembly of a non-raft localized CD8 beta chain with a non-raft localized CD8 alpha chain resulted in raft-localized CD8 alpha beta heterodimers. Using chimeric CD8 proteins, this property of the heterodimer was found to be determined by the assembly of CD8 alpha and CD8 beta extracellular regions. The presence of two CD8 alpha extracellular regions, on the other hand, appears to preclude raft localization. Thus, heterodimer formation and raft association are intimately linked for CD8 alpha beta. These results emphasize that lipid raft localization is a key feature of human CD8 alpha beta that clearly distinguishes it from CD8 alpha alpha.	Kings Coll London, Guys Hosp, Sch Med, Dept Immunobiol, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Bijlmakers, MJ (corresponding author), Kings Coll London, Guys Hosp, Sch Med, Dept Immunobiol, 2nd Floor,New Guys House, London SE1 9RT, England.	marie.bijlmakers@kcl.ac.uk	bijlmakers, marie-jose/N-5369-2014	bijlmakers, marie-jose/0000-0001-6762-1168; HAYDAY, ADRIAN/0000-0002-9495-5793	Wellcome Trust [071534] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; Balamuth F, 2004, J IMMUNOL, V172, P5887, DOI 10.4049/jimmunol.172.10.5887; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; Belanger C, 2001, FEBS LETT, V499, P59, DOI 10.1016/S0014-5793(01)02513-3; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Bosselut R, 2000, IMMUNITY, V12, P409, DOI 10.1016/S1074-7613(00)80193-4; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CROOKS MEC, 1994, IMMUNITY, V1, P277; Devine L, 2000, J IMMUNOL, V164, P833, DOI 10.4049/jimmunol.164.2.833; DISANTO JP, 1991, J IMMUNOL METHODS, V141, P123, DOI 10.1016/0022-1759(91)90218-5; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Fragoso R, 2003, J IMMUNOL, V170, P913, DOI 10.4049/jimmunol.170.2.913; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Gangadharan D, 2004, CURR OPIN IMMUNOL, V16, P264, DOI 10.1016/j.coi.2004.03.015; Gaus K, 2006, MOL MEMBR BIOL, V23, P41, DOI 10.1080/09687860500466857; Gaus K, 2005, J CELL BIOL, V171, P121, DOI 10.1083/jcb.200505047; GORMAN SD, 1988, J IMMUNOL, V140, P3646; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 2004, CURR OPIN IMMUNOL, V16, P353, DOI 10.1016/j.coi.2004.03.013; Horejsi V, 2003, IMMUNOL REV, V191, P148, DOI 10.1034/j.1600-065X.2003.00001.x; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JULIUS M, 1993, IMMUNOL TODAY, V14, P177; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KARAKI S, 1992, J IMMUNOL, V149, P1613; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; Leishman AJ, 2001, SCIENCE, V294, P1936, DOI 10.1126/science.1063564; Liu YW, 2003, IMMUNITY, V18, P205, DOI 10.1016/S1074-7613(03)00027-X; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; Percherancier Y, 2003, J BIOL CHEM, V278, P3153, DOI 10.1074/jbc.M207371200; Popik W, 2004, J BIOL CHEM, V279, P704, DOI 10.1074/jbc.M306380200; Renard V, 1996, J EXP MED, V184, P2439, DOI 10.1084/jem.184.6.2439; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; Shogomori H, 2005, J BIOL CHEM, V280, P18931, DOI 10.1074/jbc.M500247200; SIMONS W, 1997, NATURE, V387, P569; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; ZAMOYSKA R, 1994, IMMUNITY, V1, P243, DOI 10.1016/1074-7613(94)90075-2; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; Zhang J, 2000, J VIROL, V74, P4634, DOI 10.1128/JVI.74.10.4634-4644.2000; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	55	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13884	13894		10.1074/jbc.M701027200	http://dx.doi.org/10.1074/jbc.M701027200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17341584	hybrid			2022-12-27	WOS:000246060300078
J	Smith, JJ; Cummins, TR; Alphy, S; Blumenthal, KM				Smith, Jaime J.; Cummins, Theodore R.; Alphy, Sujith; Blumenthal, Kenneth M.			Molecular interactions of the gating modifier toxin ProTx-II with Nav1.5 - Implied existence of a novel toxin binding site coupled to activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; BETA-SCORPION TOXIN; VOLTAGE-SENSOR; POTASSIUM CHANNEL; TARANTULA TOXINS; ALPHA-SUBUNIT; DOMAIN-II; INACTIVATION; LOOP; IV	Voltage-gated Na+ channels are critical components in the generation of action potentials in excitable cells, but despite numerous structure-function studies on these proteins, their gating mechanism remains unclear. Peptide toxins often modify channel gating, thereby providing a great deal of information about these channels. ProTx-II is a 30-amino acid peptide toxin from the venom of the tarantula, Thrixopelma pruriens, that conforms to the inhibitory cystine knot motif and which modifies activation kinetics of Na-v and Ca-v, but not K-v, channels. ProTx-II inhibits current by shifting the voltage dependence of activation to more depolarized potentials and, therefore, differs from the classic site 4 toxins that shift voltage dependence of activation in the opposite direction. Despite this difference in functional effects, ProTx-II has been proposed to bind to neurotoxin site 4 because it modifies activation. Here, we investigate the bioactive surface of ProTx-II by alanine-scanning the toxin and analyzing the interactions of each mutant with the cardiac isoform, Na(v)1.5. The active face of the toxin is largely composed of hydrophobic and cationic residues, joining a growing group of predominantly K-v channel gating modifier toxins that are thought to interact with the lipid environment. In addition, we performed extensive mutagenesis of Na(v)1.5 to locate the receptor site with which ProTx-II interacts. Our data establish that, contrary to prior assumptions, ProTx-II does not bind to the previously characterized neurotoxin site 4, thus making it a novel probe of activation gating in Na-v channels with potential to shed new light on this process.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Indiana University System; Indiana University-Purdue University Indianapolis	Blumenthal, KM (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, 3435 Main St, Buffalo, NY 14214 USA.	kblumen@buffalo.edu						Bemporad D, 2006, BIOCHEMISTRY-US, V45, P11844, DOI 10.1021/bi061111z; Benzinger GR, 1998, J BIOL CHEM, V273, P80, DOI 10.1074/jbc.273.1.80; Bernard C, 2000, PROTEIN SCI, V9, P2059; Bosmans F, 2006, MOL PHARMACOL, V69, P419, DOI 10.1124/mol.105.015941; Brahmajothi MV, 1999, J GEN PHYSIOL, V113, P581, DOI 10.1085/jgp.113.4.581; Catterall WA, 2005, PHARMACOL REV, V57, P397, DOI 10.1124/pr.57.4.4; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; Cestele S, 2006, J BIOL CHEM, V281, P21332, DOI 10.1074/jbc.M603814200; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; CHAHINE M, 1994, NEURON, V12, P281, DOI 10.1016/0896-6273(94)90271-2; Chanda B, 2004, J GEN PHYSIOL, V123, P217, DOI 10.1085/jgp.200308971; Chanda B, 2002, J GEN PHYSIOL, V120, P629, DOI 10.1085/jgp.20028679; Cohen L, 2006, J BIOL CHEM, V281, P20673, DOI 10.1074/jbc.M603212200; Cummins TR, 1998, J NEUROSCI, V18, P9607; Hirsh JK, 1996, BRAIN RES, V706, P343, DOI 10.1016/0006-8993(95)01340-7; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jung HJ, 2005, BIOCHEMISTRY-US, V44, P6015, DOI 10.1021/bi0477034; KRAUS RL, 2002, BIOPHYS SOC 46 ANN M; Lee CW, 2004, BIOCHEMISTRY-US, V43, P890, DOI 10.1021/bi0353373; Lee SY, 2004, NATURE, V430, P232, DOI 10.1038/nature02632; Leipold E, 2006, MOL PHARMACOL, V70, P340, DOI 10.1124/mol.106.024034; Middleton RE, 2002, BIOCHEMISTRY-US, V41, P14734, DOI 10.1021/bi026546a; Priest BT, 2007, TOXICON, V49, P194, DOI 10.1016/j.toxicon.2006.09.014; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; Schoppa NE, 1998, J GEN PHYSIOL, V111, P313, DOI 10.1085/jgp.111.2.313; Seibert AL, 2003, BIOCHEMISTRY-US, V42, P14515, DOI 10.1021/bi035291d; Sheets MF, 1999, BIOPHYS J, V77, P747, DOI 10.1016/S0006-3495(99)76929-8; Smith JJ, 2005, J BIOL CHEM, V280, P11127, DOI 10.1074/jbc.M412552200; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; Wang JM, 2004, J GEN PHYSIOL, V123, P455, DOI 10.1085/jgp.200309005; WEE CL, 2006, BIOPHYS J, V92, P7; Winterfield JR, 2000, J GEN PHYSIOL, V116, P637, DOI 10.1085/jgp.116.5.637; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321	36	83	93	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12687	12697		10.1074/jbc.M610462200	http://dx.doi.org/10.1074/jbc.M610462200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17339321	hybrid			2022-12-27	WOS:000245942800038
J	Bakali, HMA; Herman, MD; Johnson, KA; Kelly, AA; Wieslander, A; Hallberg, BM; Nordlund, P				Bakali, H. M. Amin; Herman, Maria Dolores; Johnson, Kenneth A.; Kelly, Amelie A.; Wieslander, AKe; Hallberg, B. Martin; Nordlund, Par			Crystal structure of YegS, a homologue to the mammalian diacylglycerol kinases, reveals a novel regulatory metal binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBERCULOSIS NAD KINASE; ESCHERICHIA-COLI; SN-1,2-DIACYLGLYCEROL KINASE; GENE ENCODES; ZINC-FINGER; ACTIVE-SITE; HAND MOTIFS; PROTEIN; CALCIUM; COMPLEX	The human lipid kinase family controls cell proliferation, differentiation, and tumorigenesis and includes diacylglycerol kinases, sphingosine kinases, and ceramide kinases. YegS is an Escherichia coli protein with significant sequence homology to the catalytic domain of the human lipid kinases. We have solved the crystal structure of YegS and shown that it is a lipid kinase with phosphatidylglycerol kinase activity. The crystal structure reveals a two-domain protein with significant structural similarity to a family of NAD kinases. The active site is located in the interdomain cleft formed by four conserved sequence motifs. Surprisingly, the structure reveals a novel metal binding site composed of residues conserved in most lipid kinases.	Karolinska Inst, Dept Med Biochem & Biophys, Div Biophys, S-17177 Stockholm, Sweden; Univ Stockholm, Dept Biochem & Biophys, S-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm University	Nordlund, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Biophys, S-17177 Stockholm, Sweden.	par.nordlund@mbb.ki.se	Hallberg, B. Martin/C-5361-2009	Hallberg, B. Martin/0000-0002-6781-0345				Abe T, 2003, BIOCHEM J, V375, P673, DOI 10.1042/BJ20031052; Bakali HMA, 2006, ACTA CRYSTALLOGR F, V62, P295, DOI 10.1107/S1744309106004799; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bektas M, 2005, J CELL BIOL, V169, P801, DOI 10.1083/jcb.200407123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang JS, 1997, CANCER RES, V57, P5465; Cheek S, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-6; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; Dormitzer PR, 2002, EMBO J, V21, P885, DOI 10.1093/emboj/21.5.885; Evans W, 1997, CHEM BRIT, V33, P22; Garavaglia S, 2004, J BIOL CHEM, V279, P40980, DOI 10.1074/jbc.M406586200; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Imai S, 2005, J BIOL CHEM, V280, P39870, DOI 10.1074/jbc.M500669200; JACKSON BJ, 1986, J BIOL CHEM, V261, P3464; Kawai S, 2000, BIOCHEM BIOPH RES CO, V276, P57, DOI 10.1006/bbrc.2000.3433; Labesse G, 2002, TRENDS BIOCHEM SCI, V27, P273, DOI 10.1016/S0968-0004(02)02093-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4ESFEAMCB N, V26; Liu JY, 2005, J MOL BIOL, V354, P289, DOI 10.1016/j.jmb.2005.09.026; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; Masuda N, 2003, MOL MICROBIOL, V48, P699, DOI 10.1046/j.1365-2958.2003.03477.x; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Michiels J, 2002, TRENDS MICROBIOL, V10, P87, DOI 10.1016/S0966-842X(01)02284-3; Mori S, 2005, BIOCHEM BIOPH RES CO, V327, P500, DOI 10.1016/j.bbrc.2004.11.163; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owens RM, 2006, MOL MICROBIOL, V60, P1152, DOI 10.1111/j.1365-2958.2006.05174.x; Oxenoid K, 2002, BIOCHEMISTRY-US, V41, P12876, DOI 10.1021/bi020335o; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Selzner M, 2001, CANCER RES, V61, P1233; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Steinhauser D, 2004, BIOINFORMATICS, V20, P3647, DOI 10.1093/bioinformatics/bth398; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; van den Berg S, 2006, J BIOTECHNOL, V121, P291, DOI 10.1016/j.jbiotec.2005.08.006; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Waggoner DW, 2004, J BIOL CHEM, V279, P38228, DOI 10.1074/jbc.M405932200; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WALSH JP, 1986, J BIOL CHEM, V261, P6239; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Yamada K, 1997, BIOCHEM J, V321, P59, DOI 10.1042/bj3210059; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	54	29	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19644	19652		10.1074/jbc.M604852200	http://dx.doi.org/10.1074/jbc.M604852200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17351295	hybrid			2022-12-27	WOS:000247650600039
J	Liu, Q; Ponnuraj, K; Xu, Y; Ganesh, VK; Sillanpaa, J; Murray, BE; Narayana, SVL; Hook, M				Liu, Qing; Ponnuraj, Karthe; Xu, Yi; Ganesh, Vannakambadi K.; Sillanpaa, Jouko; Murray, Barbara E.; Narayana, Sthanam V. L.; Hook, Magnus			The Enterococcus faecalis MSCRAMM ACE binds its ligand by the collagen hug model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESIVE MATRIX MOLECULES; STAPHYLOCOCCUS-AUREUS; DOMAIN; PROTEIN; RESISTANCE; FIBRINOGEN; VIRULENCE; CNA	We have determined the crystal structure of the ligand binding segment of the Enterococcus faecalis collagen binding MSCRAMM ACE ( microbial surface components recognizing adhesive matrix molecules adhesin of collagen from enterococci). This segment is composed of two subdomains, N1 and N2, each adopting an IgG-like fold and forming a putative collagen binding surface at the interface between the two subdomains. This structure is very similar to that recently reported for CNA, the collagen binding MSCRAMM of Staphylococcus aureus, for which a unique ligand binding mechanism called the Collagen Hug was proposed. We suggest that ACE binds collagen by a similar mechanism and present the first biochemical evidence for this binding model. Replacing residues in the putative collagen binding trench of ACE N2 with Ala residues affected collagen binding. A closed conformation of ACE stabilized by an engineered disulfide bond is unable to bind collagen. Finally, the importance of the residues in the N2 extension in stabilizing the MSCRAMM-ligand complex is demonstrated by selected point and truncation mutations.	Texas A&M Univ, Syst Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Albert B Alkek Inst Biosci & Technol, Houston, TX 77030 USA; Univ Alabama, Sch Optometry, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA; Univ Texas, Sch Med, Ctr Study Emerging & Reemerging Pathogens, Dept Internal Med,Div Infect Dis, Houston, TX 77030 USA; Univ Madras, Dept Crystallog & Biophys, Madras 600025, Tamil Nadu, India	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Madras	Hook, M (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, 2121 W Holcombe Blvd,Suite 603, Houston, TX 77030 USA.	mhook@ibt.tamhsc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624, R37AI047923] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20624, R37 AI 47923] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON MJ, 1997, J MOL GRAPHICS, V5, P103; CLEWELL DB, 1990, EUR J CLIN MICROBIOL, V9, P90, DOI 10.1007/BF01963632; Deivanayagam CCS, 2002, EMBO J, V21, P6660, DOI 10.1093/emboj/cdf619; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; HORODNICEANU T, 1979, ANTIMICROB AGENTS CH, V16, P686, DOI 10.1128/AAC.16.5.686; JETT BD, 1994, CLIN MICROBIOL REV, V7, P462, DOI 10.1128/CMR.7.4.462-478.1994; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Murray BE, 1999, P ASSOC AM PHYSICIAN, V111, P328, DOI 10.1046/j.1525-1381.1999.99241.x; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; Nallapareddy SR, 2000, INFECT IMMUN, V68, P5218, DOI 10.1128/IAI.68.9.5218-5224.2000; Nallapareddy SR, 2000, INFECT IMMUN, V68, P5210, DOI 10.1128/IAI.68.9.5210-5217.2000; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1993, BIOCHEMISTRY-US, V32, P11428, DOI 10.1021/bi00093a021; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1992, J BIOL CHEM, V267, P4766; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; Ponnuraj K, 2002, BBA-PROTEIN STRUCT M, V1596, P173, DOI 10.1016/S0167-4838(01)00328-4; Ponnuraj K, 2003, CELL, V115, P217, DOI 10.1016/S0092-8674(03)00809-2; PONNURAJ K, 2007, IN PRESS PROTEINS; Rich RL, 1999, J BIOL CHEM, V274, P26939, DOI 10.1074/jbc.274.38.26939; Rich RL, 1998, BIOCHEMISTRY-US, V37, P15423, DOI 10.1021/bi981773r; SWITALSKI LM, 1989, J BIOL CHEM, V264, P21080; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; Visai L, 2000, J BIOL CHEM, V275, P39837, DOI 10.1074/jbc.M005297200; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zong YN, 2005, EMBO J, V24, P4224, DOI 10.1038/sj.emboj.7600888	31	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2007	282	27					19629	19637		10.1074/jbc.M611137200	http://dx.doi.org/10.1074/jbc.M611137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	184OF	17392280	hybrid			2022-12-27	WOS:000247650600037
J	McMillan, DGG; Keis, S; Dimroth, P; Cook, GM				McMillan, Duncan G. G.; Keis, Stefanie; Dimroth, Peter; Cook, Gregory M.			A specific adaptation in the a subunit of thermoalkaliphilic F1F0-ATP synthase enables ATP synthesis at high pH but not at neutral pH values	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN TA2.A1; COLI MEMBRANE-VESICLES; BACILLUS-FIRMUS OF4; PROTON-TRANSLOCATING ATPASE; AQUEOUS ACCESS CHANNELS; ESCHERICHIA-COLI; ALKALIPHILIC BACILLUS; ACTIVE-TRANSPORT; MOLECULAR CHARACTERIZATION; PROPIONIGENIUM-MODESTUM	Analysis of the atp operon from the thermoalkaliphilic Bacillus sp. TA2. A1 and comparison with other atp operons from alkaliphilic bacteria reveals the presence of a conserved lysine residue at position 180 (Bacillus sp. TA2. A1 numbering) within the a subunit of these F1Fo-ATP synthases. We hypothesize that the basic nature of this residue is ideally suited to capture protons from the bulk phase at high pH. To test this hypothesis, a heterologous expression system for the ATP synthase from Bacillus sp. TA2.A1 (TA2F(1)F(o)) was developed in Escherichia coli DK8 (Delta atp). Amino acid substitutions were made in the a subunit of TA2F(1)F(o) at position 180. Lysine (aK180) was substituted for the basic residues histidine (aK180H) or arginine (aK180R), and the uncharged residue glycine (aK180G). ATP synthesis experiments were performed in ADP plus P-i- loaded right-side-out membrane vesicles energized by ascorbate- phenazine methosulfate. When these enzyme complexes were examined for their ability to perform ATP synthesis over the pH range from 7.0 to 10.0, TA2F(1)F(o) and aK180R showed a similar pH profile having optimum ATP synthesis rates at pH 9.0-9.5 with no measurable ATP synthesis at pH 7.5. Conversely, aK180H and aK180G showed maximal ATP synthesis at pH values 8.0 and 7.5, respectively. ATP synthesis under these conditions for all enzyme forms was sensitive to DCCD. These data strongly imply that amino acid residue Lys(180) is a specific adaptation within the a subunit of TA2F(1)F(o) to facilitate proton capture at high pH. At pH values near the pK(a) of Lys(180), the trapped protons readily dissociate to reach the subunit c binding sites, but this dissociation is impeded at neutral pH values causing either a blocking of the proposed H+ channel and/or mechanism of proton translocation, and hence ATP synthesis is inhibited.	Univ Otago, Otago Sch Med Sci, Dept Microbiol & Immunol, Dunedin, New Zealand; ETH Honggerberg, Inst Mikrobiol, CH-8093 Zurich, Switzerland	University of Otago; Swiss Federal Institutes of Technology Domain; ETH Zurich	Cook, GM (corresponding author), Univ Otago, Otago Sch Med Sci, Dept Microbiol & Immunol, POB 56, Dunedin, New Zealand.	greg.cook@stonebow.otago.ac.nz	McMillan, Duncan/AAT-7415-2021; Cook, Gregory/E-5665-2011	McMillan, Duncan/0000-0001-6614-4494; 				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALTENDORF KH, 1974, J BACTERIOL, V117, P888, DOI 10.1128/JB.117.2.888-899.1974; Angevine CM, 2003, P NATL ACAD SCI USA, V100, P13179, DOI 10.1073/pnas.2234364100; Angevine CM, 2003, J BIOL CHEM, V278, P6066, DOI 10.1074/jbc.M210199200; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; Cook GM, 2003, J BACTERIOL, V185, P4442, DOI 10.1128/JB.185.15.4442-4449.2003; Dimroth P, 2006, EMBO REP, V7, P276, DOI 10.1038/sj.embor.7400646; Dimroth P, 2004, ADV MICROB PHYSIOL, V49, P175, DOI 10.1016/S0065-2911(04)49004-3; Ferguson SA, 2006, J BACTERIOL, V188, P5045, DOI 10.1128/JB.00128-06; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Fillingame RH, 1999, NOVART FDN SYMP, V221, P218; GUFFANTI AA, 1984, J BIOL CHEM, V259, P2971; GUFFANTI AA, 1985, ARCH BIOCHEM BIOPHYS, V239, P327, DOI 10.1016/0003-9861(85)90695-2; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HARTZOG PE, 1994, J BIOL CHEM, V269, P32313; HICKS DB, 1990, J BIOL CHEM, V265, P20547; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMANN A, 1990, EUR J BIOCHEM, V194, P423, DOI 10.1111/j.1432-1033.1990.tb15635.x; HOFFMANN A, 1991, EUR J BIOCHEM, V201, P467, DOI 10.1111/j.1432-1033.1991.tb16304.x; Horikoshi K, 1999, MICROBIOL MOL BIOL R, V63, P735, DOI 10.1128/MMBR.63.4.735-750.1999; IVEY DM, 1991, MOL GEN GENET, V229, P292, DOI 10.1007/BF00272169; IVEY DM, 1992, RES MICROBIOL, V143, P467, DOI 10.1016/0923-2508(92)90092-3; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1971, J BIOL CHEM, V246, P5523; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; KAIM G, 1995, J MOL BIOL, V253, P726, DOI 10.1006/jmbi.1995.0586; KASHKET ER, 1985, ANNU REV MICROBIOL, V39, P219, DOI 10.1146/annurev.mi.39.100185.001251; Keis S, 2004, BBA-GENE STRUCT EXPR, V1676, P112, DOI 10.1016/j.bbaexp.2003.11.002; Keis S, 2006, J BACTERIOL, V188, P3796, DOI 10.1128/JB.00040-06; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maurer LM, 2005, J BACTERIOL, V187, P304, DOI 10.1128/JB.187.1.304-319.2005; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; Meier T, 2002, EMBO REP, V3, P1094, DOI 10.1093/embo-reports/kvf216; Meier T, 2006, J BACTERIOL, V188, P7759, DOI 10.1128/JB.00934-06; Mitome N, 2004, P NATL ACAD SCI USA, V101, P12159, DOI 10.1073/pnas.0403545101; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; Olsson K, 2003, J BACTERIOL, V185, P461, DOI 10.1128/JB.185.2.461-465.2003; Pogoryelov D, 2005, EMBO REP, V6, P1040, DOI 10.1038/sj.embor.7400517; Rahlfs S, 1997, FEBS LETT, V404, P269, DOI 10.1016/S0014-5793(97)00088-4; RAMOS S, 1977, BIOCHEMISTRY-US, V16, P848, DOI 10.1021/bi00624a006; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTANA M, 1994, J BACTERIOL, V176, P6802, DOI 10.1128/JB.176.22.6802-6811.1994; SCHULDINER S, 1975, BIOCHEMISTRY-US, V14, P5451, DOI 10.1021/bi00696a011; Seelert H, 2003, J MOL BIOL, V333, P337, DOI 10.1016/j.jmb.2003.08.046; SHORT SA, 1974, P NATL ACAD SCI USA, V71, P5032, DOI 10.1073/pnas.71.12.5032; SHORT SA, 1975, J BIOL CHEM, V250, P4291; Stahlberg H, 2001, EMBO REP, V2, P229, DOI 10.1093/embo-reports/kve047; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stocker A, 2005, J STRUCT BIOL, V152, P140, DOI 10.1016/j.jsb.2005.08.005; STURR MG, 1994, J BACTERIOL, V176, P3111, DOI 10.1128/jb.176.11.3111-3116.1994; Tomashek JJ, 2004, J BIOL CHEM, V279, P4465, DOI 10.1074/jbc.M310826200; TSUCHIYA T, 1976, J BIOL CHEM, V251, P5315; TSUCHIYA T, 1977, J BACTERIOL, V129, P763, DOI 10.1128/JB.129.2.763-769.1977; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Wang ZX, 2004, J BIOL CHEM, V279, P26546, DOI 10.1074/jbc.M401206200; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	63	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17395	17404		10.1074/jbc.M611709200	http://dx.doi.org/10.1074/jbc.M611709200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17434874	hybrid			2022-12-27	WOS:000247084500009
J	Selent, J; Kaleta, J; Li, ZQ; Lalmanach, G; Bromme, D				Selent, Jana; Kaleta, Jadwiga; Li, Zhenqiang; Lalmanach, Gilles; Bromme, Dieter			Selective inhibition of the collagenase activity of cathepsin K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE; COLLAGENOLYTIC ACTIVITY; MOLECULAR-CLONING; COMPLEX-FORMATION; OSTEOCLASTS; EXPRESSION; DESIGN; UNIQUE	Cathepsin K, the main bone degrading protease, and chondroitin 4-sulfate (C4-S) form a complex with enhanced collagenase activity. In this report, we demonstrate the specific inhibition of the collagenase activity of cathepsin K by negatively charged polymers without affecting the overall proteolytic activity of the protease. Three different mechanisms to interfere with cathepsin-catalyzed collagen degradation are discussed: 1) inhibition of the formation of the cathepsin K/C4-S complex, 2) inhibition of the attachment of C4-S to collagen, and 3) masking of the collagenase cleavage sites in collagen. By targeting these interaction sites, collagen degradation can be modulated while the non-collagenolytic activities of cathepsin K remain intact. The main inhibitory effect on collagen degradation is due to the impeding effect on the active cathepsin K/C4-S complex. Essential structural elements in the inhibitor molecules are negative charges which compete with the sulfate groups of C4-S in the cathepsin K/C4-S complex. The inhibitory effect can be controlled by length and charge of the polymers. Longer negatively charged polymers ( e.g. polyglutamates, oligonucleotides) tend to inhibit all three mechanisms, whereas shorter ones preferentially affect the cathepsin K/C4-S complex.	Univ British Columbia, Fac Dent, Dept Oral & Biol Sci, Vancouver, BC V6J 1Z3, Canada; Univ British Columbia, Ctr Blood Res, Vancouver, BC V6J 1Z3, Canada; Bristol Myers Squibb Co, Pennington, NJ 08534 USA; Univ Tours, INSERM, U618, IFR135,Fac Med, F-37032 Tours, France	University of British Columbia; University of British Columbia; Bristol-Myers Squibb; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours	Bromme, D (corresponding author), Univ British Columbia, Fac Dent, Dept Oral & Biol Sci, 2350 Hlth Sci Mall, Vancouver, BC V6J 1Z3, Canada.	dbromme@interchange.ubc.ca	Selent, Jana/E-6912-2015	Selent, Jana/0000-0002-1844-4449; Lalmanach, Gilles/0000-0001-8562-4821	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK072070] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 48669] Funding Source: Medline; NIDDK NIH HHS [DK 072070] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347; Godat E, 2004, BIOCHEM J, V383, P501, DOI 10.1042/BJ20040864; Hou WS, 2003, BIOL CHEM, V384, P891, DOI 10.1515/BC.2003.100; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; Jameson DM, 1999, METHODS, V19, P222, DOI 10.1006/meth.1999.0853; Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727; KRANE SM, 1994, SCI AM MED, V3, P1; Li ZQ, 2004, J BIOL CHEM, V279, P5470, DOI 10.1074/jbc.M310349200; Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; McGrath ME, 1997, NAT STRUCT BIOL, V4, P105, DOI 10.1038/nsb0297-105; OBRINK B, 1971, BIOCHEM J, V121, P227; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; Thompson MJ, 1997, PROTEIN SCI, V6, P1963, DOI 10.1002/pro.5560060917; Yamashita DS, 2000, CURR PHARM DESIGN, V6, P1, DOI 10.2174/1381612003401569; Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013	21	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16492	16501		10.1074/jbc.M700242200	http://dx.doi.org/10.1074/jbc.M700242200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426030	hybrid			2022-12-27	WOS:000246794300056
J	Zhong, Q; Li, GL; Gvozdenovic-Jeremic, J; Greenberg, ML				Zhong, Quan; Li, Guiling; Gvozdenovic-Jeremic, Jelena; Greenberg, Miriam L.			Up-regulation of the cell integrity pathway in Saccharomyces cerevisiae suppresses temperature sensitivity of the pgs1 Delta mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; YEAST 1,3-BETA-GLUCAN SYNTHASE; GENOME-WIDE ANALYSIS; MAP KINASE; CARDIOLIPIN SYNTHASE; PHOSPHATIDYLGLYCEROLPHOSPHATE SYNTHASE; 1,3-BETA-D-GLUCAN SYNTHASE; SIGNALING PATHWAY; CRYSTAL-STRUCTURE; GENE-EXPRESSION	We have previously shown that mutants in the cardiolipin (CL) pathway exhibit temperature-sensitive growth defects that are not associated with mitochondrial dysfunction. The pgs1 Delta mutant, lacking the first enzyme of the CL pathway, phosphatidylglycerolphosphate synthase (Pgs1p), has a defective cell wall due to decreased beta-1,3-glucan (Zhong, Q., Gvozdenovic-Jeremic, J., Webster, P., Zhou, J., and Greenberg, M. L. (2005) Mol. Biol. Cell 16, 665-675). Disruption of KRE5, a gene involved in cell wall biogenesis, restores beta-1,3-glucan synthesis and suppresses pgs1 Delta temperature sensitivity. To gain insight into the mechanisms underlying the cell wall defect in pgs1 Delta, we show in the current report that pgs1 Delta cells have reduced glucan synthase activity and diminished levels of Fks1p, the glucan synthase catalytic subunit. In addition, activation of Slt2p, the downstream effector of the protein kinase C (PKC)-activated cell integrity pathway, was defective in pgs1 Delta. The kre5(W1166X) suppressor restored Slt2p activation and dramatically increased (> 10-fold) mRNA levels of FKS2, the alternate catalytic subunit of glucan synthase, partially restoring glucan synthase activity. Consistent with these results, up-regulation of PKC-Slt2 signaling and overexpression of FKS1 or FKS2 alleviated sensitivity of pgs1 Delta to cell wall-perturbing agents and restored growth at elevated temperature. These findings demonstrate that functional Pgs1p is essential for cell wall biogenesis and activation of the PKC-Slt2 signaling pathway.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	MLGREEN@sun.science.wayne.edu	zhong, quan/AAE-8893-2021	Zhong, Quan/0000-0003-2910-5597	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62263] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alto NM, 2002, J CELL BIOL, V158, P659, DOI 10.1083/jcb.200204081; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; Barth PG, 1996, J INHERIT METAB DIS, V19, P157, DOI 10.1007/BF01799418; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Dzugasova V, 1998, CURR GENET, V34, P297, DOI 10.1007/s002940050399; Finkielstein CV, 2006, J BIOL CHEM, V281, P27317, DOI 10.1074/jbc.M605560200; Frederick RL, 2004, J CELL BIOL, V167, P87, DOI 10.1083/jcb.200405100; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; He Q, 2004, MOL MICROBIOL, V53, P1243, DOI 10.1111/j.1365-2958.2004.04202.x; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Inoue SB, 1999, J BIOL CHEM, V274, P38119, DOI 10.1074/jbc.274.53.38119; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Janitor M, 1996, FEMS MICROBIOL LETT, V140, P43; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 1999, MOL MICROBIOL, V31, P373, DOI 10.1046/j.1365-2958.1999.01181.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kapteyn JC, 1999, MOL MICROBIOL, V31, P1835, DOI 10.1046/j.1365-2958.1999.01320.x; Kawasaki K, 1999, J BIOL CHEM, V274, P1828, DOI 10.1074/jbc.274.3.1828; Koshkin V, 2002, BIOCHEM J, V364, P317, DOI 10.1042/bj3640317; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Lussier M, 1997, GENETICS, V147, P435; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Ostrander DB, 2001, J BIOL CHEM, V276, P25262, DOI 10.1074/jbc.M103689200; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Su XF, 2006, MOL CELL BIOL, V26, P743, DOI 10.1128/MCB.26.3.743-753.2006; Terashima H, 2000, MOL GEN GENET, V264, P64, DOI 10.1007/s004380000285; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1; Utsugi T, 2002, GENES CELLS, V7, P1, DOI 10.1046/j.1356-9597.2001.00495.x; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; Watanabe D, 2001, YEAST, V18, P943, DOI 10.1002/yea.742; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Xu Y, 2006, J BIOL CHEM, V281, P39217, DOI 10.1074/jbc.M606100200; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; Zahedi RP, 2006, MOL BIOL CELL, V17, P1436, DOI 10.1091/mbc.E05-08-0740; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013; Zhong Q, 2005, MOL BIOL CELL, V16, P665, DOI 10.1091/mbc.E04-09-0808; Zhong Q, 2004, J BIOL CHEM, V279, P32294, DOI 10.1074/jbc.M403275200	62	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					15946	15953		10.1074/jbc.M701055200	http://dx.doi.org/10.1074/jbc.M701055200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17426021	hybrid			2022-12-27	WOS:000246794300003
J	Black, SA; Palamakumbura, AH; Stan, M; Trackman, PC				Black, Samuel A., Jr.; Palamakumbura, Amitha H.; Stan, Maria; Trackman, Philip C.			Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic Gingiva - Interactions between cAMP and MAPK signaling pathways, and prostaglandin E-2-EP3 receptor mediated activation of the c-JUN n-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; COLLAGEN GENE-EXPRESSION; MOUSE FIBROSIS MODEL; TGF-BETA; EPITHELIAL-CELLS; TUBULOINTERSTITIAL FIBROSIS; TARGETED DISRUPTION; LUNG FIBROBLASTS; MESANGIAL CELLS; EP(2) SUBTYPE	Prostaglandin E-2 blocks transforming growth factor TGF beta 1-induced CCN2/CTGF expression in lung and kidney fibroblasts. PGE(2) levels are high in gingival tissues yet CCN2/CTGF expression is elevated in fibrotic gingival overgrowth. Gingival fibroblast expression of CCN2/CTGF in the presence of PGE2 led us to compare the regulation of CCN2/CTGF expression in fibroblasts cultured from different tissues. Data demonstrate that the TGF beta 1-induced expression of CCN2/CTGF in human lung and renal mesangial cells is inhibited by 10 nM PGE2, whereas human gingival fibroblasts are resistant. Ten nM PGE2 increases cAMP accumulation in lung but not gingival fibroblasts, which require 1 mu M PGE2 to elevate cAMP. Micromolar PGE2 only slightly reduces the TGF beta 1-stimulated CCN2/CTGF levels in gingival cells. EP2 prostaglandin receptor activation with butaprost blocks the TGF beta 1-stimulated expression of CCN2/CTGF expression in lung, but not gingival, fibroblasts. In lung fibroblasts, inhibition of the TGF beta 1-stimulated CCN2/CTGF by PGE2, butaprost, or forskolin is due to p38, ERK, and JNK MAP kinase inhibition that is cAMP-dependent. Inhibition of any two MAPKs completely blocks CCN2/CTGF expression stimulated by TGF beta 1. These data mimic the inhibitory effects of 10 nM PGE2 and forskolin that were dependent on PKA activity. In gingival fibroblasts, the sole MAPK mediating the TGF beta 1-stimulated CCN2/CTGF expression is JNK. Whereas forskolin reduces TGF beta 1-stimulated expression of CCN2/CTGF by 35% and JNK activation in gingival fibroblasts, micromolar PGE2-stimulated JNK in gingival fibroblasts and opposes the inhibitory effects of cAMP on CCN2/CTGF expression. Stimulation of the EP3 receptor with sulprostone results in a robust increase in JNK activation in these cells. Taken together, data identify two mechanisms by which TGF beta 1-stimulated CCN2/CTGF levels in human gingival fibroblasts resist down-regulation by PGE2: (i) cAMP cross-talk with MAPK pathways is limited in gingival fibroblasts; (ii) PGE2 activation of the EP3 prostanoid receptor stimulates the activation of JNK.	Boston Univ, Goldman Sch Grad Dent, Div Oral Biol, Dept Periodont & Oral Biol, Boston, MA 02118 USA	Boston University	Trackman, PC (corresponding author), 700 Albany St, Boston, MA 02118 USA.	trackman@bu.edu	Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X	NCRR NIH HHS [M01 RR00533, M01 RR000533] Funding Source: Medline; NIDCR NIH HHS [K08 DE016609-02, K08 DE016609, R01 DE11004, R01 DE011004] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011004, K08DE016609] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Allen JT, 1999, AM J RESP CELL MOL, V21, P693, DOI 10.1165/ajrcmb.21.6.3719; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Bonniaud P, 2005, J IMMUNOL, V175, P5390, DOI 10.4049/jimmunol.175.8.5390; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brunius G, 1996, EUR J ORAL SCI, V104, P27, DOI 10.1111/j.1600-0722.1996.tb00042.x; Cheng JF, 2005, AM J PHYSIOL-CELL PH, V289, pC959, DOI 10.1152/ajpcell.00153.2005; Choung J, 1998, J CELL BIOCHEM, V71, P254, DOI 10.1002/(SICI)1097-4644(19981101)71:2<254::AID-JCB10>3.3.CO;2-L; Chujo S, 2005, J CELL PHYSIOL, V203, P447, DOI 10.1002/jcp.20251; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; del Valle-Perez B, 2004, FEBS LETT, V569, P105, DOI 10.1016/j.febslet.2004.05.058; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; di Mola FF, 1999, ANN SURG, V230, P63, DOI 10.1097/00000658-199907000-00010; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fassett J, 2006, MOL BIOL CELL, V17, P345, DOI 10.1091/mbc.E05-09-0871; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Haydont V, 2005, RADIOTHER ONCOL, V76, P219, DOI 10.1016/j.radonc.2005.06.029; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hong HH, 1999, LAB INVEST, V79, P1655; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Kantarci A, 2006, J PATHOL, V210, P59, DOI 10.1002/path.2000; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Lakos G, 2004, AM J PATHOL, V165, P203, DOI 10.1016/S0002-9440(10)63289-0; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; Leask A, 2003, J BIOL CHEM, V278, P13008, DOI 10.1074/jbc.M210366200; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Lee EH, 1999, INVEST OPHTH VIS SCI, V40, P2025; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Massague J, 2000, GENE DEV, V14, P627; MODEER T, 1992, J ORAL PATHOL MED, V21, P251, DOI 10.1111/j.1600-0714.1992.tb01005.x; MODEER T, 1992, BRIT J PHARMACOL, V106, P574, DOI 10.1111/j.1476-5381.1992.tb14377.x; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Oemar BS, 1997, ARTERIOSCL THROM VAS, V17, P1483, DOI 10.1161/01.ATV.17.8.1483; Oemar BS, 1997, CIRCULATION, V95, P831; Ohnishi H, 1998, J MOL CELL CARDIOL, V30, P2411, DOI 10.1006/jmcc.1998.0799; Paradis V, 1999, HEPATOLOGY, V30, P968, DOI 10.1002/hep.510300425; PENARROCHADIAGO M, 1990, J PERIODONTOL, V61, P571, DOI 10.1902/jop.1990.61.9.571; Preshaw PM, 2002, J CLIN PERIODONTOL, V29, P15, DOI 10.1034/j.1600-051x.2002.290103.x; Rachfal AW, 2003, HEPATOL RES, V26, P1, DOI 10.1016/S1386-6346(03)00115-3; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Ricupero DA, 1999, AM J PHYSIOL-LUNG C, V277, pL1165, DOI 10.1152/ajplung.1999.277.6.L1165; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; Sedlaczek N, 2001, AM J PATHOL, V158, P1239, DOI 10.1016/S0002-9440(10)64074-6; Tamatani T, 1998, BIOCHEM BIOPH RES CO, V251, P748, DOI 10.1006/bbrc.1998.9543; Trackman PC, 2004, CRIT REV ORAL BIOL M, V15, P165, DOI 10.1177/154411130401500305; Ueberham U, 2003, NEUROSCIENCE, V116, P1, DOI 10.1016/S0306-4522(02)00670-X; Utsugi M, 2003, AM J RESP CELL MOL, V28, P754, DOI 10.1165/rcmb.4892; Uzel MI, 2001, J PERIODONTOL, V72, P921, DOI 10.1902/jop.2001.72.7.921; van der Pauw MTM, 2000, J PERIODONTAL RES, V35, P335, DOI 10.1034/j.1600-0765.2000.035006335.x; Williams EJ, 2000, J HEPATOL, V32, P754, DOI 10.1016/S0168-8278(00)80244-5; Yokoi H, 2002, AM J PHYSIOL-RENAL, V282, pF933, DOI 10.1152/ajprenal.00122.2001; Yu J, 2002, ARCH BIOCHEM BIOPHYS, V404, P302, DOI 10.1016/S0003-9861(02)00276-X	64	59	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15416	15429		10.1074/jbc.M610432200	http://dx.doi.org/10.1074/jbc.M610432200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17428796	Green Submitted, hybrid, Green Accepted			2022-12-27	WOS:000246589600017
J	Hao, JJ; Narayanan, K; Muni, T; Ramachandran, A; George, A				Hao, Jianjun; Narayanan, Karthikeyan; Muni, Tanvi; Ramachandran, Amsaveni; George, Anne			Dentin matrix protein 4, a novel secretory calcium-binding protein that modulates odontoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ANALYSIS; DENTIN SIALOPROTEIN; GAMMA-CRYSTALLIN; IN-VITRO; EYE LENS; EXPRESSION; TISSUE; CELLS; BIOMINERALIZATION; PHOSPHOPROTEIN	Formation of calcified tissues is a well regulated process. In dentin, the odontoblasts synthesize several biomolecules that function as nucleators or inhibitors of mineralization. To identify genes that are odontoblast-specific, a subtractive hybridization technique was employed that resulted in the identification of a previously undescribed novel gene synthesized by the odontoblasts. Based on the nomenclature in our laboratory, this gene has been named dentin matrix protein 4 (DMP4). The protein encoded by mouse DMP4 cDNA contained 579 amino acids, including a 26-amino acid signal peptide. Analysis of the protein sequence demonstrated the presence of a Greek key calcium- binding domain and one conserved domain of unknown function in all the species examined thus far. Calcium binding property was confirmed by Ca-45 binding assays and the corresponding change in conformation by far-ultraviolet circular dichroism. Northern analysis demonstrated high expression levels of a single 3-kb mRNA transcript in tooth, whereas low expression levels were detected in other tissues. In situ hybridization analysis showed high expression levels of DMP4 in odontoblasts and low levels in osteoblasts and ameloblasts during tooth development. Gain and loss of function experiments demonstrated that DMP4 had the potential to differentiate mesenchymal precursor cells into functional odontoblast-like cells.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	George, A (corresponding author), Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA.	anneg@uic.edu	Narayanan, Karthikeyan/D-1957-2010	Narayanan, Karthikeyan/0000-0001-5136-2296; GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE11657, DE 13836] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657, R01DE013836] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BLUNDELL T, 1981, NATURE, V289, P771, DOI 10.1038/289771a0; George A, 1999, CONNECT TISSUE RES, V40, P49, DOI 10.3109/03008209909005277; GEORGE A, 1993, J BIOL CHEM, V268, P12624; George A, 1996, J BIOL CHEM, V271, P32869, DOI 10.1074/jbc.271.51.32869; Hao JJ, 2005, BONE, V37, P578, DOI 10.1016/j.bone.2005.05.013; Hao JJ, 2004, BONE, V34, P921, DOI 10.1016/j.bone.2004.01.020; Hao JJ, 2002, J BIOL CHEM, V277, P19976, DOI 10.1074/jbc.M112223200; Harada H, 2006, BIOCHEM BIOPH RES CO, V340, P611, DOI 10.1016/j.bbrc.2005.12.053; HARLOW E, 1998, ANTIBODIES LAB MANUA, P421; He G, 2003, NAT MATER, V2, P552, DOI 10.1038/nmat945; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MACDOUGALL M, 1995, CONNECT TISSUE RES, V22, P71; Nalbant D, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-11; Qin CL, 2003, CONNECT TISSUE RES, V44, P179, DOI 10.1080/03008200390152296; Rajini B, 2001, J BIOL CHEM, V276, P38464, DOI 10.1074/jbc.M102164200; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; Thesleff I, 2001, Adv Dent Res, V15, P14; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Witkop C J Jr, 1966, Ala J Med Sci, V3, P382; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Xu LM, 2006, J BIOL CHEM, V281, P2257, DOI 10.1074/jbc.M507695200; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	26	65	67	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15357	15365		10.1074/jbc.M701547200	http://dx.doi.org/10.1074/jbc.M701547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17369251	hybrid			2022-12-27	WOS:000246589600011
J	Zhang, HC; Bialkowska, A; Rusovici, R; Chanchevalap, S; Shim, H; Katz, JP; Yang, VW; Yun, CC				Zhang, Huanchun; Bialkowska, Agnieszka; Rusovici, Raluca; Chanchevalap, Sengthong; Shim, Hyunsuk; Katz, Jonathan P.; Yang, Vincent W.; Yun, C. Chris			Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR-5; GROWTH-FACTOR RECEPTOR; PROTEIN-COUPLED RECEPTOR; KINASE-C-DELTA; TRANSCRIPTION FACTOR; BETA-CATENIN; INTERLEUKIN-8 SECRETION; EPITHELIAL-CELLS; ACTIVATION; PHOSPHORYLATION	Among the multiple cellular effects mediated by lysophosphatidic acid (LPA), the effect on cell proliferation has extensively been investigated. A recent study showed that LPA-mediated proliferation of colon cancer cells requires activation of beta-catenin. However, the majority of colon cancer cells have deregulation of the Wnt/beta-catenin pathway. This prompted us to hypothesize the presence of additional pathway(s) activated by LPA resulting in an increase in the proliferation of colon cancer cells. Kruppel-like factor 5 (KLF5) is a transcriptional factor highly expressed in the crypt compartment of the intestinal epithelium. In this work, we investigated a role of KLF5 in LPA-mediated proliferation. We show that LPA stimulated the expression levels of KLF5 mRNA and protein in colon cancer cells and this stimulation was mediated by LPA2 and LPA3. Silencing of KLF5 expression by small interfering RNA significantly attenuated LPA-mediated proliferation of SW480 and HCT116 cells. LPA-mediated KLF5 induction was partially blocked by inhibition of the mitogen-activated protein kinase kinase and protein kinase C-delta. Moreover, we observed that LPA regulates KLF5 expression via eukaryotic elongation factor 2 kinase (eEF2k). Inhibition of calmodulin or silencing of eEF2k blocked the stimulation in KLF5 expression. Knockdown of eEF2k specifically inhibited KLF5 induction by LPA but not by fetal bovine serum or phorbol 12-myristate 13-acetate. These results identify KLF5 as a target of LPA-mediated signaling and suggest a role of KLF5 in promoting proliferation of intestinal epithelia in response to LPA.	Emory Univ, Sch Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Univ Penn, Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA	Emory University; Emory University; University of Pennsylvania	Yun, CC (corresponding author), Whitehead Bldg,Rm 201,615 Michael St, Atlanta, GA 30322 USA.	ccyun@emory.edu			NIDDK NIH HHS [R01 DK071597-01A2, R01 DK071597, R24 DK064399, DK071597, DK64399] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071597, R24DK064399] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Aoki J, 2000, ANN NY ACAD SCI, V905, P263; Cechin SR, 2005, NEUROCHEM RES, V30, P603, DOI 10.1007/s11064-005-2747-4; Chanchevalap S, 2006, NUCLEIC ACIDS RES, V34, P1216, DOI 10.1093/nar/gkl014; Chanchevalap S, 2004, FEBS LETT, V578, P99, DOI 10.1016/j.febslet.2004.10.079; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dewael Y, 2002, COMP BIOCHEM PHYS C, V131, P153, DOI 10.1016/S1532-0456(01)00288-5; Diggle TA, 2001, BIOCHEM J, V353, P621, DOI 10.1042/0264-6021:3530621; Dixon RJ, 1999, KIDNEY INT, V56, P2064, DOI 10.1046/j.1523-1755.1999.00797.x; Du JX, 2007, J BIOL CHEM, V282, P4782, DOI 10.1074/jbc.M603413200; Engelender S, 1996, MOL PHARMACOL, V50, P1243; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Feinberg MW, 2004, TRENDS CARDIOVAS MED, V14, P241, DOI 10.1016/j.tcm.2004.06.005; Gaits F, 1997, KIDNEY INT, V51, P1022, DOI 10.1038/ki.1997.143; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 2000, J BIOL CHEM, V275, P14573, DOI 10.1074/jbc.275.19.14573; Goetzl EJ, 1999, CANCER RES, V59, P4732; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hilal-Dandan R, 2004, J MOL CELL CARDIOL, V36, P481, DOI 10.1016/j.yjmcc.2003.12.010; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; HUGHES SJ, 1993, BIOCHEM J, V289, P795, DOI 10.1042/bj2890795; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Kim J, 2006, CELL SIGNAL, V18, P1695, DOI 10.1016/j.cellsig.2006.01.009; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagai R, 2005, J THROMB HAEMOST, V3, P1569, DOI 10.1111/j.1538-7836.2005.01366.x; Nandan MO, 2005, FEBS LETT, V579, P4757, DOI 10.1016/j.febslet.2005.07.053; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Radhika V, 2005, ONCOGENE, V24, P4597, DOI 10.1038/sj.onc.1208665; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Sengupta P, 2007, J BIOL CHEM, V282, P8474, DOI 10.1074/jbc.M607211200; Shida D, 2003, CANCER RES, V63, P1706; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Sorensen SD, 2003, MOL PHARMACOL, V64, P1199, DOI 10.1124/mol.64.5.1199; Sturm A, 2002, BBA-MOL CELL BIOL L, V1582, P282, DOI 10.1016/S1388-1981(02)00182-8; Subramanian N, 2006, NAT IMMUNOL, V7, P583, DOI 10.1038/ni1336; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wu J, 2002, BBA-MOL CELL BIOL L, V1582, P100, DOI 10.1016/S1388-1981(02)00143-9; Yang M, 2005, P NATL ACAD SCI USA, V102, P6027, DOI 10.1073/pnas.0501535102; Yang YZ, 2007, FASEB J, V21, P543, DOI 10.1096/fj.06-6694com; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yun CC, 2005, AM J PHYSIOL-CELL PH, V289, pC2, DOI 10.1152/ajpcell.00610.2004; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200; Zachos NC, 2005, ANNU REV PHYSIOL, V67, P411, DOI 10.1146/annurev.physiol.67.031103.153004; Zhao YT, 2006, J BIOL CHEM, V281, P19501, DOI 10.1074/jbc.M511224200; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	69	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15541	15549		10.1074/jbc.M700702200	http://dx.doi.org/10.1074/jbc.M700702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17430902	Green Accepted, hybrid			2022-12-27	WOS:000246589600031
J	Macgregor, A; Yamasaki, M; Rakovic, S; Sanders, L; Parkesh, R; Churchill, GC; Galione, A; Terrar, DA				Macgregor, Andrew; Yamasaki, Michiko; Rakovic, Stevan; Sanders, Luke; Parkesh, Raman; Churchill, Grant C.; Galione, Antony; Terrar, Derek A.			NAADP controls cross-talk between distinct Ca2+ stores in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; ENDOPLASMIC-RETICULUM; VENTRICULAR MYOCYTES; PANCREATIC ACINAR; BETA-CELLS; CALCIUM; RELEASE; CONTRACTION; RECEPTORS; COORDINATION	In cardiac muscle the sarcoplasmic reticulum (SR) plays a key role in the control of contraction, releasing Ca2+ in response to Ca2+ influx across the sarcolemma via voltage- gated Ca2+ channels. Here we report evidence for an additional distinct Ca2+ store and for actions of nicotinic acid adenine dinucleotide phosphate (NAADP) to mobilize Ca2+ from this store, leading in turn to enhanced Ca2+ loading of the SR. Photoreleased NAADP increased Ca2+ transients accompanying stimulated action potentials in ventricular myocytes. The effects were prevented by bafilomycin A (an H+-ATPase inhibitor acting on acidic Ca2+ stores), by desensitizing concentrations of NAADP, and by ryanodine and thapsigargin to suppress SR function. Bafilomycin A also suppressed staining of acidic stores with Lysotracker Red without affecting SR integrity. Cytosolic application of NAADP by means of its membrane permeant acetoxymethyl ester increased myocyte contraction and the frequency and amplitude of Ca2+ sparks, and these effects were inhibited by bafilomycin A. Effects of NAADP were associated with an increase in SR Ca2+ load and appeared to be regulated by beta-adrenoreceptor stimulation. The observations are consistent with a novel role for NAADP in cardiac muscle mediated by Ca2+ release from bafilomycin-sensitive acidic stores, which in turn enhances SR Ca2+ release by increasing SR Ca2+ load.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Oxford	Yamasaki, M (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	michiko.yamasaki@pharmacology.oxford.ac.uk	Galione, Antony/E-5884-2011	Terrar, Derek/0000-0001-9408-6594; Galione, Antony/0000-0002-4132-7646	Biotechnology and Biological Sciences Research Council [BB/D012694/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline; BBSRC [BB/D012694/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bers DM, 2000, CIRC RES, V87, P275, DOI 10.1161/01.RES.87.4.275; Boittin FX, 2002, CIRC RES, V91, P1168, DOI 10.1161/01.RES.0000047507.22487.85; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Brailoiu E, 2005, J BIOL CHEM, V280, P5646, DOI 10.1074/jbc.M408746200; Brailoiu E, 2006, J BIOL CHEM, V281, P15923, DOI 10.1074/jbc.M602249200; Cancela JM, 2003, PFLUG ARCH EUR J PHY, V446, P322, DOI 10.1007/s00424-003-1035-x; Cancela JM, 2001, ANNU REV PHYSIOL, V63, P99, DOI 10.1146/annurev.physiol.63.1.99; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Chini EN, 2002, BIOCHEM J, V362, P125, DOI 10.1042/0264-6021:3620125; Christensen KA, 2002, J CELL SCI, V115, P599; Galione A, 2005, MOL INTERV, V5, P73, DOI 10.1124/mi.5.2.4; Galione A, 2005, CELL CALCIUM, V38, P273, DOI 10.1016/j.ceca.2005.06.031; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Gerasimenko JV, 2006, J CELL SCI, V119, P226, DOI 10.1242/jcs.02721; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Iino S, 1997, CIRC RES, V81, P879; Kinnear NP, 2004, J BIOL CHEM, V279, P54319, DOI 10.1074/jbc.M406132200; Lee HC, 2005, J BIOL CHEM, V280, P33693, DOI 10.1074/jbc.R500012200; MACGREGOR AT, 2006, IN PRESS CELL CALCIU; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; Masgrau R, 2003, CURR BIOL, V13, P247, DOI 10.1016/S0960-9822(03)00041-1; MORGAN AJ, 2006, METHODS CALCIUM SIGN, P265; Navazio L, 2000, P NATL ACAD SCI USA, V97, P8693, DOI 10.1073/pnas.140217897; Patel S, 2004, BIOL CELL, V96, P19, DOI 10.1016/j.biolcel.2003.12.001; Petersen OH, 2005, CELL CALCIUM, V38, P161, DOI 10.1016/j.ceca.2005.06.023; RAKOVIC S, 2002, CYCLIC ADP RIBOSE NA, P45; VARRO A, 1993, BRIT J PHARMACOL, V109, P895, DOI 10.1111/j.1476-5381.1993.tb13702.x; Yamasaki M, 2005, FEBS J, V272, P4598, DOI 10.1111/j.1742-4658.2005.04860.x; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200; Zhang F, 2006, AM J PHYSIOL-HEART C, V291, pH274, DOI 10.1152/ajpheart.01064.2005	34	76	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15302	15311		10.1074/jbc.M611167200	http://dx.doi.org/10.1074/jbc.M611167200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387177	hybrid			2022-12-27	WOS:000246589000069
J	Zhang, R; Zhang, HF; Lin, Y; Li, JH; Pober, JS; Min, W				Zhang, Rong; Zhang, Haifeng; Lin, Yan; Li, Jiehui; Pober, Jordan S.; Min, Wang			RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is critical for tumor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; REGULATING KINASE 1; NECROSIS-FACTOR; CELL-DEATH; INDUCED ACTIVATION; APOPTOSIS; ASK1; RIP1; INHIBITOR; INDUCTION	Previously, we have shown that (A) under bar SK1-(i) under bar nteracting (p) under bar rotein 1 (AIP1, also known as DAB2IP), a novel member of the Ras-GAP (Ras-GTPase-activating protein) protein family, opens its conformation in response to tumor necrosis factor (TNF), allowing it to form a complex with TRAF2-ASK1 that leads to activation of ASK1-JNK/p38 signaling in endothelial cells (EC). In the present study, we show that a TNF-inducible 14-3-3-binding site on AIP1 is critical for the opening of its conformation and for the AIP1-mediated TNF signaling. Ser-604, located in the C-terminal domain of AIP1, was identified as a 14-3-3-binding site. TNF treatment of EC induces phosphorylation of AIP1 at Ser-604 as detected by a phospho-specific antibody, with a similar kinetics to ASK1-JNK/p38 activation. 14-3-3 associates with an open, active state of AIP1 assessed by an in vitro pulldown assay. Mutation of AIP1 at Ser-604 (AIP1-S604A) blocks TNF-induced complex formation of AIP1 with 14-3-3. TNF treatment normally induces association of AIP1 with TRAF2-ASK1. The interactions with TRAF2 and ASK1 do not occur with AIP1-S604A, suggesting that phosphorylation at this site not only creates a 14-3-3-binding site but also opens up AIP1, allowing binding to TRAF2 and ASK1. Overexpression of AIP1-S604A blocks TNF-induced ASK1-JNK activation. We further show that RIP1 (the Ser/Thr protein kinase receptor-interacting protein) associates with the GAP domain of AIP1 and mediates TNF-induced AIP1 phosphorylation at Ser-604 and JNK/p38 activation as demonstrated by both overexpression and small interfering RNA knockdown of RIP1 in EC. Furthermore, RIP1 synergizes with AIP1 (but not AIP1-S604A) in inducing both JNK/p38 activation and EC apoptosis. Our results demonstrate that RIP1-mediated AIP1 phosphorylation at the 14-3-3-binding site Ser-604 is essential for TNF-induced TRAF2-RIP1-AIP1-ASK1 complex formation and for the activation of ASK1-JNK/p38 apoptotic signaling.	Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplantat, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Immunobiol Pathol & Dermatol, New Haven, CT 06510 USA	Yale University; Yale University	Min, W (corresponding author), Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplantat, Dept Pathol, BCMM 454,295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070295, R01HL036003, R37HL036003, R01HL065978] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL070295-6, R01HL-65978-5, HV28286, HL-36003] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Devin A, 2003, EMBO REP, V4, P623, DOI 10.1038/sj.embor.embor854; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Guicciardi ME, 2003, J CLIN INVEST, V111, P1813, DOI 10.1172/JCI200318911; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; Zheng LX, 2006, MOL CELL BIOL, V26, P3505, DOI 10.1128/MCB.26.9.3505-3513.2006	29	65	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14788	14796		10.1074/jbc.M701148200	http://dx.doi.org/10.1074/jbc.M701148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389591	hybrid			2022-12-27	WOS:000246589000014
J	Connors, WL; Jokinen, J; White, DJ; Puranen, JS; Kankaanpaa, P; Upla, P; Tulla, M; Johnson, MS; Heino, J				Connors, Wendy L.; Jokinen, Johanna; White, Daniel J.; Puranen, J. Santeri; Kankaanpaa, Pasi; Upla, Paula; Tulla, Mira; Johnson, Mark S.; Heino, Jyrki			Two synergistic activation mechanisms of alpha 2 beta 1 integrin-mediated collagen binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-ADHESION; AVIDITY REGULATION; I COLLAGEN; RECEPTOR; CONFORMATION; PLATELETS; AFFINITY; BETA-1; DOMAIN	Activation of protein kinase C by 12-O-tetradecanoylphorbol-13-acetate (TPA) induces ligand-independent aggregation of a cell surface collagen receptor, alpha 2 beta 1 integrin. Concomitantly, TPA increases the avidity of alpha 2 beta 1 for collagen and the number of conformationally activated alpha 2 beta 1 integrins. The structural change was shown using a monoclonal antibody 12F1 that recognizes the "open" active) conformation of the inserted domain in the alpha 2 subunit (alpha 2I). Amino acid residue Glu-336 in alpha 2 subunit is proposed to mediate the interaction between alpha 2I domain and beta 1 subunit. Glu-336 seems to regulate a switch between open and "closed" conformations, since the mutation alpha 2E336A inhibited the TPA-related increase in the number of 12F1 positive integrins. E336A also reduced cell adhesion to collagen. However, E336A did not prevent the TPA-related increase in adhesion to collagen or alpha 2 beta 1 aggregation. Thus, alpha 2 beta 1 integrin avidity is regulated by two synergistic mechanisms, first an alpha 2E336-dependent switch to the open alpha 2I conformation, and second an alpha 2E336-independent mechanism temporally associated with receptor aggregation.	Turku Univ, Dept Biochem & Food Chem, FI-20014 Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm Sci, FI-40014 Jyvaskyla, Finland; Abo Akad Univ, Dept Biochem & Pharm, FI-20520 Turku, Finland	University of Turku; University of Jyvaskyla; Abo Akademi University	Heino, J (corresponding author), Turku Univ, Dept Biochem & Food Chem, FI-20014 Turku, Finland.	jyrki.heino@utu.fi						Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Bairoch A, 2005, NUCLEIC ACIDS RES, V33, pD154, DOI 10.1093/nar/gki070; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cambi A, 2006, MOL BIOL CELL, V17, P4270, DOI 10.1091/mbc.E05-12-1098; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017; Connors WL, 2005, ANAL BIOCHEM, V337, P246, DOI 10.1016/j.ab.2004.10.044; Cruz MA, 2005, BLOOD, V105, P1986, DOI 10.1182/blood-2004-04-1365; Czuchra A, 2006, J CELL BIOL, V174, P889, DOI 10.1083/jcb.200604060; DeLano W.L, PYMOL MOL GRAPHICS S; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Grundstrom G, 2003, EXP CELL RES, V291, P463, DOI 10.1016/j.yexcr.2003.07.010; Han JW, 2006, CURR BIOL, V16, P1796, DOI 10.1016/j.cub.2006.08.035; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Ivaska J, 1999, J CELL BIOL, V147, P401, DOI 10.1083/jcb.147.2.401; Jin M, 2004, STRUCTURE, V12, P2137, DOI 10.1016/j.str.2004.10.005; Jokinen J, 2004, J BIOL CHEM, V279, P31956, DOI 10.1074/jbc.M401409200; Kapyla J, 2004, J BIOL CHEM, V279, P51677, DOI 10.1074/jbc.M409412200; Kim M, 2004, J CELL BIOL, V167, P1241, DOI 10.1083/jcb.200404160; Lehtonen JV, 2004, J COMPUT AID MOL DES, V18, P401, DOI 10.1007/s10822-004-3752-4; Li SH, 2003, AM J PATHOL, V163, P1045, DOI 10.1016/S0002-9440(10)63464-5; LITCHFIELD DW, 1986, BIOCHEM BIOPH RES CO, V134, P1276, DOI 10.1016/0006-291X(86)90388-8; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Polanowska-Grabowska R, 1999, ARTERIOSCL THROM VAS, V19, P3044, DOI 10.1161/01.ATV.19.12.3044; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Salas A, 2004, IMMUNITY, V20, P393, DOI 10.1016/S1074-7613(04)00082-2; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Sarantos MR, 2005, J BIOL CHEM, V280, P28290, DOI 10.1074/jbc.M501662200; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Springer TA, 2004, ADV PROTEIN CHEM, V68, P29; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Upla P, 2004, MOL BIOL CELL, V15, P625, DOI 10.1091/mbc.E03-08-0588; Van de Walle GR, 2005, J BIOL CHEM, V280, P36873, DOI 10.1074/jbc.M508148200; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Velling T, 2002, J BIOL CHEM, V277, P37377, DOI 10.1074/jbc.M206286200; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; White DJ, 2004, INT J BIOCHEM CELL B, V36, P1405, DOI 10.1016/j.biocel.2003.08.016; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Yang W, 2004, P NATL ACAD SCI USA, V101, P2906, DOI 10.1073/pnas.0307340101	47	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14675	14683		10.1074/jbc.M700759200	http://dx.doi.org/10.1074/jbc.M700759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374611	hybrid			2022-12-27	WOS:000246245800081
J	Feng, RT; Ni, HM; Wang, SY; Tourkova, IL; Shurin, MR; Harada, H; Yin, XM				Feng, Rentian; Ni, Hong-Min; Wang, Shiow Y.; Tourkova, Irina L.; Shurin, Michael R.; Harada, Hisashi; Yin, Xiao-Ming			Cyanidin-3-rutinoside, a natural polyphenol antioxidant, selectively kills leukemic cells by induction of oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN-1; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; PLANT-EXTRACTS; KAPPA-B; ANTHOCYANINS; BIM; PHOSPHORYLATION; DEATH; DIFFERENTIATION	Anthocyanins are a group of naturally occurring phenolic compounds widely available in fruits and vegetables in human diets. They have broad biological activities including anti-mutagenesis and anticarcinogenesis, which are generally attributed to their antioxidant activities. We studied the effects and the mechanisms of the most common type of anthocyanins, cyanidin-3-rutinoside, in several leukemia and lymphoma cell lines. We found that cyanidin-3-rutinoside extracted and purified from the black raspberry cultivar Jewel induced apoptosis in HL-60 cells in a dose-and time-dependent manner. Paradoxically, this compound induced the accumulation of peroxides, which are involved in the induction of apoptosis in HL-60 cells. In addition, cyanidin-3-rutinoside treatment resulted in reactive oxygen species (ROS)-dependent activation of p38 MAPK and JNK, which contributed to cell death by activating the mitochondrial pathway mediated by Bim. Down-regulation of Bim or overexpression of Bcl-2 or Bcl-x(L) considerably blocked apoptosis. Notably, cyanidin-3-rutinoside treatment did not lead to increased ROS accumulation in normal human peripheral blood mononuclear cells and had no cytotoxic effects on these cells. These results indicate that cyanidin-3-rutinoside has the potential to be used in leukemia therapy with the advantages of being widely available and selective against tumors.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; USDA ARS, Beltsville Agr Res Ctr, Fruit Lab, Beltsville, MD 20705 USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; United States Department of Agriculture (USDA); Virginia Commonwealth University	Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 3550 Terrace St, Pittsburgh, PA 15261 USA.	xmyin@pitt.edu	Harada, Hisashi/H-2815-2019	Harada, Hisashi/0000-0001-5993-1289; Shurin, Michael/0000-0002-6570-7395	NATIONAL CANCER INSTITUTE [R01CA111456, R01CA083817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045252] Funding Source: NIH RePORTER; NCI NIH HHS [CA83817, CA111456] Funding Source: Medline; NINDS NIH HHS [NS045252] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chen D, 2004, P NATL ACAD SCI USA, V101, P1235, DOI 10.1073/pnas.0308050100; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; Ding M, 2006, J BIOL CHEM, V281, P17359, DOI 10.1074/jbc.M600861200; Ding WX, 2004, HEPATOLOGY, V40, P403, DOI 10.1002/hep.20310; Feng R, 2004, NUTR CANCER, V50, P80, DOI 10.1207/s15327914nc5001_11; Feng RT, 2005, J BIOL CHEM, V280, P27888, DOI 10.1074/jbc.M503347200; Fimognari C, 2005, CHEMOTHERAPY, V51, P332, DOI 10.1159/000088956; Galvano F, 2004, J NUTR BIOCHEM, V15, P2, DOI 10.1016/j.jnutbio.2003.07.004; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hagiwara A, 2001, CANCER LETT, V171, P17, DOI 10.1016/S0304-3835(01)00510-9; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Katsuzaki H, 2003, ONCOL REP, V10, P297; Lazze MC, 2004, CARCINOGENESIS, V25, P1427, DOI 10.1093/carcin/bgh138; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Lopez-Lazaro M, 2002, Curr Med Chem Anticancer Agents, V2, P691; Lu JH, 2006, FEBS LETT, V580, P3539, DOI 10.1016/j.febslet.2006.05.031; Malik A, 2005, P NATL ACAD SCI USA, V102, P14813, DOI 10.1073/pnas.0505870102; Matsuzawa A, 2005, ANTIOXID REDOX SIGN, V7, P472, DOI 10.1089/ars.2005.7.472; Mazza G., 1993, ANTHOCYANINS FRUITS; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; PATTERSON BD, 1984, ANAL BIOCHEM, V139, P487, DOI 10.1016/0003-2697(84)90039-3; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; RICHMOND R, 1981, ANAL BIOCHEM, V118, P328, DOI 10.1016/0003-2697(81)90590-X; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Serafino A, 2004, FASEB J, V18, P1940, DOI 10.1096/fj.04-1925fje; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Wang HB, 1999, J NAT PROD, V62, P294, DOI 10.1021/np980501m; Wang SY, 2005, J AGR FOOD CHEM, V53, P3156, DOI 10.1021/jf048379m; Wenzel H, 2000, CANCER RES, V60, P3823; Zheng W, 2003, J AGR FOOD CHEM, V51, P502, DOI 10.1021/jf020728u; Zheng YH, 2003, J AGR FOOD CHEM, V51, P7162, DOI 10.1021/jf030440k	43	160	172	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13468	13476		10.1074/jbc.M610616200	http://dx.doi.org/10.1074/jbc.M610616200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360708	hybrid			2022-12-27	WOS:000246060300036
J	Iguchi, H; Urashima, Y; Inagaki, Y; Ikeda, Y; Okamura, M; Tanaka, T; Uchida, A; Yamamoto, TT; Kodama, T; Sakai, J				Iguchi, Haruhisa; Urashima, Yasuyo; Inagaki, Yosuke; Ikeda, Yukio; Okamura, Masashi; Tanaka, Toshiya; Uchida, Aoi; Yamamoto, Tokuo T.; Kodama, Tatsuhiko; Sakai, Juro			SOX6 suppresses cyclin D1 promoter activity by interacting with beta-catenin and histone deacetylase 1, and its down-regulation induces pancreatic beta-cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; TRANSCRIPTIONAL ACTIVATION; INSULIN-SECRETION; COLON-CARCINOMA; GENE; DIFFERENTIATION; EXPRESSION; PATHWAY; L-SOX5; RATHER	Sex-determining region Y-box (SOX) 6 negatively regulates glucose-stimulated insulin secretion from beta-cells and is a down-regulated transcription factor in the pancreatic islet cells of hyperinsulinemic obese mice. To determine the contribution of SOX6 to insulin resistance, we analyzed the effects of SOX6 on cell proliferation. Small interfering RNA-mediated attenuation of SOX6 expression stimulated the proliferation of insulinoma INS-1E and NIH-3T3 cells, whereas retroviral overexpression resulted in inhibition of cell growth. Quantitative real time-PCR analysis revealed that the levels of cyclin D1 transcripts were markedly decreased by SOX6 overexpression. Luciferase-reporter assay with beta-catenin showed that SOX6 suppresses cyclin D1 promoter activities. In vitro binding experiments showed that the LZ/Q domain of SOX6 physically interacts with armadillo repeats 1-4 of beta-catenin. Furthermore, chromatin immunoprecipitation assay revealed that increased SOX6 expression significantly reduced the levels of acetylated histones H3 and H4 at the cyclin D1 promoter. By using a histone deacetylase (HDAC) inhibitor and co-immunoprecipitation analysis, we showed that SOX6 suppressed cyclin D1 activities by interacting with beta-catenin and HDAC1. The data presented suggest that SOX6 may be an important factor in obesity-related insulin resistance.	Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo 1538904, Japan; Japn Sci & Technol Agcy, Exploratory Res Adv Technol, Tokyo 1358904, Japan; Tohoku Univ, Ctr Adv Genome Res, Inst Dev Aging & Canc, Sendai, Miyagi 9818555, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Tohoku University	Sakai, J (corresponding author), Dainippon Sumitomo Pharma Co Ltd, Gen Sci Lab, Takarazuka, Hyogo 6650051, Japan.	jmsakai-tky@umin.ac.jp		Sakai, Juro/0000-0003-4043-1035				Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Butler AE, 2003, DIABETES, V52, P2304, DOI 10.2337/diabetes.52.9.2304; Coates JC, 2003, TRENDS CELL BIOL, V13, P463, DOI 10.1016/S0962-8924(03)00167-3; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Iguchi H, 2005, J BIOL CHEM, V280, P37669, DOI 10.1074/jbc.M505392200; Ikeda Y, 2001, J BIOL CHEM, V276, P34259, DOI 10.1074/jbc.M103848200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kitamura T, 1998, INT J HEMATOL, V67, P351; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kulkarni RN, 2004, J CLIN INVEST, V114, P828, DOI 10.1172/JCI200421845; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sambrook J., 2001, MOL CLONING LAB MANU; Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Takayasu S, 2006, P NATL ACAD SCI USA, V103, P7438, DOI 10.1073/pnas.0602371103; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200	26	113	118	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19052	19061		10.1074/jbc.M700460200	http://dx.doi.org/10.1074/jbc.M700460200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17412698	hybrid			2022-12-27	WOS:000247475300047
J	Taylor, KR; Yamasaki, K; Radek, KA; Di Nardo, A; Goodarzi, H; Golenbock, D; Beutler, B; Gallo, RL				Taylor, Kristen R.; Yamasaki, Kenshi; Radek, Katherine A.; Di Nardo, Anna; Goodarzi, Heidi; Golenbock, Douglas; Beutler, Bruce; Gallo, Richard L.			Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on toll-like receptor 4, CD44, and MD-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; GROUP-A STREPTOCOCCUS; TIR ADAPTER PROTEINS; SIGNAL-TRANSDUCTION; MURINE MACROPHAGES; GENETIC-ANALYSIS; DENDRITIC CELLS; KAPPA-B; EXPRESSION; ENDOTOXIN	Inflammation under sterile conditions is not well understood despite its importance in trauma and autoimmune disease. To investigate this process we established mouse models of sterile injury and explored the role of hyaluronan in mediating inflammation following injury. The response of cultured monocytes to hyaluronan was different than the response to lipopolysaccharide (LPS) despite both being dependent on Toll-like receptor 4 (TLR4). Cultured cells exposed to hyaluronan showed a pattern of gene induction that mimics the response seen in mouse skin after sterile injury with an increase in molecules such as transforming growth factor-beta 2 and matrix metalloproteinase-13. These factors were not induced by LPS despite the mutual dependence of both hyaluronan and LPS on TLR4. Explanation for the unique response to hyaluronan was provided by observations that a lack of TLR4 or CD44 in mice diminished the response to sterile injury, and together with MD-2, was required for responsiveness to hyaluronan in vitro. Thus, a unique complex of TLR4, MD-2, and CD44 recognizes hyaluronan. Immunoprecipitation experiments confirmed the physical association of TLR4 and CD44. Taken together, our results define a previously unknown mechanism for initiation of sterile inflammation that involves recognition of released hyaluronan fragments as an endogenous signal of tissue injury.	Univ Calif San Diego, Vet Affairs Med Ctr, Div Dermatol, San Diego, CA 92161 USA; Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Massachusetts System; University of Massachusetts Worcester; Scripps Research Institute	Gallo, RL (corresponding author), Univ Calif San Diego, Div Dermatol, MC 9111B,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	rgallo@vapop.ucsd.edu	Gallo, Richard L/A-8931-2009; Yamasaki, Kenshi/C-8905-2018; di nardo, anna/AAI-1629-2020	Gallo, Richard L/0000-0002-1401-7861; Yamasaki, Kenshi/0000-0002-5495-4956; di nardo, anna/0000-0002-5575-9968	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL057345] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beutler B, 2005, ADV EXP MED BIOL, V560, P29; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Cywes C, 2001, NATURE, V414, P648, DOI 10.1038/414648a; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; del Fresno C, 2005, J IMMUNOL, V174, P3032, DOI 10.4049/jimmunol.174.5.3032; Fitzgerald KA, 2004, MICROBES INFECT, V6, P1361, DOI 10.1016/j.micinf.2004.08.015; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hoebe K, 2004, J ENDOTOXIN RES, V10, P130, DOI 10.1179/096805104225004031; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Mummert ME, 2000, J EXP MED, V192, P769, DOI 10.1084/jem.192.6.769; Oertl A, 2005, WORLD J GASTROENTERO, V11, P6243, DOI 10.3748/wjg.v11.i40.6243; Ohno S, 2006, J BIOL CHEM, V281, P17952, DOI 10.1074/jbc.M602750200; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; SAMPSON PM, 1992, J CLIN INVEST, V90, P1492, DOI 10.1172/JCI116017; Scheibner KA, 2006, J IMMUNOL, V177, P1272, DOI 10.4049/jimmunol.177.2.1272; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Srebrow A, 2006, J CELL SCI, V119, P2635, DOI 10.1242/jcs.03053; Stern R, 2001, EXP CELL RES, V266, P167, DOI 10.1006/excr.2001.5206; Stojanov S, 2005, CURR OPIN RHEUMATOL, V17, P586, DOI 10.1097/bor.0000174210.78449.6b; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Taylor KR, 2004, J BIOL CHEM, V279, P17079, DOI 10.1074/jbc.M310859200; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Zaman A, 2005, AM J RESP CELL MOL, V33, P447, DOI 10.1165/rcmb.2004-0333OC; Zmolik JM, 2005, J HISTOCHEM CYTOCHEM, V53, P745, DOI 10.1369/jhc.4A6491.2005	51	298	311	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18265	18275		10.1074/jbc.M606352200	http://dx.doi.org/10.1074/jbc.M606352200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17400552	hybrid			2022-12-27	WOS:000247302000033
J	Lu, B; Yadav, S; Shah, PG; Liu, T; Tian, B; Pukszta, S; Villaluna, N; Kutejova, E; Newlon, CS; Santos, JH; Suzuki, CK				Lu, Bin; Yadav, Swati; Shah, Parul G.; Liu, Tong; Tian, Bin; Pukszta, Sebastian; Villaluna, Nerissa; Kutejova, Eva; Newlon, Carol S.; Santos, Janine H.; Suzuki, Carolyn K.			Roles for the human ATP-dependent lon protease in mitochondrial DNA maintenance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OXIDATIVE STRESS; BINDING PROTEIN; IN-VITRO; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; CROSS-LINKING; YEAST; REPAIR; REPLICATION	Human mitochondrial Lon is an ATP-powered proteolytic machine that specifically binds to single-stranded G-rich DNA and RNA in vitro. However, it is unknown whether Lon binds mitochondrial DNA (mtDNA) in living cells or functions in mtDNA integrity. Here, we demonstrate that Lon interacts with the mitochondrial genome in cultured cells using mtDNA immunoprecipitation (mIP). Lon associates with sites distributed primarily within one-half of the genome and preferentially with the control region for mtDNA replication and transcription. Bioinformatic analysis of mIP data revealed a G-rich consensus sequence. Consistent with these findings, in vitro experiments showed that the affinity of Lon for single-stranded DNA oligonucleotides correlates with conformity to this consensus. To examine the role of Lon in mtDNA maintenance, cells carrying an inducible short hairpin RNA for Lon depletion were used. In control and Lon-depleted cells, mtDNA copy number was essentially the same in the presence or absence of oxidative stress. However when oxidatively stressed, control cells exhibited an increased frequency of mtDNA lesions, whereas Lon-depleted cells showed little if any mtDNA damage. This suggests that oxidative mtDNA damage is permitted when Lon is present and prevented when Lon is substantially depleted. Upon oxidative stress, mIP showed reduced Lon binding to mtDNA; however binding to the control region was unaffected. It is unlikely that oxidative modification of Lon blocks its ability to bind DNA in vivo as results show that oxidized purified Lon retains sequence-specific DNA binding. Taken together, these results demonstrate that mtDNA binding is a physiological function of Lon and that cellular levels of Lon influence sensitivity to mtDNA damage. These findings suggest roles for Lon in linking protein and mtDNA quality control.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07101 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07101 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07101 USA; Slovak Acad Sci, Inst Mol Biol, Bratislava 84551, Slovakia	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Slovak Academy of Sciences	Suzuki, CK (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07101 USA.	suzukick@umdnj.edu	Kutejova, Eva/AAI-2544-2021; Lu, Bin/GQQ-3590-2022; Kutejova, Eva/K-6550-2014	Kutejova, Eva/0000-0002-0973-679X; Kutejova, Eva/0000-0002-0973-679X; Tian, Bin/0000-0001-8903-8256				ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; Ayala-Torres S, 2000, METHODS, V22, P135, DOI 10.1006/meth.2000.1054; Bailey T L, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P21; Bailey TL, 1998, BIOINFORMATICS, V14, P48, DOI 10.1093/bioinformatics/14.1.48; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Bota DA, 2002, FEBS LETT, V532, P103, DOI 10.1016/S0014-5793(02)03638-4; Bretz J, 2002, MOL MICROBIOL, V45, P397, DOI 10.1046/j.1365-2958.2002.03008.x; Bulteau AL, 2006, EXP GERONTOL, V41, P653, DOI 10.1016/j.exger.2006.03.013; CHARETTE MF, 1984, J BACTERIOL, V158, P195, DOI 10.1128/JB.158.1.195-201.1984; Cheng XL, 2005, J BIOCHEM, V138, P673, DOI 10.1093/jb/mvi169; CHUNG CH, 1982, P NATL ACAD SCI-BIOL, V79, P795, DOI 10.1073/pnas.79.3.795; Clayton DA, 2003, IUBMB LIFE, V55, P213, DOI 10.1080/1521654031000134824; DAIRAGHI DJ, 1995, J MOL BIOL, V249, P11, DOI 10.1006/jmbi.1995.9889; Das PM, 2004, BIOTECHNIQUES, V37, P961, DOI 10.2144/04376RV01; Delaval E, 2004, EUR J BIOCHEM, V271, P4559, DOI 10.1111/j.1432-1033.2004.04422.x; EICHLER DC, 1977, J BIOL CHEM, V252, P7888; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Fernandez-Silva P, 1996, Methods Enzymol, V264, P129, DOI 10.1016/S0076-6879(96)64014-2; Fu GK, 1997, J BIOL CHEM, V272, P534; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Gonzalez M, 1998, GENE DEV, V12, P3889, DOI 10.1101/gad.12.24.3889; Hazra TK, 2003, CARCINOGENESIS, V24, P155, DOI 10.1093/carcin/24.2.155; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Hu JP, 2005, J BIOL CHEM, V280, P40544, DOI 10.1074/jbc.M508772200; Jones BD, 2005, J MICROBIOL, V43, P110; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lee AYL, 2004, J BIOL CHEM, V279, P34903, DOI 10.1074/jbc.M403562200; Liu JJ, 1999, MOL MICROBIOL, V33, P415, DOI 10.1046/j.1365-2958.1999.01489.x; Liu T, 2004, J BIOL CHEM, V279, P13902, DOI 10.1074/jbc.M309642200; Lu B, 2003, GENE, V306, P45, DOI 10.1016/S0378-1119(03)00403-7; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; Meeusen S, 1999, J CELL BIOL, V145, P291, DOI 10.1083/jcb.145.2.291; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; Meeusen SL, 2005, CURR OPIN CELL BIOL, V17, P389, DOI 10.1016/j.ceb.2005.06.014; Meluh PB, 1999, METHOD ENZYMOL, V304, P414; MIYAKAWA I, 1987, J CELL SCI, V88, P431; Nomura K, 2004, J BIOL CHEM, V279, P34406, DOI 10.1074/jbc.M404725200; Nonn L, 2003, MOL CANCER RES, V1, P682; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Santos Janine H, 2006, Methods Mol Biol, V314, P183; Santos Janine H, 2002, Methods Mol Biol, V197, P159, DOI 10.1385/1-59259-284-8:159; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Shah IM, 2006, MOL MICROBIOL, V60, P199, DOI 10.1111/j.1365-2958.2006.05086.x; Shen X, 2006, DIABETES, V55, P798, DOI 10.2337/diabetes.55.03.06.db05-1039; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Tong WH, 2006, CELL METAB, V3, P199, DOI 10.1016/j.cmet.2006.02.003; TOZAWA K, 1992, J BIOL CHEM, V267, P16484; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; VANDYCK L, 1994, J BIOL CHEM, V269, P238; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wright R, 1996, GENE DEV, V10, P1532, DOI 10.1101/gad.10.12.1532; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002; ZEHNBAUER BA, 1981, P NATL ACAD SCI-BIOL, V78, P2043, DOI 10.1073/pnas.78.4.2043	60	107	114	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17363	17374		10.1074/jbc.M611540200	http://dx.doi.org/10.1074/jbc.M611540200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17420247	hybrid			2022-12-27	WOS:000247084500006
J	Maruyama, D; Nishitani, Y; Nonaka, T; Kita, A; Fukami, TA; Mio, T; Yamada-Okabe, H; Yamada-Okabe, T; Miki, K				Maruyama, Daisuke; Nishitani, Yuichi; Nonaka, Tsuyoshi; Kita, Akiko; Fukami, Takaaki A.; Mio, Toshiyuki; Yamada-Okabe, Hisafumi; Yamada-Okabe, Toshiko; Miki, Kunio			Crystal structure of uridine-diphospho-N-acetylglucosamine pyrophosphorylase from Candida albicans and catalytic reaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; ESCHERICHIA-COLI; URIDYLTRANSFERASE; SITE; IDENTIFICATION; PURIFICATION; 1-PHOSPHATE; CLONING; GLMU	Uridine-diphospho-N-acetylglucosamine (UDP-GlcNAc) is a precursor of the bacterial and fungal cell wall. It is also used in a component of N-linked glycosylation and the glycosylphosphoinositol anchor of eukaryotic proteins. It is synthesized from N-acetylglucosamine-1-phosphate (GlcNAc-1-P) and uridine-5'-triphosphate (UTP) by UDP-GlcNAc pyrophosphorylase (UAP). This is an S(N)2 reaction; the non-esterified oxygen atom of the GlcNAc-1-P phosphate group attacks the alpha-phosphate group of UTP. We determined crystal structures of UAP from Candida albicans (CaUAP1) without any ligands and also complexed with its substrate or with its product. The series of structures in different forms shows the induced fit movements of CaUAP1. Three loops approaching the ligand molecule close the active site when ligand is bound. In addition, Lys-421, instead of the metal ion in prokaryotic UAPs, is coordinated by both phosphate groups of UDP- GlcNAc and acts as a cofactor. However, a magnesium ion enhances the enzymatic activity of CaUAP1, and thus we propose that the magnesium ion increases the affinity between UTP and the enzyme by coordinating to the alpha- and gamma- phosphate group of UTP.	Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; Chugai Pharmaceut Co Ltd, Kamakura Res Labs, Kamakura, Kanagawa 2478530, Japan; Yokohama City Univ, Sch Med, Dept Hyg, Yokohama, Kanagawa 2360004, Japan; RIKEN, Harima Inst, SPring Ctr 8, Sayocho, Hyogo 6795148, Japan	Kyoto University; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Yokohama City University; RIKEN	Miki, K (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan.	miki@kuchem.kyoto-u.ac.jp						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulik DA, 1998, MOL BIOCHEM PARASIT, V95, P135, DOI 10.1016/S0166-6851(98)00076-0; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; DeLano W.L, PYMOL MOL GRAPHICS S; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HOLTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kostrewa D, 2001, J MOL BIOL, V305, P279, DOI 10.1006/jmbi.2000.4296; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Maruyama D, 2006, ACTA CRYSTALLOGR F, V62, P1206, DOI 10.1107/S1744309106044186; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; Mio T, 1999, J BIOL CHEM, V274, P424, DOI 10.1074/jbc.274.1.424; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; Mio T, 2000, BBA-GENE STRUCT EXPR, V1492, P369, DOI 10.1016/S0167-4781(00)00120-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; RAETZ CRH, 1987, ESCHERICHIA COLI SAL, V1, P498; ROGERS TJ, 1980, MICROBIOL REV, V44, P660, DOI 10.1128/MMBR.44.4.660-682.1980; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SHEU KFR, 1978, J BIOL CHEM, V253, P3378; Sulzenbacher G, 2001, J BIOL CHEM, V276, P11844, DOI 10.1074/jbc.M011225200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Wang-Gillam A, 2000, J BIOL CHEM, V275, P1433, DOI 10.1074/jbc.275.2.1433	36	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					17221	17230		10.1074/jbc.M611873200	http://dx.doi.org/10.1074/jbc.M611873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17392279	hybrid			2022-12-27	WOS:000246946500055
J	Burkhard, KA; Wilks, A				Burkhard, Kimberly A.; Wilks, Angela			Characterization of the outer membrane receptor ShuA from the heme uptake system of Shigella dysenteriae - Substrate specificity and identification of the heme protein ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON TRANSPORT-SYSTEMS; ESCHERICHIA-COLI; BINDING-PROTEIN; PSEUDOMONAS-AERUGINOSA; YERSINIA-ENTEROCOLITICA; NEISSERIA-MENINGITIDIS; CRYSTAL-STRUCTURE; HAEMOPHILUS-INFLUENZAE; CYTOPLASMIC MEMBRANE; HEMOGLOBIN RECEPTOR	Shigella dysenteriae, like many bacterial pathogens, has evolved outer membrane receptor-mediated pathways for the uptake and utilization of heme as an iron source. As a first step toward understanding the mechanism of heme uptake we have undertaken a site-directed mutagenesis, spectroscopic, and kinetic analysis of the outer membrane receptor ShuA of S. dysenteriae. Purification of the outer membrane receptor gave a single band of molecular mass 73 kDa on SDS-PAGE. Initial spectroscopic analysis of the protein in either detergent micelles or lipid bicelles revealed residual heme bound to the receptor, with a Soret maximum at 413 nm. Titration of the protein with exogenous heme gave a Soret peak at 437 nm in detergent micelles, and 402 nm in lipid bicelles. However, transfer of heme from hemoglobin yields a Soret maximum at 413 nm identical to that of the isolated protein. Further spectroscopic and kinetic analysis revealed that hemoglobin in the oxidized state is the most likely physiological substrate for ShuA. In addition, mutation of the conserved histidines, H86A or H420A, resulted in a loss of the ability of the receptor to efficiently extract heme from hemoglobin. In contrast the double mutant H86A/H420A was unable to extract heme from hemoglobin. These findings taken together confirm that both His-86 and His-420 are essential for substrate recognition, heme coordination, and transfer. Furthermore, the full-length TonB was shown to form a 1: 1 complex with either apo-ShuA H86A/H420A or the wild-type ShuA. These observations provide a basis for future studies on the coordination and transport of heme by the TonB-dependent outer membrane receptors.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Wilks, A (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 Penn St, Baltimore, MD 21201 USA.	awilks@rx.umaryland.edu			NIAID NIH HHS [AI-48551] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048551] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Annamalai R, 2004, J BACTERIOL, V186, P3578, DOI 10.1128/JB.186.11.3578-3589.2004; Bracken CS, 1999, J BACTERIOL, V181, P6063, DOI 10.1128/JB.181.19.6063-6072.1999; Braun Volkmar, 2005, V12, P210, DOI 10.1159/000081697; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P634; Carter DM, 2006, J BIOL CHEM, V281, P35413, DOI 10.1074/jbc.M607611200; Cherla RP, 2003, FEMS MICROBIOL LETT, V228, P159, DOI 10.1016/S0378-1097(03)00761-4; Clarke Teresa E., 2001, Current Topics in Medicinal Chemistry, V1, P7, DOI 10.2174/1568026013395623; Cobessi D, 2005, J MOL BIOL, V347, P121, DOI 10.1016/j.jmb.2005.01.021; COPE LD, 1995, J BACTERIOL, V177, P2644, DOI 10.1128/jb.177.10.2644-2653.1995; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Fanucci GE, 2003, J AM CHEM SOC, V125, P13932, DOI 10.1021/ja0376442; Fanucci GE, 2003, P NATL ACAD SCI USA, V100, P11382, DOI 10.1073/pnas.1932486100; Ferguson AD, 2002, BBA-BIOMEMBRANES, V1565, P318, DOI 10.1016/S0005-2736(02)00578-3; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; Fuller-Schaefer CA, 2005, J BACTERIOL, V187, P1732, DOI 10.1128/JB.187.5.1732-1739.2005; Hargrove MS, 1997, J BIOL CHEM, V272, P17385, DOI 10.1074/jbc.272.28.17385; HENDERSON DP, 1994, INFECT IMMUN, V62, P5120, DOI 10.1128/IAI.62.11.5120-5125.1994; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Izadi-Pruneyre N, 2006, J BIOL CHEM, V281, P25541, DOI 10.1074/jbc.M603698200; Jin HF, 1999, MICROBIOL-UK, V145, P905, DOI 10.1099/13500872-145-4-905; Khursigara CM, 2004, J BIOL CHEM, V279, P7405, DOI 10.1074/jbc.M311784200; Koster W, 2005, FRONT BIOSCI-LANDMRK, V10, P462, DOI 10.2741/1542; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Lansky IB, 2006, J BIOL CHEM, V281, P13652, DOI 10.1074/jbc.M600824200; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; Letoffe S, 1998, MOL MICROBIOL, V28, P1223, DOI 10.1046/j.1365-2958.1998.00885.x; LEVITT M, 1995, COMPUT PHYS COMMUN, V91, P215, DOI 10.1016/0010-4655(95)00049-L; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Lund O., 2002, CASP5 C, pA102; MILLS M, 1995, J BACTERIOL, V177, P3004, DOI 10.1128/jb.177.11.3004-3009.1995; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Nygaard TK, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-82; Nygaard TK, 2006, J BIOL CHEM, V281, P20761, DOI 10.1074/jbc.M601832200; Ochsner UA, 2000, MICROBIOL-UK, V146, P185, DOI 10.1099/00221287-146-1-185; Pawelek PD, 2006, SCIENCE, V312, P1399, DOI 10.1126/science.1128057; Perkins-Balding D, 2004, MICROBIOL MOL BIOL R, V68, P154, DOI 10.1128/MMBR.68.1.154-171.2004; Perkins-Balding D, 2003, MICROBIOL-SGM, V149, P3423, DOI 10.1099/mic.0.26448-0; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; Rossi MS, 2001, INFECT IMMUN, V69, P6707, DOI 10.1128/IAI.69.11.6707-6717.2001; Sansonetti PJ, 2001, FEMS MICROBIOL REV, V25, P3, DOI 10.1111/j.1574-6976.2001.tb00569.x; Sauter A, 2003, J BACTERIOL, V185, P5747, DOI 10.1128/JB.185.19.5747-5754.2003; Shultis DD, 2006, SCIENCE, V312, P1396, DOI 10.1126/science.1127694; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Srikumar R, 2004, MICROBIOL-SGM, V150, P1723, DOI 10.1099/mic.0.27046-0; Stojiljkovic I, 1996, J BACTERIOL, V178, P4670, DOI 10.1128/jb.178.15.4670-4678.1996; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; STOJILJKOVIC I, 1995, MOL MICROBIOL, V15, P531, DOI 10.1111/j.1365-2958.1995.tb02266.x; Turner PC, 1998, INFECT IMMUN, V66, P5215, DOI 10.1128/IAI.66.11.5215-5223.1998; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; Wandersman C, 2004, ANNU REV MICROBIOL, V58, P611, DOI 10.1146/annurev.micro.58.030603.123811; Wilks A, 2001, ARCH BIOCHEM BIOPHYS, V387, P137, DOI 10.1006/abbi.2000.2250; Wyckoff EE, 2005, J BACTERIOL, V187, P5658, DOI 10.1128/JB.187.16.5658-5664.2005	56	44	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15126	15136		10.1074/jbc.M611121200	http://dx.doi.org/10.1074/jbc.M611121200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387178	hybrid			2022-12-27	WOS:000246589000052
J	Guillemain, G; Filhoulaud, G; Da Silva-Xavier, G; Rutter, GA; Scharfmann, R				Guillemain, Ghislaine; Filhoulaud, Gaelle; Da Silva-Xavier, Gabriela; Rutter, Guy A.; Scharfmann, Raphael			Glucose is necessary for embryonic pancreatic endocrine cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ISLET BETA-CELL; GENE-EXPRESSION; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; RAT PANCREAS; ADULT-RATS; GROWTH; PROLIFERATION	Mature pancreatic cells develop during embryonic life from endodermal progenitors, and this developmental process depends on activation of a hierarchy of transcription factors. While information is available on mesodermal signals controlling pancreas development, little is known about environmental factors, such as the levels of nutrients including glucose, that may control this process. Here, we studied the effects of glucose on pancreatic cells development. We used an in vitro model where both endocrine and acinar cells develop from early pancreatic and duodenal homeobox- 1 ( PDX1)- positive embryonic pancreatic progenitors. We first showed that glucose does not have a major effect on global pancreatic cell proliferation, survival, and acinar cell development. On the other hand, glucose controlled both alpha and beta cell development. Specifically, the surface occupied by insulin- positive cells was 20- fold higher in pancreases cultured in presence than in absence of glucose, and this effect was dose- dependent over the range 0.5 - 10mM. Glucose did not appear to control beta cell development by activating the proliferation of early progenitors or beta cells themselves but instead tightly regulated cell differentiation. Thus, glucose did not modify the pattern of expression of Neurogenin3, the earliest marker of endocrine progenitor cells, but was necessary for the expression of the transcription factor NeuroD, a direct target of Neurogenin3 known to be important for proper pancreatic endocrine cell development. We conclude that glucose interferes with the pancreatic endocrine cells development by regulating the transition between Ngn3 and upstream NeuroD.	Univ Paris 05, Fac Med, INSERM, Necker Hosp,EMI 363, F-75730 Paris 15, France; U845, F-75730 Paris 15, France; Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Cell Biol, London SW7 2AZ, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Imperial College London	Guillemain, G (corresponding author), Fac Med Necker Enfants Malad, INSERM, E363, 156 Rue Vaugirard, F-75015 Paris, France.	guillemain@necker.fr	Guillemain, Ghislaine/P-7740-2017; scharfmann, raphael/L-3296-2017	Scharfmann, Raphael/0000-0001-7619-337X; Rutter, Guy/0000-0001-6360-0343; da Silva Xavier, Gabriela/0000-0002-0678-012X; Guillemain, Ghislaine/0000-0002-8256-9545	Diabetes UK [13/0004672] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Diabetes UK(Diabetes UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ainscow EK, 2002, J PHYSIOL-LONDON, V544, P429, DOI 10.1113/jphysiol.2002.022434; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; ATTALI M, 2007, IN PRESS DIABETES; Bernard C, 1998, DIABETES, V47, P1058, DOI 10.2337/diabetes.47.7.1058; Bernard C, 1999, FASEB J, V13, P1195, DOI 10.1096/fasebj.13.10.1195; Bhushan A, 2001, DEVELOPMENT, V128, P5109; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; Collombat P, 2006, MECH DEVELOP, V123, P501, DOI 10.1016/j.mod.2006.05.006; Cousin SP, 1999, BIOCHEM J, V344, P649, DOI 10.1042/0264-6021:3440649; DOIRON B, 1994, J BIOL CHEM, V269, P10213; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Duvillie B, 2003, DIABETES, V52, P2035, DOI 10.2337/diabetes.52.8.2035; Duvillie B, 2006, DIABETES, V55, P582, DOI 10.2337/diabetes.55.03.06.db05-0839; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Edsbagge J, 2005, DEVELOPMENT, V132, P1085, DOI 10.1242/dev.01643; Garofano A, 1998, DIABETOLOGIA, V41, P1114, DOI 10.1007/s001250051038; Garofano A, 1997, DIABETOLOGIA, V40, P1231, DOI 10.1007/s001250050812; Georgia S, 2004, J CLIN INVEST, V114, P963, DOI 10.1172/JCI200422098; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Hart A, 2003, DEV DYNAM, V228, P185, DOI 10.1002/dvdy.10368; Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953; Hattersley AT, 2005, DIABETES, V54, P2503, DOI 10.2337/diabetes.54.9.2503; Hebrok M, 2003, MECH DEVELOP, V120, P45, DOI 10.1016/S0925-4773(02)00331-3; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; Kim SK, 1997, DEVELOPMENT, V124, P4243; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Leclerc I, 2004, DIABETES, V53, pS67, DOI 10.2337/diabetes.53.suppl_3.S67; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Limesand SW, 2005, AM J PHYSIOL-REG I, V288, pR1297, DOI 10.1152/ajpregu.00494.2004; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martinez SC, 2006, DIABETES, V55, P1581, DOI 10.2337/db05-0678; McKinnon CM, 2006, J BIOL CHEM, V281, P39358, DOI 10.1074/jbc.M605022200; Miralles F, 1998, DEVELOPMENT, V125, P1017; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OWEN MR, 1993, BIOCHIM BIOPHYS ACTA, V1142, P11, DOI 10.1016/0005-2728(93)90079-U; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; Petrik J, 1999, ENDOCRINOLOGY, V140, P4861, DOI 10.1210/en.140.10.4861; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; Ravassard P, 1997, P NATL ACAD SCI USA, V94, P8602, DOI 10.1073/pnas.94.16.8602; Rutter CA, 2000, NEWS PHYSIOL SCI, V15, P149; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; Scharfmann R, 2000, DIABETOLOGIA, V43, P1083, DOI 10.1007/s001250051498; Srinivasan S, 2002, AM J PHYSIOL-ENDOC M, V283, pE784, DOI 10.1152/ajpendo.00177.2002; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; SWENNE I, 1982, DIABETES, V31, P754, DOI 10.2337/diab.31.9.754; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; van Eyll JM, 2004, J CELL SCI, V117, P2077, DOI 10.1242/jcs.01067; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; Xavier GD, 2003, BIOCHEM J, V371, P761; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Xavier GD, 2004, BIOCHEM J, V377, P149, DOI 10.1042/BJ20031260	68	51	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15228	15237		10.1074/jbc.M610986200	http://dx.doi.org/10.1074/jbc.M610986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376780	hybrid			2022-12-27	WOS:000246589000062
J	James, AM; Sharpley, MS; Manas, ARB; Frerman, FE; Hirst, J; Smith, RAJ; Murphy, MP				James, Andrew M.; Sharpley, Mark S.; Manas, Abdul-Rahman B.; Frerman, Frank E.; Hirst, Judy; Smith, Robin A. J.; Murphy, Michael P.			Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER FLAVOPROTEIN; HYDROPHOBIC ION INTERACTIONS; COENZYME-Q; COMPLEX-I; HEART-MITOCHONDRIA; MEMBRANES; FLUORESCENCE; NADH; SPECTROSCOPY; INHIBITORS	MitoQ(10) is a ubiquinone that accumulates within mitochondria driven by a conjugated lipophilic triphenylphosphonium cation (TPP (+)). Once there, MitoQ(10) is reduced to its active ubiquinol form, which has been used to prevent mitochondrial oxidative damage and to infer the involvement of reactive oxygen species in signaling pathways. Here we show MitoQ(10) is effectively reduced by complex II, but is a poor substrate for complex I, complex III, and electron-transferring flavoprotein (ETF): quinone oxidoreductase (ETF-QOR). This differential reactivity could be explained if the bulky TPP (+) moiety sterically hindered access of the ubiquinone group to enzyme active sites with a long, narrow access channel. Using a combination of molecular modeling and an uncharged analog of MitoQ(10) with similar sterics (tritylQ(10)), we infer that the interaction of MitoQ(10) with complex I and ETF-QOR, but not complex III, is inhibited by its bulky TPP (+) moiety. To explain its lack of reactivity with complex III we show that the TPP (+) moiety of MitoQ(10) is ineffective at quenching pyrene fluorophors deeply buried within phospholipid bilayers and thus is positioned near the membrane surface. This superficial position of the TPP (+) moiety, as well as the low solubility of MitoQ(10) in non-polar organic solvents, suggests that the concentration of the entire MitoQ(10) molecule in the membrane core is very limited. As overlaying MitoQ(10) onto the structure of complex III indicates that MitoQ(10) cannot react with complex III without its TPP (+) moiety entering the low dielectric of the membrane core, we conclude that the TPP (+) moiety does anchor the tethered ubiquinol group out of reach of the active site(s) of complex III, thus explaining its slow oxidation. In contrast the ubiquinone moiety of MitoQ(10) is able to quench fluorophors deep within the membrane core, indicating a high concentration of the ubiquinone moiety within the membrane and explaining its good antioxidant efficacy. These findings will facilitate the rational design of future mitochondria-targeted molecules.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Otago, Dept Chem, Dunedin 9001, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Otago	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	James, Andrew M/A-2639-2015; Murphy, Michael P/C-2120-2009; Hirst, Judy/F-4803-2011	James, Andrew M/0000-0002-0515-9649; Murphy, Michael P/0000-0003-1115-9618; Hirst, Judy/0000-0001-8667-6797	MRC [MC_U105663141, MC_U105663142] Funding Source: UKRI; Medical Research Council [MC_U105663142, MC_U105663141] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABRAMS FS, 1993, BIOCHEMISTRY-US, V32, P10826, DOI 10.1021/bi00091a038; Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; Asin-Cayuela J, 2004, FEBS LETT, V571, P9, DOI 10.1016/j.febslet.2004.06.045; BLATT E, 1985, BIOCHIM BIOPHYS ACTA, V822, P43, DOI 10.1016/0304-4157(85)90003-6; DARLEYUSMAR VM, 1987, MITOCHONDRIA PRACTIC, P143; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DAVEY GP, 1992, BIOCHEM J, V288, P439, DOI 10.1042/bj2880439; DuPlessis ER, 1998, BIOCHEMISTRY-US, V37, P10469, DOI 10.1021/bi980767s; ESTORNELL E, 1992, FEBS LETT, V311, P107, DOI 10.1016/0014-5793(92)81378-Y; FLEWELLING RF, 1986, BIOPHYS J, V49, P541, DOI 10.1016/S0006-3495(86)83664-5; FLEWELLING RF, 1986, BIOPHYS J, V49, P531, DOI 10.1016/S0006-3495(86)83663-3; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; Griffin KJ, 1998, EUR J BIOCHEM, V255, P125, DOI 10.1046/j.1432-1327.1998.2550125.x; GRINIUS LL, 1970, BIOCHIM BIOPHYS ACTA, V216, P1, DOI 10.1016/0005-2728(70)90153-2; James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200; Jauslin ML, 2003, FASEB J, V17, P1972, DOI 10.1096/fj.03-0240fje; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; KETTERER B, 1971, J MEMBRANE BIOL, V5, P225, DOI 10.1007/BF01870551; Koehorst RBM, 2004, BIOPHYS J, V87, P1445, DOI 10.1529/biophysj.104.043208; Lenaz G, 1998, BBA-BIOENERGETICS, V1364, P207, DOI 10.1016/S0005-2728(98)00028-0; LESTER RL, 1959, J BIOL CHEM, V234, P2169; Liberman E A, 1969, Biofizika, V14, P452; LIBERMAN EA, 1969, NATURE, V222, P1076, DOI 10.1038/2221076a0; Murphy MP, 2007, ANNU REV PHARMACOL, V47, P629, DOI 10.1146/annurev.pharmtox.47.120505.105110; Ng Y, 2005, CARCINOGENESIS, V26, P1914, DOI 10.1093/carcin/bgi163; RAMSAY RR, 1987, BIOCHEM J, V241, P883, DOI 10.1042/bj2410883; Rauchova H, 1997, ARCH BIOCHEM BIOPHYS, V344, P235, DOI 10.1006/abbi.1997.0150; Ross MF, 2005, BIOCHEMISTRY-MOSCOW+, V70, P222, DOI 10.1007/s10541-005-0104-5; Sazanov LA, 2006, SCIENCE, V311, P1430, DOI 10.1126/science.1123809; Sharpley MS, 2006, BIOCHEMISTRY-US, V45, P241, DOI 10.1021/bi051809x; Simkovic M, 2004, BIOCHEM J, V378, P633, DOI 10.1042/BJ20031272; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Tristram-Nagle S, 2004, CHEM PHYS LIPIDS, V127, P3, DOI 10.1016/j.chemphyslip.2003.09.002; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WATMOUGH NJ, 1991, BIOCHEMISTRY-US, V30, P1317, DOI 10.1021/bi00219a023; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; Zhang J, 2006, P NATL ACAD SCI USA, V103, P16212, DOI 10.1073/pnas.0604567103	38	174	176	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14708	14718		10.1074/jbc.M611463200	http://dx.doi.org/10.1074/jbc.M611463200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17369262	hybrid			2022-12-27	WOS:000246589000006
J	Rinaldo, S; Arcovito, A; Brunori, M; Cutruzzola, F				Rinaldo, Serena; Arcovito, Alessandro; Brunori, Maurizio; Cutruzzola, Francesca			Fast dissociation of nitric oxide from ferrous Pseudomonas aeruginosa cd1 nitrite reductase - A novel outlook on the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CD(1) NITRITE; ELECTRON-TRANSFER; LIGAND; HEMOGLOBIN; PROTEINS; KINETICS; BINDING; CYANIDE	The heme-containing periplasmic nitrite reductase (cd(1) NIR) is responsible for the production of nitric oxide (NO) in denitrifying bacterial species, among which are several animal and plant pathogens. Heme NIRs are homodimers, each subunit containing one covalently bound c-heme and one d(1)-heme. The reduction of nitrite to NO involves binding of nitrite to the reduced protein at the level of d(1)-heme, followed by dehydration of nitrite to yield NO and release of the latter. The crucial rate-limiting step in the catalytic mechanism is thought to be the release of NO from the d(1)-heme, which has been proposed, but never demonstrated experimentally, to occur when the iron is in the ferric form, given that the reduced NO-bound derivative was presumed to be very stable, as in other hemeproteins. We have measured for the first time the kinetics of NO binding and release from fully reduced cd(1) NIR, using the enzyme from Pseudomonas aeruginosa and its site-directed mutant H369A. Quite unexpectedly, we found that NO dissociation from the reduced d(1)-heme is very rapid, several orders of magnitude faster than that measured for b-type heme containing reduced hemeproteins. Because the rate of NO dissociation from reduced cd(1) NIR, measured in the present report, is faster than or comparable with the turnover number, contrary to expectations this event may well be on the catalytic cycle and not necessarily rate-limiting. This finding also provides a rationale for the presence in cd(1) NIR of the peculiar d(1)-heme cofactor, which has probably evolved to ensure fast product dissociation.	Univ Roma La Sapienza, Dipartimento Sci Biochim, I-00185 Rome, Italy; Consiglio Nazl Ricerche, Ist Biol & Patol Mol, I-00185 Rome, Italy; Univ Cattolica Sacro Cuore, Ist Biochim & Biochim Clin, I-00198 Rome, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Brunori, M (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	maurizio.brunori@uniroma1.it	rinaldo, serena/O-6989-2014; Arcovito, Alessandro/I-5552-2012; Cutruzzola', Francesca/G-4052-2011	rinaldo, serena/0000-0003-0682-023X; Arcovito, Alessandro/0000-0002-8384-4844; Cutruzzola', Francesca/0000-0002-4621-2135; Brunori, Maurizio/0000-0002-7795-1635				Antonini E., 1971, FRONT BIOL, V21, P19; Arai H, 2005, J BACTERIOL, V187, P3960, DOI 10.1128/JB.187.12.3960-3968.2005; Arcovito A, 2001, J BIOL CHEM, V276, P41073, DOI 10.1074/jbc.M105183200; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Azizi F, 2005, FREE RADICAL BIO MED, V39, P145, DOI 10.1016/j.freeradbiomed.2005.03.001; BARBER D, 1978, BIOCHEM J, V175, P239, DOI 10.1042/bj1750239; BARKIGIA KM, 1992, J AM CHEM SOC, V114, P1701, DOI 10.1021/ja00031a025; Barraud N, 2006, J BACTERIOL, V188, P7344, DOI 10.1128/JB.00779-06; BLATT Y, 1979, BIOCHEMISTRY-US, V18, P2917, DOI 10.1021/bi00580a037; Borisov VB, 2007, BIOCHEM BIOPH RES CO, V355, P97, DOI 10.1016/j.bbrc.2007.01.118; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; Cutruzzola F, 2001, P NATL ACAD SCI USA, V98, P2232, DOI 10.1073/pnas.041365298; Cutruzzola F, 2003, IUBMB LIFE, V55, P617, DOI 10.1080/15216540310001628672; Cutruzzola F, 1999, BBA-BIOENERGETICS, V1411, P231, DOI 10.1016/S0005-2728(99)00017-1; George SJ, 2000, J BIOL CHEM, V275, P33231, DOI 10.1074/jbc.M005033200; Hassett DJ, 2002, ADV DRUG DELIVER REV, V54, P1425, DOI 10.1016/S0169-409X(02)00152-7; Kharitonov VG, 1997, BIOCHEMISTRY-US, V36, P6814, DOI 10.1021/bi970201o; MOORE EG, 1976, J BIOL CHEM, V251, P2788; PARR SR, 1975, BIOCHEM J, V151, P51, DOI 10.1042/bj1510051; PARR SR, 1977, BIOCHEM J, V167, P447, DOI 10.1042/bj1670447; PARR SR, 1976, BIOCHEM J, V157, P423, DOI 10.1042/bj1570423; PARR SR, 1974, BIOCHEM J, V139, P273, DOI 10.1042/bj1390273; Richter CD, 2002, J BIOL CHEM, V277, P3093, DOI 10.1074/jbc.M108944200; Rinaldo S, 2007, BIOLOGY OF THE NITROGEN CYCLE, P37, DOI 10.1016/B978-044452857-5.50004-7; Sarti P, 2000, BIOCHEM BIOPH RES CO, V274, P183, DOI 10.1006/bbrc.2000.3117; SILVESTRINI MC, 1982, BIOCHEM J, V203, P445, DOI 10.1042/bj2030445; SILVESTRINI MC, 1992, BIOCHEM J, V285, P661, DOI 10.1042/bj2850661; SILVESTRINI MC, 1979, BIOCHEM J, V183, P701, DOI 10.1042/bj1830701; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Sun WL, 2002, BIOCHEM BIOPH RES CO, V291, P1, DOI 10.1006/bbrc.2002.6391; WALSH TA, 1979, BIOCHEM J, V177, P29, DOI 10.1042/bj1770029; Wilson EK, 1999, BIOCHEMISTRY-US, V38, P7556, DOI 10.1021/bi990179u; Zajicek RS, 2006, BIOCHEMISTRY-US, V45, P11208, DOI 10.1021/bi0604983; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	35	42	43	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14761	14767		10.1074/jbc.M700933200	http://dx.doi.org/10.1074/jbc.M700933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389587	hybrid			2022-12-27	WOS:000246589000011
J	Slack-Davis, JK; Martin, KH; Tilghman, RW; Iwanicki, M; Ung, EJ; Autry, C; Luzzio, MJ; Cooper, B; Kath, JC; Roberts, WG; Parsons, JT				Slack-Davis, Jill K.; Martin, Karen H.; Tilghman, Robert W.; Iwanicki, Marcin; Ung, Ethan J.; Autry, Christopher; Luzzio, Michael J.; Cooper, Beth; Kath, John C.; Roberts, W. Gregory; Parsons, J. Thomas			Cellular characterization of a novel focal adhesion kinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT SPECKLE MICROSCOPY; MIGRATING CELLS; FAK; APOPTOSIS; PROTEIN; CANCER; EXPRESSION; PATHWAYS; SURVIVAL; MOTILITY	Focal adhesion kinase (FAK) is a member of a family of nonreceptor protein-tyrosine kinases that regulates integrin and growth factor signaling pathways involved in cell migration, proliferation, and survival. FAK expression is increased in many cancers, including breast and prostate cancer. Here we describe perturbation of adhesion-mediated signaling with a FAK inhibitor, PF-573,228. In vitro, this compound inhibited purified recombinant catalytic fragment of FAK with an IC50 of 4 nM. In cultured cells, PF-573,228 inhibited FAK phosphorylation on Tyr(397) with an IC50 of 30-100 nM. Treatment of cells with concentrations of PF-573,228 that significantly decreased FAK Tyr(397) phosphorylation failed to inhibit cell growth or induce apoptosis. In contrast, treatment with PF-573,228 inhibited both chemotactic and haptotactic migration concomitant with the inhibition of focal adhesion turnover. These studies show that PF-573,228 serves as a useful tool to dissect the functions of FAK in integrin-dependent signaling pathways in normal and cancer cells and forms the basis for the generation of compounds amenable for preclinical and patient trials.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Hlth Sci Syst, Charlottesville, VA 22908 USA; Pfizer Inc, Discovery Oncol, Groton, CT 06340 USA	University of Virginia; University of Virginia; Pfizer	Parsons, JT (corresponding author), Univ Virginia, Dept Microbiol, POB 800734,Jordan Hall,1300 Jefferson Park Ave, Charlottesville, VA 22908 USA.	jtp@virginia.edu		Martin, Karen/0000-0001-8916-4092				Abbi S, 2002, HISTOL HISTOPATHOL, V17, P1163, DOI 10.14670/HH-17.1163; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; Choi HS, 2006, BIOORG MED CHEM LETT, V16, P2689, DOI 10.1016/j.bmcl.2006.02.032; Choi HS, 2006, BIOORG MED CHEM LETT, V16, P2173, DOI 10.1016/j.bmcl.2006.01.053; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Han EKH, 2004, ANTICANCER RES, V24, P3899; Hauck CR, 2001, CANCER RES, V61, P7079; Heidkamp MC, 2002, CIRC RES, V90, P1282, DOI 10.1161/01.RES.0000023201.41774.EA; Ilic D, 1998, J CELL BIOL, V143, P547; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KATH JC, 2004, Patent No. 2004056786; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; LUZZIO MJ, P ANN M AM ASS CANC, V48, P1283; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Niwa S., 2006, J CLIN ONCOL, V24, P13163, DOI [10.1200/jco.2006.24.18_suppl.13163, DOI 10.1200/JCO.2006.24.18_SUPPL.13163]; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Roberts Walter G., 2007, Proceedings of the American Association for Cancer Research Annual Meeting, V48, P1282; Salmon WC, 2002, J CELL BIOL, V158, P31, DOI 10.1083/jcb.200203022; SHI QAB, 2007, MOL CARCINOGEN, V9999; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 1999, J BIOL CHEM, V274, P27177, DOI 10.1074/jbc.274.38.27177; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; UNG EJ, 2002, Patent No. 004027018; Vallotton P, 2004, P NATL ACAD SCI USA, V101, P9660, DOI 10.1073/pnas.0300552101; Wang N, 2001, P NATL ACAD SCI USA, V98, P7765, DOI 10.1073/pnas.141199598; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	38	384	395	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14845	14852		10.1074/jbc.M606695200	http://dx.doi.org/10.1074/jbc.M606695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17395594	hybrid			2022-12-27	WOS:000246589000020
J	Guha, M; Srinivasan, S; Biswas, G; Avadhani, NG				Guha, Manti; Srinivasan, Satish; Biswas, Gopa; Avadhani, Narayan G.			Activation of a novel calcineurin-mediated insulin-like growth factor-1 receptor pathway, altered metabolism, and tumor cell invasion in cells subjected to mitochondrial respiratory stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; OXIDATIVE-PHOSPHORYLATION; INDUCED RESISTANCE; SKELETAL-MUSCLE; KINASE; EXPRESSION; APOPTOSIS; CANCER; INHIBITION; MUTATIONS	We have previously shown that disruption of mitochondrial membrane potential by depletion of mitochondrial DNA ( mtDNA) or treatment with a mitochondrial ionophore, carbonyl cyanide m-chlorophenylhydrazone, initiates a stress signaling, which causes resistance to apoptosis, and induces invasive behavior in C2C12 myocytes and A549 cells. In the present study we show that calcineurin (Cn), activated as part of this stress signaling, plays an important role in increased glucose uptake and glycolysis. Here we report that, although both insulin and insulin-like growth factor-1 receptor levels (IR and IGF1R, respectively) are increased in response to mitochondrial stress, autophosphorylation of IGF1R was selectively increased suggesting a shift in receptor pathways. Using an approach with FK506, an inhibitor of Cn, and mRNA silencing by small interference RNA we show that mitochondrial stress-activated Cn is critical for increased GLUT 4 and IGF1R expression and activation. The importance of the IGF1R pathway in cell survival under mitochondrial stress is demonstrated by increased apoptosis either by IGF1R mRNA silencing or by treatment with IGF1R inhibitors (AG1024 and picropodophyllin). This study describes a novel mechanism of mitochondrial stress-induced metabolic shift involving Cn with implications in resistance to apoptosis and tumor proliferation.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu			NATIONAL CANCER INSTITUTE [R37CA022762, R01CA022762] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA022762, CA22762, R01 CA022762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; ANTONI FA, 1993, BIOCHEM BIOPH RES CO, V194, P226, DOI 10.1006/bbrc.1993.1808; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104; Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028; Biswas G, 2005, CELL DEATH DIFFER, V12, P266, DOI 10.1038/sj.cdd.4401553; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cottrell D A, 2001, Novartis Found Symp, V235, P234; Devin A, 2001, EUR J BIOCHEM, V268, P3943, DOI 10.1046/j.1432-1327.2001.02306.x; Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; JENSSEN N, 2003, J APPL PHYSIOL, V94, P1373; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014; Liu YQ, 1998, J CLIN INVEST, V101, P1870, DOI 10.1172/JCI1211; Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macaulay SL, 2003, BIOCHEM J, V376, P123, DOI 10.1042/BJ20030130; Mazurek S, 2003, ANTICANCER RES, V23, P1149; Meierhofer D, 2004, CARCINOGENESIS, V25, P1005, DOI 10.1093/carcin/bgh104; Miccoli L, 1996, BIOCHEM J, V313, P957, DOI 10.1042/bj3130957; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Park SY, 2004, BIOCHEM BIOPH RES CO, V325, P1399, DOI 10.1016/j.bbrc.2004.10.182; Parrella P, 2001, CANCER RES, V61, P7623; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; Ryder JW, 2005, J PHYSIOL-LONDON, V567, P379, DOI 10.1113/jphysiol.2005.090829; Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5; Semenza G L, 2001, Novartis Found Symp, V240, P251; Shefi-Friedman L, 2001, AM J PHYSIOL-ENDOC M, V281, pE16, DOI 10.1152/ajpendo.2001.281.1.E16; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Singh KK, 2005, GENE, V354, P140, DOI 10.1016/j.gene.2005.03.027; SMITH RM, 1993, ARCH BIOCHEM BIOPHYS, V300, P238, DOI 10.1006/abbi.1993.1033; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; van Waveren C, 2006, CARCINOGENESIS, V27, P409, DOI 10.1093/carcin/bgi242; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watson RT, 2001, RECENT PROG HORM RES, V56, P175, DOI 10.1210/rp.56.1.175; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; YAGEL S, 1989, CANCER RES, V49, P3553; Zeviani M, 1997, MOL HUM REPROD, V3, P133, DOI 10.1093/molehr/3.2.133; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	58	45	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14536	14546		10.1074/jbc.M611693200	http://dx.doi.org/10.1074/jbc.M611693200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355970	Green Accepted, hybrid			2022-12-27	WOS:000246245800067
J	Valentine, RA; Jackson, KA; Christie, GR; Mathers, JC; Taylor, PM; Ford, D				Valentine, Ruth A.; Jackson, Kelly A.; Christie, Graham R.; Mathers, John C.; Taylor, Peter M.; Ford, Dianne			ZnT5 variant B is a bidirectional zinc transporter and mediates zinc uptake in human intestinal Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; CONFERS RESISTANCE; CLONING; FAMILY; MOUSE; GENE	Zinc is an essential micronutrient, so it is important to elucidate the molecular mechanisms of zinc homeostasis, including the functional properties of zinc transporters. Mammalian zinc transporters are classified in two major families: the SLC30 (ZnT) family and the SLC39 family. The prevailing view is that SLC30 family transporters function to reduce cytosolic zinc concentration, either through efflux across the plasma membrane or through sequestration in intracellular compartments, and that SLC39 family transporters function in the opposite direction to increase cytosolic zinc concentration. We demonstrated that human ZnT5 variant B (ZnT5B (hZTL1)), an isoform expressed at the plasma membrane, operates in both the uptake and the efflux directions when expressed in Xenopus laevis oocytes. We measured increased activity of the zinc-responsive metallothionein 2a (MT2a) promoter when ZnT5b was coexpressed with an MT2a promoter-reporter plasmid construct in human intestinal Caco-2 cells, indicating increased total intracellular zinc concentration. Increased cytoplasmic zinc concentration mediated by ZnT5B, in the absence of effects on intracellular zinc sequestration by the Golgi apparatus or endoplasmic reticulum, was also confirmed by a dramatically enhanced signal from the zinc fluorophore Rhodzin-3 throughout the cytoplasm of Caco-2 cells overexpressing ZnT5B at the plasma membrane when compared with control cells. Our findings demonstrate clearly that, in addition to mediating zinc efflux, ZnT5B at the plasma membrane can function to increase cytoplasmic zinc concentration, thus indicating a need to reevaluate the current paradigm that SLC30 family zinc transporters operate exclusively to decrease cytosolic zinc concentration.	Univ Newcastle Upon Tyne, Human Nutr Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Dent Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Clin Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Dundee, Coll Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; University of Dundee	Valentine, RA (corresponding author), Univ Newcastle Upon Tyne, Sch Dent Sci, Framlington Pl, Newcastle Upon Tyne NE2 4BW, Tyne & Wear, England.	r.a.valentine@ncl.ac.uk	Taylor, Peter M/A-4667-2010	Mathers, John/0000-0003-3406-3002; Jackson, Kelly/0000-0001-9116-3769	BBSRC [BB/D01669X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D01669X/1] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Andreini C, 2006, J PROTEOME RES, V5, P196, DOI 10.1021/pr050361j; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Cragg RA, 2005, GUT, V54, P469, DOI 10.1136/gut.2004.041962; Cragg RA, 2002, J BIOL CHEM, V277, P22789, DOI 10.1074/jbc.M200577200; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; HELSTON RM, 2006, IN PRESS PLACENTA; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Jackson KA, 2007, J BIOL CHEM, V282, P10423, DOI 10.1074/jbc.M610535200; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Kumanovics A, 2006, J BIOL CHEM, V281, P22566, DOI 10.1074/jbc.M604730200; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Peter GJ, 1999, BIOCHEM J, V343, P169, DOI 10.1042/0264-6021:3430169; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100	18	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14389	14393		10.1074/jbc.M701752200	http://dx.doi.org/10.1074/jbc.M701752200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355957	Green Accepted, hybrid			2022-12-27	WOS:000246245800051
J	Ma, W; Mishra, S; Gee, K; Mishra, JP; Nandan, D; Reiner, NE; Angel, JB; Kumar, A				Ma, Wei; Mishra, Sasmita; Gee, Katrina; Mishra, Jyoti P.; Nandan, Devki; Reiner, Neil E.; Angel, Jonathan B.; Kumar, Ashok			Cyclosporin a and FK506 inhibit IL-12p40 production through the calmodulin/calmodulin-dependent protein kinase-activated phosphoinositide 3-kinase in lipopolysaccharide-stimulated human monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE MATURATION FACTOR; NECROSIS-FACTOR-ALPHA; N-TERMINAL KINASE; HUMAN MACROPHAGES; IMMUNE-RESPONSES; PHOSPHATIDYLINOSITOL 3-KINASES; TRANSCRIPTION FACTOR; EMBRYONIC LETHALITY; NEGATIVE REGULATION; RECEPTOR LIGATION	Cyclosporine-A (CyA) and FK506 are potent immunosuppressive agents because of their ability to suppress the production of Th1 cytokines including interleukin (IL)-12. However, the mechanisms underlying the inhibitory effects of CyA and FK506 on the production of IL-12p40, a critical component of IL-12, remain unknown. Both CyA and FK506 are potent inhibitors of calcineurin in the calcium signaling pathway. Interestingly, calcium and phosphoinositide 3-kinase (PI3K) signaling pathways have been shown to negatively regulate lipopolysaccharide (LPS)-induced murine IL-12p40 production. Contrary to these observations, we show that LPS-induced IL-12p40 production in human monocytic cells is positively regulated by the calcium pathway and in particular by calmodulin-(CaM) and CaM-dependent protein kinase-II (CaMK-II)-activated PI3K. Furthermore, LPS-induced IL-12p40 production was regulated by the p110 alpha catalytic subunit of PI3K. Moreover, LPS induced IL-12p40 production through the CaM/CaMK-II-activated NF kappa B and AP- 1 transcription factors. LPS-induced IL-12p40 production is known to be regulated by the c-Jun N-terminal kinase (JNK) pathway. Importantly, both CyA and FK506 down-regulated LPS-induced IL-12p40 transcription by inhibiting CaM/CaMK-II-activated PI3K and their downstream transcription factors NF kappa B and AP-1 independent of the JNK pathway.	Childrens Hosp Eastern Ontario, Res Inst, Dept Pathol & Lab Med, Div Virol, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Res Inst, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Res Inst, Div Virol & Mol Immunol, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Div Infect Dis, Ottawa, ON K1H 8L1, Canada; Univ British Columbia, Fac Med, Div Infect Dis, Dept Med, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Med, Div Infect Dis, Dept Microbiol & Immunol, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Sci, Vancouver, BC V5Z 3J5, Canada; Vancouver Coastal Hlth Res Inst, Vancouver, BC V5Z 3J5, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Kumar, A (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Dept Pathol & Lab Med, Div Virol, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	akumar@uottawa.ca	Gee, Katrina/H-3093-2016	Angel, Jonathan B/0000-0003-3102-4462; Gee, Katrina/0000-0002-7535-2882				Antonsson A, 2003, MOL CELL BIOL, V23, P1418, DOI 10.1128/MCB.23.4.1418-1427.2003; Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; BIRON CA, 1995, CURR OPIN IMMUNOL, V7, P485, DOI 10.1016/0952-7915(95)80093-X; Bondeson J, 1999, J IMMUNOL, V162, P2939; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Cappiello MG, 2001, J IMMUNOL, V166, P4498, DOI 10.4049/jimmunol.166.7.4498; Cooper AM, 2002, J IMMUNOL, V168, P1322, DOI 10.4049/jimmunol.168.3.1322; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fukao T, 2003, TRENDS IMMUNOL, V24, P358, DOI 10.1016/S1471-4906(03)00139-X; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; GATELY MK, 1991, J IMMUNOL, V147, P874; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Hariharan S, 2000, NEW ENGL J MED, V342, P605, DOI 10.1056/NEJM200003023420901; Hawlisch H, 2005, IMMUNITY, V22, P415, DOI 10.1016/j.immuni.2005.02.006; Ho N, 1996, J EXP MED, V184, P101, DOI 10.1084/jem.184.1.101; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; IA SA, 2005, J IMMUNOL, V175, P2994; Jiang HS, 2002, TRANSPLANTATION, V73, P1808, DOI 10.1097/00007890-200206150-00019; Kang HY, 2002, J BIOL CHEM, V277, P912, DOI 10.1074/jbc.M107648200; Kasri NN, 2004, BIOL RES, V37, P577; Kasri NN, 2004, EMBO J, V23, P312, DOI 10.1038/sj.emboj.7600037; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kim Y, 2004, BIOCHEM BIOPH RES CO, V314, P695, DOI 10.1016/j.bbrc.2003.12.153; Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; Lee JS, 2004, J BIOL CHEM, V279, P9379, DOI 10.1074/jbc.M310638200; Lilienbaum A, 2003, MOL CELL BIOL, V23, P2680, DOI 10.1128/MCB.23.8.2680-2698.2003; Lim W, 2005, J IMMUNOL, V175, P5690, DOI 10.4049/jimmunol.175.9.5690; Luo J, 2005, CELL CYCLE, V4, P1309, DOI 10.4161/cc.4.10.2062; Ma W, 2004, J IMMUNOL, V172, P318, DOI 10.4049/jimmunol.172.1.318; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma XJ, 2001, ADV IMMUNOL, V79, P55; Martin M, 2003, J IMMUNOL, V171, P717, DOI 10.4049/jimmunol.171.2.717; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Mishra S, 2005, J BIOL CHEM, V280, P37536, DOI 10.1074/jbc.M504971200; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Noubir S, 2006, PROG NUCLEIC ACID RE, V81, P51, DOI 10.1016/S0079-6603(06)81002-0; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Sauma D, 2003, TRANSPL P, V35, P2515, DOI 10.1016/j.transproceed.2003.09.020; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Scott P, 1997, Semin Immunol, V9, P285, DOI 10.1006/smim.1997.0084; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Spencer VA, 2000, J CELL BIOCHEM, P27; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Sutterwala FS, 1998, J EXP MED, V188, P217, DOI 10.1084/jem.188.1.217; Sutterwala FS, 1997, J EXP MED, V185, P1977, DOI 10.1084/jem.185.11.1977; Tajima K, 2003, IMMUNOLOGY, V108, P321, DOI 10.1046/j.1365-2567.2003.01585.x; Tombes RM, 2003, GENE, V322, P17, DOI 10.1016/j.gene.2003.08.023; Utsugi M, 2003, J IMMUNOL, V171, P628, DOI 10.4049/jimmunol.171.2.628; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Waggoner SN, 2005, J IMMUNOL, V175, P4706, DOI 10.4049/jimmunol.175.7.4706; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; Wasowska BA, 2001, TRANSPLANTATION, V71, P1179, DOI 10.1097/00007890-200104270-00029; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; Woltman AM, 2000, EUR J IMMUNOL, V30, P1807, DOI 10.1002/1521-4141(200007)30:7<1807::AID-IMMU1807>3.0.CO;2-N; Yu YC, 2005, CELL CYCLE, V4, P1043, DOI 10.4161/cc.4.8.1928; Zhu C, 2003, J BIOL CHEM, V278, P39372, DOI 10.1074/jbc.M306441200	70	30	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13351	13362		10.1074/jbc.M611522200	http://dx.doi.org/10.1074/jbc.M611522200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17347151	hybrid, Green Published			2022-12-27	WOS:000246060300023
J	Fu, J; Menzies, K; Freeman, RS; Taubman, MB				Fu, Jian; Menzies, Keon; Freeman, Robert S.; Taubman, Mark B.			EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINDAU TUMOR-SUPPRESSOR; HYPOXIA-INDUCIBLE FACTOR; FACTOR-RESPONSIVE GENE; DEPENDENT CELL-DEATH; RNA-POLYMERASE-II; PROLINE HYDROXYLATION; UBIQUITIN LIGASE; FACTOR HIF; COMPLEX; SM-20	EGLN3, a member of the EGLN family of prolyl hydroxylases, has been shown to catalyze hydroxylation of the alpha subunit of hypoxia-inducible factor-alpha, which targets hypoxia- inducible factor-alpha for ubiquitination by a ubiquitin ligase complex containing the von Hippel- Lindau ( VHL) tumor suppressor. We now report that EGLN3 levels increase during C2C12 skeletal myoblast differentiation. EGLN3 small interference RNAs and EGLN3 antisense oligonucleotides blocked C2C12 differentiation and decreased levels of myogenin, a member of the MyoD family of myogenic regulatory factors, which plays a critical role in myogenic differentiation. We also report that EGLN3 interacts with and stabilizes myogenin protein, whereas VHL associates with and destabilizes myogenin via the ubiquitin- proteasome system. The effect of VHL on myogenin stability and ubiquitination can be reversed, at least in part, by overexpression of EGLN3, suggesting that its binding to myogenin may prevent VHL- mediated degradation. These data demonstrate a novel role for EGLN3 in regulating skeletal muscle differentiation and gene expression. In addition, this report provides evidence for a novel pathway that regulates myogenin expression and skeletal muscle differentiation.	Univ Rochester, Med Ctr, Inst Cardiovasc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Fu, J (corresponding author), Univ Rochester, Med Ctr, Inst Cardiovasc Res, Rochester, NY 14642 USA.	jian_fu@urmc.rochester.edu			NHLBI NIH HHS [R01 HL43302] Funding Source: Medline; NINDS NIH HHS [R01 NS034400] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034400] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAVIND L, 2001, GENOME BIOL, V3, P8; Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Barry RE, 2004, TRENDS MOL MED, V10, P466, DOI 10.1016/j.molmed.2004.07.008; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conaway RC, 2002, ADV CANCER RES, V85, P1, DOI 10.1016/S0065-230X(02)85001-1; Czyzyk-Krzeska MF, 2004, TRENDS MOL MED, V10, P146, DOI 10.1016/j.molmed.2004.02.004; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freeman RS, 2003, MOL CELLS, V16, P1; Fu J, 2003, J BIOL CHEM, V278, P52660, DOI 10.1074/jbc.M308036200; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hopfer U, 2006, J BIOL CHEM, V281, P8645, DOI 10.1074/jbc.M513751200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Madden SL, 1996, CANCER RES, V56, P5384; Mason SD, 2004, PLOS BIOL, V2, P1540, DOI 10.1371/journal.pbio.0020288; Masson N, 2004, FEBS LETT, V570, P166, DOI 10.1016/j.febslet.2004.06.040; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Moschella MC, 1999, GENE EXPRESSION, V8, P59; Mullen AJ, 2000, GENE, V242, P313, DOI 10.1016/S0378-1119(99)00519-3; Na X, 2003, EMBO J, V22, P4249, DOI 10.1093/emboj/cdg410; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Straub JA, 2003, J NEUROCHEM, V85, P318, DOI 10.1046/j.1471-4159.2003.01688.x; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wilson EM, 2004, MOL BIOL CELL, V15, P497, DOI 10.1091/mbc.E03-05-0351; Wolf G, 2002, LAB INVEST, V82, P1305, DOI 10.1097/01.LAB.0000029207.92039.2F; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yin XY, 2001, ONCOGENE, V20, P2908, DOI 10.1038/sj.onc.1204417; Yun Z, 2005, MOL CELL BIOL, V25, P3040, DOI 10.1128/MCB.25.8.3040-3055.2005	64	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12410	12418		10.1074/jbc.M608748200	http://dx.doi.org/10.1074/jbc.M608748200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17344222	hybrid			2022-12-27	WOS:000245942800009
J	Yamamoto, Y; Aoyama, Y; Shu, E; Tsunoda, K; Amagai, M; Kitajima, Y				Yamamoto, Yukari; Aoyama, Yumi; Shu, En; Tsunoda, Kazuyuki; Amagai, Masayuki; Kitajima, Yasuo			Anti-desmoglein 3 (Dsg3) monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities related to pathogenicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEMPHIGUS-VULGARIS ANTIGEN; DESMOGLEIN 3; CULTURED KERATINOCYTES; CELL-SURFACE; IGG; AUTOANTIBODIES; PROTEIN; FOLIACEUS; LOCALIZATION; DISSOCIATION	Pemphigus vulgaris (PV) is an autoimmune blistering disease, characterized by the loss of cell-cell adhesion between epidermal keratinocytes and the presence of autoantibody against desmoglein 3 (Dsg3), which provides adhesive integrity to desmosomes between adjacent keratinocytes. We have previously shown that PV-IgG purified from patients depletes desmosomes of Dsg3. However, PV-IgG contains not only antibodies against a variety of different epitopes of Dsg3 but also against other unknown antigens. Therefore, we examined whether the Dsg3-depleting activity of PV-IgG is generated specifically by antiDsg3 activity in a human squamous cell carcinoma cell line (DJM-1) and normal human keratinocytes by using four different pathogenic and nonpathogenic monoclonal antibodies against Dsg3. We demonstrate that these monoclonal antibodies deplete cells and desmosomes of Dsg3, as PV-IgG does. Individual monoclonal anti-Dsg3 antibodies display characteristic limits to their Dsg3-depleting activity, which correlates with their pathogenic activities. In combination, these antibodies exert a cumulative or synergistic effect, which may explain the potent Dsg3-depleting capability of PV-IgG, which is polyclonal. Finally, although Dsg3-depletion activity correlated with AK-monoclonal antibody pathogenicity in mouse models, the residual level of Dsg3, when below similar to 50%, does not correlate with the adhesive strength index in the present study. This may suggest that although the Dsg3 depletion is not indicative for adhesive strength, the level of Dsg3 can be used as a read-out of pathogenic changes within the cell and that the Dsg3 depletion from desmosomes plays an important role in skin fragility or susceptibility to blister formation in PV patients.	Gifu Univ, Sch Med, Dept Dermatol, Gifu 5011194, Japan; Keio Univ, Sch Med, Dept Dermatol, Keio, Tokyo 1608582, Japan	Gifu University; Keio University	Kitajima, Y (corresponding author), Yanagido 1-1, Gifu 5011194, Japan.	yaskitaj@gifu-u.ac.jp	Amagai, Masayuki/K-5325-2013; tsunoda, kazuyuki/GLR-8745-2022	Amagai, Masayuki/0000-0003-3314-7052; 				Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Amagai M, 2006, EXP DERMATOL, V15, P815, DOI 10.1111/j.1600-0625.2006.00499.x; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; ANDREW P, 1995, J INVEST DERMATOL, V105, P147; Aoyama Y, 1999, EUR J IMMUNOL, V29, P2233, DOI 10.1002/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4; Aoyama Y, 1999, J INVEST DERMATOL, V112, P67, DOI 10.1046/j.1523-1747.1999.00463.x; Berkowitz P, 2005, J BIOL CHEM, V280, P23778, DOI 10.1074/jbc.M501365200; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; Caldelari R, 2001, J CELL BIOL, V153, P823, DOI 10.1083/jcb.153.4.823; Calkins CC, 2006, J BIOL CHEM, V281, P7623, DOI 10.1074/jbc.M512447200; Cirillo N, 2007, J CELL PHYSIOL, V210, P411, DOI 10.1002/jcp.20856; Cirlllo N, 2006, FEBS LETT, V580, P3276, DOI 10.1016/j.febslet.2006.04.089; ESAKI C, 1995, J INVEST DERMATOL, V105, P329, DOI 10.1111/1523-1747.ep12319948; EYRE RW, 1988, J CLIN INVEST, V81, P807, DOI 10.1172/JCI113387; Futei Y, 2003, J AM ACAD DERMATOL, V49, P1023, DOI 10.1016/S0190-9622(03)02160-1; HASHIMOTO T, 1990, J INVEST DERMATOL, V94, P327, DOI 10.1111/1523-1747.ep12874456; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Ishii K, 1997, J IMMUNOL, V159, P2010; Ishii K, 2005, J INVEST DERMATOL, V124, P939, DOI 10.1111/j.0022-202X.2005.23714.x; IWATSUKI K, 1989, J AM ACAD DERMATOL, V20, P578, DOI 10.1016/S0190-9622(89)70066-9; Iwatsuki K, 1999, BRIT J DERMATOL, V140, P35; KARPATI S, 1993, J CELL BIOL, V122, P409, DOI 10.1083/jcb.122.2.409; Kawasaki H, 2006, J INVEST DERMATOL, V126, P2621, DOI 10.1038/sj.jid.5700450; Kitajima Y, 1999, J INVEST DERM SYMP P, V4, P137, DOI 10.1038/sj.jidsp.5640197; Kitajima Y, 2003, ARCH DERMATOL RES, V295, pS17, DOI 10.1007/s00403-002-0368-1; Kitajima Y, 2002, CLIN EXP DERMATOL, V27, P684, DOI 10.1046/j.1365-2230.2002.01116.x; KITAJIMA Y, 1987, J INVEST DERMATOL, V89, P167, DOI 10.1111/1523-1747.ep12470554; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; KOULU L, 1984, J EXP MED, V160, P1509, DOI 10.1084/jem.160.5.1509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; MILNER Y, 1989, J CELL PHYSIOL, V139, P441, DOI 10.1002/jcp.1041390229; Muller R, 2006, EXP DERMATOL, V15, P606, DOI 10.1111/j.1600-0625.2006.00451.x; Osada K, 1997, J INVEST DERMATOL, V108, P482, DOI 10.1111/1523-1747.ep12289726; PATEL HP, 1984, J INVEST DERMATOL, V83, P409, DOI 10.1111/1523-1747.ep12273480; Pelacho B, 2004, FEBS LETT, V566, P6, DOI 10.1016/j.febslet.2004.03.107; Puviani M, 2003, J INVEST DERMATOL, V120, P164, DOI 10.1046/j.1523-1747.2003.12014.x; Sato M, 2000, LAB INVEST, V80, P1583, DOI 10.1038/labinvest.3780168; Seishima M, 1997, J INVEST DERMATOL, V109, P650, DOI 10.1111/1523-1747.ep12337662; Sekiguchi M, 2001, J IMMUNOL, V167, P5439, DOI 10.4049/jimmunol.167.9.5439; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; Tsunoda K, 2003, J IMMUNOL, V170, P2170, DOI 10.4049/jimmunol.170.4.2170; Wang X, 2004, APOPTOSIS, V9, P131, DOI 10.1023/B:APPT.0000018795.05766.1f	44	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17866	17876		10.1074/jbc.M607963200	http://dx.doi.org/10.1074/jbc.M607963200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17428808	hybrid			2022-12-27	WOS:000247084500060
J	Fish, JE; Matouk, CC; Yeboah, E; Bevan, SC; Khan, M; Patil, K; Ohh, M; Marsden, PA				Fish, Jason E.; Matouk, Charles C.; Yeboah, Elizabeth; Bevan, Sian C.; Khan, Mukarram; Patil, Kedar; Ohh, Michael; Marsden, Philip A.			Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; MESSENGER-RNA TRANSLATION; SMALL INTERFERING RNAS; HIPPEL-LINDAU PROTEIN; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; 3'-UNTRANSLATED REGION; MEDIATED REGULATION; MAMMALIAN-CELLS; DOWN-REGULATION	The destabilization of endothelial nitric-oxide synthase (eNOS) mRNA in hypoxic endothelial cells may be important in the etiology of vascular diseases, such as pulmonary hypertension. Recently, an overlapping antisense transcript to eNOS/NOS3 was implicated in the post-transcriptional regulation of eNOS. We demonstrate here that expression of sONE, also known as eNOS antisense (NOS3AS) or autophagy 9-like 2 (APG9L2), is robustly induced by hypoxia or functional deficiency of von Hippel-Lindau protein. sONE is also up-regulated in the aortas of hypoxic rats. In hypoxic endothelial cells, sONE expression negatively correlates with eNOS expression. Blocking the hypoxic induction of sONE by RNA interference attenuates the fall in both eNOS RNA and protein. We provide evidence that the induction of sONE primarily involves transcript stabilization rather than increased transcriptional activity and is von Hippel-Lindau-but not hypoxia-inducible factor 2 alpha-dependent. We also demonstrate that sONE transcripts are enriched in the nucleus of normoxic cells and that hypoxia promotes an increase in the level of cytoplasmic and polyribosome-associated, sONE mRNA. The finding that eNOS expression can be regulated by an overlapping cis-antisense transcript in a stimulus-dependent fashion provides evidence that sense/antisense interactions may play a previously unappreciated role in vascular disease pathogenesis.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Div Renal, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, St Michaels Hosp, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Marsden, PA (corresponding author), Univ Toronto, Dept Med Biophys, Med Sci Bldg,Rm 7358,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Matouk, Charles/AAF-7694-2019; Marsden, Philip A/B-1441-2012	Fish, Jason/0000-0003-0640-7277				Alonso J, 1997, MOL CELL BIOL, V17, P5719, DOI 10.1128/MCB.17.10.5719; Aravin A, 2005, FEBS LETT, V579, P5830, DOI 10.1016/j.febslet.2005.08.009; Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; Berezhna SY, 2006, P NATL ACAD SCI USA, V103, P7682, DOI 10.1073/pnas.0600148103; Borsani O, 2005, CELL, V123, P1279, DOI 10.1016/j.cell.2005.11.035; Buhler M, 2002, EMBO REP, V3, P646, DOI 10.1093/embo-reports/kvf129; Calzada MJ, 2006, CANCER RES, V66, P1553, DOI 10.1158/0008-5472.CAN-05-3236; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Champion HC, 2002, P NATL ACAD SCI USA, V99, P13248, DOI 10.1073/pnas.182225899; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Coudert AE, 2005, NUCLEIC ACIDS RES, V33, P5208, DOI 10.1093/nar/gki831; Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200; Das R, 2006, GENE DEV, V20, P1100, DOI 10.1101/gad.1397406; Datta K, 2005, ONCOGENE, V24, P7850, DOI 10.1038/sj.onc.1208912; de Miguel LS, 1999, J VASC RES, V36, P201, DOI 10.1159/000025643; DeCerbo J, 2005, CURR OPIN CELL BIOL, V17, P302, DOI 10.1016/j.ceb.2005.04.008; DECKER RS, 1980, AM J PATHOL, V98, P425; Engstrom PG, 2006, PLOS GENET, V2, P564, DOI 10.1371/journal.pgen.0020047; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; Faghihi MA, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-r38; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fish JE, 2005, J BIOL CHEM, V280, P24824, DOI 10.1074/jbc.M502115200; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GRAVEN KK, 1994, J BIOL CHEM, V269, P24446; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Kiyosawa H, 2005, GENOME RES, V15, P463, DOI 10.1101/gr.3155905; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Lehner B, 2002, TRENDS GENET, V18, P63, DOI 10.1016/S0168-9525(02)02598-2; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liao JK, 1995, J CLIN INVEST, V96, P2661, DOI 10.1172/JCI118332; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McQuillan Lynda P., 1994, American Journal of Physiology, V267, pH1921; MITCHENER JS, 1976, AM J PATHOL, V83, P485; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; Nakamura E, 2006, AM J PATHOL, V168, P574, DOI 10.2353/ajpath.2006.050867; Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ozaki M, 2001, HYPERTENSION, V37, P322, DOI 10.1161/01.HYP.37.2.322; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Robb GB, 2005, NAT STRUCT MOL BIOL, V12, P133, DOI 10.1038/nsmb886; Robb GB, 2004, J BIOL CHEM, V279, P37982, DOI 10.1074/jbc.M400271200; Robertson HD, 1996, BIOCHIMIE, V78, P909, DOI 10.1016/S0300-9084(97)86712-0; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Searles CD, 1999, CIRC RES, V85, P588, DOI 10.1161/01.RES.85.7.588; Shih SC, 1998, INT J EXP PATHOL, V79, P347, DOI 10.1046/j.1365-2613.1998.00088.x; SHWEIKI D, 1992, NATURE, V359, P845; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Steudel W, 1998, J CLIN INVEST, V101, P2468, DOI 10.1172/JCI2356; Stratmann R, 1997, J NEUROPATH EXP NEUR, V56, P1242, DOI 10.1097/00005072-199711000-00009; Sun M, 2005, NUCLEIC ACIDS RES, V33, P5533, DOI 10.1093/nar/gki852; Taha C, 1999, J BIOL CHEM, V274, P33085, DOI 10.1074/jbc.274.46.33085; Tai SC, 2004, ARTERIOSCL THROM VAS, V24, P405, DOI 10.1161/01.ATV.0000109171.50229.33; Takemoto M, 2002, CIRCULATION, V106, P57, DOI 10.1161/01.CIR.0000020682.73694.AB; Toporsian M, 2000, CIRC RES, V86, P671, DOI 10.1161/01.RES.86.6.671; Ubeda M, 1999, BIOCHEM BIOPH RES CO, V262, P31, DOI 10.1006/bbrc.1999.1140; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; WANG GL, 1993, BLOOD, V82, P3610; Wang Y, 1997, J BIOL CHEM, V272, P11392; Ward ME, 2005, J CLIN INVEST, V115, P3128, DOI 10.1172/JCI20806; Weber M, 2005, CIRC RES, V96, P1161, DOI 10.1161/01.RES.0000170651.72198.fa; Wouters BG, 2005, SEMIN CELL DEV BIOL, V16, P487, DOI 10.1016/j.semcdb.2005.03.009; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yamada T, 2005, J BIOL CHEM, V280, P18283, DOI 10.1074/jbc.M413957200; Yang E, 2003, GENOME RES, V13, P1863, DOI 10.1101/gr.1272403; Yang N, 2006, NAT STRUCT MOL BIOL, V13, P763, DOI 10.1038/nsmb1141; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	76	107	121	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15652	15666		10.1074/jbc.M608318200	http://dx.doi.org/10.1074/jbc.M608318200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403686	hybrid			2022-12-27	WOS:000246589600042
J	Isenberg, JS; Jia, YF; Fukuyama, J; Switzer, CH; Wink, DA; Roberts, DD				Isenberg, Jeff S.; Jia, Yifeng; Fukuyama, Julia; Switzer, Christopher H.; Wink, David A.; Roberts, David D.			Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL RESPONSES; N-TERMINAL MYRISTOYLATION; PROTEIN-TYROSINE KINASES; CHAIN FATTY-ACIDS; METHIONINE AMINOPEPTIDASE-2; ANGIOGENESIS INHIBITOR; SELECTIVE REQUIREMENT; IN-VITRO; MEMBRANE; SYNTHASE	Although CD36 is generally recognized to be an inhibitory signaling receptor for thrombospondin- 1 (TSP1), the molecular mechanism for transduction of this signal remains unclear. Based on evidence that myristic acid and TSP1 each modulate endothelial cell nitric oxide signaling in a CD36-dependent manner, we examined the ability of TSP1 to modulate the fatty acid translocase activity of CD36. TSP1 and a CD36 antibody that mimics the activity of TSP1 inhibited myristate uptake. Recombinant TSP1 type 1 repeats were weakly inhibitory, but an anti-angiogenic peptide derived from this domain potently inhibited myristate uptake. This peptide also inhibited membrane translocation of the myristoylated CD36 signaling target Fyn and activation of Src family kinases. Myristate uptake stimulated cGMP synthesis via endothelial nitric-oxide synthase and soluble guanylyl cyclase. CD36 ligands blocked myristate-stimulated cGMP accumulation in proportion to their ability to inhibit myristate uptake. TSP1 also inhibited myristate-stimulated cGMP synthesis by engaging its receptor CD47. Myristate stimulated endothelial and vascular smooth muscle cell adhesion on type I collagen via the NO/cGMP pathway, and CD36 ligands that inhibit myristate uptake blocked this response. Therefore, the fatty acid translocase activity of CD36 elicits pro-angiogenic signaling in vascular cells, and TSP1 inhibits this response by simultaneously inhibiting fatty acid uptake via CD36 and downstream cGMP signaling via CD47.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Radiat Biol Branch, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roberts, DD (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2A33,10 Ctr Dr,MSC1500, Bethesda, MD 20892 USA.	droberts@helix.nih.gov	Roberts, David D./A-9699-2008; Switzer, Christopher/D-9203-2013	Roberts, David D./0000-0002-2481-2981; Wink, David/0000-0002-5652-7480; Azad, Mahan/0000-0002-8633-3513	NATIONAL CANCER INSTITUTE [Z01SC009174, Z01SC009172, Z01SC007281] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 SC009172-04, Z01 SC009174-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Bastie CC, 2005, J BIOL CHEM, V280, P14222, DOI 10.1074/jbc.M413625200; BULL HA, 1994, FEBS LETT, V351, P41, DOI 10.1016/0014-5793(94)00814-0; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Calzada MJ, 2004, J BIOL CHEM, V279, P41734, DOI 10.1074/jbc.M406267200; Calzada MJ, 2004, CIRC RES, V94, P462, DOI 10.1161/01.RES.0000115555.05668.93; Calzada MJ, 2003, J BIOL CHEM, V278, P40679, DOI 10.1074/jbc.M302014200; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Chandrasekaran L, 2000, MOL BIOL CELL, V11, P2885, DOI 10.1091/mbc.11.9.2885; Dawson DW, 1999, MOL PHARMACOL, V55, P332, DOI 10.1124/mol.55.2.332; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; French KJ, 2004, J PHARMACOL EXP THER, V309, P340, DOI 10.1124/jpet.103.061572; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; Haviv F, 2005, J MED CHEM, V48, P2838, DOI 10.1021/jm0401560; Hoekstra R, 2005, J CLIN ONCOL, V23, P5188, DOI 10.1200/JCO.2005.05.013; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Ignarro LJ, 2005, CURR TOP MED CHEM, V5, P595; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Isenberg JS, 2006, CARDIOVASC RES, V71, P785, DOI 10.1016/j.cardiores.2006.05.024; Isenberg JS, 2006, J BIOL CHEM, V281, P26069, DOI 10.1074/jbc.M605040200; Isenberg JS, 2005, P NATL ACAD SCI USA, V102, P13141, DOI 10.1073/pnas.0502977102; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jimenez B, 2001, ONCOGENE, V20, P3443, DOI 10.1038/sj.onc.1204464; Kallander LS, 2005, J MED CHEM, V48, P5644, DOI 10.1021/jm050408c; Kanda S, 2005, J CELL SCI, V118, P961, DOI 10.1242/jcs.01686; Kerkhoff C, 2001, BIOCHEMISTRY-US, V40, P241, DOI 10.1021/bi001791k; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Koonen DPY, 2005, BBA-MOL CELL BIOL L, V1736, P163, DOI 10.1016/j.bbalip.2005.08.018; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; Krotova K, 2006, BRIT J PHARMACOL, V148, P732, DOI 10.1038/sj.bjp.0706777; Lamalice L, 2006, J BIOL CHEM, V281, P34009, DOI 10.1074/jbc.M603928200; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; Liang XQ, 2004, J BIOL CHEM, V279, P8133, DOI 10.1074/jbc.M311180200; LIU JW, 1994, J BIOL CHEM, V269, P11691; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Maurer-Stroh S, 2002, J MOL BIOL, V317, P541, DOI 10.1006/jmbi.2002.5426; McCormick CJ, 1997, J CLIN INVEST, V100, P2521, DOI 10.1172/JCI119794; Milkiewicz M, 2005, AM J PHYSIOL-HEART C, V289, pH336, DOI 10.1152/ajpheart.01105.2004; Murad F, 2004, BIOSCIENCE REP, V24, P452, DOI 10.1007/s10540-005-2741-8; Murata R, 1997, INT J RADIAT ONCOL, V37, P1107, DOI 10.1016/S0360-3016(96)00628-1; Nyberg P, 2005, CANCER RES, V65, P3967, DOI 10.1158/0008-5472.CAN-04-2427; Perrino BA, 2001, J BIOCHEM-TOKYO, V129, P835, DOI 10.1093/oxfordjournals.jbchem.a002927; Rioux V, 2002, J NUTR BIOCHEM, V13, P66, DOI 10.1016/S0955-2863(01)00196-6; Roberts David D., 1994, Journal of Tissue Culture Methods, V16, P217, DOI 10.1007/BF01540654; Rofstad EK, 2004, INT J RADIAT ONCOL, V58, P493, DOI 10.1016/j.ijrobp.2003.09.030; Sato Y, 2004, BIOL PHARM BULL, V27, P772, DOI 10.1248/bpb.27.772; Selvakumar P, 2006, BBA-REV CANCER, V1765, P148, DOI 10.1016/j.bbcan.2005.11.001; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; Shintani S, 2006, ORAL ONCOL, V42, P66, DOI 10.1016/j.oraloncology.2005.06.010; TEICHER BA, 1994, INT J CANCER, V57, P920, DOI 10.1002/ijc.2910570624; Thorne RF, 2006, BIOCHEM BIOPH RES CO, V351, P51, DOI 10.1016/j.bbrc.2006.09.156; Tsuda S, 2002, BIOCHEM BIOPH RES CO, V290, P1354, DOI 10.1006/bbrc.2002.6345; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; VOGEL T, 1993, ARCH BIOCHEM BIOPHYS, V300, P501, DOI 10.1006/abbi.1993.1068; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Werdich Xiang Q., 2005, Angiogenesis, V8, P315; Yap R, 2005, CLIN CANCER RES, V11, P6678, DOI 10.1158/1078-0432.CCR-05-0621; Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102; Zhu WF, 2005, J BIOL CHEM, V280, P29543, DOI 10.1074/jbc.M501238200	66	103	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15404	15415		10.1074/jbc.M701638200	http://dx.doi.org/10.1074/jbc.M701638200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17416590	Green Accepted, Green Submitted, hybrid			2022-12-27	WOS:000246589600016
J	Nikodemova, M; Watters, JJ; Jackson, SJ; Yang, SK; Duncan, ID				Nikodemova, Maria; Watters, Jyoti J.; Jackson, Samuel J.; Yang, Shaun K.; Duncan, Ian D.			Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)(alpha/beta II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; AUTOIMMUNE ENCEPHALOMYELITIS; NITRIC-OXIDE; TRANSACTIVATOR; ACTIVATION; RELEASE; CELLS; MODEL; CIITA	Experimental allergic encephalomyelitis, an autoimmune disorder mediated by T cells, results in demyelination, inflammation, and axonal loss in the central nervous system (CNS). Microglia play a critical role in major histocompatibility complex class II (MHC II)-dependent antigen presentation and in reactivation of CNS-infiltrated encephalitogenic T cells. Minocycline, a tetracycline antibiotic, has profound anti-inflammatory properties and is experimentally used for treatment of many CNS disorders; however, the mechanisms involved in minocycline effects remain unknown. We show that administration of minocycline for 2 weeks ameliorated clinical severity of experimental allergic encephalomyelitis, an effect that partially involves the down-regulation of MHC II proteins in the spinal cord. Therefore, we sought to elucidate the molecular mechanisms of minocycline inhibitory effects on MHC II expression in microglia. Although complex, the co-activator class II transactivator (CIITA) is a key regulator of MHC II expression. Here we show that minocycline inhibited interferon gamma(IFN gamma)induced CIITA and MHC II mRNA. Interestingly, however, it was without effect on STAT1 phosphorylation or IRF-1 expression, transcription factors that are activated by IFN gamma and necessary for CIITA expression. Further experiments revealed that MHC II expression is down-regulated in the presence of the PKC alpha inhibitor Go6976. Minocycline inhibited IFN gamma- induced PKC alpha/beta II phosphorylation and the nuclear translocation of both PKC alpha/beta II and IRF-1 that subsequently inhibits CIITA expression. Our present data delineate a molecular pathway of minocycline action that includes inhibitory effects on PKC alpha/beta II and transcription factors that regulate the expression of critical inflammatory genes such as MHC II. Such a fundamental mechanism may underlie the pleiotropic effects of minocycline in CNS inflammatory disorders.	Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Nikodemova, M (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Med Sci, 2015 Linden Dr, Madison, WI 53706 USA.	nikodemova@svm.vetmed.wisc.edu			NINDS NIH HHS [R01 NS049033] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049033] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; de Graaf KL, 2004, J IMMUNOL, V173, P2792, DOI 10.4049/jimmunol.173.4.2792; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; El Behi M, 2005, IMMUNOL LETT, V96, P11, DOI 10.1016/j.imlet.2004.07.017; FONTANA A, 1987, IMMUNOL REV, V100, P185, DOI 10.1111/j.1600-065X.1987.tb00532.x; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; Giroux M, 2003, J IMMUNOL, V171, P4187, DOI 10.4049/jimmunol.171.8.4187; Gunther E, 2001, IMMUNOGENETICS, V53, P520, DOI 10.1007/s002510100361; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Kim SS, 2004, ARCH PHARM RES, V27, P314, DOI 10.1007/BF02980066; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; McDole J, 2006, NEUROL RES, V28, P256, DOI 10.1179/016164106X98125; Metz LM, 2004, ANN NEUROL, V55, P756, DOI 10.1002/ana.20111; Nikodemova M, 2006, J NEUROCHEM, V96, P314, DOI 10.1111/j.1471-4159.2005.03520.x; O'Keefe GM, 2002, J NEUROVIROL, V8, P496, DOI 10.1080/13550280290100941; Ponomarev ED, 2005, J NEUROSCI RES, V81, P374, DOI 10.1002/jnr.20488; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zika E, 2005, CURR OPIN IMMUNOL, V17, P58, DOI 10.1016/j.coi.2004.11.008	27	120	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15208	15216		10.1074/jbc.M611907200	http://dx.doi.org/10.1074/jbc.M611907200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17395590	hybrid			2022-12-27	WOS:000246589000060
J	Seidel, M; Alderwick, LJ; Birch, HL; Sahm, H; Eggeling, L; Besra, GS				Seidel, Mathias; Alderwick, Luke J.; Birch, Helen L.; Sahm, Hermann; Eggeling, Lothar; Besra, Gurdyal S.			Identification of a novel arabinofuranosyltransferase AftB involved in a terminal step of cell wall arabinan biosynthesis in corynebacterianeae, such as Corynebacterium glutamicum and Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOLIC ACID BIOSYNTHESIS; STRUCTURAL FEATURES; MASS-SPECTROMETRY; EMB PROTEINS; ARABINOGALACTAN; ETHAMBUTOL; LIPOARABINOMANNAN; SMEGMATIS; RECOGNITION; EXPRESSION	Arabinofuranosyltransferase enzymes, such as EmbA, EmbB, and AftA, play pivotal roles in the biosynthesis of arabinogalactan, and the anti-tuberculosis agent ethambutol (EMB) targets arabinogalactan biosynthesis through inhibition of Mt-EmbA and Mt-EmbB. Herein, we describe the identification and characterization of a novel arabinofuranosyltransferase, now termed AftB (Rv3805c), which is essential in Mycobacterium tuberculosis. Deletion of its orthologue NCgl2780 in the closely related species Corynebacterium glutamicum resulted in a viable mutant. Analysis of the cell wall-associated lipids from the deletion mutant revealed a decreased abundance of cell wall-bound mycolic acids, consistent with a partial loss of mycolylation sites. Subsequent glycosyl linkage analysis of arabinogalactan also revealed the complete absence of terminal beta(1 -> 2)-linked arabinofuranosyl residues. The deletion mutant biochemical phenotype was fully complemented by either Mt-AftB or Cg-AftB, but not with muteins of Mt-AftB, where the two adjacent aspartic acid residues, which have been suggested to be involved in glycosyltransferase activity, were replaced by alanine. In addition, the use of C. glutamicum and C. glutamicum Delta aftB in an in vitro assay utilizing the sugar donor beta-D-arabinofuranosyl-1-monophosphoryl-decaprenol together with the neoglycolipid acceptor alpha-D-Araf-(1 -> 5)-alpha-D-Araf-O-C-8 as a substrate confirmed AftB as a terminal beta(1 -> 2) arabinofuranosyltransferase, which was also insensitive to EMB. Altogether, these studies have shed further light on the complexities of Corynebacterianeae cell wall biosynthesis, and Mt-AftB represents a potential new drug target.	Res Ctr Jeulich, Inst Biotechnol 1, D-52425 Julich, Germany; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Besra, GS (corresponding author), Res Ctr Jeulich, Inst Biotechnol 1, D-52425 Julich, Germany.	g.besra@bham.ac.uk		Alderwick, Luke/0000-0002-1257-6053; Besra, Gurdyal/0000-0002-5605-0395	MRC [G0500590] Funding Source: UKRI; Medical Research Council [G0500590] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Alderwick LJ, 2005, J BIOL CHEM, V280, P32362, DOI 10.1074/jbc.M506339200; Alderwick LJ, 2006, GLYCOBIOLOGY, V16, P1073, DOI 10.1093/glycob/cwl030; Alderwick LJ, 2006, J BIOL CHEM, V281, P15653, DOI 10.1074/jbc.M600045200; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; Berg S, 2005, J BIOL CHEM, V280, P5651, DOI 10.1074/jbc.M411418200; BERG S, 2007, GLYCOBIOLOGY AD 0129; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; Coutinho P. M., 1999, RECENT ADV CARBOHYDR; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; Eggeling L, 2005, HDB CORYNEBACTERIUM, P535; EIKMANNS BJ, 1991, GENE, V102, P93, DOI 10.1016/0378-1119(91)90545-M; Escuyer VE, 2001, J BIOL CHEM, V276, P48854, DOI 10.1074/jbc.M102272200; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; Huang HR, 2005, J BIOL CHEM, V280, P24539, DOI 10.1074/jbc.M504068200; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; Kremer L, 2001, J BIOL CHEM, V276, P26430, DOI 10.1074/jbc.M102022200; Lee RE, 1998, BIOORG MED CHEM LETT, V8, P951, DOI 10.1016/S0960-894X(98)00147-4; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; Lee RE, 1997, GLYCOBIOLOGY, V7, P1121, DOI 10.1093/glycob/7.8.1121; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; Mikusova K, 2000, J BIOL CHEM, V275, P33890, DOI 10.1074/jbc.M006875200; Mikusova K, 2005, J BACTERIOL, V187, P8020, DOI 10.1128/JB.187.23.8020-8025.2005; Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4; Pan F, 2001, J BACTERIOL, V183, P3991, DOI 10.1128/JB.183.13.3991-3998.2001; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Puech V, 2001, MICROBIOL-SGM, V147, P1365, DOI 10.1099/00221287-147-5-1365; Radmacher E, 2005, MICROBIOL-SGM, V151, P1359, DOI 10.1099/mic.0.27804-0; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Seidel M, 2007, GLYCOBIOLOGY, V17, P210, DOI 10.1093/glycob/cwl066; Shi LB, 2006, J BIOL CHEM, V281, P19512, DOI 10.1074/jbc.M513846200; Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; Telenti A, 1997, NAT MED, V3, P567, DOI 10.1038/nm0597-567; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; Zhang N, 2003, MOL MICROBIOL, V50, P69, DOI 10.1046/j.1365-2958.2003.03681.x; Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877	46	89	96	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14729	14740		10.1074/jbc.M700271200	http://dx.doi.org/10.1074/jbc.M700271200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387176	hybrid			2022-12-27	WOS:000246589000008
J	Zhuang, HY; Matsunami, H				Zhuang, Hanyi; Matsunami, Hiroaki			Synergism of accessory factors in functional expression of mammalian odorant receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE OLFACTORY RECEPTOR; MOLECULAR-BASIS; IDENTIFICATION; SPECIFICITY; PROTEINS; LIGANDS; NEURONS; FAMILY; CELLS; RECONSTITUTION	The discovery of odorant receptors led to endeavors in matching them with their cognate ligands. Although it has been challenging to functionally express odorant receptors in heterologous cells, previous studies have linked efficient odorant receptor expression with N-terminal modifications and accessory proteins, including the receptor-transporting proteins ( RTPs) and Ric8b. Here we have shown that a shorter form of RTP1, RTP1S, supports robust cell-surface and functional expression of representative odorant receptors. Using a combination of accessory proteins, including RTP1S, Ric8b, and G(alpha olf), a diverse set of untagged odorant receptors were successfully expressed heterologously due to the synergistic effects among the various accessory proteins. Furthermore, the addition of an N-terminal rhodopsin tag to the odorant receptors, along with the same set of accessory proteins, exhibits an additional level of synergism, inducing enhanced odorant receptor responses to odorants and thus defining a more efficient heterologous expression system. We then showed that the presence or absence of different N-terminal tags has little effect on the ligand specificity of odorant receptors, although the amount of receptor expressed can play a role in the ligand response profile. The accuracy of the odorant receptor heterologous expression system involving tagged odorant receptors and various accessory proteins promises success in high throughput de-orphaning of mammalian odorant receptors.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Duke University	Matsunami, H (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, 264 CARL Bldg,Res Dr, Durham, NC 27710 USA.	hiroaki.matsunami@duke.edu			NIDCD NIH HHS [DC05782, DC008480] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005782, F31DC008480] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Abaffy T, 2007, J BIOL CHEM, V282, P1216, DOI 10.1074/jbc.M609355200; Abaffy T, 2006, J NEUROCHEM, V97, P1506, DOI 10.1111/j.1471-4159.2006.03859.x; Barnea G, 2004, SCIENCE, V304, P1468, DOI 10.1126/science.1096146; Belluscio L, 2002, NATURE, V419, P296, DOI 10.1038/nature01001; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Burstein ES, 1997, MOL PHARMACOL, V51, P312, DOI 10.1124/mol.51.2.312; Chen G, 2000, MOL PHARMACOL, V57, P125; Ford DJ, 2002, J PHARMACOL EXP THER, V300, P810, DOI 10.1124/jpet.300.3.810; Gaillard I, 2002, EUR J NEUROSCI, V15, P409, DOI 10.1046/j.0953-816x.2001.01871.x; Grosmaitre X, 2006, P NATL ACAD SCI USA, V103, P1970, DOI 10.1073/pnas.0508491103; Hague C, 2004, P NATL ACAD SCI USA, V101, P13672, DOI 10.1073/pnas.0403854101; Imai T, 2006, SCIENCE, V314, P657, DOI 10.1126/science.1131794; Ishimaru Y, 2006, P NATL ACAD SCI USA, V103, P12569, DOI 10.1073/pnas.0602702103; Ivic L, 2002, J NEUROBIOL, V50, P56, DOI 10.1002/neu.10016; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Katada S, 2003, BIOCHEM BIOPH RES CO, V305, P964, DOI 10.1016/S0006-291X(03)00863-5; Katada S, 2004, J NEUROCHEM, V90, P1453, DOI 10.1111/j.1471-4159.2004.02619.x; Kenakin T, 1996, PHARMACOL REV, V48, P413; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; LAIRD DW, 1988, INVEST OPHTH VIS SCI, V29, P419; Lu M, 2003, TRAFFIC, V4, P416, DOI 10.1034/j.1600-0854.2003.00097.x; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; McClintock TS, 1997, MOL BRAIN RES, V48, P270, DOI 10.1016/S0169-328X(97)00099-5; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Neuhaus EM, 2006, CHEM SENSES, V31, P445, DOI 10.1093/chemse/bjj049; Oka Y, 2006, NEURON, V52, P857, DOI 10.1016/j.neuron.2006.10.019; Saito H, 2004, CELL, V119, P679, DOI 10.1016/j.cell.2004.11.021; Shirokova E, 2005, J BIOL CHEM, V280, P11807, DOI 10.1074/jbc.M411508200; Spehr M, 2003, SCIENCE, V299, P2054, DOI 10.1126/science.1080376; Strotmann J, 2004, J NEUROSCI, V24, P7754, DOI 10.1523/JNEUROSCI.2588-04.2004; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; Von Dannecker LEC, 2005, J NEUROSCI, V25, P3793, DOI 10.1523/JNEUROSCI.4595-04.2005; Von Dannecker LEC, 2006, P NATL ACAD SCI USA, V103, P9310, DOI 10.1073/pnas.0600697103; Wellerdieck C, 1997, CHEM SENSES, V22, P467, DOI 10.1093/chemse/22.4.467; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	36	131	144	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15284	15293		10.1074/jbc.M700386200	http://dx.doi.org/10.1074/jbc.M700386200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387175	hybrid			2022-12-27	WOS:000246589000067
J	Bowler, MW; Montgomery, MG; Leslie, AGW; Walker, JE				Bowler, Matthew W.; Montgomery, Martin G.; Leslie, Andrew G. W.; Walker, John E.			Ground state structure of F-1-ATPase from bovine heart mitochondria at 1.9 a resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROTARY CATALYTIC MECHANISM; NUCLEOTIDE-BINDING; ATP HYDROLYSIS; SITES; F(1)-ATPASE; REFINEMENT; F1-ATPASE; FLUORIDE; SYNTHASE; PROVIDES	The structure of bovine F-1-ATPase, crystallized in the presence of AMP-PNP and ADP, but in the absence of azide, has been determined at 1.9 angstrom resolution. This structure has been compared with the previously described structure of bovine F-1-ATPase determined at 1.95 angstrom resolution with crystals grown under the same conditions but in the presence of azide. The two structures are extremely similar, but they differ in the nucleotides that are bound to the catalytic site in the beta(DP)-subunit. In the present structure, the nucleotide binding sites in the beta(DP)- and beta(TP)-subunits are both occupied by AMP-PNP, whereas in the earlier structure, the beta(TP) site was occupied by AMP-PNP and the beta(DP) site by ADP, where its binding is enhanced by a bound azide ion. Also, the conformation of the side chain of the catalytically important residue, alpha Arg-373 differs in the beta(DP)- and beta(TP)- subunits. Thus, the structure with bound azide represents the ADP inhibited state of the enzyme, and the new structure represents a ground state intermediate in the active catalytic cycle of ATP hydrolysis.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Leslie, AGW (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	andrew@mrc-lmb.cam.ac.uk; walker@mrc-dunn.cam.ac.uk	Bowler, Matthew/I-7461-2019; Bowler, Matthew/B-5722-2011	Bowler, Matthew/0000-0003-0465-3351; Bowler, Matthew/0000-0003-0465-3351; Walker, John/0000-0001-7929-2162	MRC [MC_U105663150, MC_U105184325] Funding Source: UKRI; Medical Research Council [MC_U105184325, MC_U105663150] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Abrahams JP, 1996, P NATL ACAD SCI USA, V93, P9420, DOI 10.1073/pnas.93.18.9420; Bowler MW, 2006, ACTA CRYSTALLOGR D, V62, P991, DOI 10.1107/S0907444906020877; Bowler MW, 2006, P NATL ACAD SCI USA, V103, P8646, DOI 10.1073/pnas.0602915103; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DeLano W.L, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Kabaleeswaran V, 2006, EMBO J, V25, P5433, DOI 10.1038/sj.emboj.7601410; Kagawa R, 2004, EMBO J, V23, P2734, DOI 10.1038/sj.emboj.7600293; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LESLIE AG, 1992, JOINT CCP4 EACMB NEW, V26; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; WEBER J, 1993, J BIOL CHEM, V268, P20126	25	161	163	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14238	14242		10.1074/jbc.M700203200	http://dx.doi.org/10.1074/jbc.M700203200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17350959	hybrid			2022-12-27	WOS:000246245800034
J	Sastry, KSR; Karpova, Y; Prokopovich, S; Smith, AJ; Essau, B; Gersappe, A; Carson, JP; Weber, MJ; Register, TC; Chen, YQ; Penn, RB; Kulik, G				Sastry, Konduru S. R.; Karpova, Yelena; Prokopovich, Sergey; Smith, Adrienne J.; Essau, Brian; Gersappe, Avynash; Carson, Jonathan P.; Weber, Michael J.; Register, Thomas C.; Chen, Yong Q.; Penn, Raymond B.; Kulik, George			Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATE-CANCER; EPIDERMAL-GROWTH-FACTOR; ANDROGEN RECEPTOR; RADICAL PROSTATECTOMY; SIGNALING PATHWAYS; BREAST-CANCER; CYCLIC-AMP; STRESS; LNCAP; CARCINOMA	The stress hormone epinephrine is known to elicit multiple systemic effects that include changes in cardiovascular parameters and immune responses. However, information about its direct action on cancer cells is limited. Here we provide evidence that epinephrine reduces sensitivity of cancer cells to apoptosis through interaction with beta(2)-adrenergic receptors. The antiapoptotic mechanism of epinephrine primarily involves phosphorylation and inactivation of the proapoptotic protein BAD by cAMP-dependent protein kinase. Moreover, BAD phosphorylation was observed at epinephrine concentrations found after acute and chronic psychosocial stress. Antiapoptotic signaling by epinephrine could be one of the mechanisms by which stress promotes tumorigenesis and decreases the efficacy of anti-cancer therapies.	Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Comparat Med Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	Wake Forest University; Wake Forest University; Wake Forest University; University of Virginia	Kulik, G (corresponding author), Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA.	gkulik@wfubmc.edu	Sastry, Konduru Seetharama/GQY-6005-2022; Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708; Register, Thomas/0000-0002-4078-0166	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058506, R01HL058506] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58506] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayala GE, 2006, CANCER RES, V66, P5159, DOI 10.1158/0008-5472.CAN-05-1847; Ben-Eliyahu S, 2000, NEUROIMMUNOMODULAT, V8, P154, DOI 10.1159/000054276; BONKHOFF H, 1991, PROSTATE, V19, P91, DOI 10.1002/pros.2990190202; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Cohen S, 1998, J NATL CANCER I, V90, P3, DOI 10.1093/jnci/90.1.3; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Dent G, 2001, BRIT J PHARMACOL, V133, P1199, DOI 10.1038/sj.bjp.0704214; Garcia-Fernandez MO, 2003, PEPTIDES, V24, P893, DOI 10.1016/S0196-9781(03)00162-1; Gold SA, 2004, BIOL PSYCHOL, V67, P261, DOI 10.1016/j.biopsycho.2003.12.001; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Grouzmann E, 2003, PFLUG ARCH EUR J PHY, V447, P254, DOI 10.1007/s00424-003-1140-x; Guo MH, 2005, BIOCHEMISTRY-US, V44, P13771, DOI 10.1021/bi051255y; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; ISAACS JT, 1992, J ANDROL, V13, P457; Kasbohm EA, 2005, J BIOL CHEM, V280, P11583, DOI 10.1074/jbc.M414423200; Kim J, 2005, J MOL ENDOCRINOL, V34, P107, DOI 10.1677/jme.1.01701; Kimura K, 2001, CANCER RES, V61, P5611; Lutgendorf SK, 2003, CLIN CANCER RES, V9, P4514; McConkey DJ, 1996, CANCER RES, V56, P5594; Nagmani R, 2003, BIOCHEM PHARMACOL, V65, P1489, DOI 10.1016/S0006-2952(03)00105-9; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Nelson JB, 2005, NEOPLASIA, V7, P631, DOI 10.1593/neo.04787; Perron L, 2004, CANCER CAUSE CONTROL, V15, P535, DOI 10.1023/B:CACO.0000036152.58271.5e; Philipp M, 2004, PHARMACOL THERAPEUT, V101, P65, DOI 10.1016/j.pharmthera.2003.10.004; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Porter AT, 2001, UROL ONCOL, V6, P131, DOI 10.1016/S1078-1439(00)00124-1; POYET P, 1986, PROSTATE, V9, P237, DOI 10.1002/pros.2990090304; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Sastry KSR, 2006, J BIOL CHEM, V281, P27367, DOI 10.1074/jbc.M511485200; Sastry KSR, 2006, J BIOL CHEM, V281, P20891, DOI 10.1074/jbc.M602928200; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698; Spiegel D, 2003, BIOL PSYCHIAT, V54, P269, DOI 10.1016/S0006-3223(03)00566-3; Su FX, 2005, BIOCHEM BIOPH RES CO, V329, P888, DOI 10.1016/j.bbrc.2005.02.056; Sumitomo M, 2001, CANCER RES, V61, P3294; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Taub JS, 2003, CANCER RES, V63, P2037; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; THALMANN GN, 1994, CANCER RES, V54, P2577; Theodorescu D, 1997, CANCER, V80, P2109, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2109::AID-CNCR10>3.0.CO;2-2; Tombal B, 2000, PROSTATE, V43, P303; Ullrich PM, 2003, J UROLOGY, V169, P1449, DOI 10.1097/01.ju.0000053243.87457.60; VANDEWALLE B, 1990, J CANCER RES CLIN, V116, P303, DOI 10.1007/BF01612908; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; WORTSMAN J, 1984, AM J MED, V77, P779, DOI 10.1016/0002-9343(84)90512-6; Xu LL, 2000, CANCER RES, V60, P6568	51	144	148	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14094	14100		10.1074/jbc.M611370200	http://dx.doi.org/10.1074/jbc.M611370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17353197	hybrid			2022-12-27	WOS:000246245800019
J	Zofall, M; Grewal, SIS				Zofall, Martin; Grewal, Shiv I. S.			HULC, a histone H2B ubiquitinating complex, modulates heterochromatin independent of histone methylation in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H3 LYSINE-4 METHYLATION; JMJC DOMAIN PROTEIN; TRANSCRIPTIONAL ACTIVATION; SCHIZOSACCHAROMYCES-POMBE; CHROMODOMAIN PROTEIN; CONJUGATING ENZYMES; EPIGENETIC CONTROL; UBIQUITYLATION; RAD6; GENE	Heterochromatin in fission yeast is targeted dynamically by opposing chromatin-modifying activities capable of alleviating or promoting transcriptional gene silencing. In this study, we report the biochemical and genetic characterization of a ubiquitin-conjugating enzyme Rhp6 (a homolog of budding yeast Rad6), which has been shown to negatively affect stability of heterochromatic structures. We show that Rhp6 is a component of the multisubunit protein complex (termed HULC) that also contains two RING finger proteins Rfp1 and Rfp2, sharing homology with budding yeast Bre1 protein and a unique serine-rich protein Shf1. HULC is required for ubiquitination of histone H2B at lysine 119 (H2B-K119), and it localizes to heterochromatic sequences. Moreover, our analyses suggest that Rhp6-induced changes in heterochromatic silencing are mediated predominantly through H2B ubiquitination (ubH2B), and they correlate with increased RNA polymerase II levels at repeat elements embedded within heterochromatin domains. Interestingly, heterochromatic derepression caused by Rhp6 occurs independently of the involvement of HULC subunits and ubH2B in methylation of histone H3 at lysine 4 (H3K4me). These analyses implicate ubH2B in modulation of heterochromatin, which has important implications for dynamics and many functions associated with heterochromatic structures.	NCI, Biochem & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Grewal, SIS (corresponding author), NCI, Biochem & Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	grewals@mail.nih.gov			Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Ayoub N, 2003, MOL CELL BIOL, V23, P4356, DOI 10.1128/MCB.23.12.4356-4370.2003; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Belotserkovskaya R, 2004, CURR OPIN GENET DEV, V14, P139, DOI 10.1016/j.gde.2004.02.004; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bjerling P, 2002, MOL CELL BIOL, V22, P2170, DOI 10.1128/MCB.22.7.2170-2181.2002; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Cam HP, 2005, NAT GENET, V37, P809, DOI 10.1038/ng1602; Choi ES, 2002, MOL CELL BIOL, V22, P8366, DOI 10.1128/MCB.22.23.8366-8374.2002; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; Djupedal I, 2005, GENE DEV, V19, P2301, DOI 10.1101/gad.344205; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Ekwall K, 2005, TRENDS GENET, V21, P608, DOI 10.1016/j.tig.2005.08.009; Emre NCT, 2004, COLD SPRING HARB SYM, V69, P289, DOI 10.1101/sqb.2004.69.289; Emre NCT, 2005, MOL CELL, V17, P585, DOI 10.1016/j.molcel.2005.01.007; Freeman-Cook LL, 2005, GENETICS, V169, P1243, DOI 10.1534/genetics.104.032714; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Grewal SIS, 1998, GENETICS, V150, P563; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Huisinga KL, 2006, CHROMOSOMA, V115, P110, DOI 10.1007/s00412-006-0052-x; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jia ST, 2005, NAT CELL BIOL, V7, P1007, DOI 10.1038/ncb1300; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Kato H, 2005, SCIENCE, V309, P467, DOI 10.1126/science.1114955; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Maruyama T, 2006, EMBO J, V25, P2420, DOI 10.1038/sj.emboj.7601110; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Naresh A, 2003, J BIOL CHEM, V278, P9185, DOI 10.1074/jbc.M212732200; Nielsen IS, 2002, EUKARYOT CELL, V1, P613, DOI 10.1128/EC1.4.613-625.2002; Noma K, 2004, NAT GENET, V36, P1174, DOI 10.1038/ng1452; Noma K, 2002, P NATL ACAD SCI USA, V99, P16438, DOI 10.1073/pnas.182436399; Osley MA, 2006, RES PRO CEL, V41, P47, DOI 10.1007/006; Partridge JF, 2002, CURR BIOL, V12, P1652, DOI 10.1016/S0960-9822(02)01177-6; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PRAKASH L, 1989, GENOME, V31, P597, DOI 10.1139/g89-111; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roguev A, 2003, J BIOL CHEM, V278, P8487, DOI 10.1074/jbc.M209562200; Sadaie M, 2004, EMBO J, V23, P3825, DOI 10.1038/sj.emboj.7600401; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schotta Gunnar, 2004, Novartis Found Symp, V259, P22; Shankaranarayana GD, 2003, CURR BIOL, V13, P1240, DOI 10.1016/S0960-9822(03)00489-5; Singh J, 1998, MOL CELL BIOL, V18, P5511, DOI 10.1128/MCB.18.9.5511; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sugiyama T, 2007, CELL, V128, P491, DOI 10.1016/j.cell.2006.12.035; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; VANHOLDE KE, 1989, CHROMATIN, P111; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Xiao TJ, 2005, MOL CELL BIOL, V25, P637, DOI 10.1128/MCB.25.2.637-651.2005; Yamada T, 2005, MOL CELL, V20, P173, DOI 10.1016/j.molcel.2005.10.002; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zofall M, 2006, MOL CELL, V22, P681, DOI 10.1016/j.molcel.2006.05.010	74	41	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14065	14072		10.1074/jbc.M700292200	http://dx.doi.org/10.1074/jbc.M700292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17363370	hybrid			2022-12-27	WOS:000246245800016
J	Dupre, DJ; Robitaille, M; Richer, M; Ethier, N; Mamarbachi, AM; Hebert, TE				Dupre, Denis J.; Robitaille, Melanie; Richer, Maxime; Ethier, Nathalie; Mamarbachi, Aida M.; Hebert, Terence E.			Dopamine receptor-interacting protein 78 acts as a molecular chaperone for G gamma subunits before assembly with G beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSDUCIN-LIKE PROTEIN; HETEROTRIMERIC G-PROTEINS; FORM STABLE COMPLEXES; ENDOPLASMIC-RETICULUM; COUPLED RECEPTORS; ADENYLYL-CYCLASE; DIMER FORMATION; IDENTIFICATION; TRAFFICKING; MODULATION	Heterotrimeric G proteins play a central role in intracellular communication mediated by extracellular signals, and both G alpha and G beta gamma subunits regulate effectors downstream of activated receptors. The particular constituents of the G protein heterotrimer affect both specificity and efficiency of signal transduction. However, little is known about mechanistic aspects of G protein assembly in the cell that would certainly contribute to formation of heterotrimers of specific composition. It was recently shown that phosducin-like protein (PhLP) modulated both G beta gamma expression and subsequent signaling by chaperoning nascent G beta and facilitating heterodimer formation with G gamma subunits Lukov, G. L., Hu, T., McLaughlin, J. N., Hamm, H. E., and Willardson, B. M. ( 2005) EMBOJ. 24, 1965 - 1975; Humrich, J., Bermel, C., Bunemann, M., Harmark, L., Frost, R., Quitterer, U., and Lohse, M. J. ( 2005) J. Biol. Chem. 280, 20042 - 20050). Here we demonstrate using a variety of techniques that DRiP78, an endoplasmic reticulum resident protein known to regulate the trafficking of several seven transmembrane receptors, interacts specifically with the G gamma subunit but not G beta or G alpha subunits. Furthermore, we demonstrate that DRiP78 and the G beta subunit can compete for the G gamma subunit. DRiP78 also protects G gamma from degradation until a stable partner such as G beta is provided. Furthermore, DRiP78 interaction may represent a mechanism for assembly of specific G beta gamma heterodimers, as selectivity was observed among G gamma isoforms for interaction with DRiP78 depending on the presence of particular G beta subunits. Interestingly, we could detect an interaction between DRiP78 and PhLP, suggesting a role of DRiP78 in the assembly of G beta gamma by linking G gamma to PhLP center dot G beta complexes. Our results, therefore, suggest a role of DRiP78 as a chaperone in the assembly of G beta gamma subunits of the G protein.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Inst Cardiol Montreal, Montreal, PQ H1T 1C8, Canada	McGill University; Universite de Montreal; Universite de Montreal; Institut de Cardiologie de Montreal	Hebert, TE (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.	terence.hebert@mcgill.ca	Robitaille, Melanie/ABA-5861-2020; Dupre, Denis J/AAI-2631-2021	Robitaille, Melanie/0000-0001-9354-5162; Dupre, Denis J/0000-0001-6401-6157				Akgoz M, 2002, J BIOL CHEM, V277, P19573, DOI 10.1074/jbc.M201546200; Azpiazu I, 2002, METHOD ENZYMOL, V344, P112; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Chen JX, 2003, J HUM GENET, V48, P217, DOI 10.1007/s10038-003-0012-8; Chinault SL, 2003, J BIOL CHEM, V278, P20638, DOI 10.1074/jbc.M212701200; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Cook LA, 2001, PROTEIN SCI, V10, P2548, DOI 10.1110/ps.ps.26401; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; Dingus J, 2005, BIOCHEMISTRY-US, V44, P11882, DOI 10.1021/bi0504254; Doering CJ, 2004, J BIOL CHEM, V279, P29709, DOI 10.1074/jbc.M308693200; Dupre DJ, 2006, J BIOL CHEM, V281, P34561, DOI 10.1074/jbc.M605012200; Dupre DJ, 2006, CELL SIGNAL, V18, P1549, DOI 10.1016/j.cellsig.2006.03.009; Ellis R J, 1990, Semin Cell Biol, V1, P1; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P2039; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Humrich J, 2005, J BIOL CHEM, V280, P20042, DOI 10.1074/jbc.M409233200; Hurowitz EH, 2000, DNA RES, V7, P111, DOI 10.1093/dnares/7.2.111; Hynes TR, 2004, J BIOL CHEM, V279, P30279, DOI 10.1074/jbc.M401432200; INANOBE A, 1994, J BIOCHEM, V115, P486, DOI 10.1093/oxfordjournals.jbchem.a124363; Judd R. C., 2002, PROTEIN PROTOCOLS HD, P73; Knol JC, 2005, MOL CELL BIOL, V25, P8393, DOI 10.1128/MCB.25.18.8393-8400.2005; Lackner T, 2005, J VIROL, V79, P9746, DOI 10.1128/JVI.79.15.9746-9755.2005; Lacoste C, 2006, DEV BIOL, V294, P181, DOI 10.1016/j.ydbio.2006.02.039; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Le-Niculescu H, 2005, J BIOL CHEM, V280, P22012, DOI 10.1074/jbc.M501833200; LeClerc PC, 2002, ENDOCRINOLOGY, V143, P4702, DOI 10.1210/en.2002-220679; Lukov GL, 2006, J BIOL CHEM, V281, P22261, DOI 10.1074/jbc.M601590200; Lukov GL, 2005, EMBO J, V24, P1965, DOI 10.1038/sj.emboj.7600673; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Miller LC, 2003, J BIOL CHEM, V278, P53072, DOI 10.1074/jbc.M306230200; Miller LC, 2003, J CELL SCI, V116, P2967, DOI 10.1242/jcs.00595; Natochin M, 2005, J BIOL CHEM, V280, P30236, DOI 10.1074/jbc.M500722200; Pfleger KDG, 2006, NAT METHODS, V3, P165, DOI 10.1038/nmeth841; Rebois RV, 2006, J CELL SCI, V119, P2807, DOI 10.1242/jcs.03021; Rebois RV, 2003, RECEPTOR CHANNEL, V9, P169, DOI 10.1080/10606820308243; Robishaw JD, 2004, CURR OPIN CELL BIOL, V16, P206, DOI 10.1016/j.ceb.2004.02.007; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; Takida S, 2004, FEBS LETT, V567, P209, DOI 10.1016/j.febslet.2004.04.062; Takida S, 2003, J BIOL CHEM, V278, P17284, DOI 10.1074/jbc.M213239200; Thibault C, 1997, J BIOL CHEM, V272, P12253, DOI 10.1074/jbc.272.19.12253; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; Wang Q, 2001, J BIOL CHEM, V276, P39386, DOI 10.1074/jbc.M104981200	53	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13703	13715		10.1074/jbc.M608846200	http://dx.doi.org/10.1074/jbc.M608846200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17363375	hybrid			2022-12-27	WOS:000246060300060
J	Edwards, SR; Wandless, TJ				Edwards, Sarah R.; Wandless, Thomas J.			The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ANALOGS; SPECIFICITY; MICE	Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein ( FKBP12, or FKBP) and the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin ( mTOR) kinase. The resulting ternary complex has been used to conditionally perturb protein function, and one such method involves perturbation of a protein of interest through its mislocalization. We synthesized two rapamycin derivatives that possess large sub-stituents at the C-16 position within the FRB-binding interface, and these derivatives were screened against a library of FRB mutants using a three-hybrid assay in Saccharomyces cerevisiae. Several FRB mutants responded to one of the rapamycin derivatives, and twenty of these mutants were further characterized in mammalian cells. The mutants most responsive to the ligand were fused to yellow fluorescent protein, and fluorescence levels in the presence and absence of the ligand were measured to determine stability of the fusion proteins. Wild-type and mutant FRB domains were expressed at low levels in the absence of the rapamycin derivative, and expression levels rose up to 10-fold upon treatment with ligand. The synthetic rapamycin derivatives were further analyzed using quantitative mass spectrometry, and one of the compounds was found to contain contaminating rapamycin. Furthermore, uncontaminated analogs retained the ability to inhibit mTOR, although with diminished potency relative to rapamycin. The ligand-dependent stability displayed by wild-type FRB and FRB mutants as well as the inhibitory potential and purity of the rapamycin derivatives should be considered as potentially confounding experimental variables when using these systems.	Stanford Univ, Dept Chem & Syst Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; Stanford University	Wandless, TJ (corresponding author), Stanford Univ, Dept Chem & Syst Biol, Stanford, CA 94305 USA.	wandless@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068589] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM068589-03, GM068589, R01 GM068589-04, R01 GM068589, R01 GM068589-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025; Bayle JH, 2006, CHEM BIOL, V13, P99, DOI 10.1016/j.chembiol.2005.10.017; Biggar SR, 2000, J BIOL CHEM, V275, P25381, DOI 10.1074/jbc.M002991200; Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Inoue T, 2005, NAT METHODS, V2, P415, DOI 10.1038/NMETH763; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Liberles SD, 1997, P NATL ACAD SCI USA, V94, P7825, DOI 10.1073/pnas.94.15.7825; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; LUENGO JI, 1995, CHEM BIOL, V2, P471, DOI 10.1016/1074-5521(95)90264-3; Park IH, 2005, EXP CELL RES, V309, P211, DOI 10.1016/j.yexcr.2005.05.017; Ryding ADS, 2001, J ENDOCRINOL, V171, P1, DOI 10.1677/joe.0.1710001; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Stankunas K, 2003, MOL CELL, V12, P1615, DOI 10.1016/S1097-2765(03)00491-X; Suh BC, 2006, SCIENCE, V314, P1454, DOI 10.1126/science.1131163; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Zaccolo M, 1996, J MOL BIOL, V255, P589, DOI 10.1006/jmbi.1996.0049	22	71	75	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13395	13401		10.1074/jbc.M700498200	http://dx.doi.org/10.1074/jbc.M700498200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350953	Green Accepted, hybrid			2022-12-27	WOS:000246060300028
J	Furuta, K; Nakayama, K; Sugimoto, Y; Ichikawa, A; Tanaka, S				Furuta, Kazuyuki; Nakayama, Kazuhisa; Sugimoto, Yukihiko; Ichikawa, Atsushi; Tanaka, Satoshi			Activation of histidine decarboxylase through post-translational cleavage by caspase-9 in a mouse mastocytoma P-815	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIA CELLS; SODIUM-BUTYRATE; MAST-CELLS; HISTAMINE; EXPRESSION; LINE; APOPTOSIS; MICE; PURIFICATION; SEQUENCE	(L)-Histidine decarboxylase (HDC) is the rate-limiting enzyme for histamine synthesis in mammals. Although accumulating evidence has indicated the post-translational processing of HDC, it remains unknown what kinds of proteases are involved. We investigated the processing of HDC in a mouse mastocytoma, P-815, using a lentiviral expression system. HDC was expressed as a 74-kDa precursor form, which is cleaved to yield the 55- and 60-kDa forms upon treatment with butyrate. Alanine-scanning mutations revealed that two tandem aspartate residues (Asp(517) -Asp(518), Asp(550)- Asp(551)) are critical for the processing. Treatment with butyrate caused an increase in the enzyme activity of the cells expressing the wild type HDC, but not in the cells expressing the processing-incompetent mutant. An increase in histamine synthesis by butyrate was accompanied by formation of the 55- and 60-kDa form of HDC. In addition, the in vitro translated 74-kDa form of HDC was found to undergo a limited cleavage by purified human caspase-9, whereas the alanine-substituted mutants were not. Processing and enzymatic activation of HDC in P-815 cells was enhanced in the presence of a Zn2+ chelator, TPEN. Although treatment with butyrate and TPEN drastically augmented the protease activity of caspase-3, and -9, no apoptotic cell death was observed. Both enzymatic activation and processing of HDC were completely suppressed by a pan-caspase inhibitor, partially but significantly by a specific inhibitor for caspase-9, but not by a caspase-3 inhibitor. These results suggest that, in P-815 cells, histamine synthesis is augmented through the post-translational cleavage of HDC, which is mediated by caspase-9.	Mukogawa Womens Univ, Sch Pharmaceut Sci, Dept Immunobiol, Nishinomiya, Hyogo 6638179, Japan; Mukogawa Womens Univ, Sch Pharmaceut Sci, Dept Physiol Chem, Nishinomiya, Hyogo 6638179, Japan; Kyoto Univ, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan	Mukogawa Women's University; Mukogawa Women's University; Kyoto University	Tanaka, S (corresponding author), Mukogawa Womens Univ, Sch Pharmaceut Sci, Dept Immunobiol, Nishinomiya, Hyogo 6638179, Japan.	s_tanaka@mukogawa-u.ac.jp	Tanaka, Satoshi/H-6800-2019; Nakayama, Kazuhisa/ABF-2924-2020; TANAKA, Satoshi/B-1624-2011; Sugimoto, Yukihiko/AAV-6470-2021	Tanaka, Satoshi/0000-0002-3468-7694; TANAKA, Satoshi/0000-0002-3468-7694; Sugimoto, Yukihiko/0000-0001-6973-932X; Nakayama, Kazuhisa/0000-0001-7701-7183				BEAVEN MA, 1978, HISTAMINE ITS ROLE P; BELL PA, 1982, BIOCHEM BIOPH RES CO, V104, P1202, DOI 10.1016/0006-291X(82)91378-X; Bryce PJ, 2006, J CLIN INVEST, V116, P1624, DOI 10.1172/JCI26150; Dartsch C, 1998, REGUL PEPTIDES, V77, P33, DOI 10.1016/S0167-0115(98)00045-7; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; de Esch IJP, 2005, TRENDS PHARMACOL SCI, V26, P462, DOI 10.1016/j.tips.2005.07.002; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fleming JV, 2004, BIOCHEM J, V381, P769, DOI 10.1042/BJ20031553; Fleming JV, 2003, J BIOL CHEM, V278, P686, DOI 10.1074/jbc.M210718200; FRIEND C, 1987, CANCER RES, V47, P378; GALLI SJ, 1982, J CELL BIOL, V95, P435, DOI 10.1083/jcb.95.2.435; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Haas H, 2003, NAT REV NEUROSCI, V4, P121, DOI 10.1038/nrn1034; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hirasawa N, 2001, EUR J PHARMACOL, V418, P23, DOI 10.1016/S0014-2999(01)00931-1; Ho LH, 2004, J IMMUNOL, V172, P7750, DOI 10.4049/jimmunol.172.12.7750; JACOBSSON KG, 1985, J BIOL CHEM, V260, P2154; JOSEPH DR, 1990, P NATL ACAD SCI USA, V87, P733, DOI 10.1073/pnas.87.2.733; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; MARTIN SAM, 1986, BIOCHEM J, V234, P349, DOI 10.1042/bj2340349; MORI Y, 1980, EXP CELL RES, V127, P465, DOI 10.1016/0014-4827(80)90455-3; MORI Y, 1979, EXP CELL RES, V118, P15, DOI 10.1016/0014-4827(79)90578-0; Musio S, 2006, J IMMUNOL, V176, P17, DOI 10.4049/jimmunol.176.1.17; OHMORI E, 1990, J BIOCHEM, V107, P834, DOI 10.1093/oxfordjournals.jbchem.a123134; Ohtsu H, 2001, FEBS LETT, V502, P53, DOI 10.1016/S0014-5793(01)02663-1; Ohtsu H, 1996, J BIOL CHEM, V271, P28439, DOI 10.1074/jbc.271.45.28439; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; Rodriguez-Agudo D, 2000, BIOCHEM BIOPH RES CO, V271, P777, DOI 10.1006/bbrc.2000.2715; Safina F, 2002, J BIOL CHEM, V277, P14211, DOI 10.1074/jbc.M200702200; Samuelson LC, 2003, ANNU REV PHYSIOL, V65, P383, DOI 10.1146/annurev.physiol.65.092101.142213; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; Suzuki S, 1998, FEBS LETT, V437, P44, DOI 10.1016/S0014-5793(98)01195-8; TAGUCHI Y, 1984, J BIOL CHEM, V259, P5214; Tanaka S, 2002, J EXP MED, V196, P229, DOI 10.1084/jem.20012037; Tanaka S, 1998, J BIOL CHEM, V273, P8177, DOI 10.1074/jbc.273.14.8177; Tanaka S, 2004, EUR J IMMUNOL, V34, P1472, DOI 10.1002/eji.200324636; Tanaka S, 1997, FEBS LETT, V417, P203, DOI 10.1016/S0014-5793(97)01281-7; TANAKA S, 1995, BBA-PROTEIN STRUCT M, V1253, P9, DOI 10.1016/0167-4838(95)00185-W; Tanaka S, 2006, J PHARMACOL SCI, V101, P19, DOI 10.1254/jphs.FMJ06001X5; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4; YAMAMOTO J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P431, DOI 10.1016/0167-4781(93)90011-2; YAMAMOTO J, 1990, FEBS LETT, V276, P214, DOI 10.1016/0014-5793(90)80545-T; YAMAUCHI K, 1990, NUCLEIC ACIDS RES, V18, P5891, DOI 10.1093/nar/18.19.5891; Yatsunami K, 1995, J BIOL CHEM, V270, P30813, DOI 10.1074/jbc.270.51.30813; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247	49	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13438	13446		10.1074/jbc.M609943200	http://dx.doi.org/10.1074/jbc.M609943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360717	hybrid			2022-12-27	WOS:000246060300033
J	Narita, SI; Tokuda, H				Narita, Shin-ichiro; Tokuda, Hajime			Amino acids at positions 3 and 4 determine the membrane specificity of Pseudomonas aeruginosa lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG EFFLUX SYSTEM; MEXA-MEXB-OPRM; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; FUSION PROTEIN; BACTERIAL LIPOPROTEINS; ANTIBIOTIC EXTRUSION; TRANSPORTER; IDENTIFICATION; TRANSLOCATION	Escherichia coli lipoproteins with Asp at position 2 remain in the inner membrane, whereas those having other amino acids are targeted to the outer membrane by the Lol system. However, inner membrane lipoproteins without Asp at position 2 are found in other Gram-negative bacteria. MexA of Pseudomonas aeruginosa, an inner membrane-specific lipoprotein involved in multidrug efflux, has Gly at position 2. To identify the residue or region of MexA that functions as an inner membrane retention signal, we constructed chimeric lipoproteins comprising various regions of MexA and an outer membrane lipoprotein, OprM, and analyzed their membrane localization. Lys and Ser at positions 3 and 4, respectively, were found to be critical for the inner membrane localization of MexA in P. aeruginosa. Substitution of these residues with Leu and Ile, which are present in OprM, was sufficient to target the chimeric lipoprotein to the outer membrane and to abolish the ability of MexA to confer drug resistance. The membrane specificity of a model lipoprotein, lipoMalE, a lipidated variant of the periplasmic maltose-binding protein of E. coli, was also determined by the residues at positions 3 and 4 in P. aeruginosa. In contrast to the widely accepted "+ 2 rule" for E. coli lipoproteins, these results suggest a new "+ 3, + 4 rule" for lipoprotein sorting in P. aeruginosa, namely, the final destination of lipoproteins is determined by the residues at positions 3 and 4.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	htokuda@iam.u-tokyo.ac.jp		Narita, Shin-ichiro/0000-0001-9425-2943				Akama H, 2004, J BIOL CHEM, V279, P25939, DOI 10.1074/jbc.C400164200; Babu MM, 2006, J BACTERIOL, V188, P2761, DOI 10.1128/JB.188.8.2761-2773.2006; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Eda S, 2006, FEMS MICROBIOL LETT, V254, P101, DOI 10.1111/j.1574-6968.2005.00010.x; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; Guan L, 2001, J BACTERIOL, V183, P1734, DOI 10.1128/JB.183.5.1734-1739.2001; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Higgins MK, 2004, P NATL ACAD SCI USA, V101, P9994, DOI 10.1073/pnas.0400375101; Ikegami A, 2005, BIOSCI BIOTECH BIOCH, V69, P1595, DOI 10.1271/bbb.69.1595; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; KLEIN JR, 1991, MOL GEN GENET, V230, P230, DOI 10.1007/BF00290673; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewenza S, 2005, GENOME RES, V15, P321, DOI 10.1101/gr.3257305; Lewenza S, 2006, J BACTERIOL, V188, P3516, DOI 10.1128/JB.188.10.3516-3524.2006; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; Li XZ, 2001, J BACTERIOL, V183, P12, DOI 10.1128/JB.183.1.12-27.2001; Lim A, 1997, MICROBIOL-SGM, V143, P1709, DOI 10.1099/00221287-143-5-1709; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; Nakajima A, 2000, J BIOL CHEM, V275, P30064, DOI 10.1074/jbc.M005742200; Narita S, 2006, FEBS LETT, V580, P1164, DOI 10.1016/j.febslet.2005.10.038; Narita S, 2002, J BACTERIOL, V184, P1417, DOI 10.1128/JB.184.5.1417-1422.2002; Nehme D, 2005, ANTIMICROB AGENTS CH, V49, P4375, DOI 10.1128/AAC.49.10.4375-4378.2005; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SEIFFER D, 1993, FEMS MICROBIOL LETT, V107, P175; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Tanaka S, 2007, J BIOL CHEM, V282, P13379, DOI 10.1074/jbc.M611840200; TANI K, 1990, J BIOL CHEM, V265, P17341; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; Tokuda H, 2007, PERIPLASM, P67; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; Yoneyama H, 2000, J BIOL CHEM, V275, P4628, DOI 10.1074/jbc.275.7.4628; Yoneyama H, 1998, BIOCHEM BIOPH RES CO, V244, P898, DOI 10.1006/bbrc.1998.8351	39	55	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13372	13378		10.1074/jbc.M611839200	http://dx.doi.org/10.1074/jbc.M611839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350956	hybrid			2022-12-27	WOS:000246060300025
J	Costanzo, G; Saladino, R; Crestini, C; Ciciriello, F; Di Mauro, E				Costanzo, Giovanna; Saladino, Raffaele; Crestini, Claudia; Ciciriello, Fabiana; Di Mauro, Ernesto			Nucleoside phosphorylation by phosphate minerals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREBIOTIC SYNTHESIS; DIFFERENTIAL STABILITY; INFORMATIONAL POLYMERS; NUCLEIC-ACIDS; FORMAMIDE; ORIGIN; HYDROLYSIS; RNA; MONTMORILLONITE; KINETICS	In the presence of formamide, crystal phosphate minerals may act as phosphate donors to nucleosides, yielding both 5 '-and, to a lesser extent, 3 '-phosphorylated forms. With the mineral Libethenite the formation of 5 '-AMP can be as high as 6% of the adenosine input and last for at least 10(3) h. At high concentrations, soluble non-mineral phosphate donors (KH2PO4 or 5 '-CMP) afford 2 '- and 2 ': 3 '-cyclic AMP in addition to 5 '-and 3 '-AMP. The phosphate minerals analyzed were Herderite Ca[BePO4F], Hureaulite Mn2+ (5)(PO3(OH)(2)(PO4)(2)(H2O)(4), Libethenite Cu2+ (2)(PO4)(OH), Pyromorphite Pb-5(PO4)(3)Cl, Turquoise Cu2+ Al-6(PO4)(4)(OH)(8)(H2O)(4), Fluorapatite Ca-5(PO4)(3)F, Hydroxylapatite Ca-5(PO4)(3)OH, Vivianite Fe2+ (3)(PO4)(2)(H2O)(8), Cornetite Cu2+ (3)(PO4)(OH)(3), Pseudomalachite Cu2+ (5)(PO4)(2)(OH)(4), Reichenbachite Cu2+ (5)(PO4)(2)(OH)(4), and Ludjibaite Cu2+ (5)(PO4)(2)(OH)(4)). Based on their behavior in the formamide-driven nucleoside phosphorylation reaction, these minerals can be characterized as: 1) inactive, 2) low level phosphorylating agents, or 3) active phosphorylating agents. Instances were detected (Libethenite and Hydroxylapatite) in which phosphorylation occurs on the mineral surface, followed by release of the phosphorylated compounds. Libethenite and Cornetite markedly protect the beta-glycosidic bond. Thus, activated nucleic monomers can form in a liquid non-aqueous environment in conditions compatible with the thermodynamics of polymerization, providing a solution to the standard-state Gibbs free energy change (Delta G(o,)) problem, the major obstacle for polymerizations in the liquid phase in plausible prebiotic scenarios.	Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Sci & Tecnol Chim, I-00133 Rome, Italy; Univ Tuscia, Dipartimento Agrobiol & Agrochim, I-01100 Viterbo, Italy; CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy	Sapienza University Rome; University of Rome Tor Vergata; Tuscia University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Di Mauro, E (corresponding author), Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	Ernesto.dimauro@uniroma1.it	Crestini, Claudia/O-6781-2015; Ciciriello, Fabiana/AAA-8065-2020	Crestini, Claudia/0000-0001-9903-2675; Ciciriello, Fabiana/0000-0003-1493-9767				ACEVEDO OL, 1986, NATURE, V321, P790, DOI 10.1038/321790a0; Akhter MS, 2003, COLLOID SURFACE A, V219, P281, DOI 10.1016/S0927-7757(03)00055-4; ANSLYN E, 1989, J AM CHEM SOC, V111, P4473, DOI 10.1021/ja00194a050; Bean HD, 2006, ORIGINS LIFE EVOL B, V36, P39, DOI 10.1007/s11084-005-2082-4; BECK A, 1967, SCIENCE, V157, P952, DOI 10.1126/science.157.3791.952; Benner SA, 2005, NAT REV GENET, V6, P533, DOI 10.1038/nrg1637; BRESLOW R, 1990, J AM CHEM SOC, V112, P9621, DOI 10.1021/ja00182a022; CAIRNSSMITH AG, 1966, J THEOR BIOL, V10, P53, DOI 10.1016/0022-5193(66)90178-0; CAIRNSSMITH AG, 1992, ORIGINS LIFE EVOL B, V22, P161, DOI 10.1007/BF01808023; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CORCORAN R, 1985, ANAL BIOCHEM, V144, P563, DOI 10.1016/0003-2697(85)90154-X; DeGraaf RM, 1997, J MOL EVOL, V44, P237, DOI 10.1007/PL00006140; Ertem G, 1998, ORIGINS LIFE EVOL B, V28, P485, DOI 10.1023/A:1006510228943; FERRIS JP, 1992, SCIENCE, V257, P1387, DOI 10.1126/science.1529338; Franchi M, 2003, ORIGINS LIFE EVOL B, V33, P1, DOI 10.1023/A:1023982008714; GERLT JA, 1975, J BIOL CHEM, V250, P5059; Grenha R, 2005, ACTA CRYSTALLOGR F, V61, P459, DOI 10.1107/S174430910501095X; Hartman H, 1998, ORIGINS LIFE EVOL B, V28, P515, DOI 10.1023/A:1006548904157; Hazen RM, 2001, SCI AM, V284, P76, DOI 10.1038/scientificamerican0401-76; Huminicki DMC, 2002, REV MINERAL GEOCHEM, V48, P123, DOI 10.2138/rmg.2002.48.5; JARVINEN P, 1991, J ORG CHEM, V56, P5396, DOI 10.1021/jo00018a037; JONES NR, 1960, ANALYST, V85, P810, DOI 10.1039/an9608500810; JOYCE GF, 1984, J MOL BIOL, V176, P279, DOI 10.1016/0022-2836(84)90425-X; LOHRMANN R, 1968, SCIENCE, V161, P64, DOI 10.1126/science.161.3836.64; LOHRMANN R, 1971, SCIENCE, V171, P490, DOI 10.1126/science.171.3970.490; Millar TJ, 2004, ASTROPHYS SPACE SC L, V305, P17; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; OIVANEN M, 1991, J ORG CHEM, V56, P3623, DOI 10.1021/jo00011a032; PITHA J, 1970, BIOCHIM BIOPHYS ACTA, V204, P39, DOI 10.1016/0005-2787(70)90488-0; Reimann R, 1999, ORIGINS LIFE EVOL B, V29, P229, DOI 10.1023/A:1006580009791; Saladino R, 2006, J BIOL CHEM, V281, P5790, DOI 10.1074/jbc.M512545200; Saladino R, 2005, J BIOL CHEM, V280, P35658, DOI 10.1074/jbc.M504537200; Saladino R, 2005, CHEMBIOCHEM, V6, P1368, DOI 10.1002/cbic.200500035; Saladino R, 2004, CHEMBIOCHEM, V5, P1558, DOI 10.1002/cbic.200400119; Saladino R, 2003, CHEMBIOCHEM, V4, P514, DOI 10.1002/cbic.200300567; Saladino R, 2001, BIOORGAN MED CHEM, V9, P1249, DOI 10.1016/S0968-0896(00)00340-0; Saladino R, 2006, CHEMBIOCHEM, V7, P1707, DOI 10.1002/cbic.200600139; SCHELLERKRATTIGER V, 1986, INORG CHEM, V25, P2628, DOI 10.1021/ic00235a028; SCHNEIDER KC, 1990, J AM CHEM SOC, V112, P453, DOI 10.1021/ja00157a073; SCHOFFSTALL AM, 1988, ORIGINS LIFE EVOL B, V18, P389, DOI 10.1007/BF01808217; SCHOFFSTALL AM, 1976, ORIGINS LIFE EVOL B, V7, P399, DOI 10.1007/BF00927935; SCHOFFSTALL AM, 1985, ORIGINS LIFE EVOL B, V15, P141, DOI 10.1007/BF01809496; SCHOFFSTALL AM, 1982, ORIGINS LIFE EVOL B, V12, P143, DOI 10.1007/BF00927141; Schwartz AW, 1997, ORIGINS LIFE EVOL B, V27, P505, DOI 10.1023/A:1006536817887; Shapiro R, 1999, P NATL ACAD SCI USA, V96, P4396, DOI 10.1073/pnas.96.8.4396; Shirota H, 2004, LANGMUIR, V20, P329, DOI 10.1021/la030161r; Soukup GA, 1999, RNA, V5, P1308, DOI 10.1017/S1355838299990891; USHER DA, 1976, SCIENCE, V192, P53, DOI 10.1126/science.1257755; USHER DA, 1976, P NATL ACAD SCI USA, V73, P1149, DOI 10.1073/pnas.73.4.1149; VANHOLDE K, 1980, ORIGINS LIFE EVOL B, P31; WESTHEIMER FH, 1968, ACCOUNTS CHEM RES, V1, P70, DOI 10.1021/ar50003a002; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; WINTER D, 1995, ORIGINS LIFE EVOL B, V25, P61, DOI 10.1007/BF01581574; YAMAGATA Y, 1991, NATURE, V352, P516, DOI 10.1038/352516a0; Zubay G, 2001, ORIGINS LIFE EVOL B, V31, P87, DOI 10.1023/A:1006722423070	55	90	95	0	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16729	16735		10.1074/jbc.M611346200	http://dx.doi.org/10.1074/jbc.M611346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17412692	Green Published, hybrid			2022-12-27	WOS:000246946500004
J	Saikia, S; Parker, EJ; Koulman, A; Scott, B				Saikia, Sanjay; Parker, Emily J.; Koulman, Albert; Scott, Barry			Defining paxilline biosynthesis in Penicillium paxilli - Functional characterization of two cytochrome p450 monooxygenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIBBERELLA-FUJIKUROI ENCODES; DITERPENE GENE-CLUSTER; INDOLE-DITERPENE; MOLECULAR-CLONING; TRANSFORMATION; REGULATOR; PASPALINE; ENDOPHYTE; PRODUCTS; OXIDASE	Indole diterpenes are a large, structurally and functionally diverse group of secondary metabolites produced by filamentous fungi. Biosynthetic schemes have been proposed for these metabolites but until recently none of the proposed steps had been validated by biochemical or genetic studies. Using Penicillium paxilli as a model experimental system to study indole diterpene biosynthesis we previously showed by deletion analysis that a cluster of seven genes is required for paxilline biosynthesis. Two of these pax genes, paxP and paxQ (encoding cytochrome P450 monooxygenases), are required in the later steps in this pathway. Here, we describe the function of paxP and paxQ gene products by feeding proposed paxilline intermediates to strains lacking the pax cluster but containing ectopically integrated copies of paxP or paxQ. Transformants containing paxP converted paspaline into 13-desoxypaxilline as the major product and beta-PC-M6 as the minor product. beta-PC-M6, but not alpha-PC-M6, was also a substrate for PaxP and was converted to 13-desoxypaxilline. paxQ-containing transformants converted 13-desoxypaxilline into paxilline. These results confirm that paspaline, beta-PC-M6, and 13-desoxypaxilline are paxilline intermediates and that paspaline and beta-PC-M6 are substrates for PaxP, and 13-desoxypaxilline is a substrate for PaxQ. PaxP and PaxQ also utilized beta-paxitriol and beta-PC-M6 as substrates converting them to paxilline and alpha-paxitriol, respectively. These findings have allowed us to delineate clearly the biosynthetic pathway for paxilline for the first time.	Massey Univ, Inst Mol Biosci, Palmerston North, New Zealand; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand; AgResearch, Grassland Res Ctr, Palmerston North, New Zealand	Massey University; Massey University; AgResearch - New Zealand	Scott, B (corresponding author), Massey Univ, Inst Mol Biosci, Private Bag 11222, Palmerston North, New Zealand.	d.b.scott@massey.ac.nz	Scott, David/J-3135-2013; Koulman, Albert/B-2967-2009	Koulman, Albert/0000-0001-9998-051X; Parker, Emily/0000-0002-9571-9987				ACKLIN W, 1977, CHIMIA, V31, P63; Bok JW, 2006, CHEM BIOL, V13, P31, DOI 10.1016/j.chembiol.2005.10.008; Bok JW, 2005, EUKARYOT CELL, V4, P1574, DOI 10.1128/EC.4.9.1574-1582.2005; Bok JW, 2004, EUKARYOT CELL, V3, P527, DOI 10.1128/EC.3.2.527-535.2004; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Byrne KM, 2002, J AM CHEM SOC, V124, P7055, DOI 10.1021/ja017183p; Chiou CH, 2002, APPL ENVIRON MICROB, V68, P306, DOI 10.1128/AEM.68.1.306-315.2002; DE JESUS AE, 1983, J CHEM SOC PERK T 1, P1863, DOI 10.1039/p19830001863; FISCHER RT, 1989, J LIPID RES, V30, P1621; Gatenby WA, 1999, J AGR FOOD CHEM, V47, P1092, DOI 10.1021/jf980767z; GLOER JB, 1995, ACCOUNTS CHEM RES, V28, P343, DOI 10.1021/ar00056a004; ITOH Y, 1994, CURR GENET, V25, P508, DOI 10.1007/BF00351670; Kawaide H, 2006, BIOSCI BIOTECH BIOCH, V70, P583, DOI 10.1271/bbb.70.583; Lamb DC, 1999, FEBS LETT, V462, P283, DOI 10.1016/S0014-5793(99)01548-3; LAWS I, 1989, J GEN MICROBIOL, V135, P2679; Malonek S, 2005, APPL ENVIRON MICROB, V71, P1462, DOI 10.1128/AEM.71.3.1462-1472.2005; MANTLE PG, 1994, PHYTOCHEMISTRY, V36, P1209, DOI 10.1016/S0031-9422(00)89639-9; McMillan LK, 2003, MOL GENET GENOMICS, V270, P9, DOI 10.1007/s00438-003-0887-2; Mihlan M, 2003, MOL MICROBIOL, V47, P975, DOI 10.1046/j.1365-2958.2003.03326.x; MILES CO, 1992, J AGR FOOD CHEM, V40, P234, DOI 10.1021/jf00014a013; MundayFinch SC, 1996, PHYTOCHEMISTRY, V41, P327, DOI 10.1016/0031-9422(95)00515-3; Namiki F, 2001, MOL PLANT MICROBE IN, V14, P580, DOI 10.1094/MPMI.2001.14.4.580; Parker EJ, 2005, MYCOLOGY S, V22, P405; PENN J, 1994, PHYTOCHEMISTRY, V35, P921, DOI 10.1016/S0031-9422(00)90639-3; Ro DK, 2005, P NATL ACAD SCI USA, V102, P8060, DOI 10.1073/pnas.0500825102; Rojas MC, 2001, P NATL ACAD SCI USA, V98, P5838, DOI 10.1073/pnas.091096298; Saikia S, 2006, FEBS LETT, V580, P1625, DOI 10.1016/j.febslet.2006.02.008; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT B, 2004, ADV FUNGAL BIOTECHNO, P163; Steyn P S, 1985, Fortschr Chem Org Naturst, V48, P1; SUZUKI K, 1993, BIOCHIM BIOPHYS ACTA, V1203, P215, DOI 10.1016/0167-4838(93)90086-7; Tudzynski B, 2005, APPL MICROBIOL BIOT, V66, P597, DOI 10.1007/s00253-004-1805-1; Tudzynski B, 1999, MOL GEN GENET, V261, P106, DOI 10.1007/s004380050950; Tudzynski B, 2001, APPL ENVIRON MICROB, V67, P3514, DOI 10.1128/AEM.67.8.3514-3522.2001; Yoder OC, 1988, ADV PLANT PATHOL, P93, DOI 10.1016/B978-0-12-033706-4.50009-8; Young C, 1998, CURR GENET, V33, P368, DOI 10.1007/s002940050349; Young C, 2001, MOL MICROBIOL, V39, P754, DOI 10.1046/j.1365-2958.2001.02265.x; Young CA, 2005, MOL GENET GENOMICS, V274, P13, DOI 10.1007/s00438-005-1130-0; Young CA, 2006, FUNGAL GENET BIOL, V43, P679, DOI 10.1016/j.fgb.2006.04.004; Zhang S, 2004, APPL ENVIRON MICROB, V70, P6875, DOI 10.1128/AEM.70.11.6875-6883.2004	40	45	48	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16829	16837		10.1074/jbc.M701626200	http://dx.doi.org/10.1074/jbc.M701626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17428785	hybrid			2022-12-27	WOS:000246946500015
J	DeFord-Watts, LM; Young, JA; Pitcher, LA; van Oers, NSC				DeFord-Watts, Laura M.; Young, Jennifer A.; Pitcher, Lisa A.; van Oers, Nicolai S. C.			The membrane-proximal portion of CD3 is an element of associates with the serine/threonine kinase GRK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; TCR-ZETA SUBUNIT; ANTIGEN RECEPTOR; TYROSINE KINASES; PROTEIN-KINASE; DEPENDENT DEGRADATION; SIGNAL-TRANSDUCTION; ACTIVATION; CD3-EPSILON; PHOSPHORYLATION	The activation of protein kinases is one of the primary mechanisms whereby T cell receptors (TCR) propagate intracellular signals. To date, the majority of kinases known to be involved in the early stages of TCR signaling are protein-tyrosine kinases such as Lck, Fyn, and ZAP-70. Here we report a constitutive association between the TCR and a serine/threonine kinase, which was mediated through the membrane-proximal portion of CD3 epsilon. Mass spectrometry analysis of CD3 epsilon-associated proteins identified G protein-coupled receptor kinase 2 (GRK2) as a candidate Ser/Thr kinase. Transient transfection assays and Western blot analysis verified the ability of GRK2 to interact with the cytoplasmic domain of CD3 epsilon within a cell. These findings are consistent with recent reports demonstrating the ability of certain G protein-coupled receptors (GPCR) and G proteins to physically associate with the alpha/beta TCR. Because GRK2 is primarily involved in arresting GPCR signals, its interaction with CD3 epsilon may provide a novel means whereby the TCR can negatively regulate signals generated through GPCRs.	Univ Texas, Dept Immunol, Southwestern Med Ctr, Dallas, TX 75390 USA; Univ Texas, Dept Microbiol, Southwestern Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	van Oers, NSC (corresponding author), Univ Texas, Dept Immunol, Southwestern Med Ctr, Dallas, TX 75390 USA.	nicolai.vanoers@utsouthwestern.edu	Van+Oers, Nicolai/ABA-2437-2021	van Oers, Nicolai/0000-0002-6545-8405	NIAID NIH HHS [5T32AI005284] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI005284] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alarcon B, 2003, IMMUNOL REV, V191, P38, DOI 10.1034/j.1600-065X.2003.00017.x; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; Call ME, 2005, ANNU REV IMMUNOL, V23, P101, DOI 10.1146/annurev.immunol.23.021704.115625; Cen O, 2003, J BIOL CHEM, V278, P8837, DOI 10.1074/jbc.M208261200; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; DeJarnette JB, 1998, P NATL ACAD SCI USA, V95, P14909, DOI 10.1073/pnas.95.25.14909; Elorza A, 2000, MOL PHARMACOL, V57, P778, DOI 10.1124/mol.57.4.778; Elorza A, 2003, J BIOL CHEM, V278, P29164, DOI 10.1074/jbc.M304314200; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Gil D, 2002, CELL, V109, P901, DOI 10.1016/S0092-8674(02)00799-7; Gil D, 2001, J BIOL CHEM, V276, P11174, DOI 10.1074/jbc.M010114200; Hernandez-Lopez C, 2002, BLOOD, V99, P546, DOI 10.1182/blood.V99.2.546; Krasel C, 2001, J BIOL CHEM, V276, P1911, DOI 10.1074/jbc.M008773200; Kumar A, 2006, IMMUNITY, V25, P213, DOI 10.1016/j.immuni.2006.06.015; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Lombardi MS, 1999, FASEB J, V13, P715, DOI 10.1096/fasebj.13.6.715; Loza MJ, 2006, BLOOD, V107, P2052, DOI 10.1182/blood-2005-08-3265; Lysechko TL, 2005, J IMMUNOL, V174, P7807, DOI 10.4049/jimmunol.174.12.7807; Malissen B, 2003, IMMUNOL REV, V191, P7, DOI 10.1034/j.1600-065X.2003.00016.x; Minguet S, 2007, IMMUNITY, V26, P43, DOI 10.1016/j.immuni.2006.10.019; Mor A, 2006, ANNU REV IMMUNOL, V24, P771, DOI 10.1146/annurev.immunol.24.021605.090723; Nakano H, 1996, J BIOL CHEM, V271, P6483, DOI 10.1074/jbc.271.11.6483; Osman N, 1996, EUR J IMMUNOL, V26, P1063, DOI 10.1002/eji.1830260516; Ottoson NC, 2001, J IMMUNOL, V167, P1857, DOI 10.4049/jimmunol.167.4.1857; Peacock JW, 1999, J IMMUNOL, V162, P215; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SHINKAI Y, 1995, IMMUNITY, V2, P401; Sommers CL, 2000, J EXP MED, V192, P913, DOI 10.1084/jem.192.6.913; SONG WH, 1995, NUCLEIC ACIDS RES, V23, P3609, DOI 10.1093/nar/23.17.3609; Stanners J, 1995, J BIOL CHEM, V270, P30635, DOI 10.1074/jbc.270.51.30635; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Szymczak AL, 2005, J IMMUNOL, V175, P270, DOI 10.4049/jimmunol.175.1.270; Theilade J., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P139, DOI 10.2174/1568008013341352; Tong A, 2005, J BIOL CHEM, V280, P38297, DOI 10.1074/jbc.M508123200; Tsuchida M, 1999, J BIOL CHEM, V274, P6735, DOI 10.1074/jbc.274.10.6735; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VANOERS NSC, 1995, J EXP MED, V182, P1585, DOI 10.1084/jem.182.5.1585; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang BH, 1998, PLANTA MED, V64, P195, DOI 10.1055/s-2006-957407; Yamazaki T, 1999, J BIOL CHEM, V274, P18173, DOI 10.1074/jbc.274.26.18173	51	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16126	16134		10.1074/jbc.M609418200	http://dx.doi.org/10.1074/jbc.M609418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17420248	hybrid			2022-12-27	WOS:000246794300021
J	Kroh, HK; Tans, G; Nicolaes, GAF; Rosing, J; Bock, PE				Kroh, Heather K.; Tans, Guido; Nicolaes, Gerry A. F.; Rosing, Jan; Bock, Paul E.			Expression of allosteric linkage between the sodium ion binding site and exosite I of thrombin during prothrombin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-V ACTIVATION; MACROMOLECULAR SUBSTRATE RECOGNITION; BLOOD-COAGULATION PROTEINASES; PEPTIDE CHLOROMETHYL KETONES; FACTOR-XA; ACTIVE-SITE; NA+ BINDING; FLUORESCENCE PROBES; CRYSTAL-STRUCTURE; SERINE PROTEASES	The specificity of thrombin for procoagulant and anticoagulant substrates is regulated allosterically by Na+. Ordered cleavage of prothrombin (ProT) at Arg(320) by the prothrombinase complex generates proteolytically active, meizothrombin (MzT), followed by cleavage at Arg(271) to produce thrombin and fragment 1.2. The alternative pathway of initial cleavage at Arg271 produces the inactive zymogen form, the prethrombin 2 (Pre 2).fragment 1.2 complex, which is cleaved subsequently at Arg320. Cleavage at Arg320 of ProT or prethrombin 1 ( Pre 1) activates the catalytic site and the precursor form of exosite I (proexosite I). To determine the pathway of expression of Na+ (pro) exosite I linkage during ProT activation, the effects of Na+ on the affinity of fluorescein-labeled hirudin-(54-65) ([5F] Hir-(54-65)(SO3-)) for the zymogens, ProT, Pre 1, and Pre 2, and for the proteinases, MzT and MzT-desfragment 1 ( MzT(-F1)) were quantitated. The zymogens showed no significant linkage between proexosite I and Na+, whereas cleavage at Arg320 caused the affinities of MzT and MzT(-F1) for [5F] Hir-(54-65)(SO3-) to be enhanced by Na+ 8- to 10-fold and 5- to 6-fold, respectively. MzT and MzT-(F1) showed kinetically different mechanisms of Na+ enhancement of chromogenic substrate hydrolysis. The results demonstrate for the first time that MzT is regulated allosterically by Na+. The results suggest that the distinctive procoagulant substrate specificity of MzT, in activating factor V and factor VIII on membranes, and the anticoagulant, membrane-modulated activation of protein C by MzT bound to thrombomodulin are regulated by Na+- induced allosteric transition. Further, the Na+ enhancement in MzT activity and exosite I affinity may function in directing the sequential ProT activation pathway by accelerating thrombin formation from the MzT fast form.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Univ Maastricht, Dept Biochem, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands	Vanderbilt University; Maastricht University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37232 USA.	paul.bock@vanderbilt.edu	Nicolaes, Gerry A.F./A-8421-2016	Nicolaes, Gerry A.F./0000-0002-2482-0412	NHLBI NIH HHS [R01 HL038779-21, HL 07751, R01 HL038779, HL038779] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038779, R01HL038779, T32HL007751] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2003, J BIOL CHEM, V278, P44482, DOI 10.1074/jbc.M306917200; Anderson PJ, 2003, J BIOL CHEM, V278, P44489, DOI 10.1074/jbc.M306916200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; Arocas V, 1998, THROMB HAEMOSTASIS, V79, P1157, DOI 10.1055/s-0037-1615033; AYALA YM, 1995, J MOL BIOL, V253, P787, DOI 10.1006/jmbi.1995.0591; Bah A, 2006, J BIOL CHEM, V281, P40049, DOI 10.1074/jbc.M608600200; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bianchini EP, 2005, P NATL ACAD SCI USA, V102, P10099, DOI 10.1073/pnas.0504704102; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Bode W, 2005, J THROMB HAEMOST, V3, P2379, DOI 10.1111/j.1538-7836.2005.01356.x; Bode W, 2006, BLOOD CELL MOL DIS, V36, P122, DOI 10.1016/j.bcmd.2005.12.027; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Bukys MA, 2006, J BIOL CHEM, V281, P18569, DOI 10.1074/jbc.M600752200; Carrell CJ, 2006, BIOPHYS CHEM, V121, P177, DOI 10.1016/j.bpc.2005.12.008; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; COTE HCF, 1994, J BIOL CHEM, V269, P11374; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; Di Cera E, 2004, CR BIOL, V327, P1065, DOI 10.1016/j.crvi.2004.07.011; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1982, J BIOL CHEM, V257, P7944; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Griffon N, 2001, BIOPHYS CHEM, V90, P89, DOI 10.1016/S0301-4622(01)00129-6; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; Huntington JA, 2005, J THROMB HAEMOST, V3, P1861, DOI 10.1111/j.1538-7836.2005.01363.x; Krishnaswamy S, 2005, J THROMB HAEMOST, V3, P54, DOI 10.1111/j.1538-7836.2004.01021.x; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; Orcutt SJ, 2004, J BIOL CHEM, V279, P54927, DOI 10.1074/jbc.M410866200; Orcutt SJ, 2002, J BIOL CHEM, V277, P46191, DOI 10.1074/jbc.M208677200; Page MJ, 2005, J THROMB HAEMOST, V3, P2401, DOI 10.1111/j.1538-7836.2005.01456.x; Petrovan RJ, 1998, BIOCHEMISTRY-US, V37, P1185, DOI 10.1021/bi971948h; Pineda AO, 2006, J BIOL CHEM, V281, P32922, DOI 10.1074/jbc.M605530200; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Prasad S, 2004, J BIOL CHEM, V279, P10103, DOI 10.1074/jbc.M312614200; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Segel I.H., 1993, ENZYME KINETICS, P227; TANS G, 1994, J BIOL CHEM, V269, P15969; TANS G, 1991, J BIOL CHEM, V266, P21864; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Wilkens M, 2002, J BIOL CHEM, V277, P9366, DOI 10.1074/jbc.M110848200; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	61	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16095	16104		10.1074/jbc.M610577200	http://dx.doi.org/10.1074/jbc.M610577200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17430903	Green Accepted, hybrid			2022-12-27	WOS:000246794300018
J	Viana, R; Towler, MC; Pan, DA; Carling, D; Viollet, B; Hardie, DG; Sanz, P				Viana, Rosa; Towler, Mhairi C.; Pan, David A.; Carling, David; Viollet, Benoit; Hardie, D. Grahame; Sanz, Pascual			A conserved sequence immediately N-terminal to the Bateman domains in AMP-activated protein kinase gamma subunits is required for the interaction with the beta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSON-WHITE-SYNDROME; SKELETAL-MUSCLE; HYPERTROPHIC CARDIOMYOPATHY; CARDIAC-HYPERTROPHY; IN-VITRO; MUTATIONS; DISEASE; GLUCOSE; GLYCOGEN; SYSTEM	Mammalian AMP-activated protein kinase is a serine/threonine protein kinase that acts as a sensor of cellular energy status. AMP-activated protein kinase is a heterotrimer of three different subunits, i.e. alpha, beta and gamma, with alpha being the catalytic subunit and beta and gamma having regulatory roles. Although several studies have defined different domains in alpha and beta involved in the interaction with the other subunits of the complex, little is known about the regions of the gamma subunits involved in these interactions. To study this, we have made sequential deletions from the N termini of the gamma subunit isoforms and studied the interactions with alpha and beta subunits, both by two-hybrid analysis and by co-immunoprecipitation. Our results suggest that a conserved region of 20-25 amino acids in gamma 1, gamma 2, and gamma 3, immediately N-terminal to the Bateman domains, is required for the formation of a functional, active alpha beta gamma complex. This region is required for the interaction with the beta subunits. The interaction between the beta and gamma subunits does not require this region and occurs instead within the Bateman domains of the gamma subunit, although the beta-gamma interaction does appear to stabilize the beta-gamma interaction. In addition, sequential deletions from the C termini of the gamma subunits indicate that deletion of any of the CBS (cystathionine beta-synthase) motifs prevents the formation of a functional complex with the alpha and beta subunits.	Consejo Super Invest Cientificas, Inst Biomed Valencia, Valencia 46010, Spain; Inst Salud Carlos 3, Ctr Invest Biomed Red Enfermedades Raras, Valencia 46010, Spain; Hammersmith Hosp, Imp Coll, Med Res Ctr, Clin Sci Ctr,Cellular Stress Grp, London W12 0NN, England; Univ Dundee, Coll Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; Univ Paris 05, Inst Cochin, CNRS, UMR 8104, F-75014 Paris, France; INSERM, U567, F-75014 Paris, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Imperial College London; University of Dundee; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Sanz, P (corresponding author), Consejo Super Invest Cientificas, Inst Biomed Valencia, Jaime Roig 11, Valencia 46010, Spain.	sanz@ibv.csic.es	Carling, David/F-1943-2014; Viana, Rosa/L-1922-2014; Sanz, Pascual/K-2751-2014; Viollet, Benoit/N-2397-2019; Hardie, David/Z-1979-2019; Viollet, Benoit/O-6927-2017	Carling, David/0000-0002-2316-1830; Viana, Rosa/0000-0002-0036-0669; Sanz, Pascual/0000-0002-2399-4103; Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Hardie, Grahame/0000-0002-8373-7379	Medical Research Council [MC_U120027537] Funding Source: Medline; Wellcome Trust [080982] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ahmad F, 2005, ANNU REV GENOM HUM G, V6, P185, DOI 10.1146/annurev.genom.6.080604.162132; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Burwinkel B, 2005, AM J HUM GENET, V76, P1034, DOI 10.1086/430840; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; Daniel T, 2002, J BIOL CHEM, V277, P51017, DOI 10.1074/jbc.M207093200; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Gimeno-Alcaniz JV, 2003, J MOL BIOL, V333, P201, DOI 10.1016/j.jmb.2003.08.022; GOLEMIS EA, 1997, CURRENT PROTOCOLS MO, P201; Gollob MH, 2001, CIRCULATION, V104, P3030, DOI 10.1161/hc5001.102111; Gollob MH, 2001, NEW ENGL J MED, V344, P1823, DOI 10.1056/NEJM200106143442403; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 2000, METH MOL B, V99, P63; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Iseli TJ, 2005, J BIOL CHEM, V280, P13395, DOI 10.1074/jbc.M412993200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jiang R, 1996, GENE DEV, V10, P3105, DOI 10.1101/gad.10.24.3105; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Leech A, 2003, EUKARYOT CELL, V2, P265, DOI 10.1128/EC.2.2.265-273.2003; LEGRAIN P, 1994, NUCLEIC ACIDS RES, V22, P3241, DOI 10.1093/nar/22.15.3241; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Polekhina G, 2005, STRUCTURE, V13, P1453, DOI 10.1016/j.str.2005.07.008; Rose MD., 1990, METHODS YEAST GENETI; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Thornton C, 1998, J BIOL CHEM, V273, P12443, DOI 10.1074/jbc.273.20.12443; Townley R, 2007, SCIENCE, V315, P1726, DOI 10.1126/science.1137503; Wojtaszewski JFP, 2005, J PHYSIOL-LONDON, V564, P563, DOI 10.1113/jphysiol.2005.082669; Wong KA, 2006, J BIOL CHEM, V281, P36434, DOI 10.1074/jbc.M607410200; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4	41	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16117	16125		10.1074/jbc.M611804200	http://dx.doi.org/10.1074/jbc.M611804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17403675	Green Accepted, hybrid, Green Submitted			2022-12-27	WOS:000246794300020
J	Unno, H; Ichimaida, F; Suzuki, H; Takahashi, S; Tanaka, Y; Saito, A; Nishino, T; Kusunoki, M; Nakayama, T				Unno, Hideaki; Ichimaida, Fumiko; Suzuki, Hirokazu; Takahashi, Seiji; Tanaka, Yoshikazu; Saito, Atsushi; Nishino, Tokuzo; Kusunoki, Masami; Nakayama, Toru			Structural and mutational studies of anthocyanin malonyltransferases establish the features of BAHD enzyme catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALVIA-SPLENDENS FLOWERS; CRYSTAL-STRUCTURE; CDNA CLONING; ACYLTRANSFERASE; MECHANISM; COA; 5-O-GLUCOSIDE-6'''-O-MALONYLTRANSFERASE; ACETYLTRANSFERASE; MALONYLATION; EXPRESSION	The BAHD family is a class of acyl-CoA-dependent acyltransferases that are involved in plant secondary metabolism and show a diverse range of specificities for acyl acceptors. Anthocyanin acyltransferases make up an important class of the BAHD family and catalyze the acylation of anthocyanins that are responsible for most of the red-to-blue colors of flowers. Here, we describe crystallographic and mutational studies of three similar anthocyanin malonyltransferases from red chrysanthemum petals: anthocyanidin 3O-glucoside-6 ''-O-malonyltransferase ( Dm3MaT1), anthocyanidin 3-O-glucoside-3 '', 6 ''-O-dimalonyltransferase (Dm3MaT2), and a homolog ( Dm3MaT3). Mutational analyses revealed that seven amino acid residues in the N- and C-terminal regions are important for the differential acyl-acceptor specificity between Dm3MaT1 and Dm3MaT2. Crystallographic studies of Dm3MaT3 provided the first structure of a BAHD member, complexed with acyl-CoA, showing the detailed interactions between the enzyme and acyl-CoA molecules. The structure, combined with the results of mutational analyses, allowed us to identify the acyl-acceptor binding site of anthocyanin malonyltransferases, which is structurally different from the corresponding portion of vinorine synthase, another BAHD member, thus permitting the diversity of the acyl-acceptor specificity of BAHD family to be understood.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Sun Res Ctr, Osaka 6188503, Japan	Osaka University; Tohoku University	Kusunoki, M (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kusunoki@protein.osaka-u.ac.jp; nakayama@seika.che.tohoku.ac.jp	Suzuki, Hirokazu/AAG-2285-2020; Hideaki, UNNO/ABG-9471-2020	Suzuki, Hirokazu/0000-0002-9507-6467; Hideaki, UNNO/0000-0001-5917-269X; Takahashi, Seiji/0000-0002-2288-4340				Buglino J, 2004, J BIOL CHEM, V279, P30634, DOI 10.1074/jbc.M404011200; D'Auria JC, 2006, CURR OPIN PLANT BIOL, V9, P331, DOI 10.1016/j.pbi.2006.03.016; DeLano W.L, PYMOL MOL GRAPHICS S; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Fujiwara H, 1998, PLANT J, V16, P421, DOI 10.1046/j.1365-313x.1998.00312.x; INO I, 1993, PHYTOCHEMISTRY, V32, P1425, DOI 10.1016/0031-9422(93)85151-G; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakayama T, 2003, J MOL CATAL B-ENZYM, V23, P117, DOI 10.1016/S1381-1177(03)00078-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Segel IH, 1975, ENZYME KINETICS, P623; St-Pierre B, 1998, PLANT J, V14, P703, DOI 10.1046/j.1365-313x.1998.00174.x; St-Pierre B, 2000, RECENT ADV PHYTOCHEM, V34, P285, DOI 10.1016/S0079-9920(00)80010-6; Strack D., 1994, FLAVONOIDS ADV RES 1, P1; Suzuki H, 2004, PLANT J, V38, P994, DOI 10.1111/j.1365-313X.2004.02101.x; Suzuki H, 2003, BIOCHEMISTRY-US, V42, P1764, DOI 10.1021/bi020618g; Suzuki H, 2002, PLANT PHYSIOL, V130, P2142, DOI 10.1104/pp.010447; Suzuki H, 2001, J BIOL CHEM, V276, P49013, DOI 10.1074/jbc.M108444200; Suzuki H., 2003, PLANT BIOTECHNOL-NAR, V20, P229, DOI [10.5511/plantbiotechnology.20.229, DOI 10.5511/PLANTBIOTECHNOLOGY.20.229]; Taguchi G, 2005, PLANT J, V42, P481, DOI 10.1111/j.1365-313X.2005.02387.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Yonekura-Sakakibara K, 2000, PLANT CELL PHYSIOL, V41, P495, DOI 10.1093/pcp/41.4.495	30	69	76	5	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15812	15822		10.1074/jbc.M700638200	http://dx.doi.org/10.1074/jbc.M700638200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17383962	hybrid			2022-12-27	WOS:000246589600056
J	Zhang, JP; Vinuela, A; Neely, MH; Hallett, PJ; Grant, SGN; Miller, GM; Isacson, O; Caron, MG; Yao, WD				Zhang, Jingping; Vinuela, Angel; Neely, Mark H.; Hallett, Penelope J.; Grant, Seth G. N.; Miller, Gregory M.; Isacson, Ole; Caron, Marc G.; Yao, Wei-Dong			Inhibition of the dopamine D1 receptor signaling by PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; AGONIST-INDUCED DESENSITIZATION; D-ASPARTATE RECEPTORS; POSTSYNAPTIC DENSITY; CEREBRAL-CORTEX; D-1 RECEPTOR; PROTEIN; INTERNALIZATION; MEMBRANE; DYNAMIN	Dopamine D1 receptors play an important role in movement, reward, and learning and are implicated in a number of neurological and psychiatric disorders. These receptors are concentrated in dendritic spines of neurons, including the spine head and the postsynaptic density. D1 within spines is thought to modulate the local channels and receptors to control the excitability and synaptic properties of spines. The molecular mechanisms mediating D1 trafficking, anchorage, and function in spines remain elusive. Here we show that the synaptic scaffolding protein PSD-95 thought to play a role in stabilizing glutamate receptors in the postsynaptic density, interacts with D1 and regulates its trafficking and function. Interestingly, the D1-PSD-95 interaction does not require the well characterized domains of PSD-95 but is mediated by the carboxyl-terminal tail of D1 and the NH2 terminus of PSD-95, a region that is recognized only recently to participate in protein-protein interaction. Co-expression of PSD-95 with D1 in mammalian cells inhibits the D1-mediated cAMP accumulation without altering the total expression level or the agonist binding properties of the receptor. The diminished D1 signaling is mediated by reduced D1 expression at the cell surface as a consequence of an enhanced constitutive, dynamin-dependent endocytosis. In addition, genetically engineered mice lacking PSD-95 show a heightened behavioral response to either a D1 agonist or the psychostimulant amphetamine. These studies demonstrate a role for a glutamatergic scaffold in dopamine receptor signaling and trafficking and identify a new potential target for the modulation of abnormal dopaminergic function.	Harvard Univ, Sch Med, Dept Psychiat, New England Primate Res Ctr, Southborough, MA 01772 USA; Harvard Univ, Sch Med, McLean Hosp, Neuroregenerat Lab, Belmont, MA 02478 USA; Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Harvard University; Harvard University; McLean Hospital; Wellcome Trust Sanger Institute; Duke University	Yao, WD (corresponding author), Harvard Univ, Sch Med, Dept Psychiat, New England Primate Res Ctr, 1 Pine Hill Dr, Southborough, MA 01772 USA.	wei-dong_yao@hms.harvard.edu	Zhang, Jingping/ABA-4179-2020	Zhang, Jingping/0000-0002-7800-9617; Hallett, Penelope/0000-0002-8858-9096; Isacson, Ole/0000-0001-8091-8302; Grant, Seth/0000-0001-8732-8735	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168, K26RR000168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS039793] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00168, P51 RR000168-430106, P51 RR000168, K26 RR000168] Funding Source: Medline; NINDS NIH HHS [P50 NS039793, P50 NS039793-08, P50 NS039793-07, P50 NS39793] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bergson C, 1995, J NEUROSCI, V15, P7821; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bibb JA, 2005, CELL, V122, P153, DOI 10.1016/j.cell.2005.07.011; Bozzi Y, 2006, TRENDS NEUROSCI, V29, P167, DOI 10.1016/j.tins.2006.01.002; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CEPEDA C, 2006, SCI STKE, V333, pPE20; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; Elias GM, 2006, NEURON, V52, P307, DOI 10.1016/j.neuron.2006.09.012; Fiorentini C, 2003, J BIOL CHEM, V278, P20196, DOI 10.1074/jbc.M213140200; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOLDMANRAKIC PS, 1989, P NATL ACAD SCI USA, V86, P9015, DOI 10.1073/pnas.86.22.9015; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; HERSCH SM, 1995, J NEUROSCI, V15, P5222; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hunt CA, 1996, J NEUROSCI, V16, P1380; Jassen AK, 2006, MOL PHARMACOL, V70, P71, DOI 10.1124/mol.105.021998; Jiang D, 1999, MOL PHARMACOL, V56, P675; Kalia LV, 2006, EMBO J, V25, P4971, DOI 10.1038/sj.emboj.7601342; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kim OJ, 2002, J NEUROSCI, V22, P5920; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lachowicz JE, 1997, PHARMACOL TOXICOL, V81, P105, DOI 10.1111/j.1600-0773.1997.tb00039.x; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; LEVEY AI, 1993, P NATL ACAD SCI USA, V90, P8861, DOI 10.1073/pnas.90.19.8861; Lezcano N, 2000, SCIENCE, V287, P1660, DOI 10.1126/science.287.5458.1660; Li ZR, 2006, J BIOL CHEM, V281, P11066, DOI 10.1074/jbc.M600113200; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; Niethammer M, 1996, J NEUROSCI, V16, P2157; Pei L, 2004, J NEUROSCI, V24, P1149, DOI 10.1523/JNEUROSCI.3922-03.2004; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Schluter OM, 2006, NEURON, V51, P99, DOI 10.1016/j.neuron.2006.05.016; Sesack SR, 2003, ANN NY ACAD SCI, V1003, P36, DOI 10.1196/annals.1300.066; SMILEY JF, 1994, P NATL ACAD SCI USA, V91, P5720, DOI 10.1073/pnas.91.12.5720; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; Stein V, 2003, J NEUROSCI, V23, P5503; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Xia ZQ, 2003, J BIOL CHEM, V278, P21901, DOI 10.1074/jbc.M301905200; Yao WD, 2004, NEURON, V41, P625, DOI 10.1016/S0896-6273(04)00048-0; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	53	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15778	15789		10.1074/jbc.M611485200	http://dx.doi.org/10.1074/jbc.M611485200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17369255	hybrid, Green Accepted			2022-12-27	WOS:000246589600053
J	Castello, PR; Drechsel, DA; Patel, M				Castello, Pablo R.; Drechsel, Derek A.; Patel, Manisha			Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVIRONMENTAL RISK-FACTORS; PARKINSONS-DISEASE; RESPIRATORY-CHAIN; HYDROGEN-PEROXIDE; SUPEROXIDE; TOXICITY; MANEB; NEUROTOXICITY; GLUTATHIONE; MECHANISM	Paraquat (PQ(2+)) is a prototypic toxin known to exert injurious effects through oxidative stress and bears a structural similarity to the Parkinson disease toxicant, 1-methyl-4-pheynlpyridinium. The cellular sources of PQ(2+)- induced reactive oxygen species (ROS) production, specifically in neuronal tissue, remain to be identified. The goal of this study was to determine the involvement of brain mitochondria in PQ(2+)-induced ROS production. Highly purified rat brain mitochondria were obtained using a Percoll density gradient method. PQ(2+)-induced hydrogen peroxide (H2O2) production was measured by fluorometric and polarographic methods. The production of H2O2 was evaluated in the presence of inhibitors and modulators of the mitochondrial respiratory chain. The results presented here suggest that in the rat brain, ( a) mitochondria are a principal cellular site of PQ(2+)-induced H2O2 production, (b) PQ(2+)-induced H2O2 production requires the presence of respiratory substrates, (c) complex III of the electron transport chain is centrally involved in H2O2 production by PQ(2+), and (d) the mechanism by which PQ(2+) generates H2O2 depends on the mitochondrial inner transmembrane potential. These observations were further confirmed by measuringPQ(2+)-induced H2O2 production in primary neuronal cells derived from the midbrain. These findings shed light on the mechanism through which mitochondria may contribute to ROS production by other environmental and endogenous redox cycling agents implicated in Parkinson's disease.	Univ Colorado, Dept Pharmaceut Sci, Denver, CO 80262 USA; Ctr Hlth Sci, Denver, CO 80262 USA	University of Colorado System; University of Colorado Denver	Patel, M (corresponding author), Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,C238, Denver, CO 80262 USA.	manisha.patel@uchsc.edu	Castello, Pablo R/AAL-7069-2021		NINDS NIH HHS [NS045748, R01 NS045748, R01 NS045748-05A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045748] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson MF, 2000, BRAIN RES PROTOC, V5, P95, DOI 10.1016/S1385-299X(99)00060-4; Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Aoki S, 2002, MED MYCOL, V40, P13, DOI 10.1080/mmy.40.1.13.19; Arkblad EL, 2005, FREE RADICAL BIO MED, V38, P1518, DOI 10.1016/j.freeradbiomed.2005.02.012; Bishop AL, 2007, MOL MICROBIOL, V63, P507, DOI 10.1111/j.1365-2958.2006.05504.x; BLASZCZYNSKI M, 1985, ACTA MICROBIOL POL, V34, P243; Bonilla E, 2006, NEUROCHEM RES, V31, P1425, DOI 10.1007/s11064-006-9194-8; Bove Jordi, 2005, NeuroRx, V2, P484, DOI 10.1602/neurorx.2.3.484; BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Cicchetti F, 2005, NEUROBIOL DIS, V20, P360, DOI 10.1016/j.nbd.2005.03.018; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Day BJ, 1999, P NATL ACAD SCI USA, V96, P12760, DOI 10.1073/pnas.96.22.12760; Di Monte DA, 2003, LANCET NEUROL, V2, P531, DOI 10.1016/S1474-4422(03)00501-5; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; FUKUSHIMA T, 1995, J NEUROSCI RES, V42, P385, DOI 10.1002/jnr.490420313; Gomez C, 2007, FRONT BIOSCI-LANDMRK, V12, P1079, DOI 10.2741/2128; GRANT HC, 1980, HISTOPATHOLOGY, V4, P185, DOI 10.1111/j.1365-2559.1980.tb02911.x; HUGHES JT, 1988, NEUROTOXICOLOGY, V9, P243; ILETT KF, 1974, TOXICOL APPL PHARM, V28, P216, DOI 10.1016/0041-008X(74)90007-6; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; MASON RP, 1990, ENVIRON HEALTH PERSP, V87, P237, DOI 10.2307/3431031; Matsuno-Yagi A, 2001, J BIOL CHEM, V276, P19006, DOI 10.1074/jbc.M101446200; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; MONTGOMERY MR, 1976, TOXICOL APPL PHARM, V36, P543, DOI 10.1016/0041-008X(76)90233-7; Nicholls DG, 2004, AGING CELL, V3, P35, DOI 10.1111/j.1474-9728.2003.00079.x; PALMEIRA CM, 1995, BBA-BIOENERGETICS, V1229, P187, DOI 10.1016/0005-2728(94)00202-G; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; Peng J, 2004, J BIOL CHEM, V279, P32626, DOI 10.1074/jbc.M404596200; Purisai MG, 2007, NEUROBIOL DIS, V25, P392, DOI 10.1016/j.nbd.2006.10.008; Richardson JR, 2005, TOXICOL SCI, V88, P193, DOI 10.1093/toxsci/kfi304; SATO B, 1995, BBA-MOL CELL RES, V1268, P20, DOI 10.1016/0167-4889(95)00035-Q; Shimizu K, 2001, BRAIN RES, V906, P135, DOI 10.1016/S0006-8993(01)02577-X; Taylor PJ, 2001, J ANAL TOXICOL, V25, P456, DOI 10.1093/jat/25.6.456; Thiruchelvam M, 2003, EUR J NEUROSCI, V18, P589, DOI 10.1046/j.1460-9568.2003.02781.x; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Veech RL, 2005, OXIDAT STRESS DIS, V18, P65; Votyakova TV, 2004, ARCH BIOCHEM BIOPHYS, V431, P138, DOI 10.1016/j.abb.2004.07.025; WINTERBOURN CC, 1984, ARCH BIOCHEM BIOPHYS, V235, P116, DOI 10.1016/0003-9861(84)90260-1; Wu XF, 2005, ANTIOXID REDOX SIGN, V7, P654, DOI 10.1089/ars.2005.7.654; Zhang L, 1998, J BIOL CHEM, V273, P33972, DOI 10.1074/jbc.273.51.33972; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	45	317	335	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14186	14193		10.1074/jbc.M700827200	http://dx.doi.org/10.1074/jbc.M700827200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17389593	Green Accepted, hybrid			2022-12-27	WOS:000246245800029
J	Forrester, MT; Foster, MW; Stamler, JS				Forrester, Michael T.; Foster, Matthew W.; Stamler, Jonathan S.			Assessment and application of the biotin switch technique for examining protein S-nitrosylation under conditions of pharmacologically induced oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; VASCULAR ENDOTHELIAL-CELLS; ASCORBIC-ACID; IN-VIVO; VITAMIN-C; GLUTATHIONE; NITROSOTHIOLS; BINDING; GAPDH; MITOCHONDRIA	Protein S-nitrosylation has emerged as a principal mechanism by which nitric oxide exerts biological effects. Among methods for studying protein S-nitrosylation, the biotin switch technique (BST) has rapidly gained popularity because of the ease with which it can detect individual S-nitrosylated (SNO) proteins in biological samples. The identification of SNO sites by the BST relies on the ability of ascorbate to generate a thiol from an S-nitrosothiol, but not from alternatively S-oxidized thiols (e.g. disulfides, sulfenic acids). However, the specificity of this reaction has recently been challenged, prompting several claims that the BST may produce false-positive results and raising concerns about the application of the BST under oxidizing conditions. Here we perform a comparative analysis of the BST using differentially S-oxidized and S-nitrosylated forms of protein tyrosine phosphatase 1B, as well as intact and lysed human embryonic kidney 293 cells treated with S-oxidizing and S-nitrosylating agents, and verify that the assay is highly specific for SNO. Strikingly, exposure of samples to indirect sunlight from a laboratory window resulted in artifactual ascorbate-dependent signals that are likely promoted by the semidehydroascorbate radical; protection from sunlight eliminated the artifact. In contrast, exposure of SNO proteins to a strong ultraviolet light source (SNO photolysis) prior to the BST provided independent verification of assay specificity. By combining BST with photolysis, we have shown that anti-cancer drug-induced oxidative stress facilitates the S-nitrosylation of the major apoptotic effector glyceraldehyde-3-phosphate dehydrogenase. Collectively, these experiments demonstrate that SNO-dependent signaling pathways can be modulated by oxidative conditions and suggest a potential role for S-nitrosylation in antineoplastic drug action.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Med Scientist Training Program, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 2612, Durham, NC 27710 USA.	staml001@mc.duke.edu		Stamler, Jonathan/0000-0002-6866-1572				ARRICK BA, 1984, CANCER RES, V44, P4224; Barrett DM, 2005, J BIOL CHEM, V280, P14453, DOI 10.1074/jbc.M411523200; BECKER K, 1995, METHOD ENZYMOL, V251, P173, DOI 10.1016/0076-6879(95)51120-2; Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Chung KKK, 2004, SCIENCE, V304, P1328, DOI 10.1126/science.1093891; Chvanov M, 2006, EMBO J, V25, P3024, DOI 10.1038/sj.emboj.7601207; Corrales FJ, 1999, J HEPATOL, V31, P887, DOI 10.1016/S0168-8278(99)80291-8; Dahm CC, 2006, J BIOL CHEM, V281, P10056, DOI 10.1074/jbc.M512203200; DAQUINO M, 1989, BIOCHEM BIOPH RES CO, V161, P1199, DOI 10.1016/0006-291X(89)91369-7; Davisson RL, 1996, HYPERTENSION, V28, P354, DOI 10.1161/01.HYP.28.3.354; Erwin PA, 2005, J BIOL CHEM, V280, P19888, DOI 10.1074/jbc.M413058200; FLEMING JE, 1983, Z NATURFORSCH C, V38, P859; Foster MW, 2004, J BIOL CHEM, V279, P25891, DOI 10.1074/jbc.M313853200; FRISCHER H, 1977, J LAB CLIN MED, V89, P1080; FRISCHER H, 1993, J CLIN INVEST, V92, P2761, DOI 10.1172/JCI116894; Hao G, 2004, J BIOL CHEM, V279, P36192, DOI 10.1074/jbc.M404866200; Hara MR, 2006, BBA-MOL BASIS DIS, V1762, P502, DOI 10.1016/j.bbadis.2006.01.012; Hara MR, 2006, P NATL ACAD SCI USA, V103, P3887, DOI 10.1073/pnas.0511321103; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Holmes AJ, 2000, J CHEM SOC PERK T 2, P1639, DOI 10.1039/b004028m; Hou YC, 1998, BIOORG MED CHEM LETT, V8, P3065, DOI 10.1016/S0960-894X(98)00563-0; Huang B, 2006, FREE RADICAL BIO MED, V41, P562, DOI 10.1016/j.freeradbiomed.2006.03.006; Huang Y, 2005, NEURON, V46, P533, DOI 10.1016/j.neuron.2005.03.028; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407; KOPPENOL WH, 1993, FREE RADICAL BIO MED, V14, P91, DOI 10.1016/0891-5849(93)90513-T; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Landino LM, 2006, BIOCHEM BIOPH RES CO, V340, P347, DOI 10.1016/j.bbrc.2005.12.013; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; May JM, 2005, FREE RADICAL BIO MED, V39, P1449, DOI 10.1016/j.freeradbiomed.2005.07.006; MILES AM, 1995, BIOCHEMISTRY-US, V34, P6941, DOI 10.1021/bi00021a005; NJUS D, 1991, FEBS LETT, V284, P147, DOI 10.1016/0014-5793(91)80672-P; Permyakov EA, 2003, PROTEINS, V51, P498, DOI 10.1002/prot.10371; Rizzo MA, 2003, J CELL BIOL, V161, P243, DOI 10.1083/jcb.200301063; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; WALMSLEY TA, 1987, CLIN CHEM, V33, P1928; Wang GF, 2006, P NATL ACAD SCI USA, V103, P1295, DOI 10.1073/pnas.0508354103; WILLIAMS NH, 1982, AUST J CHEM, V35, P1133, DOI 10.1071/CH9821133; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; Yasukawa T, 2005, J BIOL CHEM, V280, P7511, DOI 10.1074/jbc.M411871200	47	172	179	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13977	13983		10.1074/jbc.M609684200	http://dx.doi.org/10.1074/jbc.M609684200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17376775	hybrid			2022-12-27	WOS:000246245800007
J	Benfante, R; Flora, A; Di Lascio, S; Cargnin, F; Longhi, R; Colombo, S; Clementi, F; Fornasari, D				Benfante, Roberta; Flora, Adriano; Di Lascio, Simona; Cargnin, Francesca; Longhi, Renato; Colombo, Sara; Clementi, Francesco; Fornasari, Diego			Transcription factor PHOX2A regulates the human alpha 3 nicotinic receptor subunit gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-BETA-HYDROXYLASE; HOMEODOMAIN PROTEIN; FUNCTIONAL-CHARACTERIZATION; AUTONOMIC GANGLIA; MINIMAL PROMOTER; BINDING SITES; STEM-CELLS; EXPRESSION; DNA; DIFFERENTIATION	PHOX2A is a paired-like homeodomain transcription factor that participates in specifying the autonomic nervous system. It is also involved in the transcriptional control of the noradrenergic neurotransmitter phenotype as it regulates the gene expression of tyrosine hydroxylase and dopamine-beta-hydroxylase. The results of this study show that the human orthologue of PHOX2A is also capable of regulating the transcription of the human alpha 3 nicotinic acetylcholine receptor gene, which encodes the ligand-binding subunit of the ganglionic type nicotinic receptor. In particular, we demonstrated by chromatin immunoprecipitation and DNA pulldown assays that PHOX2A assembles on the SacI-NcoI region of alpha 3 promoter and, by co-transfection experiments, that it exerts its transcriptional effects by acting through the 60-bp minimal promoter. PHOX2A does not seem to bind to DNA directly, and its DNA binding domain seems to be partially dispensable for the regulation of alpha 3 gene transcription. However, as suggested by the findings of our co-immunoprecipitation assays, it may establish direct or indirect protein-protein interactions with Sp1, thus regulating the expression of alpha 3 through a DNA-independent mechanism. As the alpha 3 subunit is expressed in every terminally differentiated ganglionic cell, this is the first example of a " pan-autonomic" gene whose expression is regulated by PHOX2 proteins.	Univ Milan, Dept Pharmacol, Sch Med, I-20129 Milan, Italy; CNR, Inst Neurosci, Cellular & Mol Pharmacol Sect, I-20129 Milan, Italy; CNR, Inst Chem & Mol Recognit, I-20131 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20129 Milan, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR); University of Milan	Fornasari, D (corresponding author), Univ Milan, Dept Pharmacol, Sch Med, Via Vanvitelli 32, I-20129 Milan, Italy.	diego.fornasari@unimi.it	Benfante, Roberta/C-1513-2015	Benfante, Roberta/0000-0001-5396-5429; COLOMBO, SARA FRANCESCA/0000-0001-9714-3961; Fornasari, Diego/0000-0002-9668-3103				Adachi M, 2002, J BIOL CHEM, V277, P22915, DOI 10.1074/jbc.M201695200; Battaglioli E, 1998, J NEUROCHEM, V71, P1261; Billeter M, 1996, PROG BIOPHYS MOL BIO, V66, P211, DOI 10.1016/S0079-6107(97)00006-0; Brunet JF, 2002, CURR OPIN GENET DEV, V12, P435, DOI 10.1016/S0959-437X(02)00322-2; Campos-Caro A, 1999, J BIOL CHEM, V274, P4693, DOI 10.1074/jbc.274.8.4693; Cargnin F, 2005, J BIOL CHEM, V280, P37439, DOI 10.1074/jbc.M508368200; Coppola E, 2005, EMBO J, V24, P4392, DOI 10.1038/sj.emboj.7600897; D'Elia AV, 2001, HUM MUTAT, V18, P361, DOI 10.1002/humu.1207; Flora A, 2000, J NEUROCHEM, V75, P18, DOI 10.1046/j.1471-4159.2000.0750018.x; Flora A, 2001, J NEUROSCI, V21, P7037, DOI 10.1523/JNEUROSCI.21-18-07037.2001; Fornasari D, 1997, MOL PHARMACOL, V51, P250, DOI 10.1124/mol.51.2.250; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Howard MJ, 2005, DEV BIOL, V277, P271, DOI 10.1016/j.ydbio.2004.09.034; HOWARD MJ, 1995, DEV BIOL, V170, P479, DOI 10.1006/dbio.1995.1231; Kim HS, 1998, J NEUROSCI, V18, P8247; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Liu Q, 1999, J NEUROSCI, V19, P9747; McDonough J, 2000, J BIOL CHEM, V275, P28962, DOI 10.1074/jbc.M004181200; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; RAIMONDI E, 1992, GENOMICS, V12, P849, DOI 10.1016/0888-7543(92)90324-L; Rychlik JL, 2003, J BIOL CHEM, V278, P49652, DOI 10.1074/jbc.M308577200; Shimakura J, 2006, BIOCHEM PHARMACOL, V71, P1581, DOI 10.1016/j.bcp.2006.03.001; Swanson DJ, 2000, J BIOL CHEM, V275, P2911, DOI 10.1074/jbc.275.4.2911; TAYLOR P, 2006, GOODMAN GILMANS PHAR, P217; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200; VALARCHE I, 1993, DEVELOPMENT, V119, P881; Wang NS, 2002, PROG NEUROBIOL, V68, P341, DOI 10.1016/S0301-0082(02)00106-5; Wegner M, 2005, TRENDS NEUROSCI, V28, P583, DOI 10.1016/j.tins.2005.08.008; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Xu HM, 2003, DEV BIOL, V262, P183, DOI 10.1016/S0012-1606(03)00361-0; Xu XH, 2006, MOL CELL BIOL, V26, P5636, DOI 10.1128/MCB.00456-06; Yang CY, 1998, J NEUROCHEM, V71, P1813; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514	39	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13290	13302		10.1074/jbc.M608616200	http://dx.doi.org/10.1074/jbc.M608616200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17344216	hybrid			2022-12-27	WOS:000246060300017
J	Lavrik, IN; Golks, A; Riess, D; Bentele, M; Eils, R; Krammer, PH				Lavrik, Inna N.; Golks, Alexander; Riess, Dagmar; Bentele, Martin; Eils, Roland; Krammer, Peter H.			Analysis of CD95 threshold signaling - Triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CASPASE-8 ACTIVATION; MONOCLONAL-ANTIBODY; APOPTOSIS; INDUCTION; REGULATOR; MECHANISM; VARIANTS; FLICE; ERK	Recently we generated a mathematical model (Bentele, M., Lavrik, I., Ulrich, M., Stosser, S., Heermann, D. W., Kalthoff, H., Krammer, P. H., and Eils, R. ( 004) J. Cell Biol. 166, 839 - 851) of signaling in CD95(Fas/ APO-1)-mediated apoptosis. Mathematical modeling in combination with experimental data provided new insights into CD95-mediated apoptosis and allowed us to establish a threshold mechanism of life and death. Here, we further assessed the predictability of the model experimentally by a detailed analysis of the threshold behavior of CD95 signaling. Using the model predictions for the mechanism of the threshold behavior we found that the CD95 DISC (death-inducing signaling complex) is formed at the cell membrane upon stimulation with low concentrations of agonistic anti-APO-1 monoclonal antibodies; however, activation of procaspase-8 at the DISC is blocked due to high cellular FLICE-inhibitory protein recruitment into the DISC. Given that death signaling does not occur upon CD95 stimulation at low (threshold) anti-APO-1 concentrations, we also analyzed survival signaling, focusing on mitogen-activated protein kinase activation. Interestingly, we found that mitogen-activated protein kinase activation takes place under threshold conditions. These findings show that triggering of CD95 can signal both life or death, depending on the strength of the stimulus.	German Canc Res Ctr, Div Immunogenet, Tumorimmunol Program, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Theroet Bioinformat, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Krammer, PH (corresponding author), German Canc Res Ctr, Div Immunogenet, Tumorimmunol Program, Neurnheimer Feld 280, D-69120 Heidelberg, Germany.	p.krammer@dkfz.de	Lavrik, Inna N/C-1700-2009; Eils, Roland/B-6121-2009	Lavrik, Inna N/0000-0002-9324-309X; Eils, Roland/0000-0002-0034-4036				Bentele M, 2004, J CELL BIOL, V166, P839, DOI 10.1083/jcb.200404158; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Desbarats J, 2003, NAT CELL BIOL, V5, P118, DOI 10.1038/ncb916; DHEIN J, 1992, J IMMUNOL, V149, P3166; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lavrik I, 2003, CELL DEATH DIFFER, V10, P144, DOI 10.1038/sj.cdd.4401156; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Legembre P, 2004, EMBO REP, V5, P1084, DOI 10.1038/sj.embor.7400280; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Peter ME, 2005, BBA-REV CANCER, V1755, P25, DOI 10.1016/j.bbcan.2005.01.001; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; Sole C, 2004, J CELL BIOL, V167, P479, DOI 10.1083/jcb.200403093; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Zuliani C, 2006, CELL DEATH DIFFER, V13, P31, DOI 10.1038/sj.cdd.4401720	23	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13664	13671		10.1074/jbc.M700434200	http://dx.doi.org/10.1074/jbc.M700434200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17347143	hybrid			2022-12-27	WOS:000246060300056
J	Li, YJ; Lu, J; Prochownik, EV				Li, Youjun; Lu, Jie; Prochownik, Edward V.			Dual role for SUMO E2 conjugase Ubc9 in modulating the transforming and growth-promoting properties of the HMGA1b architectural transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A PROTEINS; C-MYC; TUMOR-SUPPRESSOR; TRANSGENIC MICE; TARGET GENES; INTERACTS; PROLIFERATION; EXPRESSION; HMGI(Y); I/Y	Members of the HMGA1 ( high mobility group A1) family of architectural transcription factors, HMGA1a and HMGA1b, play important roles in many normal cellular processes and in tumorigenesis. We performed a yeast two-hybrid screen for HMGA1-interacting proteins and identified the SUMO E2 conjugase Ubc9 as one such partner. The Ubc9-interacting domain of HMGA1 is bipartite, consisting of a proline-rich region near the N terminus and an acidic domain at the extreme C terminus, whereas the HMGA1-interacting domain of Ubc9 comprises a single region previously shown to associate with and SUMOylate other transcription factors. Consistent with these findings, endogenous HMGA1 proteins and Ubc9 could be co-immunoprecipitated from several human cell lines. Studies with HMGA1b proteins containing mutations of either or both Ubc9-interacting domains and with Ubc9-depleted cell lines indicated that the proline-rich domain of HMGA1b positively influences transformation and growth, whereas the acidic domain negatively influences these properties. None of the changes in HMGA1 protein functions mediated by Ubc9 appears to require SUMOylation. These findings are consistent with the idea that Ubc9 can act as both a positive and negative regulator of proliferation and transformation via its non-SUMO-dependent interaction with HMGA1 proteins.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Hematol Oncol Sect, Dept Mol Genet & Biochem,Rangos Res Ctr,Med Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Hematol Oncol Sect, Dept Mol Genet & Biochem,Rangos Res Ctr,Med Ctr, Rm 8124,3460 5th Ave, Pittsburgh, PA 15213 USA.	procev@chp.edu			NATIONAL CANCER INSTITUTE [R01CA105033] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA105033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrieux J, 2006, CANCER GENET CYTOGEN, V164, P84, DOI 10.1016/j.cancergencyto.2005.06.018; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; CLAUS P, 1994, J BIOL CHEM, V269, P33042; Dhar A, 2004, ONCOGENE, V23, P4466, DOI 10.1038/sj.onc.1207581; Dolde CE, 2002, BREAST CANCER RES TR, V71, P181, DOI 10.1023/A:1014444114804; Duprez E, 1999, J CELL SCI, V112, P381; Edberg DD, 2005, J BIOL CHEM, V280, P8961, DOI 10.1074/jbc.M407348200; Edberg DD, 2004, BIOCHEMISTRY-US, V43, P11500, DOI 10.1021/bi049833i; Fedele M, 2005, ONCOGENE, V24, P3427, DOI 10.1038/sj.onc.1208501; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; FRASCA F, 2006, CANCER RES, P2980; Giannini G, 2005, CANCER LETT, V228, P97, DOI 10.1016/j.canlet.2005.01.045; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Hommura F, 2004, MOL CANCER RES, V2, P305; Hoyos JM, 2004, CANCER RES, V64, P5728, DOI 10.1158/0008-5472.CAN-04-1410; Kazmierczak B, 1999, GENE CHROMOSOME CANC, V26, P125; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kobayashi S, 2004, J MOL ENDOCRINOL, V32, P69, DOI 10.1677/jme.0.0320069; Kurtzman AL, 2001, P NATL ACAD SCI USA, V98, P5602, DOI 10.1073/pnas.101129698; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Li YJ, 2006, MOL CELL BIOL, V26, P3401, DOI 10.1128/MCB.26.9.3401-3413.2006; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Liu F, 2001, IMMUNOL RES, V24, P13, DOI 10.1385/IR:24:1:13; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Mo YY, 2005, EXPERT OPIN THER TAR, V9, P1203, DOI 10.1517/14728222.9.6.1203; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Pan X, 2006, BIOCHEM BIOPH RES CO, V344, P727, DOI 10.1016/j.bbrc.2006.03.194; Pierantoni GM, 2006, CELL DEATH DIFFER, V13, P1554, DOI 10.1038/sj.cdd.4401839; Pierantoni GM, 2003, CARCINOGENESIS, V24, P1861, DOI 10.1093/carcin/bgg149; Rangasamy D, 2000, J BIOL CHEM, V275, P37999, DOI 10.1074/jbc.M007777200; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rogulski K, 2005, ONCOGENE, V24, P7524, DOI 10.1038/sj.onc.1208897; Rothermund K, 2005, CANCER RES, V65, P2097, DOI 10.1158/0008-5472.CAN-04-2928; Sarhadi V, 2006, J PATHOL, V209, P206, DOI 10.1002/path.1960; Sornberger KS, 1999, CANCER GENET CYTOGEN, V114, P9, DOI 10.1016/S0165-4608(99)00054-0; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Takaha N, 2004, PROSTATE, V60, P160, DOI 10.1002/pros.20049; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Wood LJ, 2000, CANCER RES, V60, P4256; Xu Y, 2004, CANCER RES, V64, P3371, DOI 10.1158/0008-5472.CAN-04-0044; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	53	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13363	13371		10.1074/jbc.M610919200	http://dx.doi.org/10.1074/jbc.M610919200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350957	hybrid			2022-12-27	WOS:000246060300024
J	Yang, LQ; Lin, CR; Zhao, SM; Wang, HZ; Liu, ZR				Yang, Liuqing; Lin, Chunru; Zhao, Shumin; Wang, Haizhen; Liu, Zhi-Ren			Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-ALPHA; ABL FAMILY KINASES; DEAD-BOX; BETA-CATENIN; TYROSINE KINASE; DNA-DAMAGE; APOPTOTIC RESPONSE; PDGF RECEPTORS; GLIOMA-CELLS	p68 RNA helicase is a protypical member of DEAD box family RNA helicase. The protein plays an important role in the cell developmental program and organ maturation. We demonstrated previously that, in response to growth factor platelet-derived growth factor (PDGF)-BB stimulation, p68 is phosphorylated at Tyr(593), and the phosphorylation of p68 promotes epithelial-mesenchymal transition via promoting beta-catenin nuclear translocation (Yang, L., Lin, C., and Liu, Z. R. (2006) Cell 127, 139 -155). We show here that the tyrosine phosphorylation of p68 also mediates the effects of PDGF in stimulating cell proliferation. The phosphorylated p68 (referred to as phospho-p68) promotes cell proliferation by activating the transcription of cyclin D1 and c-Myc genes. We show that the ATPase/helicase activities of p68 are required for the activation of cyclin D1 transcription. The phospho-p68 participates in the complex assembled at the cyclin D1 and c-Myc promoters, which strongly suggests a direct role in transcriptional regulation. Furthermore, our data demonstrated that the phosphorylation of p68 at Tyr593 plays a role in mediating the autocrine loop effects of PDGF, suggesting an important role for p68 phosphorylation in cell proliferation.	Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University System of Georgia; Georgia State University	Liu, ZR (corresponding author), Georgia State Univ, Dept Biol, Univ Pl Atlanta, Atlanta, GA 30303 USA.	biozrl@langate.gsu.edu	Yang, Liuqing/B-7935-2011		NIGMS NIH HHS [GM063874] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063874] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agami R, 1999, NATURE, V399, P809; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; BENITO M, 1993, GROWTH REGULAT, V3, P172; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Betsholtz Christer, 2003, Birth Defects Research, V69, P272, DOI 10.1002/bdrc.10030; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509; Buszczak M, 2006, GENE DEV, V20, P977, DOI 10.1101/gad.1396306; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chin LS, 1997, CLIN CANCER RES, V3, P771; CHUNG CK, 1992, CANCER RES, V52, P3453; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; Dubey P, 1997, J EXP MED, V185, P695, DOI 10.1084/jem.185.4.695; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FELLSTROM B, 1989, KIDNEY INT, V36, P1099, DOI 10.1038/ki.1989.306; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gong JG, 1999, NATURE, V399, P806; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; GUHA A, 1991, Pediatric Neurosurgery, V17, P14, DOI 10.1159/000120559; Heinlein UAO, 1998, J PATHOL, V184, P345, DOI 10.1002/(SICI)1096-9896(199804)184:4<345::AID-PATH1243>3.0.CO;2-6; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Huang YL, 2002, J BIOL CHEM, V277, P12810, DOI 10.1074/jbc.M200182200; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Katano M, 1998, ANN SURG, V227, P365, DOI 10.1097/00000658-199803000-00008; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lassman Andrew B, 2004, Curr Neurol Neurosci Rep, V4, P228, DOI 10.1007/s11910-004-0043-3; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Lin CR, 2005, MOL CELL BIOL, V25, P7484, DOI 10.1128/MCB.25.17.7484-7493.2005; Lokker NA, 2002, CANCER RES, V62, P3729; Matei D, 2006, ONCOGENE, V25, P2060, DOI 10.1038/sj.onc.1209232; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; Paques M, 1997, DIABETES METAB, V23, P125; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Perona Rosario, 2006, Clin Transl Oncol, V8, P77, DOI 10.1007/s12094-006-0162-1; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Rowlands TM, 2004, CELL CYCLE, V3, P145; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Shih AH, 2006, CANCER LETT, V232, P139, DOI 10.1016/j.canlet.2005.02.002; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Stice LL, 1999, FRONT BIOSCI, V4, P72; Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tumber A, 2000, J ENDOCRINOL, V167, P383, DOI 10.1677/joe.0.1670383; Van Etten RA, 2003, CURR BIOL, V13, pR608, DOI 10.1016/S0960-9822(03)00528-1; Wei Y, 2001, Yi Chuan Xue Bao, V28, P991; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003; Woodring PJ, 2004, J CELL BIOL, V165, P493, DOI 10.1083/jcb.200312171; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yu JH, 2003, J BIOCHEM MOL BIOL, V36, P49; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	75	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16811	16819		10.1074/jbc.M610488200	http://dx.doi.org/10.1074/jbc.M610488200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17412694	hybrid			2022-12-27	WOS:000246946500013
J	Sakamoto, Y; Watanabe, S; Ichimura, T; Kawasuji, M; Koseki, H; Baba, H; Nakao, M				Sakamoto, Yasuo; Watanabe, Sugiko; Ichimura, Takaya; Kawasuji, Michio; Koseki, Haruhiko; Baba, Hideo; Nakao, Mitsuyoshi			Overlapping roles of the methylated DNA-binding protein MBD1 and polycomb group proteins in transcriptional repression of HOXA genes and heterochromatin foci formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; HISTONE H3; DEVELOPMENTAL REGULATORS; COMPLEXES; INTERACTS; CHROMATIN; CANCER; MECHANISMS; MEMORY; MLL	Methylated DNA binding domain (MBD) proteins and Polycomb group ( PcG) proteins maintain epigenetic silencing of transcriptional activity. We report that the DNA methylation-mediated repressor MBD1 interacts with Ring1b and hPc2, the major components of Polycomb repressive complex 1. The cysteine-rich CXXC domains of MBD1 bound to Ring1b and the chromodomain of hPc2. Chromatin immunoprecipitation analysis revealed that MBD1 and hPc2 were present in silenced Homeobox A (HOXA) genes which could be reactivated by knockdown of either MBD1 or hPc2, suggesting that MBD1 and hPc2 cooperate for transcriptional repression of HOXA genes. In the nuclei of HeLa cells, MBD1 existed in close association with these PcG proteins in some heterochromatin foci, whereas an MBD1 mutant lacking the CXXC domains or an hPc2 mutant lacking the chromodomain lost this colocalization in foci. Use of the DNA demethylating agent 5-azadeoxycytidine abolished the formation of MBD1 foci but not PcG foci. Knockdown of MBD1 by small interfering RNAs did not affect the foci containing hPc2 and Ring1b, whereas the MBD1 foci were not influenced by knockdown of hPc2. These indicate that the heterochromatin foci showing MBD1 and hPc2 colocalization arise through the interaction of MBD1 and hPc2 and that the foci of MBD1 are separable from those of the PcG proteins per se. Our present findings suggest that MBD1 and PcG proteins have overlapping roles in epigenetic gene silencing and heterochromatin foci formation through their interactions.	Kumamoto Univ, Grad Sch Med Sci, Dept Regenerat Med, Inst Mol Embryol & Genet, Kumamoto 860, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kumamoto 860, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto 860, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Surg, Kumamoto 860, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; RIKEN	Nakao, M (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Regenerat Med, Inst Mol Embryol & Genet, 2-2-1 Honjo, Kumamoto 860, Japan.	mnakao@gpo.kumamoto-u.ac.jp	Koseki, Haruhiko/I-3825-2014; Watanabe, Sugiko/Q-6201-2019	Koseki, Haruhiko/0000-0001-8424-5854; Watanabe, Sugiko/0000-0002-2120-9546				BAYLIN SB, 2005, HUM MOL GENET S1, V2, P4; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Damelin M, 2006, NAT STRUCT MOL BIOL, V13, P100, DOI 10.1038/nsmb0206-100; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hernandez-Munoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005; Ichimura T, 2005, J BIOL CHEM, V280, P13928, DOI 10.1074/jbc.M413654200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jorgensen HF, 2004, MOL CELL BIOL, V24, P3387, DOI 10.1128/MCB.24.8.3387-3395.2004; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Mager J, 2003, NAT GENET, V33, P502, DOI 10.1038/ng1125; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shiraishi M, 2002, ONCOGENE, V21, P3659, DOI 10.1038/sj.onc.1205453; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Taghavi P, 2006, NATURE, V439, P794, DOI 10.1038/439794a; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Wang HB, 2003, MOL CELL, V12, P475, DOI 10.1016/j.molcel.2003.08.007; Watanabe S, 2003, P NATL ACAD SCI USA, V100, P12859, DOI 10.1073/pnas.2131819100; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100	46	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16391	16400		10.1074/jbc.M700011200	http://dx.doi.org/10.1074/jbc.M700011200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17428788	hybrid			2022-12-27	WOS:000246794300047
J	Heo, K; Kim, B; Kim, K; Choi, J; Kim, H; Zhan, YX; Ranish, JA; An, W				Heo, Kyu; Kim, Bong; Kim, Kyunghwan; Choi, Jongkyu; Kim, Hyunjung; Zhan, Yuxia; Ranish, Jeffrey A.; An, Woojin			Isolation and characterization of proteins associated with histone H3 tails in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; FACILITATES TRANSCRIPTION; LYSINE METHYLATION; NUCLEAR RECEPTORS; CHROMATIN; NUCLEOSOME; BINDING; COMPLEX; CODE; ACETYLATION	The histoneH3amino-terminal tails play an important role in regulating chromatin transcription. Although the mechanisms by which the H3 tail modulates transcription are not well understood, recent discoveries of specific interactions of regulatory factors with H3 tails suggest that H3 tails are a key player in the precise regulation of transcription activity. To investigate the recruitment-based action of H3 tails in chromatin transcription, we purified H3 tail-associated proteins from HeLa cells that stably express epitope-tagged H3 tails. This approach resulted in the identification of multiple histone methyltransferase activities and transcription regulatory factors that are specifically associated with expressed H3 tail domains. Point mutations of Lys-9 and Lys-27 to block cellular modifications of the tail domains completely abolished the association of specific factors, including HP1 and several repressors. Importantly, our transcription analysis revealed that the purified factors can significantly stimulate p300-mediated transcription from chromatin templates. These results implicate that the H3 tail, when accessible in relaxed chromatin, acts as a transcriptional regulator by mediating recruitment of specific sets of cofactors.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Inst Syst Biol, Seattle, WA 98103 USA	University of Southern California; Institute for Systems Biology (ISB)	An, W (corresponding author), Childrens Hosp Los Angeles, 4650 Sunset Blvd,SRT-1014, Los Angeles, CA 90027 USA.	woojinan@usc.edu		Heo, Kyu/0000-0001-8833-4731				An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; An WJ, 2004, METHOD ENZYMOL, V377, P460; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Angelov D, 2006, EMBO J, V25, P1669, DOI 10.1038/sj.emboj.7601046; Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Bustin M, 2005, MOL CELL, V17, P617, DOI 10.1016/j.molcel.2005.02.019; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cosgrove MS, 2005, BIOCHEM CELL BIOL, V83, P468, DOI 10.1139/O05-137; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; Malik S, 2003, METHOD ENZYMOL, V364, P257; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6; Schneider R, 2004, J BIOL CHEM, V279, P23859, DOI 10.1074/jbc.C400151200; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomas CE, 2006, J PROTEOME RES, V5, P240, DOI 10.1021/pr050266a; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Holde K.E., 1988, CHROMATIN; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zheng CY, 2003, BIOPOLYMERS, V68, P539, DOI 10.1002/bip.10303; Zlatanova J, 1998, BIOESSAYS, V20, P584, DOI 10.1002/(SICI)1521-1878(199807)20:7<584::AID-BIES10>3.0.CO;2-W	50	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15476	15483		10.1074/jbc.M610270200	http://dx.doi.org/10.1074/jbc.M610270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403666	hybrid			2022-12-27	WOS:000246589600023
J	Vlahakis, NE; Young, BA; Atakilit, A; Hawkridge, AE; Issaka, RB; Boudreau, N; Sheppard, D				Vlahakis, Nicholas E.; Young, Bradford A.; Atakilit, Amha; Hawkridge, Anne E.; Issaka, Rachel B.; Boudreau, Nancy; Sheppard, Dean			Integrin alpha 9 beta 1 directly binds to vascular endothelial growth factor (VEGF)- a and contributes to VEGF-A-induced angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; PATHOLOGICAL ANGIOGENESIS; RECEPTOR ACTIVATION; MICE LACKING; III REPEAT; EXPRESSION; MIGRATION; TENASCIN; INTEGRIN-ALPHA-9-BETA-1; PHOSPHORYLATION	Vascular endothelial growth factor A (VEGF-A) is a potent inducer of angiogenesis. We now show that VEGF-A-induced adhesion and migration of human endothelial cells are dependent on the integrin alpha 9 beta 1 and that VEGF-A is a direct ligand for this integrin. Adhesion and migration of these cells on the 165 and 121 isoforms of VEGF-A depend on cooperative input from alpha 9 beta 1 and the cognate receptor for VEGF-A, VEGF receptor 2 (VEGF-R2). Unlike alpha 3 beta 1 or alpha v beta 3 integrins, alpha 9 beta 1 was also found to bind the 121 isoform of VEGF-A. This interaction appears to be biologically significant, because alpha 9 beta 1-blocking antibody dramatically and specifically inhibited angiogenesis induced by VEGF-A165 or -121. Together with our previous findings that alpha 9 beta 1 directly binds to VEGF-C and -D and contributes to lymphangiogenesis, these results identify the integrin alpha 9 beta 1 as a potential pharmacotherapeutic target for inhibition of pathogenic angiogenesis and lymphangiogenesis.	Mayo Clin, Coll Med, Thorac Dis Res Unit, Rochester, MN 55905 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA	Mayo Clinic; University of California System; University of California San Francisco	Vlahakis, NE (corresponding author), Mayo Clin, Coll Med, Thorac Dis Res Unit, 200 1st St SW, Rochester, MN 55905 USA.	vlahakis.nicholas@mayo.edu; dean.sheppard@ucsf.edu			NHLBI NIH HHS [R01 HL64353] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064353] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbiser JL, 2000, AM J PATHOL, V156, P1469, DOI 10.1016/S0002-9440(10)65015-8; Ashikari- Hada S, 2005, J BIOL CHEM, V280, P31508, DOI 10.1074/jbc.M414581200; Boudreau NJ, 2004, J BIOL CHEM, V279, P4862, DOI 10.1074/jbc.M305190200; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carmeliet P, 2002, NAT MED, V8, P14, DOI 10.1038/nm0102-14; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Garmy-Susini B, 2005, J CLIN INVEST, V115, P1542, DOI 10.1172/JCI23445; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Huang XZ, 2000, MOL CELL BIOL, V20, P5208, DOI 10.1128/MCB.20.14.5208-5215.2000; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Jussila L, 2002, PHYSIOL REV, V82, P673, DOI 10.1152/physrev.00005.2002; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; MISHIMA K, 2007, MOL BIOL CELL, DOI DOI 10.1091/7BC.E06-09-0780; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Perruzzi CA, 2003, J INVEST DERMATOL, V120, P1100, DOI 10.1046/j.1523-1747.2003.12236.x; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Smyth SS, 2002, J CELL BIOL, V158, P17, DOI 10.1083/jcb.200202100; Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; Vlahakis NE, 2005, J BIOL CHEM, V280, P4544, DOI 10.1074/jbc.M412816200; Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YANG JT, 1995, DEVELOPMENT, V121, P549; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423; Young BA, 2001, MOL BIOL CELL, V12, P3214, DOI 10.1091/mbc.12.10.3214; Zhang XF, 2005, J CELL PHYSIOL, V202, P205, DOI 10.1002/jcp.20106	40	97	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15187	15196		10.1074/jbc.M609323200	http://dx.doi.org/10.1074/jbc.M609323200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17363377	hybrid			2022-12-27	WOS:000246589000058
J	Prager, K; Wang-Eckhardt, LH; Fluhrer, R; Killick, R; Barth, E; Hampel, H; Haass, C; Walter, J				Prager, Kai; Wang-Eckhardt, Lihua; Fluhrer, Regina; Killick, Richard; Barth, Esther; Hampel, Heike; Haass, Christian; Walter, Jochen			A structural switch of presenilin 1 by glycogen synthase kinase 3 beta-mediated phosphorylation regulates the interaction with beta-catenin and its nuclear signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; SUBCELLULAR-LOCALIZATION; PROTEOLYTIC FRAGMENTS; WILD-TYPE; IN-VIVO; C-MYC; CLEAVAGE; WNT	Presenilins (PS) are critical components of the gamma-secretase complex that mediates cleavage of type I membrane proteins including the beta-amyloid precursor protein to generate the amyloid beta-peptide. In addition, PS1 interacts with beta-catenin and facilitates its metabolism. We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3 beta (GSK3 beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells. The structural change of PS1 reduces the interaction with beta-catenin leading to decreased phosphorylation and ubiquitination of beta-catenin. The decreased interaction of PS1 with beta-catenin leads to stabilization of beta-catenin thereby increasing its nuclear signaling and the transcription of target genes, including c-MYC. Consistent with increased expression of c-myc, a PS1 mutant that mimics phosphorylated PS1 increased cell proliferation as compared with wild-type PS1. These results indicate a regulatory mechanism in which GSK3 beta-mediated phosphorylation induces a structural change of the hydrophilic loop of PS1 thereby negatively modulating the formation of a ternary complex between beta-catenin, PS1, and GSK3 beta, which leads to stabilization of beta-catenin.	Univ Bonn, Dept Neurol, D-53127 Bonn, Germany; Univ Munich, Dept Biochem, D-80336 Munich, Germany; Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5 8AF, England	University of Bonn; University of Munich; University of London; King's College London	Walter, J (corresponding author), Sigmund Freud Str 25, D-53127 Bonn, Germany.	Jochen.Walter@ukb.uni-bonn.de	Wang, Caihong/T-5837-2019; Fluhrer, Regina/F-2642-2011; Walter, Jochen/B-3677-2014	Wang, Caihong/0000-0002-6808-3709; Walter, Jochen/0000-0002-4678-2912; Killick, Richard/0000-0002-8815-3436				Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Bamji SX, 2003, NEURON, V40, P719, DOI 10.1016/S0896-6273(03)00718-9; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Dang CV, 1999, MOL CELL BIOL, V19, P1; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Fluhrer R, 2004, J BIOL CHEM, V279, P1585, DOI 10.1074/jbc.M306653200; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kaether C, 2006, TRAFFIC, V7, P408, DOI 10.1111/j.1600-0854.2006.00396.x; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Killick R, 2001, J BIOL CHEM, V276, P48554, DOI 10.1074/jbc.M108332200; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kirschenbaum F, 2001, J BIOL CHEM, V276, P7366, DOI 10.1074/jbc.M004697200; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; McCarthy JV, 2005, BIOCHEM SOC T, V33, P568, DOI 10.1042/BST0330568; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Reiss K, 2005, EMBO J, V24, P742, DOI 10.1038/sj.emboj.7600548; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Serban G, 2005, J BIOL CHEM, V280, P36007, DOI 10.1074/jbc.M507503200; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Uemura K, 2006, BIOCHEM BIOPH RES CO, V345, P951, DOI 10.1016/j.bbrc.2006.04.157; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Ye YH, 1999, J CELL BIOL, V146, P1351, DOI 10.1083/jcb.146.6.1351	48	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14083	14093		10.1074/jbc.M608437200	http://dx.doi.org/10.1074/jbc.M608437200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360711	hybrid, Green Published			2022-12-27	WOS:000246245800018
J	Roux, PP; Shahbazian, D; Vu, H; Holz, MK; Cohen, MS; Taunton, J; Sonenberg, N; Blenis, J				Roux, Philippe P.; Shahbazian, David; Vu, Hieu; Holz, Marina K.; Cohen, Michael S.; Taunton, Jack; Sonenberg, Nahum; Blenis, John			RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS; MAP2 KINASE; MECHANISMS; COMPLEX; GROWTH; MTOR; IDENTIFICATION; ACTIVATION; TARGET; RAS	Converging signals from the mammalian target of rapamycin (mTOR) and phosphoinositide 3-kinase (PI3K) pathways are well established to modulate translation initiation. Less is known regarding the molecular basis of protein synthesis regulated by other inputs, such as agonists of the Ras/extracellular signal-regulated kinase (ERK) signaling cascade. Ribosomal protein (rp) S6 is a component of the 40S ribosomal subunit that becomes phosphorylated at several serine residues upon mitogen stimulation, but the exact molecular mechanisms regulating its phosphorylation and the function of phosphorylated rpS6 is poorly understood. Here, we provide evidence that activation of the p90 ribosomal S6 kinases (RSKs) by serum, growth factors, tumor promoting phorbol esters, and oncogenic Ras is required for rpS6 phosphorylation downstream of the Ras/ERK signaling cascade. We demonstrate that while ribosomal S6 kinase 1 (S6K1) phosphorylates rpS6 at all sites, RSK exclusively phosphorylates rpS6 at Ser(235/236) in vitro and in vivo using an mTOR independent mechanism. Mutation of rpS6 at Ser(235/236) reveals that phosphorylation of these sites promotes its recruitment to the 7-methylguanosine cap complex, suggesting that Ras/ERK signaling regulates assembly of the translation preinitiation complex. These data demonstrate that RSK provides an mTOR-independent pathway linking the Ras/ERK signaling cascade to the translational machinery.	Univ Montreal, IRIC, Stn Ctr Ville, Dept Pathol & Cell Biol, Montreal, PQ H3C 3J7, Canada; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	Universite de Montreal; Harvard University; Harvard Medical School; McGill University; University of California System; University of California San Francisco	Roux, PP (corresponding author), Univ Montreal, IRIC, Stn Ctr Ville, Dept Pathol & Cell Biol, POB 6128, Montreal, PQ H3C 3J7, Canada.	philippe.roux@umontreal.ca	Roux, Philippe P./J-3996-2012	Roux, Philippe P./0000-0002-5962-0250	NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071434] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA046595, CA46595, R37 CA046595] Funding Source: Medline; NIGMS NIH HHS [R01 GM071434-04, GM071434, GM5140, R01 GM071434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anjum R, 2005, CURR BIOL, V15, P1762, DOI 10.1016/j.cub.2005.08.050; Averous J, 2006, ONCOGENE, V25, P6423, DOI 10.1038/sj.onc.1209887; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANDI HR, 1993, J BIOL CHEM, V268, P4530; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BURKHARD SJ, 1983, J BIOL CHEM, V258, P4003; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; GRESSNER AM, 1974, J BIOL CHEM, V249, P6917; Hauge C, 2006, J CELL SCI, V119, P3021, DOI 10.1242/jcs.02950; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Kelleher RJ, 2004, NEURON, V44, P59, DOI 10.1016/j.neuron.2004.09.013; KRIEG J, 1988, J BIOL CHEM, V263, P11473; Kruger M, 2001, MOL CELL BIOL, V21, P8357, DOI 10.1128/MCB.21.24.8357-8364.2001; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; NYGARD O, 1990, J BIOL CHEM, V265, P6030; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Roux PP, 2003, MOL CELL BIOL, V23, P4796, DOI 10.1128/MCB.23.14.4796-4804.2003; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; THOMAS G, 1979, P NATL ACAD SCI USA, V76, P3952, DOI 10.1073/pnas.76.8.3952; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045	39	536	546	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14056	14064		10.1074/jbc.M700906200	http://dx.doi.org/10.1074/jbc.M700906200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360704	Green Accepted, hybrid, Green Published			2022-12-27	WOS:000246245800015
J	Spichal, L; Krystof, V; Paprskarova, M; Lenobel, R; Styskala, J; Binarova, P; Cenklova, V; De Veylder, L; Inze, D; Kontopidis, G; Fischer, PM; Schmuelling, T; Strnad, M				Spichal, Lukas; Krystof, Vladimir; Paprskarova, Martina; Lenobel, Rene; Styskala, Jakub; Binarova, Pavla; Cenklova, Vera; De Veylder, Lieven; Inze, Dirk; Kontopidis, George; Fischer, Peter M.; Schm elling, Thomas; Strnad, Miroslav			Classical anticytokinins do not interact with cytokinin receptors but inhibit cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITORS; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; HISTIDINE KINASE; PURINE ANALOGS; CELL-CYCLE; FAMILY; ACTIVATION; SHOOT; ASSAY	Cytokinins are a class of plant hormones that regulate the cell cycle and diverse developmental and physiological processes. Several compounds have been identified that antagonize the effects of cytokinins. Based on structural similarities and competitive inhibition, it has been assumed that these anticytokinins act through a common cellular target, namely the cytokinin receptor. Here, we examined directly the possibility that various representative classical anticytokinins inhibit the Arabidopsis cytokinin receptors CRE1/AHK4 (cytokinin response 1/Arabidopsis histidine kinase 4) and AHK3 ( Arabidopsis histidine kinase 3). We show that pyrrolo[2,3-d] pyrimidine and pyrazolo[ 4,3-d] pyrimidine anticytokinins do not act as competitors of cytokinins at the receptor level. Flow cytometry and microscopic analyses revealed that anticytokinins inhibit the cell cycle and cause disorganization of the microtubular cytoskeleton and apoptosis. This is consistent with the hypothesis that they inhibit regulatory cyclin-dependent kinase (CDK) enzymes. Biochemical studies demonstrated inhibition by selected anticytokinins of both Arabidopsis and human CDKs. X-ray determination of the crystal structure of a human CDK2-anticytokinin complex demonstrated that the antagonist occupies the ATP-binding site of CDK2. Finally, treatment of human cancer cell lines with anticytokinins demonstrated their ability to kill human cells with similar effectiveness as known CDK inhibitors.	AS CR, Inst Expt Bot, Lab Growth Regulators, Olomouc 78371, Czech Republic; Palacky Univ, Olomouc 78371, Czech Republic; AS CR, Inst Microbiol, Prague 14220 4, Czech Republic; AS CR, Inst Expt Bot, Lab Cell Biol & Cytoskeleton, Olomouc 77200, Czech Republic; Univ Ghent VIB, Dept Mol Genet, B-9052 Ghent, Belgium; Univ Ghent VIB, Flanders Inst Biotechnol, Dept Plant Syst Biol, B-9052 Ghent, Belgium; Cyclacel Ltd, Dundee DD1 5JJ, Scotland; Free Univ Berlin, Inst Biol Appl Genet, D-14195 Berlin, Germany	Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences; Palacky University Olomouc; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences; Flanders Institute for Biotechnology (VIB); Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Cyclacel Pharmaceuticals Inc.; Free University of Berlin	Strnad, M (corresponding author), Slechtitelu 11, CZ-78371 Olomouc, Czech Republic.	miroslav.strnad@upol.cz	Fischer, Peter/E-5657-2010; LENOBEL, René/AAD-5606-2020; Strnad, Miroslav/H-1858-2014; Spichal, Lukas/H-6873-2014; de veylder, lieven/AAM-9909-2020; Inzé, Dirk/AAW-6381-2021; Krystof, Vladimir/B-9499-2009; Binarova, Pavla/H-3562-2014	Fischer, Peter/0000-0002-5866-9271; Strnad, Miroslav/0000-0002-2806-794X; de veylder, lieven/0000-0003-1150-4426; Inzé, Dirk/0000-0002-3217-8407; Krystof, Vladimir/0000-0001-5838-2118; Binarova, Pavla/0000-0002-7203-2250; Spichal, Lukas/0000-0001-6483-8628; Lenobel, Rene/0000-0001-7387-0056				Binarova P, 1998, PLANT J, V16, P697, DOI 10.1046/j.1365-313x.1998.00340.x; BINAROVA P, 1993, CELL BIOL INT, V17, P847, DOI 10.1006/cbir.1993.1147; Bogre L, 1997, PLANT PHYSIOL, V113, P841, DOI 10.1104/pp.113.3.841; D'Agostino IB, 2000, PLANT PHYSIOL, V124, P1706, DOI 10.1104/pp.124.4.1706; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DOLEZEL J, 1992, PLANTA, V188, P93, DOI 10.1007/BF00198944; Ferreira FJ, 2005, CURR OPIN PLANT BIOL, V8, P518, DOI 10.1016/j.pbi.2005.07.013; Fischer PM, 2005, EXPERT OPIN INV DRUG, V14, P457, DOI 10.1517/13543784.14.4.457; Fischer PM, 2004, CELL CYCLE, V3, P742; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GREGORINI G, 1980, PLANT PHYSIOL, V65, P363, DOI 10.1104/pp.65.2.363; Havlicek L, 1997, J MED CHEM, V40, P408, DOI 10.1021/jm960666x; HECHT SM, 1971, P NATL ACAD SCI USA, V68, P2608, DOI 10.1073/pnas.68.10.2608; Heyl A, 2003, CURR OPIN PLANT BIOL, V6, P480, DOI 10.1016/S1369-5266(03)00087-6; Heyl A, 2006, ANNU PLANT REV, V24, P93; Higuchi M, 2004, P NATL ACAD SCI USA, V101, P8821, DOI 10.1073/pnas.0402887101; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; IWAMURA H, 1979, PHYTOCHEMISTRY, V18, P217, DOI 10.1016/0031-9422(79)80058-8; Iwamura H., 1994, CYTOKININS CHEM ACTI, P43; LUCRETTI S, 1995, METHODS PLANT CELL B, P61; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Mok MC., 1994, CYTOKININS CHEM ACTI, P155, DOI DOI 10.1201/9781351071284; Moravcova D, 2003, BIOORG MED CHEM LETT, V13, P2989, DOI 10.1016/S0960-894X(03)00631-0; Nishimura C, 2004, PLANT CELL, V16, P1365, DOI 10.1105/tpc.021477; Riefler M, 2006, PLANT CELL, V18, P40, DOI 10.1105/tpc.105.037796; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; Romanov GA, 2005, ANAL BIOCHEM, V347, P129, DOI 10.1016/j.ab.2005.09.012; Romanov GA, 2002, FEBS LETT, V515, P39, DOI 10.1016/S0014-5793(02)02415-8; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SKOOG F, 1975, P NATL ACAD SCI USA, V72, P3508, DOI 10.1073/pnas.72.9.3508; SKOOG F, 1970, ANN REV PLANT PHYSIO, V21, P359, DOI 10.1146/annurev.pp.21.060170.002043; SKOOG F, 1973, PHYTOCHEMISTRY, V12, P25, DOI 10.1016/S0031-9422(00)84620-8; SKOOG F, 1967, PHYTOCHEMISTRY, V6, P1169, DOI 10.1016/S0031-9422(00)86080-X; Spichal L, 2004, PLANT CELL PHYSIOL, V45, P1299, DOI 10.1093/pcp/pch132; Suzuki T, 2001, PLANT CELL PHYSIOL, V42, P107, DOI 10.1093/pcp/pce037; Ueguchi C, 2001, PLANT CELL PHYSIOL, V42, P751, DOI 10.1093/pcp/pce094; Verkest A, 2005, PLANT CELL, V17, P1723, DOI 10.1105/tpc.105.032383; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wang SD, 2004, J MED CHEM, V47, P1662, DOI 10.1021/jm0309957; Werner T, 2003, PLANT CELL, V15, P2532, DOI 10.1105/tpc.014928; Wu SY, 2003, STRUCTURE, V11, P399, DOI 10.1016/S0969-2126(03)00060-1; Yamada H, 2001, PLANT CELL PHYSIOL, V42, P1017, DOI 10.1093/pcp/pce127; Yonekura-Sakakibara K, 2004, PLANT PHYSIOL, V134, P1654, DOI 10.1104/pp.103.037176; Zhang K, 1996, PLANTA, V200, P2	48	19	19	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14356	14363		10.1074/jbc.M609750200	http://dx.doi.org/10.1074/jbc.M609750200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17339323	hybrid			2022-12-27	WOS:000246245800047
J	Layer, G; Gaddam, SA; Ayala-Castro, CN; Choudens, SO; Lascoux, D; Fontecave, M; Outten, FW				Layer, Gunhild; Gaddam, S. Aparna; Ayala-Castro, Carla N.; Ollagnier-de Choudens, Sandrine; Lascoux, David; Fontecave, Marc; Outten, F. Wayne			SufE transfers sulfur from SufS to SufB for iron-sulfur cluster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; ESCHERICHIA-COLI; CYSTEINE DESULFURASE; SELENOCYSTEINE LYASE; ERWINIA-CHRYSANTHEMI; CRYSTAL-STRUCTURE; OXIDATIVE STRESS; GENE-CLUSTER; PROTEIN; BIOSYNTHESIS	Iron-sulfur (Fe-S) clusters are key metal cofactors of metabolic, regulatory, and stress response proteins in most organisms. The unique properties of these clusters make them susceptible to disruption by iron starvation or oxidative stress. Both iron and sulfur can be perturbed under stress conditions, leading to Fe-S cluster defects. Bacteria and higher plants contain a specialized system for Fe-S cluster biosynthesis under stress, namely the Suf pathway. In Escherichia coli the Suf pathway consists of six proteins with functions that are only partially characterized. Here we describe how the SufS and SufE proteins interact with the SufBCD protein complex to facilitate sulfur liberation from cysteine and donation for Fe-S cluster assembly. It was previously shown that the cysteine desulfurase SufS donates sulfur to the sulfur transfer protein SufE. We have found here that SufE in turn interacts with the SufB protein for sulfur transfer to that protein. The interaction occurs only if SufC is present. Furthermore, SufB can act as a site for Fe-S cluster assembly in the Suf system. This provides the first evidence of a novel site for Fe-S cluster assembly in the SufBCD complex.	Univ Grenoble 1, CEA Grenoble, iRTSV LCBM, CNRS,UMR 5249, F-38054 Grenoble 09, France; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ Grenoble 1, CEA, CNRS, Lab Spect Masse Prot,Inst Biol Struct, F-38027 Grenoble 1, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Choudens, SO (corresponding author), Univ Grenoble 1, CEA Grenoble, iRTSV LCBM, CNRS,UMR 5249, 17 Ave Martyrs, F-38054 Grenoble 09, France.	sollagnier@cea.fr; wayne.outten@chem.sc.edu		Outten, Franklin/0000-0002-9095-0194; Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Badger J, 2005, PROTEINS, V60, P787, DOI 10.1002/prot.20541; Balasubramanian R, 2006, J BACTERIOL, V188, P3182, DOI 10.1128/JB.188.9.3182-3191.2006; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Eccleston JF, 2006, J BIOL CHEM, V281, P8371, DOI 10.1074/jbc.M513455200; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Fontecave M, 2005, J BIOL INORG CHEM, V10, P713, DOI 10.1007/s00775-005-0025-1; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; Goldsmith-Fischman S, 2004, J MOL BIOL, V344, P549, DOI 10.1016/j.jmb.2004.08.074; Huet G, 2005, J BACTERIOL, V187, P6137, DOI 10.1128/JB.187.17.6137-6146.2005; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kitaoka S, 2006, FEBS LETT, V580, P137, DOI 10.1016/j.febslet.2005.11.058; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lill R, 2006, ANNU REV CELL DEV BI, V22, P457, DOI 10.1146/annurev.cellbio.22.010305.104538; Liu GH, 2005, PROTEIN SCI, V14, P1597, DOI 10.1110/ps.041322705; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 2002, J BIOCHEM, V131, P679, DOI 10.1093/oxfordjournals.jbchem.a003151; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Ollagnier-De-Choudens S, 2003, FEBS LETT, V555, P263, DOI 10.1016/S0014-5793(03)01244-4; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Rangachari K, 2002, FEBS LETT, V514, P225, DOI 10.1016/S0014-5793(02)02369-4; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Wada K, 2005, FEBS LETT, V579, P6543, DOI 10.1016/j.febslet.2005.10.046; Yoshida A., 1970, METHODS ENZYMOLOGY A, V17, P176; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	32	119	120	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13342	13350		10.1074/jbc.M608555200	http://dx.doi.org/10.1074/jbc.M608555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17350958	hybrid			2022-12-27	WOS:000246060300022
J	Bernstein, JR; Bulter, T; Shen, CR; Liao, JC				Bernstein, Jeffrey R.; Bulter, Thomas; Shen, Claire R.; Liao, James C.			Directed evolution of ribosomal protein S1 for enhanced translational efficiency of high GC Rhodopseudomonas palustris DNA in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; IN-VITRO; INITIATION; EXPRESSION; CLONING; GENES; REGION; STRATEGIES; SELECTION; SEQUENCE	The expression of foreign DNA in Escherichia coli is important in biotechnological applications. However, the translation of genes from GC-rich organisms is inefficient in E. coli. To overcome this problem, we applied directed evolution to E. coli ribosomal protein S1. Two selected mutants enabled 12- and 8-fold higher expression levels from GC-rich DNA targets. General improvements in translation efficiency over a range of genes from Rhodopseudomonas palustris and E. coli was achieved using an S1 mutant selected against multiple genes from R. palustris. This method opens new opportunities for the expression of GC-rich genes in E. coli.	Univ Calif Los Angeles, Dept Chem & Biomol Engn, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Biomed Engn & Interdepartamental Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Liao, JC (corresponding author), 5531 Boelter Hall,420 Westwood Plaza, Los Angeles, CA 90095 USA.	liaoj@ucla.edu		Liao, James/0000-0002-4580-7276; Bulter, Thomas/0000-0002-7968-5844	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077625] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM077625-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARVIDSON DN, 1991, BIOTECHNIQUES, V11, P733; Boni IV, 2000, J BACTERIOL, V182, P5872, DOI 10.1128/JB.182.20.5872-5879.2000; Brodersen DE, 2005, FEBS J, V272, P2098, DOI 10.1111/j.1742-4658.2005.04651.x; Bulter T, 2003, BIOTECHNOL BIOENG, V84, P815, DOI 10.1002/bit.10845; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Draper DE, 1999, NUCLEIC ACIDS RES, V27, P381, DOI 10.1093/nar/27.2.381; Egland PG, 1999, J BACTERIOL, V181, P2102, DOI 10.1128/JB.181.7.2102-2109.1999; FARWELL MA, 1992, MOL MICROBIOL, V6, P3375, DOI 10.1111/j.1365-2958.1992.tb02205.x; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Grill S, 2001, FEBS LETT, V495, P167, DOI 10.1016/S0014-5793(01)02378-X; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Heinz C, 2003, J CHROMATOGR B, V790, P337, DOI 10.1016/S1570-0232(03)00130-2; ISHIDA M, 1994, J BACTERIOL, V176, P2767, DOI 10.1128/JB.176.9.2767-2770.1994; Ishida M, 2002, J BIOCHEM, V132, P63, DOI 10.1093/oxfordjournals.jbchem.a003199; Itaya M, 2005, P NATL ACAD SCI USA, V102, P15971, DOI 10.1073/pnas.0503868102; Komarova AV, 2005, J BACTERIOL, V187, P1344, DOI 10.1128/JB.187.4.1344-1349.2005; Komarova AV, 2002, RNA, V8, P1137, DOI 10.1017/S1355838202029990; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Larimer FW, 2004, NAT BIOTECHNOL, V22, P55, DOI 10.1038/nbt923; Laursen BS, 2005, MICROBIOL MOL BIOL R, V69, P101, DOI 10.1128/MMBR.69.1.101-123.2005; Leem SH, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng029; Lessard IAD, 1998, CHEM BIOL, V5, P489, DOI 10.1016/S1074-5521(98)90005-9; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Martin VJJ, 2003, NAT BIOTECHNOL, V21, P796, DOI 10.1038/nbt833; McGinness KE, 2004, P NATL ACAD SCI USA, V101, P13454, DOI 10.1073/pnas.0405521101; MELANCON P, 1990, BIOCHEMISTRY-US, V29, P3402, DOI 10.1021/bi00465a037; MISAWA N, 1995, J BACTERIOL, V177, P6575, DOI 10.1128/jb.177.22.6575-6584.1995; Navarre WW, 2006, SCIENCE, V313, P236, DOI 10.1126/science.1128794; POTAPOV AP, 1992, BIOCHEM INT, V27, P745; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Rohlin L, 2005, J BACTERIOL, V187, P6046, DOI 10.1128/JB.187.17.6046-6057.2005; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; Sukhodolets MV, 2006, RNA, V12, P1505, DOI 10.1261/rna.2321606; TONG IT, 1991, APPL ENVIRON MICROB, V57, P3541, DOI 10.1128/AEM.57.12.3541-3546.1991; TZAREVA NV, 1994, FEBS LETT, V337, P189, DOI 10.1016/0014-5793(94)80271-8; Voges D, 2004, BIOCHEM BIOPH RES CO, V318, P601, DOI 10.1016/j.bbrc.2004.04.064; Wang CW, 2000, BIOTECHNOL PROGR, V16, P922, DOI 10.1021/bp000124f	43	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					18929	18936		10.1074/jbc.M701395200	http://dx.doi.org/10.1074/jbc.M701395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17412688	hybrid			2022-12-27	WOS:000247475300034
J	Voloshin, ON; Camerini-Otero, RD				Voloshin, Oleg N.; Camerini-Otero, R. Daniel			The DinG protein from Escherichia coli is a structure-specific helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FORK REVERSAL; DNA SUBSTRATE-SPECIFICITY; HOMOLOGOUS RECOMBINATION; XERODERMA-PIGMENTOSUM; GENE ENCODES; REPAIR; BINDING; BACH1; RECA; STRAND	The Escherichia coli DinG protein is a DNA damage-inducible member of the helicase superfamily 2. Using a panel of synthetic substrates, we have systematically investigated structural requirements for DNA unwinding by DinG. We have found that the helicase does not unwind blunt-ended DNAs or substrates with 3'-ss tails. On the other hand, the 5'-ss tails of 11-15 nucleotides are sufficient to initiate DNA duplex unwinding; bifurcated substrates further facilitate helicase activity. DinG is active on 5'-flap structures; however, it is unable to unwind 3'-flaps. Similarly to the homologous Saccharomyces cerevisiae Rad3 helicase, DinG unwinds DNA.RNA duplexes. DinG is active on synthetic D-loops and R-loops. The ability of the enzyme to unwind D-loops formed on superhelical plasmid DNA by the E. coli recombinase RecA suggests that D-loops may be natural substrates for DinG. Although the availability of 5'-ssDNA tails is a strict requirement for duplex unwinding by DinG, the unwinding of D-loops can be initiated on substrates without any ss tails. Since DinG is DNA damage-inducible and is active on D-loops and forked structures, which mimic intermediates of homologous recombination and replication, we conclude that this helicase may be involved in recombinational DNA repair and the resumption of replication after DNA damage.	NIDDK, NIH, Genet & Biochem Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Camerini-Otero, RD (corresponding author), Genet & Biochem Branch, 5 Mem Dr,Rm 201,MSC 0538, Bethesda, MD 20892 USA.	camerini@ncifcrf.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052032, Z01DK052033, ZIADK052033, ZIADK052032] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anand SP, 2004, NUCLEIC ACIDS RES, V32, P3190, DOI 10.1093/nar/gkh641; Baharoglu Z, 2006, EMBO J, V25, P596, DOI 10.1038/sj.emboj.7600941; BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; Baran N, 1997, NUCLEIC ACIDS RES, V25, P297, DOI 10.1093/nar/25.2.297; Bartos JD, 2006, J BIOL CHEM, V281, P32227, DOI 10.1074/jbc.M606310200; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Cadman CJ, 2006, J MOL BIOL, V362, P18, DOI 10.1016/j.jmb.2006.06.032; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; CarlesKinch K, 1997, EMBO J, V16, P4142, DOI 10.1093/emboj/16.13.4142; Courcelle J, 2001, GENETICS, V158, P41; Courcelle J, 2003, ANNU REV GENET, V37, P611, DOI 10.1146/annurev.genet.37.110801.142616; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Fernandez de Henestrosa AR, 2000, MOL MICROBIOL, V35, P1560, DOI 10.1046/j.1365-2958.2000.01826.x; Flores MJ, 2004, EMBO REP, V5, P983, DOI 10.1038/sj.embor.7400262; Fujikane R, 2006, GENES CELLS, V11, P99, DOI 10.1111/j.1365-2443.2006.00925.x; Grompone G, 2002, MOL MICROBIOL, V44, P1331, DOI 10.1046/j.1365-2958.2002.02962.x; Gupta R, 2005, J BIOL CHEM, V280, P25450, DOI 10.1074/jbc.M501995200; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; Huber MD, 2002, NUCLEIC ACIDS RES, V30, P3954, DOI 10.1093/nar/gkf530; INOUE H, 1987, NUCLEIC ACIDS RES, V15, P6131, DOI 10.1093/nar/15.15.6131; Jones JM, 2001, J MOL BIOL, V312, P935, DOI 10.1006/jmbi.2001.4930; Kanagaraj R, 2006, NUCLEIC ACIDS RES, V34, P5217, DOI 10.1093/nar/gkl677; Khil PP, 2002, MOL MICROBIOL, V44, P89, DOI 10.1046/j.1365-2958.2002.02878.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P1497, DOI 10.1093/nar/21.6.1497; Kopel V, 1996, NUCLEIC ACIDS RES, V24, P330, DOI 10.1093/nar/24.2.330; Kuusk S, 2005, J BIOL CHEM, V280, P24322, DOI 10.1074/jbc.M500354200; LESNIK EA, 1993, BIOCHEMISTRY-US, V32, P7832, DOI 10.1021/bi00081a031; Lewis K, 2000, MICROBIOL MOL BIOL R, V64, P503, DOI 10.1128/MMBR.64.3.503-514.2000; LEWIS LK, 1992, J BACTERIOL, V174, P3377, DOI 10.1128/jb.174.10.3377-3385.1992; LEWIS LK, 1992, J BACTERIOL, V174, P5110, DOI 10.1128/JB.174.15.5110-5116.1992; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Lubini P, 1994, CHEM BIOL, V1, P39, DOI 10.1016/1074-5521(94)90039-6; Lukianova OA, 2005, CURR OPIN CHEM BIOL, V9, P145, DOI 10.1016/j.cbpa.2005.02.006; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; McGlynn P, 2000, NUCLEIC ACIDS RES, V28, P2324, DOI 10.1093/nar/28.12.2324; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 1999, NUCLEIC ACIDS RES, V27, P3049, DOI 10.1093/nar/27.15.3049; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Ozsoy AZ, 2003, NUCLEIC ACIDS RES, V31, P1554, DOI 10.1093/nar/gkg243; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159; Pichierri P, 2004, EMBO J, V23, P3154, DOI 10.1038/sj.emboj.7600277; Ralf C, 2006, J BIOL CHEM, V281, P22839, DOI 10.1074/jbc.M604268200; Rudolf J, 2006, MOL CELL, V23, P801, DOI 10.1016/j.molcel.2006.07.019; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Sun H, 1999, NUCLEIC ACIDS RES, V27, P1978, DOI 10.1093/nar/27.9.1978; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Van Dyk TK, 2001, J BACTERIOL, V183, P5496, DOI 10.1128/JB.183.19.5496-5505.2001; Voloshin ON, 2000, J MOL BIOL, V303, P709, DOI 10.1006/jmbi.2000.4163; Voloshin ON, 2003, J BIOL CHEM, V278, P28284, DOI 10.1074/jbc.M301188200; Warfield KL, 2006, CURR OPIN MOL THER, V8, P93; Weiss DS, 2004, MOL MICROBIOL, V54, P588, DOI 10.1111/j.1365-2958.2004.04283.x; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x; Wu L, 2006, ANNU REV GENET, V40, P279, DOI 10.1146/annurev.genet.40.110405.090636	69	60	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2007	282	25					18437	18447		10.1074/jbc.M700376200	http://dx.doi.org/10.1074/jbc.M700376200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	179PK	17416902	hybrid			2022-12-27	WOS:000247302000050
J	Klutts, JS; Levery, SB; Doering, TL				Klutts, J. Stacey; Levery, Steven B.; Doering, Tamara L.			A beta-1,2-xylosyltransferase from Cryptococcus neoformans defines a new family of glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE; CATALYTIC MECHANISM; VIRULENCE; YEAST; LAURENTII; PROTEIN; ALPHA-1,3-MANNOSYLTRANSFERASE; METHYLATION; REQUIRES; PATHWAY	Cryptococcus neoformans is an opportunistic fungal pathogen characterized by a prominent polysaccharide capsule that envelops the cell. Although this capsule is dispensable for in vitro growth, its presence is essential for virulence. The capsule is primarily made of two xylose-containing polysaccharides, glucuronoxylomannan and galactoxylomannan. There are likely to be multiple xylosyltransferases (XTs) involved in capsule synthesis, and the activities of these enzymes are potentially important for cryptococcal virulence. A beta-1,2-xylosyltransferase with specificity appropriate for capsule synthesis was purified similar to 3000-fold from C. neoformans, and the corresponding gene was identified and cloned. This sequence conferred XT activity when expressed in Saccharomyces cerevisiae, which lacks endogenous XT activity. The gene, termed CXT1 for cryptococcal xylosyltransferase 1, encodes a 79-kDa type II membrane protein with an N-linked glycosylation site and two DXD motifs. These latter motifs are believed to coordinate divalent cation binding in the activity of glycosyltransferases. Site-directed mutagenesis of one DXD motif abolished Cxt1p activity, even though this activity does not depend on the addition of a divalent cation. This may indicate a novel catalytic mechanism for glycosyl transfer. Five homologs of Cxt1p were found in the genome sequence of C. neoformans and 34 within the sequences of other fungi, although none were found in other organisms. Many of the homologous proteins are similar in size to Cxt1p, and all are conserved with respect to the essential DXD motif. These proteins represent a new family of glycosyltransferases, found exclusively within the fungal kingdom.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA	Washington University (WUSTL); Washington University (WUSTL); University System Of New Hampshire; University of New Hampshire	Doering, TL (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave,Campus Box 8230, St Louis, MO 63110 USA.	doering@wustl.edu		Klutts, James/0000-0003-3788-1940	NCRR NIH HHS [R21 RR20355] Funding Source: Medline; NIGMS NIH HHS [GM R01 071007, F32 GM072341, R01 GM071007, G32 GM 072341] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR020355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071007, F32GM072341] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 2003, CURRENT PROTOCOLS MO, V2, P13; Bar-Peled M, 2001, P NATL ACAD SCI USA, V98, P12003, DOI 10.1073/pnas.211229198; Barchiesi F, 2005, J INFECTION, V51, P10, DOI 10.1016/j.jinf.2004.07.013; Bencur P, 2005, BIOCHEM J, V388, P515, DOI 10.1042/BJ20042091; Bose I, 2003, EUKARYOT CELL, V2, P655, DOI 10.1128/EC.2.4.655-663.2003; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Chang YC, 1996, INFECT IMMUN, V64, P1977, DOI 10.1128/IAI.64.6.1977-1983.1996; CHANG YC, 1994, MOL CELL BIOL, V14, P4912, DOI 10.1128/MCB.14.7.4912; Chang YC, 1998, INFECT IMMUN, V66, P2230, DOI 10.1128/IAI.66.5.2230-2236.1998; Chayakulkeeree M, 2006, INFECT DIS CLIN N AM, V20, P507, DOI 10.1016/j.idc.2006.07.001; Cherniak R, 1998, CLIN DIAGN LAB IMMUN, V5, P146; Ciucanu I, 2003, J AM CHEM SOC, V125, P16213, DOI 10.1021/ja035660t; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Doering TL, 1999, J BACTERIOL, V181, P5482, DOI 10.1128/JB.181.17.5482-5488.1999; Fries BC, 1999, INFECT IMMUN, V67, P6076, DOI 10.1128/IAI.67.11.6076-6083.1999; Goldman DL, 1998, P NATL ACAD SCI USA, V95, P14967, DOI 10.1073/pnas.95.25.14967; Griffith CL, 2004, J BIOL CHEM, V279, P51669, DOI 10.1074/jbc.M408889200; Heise N, 2002, GLYCOBIOLOGY, V12, P409, DOI 10.1093/glycob/cwf053; HELLERQVIST CG, 1990, METHOD ENZYMOL, V193, P554, DOI 10.1016/0076-6879(90)93438-Q; HELLERQVIST CG, 1990, METHOD BIOCHEM ANAL, V34, P91; Hodson N, 2000, J BIOL CHEM, V275, P27311; Jain N, 2006, FEMS YEAST RES, V6, P480, DOI 10.1111/j.1567-1364.2006.00039.x; Janbon G, 2001, MOL MICROBIOL, V42, P453, DOI 10.1046/j.1365-2958.2001.02651.x; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; Klutts JS, 2006, FEMS YEAST RES, V6, P499, DOI 10.1111/j.1567-1364.2006.00054.x; KWONCHUNG KJ, 1986, INFECT IMMUN, V51, P218, DOI 10.1128/IAI.51.1.218-223.1986; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; McFadden DC, 2006, J BIOL CHEM, V281, P1868, DOI 10.1074/jbc.M509465200; Moyrand F, 2004, EUKARYOT CELL, V3, P1513, DOI 10.1128/EC.3.6.1513-1524.2004; Moyrand F, 2002, MOL MICROBIOL, V45, P837, DOI 10.1046/j.1365-2958.2002.03059.x; Okabayashi K, 2007, MYCOPATHOLOGIA, V163, P1, DOI 10.1007/s11046-006-0083-0; Packer NH, 1998, GLYCOCONJUGATE J, V15, P737, DOI 10.1023/A:1006983125913; RAIZADA MK, 1975, J BIOL CHEM, V250, P3310; Reese AJ, 2007, MOL MICROBIOL, V63, P1385, DOI 10.1111/j.1365-2958.2006.05551.x; SCHUTZBACH JS, 1974, J BIOL CHEM, V249, P2953; SCHUTZBACH JS, 1972, J BIOL CHEM, V247, P6574; Shibayama K, 1999, FEMS MICROBIOL LETT, V174, P105, DOI 10.1111/j.1574-6968.1999.tb13555.x; Sommer U, 2003, J BIOL CHEM, V278, P47724, DOI 10.1074/jbc.M307223200; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Vaishnav VV, 1998, CARBOHYD RES, V306, P315, DOI 10.1016/S0008-6215(97)10058-1; Vecchiarelli A, 2005, CURR MOL MED, V5, P413, DOI 10.2174/1566524054022585; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; WILSON DE, 1968, P SOC EXP BIOL MED, V127, P820, DOI 10.3181/00379727-127-32812; Zhang YN, 1999, GLYCOBIOLOGY, V9, P815, DOI 10.1093/glycob/9.8.815	47	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2007	282	24					17890	17899		10.1074/jbc.M701941200	http://dx.doi.org/10.1074/jbc.M701941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	176KS	17430900	hybrid			2022-12-27	WOS:000247084500062
J	Korneeva, VS; Cameron, CE				Korneeva, Victoria S.; Cameron, Craig E.			Structure-function relationships of the viral RNA-dependent RNA polymerase - Fidelity, replication speed, and initiation mechanism determined by a residue in the ribose-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLIOVIRUS RNA; RIBONUCLEOTIDE REDUCTASE; INTERMOLECULAR URIDYLYLATION; LETHAL MUTAGENESIS; VPG URIDYLYLATION; PROTEIN; CIS; IDENTIFICATION; LOCALIZATION; 3D(POL)	Studies of the RNA-dependent RNA polymerase (RdRp) from poliovirus (PV), 3Dpol, have shown that Asn-297 permits this enzyme to distinguish ribose from 2'-deoxyribose. All animal RNA viruses have Asn at the structurally homologous position of their polymerases, suggesting a conserved function for this residue. However, all prokaryotic RNA viruses have Glu at this position. In the presence of Mg2+, the apparent affinity of Glu-297 3Dpol for 2'-deoxyribonucleotides was decreased by 6-fold relative to wild type without a substantial difference in the fidelity of 2'-dNMP incorporation. The fidelity of ribonucleotide misincorporation for Glu-297 3Dpol was reduced by 14-fold relative to wild type. A 4- to 11-fold reduction in the rate of ribonucleotide incorporation was observed. Glu-297 PV was unable to grow in HeLa cells due to a replication defect equivalent to that observed for a mutant PV encoding an inactive polymerase. Evaluation of the protein-(VPg)-primed initiation reaction showed that only half of the Glu-297 3Dpol initiation complexes were capable of producing VPg-pUpU product and that the overall yield of uridylylated VPg products was reduced by 20-fold relative to wild-type enzyme, a circumstance attributable to a reduced affinity for UTP. These studies identify the first RdRp derivative with a mutator phenotype and provide a mechanistic basis for the elevated mutation frequency of RNA phage relative to animal RNA viruses observed in culture. Although protein-primed initiation and RNA-primed elongation complexes employ the same polymerase active site, the functional differences reported here imply significant structural differences between these complexes.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	cec9@psu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053531, R56AI053531] Funding Source: NIH RePORTER; NIAID NIH HHS [AI053531, R01 AI053531, R01 AI053531-05, R37 AI053531, R56 AI053531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMBROS V, 1978, J BIOL CHEM, V253, P5263; An XX, 2006, GENETICS, V173, P63, DOI 10.1534/genetics.105.055236; Arnold JJ, 2005, J BIOL CHEM, V280, P25706, DOI 10.1074/jbc.M503444200; Arnold JJ, 2004, BIOCHEMISTRY-US, V43, P5126, DOI 10.1021/bi035212y; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; Bull JJ, 2007, J VIROL, V81, P2930, DOI 10.1128/JVI.01624-06; Castro C, 2005, VIRUS RES, V107, P141, DOI 10.1016/j.virusres.2004.11.004; Cornell CT, 2002, VIROLOGY, V298, P200, DOI 10.1006/viro.2002.1481; CRAWFORD NM, 1983, P NATL ACAD SCI-BIOL, V80, P7452, DOI 10.1073/pnas.80.24.7452; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Crotty S, 2003, J VIROL, V77, P5378, DOI 10.1128/JVI.77.9.5378-5388.2003; Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598; DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171; Ferrer-Orta C, 2006, EMBO J, V25, P880, DOI 10.1038/sj.emboj.7600971; Franco D, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-86; Gohara DW, 2000, J BIOL CHEM, V275, P25523, DOI 10.1074/jbc.M002671200; Gohara DW, 2004, BIOCHEMISTRY-US, V43, P5149, DOI 10.1021/bi035429s; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; Harki DA, 2002, BIOCHEMISTRY-US, V41, P9026, DOI 10.1021/bi026120w; Harki DA, 2006, J MED CHEM, V49, P6166, DOI 10.1021/jm060872x; Hayden FG, 2006, CURR OPIN INFECT DIS, V19, P169, DOI 10.1097/01.qco.0000216628.51563.b1; Hayden FG, 1999, ADV EXP MED BIOL, V458, P55; Herold J, 2000, J VIROL, V74, P6394, DOI 10.1128/JVI.74.14.6394-6400.2000; Jain R, 2006, BIOTECHNOL PROGR, V22, P1650, DOI 10.1021/bp060161s; Jochmans D, 2006, J VIROL, V80, P12283, DOI 10.1128/JVI.00889-06; Kim WR, 2002, HEPATOLOGY, V36, pS30, DOI 10.1053/jhep.2002.36791; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Lee YD, 2006, GENE DEV, V20, P334, DOI 10.1101/gad.1380506; Lyle JM, 2002, J BIOL CHEM, V277, P16324, DOI 10.1074/jbc.M112429200; Lyons T, 2001, J VIROL, V75, P10696, DOI 10.1128/JVI.75.22.10696-10708.2001; Murray KE, 2003, J VIROL, V77, P4739, DOI 10.1128/JVI.77.8.4739-4750.2003; Nakaishi T, 2002, J BIOSCI BIOENG, V93, P322, DOI 10.1263/jbb.93.322; Parsley TB, 1999, J BIOL CHEM, V274, P12867, DOI 10.1074/jbc.274.18.12867; Pathak HB, 2002, J BIOL CHEM, V277, P31551, DOI 10.1074/jbc.M204408200; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 2003, J BIOL CHEM, V278, P43951, DOI 10.1074/jbc.M307441200; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Richards OC, 2006, J VIROL, V80, P7405, DOI 10.1128/JVI.02533-05; Rieder E, 2000, J VIROL, V74, P10371, DOI 10.1128/JVI.74.22.10371-10380.2000; Semler BL, 2002, MOL BIOL PICORNAVIRU; Sharma N, 2005, J VIROL, V79, P3565, DOI 10.1128/JVI.79.6.3565-3577.2005; Tellez AB, 2006, J MOL BIOL, V357, P665, DOI 10.1016/j.jmb.2005.12.044; Thompson AA, 2004, EMBO J, V23, P3462, DOI 10.1038/sj.emboj.7600357; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Vignuzzi M, 2005, VIRUS RES, V107, P173, DOI 10.1016/j.virusres.2004.11.007; Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005; XIANG WK, 1995, J VIROL, V69, P3658, DOI 10.1128/JVI.69.6.3658-3667.1995; Yang Y, 2004, J BIOL CHEM, V279, P12659, DOI 10.1074/jbc.M312992200; Yao RJ, 2003, P NATL ACAD SCI USA, V100, P6628, DOI 10.1073/pnas.1131932100	52	48	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16135	16145		10.1074/jbc.M610090200	http://dx.doi.org/10.1074/jbc.M610090200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17400557	Green Accepted, hybrid			2022-12-27	WOS:000246794300022
J	Meloni, G; Faller, P; Vasak, M				Meloni, Gabriele; Faller, Peter; Vasak, Milan			Redox silencing of copper in metal-linked neurodegenerative disorders reaction of Zn(7)metallothionein-3 with Cu2+ ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-INHIBITORY FACTOR; ALZHEIMERS-DISEASE BRAIN; OXIDATIVE STRESS; AMYLOID-BETA; METALLOTHIONEIN-III; TERMINAL DOMAIN; STRUCTURAL-CHARACTERIZATION; PHOTOPHYSICAL PROPERTIES; BIOINORGANIC CHEMISTRY; TRANSCRIPTION FACTOR	Dysregulation of copper and zinc homeostasis in the brain plays a critical role in Alzheimer disease (AD). Copper binding to amyloid-beta peptide (A beta) is linked with the neurotoxicity of A beta and free radical damage. Metallothionein-3 (MT-3) is a small cysteine- and metal-rich protein expressed in the brain and found down-regulated in AD. This protein occurs intra- and extracellularly, and it plays an important role in the metabolism of zinc and copper. In cell cultures Zn7MT-3, by an unknown mechanism, protects neurons from the toxicity of A beta. We have, therefore, used a range of complementary spectroscopic and biochemical methods to characterize the interaction of Zn7MT-3 with free Cu2+ ions. We show that Zn7MT-3 scavenges free Cu2+ ions through their reduction to Cu+ and binding to the protein. In this reaction thiolate ligands are oxidized to disulfides concomitant with Zn2+ release. The binding of the first four Cu2+ is cooperative forming a Cu(I)(4)-thiolate cluster in the N-terminal domain of Cu-4, Zn4MT-3 together with two disulfides bonds. The Cu-4-thiolate cluster exhibits an unusual stability toward air oxygen. The results of UV-visible, CD, and Cu(I) phosphorescence at 77 K suggest the existence of metal-metal interactions in this cluster. We have demonstrated that Zn7MT-3 in the presence of ascorbate completely quenches the copper-catalyzed hydroxyl radical (OH.) production. Thus, zinc-thiolate clusters in Zn7MT-3 can efficiently silence the redox-active free Cu2+ ions. The biological implication of our studies as to the protective role of Zn7MT-3 from the Cu2+ toxicity in AD and other neurodegenerative disorders is discussed.	Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; Lab Chimie Coordinat, F-31077 Toulouse, France	University of Zurich	Vasak, M (corresponding author), Univ Zurich, Dept Biochem, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	mvasak@bioc.unizh.ch	Faller, Peter/B-9614-2018	Faller, Peter/0000-0001-8013-0806; Meloni, Gabriele/0000-0003-4976-1401				Adlard PA, 2006, J ALZHEIMERS DIS, V10, P145; Aravindakumar CT, 1999, BIOCHEM J, V344, P253, DOI 10.1042/0264-6021:3440253; AVDEEF A, 1978, INORG CHEM, V17, P2182, DOI 10.1021/ic50186a031; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Belle C, 2005, J INORG BIOCHEM, V99, P1929, DOI 10.1016/j.jinorgbio.2005.06.013; Bogumil R, 1998, EUR J BIOCHEM, V255, P172, DOI 10.1046/j.1432-1327.1998.2550172.x; Bogumil R, 1996, EUR J BIOCHEM, V238, P698, DOI 10.1111/j.1432-1033.1996.0698w.x; Brezova V, 2003, J PHYS CHEM B, V107, P2415, DOI 10.1021/jp027743m; Brown DR, 2004, DALTON T, P1907, DOI 10.1039/b401985g; Burkitt MJ, 2001, ARCH BIOCHEM BIOPHYS, V394, P117, DOI 10.1006/abbi.2001.2509; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; Cai L, 2005, CURR MED CHEM, V12, P2753, DOI 10.2174/092986705774462950; Calderone V, 2005, P NATL ACAD SCI USA, V102, P51, DOI 10.1073/pnas.0408254101; CASASFINET JR, 1991, FEBS LETT, V281, P205, DOI 10.1016/0014-5793(91)80394-I; Cookson MR, 1999, BRAIN PATHOL, V9, P165; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Doraiswamy PM, 2004, LANCET NEUROL, V3, P431, DOI 10.1016/S1474-4422(04)00809-9; Faller P, 1999, BIOCHEMISTRY-US, V38, P10158, DOI 10.1021/bi990489c; Farrell RA, 1996, BIOCHEMISTRY-US, V35, P1571, DOI 10.1021/bi9517087; FELIX K, 1993, BIOCHIM BIOPHYS ACTA, V1203, P104, DOI 10.1016/0167-4838(93)90042-P; FORD PC, 1993, ACCOUNTS CHEM RES, V26, P220, DOI 10.1021/ar00028a013; Ford PC, 1999, CHEM REV, V99, P3625, DOI 10.1021/cr960109i; Gaggelli E, 2006, CHEM REV, V106, P1995, DOI 10.1021/cr040410w; Hasler DW, 2000, BIOCHEMISTRY-US, V39, P14567, DOI 10.1021/bi001569f; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Irie Y, 2001, BIOCHEM BIOPH RES CO, V282, P416, DOI 10.1006/bbrc.2001.4594; Kawashima T, 2000, DEMENT GERIATR COGN, V11, P251, DOI 10.1159/000017247; KHAN MMT, 1967, J AM CHEM SOC, V89, P4176, DOI 10.1021/ja00992a036; Kitzberger R, 2005, METAB BRAIN DIS, V20, P295, DOI 10.1007/s11011-005-7910-8; Knipp M, 2005, BIOCHEMISTRY-US, V44, P3159, DOI 10.1021/bi047636d; KYLE KR, 1991, J AM CHEM SOC, V113, P2954, DOI 10.1021/ja00008a026; Manevich Y, 1997, RADIAT RES, V148, P580, DOI 10.2307/3579734; Martin BL, 2006, MOL CELL BIOCHEM, V283, P129, DOI 10.1007/s11010-006-2390-7; MASTERS BA, 1994, J NEUROSCI, V14, P5844; Maynard CJ, 2005, INT J EXP PATHOL, V86, P147, DOI 10.1111/j.0959-9673.2005.00434.x; MEHROTRA PK, 1978, INORG CHEM, V17, P2187, DOI 10.1021/ic50186a032; Meloni G, 2005, J BIOCHEM BIOPH METH, V64, P76, DOI 10.1016/j.jbbm.2005.05.005; Ohta T, 2000, INORG CHEM, V39, P4358, DOI 10.1021/ic000018a; Oz G, 2001, BIOCHEMISTRY-US, V40, P11433, DOI 10.1021/bi010827l; PEDERSEN AO, 1980, EUR J BIOCHEM, V106, P291; POUNTNEY DL, 1994, FEBS LETT, V345, P193, DOI 10.1016/0014-5793(94)00452-8; POUNTNEY DL, 1994, BIOCHEMISTRY-US, V33, P9699, DOI 10.1021/bi00198a040; PRESTA A, 1994, CHIRALITY, V6, P521, DOI 10.1002/chir.530060703; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rasia RM, 2005, P NATL ACAD SCI USA, V102, P4294, DOI 10.1073/pnas.0407881102; Raveh O, 2000, FREE RADICAL BIO MED, V29, P131, DOI 10.1016/S0891-5849(00)00332-4; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; Romero-Isart N, 2002, J BIOL CHEM, V277, P37023, DOI 10.1074/jbc.M205730200; Roschitzki B, 2003, BIOCHEMISTRY-US, V42, P9822, DOI 10.1021/bi034816z; Roschitzki B, 2002, J BIOL INORG CHEM, V7, P611, DOI 10.1007/s00775-002-0339-1; SABIN F, 1992, INORG CHEM, V31, P1941, DOI 10.1021/ic00036a040; Sogawa CA, 2001, ACTA MED OKAYAMA, V55, P1; STEVENSON KL, 1988, INORG CHEM, V27, P3472, DOI 10.1021/ic00293a009; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Uchida Y, 2002, J BIOL CHEM, V277, P32353, DOI 10.1074/jbc.M111263200; Vaher M, 2001, J INORG BIOCHEM, V83, P1, DOI 10.1016/S0162-0134(00)00183-5; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; Varma S D, 1990, Lens Eye Toxic Res, V7, P49; VASAK M, 1991, METHOD ENZYMOL, V205, P452; VASAK M, 1981, BIOCHEMISTRY-US, V20, P2852, DOI 10.1021/bi00513a022; Wang H, 2006, FEBS LETT, V580, P795, DOI 10.1016/j.febslet.2005.12.099; WESER U, 1985, STRUCT BOND, V61, P145; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350; Yu WH, 2001, BRAIN RES, V894, P37, DOI 10.1016/S0006-8993(00)03196-6; Zangger K, 2001, FASEB J, V15, P1303, DOI 10.1096/fj.00-0641fje	67	101	104	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2007	282	22					16068	16078		10.1074/jbc.M701357200	http://dx.doi.org/10.1074/jbc.M701357200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	172HH	17389590	hybrid			2022-12-27	WOS:000246794300015
J	Boggio, R; Passafaro, A; Chiocca, S				Boggio, Roberto; Passafaro, Alfonso; Chiocca, Susanna			Targeting SUMO E1 to ubiquitin ligases - A viral strategy to counteract sumoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; SOCS-BOX; HISTONE DEACETYLASE-1; ADENOVIRUS; DEGRADATION; COMPLEX; IDENTIFICATION; ELONGATION; ACTIVATION; MECHANISM	SUMO-1 (small ubiquitin-related modifier-1) is a ubiquitin-like family member that is conjugated to its substrates through three discrete enzymatic steps, activation (involving the E1 enzyme (SAE1/SAE2)), conjugation (involving the E2 enzyme), and substrate modification (through the cooperation of the E2 and E3 protein ligases). The adenoviral protein Gam1 inactivates E1, both in vitro and in vivo, followed by SAE1/SAE2 degradation. We have shown here that Gam1 possesses a C-terminal SOCS domain that allows its interaction with two cellular cullin RING ( really interesting new gene) ubiquitin ligases. We demonstrate that Gam1 is necessary for the recruitment of SAE1/SAE2 into Cul2/5-EloB/C-Roc1 ubiquitin ligase complexes and for subsequent SAE1 ubiquitylation and degradation. The degradation of SAE2 is not tightly related to Gam1 but is a consequent effect of SAE1 disappearance. These results reveal the mechanism by which a viral protein inactivates and subsequently degrades an essential cellular enzyme, arresting a key regulatory pathway.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Chiocca, S (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	susanna.chiocca@ifom-ieo-campus.it	Chiocca, Susanna/AAC-8863-2019; Chiocca, Susanna/K-5233-2016	Chiocca, Susanna/0000-0002-9721-0850				Barry Michele, 2006, Sci STKE, V2006, ppe21; Blanchette P, 2004, MOL CELL BIOL, V24, P9619, DOI 10.1128/MCB.24.21.9619-9629.2004; Boggio R, 2004, MOL CELL, V16, P549, DOI 10.1016/j.molcel.2004.11.007; Chiocca S, 1997, J VIROL, V71, P3168, DOI 10.1128/JVI.71.4.3168-3177.1997; Chiocca S, 2002, CURR BIOL, V12, P594, DOI 10.1016/S0960-9822(02)00720-0; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rose KM, 2004, TRENDS MOL MED, V10, P291, DOI 10.1016/j.molmed.2004.04.008; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204	22	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15376	15382		10.1074/jbc.M700889200	http://dx.doi.org/10.1074/jbc.M700889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17392274	hybrid			2022-12-27	WOS:000246589600013
J	Dodd, JR; Christie, DL				Dodd, Joanna R.; Christie, David L.			Selective amino acid substitutions convert the creatine transporter to a gamma-aminobutyric acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE DOMAIN-I; DEPENDENT NEUROTRANSMITTER TRANSPORTERS; SEROTONIN TRANSPORTER; TRANSLOCATION PATHWAY; BACTERIAL HOMOLOG; GABA TRANSPORTER; MOUSE-BRAIN; SUBSTRATE; FAMILY; EXPRESSION	The creatine transporter (CRT) is a member of a large family of sodium-dependent neurotransmitter and amino acid transporters. The CRT is closely related to the gamma-aminobutyric acid (GABA) transporter, GAT-1, yet GABA is not an effective substrate for the CRT. The high resolution structure of a prokaryotic homologue, LeuT has revealed precise details of the substrate binding site for leucine(Yamashita, A., Singh, S. K., Kawate, T., Jin, Y., and Gouaux, E. (2005) Nature 437, 215-223). We have now designed mutations based on sequence comparisons of the CRT with GABA transporters and the LeuT structural template in an attempt to alter the substrate specificity of the CRT. Combinations of two or three amino acid substitutions at four selected positions resulted in the loss of creatine transport activity and gain of a specific GABA transport function. GABA transport by the "gain of function" mutants was sensitive to nipecotic acid, a competitive inhibitor of GABA transporters. Our results show LeuT to be a good structural model to identify amino acid residues involved in the substrate and inhibitor selectivity of eukaryotic sodium-dependent neurotransmitter and amino acid transporters. However, modification of the binding site alone appears to be insufficient for efficient substrate translocation. Additional residues must mediate the conformational changes required for the diffusion of substrate from the binding site to the cytoplasm.	Univ Auckland, Sch Biol Sci, Mol Cellular & Dev Biol Sect, Auckland Mail Ctr, Auckland 1142, New Zealand	University of Auckland	Christie, DL (corresponding author), Univ Auckland, Sch Biol Sci, Mol Cellular & Dev Biol Sect, Auckland Mail Ctr, Private Bag 92019, Auckland 1142, New Zealand.	d.christie@auckland.ac.nz	Christie, David L/C-8065-2009					Androutsellis-Theotokis A, 2003, J BIOL CHEM, V278, P12703, DOI 10.1074/jbc.M206563200; Beuming T, 2006, MOL PHARMACOL, V70, P1630, DOI 10.1124/mol.106.026120; Broer S, 2006, NEUROCHEM INT, V48, P559, DOI 10.1016/j.neuint.2005.11.021; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; Dodd JR, 2005, J BIOL CHEM, V280, P32649, DOI 10.1074/jbc.M506723200; Dodd JR, 2001, J BIOL CHEM, V276, P46983, DOI 10.1074/jbc.M107137200; Dodd JR, 1999, BBA-GEN SUBJECTS, V1472, P128, DOI 10.1016/S0304-4165(99)00113-0; Gether U, 2006, TRENDS PHARMACOL SCI, V27, P375, DOI 10.1016/j.tips.2006.05.003; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; GUIMBAL C, 1993, J BIOL CHEM, V268, P8418; GUIMBAL C, 1994, J MOL BIOL, V241, P317, DOI 10.1006/jmbi.1994.1507; Henry LK, 2006, NEURON, V49, P791, DOI 10.1016/j.neuron.2006.03.002; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; JOHNSTON GAR, 1976, J NEUROCHEM, V26, P83; Kanner BI, 2005, NATURE, V437, P203, DOI 10.1038/437203a; Kanner BI, 2003, J BIOL CHEM, V278, P3705, DOI 10.1074/jbc.M210525200; Kovalev G I, 1981, Biull Eksp Biol Med, V91, P692; LIU QR, 1993, J BIOL CHEM, V268, P2106; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; Melamed N, 2004, MOL PHARMACOL, V65, P1452, DOI 10.1124/mol.65.6.1452; Nelson N, 1998, J NEUROCHEM, V71, P1785; Quick M, 2006, J BIOL CHEM, V281, P26444, DOI 10.1074/jbc.M602438200; Rosenberg EH, 2004, AM J HUM GENET, V75, P97, DOI 10.1086/422102; Saier MH, 1999, J CELL BIOCHEM, P84; Salomons GS, 2003, J INHERIT METAB DIS, V26, P309, DOI 10.1023/A:1024405821638; Snow RJ, 2001, MOL CELL BIOCHEM, V224, P169, DOI 10.1023/A:1011908606819; TANFORD C, 1983, P NATL ACAD SCI-BIOL, V80, P3701, DOI 10.1073/pnas.80.12.3701; Wyss M, 2002, NEUROSCIENCE, V112, P243, DOI 10.1016/S0306-4522(02)00088-X; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang YW, 2006, J BIOL CHEM, V281, P36213, DOI 10.1074/jbc.M605468200; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200	34	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15528	15533		10.1074/jbc.M611705200	http://dx.doi.org/10.1074/jbc.M611705200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400549	hybrid			2022-12-27	WOS:000246589600029
J	Horion, J; Gloire, G; El Mjiyad, N; Quivy, V; Vermeulen, L; Vanden Berghe, W; Haegeman, G; Van Lint, C; Piette, J; Habraken, Y				Horion, Julie; Gloire, Geoffrey; El Mjiyad, Nadia; Quivy, Vincent; Vermeulen, Linda; Vanden Berghe, Wim; Haegeman, Guy; Van Lint, Carine; Piette, Jacques; Habraken, Yvette			Histone deacetylase inhibitor trichostatin A sustains sodium pervanadate-induced NF-kappa B activation by delaying I kappa B alpha mRNA resynthesis - Comparison with tumor necrosis factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-1 MSK1; TYROSINE PHOSPHORYLATION; OXIDATIVE STRESS; TRANSCRIPTIONAL ACTIVATION; PHOTODYNAMIC THERAPY; GENE-EXPRESSION; CELLS; P65; ACETYLATION; PATHWAY	NF-kappa B is a crucial transcription factor tightly regulated by protein interactions and post-translational modifications, like phosphorylation and acetylation. A previous study has shown that trichostatin A (TSA), a histone deacetylase inhibitor, potentiates tumor necrosis factor (TNF) alpha-elicited NF-kappa B activation and delays I kappa B alpha cytoplasmic reappearance. Here, we demonstrated that TSA also prolongs NF-kappa B activation when induced by the insulino-mimetic pervanadate (PV), a tyrosine phosphatase inhibitor that initiates an atypical NF-kappa B signaling. This extension is similarly correlated with delayed I kappa B alpha cytoplasmic reappearance. However, whereas TSA causes a prolonged IKK activity when added to TNF alpha, it does not when added to PV. Instead, quantitative reverse transcriptase-PCR revealed a decrease of i kappa b alpha mRNA level after TSA addition to PV stimulation. This synthesis deficit of the inhibitor could explain the sustained NF-kappa B residence in the nucleus. In vivo analysis by chromatin immunoprecipitation assays uncovered that, for PV induction but not for TNF alpha, the presence of TSA provokes several impairments on the i kappa b alpha promoter: (i) diminution of RNA Pol II recruitment; (ii) reduced acetylation and phosphorylation of histone H3-Lys(14) and -Ser(10), respectively; (iii) decreased presence of phosphorylated p65-Ser536; and (iv) reduction of IKK alpha binding. The recruitment of these proteins on the icam-1 promoter, another NF-kappa B-regulated gene, is not equally affected, suggesting a promoter specificity of PV with TSA stimulation. Taken together, these data suggest that TSA acts differently depending on the NF-kappa B pathway and the targeted promoter in question. This indicates that one overall histone deacetylase role is to inhibit NF-kappa B activation by molecular mechanisms specific of the stimulus and the promoter.	Univ Liege, GIGA R, Lab Virol & Immunol, B-4000 Cointe Ougree, Belgium; Univ Brussels, IBMM, Mol Virol Lab, B-6041 Gosselies, Belgium; Univ Ghent, LEGEST, B-9000 Ghent, Belgium	University of Liege; Universite Libre de Bruxelles; Ghent University	Habraken, Y (corresponding author), Univ Liege, GIGA R, Lab Virol & Immunol, B-4000 Cointe Ougree, Belgium.	yvette.habraken@ulg.ac.be	Berghe, Wim Vanden/S-6425-2018; Vanden Berghe, Wim/HGE-4696-2022	Berghe, Wim Vanden/0000-0003-0161-7355; 				Adam E, 2003, MOL CELL BIOL, V23, P6200, DOI 10.1128/MCB.23.17.6200-6209.2003; Algarte M, 1999, MOL CELL BIOL, V19, P6140; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Campbell KJ, 2004, BIOCHEM SOC T, V32, P1087, DOI 10.1042/BST0321087; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Gloire G, 2006, ONCOGENE, V25, P5485, DOI 10.1038/sj.onc.1209542; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1081, DOI 10.1016/j.bcp.2006.06.017; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Quivy V, 2004, BIOCHEM PHARMACOL, V68, P1221, DOI 10.1016/j.bcp.2004.05.039; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Srivastava AK, 2005, DIABETIC MED, V22, P2, DOI 10.1111/j.1464-5491.2004.01381.x; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; VAN LC, 1996, GENE EXPRESSION, V5, P245; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2006, CANC TREAT, V130, P89; Vertegaal ACO, 2000, CELL SIGNAL, V12, P759, DOI 10.1016/S0898-6568(00)00133-9; Volanti C, 2005, ONCOGENE, V24, P2981, DOI 10.1038/sj.onc.1208481; Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	45	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15383	15393		10.1074/jbc.M609166200	http://dx.doi.org/10.1074/jbc.M609166200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17409387	hybrid			2022-12-27	WOS:000246589600014
J	Kim, D; Probst, L; Das, C; Tucker, PW				Kim, Dongkyoon; Probst, Loren; Das, Chhaya; Tucker, Philip W.			REKLES is an ARID3-restricted multifunctional domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; NUCLEAR-MATRIX; ARID FAMILY; PROTEIN; TRANSCRIPTION; GENE; BRIGHT; REGIONS; COMPLEX; SATB1	Bright/Dril1/ARID3a is a B cell-specific, matrix association (or attachment) region-binding transcriptional regulator of immunoglobulin heavy chain genes and of E2F1-dependent cell cycle progression. Bright contains a central DNA binding domain termed ARID(AT-rich interacting domain) and a C-terminal region termed REKLES (for a conserved amino acid motif). The ARID domain has been identified in seven highly conserved families of metazoan proteins (ARID1-5 and JARID1-2), whereas REKLES is found only in the ARID3 subfamily (composed of Bright/ARID3a, Bdp/ARID3b, and Bright-like/ARID3c). REKLES consists of two subdomains: a modestly conserved N-terminal REKLES alpha and a highly conserved (among ARID3 orthologous proteins) C-terminal REKLES beta. Previously we showed that Bright undergoes nucleocytoplasmic shuttling and that REKLES alpha and -beta were required, respectively, for nuclear import and Crm1-dependent nuclear export. Here we show that Bright further requires REKLES beta for self- association or paralogue association and for nuclear matrix targeting. REKLES promotes and regulates the extent of Bright multimerization, which occurs in the absence or presence of target DNA and is necessary for specific DNA binding. REKLES beta-mediated interaction of Bright with Bdp, which localizes strictly to the nucleus, traps Bright within the nucleus via neutralization of its nuclear export activity. These results identify REKLES as a multifunctional domain that has co-evolved with and regulates functional properties of the ARID3 DNA binding domain.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Tucker, PW (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, 1 Univ Stn A5000,NMS1-124, Austin, TX 78712 USA.	philtucker@mail.utexas.edu						Alvarez JD, 2000, GENE DEV, V14, P521; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; Goebel P, 2002, J IMMUNOL, V169, P2477, DOI 10.4049/jimmunol.169.5.2477; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Iwahara J, 2002, EMBO J, V21, P1197, DOI 10.1093/emboj/21.5.1197; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P192; Kaplan MH, 2001, J BIOL CHEM, V276, P21325, DOI 10.1074/jbc.M100836200; Kim D, 2006, MOL CELL BIOL, V26, P2187, DOI 10.1128/MCB.26.6.2187-2201.2006; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Kim S, 2004, J BIOL CHEM, V279, P16670, DOI 10.1074/jbc.M312115200; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; Nixon JC, 2004, J BIOL CHEM, V279, P52465, DOI 10.1074/jbc.M403028200; Numata S, 1999, CANCER RES, V59, P3741; Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145; Peeper DS, 2002, NAT CELL BIOL, V4, P148, DOI 10.1038/ncb742; Reich NC, 2006, NAT REV IMMUNOL, V6, P602, DOI 10.1038/nri1885; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Seo J, 2005, J BIOL CHEM, V280, P24600, DOI 10.1074/jbc.M414076200; Shandala T, 2002, INT J DEV BIOL, V46, P423; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Webb C, 1999, COLD SPRING HARB SYM, V64, P109, DOI 10.1101/sqb.1999.64.109; Webb CF, 1998, J IMMUNOL, V160, P4747; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; WEBB CF, 1991, MOL CELL BIOL, V11, P5197, DOI 10.1128/MCB.11.10.5197; Whitson RH, 1999, BIOCHEM BIOPH RES CO, V258, P326, DOI 10.1006/bbrc.1999.0643; Wilsker D, 2005, GENOMICS, V86, P242, DOI 10.1016/j.ygeno.2005.03.013; Wilsker D, 2004, NUCLEIC ACIDS RES, V32, P1345, DOI 10.1093/nar/gkh277; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Zhu LY, 2001, BIOCHEMISTRY-US, V40, P9142, DOI 10.1021/bi010476a; Zong RT, 2000, EMBO J, V19, P4123, DOI 10.1093/emboj/19.15.4123	31	21	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15768	15777		10.1074/jbc.M700397200	http://dx.doi.org/10.1074/jbc.M700397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17400556	hybrid			2022-12-27	WOS:000246589600052
J	Rosenbluh, J; Hayouka, Z; Loya, S; Levin, A; Armon-Omer, A; Britan, E; Hizi, A; Kotler, M; Friedler, A; Loyter, A				Rosenbluh, Joseph; Hayouka, Zvi; Loya, Shoshana; Levin, Aviad; Armon-Omer, Ayelet; Britan, Elena; Hizi, Amnon; Kotler, Moshe; Friedler, Assaf; Loyter, Abraham			Interaction between HIV-1 Rev and integrase proteins - A basis for the development of anti-HIV peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-LOCALIZATION SIGNAL; REVERSE-TRANSCRIPTASE; TYPE-1 INTEGRASE; MAMMALIAN-CELLS; IN-VITRO; INHIBITORS; IMPORT; ASSAYS; MULTIMERIZATION	Human immunodeficiency virus 1 (HIV-1) Rev and integrase ( IN) proteins are required within the nuclei of infected cells in the late and early phases of the viral replication cycle, respectively. Here we show using various biochemical methods, that these two proteins interact with each other in vitro and in vivo. Peptide mapping and fluorescence anisotropy showed that IN binds residues 1-30 and 49-74 of Rev. Following this observation, we identified two short Rev-derived peptides that inhibit the 3'-end processing and strand-transfer enzymatic activities of IN in vitro. The peptides bound IN in vitro, penetrated into cultured cells, and significantly inhibited HIV-1 in multinuclear activation of a galactosidase indicator (MAGI) and lymphoid cultured cells. Real time PCR analysis revealed that the inhibition of HIV-1 multiplication is due to inhibition of the catalytic activity of the viral IN. The present work describes novel anti-HIV-1 lead peptides that inhibit viral replication in cultured cells by blocking DNA integration in vivo.	Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Organ Chem, Inst Chem, IL-91904 Jerusalem, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pathol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem	Loyter, A (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	loyter@mail.ls.huji.ac.il		Rosenbluh, Joseph/0000-0001-9815-8049				Armon-Omer A, 2004, J MOL BIOL, V336, P1117, DOI 10.1016/j.jmb.2003.11.057; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Cereseto A, 2005, EMBO J, V24, P3070, DOI 10.1038/sj.emboj.7600770; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Chiu TK, 2004, CURR TOP MED CHEM, V4, P965, DOI 10.2174/1568026043388547; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Daelemans D, 2004, J BIOL CHEM, V279, P50167, DOI 10.1074/jbc.M407713200; de Soultrait VR, 2003, CURR MED CHEM, V10, P1765; de Soultrait VR, 2002, J MOL BIOL, V318, P45, DOI 10.1016/S0022-2836(02)00033-5; Demart S, 2003, EXP CELL RES, V291, P484, DOI 10.1016/j.yexcr.2003.07.011; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; Desjobert C, 2004, BIOCHEMISTRY-US, V43, P13097, DOI 10.1021/bi049385e; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; Faure A, 2005, NUCLEIC ACIDS RES, V33, P977, DOI 10.1093/nar/gki241; Fineberg K, 2003, BIOCHEMISTRY-US, V42, P2625, DOI 10.1021/bi0206199; Gleenberg IO, 2005, J BIOL CHEM, V280, P21987, DOI 10.1074/jbc.M414679200; Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673; Hoppe-Seyler F, 2004, CURR MOL MED, V4, P529, DOI 10.2174/1566524043360519; Hwang Y, 2000, NUCLEIC ACIDS RES, V28, P4884, DOI 10.1093/nar/28.24.4884; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Kass G, 2006, J GEN VIROL, V87, P2709, DOI 10.1099/vir.0.82021-0; Kerppola TK, 2006, NAT REV MOL CELL BIO, V7, P449, DOI 10.1038/nrm1929; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Li L, 2005, CELL RES, V15, P923, DOI 10.1038/sj.cr.7290370; LOYTER A, 1982, P NATL ACAD SCI-BIOL, V79, P422, DOI 10.1073/pnas.79.2.422; LUTZKE RAP, 1995, P NATL ACAD SCI USA, V92, P11456, DOI 10.1073/pnas.92.25.11456; Magliery TJ, 2005, J AM CHEM SOC, V127, P146, DOI 10.1021/ja046699g; Marchand C, 2001, METHOD ENZYMOL, V340, P624; Maroun RG, 2001, BIOCHEMISTRY-US, V40, P13840, DOI 10.1021/bi011328n; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Rosenbluh J, 2006, ANAL BIOCHEM, V352, P157, DOI 10.1016/j.ab.2006.03.002; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Van Maele B, 2005, AIDS REV, V7, P26; Watts NR, 1998, J STRUCT BIOL, V121, P41, DOI 10.1006/jsbi.1998.3964; Yamamoto N, 2006, VIRUS GENES, V32, P105, DOI 10.1007/s11262-005-5851-2	40	48	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15743	15753		10.1074/jbc.M609864200	http://dx.doi.org/10.1074/jbc.M609864200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17403681	hybrid			2022-12-27	WOS:000246589600050
J	Fitsialos, G; Chassot, AA; Turchi, L; Dayem, MA; LeBrigand, K; Moreilhon, C; Meneguzzi, G; Busca, R; Mari, B; Barbry, P; Ponzio, G				Fitsialos, Giorgos; Chassot, Anne-Amandine; Turchi, Laurent; Dayem, Manal A.; LeBrigand, Kevin; Moreilhon, Chimene; Meneguzzi, Guerrino; Busca, Roser; Mari, Bernard; Barbry, Pascal; Ponzio, Gilles			Transcriptional signature of epidermal keratinocytes subjected to in vitro scratch wounding reveals selective roles for ERK1/2, p38, and phosphatidylinositol 3-kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL MIGRATION; NF-KAPPA-B; TGF-BETA; GENE-EXPRESSION; CARCINOMA-CELLS; FACTOR-ALPHA; VAV FAMILY; CROSS-TALK; TNF-ALPHA; ACTIVATION	Covering denuded dermal surfaces after injury requires migration, proliferation, and differentiation of skin keratinocytes. To clarify the major traits controlling these intermingled biological events, we surveyed the genomic modifications occurring during the course of a scratch wound closure of cultured human keratinocytes. Using a DNA microarray approach, we report the identification of 161 new markers of epidermal repair. Expression data, combined with functional analysis performed with specific inhibitors of ERK, p38(MAPK) and phosphatidylinositol 3-kinase ( PI3K), demonstrate that kinase pathways exert very selective functions by precisely controlling the expression of specific genes. Inhibition of the ERK pathway totally blocks the wound closure and inactivates many early transcription factors and EGF-type growth factors. p38(MAPK) inhibition only delays "healing," probably in line with the control of genes involved in the propagation of injury-initiated signaling. In contrast, PI3K inhibition accelerates the scratch closure and potentiates the scratch-dependent stimulation of three genes related to epithelial cell transformation, namely HAS3, HBEGF, and ETS1. Our results define in vitro human keratinocyte wound closure as a repair process resulting from a fine balance between positive signals controlled by ERK and p38(MAPK) and negative ones triggered by PI3K. The perturbation of any of these pathways might lead to dysfunction in the healing process, similar to those observed in pathological wounding phenotypes, such as hypertrophic scars or keloids.	INSERM U634, F-06107 Nice 2, France; Univ Nice Sophia Antipolis, IFR50, Fac Med, F-06107 Nice 2, France; CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Sophia Antipolis, France; Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Sophia Antipolis, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur	Ponzio, G (corresponding author), INSERM U634, 28 Ave de Valombrose, F-06107 Nice 2, France.	ponzio@unice.fr	Mari, Bernard P/D-7445-2015; Mari, Bernard/Q-5832-2019; Li, Chia Cheng/D-9906-2015; Barbry, Pascal/O-5021-2016; Chassot, Anne-Amandine/O-2102-2016; Mari, Bernard P/GVS-3100-2022; Ponzio, Gilles/Q-1256-2016; Mari, Bernard P/F-8960-2013	Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Barbry, Pascal/0000-0001-9632-6483; Chassot, Anne-Amandine/0000-0003-1242-9456; Mari, Bernard P/0000-0002-0422-9182; Ponzio, Gilles/0000-0003-2741-0248; Mari, Bernard P/0000-0002-0422-9182; Meneguzzi, Guerrino/0000-0002-1609-6540; Turchi, Laurent/0000-0003-2020-5831				Amendt C, 2002, J CELL SCI, V115, P2189; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Banno T, 2004, J BIOL CHEM, V279, P32633, DOI 10.1074/jbc.M400642200; Bechtel MJ, 1998, BRIT J DERMATOL, V138, P22; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Blomme EAG, 1999, J INVEST DERMATOL, V112, P788, DOI 10.1046/j.1523-1747.1999.00561.x; Bryant M, 2000, HUM GENE THER, V11, P2143, DOI 10.1089/104303400750001444; Bullard KM, 2003, INT J CANCER, V107, P739, DOI 10.1002/ijc.11475; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; Cole J, 2001, WOUND REPAIR REGEN, V9, P360, DOI 10.1046/j.1524-475x.2001.00360.x; Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Darboux I, 1998, BIOCHEM BIOPH RES CO, V246, P210, DOI 10.1006/bbrc.1998.8183; Darboux I, 1998, J BIOL CHEM, V273, P9424, DOI 10.1074/jbc.273.16.9424; Das A, 2006, J BIOL CHEM, V281, P39105, DOI 10.1074/jbc.M607720200; Didier G, 2002, BIOINFORMATICS, V18, P490, DOI 10.1093/bioinformatics/18.3.490; Dudoit S, 2000, Biostatistics, V1, P1, DOI 10.1093/biostatistics/1.1.1; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fathke C, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-4; Feezor RJ, 2004, PHYSIOL GENOMICS, V16, P341, DOI 10.1152/physiolgenomics.00101.2003; Florin L, 2004, ONCOGENE, V23, P7005, DOI 10.1038/sj.onc.1207938; Fong WF, 2001, BBA-GENE STRUCT EXPR, V1517, P250, DOI 10.1016/S0167-4781(00)00287-6; Fujikawa K, 2002, P NATL ACAD SCI USA, V99, P4313, DOI 10.1073/pnas.052715699; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; Futagami A, 2002, LAB INVEST, V82, P1503, DOI 10.1097/01.LAB.0000035024.75914.39; Gil-Henn H, 2003, J BIOL CHEM, V278, P15579, DOI 10.1074/jbc.M210273200; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Grose R, 2003, METH MOLEC MED, V78, P191; Harper EG, 2005, J CELL SCI, V118, P3471, DOI 10.1242/jcs.02475; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Heyninck K, 2003, FEBS LETT, V536, P135, DOI 10.1016/S0014-5793(03)00041-3; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hunter SG, 2006, MOL CELL BIOL, V26, P4830, DOI 10.1128/MCB.02215-05; Ishida Y, 2004, J IMMUNOL, V172, P1848, DOI 10.4049/jimmunol.172.3.1848; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/88213; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kampfer H, 2000, EUR CYTOKINE NETW, V11, P626; Karin M, 2004, ANN RHEUM DIS, V63, P62, DOI 10.1136/ard.2004.028274; KER RMK, 2001, BIOSTATISTICS, V2, P183; Kurschat P, 2006, J BIOL CHEM, V281, P2721, DOI 10.1074/jbc.M507860200; Lan L, 2005, J INVEST DERMATOL, V124, P602, DOI 10.1111/j.0022-202X.2005.23620.x; Le Brigand K, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl485; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; Li Y, 2006, J INVEST DERMATOL, V126, P2096, DOI 10.1038/sj.jid.5700350; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Lu D, 2007, BIOCHEM J, V401, P559, DOI 10.1042/BJ20061081; Lyu J, 2006, CORNEA, V25, pS24, DOI 10.1097/01.ico.0000247209.01262.4e; Mallipeddi R, 2002, CLIN EXP DERMATOL, V27, P616, DOI 10.1046/j.1365-2230.2002.01130.x; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Myagmar BE, 2005, BIOCHEM BIOPH RES CO, V329, P1046, DOI 10.1016/j.bbrc.2005.02.069; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Okuse T, 2005, WOUND REPAIR REGEN, V13, P491, DOI 10.1111/j.1067-1927.2005.00069.x; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Pande P, 1999, J PATHOL, V189, P40, DOI 10.1002/(SICI)1096-9896(199909)189:1<40::AID-PATH405>3.0.CO;2-#; Patel GK, 2006, J INVEST DERMATOL, V126, P497, DOI 10.1038/sj.jid.5700101; Pedersen TX, 2003, ONCOGENE, V22, P3964, DOI 10.1038/sj.onc.1206614; Providence KM, 2004, J CELL PHYSIOL, V200, P297, DOI 10.1002/jcp.20016; Reichelt J, 2004, J INVEST DERMATOL, V123, P973, DOI 10.1111/j.0022-202X.2004.23426.x; Reichelt J, 2001, MOL BIOL CELL, V12, P1557, DOI 10.1091/mbc.12.6.1557; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Richardson RJ, 2006, NAT GENET, V38, P1329, DOI 10.1038/ng1894; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Santos M, 2002, J BIOL CHEM, V277, P35371, DOI 10.1074/jbc.M205143200; Sastry SK, 2002, J CELL SCI, V115, P4305, DOI 10.1242/jcs.00105; Sato M, 2006, ACTA DERM-VENEREOL, V86, P300, DOI 10.2340/00015555-0101; SCHAFER BM, 1994, AM J PATHOL, V144, P1269; Simpson MA, 2001, J BIOL CHEM, V276, P17949, DOI 10.1074/jbc.M010064200; Stepp MA, 1996, INVEST OPHTH VIS SCI, V37, P1593; Steude J, 2002, J INVEST DERMATOL, V119, P1254, DOI 10.1046/j.1523-1747.2002.19616.x; Sulyok S, 2004, MOL CELL ENDOCRINOL, V225, P127, DOI 10.1016/j.mce.2004.07.011; Tammi R, 2005, J INVEST DERMATOL, V124, P898, DOI 10.1111/j.0022-202X.2005.23697.x; Theilgaard-Monch K, 2004, J IMMUNOL, V172, P7684, DOI 10.4049/jimmunol.172.12.7684; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Turchi L, 2002, J INVEST DERMATOL, V119, P56, DOI 10.1046/j.1523-1747.2002.01805.x; Turchi L, 2003, J INVEST DERMATOL, V121, P1291, DOI 10.1111/j.1523-1747.2003.12627.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uno K, 2004, BIOCHEM BIOPH RES CO, V315, P928, DOI 10.1016/j.bbrc.2004.01.146; Usui ML, 2005, WOUND REPAIR REGEN, V13, P468, DOI 10.1111/j.1067-1927.2005.00067.x; Wang T, 2007, BIOCHEM BIOPH RES CO, V352, P203, DOI 10.1016/j.bbrc.2006.11.006; Ward Y, 2002, J CELL BIOL, V157, P291, DOI 10.1083/jcb.200111026; Wells CM, 2005, EXP CELL RES, V310, P303, DOI 10.1016/j.yexcr.2005.07.015; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Werner S, 2001, ONCOGENE, V20, P7494, DOI 10.1038/sj.onc.1204937; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yates S, 2002, WOUND REPAIR REGEN, V10, P5, DOI 10.1046/j.1524-475X.2002.10902.x; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhang ZG, 2006, J CELL SCI, V119, P1886, DOI 10.1242/jcs.02921	93	96	97	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15090	15102		10.1074/jbc.M606094200	http://dx.doi.org/10.1074/jbc.M606094200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17363378	hybrid			2022-12-27	WOS:000246589000049
J	Lemieux, GA; Blumenkron, F; Yeung, N; Zhou, P; Williams, J; Grammer, AC; Petrovich, R; Lipsky, PE; Moss, ML; Werb, Z				Lemieux, George A.; Blumenkron, Fernando; Yeung, Nolan; Zhou, Pei; Williams, Jason; Grammer, Amrie C.; Petrovich, Robert; Lipsky, Peter E.; Moss, Marcia L.; Werb, Zena			The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RII; PRIMARY HUMAN MONOCYTES; SOLUBLE CD23; B-CELLS; PRECURSOR PROTEIN; FC-EPSILON-RII/CD23; DISEASE; CD11B; ACTIVATION; INHIBITION	The low affinity IgE receptor, Fc epsilon RII (CD23), is both a positive and negative regulator of IgE synthesis. The proteinase activity that converts the membrane-bound form of CD23 into a soluble species (sCD23) is an important regulator of the function of CD23 and may be an important therapeutic target for the control of allergy and inflammation. We have characterized the catalytic activity of ADAM (a disintegrin and metalloproteinase) 10 toward human CD23. We found that ADAM10 efficiently catalyzes the cleavage of peptides derived from two distinct cleavage sites in the CD23 backbone. Tissue inhibitors of metalloproteinases and a specific prodomain-based inhibitor of ADAM10 perturb the release of endogenously produced CD23 from human leukemia cell lines as well as primary cultures of human B-cells. Expression of a mutant metalloproteinase- deficient construct of ADAM10 partially inhibited the production of sCD23. Similarly, small inhibitory RNA knockdown of ADAM10 partially inhibited CD23 release and resulted in the accumulation of the membrane-bound form of CD23 on the cells. ADAM10 contributes to CD23 shedding and thus could be considered a potential therapeutic target for the treatment of allergic disease.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biomed Sci, San Francisco, CA 94143 USA; Cognosci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Durham, NC 27710 USA; NIAMS, B Cell Biol Grp, Autoimmun Branch, NIH, Bethesda, MD 20892 USA; NIEHS, NIH, Durham, NC 27710 USA; BioZyme Inc, Apex, NC 27523 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Moss, ML (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	mmoss@biozyme-inc.com; zena.werb@ucsf.edu	Zhou, Pei/O-6704-2019	Zhou, Pei/0000-0002-7823-3416; Grammer, Amrie/0000-0001-7142-2284	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007731, R01HL075602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101564, Z01ES102487] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL75602, R01 HL075602-01, HL07731, T32 HL007731, R01 HL075602] Funding Source: Medline; NIAID NIH HHS [P01 AI053194-01, P01 AI053194, AI053194] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; Aubry JP, 1997, J IMMUNOL, V159, P614; BARTLETT WC, 1995, J IMMUNOL, V154, P4240; BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; BEAVIL RL, 1995, IMMUNOLOGY, V84, P202; Becherer JD, 2003, CURR TOP DEV BIOL, V54, P101, DOI 10.1016/S0070-2153(03)54006-6; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BONEFOY JY, 1997, INT REV IMMUNOL, V16, P13; Christie G, 1997, EUR J IMMUNOL, V27, P3228, DOI 10.1002/eji.1830271221; DELESPESSE G, 1992, IMMUNOL REV, V125, P77, DOI 10.1111/j.1600-065X.1992.tb00626.x; DIERKS SE, 1993, J IMMUNOL, V150, P2372; Fourie AM, 2003, J BIOL CHEM, V278, P30469, DOI 10.1074/jbc.M213157200; Garton KJ, 2006, J LEUKOCYTE BIOL, V79, P1105, DOI 10.1189/jlb.0106038; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hibbert RG, 2005, J EXP MED, V202, P751, DOI 10.1084/jem.20050811; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Kilmon MA, 2001, J IMMUNOL, V167, P3139, DOI 10.4049/jimmunol.167.6.3139; LecoanetHenchoz S, 1997, EUR J IMMUNOL, V27, P2290, DOI 10.1002/eji.1830270924; LECOANETHENCHOZ S, 1995, IMMUNITY, V3, P19; LETELLIER M, 1989, MOL IMMUNOL, V26, P1105, DOI 10.1016/0161-5890(89)90054-0; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Marolewski AE, 1998, BIOCHEM J, V333, P573, DOI 10.1042/bj3330573; Mayer RJ, 2000, CLIN EXP ALLERGY, V30, P719; MOSSALAYI MD, 1992, EMBO J, V1, P4323; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Rezzonico R, 2000, BLOOD, V95, P3868; Rezzonico R, 2001, BLOOD, V97, P2932, DOI 10.1182/blood.V97.10.2932; SANTAMARIA LF, 1993, HUM IMMUNOL, V37, P23, DOI 10.1016/0198-8859(93)90139-R; Schafer B, 2004, J BIOL CHEM, V279, P47929, DOI 10.1074/jbc.M400129200; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Solomon KA, 1999, J IMMUNOL, V163, P4105; TEXIDO G, 1994, J IMMUNOL, V153, P3028; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; Weskamp G, 2006, NAT IMMUNOL, V7, P1293, DOI 10.1038/ni1399; White JM, 2003, CURR OPIN CELL BIOL, V15, P598, DOI 10.1016/j.ceb.2003.08.001; Williams J W, 1979, Methods Enzymol, V63, P437; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0	45	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14836	14844		10.1074/jbc.M608414200	http://dx.doi.org/10.1074/jbc.M608414200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17389606	hybrid, Green Accepted			2022-12-27	WOS:000246589000019
J	Muller, F; Demeny, MA; Tora, L				Muller, Ferenc; Demeny, Mate A.; Tora, Laszlo			New problems in RNA polymerase II transcription initiation: Matching the diversity of core promoters with a variety of promoter recognition factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TATA-BINDING PROTEIN; GENOME-WIDE ANALYSIS; GENE-EXPRESSION; IN-VIVO; FUNCTIONAL-CHARACTERIZATION; COMPREHENSIVE ANALYSIS; BOX; TBP; IDENTIFICATION; ELEMENTS		Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany; Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS UMR 7104, INSERM U596, F-67400 Illkirch Graffenstaden, France	Helmholtz Association; Karlsruhe Institute of Technology; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Muller, F (corresponding author), Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany.	Ferenc.Mueller@itg.fzk.de; laszlo@igbmc.u-strasbg.fr	Tora, Laszlo/E-9999-2018; Muller, Ferenc/C-6426-2009	Tora, Laszlo/0000-0001-7398-2250; mueller, ferenc/0000-0002-0996-774X				Aerts S, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-34; Baek D, 2007, GENOME RES, V17, P145, DOI 10.1101/gr.5872707; Bajic VB, 2004, NAT BIOTECHNOL, V22, P1467, DOI 10.1038/nbt1032; Bajic VB, 2006, PLOS GENET, V2, P614, DOI 10.1371/journal.pgen.0020054; Barrera LO, 2006, CURR OPIN CELL BIOL, V18, P291, DOI 10.1016/j.ceb.2006.04.002; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Bell B, 2001, MOL CELL, V8, P591, DOI 10.1016/S1097-2765(01)00325-2; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Carninci P, 2006, TRENDS GENET, V22, P501, DOI 10.1016/j.tig.2006.07.003; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHARGAFF E, 1951, FED PROC, V10, P654; Chen Z, 2000, MOL CELL BIOL, V20, P5064, DOI 10.1128/MCB.20.14.5064-5076.2000; Chen Z, 2003, MOL CELL BIOL, V23, P7350, DOI 10.1128/MCB.23.20.7350-7362.2003; Chong JA, 2005, MOL CELL BIOL, V25, P2632, DOI 10.1128/MCB.25.7.2632-2643.2005; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; Cooper SJ, 2006, GENOME RES, V16, P1, DOI 10.1101/gr.4222606; Dantonel JC, 1999, TRENDS BIOCHEM SCI, V24, P335, DOI 10.1016/S0968-0004(99)01436-X; Davis W, 2000, DEV BIOL, V218, P275, DOI 10.1006/dbio.1999.9486; Demeny MA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000316; Duan ZJ, 2002, P NATL ACAD SCI USA, V99, P5509, DOI 10.1073/pnas.072084499; Ernst P, 1996, MOL CELL BIOL, V16, P6121; FitzGerald PC, 2004, GENOME RES, V14, P1562, DOI 10.1101/gr.1953904; Frontini M, 2005, MOL CELL BIOL, V25, P4638, DOI 10.1128/MCB.25.11.4638-4649.2005; Gross P, 2006, BIOCHEM SOC SYMP, V73, P225; HAM J, 1994, EMBO J, V13, P147, DOI 10.1002/j.1460-2075.1994.tb06244.x; Hiller M, 2004, DEVELOPMENT, V131, P5297, DOI 10.1242/dev.01314; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; Indra AK, 2005, DEV BIOL, V285, P28, DOI 10.1016/j.ydbio.2005.05.043; Jallow Z, 2004, P NATL ACAD SCI USA, V101, P13525, DOI 10.1073/pnas.0405536101; Juven-Gershon T, 2006, BIOCHEM SOC T, V34, P1047, DOI 10.1042/BST0341047; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; Kawaji H, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-12-r118; Kim JW, 2004, MOL CELL BIOL, V24, P8104, DOI 10.1128/MCB.24.18.8104-8112.2004; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kimura K, 2006, GENOME RES, V16, P55, DOI 10.1101/gr.4039406; Kulkarni MM, 2003, DEVELOPMENT, V130, P6569, DOI 10.1242/dev.00890; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Latinkic BV, 1997, GENE DEV, V11, P3265, DOI 10.1101/gad.11.23.3265; Lee DH, 2005, MOL CELL BIOL, V25, P9674, DOI 10.1128/MCB.25.21.9674-9686.2005; Leurent C, 2004, EMBO J, V23, P719, DOI 10.1038/sj.emboj.7600111; Lewis BA, 2005, MOL CELL, V18, P471, DOI 10.1016/j.molcel.2005.04.005; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAJUMDER S, 1994, MOL CELL BIOL, V14, P4258, DOI 10.1128/MCB.14.6.4258; Marr MT, 2006, GENE DEV, V20, P1458, DOI 10.1101/gad.1418806; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; Mohan WS, 2003, MOL CELL BIOL, V23, P4307, DOI 10.1128/MCB.23.12.4307-4318.2003; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Muller F, 2004, EMBO J, V23, P2, DOI 10.1038/sj.emboj.7600027; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; Persengiev SP, 2003, P NATL ACAD SCI USA, V100, P14887, DOI 10.1073/pnas.2036440100; QUITSCHKE WW, 1989, MOL CELL BIOL, V9, P3218, DOI 10.1128/MCB.9.8.3218; Roeder RG, 2003, NAT MED, V9, P1239, DOI 10.1038/nm938; Schug J, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-4-r33; Shao HS, 2005, MOL CELL BIOL, V25, P206, DOI 10.1128/MCB.25.1.206-219.2005; Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Tokusumi Y, 2007, MOL CELL BIOL, V27, P1844, DOI 10.1128/MCB.01363-06; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; Wright KJ, 2006, P NATL ACAD SCI USA, V103, P12347, DOI 10.1073/pnas.0605499103; Xiao LJ, 2006, GENE EXPR PATTERNS, V6, P409, DOI 10.1016/j.modgep.2005.09.005	72	78	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14685	14689		10.1074/jbc.R700012200	http://dx.doi.org/10.1074/jbc.R700012200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17395580	Green Published, hybrid			2022-12-27	WOS:000246589000003
J	Seki, A; Fang, GW				Seki, Akiko; Fang, Guowei			CKAP2 is a spindle-associated protein degraded by APC/C-cdh1 during mitotic exit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; CYTOSKELETON-ASSOCIATED PROTEIN; CELL-CYCLE; PROTEOLYSIS; MITOSIS; CDC20; COMPLEX/CYCLOSOME; IDENTIFICATION; DEGRADATION; INHIBITION	We reported here an efficient and generally applicable genomic analysis that uses transcriptional profiling to identify candidate substrates of regulatory enzymes, such as kinases and ubiquitin ligases. We applied this strategy to the anaphase-promoting complex/cyclosome ( APC/C), a ubiquitin ligase that controls sister chromatid separation and exit from mitosis. We found that a microtubule-associated protein, CKAP2, is a substrate of APC/C and demonstrated that ubiquitination and degradation of CKAP2 in vitro require a KEN-box and is mediated by Cdh1, an activator of APC/C. We showed that the levels of CKAP2 fluctuated across the cell cycle in culture cells, high in mitosis and low during mitotic exit. Overexpression of Cdh1 reduced the levels of CKAP2 in a KEN-box-dependent manner, while knockdown of Cdh1 increased the half-life of CKAP2. CKAP2 associated with centrosomal microtubules in late G(2), but only after the separation of the duplicated centrosomes. During mitosis, CKAP2 associated with spindle poles and with spindle microtubules from prophase through anaphase and disappeared from microtubules during cytokinesis. The function of CKAP2 during mitosis does not seem essential, as efficient knockdown of CKAP2 neither altered the cell cycle distribution of the cells, nor generated observable mitotic defects. On the other hand, ectopic expression of either the wild-type or a non-degradable CKAP2 led to a mitotic arrest with monopolar spindles containing highly bundled microtubules. We concluded that CKAP2 is a physiological substrate of APC/C during mitotic exit and that a tight regulation of the CKAP2 protein level is critical for the normal mitotic progression.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Fang, GW (corresponding author), Stanford Univ, Dept Biol Sci, 337 Campus Dr,Lokey Bldg,Rm 137, Stanford, CA 94305 USA.	gwfang@stanford.edu			NIGMS NIH HHS [GM062852] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062852] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae CD, 2003, J CANCER RES CLIN, V129, P621, DOI 10.1007/s00432-003-0484-0; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Ciechanover A, 2005, ANGEW CHEM INT EDIT, V44, P5944, DOI 10.1002/anie.200501428; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1999, PHILOS T ROY SOC B, V354, P1583, DOI 10.1098/rstb.1999.0502; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Jeon SM, 2006, BIOCHEM BIOPH RES CO, V348, P222, DOI 10.1016/j.bbrc.2006.07.046; Jin Y, 2004, CANCER SCI, V95, P815, DOI 10.1111/j.1349-7006.2004.tb02187.x; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Li A, 2005, EMBO J, V24, P395, DOI 10.1038/sj.emboj.7600520; Maouche-Chretien L, 1998, ONCOGENE, V17, P1245, DOI 10.1038/sj.onc.1202048; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2000, GENE DEV, V14, P655; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Stewart S, 2005, MOL CELL BIOL, V25, P10516, DOI 10.1128/MCB.25.23.10516-10527.2005; Stewart S, 2005, CANCER RES, V65, P8730, DOI 10.1158/0008-5472.CAN-05-1500; Stroschein SL, 2001, GENE DEV, V15, P2822; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Tsuchihara K, 2005, CANCER RES, V65, P6685, DOI 10.1158/0008-5472.CAN-04-4223; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wong J, 2006, J CELL BIOL, V173, P879, DOI 10.1083/jcb.200511132; Zhao WM, 2006, MOL BIOL CELL, V17, P3881, DOI 10.1091/mbc.E06-01-0015; Zhao WM, 2005, J BIOL CHEM, V280, P33516, DOI 10.1074/jbc.M504657200	34	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15103	15113		10.1074/jbc.M701688200	http://dx.doi.org/10.1074/jbc.M701688200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17376772	hybrid			2022-12-27	WOS:000246589000050
J	Zhu, H; Toso, R; Camire, RM				Zhu, Hua; Toso, Raffaella; Camire, Rodney M.			Inhibitory sequences within the B-domain stabilize circulating factor V in an inactive state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; COAGULATION-FACTOR-V; BOVINE FACTOR-V; FACTOR-XA; FACTOR-VIII; CLEAVAGE REQUIREMENTS; PROTHROMBIN ACTIVATOR; ELECTRON-MICROSCOPY; BLOOD-COAGULATION; COFACTOR FUNCTION	Blood coagulation factor V circulates as a procofactor with little or no procoagulant activity. It is activated to factor Va by thrombin following proteolytic removal of a large central B-domain. Although this reaction is well studied, the mechanism by which bond cleavage and B-domain release facilitate the transition to the active cofactor state has not been defined. Here we show that deletion or substitution of specific B-domain sequences drives the expression of procoagulant function without the need for proteolytic processing. Conversion to the constitutively active cofactor state is related, at least in part, to a cluster of amino acids that is highly basic and well conserved across the vertebrate lineage. Our findings demonstrate that discrete sequences in the B-domain serve to stabilize the inactive procofactor state, with proteolysis primarily functioning to remove these inhibitory constraints. These unexpected results provide new insight into the mechanism of factor V activation.	Childrens Hosp Philadelphia, Div Hematol, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Camire, RM (corresponding author), Childrens Hosp Philadelphia, Div Hematol, Dept Pediat, 302E Abramson Res Ctr,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	rcamire@mail.med.upenn.edu	Toso, Raffaella/I-5202-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL074124, T32HL007439] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL-07439-26, P01 HL-74124-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams TE, 2004, P NATL ACAD SCI USA, V101, P8918, DOI 10.1073/pnas.0403072101; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bevington PR., 2002, DATA REDUCTION ERROR; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Davidson CJ, 2003, J THROMB HAEMOST, V1, P1487, DOI 10.1046/j.1538-7836.2003.00334.x; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; Doolittle RF, 2003, J THROMB HAEMOST, V1, P1559, DOI 10.1046/j.1538-7836.2003.00278.x; ESMON CT, 1979, J BIOL CHEM, V254, P964; Fay PJ, 2004, BLOOD REV, V18, P1, DOI 10.1016/S0268-960X(03)00025-0; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FOSTER WB, 1983, J BIOL CHEM, V258, P5608; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; Gomori G, 1942, J LAB CLIN MED, V27, P955; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; Jiang Y, 2003, P NATL ACAD SCI USA, V100, P7527, DOI 10.1073/pnas.0932632100; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; Kalafatis M, 2003, J BIOL CHEM, V278, P33550, DOI 10.1074/jbc.M303153200; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; KANE WH, 1981, J BIOL CHEM, V256, P1002; KANE WH, 2006, HEMOSTASIS THROMBOSI, P177; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; Khan AR, 1999, P NATL ACAD SCI USA, V96, P10968, DOI 10.1073/pnas.96.20.10968; Khan AR, 1998, PROTEIN SCI, V7, P815; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAMPE PD, 1984, J BIOL CHEM, V259, P9959; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; Le TNM, 2005, THROMB HAEMOSTASIS, V93, P420, DOI 10.1160/TH040-11-0707; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; Mann KG, 2003, BLOOD, V101, P20, DOI 10.1182/blood-2002-01-0290; MARQUETTE KA, 1995, BLOOD, V86, P3026; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; MOSESSON MW, 1990, J BIOL CHEM, V265, P8863; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; Pierre LS, 2005, MOL BIOL EVOL, V22, P1853, DOI 10.1093/molbev/msi181; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; Rao VS, 2003, BLOOD, V102, P1347, DOI 10.1182/blood-2002-12-3839; Steen M, 2002, J BIOL CHEM, V277, P38424, DOI 10.1074/jbc.M204972200; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; Thorelli E, 1998, THROMB HAEMOSTASIS, V80, P92, DOI 10.1055/s-0037-1615145; Toso R, 2006, J BIOL CHEM, V281, P8773, DOI 10.1074/jbc.M511419200; Toso R, 2004, J BIOL CHEM, V279, P21643, DOI 10.1074/jbc.M402107200; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VOS HL, 2005, J THROMB HAEMOST, V3	58	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15033	15039		10.1074/jbc.M701315200	http://dx.doi.org/10.1074/jbc.M701315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17387173	hybrid			2022-12-27	WOS:000246589000042
J	Guan, LJ; Song, K; Pysz, MA; Curry, KJ; Hizli, AA; Danielpour, D; Black, AR; Black, JD				Guan, Lingjie; Song, Kyung; Pysz, Marybeth A.; Curry, Kathryn J.; Hizli, A. Asli; Danielpour, David; Black, Adrian R.; Black, Jennifer D.			Protein kinase C-mediated down-regulation of cyclin D1 involves activation of the translational repressor 4E-BP1 via a phosphoinositide 3-Kinase/Akt-independent, protein phosphatase 2A-dependent mechanism in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CAP-DEPENDENT INITIATION; INDUCED AKT ACTIVATION; PROSTATE-CANCER CELLS; MESSENGER-RNA; INDUCED APOPTOSIS; OXIDATIVE STRESS; S6 KINASE; TYROSINE PHOSPHORYLATION; 4E-BINDING PROTEIN-1; (S/T)P SITES	We reported previously that protein kinase C alpha (PKC alpha), a negative regulator of cell growth in the intestinal epithelium, inhibits cyclin D1 translation by inducing hypophosphorylation/ activation of the translational repressor 4E-BP1. The current study explores the molecular mechanisms underlying PKC/PKC alpha-induced activation of 4E-BP1 in IEC-18 nontransformed rat ileal crypt cells. PKC signaling is shown to promote dephosphorylation of Thr(45) and Ser(64) on 4E-BP1, residues directly involved in its association with eIF4E. Consistent with the known role of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway in regulation of 4E-BP1, PKC signaling transiently inhibited PI3K activity and Akt phosphorylation in IEC-18 cells. However, PKC/PKC alpha-induced activation of 4E-BP1 was not prevented by constitutively active mutants of PI3K or Akt, indicating that blockade of PI3K/ Akt signaling is not the primary effector of 4E-BP1 activation. This idea is supported by the fact that PKC activation did not alter S6 kinase activity in these cells. Further analysis indicated that PKC-mediated 4E-BP1 hypophosphorylation is dependent on the activity of protein phosphatase 2A (PP2A). PKC signaling induced an similar to 2-fold increase in PP2A activity, and phosphatase inhibition blocked the effects of PKC agonists on 4E-BP1 phosphorylation and cyclin D1 expression. H2O2 and ceramide, two naturally occurring PKC alpha agonists that promote growth arrest in intestinal cells, activate 4E-BP1 in PKC/PKC alpha-dependent manner, supporting the physiological significance of the findings. Together, our studies indicate that activation of PP2A is an important mechanism underlying PKC/PKC alpha-induced inhibition of cap-dependent translation and growth suppression in intestinal epithelial cells.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Comprehens Canc Ctr, Res Labs, Cleveland, OH 44106 USA	Roswell Park Cancer Institute; Case Western Reserve University; Case Western Reserve University	Black, JD (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	jennifer.black@roswellpark.org		HIZLI DENIZ, AYSEN ASLI/0000-0003-0490-7737	NATIONAL CANCER INSTITUTE [F32CA113048, P30CA016056, R01CA102074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060632, R01DK054909, R56DK060632] Funding Source: NIH RePORTER; NCI NIH HHS [CA102074, CA16056, CA113048] Funding Source: Medline; NIDDK NIH HHS [DK60632, DK54909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdala-Valencia H, 2006, J IMMUNOL, V177, P6379, DOI 10.4049/jimmunol.177.9.6379; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvi F, 2007, CELL MOL LIFE SCI, V64, P263, DOI 10.1007/s00018-006-6363-5; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Aschrafi A, 2003, BBA-MOL CELL BIOL L, V1634, P30, DOI 10.1016/j.bbalip.2003.08.004; Awasthi S, 2001, AM J PHYSIOL-LUNG C, V281, pL108, DOI 10.1152/ajplung.2001.281.1.L108; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Black JD, 2001, GASTROENTEROLOGY, V120, P1868, DOI 10.1053/gast.2001.25287; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cerbon J, 2003, BIOCHEM J, V373, P917, DOI 10.1042/BJ20021732; Chen CL, 2006, MOL PHARMACOL, V70, P510, DOI 10.1124/mol.106.024059; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Clark JA, 2004, J BIOL CHEM, V279, P9233, DOI 10.1074/jbc.M312268200; CLEMENS MJ, 1992, J CELL SCI, V103, P881; Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Di Mari JF, 2005, GASTROENTEROLOGY, V128, P2131, DOI 10.1053/j.gastro.2004.09.078; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Engler JA, 1999, DIGEST DIS SCI, V44, P1902, DOI 10.1023/A:1018815327769; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Giron-Calle J, 2002, J PHARMACOL EXP THER, V301, P87, DOI 10.1124/jpet.301.1.87; Gotoh Y, 2002, CELL PROLIFERAT, V35, P221, DOI 10.1046/j.1365-2184.2002.00241.x; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hizli AA, 2006, J BIOL CHEM, V281, P14596, DOI 10.1074/jbc.M601959200; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Ivaska J, 2003, BIOCHEM SOC T, V31, P90, DOI 10.1042/bst0310090; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; KahlRainer P, 1996, GASTROENTEROLOGY, V110, P1753, DOI 10.1053/gast.1996.v110.pm8964400; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; LEE TH, 1994, MOL BIOL CELL, V5, P323, DOI 10.1091/mbc.5.3.323; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Li LW, 2006, J BIOL CHEM, V281, P3237, DOI 10.1074/jbc.M512167200; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Li Y, 2004, J BIOL CHEM, V279, P45304, DOI 10.1074/jbc.C400186200; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Miron M, 2003, MOL CELL BIOL, V23, P9117, DOI 10.1128/MCB.23.24.9117-9126.2003; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Motley ED, 2001, CELL MOL BIOL, V47, P1059; Motley ED, 2002, HYPERTENSION, V39, P508, DOI 10.1161/hy02t2.102907; Nien WL, 2007, MOL CELL ENDOCRINOL, V263, P10, DOI 10.1016/j.mce.2006.08.015; Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268; Palmantier R, 2001, CANCER RES, V61, P2445; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Prickett TD, 2006, J BIOL CHEM, V281, P30503, DOI 10.1074/jbc.M601054200; Proud CG, 2006, BIOCHEM SOC T, V34, P213, DOI 10.1042/BST0340213; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Ragolia L, 2003, AM J PHYSIOL-CELL PH, V284, pC119, DOI 10.1152/ajpcell.00247.2002; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Samari HR, 2005, BIOCHEM J, V386, P237, DOI 10.1042/BJ20040609; Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200; Schmelz EM, 1999, CANCER RES, V59, P5768; Selzner M, 2001, CANCER RES, V61, P1233; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE74, DOI 10.1152/ajpendo.2000.279.1.E74; Sipeki S, 2006, BIOCHEM BIOPH RES CO, V339, P122, DOI 10.1016/j.bbrc.2005.10.194; Song KY, 2006, EMBO J, V25, P58, DOI 10.1038/sj.emboj.7600917; Sun M, 2001, CANCER RES, V61, P5985; TAHER MM, 1993, ARCH BIOCHEM BIOPHYS, V303, P260, DOI 10.1006/abbi.1993.1281; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Weigel G, 1997, THROMB RES, V87, P363, DOI 10.1016/S0049-3848(97)00140-0; Wen HC, 2003, CELL SIGNAL, V15, P37, DOI 10.1016/S0898-6568(02)00047-5; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377; Zhou CX, 2003, MOL CANCER THER, V2, P789	115	66	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14213	14225		10.1074/jbc.M610513200	http://dx.doi.org/10.1074/jbc.M610513200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17360714	hybrid			2022-12-27	WOS:000246245800032
J	Makino, Y; Uenishi, R; Okamoto, K; Isoe, T; Hosono, O; Tanaka, H; Kanopka, A; Poellinger, L; Haneda, M; Morimoto, C				Makino, Yuichi; Uenishi, Rie; Okamoto, Kensaku; Isoe, Tsubasa; Hosono, Osamu; Tanaka, Hirotoshi; Kanopka, Arvydas; Poellinger, Lorenz; Haneda, Masakazu; Morimoto, Chikao			Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1) - A negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NF-KAPPA-B; FACTOR-I; T-CELLS; ALPHA; HYDROXYLATION; IDENTIFICATION; HIF-1-ALPHA; MECHANISMS; RESPONSES	The inhibitory PAS (Per/Arnt/Sim) domain protein (IPAS), a dominant negative regulator of hypoxia-inducible transcription factors (HIFs), is potentially implicated in negative regulation of angiogenesis in such tissues as the avascular cornea of the eye. We have previously shown IPAS mRNA expression is up-regulated in hypoxic tissues, which at least in part involves hypoxia-dependent alternative splicing of the transcripts from the IPAS/HIF-3 alpha locus. In the present study, we demonstrate that a hypoxia-driven transcriptional mechanism also plays a role in augmentation of IPAS gene expression. Isolation and analyses of the promoter region flanking to the first exon of IPAS gene revealed a functional hypoxia response element at position -834 to -799, whereas the sequence upstream of the HIF-3 alpha first exon scarcely responded to hypoxic stimuli. A transient transfection experiment demonstrated that HIF-1 alpha mediates IPAS promoter activation via the functional hypoxia response element under hypoxic conditions and that a constitutively active form of HIF-1 alpha is sufficient for induction of the promoter in normoxic cells. Moreover, chromatin immunoprecipitation and electrophoretic mobility shift assays showed binding of the HIF-1 complex to the element in a hypoxia-dependent manner. Taken together, HIF-1 directly up-regulates IPAS gene expression through a mechanism distinct from RNA splicing, providing a further level of negative feedback gene regulation in adaptive responses to hypoxic/ischemic conditions.	Asahikawa Med Coll, Dept Internal Med, Sect Metab & Biosyst Sci, Asahikawa, Hokkaido 0788510, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; Inst Biotechnol, LT-2028 Vilnius, Lithuania; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Asahikawa Medical College; University of Tokyo; Japan Science & Technology Agency (JST); Vilnius University; Karolinska Institutet	Makino, Y (corresponding author), Asahikawa Med Coll, Dept Internal Med, Sect Metab & Biosyst Sci, 2-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan.	makino@asahikawa-med.ac.jp						Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jelkmann W, 2003, J ENDOCRINOL INVEST, V26, P832, DOI 10.1007/BF03345232; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kornblihtt AR, 2005, CURR OPIN CELL BIOL, V17, P262, DOI 10.1016/j.ceb.2005.04.014; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Leonard MO, 2003, J BIOL CHEM, V278, P40296, DOI 10.1074/jbc.M302560200; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Makino Y, 2003, J IMMUNOL, V171, P6534, DOI 10.4049/jimmunol.171.12.6534; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Nakamura H, 2005, J IMMUNOL, V174, P7592, DOI 10.4049/jimmunol.174.12.7592; Olenyuk BZ, 2004, P NATL ACAD SCI USA, V101, P16768, DOI 10.1073/pnas.0407617101; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P845; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang RS, 2006, FASEB J, V20, P1275, DOI 10.1096/fj.06-5839fje	42	85	89	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14073	14082		10.1074/jbc.M700732200	http://dx.doi.org/10.1074/jbc.M700732200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17355974	hybrid			2022-12-27	WOS:000246245800017
J	Yan, Q; Liu, WB; Qin, JC; Liu, JP; Chen, HG; Huang, XQ; Chen, LL; Sun, SM; Deng, M; Gong, LL; Li, Y; Zhang, L; Liu, Y; Feng, H; Xiao, YM; Liu, Y; Li, DWC				Yan, Qin; Liu, Wen-Bin; Qin, Jichao; Liu, Jinping; Chen, He-Ge; Huang, Xiaoqin; Chen, Lili; Sun, Shuming; Deng, Mi; Gong, Lili; Li, Yong; Zhang, Lan; Liu, Yan; Feng, Hao; Xiao, Yamei; Liu, Yun; Li, David W. -C.			Protein phosphatase-1 modulates the function of Pax-6, a transcription factor controlling brain and eye development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS EPITHELIAL-CELLS; ALPHA-A-CRYSTALLIN; INDUCED APOPTOSIS; GENE-EXPRESSION; EYELESS GENE; MOUSE LENS; INDUCTION; PHOSPHORYLATION; TRANSACTIVATION; DROSOPHILA	Pax-6 is an evolutionarily conserved transcription factor and acts high up in the regulatory hierarchy controlling eye and brain development in humans, mice, zebrafish, and Drosophila. Previous studies have shown that Pax-6 is a phosphoprotein, and its phosphorylation by ERK, p38, and homeodomain-interacting protein kinase 2 greatly enhances its transactivation activity. However, the protein phosphatases responsible for the dephosphorylation of Pax-6 remain unknown. Here, we present both in vitro and in vivo evidence to show that protein serine/threonine phosphatase-1 is a major phosphatase that directly dephosphorylates Pax-6. First, purified protein phosphatase-1 directly dephosphorylates Pax-6 in vitro. Second, immunoprecipitation-linked Western blot revealed that both protein phosphatase-1 alpha and protein phosphatase-1 alpha interact with Pax-6. Third, overexpression of protein phosphatase-1 in human lens epithelial cells leads to dephosphorylation of Pax-6. Finally, inhibition of protein phosphatase-1 activity by calyculin A or knockdown of protein phosphatase-1 alpha and protein phosphatase-1 alpha by RNA interference leads to enhanced phosphorylation of Pax-6. Moreover, our results also demonstrate that dephosphorylation of Pax-6 by protein phosphatase-1 significantly modulates its function in regulating expression of both exogenous and endogenous genes. These results demonstrate that protein phosphatase 1 acts as a major phosphatase to dephosphorylate Pax-6 and modulate its function.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Ophthalmol & Visual Sci, Omaha, NE 68198 USA; Hunan Normal Univ, Coll Life Sci, Changsha 410081, Hunan, Peoples R China	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Hunan Normal University	Li, DWC (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	dwli1688@hotmail.com	chen, hege/GYV-5810-2022; Gong, Lili/F-8452-2014; Yan, Qin/F-5161-2012; Li, David/AAN-9205-2021; liu, wen/HGE-3071-2022; Yan, Qin/K-3539-2013; Deng, Mi/K-8699-2012	Gong, Lili/0000-0002-6533-5333; Yan, Qin/0000-0002-6344-6398; Deng, Mi/0000-0003-4291-0144; Qin, Jichao/0000-0002-2961-7624	NEI NIH HHS [R01 EY015765, R01 EY15765] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015765] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Bastians H, 1996, J CELL SCI, V109, P2865; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; Chauhan BK, 2002, J BIOL CHEM, V277, P11539, DOI 10.1074/jbc.M110531200; Chauhan BK, 2002, GENES CELLS, V7, P1267, DOI 10.1046/j.1365-2443.2002.00602.x; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; Davis JA, 1996, J NEUROSCI, V16, P5082; Dellovade TL, 1998, J COMP NEUROL, V402, P402; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; Duncan MK, 2000, INVEST OPHTH VIS SCI, V41, P464; Duncan MK, 2000, J CELL SCI, V113, P3173; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; Gallego M, 2005, CURR OPIN CELL BIOL, V17, P197, DOI 10.1016/j.ceb.2005.01.002; Gehring WJ, 2002, INT J DEV BIOL, V46, P65; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GopalSrivastava R, 1996, J BIOL CHEM, V271, P23029, DOI 10.1074/jbc.271.38.23029; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; Grogg MW, 2005, NATURE, V438, P858, DOI 10.1038/nature04175; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Kim EA, 2006, J BIOL CHEM, V281, P7489, DOI 10.1074/jbc.M507227200; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Krucher NA, 2006, EXP CELL RES, V312, P2757, DOI 10.1016/j.yexcr.2006.05.002; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; LI WC, 2001, INVEST OPHTH VIS SCI, V42, P2603; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu JP, 2004, EXP EYE RES, V79, P393, DOI 10.1016/j.exer.2004.06.015; Mallick BN, 2000, J NEUROCHEM, V74, P1574, DOI 10.1046/j.1471-4159.2000.0741574.x; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; Wang J, 2005, J BIOL CHEM, V280, P22776, DOI 10.1074/jbc.M500032200; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Zygar CA, 1998, DEVELOPMENT, V125, P3509	49	42	48	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					13954	13965		10.1074/jbc.M611476200	http://dx.doi.org/10.1074/jbc.M611476200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17374606	hybrid			2022-12-27	WOS:000246245800005
J	Gardsvoll, H; Ploug, M				Gardsvoll, Henrik; Ploug, Michael			Mapping of the vitronectin-binding site on the urokinase receptor - Involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; LIGAND-BINDING; CELL-ADHESION; COMBINATORIAL CHEMISTRY; FUNCTIONAL EPITOPE; ANTHRAX TOXIN; PEPTIDE; IDENTIFICATION; MUTAGENESIS; POTENTIATION	The urokinase-type plasminogen activator receptor (uPAR) has been implicated as a modulator of several biochemical processes that are active during tumor invasion and metastasis, e. g. extracellular proteolysis, cell adhesion, and cell motility. The structural basis for the high affinity interaction between the urokinase-type plasminogen activator (uPA) and uPAR, which focuses cell surface-associated plasminogen activation in vivo, is now thoroughly characterized by site- directed mutagenesis studies and x-ray crystallography. In contrast, the structural basis for the interaction between uPAR and the extracellular matrix protein vitronectin, which is involved in the regulation of cell adhesion and motility, remains to be clarified. In this study, we have identified the functional epitope on uPAR that is responsible for its interaction with the full-length, extended form of vitronectin by using a comprehensive alanine-scanning library of purified single-site uPAR mutants (244 positions tested). Interestingly, the five residues identified as "hot spots" for vitronectin binding form a contiguous epitope consisting of two exposed loops connecting the central four-stranded beta-sheet in uPAR domain I (Trp(32), Arg(58), and Ile(63)) as well as a proximal region of the flexible linker peptide connecting uPAR domains I and II (Arg(91) and Tyr(92)). This binding topology provides the molecular basis for the observation that uPAR can form a ternary complex with uPA and vitronectin. Furthermore, it raises the intriguing possibility that the canonical receptor and inhibitor for uPA (uPAR and PAI-1) may have reached a convergent solution for binding to the somatomedin B domain of vitronectin.	Rigshosp, Finsen Lab, Copenhagen Bioctr, DK-2200 Copenhagen N, Denmark	Rigshospitalet	Ploug, M (corresponding author), Rigshosp, Finsen Lab, Copenhagen Bioctr, Bldg 3,3rd Floor,Ole Maaloes Vej 5, DK-2200 Copenhagen N, Denmark.	m-ploug@finsenlab.dk		Ploug, Michael/0000-0003-2215-4265				Barinka C, 2006, J MOL BIOL, V363, P482, DOI 10.1016/j.jmb.2006.08.063; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; Bdeir K, 2000, J BIOL CHEM, V275, P28532, DOI 10.1074/jbc.M001595200; Bolon I, 2004, AM J PATHOL, V164, P2299, DOI 10.1016/S0002-9440(10)63786-8; Cunningham O, 2003, EMBO J, V22, P5994, DOI 10.1093/emboj/cdg588; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; ELLIS V, 1989, J BIOL CHEM, V264, P2185; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Gardsvoll H, 1999, J BIOL CHEM, V274, P37995, DOI 10.1074/jbc.274.53.37995; Gardsvoll H, 2004, PROTEIN EXPRES PURIF, V34, P284, DOI 10.1016/j.pep.2003.12.002; Gardsvoll H, 2007, PROTEIN EXPRES PURIF, V52, P384, DOI 10.1016/j.pep.2006.11.013; Gardsvoll H, 2006, J BIOL CHEM, V281, P19260, DOI 10.1074/jbc.M513583200; Gargiulo L, 2005, J BIOL CHEM, V280, P25225, DOI 10.1074/jbc.M412605200; Hoyer-Hansen G, 1997, FEBS LETT, V420, P79, DOI 10.1016/S0014-5793(97)01491-9; Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143; Jacobsen B, 2007, PROTEIN EXPRES PURIF, V52, P286, DOI 10.1016/j.pep.2006.08.011; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; Jorgensen TJD, 2004, BIOCHEMISTRY-US, V43, P15044, DOI 10.1021/bi048706j; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Li Y, 2003, J BIOL CHEM, V278, P29925, DOI 10.1074/jbc.M300751200; Liu SH, 2003, P NATL ACAD SCI USA, V100, P657, DOI 10.1073/pnas.0236849100; Liu SH, 2001, J BIOL CHEM, V276, P17976, DOI 10.1074/jbc.M011085200; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; MOSER TL, 1995, BIOCHEM J, V307, P867, DOI 10.1042/bj3070867; Okumura Y, 2002, J BIOL CHEM, V277, P9395, DOI 10.1074/jbc.M111225200; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; Ploug M, 1998, BIOCHEMISTRY-US, V37, P16494, DOI 10.1021/bi981203r; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Ploug M, 1998, BIOCHEMISTRY-US, V37, P3612, DOI 10.1021/bi972787k; Pluskota E, 2003, BLOOD, V101, P1582, DOI 10.1182/blood-2002-06-1842; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Romer J, 2004, CURR PHARM DESIGN, V10, P2359, DOI 10.2174/1381612043383962; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; RONNE E, 1994, J IMMUNOL METHODS, V167, P91, DOI 10.1016/0022-1759(94)90078-7; Seger D, 1998, J BIOL CHEM, V273, P24805, DOI 10.1074/jbc.273.38.24805; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Sidenius N, 2002, J BIOL CHEM, V277, P27982, DOI 10.1074/jbc.M111736200; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; Wei Y, 2005, J CELL BIOL, V168, P501, DOI 10.1083/jcb.200404112; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943; Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817	49	90	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13561	13572		10.1074/jbc.M610184200	http://dx.doi.org/10.1074/jbc.M610184200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17355965	hybrid			2022-12-27	WOS:000246060300045
J	Lefebvre-Legendre, L; Rappaport, F; Finazzi, G; Ceol, M; Grivet, C; Hopfgartner, G; Rochaix, JD				Lefebvre-Legendre, Linnka; Rappaport, Fabrice; Finazzi, Giovanni; Ceol, Mauro; Grivet, Chantal; Hopfgartner, Gerard; Rochaix, Jean-David			Loss of phylloquinone in Chlamydomonas affects plastoquinone pool size and photosystem II synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC-PATHWAY MUTANTS; SYNECHOCYSTIS SP PCC-6803; SITE-DIRECTED MUTAGENESIS; CYCLIC ELECTRON FLOW; IN-VIVO ANALYSIS; FOREIGN QUINONE; A(1) SITE; MESSENGER-RNA; INSERTIONAL INACTIVATION; CHARGE RECOMBINATION	Phylloquinone functions as the electron transfer cofactor at the A(1) site of photosystem I. We have isolated and characterized a mutant of Chlamydomonas reinhardtii, menD1, that is deficient in MenD, which encodes 2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase, an enzyme that catalyzes the first specific step of the phylloquinone biosynthetic pathway. The mutant is photosynthetically active but light-sensitive. Analysis of total pigments by mass spectrometry reveals that phylloquinone is absent in menD1, but plastoquinone levels are not affected. This is further confirmed by the rescue of menD1 by addition of phylloquinone to the growth medium. Analysis of electron transfer by absorption spectroscopy indicates that plastoquinone replaces phylloquinone in photosystem I and that electron transfer from A1 to the iron-sulfur centers is slowed down at least 40-fold. Consistent with a replacement of phylloquinone by plastoquinone, the size of the free plastoquinone pool of menD1 is reduced by 20-30%. In contrast to cyanobacterial MenD-deficient mutants, photosystem I accumulates normally in menD1, whereas the level of photosystem II declines. This decrease is because of reduced synthesis of the photosystem II core subunits. The relationship between plastoquinone occupancy of the A(1) site in photosystem I and the reduced accumulation of photosystem II is discussed.	Univ Geneva, Dept Mol Biol & Plant Biol, CH-1211 Geneva 4, Switzerland; Univ Paris 06, CNRS, UMR 7141, Inst Biol Physicochim, F-75005 Paris, France; Univ Geneva, Univ Lausanne, Sch Pharmaceut Sci, CH-1211 Geneva 4, Switzerland	University of Geneva; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; University of Geneva; University of Lausanne	Rochaix, JD (corresponding author), Univ Geneva, Dept Mol Biol & Plant Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.	Jean-David.Rochaix@molbio.unige.ch	Rochaix, Jean-David/ABC-5243-2020	Rappaport, Fabrice/0000-0001-9377-4934				Agalarov R, 2003, BBA-BIOENERGETICS, V1604, P7, DOI 10.1016/S0005-2728(03)00024-0; Barkan A, 2000, BIOCHIMIE, V82, P559, DOI 10.1016/S0300-9084(00)00602-7; Bautista JA, 2005, J BIOL CHEM, V280, P20030, DOI 10.1074/jbc.M500809200; Beal D, 1999, REV SCI INSTRUM, V70, P202, DOI 10.1063/1.1149566; BENNOUN P, 1969, BIOCHIM BIOPHYS ACTA, V189, P85, DOI 10.1016/0005-2728(69)90229-1; BENSASSON R, 1973, BIOCHIM BIOPHYS ACTA, V325, P175, DOI 10.1016/0005-2728(73)90163-1; Berthold D. A., 1993, Plant Molecular Biology Reporter, V11, P338, DOI 10.1007/BF02905336; BOTTIN H, 1991, BIOCHIM BIOPHYS ACTA, V1057, P331, DOI 10.1016/S0005-2728(05)80144-6; Boudreau E, 1997, EMBO J, V16, P6095, DOI 10.1093/emboj/16.20.6095; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; Dashdorj N, 2005, BIOPHYS J, V88, P1238, DOI 10.1529/biophysj.104.050963; Dauvillee D, 2003, EMBO J, V22, P6378, DOI 10.1093/emboj/cdg591; DELEPELAIRE P, 1978, BIOCHIM BIOPHYS ACTA, V502, P183, DOI 10.1016/0005-2728(78)90040-3; Depege N, 2003, SCIENCE, V299, P1572, DOI 10.1126/science.1081397; Diner BA, 2001, BIOCHEMISTRY-US, V40, P9265, DOI 10.1021/bi010121r; DURRANT I, 1990, NATURE, V346, P297, DOI 10.1038/346297a0; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; Finazzi G, 2002, EMBO REP, V3, P280, DOI 10.1093/embo-reports/kvf047; Finazzi G, 1999, BBA-BIOENERGETICS, V1413, P117, DOI 10.1016/S0005-2728(99)00089-4; Fischer N, 1997, BIOCHEMISTRY-US, V36, P93, DOI 10.1021/bi962244v; Fleischmann MM, 1999, J BIOL CHEM, V274, P30987, DOI 10.1074/jbc.274.43.30987; Gross J, 2006, J BIOL CHEM, V281, P17189, DOI 10.1074/jbc.M601754200; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; Haldrup A, 2000, J BIOL CHEM, V275, P31211, DOI 10.1074/jbc.M002933200; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P1; Irihimovitch V, 2000, J BIOL CHEM, V275, P16289, DOI 10.1074/jbc.275.21.16289; Iwata S, 2004, CURR OPIN STRUC BIOL, V14, P447, DOI 10.1016/j.sbi.2004.07.002; Johnson TW, 2001, J BIOL CHEM, V276, P39512, DOI 10.1074/jbc.M104040200; Johnson TW, 2000, J BIOL CHEM, V275, P8523, DOI 10.1074/jbc.275.12.8523; Johnson TW, 2003, BBA-BIOENERGETICS, V1557, P67, DOI 10.1016/S0005-2728(02)00396-1; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; Joliot P, 2004, BBA-BIOENERGETICS, V1656, P166, DOI 10.1016/j.bbabio.2004.03.010; JOLIOT P, 1992, BIOCHIM BIOPHYS ACTA, V1102, P53, DOI 10.1016/0167-4838(92)90498-3; Keren N, 1997, P NATL ACAD SCI USA, V94, P1579, DOI 10.1073/pnas.94.4.1579; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; LAVERGNE J, 1991, TRENDS BIOCHEM SCI, V16, P129, DOI 10.1016/0968-0004(91)90054-Y; Li YJ, 2004, BIOCHEMISTRY-US, V43, P12634, DOI 10.1021/bi036329p; Meganathan R, 2001, VITAM HORM, V61, P173; Merendino L, 2003, PLANT MOL BIOL, V53, P371, DOI 10.1023/B:PLAN.0000006941.56233.42; Minai L, 2006, PLANT CELL, V18, P159, DOI 10.1105/tpc.105.037705; Nelson N, 2005, BIOESSAYS, V27, P914, DOI 10.1002/bies.20278; Pfannschmidt T, 2003, TRENDS PLANT SCI, V8, P33, DOI 10.1016/S1360-1385(02)00005-5; Rappaport F, 2007, BBA-BIOENERGETICS, V1767, P56, DOI 10.1016/j.bbabio.2006.10.002; Redding K, 1998, EMBO J, V17, P50, DOI 10.1093/emboj/17.1.50; Rochaix JD, 2000, BIOCHIMIE, V82, P635, DOI 10.1016/S0300-9084(00)00604-0; Sakuragi Y, 2002, BIOCHEMISTRY-US, V41, P394, DOI 10.1021/bi011297w; SAMBROOK J, 1989, MOL CLONIGN LAB MANU; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; SCHLIEPHAKE W, 1968, Z NATURFORSCH PT B, VB 23, P1571; Semenov AY, 2000, J BIOL CHEM, V275, P23429, DOI 10.1074/jbc.M000508200; Shimada H, 2005, PLANT J, V41, P627, DOI 10.1111/j.1365-313X.2004.02326.x; Shinkarev VP, 2002, BIOPHYS J, V83, P2885, DOI 10.1016/S0006-3495(02)75298-3; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trebitsh T, 2000, MOL CELL BIOL, V20, P1116, DOI 10.1128/MCB.20.4.1116-1123.2000; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P849, DOI 10.1021/bi00054a016; ZER H, 1994, J BIOL CHEM, V269, P17670; Zybailov B, 2000, J BIOL CHEM, V275, P8531, DOI 10.1074/jbc.275.12.8531	60	31	33	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13250	13263		10.1074/jbc.M610249200	http://dx.doi.org/10.1074/jbc.M610249200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17339322	hybrid			2022-12-27	WOS:000246060300013
J	Mirza, M; Robinson, P; Kremneva, E; Copeland, O; Nikolaeva, O; Watkins, H; Levitsky, D; Redwood, C; EL-Mezgueldi, M; Marston, S				Mirza, Mahmooda; Robinson, Paul; Kremneva, Elena; Copeland, O'neal; Nikolaeva, Olga; Watkins, Hugh; Levitsky, Dimitry; Redwood, Charles; EL-Mezgueldi, Mohammed; Marston, Steven			The effect of mutations in alpha-tropomyosin (E40K and E54K) that cause familial dilated cardiomyopathy on the regulatory mechanism of cardiac muscle thin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTROPHIC CARDIOMYOPATHY; ACTIN-FILAMENTS; SMOOTH-MUSCLE; SKELETAL; MYOSIN; SUBFRAGMENT-1; SEPARATION; ASP175ASN; STATES; GENES	E40K and E54K mutations in alpha-tropomyosin cause inherited dilated cardiomyopathy. Previously we showed, using Ala-Ser alpha-tropomyosin (AS-alpha-Tm) expressed in Escherichia coli, that both mutations decrease Ca2+ sensitivity. E40K also reduces V-max of actin-Tm-activated S-1 ATPase by 18%. We investigated cooperative allosteric regulation by native Tm, AS-alpha-Tm, and the two dilated cardiomyopathy-causing mutants. AS-alpha-Tm has a lower cooperative unit size (6.5) than native-alpha-tropomyosin (10.0). The E40K mutation reduced the size of the cooperative unit to 3.7, whereas E54K increased it to 8.0. For the equilibrium between On and Off states, the K-T value was the same for all actin-Tm species; however, the K-T value of actin-Tm-troponin at pCa 5 was 50% less for AS-alpha-Tm E40K than for AS-alpha-Tm and AS-alpha-Tm E54K. K-b, the "closed" to "blocked" equilibrium constant, was the same for all tropomyosin species. The E40K mutation reduced the affinity of tropomyosin for actin by 1.74-fold, but only when in the On state (in the presence of S-1). In contrast the E54K mutation reduced affinity by 3.5-fold only in the Off state. Differential scanning calorimetry measurements of AS-alpha-Tm showed that domain 3, assigned to the N terminus of tropomyosin, was strongly destabilized by both mutations. Additionally with AS-alpha-Tm E54K, we observed a unique new domain at 55 degrees C accounting for 25% of enthalpy indicating stabilization of part of the tropomyosin. The disease-causing mechanism of the E40K mutation may be accounted for by destabilization of the On state of the thin filaments; however, the E54K mutation has a more complex effect on tropomyosin structure and function.	Imperial Coll London, Natl Heart & Lung Inst, London SW3 6LY, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Univ Oxford, Dept Cardiovasc Med, Oxford OX3 7BN, England; Russian Acad Sci, AN Bach Inst Biochem, Moscow 119071, Russia; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119992, Russia	Imperial College London; University of Leicester; University of Oxford; Research Center of Biotechnology RAS; Russian Academy of Sciences; Lomonosov Moscow State University	Marston, S (corresponding author), Imperial Coll London, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	s.marston@imperial.ac.uk		Watkins, Hugh/0000-0002-5287-9016	British Heart Foundation [RG/07/012/24110] Funding Source: Medline; Wellcome Trust Funding Source: Medline	British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)		Ansari S, 2003, J MUSCLE RES CELL M, V24, P513, DOI 10.1023/B:JURE.0000009812.74980.13; BAILEY K, 1948, BIOCHEM J, V43, P271, DOI 10.1042/bj0430271; Bing W, 2000, BIOCHEM J, V350, P693, DOI 10.1042/0264-6021:3500693; Bing W, 2000, J MOL CELL CARDIOL, V32, P1489, DOI 10.1006/jmcc.2000.1182; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Chang AN, 2005, J BIOL CHEM, V280, P34343, DOI 10.1074/jbc.M505014200; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; GEEVES MA, 1994, BIOPHYS J, V67, P273, DOI 10.1016/S0006-3495(94)80478-3; Greenfield NJ, 2003, BIOCHEMISTRY-US, V42, P614, DOI 10.1021/bi026989e; HEAD JG, 1995, EUR J BIOCHEM, V227, P694, DOI 10.1111/j.1432-1033.1995.tb20190.x; Heller MJ, 2003, J BIOL CHEM, V278, P41742, DOI 10.1074/jbc.M303408200; Hilario E, 2004, EUR J BIOCHEM, V271, P4132, DOI 10.1111/j.1432-1033.2004.04351.x; Holthauzen LMF, 2004, J BIOL CHEM, V279, P15204, DOI 10.1074/jbc.M308904200; ISHII Y, 1987, BIOCHEMISTRY-US, V26, P4922, DOI 10.1021/bi00390a005; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Kremneva E, 2006, FEBS J, V273, P588, DOI 10.1111/j.1742-4658.2005.05092.x; Kremneva E, 2004, BIOPHYS J, V87, P3922, DOI 10.1529/biophysj.104.048793; Lehrer SS, 1997, BIOCHEMISTRY-US, V36, P13449, DOI 10.1021/bi971568w; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; Lehrer SS, 1998, J MOL BIOL, V277, P1081, DOI 10.1006/jmbi.1998.1654; Levitsky DI, 2000, EUR J BIOCHEM, V267, P1869, DOI 10.1046/j.1432-1327.2000.01192.x; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; Maytum R, 2003, J BIOL CHEM, V278, P6696, DOI 10.1074/jbc.M210690200; Maytum R, 2001, BIOCHEMISTRY-US, V40, P7334, DOI 10.1021/bi010072i; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; Messer AE, 2007, J MOL CELL CARDIOL, V42, P247, DOI 10.1016/j.yjmcc.2006.08.017; Mirza M, 2005, J BIOL CHEM, V280, P28498, DOI 10.1074/jbc.M412281200; Mogensen J, 2004, J AM COLL CARDIOL, V44, P2033, DOI 10.1016/j.jacc.2004.08.027; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Olson TM, 2001, J MOL CELL CARDIOL, V33, P723, DOI 10.1006/jmcc.2000.1339; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; ROBINSON P, 2007, BIOPHYS J, V91, P362; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; STEWART M, 1975, NATURE, V257, P331, DOI 10.1038/257331a0; Straub F.B., 1942, STUDIES I MED CHEM U, P3; SWARTZ DR, 1992, J BIOL CHEM, V267, P20497; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WU B, 1997, BIOCHEM BIOPH RES CO, V236, P760	43	63	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13487	13497		10.1074/jbc.M701071200	http://dx.doi.org/10.1074/jbc.M701071200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17360712	hybrid			2022-12-27	WOS:000246060300038
